{
    "0": {
        "output": "Based on the patient note provided, let's go through the inclusion criteria for the clinical trial one by one to assess the patient's eligibility:\n\n- Must live in the United States: The patient note does not specify the patient\u2019s location. Further information is needed to confirm this criterion.\n- Must understand and write English: The patient note does not provide information about the patient's language abilities. Further information is needed to confirm this criterion.\n- Must have access to a computer with e-mail and expect to have this access for at least 3 years: The patient note does not mention the patient's access to a computer or email. Further information is needed to confirm this criterion.\n- Must be 18 years old: The patient is 58 years old, which satisfies this criterion.\n- Must have seen a doctor for back pain at least once in the past year: The patient presents with chest pain, not back pain. There is no mention of back pain or a history of back pain in the patient note. Therefore, this criterion is not met.\n\nBased on the information provided in the patient note, the patient does not meet one of the key inclusion criteria for the clinical trial, which is having seen a doctor for back pain at least once in the past year. However, since other necessary information regarding residency, language ability, and computer access is missing, a final determination cannot be made solely based on the information provided.\n\nTherefore, the trial-level eligibility for this patient based on the information given would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the Beta-Blocker Heart Attack Trial (BHAT).\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known history of hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Men and women, ages 30 to 69.\n- Documented myocardial infarction.\n\nAssessment:\nThe patient's age fits within the inclusion criteria (ages 30 to 69). However, there is no documentation of a myocardial infarction presented in the patient note. The symptoms described could potentially be related to a cardiac event, but there is no clear evidence of a documented myocardial infarction based on the information provided. For this patient to be eligible for the BHAT, there needs to be a documented myocardial infarction, which is not indicated in the patient note.\n\nGiven the information provided, the patient does not currently meet the specific inclusion criterion of having a documented myocardial infarction. Therefore, the patient would not be referred for this clinical trial based on the data available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2": {
        "output": "Upon reviewing the patient's information and the clinical trial details, here are the key points for consideration:\n\nPatient Information:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Non-smoker, no diabetes, no hypercholesterolemia, no family history of heart disease\n- Not currently on any medication\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Information:\n- Title: Hypertension Prevention Trial (HPT) Feasibility Study\n- Focus: Nutritional interventions for the primary prevention of hypertension\n- Inclusion Criteria:\n  - Men and women, ages 25 to 49\n  - Diastolic blood pressure between 78 and 89 mm Hg\n  - Free of major disease\n  - Not on a special diet or antihypertensive medication at entry\n  - Some mild to moderately obese subjects\n\nAssessment of Eligibility:\n- The patient is 58 years old, which is outside the specified age range of 25 to 49 years.\n- The patient has hypertension and obesity, which could be relevant to the trial's focus on nutritional interventions for hypertension prevention. However, the trial specifically aims at the primary prevention of hypertension, and the patient is already known to have hypertension.\n- The patient\u2019s current diastolic blood pressure is not provided in the note, so we cannot assess whether it falls within the specified range of 78 to 89 mm Hg.\n- The patient is not on a special diet or antihypertensive medication, which aligns with one of the trial's inclusion criteria.\n\nBased on the information provided, the patient does not meet the age criterion for the clinical trial. Even though other aspects of her condition might be of interest to the study, the age criterion is a hard stop, and therefore, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "3": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Diabetes and Heart Disease Risk in Blacks,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial:\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Not currently on any medications\n\nInclusion criteria:\n- Ethnicity: Black (African Americans born in the United States with American-born parents or Africans living in the United States with African-born parents)\n- Age: Between 18 and 70 years\n- Medical History: Self-identified as healthy, without established coronary artery disease as evidenced by history of myocardial infarction, coronary artery bypass surgery, or PTCA, or if they have such a history, they are not currently having angina\n\nExclusion criteria:\n- Black Ethnicity other than American or African\n- Medications known to alter the parameters under investigation\n- Diabetes\n- Pregnant or breastfeeding women, or women with an infant less than four months of age\n- Women on injectable hormonal contraception\n\nAssessment:\n- The patient is a 58-year-old African-American woman, which fits the ethnic and age criteria.\n- The patient identifies as having hypertension and obesity but does not report any history of diabetes, which is specifically listed in the exclusion criteria.\n- There is no indication that the patient is taking any medications that would alter study parameters or that she is pregnant, breastfeeding, or on injectable hormonal contraception.\n- The patient's medical history does not include an established coronary artery disease with current angina, which could have excluded her based on the inclusion criteria.\n\nConsidering the information provided, the patient appears to meet the inclusion criteria and does not fall under any of the exclusion criteria. Therefore, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "4": {
        "output": "Based on the information provided, the patient in the note is a 58-year-old African-American woman who presents with episodic chest pain, hypertension, and obesity. However, the clinical trial is specifically looking to prevent recurrent strokes in African Americans who have had a non-cardioembolic ischemic stroke at least 7 days, but no more than 90 days before entering the trial.\n\nThe patient note does not mention a history of stroke, let alone a non-cardioembolic ischemic stroke within the specified time frame. Therefore, based on the inclusion criteria provided, this patient would not be eligible for the clinical trial focused on stroke prevention.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "5": {
        "output": "Assessing the patient's eligibility for the \"Muscatine Heart Study\" clinical trial:\n\nThe patient is a 58-year-old African-American woman presenting with symptoms that might suggest a cardiac event, such as episodic pressing/burning anterior chest pain that radiates to the back and is associated with nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n\nThe clinical trial in question is the \"Muscatine Heart Study,\" which aims to study risk factors for coronary heart disease and hypertension among children and adults. The trial has no specific eligibility criteria listed.\n\nGiven that there are no eligibility criteria provided for this clinical trial, theoretically, any patient could be considered for inclusion. However, it is essential to note that the patient's current clinical presentation should be adequately addressed and stabilized before considering her participation in any study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "6": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial titled \"The Jackson Heart Study of Cardiovascular Disease Among African Americans.\"\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Non-specific EKG changes\n\nClinical Trial Inclusion Criteria:\n- African American\n- Residents of Jackson, Mississippi\n\nAssessment:\nThe patient meets the African American ethnicity criterion for the clinical trial. However, there is no information about the patient's residency to confirm whether she is a resident of Jackson, Mississippi, which is a specific inclusion criterion for this clinical trial.\n\nWithout confirmation of the patient's residency, we cannot fully determine her eligibility. If the patient is indeed a resident of Jackson, Mississippi, she would be eligible. This information needs to be verified before a final decision can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "7": {
        "output": "Given that the clinical trial titled \"Racial Variation in ACE--Genetic and Physiologic Bases\" does not provide specific inclusion criteria, and considering that the patient is an African-American woman who presents with hypertension, which is related to blood pressure variation, she could potentially be of interest for the study given its focus on blood pressure variation in African Americans.\n\nHowever, it's important to note that without detailed inclusion criteria, it's not possible to definitively ascertain her eligibility based solely on the information provided. Therefore, additional information would be required from the clinical trial's organizers to make a fully informed decision.\n\nBased on the information available, I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "8": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure,\" we need to match the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nFrom the patient note, we have the following information about the patient:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Currently takes no medications\n- Normal physical examination\n- The EKG shows nonspecific changes\n\nThe inclusion criteria for the trial are:\n- Age \u2265 18 years\n- Ischemic or nonischemic cardiomyopathy with symptoms of NYHA Class III or IV chronic heart failure\n- LVEF \u2264 35%\n- LVEDD > 2.7 cm/m^2\n- On optimal conventional heart failure therapy\n- Failed initiation or up-titration of a beta-blocker due to hemodynamic intolerance\n\nBased on the patient note, there is no evidence that the patient has chronic heart failure, let alone NYHA Class III or IV chronic heart failure. The patient also does not have a documented left ventricular ejection fraction (LVEF) or left ventricular end diastolic dimension (LVEDD). Additionally, there is no indication that the patient has been on heart failure therapy or has had issues tolerating beta-blockers.\n\nSince the patient does not meet the key inclusion criteria related to the diagnosis of chronic heart failure and the specific requirements regarding heart function and treatment history, we would not consider this patient eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "9": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain,\" let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 58 years old\n- Presenting symptoms: episodic pressing/burning anterior chest pain, radiating to the back, with nausea, diaphoresis, and mild dyspnea\n- Known medical history: hypertension, obesity\n- Medication: No current medications\n- Physical examination: Normal\n- EKG: Nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Chronic back pain for at least 6 months\n- Treatment by medication or physical therapy\n\nComparison:\n- The patient does not mention chronic back pain; instead, she has episodic chest pain that started very recently.\n- There is no indication that the patient has been treated for back pain, either by medication or physical therapy.\n\nSince the patient does not have chronic back pain and is not undergoing treatment for such a condition, she does not meet the inclusion criteria for the clinical trial, which is specifically targeting individuals with chronic back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "10": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman who presents to the ER with episodic pressing/burning anterior chest pain and is known to have hypertension and obesity. The clinical trial in question is investigating the influence of amlodipine on the mortality of patients with end-stage renal failure who are undergoing chronic hemodialysis treatment.\n\nTo determine the eligibility of the patient for the clinical trial, we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial:\n\nInclusion criteria for the clinical trial:\n- End-stage renal disease\n- Hemodialysis\n- Hypertension\n- Written informed consent\n\nPatient characteristics and medical condition:\n- 58-year-old African-American woman\n- Hypertension\n- Episodic chest pain\n- No indication of end-stage renal disease or hemodialysis treatment\n\nWhile the patient does have hypertension, which is one of the inclusion criteria, there is no mention in the patient note of end-stage renal disease or that the patient is undergoing hemodialysis treatment. Since the clinical trial specifically requires participants to have end-stage renal failure and be on chronic hemodialysis treatment, this patient does not meet the key inclusion criteria for the trial.\n\nTherefore, based on the information given, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "11": {
        "output": "Based on the patient note provided, the 58-year-old woman presents with hypertension, evidenced by her known medical condition, but there is no mention of her having type 2 diabetes or impaired glucose tolerance. The clinical trial in question is specifically looking for hypertensive patients with a clinical diagnosis of type 2 diabetes or impaired glucose tolerance.\n\nSince the patient does have a clinical diagnosis of hypertension, she meets part of the inclusion criteria. However, without information on her glucose tolerance or a diagnosis of type 2 diabetes, we cannot fully determine her eligibility for this trial. Additional information would be required to make a complete assessment.\n\nGiven the information available, I would consider referring this patient to the clinical trial upon further investigation to determine if she has type 2 diabetes or impaired glucose tolerance.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "12": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nPatient Characteristics:\n- Age: 58 years old\n- Known hypertension\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- No current medications\n- No history of diabetes, hypercholesterolemia, or family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Outpatients aged 65 years or older, and less than 85 years\n- Current antihypertensive treatment with monotherapy\n- SBP \u2265 140mmHg or DBP \u2265 90mmHg on two measurements on two clinic visits\n- At least one of the following risk factors:\n  - Diabetes mellitus Type 2\n  - History of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or TIA\n  - Diagnosis of asymptomatic cerebrovascular disease\n  - History of myocardial infarction\n  - Diagnosis of angina pectoris or heart failure (NYHA I or II)\n  - Diagnosis of left ventricular hypertrophy\n  - Diagnosis of aortic aneurysm\n  - History of aortic dissection\n  - Diagnosis of arteriosclerotic peripheral arterial obstruction\n  - Serum creatinine: 1.2-2.5mg/dL (male); 1.0-2.5mg/dL (female)\n  - Proteinuria: \u2265 +1\n\nComparison of Patient Characteristics to Inclusion Criteria:\n- The patient is 58 years old, which is younger than the required 65 years or older for the trial.\n- The patient is not currently on antihypertensive treatment, as they are not taking any medications.\n- Blood pressure measurements are not provided, so we cannot assess this criterion.\n- There is no mention of any of the listed risk factors, such as diabetes type 2, history of cardiovascular or cerebrovascular events, diagnosis of left ventricular hypertrophy, or laboratory results for serum creatinine and proteinuria.\n\nConclusion:\nBased on the information provided, the patient does not meet the age criterion, is not currently receiving antihypertensive treatment with monotherapy, and there is no evidence of the specified risk factors or lab results. Therefore, this patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "13": {
        "output": "The patient note describes a 58-year-old African-American woman who presents with new-onset chest pain, hypertension, and obesity. The patient's chest pain is not typical for angina, as it does not increase on inspiration and is accompanied by nausea, diaphoresis, and mild dyspnea. The patient's EKG shows nonspecific changes, and she is not currently on any medication for her hypertension.\n\nThe clinical trial is focused on individuals with mild essential hypertension to study the effects of an ACE inhibitor and an ARB on blood pressure and hormonal responses. The inclusion criteria for the clinical trial are as follows:\n\n- Essential Hypertension\n- SBP 140-159 mmHg\n- DBP 90-99 mmHg\n\nThe patient note indicates that she has hypertension, which is one of the inclusion criteria. However, the patient's specific blood pressure values (SBP and DBP) at the time of the evaluation are not provided. Essential hypertension is typically diagnosed based on repeated blood pressure measurements, and we do not have enough information from the patient note to determine if she has been diagnosed with essential hypertension or if her blood pressure falls within the specified range. \n\nBased on the information given, we cannot confirm her eligibility without further investigation into her diagnosis and blood pressure readings. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "14": {
        "output": "Based on the patient note and the clinical trial criteria provided, let's evaluate the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical Trial Criteria:\n- Outpatients \u226518 years of age\n- Diagnosed with clinically stable angina pectoris\n\nThe patient is over 18 years of age and presents with symptoms that could be suggestive of angina pectoris, such as episodic chest pain that began recently. However, the diagnosis of \"clinically stable angina pectoris\" has not been established yet based on the information in the patient note. Further investigations would be required to confirm the diagnosis and ascertain whether the angina is stable.\n\nWithout confirmation of stable angina, it's not possible to definitively say that the patient meets all the inclusion criteria. Therefore, further investigation is needed before the patient could be referred to the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "15": {
        "output": "The patient note describes a 58-year-old African-American woman presenting with symptoms that may be indicative of a cardiovascular event, such as chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea. She has a known history of hypertension and obesity, which are two risk factors mentioned in the inclusion criteria for the KYOTO HEART Study. The patient does not have diabetes, a smoking habit, hypercholesterolemia, or a family history of heart disease. There's no mention of chronic heart failure or a history of ischemic heart disease (IHD) or cerebrovascular disease. The EKG shows nonspecific changes, which could be interpreted as an electrocardiogram (ECG) abnormality.\n\nBased on the information provided:\n\n- The patient has a clinical diagnosis of hypertension.\n- The patient has obesity, which is one of the risk factors listed in the inclusion criteria (BMI>25 is assumed based on the mention of obesity).\n- There are nonspecific changes on the EKG, which might be considered an ECG abnormality; however, this would require further clarification since \"nonspecific changes\" can mean various things and may not necessarily equate to the LVH mentioned in the inclusion criteria.\n\nGiven the patient has at least two risk factors from the inclusion criteria (hypertension and obesity), I would consider referring this patient to the KYOTO HEART Study upon further investigation, particularly to clarify the EKG findings and ensure they meet the trial's definition of ECG abnormality.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "16": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not meet the eligibility criteria as specified for the trial. The trial is specifically targeting patients with a history of diabetes for at least 5 years, and the patient in the note does not mention having diabetes, only hypertension and obesity. Since having diabetes is a requirement for the trial, and there is no indication that the patient has diabetes, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "17": {
        "output": "Based on the inclusion criteria provided for the clinical trial titled \"Understanding Pediatric Chest Pain and Other Symptoms,\" the key points are:\n\n- Age between 8-18 years old\n- Pediatric patients with referrals for innocent heart murmurs\n- Pediatric patients experiencing chest pain\n- Must be English speaking\n\nThe patient in the provided note is a 58-year-old African-American woman who presents with chest pain. This patient does not meet the age criteria, as she is well beyond the 8-18 years of age requirement for the study.\n\nTherefore, the patient is not eligible for the clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "18": {
        "output": "Upon reviewing the patient's presentation and the inclusion criteria of the clinical trial, it appears that the patient's symptoms suggest she may be experiencing an episode related to a cardiovascular condition, potentially ischemic heart disease (IHD), given the description of episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea. However, there is no definitive diagnosis of heart failure (HF) or ischemic heart disease provided in the patient note, which are specific conditions required for eligibility in the clinical trial.\n\nFurthermore, the clinical trial is focused on improving the quality of prescribing for patients with chronic cardiovascular disease, specifically CHF or IHD, who are not currently being treated with ACE inhibitors/angiotensin receptor blockers for HF or statins for IHD. Since the patient is not on any medications, she might fit this part of the criteria if she were to have a diagnosis of HF or IHD.\n\nGiven that the patient\u2019s current symptoms and medical history have not yet established a diagnosis of chronic cardiovascular disease such as CHF or IHD, further investigation would be necessary to determine if the patient fits the diagnosis criteria for the trial. Therefore, at this stage, the patient's eligibility for the trial is uncertain, and more information is needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "19": {
        "output": "Based on the information provided in the patient note, we have a 58-year-old African-American woman who presents with hypertension, one of the conditions being targeted in the clinical trial. She is also above 18 years of age, which meets another inclusion criterion for the trial.\n\nThe patient's presenting symptoms do not seem to be directly related to her hypertension, as they are more indicative of an acute coronary syndrome rather than uncontrolled hypertension. However, since the trial is comparing different combinations of medications for the treatment of high blood pressure and she is known to have hypertension, her condition aligns with the study's focus.\n\nThe trial does not mention the need for the hypertension to be uncontrolled or resistant to treatment, nor does it specify any additional criteria such as the severity of hypertension or any previous treatment.\n\nGiven the information provided, the patient meets the basic inclusion criteria for age (>18 years) and has a diagnosis of high blood pressure. Therefore, she could potentially be eligible for the trial that aims to compare hypertension treatments.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "20": {
        "output": "The patient in the note is presenting with symptoms suggestive of a cardiac event (episodic pressing/burning anterior chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea). The patient has a history of hypertension and obesity and is currently not on any medications. There is no mention of breast cancer in the patient's history.\n\nThe clinical trial in question is designed for metastatic breast cancer (MBC) patients who are resistant to hormonal therapy, have ER (-) status, have not been treated with anthracyclines for MBC or taxanes before, and who are within a certain age range with specific blood counts and liver function tests.\n\nSince the patient note does not mention metastatic breast cancer or any cancer diagnosis, the patient does not meet the disease-specific inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "21": {
        "output": "Given the patient's presentation of episodic pressing/burning anterior chest pain that began while walking and radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea, there is a possibility of stable angina pectoris. The patient has risk factors such as hypertension and obesity, which could contribute to angina. However, there are a few considerations before determining the trial-level eligibility:\n\n1. The patient note does not confirm a diagnosis of chronic stable angina pectoris. While the symptoms are suggestive, a confirmed diagnosis would be necessary.\n2. There is no mention of documented coronary artery disease in the patient note.\n3. The patient has not been described as having been previously treated with atenolol or any other beta-blocker agent.\n4. There's no information provided on an exercise tolerance test, which is one of the inclusion criteria.\n\nConsidering these points, while the patient may potentially have angina, there is not enough evidence in the patient note to confirm that she meets all the inclusion criteria for the trial. Further investigation would be needed to confirm the diagnosis of stable angina pectoris, the presence of coronary artery disease, previous beta-blocker treatment, and exercise tolerance test results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "22": {
        "output": "The patient is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain that started while walking. The pain radiates to the back and is accompanied by nausea, diaphoresis, and mild dyspnea. She has hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. The EKG shows nonspecific changes.\n\nLet's assess her eligibility against the inclusion criteria for the clinical trial titled \"Rosiglitazone Versus Placebo in Chronic Stable Angina\":\n\n1. Chronic stable angina - The patient presents with chest pain, but there is no mention of whether it has been diagnosed as chronic stable angina. Further investigation is required to confirm this diagnosis.\n2. Previous positive exercise tolerance test - There is no information provided about any previous exercise tolerance tests.\n3. Disease not suitable for coronary intervention - There is no information provided about the suitability of the disease for coronary intervention.\n4. Do not have overt diabetes - The patient denies diabetes, meeting this criterion.\n5. Body mass index (BMI) greater than 25 - The patient is described as obese, which likely meets the BMI criterion, but the exact BMI is not provided.\n\nBased on the available information, the patient may potentially meet some of the inclusion criteria for the clinical trial. However, there is a need for further investigation to confirm the diagnosis of chronic stable angina, the history of exercise tolerance tests, and whether the patient's disease is not suitable for coronary intervention. Therefore, the appropriate level of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "23": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis,\" let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- Age: 58-year-old\n- Gender: Female\n- Health Conditions: Episodic pressing/burning anterior chest pain, hypertension, obesity\n- Other Information: No current medications, non-smoker, no diabetes, no hypercholesterolemia, no family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Women aged 50 and older\n- Lumbar spine BMD (L1 to L4) T score between 0 and -2.0\n- At least 3 years postmenopausal\n\nThe patient meets the age and gender requirements for the clinical trial as she is a 58-year-old woman. However, there is no information provided about her menopausal status or bone mineral density (BMD) T score. Without this information, we cannot conclude that she fully meets the inclusion criteria. Therefore, further investigation is necessary to determine her menopausal status and BMD T score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "24": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- Age: 58 years old\n- Presents with: episodic pressing/burning anterior chest pain, hypertension, obesity\n- No current medications\n- No mention of low back pain (LBP)\n\nClinical Trial Inclusion Criteria:\n- Age: 21 to 55 years old\n- Diagnosis: Idiopathic mechanical low back pain (LBP)\n- LBP classified as subacute (4-12 weeks) or chronic (more than 12 weeks), with the current episode at least four weeks prior\n- Required: Written Informed Consent\n- A minimum baseline score on the Roland Morris Disability Questionnaire (RMQ) of 6 points\n\nThe patient does not meet the age criterion, as she is 58 years old and the trial specifies an age range of 21 to 55 years. Additionally, the patient does not present with low back pain, which is a requirement for the clinical trial. Therefore, this patient would not be eligible for referral to the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "25": {
        "output": "Based on the information provided, the 58-year-old African-American woman presents with symptoms that could suggest acute coronary syndrome (ACS), such as episodic pressing/burning anterior chest pain with associated symptoms like nausea, diaphoresis, and mild dyspnea. Her EKG shows nonspecific changes, which does not rule out the possibility of ACS.\n\nThe clinical trial in question is targeting patients with ACS, specifically looking to evaluate the efficacy and safety of intravenous versus sublingual isosorbide dinitrate for the relief of acute anginal pain episodes in ACS patients.\n\nTo determine if this patient is eligible for the clinical trial, we need to match her characteristics and situation with the inclusion criteria:\n\n- Age > 18 years or older. (The patient is 58, so this criterion is met.)\n- Admission to the ICCU with ACS (non-ST elevation acute coronary syndrome or 24 hours after ST elevation myocardial infarction). (The patient's description suggests a potential ACS, but there is no clear statement that she has been admitted with ACS. Further investigation, such as troponin levels and a more comprehensive EKG interpretation, would be required.)\n- Presence of ischemic symptoms (\u22655 minutes) during hospitalization. (The patient has had symptoms suggesting ischemia, but we would need confirmation of hospitalization and symptom duration during that time.)\n- Pain assessment of 3 out of 10 on Visual Analog Scale (VAS) 1 or dynamic ECG findings (ST segment deviation \u22650.05 mV or T wave inversion \u2265 0.3 mV). (The patient has chest pain and nonspecific EKG changes, but specific measurements of ST deviation or T wave inversion are not provided, nor is a pain assessment on the VAS.)\n- Willing and able to provide written informed consent according to the regulations of the Ministry of Health and the Helsinki committee instructions. (There is no information on the patient's willingness or ability to consent.)\n\nGiven the current information, the patient potentially fits the age and symptom criteria for the clinical trial, but additional information would be necessary to confirm her eligibility, especially regarding the diagnosis of ACS, the severity and duration of her symptoms during hospitalization, and her consent to participate.\n\nTherefore, the assessment of trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "26": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with symptoms of episodic chest pain, hypertension, and obesity. There is no mention of her having pulmonary hypertension, let alone chronic thromboembolic pulmonary hypertension (CTEPH), which is the condition specified in the inclusion criteria of the clinical trial.\n\nThe clinical trial is specifically looking for patients with a diagnosis of CTEPH to participate in a study regarding gene mutations in secondary pulmonary hypertension. Since the patient does not have a documented diagnosis of CTEPH, she does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "27": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- Non-specific EKG changes\n\nClinical trial:\n- Title: Evaluating the Link Between Neighborhood Environments and Obesity Among African American Women\n- Inclusion criteria:\n  - Participating in the BWHS study\n  - Residing in New York, Los Angeles, or Chicago\n\nThe patient in the note is an African-American woman with obesity, which aligns with the population of interest for the clinical trial. However, the inclusion criteria specifically state that participants must be part of the Black Women's Health Study (BWHS) and must reside in New York, Los Angeles, or Chicago. The patient note does not mention if the patient is a part of the BWHS study, nor does it specify her residence.\n\nGiven the information available, we cannot confirm the patient's participation in the BWHS study or her residency in one of the specified cities. Therefore, we would not be able to refer her for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "28": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain that began two days earlier. The pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea but is not increased on inspiration. The patient has a history of hypertension and obesity, and the EKG shows nonspecific changes.\n\nThe clinical trial is seeking patients with an acute episode of chest pain of less than 7 days' duration as the primary reason for admission to a chest pain clinic, who are suspected of acute coronary infarction but with a negative diagnosis confirmed by normal coronary enzymes and normal ECG, and with pain arising from the thorax and/or neck. Additionally, patients must be able to read and understand Danish.\n\nGiven that the patient note does not mention the status of coronary enzymes, which is a key factor in determining the eligibility for the clinical trial, we cannot be certain if the patient fits the criteria of having a negative diagnosis confirmed by normal coronary enzymes. Moreover, the ability to read and understand Danish is a requirement, and there is no information about the patient's language abilities.\n\nWithout confirmation of normal coronary enzymes and the patient's ability to read and understand Danish, we cannot determine with high certainty if the patient is eligible for the trial. Therefore, based on the information available, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "29": {
        "output": "Based on the patient note provided, the patient is a 58-year-old African-American woman presenting with chest pain, hypertension, and obesity. There is no mention of Prader-Willi syndrome (PWS) or Early-onset Morbid Obesity (EMO) before the age of 4 years in the patient's note. Additionally, the patient exceeds the age limit of 30 years for the EMO group as specified in the inclusion criteria of the clinical trial.\n\nGiven the patient's age, the absence of a documented medical history of Early-onset Morbid Obesity, and no mention of Prader-Willi syndrome, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "30": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the eligibility of the patient for the trial:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic pressing/burning anterior chest pain\n- Symptoms started while walking, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- More than 10 years old\n- Electrocardiographic diagnosis of SVT\n- SVT not converted by the vagal manoeuvres\n\nComparison:\n- The patient is more than 10 years old, which meets the age criterion.\n- However, the clinical trial specifically requires an electrocardiographic diagnosis of Supraventricular Tachycardia (SVT), and the patient's EKG only shows nonspecific changes, not a diagnosis of SVT.\n- There is no indication from the patient note that SVT was diagnosed or that vagal manoeuvres were attempted or failed to convert an SVT episode.\n\nGiven that the patient does not have a documented diagnosis of SVT, which is a critical inclusion criterion for participation in the trial, she would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "31": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic anterior chest pain, which is not related to primary spontaneous pneumothorax. The clinical trial in question is focused on the prevention of recurrence in patients who have experienced a first episode of primary spontaneous pneumothorax.\n\nBased on the inclusion criteria detailed for the clinical trial, the patient does not meet several key eligibility requirements:\n\n1. Age between 15 and 40 years old \u2013 The patient is 58 years old, which is outside the specified age range for the trial.\n2. First episode of spontaneous pneumothorax \u2013 There is no indication in the patient's note that she has experienced a pneumothorax.\n3. Symptomatic (dyspnea or chest pain) or the rim of air is > 2cm on CXR requiring simple aspiration \u2013 The patient's symptoms are related to chest pain, but there is no indication of pneumothorax or the need for simple aspiration based on chest x-ray findings.\n4. Complete or nearly complete and persistent lung expansion immediately following manual aspiration \u2013 Again, there is no indication of a procedure for pneumothorax that the patient has undergone.\n\nGiven the information provided, this patient does not meet the inclusion criteria for the clinical trial focused on primary spontaneous pneumothorax and minocycline pleurodesis. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "32": {
        "output": "Based on the information provided in the patient note, the patient is a 58-year-old African-American woman who presents with chest pain, hypertension, and obesity. There is no mention in the patient note of her having pulmonary arterial hypertension (PAH) or any indication that she has participated in the NCT00046319 study, which is a prerequisite for enrollment in the AMB-220-E study.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Must have completed Visit 14/Week 24 of the NCT00046319 study.\n2. Women of childbearing potential must have a negative urine pregnancy test at the Screening/Enrollment Visit and agree to use reliable double barrier methods of contraception until study completion and for >=4 weeks following their final study visit.\n3. Must have completed the Down-titration Period of NCT00046319 prior to enrollment in AMB-220-E and will meet the following additional criteria:\n   - Subjects with a diagnosis of HIV must have stable disease status at the time of Screening/Enrollment.\n4. Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening Visit.\n\nSince there is no evidence that the patient meets the specific inclusion criteria for the clinical trial, particularly the requirement of having completed a prior study related to PAH (NCT00046319), she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "33": {
        "output": "Given the patient's description and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nThe patient is a 58-year-old African-American woman presenting with hypertension, as indicated by her known medical condition. The clinical trial's inclusion criteria specify the following:\n\n1. Outpatients aged 65 years or older, and less than 85 years (at the time of informed consent), regardless of sex.\n2. Systolic blood pressure (SBP) \u2265140 mmHg or diastolic blood pressure (DBP) \u226590 mmHg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications.\n3. Systolic blood pressure (SBP) \u2265160 mmHg or diastolic blood pressure (DBP) \u2265100 mmHg in a sitting position on two consecutive measurements at clinic without antihypertensive medication.\n4. Require at least one of the following medical history or risk factors.\n\nThe patient does not meet the age criterion, as she is 58 and the study requires participants to be 65 or older. Furthermore, the patient's blood pressure measurements are not provided, so we cannot confirm whether she meets the hypertension criteria. There is no mention of her having any of the listed medical history or risk factors required by the trial.\n\nBased on the information provided, the patient does not meet the age inclusion criteria and insufficient data is available regarding her blood pressure and risk factors to determine eligibility in those areas. Therefore, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "34": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the clinical trial titled \"Treatment Study Comparing Manual Treatment or Advice in Acute, Musculoskeletal Chest Pain.\"\n\nPatient Note Evaluation:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Pain started while walking, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- No increase in pain on inspiration\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Not currently on any medications\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Have chest pain as their primary complaint. (Patient has chest pain as the primary complaint)\n- Have an acute episode of pain of less than 7 days duration before admission. (Patient's pain began two days earlier)\n- Consent to the standardized evaluation program at the chest pain clinic. (Assuming consent can be obtained)\n- Have pain in the thorax and/or neck. (Patient has thorax pain)\n- Be able to read and understand Danish. (No information provided)\n- Be between 18 and 75 years of age. (Patient is 58 years old)\n- Be a resident of the Funen County. (No information provided)\n\nExclusion Criteria for the Clinical Trial:\n- ACS or other obvious reasons for chest pain have been excluded. (No information on whether ACS or other conditions have been excluded)\n- Patients will not be included if they have had PCI or CABG, or if they have a verified clinical condition resulting in chest pain, inflammatory joint disease, insulin-dependent diabetes, fibromyalgia, malignant disease, apoplexy, dementia, unable to cooperate, major osseous anomaly, osteoporosis, pregnancy, or do not want to participate. (None of these exclusion criteria are mentioned in the patient note)\n\nBased on the available information, the patient appears to meet some of the inclusion criteria: primary complaint of chest pain, acute episode of pain of less than 7 days, pain in the thorax, age between 18 and 75 years, and no exclusion criteria are explicitly mentioned. However, we do not have information about the patient's ability to read and understand Danish or whether they are a resident of Funen County. Additionally, we do not know if ACS or other conditions have been excluded as potential causes of her chest pain, which would be necessary to determine before inclusion in the study.\n\nGiven these gaps in information, further investigation would be required to determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "35": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the following reasons:\n\n1. The patient is a 58-year-old African-American woman.\n2. The clinical trial is specifically looking for male participants.\n3. The trial requires a diagnosis of stable angina with support from the patient's history, diagnostic exercise test, or angiographic evidence of CAD.\n\nSince the trial's inclusion criteria explicitly state that participants must be male and have angina, and the patient in the note is a woman who presents with chest pain but without a confirmed diagnosis of angina, she would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "36": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with chest pain, hypertension, and obesity. She has no diagnosis of gastric carcinoma and no mention of previous treatments for such a disease.\n\nThe clinical trial is specifically looking for participants with advanced gastric cancer that is ErbB2 amplified and who have undergone specific prior treatments for gastric carcinoma (including 5-fluoropyrimidine and/or cisplatin). The patient does not meet the key inclusion criteria of having gastric cancer or having received the specified prior treatments. Additionally, the patient does not fit any of the other detailed inclusion or exclusion criteria related to the specific medical condition and treatment history required for this study.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "37": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, we can determine the following:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain. She has known risk factors for cardiovascular disease, including hypertension and obesity. She denies smoking, diabetes, and hypercholesterolemia. The clinical trial is looking for participants with at least one modifiable cardiovascular risk factor.\n\nGiven that the patient has hypertension and obesity, which are listed as modifiable cardiovascular risk factors in the trial's inclusion criteria, she would be eligible for the trial. Her age is not a disqualifying factor, and her presentation with chest pain is relevant to the focus of the trial on cardiovascular risk-related behaviors and health attitudes.\n\nThe patient's physical examination is normal, and there are nonspecific changes on the EKG, which do not exclude her from participating in the trial. Since there is no mention of other exclusion criteria and the patient meets the trial's inclusion criteria, she would be considered a suitable candidate for referral.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "38": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet the specified criteria for the trial. The patient presents with symptoms potentially indicative of a cardiac event, but there is no mention of Hodgkin Lymphoma (HL) in their medical history. Additionally, the trial requires participants to have a biopsy-proven diagnosis of HL and to have participated in specific IRB-approved protocols for the first-line treatment of HL between 1975-2000.\n\nSince the patient note does not include any history of Hodgkin Lymphoma or treatment for it, the patient would not be eligible for this specific clinical trial focused on the quality of life among survivors of Hodgkin Lymphoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "39": {
        "output": "The patient in the note is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The patient does not meet the specific inclusion criteria for the clinical trial, which requires that the patient must have been investigated for chest pain or palpitation 6 months ago at the Cardiological Out-patient Clinic, Molde Hospital. Since there is no information indicating that the patient has been previously investigated at the specified clinic, she does not qualify for the trial based on the provided criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "40": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to meet the criteria for the trial:\n\n- The patient in the note is presenting with chest pain, hypertension, and obesity. There is no mention of systemic sclerosis or digital ulcers, which are the focus of the clinical trial.\n- The trial is specifically for patients with digital gangrene or ulcers in the context of severe secondary Raynaud's phenomenon associated with systemic sclerosis. \n- The trial also requires patients to be on stable therapy with vasoactive drugs and unchanged immunosuppressive therapy 3 months before the treatment with sildenafil. The patient note does not provide any information on such treatments.\n- There is no mention of the patient having any effect of prostacyclin treatment, contraindications for prostacyclins, or reasons for excluding this therapy, which are part of the inclusion criteria.\n\nGiven these observations, the patient described in the note does not match the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "41": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of a cardiac event, such as episodic anterior chest pain with radiation to the back, accompanied by nausea, diaphoresis, and mild dyspnea. The patient has a history of hypertension and obesity, but there is no mention of a malignant pleural effusion or any indication that she is undergoing or requires pleurodesis.\n\nThe clinical trial in question is focused on patients who are undergoing pleurodesis for malignant pleural effusion. Inclusion criteria specify that the patient must have a diagnosis of malignant pleural effusion confirmed by histological evidence or typical features seen during thoracoscopy, among other criteria related to health status and previous treatments.\n\nSince the patient does not have a documented diagnosis of malignant pleural effusion and there is no evidence that she is undergoing or requires pleurodesis, she does not meet the disease characteristic criteria for the clinical trial.\n\nTherefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "42": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and situation with the inclusion criteria of the trial. Let's review the patient note and the inclusion criteria:\n\nPatient note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- No current medications\n- Normal physical examination\n- Nonspecific changes on EKG\n\nClinical trial inclusion criteria:\n- Men and women admitted for an IHD event (acute coronary syndrome or revascularization procedure) who are at low or moderate risk\n- Regular Internet access (home, work, or other environment)\n- Over 18 years of age\n- Permission of the attending physician\n- Able to read, write and understand English without difficulty\n- No physical limitations to regular activity\n\nBased on the information provided in the patient note, there is no clear indication that the patient has been admitted for an ischemic heart disease (IHD) event such as acute coronary syndrome or a revascularization procedure. The patient presents with symptoms that could be suggestive of an IHD event, but there is no confirmation of such a diagnosis or admission for such an event in the note provided.\n\nAs the patient's eligibility for the clinical trial hinges on confirmation of an IHD event and the other criteria, more information would be required to make a definitive determination regarding her eligibility. For instance, if further investigation confirmed an IHD event and the patient met all other inclusion criteria, she might be eligible to participate in the trial.\n\nGiven the information at hand, which does not confirm an IHD event, the patient does not currently meet all the inclusion criteria as specified. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "43": {
        "output": "The patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of a cardiovascular event (chest pain, nausea, diaphoresis, and mild dyspnea), but there is no mention of diabetes in her medical history. She is known to have hypertension and obesity, which are risk factors for type 2 diabetes, yet she does not have a current diagnosis of diabetes nor is there any indication that she has been recently diagnosed with diabetes.\n\nThe clinical trial in question is specifically targeting individuals with a new onset of type 2 diabetes and a BMI greater than 25 kg/m^2. Since the patient does not have a diagnosis of type 2 diabetes, she would not meet the inclusion criteria for the trial.\n\nBased on the patient's information and the trial's inclusion criteria, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "44": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain with accompanying symptoms\n- Known to have hypertension and obesity\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Currently takes no medications\n- Normal physical examination\n- EKG shows nonspecific changes\n- There is no mention of breast cancer in the patient's history or current medical issues\n\nClinical Trial:\n- Title: A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx\n- Inclusion Criteria: Patients with metastatic breast cancer\n\nThe patient in the note does not have a diagnosis of metastatic breast cancer, which is a specific requirement for the clinical trial in question. Therefore, she would not be eligible for this trial as she does not meet the primary inclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "45": {
        "output": "Based on the information provided, the patient does not meet the inclusion criteria for the clinical trial:\n\n- The patient does not have a clinical diagnosis of COPD.\n- There is no indication that the patient has a smoking history, let alone a > 15 pack year smoking history.\n\nGiven that the patient does not meet the primary inclusion criteria for the clinical trial, which specifically targets individuals with COPD and a significant smoking history, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "46": {
        "output": "Based on the given patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiating to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Takes no medications\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical trial summary:\n- Title: Neuromuscular Balance in Low Back Pain\n- Interventional study to investigate the effectiveness of neuromuscular balance in lumbar pain\n- Inclusion Criteria: Patients with low back pain between 20 and 55 years old, submitted to a physical therapy treatment\n\nThe patient's age (58 years old) is beyond the specified age range for the clinical trial (20 to 55 years old). Therefore, this patient would not meet the age inclusion criteria for this trial. Additionally, the patient does not present with low back pain, which is another key inclusion criterion for participation in the neuromuscular balance study.\n\nGiven these factors, the patient does not meet the inclusion criteria of the clinical trial due to age and the absence of low back pain as a presenting complaint.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "47": {
        "output": "Based on the provided patient note, the 58-year-old African-American woman does not meet the inclusion criteria of the clinical trial. The trial is focusing on African American women at high risk for HIV and requires participants to have current substance abuse, current high-risk sexual behavior, and African American racial identification.\n\nThe patient in question presents with symptoms that suggest a possible cardiac issue rather than being at high risk for HIV. There is no mention of substance abuse or high-risk sexual behavior in her history. Therefore, she would not be eligible for this trial based on the information presented.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "48": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria provided for the trial.\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier\n- Pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No medications currently taken\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Age between 18 and 80 years\n- Females of childbearing potential must have a negative pregnancy test, not be breastfeeding, and be on a method of contraception\n- Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation\n- Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or ECG changes\n- Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)\n- Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0\n- All anti-angina regimen discontinued, except short-acting nitroglycerin and one beta-blocker or calcium channel blocker\n- Patient must understand and be willing, able, and likely to comply with all study procedures and restrictions\n- Patient must be able to give voluntary written informed consent\n\nAssessment:\n- The patient is within the age range required for the trial.\n- The patient is a female, and if of childbearing potential, would need to meet the trial's requirements regarding pregnancy testing and contraception, which we don't have information on.\n- The patient presents with chest pain that could be indicative of angina, but there is no documented evidence of chronic stable angina for over 3 months, nor is there confirmation of significant coronary artery disease.\n- The patient's angina classification cannot be determined based on the information provided; more investigation would be needed to determine if it is moderate angina (Class II or III).\n- There is no information on the patient's exercise tolerance or results of an exercise tolerance test (ETT).\n- The patient is not on any anti-angina regimen, so this criterion is not applicable.\n- The patient's ability to understand and comply with the study procedures, as well as to provide informed consent, cannot be assessed from the information provided.\n\nGiven the available information, the patient does not clearly meet several key inclusion criteria, such as documented history of myocardial infarction or significant coronary artery disease, and there is no evidence of chronic stable angina. Therefore, further investigation would be necessary to determine if the patient's recent onset of chest pain qualifies as chronic stable angina and to obtain documentation of coronary artery disease.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "49": {
        "output": "The patient presented is a 58-year-old African-American woman with episodic anterior chest pain, hypertension, and obesity. There is no mention of heart failure or any objective evidence of systolic dysfunction (ejection fraction \u226440%) in the patient note. Additionally, the patient is not currently taking any medications, which means there is no information about her being beta-blocker na\u00efve or having been excluded from beta-blockers within the previous 30 days, as per the inclusion criteria of the clinical trial.\n\nThe clinical trial in question is focusing on patients with Class C heart failure who are beta-blocker na\u00efve and have objective evidence of systolic dysfunction. Since the patient's note does not provide information that the patient fits these criteria, she does not meet the specific inclusion criteria outlined for the trial.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "50": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the clinical trial focused on the prevalence and outcome of brachial artery endothelial function in morbidly obese patients undergoing bariatric surgery.\n\nThe patient is described as a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, known hypertension, and obesity. The clinical trial is looking for morbidly obese patients who fulfill the NIH criteria for surgical intervention. The NIH criteria for bariatric surgery typically include a body mass index (BMI) of 40 or higher (morbid obesity), or a BMI of 35 or higher with obesity-related conditions. The note does not provide specific information about the patient's BMI or whether she fulfills the NIH criteria for surgical intervention.\n\nSince the patient note does not provide enough information about the patient's BMI to determine if she is morbidly obese according to the NIH criteria, we cannot immediately conclude that she is eligible for the trial. Further investigation into her BMI and eligibility for bariatric surgery would be necessary before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "51": {
        "output": "The patient described is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, and she is known to have hypertension and obesity. There is no mention of her having diabetes or impaired glucose tolerance. Additionally, there is no indication that she has undergone bariatric surgery, which is part of the study's second part. The patient's eligibility for the clinical trial titled \"The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study\" is based on the inclusion criteria provided:\n\n1. Lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance\n2. Obese (BMI >30 kg/m2) subjects also with normal glucose tolerance.\n3. Obese with impaired glucose tolerance\n4. Obese with diet-controlled diabetes mellitus\n5. Morbid obesity, type 2 diabetes, and post-bariatric surgery (study part 2)\n\nSince the patient is described as obese, she could potentially fit into categories 2, 3, or 4, but it is not clear from the patient note whether she has normal glucose tolerance, impaired glucose tolerance, or diet-controlled diabetes mellitus as there is no information regarding her glucose tolerance status.\n\nGiven the information available, the patient could potentially be eligible based on her obesity, but further investigation is required to determine her glucose tolerance status. Therefore, it is appropriate to consider referring the patient to the clinical trial upon further investigation to establish her glucose tolerance status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "52": {
        "output": "Based on the provided patient note and the clinical trial information, the patient presents with episodic chest pain, but there is no documentation of her having heart failure, which is the condition being studied in the clinical trial. The clinical trial is specifically interested in randomized controlled trials of beta-blocker therapy in patients with documented heart failure.\n\nSince the patient does not have a documented history of heart failure, she would not meet the inclusion criteria for this clinical trial. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "53": {
        "output": "",
        "label": 0
    },
    "54": {
        "output": "",
        "label": 0
    },
    "55": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea\n- Hypertension and obesity\n- Takes no medications\n- Normal physical examination\n- Nonspecific changes in EKG\n\nClinical Trial Inclusion Criteria:\n- Between the age of 19 and 55 years old\n- Able to walk without assistance and/or assistive devices at least 4.7 meters\n- Have adequate hearing acuity to detect verbal instructions\n- Have adequate visual acuity to walk safely in usual ambient lighting without holding onto objects\n- Be able to speak and comprehend English\n- Have sufficient cognitive ability to follow instructions, and to provide informed consent, as defined by a Mini Mental Status Examination score of greater than 23 out of 30, performed by the research coordinator\n\nThe patient does not meet the age requirement of the clinical trial (the patient is 58 years old, while the trial requires participants to be between 19 and 55 years old). Therefore, this patient would not be eligible for this clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "56": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it does not appear that the patient would be eligible for this trial. The patient presents with episodic chest pain, hypertension, and obesity, but there is no indication of a diagnosis of malignant pleural effusion or any cancer. The inclusion criteria for the trial specifically require a clinically confident diagnosis of malignant pleural effusion requiring pleurodesis, which is not mentioned in the patient's presentation. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "57": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient in question does not appear to meet the specific criteria required for participation in the trial. The inclusion criteria for the trial specify that participants must have Type 2 diabetes or Pre-Diabetes. The patient note does not mention that the patient has Type 2 diabetes or Pre-Diabetes; rather, it mentions hypertension and obesity without any reference to diabetes.\n\nGiven that the patient does not meet the key inclusion criteria for the clinical trial, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "58": {
        "output": "To assess the eligibility of the 58-year-old African-American woman for the clinical trial titled \"Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment,\" let's review the inclusion criteria against the patient's note:\n\n1. Patients over 18 years of age - The patient is 58 years old, which meets this criterion.\n2. Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg) - The patient has a known history of hypertension, but specific blood pressure values are not provided. We would need this information to determine eligibility definitively.\n3. Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation) - The patient note does not mention any previous treatment with ACE inhibitors, nor does it indicate any intolerance to such medications. This information would be needed to assess eligibility.\n\nBased on the information provided in the patient's note, there is not enough evidence to determine if the patient meets the second and third inclusion criteria for the clinical trial. Therefore, further investigation would be necessary to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "59": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment, let's assess the patient's eligibility:\n\nThe inclusion criteria for the clinical trial are:\n1. Healthy\n2. 20-49 years old\n3. Pregnant with a singleton\n4. Low back pain began during pregnancy and has lasted more than one week\n5. Low back pain is reproducible with palpation\n\nThe patient note describes a 58-year-old African-American woman who presents with episodic pressing/burning anterior chest pain. There is no indication that the patient is pregnant, which is a key inclusion criterion for the trial. Furthermore, the patient's age is outside the specified range of 20-49 years old. Additionally, the patient's symptoms do not match the requirement of low back pain that began during pregnancy.\n\nGiven these mismatches with the inclusion criteria, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "60": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No mention of sickle cell disease (SCD) or hemoglobinopathy\n- No mention of sPLA2 levels\n- No mention of fever or chest radiograph findings\n\nClinical Trial Inclusion Criteria:\n- Hemoglobin diagnosis of SS, SC, or S-\u03b2 thalassemia\n- No clinically apparent ACS\n- No prior participation in the study\n- For the Trial Cohort: sPLA2 level greater than 100 ng/mL, fever greater than 38.0\u00ba C, chest radiograph negative for new pulmonary infiltrate, hemoglobin levels equal or less than 10 g/dL, informed consent\n\nThe patient in the note does not mention a diagnosis of sickle cell disease, which is a key inclusion criterion for the study. Additionally, there is no information provided about sPLA2 levels, fever, or chest radiograph findings that are required for the trial cohort. Since the patient's presentation and medical history do not align with the specific requirements of the clinical trial, she does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "61": {
        "output": "The patient note describes a 58-year-old African-American woman who presents to the ER with symptoms that could be consistent with acute coronary syndromes, such as episodic pressing/burning anterior chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea. These symptoms align with the inclusion criteria for the clinical trial, which is investigating the biomarker copeptin in patients with Acute Myocardial Infarction (AMI). She meets the age criteria and presents with symptoms consistent with acute coronary syndromes. However, it is not explicitly stated when the symptoms began, except that the pain started two days earlier, and the latest episode ended half an hour prior to her arrival.\n\nThe inclusion criteria require that the subject must present to the Emergency Department within 6 hours of the onset of the most recent symptoms. Since it is not clear whether her most recent episode of pain, which ended half an hour prior to her arrival, started less than 6 hours before presenting to the ER, this information would need to be verified.\n\nAdditionally, the patient must agree to abide by all aspects of the protocol, including all telephone follow-up, which is not addressed in the patient note and would require further confirmation from the patient.\n\nGiven the information, the patient appears to meet most inclusion criteria but requires confirmation regarding the timing of the most recent symptoms and her agreement to follow the protocol.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "62": {
        "output": "The patient in the note is a 58-year-old African-American woman presenting with symptoms consistent with possible cardiac issues. The clinical trial in question is looking at the effectiveness of the MEND Programme in treating childhood obesity. The inclusion criteria for the clinical trial specifically require participants to be children aged 7-13 years old who are overweight or obese and are enrolled in the MEND Programme.\n\nBased on the information provided in the patient note, the patient does not meet the age criteria, as she is 58 years old, and the trial targets children between 7-13 years of age. Additionally, there is no mention of the patient being enrolled in the MEND Programme or her being a child with obesity.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "63": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can analyze the patient's eligibility for the trial as follows:\n\nThe patient:\n- Is a 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier.\n- Has pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- Has known hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Takes no medications.\n- Has a physical examination that is normal.\n- EKG shows nonspecific changes.\n\nThe clinical trial's inclusion criteria:\n- Patients with intermediate (>20%, <90%) risk of ischemic heart disease (IHD) based on age, gender, symptoms, and exercise stress test results.\n\nThe patient's presentation with episodic chest pain that began during exertion and is accompanied by other symptoms suggestive of cardiac ischemia (nausea, diaphoresis, mild dyspnea) could indicate an intermediate risk of ischemic heart disease. However, we do not have information about the results of an exercise stress test, which is a necessary component of the risk assessment according to the clinical trial's inclusion criteria.\n\nGiven that the patient presents with symptoms that could suggest IHD and the risk assessment is based on several factors, including symptoms, without additional information particularly the results of an exercise stress test, it is not possible to definitively determine the patient's risk level for IHD.\n\nTherefore, the patient might be a candidate for further investigation to establish her risk level of IHD, which would include an exercise stress test and potentially other assessments as per the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "64": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain.\n- The pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- She currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must have a medical history and physical and neurological examinations that support a clinical diagnosis of acute low back pain that is felt down to the lower leg below the knee, with the onset no longer than 30 days before Visit 1.\n- Patients must report qualifying pain intensity scores at Visit 1.\n- Patients must be appropriate candidates for treatment with oral opioid pain medication in the investigator's clinical judgment.\n- Patients must be able to verbalize pain characteristics and complete all protocol-required measurements/assessments without assistance.\n- Patients must be medically stable on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening.\n\nComparison:\n- The patient's symptoms are primarily related to chest pain, not low back pain. There is no mention of low back pain or pain that is felt down to the lower leg below the knee.\n- The onset of the patient's symptoms and whether they are associated with low back pain are not specified.\n- The patient's overall presentation does not seem to match the clinical diagnosis of acute low back pain required by the trial.\n\nGiven the information provided in the patient note, the patient's condition does not seem to meet the specific inclusion criteria related to the diagnosis of acute low back pain, which is the focus of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "65": {
        "output": "",
        "label": 0
    },
    "66": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we need to assess if the patient is eligible for the trial which is focused on patients with hypertension and obstructive sleep apnea (OSA) who are not well controlled on continuous positive airway pressure (CPAP) therapy.\n\nFrom the patient note:\n- The patient is 58 years old, which meets the age criterion of being \u2265 18 years.\n- The patient has hypertension, one of the conditions of interest for the trial.\n- There is no mention of the patient having obstructive sleep apnea or being treated with CPAP.\n- There is no information provided regarding the patient's blood pressure measurements to confirm if the hypertension is uncontrolled by the standards of the trial (systolic >130 mmHg or diastolic >80 mmHg).\n\nThe patient does not clearly meet two critical inclusion criteria:\n1. Diagnosis of OSA and treatment with CPAP.\n2. Uncontrolled hypertension despite CPAP therapy.\n\nWithout evidence of OSA or CPAP use, and without blood pressure readings, it's impossible to definitively conclude the patient's eligibility for the trial. Therefore, further investigation would be needed to determine if the patient has OSA, if they have been treated with CPAP, and if their hypertension is uncontrolled despite CPAP therapy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "67": {
        "output": "Based on the provided patient note, the 58-year-old African-American woman presents with episodic chest pain, hypertension, and obesity. However, there is no mention of type-II-diabetes mellitus in her medical history or current health status.\n\nThe inclusion criteria for the clinical trial titled \"Resistant Hypertension in Patients With Type-II-Diabetes Mellitus\" are:\n\n- Age 18-80 years\n- Informed consent\n- Hypertension\n- Type-II-diabetes mellitus\n\nThe patient does meet the age criteria and has hypertension but does not meet the criteria for type-II-diabetes mellitus, which is a requirement for this specific clinical trial. Therefore, she would not be a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "68": {
        "output": "Considering the patient note and the inclusion criteria for the clinical trial on Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- No medication currently taken.\n- No known history of smoking, diabetes, hypercholesterolemia, or family history of heart disease.\n- EKG shows nonspecific changes.\n\nClinical trial inclusion criteria:\n- Over 18 years old.\n- CCT > 60 ml/min (not provided in the patient note).\n- No IHD (Ischemic heart disease) (patient's condition suggests a need for differential diagnosis but IHD is not confirmed).\n- No hyper/hypoparathyroidism (not provided in the patient note).\n- No active malignancy (not provided in the patient note).\n- Not taking calcium, phosphate (patient is not currently taking any medications).\n\nBased on the information available from the patient note, the patient meets some of the inclusion criteria (age over 18, not currently taking exclusory medications). However, there is missing information about the patient's creatinine clearance (CCT), history of hyper/hypoparathyroidism, active malignancy, and whether she has ischemic heart disease (IHD), which would require further investigation before a referral could be made. The symptoms described in the patient note might be suggestive of a cardiac issue, which could potentially be IHD. This would need to be clarified as part of the further investigation.\n\nGiven the need for additional information to conclusively determine eligibility, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "69": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Pain not increased on inspiration\n- Known to have hypertension and obesity\n- No medications currently taken\n- Normal physical examination\n- EKG shows nonspecific changes\n- No history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Aged \u226518 years at the time of randomization\n- Presumed diagnosis of STE-ACS with onset of symptoms of >20 minutes and <12 hours with specific EKG criteria\n- Provided written informed consent before initiation of any study-related procedures\n- Presented either via ambulance or to a center where PCI is not performed\n- Emergent angiography and primary PCI if indicated <2 hours after first medical contact\n\nComparison:\n- The patient is 58 years old, which meets the age criterion.\n- The patient's symptoms could suggest acute coronary syndrome (ACS), but the EKG does not show ST segment elevation, new left bundle branch block, or the specific infero-lateral myocardial infarction pattern described in the trial's inclusion criteria.\n- Since the EKG changes are nonspecific and do not meet the trial's defined criteria for STE-ACS, the patient's condition does not align with the presumed diagnosis required for the trial.\n- There is no mention of the patient presenting via ambulance or to a center where PCI is not performed, nor is there any indication that written informed consent has been provided or that angiography and PCI are planned within the specified timeframe.\n\nGiven the information from the patient note, the patient does not appear to meet the specific diagnostic criteria for STE-ACS as required by the clinical trial. As such, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "70": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial in question. The patient presents with symptoms suggestive of cardiac issues, and there is no mention of allergic conjunctivitis or a positive bilateral conjunctival allergen challenge reaction, which are required for inclusion in the study on the efficacy of AC-150 for the treatment of allergic conjunctivitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "71": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents to the ER with symptoms that suggest she may be experiencing angina: episodic pressing/burning anterior chest pain that began while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. She also has a history of hypertension and obesity.\n\nThe clinical trial in question is looking to compare vascular remodeling between different antianginal medications. It mentions specific inclusion criteria related to the type of angina and the treatment history:\n\n1. Stable angina patients whose coronary lesions are confirmed by angiography or who receive PCI.\n2. Unstable Angina/NSTEMI patients who completed PCI for main lesions.\n3. Patients with either systolic blood pressure > 130 mmHg or diastolic > 80 mmHg, or patients on anti-hypertensive drugs.\n\nThe patient in the note presents with hypertension and is likely to have a systolic blood pressure > 130 mmHg or diastolic > 80 mmHg, although specific blood pressure values are not provided. However, the inclusion criteria also require confirmation of coronary lesions by angiography or a history of PCI, which is not mentioned in the patient's history.\n\nGiven the lack of specific information on confirmed coronary lesions or PCI history, and the fact that the woman is presenting with her first episode of this kind of chest pain, it is not clear if she would meet the specific clinical requirements for the trial. There is a possibility she could be experiencing stable angina, but further investigation is needed to confirm this and whether her condition fits the trial's requirements. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "72": {
        "output": "Given the information provided in the patient note, we know the following:\n\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain.\n- She has a history of hypertension and obesity.\n- She is a non-smoker.\n- Her physical examination is normal, with nonspecific EKG changes.\n\nNow, comparing this to the inclusion criteria of the clinical trial:\n\n- Subjects with BMI over 25.0 kg/m^2\n- Non-smoker\n\nThe patient note confirms that the patient is obese and a non-smoker, which matches the inclusion criteria of the clinical trial. However, there is no specific Body Mass Index (BMI) value provided in the patient note. Since the patient is described as obese, it can be inferred that her BMI is over 30 kg/m^2, which would meet the criterion of a BMI over 25.0 kg/m^2.\n\nBased on the information given, it seems that the patient does meet the inclusion criteria of being overweight/obese and a non-smoker. There are no other exclusion criteria provided that would disqualify the patient from participating in the trial based on the information available in the patient note.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "73": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility step by step.\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain that started while walking, with radiation to the back, nausea, diaphoresis, and mild dyspnea.\n- The patient has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of unstable angina and non-Q wave myocardial infarction\n- Age 18-75 years\n- Diameter stenosis of coronary artery <70% diameter stenosis by visual estimation\n- Blood pressure >110/70 mmHg\n- Heart rate 60-100 bpm\n- No cardiac arrhythmias\n\nEligibility Assessment:\n- Age: The patient is 58 years old, which falls into the required age range of 18-75 years.\n- Diagnosis: The patient presents with chest pain that could possibly be due to unstable angina; however, there is no confirmed diagnosis of unstable angina or non-Q wave myocardial infarction provided in the note.\n- Diameter stenosis: There is no information about the patient having a confirmed diameter stenosis of the coronary artery.\n- Blood pressure: The patient's blood pressure is not mentioned in the note.\n- Heart rate: The patient's heart rate is not mentioned in the note.\n- Cardiac arrhythmias: The patient's EKG shows nonspecific changes, but there is no mention of cardiac arrhythmias.\n\nGiven the provided information, we cannot confirm that the patient has a diagnosis of unstable angina or non-Q wave myocardial infarction, nor do we have data on coronary artery stenosis, blood pressure, or heart rate. Due to the lack of specific diagnostic information and other required clinical parameters, the patient does not clearly meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "74": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, hypertension, and obesity. She does not have a history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease and takes no medications.\n\nThe clinical trial is assessing the use of E-Z Clean ACE electrosurgical electrodes in certain surgical procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lift, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.\n\nUpon reviewing the inclusion criteria for the clinical trial, the patient does not meet the criteria for several reasons:\n1. There is no indication that the patient is undergoing any of the listed surgeries (abdominoplasty, bilateral breast reduction, etc.).\n2. The patient's current medical condition (chest pain, hypertension, obesity) is not related to the target of the clinical trial, which is focused on surgical procedures.\n3. The patient's age fits within the specified range (>18 years of age or < 60 years old), which is the only matching criterion.\n\nSince the patient does not meet the necessary clinical trial criteria aside from age, it would not be appropriate to refer her for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "75": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nPatient note summary:\n- 58-year-old African-American woman with episodic anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- No current medications.\n- Physical examination normal.\n- EKG shows nonspecific changes.\n\nClinical trial inclusion criteria:\n- Ischemic heart disease patient.\n- Given loading or maintenance dose of clopidogrel and in need of it for 1 or more months.\n- In need of additional drug for optimal blood pressure control (aim blood pressure <130/90) or angina control.\n\nThe patient presents with symptoms suggestive of ischemic heart disease (angina-like chest pain) and is known to have hypertension, which might require additional medication for optimal blood pressure control. However, there is no clear indication that she has been diagnosed with ischemic heart disease or that she is currently taking clopidogrel, which are both required for participation in the clinical trial.\n\nTherefore, before referring this patient to the clinical trial, further investigation is required to confirm a diagnosis of ischemic heart disease and to determine whether she is a candidate for clopidogrel therapy. If these conditions are met, she may also require additional medication for blood pressure control, which aligns with the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "76": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic anterior chest pain, known to have hypertension, and is not currently taking any medications. The clinical trial in question is investigating the tolerability of telmisartan treatment in patients who had to stop previous ACE-I treatment due to cough.\n\nLet's assess this patient's eligibility for the trial based on the inclusion criteria:\n\n- Hypertension: The patient has hypertension.\n- Age > 18: The patient is 58 years old.\n- ACE-I related cough: There is no mention in the patient note of her having a cough related to ACE-I treatment. In fact, the patient currently takes no medications, which implies she has not been on ACE-I treatment, or at least not recently.\n\nBased on the information provided, this patient does not meet all the inclusion criteria specifically because there is no evidence of an ACE-I related cough or previous treatment with an ACE-I.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "77": {
        "output": "The patient is a 58-year-old African-American woman presenting with chest pain, known hypertension, and obesity. She does not have a history of cancer, specifically no mention of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx supraglottix, or any cancer for that matter. The clinical trial in question is specifically looking for patients with histologically confirmed squamous cell carcinoma in specific regions of the head and neck, with locally advanced disease.\n\nThe patient's presentation does not meet the inclusion criteria for the clinical trial, which are clearly defined and centered around a specific cancer diagnosis and stage. As such, this patient would not be eligible for the clinical trial focused on the treatment of locally advanced head and neck cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "78": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note summary:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea but no increase in pain on inspiration.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- She is not on any medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n- There is no mention of the patient having acute renal failure (ARF) or requiring renal replacement therapy.\n\nClinical trial summary:\n- The study is comparing continuous versus intermittent hemodialysis in ICU patients.\n- The inclusion criteria are all ICU patients requiring renal replacement therapy.\n\nAssessment of eligibility:\nThe patient does not meet the inclusion criteria for the clinical trial, as there is no indication that she has acute renal failure or is in need of renal replacement therapy. As such, she is not a candidate for a trial that is focused on patients with ARF who are in the ICU requiring renal replacement therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "79": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Treatment of Coronary Heart Disease With Amiloride,\" let's assess the patient's eligibility:\n\nPatient's characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Male or female; age 35-75 years having angina (Canada Cardiovascular Society Class II-IV)\n- Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure \u2265140 mm Hg, or diastolic blood pressure \u226590 mmHg\n- ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)\n- ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)\n- Serum potassium < 5.0 mmol/L prior to randomization\n- Negative pregnancy test in child-bearing potential women\n- Willing to comply with scheduled visits\n- Informed consent form signed by the subject\n\nFrom the information provided:\n- The patient is within the age range specified (35-75 years).\n- The patient is known to have hypertension, which could meet the hypertension requirement if documented blood pressure readings are within the specified range or if she starts taking anti-hypertensive medication.\n- The patient has chest pain, which might be angina, but this is not confirmed as being of the Canada Cardiovascular Society Class II-IV. Further investigation would be needed to determine the classification of her angina.\n- The EKG shows nonspecific changes, which does not clearly meet the criteria for ST-T changes of LVH or ischemia. More detailed ECG analysis or additional tests may be required to clarify this.\n- Serum potassium levels are not reported, so this would need to be measured.\n- Assuming she is not pregnant and willing to give informed consent, the last two criteria could be met.\n\nDue to the lack of specific information regarding the classification of the patient's chest pain, the detailed blood pressure measurements, the exact nature of the EKG changes, and the serum potassium level, I would not be able to refer this patient for the clinical trial without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "80": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No mention of chronic low back pain or use of pain medication for such pain\n- No information about waist circumference\n- No mention of episodes of low back pain or ability to participate in exercise\n- No information about cardiovascular responses during a screening graded maximal walk test\n\nClinical Trial Inclusion Criteria:\n- Chronic low back pain for >6 months\n- >3 pain episodes per week\n- Waist circumferences \u226588 cm for women\n- Willing and able to participate in regular exercise for 14 weeks\n- Using pain medications to control low back pain\n- Free of abnormal cardiovascular responses during a screening graded maximal walk test\n\nComparison:\n- The patient does not mention having chronic low back pain, which is a primary requirement for the clinical trial.\n- There is no information on the frequency of pain episodes or use of pain medication for back pain, as the patient's presenting symptoms are related to chest pain.\n- The patient's waist circumference is not provided.\n- We do not have information on the patient's willingness or ability to participate in an exercise program or the results of a cardiovascular screening test.\n\nConclusion:\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which specifically targets obese older adults with chronic low back pain. Since the patient's presenting problem is unrelated to the focus of the study, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "81": {
        "output": "Assessing the eligibility of the 58-year-old African-American woman for the clinical trial titled \"Expressive Writing for Heart Healing\" based on the inclusion criteria provided:\n\nInclusion Criteria for the Trial:\n1. Obesity\n2. Ischemic Heart Disease (IHD)\n3. Signed informed consent\n\nPatient Information:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nThe patient fulfills the criterion for obesity. However, there is currently no specific diagnosis of Ischemic Heart Disease (IHD) mentioned in the patient's note. The symptoms described could be suggestive of IHD, and further investigation such as cardiac enzyme tests, further EKGs, or imaging might be warranted to confirm a diagnosis of IHD.\n\nGiven the information provided, the patient meets the criterion of obesity but has not been confirmed to have Ischemic Heart Disease. Therefore, she would not be immediately eligible for the trial based on the criteria provided. Further investigation into the cause of her chest pain is needed to determine if it is due to IHD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "82": {
        "output": "",
        "label": 0
    },
    "83": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study,\" we must compare the patient's characteristics and conditions to the inclusion criteria of the study.\n\nThe inclusion criteria specify:\n\n1. Age 18 to 80, male or female.\n2. Patients must fulfill the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin for the previous 3 months (with symptom onset at least 6 months before diagnosis), including all of the following:\n   - Midline chest pain or discomfort that is not of burning quality.\n   - Absence of evidence that gastroesophageal reflux is the cause of the symptom.\n   - Absence of histopathology-based esophageal motility disorders.\n3. Persistent symptoms despite a trial of antidepressant therapy, as defined by either:\n   - Chest pain despite at least a continuous 4-week trial of at least one antidepressant within the last 6 months; or\n   - Intolerance of at least one antidepressant within the last 6 months.\n4. Negative cardiac evaluation (negative cardiac stress test or negative coronary angiogram).\n5. Negative gastrointestinal evaluation for the cause of the pain, defined by the absence of Los Angeles grade C or D erosive esophagitis on endoscopy, persistent chest pain on PPI therapy, and no association of chest pain with reflux episodes on an ambulatory pH or pH-impedance study, defined as a symptom index <50% or symptom association probability <95% for chest pain.\n\nThe patient note presents a 58-year-old African-American woman with episodic pressing/burning anterior chest pain that began two days earlier. She has a history of hypertension and obesity but no history of heart disease or gastroesophageal reflux disease (GERD). She has not been on any medications, including antidepressants.\n\nFrom the information provided, the patient:\n\n- Meets the age criterion (1).\n- Does not meet the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin (2) as the patient's chest pain is of burning quality.\n- Does not have a documented trial of antidepressant therapy for chest pain, nor is there mention of intolerance to such therapy (3).\n- The patient's cardiac evaluation has nonspecific changes, but it's unclear if a full cardiac workup including stress tests or coronary angiograms has been performed (4).\n- There is no information on a gastrointestinal evaluation for the cause of the pain, including endoscopy or pH-impedance study (5).\n\nGiven the information available, the patient does not clearly meet several of the inclusion criteria, particularly those related to the specific type of chest pain and the required trials of antidepressant therapy. Additionally, we lack information on formal cardiac and gastrointestinal evaluations. Based on the information provided, the patient would not be eligible for the trial as the chest pain does not fit the characteristics defined by the inclusion criteria, and there is no documented trial of antidepressant therapy or completion of the required evaluations.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "84": {
        "output": "After reviewing the patient's details and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Details:\n- A 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Currently takes no medications\n- Physical examination is normal\n- The EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Major\n- Men\n- Obese BMI>30\n- No aspirin treatment before inclusion\n- Coronary exploration: coronary angiography or tomography coronary angiography\n- Chest pain like stable angina\n\nAssessment:\nThe patient meets some of the inclusion criteria such as being obese. However, the major inclusion criteria specify \"Men,\" which implies that the study is looking specifically for male participants. Given that the patient is a woman, she does not meet this criterion. Additionally, there's no information provided about whether she has undergone coronary exploration (coronary angiography or tomography coronary angiography), which is another inclusion criterion.\n\nTherefore, despite the patient having some of the conditions of interest (obesity and chest pain like stable angina), she does not meet the gender requirement, which is a major inclusion criteria for the trial. Hence, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "85": {
        "output": "The patient is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, known hypertension and obesity, and no medications. The clinical trial is looking to study the contribution of osteopathy on the reduction of pain in adult patients with cystic fibrosis.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Diagnosis of cystic fibrosis (positive sweat test and/or presence of 2 disease-causing mutations in the CFTR gene)\n- Age > 18 years\n- Patient with chronic chest, neck, or back pain\n- Written Informed Consent\n- With health insurance\n\nBased on the information provided in the patient note, there is no mention of the patient having cystic fibrosis or a diagnosis that fits the inclusion criteria for the clinical trial. Therefore, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "86": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient, a 58-year-old African-American woman presenting with chest pain, does not meet the inclusion criteria which specifically require a positive bilateral conjunctival allergen challenge (CAC) reaction, indicating allergic conjunctivitis. Since the patient's symptoms and medical history do not suggest allergic conjunctivitis, and there is no mention of a positive CAC reaction, she would not be eligible for this clinical trial focused on the efficacy of AC-170 for treating allergic conjunctivitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "87": {
        "output": "",
        "label": 0
    },
    "88": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not appear to meet the necessary criteria for this specific clinical trial. The trial is targeting patients with asthma or COPD, and there is no mention of either condition in the patient's history. Instead, the patient presents with symptoms that could be indicative of a cardiac issue, such as chest pain, which is not relevant to the criteria for this trial.\n\nThe inclusion criteria for the trial are:\n1. A documented diagnosis of asthma or COPD in accordance with guidelines.\n2. A stable condition, defined as a disease without exacerbation for at least 1 month prior to study enrolment.\n3. A mean heart rate (HR) in Holter ECG recording of \u2265 60 bpm.\n\nThe patient note does not mention asthma or COPD, nor is there any information about a heart rate measurement or the stability of any chronic obstructive airway disease.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "89": {
        "output": "",
        "label": 1
    },
    "90": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion and exclusion criteria, the patient appears to have symptoms that could suggest acute coronary syndrome (ACS), such as episodic pressing/burning anterior chest pain that started during physical activity, with accompanying nausea, diaphoresis, and mild dyspnea. The patient's age (58 years old) and her racial background (African-American) are also consistent with the inclusive nature of the trial, which does not specify any racial or ethnic restrictions.\n\nThe inclusion criteria for the trial are as follows:\n- Acute myocardial infarction, acute coronary syndrome, unstable angina\n- Men and women\n- All races and ethnicities\n\nThe exclusion criteria for the trial are as follows:\n- Age < 21 years\n\nThe patient does not fall into the exclusion criteria, as she is 58 years old. Given that the patient's symptoms could be consistent with ACS and the trial is looking for individuals with ACS care-seeking behavior, it would be appropriate to consider referring this patient for further evaluation to confirm the diagnosis and determine her eligibility for the clinical trial. It is important to note that a definitive diagnosis of ACS is not confirmed in the patient note, but the symptoms are suggestive enough to warrant further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "91": {
        "output": "Given the patient's description and the clinical trial's inclusion criteria, we can assess the eligibility of the patient for the trial.\n\nPatient's characteristics:\n- Age: 58 years old\n- Gender: Female\n- Known health conditions: Hypertension, obesity\n- No medications currently being taken\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n\nClinical trial's inclusion criteria:\n- Age 18 to 50 years\n- Understanding and willingness to sign informed consent\n- Ability to participate in all study aspects and comply with study requirements\n- BMI of 40 - 45 or 30 to 39.9 with one or more co-morbid diseases (hypertension, dyslipidemia, obstructive sleep apnea, diabetes mellitus)\n- Fully ambulatory without chronic reliance on walking aids\n- Sufficient and stable medical health\n- Has a primary care physician\n- Has failed standard obesity therapy\n- Agrees to refrain from certain surgeries affecting body weight during the trial\n\nBased on the above information, the patient does not meet the age criterion for the clinical trial, which specifies that participants must be between 18 and 50 years old. The patient is 58 years old, which is outside the specified age range.\n\nIn this case, no further investigation is needed as the age criterion is a hard stop, and the patient does not qualify for the trial based on this critical inclusion criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "92": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman has a history of hypertension, which is one of the inclusion criteria for the clinical trial. However, there is no mention of her being treated with angiotensin converting enzyme (ACE) inhibitors, which is another requirement for eligibility in the trial.\n\nThe clinical trial is focused on patients who are already being treated with ACE inhibitors and aims to study the effects of switching to Angiotensin II Receptor Type I (AT1) blockers. Since the patient is not currently taking any medications, including ACE inhibitors, she does not meet this specific inclusion criterion.\n\nTherefore, the patient would not be eligible for this clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "93": {
        "output": "In reviewing the patient's information and comparing it to the inclusion criteria of the clinical trial, we can determine the patient's eligibility:\n\nPatient's Characteristics:\n- A 58-year-old African-American woman\n- Presents with chest pain, hypertension, and obesity\n- No history of cancer mentioned\n- No medications currently taken\n\nClinical Trial Inclusion Criteria:\n- Patient age 18 years or older who self-identifies as African-American (the patient meets this criterion)\n- In early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancer (the patient's note does not mention breast cancer)\n- Receiving health care primarily through an HMO (no information is given regarding this)\n- Exclusion for breast cancer survivors with other major disabling medical conditions (the patient's note does not mention any psychiatric or substance abuse conditions)\n\nBased on the available information, the patient does not meet the key inclusion criterion of being a breast cancer survivor. Therefore, she would not be eligible for this clinical trial focused on breast cancer survivors.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "94": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial on chronic stable angina, let's evaluate the patient's eligibility:\n\n- The patient is a 58-year-old African-American woman. This meets the age requirement of >20 years set by the study.\n- The patient presents with episodic pressing/burning anterior chest pain that started while walking, which could be consistent with effort-induced angina. However, there is no mention of the pain being relieved by rest or nitroglycerin, nor is there any mention of catheterization-documented coronary artery disease or previous myocardial infarction.\n- The patient does not have a history of myocardial infarction within the preceding 3 months, which fits the exclusion criteria.\n- The EKG shows nonspecific changes, not necessarily indicative of ST-segment depression, which is a requirement for inclusion (positive ETT with ST-segment depression \u2265 1 mm).\n- There are no details provided about the patient's menopausal status, contraception use, lactation status, or pregnancy test results, which are necessary to fully assess eligibility. However, these could potentially be determined with further investigation.\n- The patient's physical examination is normal, and there is no mention of any conditions that would interfere with performance of an exercise tolerance test.\n\nGiven the information available, the patient may potentially have effort-induced angina but does not clearly meet all the inclusion criteria for the clinical trial. Specifically, there is a lack of documented coronary artery disease or previous myocardial infarction and no clear evidence of a positive ETT. Therefore, further investigation would be needed to determine her eligibility, such as confirming the nature of her chest pain and conducting an exercise tolerance test to meet the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "95": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block\", let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- Age: 58 years old, which falls within the 18 - 75 years age range required by the trial.\n- Symptoms: The patient presents with episodic pressing/burning anterior chest pain, which began two days earlier and could be considered as ischemic discomfort. The pain is at rest and has been present for more than 20 minutes within the previous 24 hours.\n- EKG findings: The EKG shows nonspecific changes; there is no mention of left bundle-branch block (LBBB).\n- Additional factors: The patient has hypertension and obesity, but there is no mention of acute coronary syndrome (ACS) or the need for urgent coronary angiography.\n\nThe inclusion criteria for the trial are as follows:\n- Age 18 - 75 years (the patient meets this criterion).\n- Ischemic discomfort at rest \u226520 minutes within previous 24 hours (the patient meets this criterion based on the description).\n- Any LBBB on the EKG (the patient's EKG does not mention LBBB).\n- Urgent coronary angiography, ideally within 90 minutes after admission (there is no information provided about the need for urgent coronary angiography).\n\nSince the patient's EKG does not show LBBB, one of the key inclusion criteria for the trial is not met. Therefore, despite meeting other criteria, this factor alone would exclude the patient from participating in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "96": {
        "output": "Based on the provided patient note and the inclusion criteria for the GENOCOR clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, which could be indicative of ischemic heart disease.\n- The pain started while she was walking and radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- No current medications are being taken.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Patients affected by a history of ischemic heart disease (IHD) with a non-fatal evolution (angina or AMI as the first manifestation).\n- Age at the onset of the disease (<50 or >60 years).\n- Patients with acute coronary syndrome as the first manifestation of coronary disease, admitted to the coronary unit within 6 hours from the onset of symptoms.\n\nComparative Assessment:\n- The patient's age fits one of the criteria for the trial (>60 years).\n- The patient's symptoms could suggest an acute coronary syndrome, which is relevant to the trial's focus on ischemic heart disease.\n- However, there is no clear indication that the patient has a confirmed diagnosis of IHD or that this is the first manifestation of coronary disease.\n- There is no information on whether the patient was admitted to the coronary unit within 6 hours from the onset of symptoms.\n\nConclusion:\nGiven the potential relevance of the patient's symptoms to ischemic heart disease and the fact that her age aligns with the inclusion criteria, further investigation is needed to confirm a diagnosis of IHD or acute coronary syndrome. If confirmed, she could potentially fit the trial's criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "97": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific requirements for the clinical trial that focuses on sacroiliac joint pain. The patient presents with episodic pressing/burning anterior chest pain, which is unrelated to sacroiliac joint pain. Furthermore, there is no mention of unilateral pain near the sacroiliac joint or positive results on sacroiliac joint provocation tests. The symptoms and history given in the patient note suggest a cardiovascular rather than musculoskeletal issue.\n\nTherefore, this patient would not be a suitable candidate for the clinical trial on the effectiveness of the compression belt for patients with sacroiliac joint pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "98": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, this patient does not appear to be a candidate for the clinical trial in question. The patient presents with symptoms potentially indicative of cardiovascular issues (chest pain, nausea, diaphoresis, and mild dyspnea), while the clinical trial is focused on patients with Primary Open Angle Glaucoma (POAG) and involves assessing intraocular pressure (IOP) fluctuations in relation to a specific surgical intervention (Deep Sclerectomy With Collagen Implant).\n\nThe inclusion criteria for the clinical trial specifically mention:\n- Diagnosis of POAG\n- Documented glaucomatous visual field (VF) damage\n- Progressing glaucomatous damage justifying a surgical procedure (DSCI)\n- Age \u226518 years\n- Specific requirements regarding refractive error of the study eye\n\nThe patient note does not indicate that the patient has POAG or any visual field damage. There is no mention of glaucoma or any related treatments, surgeries, or symptoms. The patient's presentation is unrelated to the diseases and conditions being studied in the trial, and there is no information to suggest that she would meet the specific requirements for refractive error, as her visual status is not discussed.\n\nTherefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "99": {
        "output": "",
        "label": 0
    },
    "100": {
        "output": "Based on the information provided in the patient note, the 58-year-old African-American woman presents with episodic pressing/burning anterior chest pain, hypertension, and obesity. She does not have a history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease. Her EKG shows nonspecific changes, and there is no mention of inappropriate sinus tachycardia or any heart rate measurements.\n\nThe inclusion criteria for the clinical trial on Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia require a diagnosis of inappropriate sinus tachycardia characterized by a heart rate (HR) greater than 100 bpm at rest on an ECG and/or a medium Holter ECG HR greater than 90 bpm, in addition to being over 18 years of age.\n\nGiven that the patient note does not provide any information on the patient's heart rate or a diagnosis of inappropriate sinus tachycardia, we cannot conclude that she meets the inclusion criteria based on the data provided. Therefore, further investigation would be needed to assess her heart rate and determine if she has inappropriate sinus tachycardia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "101": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient does not appear to meet the specific conditions required for the clinical trial in question. The clinical trial is specifically for HER-2 negative metastatic breast cancer patients, and there is no indication in the patient note that the woman has been diagnosed with breast cancer, let alone HER-2 negative metastatic breast cancer. Instead, the patient presents with symptoms that may be indicative of a cardiac issue, not cancer.\n\nThe clinical trial inclusion criteria also require the patient to have had exposure to anthracyclines and taxanes in either a neoadjuvant/adjuvant or metastatic setting and to have documented disease progression after the first or second line of treatment. None of these details is provided in the patient's note, which further supports the idea that the patient does not have a history of breast cancer treatment.\n\nSince the patient does not have a documented diagnosis of metastatic breast cancer, nor any treatment history that aligns with the inclusion criteria of the trial, she is not eligible to participate in this clinical study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "102": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with episodic anterior chest pain, which is non-acute since it started two days earlier. The pain is not increased on inspiration, and she has a history of hypertension and obesity, which are risk factors for coronary artery disease (CAD). However, she denies other risk factors such as diabetes, hypercholesterolemia, or a family history of heart disease. The EKG shows nonspecific changes.\n\nThe clinical trial in question is focused on the use of CT calcium scoring in patients with suspected stable angina. The inclusion criteria specify that the patient should have non-acute chest pain, should have undergone CT calcium scoring, and all relevant risk factor information should be available.\n\nThe patient appears to have non-acute chest pain, which is one of the inclusion criteria. However, it is not indicated in the patient note whether she has undergone CT calcium scoring or if all relevant risk factor information is available. For a patient to be eligible for this trial, it is necessary to have already undergone a CT calcium scoring or to be a candidate for such a test based on the clinical assessment.\n\nGiven the information presented, it's not entirely clear whether the patient has undergone CT calcium scoring, which is a critical part of the trial's inclusion criteria. The patient does have non-acute chest pain, which is aligned with the trial's focus, but the absence of CTCS in her history makes her eligibility uncertain.\n\nTherefore, additional information would be needed to determine her eligibility. If she is a candidate for CT calcium scoring, she could potentially be referred to the trial. However, without confirmation that she meets all the inclusion criteria, it would not be appropriate to refer her at this time.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "103": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, it appears that the patient's condition does not match the focus of the study. The patient presents with symptoms that are suggestive of a cardiac issue rather than a renal condition. The clinical trial is specifically evaluating the protective effects of certain substances against renal injuries induced by extracorporeal shock wave lithotripsy in patients with a solitary renal stone.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Well functioning kidney (serum creatinine <1.2 mg/dl).\n2. Solitary renal stone.\n3. Size: 25 mm or less in the largest diameter.\n\nThe patient note does not mention any renal issues, kidney stones, or the need for extracorporeal shock wave lithotripsy. Instead, it describes a presentation that could be consistent with an acute coronary syndrome or other cardiac conditions, which is unrelated to the focus of the clinical trial.\n\nTherefore, the patient described in the note does not meet the inclusion criteria for the clinical trial, and I would not refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "104": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman who presents with episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The patient's current condition does not indicate that she has been diagnosed with severe hypertension based on the provided note; however, she is known to have hypertension, which is a relevant factor. \n\nThe inclusion criteria for the clinical trial are a diagnosis of severe hypertension, which must be determined through current findings, medical history, and physical examination.\n\nGiven that the patient note indicates a history of hypertension, it is possible that further investigation could reveal whether her hypertension is considered severe, which would make her eligible for the study. Therefore, the patient may be a candidate for the clinical trial upon further investigation to confirm the severity of her hypertension.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "105": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question does not meet the inclusion criteria for the clinical trial. The trial is specifically interested in women undergoing an Elective Lower Segment Caesarean Section (EL LSCS) with a viable, singleton pregnancy of at least 37 weeks gestation. The patient presenting to the ER does not fit this description, as there is no mention of her being pregnant or undergoing an EL LSCS. Additionally, the clinical trial is focused on the haemodynamic and cardiovascular effects of carbetocin and oxytocin during and after this specific type of caesarean section, which is not relevant to the patient's presenting symptoms of chest pain.\n\nTherefore, the patient is not eligible for this clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "106": {
        "output": "",
        "label": 2
    },
    "107": {
        "output": "Based on the patient note provided, the patient is a 58-year-old African-American woman who presents with episodic pressing/burning anterior chest pain that began for the first time in her life, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. She has hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. The patient takes no medications, and the physical examination is normal with nonspecific changes in the EKG.\n\nThe clinical trial in question is focused on the usefulness of chest wall tenderness as a bedside test to exclude acute coronary syndrome in different demographic groups. The inclusion criteria for the trial are:\n\n- All patients over the age of 18 years presenting with the leading symptom of first-time or recurrent acute chest pain in the emergency room.\n- The exclusion criteria include missing informed consent, cardiopulmonary unstable patients, no self-reported chest pain, recent thoracic surgery within 1 year, inflammatory joint disease, fibromyalgia, and cardiogenic shock.\n\nThe patient in question meets the age requirement and presents with acute chest pain, which is the leading symptom required for inclusion in the study. There are no indications in the patient note that she is cardiopulmonary unstable, has not provided informed consent, or has any of the other listed exclusion criteria.\n\nTherefore, based on the information provided in the patient note and the inclusion/exclusion criteria of the clinical trial, the patient seems to be an appropriate candidate for this study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "108": {
        "output": "",
        "label": 0
    },
    "109": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Efficacy of Euminz\u00ae for Tension-Type Headache,\" we will assess the patient's eligibility for the trial.\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea. The symptoms started while she was walking and are not increased on inspiration. She has a history of hypertension and obesity. The EKG shows nonspecific changes.\n\nThe inclusion criteria for the trial are:\n- Male and female patients from 18 years onwards\n- History of episodic tension-type headache (ETTH) for at least one year, with \u22652 days per month with such a headache\n- Onset of TTH below 65 years of age\n- At least 10 previous headache attacks meeting specific criteria (lasting 30 minutes to 7 days, certain pain characteristics, not accompanied by nausea/vomiting, not accompanied by both photophobia and phonophobia)\n- 3 months retrospective history\n- Willingness and ability to keep a patient's diary and comply with procedures\n- Written informed consent\n\nThe patient's symptoms are more indicative of chest pain rather than tension-type headache. The pain does not meet the criteria for TTH, such as pressing or tightening quality, bilateral location, and not being aggravated by routine physical activity. Additionally, the patient's headache is not described, and there is no indication that she meets the criteria related to the headache characteristics required by the trial.\n\nGiven the information in the patient note, there is no evidence that this patient has a history of ETTH, and her current symptoms do not align with the characteristics of TTH as described in the inclusion criteria.\n\nTherefore, this patient does not meet the inclusion criteria for the \"Efficacy of Euminz\u00ae for Tension-Type Headache\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "110": {
        "output": "To assess this patient's eligibility for the clinical trial titled \"The ACS Ethnicity Platelet Function Study,\" we need to compare the patient's characteristics and condition with the inclusion criteria provided by the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Female (postmenopausal or surgically sterile) and/or male aged 18 years or older.\n2. Presenting with Acute Coronary Syndrome (ACS) fulfilling the following:\n   - Symptoms or new ECG changes (ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG).\n   - Elevation of biomarkers (CK-MB \u22652 ULN or troponin \u2265 ULN).\n3. Self-identified as African-American.\n4. Treatment with 75-100mg ASA daily.\n\nThe patient note provides the following information:\n\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Physical examination is normal, but the EKG shows nonspecific changes.\n- There is no information provided about the patient's menopausal status, biomarker levels, or if she is taking ASA (Aspirin).\n\nBased on the information provided:\n\n- The patient is African-American, which meets one of the inclusion criteria.\n- The patient is a woman, and while her menopausal status is not specified, her age suggests she could be postmenopausal, which would meet the gender and age criteria.\n- The patient has chest pain and nonspecific EKG changes, which could suggest ACS, but we do not have information about ST segment elevation/depression or biomarker levels to confirm ACS according to the trial's definition.\n- There is no information on ASA treatment.\n\nGiven the lack of specific information on menopausal status, biomarker levels, and ASA treatment, it is unclear whether the patient fully meets all the inclusion criteria. Therefore, further investigation would be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "111": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman is presenting with episodic pressing/burning anterior chest pain, which started while walking and is accompanied by nausea, diaphoresis, and mild dyspnea. There is no mention of her experiencing chronic low back pain, nor is there any indication that she has a neuropathic pain component in her condition. The clinical trial in question is specifically for patients with severe chronic low back pain with a neuropathic component, and since the patient's symptoms do not match the trial's inclusion criteria, she would not be eligible for this trial.\n\nTo summarize, the patient:\n- Does not have a diagnosis of chronic low back pain.\n- There is no mention of her pain requiring a strong analgesic or having a pain intensity score of 6 points or higher.\n- There is no provided painDETECT diagnostic screening questionnaire score.\n- There are no details suggesting her pain has a neuropathic component.\n\nGiven the mismatch between the patient's condition and the trial's inclusion criteria, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "112": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the specific requirements for the trial. The trial is specifically for patients with Pulmonary Arterial Hypertension (PAH) who have already completed a previous study (AC-055-401). The patient in the note presents with symptoms that may suggest a cardiovascular issue, but there is no mention of a PAH diagnosis or participation in the specified prior study. Additionally, the patient's current medical presentation is not directly related to PAH or the trial's focus.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "113": {
        "output": "Based on the information provided, let's evaluate the patient's eligibility for the clinical trial titled \"Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease\":\n\n1. The patient has hypertension, which could potentially lead to left ventricular hypertrophy (LVH), but there is no indication in the note that she has been diagnosed with LVH or that an echocardiogram has been performed to determine LVMI.\n\n2. The patient has no documented history of diabetes and is not currently taking any medications, which suggests that she may have normal glucose tolerance; however, this has not been confirmed with testing.\n\n3. The patient's presentation of chest pain could be indicative of coronary artery disease (CAD) or a previous myocardial infarction, but this has not been confirmed. The patient has not been documented to have angiographically documented coronary artery disease or a previous history of myocardial infarction.\n\n4. The patient's blood pressure is not provided in the note, so we cannot confirm whether it meets the trial's criteria (office BP < 130/80 mm Hg).\n\n5. There is no evidence in the provided note that the patient has been diagnosed with ischemic heart disease (IHD).\n\nBased on the information available in the patient note, we do not have sufficient evidence to confirm that the patient meets the inclusion criteria for the clinical trial. Specifically, we lack confirmation of normal glucose tolerance, documented IHD, and the presence of LVH. Additionally, there is no information on the patient's blood pressure readings.\n\nTherefore, the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "114": {
        "output": "",
        "label": 0
    },
    "115": {
        "output": "The patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of an acute coronary syndrome (ACS), such as chest pain, nausea, diaphoresis, and mild dyspnea. However, the patient note does not confirm a diagnosis of STEMI or NSTEMI, which is a requirement for the clinical trial in question.\n\nThe clinical trial is focused on patients hospitalized for ACS within 24 hours of symptom onset with a confirmed diagnosis of STEMI or NSTEMI. In this case, the patient is in the ER, and there is no mention of hospitalization or a confirmed diagnosis of STEMI or NSTEMI, only nonspecific EKG changes.\n\nBased on the information provided, we cannot confirm whether this patient would meet the inclusion criteria of being hospitalized and diagnosed with STEMI or NSTEMI. Therefore, the patient may need further evaluation, such as additional cardiac imaging or biomarkers, to confirm the diagnosis.\n\nGiven this, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "116": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the \"Healthy Body Study\" clinical trial, it appears that the patient does not meet the specified criteria for participation in the study. The patient is a 58-year-old African-American woman with hypertension and obesity, presenting with episodic chest pain, but there is no mention of body image concerns, sub-threshold eating disorder symptomatology, or being overweight but not obese as per the defined BMI range. Moreover, the study specifically notes that it is only open to patients at the Mount Sinai Adolescent Health Center, and there is no indication that the patient is connected to this center.\n\nGiven that the patient's characteristics do not match the inclusion criteria and the study's location requirement, it is clear that the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "117": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the trial. The clinical trial is specifically for patients undergoing removal of a chest tube after lung surgery and requires patients to be able to indicate the pain score. The patient in the note presents with episodic chest pain unrelated to lung surgery or chest tube removal; therefore, she does not meet the inclusion criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "118": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Diet and Prevention of Ischemic Heart Disease: a Translational Approach.\"\n\nPatient Characteristics:\n- 58-year-old African-American woman \n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Not currently taking medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Healthy men and women aged 30 to 65 years\n- One or more self-assessed ischemic heart disease risk factors at screening: physical inactivity, overweight or obese (BMI \u2265 25/m^2), waist circumference (\u2265 80 cm for women, \u2265 94 cm for men)\n- Motivation and willingness to be randomized to any of the groups and to follow the given protocol\n\nComparison:\n- Age: The patient is 58 years old, which matches the age criterion (30 to 65 years).\n- Risk factors: The patient has hypertension and obesity, which are risk factors for ischemic heart disease.\n- Motivation and willingness: While the patient's motivation and willingness are not explicitly mentioned in the note, we could infer that if she is seeking medical help for her condition, she might be motivated to participate in a study to improve her health.\n\nBased on the available information, the patient meets the criteria of being within the age range and having risk factors for ischemic heart disease (hypertension and obesity). However, as the trial specifies healthy individuals and the patient presents with symptoms that could be indicative of active cardiac issues, it is not clear if she would be considered \"healthy\" in the context of the study. Furthermore, there is no information on her physical activity levels or willingness to participate in such a trial. Therefore, additional information would be needed to fully ascertain her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "119": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Currently takes no medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Live in Ribeir\u00e3o Preto, S\u00e3o Paulo - Brazil\n- Age between 18 and 40 years old\n- Female gender\n- Regular menses\n- Weight inferior than 120 Kg and BMI between 30 and 40 kg/m^2, for the group with obesity\n- BMI between 18.5 and 24.9 kg/m^2, for the group without obesity\n\nComparison:\n- The patient is a woman, which fits the gender requirement.\n- However, the patient's age (58) is outside the specified range of 18 to 40 years old.\n- The trial requires participants to live in Ribeir\u00e3o Preto, S\u00e3o Paulo - Brazil. There is no information on the patient's residence.\n- There is no information on the patient's menstrual status or exact weight and BMI to determine if she fits the obesity criteria in terms of BMI between 30 and 40 kg/m^2.\n\nGiven the lack of information on some of the criteria and the clear mismatch in the age requirement, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "120": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The EKG shows nonspecific changes. There's no mention of a previous diagnosis of chronic stable angina, which is one of the inclusion criteria for the clinical trial.\n\nThe clinical trial is focused on patients with chronic stable angina of at least 2 months duration. Additionally, after a screening visit, the patient must have a positive exercise ECG, dobutamine stress echocardiogram, myocardial perfusion scan (MPI), or coronary angiogram to be included in the study.\n\nGiven that the patient's chest pain began only two days earlier and there is no indication that she has been diagnosed with chronic stable angina, she does not currently meet the inclusion criteria of having angina for at least 2 months. Furthermore, she has not undergone any of the required diagnostic tests that would qualify her for the trial following a screening visit.\n\nSince the information provided does not indicate that this patient has chronic stable angina or has undergone any of the specific tests required for inclusion in the study, there is not enough evidence to suggest she would be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "121": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess the following:\n\n- The patient's age is 58 years old, which meets the age criterion of being 18 years or older.\n- The patient presents with chest pain and is in the emergency room, but there is no mention of requiring intubation and mechanical ventilation.\n- The patient is known to have obesity, but there is no specific BMI provided. The inclusion criteria require a BMI of \u226540 kg/m^2.\n- There is no information provided about the patient's intra-abdominal pressure (IAP), which needs to be \u226512 mmHg for inclusion.\n\nGiven that the patient does not currently meet the specific criteria of requiring intubation and mechanical ventilation and there is no information on BMI or IAP, it is not possible to conclude that this patient would be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "122": {
        "output": "The patient in the note is a 58-year-old African-American woman with obesity and hypertension. She presents with symptoms suggestive of a cardiac event, but her eligibility for the clinical trial in question is based on the inclusion criteria specific to weight and age.\n\nThe inclusion criteria for the trial are:\n1. Subjects aged between 21 -65 years\n2. Subjects with BMI > 23 Kg/m^2\n\nThe patient fits the age criteria as she is 58 years old. Although her exact BMI is not provided, it is mentioned that she is known to have obesity. The clinical definition of obesity typically involves having a BMI over 30 Kg/m^2, which exceeds the trial's requirement of a BMI over 23 Kg/m^2. \n\nGiven the information provided, the patient meets both inclusion criteria for age and BMI. Therefore, she is highly likely to be eligible for the clinical trial on Protein Supplementation and Weight Loss.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "123": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- Non-specific changes on EKG\n\nClinical Trial:\n- Title: Dietary Nitrate in COPD\n- Focus: Improvement of exercise capacity in COPD patients through acute nitrate consumption\n- Inclusion criteria: \n  - Information consenting out-patients with a previous physician diagnosis of COPD\n  - Clinically stable\n  - Ambulatory\n\nThe patient in the note does not have a physician diagnosis of COPD. The symptoms described (chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea) are not indicative of COPD, which is typically characterized by chronic respiratory symptoms such as chronic cough, sputum production, and shortness of breath. Thus, there is no evidence in the patient note to suggest that the patient has COPD, which is a requirement for the clinical trial.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial, as there is no mention of a COPD diagnosis, which is a key inclusion criterion. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "124": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Empowered Sisters Project Making Choices Reducing Risks,\" let's assess the patient's eligibility:\n\n- The patient is a 58-year-old African-American woman, which aligns with the criteria for African American/ African Caribbean/African heritage/Mixed.\n- The age criteria for the trial is 18 - 44 years, and the patient is 58 years old, which exceeds the maximum age limit.\n- There is no mention of abuse by an intimate male partner in the patient note, which is a requirement for the trial.\n- There is no information provided about the patient's residency or plans to remain in the US Virgin Islands for the next two years.\n\nGiven this information, the patient does not meet several key inclusion criteria: she is over the age limit, and there is no indication of abuse by an intimate partner or her residency in the US Virgin Islands. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "125": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Has hypertension and obesity\n- No current medications\n- Normal physical examination\n- Non-specific EKG changes\n- No mention of end-stage renal disease (ESRD) or hemodialysis\n\nClinical trial inclusion criteria:\n- Able to give informed consent\n- Age \u2265 18 years\n- Body weight > 100 lb or BMI > 18.5\n- End-stage renal disease with hemodialysis in-center three times per week\n- Not missing any treatments in the preceding two weeks and in compliance with health care provider instructions\n- At least two episodes of intra-dialytic hypotension (IDH) in the last month\n- Hemoglobin greater than or equal to 9.0 g/dL and up to 15.0 g/dL\n\nThe patient does not meet several key inclusion criteria for the trial, most notably, she does not have a diagnosis of end-stage renal disease, is not on hemodialysis, and there is no mention of her experiencing intra-dialytic hypotension. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "126": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to match the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Not currently on any medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Female or male aged \u226518 years\n- A patient information letter has been sent by the Investigator to the patient\n- Patient discharged alive from the hospital to home following ACS (diagnosed with STEMI, NSTEMI, or UA)\n- ACS is either UA or myocardial infarction of Type 1\n- ACS after 1st July 2012 and before 1st June 2013\n- Patient on ticagrelor, prasugrel, or clopidogrel treatment at discharge following an ACS\n\nBased on the information provided, the patient has not yet been diagnosed with ACS, and there is no mention of her being treated with ticagrelor, prasugrel, or clopidogrel at discharge. Additionally, the patient's episode of chest pain started two days ago, and there is no indication that it falls within the specified date range of the clinical trial (after 1st July 2012 and before 1st June 2013). Therefore, the patient does not meet several key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "127": {
        "output": "",
        "label": 0
    },
    "128": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Efficacy and Safety of Lacidipine in Chronic Stable Angina,\" we need to compare the patient's characteristics and symptoms with the inclusion criteria of the trial.\n\nHere are the patient's relevant characteristics from the note:\n- The patient is a 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier.\n- The pain is exertional, starting while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nNow let's look at the clinical trial inclusion criteria:\n- Age 18 to 80 years.\n- History of stable, exertional angina pectoris (CCS class II to III) for at least 3 months prior to enrolment.\n- Not currently receiving treatment with antianginal medication (other than short-acting nitrates).\n- Two treadmill exercise tests demonstrating \u2265 0.1 mV of horizontal or down sloping ST-segment depression.\n- Difference in symptom-limited exercise duration between two tests must not exceed 20%.\n- Total treadmill exercise duration > 3 minutes on a standard Bruce protocol.\n- Coronary artery disease, preferably documented by myocardial infarction or coronary angiography showing \u2265 50% reduction in luminal diameter of one or more coronary arteries.\n\nBased on the patient note, the patient does present with episodic pressing/burning anterior chest pain that is exertional, which could suggest angina, but there are several pieces of information missing to fully determine eligibility:\n- The patient's chest pain is a new occurrence, not documented for at least 3 months.\n- It is not specified if her angina is of the stable type required by the trial (CCS class II to III).\n- There is no documentation of the patient performing treadmill exercise tests or results showing ST-segment depression.\n- There is no mention of any previous diagnosis of coronary artery disease, myocardial infarction, or results of coronary angiography.\n\nAt this stage, the patient's eligibility for the trial is uncertain due to insufficient information. Further investigation and testing would be required to determine if the patient's condition aligns with stable exertional angina pectoris and to document the presence of coronary artery disease as per the trial's inclusion criteria.\n\nGiven the lack of information and the newness of the patient's symptoms, it seems premature to refer this patient to the clinical trial without further diagnostic work to establish the chronicity and nature of the angina, as well as to confirm the presence of coronary artery disease.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "129": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman with hypertension and obesity, which are two of the comorbidities listed in the inclusion criteria of the clinical trial. The clinical trial is looking for morbidly obese patients with a BMI >30 who also have one of the comorbidities: type 2 diabetes, dyslipidemia, or hypertension, or patients with a BMI >35.\n\nAlthough the patient's exact BMI is not provided, she is identified as having obesity. Since she has hypertension, she meets the first part of the inclusion criteria if her obesity is indeed morbid (BMI >30). However, without explicit information confirming her BMI as over 30 or over 35, we cannot definitively conclude her eligibility.\n\nGiven the information available, she is a potential candidate for the study because she has a comorbidity associated with morbid obesity (hypertension). However, further investigation is required to confirm her BMI and ensure that it meets the trial's definition of morbid obesity.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "130": {
        "output": "",
        "label": 1
    },
    "131": {
        "output": "Based on the information provided in the patient note, the patient is a 58-year-old African-American woman with episodic chest pain, hypertension, and obesity. However, there is no mention of carpal tunnel syndrome or that she underwent surgery for it, particularly under intravenous regional anesthesia between January 2009 and January 2010, which is the specific inclusion criterion for the clinical trial provided.\n\nGiven that the patient does not meet the primary inclusion criteria for the clinical trial (having been operated on due to carpal tunnel syndrome under intravenous regional anesthesia within the specified timeframe), she would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "132": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\n- The patient is 58 years old, which meets the criterion of being \u2265 18 years of age.\n- The patient is of African-American descent, which is one of the ethnicities included in the criteria.\n- The patient presents with chest pain, but there is no mention of atrial fibrillation (AF) or a history of AF episodes. The inclusion criteria specifically require a history of typical or early-onset symptomatic paroxysmal/persistent AF with \u22652 episodes/month.\n- The EKG shows nonspecific changes, and there is no indication that it shows atrial fibrillation or that AF was recorded within 1 month of randomization.\n\nSince there is no mention of atrial fibrillation in the patient's history or EKG, the patient does not meet the specific disease criteria required for the clinical trial. Therefore, the patient would not be eligible for this atrial fibrillation pharmacogenetic study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "133": {
        "output": "Based on the patient's presentation and the inclusion criteria for the clinical trial titled \"Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome,\" let's evaluate the patient's eligibility:\n\n1. The patient is a 58-year-old African-American woman. The inclusion criteria specify women age 18 years or older, so she meets the age criterion.\n\n2. The patient presents with episodic pressing/burning anterior chest pain that began two days earlier, which is consistent with the trial's requirement for symptoms of non-ST-elevation acute coronary syndrome (new onset chest discomfort that occurs at rest or with low levels of activity/emotion within the preceding 48 hours).\n\n3. However, the inclusion criteria also require one of the following: elevated troponin T, elevated creatinine kinase MB-isoenzyme, elevated NT-pro-BNP, ST-segment depression, or a TIMI risk score greater than 2. The patient note does not provide information on these specific tests or results, which are essential for confirming the diagnosis and severity of acute coronary syndrome.\n\nSince the patient's note lacks specifics regarding the required diagnostic criteria (elevated cardiac biomarkers or EKG changes), we cannot definitively determine her eligibility. However, given her symptoms and the high suspicion of an acute coronary syndrome, it would be prudent to consider referring her for the clinical trial upon further investigation, which would include the necessary cardiac biomarker tests and EKG analysis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "134": {
        "output": "To assess the patient's eligibility for the ACE Stapler Sub Study, we will compare the patient's characteristics and conditions with the inclusion criteria listed for the clinical trial.\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- BMI is not specified but is described as obese\n- Physical examination is normal\n- Has reliable transportation and sufficient time to attend all follow-up visits (assumed)\n- Failed standard obesity therapy is not mentioned\n- Willingness to sign informed consent, willingness to participate, and having a primary care physician are not mentioned but could potentially be met upon further discussion with the patient\n\nInclusion Criteria for the ACE Stapler Sub Study:\n- Must understand and be willing to sign an informed consent document\n- Must be willing and able to participate in all aspects of the study and comply with study requirements\n- BMI of 40 - 45 or 30 to 39.9 with one or more co-morbid diseases expected to improve with weight loss (hypertension, dyslipidemia, obstructive sleep apnea, diabetes mellitus)\n- Fully ambulatory, without chronic reliance on walking aids\n- Sufficient and stable medical health\n- Have a primary care physician to manage co-morbid conditions\n- Failed standard obesity therapy (diet, exercise, behavior modification, pharmacologic agents)\n- Agrees to refrain from reconstructive surgery that may affect body weight during the trial\n- Must be included in the main study\n\nBased on the information provided, the patient is obese and has hypertension, which are two criteria that potentially qualify her for the main ACE stapling study. However, the patient's BMI is not provided, which is necessary to determine eligibility. Furthermore, there is no mention of her having failed standard obesity therapies or of her willingness to participate in the study, which are both required criteria for inclusion.\n\nGiven the lack of specific information on her BMI and previous obesity treatments, as well as confirmation of her willingness to participate and other logistical requirements, I would say:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include obtaining the patient's BMI, confirming her failure with standard obesity therapies, assessing her willingness to sign the informed consent and participate in the study, and ensuring she has a primary care physician for management of her co-morbid conditions.",
        "label": 2
    },
    "135": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific inclusion criteria for the study. The clinical trial is evaluating a monitoring method for the effectiveness of sympathetic blocks, specifically lumbar sympathetic blocks, and the inclusion criteria are:\n\n- Patients presenting for sympathetic block of the lower extremity (lumbar sympathetic block)\n- Ages 18-99\n\nThe patient in the note is presenting with episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea, which are not indicative of a condition requiring a sympathetic block of the lower extremity. There is no mention of the patient needing or being evaluated for a lumbar sympathetic block. Therefore, the patient's symptoms and current medical evaluation do not align with the clinical trial's focus or requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "136": {
        "output": "The patient presented is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, hypertension, and obesity. She has no history of surgery indicated in the note and is not described as having undergone a unilateral total hip replacement (THR) or total knee replacement (TKR), which are the types of patients the clinical trial is targeting.\n\nThe clinical trial in question is focused on monitoring postoperative pain in patients who have undergone THR or TKR surgeries using electrical skin conductance. The inclusion criteria for this clinical trial are:\n\n- Patients undergoing unilateral THR and TKR who are between the ages of 18 and 85 regardless of the anesthesia and postoperative analgesia type.\n- Patients participating in other studies may participate in this study as well.\n- Patients with Motor Activity Assessment Scale (MAAS) Score of 3 and 4.\n\nThe patient in the note does not fit the profile of the clinical trial's target population as there is no indication that she has undergone or is scheduled for THR or TKR surgery, and there is no mention of her MAAS score.\n\nTherefore, based on the information provided in the patient note and the clinical trial's inclusion criteria, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "137": {
        "output": "Based on the information given in the patient note, the patient is a 58-year-old African-American woman presenting with episodic chest pain, hypertension, and obesity. There is no mention of her having multiple sclerosis (MS) or any related symptoms. The clinical trial in question is specifically for patients with relapsing-remitting multiple sclerosis (RRMS) who meet the McDonald criteria, have had an onset of MS within one year before enrolment, have \u2265 1 Gd+ lesions at a brain MRI scan performed within three months before enrolment, have not received previous disease-modifying and/or immunosuppressive treatments for MS, and have a baseline EDSS between 0.0 and 5.0.\n\nSince the patient in the note does not have a diagnosis of MS, nor any indication that she has RRMS or meets any of the other specific inclusion criteria related to MS, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "138": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with symptoms that are suggestive of angina pectoris: episodic pressing/burning anterior chest pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. These symptoms seem to match the first inclusion criterion of the clinical trial which requires symptoms of angina pectoris.\n\nHowever, the inclusion criteria also specify the need for angiographic evidence of epicardial coronary artery stenosis referred for PCI, a flow-limiting lesion with a Fractional Flow Reserve \u22640.80, and an existing beta blocker prescription. It is not mentioned in the patient note that the woman has undergone angiography, has a documented flow-limiting lesion, or is on beta blocker therapy. Furthermore, there is no mention of an echocardiogram being performed in the preceding 12 months, which is another requirement for the trial. Lastly, we do not have information regarding the patient's consent, which is essential for participation in the trial.\n\nConsidering the missing information and the fact that the patient does not currently meet several of the explicit inclusion criteria, it would be premature to refer her to this clinical trial without further diagnostic workup to confirm the presence of flow-limiting coronary artery stenosis and to fulfill the other requirements. Therefore, at this stage, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "139": {
        "output": "To determine the patient's eligibility for the PACIFIC clinical trial, we need to review the patient's note against the inclusion criteria:\n\nInclusion Criteria Analysis:\n1. Age 18-65: The patient is 58 years old, which fits the age criterion.\n2. Overweight, with a BMI between 25 and 45: The patient is described as obese, which suggests a BMI over 30, so this criterion is likely met.\n3. English language skills at the 5th grade reading level: There is no information provided regarding the patient's language skills.\n4. Free of major medical conditions: The patient has hypertension, which is not listed among the exclusions, but she presented with chest pain, which might suggest underlying coronary heart disease or angina, conditions that would exclude her.\n5. No bulimia, anorexia, significant cognitive impairment, psychotic disorder, or unstable psychiatric illness: There is no information on these conditions, so we have to assume she does not have them.\n6. Not moving out of the San Diego area for the duration of the study enrollment: The location of the patient is not specified.\n7. Not pregnant, planning to get pregnant, or lactating: There is no information provided on this.\n8. Not taking medication for weight loss or that may impair physical activity tolerance or performance: The patient is not currently taking any medications.\n9. No medical or psychological problems, or taking medications that could make adherence with the study protocol difficult or dangerous: The patient's hypertension and episode of chest pain could potentially make adherence to the study protocol difficult or dangerous.\n10. No history of bariatric surgery: There is no information provided on this.\n11. Not currently enrolled in an organized weight control program: There is no information provided on this.\n\nSince the patient presents with episodic chest pain that could suggest underlying coronary heart disease or recent symptoms of angina, it is imperative to further investigate these symptoms before referring her to a clinical trial focusing on weight control and physical activity. Without more information on her medical clearance for physical activity, her language skills, location, pregnancy status, and other potential medical exclusions, the decision to refer her is not straightforward.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "140": {
        "output": "Given the patient's characteristics and the inclusion criteria for the clinical trial titled \"Anti-hypertensive Effect of Mycelia of Antrodia Cinnamomea,\" let's determine the patient's eligibility:\n\nPatient characteristics:\n- Age: 58-year-old woman\n- Known hypertension\n- No current medication for hypertension\n- SBP and DBP not specified\n\nClinical trial inclusion criteria:\n- Untreated hypertensive men or women\n- Age between 20 and 80 years old\n- SBP between 130 and 179 mmHg\n- DBP between 85 and 109 mmHg\n\nThe patient is within the age range required for the trial and has a known history of hypertension. However, the specific blood pressure values (SBP and DBP) for this patient are not provided. Since the patient is described as having hypertension and no current medication for it, she could potentially meet the criteria of \"untreated hypertensive.\" Therefore, further investigation is needed to determine her specific blood pressure measurements to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "141": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- No current medications are mentioned.\n- No prior heparin or low molecular weight heparin (LMWH) treatment is mentioned.\n- She has not mentioned if she has agreed to participate in a study or signed an informed consent, but this can typically be addressed at the time of recruitment.\n\nClinical Trial Inclusion Criteria:\n- Subjects with compatible symptoms with an acute coronary syndrome, for at least 15 minutes and not older than 3 hours.\n- Both men and women are eligible.\n- Patients who did not receive heparin or LMWH before the initial blood sample.\n- Patients agreeing to participate in the study and who signed an informed consent.\n\nComparison:\n- The patient's age fits the criterion of being over 18 years old.\n- The symptoms described could be compatible with an acute coronary syndrome, which is part of the inclusion criteria.\n- There is no mention of the patient receiving heparin or LMWH, so it's assumed that she has not.\n- The informed consent part is procedural and can be obtained if the patient agrees to participate.\n\nGiven that the patient presents with symptoms that may be related to acute coronary syndrome and other criteria (such as not having received heparin/LMWH) seem to be met, it is reasonable to consider the patient for the clinical trial upon further investigation, such as confirming the timing and nature of the chest pain, as well as obtaining informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "142": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial:\n\nThe clinical trial is focused on the effect of a meal replacement on weight loss in obesity patients with metabolic syndrome.\n\nInclusion Criteria for the trial:\n\n1. Body mass index (BMI) more than or equal to 25 kg/m^2\n2. Patients with metabolic syndrome\n3. Patients who are on anti-hypertensive drugs, oral hypoglycemic drugs, and lipid-lowering drugs.\n\nPatient information:\n\n1. The patient has obesity, as indicated by the mention of obesity in the note.\n2. The patient has hypertension, which is a component of metabolic syndrome.\n3. The patient is not currently taking any medications, which includes the absence of anti-hypertensive drugs, oral hypoglycemic drugs, or lipid-lowering drugs.\n\nFrom the patient's description, while she does have obesity and hypertension, she does not meet all the criteria listed for the trial. Specifically, she is not currently taking any medications for her hypertension, which does not fulfill the criteria of being on anti-hypertensive drugs. Additionally, there is no mention of her having other components of metabolic syndrome, such as dyslipidemia or insulin resistance.\n\nGiven that the patient does not currently meet all of the inclusion criteria, particularly the requirement for medication, the assessment for eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "143": {
        "output": "After evaluating the patient note against the inclusion criteria of the clinical trial titled \"Study Of Angiomax In Infants Under Six Months With Thrombosis,\" it is clear that the patient does not meet the age requirement of being less than 6 months old. The patient is a 67-year-old woman, which is well beyond the specified age range for the trial participants. Therefore, she is not eligible for this clinical study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "144": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Use of Activated Recombinant FVII in Spinal Surgery,\" the patient does not appear to be eligible for this clinical trial.\n\nThe patient note describes a 67-year-old woman with a complication likely related to a cardiac catheterization procedure, presenting with a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms suggest a vascular issue, possibly a femoral artery pseudoaneurysm or occlusion, which is unrelated to spinal surgery.\n\nThe inclusion criteria for the clinical trial specify that the study is looking for patients who are undergoing elective spinal fusion surgery. Since the patient described is not undergoing spinal fusion surgery, nor is there any indication that she has a condition that would require such surgery, she does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "145": {
        "output": "The patient described is a 67-year-old woman who underwent cardiac catheterization and is now presenting with signs of a possible vascular complication (cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the catheterization site). This suggests that she might be experiencing a vascular emergency, such as a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is looking at the safe and feasible use of an endovascular cooling device in patients with hypothermic cardiopulmonary resuscitation (CPR). The inclusion criteria specify non-traumatic collapsed patients with persistent pulsation more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and a consciousness level of less than GCS 5 points.\n\nThe patient described does not meet the inclusion criteria for this trial, as there is no indication that she has experienced cardiac arrest or required CPR, nor is there any information provided about her level of consciousness or GCS score. Instead, she appears to be experiencing a post-procedural complication unrelated to cardiac arrest or the need for hypothermic CPR.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "146": {
        "output": "Given the patient note, we have a 67-year-old woman who underwent cardiac catheterization and is now presenting with a cool right foot and a pulsatile mass in her right groin. This clinical information indicates a potential complication from the catheterization, such as a femoral artery pseudoaneurysm or occlusion, but does not mention hypertension or its treatment.\n\nThe clinical trial in question is focused on the efficacy and safety of valsartan versus amlodipine in postmenopausal women with hypertension. The trial's inclusion criteria are:\n1. Postmenopausal women\n2. Mild to moderate hypertension\n3. Statin therapy or LDL \u2264 4.1 mmol/L\n\nThe patient note does not provide information on whether the patient is postmenopausal, has hypertension, or is on statin therapy or has an LDL level \u2264 4.1 mmol/L.\n\nBased on the information provided in the patient note, we do not have enough evidence to determine if the patient meets the inclusion criteria for the clinical trial. Thus, further investigation would be needed to assess her eligibility, particularly concerning her menopausal status, blood pressure, and cholesterol management.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "147": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- 67-year-old woman\n- Underwent cardiac catheterization earlier in the morning\n- Complains of a cool right foot after the procedure\n- Has a pulsatile mass in her right groin\n- Loss of distal pulses\n- Auscultation reveals a bruit over the femoral artery entry point\n\nClinical Trial Summary:\n- Title: Catheter Thrombectomy in Patients With Massive Pulmonary Embolism\n- Target population: Patients with massive pulmonary embolism suitable for mechanical thrombectomy\n- Age criteria: \u2265 18 years\n- Specific condition: Massive pulmonary embolism and cardiogenic shock\n- Inclusion criteria include specific requirements related to pulmonary embolism, cardiogenic shock, and contraindications to PE thrombolysis\n- Exclusion criteria include systemic embolism with certain heart defects, free-floating heart thrombi, and life expectancy less than one month due to underlying disease\n\nThe patient in the note does not mention any symptoms or diagnosis of pulmonary embolism or cardiogenic shock. Instead, the patient's symptoms suggest a potential complication from cardiac catheterization, possibly a femoral artery pseudoaneurysm or occlusion, as indicated by a cool foot, pulsatile mass, and loss of distal pulses. These symptoms do not align with the inclusion criteria for the clinical trial, which focus on massive pulmonary embolism.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial on catheter thrombectomy in patients with massive pulmonary embolism.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "148": {
        "output": "Based on the patient note and the clinical trial provided:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaints of a cool right foot after the procedure\n- Pulsatile mass in right groin\n- Loss of distal pulses\n- Bruit over the entry point of the right femoral artery\n\nClinical Trial:\n- Title: Evaluation of Residual Urine After Intermittent Catheterisation\n- Summary: Study to compare residual urine after using two different hydrophilic coated intermittent catheters in a randomized, single-blinded, crossover study including 24 healthy males.\n- Inclusion Criteria:\n  - Male\n  - 18 years and above\n  - A negative urine dip-stick\n  - Have signed informed written consent\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- The patient is female, while the trial is specifically including only males.\n- The trial is including healthy individuals, and the patient is currently experiencing a medical issue related to a cardiac catheterization procedure.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "149": {
        "output": "",
        "label": 0
    },
    "150": {
        "output": "The patient note describes a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is now presenting with symptoms that could be indicative of a vascular complication such as a pseudoaneurysm or occlusion, given the cool extremity, pulsatile mass, loss of distal pulses, and bruit.\n\nThe clinical trial in question is looking to recruit patients with critical limb ischemia, specifically those with Fontaine stage III or IV or Rutherford category 4, 5, or 6, who also have a stenotic or occluded infrapopliteal artery that meets certain specifications.\n\nThe patient's current condition must be critically evaluated against the inclusion criteria of the clinical trial:\n\n1. Age > 18 years - The patient is 67 years old, which meets this criterion.\n2. If female patient with childbearing potential, not pregnant, and using reliable birth control - This may not be applicable given her age, but it's not discussed in the patient note.\n3. Willing and able to comply with follow-up - This is not discussed in the patient note.\n4. Critical Limb Ischemia, Fontaine stage III or IV or Rutherford category 4, 5, or 6 - The patient note does not specify that the patient has critical limb ischemia or describe symptoms consistent with Fontaine stage III/IV or Rutherford categories 4-6 (such as ischemic rest pain, tissue loss, or gangrene).\n5. Stenotic or occluded infrapopliteal artery with a lesion length \u2264 60 mm - The patient note does not provide information about the presence of stenotic or occluded infrapopliteal arteries or the specifics of any such lesions.\n6. Artery to be treated with a diameter of \u22652mm and \u22644mm - The patient note does not provide this information.\n7. Patent common iliac, external iliac, superficial femoral, and popliteal artery on the ipsilateral side prior to randomization - The patient note does not provide this information.\n8. At least one patent crural artery with expected unobstructed runoff to ankle level after treatment - The patient note does not provide this information.\n\nGiven that the patient note does not provide evidence that the patient has critical limb ischemia or other specific conditions required by the trial's inclusion criteria, and there is insufficient information to determine her eligibility based on the vascular status required by the trial, the patient does not appear to be a match for the clinical trial as described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "151": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following cardiac catheterization, specifically a cool right foot and a pulsatile mass in her right groin with loss of distal pulses and a bruit over the point at which the right femoral artery was entered. This suggests the possibility of a femoral artery complication, such as a pseudoaneurysm or occlusion.\n\nThe clinical trial in question is assessing the efficacy of carotid artery stenting (CAS) versus best medical treatment for patients with asymptomatic high-grade carotid artery stenosis. The inclusion criteria for this trial are specifically focused on patients who have atherosclerosis as the underlying disease, with an asymptomatic stenosis greater than 80% in the carotid artery. Additionally, there needs to be neurologist's consent for the potential performance of CAS.\n\nBased on the information given, the patient in the note does not fit the inclusion criteria for the clinical trial. The patient's current medical issue is related to a complication from cardiac catheterization rather than asymptomatic carotid artery stenosis. There is no mention of carotid artery disease, nor is there any indication of the patient having asymptomatic high-grade carotid artery stenosis.\n\nTherefore, the patient would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "152": {
        "output": "Upon reviewing the patient note and the clinical trial information, it appears that the patient is a 67-year-old woman who has recently undergone cardiac catheterization via the right femoral artery and is now presenting with complications, specifically a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the catheter entry point. These signs suggest a possible vascular complication such as a pseudoaneurysm or arterial occlusion.\n\nThe clinical trial in question is focused on assessing the safety and feasibility of the 7F Ensure Medical Vascular Closure Devices in patients undergoing diagnostic or interventional coronary procedures. The patient's current condition seems to be a complication from a coronary procedure, which may require emergent vascular surgery. However, the inclusion criteria for the trial specifically mention patients who are scheduled for a coronary diagnostic or interventional procedure, not those who have already completed one and are experiencing complications.\n\nFurthermore, the trial requires that the participant has a 7F arterial puncture located in the common femoral artery and a femoral artery with a lumen diameter of at least 5 mm. There is no information provided in the patient note regarding the size of the femoral artery or whether the current complication would exclude the patient from participating in such a trial.\n\nBased on the available information, the patient does not meet the inclusion criteria as outlined for the clinical trial, as she is not scheduled for a new procedure but is rather experiencing complications from a procedure that has already taken place. Therefore, the patient is not a suitable candidate for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "153": {
        "output": "In this scenario, the 67-year-old woman in the patient note is presenting with a cool right foot and a pulsatile mass in the right groin after undergoing cardiac catheterization. The clinical trial in question is focused on monitoring tissue transfer flaps by Modulated Imaging (MI) Spectroscopy in patients who are undergoing reconstructive surgery using either a pedicle or free tissue transfer flap.\n\nThe patient in question does not seem to be a candidate for reconstructive surgery using tissue transfer flaps, which is the primary focus of the clinical trial. The issue she is experiencing is related to a complication from cardiac catheterization, not reconstructive surgery. Additionally, there are no indications in the patient note that she is planned to undergo the type of reconstructive surgery relevant to the study.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, this patient does not meet the inclusion criteria for the study. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "154": {
        "output": "",
        "label": 1
    },
    "155": {
        "output": "Based on the patient note, the 67-year-old woman underwent cardiac catheterization via the right femoral artery and is now experiencing complications, specifically a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the femoral artery. These symptoms suggest a vascular complication from the procedure.\n\nThe clinical trial titled \"Prospective Registry on Vascular Access in Interventions in Lazio Region\" is looking to monitor outcomes of any percutaneous cardiovascular procedure, which includes cardiac catheterization.\n\nSince the inclusion criteria for the clinical trial are:\n- All patients undergoing any percutaneous cardiovascular procedure\n\nAnd the patient underwent cardiac catheterization, which is a percutaneous cardiovascular procedure, she meets the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "156": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"RISE: A Clinical Evaluation of the StarClose\u2122 Vascular Closure System\" involves comparing the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot after the procedure\n- Pulsatile mass in the right groin\n- Loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical trial inclusion criteria:\n- Age 18-85\n- Acceptable candidate for an elective, non-emergent diagnostic procedure performed percutaneously via the common femoral artery\n- Acceptable candidate for emergent vascular surgery\n- Agrees to follow-up evaluations\n- If part of the ultrasound sub-study, agrees to have a post-procedure ultrasound\n- Informed consent provided\n\nClinical trial exclusion criteria relevant to the patient's situation:\n- History of ipsilateral femoral arterial puncture within the previous three months or history of vascular closure device deployment in the ipsilateral femoral artery at any time\n- Presence or previous use of an intra-aortic balloon pump through the existing arterial puncture site\n- Subject has intra-procedural bleeding around the access site\n- Presence of clinically significant hematoma in ipsilateral femoral artery prior to arterial closure\n\nBased on the patient's recent cardiac catheterization, it is unclear whether a vascular closure device was used, which would exclude her if it had been deployed in the ipsilateral femoral artery. Additionally, the presence of a pulsatile mass could indicate a complication such as a hematoma or pseudoaneurysm, which would also potentially exclude her. Without more specific information about the details of her procedure and complications, a definite conclusion cannot be reached.\n\nGiven the potential complications and the lack of detailed information, further investigation is needed to determine her eligibility:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "157": {
        "output": "After reviewing the patient note and the clinical trial information, we can determine the trial-level eligibility for this patient as follows:\n\nThe clinical trial's inclusion criteria are:\n1. Significant pulmonary arterial hypertension (mean pulmonary artery pressure > 25 mm Hg)\n2. Patients aged 4-18 years\n3. Routine cardiac catheterization clinically indicated for deciding therapeutic treatment\n4. Informed assent/consent from patient/parent\n\nThe patient in the note is a 67-year-old woman who underwent cardiac catheterization, which does not align with the age range specified in the clinical trial inclusion criteria (4-18 years). Additionally, the trial is focused on children with pulmonary arterial hypertension, and there is no mention of this condition in the patient's note. The clinical trial also requires a routine cardiac catheterization to be clinically indicated for deciding therapeutic treatment, which we cannot confirm from the patient note, as it only mentions that she underwent a catheterization procedure.\n\nBased on the information provided, this patient does not meet the age criterion, and there is no information suggesting that she has pulmonary arterial hypertension. Therefore, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "158": {
        "output": "Based on the patient note, the 67-year-old woman had undergone cardiac catheterization and is now presenting with symptoms suggestive of a vascular complication, specifically a possible femoral artery pseudoaneurysm or occlusion, given the cool foot, loss of distal pulses, and a pulsatile mass with a bruit.\n\nFor the clinical trial in question, the inclusion criteria are:\n\n1. Sustained return of spontaneous circulation (ROSC) after cardiac arrest, for more than 30 min\n2. Patients aged between 18 to 80 years.\n3. Patients who are hemodynamically stable, with a systolic BP > 90 mmHg with or without inotropic support.\n4. Patients comatose or unresponsive post-resuscitation\n\nThe provided patient note does not mention a cardiac arrest or a sustained return of spontaneous circulation (ROSC). The focus of the note is on a vascular complication following a cardiac procedure. There is no indication that the patient has suffered a cardiac arrest or that she is comatose or unresponsive post-resuscitation. Therefore, she does not meet the specific inclusion criteria for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "159": {
        "output": "Based on the information provided, the patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery and is now experiencing complications potentially related to the procedure. The clinical trial in question is investigating the use of suture-mediated closure devices for femoral venous access and is seeking participants who are over the age of 18 and who have received suture-mediated femoral vein closure following catheterization.\n\nThe patient note does not explicitly state that the patient received a suture-mediated closure device; however, it is implied that she has undergone a procedure that involved femoral access. The complication described (a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the access site) is relevant to the trial's focus on complications associated with femoral access and closure.\n\nGiven that the trial is interested in understanding predictors of success and complications with suture-mediated closure devices, and that the patient has a complication that is potentially related to femoral access, she may be of interest to the trial. However, further information would be required to confirm that she received a suture-mediated closure device as part of her procedure. If she did, she would meet the inclusion criteria based on her age and the fact that she received femoral vein catheterization.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "160": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we should evaluate the eligibility as follows:\n\nPatient Note:\n\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaining of a cool right foot after the procedure\n- Pulsatile mass in right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery\n\nClinical Trial Inclusion Criteria:\n\n- ROSC after SCA due to VF/VT or PEA/Asystole\n- GCS 3\n\nThe patient note does not mention a sudden cardiac arrest (SCA) or any details regarding a Glasgow Coma Scale (GCS) score. The patient is dealing with a complication from a cardiac catheterization, which does not align with the clinical trial's focus on post-cardiac arrest outcomes and therapeutic hypothermia.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "161": {
        "output": "Based on the provided patient note and the inclusion criteria for the PROTECT Continued Access Post Marketing Surveillance Trial, here is the assessment:\n\nPatient note summary:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Has a pulsatile mass in her right groin with loss of distal pulses\n- Bruit over the point at which the right femoral artery was entered\n\nClinical trial inclusion criteria:\n1. Patient is > 18 years of age (or minimum age as required by local regulations).\n2. The patient or patient's legal representative has consented to participate and has authorized the collection and release of his medical information by signing the Patient Informed Consent Form.\n3. All lesions requiring interventions (target lesions - one to a maximum of four) in one or more native coronary arteries are amendable for implantation of one or more Endeavor\u00ae Zotarolimus Eluting Coronary Stent System.\n4. Patient indication, lesion length, and vessel diameter of the target lesion(s) are according to the 'Indications for Use' as mentioned in the 'Instructions for Use' that comes with every Endeavor\u00ae Zotarolimus Eluting Coronary Stent System.\n5. The patient is willing and able to cooperate with study procedures and required follow-up visits.\n\nAssessment:\nThe patient is of appropriate age for the trial (>18 years). However, the patient note does not provide information about her consent, the specific nature of her coronary artery lesions, or whether they are amendable to the Endeavor\u00ae Zotarolimus Eluting Coronary Stent System. Additionally, the patient is currently presenting with complications potentially related to cardiac catheterization, which is not necessarily aligned with the trial's focus on safety information for patients treated with a specific drug-eluting stent system. There is no mention of coronary artery disease or lesions that would require stenting in the patient note.\n\nGiven the lack of information on several key inclusion criteria and the fact that the patient's current condition does not directly suggest a need for coronary artery stenting, it is not possible to conclude with certainty that the patient is eligible for this trial. Therefore, further investigation would be required to determine if the patient has coronary lesions amendable to stenting with the Endeavor\u00ae Zotarolimus Eluting Coronary Stent System and to obtain the patient's consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "162": {
        "output": "",
        "label": 0
    },
    "163": {
        "output": "Given the patient note, we have a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is experiencing complications potentially related to femoral artery access (a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point).\n\nNow, comparing the patient's situation with the inclusion criteria of the clinical trial:\n\n1. The patient must be at least 18 years old - The patient is 67 years old, which meets this criterion.\n2. Patients undergoing femoral access coronary angiography - The patient has undergone cardiac catheterization, which typically involves coronary angiography through femoral access.\n3. Patient must be competent for providing informed, written consent - There is no information provided about the patient's competence, but there is no indication that the patient is not competent.\n4. Only 6F sheath - There is no information regarding the size of the sheath used during the patient's procedure.\n\nThe patient meets most of the known inclusion criteria; however, the size of the sheath used is not specified in the patient note. Since this is a crucial part of the inclusion criteria and we lack this information, we cannot fully determine eligibility without further investigation.\n\nTherefore, the assessment for trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "164": {
        "output": "",
        "label": 0
    },
    "165": {
        "output": "Based on the patient note provided, the 67-year-old woman has recently undergone cardiac catheterization via the right femoral artery and is now experiencing symptoms suggesting a possible complication, such as a hematoma or pseudoaneurysm (cool foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery).\n\nThe clinical trial in question is assessing the safety and efficacy of the QuickClose Design 9 closure device in patients undergoing diagnostic or therapeutic angiogram procedures. The trial's inclusion criteria specify that the patient must provide informed consent, be scheduled for a coronary or peripheral diagnostic or interventional procedure, have a target vessel with a lumen diameter \u2265 6 mm, be willing to comply with follow-up requirements, and have a 5-7F arterial puncture located in the common femoral artery.\n\nGiven the patient's current condition, which appears to be a complication from the cardiac catheterization rather than her being scheduled for a new procedure, she does not meet the inclusion criteria for the trial. The trial is specifically looking for patients who are scheduled for a procedure, not those who have already undergone one and are experiencing complications.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "166": {
        "output": "Based on the information provided, the patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery. The clinical trial in question is investigating the use of local anesthetic for pain control in pediatric cardiac catheterization patients.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Ages 7-18 years\n- Scheduled for cardiac catheterization through the femoral artery and/or vein under general anesthetic\n- Ability to speak and understand English\n- No apparent cognitive impairments\n\nThe patient in the note does not meet the age criterion, as she is 67 years old and the trial specifically includes pediatric patients aged 7-18 years. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "167": {
        "output": "Based on the information provided in the patient note, the 67-year-old woman who underwent cardiac catheterization is now presenting with a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the right femoral artery entry point. These symptoms suggest the possibility of a vascular complication, potentially an arterial occlusion or a pseudoaneurysm, as a result of the cardiac catheterization procedure.\n\nThe clinical trial in question is focusing on the feasibility of peripheral angioplasty in diabetic patients with type C and D lesions as per the TASC II criteria, with a focus on chronic critical ischemia.\n\nTo determine the patient's eligibility for the clinical trial, we need to assess whether the patient meets the following inclusion criteria:\n\n1. Adult diabetic patients type 1 or 2\n2. Chronic critical ischemia as defined by TASC 2007 criteria (pain at rest, and/or ulcer or gangrene due to arteriopathy: transcutaneous oximetry < 30 mmHg or pressure on the ankle < 70 mmHg)\n\nThe patient note does not mention diabetes or chronic critical ischemia. The symptoms described are acute, following a procedure, while the trial is concerned with chronic conditions. Moreover, there is no information about the patient's diabetic status or whether she meets the criteria for chronic critical ischemia.\n\nTherefore, based on the available information, the patient does not meet the specified inclusion criteria for the clinical trial as she does not have confirmed diabetes, nor is there any mention of chronic critical ischemia as defined by the TASC 2007 criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "168": {
        "output": "",
        "label": 0
    },
    "169": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following a cardiac catheterization procedure. She is presenting with a cool foot, loss of distal pulses, and a pulsatile mass in the groin, which are signs that could suggest a vascular complication such as a pseudoaneurysm or occlusion.\n\nThe clinical trial is focused on comparing the safety and efficacy of sirolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents. It is aimed at patients with symptomatic coronary artery disease requiring percutaneous coronary intervention (PCI).\n\nBased on the provided information, the patient could potentially meet the following inclusion criteria for the clinical trial:\n\n- Age \u226518 years (the patient is 67 years old)\n- Symptomatic coronary artery disease (if the reason for cardiac catheterization was due to coronary artery disease, which is not uncommon)\n\nHowever, the patient note does not provide sufficient information to confirm the following:\n\n- Whether the patient has symptomatic coronary artery disease that includes conditions such as chronic stable angina, silent ischemia, or acute coronary syndromes\n- Presence of one or more coronary artery stenoses >50%\n- If the condition can be treated with a stent ranging in diameter from 2.25 to 4.0 mm and can be covered with one or multiple stents\n\nMoreover, there are no exclusion criteria that the patient note clearly satisfies to exclude the patient from the trial. Therefore, given the limited information available, the patient could be considered for the trial if further investigation confirms symptomatic coronary artery disease that requires PCI with stent placement. However, the current symptoms she is presenting (cool foot, loss of distal pulses, pulsatile mass in the groin) suggest a vascular complication that would likely need to be addressed before considering stent placement.\n\nTherefore, based on the information provided, and assuming the patient's cardiac catheterization was due to coronary artery disease that could be treated with stenting:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "170": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following a cardiac catheterization procedure via the right femoral artery. The patient has a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery. This scenario suggests the patient is facing an issue related to the catheterization procedure, possibly a vascular complication such as a pseudoaneurysm or arteriovenous fistula.\n\nThe clinical trial in question is investigating the use of central venous catheters in the critical care setting and comparing the complications between different sites of catheterization (subclavian, internal jugular, and femoral). The inclusion criteria for the trial are quite straightforward:\n\n1. Patient admitted to the Intensive Care Unit (ICU).\n2. Requiring Central Venous Catheterization.\n\nBased on the patient note, there is no information to suggest that this patient is currently admitted to the ICU, nor is there any indication that the patient requires central venous catheterization for the management of her condition at this time. The complication she is experiencing is related to a previous catheterization procedure, not an indication for a new central venous catheter placement.\n\nGiven the lack of information connecting the patient's current situation to the inclusion criteria of the trial, it is unlikely that this patient would be referred for the clinical trial concerning the use of central venous catheters. The patient's current medical issue does not seem to align with the focus of the trial, which is on the initial placement of central venous catheters in ICU patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "171": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here is the analysis:\n\nPatient Note Summary:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Examination findings: pulsatile mass in the right groin, loss of distal pulses, bruit over the femoral artery entry point\n\nClinical Trial Summary:\n- Assessing the effect of acute inflammation on arterial stiffness and microcirculation\n- Patients with severe sepsis compared with matched controls\n- Inclusion criteria for controls: 18+ years, normal clinical examination and ECG, normal biological tests, BMI 18-27 kg/m\u00b2, informed consent\n- Inclusion criteria for patients group: 18+ years, severe sepsis with organ failure or tissue hypoperfusion, BMI 18-27 kg/m\u00b2, informed consent\n\nThe clinical trial is looking for two groups of participants: a control group and a patient group with severe sepsis. The patient in question has undergone a cardiac procedure and is experiencing symptoms that may indicate a vascular complication such as a femoral artery pseudoaneurysm or occlusion, but there is no mention of an infection or severe sepsis. Therefore, based on the information provided, this patient does not meet the inclusion criteria for either the control group or the patient group within the trial, as there is no indication of severe sepsis or the required matching with septic patients for the control group.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "172": {
        "output": "Considering the given patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 67-year-old woman, which fits within the age range of the inclusion criteria (19-90 years).\n- She underwent cardiac catheterization via the right femoral artery and is now presenting with a potential complication, as evidenced by a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit on auscultation over the right femoral artery entry point.\n\nClinical Trial Inclusion Criteria Analysis:\n- The clinical trial is investigating the use of an amplified stethoscope (AudioDoc) to detect the presence of bruits in the carotid and femoral arteries.\n- The inclusion criteria require participants to be between the ages of 19-90 and to be having a clinical ultrasound evaluation of the carotid or femoral artery.\n\nComparison:\n- The patient falls within the required age range.\n- The patient has signs suggestive of a femoral artery issue (specifically, a bruit over the femoral artery), which may warrant a clinical ultrasound evaluation. This could potentially make her a candidate for the study as the study aims to compare the detection of bruit using the AudioDoc with traditional auscultation and ultrasound.\n\nGiven the information provided, the patient could be considered for the clinical trial if a clinical ultrasound evaluation of the femoral artery is planned or deemed necessary due to her current presentation. However, an important factor is whether the trial is specifically looking for patients with potential arterial complications from procedures like cardiac catheterization or if it is more generally about detecting stenosis in asymptomatic patients.\n\nBased on the available information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "173": {
        "output": "Based on the patient note, the 67-year-old woman has undergone cardiac catheterization via the right femoral artery and is now experiencing complications related to the procedure, indicated by a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the access point.\n\nThe clinical trial in question is investigating the safety and efficacy of the CELT ACD\u00ae Vascular Closure Device, which is used to achieve hemostasis in the common femoral artery access site in patients who are undergoing percutaneous intervention (PCI) procedures with anticoagulation.\n\nTo determine trial-level eligibility, we must match the inclusion criteria with the patient's situation:\n\n1. Over 18 years of age - The patient is 67 years old, which meets this criterion.\n2. Each patient, or his or her guardian or legal representative, is willing to give informed consent - There is no information provided about the patient's willingness or capacity to consent, but we can assume that if the patient is competent, she can provide consent.\n3. Clinically indicated for an intra-arterial procedure involving access through the common femoral artery and conducted through an access sheath size of between 6F and 7F inclusive - The patient has already undergone a procedure through the right femoral artery, which suggests she has met this criterion.\n\nAlthough the patient has undergone a procedure that would potentially involve the use of the CELT ACD\u00ae Vascular Closure Device, there are no details indicating the patient is currently on anticoagulation or scheduled for another procedure that would require the device.\n\nGiven that the patient has had a recent arterial procedure and is experiencing complications that could potentially be addressed by the CELT ACD\u00ae device, there is a possibility that she might be considered for the trial if she requires further intervention. However, without further information regarding her current anticoagulation status or whether additional intervention is planned, we cannot be certain that she would be eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "174": {
        "output": "Based on the information provided:\n\nThe patient is a 67-year-old woman who underwent cardiac catheterization and is now experiencing symptoms that suggest a possible complication of the procedure, such as a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is focused on the use of fibrin-based adhesive for the prevention of surgical complications in kidney transplantation patients.\n\nThe inclusion criteria for the clinical trial are:\n- Patients candidates to renal transplantation\n\nThe patient in question is not indicated as being a candidate for renal transplantation. Instead, she is currently dealing with a potential vascular complication from a cardiac catheterization. There is no mention of the patient requiring a kidney transplant or having any related conditions that would make her a candidate for such a procedure.\n\nTherefore, based on the information provided and the mismatch between the patient's current medical issue and the focus of the clinical trial, the patient would not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "175": {
        "output": "Based on the inclusion criteria provided for the clinical trial, the patient in the note appears to be eligible for the study. The trial is focused on patients who have undergone cardiac surgery. The patient described underwent cardiac catheterization, which is a common procedure related to cardiac care, and is experiencing post-procedural complications which may be of interest to the study. Although the trial's inclusion criteria are broad (\"All cardiac surgical patients\"), it is reasonable to assume that patients who have complications after a cardiac-related procedure, such as cardiac catheterization, would be relevant to the study objectives.\n\nTherefore, considering the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "176": {
        "output": "Based on the patient note, the patient is a 67-year-old woman who underwent cardiac catheterization and is now experiencing complications potentially indicative of a vascular issue, such as a pseudoaneurysm or arteriovenous fistula, given the presence of a pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point.\n\nThe clinical trial in question is looking to recruit patients who are undergoing elective carotid endarterectomy, open or endovascular abdominal aortic aneurysm repair, or surgical lower limb revascularization. The patient in the note has undergone a cardiac catheterization, not any of the surgical procedures mentioned as part of the inclusion criteria for the trial.\n\nWhile the patient does meet the age criterion for inclusion (age greater than 18 years) and may be willing to give full informed consent (although this is not explicitly stated in the patient note), the patient is not currently undergoing any of the specific vascular operations listed in the trial's inclusion criteria.\n\nTherefore, based on the available information, this patient would not be a candidate for referral to the \"Preconditioning Shields Against Vascular Events in Surgery\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "177": {
        "output": "The patient note describes a 67-year-old woman who underwent cardiac catheterization and is now presenting with signs of a vascular complication, specifically a pulsatile mass, loss of distal pulses, and a bruit over the entry point of the right femoral artery. These symptoms suggest the possibility of a femoral artery pseudoaneurysm or occlusion rather than an acute ischemic stroke, which is the focus of the clinical trial described.\n\nThe clinical trial is focused on patients who have had a supratentorial acute ischemic stroke and are being considered for mechanical thrombectomy device treatment in addition to IV thrombolytic drug treatment. The inclusion criteria specify that the patient must have had a clinical diagnosis of supratentorial acute ischemic stroke, a neurological deficit with an NIHSS score \u22656, and eligibility for IV rtPA treatment within a certain time frame after stroke onset, among other specific criteria.\n\nBased on the information provided, the 67-year-old woman does not meet the inclusion criteria for this particular clinical trial as she does not have a diagnosis of acute ischemic stroke but rather a vascular issue related to a cardiac catheterization procedure.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "178": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 67-year-old woman with a recent cardiac catheterization experiencing a complication that could suggest a femoral artery issue, such as an arteriovenous fistula or pseudoaneurysm. However, the clinical trial in question is focused on the timing of antiretroviral treatment (ART) and its effects on arterial stiffness in the context of HIV treatment.\n\nThe inclusion criteria for the trial are quite specific:\n\n1. Simultaneous co-enrollment in the START study\n2. Signed informed consent\n\nThere is no information given in the patient note regarding HIV status or enrollment in the START study. The complication the woman is experiencing is unrelated to the focus of the clinical trial, which is on HIV treatment and arterial stiffness.\n\nTherefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "179": {
        "output": "",
        "label": 0
    },
    "180": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaining of a cool right foot\n- Pulsatile mass in right groin, loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical Trial Inclusion Criteria:\n- Women\n- Diagnosis of diabetes\n- Diagnosis of peripheral arterial disease (PAD)\n\nThe patient note indicates that the woman is experiencing symptoms that may be indicative of a complication from cardiac catheterization, such as a potential femoral artery injury or occlusion. However, there is no information provided in the note that the woman has been diagnosed with diabetes or peripheral arterial disease, which are required conditions for eligibility in the clinical trial.\n\nGiven the lack of information regarding a diagnosis of diabetes or PAD, it is not possible to definitively assess the patient's eligibility for the trial based solely on the provided patient note. Thus, further investigation would be needed to determine if the patient has the diagnoses required for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "181": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility:\n\nPatient Note Assessment:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization.\n- There is no mention of chronic heart failure or any details about her left ventricular function.\n- There is no information provided about her New York Heart Association (NYHA) class or Left Ventricular Ejection Fraction (LVEF).\n- There is no information on the patient's heart failure treatment or stability.\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years of age.\n- Patients with chronic heart failure (ischemic and non-ischemic etiology).\n- NYHA class II-IV.\n- LVEF \u2264 35%.\n- Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, stable for at least four weeks.\n- Informed consent must be given prior to enrollment.\n\nThe patient's eligibility cannot be definitively determined from the information provided. The patient note does not mention chronic heart failure or severe left ventricular dysfunction, nor does it provide any details that would allow us to infer her NYHA class or LVEF. Thus, we do not have enough information to determine if the patient meets the specific criteria for this trial. However, given that the patient does have a cardiac-related issue and is of the age group that often has heart failure, further investigation would be needed to assess her eligibility.\n\nTherefore, the assessment of eligibility for this patient, given the information provided, is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "182": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization via the right femoral artery earlier in the morning.\n- She is now complaining of a cool right foot, has a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery.\n\nClinical Trial Inclusion Criteria:\n- Over 18 years of age.\n- Willing to give informed consent.\n- Clinically indicated for an endovascular procedure involving access through the femoral artery, with an access puncture of 18 - 24 F.\n- Females who are not pregnant or lactating, and not planning to become pregnant \u2264 12 months.\n\nAssessment:\n- The patient is over 18 years of age (meets criteria).\n- There is no information regarding the patient's willingness to give informed consent, but this can typically be obtained if the patient agrees to participate (potential to meet criteria upon patient agreement).\n- The patient has recently undergone a procedure involving access through the femoral artery, but it is not stated whether the access puncture is in the range of 18 - 24 F. This information is crucial to determine eligibility (requires further investigation).\n- The patient's pregnancy status is not mentioned, so it would need to be confirmed that she is not pregnant, lactating, or planning to become pregnant in the next 12 months (requires further investigation).\n\nGiven that the patient has just had a procedure that could potentially align with the trial's requirements for a femoral artery access puncture, and assuming that the puncture size and pregnancy status can be confirmed to meet trial criteria, the patient could be considered for the trial. However, because there is not enough information on the puncture size and pregnancy status, I would lean towards further investigation before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "183": {
        "output": "Given the patient note and the clinical trial information provided, we must compare the patient's condition to the inclusion criteria of the clinical trial to assess eligibility.\n\nPatient note key points:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization earlier in the morning.\n- She is now experiencing symptoms suggestive of a vascular complication (cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery entry point).\n\nClinical trial key points:\n- The study focuses on patients who have been successfully resuscitated from cardiac arrest.\n- It aims to explore the benefits of total body cooling in patients with pulseless electrical activity (PEA) after cardiac arrest.\n- Inclusion criteria specify patients admitted to the ICU postcardiac arrest.\n\nFrom the available information, the patient in question does not appear to have suffered from cardiac arrest. Instead, she seems to be experiencing complications from a cardiac catheterization procedure. Therefore, she does not meet the primary reason for ICU admission required by the trial's inclusion criteria, which is postcardiac arrest.\n\nSince the patient's current medical situation does not align with the inclusion criteria, which specifically targets postcardiac arrest patients, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "184": {
        "output": "Based on the provided patient note and the clinical trial details:\n\nPatient note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Presenting with a pulsatile mass in the right groin with loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical trial:\n- Title: Immediate Mobilization After Cardiac Catheterisation\n- Purpose: Investigate frequency of bleeding and hematomas in patients mobilized immediately after the procedure vs. two hours post-procedure\n- Inclusion criteria:\n  - CAG or PCI performed via the femoral artery\n  - No hematoma in the groin (> 5 cm in diameter)\n  - Heparin reversed with protamine after PCI\n\nAssessment:\nThe patient underwent cardiac catheterization via the femoral artery, which aligns with the trial's inclusion criteria. However, the patient is showing signs of a possible post-procedure complication (cool foot, pulsatile mass, loss of distal pulses, and a bruit), which may indicate vascular complications such as an arterial occlusion or a forming hematoma. There is no information provided regarding the size of the hematoma, if present, or whether heparin was reversed with protamine. These are critical pieces of information needed to assess the patient's eligibility for the trial.\n\nGiven that the patient appears to be experiencing complications, which could be contraindications for immediate mobilization (not explicitly stated in the inclusion criteria but could be inferred as a safety concern), the patient would not be referred to the clinical trial until further investigation and stabilization of her condition. Therefore, the patient's eligibility for the trial is questionable without additional information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "185": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient described does not seem to be a good candidate for this specific trial. Here are the reasons:\n\n- The clinical trial is looking for patients who have undergone coronary artery bypass graft surgery (CABG) with cardiopulmonary bypass (CPB).\n- The inclusion criteria specify the use of the left internal thoracic artery and/or saphena, which indicates that the trial is focused on patients who have had specific types of grafts used in their cardiac surgery.\n- The patient must have remained in spontaneous ventilation on the first postoperative day, meaning they should not have required assisted ventilation.\n- The trial requires the absence of chronic or acute pulmonary disease.\n- Participants must give written informed consent.\n\nThe patient in the note underwent cardiac catheterization, not CABG surgery, and there is no indication of the patient having coronary artery disease confirmed by angiography or the use of the left internal thoracic artery and/or saphena as required by the trial. Additionally, there is no mention of the patient's respiratory status post-procedure or whether they have a pulmonary disease, which is an important part of the inclusion criteria. The main concern in the patient note is the development of a complication at the catheterization site (a pulsatile mass in the groin and cool foot suggesting a vascular complication), which is not related to the focus of the clinical trial on respiratory depression after CABG.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial on postoperative respiratory depression after cardiac surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "186": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following cardiac catheterization, specifically a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These findings suggest a vascular issue, possibly a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is investigating the effects of remote ischemic preconditioning (RIPC) on patients undergoing major vascular surgery. The inclusion criteria for the trial are:\n\n1. Age greater than 18 years\n2. Patient willing to give full informed consent for participation\n3. Patients undergoing elective carotid endarterectomy or\n4. Patients undergoing open abdominal aortic aneurysm repair or\n5. Patients undergoing endovascular abdominal aneurysm repair or\n6. Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)\n\nBased on the information provided in the patient note, the patient has not been described as undergoing any of the specific surgical procedures listed in the inclusion criteria. She has undergone cardiac catheterization, which is not mentioned in the trial's inclusion criteria. Therefore, it does not appear that this patient's current medical issue (complication post-cardiac catheterization) is related to the types of surgeries that are being studied in the trial (carotid endarterectomy, abdominal aortic aneurysm repair, or lower limb revascularisation).\n\nThus, based on the available information, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "187": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaints of a cool right foot after the procedure\n- Examination shows a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery\n\nClinical Trial:\n- Title: Left vs. Right Radial Approach for Routine Catheterization of Heart Transplant Patients\n- Summary: Compares trans right radial versus trans left radial approach in orthotopic heart transplantation patients undergoing routine coronary angiography\n- Inclusion Criteria: Transplanted patients scheduled for routine coronary angiography, age >18 years old\n\nAssessment:\nThe patient in the note has undergone cardiac catheterization and is experiencing complications potentially related to the procedure. However, there is no indication in the patient note that she is a heart transplant patient or that she is scheduled for routine coronary angiography, which are the key inclusion criteria for the clinical trial in question. Therefore, based on the information provided, the patient does not meet the inclusion criteria of being a heart transplant patient scheduled for routine coronary angiography.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "188": {
        "output": "In the given patient note, a 67-year-old woman is experiencing complications following cardiac catheterization via the right femoral artery. The clinical trial in question is investigating the use of a radioprotective device during cardiac catheterization in patients with acute coronary syndromes.\n\nThe inclusion criteria for the trial include:\n- Unstable angina with an indication for invasive stratification\n- Acute coronary syndrome without ST-segment elevation\n- Acute coronary syndrome with ST-segment elevation\n- Patient informed of the nature of the study and have signed the Informed Consent\n- Patient suitable for coronary angiography and / or percutaneous coronary intervention either by radial access or the femoral\n\nThe patient note does not mention acute coronary syndrome or unstable angina, which are key components of the inclusion criteria for the trial. Instead, the note describes a complication following a cardiac catheterization procedure. Moreover, there is no indication whether the patient was informed about the study or has signed the Informed Consent, which is a requirement for participation.\n\nGiven that the current medical issue described (a cool right foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point) may not directly align with the acute coronary syndromes mentioned in the inclusion criteria, and there is no information about the patient's consent or suitability for the procedures as per the trial's requirements, the patient does not appear to fit the inclusion criteria based solely on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "189": {
        "output": "Based on the patient note provided, the 67-year-old woman presented with a cool right foot and a pulsatile mass in her right groin following cardiac catheterization. She also has a loss of distal pulses and a bruit is audible over the point at which the right femoral artery was entered. This clinical presentation is suggestive of a vascular complication related to the cardiac catheterization, potentially a femoral artery pseudoaneurysm or occlusion, but not related to hemorrhoids or their treatment.\n\nThe clinical trial in question is focused on comparing different treatments for symptomatic grade III or IV hemorrhoids. The inclusion criteria specifically mention patients with symptomatic grade III or IV hemorrhoids eligible for surgical treatment with HAL-RAR or excision hemorrhoidectomy.\n\nSince the patient's current medical issue is unrelated to hemorrhoids, she does not meet the inclusion criteria for this trial, which are symptomatic grade III or IV hemorrhoids. Therefore, the patient would not be eligible for this clinical trial focused on hemorrhoid treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "190": {
        "output": "Based on the patient note, the 67-year-old woman underwent cardiac catheterization and is now presenting with symptoms suggestive of a vascular complication, specifically a potential femoral artery pseudoaneurysm or occlusion as indicated by the cool foot, loss of distal pulses, pulsatile mass, and bruit.\n\nThe clinical trial in question is focused on comparing the MynxGrip Vascular Closure Device to manual compression for closure after femoral access angiography, which is relevant to the patient's current situation given she has just undergone a procedure involving femoral artery access.\n\nThe inclusion criteria for the clinical trial specify that participants must be over 18 years old, able to provide valid informed consent, and have undergone a coronary angiography (CAG), possibly including additional intracoronary measurements or imaging.\n\nThe patient note does not mention if the cardiac catheterization was specifically a coronary angiography (CAG) or if it involved any of the specialized intracoronary procedures listed (FFR, IVUS, OCT, NIRS). However, given the patient has recently undergone a procedure involving femoral artery access, it is possible that she could be a candidate for the study if the procedure aligns with the trial's specifics regarding angiography.\n\nTherefore, based on the available information, the patient could potentially be eligible for the trial pending confirmation that her cardiac catheterization procedure matches the type of procedure the trial is investigating (CAG with or without the listed intracoronary procedures). \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "191": {
        "output": "",
        "label": 1
    },
    "192": {
        "output": "Based on the information provided, the 67-year-old woman has undergone cardiac catheterization via the right femoral artery and is now experiencing symptoms that suggest possible complications from the procedure, such as a pulsatile mass in her groin and loss of distal pulses, which could indicate a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is investigating the duration and adverse events of non-cuffed catheters in patients with chronic renal failure requiring hemodialysis. The inclusion criteria for the trial are:\n\n1. Chronic renal failure requiring hemodialysis.\n2. No medical history of central vena catheterization.\n3. Maintenance hemodialysis after central vena catheterization.\n4. Signed informed consent.\n\nThe patient's current medical issue, as described in the note, does not appear to be related to chronic renal failure or the need for hemodialysis. Additionally, there is no mention of her having chronic renal failure or being on hemodialysis. Therefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "193": {
        "output": "Based on the patient note provided, the 67-year-old woman is presenting with symptoms suggestive of a vascular complication, possibly a femoral artery pseudoaneurysm or occlusion, following a cardiac catheterization procedure. There is no mention of carotid stenosis or any related conditions in the patient note. \n\nThe clinical trial in question is focused on individuals with carotid stenosis greater than 60% as per NASCET criteria and is comparing the thrombogenicity of different materials used in carotid endarterectomy. \n\nSince the patient's current medical issue does not align with the inclusion criteria of the clinical trial \u2013 which specifically requires participants to have carotid stenosis \u2013 she would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "194": {
        "output": "Based on the patient note provided, here is the assessment:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot after the procedure\n- Has a pulsatile mass in her right groin\n- Loss of distal pulses\n- Bruit over the entry point of the right femoral artery\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18\n- Patient undergoing vascular surgery that includes a groin incision\n- Types of surgeries include infrainguinal bypass and femoral endarterectomy among others\n- Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent\n\nAssessment:\nThe patient is 67 years old, which satisfies the age criterion. However, the patient has just undergone cardiac catheterization and is experiencing complications that suggest the possible development of a femoral artery pseudoaneurysm or occlusion, rather than having had vascular surgery involving a groin incision. The trial specifies that patients must be undergoing vascular surgery that includes a groin incision.\n\nSince the patient is not currently scheduled for or recovering from vascular surgery that includes a groin incision, she does not meet the inclusion criteria for the trial based on the information provided. While vascular intervention may potentially be required due to her current complication, there's no indication that this is planned or that she would be undergoing the specific types of vascular surgery listed in the trial criteria.\n\nTherefore, based on the information available, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "195": {
        "output": "Based on the information provided, the 67-year-old woman who is experiencing complications post-cardiac catheterization does not meet the inclusion criteria for the clinical trial in question. The trial is specifically looking at the effects of surgical safety checklists on perioperative complications in children undergoing noncardiac surgery in Ontario, Canada. The inclusion criteria state that participants must be surgical patients aged between >28 days and <18 years on the day of the surgical intervention.\n\nSince the patient in question is 67 years old, she is well outside the specified age range for this study, which is focused on children. Additionally, her current medical issue is related to a cardiac intervention, not a noncardiac surgical intervention.\n\nGiven these discrepancies between the patient's characteristics and the trial's inclusion criteria, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "196": {
        "output": "Based on the information provided, the patient in question underwent cardiac catheterization and is now presenting with complications potentially related to the procedure, including a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms suggest a vascular complication, possibly a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is focused on patients indicated for typical atrial flutter ablation and is investigating the use of intracardiac echocardiography (ICE) in the ablation procedure. The only listed inclusion criterion is having an indication for atrial flutter ablation.\n\nThe patient's current condition does not indicate that she has atrial flutter or that she is a candidate for atrial flutter ablation. Therefore, she does not meet the inclusion criteria for this clinical trial, which specifically requires an indication for atrial flutter ablation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "197": {
        "output": "The patient note describes a 67-year-old woman who underwent cardiac catheterization and is now presenting with a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms are indicative of a vascular complication from the procedure, possibly a femoral artery pseudoaneurysm or occlusion, which requires immediate medical attention.\n\nThe clinical trial in question is focused on comparing the efficacy of continuous adductor canal blocks versus low dose femoral nerve blocks for early rehabilitation after total knee arthroplasty (TKA). The inclusion criteria specifically require patients who are able to consent to regional anesthesia and are having primary total knee arthroplasty/replacement.\n\nBased on the information provided, the patient in the note is not undergoing a total knee arthroplasty but is experiencing a complication from a cardiac procedure. Therefore, she does not meet the inclusion criteria for the clinical trial, which is specifically targeting patients undergoing TKA and assessing pain management strategies postoperatively.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "198": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we need to assess whether the 67-year-old woman is a candidate for the clinical trial comparing modified Non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) to Brachiocephalic arteriovenous fistula (BCAVF) in hemodialysis patients.\n\nThe patient is a 67-year-old woman who has had a cardiac catheterization and is now experiencing issues with her right foot, suggestive of vascular complications such as a pseudoaneurysm or occlusion given the presence of a pulsatile mass and loss of distal pulses.\n\nThe inclusion criteria for the clinical trial are:\n1. Age from 18 to 75 years\n2. Radial artery diameter <2.0 mm or cephalic vein diameter in the forearm <2.5 mm\n3. Brachial artery diameter \u2265 2 mm\n\nThe patient falls within the age range specified (67 years old). However, the patient note does not provide information about the diameters of her radial or brachial arteries or the cephalic vein in her forearm. Additionally, there is no information indicating that she is a hemodialysis patient or that she requires an arteriovenous fistula for hemodialysis access.\n\nGiven the lack of information on her vascular measurements and hemodialysis status, we cannot conclusively determine her eligibility. The patient's current vascular issue following cardiac catheterization is also not directly relevant to the trial's focus, which is on vascular access for hemodialysis.\n\nTherefore, based on the available information:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "199": {
        "output": "The patient described in the note is a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is experiencing complications potentially related to the procedure, such as a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point.\n\nThe clinical trial in question is focused on patients with pulmonary arterial hypertension (PAH), specifically targeting those who have not had their condition controlled by optimal medical management, and are classified as NYHA class III or IV. The intervention being studied is pulmonary artery denervation.\n\nTo assess the patient's eligibility for the clinical trial, we must compare her condition and situation with the inclusion criteria stated for the trial:\n\n- Patients with pulmonary artery hypertension (group 1 of the Nice classification of pulmonary hypertension)\n- Aged over 18 years old\n- NYHA class III or IV\n- Not controlled by optimal medical management\n- Signed informed consent\n\nThe patient note does not mention pulmonary arterial hypertension, nor does it describe any symptoms or treatments related to PAH. The only condition mentioned is related to complications post cardiac catheterization. There's no indication that the patient has PAH, is in NYHA class III or IV for heart failure, or is on any relevant therapies for PAH.\n\nBased on the information provided, there is no indication that this patient would meet the criteria for the clinical trial focused on pulmonary arterial hypertension as her condition (complications post cardiac catheterization) does not align with the target disease (PAH) of the study.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "200": {
        "output": "Given the information provided in the patient note:\n\nA physician is called to see a 67-year-old woman who underwent cardiac catheterization via the right femoral artery earlier in the morning. She is now complaining of a cool right foot. Upon examination she has a pulsatile mass in her right groin with loss of distal pulses, and auscultation reveals a bruit over the point at which the right femoral artery was entered.\n\nAnd the clinical trial in question:\n\nTitle: Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment\n\nInclusion criteria are:\n- Minimum 18 years old\n- Diagnosed with PAH or non-operable CTEPH or operated CTEPH with persistent pulmonary hypertension\n- Diagnosis of PAH based on cardiac catheterization\n- Diagnosis of CTEPH confirmed by contrast-enhanced spiral chest CT, pulmonary angiography, and V/Q scintigraphy\n- Recent diagnosis of sleep-disordered breathing (polysomnography realized within 3 months before inclusion showing AHI above 15)\n- Stable clinical condition for at least 3 months before inclusion as defined by NYHA and a walking distance difference within 10% of the previous 3 months and no change in medical therapy during this 3 months\n\nThe patient in the note is not explicitly stated to have pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or sleep-disordered breathing. The patient's issue seems to be related to a complication from a cardiac catheterization procedure, with no mention of pulmonary hypertension or sleep disordered breathing. Thus, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "201": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot\n- Pulsatile mass in her right groin with loss of distal pulses\n- Bruit over the point at which the right femoral artery was entered\n\nClinical trial inclusion criteria:\n- Newly healed leg or diabetic foot ulcer within past 7 - 14 days\n- Ankle brachial index 0.8- 1.3mmHg (rule out absence of arterial disease)\n- Willing to wear compression stockings and appropriate footwear\n- Working freezer\n\nThe patient in question is presenting with a cool right foot and a pulsatile mass in her right groin following cardiac catheterization, which are indicative of a possible vascular complication, such as a pseudoaneurysm or arterial occlusion, rather than a healed leg or diabetic foot ulcer. There is no mention of the patient having a leg or diabetic foot ulcer, let alone one that has healed within the past 7 - 14 days. Thus, the patient does not meet the study's specific inclusion criteria regarding the ulcer healing status.\n\nAdditionally, the presence of a pulsatile mass with a loss of distal pulses suggests that the patient may have arterial disease, which could potentially be contraindicated as per the trial's inclusion criteria that require an ankle brachial index between 0.8 and 1.3mmHg to rule out the absence of arterial disease.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial, and it would not be appropriate to refer her for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "202": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia\", let's compare the patient's characteristics with the inclusion criteria provided:\n\nPatient's Characteristics:\n- Age: 67-year-old woman\n- Condition: Complaints of a cool right foot after cardiac catheterization, pulsatile mass in right groin, loss of distal pulses, and bruit over the point at which the right femoral artery was entered.\n\nInclusion Criteria:\n1. Willing, able, and committed to participate in the procedures for the full length of the study.\n2. All ethnic groups, male or female above the age of 18 years.\n3. Diagnosis of non-reconstructable arterial disease and critical limb ischaemia (with a minimum of duplex ultrasound and an MDT discussion to have reached this diagnosis)\n4. Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device.\n5. Blood pressure currently under moderate control (< 160/100mmHg)\n6. History of uncomplicated cardiovascular events beyond 3 months.\n7. No current foot ulceration\n\nFrom the patient note, we do not have enough information to confirm that the patient has non-reconstructable arterial disease and critical limb ischaemia, which is a key criterion for this study. While the symptoms mentioned suggest a vascular problem, likely related to the catheterization procedure, they do not necessarily indicate critical limb ischaemia. Moreover, a diagnosis of critical limb ischaemia would typically require more detailed investigation such as duplex ultrasound and multidisciplinary team (MDT) discussion, which are not mentioned in the patient note.\n\nGiven the lack of information confirming a diagnosis of critical limb ischaemia, and the fact that the patient's current symptoms seem to be acute and related to a recent procedure, it is not clear that this patient would meet all the necessary inclusion criteria for this trial.\n\nTherefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "203": {
        "output": "After reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the patient's eligibility as follows:\n\nThe inclusion criteria for the trial are:\n1. Age 18-60 years\n2. Right-handed non-smokers\n3. Diagnosed with facial pain\n4. Continuous pain for more than 3 months\n5. Spontaneous pain greater than 3 of 10\n6. Allodynia to brush greater than 5 of 10\n\nThe patient in question is a 40-year-old woman, which fits the age criterion. However, there is no information provided about her being right-handed, a non-smoker, or having facial pain, specifically. The patient note indicates she has excruciating pain in her right arm, not her face. There is also no mention of the duration of her pain, whether it is continuous or not, or the presence of allodynia.\n\nGiven that the patient's condition does not match the specific requirements of the trial (which are focused on facial pain, not arm pain), she would not meet the necessary inclusion criteria for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "204": {
        "output": "Based on the patient note provided, the patient is a 40-year-old woman who presents to the ER with excruciating pain in her right arm that began an hour prior to admission. There is no indication of diabetic peripheral neuropathic pain or diabetes in the patient's history. In addition, the pain she is experiencing is acute, localized to her right arm, and there is no mention of it being present for at least 6 months as required by the clinical trial's inclusion criteria.\n\nThe clinical trial's target population is patients with pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes, with the pain beginning in the feet and present for at least 6 months. Additionally, participants need to score 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.\n\nSince the patient does not exhibit the specific type of pain (diabetic peripheral neuropathic pain) described in the inclusion criteria and there is no mention of diabetes or chronic pain present for at least 6 months, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "205": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 40-year-old woman with no past medical history who presents with excruciating pain in her right arm. She is pale, in moderate discomfort, tachypneic, tachycardic, and hypotensive (blood pressure 80/60), but she does not have any discoloration or movement limitation in her right arm.\n\nThe clinical trial in question is looking to recruit asymptomatic subjects older than 40 years of age without any history of coronary artery disease (CAD) but one cardiovascular risk factor with documented silent ischemia. The patient does not have a history of CAD mentioned, but she is not asymptomatic as she presents with excruciating pain in her right arm. Additionally, there is no mention of documented silent myocardial ischemia type I or any cardiovascular risk factors.\n\nGiven the information provided, the patient does not meet the inclusion criteria of being asymptomatic or having documented silent ischemia. Thus, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "206": {
        "output": "Based on the patient note provided, the 40-year-old woman presents with excruciating pain in her right arm, which is an acute symptom rather than chronic or recurrent right lower abdominal quadrant pain. The clinical trial in question is specifically studying the effects of elective laparoscopic appendectomy on patients with persistent or recurrent lower abdominal quadrant pain, and this patient's symptoms do not align with the condition being studied.\n\nGiven that the patient's current complaint does not match the inclusion criteria of chronic or recurrent right lower abdominal quadrant pain and there is no mention of a history of such pain, it is not appropriate to refer this patient to the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "207": {
        "output": "The patient presented in the note is a 40-year-old woman with severe pain in her right arm. There is no indication of brain trauma or any mention of a head injury. The clinical trial in question is specifically seeking patients who have suffered acute moderate brain trauma, and the tools being used (MR spectroscopy and diffusion tensor imaging) are meant to assess brain injury and its correlation with clinical outcomes.\n\nSince there is no evidence in the patient note that suggests the patient has suffered from a brain injury, she does not meet the inclusion criteria for the clinical trial, which is focused on patients with moderate brain trauma. Therefore, based on the information provided, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "208": {
        "output": "Upon reviewing the patient's note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the necessary criteria for inclusion in the trial.\n\nThe patient is a 40-year-old woman with no past medical history of diabetes and currently presents with symptoms unrelated to Type 2 Diabetes Mellitus. The clinical trial is specifically looking for asymptomatic subjects with Type 2 Diabetes Mellitus and has an age range of 50-75 years for its participants.\n\nSince the patient does not have a diagnosis of Type 2 Diabetes Mellitus and is also below the age range specified in the inclusion criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "209": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for Low Level Laser Therapy to Reduce Chronic Pain, let's compare the necessary elements:\n\nPatient Characteristics:\n- Age: 40 years old (Inclusion criteria: 18-65 years of age)\n- Pain: Excruciating pain in the right arm (Inclusion criteria: Muscular-skeletal pain in the neck/shoulder region)\n- Chronicity: No mention of the duration of pain (Inclusion criteria requires acute and chronic pain)\n- Range of motion: No movement limitation (Inclusion criteria: Restricted range of motion in the neck/shoulder region)\n- Location: Pain is in the right arm, not specified as neck/shoulder (Inclusion criteria specifically mentions neck/shoulder region)\n- VAS score: Not provided (Inclusion criteria: Rating of 30 or greater on the VAS pain scale)\n\nFrom the information given, the patient's pain is not specified to be in the neck/shoulder region, which is a requirement for the clinical trial. The chronicity of the pain is also not mentioned, and there is no information on the VAS score or any indication of fibrosis, scar tissue, inflammation, altered function, or muscle strains specifically in the neck/shoulder region.\n\nGiven the mismatch between the patient's presenting symptoms and the inclusion criteria for the clinical trial, particularly the location of the pain, and the lack of information on several other criteria, the patient does not appear to be a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "210": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the eligibility requirements for the trial. The trial is focused on patients who have had a second generation drug-eluting stent implanted due to angina pectoris or documented silent ischemia. The patient in the note is presenting with pain in her right arm, with no mention of angina, silent ischemia, or any stent implantation.\n\nThe patient note does not provide any information that aligns with the inclusion criteria of the clinical trial, such as the diagnosis of angina pectoris, unstable angina pectoris, or documented silent ischemia, nor does it mention the patient having undergone any stent implantation.\n\nTherefore, based on the available information, the patient does not qualify for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "211": {
        "output": "Based on the patient note provided, the 40-year-old woman presents with acute pain in her right arm, without any prior medical history that is mentioned. There is no indication in the patient note that she has been diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), nor are there any details suggesting a progressive or relapsing dysfunction from motor and sensory or symmetric motor nerve only in at least one limb, which is required for eligibility in the clinical trial.\n\nThe clinical trial in question is specifically looking for subjects with CIDP, either newly diagnosed or with a history of the condition with specific treatment criteria. Since the patient does not have a documented history of CIDP or treatment for CIDP, she does not meet the inclusion criteria for this clinical trial based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "212": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 40-year-old woman.\n- She presents with excruciating pain in her right arm without prior trauma.\n- She is pale, tachypneic, tachycardic, and hypotensive (blood pressure is 80/60).\n- There are no signs of discoloration or movement limitation in her right arm.\n\nClinical Trial Inclusion Criteria:\n- The patient must be ventilated and in sinus rhythm.\n- The patient must have septic shock requiring a hemodynamic assessment.\n\nThe patient note indicates that the woman is in moderate discomfort and shows signs of possible shock (evidenced by tachypnea, tachycardia, and hypotension), but there is no specific mention of septic shock or the need for mechanical ventilation.\n\nThe diagnosis of septic shock would typically require signs of infection along with the hemodynamic disturbances. The patient's presentation with excruciating pain, without fever or other signs of infection, does not specifically point to septic shock.\n\nThe patient is not described as being ventilated, which is a specific requirement for this trial's inclusion criteria. Additionally, there is no explicit mention of sinus rhythm, although there is no indication of arrhythmia either.\n\nGiven the information provided, the patient does not clearly meet the criteria for the clinical trial. She may require further assessment to determine if she is indeed experiencing septic shock and if mechanical ventilation is needed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "213": {
        "output": "",
        "label": 0
    },
    "214": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria for the clinical trial on palmar-plantar erythrodysesthesia (PPE) treatment with topical sildenafil.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Receiving capecitabine or sunitinib as part of routine standard care.\n- CTCAE version 4.0, grade 1-3 PPE.\n- Adults age \u2265 18\n- Karnofsky (KPS) performance status of \u226570%\n- Adequate organ and marrow function as defined in the criteria.\n- Not pregnant or lactating.\n- Use of adequate birth control (for women of childbearing potential).\n- Ability to understand and the willingness to sign a written informed consent document.\n\nThe patient note presents a 40-year-old woman with excruciating pain in her right arm, without any mention of cancer treatment or palmar-plantar erythrodysesthesia (PPE). There is no indication that she is receiving capecitabine or sunitinib, which are specific medications linked to the development of HFS/PPE and are required for inclusion in the study.\n\nBased on the information provided in the patient note, which does not mention any of the key inclusion criteria relevant to the clinical trial (e.g., no mention of cancer treatment, PPE, or relevant medications), the patient does not meet the inclusion criteria for the clinical trial on PPE treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "215": {
        "output": "Based on the information provided in the patient note, the 40-year-old woman presents with excruciating pain in her right arm, is pale, in moderate discomfort, tachypneic, tachycardic, with a low blood pressure of 80/60, but without discoloration or movement limitation in her arm. There is no mention of infection, fever, or other systemic signs that would suggest sepsis. The clinical trial in question is looking for patients with septic shock, which is defined by the presence of infection along with other systemic signs and the necessity of vasopressor treatment.\n\nThe patient in the note does not clearly fulfill the criteria for septic shock as defined by the inclusion criteria. While she has some signs that could be associated with sepsis, such as being pale, tachypneic, tachycardic, and hypotensive, there is no documented or strong suspicion of infection mentioned, nor is there any indication that she requires vasopressor treatment. Furthermore, the inclusion criteria specify that the patient must meet 2 or more SIRS criteria and have a shock that requires vasopressor treatment. The patient note does not provide enough evidence to confidently assert that this patient has septic shock or meets the specific SIRS criteria.\n\nGiven the lack of clear evidence of infection or septic shock, it would be inappropriate to refer this patient for the septic shock clinical trial based on the information provided. However, further investigation would be needed to fully assess for sepsis or other conditions, but as per the given scenario, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "216": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Assessment:\n- The patient is a 40-year-old woman, which satisfies the age requirement of being \u2265 18 years of age.\n- The patient presents to the ER with excruciating pain in her right arm, with no mention of stable angina pectoris or silent ischemia (positive stress test without chest pain).\n- There is no mention of the patient being scheduled for coronary angiography or possible angioplasty, which is required for the trial.\n- The patient's current medication regimen is not mentioned, so we cannot confirm if she is on dual anti-platelet therapy with aspirin and clopidogrel.\n- The patient's willingness and ability to conform to the requirements of the study and whether she has signed an informed consent cannot be determined from the note.\n- There is no information on whether the patient has any illness or condition that would impair the results of the study.\n- It is not indicated whether the patient is of childbearing potential or if a pregnancy test has been performed.\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years.\n- Presents with stable angina pectoris, or silent ischemia.\n- Scheduled for coronary angiography, with possible angioplasty.\n- Able to tolerate and on dual anti-platelet therapy with aspirin and clopidogrel.\n- Able and willing to conform to study requirements and has signed an informed consent.\n- No illness or condition that would impair study results.\n- Women of childbearing potential must have a negative pregnancy test.\n\nGiven the information in the patient note, the patient does not clearly meet the specific disease condition criteria (stable angina or silent ischemia) for the clinical trial, nor is there any mention of the patient being scheduled for PCI or being on the specified medications. Therefore, we cannot conclude that the patient is eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "217": {
        "output": "Based on the provided patient note, the patient is a 40-year-old woman who presents with excruciating pain in her right arm without prior trauma. She is pale, in moderate discomfort, tachypneic, tachycardic, and hypotensive with a blood pressure of 80/60. While she does exhibit some signs that could be associated with shock (tachycardia and hypotension), there is no clear evidence from the note that she meets all the criteria for septic shock or acute respiratory distress syndrome (ARDS) as required by the clinical trial's inclusion criteria.\n\nThe inclusion criteria for the clinical trial specify that patients must be diagnosed with shock or ARDS. For shock, four criteria must be present, including a heart rate of at least 90/min, a respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower or the use of mechanical ventilation, the use of vasopressors to maintain a systolic blood pressure of at least 90mmHg despite fluid resuscitation, and at least one sign of hypoperfusion.\n\nFor ARDS, the criteria include an acute decrease in PaO2/FIO2 to 200mmHg or lower, bilateral pulmonary infiltrates or a chest radiograph consistent with edema, no clinical evidence of left atrial hypertension, and the requirement for positive pressure ventilation.\n\nFrom the patient note, we do not have enough information to confirm a diagnosis of shock or ARDS. There are no details about her heart rate, PaCO2 levels, urine output, neurological dysfunction, plasma lactate levels, PaO2/FIO2 ratio, or chest radiograph findings. Moreover, there is no mention of the use of vasopressors or positive pressure ventilation.\n\nTherefore, based on the information provided, we cannot conclusively determine that the patient meets the inclusion criteria for the clinical trial. Further investigation would be needed to ascertain whether she has shock or ARDS according to the trial's definitions.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "218": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not appear to meet the specified criteria for the study on PTSD. The patient note does not mention any diagnosis of PTSD or any related symptoms; instead, it describes acute pain in the patient's right arm with no clear cause. The inclusion criteria require a diagnosis of PTSD according to the DSM-IV criteria, as well as a certain severity of PTSD symptoms as measured by the CAPS score.\n\nWithout any indication of PTSD in the patient's described condition, there is no basis to refer this patient to the PTSD clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "219": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess that the patient:\n\n- Is a 40-year-old woman\n- Presents with acute pain in her right arm\n- Is pale, tachypneic, and tachycardic\n- Has normal body temperature\n- Has low blood pressure (80/60)\n- Her right arm has no discoloration or movement limitation\n- There is no mention of Chagas disease or any related diagnosis\n\nThe clinical trial's inclusion criteria specify that the patient must:\n\n- Have Chagas disease, confirmed by two serological tests\n- Show evidence of certain electrical disorders on diagnostic tests\n- Be asymptomatic or have minimal isolated unspecific symptoms not consistent with serious cardiac conditions\n- Have ejection fraction of left ventricle >35%\n- Be able to give written informed consent\n- Be > 21 years old\n- Be able to return for follow-up visits as required\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial because there is no indication that she has Chagas disease or any of the specific cardiac conditions listed in the inclusion criteria. Since one of the primary inclusion criteria (having Chagas disease) is not met, it is clear that this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "220": {
        "output": "Given the patient note and the clinical trial's inclusion criteria:\n\nPatient Note:\n- 40-year-old woman\n- Presents with excruciating pain in her right arm\n- No history of trauma\n- Pale, moderate discomfort\n- Tachypneic and tachycardic\n- Normal body temperature\n- Low blood pressure (80/60)\n- Right arm has no discoloration or movement limitation\n\nClinical Trial:\n- Title: Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in Patients With Symptoms and Signs in Favor of PTE\n- Inclusion Criteria: Patients with signs or symptoms in favor of Pulmonary Thromboemboli (PTE) who come to the emergency department\n\nThe patient has presented with symptoms that could be suggestive of a serious condition, but the provided information does not specifically indicate signs or symptoms that are clearly in favor of Pulmonary Thromboembolism (PTE). Symptoms of PTE typically include shortness of breath, chest pain, cough, and sometimes symptoms like those of a heart attack. While the patient is tachypneic and tachycardic, which might occur with PTE, there is no clear evidence of respiratory symptoms or chest pain mentioned.\n\nSince the patient's presentation is not specific for PTE, but the low blood pressure and tachycardia could potentially be associated with some form of embolism, further investigation would be needed to ascertain the cause of her symptoms and whether they could be related to PTE. Therefore, additional diagnostic workup would be required before considering her for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "221": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility appears to be as follows:\n\nThe patient is a 40-year-old woman who presents with excruciating pain in her right arm, which is not related to chest pain or symptoms consistent with possible Acute Coronary Syndrome (ACS). The inclusion criteria for the clinical trial require participants to be at least 21 years old and to have chest discomfort or other symptoms consistent with possible ACS. Additionally, the treating physician should feel that the patient could be discharged home if cardiac disease was excluded.\n\nSince this patient presents with arm pain and not chest pain, and there is no indication that the symptoms are consistent with possible ACS, she does not meet the inclusion criteria specified for the clinical trial. Therefore, she would not be referred for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "222": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient does not meet the criteria for the clinical trial.\n\nThe clinical trial is looking for primiparous women who have had a vaginal delivery, vacuum-assisted-vaginal-delivery (VAVD), or forceps-assisted-vaginal-delivery (FAVD) of a neonate of gestational age 27 completed weeks, who are also experiencing issues with anal incontinence as a result of obstetric trauma.\n\nThe patient note describes a 40-year-old woman presenting with excruciating pain in her right arm, with no mention of recent childbirth, anal incontinence, or obstetric trauma. Therefore, she does not match the population targeted by the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "223": {
        "output": "Based on the provided patient note, the 40-year-old woman presents to the ER with excruciating pain in her right arm that had started 1 hour prior to her admission. The intensity of her pain is described as excruciating, which suggests it would be greater than 3 out of 10 on any standardized pain scale, although the exact number is not provided in the note. This meets the inclusion criteria of the clinical trial, which requires patients to report pain greater than or equal to 3 out of 10. \n\nTherefore, considering the information given, the patient appears to meet the inclusion criteria for the clinical trial titled \"Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "224": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- A 40-year-old woman with excruciating arm pain, no mention of hand dystonia or any movement disorder.\n- She is right-handed, which fits one of the criteria.\n- No information is given about her caffeine or alcohol consumption, open scalp wounds, or drug use.\n- No information about any neurological abnormalities besides the arm pain she is presenting with.\n- No information is provided on her mental health status, other neurological disorders, history of head injury, implanted medical devices, hearing loss, or medication use.\n\nClinical Trial Inclusion Criteria:\n- Confirmed diagnosis of focal hand dystonia (patients only).\n- Between age 18 and 70 years.\n- Able to give informed consent.\n- Right-handed.\n- Agrees to not drink caffeine or alcohol for 48 hours before the study session.\n- No open scalp wounds or scalp infections.\n- No use of illegal drugs within the past 6 months, etc.\n\nThe patient note does not indicate that the patient has focal hand dystonia, which is a primary requirement for participation in the clinical trial. Although the patient's exact condition is not fully disclosed, the information given points to an acute event rather than a chronic movement disorder. Therefore, based on the information provided in the patient note, the patient does not meet the key inclusion criterion of having a confirmed diagnosis of focal hand dystonia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "225": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Details:\n- 40-year-old woman\n- No past medical history\n- Presenting with excruciating pain in her right arm\n- No trauma reported\n- Tachypneic and tachycardic\n- Blood pressure is 80/60\n- No discoloration or movement limitation of the arm\n\nClinical Trial Inclusion Criteria:\n- Written informed consent by patient or relative\n- Time in ICU < 48 hours\n- Septic shock\n- Pulmonary artery catheter and radial arterial catheter\n- Age 18 - 75 years\n- Sinus rhythm\n- Need for norepinephrine over 0.1 ug/kg/min but otherwise hemodynamically stable\n- Mechanical ventilation with sedation\n- Pwcp <18 mmHg\n\nAnalysis:\n- The patient's age fits within the trial's inclusion criteria (18 - 75 years).\n- There is no mention of the patient being in septic shock, having a pulmonary artery or radial arterial catheter, or being mechanically ventilated with sedation.\n- The low blood pressure (hypotension) may be indicative of a critical condition, but we do not have enough information to diagnose septic shock.\n- The symptom of excruciating pain without discoloration or movement limitation does not align with typical septic shock presentation.\n- The patient's cardiac rhythm is not mentioned, so we cannot confirm sinus rhythm.\n- There is no information on the patient requiring norepinephrine or being hemodynamically stable.\n- The patient does not appear to be in the ICU, which is another requirement for the trial.\n\nGiven the information provided in the patient note, there is insufficient evidence to suggest that the patient meets the inclusion criteria for the clinical trial, particularly the specific criteria related to septic shock and the interventions required (e.g., norepinephrine administration, mechanical ventilation). Therefore, the patient is not a suitable candidate for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "226": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Summary:\n- A 40-year-old woman\n- No history of pulmonary hypertension mentioned\n- Presents with excruciating pain in her right arm\n- Tachypneic, tachycardic, hypotensive\n- No discoloration or movement limitation of the arm\n\nClinical Trial Inclusion Criteria:\n- Man or woman aged over 18\n- With suspicion or diagnosis of pulmonary hypertension\n- For the prospective arm: Scheduled to undergo right heart catheterization\n- Able and willing to give informed consent\n- For the retrospective arm: Diagnosis of pulmonary hypertension confirmed by right heart catheterization in the past\n\nAssessment of Eligibility:\nThe patient does not have a diagnosis of pulmonary hypertension, nor is there any mention of a suspicion of pulmonary hypertension or that she is scheduled to undergo right heart catheterization. Therefore, the patient does not meet the specific inclusion criteria related to pulmonary hypertension for either the prospective or retrospective arm of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "227": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 40-year-old woman\n- Presents with excruciating pain in her right arm, no history of trauma\n- Signs of distress: pale, moderate discomfort, tachypneic, tachycardic\n- Hypotensive (80/60)\n- No discoloration or movement limitation in the right arm\n\nClinical Trial Inclusion Criteria:\n- Admitted to the hospital for care of injuries\n- Have a greater than minimal (moderate to highest) level of VTE risk\n\nThe provided patient note does not indicate that the woman has been admitted for care of injuries related to trauma. The patient presents with pain in her right arm without any trauma and the symptoms could suggest other medical conditions rather than injuries from trauma. There is no specific information given about a VTE risk level for this patient.\n\nGiven the lack of evidence from the patient note that the patient has been admitted for trauma-related injuries or has a documented moderate to highest level of VTE risk, she does not seem to meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "228": {
        "output": "",
        "label": 0
    },
    "229": {
        "output": "Given the patient note and the clinical trial information provided, here is the assessment:\n\nPatient Note Assessment:\n- The patient is a 40-year-old woman with acute pain in her right arm.\n- She presents with hypotension, tachycardia, and tachypnea but no trauma or discoloration, and movement is not limited in her right arm.\n\nClinical Trial Assessment:\n- The trial is focused on diagnosing pneumonia under low-resource conditions in children.\n- The inclusion criteria specify that participants must be children below 5 years old meeting the WHO age-dependent tachypnea criteria.\n\nComparison:\n- The patient in the note is a 40-year-old woman, which does not match the age criterion for the clinical trial, which is specifically for children below 5 years old.\n\nConclusion:\nThe patient does not meet the age inclusion criteria for the clinical trial, as she is well above the maximum age limit of 5 years. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "230": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient would not be eligible for the clinical trial. The trial is specifically looking for asymptomatic subjects between the ages of 18 and 30 years old. The patient is a 40-year-old woman who presents with excruciating pain in her right arm, which means she is symptomatic and also outside the age range specified in the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "231": {
        "output": "In the provided patient note, we have a 40-year-old woman who presents to the ER with excruciating pain in her right arm, without a history of trauma. She is pale, in moderate discomfort, tachypneic, and tachycardic, with normal body temperature and low blood pressure. There is no mention of chest pain, angina, or symptoms that would typically be associated with acute coronary syndrome (ACS). Additionally, there is no information provided about her GRACE risk score or levels of high-sensitivity cardiac troponin (hs-cTn).\n\nThe clinical trial is focused on patients presenting with typical angina pectoris, who have a low GRACE risk score, are at least 18 years old, and provide informed consent. The patient in the note does not present with typical angina pectoris, which is a requirement for the clinical trial's inclusion criteria. Without this information, we cannot determine whether the patient's condition is related to ACS, nor can we confirm that she meets other specific inclusion criteria such as the GRACE risk score.\n\nGiven that the patient does not present with symptoms of ACS and no further information is available to suggest a diagnosis of ACS or a low GRACE risk score, it would be inappropriate to refer her to this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "232": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the eligibility of the patient:\n\nPatient Note:\n- A 40-year-old woman with severe pain in her right arm, tachypneic and tachycardic, with a blood pressure reading of 80/60.\n\nClinical Trial Inclusion Criteria:\n- Healthy Caucasian male subjects aged between 18 and 45 years (inclusive) at screening.\n- Subjects must be in good health with no clinically significant findings on physical examination, among other specific health criteria.\n\nThe patient in the note does not meet a number of key inclusion criteria for the clinical trial:\n\n1. Gender: The trial is specifically looking for male subjects, while the patient is a woman.\n2. Health status: The patient presents with severe pain and abnormal vital signs, which does not align with the requirement for healthy subjects with no clinically significant findings.\n3. The patient's current medical emergency (severe pain and abnormal vital signs) would require immediate attention and treatment, which is not compatible with the nature of a Phase 1 trial in healthy volunteers.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "233": {
        "output": "Assessing the eligibility of the presented patient for the clinical trial titled \"Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain\" requires a comparison of the patient's characteristics and medical condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- A 40-year-old woman\n- No past medical history mentioned\n- Presents with excruciating pain in her right arm\n- No mention of knee pain or osteoarthritis\n\nClinical Trial Inclusion Criteria:\n- Age 45 to 80 years old\n- Clinical diagnosis of osteoarthritis in one target knee\n- Knee pain and other specified criteria related to osteoarthritis\n- Symptoms associated with osteoarthritis of the knee for \u2265 6 months\n- Knee pain requiring NSAID or other therapy for \u2265 15 days in the prior month\n- Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification Grade 2 or 3\n- Meets pain assessment entry criteria as defined by the study\n- No significant change in physical activity or therapy for the past 3 months\n- Able to provide written informed consent and comply with trial requirements\n\nThe patient in question does not meet the age criterion, as she is 40 years old and the trial requires participants to be between 45 and 80 years old. Additionally, the patient presents with pain in her right arm, not knee pain associated with osteoarthritis. There is no mention of a diagnosis of osteoarthritis, knee pain, or any treatment related to osteoarthritis, and no information provided about the patient's history that would suggest she meets the clinical diagnosis criteria for osteoarthritis of the knee as per the American College of Rheumatology (ACR) criteria.\n\nGiven the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial on osteoarthritis of the knee. She is not the right age, and there is no indication that she has osteoarthritis or knee pain, which are fundamental requirements for participation in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "234": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, here's the assessment:\n\nPatient Note:\n- A 40-year-old woman\n- No past medical history\n- Presents with excruciating pain in her right arm\n- No discoloration or movement limitation in the arm\n- Tachypneic and tachycardic\n- Blood pressure is 80/60\n\nClinical Trial Inclusion Criteria:\n- Patients needing venous blood sampling or insertion of an intravenous cannula\n- Normal development according to parents\n\nIn this case, the patient is an adult who might need venous blood sampling or insertion of an intravenous cannula because she is in the emergency room with a medical condition that could require such procedures for diagnosis or treatment. However, the trial specifically mentions a \"medical clown in a pediatric emergency department,\" which implies that the trial is aimed at children. Furthermore, the assessment of development \"according to parents\" also suggests the trial is aimed at pediatric patients, not adults.\n\nGiven that the patient is 40 years old and the study seems to be specifically designed for pediatric patients (children), she does not meet the inclusion criteria for age and the context of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "235": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 40-year-old woman.\n- She presents with excruciating pain in her right arm.\n- There is no mention of trauma.\n- Her vital signs indicate possible shock (pale, moderate discomfort, tachypneic, tachycardic, hypotension).\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is seeking 30 healthy volunteers.\n- Volunteers must not have consumed coffee or any other substances that could affect the autonomic nervous system.\n\nComparison:\n- The patient is not healthy as she presents with symptoms indicating a medical emergency, possibly hypovolemic shock.\n- The trial requires healthy volunteers, which the patient clearly is not, due to her current medical condition.\n\nConclusion:\nThe patient does not meet the inclusion criteria for the clinical trial as she is not a healthy volunteer, which is a primary requirement for participation in this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "236": {
        "output": "",
        "label": 1
    },
    "237": {
        "output": "It seems that the information about the clinical trial, including its title, target diseases, interventions, summary, and inclusion criteria, is incomplete. Without these details, I am unable to assess the eligibility of the 40-year-old woman for the clinical trial based on her presentation to the ER with excruciating pain in her right arm.\n\nTo determine the patient's eligibility, I would need to know the specific inclusion criteria of the clinical trial to compare against the patient's medical condition and characteristics. Since this information is not provided, I cannot establish a trial-level eligibility assessment for this patient.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "238": {
        "output": "Based on the information provided, the patient is a 40-year-old woman who presents to the ER with excruciating pain in her right arm, without any past medical history that mentions scoliosis or any related condition. There is no mention of adolescent idiopathic scoliosis (AIS), and the patient's age does not meet the specified range of 14 to 16 years old as required by the clinical trial. Moreover, there is no indication that the patient has any spinal deformity, let alone a specific right thoracic scoliosis with a Cobb angle between 20 and 40\u00b0.\n\nThe inclusion criteria for the clinical trial are quite specific:\n- Female (the patient meets this criterion)\n- Between 14 and 16 years old (the patient does not meet this criterion)\n- Normal neurological examination (no information provided)\n- Right handed (no information provided)\n- Informed consent (no information provided)\n- Informed consent form signed by a parent or a holder of parental authority (not applicable as the patient is an adult)\n- Affiliated to medical insurance (no information provided)\n- Negative urine pregnancy test (no information provided)\n- For patients (A-STD): right thoracic scoliosis with a Cobb angle between 20 and 40\u00b0 (the patient does not meet this criterion)\n- For healthy volunteers (A-N): no clinical scoliosis (no information provided, but the patient's age is not within the required range)\n\nGiven the information available and the mismatch between the patient's age and the specified age range in the inclusion criteria, as well as the lack of any mention of scoliosis, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "239": {
        "output": "",
        "label": 0
    },
    "240": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 40-year-old woman\n- No past medical history\n- Presents with excruciating pain in her right arm without trauma\n- Tachypneic and tachycardic\n- Hypotensive (BP 80/60)\n- No discoloration or movement limitation in the right arm\n\nClinical Trial Inclusion Criteria:\n- Trauma patients \u2265 18 years of all severity stages\n- Admitted through the emergency room\n\nAssessment:\nThe clinical trial is specifically looking for trauma patients. The patient presented in the note does not report any trauma but is experiencing excruciating pain in her right arm. Although she is clearly in an emergency situation, there is no indication that her condition is a result of trauma. Therefore, she does not meet the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "241": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 40-year-old woman presenting with excruciating pain in her right arm, which is unrelated to any trauma. The clinical trial in question is focused on patients with ankle fractures and the effectiveness of a compression treatment regimen post-surgery. The inclusion criteria for the trial are patients operated on at Nordsj\u00e6llands Hospital's department of Orthopaedic surgery for mono-, bi-, and trimalleolar fractures and an age above 18 years.\n\nGiven that the patient's condition (excruciating pain in the right arm) does not match the target condition of the clinical trial (ankle fractures), she would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "242": {
        "output": "The patient in the note is a 40-year-old woman who presents with excruciating pain in her right arm, with no past medical history of trauma. The clinical trial in question is focused on preventing intrusive memories and posttraumatic stress symptoms after an emergency cesarean section.\n\nTo determine the eligibility of the patient for the clinical trial, we must match the patient's characteristics and situation with the inclusion criteria specified by the trial:\n\n1. Female, aged 18+ years - The patient is a 40-year-old woman, so this criterion is met.\n2. Had emergency caesarean section within the past 6 hours - There is no indication in the patient note that she has had an emergency cesarean section, let alone within the past 6 hours.\n3. Have given birth to a live baby at \u2265 37 weeks gestation - The patient note does not mention pregnancy, childbirth, or any related events.\n\nGiven that the patient does not meet two of the three critical inclusion criteria for the clinical trial, specifically having had an emergency cesarean section and giving birth to a live baby at \u2265 37 weeks gestation, she would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "243": {
        "output": "",
        "label": 0
    },
    "244": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 40-year-old woman with excruciating pain in her right arm\n- No past medical history mentioned\n- Presents with tachypnea and tachycardia, hypotension but no fever\n- Right arm has no discoloration or movement limitation\n- No mention of tuberculosis (TB) symptoms or diagnosis\n\nClinical Trial Inclusion Criteria:\n- TB patients or suspected TB patients with specific symptoms/signs\n- Non-TB participants with clear lung disease but excluding pulmonary tuberculosis\n- Suspected TB participants with lung disease showing certain respiratory symptoms\n- Age 18 to 65 years old, no gender limitation\n- Consent and signed informed consent forms (ICF)\n- Willing to comply with follow-up\n\nGiven the information presented:\n- The patient does not exhibit symptoms or a diagnosis of tuberculosis or lung disease. The symptoms described in the patient note (excruciating arm pain, tachypnea, tachycardia, hypotension) are not consistent with TB or respiratory system diseases.\n- The patient's age falls within the inclusion criteria (18 to 65 years old).\n- There is no information given about the patient's consent or willingness to comply with follow-up, but this is a standard process for all trial participants.\n\nSince there is no indication that the patient has TB or a lung disease based on the patient note, and since the symptoms that the patient is presenting with do not match the inclusion criteria for the clinical trial, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "245": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial described, we need to compare the patient's characteristics to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old woman\n- Complaints of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Presence of a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Women aged 25 through 44\n- Body mass index (BMI) of 21 through 30\n\nBased on the patient note provided, the patient is a 25-year-old woman, which fits within the age range of 25 through 44 years required by the trial. However, the patient's BMI is not provided in the note. The patient's complaints, such as weight gain, suggest that she may be experiencing symptoms related to thyroid dysfunction (e.g., hypothyroidism), which is characterized by symptoms such as fatigue, hair loss, voice changes, weight gain, cold intolerance, and sometimes a thyroid mass. The presence of a midline cervical mass could also suggest a thyroid-related condition.\n\nWhile the patient's symptoms could potentially relate to weight changes, the specific information about her BMI is not included in the patient note. The BMI is a requirement for the trial inclusion, and without this information, we cannot conclusively determine her eligibility.\n\nTherefore, based on the information provided, further investigation would be needed to calculate her BMI and to determine if she fits within the BMI range of 21 through 30 as required by the clinical trial. If her BMI falls within the specified range, she would be eligible based on the age and BMI criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "246": {
        "output": "Based on the patient note and the inclusion criteria provided for the Thyroxine Titration Study, the patient's eligibility for the trial is as follows:\n\nThe patient is a 25-year-old woman, which satisfies the first criterion of being older than 18 years of age. She presents with symptoms that could be suggestive of hypothyroidism such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance. She also has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology.\n\nHowever, to determine her eligibility for this trial, we would need additional information:\n- Confirmation of primary hypothyroidism of \u22656 months duration, arising from autoimmune hypothyroidism, thyroidectomy, or radioiodine treatment.\n- Current thyroxine dose, which needs to be \u2265100 mcg/day.\n- Stability of the thyroxine dose in the past 2 months.\n- Current serum TSH level, which should be between 0.1-4.8 mU/L.\n- Information on the use of adequate contraceptive measures if she is of childbearing age.\n\nSince this information is not provided in the patient note, it is not possible to definitively determine her eligibility for the clinical trial. Therefore, further investigation is needed to acquire this information before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "247": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial.\n\nPatient Note:\n- A 25-year-old woman\n- Complains of prolonged fatigue\n- No difficulty sleeping reported\n- Sleeps an average of 8 hours a night\n- Notable hair loss, change in voice, weight gain, and cold intolerance\n- Presence of a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Patients aged 25 with insomnia\n- Stable sleep/wake schedule with a preferred sleep phase between 10:00 PM and 8:00 AM\n- Residence in the Greater Rochester NY area\n- Diagnosis of Psychophysiological Insomnia according to the ICSD, with specific symptoms and duration\n\nThe patient in the note is indeed 25 years old, which matches the age requirement of the trial. However, the patient denies difficulty sleeping and does not complain of insomnia, which is a primary requirement for the study. The patient's symptoms are more indicative of a thyroid dysfunction (e.g., hypothyroidism, given the hair loss, voice change, weight gain, cold intolerance, and presence of a cervical mass), rather than insomnia.\n\nSince there is no indication that this patient has insomnia or impaired daytime function due to sleep disturbances, as required by the trial's inclusion criteria, we would not refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "248": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder (fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass). The clinical trial in question is looking at the effects of weight loss on sleep-disordered breathing in obese, type 2 diabetic patients with obstructive sleep apnea.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Enrollment in Look AHEAD.\n2. Type II Diabetes and Sleep Apnea.\n\nThe patient note does not mention that the patient has type II diabetes or sleep apnea, nor does it state her enrollment in Look AHEAD. Instead, it presents a different set of symptoms that are not related to the inclusion criteria of the clinical trial.\n\nBased on the available information and the lack of any mention of the patient's diabetes status, obstructive sleep apnea, or enrollment in Look AHEAD, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "249": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and conditions with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics from the patient note:\n- 25-year-old woman\n- Complaints of prolonged fatigue\n- Sleeps an average of 8 hours a night\n- Hair loss, voice change, weight gain, cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical trial inclusion criteria:\n- 18 to 50 year old obese men and premenopausal women\n- BMI between 29-55\n- Chronically (for more than 6 months) sleep-deprived, defined as sleeping on a regular basis less than or equal to approximately 6-1/2 hours/night by history and objective devices\n\nClinical trial exclusion criteria of relevance:\n- Diagnosed sleep disorders\n- Unstable weight (voluntary losses in BMI greater than 5% over the past 6 months)\n- Untreated or uncontrolled diabetes\n- Severe uncontrolled hypertension\n- Other chronic organ disease diagnosis including COPD, chronic cardiac arrhythmia requiring treatments, gastro-esophageal disorders associated with sleep-related symptoms\n- Chronic use of prescription or over-the-counter medications known to affect sleep\n- Chronic fatigue syndrome and fibromyalgia\n- Endocrine disorders known to affect sleep, such as acromegaly, hypothyroidism (unless on a stable replacement dose of thyroid hormone), Cushing disease\n- Poorly controlled major depression\n- Medication and substance abuse\n- Pregnancy and lactation\n- Menopause\n- Chronic excessive caffeine use\n\nBased on the patient note, the patient does not meet the inclusion criteria for the clinical trial as she does not complain of sleep deprivation (she sleeps 8 hours a night) and there is no mention of her being obese (BMI between 29-55) or chronically sleep-deprived.\n\nMoreover, the patient's symptoms such as hair loss, voice change, weight gain, cold intolerance, and the presence of an anterior cervical mass suggest that she may have an underlying thyroid disorder, possibly hypothyroidism, which is listed as an exclusion criterion unless the patient is on a stable replacement dose of thyroid hormone. However, there is no information provided about her thyroid hormone levels or whether she has been diagnosed or is under treatment for hypothyroidism.\n\nGiven the available information, this patient does not meet the inclusion criteria for obesity and chronic sleep deprivation and potentially has an excluding condition (possible thyroid disorder), and thus would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "250": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, such as fatigue, hair loss, voice change, weight gain, cold intolerance, and a noticeable anterior cervical mass. These symptoms and physical findings do not align with the inclusion criteria specified for the clinical trial, which is focused on individuals diagnosed with type 2 diabetes and involves treatment with basal insulin therapy.\n\nThe inclusion criteria for the trial involve:\n- A diagnosis of type 2 diabetes\n- HbA1C <= 12.0% within the past 12 months\n- BMI <= 45.0 kg/m2\n- Initiation, addition of, change to, or continuation of basal insulin therapy with insulin detemir\n\nThere is no indication from the patient note that this woman has been diagnosed with type 2 diabetes, nor are there any details about her HbA1C levels, BMI, or any insulin therapy. Therefore, based on the information provided, she does not meet the inclusion criteria for the diabetes clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "251": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that could be suggestive of a thyroid disorder, such as prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms align with common manifestations of autoimmune thyroiditis (e.g., Hashimoto's thyroiditis).\n\nThe clinical trial in question is focusing on Selenium Treatment in Autoimmune Thyroiditis (AIT). The inclusion criteria for this trial are clinically approved AIT patients who do not use any medication other than LT4 (levothyroxine) to keep TSH in the lower half of the normal range.\n\nThe patient note does not provide enough information to determine with certainty whether the patient has AIT or whether she is taking LT4. Furthermore, it does not mention her thyroid-stimulating hormone (TSH) levels or whether she has been clinically approved as having AIT.\n\nGiven the absence of this critical information, an assessment of eligibility cannot be definitively made. However, the symptoms presented are suggestive of a thyroid condition that could potentially be AIT. Therefore, it would be prudent to consider referring the patient for further investigation to confirm the diagnosis and treatment status before making a final decision about her eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "252": {
        "output": "The patient note describes a 25-year-old woman with symptoms that are suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance, as well as a notable anterior cervical mass. These symptoms and examination findings could indicate primary hypothyroidism, but there's no clear evidence of secondary hypothyroidism (central hypothyroidism), which involves the pituitary gland.\n\nThe clinical trial is investigating treatment in patients with central hypothyroidism, specifically looking at body weight-adjusted doses of thyroxin and triiodothyronine supplementation. \n\nThe inclusion criteria for the clinical trial are:\n1. Hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin, or ADH deficiency)\n2. Termination of surgical or radiation treatment of pituitary tumors at least six months before study entry\n3. BMI of 20 - 39.9 kg/m2\n4. Non-smoking status\n\nBased on the information provided in the patient note, we cannot confirm that the patient meets any of the inclusion criteria. There is no mention of hypopituitarism, history of pituitary tumors, or the patient's BMI or smoking status.\n\nFor these reasons, the patient does not appear to meet the inclusion criteria for the clinical trial, and additional information would be required to determine her eligibility. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "253": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that are suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance. Additionally, she has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology.\n\nThe inclusion criteria for the clinical trial are focused on patients with manifest hypothyroidism or subclinical hypothyroidism, with specific TSH and T3/T4 levels defining each condition. However, the patient note does not provide any laboratory results to confirm a diagnosis of hypothyroidism or subclinical hypothyroidism. Without this information, we cannot definitively determine whether the patient meets the trial's inclusion criteria based on TSH and T3/T4 levels.\n\nGiven the symptoms described in the patient note, there is a suspicion of hypothyroidism, which makes the patient potentially relevant for the clinical trial. However, to confirm eligibility, further investigation is required to obtain the necessary thyroid function test results.\n\nTherefore, the trial-level eligibility for this patient would be:\n\n`Trial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.`",
        "label": 2
    },
    "254": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial.\n\nThe patient is a 25-year-old woman presenting with symptoms like fatigue, hair loss, voice change, weight gain, cold intolerance, and a noticeable cervical mass. These symptoms suggest she may have a thyroid disorder, possibly hypothyroidism. However, the clinical trial in question is specifically for preterm infants with hypothyroxinemia, which is not relevant to the adult patient described.\n\nThe inclusion criteria for the trial are:\n- Birth weight: less than 1500g\n- Gestation: 22 weeks 0 day \u2264\n- Serum free thyroxine level lower than 0.8 ng/dl\n- Serum thyrotropin lower than 10 \u03bcU/ml\n- Age of between 2 and 4 weeks after birth\n- Informed consent\n\nThe patient being an adult does not meet the criteria related to birth weight, gestation age, age after birth, or the specific condition being studied (hypothyroxinemia in VLBW infants).\n\nTherefore, the patient is not eligible for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "255": {
        "output": "",
        "label": 0
    },
    "256": {
        "output": "Based on the patient note provided, the 25-year-old woman is experiencing symptoms such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance, as well as a noticeable anterior cervical mass. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the signs mentioned.\n\nComparing this patient's situation to the inclusion criteria of the clinical trial titled \"Weight Gain Prevention,\" we can see the following matches:\n\n1. Age 18-35: The patient is 25 years old, which fits within the specified age range.\n2. Interested in preventing weight gain: While the patient does report weight gain, there is no explicit statement of her interest in preventing further weight gain. However, given that weight gain is a concern, it could be inferred that she might be interested.\n\nThe only criterion that we do not have information on is her Body Mass Index (BMI). The trial requires a BMI between 23 and 30. Without knowledge of her height and weight, we cannot calculate her BMI and thus cannot confirm her eligibility based on this criterion.\n\nGiven that the patient fits two of the three known inclusion criteria but lacks information on BMI, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "257": {
        "output": "The patient is a 25-year-old woman presenting with symptoms of prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a uniform anterior cervical mass at the midline. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the presence of a thyroid mass and classic symptoms of low thyroid hormone levels.\n\nThe clinical trial in question is focused on the treatment of Essential Tremor (ET) using Pregabalin. The inclusion criteria for the trial specify that participants must have a diagnosis of ET based on the TRIG criteria, be aged between 18 and 80, be in generally good health, and meet certain other conditions, including medication restrictions and methods of contraception for women of childbearing age.\n\nBased on the information given, the patient does not present with symptoms of Essential Tremor and instead has symptoms that suggest a thyroid disorder. There is no mention of tremor, ET, or any related condition in the patient's note. Therefore, this patient does not meet the inclusion criteria for the clinical trial on Pregabalin in the treatment of Essential Tremor.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "258": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- A 25-year-old woman\n- Complaining of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- BMI 30-39.9 kg/m2\n- Age 25-50 years\n- No more than 3 kg weight loss during the past three months\n- Negative pregnancy test at entry; requirement for contraception if of childbearing potential\n\nAssessment:\n- The patient's age (25 years) fits within the trial's age criteria (25-50 years).\n- The trial requires participants to have a BMI between 30-39.9 kg/m2. There is no information provided about the patient's weight or height to calculate her BMI.\n- There is no mention of weight loss or gain specifics in the past three months, only that there has been weight gain over the previous 6 months.\n- There are no details provided about the patient's pregnancy status or contraception use.\n- The patient's symptoms suggest a possible thyroid disorder, which could be unrelated to the trial's focus on weight maintenance and the role of dairy.\n\nGiven the information provided, it is not possible to definitively determine the patient's BMI or other factors that would confirm eligibility for the trial. Therefore, further investigation would be needed to assess BMI and other relevant details such as pregnancy status and detailed weight history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "259": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance. Additionally, she has a physical examination finding of a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of a thyroid gland abnormality.\n\nThe clinical trial in question is looking for premenopausal women with overt primary hypothyroidism, characterized by reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis who have not received thyroid hormones.\n\nWhile the patient's symptoms are suggestive of hypothyroidism, the patient note does not explicitly confirm the diagnosis of primary hypothyroidism with laboratory values (reduced T4 and increased TSH concentrations). Furthermore, it does not mention the menopausal status of the patient, nor does it indicate whether the patient has received thyroid hormone treatment in the past.\n\nBecause the patient note lacks specific laboratory confirmation of hypothyroidism, as well as details on the patient's menopausal status and prior thyroid hormone treatment, we cannot definitively determine if she meets the inclusion criteria based solely on the information provided.\n\nTherefore, the patient may potentially be a candidate for the clinical trial, but further investigation is needed to confirm the diagnosis of hypothyroidism and other inclusion criteria. Thus, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "260": {
        "output": "Let's assess the eligibility of the 25-year-old woman for the clinical trial \"Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units\" based on the inclusion criteria provided:\n\n1. The patient must be between 18 and 64 years of age (this patient is 25, so she meets this criterion).\n2. The patient must be English-speaking (the patient note does not specify language proficiency, so we would need more information).\n3. The patient must be currently receiving a serotonergic agent or scheduled to receive a new or change in serotonergic psychotropic agents for their psychiatric condition, or have been on a stable regimen without any weight gain in the last 3 months (the patient note does not mention any psychiatric condition or serotonergic medication usage, so we cannot determine eligibility based on this criterion without further information).\n4. The subject must have capacity to obtain and give informed consent (we would need more information to determine this).\n5. The subject must express concern about weight gain as a potential serotonin side effect (the patient note mentions weight gain, but not in the context of serotonergic medication side effects, so we would need more information).\n6. The patient must be in good health as determined by a medical and psychiatric history, medical examination, and cannot have major medical illness (the patient note mentions symptoms that may suggest a thyroid disorder, e.g., hair loss, voice change, cold intolerance, and a cervical mass, which could be indicative of a medical illness; thus, we would need more information).\n7. Women must meet certain criteria regarding contraception, pregnancy, and childbearing potential (the patient note does not provide information on this, so we would need more information).\n8. The patient must be willing and able to comply with study restrictions and remain at the clinic for the required duration, and willing to return for follow-up (we would need more information to determine this).\n9. The patient must be a voluntary admission inpatient at SUNY Upstate Medical University's Psychiatric department to enroll in the study (the patient note does not mention any current hospitalization, so we would need more information).\n\nBased on the information provided, we cannot determine whether the patient is currently receiving serotonergic medication, is concerned about weight gain due to these medications, is in good health without major medical illness, meets the contraception requirements, or is a voluntary inpatient at the specified institution. Therefore, further investigation would be needed to determine if this patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "261": {
        "output": "",
        "label": 0
    },
    "262": {
        "output": "Based on the patient note provided, the 25-year-old woman is complaining of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and has a prominent, soft, uniform anterior cervical mass at the midline. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the presence of a cervical mass (likely the thyroid gland), fatigue, weight gain, and cold intolerance.\n\nThe clinical trial in question is focused on patients with fibromyalgia, and the inclusion criteria specifically require a diagnosis of fibromyalgia using ACR (American College of Rheumatology) criteria. There is no mention in the patient note of musculoskeletal pain, tender points, or other symptoms consistent with fibromyalgia. Furthermore, fibromyalgia is a diagnosis of exclusion, and symptoms of thyroid dysfunction would likely need to be addressed and ruled out before considering a fibromyalgia diagnosis.\n\nGiven that the patient's symptoms do not align with the inclusion criteria of the clinical trial, and there is no information to suggest that the patient has been diagnosed with fibromyalgia, the patient would not be eligible for this specific study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "263": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She presents with symptoms suggestive of a thyroid disorder (prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and anterior cervical mass).\n\nClinical Trial Analysis:\n- The title of the clinical trial is \"Overnight Weight Loss and Sleep Structure.\"\n- The study aims to evaluate overnight weight loss in relation to sleep structure, compare weight loss during sleep versus awake rest, and compare night weight loss profiles between normal and obese volunteers.\n- The inclusion criteria for the clinical trial are not very detailed but mention \"normal and obese volunteers.\"\n\nAlthough the patient presents with symptoms that may indicate a thyroid disorder and not specifically related to sleep or weight concerns, the trial does not specify any exclusion criteria that would prevent her from participating based on these symptoms. Given that the trial is accepting \"normal and obese volunteers,\" and no other specific characteristics are required, the patient's current health status does not appear to disqualify her.\n\nHowever, without additional information on the patient's weight status (normal or obese) and without any specific exclusion criteria provided from the trial, it is not possible to determine with high certainty whether this patient should be referred. Therefore, further investigation would be needed to assess the patient's weight status and other potential factors that may affect her eligibility for the trial in question.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "264": {
        "output": "The patient in question is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder, given the complaints of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms and findings are not consistent with the diagnosis of rheumatoid arthritis (RA).\n\nThe clinical trial provided is investigating the role of sleep and immunity in patients with rheumatoid arthritis and is specifically targeting those who meet the American College of Rheumatology revised criteria for RA, which include joint-related symptoms and findings, presence of serum rheumatoid factor, and radiographic changes, among others. The patient described in the note does not mention any joint complaints, rheumatoid nodules, serum rheumatoid factor, or radiographic changes that suggest RA. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nBased on the information provided, this patient does not have a diagnosis of rheumatoid arthritis and does not meet the inclusion criteria specified for the clinical trial focused on sleep and immunity in RA patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "265": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She is presenting with symptoms of fatigue, hair loss, voice change, weight gain, and cold intolerance.\n- She has a prominent, soft, uniform anterior cervical mass at the midline.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking for obese and morbidly obese women (BMI 30 - 50).\n- The women must be 25 years and older.\n- They must be undergoing laparoscopic gastric bypass surgery.\n- They must present with at least either metabolic syndrome or diabetes.\n\nComparison:\n- The patient's age matches the inclusion criteria (25 years and older).\n- There is no information provided about the patient's BMI or obesity status.\n- The trial specifically targets patients undergoing laparoscopic gastric bypass surgery, which is not mentioned in the patient note.\n- The patient does not mention having metabolic syndrome or diabetes, and the symptoms described may suggest a thyroid issue rather than the conditions required for the trial.\n\nGiven the information available, the patient does not seem to meet the key inclusion criteria for the clinical trial, particularly regarding the requirement for laparoscopic gastric bypass surgery and having metabolic syndrome or diabetes.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "266": {
        "output": "Based on the patient note, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, possibly hypothyroidism, given the fatigue, hair loss, voice change, weight gain, cold intolerance, and the presence of a cervical mass. There is no mention of lung cancer or any details that would suggest a diagnosis of stage IIIB/IV lung adenocarcinoma with EGFR mutations.\n\nThe clinical trial in question is specifically for patients who have been diagnosed with stage IIIB/IV lung adenocarcinoma with EGFR mutations and who have not received any prior treatment for lung adenocarcinoma. The inclusion criteria for the trial are quite clear, and the patient described does not fit these criteria, as there is no information provided about a lung adenocarcinoma diagnosis or EGFR mutations.\n\nSince the patient's condition and the inclusion criteria for the clinical trial do not match, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "267": {
        "output": "The patient note describes a 25-year-old woman with symptoms suggestive of hypothyroidism, such as prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a noticeable anterior cervical mass. The clinical trial in question is an observational study on the initial treatment of hypothyroidism in France.\n\nThe inclusion criteria for the clinical trial are:\n1. Recently diagnosed hypothyroid subject (either during the inclusion period, or within the 6 previous months)\n2. Subject who has given his/her oral consent for participation\n\nBased on the information provided in the patient note, this patient seems to meet the criteria for the clinical trial, assuming her symptoms and the cervical mass lead to a diagnosis of hypothyroidism, and that this diagnosis is recent (within the last 6 months). However, the note does not explicitly state that she has been diagnosed with hypothyroidism, only that she presents with symptoms that could indicate this condition.\n\nGiven that the patient's symptoms are highly suggestive of hypothyroidism and align with the focus of the clinical trial, and assuming the diagnosis is confirmed and recent, there is potential for the patient to be eligible for the trial. However, further investigation is needed to confirm the diagnosis and recency before she can be referred.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "268": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms suggestive of hypothyroidism rather than major depressive disorder (MDD). The symptoms include prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass, which could indicate a thyroid issue.\n\nThe clinical trial in question is specifically looking at the utilization of Desvenlafaxine Succinate Sustained-Release (Pristiq) among psychiatrists and primary care physicians in the treatment of patients with major depressive disorder (MDD). The inclusion criteria for patients in this trial are quite clear: patients must be diagnosed with MDD and treated with pharmacotherapy.\n\nSince the patient described does not have a diagnosis of MDD, she does not meet the inclusion criteria for this clinical trial. Therefore, it would not be appropriate to refer her to this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "269": {
        "output": "",
        "label": 0
    },
    "270": {
        "output": "The patient note describes a 25-year-old woman presenting with symptoms suggestive of hypothyroidism (fatigue, hair loss, change in voice, weight gain, cold intolerance) and a physical finding of an anterior cervical mass, which could suggest a thyroid origin of her symptoms. However, there is no specific mention of pituitary surgery or radiotherapy, nor is there laboratory documentation provided to confirm central hypothyroidism or other hormonal deficiencies.\n\nThe clinical trial is looking for patients with clinical evidence of central hypothyroidism, specifically those who have undergone pituitary surgery and/or radiotherapy, along with laboratory confirmation of central hypothyroidism. The trial also includes patients with concurrent hormonal deficiencies in other axes.\n\nSince there is no evidence in the patient note to suggest that the patient has undergone pituitary surgery or radiotherapy, nor is there laboratory evidence of central hypothyroidism provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "271": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of thyroid dysfunction (fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass). There is no mention of melanoma or any form of cancer, let alone metastatic melanoma which is the target disease for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial explicitly require:\n- Histologically confirmed melanoma with evidence of metastatic disease\n- Measurable disease by physical examination or radiologic assessment\n- Specific requirements related to prior treatments, blood counts, organ function, HLA typing, agreement to undergo biopsy, and willingness to use contraception if of child-bearing potential\n\nGiven that there is no indication that the patient has melanoma, much less metastatic melanoma, she does not meet the fundamental inclusion criteria for the clinical trial. Therefore, it would not be appropriate to refer this patient to the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "272": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the study. The clinical trial is focused on male patients aged 18 to 70 years old with androgenetic alopecia, as determined by the Hamilton-Norwood Scale. The patient in the note is a 25-year-old woman presenting with symptoms that suggest a thyroid issue (fatigue, hair loss, voice changes, weight gain, cold intolerance, and a cervical mass), which is not related to androgenetic alopecia.\n\nTherefore, the patient does not meet the gender and condition-specific inclusion criteria of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "273": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of a thyroid disorder: fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms could be consistent with autoimmune thyroiditis, such as Hashimoto's thyroiditis, but there is no explicit mention of her having positive antibodies against thyroid peroxidase or sonographic evidence, which are required according to the inclusion criteria of the clinical trial.\n\nThe clinical trial is focused on subjects with autoimmune thyroiditis and specifically mentions the need for positive antibodies against thyroid peroxidase and sonographic evidence consistent with Hashimoto's thyroiditis.\n\nSince we do not have information regarding her antibodies status or sonographic findings, further investigation would be necessary to determine if she has autoimmune thyroiditis and meets the specific inclusion criteria of the trial.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "274": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that are suggestive of hypothyroidism, such as prolonged fatigue, hair loss, a change in voice, weight gain, and cold intolerance. Additionally, she has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology. However, the clinical trial in question is focused on central hypothyroidism, a specific form of hypothyroidism due to insufficient stimulation by thyroid-stimulating hormone (TSH) from the pituitary gland, typically in the setting of pituitary insufficiency.\n\nThe inclusion criteria for the trial specify that all patients must have pituitary hypopituitarism. The patient note does not mention pituitary hypopituitarism or any other signs of pituitary dysfunction. The symptoms mentioned could suggest primary hypothyroidism, but there is no clear indication of central hypothyroidism or pituitary involvement.\n\nWithout further information confirming a diagnosis of pituitary hypopituitarism, we cannot assume that this patient would meet the inclusion criteria based solely on the symptoms described. Therefore, additional investigation, such as hormone level testing and imaging, would be needed to determine if the patient has central hypothyroidism due to pituitary insufficiency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "275": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old woman presenting with symptoms that may suggest hypothyroidism, such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance. The clinical examination finding of a prominent, soft, uniform anterior cervical mass at the midline could also be related to thyroid pathology. However, there is no mention of Down syndrome or any karyotype analysis in the patient's note.\n\nThe clinical trial in question is specifically targeting young children with Down syndrome and aims to assess the efficacy of treatment with L-thyroxine and folinic acid on their psychomotor development. The inclusion criteria also specify the need for a karyotype demonstrating trisomy 21 and an age range of 6 to 18 months, among other things.\n\nGiven that the patient described does not fit the age criterion (25 years old vs. the required 6 to 18 months), does not have a diagnosis of Down syndrome, and the trial is specifically for a very different patient population (young children with Down syndrome), this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "276": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it appears that the patient may have symptoms suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance, along with a notable anterior cervical mass. However, there is no mention in the patient note of a confirmed diagnosis of primary hypothyroidism or that the patient has been on levothyroxine treatment for at least 6 months, which are part of the inclusion criteria for the clinical trial.\n\nGiven the information provided:\n\n- The patient is within the age range of 18 to 65 years old, meeting that aspect of the inclusion criteria.\n- The symptoms presented could be consistent with hypothyroidism, and the presence of an anterior cervical mass might suggest thyroid pathology which could be related to her symptoms.\n- There is no confirmation of a hypothyroidism diagnosis or levothyroxine treatment history in the patient note.\n\nWe would need additional information to definitively assess the patient's eligibility, such as confirmation of a hypothyroidism diagnosis and details of any current or past treatments. Therefore, based on the available information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "277": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Trastuzumab & Pertuzumab Followed by T-DM1 in MBC\", we need to compare the patient's information with the inclusion and exclusion criteria of the trial.\n\nPatient Information:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria for First-Line Therapy:\n- Histologically confirmed breast cancer with distant metastases\n- HER2-positive tumor according to central pathology testing\n- Women aged \u226518 years\n- WHO performance status 0 to 2\n- Adequate organ function with specified laboratory results\n- LVEF \u226550%\n\nClinical Trial Exclusion Criteria for First-Line Therapy:\n- Prior chemotherapy for inoperable locally advanced or metastatic breast cancer (exceptions apply)\n- Prior anti-HER2 treatment for metastatic or inoperable breast cancer (exceptions apply)\n- More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month (exceptions apply)\n- Known leptomeningeal or CNS metastases\n- Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion)\n\nBased on the patient note, there is no mention of breast cancer or HER2-positive status, which are critical inclusion criteria for the clinical trial. The patient's symptoms and the presence of an anterior cervical mass suggest a possible thyroid issue rather than breast cancer. Therefore, there is no indication that this patient would be eligible for a clinical trial focusing on HER2-positive metastatic breast cancer treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "278": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, we can analyze the patient's eligibility:\n\nPatient Note Summary:\n- 25-year-old woman\n- Presents with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Summary:\n- Focus on differentiated thyroid cancer (DTC) follow-up\n- Aims to induce TSH elevation by decreasing the L-thyroxin dose\n\nInclusion Criteria for the Clinical Trial:\n- Differentiated thyroid cancer\n- Treated by thyroidectomy and at least 1 ablation with 131-I > 5 months ago\n- TSH < 4 imU/L\n\nComparison:\n- The patient presents with symptoms that could be indicative of a thyroid issue (fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass), which might suggest thyroid cancer, but there is no explicit mention of a diagnosis of differentiated thyroid cancer.\n- There is no information provided regarding treatment history, such as thyroidectomy or radioiodine treatment.\n- The patient's TSH levels are not provided.\n\nConclusion:\nThe information given does not confirm that the patient has been diagnosed with differentiated thyroid cancer, nor does it provide any details about treatments she may have undergone (such as thyroidectomy or radioiodine ablation), or her current TSH levels. Therefore, based on the information provided, we cannot definitively determine if the patient has met the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation. \n\nFurther investigation into the patient's medical history, specifically regarding the presence of differentiated thyroid cancer, treatment received, and current TSH levels, would be necessary to accurately determine eligibility.",
        "label": 1
    },
    "279": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Ages 40\u201375 years old\n- Diagnosis of overt or subclinical hypothyroidism on two occasions with a minimum interval period of three months\n\nThe patient in question is 25 years old, which does not meet the age criterion of the clinical trial that requires participants to be between 40 and 75 years old. Although the symptoms and the presence of an anterior cervical mass suggest the possibility of hypothyroidism, which is relevant to the clinical trial, the age mismatch alone is sufficient to determine that the patient is not eligible for this particular trial.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "280": {
        "output": "Based on the patient note provided, the patient is a 25-year-old woman presenting symptoms that are suggestive of a thyroid disorder, indicated by fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent cervical mass. The clinical trial in question is specifically targeting emergency physicians to study the effect of stress and work shifts on biomarkers.\n\nThe patient described does not meet the inclusion criterion for the clinical trial, as she is not an emergency physician. Therefore, there is no relevance of her symptoms or potential diagnosis to the objectives of the clinical trial, and she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "281": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism: prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance, along with a noticeable anterior cervical mass, which could be indicative of a thyroid issue such as a goiter.\n\nThe clinical trial in question is focused on the prevention of chemotherapy-induced alopecia in women with breast cancer undergoing certain types of neoadjuvant or adjuvant chemotherapy. To be eligible for this trial, a patient must meet the following inclusion criteria:\n\n1. New diagnosis of breast cancer stage 1-2.\n2. Planning to undergo neoadjuvant or adjuvant chemotherapy with a curative intent.\n3. Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or taxane-based chemotherapy regimen.\n4. The patient must meet specific chemotherapy regimen requirements.\n5. Concurrent use of trastuzumab and/or pertuzumab at standard doses is allowed.\n6. TSH within normal range collected within 1 year prior to treatment.\n7. If the patient has a history of diabetes, Hemoglobin A1c must be drawn within 3 months prior to treatment and be within normal limits.\n8. CBC and CMP should be done within 4 weeks prior to treatment and found to be within acceptable limits.\n\nThe patient in the note does not mention a diagnosis of breast cancer or any plan to undergo chemotherapy. Therefore, based on the available information, this patient would not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "282": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms consistent with hypothyroidism (prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent thyroid mass). There is no mention of a cancer diagnosis, let alone advanced stage III or IV cancer, which is a requirement for the clinical trial in question.\n\nGiven that the inclusion criteria for the clinical trial specifically require participants to have a stage III or IV cancer diagnosis, and there's no indication that the patient has cancer, she would not meet the criteria for this particular study. Additionally, the trial requires participants to have a Karnofsky Performance Status score and to have been cleared for physical activity, neither of which is addressed in the patient note.\n\nTherefore, based on the information given, the patient does not meet the trial's inclusion criteria. The assessment of eligibility for this patient for the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "283": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Men and women between 25 and 65 years of age\n- Overweight or Class I or Class II BMI\n- Walk without assistance\n- Commit to a schedule of assessment visits\n\nThe patient is a 25-year-old woman, which fits the age criterion. However, there is no information provided about her being overweight or about her BMI classification, which is a crucial piece of information necessary to meet the clinical trial's inclusion criteria. Furthermore, there is no mention of her ability to walk without assistance or her willingness to commit to a schedule of assessment visits. \n\nThe patient's symptoms (prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance, along with a thyroid mass) suggest a possible thyroid disorder, which is not related to the purpose of the clinical trial focused on obesity and lifestyle changes. \n\nGiven the lack of information on her BMI and the fact that the patient's presenting symptoms do not align with the focus of the trial on preventing long-term weight gain in overweight and obese adults, I would not refer this patient for this clinical trial without further information confirming her BMI status.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "284": {
        "output": "Based on the patient note provided:\n\nThe patient is a 25-year-old woman who presents with symptoms suggestive of a thyroid disorder: prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a anterior cervical mass, which could indicate a thyroid condition such as hypothyroidism.\n\nNow, let's compare this to the clinical trial inclusion criteria:\n\n1. 18 years of age or older - The patient meets this criterion.\n2. Known Asthma - There is no mention of asthma in the patient's note.\n3. The exacerbation is defined as moderate or severe - Since asthma is not mentioned, there is no exacerbation.\n4. Not currently enrolled as an active participant in another clinical trial - There's no information provided about participation in other clinical trials.\n5. The patient or first degree family relative (in cases where the patient is intubated) has authorized his/her consent to participate in this trial - Consent can be obtained if the patient agrees to participate.\n\nThe key eligibility factor that is not met is the diagnosis of asthma and specifically an asthma exacerbation. The patient's presentation does not suggest asthma or an exacerbation; instead, her symptoms point towards a possible thyroid disorder.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on Thyroid Hormones Treatment in Asthma Exacerbation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "285": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient in question does not meet the specific requirements for this clinical trial. The trial is focused on pregnant women with hypothyroidism who are being treated with levothyroxine (L-T4). The patient note does not mention pregnancy or a confirmed diagnosis of hypothyroidism being treated with L-T4, although symptoms such as fatigue, hair loss, voice changes, weight gain, cold intolerance, and a cervical mass could suggest hypothyroidism. However, without confirmation of both pregnancy and a hypothyroidism diagnosis being actively treated with L-T4, the patient does not meet the inclusion criteria as listed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "286": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms suggestive of a thyroid disorder: prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms could be indicative of Hashimoto's thyroiditis (HT), but the note does not confirm a diagnosis of HT nor does it mention the presence of positive serum anti-TPO antibody or anti-thyroglobulin antibody, which are required for the diagnosis according to the trial's inclusion criteria. Additionally, there is no information provided about the patient's thyroid function tests (free T4 and TSH levels) to confirm a euthyroid state.\n\nGiven the lack of specific diagnostic information and thyroid function test results, I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis of HT and ensure she meets the euthyroid criteria. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "287": {
        "output": "Based on the patient note, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, including fatigue, hair loss, change in voice, weight gain, cold intolerance, and the presence of an anterior cervical mass. These symptoms could potentially indicate hypo- or hyperthyroidism, which is relevant to the clinical trial in question.\n\nThe clinical trial is looking to study the prevalence of thyroid disorders in Malaysia, including hypo- and hyperthyroidism, and its association with different ethnicity and iodine status. The inclusion criteria for the clinical trial are quite broad: participants must be aged 18 years or older at the time of sampling and be Malaysian citizens.\n\nGiven that the patient is 25 years old, she meets the age criterion. However, the patient note does not specify her ethnicity or citizenship. Assuming the patient is a Malaysian citizen (since the patient presents to a clinic and the trial is a nationwide multicentre study in Malaysia), she would meet the criteria based on age and potentially the presenting symptoms suggestive of a thyroid disorder.\n\nHowever, without confirmation of the patient's citizenship, it is not possible to definitively determine her eligibility for the trial. Therefore, further investigation is required to ascertain her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "288": {
        "output": "Based on the information provided, the patient is a 25-year-old woman who presents with symptoms of prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a noticeable anterior cervical mass. These symptoms suggest an endocrine disorder, possibly related to thyroid function, but there is no indication that the patient has been referred by a primary care physician for health coaching, nor is there any information regarding inadequate sleep, poor diet, physical inactivity, or the need for weight loss as per the recommendation of a health care provider. Additionally, the patient falls short of the inclusion criteria regarding age, as she is 25 years old and the study requires participants to be 21 years and over. \n\nHowever, the patient does meet the criteria of being an adult and presumably speaks English, given she is presenting to the clinic and communicating her symptoms. There is no information provided about whether she has a telephone for follow-up, but this is a common possession and could easily be confirmed.\n\nGiven the lack of explicit referral for health coaching, the age discrepancy, and the absence of information about whether a telephone is available for follow-up, this patient does not clearly meet all of the stated inclusion criteria for the clinical trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "289": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She presents with prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass.\n- There is no mention of insomnia or sleep-related issues.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 21 and 80 years. (The patient is 25 years old, which meets this criterion.)\n- Must have a diagnosis or meet the Research Diagnostic Criteria for insomnia disorder. (The patient note does not mention insomnia or difficulty sleeping.)\n- Score > 14 on the Insomnia Severity Index. (There is no information on whether the patient has been evaluated with this index.)\n- Report insomnia for > 3 months. (There is no mention of insomnia duration in the patient note.)\n- Have sleep difficulties > 3 nights per week. (The patient denies difficulty sleeping.)\n- Score < 3 on the Epworth Sleepiness Scale (ESS). (There is no information on the patient's ESS score.)\n- Score > 40 on the Hyperarousal Scale and report an inability to nap in the daytime. (There is no information on the patient's Hyperarousal Scale score or her ability to nap.)\n\nGiven that the patient does not present with insomnia or related sleep issues, she does not appear to meet the inclusion criteria for a trial focused on the impact of hyperarousal on cognitive task performance among insomnia sufferers. There is no evidence in the patient note that would align with the requirements of the trial, particularly the need for a diagnosis of insomnia disorder and related sleep difficulties.\n\nTherefore, the patient is not a match for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "290": {
        "output": "The patient is a 25-year-old woman presenting with symptoms of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent cervical mass. These symptoms and clinical findings suggest that the patient may have a thyroid disorder, such as hypothyroidism, rather than androgenetic alopecia (female pattern hair loss), which is the target condition for the clinical trial.\n\nThe inclusion criteria for the clinical trial titled \"Hairstetics\u2122 Anchoring System in Female Pattern Hair Loss (HAS-FPHL)\" are as follows:\n\n- Age \u2265 19 yrs.\n- Female patients with androgenetic alopecia (FPHL).\n- Specific pre-treatment hematology and coagulation values within the stated limits.\n- A life expectancy of at least the duration of the trial.\n- Signed informed consent and post-implantation protocol.\n\nThe patient note does not mention androgenetic alopecia, nor does it provide the necessary hematology and coagulation values. Furthermore, the symptoms described do not align with FPHL but rather suggest a different medical issue. Therefore, based on the information provided, the patient does not meet the inclusion criteria specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "291": {
        "output": "Given the patient note:\n\n- The patient is a 25-year-old woman.\n- She presents with symptoms suggestive of hypothyroidism (fatigue, hair loss, voice changes, weight gain, cold intolerance, and a midline anterior cervical mass).\n\nGiven the clinical trial:\n\n- The trial is looking for participants who are:\n  - \u226518 years old\n  - In a low-risk singleton pregnancy\n  - Entering the last trimester of pregnancy (in the range of 26-30 weeks of gestation)\n  - Residing in the Greater Accra Metropolitan Area or area served by the Korle Bu Teaching Hospital\n  - Fluent in either English, Twi, or Ga.\n\nThe patient note does not indicate that the woman is pregnant, let alone in her last trimester of pregnancy. Therefore, she does not meet the essential inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "292": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note summary:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical trial summary:\n- Title: The GlasVEGAS Study\n- Focus: Investigating fat storage and metabolic risk factors associated with weight gain and loss in South Asians and Europeans\n- Inclusion criteria: Men of European or South Asian origin, BMI <25 kg/m^2, weight stable for >6 months\n\nThe patient in the note is a 25-year-old woman with symptoms suggestive of a thyroid condition, given the presence of a cervical mass and symptoms like fatigue, hair loss, and cold intolerance. The clinical trial is specifically looking for men of European or South Asian origin with a BMI <25 kg/m^2 who have been weight stable.\n\nThe patient does not meet the gender requirement (the study is looking for men) nor the ethnic background criteria specified for the study (European or South Asian origin).\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "293": {
        "output": "The patient note describes a 25-year-old woman with symptoms suggestive of a thyroid disorder, such as fatigue, hair loss, voice changes, weight gain, and cold intolerance. She also has a notable anterior cervical mass, which could be indicative of a thyroid enlargement or goiter.\n\nThe clinical trial aims to analyze DNA methylation status in patients with autoimmune thyroid diseases, specifically Hashimoto Thyroiditis (HT) and Graves Disease (GD). The inclusion criteria for HT include positive titers of anti-TPO or anti-Tg antibodies and at least one of the following: abnormal thyroid function requiring substitution treatment, increased volume of thyroid gland, or morphological changes on ultrasound of the thyroid gland. For GD, the criteria include positive titers of anti-TSI antibodies, decreased TSH levels, and increased levels of fT4 or fT3.\n\nTo determine the eligibility of this patient for the trial, we would need additional information regarding her thyroid function tests (including TSH, fT4, fT3) and antibody status (anti-TPO, anti-Tg for HT, and anti-TSI for GD). An ultrasound could also provide evidence of morphological changes in the thyroid gland.\n\nGiven the patient's symptoms and the presence of a thyroid mass, she is a candidate for further testing to confirm a diagnosis of an autoimmune thyroid disease. If such a diagnosis is made and meets the trial's inclusion criteria, she could potentially be a candidate for the study. However, based on the information provided in the patient note alone, we do not have enough information to determine whether she meets the specific inclusion criteria for this trial, particularly the laboratory and ultrasound findings.\n\nTherefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "294": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms that may suggest hypothyroidism, such as fatigue, hair loss, voice change, weight gain, cold intolerance, and a notable anterior cervical mass. However, the clinical trial in question specifically targets patients with subclinical hypothyroidism following head and neck surgery for cancer, treated with curative intent.\n\nThe patient note does not mention any history of head and neck cancer, surgery, or any indication that she has been treated for such conditions. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which requires a diagnosis of head and neck cancer treated with surgery, and a subsequent diagnosis of subclinical hypothyroidism.\n\nGiven the information provided, the patient does not appear to be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "295": {
        "output": "",
        "label": 0
    },
    "296": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism, such as prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent, soft, uniform anterior cervical mass at the midline, which could possibly be an enlarged thyroid gland.\n\nThe clinical trial in question is looking for patients aged 20 to 80 years scheduled to receive neck dissection due to head and neck cancer. The patient described does not have a diagnosis of head and neck cancer, and there is no indication that she is scheduled to receive neck dissection.\n\nTherefore, this patient does not meet the inclusion criteria of the clinical trial, which specifically requires patients to have head and neck cancer and be scheduled for neck dissection.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "297": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet the key criteria for this clinical study. The patient is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder (fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass), which is not related to pediatric obstructive sleep apnea/hypopnea syndrome (OSAHS). Additionally, the trial specifically targets children between 2 and 18 years old with confirmed OSAHS, which is not applicable to this patient.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "298": {
        "output": "Based on the patient note provided, the 30-year-old woman presents with shortness of breath, but there is no indication that she has been diagnosed with breast or lung cancer, which are the target diseases for the clinical trial in question. The inclusion criteria for the trial clearly state that patients must have a diagnosis of local or metastatic breast or lung cancer and that the shortness of breath must have started after the cancer diagnosis. Given that the patient does not meet these key inclusion criteria, she would not be eligible for the acupuncture for shortness of breath in cancer patients clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "299": {
        "output": "The patient described in the note is a 30-year-old woman presenting with shortness of breath. To determine if she is eligible for the clinical trial titled \"BNP Testing in Patients With SOB on Presentation to ED,\" we need to compare her characteristics to the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Patients presenting to the ED with shortness of breath.\n2. Patients who are over 40 years old.\n3. Patients with an emergency department triage category of 3 or higher.\n\nThe patient in the note does meet the first criterion, as she presents with shortness of breath. However, she does not meet the second criterion because she is only 30 years old. The third criterion regarding the emergency department triage category is not mentioned in the patient note.\n\nBased on the information provided, the patient does not meet one of the key age criteria for the trial. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "300": {
        "output": "",
        "label": 1
    },
    "301": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 30-year-old woman presents with shortness of breath that started 2 hours before admission.\n- She is tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%.\n- Chest X-ray and CBC are normal.\n- She recently gave birth 3 weeks prior.\n- There is no mention of pulmonary hypertension (mean PA > 35 mmHg), ARDS, or signs of heart failure.\n\nClinical Trial Inclusion Criteria:\n- Patients admitted to the ICU with pulmonary hypertension (mean PA > 35 mmHg).\n- Patients in ICU with postoperative pulmonary hypertension (mean PA > 35 mmHg).\n- Patients with ARDS (PaO2/FiO2 < 200, bilateral infiltrates on chest X-ray, and a wedge < 20 mm Hg).\n\nThe patient in the provided note does not directly meet any of the specified inclusion criteria for the clinical trial. There is no indication that the patient has pulmonary hypertension or ARDS, nor is there information on any postoperative conditions or the specific pulmonary arterial pressure. Additionally, the chest X-ray is noted as normal, which would not fit the criteria for ARDS that requires bilateral infiltrates.\n\nGiven the information provided, the patient does not appear to have the conditions being studied in the clinical trial (pulmonary hypertension or ARDS). Therefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "302": {
        "output": "",
        "label": 0
    },
    "303": {
        "output": "After reviewing the patient note and the clinical trial information, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 30-year-old woman\n- Gave birth 3 weeks prior\n- Presenting with shortness of breath\n\nClinical Trial Inclusion Criteria:\n- Must be 18 years or older\n- Must have been pregnant and enrolled by 10 weeks of gestation\n- Planned to carry pregnancy to term\n- No plans to move before delivery\n- English speaking\n- Found to have fibroids at either their 7-week or 22-week ultrasound examination during pregnancy\n\nClinical Trial Exclusion Criteria for MRI (if relevant to the patient's participation):\n- Weight greater than 250 pounds\n- Currently pregnant\n- Certain types of metal in the body\n- History of claustrophobia\n- Previous severe reaction to MRI contrast\n- Chronic kidney disease\n\nBased on the information provided:\n- The patient is 30 years old and English speaking, which meets two of the trial's inclusion criteria.\n- The patient has recently given birth, which suggests she carried a pregnancy to term.\n\nHowever, the clinical trial specifically requires participants who were found to have fibroids during their pregnancy. There is no mention of the patient having fibroids or being part of the Right From The Start Study during her pregnancy. Without evidence that she has fibroids, she does not meet one of the key inclusion criteria for the postpregnancy study.\n\nGiven this information, the patient does not meet the necessary inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "304": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Family Spirit Study,\" let's review the patient's eligibility:\n\nPatient Note:\n- The patient is a 30-year-old woman.\n- She recently gave birth to a healthy child 3 weeks before.\n- No mention of Native American heritage or tribal membership.\n- No information about pregnancy at the time of conception (as the patient has recently given birth).\n- No mention of residing in the Reservation Service Unit Catchment Area or within 60 miles of the Indian Health Service Unit Headquarters.\n\nClinical Trial Inclusion Criteria:\n- Native American pregnant teens or young women ages 12-22 years old at the time of conception.\n- Women ages 20-22 years at the time of conception must be pregnant for the first time.\n- Partners of pregnant teens must be between the ages of 12-24.\n- Pregnant <28 weeks gestation and able to meet the requirements for completing the program in a timely way.\n- An enrolled tribal member.\n- Reside in the Reservation Service Unit Catchment Area and within 60 miles of the Indian Health Service Unit Headquarters.\n\nGiven the information provided in the patient note, the patient does not meet the specific demographic requirements (Native American heritage, tribal membership, residency requirements) nor the pregnancy-related inclusion criteria for the \"Family Spirit Study.\" Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "305": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods,\" the patient does not meet the specific inclusion criteria. The criteria require participants to be in the first trimester of a normal pregnancy and to have a normal baseline echocardiogram. The patient in question is postpartum, having given birth 3 weeks prior, and is thus not in the first trimester of pregnancy.\n\nIn addition, the patient is presenting with shortness of breath, tachypnea, and tachycardia, which may not align with being considered \"healthy,\" another requirement of the study's inclusion criteria. While the patient's chest x-ray and CBC are normal, her current symptoms could be indicative of a condition that warrants further investigation and may exclude her from being considered healthy at this time.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "306": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the inclusion criteria for the study.\n\nThe inclusion criteria specify:\n1. Gestational age at birth of the infant: 23 0/7 - 27 6/7 weeks\n2. Enrollment in the COT trial at specified locations\n3. Postnatal age of the infant: between 21 days and 70 days\n4. Informed written consent obtained from at least one of the parents\n\nThe patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. The inclusion criteria are specifically for very preterm infants, and there is no indication that the woman's child was very preterm or enrolled in the COT trial. Therefore, the patient herself is not applicable for the trial, and the information provided does not indicate that her child is a candidate either.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "307": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Long-term Oxygen Treatment Trial,\" the patient does not appear to be eligible for this trial. Here's the breakdown:\n\n- The patient is a 30-year-old woman, which does not meet the trial's age criterion of at least 40 years.\n- There is no mention of COPD in the patient's note. Instead, the patient presents with shortness of breath postpartum, which is not necessarily indicative of COPD.\n- Dyspnea is present, but there is no indication that it's related to COPD, nor is there a mention of the MMRC scale in the patient note.\n- There are no lung function test results (FEV1, FVC) provided in the patient note to assess COPD severity.\n- The patient's oxygen saturation levels are mentioned (92%), but without evidence of COPD, this is not relevant to the trial's criteria.\n- There is no mention of the patient's smoking history, which is a requirement for the trial (at least 10 pack-years of tobacco cigarette smoking).\n- The patient does not appear to be on supplemental oxygen, which is a condition for part of the trial's inclusion criteria.\n- Lastly, there is no indication that the patient is a Medicare beneficiary with both Part A and Part B coverage or willing to personally cover costs, another criterion for the trial.\n\nBased on this analysis, the patient does not meet several key inclusion criteria for the clinical trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "308": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 30-year-old woman who presents with shortness of breath and was recently admitted presenting symptoms like being apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. She has had a chest x-ray that was noted to be normal.\n\nThe clinical trial in question is focused on the effects of X-ray computed tomography (CT) on blood reactive oxygen species (ROS) levels. The inclusion criteria for the trial are quite specific: the participants must be part of a health check program at the hospital conducting the study and are scheduled to receive an X-ray CT examination for either lung or heart health as part of that health check.\n\nThe patient note does not mention that the woman is part of a health check program or that she is scheduled for an X-ray CT examination for her lungs or heart. The fact that she has had a chest x-ray does not meet the criterion of having a scheduled CT examination. Without any information suggesting that she is part of the health check program or scheduled for a CT scan, this patient does not meet the inclusion criteria as stated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "309": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether the patient would be eligible for the clinical trial.\n\nPatient note:\n- 30-year-old woman\n- General health is good\n- Presenting with shortness of breath\n- History of 2 natural abortions\n- Gave birth to a healthy child 3 weeks prior\n- Normal chest x-ray and CBC\n\nClinical trial:\n- Title: Postpartum Anemia and Postpartum Depression\n- Focus: Relationship between postpartum anemia and postpartum depression\n- Participants: Women delivered by elective term cesarean section\n- Inclusion criteria: Women after term elective cesarean section\n\nThe inclusion criteria for the clinical trial specify that participants must be women who have undergone a term elective cesarean section. The patient presented has recently given birth but there is no information to suggest that she underwent a cesarean section, let alone an elective term one. Therefore, based on the information provided, the patient does not meet the inclusion criteria of having had an elective term cesarean section.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "310": {
        "output": "Based on the patient note provided, the 30-year-old woman has presented with shortness of breath, which is not necessarily indicative of asthma but rather could be related to a postpartum condition, given she gave birth 3 weeks before. Her physical examination is otherwise unremarkable, which includes normal blood pressure and a normal chest x-ray. The oxygen saturation is 92%, which is below the normal threshold set by the trial's inclusion criteria (> 94%).\n\nThe clinical trial is comparing responses to an inhalational challenge in individuals with allergic asthma and normal volunteers. To qualify as a normal volunteer, the trial specifies that participants must have normal lung function, normal oxygen saturation, and pass a methacholine inhalation challenge, among other criteria. For allergic asthmatics, the criteria include a history of asthma, positive methacholine test, and allergic sensitization confirmed by positive AST.\n\nWhile the woman's oxygen saturation is slightly below the normal threshold for the trial and she has shortness of breath, there is no indication she has asthma or a history of allergic reactions, both of which are necessary for the allergic asthmatics group. Additionally, since she's recently given birth, the cause of her symptoms may be related to other postpartum conditions not related to the objectives of the trial.\n\nGiven the information, it's not clear whether she would meet the normal lung function criteria or pass a methacholine inhalation challenge. Without further investigation to clarify her lung function and a negative methacholine test, she would not immediately qualify for the healthy control group either.\n\nTherefore, the assessment of trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be required to determine if her shortness of breath is indicative of an underlying condition that would exclude her from the study. Additionally, her recent childbirth and the fact that there was no mention of an asthma diagnosis or allergic sensitization in her history suggest that she may not meet the inclusion criteria for either the healthy controls or the allergic asthmatics groups.",
        "label": 0
    },
    "311": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess whether the patient fits the inclusion criteria based on the patient note provided.\n\nInclusion Criteria for the Clinical Trial:\n1. Diagnosis of acute pulmonary embolism (PE) with symptoms present <14 days and confirmed by CT angiography.\n2. Initial evaluation for PE based on new or unexplained cardiopulmonary or chest-related clinical features consistent with PE.\n3. Systolic blood pressure (SBP) > 89 mm Hg at the time of enrollment (or a history of low blood pressure without symptoms of shock if SBP < 90 mm Hg)\n4. Oxygen saturation (SaO2%) > 80% at the time of enrollment.\n5. Borg score greater than 4/10.\n\nPatient Note Assessment:\n1. The patient presents with shortness of breath, which could be consistent with PE.\n2. The onset of shortness of breath was 2 hours before admission, fitting the criteria for recent onset.\n3. The patient's blood pressure is 110/70, which is above the threshold of 89 mm Hg.\n4. The patient's oxygen saturation is 92%, which is above the threshold of 80%.\n5. The patient is described as tachypneic and tachycardic, which can be clinical features associated with PE.\n6. However, there is no mention of a confirmed diagnosis of PE with CT angiography.\n7. The Borg score is not mentioned, so we do not have information on the severity of dyspnea according to the patient\u2019s subjective assessment.\n\nGiven that the patient presents with symptoms that could be consistent with PE (shortness of breath, tachypnea, tachycardia) and meets some of the physiological criteria (SBP and SaO2%), they could potentially be eligible for the trial. However, without confirmation of PE through CT angiography and the absence of a documented Borg score, we cannot conclusively determine eligibility. Therefore, the patient may require further evaluation to confirm the diagnosis and assess the severity of dyspnea before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "312": {
        "output": "The patient in question is a 30-year-old woman who recently gave birth and is presenting with shortness of breath. This patient does not fit the inclusion criteria for the clinical trial provided, which is specifically seeking to enroll preterm very low birth weight infants with shock, in a specific gestational week range, and with specific birth weight criteria.\n\nThe clinical trial is not applicable to the woman in the patient note because she is not an infant, she is not within the specified gestational week range, her birth weight is not mentioned (and is obviously not within the specified range for very low birth weight infants), and there is no indication that she is experiencing shock or requires vasopressor therapy. Additionally, the trial is looking to enroll infants born at a specific institution (AIIMS), which has no bearing on the adult patient.\n\nBased on the information provided, the patient note is completely unrelated to the target population for the clinical trial, and therefore, the patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "313": {
        "output": "Given the patient's presentation and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the trial. Let's assess the patient against the criteria:\n\n1. The patient is a 30-year-old woman, which meets the age requirement (age \u2265 18 years).\n2. She has recently given birth, which places her in the postpartum period.\n3. The patient presents with shortness of breath, which could be a symptom related to venous thromboembolism (VTE), but there is no direct indication that she has VTE or has been treated for it.\n4. The patient has had two natural abortions, which is mentioned in the inclusion criteria as a consideration for the study (history of abortion).\n\nHowever, the inclusion criteria specifically state that patients should have been treated with fondaparinux pre-, peri- and/or postpartum for more than 7 days for VTE prophylaxis or treatment. There is no information provided in the patient note that suggests the patient has been treated with fondaparinux or has a diagnosed VTE.\n\nGiven the information provided, we do not have evidence of fondaparinux treatment or VTE diagnosis. Therefore, based on the available information, we would not refer the patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "314": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note:\n- The patient is a 30-year-old woman.\n- She presented with shortness of breath that started 2 hours before admission.\n- She had given birth to a healthy child 3 weeks prior.\n- She shows signs of being apprehensive, tachypneic, and tachycardic, with oxygen saturation at 92%.\n- Her chest x-ray and CBC are normal.\n- There is no mention of the patient being mechanically ventilated or in the process of weaning from mechanical ventilation.\n\nClinical Trial Inclusion Criteria:\n- The trial is focused on the safety, feasibility, and efficacy of a computerized protocol integrated into a ventilator for patients during the weaning phase from mechanical ventilation.\n- The patient must be ready to begin weaning from mechanical ventilation as determined by the attending physician.\n- The patient must be able to breathe spontaneously or already be breathing spontaneously.\n- No vasopressor or inotropic medication, unless in small doses of specific medications.\n- Specific requirements related to mechanical ventilation settings and blood gas parameters.\n\nGiven that the patient in the note is not described as being mechanically ventilated nor in the process of weaning from mechanical ventilation, she does not meet the key inclusion criteria of the clinical trial. The trial specifically requires patients who are undergoing weaning from mechanical ventilation, and there is no information to suggest that this patient is in that clinical situation. Therefore, this patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "315": {
        "output": "",
        "label": 1
    },
    "316": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Oxygen Saturation Monitoring During Surgery,\" the assessment of the patient's eligibility is as follows:\n\n- The patient is a 30-year-old woman, which does not meet the age criterion of \"Age greater than 21 years.\" However, she is only short by one year, which may be considered a minor discrepancy depending on the strictness of the trial's screening process.\n- The patient presents with shortness of breath that started 2 hours before admission, but there is no information suggesting she is scheduled for a procedure that requires analgesia or sedation.\n- There is no indication of the patient having Obstructive Sleep Apnea (OSA), which seems to be a focus of the study, nor is there any information about her ASA classification.\n- The trial appears to be focused on patients who are at risk for OSA during surgery, and this patient's current medical issue does not seem to align with the study's objectives.\n\nGiven the information provided, it is unlikely that this patient would be considered for referral to this particular clinical trial based on the mismatch of her current medical situation with the study's focus and lack of information fulfilling the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "317": {
        "output": "Based on the information provided, the patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. The clinical trial in question is aimed at identifying risk factors for fetomaternal hemorrhage (FMH) and is seeking to enroll women admitted for term delivery at the Mount Sinai Medical Center.\n\nSince the patient has already delivered her child and is not currently admitted for term delivery, she does not meet the inclusion criteria for the clinical trial, which specifically seeks women who are admitted for term delivery.\n\nTherefore, the assessment of the patient's eligibility for the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "318": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Carbetocin at Elective Cesarean Delivery.\"\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman.\n- She recently gave birth to a healthy child 3 weeks prior.\n- She presents with shortness of breath, which is not related to the clinical trial's focus.\n- There is no mention of her undergoing an elective cesarean delivery or planning one.\n\nClinical Trial Inclusion Criteria Analysis:\n- All patients planned for elective cesarean delivery under spinal anesthesia.\n- All patients who gave written informed consent to participate in this study.\n\nAssessment:\nThe patient in the note does not meet the inclusion criteria for the clinical trial as there is no indication that she is planning to have an elective cesarean delivery. The trial is specifically looking for patients who are planned for an elective cesarean delivery under spinal anesthesia, and the patient just gave birth 3 weeks ago through what is presumed to be a vaginal delivery since cesarean delivery is not mentioned.\n\nGiven the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "319": {
        "output": "",
        "label": 0
    },
    "320": {
        "output": "Based on the patient note provided, the 30-year-old woman recently gave birth and is experiencing shortness of breath, tachypnea, and tachycardia. However, there is no mention of her delivery method, be it cesarean section or vaginal delivery. To determine eligibility for the clinical trial focused on \"Venous Thromboembolism Prophylaxis Post Cesarean Section,\" we must consider the inclusion criteria:\n\n1. Age > 18 years old - The patient is 30 years old, which meets this criterion.\n2. Delivered by cesarean section (emergency or planned) - There is no information provided about the delivery method.\n3. Signed, informed consent - This is a procedural aspect that the patient can fulfill if eligible.\n4. Ready access to a local health service - There is no information provided that contradicts this criterion.\n5. Capable of using Tinzaparin - There is no information provided against this, but it is also not confirmed.\n\nGiven that the critical inclusion criterion regarding delivery method is not addressed in the patient note, it is not possible to definitively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "321": {
        "output": "Given the patient note, the patient is a 30-year-old woman who has recently given birth to a healthy child 3 weeks prior and is now presenting with shortness of breath. There is no indication that the patient is currently planned for an elective cesarean delivery, which is a specific inclusion criterion for the clinical trial in question. The clinical trial is looking to recruit patients who are planned for elective cesarean delivery under spinal anesthesia, and the patient does not fit this description.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "322": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression,\" we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient characteristics:\n- A 30-year-old woman\n- Recently gave birth to a healthy child 3 weeks ago\n- Planning to breastfeed (implied since she recently gave birth, however, not explicitly stated)\n- Experiencing shortness of breath, tachypnea, and tachycardia but otherwise generally healthy\n\nClinical trial inclusion criteria:\n- Age > 18 years old\n- > 24 0/7 weeks pregnant at the time of enrollment\n- Planning to deliver at Magee-Womens Hospital and to breastfeed\n- Plans to use DMPA for postpartum contraception for at least 6 months\n- Willing and able to provide informed consent in English and to comply with study protocol\n\nAssessment:\n- The patient is over 18 years old, which meets the first criterion.\n- The patient has already delivered, which does not meet the second criterion as it specifies being more than 24 0/7 weeks pregnant at the time of enrollment.\n- It is not specified whether the patient plans to deliver at Magee-Womens Hospital, which is a requirement.\n- There is no information provided about the patient's intention to use DMPA for postpartum contraception.\n- The ability to provide informed consent in English and comply with the study protocol cannot be assessed from the given information.\n\nGiven that the patient has already given birth, she does not meet the criterion of being pregnant at the time of enrollment. Additionally, there is insufficient information regarding the patient's intentions to use DMPA and whether she was planning to deliver at Magee-Womens Hospital.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "323": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether this patient is eligible for the trial based on the inclusion criteria.\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman.\n- She presents with shortness of breath that started 2 hours before admission.\n- She has had no significant health problems in the past besides 2 natural abortions and recently gave birth to a healthy child.\n- She is currently experiencing tachypnea (rapid breathing), tachycardia (rapid heart rate), and has a slightly reduced oxygen saturation at 92%.\n- Her chest x-ray and CBC are normal.\n\nClinical Trial Analysis:\n- The title of the study is \"Change in Peripheral Oxygen Saturation by Using Different Breathing Procedures in High Altitude.\"\n- The aim is to explore whether different types of breathing procedures can improve peripheral oxygen saturation to reduce the risk of acute mountain sickness or high altitude pulmonary edema.\n- The inclusion criteria mentioned are not detailed, but there is a note on exclusion criteria regarding \"acute clinically significant inter-current diseases.\"\n\nAssessment:\n- The patient appears to be suffering from an acute condition, as indicated by the sudden onset of shortness of breath, tachypnea, tachycardia, and reduced oxygen saturation.\n- There is no indication that the patient is at high altitude or that she is suffering from acute mountain sickness or high altitude pulmonary edema.\n- The exclusion criteria specifically mention acute clinically significant inter-current diseases, which could potentially include the patient's current condition (acute shortness of breath).\n\nGiven the lack of information connecting the patient's condition to high altitude illnesses and the fact that her acute symptoms may potentially fall under the exclusion criteria, it seems that this patient would not be a candidate for the trial. However, without explicit confirmation that the patient's current condition is considered an \"acute clinically significant inter-current disease\" within the context of the trial, there is some uncertainty.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "324": {
        "output": "Based on the information provided:\n\nThe patient in question is a 30-year-old woman presenting with shortness of breath, tachypnea, tachycardia, and a slightly lowered oxygen saturation. There are no indications of bronchiolitis, which is typically a condition affecting infants and young children. Furthermore, the patient's chest x-ray and CBC are normal, suggesting no apparent respiratory infection, which is common in bronchiolitis.\n\nThe clinical trial in question is targeting children under 18 months of age with a clinical diagnosis of bronchiolitis, requiring hospital admission for observation and oxygen therapy. Since the patient is an adult and there is no mention of bronchiolitis or any other criteria that would match the inclusion criteria of the trial, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "325": {
        "output": "",
        "label": 0
    },
    "326": {
        "output": "Based on the information provided in the patient note, the 30-year-old woman does not meet the inclusion criteria for the clinical trial. The inclusion criteria specify that the patient must have given birth to a premature child (less than 36 weeks of gestation and/or less than 2 kg birthweight) and there must have been a separation of the child and mother since birth. The patient note does not mention that the child was premature or that there has been a separation since birth. In fact, the only information about her recent childbirth is that she had given birth to a healthy child 3 weeks before. Without information to suggest that the child was premature or that there was a separation, the patient does not meet the specified criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "327": {
        "output": "Based on the information provided, the patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks before. The clinical trial in question is evaluating the effectiveness of a program to support breastfeeding after short-term hospitalization.\n\nThe inclusion criteria for the clinical trial is very specific: it requires pregnant women who are in gestational weeks 35-36. Since the patient has already given birth and is not currently pregnant, she does not meet the inclusion criteria for participation in the study.\n\nTherefore, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "328": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nHere are the relevant inclusion criteria for the trial:\n\n- Men of ages 18 and 30 (Dates of birth 1973-1985) or 55-92 years old (Dates of birth 1911-1948).\n- Must not currently be a cigarette smoker. If an ex-smoker then has not smoked for at least 10 years and consumption were no more than 10 pack years.\n- Agrees to volunteers for the study and willing to sign the informed consent form.\n- Negative/normal screening tests for respiratory diseases and cardiac conditions.\n- Normal spirometry and impedance oscillometry measurements.\n- Negative physical examination of the chest.\n- Exhaled nitric oxide concentration within specified limits for age groups.\n\nThe patient note gives us the following information:\n\n- The patient is a 30-year-old woman.\n- The patient presents with shortness of breath, which is a respiratory complaint.\n- There is no information on smoking history or willingness to volunteer and sign an informed consent form.\n- There is no information on spirometry, impedance oscillometry, or exhaled nitric oxide concentration.\n\nBased on the information provided, the patient does not meet the following inclusion criteria:\n\n- The patient is not a man (the trial specifically states men of certain ages).\n- The patient has a current respiratory complaint (shortness of breath), which is against the criteria that deny current respiratory complaints.\n\nGiven that the patient is a woman, which is not within the specified gender inclusion criteria, and she has a respiratory complaint, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "329": {
        "output": "Based on the patient note and the inclusion criteria of the given clinical trial, let's assess the eligibility:\n\nPatient Note Summary:\n- 30-year-old woman\n- Presents with shortness of breath\n- Gave birth 3 weeks prior\n- Tachypneic and tachycardic, with a blood pressure of 110/70 and oxygen saturation 92%\n- Normal chest x-ray and CBC\n\nClinical Trial Inclusion Criteria Summary:\n- Healthy males within the age range of 18 to 50 years\n- Body mass index within 18-25 Kg/m^2\n- Various health and lifestyle requirements (no significant diseases, normal ECG and chest X-Ray, no history of certain conditions, no recent participation in other clinical studies, etc.)\n\nEligibility Assessment:\n- Gender: The trial requires male participants, and the patient is a female.\n- Health status: The trial requires healthy participants, and the patient presents with shortness of breath, which may not be considered a healthy condition.\n- Postpartum: The patient recently gave birth, which may influence her health status and could be a factor in her current condition.\n\nGiven the patient is female and the trial explicitly requires male participants, along with the additional health concerns present, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "330": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient is not eligible for this clinical trial. The patient is a 30-year-old woman who has just given birth, which puts her in the immediate postpartum period, not the first or second trimester of pregnancy as required by the trial's inclusion criteria. Additionally, there is no information provided that suggests she has a history of tobacco use or nicotine dependence in the past 90 days or year, which are also part of the inclusion criteria for the trial.\n\nTherefore, this patient would not be referred for this clinical trial since she does not meet the necessary inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "331": {
        "output": "Based on the provided clinical trial inclusion criteria and the patient note, let's assess the patient's eligibility:\n\n1. Healthy pregnant females > 18 years of age - The patient is 30 years old.\n2. Singleton pregnancies (either nulliparous or multiparous) - The patient recently gave birth to a healthy child, so she is not currently pregnant.\n3. Less than 17 weeks gestation - Not applicable as the patient is not pregnant.\n4. A pre-pregnancy BMI < 40 kg/m^2 - The note does not provide information on the patient's pre-pregnancy BMI.\n5. Plans to deliver at a Hamilton or London regional hospital or by home birth - Not applicable as the patient is not currently pregnant.\n6. Able to tolerate dairy foods - The note does not provide information on this.\n7. Approval of primary care provider - The note does not provide information on this.\n8. Able to provide signed informed consent - The patient is an adult and likely capable of providing consent, but this is not explicitly stated.\n\nGiven that the patient is not currently pregnant, she does not meet the fundamental requirement of the clinical trial, which is targeting healthy pregnant females. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "332": {
        "output": "Given the patient note, we can assess the eligibility of the patient for the clinical trial based on the inclusion criteria provided.\n\nInclusion criteria for the clinical trial:\n1. Men and women aged between 18 and 35 years.\n2. Nonsmokers.\n3. Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.\n4. Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant.\n5. Normal ophthalmic findings, ametropy < 3 Dpt.\n\nPatient characteristics from the note:\n- A 30-year-old woman.\n- Generally healthy.\n- Non-smoker status is not mentioned.\n- Normal findings in the medical history and physical examination, except for shortness of breath, tachypnea, and tachycardia.\n- Normal laboratory values (CBC is normal).\n- Normal ophthalmic findings are not mentioned; ametropy status is unknown.\n\nThe patient is within the age range of 18 to 35 years, which meets the first criterion. However, there is no information provided about her smoking status, which is required by the second criterion. The presence of shortness of breath, tachypnea, and tachycardia might be considered clinically relevant abnormalities, and we do not have information on whether the investigator would consider these abnormalities irrelevant. Additionally, there is no information on her ophthalmic findings or ametropy, which are relevant to the fourth and fifth criteria.\n\nBased on the available information, the patient meets some of the inclusion criteria (age and normal CBC), but there is insufficient information to determine her eligibility regarding non-smoker status, clinical relevance of her current symptoms, and ophthalmic findings. Therefore, further investigation is needed to assess these areas before a referral can be considered.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "333": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Summary:\n- 30-year-old woman\n- Shortness of breath started 2 hours before admission\n- Recent childbirth 3 weeks prior\n- No past health problems except for 2 natural abortions\n- Apprehensive, tachypneic, tachycardic\n- Blood pressure: 110/70, oxygen saturation: 92%\n- Normal chest x-ray and CBC\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Caval filtration clinically indicated for prevention of pulmonary embolism in patients with venous thromboembolic disease or at high risk for venous thromboembolic disease, including patients with:\n  - Issues with anticoagulant therapy (contraindications, failures, complications, high risk, etc.)\n  - Specific conditions such as pulmonary embolus, iliocaval DVT, severe trauma, high-risk surgeries, etc.\n\nAssessment:\nThe clinical trial is focused on patients who require an inferior vena cava filter for the prevention of pulmonary embolism, specifically in the context of venous thromboembolic disease or high risk for such disease. The patient in the note presents with shortness of breath soon after childbirth, which could be a sign of various conditions, including a possible pulmonary embolism. However, there is no mention of venous thromboembolic disease or a high risk for it in the patient's note. The normal chest x-ray and CBC do not support an immediate diagnosis of pulmonary embolism or DVT, and there is no information about any contraindications to anticoagulant therapy that the patient might have.\n\nGiven the information provided, the patient does not clearly meet the inclusion criteria for the clinical trial. There is a potential for venous thromboembolic disease given her recent childbirth (a risk factor for thromboembolic events), but this is not confirmed, and further investigations would be needed to establish a diagnosis. Therefore, on the three-point scale, the assessment for this trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "334": {
        "output": "",
        "label": 0
    },
    "335": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient described is a 30-year-old woman presenting with shortness of breath. The trial is focused on the treatment of Transient Tachypnea of the Newborn (TTN), a condition affecting late preterm and term infants. \n\nThe patient in question is not a newborn nor is there any indication that her newborn child is experiencing TTN. Moreover, the inclusion criteria specifically mention that the trial is for late preterm and term infants diagnosed with TTN, and there is no mention of the mother's health status being a factor for inclusion.\n\nGiven these facts, the patient does not meet the inclusion criteria for the clinical trial because she is not a newborn, the actual subject of the study. Therefore, we would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "336": {
        "output": "Based on the information provided, the patient presented with shortness of breath, which started 2 hours before admission. The patient is a 30-year-old woman who recently gave birth and has no history of chronic health problems mentioned, other than natural abortions. The physical examination findings include tachypnea, tachycardia, normal blood pressure, and slightly reduced oxygen saturation, but no mention of chronic obstructive pulmonary disease (COPD) or residence at a low altitude.\n\nThe clinical trial in question is focused on patients with chronic obstructive pulmonary disease (COPD) of GOLD grade 2-3 who reside at low altitude (<800 m). As there is no mention of COPD in the patient's history or current symptoms indicative of COPD, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "337": {
        "output": "Based on the patient note provided, the patient is a 30-year-old woman presenting with symptoms that could be suggestive of a pulmonary embolism, such as shortness of breath, which started 2 hours before admission, and she is also noted to be tachypneic and tachycardic. The clinical trial in question is assessing the efficacy of low-dose versus full-dose contrast CT pulmonary angiography in detecting emboli.\n\nThe inclusion criteria for the trial are patients referred for CT pulmonary angiogram to exclude pulmonary embolus. Since the patient's symptoms could be indicative of a pulmonary embolism, and she may be referred for a CT pulmonary angiogram to exclude this diagnosis, she fits the inclusion criteria for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial and it is highly likely that she would be referred for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "338": {
        "output": "The patient in question is a 30-year-old woman who has recently given birth and is presenting with symptoms of shortness of breath, which could be indicative of several possible conditions but is not explicitly related to any neonatal issues that would require ventilation support, as per the information provided.\n\nThe clinical trial in question is focused on infants at 24-36 weeks corrected gestational age who are already on high frequency oscillatory ventilation. The patient herself is not the subject of the clinical trial, rather her newborn infant could potentially be a subject if they met the specific inclusion criteria. However, there is no information given in the patient note that suggests her 3-week old child is experiencing any issues requiring ventilation, much less high frequency oscillatory ventilation.\n\nBased on the information provided, the patient and/or her infant do not meet the inclusion criteria for the clinical trial, which requires infants already ventilated with high frequency ventilation, and requiring a certain range of FiO2 to maintain oxygen saturation.\n\nTherefore, the patient (and by extension, her child) does not appear to be eligible for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "339": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the clinical trial. The trial is designed for premature infants born less than 30 completed weeks gestation, whereas the patient is a 30-year-old woman who recently gave birth to a healthy child. Therefore, she is not eligible for a study focused on premature infants.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "340": {
        "output": "Based on the information provided:\n\nThe patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. She presents with shortness of breath that started 2 hours before admission, and she is experiencing symptoms such as being apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. \n\nThe clinical trial in question is investigating the effect of a father inclusive psychoeducation program on postnatal depression. The inclusion criteria for this trial are:\n\n1. Aged 18 or above;\n2. First-time parents;\n3. Able to speak and read the Chinese language; and\n4. Hong Kong residents.\n\nThe patient fits the age criterion and is a first-time parent. However, there is no information provided about her ability to speak and read the Chinese language, nor whether she is a Hong Kong resident. These two criteria are crucial for determining eligibility for this specific trial. Without this information, we cannot definitively say whether she would be eligible or not.\n\nGiven the information gap regarding language and residency status, I would rate the eligibility as:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "341": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not seem to fit the requirements of the study. The clinical trial is focused on the effects of postpartum maternal vitamin A supplementation, and the inclusion criteria mention pregnant women of >18 years of age with low-risk obstetrics, but there is no clear indication that the patient is either pregnant or has a low-risk obstetric profile at the time of presentation. Moreover, the patient presented with symptoms of shortness of breath, for which she is seeking medical attention, and this symptom does not appear to be related to the focus of the clinical trial.\n\nGiven these discrepancies, the patient described in the note does not meet the inclusion criteria for the clinical trial provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "342": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the criteria for participation. The clinical trial is focused on neurocognitive and immunological development in infants fed a new infant formula compared to a standard formula or breastfeeding. The inclusion criteria are specific to newborns and infants in terms of gestational age at birth, birth weight, age at inclusion, breastfeeding status, Apgar score, and umbilical pH.\n\nThe patient is a 30-year-old woman and, as such, does not fit the demographic of the study participants, which are infants. Therefore, this patient would not be eligible to participate in the study based on the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "343": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the study. The clinical trial is looking for patients with precapillary pulmonary hypertension or interstitial lung disease, who are in the New York Heart Association class 2-3, and who reside at low altitude (<800m).\n\nThe patient note describes a 30-year-old woman presenting with shortness of breath, tachypnea, and tachycardia, with a recent childbirth history. There is no indication that she has pulmonary hypertension or interstitial lung disease, nor is there any mention of her residing at a low altitude or her NYHA class. The patient's symptoms could be related to a number of different causes, and without further information indicating a diagnosis of either precapillary pulmonary hypertension or interstitial lung disease, she would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "344": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the patient note and the inclusion and exclusion criteria provided:\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman, which fits within the age range of 18-45 years specified in the inclusion criteria.\n- She has recently given birth to a healthy child 3 weeks prior, which aligns with the trial's inclusion of postpartum women.\n- The patient presents with shortness of breath, which started 2 hours before admission. This may suggest an acute condition but is not directly related to postpartum depression or sexual functioning.\n- The patient's blood pressure is within normal limits, and there's no indication of any of the exclusion conditions such as thrombophlebitis, thromboembolic disorders, diabetes mellitus, etc.\n- The patient is not described as breastfeeding, which is one of the exclusion criteria.\n- There is no mention of the patient's desire for contraception postpartum, which is a requirement for the medication groups. However, since there's also a control group that chooses not to use oral contraceptives postpartum, she could potentially fit into that group.\n- The patient has no history of depression, mood disorders, or psychiatric disorders mentioned, which satisfies both the medication and control group exclusion criteria.\n- There is no information provided about whether the patient had a cesarean section, her smoking status, or any history of alcohol or drug use.\n\nGiven the information presented in the patient note, the patient fits the age criteria and is in the postpartum period, which are key inclusion criteria for the clinical trial. However, there are some uncertainties:\n\n1. It is not clear if the patient desires contraception postpartum, which is necessary for the medication groups.\n2. The patient's method of delivery (cesarean section or not) is unknown.\n3. There is no information on the patient's smoking status, history of alcohol or drug use, or her opinion on using hormonal contraception.\n\nDue to these uncertainties and the lack of explicit information on some of the inclusion and exclusion criteria, further investigation is required before making a definitive decision on her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "345": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman, which meets the age criterion.\n- She gave birth to a healthy child 3 weeks before, meeting the criterion of having delivered at an estimated gestational age (EGA) \u226537 weeks.\n- She is within the postpartum period as she is 3 weeks postpartum, which adheres to the inclusion criteria.\n- The intent to breastfeed is not explicitly stated, but since breastfeeding rates are being studied, it can be inferred that the patient intended to breastfeed.\n- Breastfeeding initiation within the first 48 hours of delivery is not mentioned, so this is not verifiable from the note.\n- The infant's rooming-in status is not mentioned.\n- The patient's ability to speak English and complete surveys is not mentioned.\n- There's no information about the patient's military system affiliation or plans to move in the upcoming 6 months.\n- Willingness to render informed consent is typically assessed at the time of recruitment and is not something that can be determined from the note.\n\nClinical Trial Inclusion Criteria Checklist:\n- Age 18 or above at the time of delivery \u2714\ufe0f\n- Delivery of live born infant at EGA \u226537 weeks \u2714\ufe0f\n- Postpartum primiparous patients within the first 48 hours after delivery (the patient is 3 weeks postpartum, which does not strictly meet this criterion) \u274c\n- Patient intent to breastfeed (not explicitly stated but implied) \u2753\n- Breastfeeding initiated within the first 48 hours of delivery and/or prior to hospital discharge (not mentioned) \u2753\n- Infant is continuously rooming in with the mother from the time of delivery (not mentioned) \u2753\n- English-speaking (not mentioned) \u2753\n- Able to read and complete surveys (not mentioned) \u2753\n- No anticipated discharge from military system, Tricare benefits, or move planned in the upcoming 6 months (not mentioned) \u2753\n- Willing to render informed consent (assumed for every patient but not explicitly mentioned) \u2753\n\nBased on this analysis, the key piece of information missing is whether the patient meets the criterion of being a \"postpartum primiparous patient within the first 48 hours after delivery.\" Since the patient is 3 weeks postpartum, she does not meet this inclusion criterion. There is also a lack of information on several other criteria, which would require further investigation to determine eligibility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "346": {
        "output": "To determine the patient's eligibility for the \"nuMoM2b Heart Health Study\" clinical trial, we must assess whether she meets the inclusion criteria outlined for the study. Let's review the given patient note against the inclusion criteria:\n\nPatient Note Review:\n- The patient is a 30-year-old woman.\n- She has recently given birth to a healthy child 3 weeks prior.\n- She has had two natural abortions in the past.\n- She is presenting with shortness of breath, tachypnea, tachycardia, and reduced oxygen saturation.\n\nInclusion Criteria for the Clinical Trial:\n- Agreed to contact for future studies during nuMoM2b and not subsequently withdrawn from the cohort.\n- Have pregnancy outcome data from the nuMoM2b study.\n- At least 18 years of age.\n- Consented for participation in interval contacts and not subsequently withdrawn.\n- Between 2 and 3.5 years after the nuMoM2b pregnancy ended.\n- Self-report at least 6 months postpartum from any subsequent pregnancy.\n- Self-report not currently pregnant.\n- Participation in the in-clinic visit.\n- Participation in the sleep breathing substudy of nuMoM2b with at least one sleep breathing assessment providing valid data.\n- Not currently using positive airway pressure (PAP) therapy or other treatments for sleep apnea.\n- Not on continuous oral steroid therapy for asthma, or using oxygen supplementation for a medical condition.\n\nComparison:\n- The patient is of eligible age (\u2265 18 years).\n- However, there is no information provided that indicates whether the patient was part of the nuMoM2b cohort or that she consented for interval contact.\n- The patient has given birth 3 weeks ago, which is well within the 2 to 3.5 years postpartum period required by the study. However, participants must be at least 6 months postpartum from any subsequent pregnancy, which she is not.\n- The patient is not currently pregnant, which aligns with the study requirements.\n\nGiven the available information, there is no indication that the patient was part of the previous nuMoM2b study, which is a crucial requirement for participation in this follow-up study. Additionally, the patient is not at least 6 months postpartum from any subsequent pregnancy, which is another requirement for the study.\n\nBased on the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet several key criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "347": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion and exclusion criteria, it is clear that this patient does not meet the specific requirements for inclusion in the clinical trial. The trial is focused on patients undergoing major lung resection for malignancies and evaluating the incidence of VTE after such surgeries. \n\nThe patient in the note presents with shortness of breath and a history of recent childbirth but does not have any mention of lung cancer or the need for lung resection surgery. Therefore, this patient is not eligible for the clinical trial in question, which requires the patient to have a diagnosis of resectable lung cancer or metastatic lung disease eligible for complete metastasectomy and to be undergoing specific lung surgeries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "348": {
        "output": "",
        "label": 1
    },
    "349": {
        "output": "The patient in question is a 30-year-old woman who recently gave birth and is presenting with shortness of breath, which started 2 hours before admission. There is no mention of preeclampsia in her medical history, and she has not been described as having been treated with magnesium sulfate before delivery.\n\nThe clinical trial is specifically looking for women with severe preeclampsia or severe preeclampsia aggregated to chronic hypertension who were treated with 4-6 grams of magnesium sulfate for impregnation with a minimum of 8 hours continuous of magnesium sulfate before delivery.\n\nGiven that the patient's condition does not match the inclusion criteria (which specifically mentions severe preeclampsia and treatment with magnesium sulfate), she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "350": {
        "output": "Given the patient note, we have a 30-year-old woman who has recently given birth. The clinical trial's inclusion criteria require participants to be either aged 16-18 and married or aged 18+ and in a co-habiting relationship. Furthermore, participants need to be pregnant within 24-36 weeks, have no obstetric risk factors requiring hospital delivery, live no more than one hour away on foot from the city, not planning to move from the city, and give informed consent.\n\nThe patient in the note is not currently pregnant, as she gave birth three weeks prior, and there is no information about her marital status or whether she is co-habiting. Even if she met the marital or co-habitation criteria, she does not meet the pregnancy criteria as she is not currently within the 24-36 weeks of pregnancy required by the trial.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "351": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, we can determine the patient's eligibility. \n\nThe patient is a 30-year-old woman presenting with shortness of breath, which began 2 hours before admission. She is also described as apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. The physical examination is otherwise unremarkable, and her chest x-ray and CBC are normal. \n\nThe clinical trial in question is focused on children with fast breathing pneumonia and is comparing amoxicillin with placebo. The inclusion criteria specify that the trial is for children with a history of cough or difficult breathing for less than 14 days and with a respiratory rate above a certain threshold specific to their age group. Additionally, informed consent by a legal guardian is required.\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n1. The patient is a 30-year-old woman, not a pre-school child (2-59 months old).\n2. There is no mention of the patient having a history of cough or difficult breathing for less than 14 days.\n3. The patient's respiratory rate is not mentioned, and even if it were, the criteria are specific to young children.\n4. The patient is not being presented as part of a legal guardian and is capable of providing consent herself.\n\nTherefore, this patient would not be eligible for the clinical trial based on the mismatch of age and the absence of specified symptoms and conditions related to the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "352": {
        "output": "Based on the patient note provided, the patient is a 30-year-old woman who has recently given birth to a healthy child and is currently experiencing shortness of breath. There is no mention of her breastfeeding status or whether she is experiencing pain during breastfeeding, which is the focus of the clinical trial.\n\nThe clinical trial is investigating the use of a dental support device (Leboride) during breastfeeding as a means for pain control. The inclusion criteria for the trial are:\n\n1. Maternal age 18-45 years.\n2. Normal vital signs.\n\nThe patient fits the age criterion (30 years old). However, the patient's vital signs are not entirely normal as she presents with tachypnea and tachycardia, and her oxygen saturation is slightly below the normal range (92% instead of the normal range of 95-100%). Since the trial specifically requires normal vital signs, this could be a point of concern.\n\nAdditionally, there is no information provided about pain during breastfeeding, which is a key aspect of what the trial is studying. Therefore, we cannot conclude that she is experiencing an issue that the trial aims to address. It's important to note that clinical trial referrals should consider not only the eligibility criteria but also the relevance of the trial to the patient's condition.\n\nGiven this information, the patient does not fully meet the inclusion criteria due to her abnormal vital signs, and there is no information about her experiencing pain during breastfeeding, which is the focus of the trial. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "353": {
        "output": "Based on the information provided, the patient in question is a 30-year-old woman who presents with shortness of breath that started 2 hours before admission. She has a recent history of childbirth and has experienced two natural abortions. Her current vital signs show tachypnea, tachycardia, and an oxygen saturation of 92%, but her chest x-ray and CBC are normal.\n\nThe clinical trial in question is studying the effects of sound energy on pulmonary gas exchange and is seeking healthy male or female volunteers. However, the inclusion criteria for the clinical trial are not fully detailed in the information provided. If \"healthy\" is defined as having no active medical issues, the patient's current presentation with shortness of breath would potentially exclude her from being considered healthy at this time. Furthermore, the shortness of breath could be a sign of an underlying condition that needs to be addressed before she can participate in a study.\n\nGiven the lack of detailed inclusion criteria, but considering the patient's current symptoms, it is not clear whether she would be an ideal candidate for a study on healthy volunteers without further information on her condition and the specific requirements of the trial. Therefore, I would lean towards:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "354": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to assess whether the patient is eligible for the trial focusing on using sodium lactate Ringer's injection to resuscitate septic shock patients.\n\nPatient Note Summary:\n- 30-year-old woman\n- Presents with shortness of breath, tachypnea, tachycardia\n- Blood pressure is 110/70, oxygen saturation 92%\n- Chest x-ray and CBC are normal\n- Recently gave birth (3 weeks prior)\n- No other health problems except for 2 natural abortions\n\nClinical Trial Inclusion Criteria:\n- Diagnosis in patients with septic shock\n\nAnalysis:\nThe patient presents with symptoms that could be associated with a variety of conditions, including but not limited to postpartum complications, pulmonary embolism, or other cardiopulmonary issues. However, the normal chest x-ray and CBC, as well as a lack of information on fever, infection, or organ dysfunction, do not support a clear diagnosis of septic shock at this time. To be considered for inclusion in the trial, the patient would need a definitive diagnosis of septic shock.\n\nGiven the information at hand, the patient does not meet the inclusion criteria for the clinical trial, as there is no indication of septic shock from the patient note. Additional information and further medical evaluation would be necessary to determine if the patient's condition aligns with septic shock. Therefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "355": {
        "output": "Based on the information provided in the patient note, the woman is 30 years old and has recently given birth, which makes her potentially relevant to the clinical trial concerning the treatment of postpartum anemia. The clinical trial's inclusion criteria specify that participants must be women above 18 years old after giving birth, which fits the patient's profile.\n\nHowever, the inclusion criteria also specify that participants must suffer from iron deficiency anemia, defined as hemoglobin < 9.5 g/dl. The patient note does not provide any information regarding the patient's hemoglobin levels or a diagnosis of iron deficiency anemia. The patient presents with shortness of breath, which can be a symptom of anemia, but her CBC is normal, suggesting that her hemoglobin level may not be below the threshold required for the trial.\n\nSince the patient's eligibility regarding the specific criteria of iron deficiency anemia (hemoglobin < 9.5 g/dl) cannot be confirmed with the information provided, further investigation would be needed to determine her hemoglobin level and confirm the diagnosis of iron deficiency anemia.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "356": {
        "output": "",
        "label": 1
    },
    "357": {
        "output": "Given the patient note:\n\n- The patient is a 30-year-old woman.\n- She has given birth to a healthy child 3 weeks before.\n- She presents with shortness of breath but has no history of health problems other than 2 natural abortions.\n\nThe clinical trial's inclusion criteria are:\n\n- Women who are more than 28 weeks pregnant OR up to 9 months post-birth.\n\nBased on the provided information, the patient is within 9 months post-birth, which aligns with the clinical trial's inclusion criteria concerning the time frame post-birth.\n\nHowever, there is no indication in the patient note that the woman is experiencing symptoms of postnatal depression, which is the focus of the clinical trial. The trial is specifically about the impact of creative interventions on symptoms of Postnatal Depression (PND), and without information on whether the patient is experiencing PND, we cannot conclusively determine her eligibility.\n\nGiven the lack of information regarding PND symptoms in the patient's note but considering she is within the post-birth timeframe, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "358": {
        "output": "Given the patient note, the 30-year-old woman who presented with shortness of breath had given birth 3 weeks prior to admission. She is no longer pregnant, which is a key criterion for the clinical trial in question. The clinical trial is specifically targeting pregnant women who are hospitalized.\n\nSince the patient is not currently pregnant, she does not meet the inclusion criteria of being a hospitalized pregnant woman. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "359": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question does not meet the inclusion criteria for the clinical trial.\n\nThe clinical trial is specifically targeted at pediatric patients between one and 18 years of age who require an endotracheal tube and are classified as ASA class I to III. The patient described in the note is a 30-year-old woman, which immediately disqualifies her from the study, as she is not within the specified age range for pediatric patients.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "360": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient's characteristics:\n- A 30-year-old woman\n- Generally healthy\n- Presented with shortness of breath, tachypneic, tachycardic, blood pressure 110/70, oxygen saturation 92%\n- Gave birth 3 weeks prior\n- No signs of severe PE (shock, hypotension)\n- No mention of any contraindications to iodinated contrast medium\n- Age > 18 years\n- No mention of health insurance status\n- No mention of the ability to give informed consent or the possibility of a 3-month follow-up\n\nClinical Trial Inclusion Criteria:\n- Women with clinically suspected pulmonary embolism (PE) during the first 6 weeks postpartum, without any sign of severe PE\n- No contraindications to iodinated contrast medium injection\n- Age > 18 years\n- Health insurance\n- Possibility to have a 3-month follow-up\n- Obtention of written informed consent (ability to give consent)\n\nThe patient appears to meet the following criteria:\n- She is within the first 6 weeks postpartum.\n- She is presenting with symptoms that could be indicative of PE (shortness of breath, tachypnea, tachycardia), though no diagnosis of PE is mentioned.\n- She is older than 18 years.\n- No severe PE is indicated in the note.\n- There is no mention of a previous allergic reaction to iodinated contrast medium, renal insufficiency, or uncontrolled hyperthyroidism.\n\nHowever, the following information is not provided or confirmed in the patient note:\n- Whether she has health insurance.\n- Whether she can be followed up for 3 months.\n- Whether she is capable and willing to give informed consent.\n\nGiven that the patient aligns with several of the inclusion criteria but there is missing information regarding health insurance, the possibility of a 3-month follow-up, and the ability to give informed consent, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "361": {
        "output": "Based on the provided information, the patient in question is an 85-year-old man with a gradual decrease in his level of consciousness and a recent decline in mobility and self-feeding abilities. The clinical trial in question is investigating the relationship between vitamin D, fingernail thickness, and bone density.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Females 25-75 years of age with no known bone disorders\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- Gender: The trial is looking for female participants, and the patient is male.\n- Age: The trial is looking for participants between the ages of 25-75, and the patient is 85 years old.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "362": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Biomarkers and Early Alzheimer's Disease,\" we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nThe inclusion criteria are as follows:\n1. Individuals of either sex, with a high school education, and between the ages of 60 and 80 years living in the New York City metropolitan area.\n2. Minimum of 12 years of education.\n3. Participants will be classified as within normal limits on medical, psychiatric, and neuropsychological examinations (performance that is better than -1.5 sd of the NYU norm-based WMS-R delayed memory index).\n4. Participants will have a global deterioration scale (GDS) = 1 or 2. Those enrolled in the High-Risk group will have a GDS = 2 and have a score of >25 on the Memory Complaint Questionnaire (MCQ). In high-risk memory loss cases, an informed family member or caregiver will be interviewed to confirm that the participant can perform specific tasks.\n\nNow, let's assess the patient's eligibility based on the provided patient note:\n\n1. The patient is an 85-year-old man, which exceeds the maximum age limit of 80 years set by the trial.\n2. There is no information provided about the patient's level of education.\n3. The patient is experiencing a gradual decrease in his level of consciousness, and he has stopped walking and eating by himself, which may indicate that his performance on neuropsychological examinations would be outside the normal limits required by the trial.\n4. There is no information provided about the patient's GDS or MCQ scores, but the acute change in his level of consciousness and the inability to walk or eat independently suggest that he may not be within the GDS = 1 or 2 requirement.\n\nBased on the provided information, the patient does not meet the age criterion and likely does not meet other criteria regarding neuropsychological performance and the global deterioration scale. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "363": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Donepezil in Preventing Delirium in Hospitalized Elderly,\" let's consider the eligibility of the patient:\n\nPatient note:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No fever, cough, rash, or diarrhea reported.\n- History of a car accident 3 weeks prior with a normal head CT at that time.\n- He is brought to the ER, but we do not have information about a hip fracture or any surgical repair plans.\n\nClinical trial inclusion criteria:\n- Community-dwelling individuals aged 65 or older.\n- Admitted to Methodist Hospital for surgical repair of hip fracture.\n- No evidence of delirium at admission to the hospital.\n- MMSE total score below 24 points after adjustment for education and age.\n- Consent to participate in the study.\n\nBased on the patient note, the patient is within the age range for the clinical trial. However, there are several points that need to be clarified to determine eligibility:\n\n1. It is not specified if the patient is community-dwelling.\n2. There is no information on whether the patient is admitted for surgical repair of a hip fracture; the reason for ER admission seems to be related to decreased consciousness rather than a hip fracture.\n3. The patient has a decreased level of consciousness, which could be indicative of delirium, making the criteria of \"no evidence of delirium at admission\" questionable.\n4. We do not have the patient's MMSE score, which is required to meet the inclusion criteria.\n5. There is no mention of whether the patient or his legal representative has given consent to participate in any study.\n\nWithout further information, especially regarding the patient's mental status (MMSE score), evidence of delirium, and the specific reason for ER admission (whether it's related to a hip fracture requiring surgical repair), we cannot confidently refer this patient to the trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "364": {
        "output": "",
        "label": 0
    },
    "365": {
        "output": "The patient in question is an 85-year-old man who was brought to the ER due to a gradual decrease in his level of consciousness. He stopped walking and eating by himself over the last three days but had no fever, cough, rash, or diarrhea. He was involved in a car accident 3 weeks prior, after which a head CT was performed and was normal at that time. \n\nThe clinical trial in question is studying the use of beta-blockers in elderly trauma patients. The inclusion criteria for the trial are:\n- All trauma patients admitted to the ICU \n- >55 years of age \n- With a primary diagnosis of injury\n\nThe patient is 85 years old, which fits the age criterion of being over 55 years of age. He was involved in a car accident, which could be considered a traumatic event. However, the patient note does not specify that the patient was admitted to the ICU with a primary diagnosis of injury. The decrease in the level of consciousness and the cessation of walking and eating could be related to many causes and do not necessarily confirm a direct link to the prior car accident or suggest a primary diagnosis of trauma.\n\nGiven that the patient was involved in a car accident recently, it is possible that he could fit the study's criteria, but there is not enough information in the patient note to confirm his eligibility based solely on the information provided. The note does not explicitly state that his current condition is due to the trauma from the car accident, nor does it mention an ICU admission with a primary diagnosis of injury as a result of the trauma.\n\nThus, referring this patient to the clinical trial would require further investigation into his medical records, particularly to understand the cause of his current symptoms and whether he was indeed admitted to the ICU with a primary diagnosis related to the trauma. Without this information, it's not possible to definitively determine his eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "366": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial titled \"Characteristics of Blood-Brain Barrier Permeability in Neurological Patients.\"\n\nPatient's Characteristics:\n- 85-year-old man\n- Gradual decrease in consciousness over the last 3 days\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at the time of the car accident\n\nClinical Trial Inclusion Criteria:\n- One week following: Traumatic Brain Injury or Cerebro-Vascular Accident\n- Subsequent brain CT showing cerebral cortex injury\n\nThe patient does not meet the inclusion criteria as specified for the clinical trial. There is no mention of a traumatic brain injury or cerebro-vascular accident occurring one week prior to the potential study enrollment. Additionally, there is no information about a subsequent CT showing cerebral cortex injury post the car accident. The patient had a normal head CT at the time of the accident, and the decrease in consciousness started much later (about 3 weeks after the accident).\n\nGiven the lack of alignment with the inclusion criteria, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "367": {
        "output": "Based on the information provided, the patient in the note is an 85-year-old man, which does not meet the inclusion criteria for age in the clinical trial mentioned. The trial specifically includes all asymptomatic trauma patients from 0 to 15 years old, and the patient is well beyond this age range. Additionally, the patient is not asymptomatic; he presents with a gradual decrease in his level of consciousness and has stopped walking and eating by himself.\n\nTherefore, this patient would not be eligible for the described clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "368": {
        "output": "Based on the patient note provided, the 85-year-old man brought to the ER due to a gradual decrease in his level of consciousness, with recent changes in mobility and eating, could potentially be experiencing symptoms related to dementia. However, there is no explicit mention of a dementia diagnosis by a physician in the patient note. Moreover, his Mini-Mental State Examination (MMSE) score is not provided in the note, which is a requirement for inclusion in the clinical trial.\n\nGiven the information provided:\n\n- The patient meets the age criterion (65 years of age or older).\n- There is no clear diagnosis of dementia stated, which is an essential inclusion criterion.\n- The MMSE score is not mentioned, which is needed to determine eligibility.\n- There is no information about the patient's ability to participate in the therapy sessions once a week for 6 weeks.\n\nDue to the absence of a clear diagnosis of dementia and the lack of an MMSE score, we cannot definitively determine the patient's eligibility. Therefore, further investigation would be needed to obtain this information before a referral could be made. The patient's ability to participate consistently would also need to be assessed given his recent decline.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "369": {
        "output": "Based on the provided information, the 85-year-old man does not meet the inclusion criteria for the clinical trial titled \"Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults.\" The inclusion criteria specify that participants must be healthy, male between 65-75 years old, have a valid Ontario driver's license, be an active driver (driving greater than or equal to three times per week), provide written, informed consent, and live in Toronto/Thunder Bay.\n\nThe patient in question is 85 years old, which is above the age range specified in the trial's inclusion criteria. Additionally, the patient has experienced a gradual decrease in the level of consciousness and has stopped walking and eating by himself, which suggests that he is not healthy, and therefore, does not meet the \"healthy\" criterion. There is also no information to confirm if he meets the other criteria such as having a valid Ontario driver's license, being an active driver, being able to provide informed consent, and living in Toronto/Thunder Bay.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "370": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Delirium Recall in Advanced Cancer Patients,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are as follows:\n1. Presence of advanced cancer, defined as local recurrent and/or metastatic.\n2. History of an episode of delirium during the patient's current inpatient admission; diagnosis of delirium will be made by one of the palliative care specialists according to DSM-IV-TR criteria.\n3. Complete recovery from the episode of delirium if it occurred, with the patient being approached within 3 days for the possibility of inclusion in the study.\n4. Ability to communicate in the English language.\n5. Caregiver who is 18 years of age or older, is able to communicate in English and comprehend the assessment questionnaire, and is at the bedside for a significant length of time each day during the delirium episode. Both the patient and their caregiver must agree to participate for inclusion in the study.\n6. Written informed consent signed by the patients and the participating caregivers.\n7. MDAS < 13 (Scores of 13 or above likely reflect the presence of delirium).\n8. Recruitment from the palliative care mobile team or the inpatient palliative care unit.\n\nThe patient note mentions:\n- An 85-year-old man with a gradual decrease in the level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No fever, cough, rash, or diarrhea reported.\n- He had a car accident 3 weeks prior and a normal head CT at that time.\n- There is no mention of advanced cancer, delirium, or recovery from delirium.\n\nBased on the provided patient note, the following points are noted:\n- There is no mention of the patient having advanced cancer, which is a primary requirement for the trial.\n- The patient has had a decrease in consciousness, but there is no explicit mention of an episode of delirium or a diagnosis of delirium made by a palliative care specialist.\n- There is no information on whether the patient has had a complete recovery from delirium, nor is there a timeline that matches the criteria of being approached within 3 days post-recovery.\n- There is no information on the patient's ability to communicate in English, the presence of a caregiver, or the caregiver's ability to communicate in English.\n- There is no indication that written informed consent has been provided by the patient or a caregiver.\n- The patient's MDAS score is not provided.\n- There is no information regarding the patient's recruitment from the palliative care mobile team or the inpatient palliative care unit.\n\nGiven the lack of information about advanced cancer, delirium, and other specific inclusion criteria, the patient does not appear to meet the requirements for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "371": {
        "output": "The patient is an 85-year-old man who has experienced a gradual decrease in his level of consciousness, cessation of walking and eating by himself, and no fever, cough, rash, or diarrhea. It's noted that he was involved in a car accident 3 weeks prior and had a normal head CT at that time.\n\nNow, let's compare the patient's situation to the inclusion criteria for the clinical trial:\n\n1. At least one fall in the last 6 months: The patient note does not mention any falls, so we cannot confirm this criterion is met based on the provided information.\n\n2. Living in their own home or in a home for the aged: There is no information provided about the patient's living situation.\n\n3. Availability of a primary caregiver caring for the patient at least once a week: The patient's daughter is mentioned, which might imply she could be a primary caregiver, but the frequency of care is not specified.\n\n4. Ability to walk 15 meters independently (use of a walking aid is permitted): The patient has stopped walking, meaning he currently does not meet this criterion.\n\n5. Life expectancy of more than 6 months, as judged by their geriatrician: There is no information provided about the patient's life expectancy.\n\nBased on the available information, the patient does not clearly meet several of the inclusion criteria, specifically the ability to walk 15 meters independently and the documented history of at least one fall in the last 6 months. Furthermore, other criteria such as living situation and life expectancy are not addressed in the patient note. Therefore, we would not refer this patient for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "372": {
        "output": "Based on the patient note provided, the 85-year-old man has experienced a gradual decrease in the level of consciousness and stopped walking and eating by himself. There is no mention of urinary incontinence, walking difficulties specifically in both legs, or mental impairment. Furthermore, there is no information provided regarding brain imaging results (CT or MRI) that show enlarged ventricles, nor is there an MMSE score available to determine the level of mental impairment.\n\nGiven the lack of detailed information in the patient note that matches the specific inclusion criteria for the clinical trial on normal pressure hydrocephalus (NPH), such as specific walking difficulties, mental impairment, urinary incontinence, and brain imaging findings, it is not possible to confidently refer this patient for the trial. More information would be needed to make an accurate assessment of his eligibility.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "373": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided inclusion criteria, we need to compare the patient's characteristics with those criteria.\n\nInclusion Criteria for the trial:\n1. Adults, 18-65 years old\n2. One or more mild-moderate TBI's characterized by loss of consciousness due to blast injury that is a minimum of one year old and occurred after 9/11/2001\n3. Absence of acute cardiac arrest or hemorrhagic shock at time of TBI.\n4. Absence of intracranial neurosurgery post-TBI\n5. Disability Rating Scale of 0-3\n6. Negative Michigan Alcohol Screening Test (MAST)\n7. Negative Drug Abuse Screening Test (DAST)\n8. Negative urine toxicology screen for drugs of abuse\n9. Negative pregnancy test in females\n10. Otherwise good health\n11. Less than 90% on the Percent Back to Normal Rating Scale\n\nPatient's Characteristics:\n- An 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at that time\n\nThe patient's age (85 years old) does not meet the age criterion of the clinical trial (18-65 years old). Additionally, there is no information provided about a TBI due to a blast injury or the absence of acute cardiac arrest or hemorrhagic shock at the time of the TBI. Furthermore, the patient's recent history does not suggest a TBI that occurred after 9/11/2001. The other criteria such as the Disability Rating Scale, MAST, DAST, and urine toxicology screen cannot be assessed from the given patient note, but the patient's age alone is a clear exclusion factor.\n\nBased on the information provided, the patient is not eligible for the clinical trial due to not meeting the age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "374": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical trial:\n- Title: Analysis of Balance in the Aging Process\n- Objective: To evaluate the functional balance in the aging process\n- Inclusion criteria: Absence of the basic pathology that interferes directly in the balance\n\nThe patient is an 85-year-old man experiencing a decline in his level of consciousness and functional abilities, which could be indicative of an underlying pathology not yet diagnosed. While the trial focuses on analyzing balance in older individuals and the patient falls within the age range, the inclusion criteria specify that participants should not have a basic pathology that directly interferes with balance.\n\nGiven the patient's recent changes in consciousness and abilities, it's possible that there may be an underlying condition affecting his balance. Therefore, further investigation would be required to determine whether the patient's current health status is related to a basic pathology that would interfere with balance assessments in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "375": {
        "output": "Based on the patient note provided, the patient is an 85-year-old man who was brought to the ER due to a gradual decrease in his level of consciousness. He has had a recent decline in his ability to walk and eat by himself. Importantly, there is no mention of the patient being on vitamin K antagonists (VKA), having an increased INR, or having a spontaneous intracerebral hemorrhage (ICH) or subdural hematoma (SDH) diagnosed by CT scanning within 12 hours of symptom onset. Therefore, we cannot determine based on the information provided whether any of the inclusion criteria for the clinical trial titled \"International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage\" are met.\n\nSince we do not have evidence that the patient meets the specific inclusion criteria of being on VKA therapy and having an INR \u2265 2, or that he has a spontaneous ICH or SDH diagnosed by CT scanning within the required timeframe, we cannot refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "376": {
        "output": "Based on the information provided in the patient note, the 85-year-old man was brought to the ER due to a gradual decrease in his level of consciousness and had stopped walking and eating by himself. There is no mention of him being a veteran, having PTSD, or meeting the DSM-IV criteria for PTSD. The clinical trial in question is specifically looking for veterans who meet the DSM-IV criteria for PTSD and aims to study the neural correlates of cognitive rehabilitation in such individuals.\n\nGiven that the patient note does not indicate that the patient is a veteran or has PTSD, there is no basis for referring this patient to the clinical trial mentioned. Therefore, the trial-level eligibility for this patient for the clinical trial titled \"Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)\" is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "377": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient in question is an 85-year-old man who has experienced a gradual decrease in his level of consciousness and has stopped walking and eating by himself. It is noted that the patient was involved in a car accident 3 weeks prior to admission and had a normal head CT at that time.\n\nFor the clinical trial titled \"Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder,\" the inclusion criteria are as follows:\n\n1. At least 18 years of age and non-active duty.\n2. Either normal (no history of head injury) -OR- TBI (injury since Jan. 1, 2002).\n\nThe patient meets the age criterion as he is 85 years old and there is no information that suggests he is on active duty. However, the patient's head CT was normal following the car accident, and there is no clear indication from the provided note that he has a traumatic brain injury. The clinical trial is specifically interested in individuals with a normal brain or a history of TBI. Since the patient does not have a documented TBI but experienced a car accident which could potentially lead to late-onset symptoms not yet diagnosed, there may be a possibility of TBI that has not been identified by the normal CT scan done immediately after the accident.\n\nBased on the information provided and considering the potential for undiagnosed TBI due to the recent car accident, I would say:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "378": {
        "output": "Based on the patient note provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and recent changes in mobility and feeding behavior could be exhibiting signs of delirium. The patient's age and current location in the emergency department appear to meet the inclusion criteria for the clinical trial, which are:\n\n1. 65 years of age or greater\n2. In the Emergency Department for less than 12 hours at the time of enrollment\n\nSince the patient note does not specify the exact time the patient has been in the ER, it is assumed that, given he is currently being described as in the ER, he falls within the 12-hour window.\n\nGiven these considerations, the patient is a match for the age criterion and is currently in the ER, which makes him a likely candidate for the trial on delirium screening.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "379": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 85 years old (meets the age criteria of 65-85 years)\n- Independent in activities of daily living: Unknown\n- Able to walk without assistance for at least 10 minutes: As of the last 3 days, the patient stopped walking, which suggests he may not meet this criterion currently.\n- Cognitively intact (Mini Mental State Exam \u226524): The gradual decrease in the level of consciousness could indicate cognitive impairment; however, the actual MMSE score is unknown.\n- Reported 2 or more falls within 6 months prior to the beginning of the study: There is no information provided about previous falls.\n\nGiven the information from the patient note, the patient does not clearly meet all of the inclusion criteria for the clinical trial. Specifically, the criteria related to walking without assistance and cognitive integrity are not met based on the provided information. Additionally, there is no information about the patient's history of falls, which is a critical inclusion criterion for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "380": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Imaging of Traumatic Brain Injury,\" let's assess the patient's eligibility:\n\n- Age: The patient is 85 years old, which meets the criterion of being \"Age 18 or older.\"\n- Evidence of external head injury or facial trauma, or mechanism of injury consistent with brain trauma: The patient was involved in a car accident 3 weeks prior to admission, which could be consistent with brain trauma. However, the patient note indicates that he had a normal head CT at that time.\n- Residence and attendance: There is no information provided about the patient's residence or willingness to attend follow-up appointments at the University of Maryland Medical Center.\n\nGiven the patient's age meets the criteria and there is a history of a car accident, there could be potential for TBI despite the normal head CT. However, we lack information about the patient's residence and their ability or willingness to attend follow-up appointments, which are part of the inclusion criteria. Additionally, the gradual decrease in the level of consciousness may or may not be related to the car accident, as no direct evidence of head injury is provided.\n\nConsidering the above, the patient could potentially be eligible for the trial if further investigation confirms a mechanism of injury consistent with brain trauma and if the patient resides within the required distance and agrees to follow-up appointments. Thus, further information would be needed to make a definitive referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "381": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the patient's eligibility for the trial:\n\nPatient characteristics:\n- 85-year-old man\n- Brought to the ER because of a gradual decrease in the level of consciousness\n- Stopped walking and eating by himself recently\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical trial inclusion criteria:\n- Elderly patient (\u2265 75 years)\n- Patient with planned hip fracture surgery within 48 hours after the hip fracture\n- Patient willing and able to complete the requirements of this study including the signature of the written informed consent\n\nComparing the patient's characteristics with the clinical trial inclusion criteria:\n- The patient is 85 years old, which meets the age criterion of being an elderly patient (\u2265 75 years).\n- However, there is no mention of the patient having a hip fracture or planning to undergo hip fracture surgery. The patient's decreased level of consciousness and cessation of walking and eating by himself could be due to various other medical conditions and not necessarily related to a hip fracture.\n- There is also no information indicating that the patient is willing and able to complete the requirements of the study, including providing written informed consent, as his level of consciousness is decreased.\n\nGiven the information provided, the patient does not meet the inclusion criteria related to hip fracture surgery, and there is insufficient information to determine his ability to consent. Therefore, this patient would not be eligible for the clinical trial as described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "382": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER due to a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea is reported.\n- He was involved in a car accident 3 weeks prior to admission and had a normal head CT at that time.\n\nClinical Trial Criteria:\n- Involved in or witnessed a car accident at least 6 months ago.\n- PTSD or distress or impairment in important areas of functioning following the car accident.\n\nAssessment:\n- The patient was involved in a car accident, which aligns with the trial's focus on individuals who have experienced an MVA trauma.\n- However, the inclusion criteria specify that the car accident must have occurred at least 6 months ago, and the patient's accident occurred only 3 weeks prior.\n- There is no mention of PTSD, distress, or impairment in important areas of functioning after the car accident in the patient note. The current symptoms (decrease in the level of consciousness, stopped walking and eating) may or may not be related to posttraumatic stress.\n\nGiven that the patient's accident did not occur at least 6 months ago and there is no clear indication of PTSD or related distress or impairment, the patient does not meet the inclusion criteria of the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "383": {
        "output": "The patient is an 85-year-old man who is experiencing a gradual decrease in his level of consciousness. He has been brought to the ER because he stopped walking and eating by himself. There is no mention of surgery or any upcoming surgical procedure. The patient's current condition does not seem to be related to a postoperative state.\n\nThe clinical trial in question is focused on preventing postoperative delirium in the elderly, specifically in those who are admitted for scheduled surgery. The inclusion criteria state that the subject must be aged over 75 years, which fits the patient's age. However, the patient has not been admitted for a scheduled surgery, which is a critical requirement for participation in the trial.\n\nGiven that the patient does not meet the requirement of being admitted for a scheduled surgery, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "384": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Information:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- Involved in a car accident 3 weeks prior\n- No fever, cough, rash, or diarrhea\n- Had a normal head CT after the accident\n\nClinical Trial Inclusion Criteria:\n- Age 65 years and older (patient meets this criterion)\n- Must reside in Greve in Chianti or Bagno A Ripoli, Italy (no information provided regarding the patient's residence)\n- Subjects with moderate cognitive problems can be included if consent can be provided by a first-degree relative or another relative living with or close to the participant (patient has a decrease in consciousness, so this may apply if he has cognitive issues and if the daughter can consent)\n\nExclusion Criteria:\n- Children (patient does not meet this exclusion criterion as he is 85 years old)\n\nConsidering the information provided, the patient meets the age criterion. However, there is no information on whether the patient is an original participant in the InChianti Mobility Study or whether he resides in the specified Italian regions, which are both critical inclusion criteria for this study. Additionally, the patient's current medical condition and the fact that he is in the ER with decreased consciousness may impact the ability to participate in the study, depending on the nature and extent of his medical issues.\n\nGiven the lack of information on the patient's residence and participation in the original study, and the current acute medical condition, it is not possible to determine with certainty whether the patient would be eligible without further investigation. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "385": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man, which matches the age criterion of the trial (\u226565 years old).\n- There is no mention of the patient's nationality; however, the trial specifies Japanese volunteers. Since the patient's nationality is not stated, we cannot assume he is Japanese.\n- The patient is currently not healthy as he has been brought to the ER due to a decrease in his level of consciousness and inability to walk or eat by himself. The trial requires healthy volunteers.\n- There is no information on the patient's BMI or weight, but given his current health condition, it is likely irrelevant to the inclusion criteria.\n- The patient's ability to comply with the requirements of the study is in question due to his decreased level of consciousness.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking for healthy elderly male and female Japanese volunteers who are \u226565 years old.\n- Participants need to have a BMI of \u226518 and \u226427 kg/m^2 and weigh \u226545 kg.\n- Participants must be able to understand and comply with the requirements of the study.\n\nThe patient does not meet the inclusion criteria for being a healthy volunteer, and there is no information confirming his nationality as Japanese or his ability to understand and comply with the study requirements. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "386": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we must determine if the patient is eligible for the trial. The patient note describes an 85-year-old man with a recent decrease in his level of consciousness, but there is no mention of a current olecranon fracture or any related symptoms. The clinical trial is specifically for patients aged 75 years or older who present with an isolated olecranon fracture within two weeks of the incident.\n\nSince the patient note does not indicate that the patient has an olecranon fracture or that the patient's condition is related to such a fracture, the patient does not meet the specified inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "387": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?\", we must compare the patient's characteristics and circumstances with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 85-year-old man\n- Brought to ER due to a gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- History of a car accident 3 weeks prior, with a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Completion of informed consent by the patient or a legally appointed guardian\n- Age \u2265 50 years\n- Sustained mild head trauma with a visit to the emergency department of the Hadassah-Hebrew University Medical Center within 24 hours after trauma\n- Low-dose aspirin therapy (75-100 mg) at the time of head trauma\n- Admission non-contrast head CT with no evidence of intracranial hemorrhage or skull fracture, as assessed by the neurosurgical resident on call and confirmed by an attending neuroradiologist\n\nAssessment:\n- The patient is 85 years old, which satisfies the age criterion.\n- The patient had a car accident, which could be considered mild head trauma, but there is no mention of low-dose aspirin therapy at the time of the head trauma, which is a specific requirement.\n- There is no information indicating that the patient visited the emergency department at Hadassah-Hebrew University Medical Center within 24 hours after the trauma, which is another specific requirement.\n- The patient had a head CT that showed no intracranial hemorrhage or skull fracture, which aligns with one of the criteria.\n- It is unclear if informed consent can be obtained due to the patient's decreased level of consciousness.\n\nGiven the information provided, the patient does not meet all the explicit inclusion criteria, specifically regarding the timing of the emergency department visit and the low-dose aspirin therapy at the time of trauma. Without additional information confirming these criteria, we cannot assume eligibility. Furthermore, the patient's decreased level of consciousness may impede the ability to obtain informed consent, unless a legally appointed guardian is available.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "388": {
        "output": "Based on the patient note provided:\n\nAn 85-year-old man is brought to the ER because of gradual decrease in his level of consciousness. In the last 3 days he stopped walking and eating by himself. He has had no fever, cough, rash or diarrhea. His daughter recalls that he had been involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nAnd comparing it with the inclusion criteria of the clinical trial:\n\nInclusion Criteria:\n\n- Subjects of 18 years old or older\n- CKD stage 3 according to GFR-MDRD equation.\n- Two consecutive stable plasma Creatinine levels during the last 2 months.\n- Elective computed tomography (CT) with a nonionic low-osmolality radiographic contrast agent.\n\nThe patient does not seem to meet the specific inclusion criteria for the clinical trial. There is no information provided that the patient has CKD stage 3, nor is there any mention of stable plasma Creatinine levels or an upcoming elective CT scan with contrast. His current medical issue seems unrelated to the focus of the clinical trial on contrast media-induced nephropathy (CIAKI).\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "389": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man.\n- He has a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No mention of fever, cough, rash, or diarrhea.\n- Was involved in a car accident 3 weeks prior.\n- Had a normal head CT after the accident.\n- No information provided about undergoing spine surgery or having a history of spine issues.\n\nClinical Trial Inclusion Criteria:\n- The participant must be \u2265 70 years old.\n- The participant must be undergoing lumbar spine surgery, posterior cervical spine surgery, or anterior cervical spine surgery > 2 levels.\n\nAssessment:\n- The patient meets the age requirement of being \u2265 70 years old.\n- However, there is no information provided that indicates the patient is undergoing or has undergone any lumbar spine surgery, posterior cervical spine surgery, or anterior cervical spine surgery > 2 levels. Thus, we cannot confirm their eligibility based only on the age criterion.\n\nBased on the available information, we do not have sufficient evidence to determine if the patient meets all the necessary inclusion criteria for this clinical trial. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe further investigation would be to clarify whether the patient is planned for or has undergone spine surgery, as indicated by the trial's inclusion criteria. If the patient is scheduled for or has had spine surgery, then their eligibility might be reconsidered.",
        "label": 0
    },
    "390": {
        "output": "The patient in the note is an 85-year-old man who has experienced a gradual decrease in his level of consciousness. He also has a recent history of being involved in a car accident, however, his head CT was normal at that time. The clinical trial is looking for patients with different types of traumatic brain injury (TBI), and the inclusion criteria simply state \"all patients with traumatic brain injury.\"\n\nGiven that the patient had a normal head CT after the car accident, there is no specific indication from the patient note that he has a traumatic brain injury at this time. The decrease in the level of consciousness could be due to numerous other causes that are not necessarily related to TBI. Without evidence of TBI in the patient's history or presentation, this does not meet the inclusion criteria as specified by the clinical trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "391": {
        "output": "",
        "label": 2
    },
    "392": {
        "output": "Based on the information provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and a recent history of stopping walking and eating by himself may be experiencing symptoms consistent with delirium. The lack of fever, cough, rash, or diarrhea, combined with the timeline of symptom development and the recent car accident, suggest a possible acute change in his mental status, which could fit the criteria for delirium.\n\nThe clinical trial in question is investigating the use of donepezil for the treatment of delirium in the elderly. The inclusion criteria for this trial are:\n\n1. Over 60 years old\n2. Delirium according to the CAM-ICU\n3. Informed consent (legal representatives)\n\nGiven that the patient is 85 years old, he meets the age criterion. The patient's symptoms may suggest delirium, but we do not have information that a CAM-ICU assessment has been conducted. Since the patient's level of consciousness is decreased, informed consent would need to be obtained from legal representatives, which seems possible given that the patient's daughter is involved in his care.\n\nWhile the patient's presentation is suggestive of delirium, further assessment using the CAM-ICU is necessary to confirm the diagnosis and thus his eligibility for the trial. Based on the information given, the assessment of this patient's eligibility for the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "393": {
        "output": "",
        "label": 0
    },
    "394": {
        "output": "Based on the patient note and the clinical trial information provided, we need to assess the eligibility of an 85-year-old man who has experienced a gradual decrease in his level of consciousness, with recent changes in his ability to walk and eat by himself, and no fever, cough, rash, or diarrhea. This patient was also involved in a car accident 3 weeks prior to his admission but had a normal head CT at that time.\n\nThe clinical trial is focused on the incidence, severity, and treatment of delirium in cardiac surgery patients and is looking specifically to include:\n\n- Adult patients admitted for cardiac surgery at the department of cardiothoracic surgery, Rigshospitalet, Denmark\n\nGiven the information provided:\n\n- The patient's current medical issue (decreased level of consciousness and recent functional decline) could be related to delirium, but there is no specific mention of delirium or cardiac surgery in the patient note.\n- The trial specifically requires patients who are admitted for cardiac surgery, and there is no indication that this patient is undergoing or has undergone cardiac surgery.\n- The location of the trial is specified as Rigshospitalet in Denmark, and there is no information given about the patient's location or whether he could be transferred to this facility.\n\nWithout evidence that this patient is undergoing cardiac surgery, we cannot assume that he is eligible for the trial based on the provided inclusion criteria. However, considering that the patient is experiencing a decline in mental status, which could potentially be delirium, and if he were to undergo cardiac surgery, there might be a scenario where further investigation is warranted to determine if he could eventually be eligible.\n\nTherefore, the patient's eligibility based on the information provided is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "395": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Hair Cortisol Level as a Predictor of PTSD Development,\" the patient does not meet the eligibility criteria for the following reasons:\n\n1. Age: The trial specifies that participants must be between the ages of 18 and 50. The patient is 85 years old, which is well beyond the age limit.\n2. Timing of ER visit: The trial requires participants to be brought to the ER within hours of the traumatic event, but the patient was brought to the ER 3 weeks after the car accident.\n3. Traumatic event criteria: The inclusion criteria specify that the participant must have experienced a traumatic event fitting certain criteria from the DSM-IV-TR related to Acute Stress Disorder (ASD). This is not detailed in the patient note, and considering the time elapsed since the event, it might not be applicable.\n\nGiven these discrepancies, the patient is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "396": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 85-year-old man\n- Gradual decrease in his level of consciousness over the last 3 days\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years\n- Onset of clinical symptoms of subarachnoid or intracranial hemorrhage or trauma suffered less than 72h\n- Indication for implanting a tissue oxygen and intracranial pressure probe\n- A signed informed consent by the patient or legal guardian\n\nAssessment:\n- The patient is over 18 years old, which meets one of the inclusion criteria.\n- However, the onset of clinical symptoms, as described in the patient note, does not mention any subarachnoid or intracranial hemorrhage or trauma within the past 72 hours. Instead, the car accident occurred 3 weeks prior, and at that time, the head CT was normal.\n- There is no information given about the indication for implanting a tissue oxygen and intracranial pressure probe.\n- There is also no information about whether informed consent can be obtained from the patient or a legal guardian.\n\nGiven the information available, the patient does not meet the critical inclusion criterion regarding the onset of clinical symptoms related to subarachnoid or intracranial hemorrhage or trauma within the last 72 hours.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "397": {
        "output": "The patient note describes an 85-year-old man who has experienced a gradual decrease in his level of consciousness, has stopped walking and eating by himself, and has no fever, cough, rash, or diarrhea. It is also mentioned that he was involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nThe clinical trial in question is focused on patients who have had a cerebrovascular attack (ischemic or hemorrhagic) and involves continuous video-EEG monitoring to detect epileptiform discharges and their potential effect on functional outcomes.\n\nThe inclusion criteria for the clinical trial are:\n- Patients with ischemic arteria cerebri media infarct\n- Patients with spontaneous intraparenchymal bleeding\n\nBased on the patient note, there is no evidence provided that this particular patient has had an ischemic arteria cerebri media infarct or spontaneous intraparenchymal bleeding. The note only mentions a car accident and a decrease in the level of consciousness, without details that would suggest a stroke or cerebrovascular attack.\n\nGiven the absence of information suggesting that this patient has had a stroke or a cerebrovascular attack, we cannot assume that he meets the inclusion criteria for the clinical trial. Hence, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "398": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man with a gradual decrease in consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at the time of the accident\n\nClinical Trial:\n- Title: Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage\n- Inclusion Criteria: Patient at least 18 years of age presenting with a symptomatic chronic subdural hematoma, verified on cranial CT or MRI\n\nAssessment:\nThe clinical trial is focused on patients with a chronic subdural hematoma. The patient in question has experienced a recent decline in consciousness and was previously involved in a car accident. However, there is no mention of a chronic subdural hematoma diagnosis in the patient note. Furthermore, the patient had a normal head CT after the car accident, which suggests that at that time, there was no chronic subdural hematoma detected.\n\nGiven the lack of information regarding a chronic subdural hematoma diagnosis and the fact that the patient's symptoms could be attributable to other causes, it is not possible to determine from the patient note whether the patient has a symptomatic chronic subdural hematoma, which is a critical inclusion criterion for the clinical trial. Therefore, further investigation would be necessary to ascertain the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "399": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the requirements for this clinical trial. The inclusion criteria specify that participants must be female, 50 years or older, have a diagnosis of overactive bladder (OAB), be English literate, able to swallow oral medication, and have the cognitive ability to give consent.\n\nThe patient note describes an 85-year-old man who was brought to the ER due to a decrease in consciousness and recent inability to walk and eat by himself. There is no mention of a diagnosis of OAB, and the patient's current state suggests that he may not have the cognitive ability to give consent due to the described decrease in his level of consciousness.\n\nGiven that the patient is male and there's no indication of OAB or the ability to consent, he would not be eligible for this clinical trial focused on the effect of anticholinergics on cognitive function in elderly women with OAB.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "400": {
        "output": "Based on the inclusion criteria provided for the clinical trial, which focuses on patients who have been prescribed Rivaroxaban for the first time compared to those who have been prescribed Phenprocoumon for the first time, there is no information given in the patient note regarding a prescription for either Rivaroxaban or Phenprocoumon. The patient's presentation with decreased level of consciousness and recent history of a car accident does not directly relate to the criteria for the study of Rivaroxaban use.\n\nSince the patient note does not mention any use of Rivaroxaban or Phenprocoumon, and there is no indication that the patient's condition is related to anticoagulant use, which is the focus of the trial, we cannot determine from the given information whether the patient would be eligible for the clinical trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "401": {
        "output": "To determine the trial-level eligibility of the patient, we need to assess the patient's condition against the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients who meet the Peterson diagnostic criteria of MCI:\n   - memory complaints (preferably confirmed by an informant).\n   - memory impairment according to age and education.\n   - preserved general cognitive function.\n   - intact activities of daily living, absence of dementia.\n\nThe patient note provides the following information:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea is reported.\n- He had a car accident 3 weeks prior, with a normal head CT at that time.\n\nBased on the patient note, there is no direct information about memory complaints, memory impairment according to age and education, preserved general cognitive function, or intact activities of daily living. The patient's decrease in consciousness level and inability to walk or eat by himself in the past few days could suggest a more acute or severe condition than MCI. The recent head trauma and the absence of symptoms such as fever or rash point away from an infectious or inflammatory etiology but do not confirm a diagnosis of MCI.\n\nWhile the patient's age fits within a demographic that could experience MCI, the information provided does not allow us to confirm that the patient meets the specific Peterson diagnostic criteria of MCI required for inclusion in the clinical trial. Further investigation would be necessary to determine if the patient has memory complaints, memory impairment according to age and education, preserved general cognitive function, and intact activities of daily living.\n\nTherefore, based on the information provided, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "402": {
        "output": "Based on the patient note and the clinical trial information provided, let's evaluate the patient's eligibility step by step:\n\nPatient Note:\n- 85-year-old man\n\nClinical Trial Inclusion Criteria:\n- Adult patients \u2265 18 yrs of age, < 76 yrs of age\n- Admitted to MICU (3B and 3C) or SICU (8C, 8D, 11C)\n- Surrogate present to provide informed consent when patient is not able\n- RASS score of >-3, < +1\n- CAM positive\n- Enteral access\n\nThe patient does not meet the age criterion, as they are 85 years old and the clinical trial requires participants to be less than 76 years old. Therefore, this patient would not be eligible for the clinical trial based on the age criterion alone. Other aspects of the patient's condition or situation, such as the location of care, RASS score, CAM positivity, and presence of enteral access, have not been specified in the patient note, but the age exclusion is definitive.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "403": {
        "output": "Considering the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself.\n- No mention of fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior.\n- He had a normal head CT at that time.\n- There is no indication that the patient is currently intubated or expected to be on mechanical ventilation for more than 24 hours.\n\nClinical Trial Inclusion Criteria:\n- Endotracheally intubated\n- Expected time on ventilator > 24 hours\n- Age \u2265 18 years\n- Informed consent\n\nThe patient does not currently meet the inclusion criteria as there is no information suggesting that he is endotracheally intubated or expected to be on mechanical ventilation for more than 24 hours. Since the patient's condition does not match the key characteristics required for the trial, he would not be considered for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "404": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"An Investigation Into the Mechanism of Inhalation Cough Challenge,\" let\u2019s assess the patient\u2019s eligibility.\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in consciousness\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Had a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Significant cough symptoms, score >20/70 on the Hull Airways Reflux Questionnaire\n- Current non-smokers\n- Stable medication for at least one month\n- Able to attend the trials unit on at least 3 occasions\n- Normal lung function\n- Able to give informed consent\n\nAssessment:\n- The patient note does not mention cough symptoms, which is a primary requirement for the clinical trial.\n- The patient\u2019s current medical condition (decreased level of consciousness) may impair his ability to give informed consent.\n- It is not specified if the patient is a non-smoker or if his medication is stable, as required by the trial criteria.\n- The patient\u2019s ability to attend the trial unit on at least 3 occasions is questionable given his recent decline in health and hospital admission.\n\nConsidering these points, the patient does not meet the key inclusion criteria of having significant cough symptoms and the ability to give informed consent. Thus, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "405": {
        "output": "Based on the patient note provided, the 85-year-old man is brought to the ER with a gradual decrease in his level of consciousness and has stopped walking and eating by himself. However, there is no mention of him being a nursing home resident, which is one of the inclusion criteria for the clinical trial titled \"Cognitive Impairment and Balance in Elderly.\"\n\nSince there is a lack of information regarding whether the patient resides in a nursing home, we cannot definitively determine his eligibility for the clinical trial. Therefore, further investigation is necessary to ascertain if he meets the criteria of being a nursing home resident.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "406": {
        "output": "Based on the information provided:\n\n- The patient is an 85-year-old man, which meets the age criterion of being 65 years and older for the clinical trial.\n- The patient was brought to the ER with a gradual decrease in the level of consciousness, which could be indicative of an acute medical condition or complication, potentially related to a trauma given his car accident history, even though the head CT was normal at that time.\n\nWhile there are no specific details provided about the medical condition leading to the hospital admission, the age of the patient alone meets the inclusion criteria for the study focused on Delirium in Elderly patients Admitted to Trauma. Since delirium is a common acute condition in the elderly, especially after trauma or during hospitalization, and the patient's presentation is consistent with a possible delirium (change in the level of consciousness, recent trauma), it is reasonable to consider the patient for the trial.\n\nHowever, without explicit confirmation that the patient has delirium or more details on his medical condition, the referral would be contingent on further clinical evaluation to confirm that delirium is indeed the issue being faced, as per the study's interest.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "407": {
        "output": "Assessing the patient's eligibility for the \"Florbetapir Calibration to the Centiloid Scale\" clinical trial:\n\nPatient's characteristics:\n- 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself over the past 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- No further information on cognitive status or MMSE score\n\nClinical Trial Inclusion Criteria:\n- Cognitively Normal Subjects: Males or females \u2265 21 and \u2264 45 years of age, MMSE \u2265 29\n- Clinically Diagnosed AD Subject: Males or females \u2265 50 years of age, meet clinical criteria for dementia due to probable AD, MMSE \u2265 16 and \u2264 26\n- Possible AD Subject: Males or females \u2265 50 years of age, meet clinical criteria for dementia due to possible AD, MMSE \u2265 16 and \u2264 26\n- MCI Subject: Males or females \u2265 60 years of age with cognitive impairment (not dementia), MMSE >24 and <29\n- At Risk Elderly Subject: Cognitively normal males or females that are known ApoE4 carriers and \u2265 75 years of age, MMSE \u2265 27\n\nGiven the information provided, the patient does not meet any of the specified inclusion criteria. The patient is 85 years old, which falls outside the age range for the \"Cognitively Normal Subjects\" category and there is no indication that he is a known ApoE4 carrier. Additionally, there is no information about a diagnosis of Alzheimer's disease or cognitive impairment, nor is there an MMSE score provided to determine cognitive status.\n\nBased on the information at hand, the patient does not seem to fit any of the inclusion criteria categories for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "408": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- No recent surgery mentioned\n- No mention of undergoing scheduled surgery or providing informed consent\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 60 years\n- American Society of Anesthesiologists (ASA) physical status 1-3\n- Undergoing scheduled surgery\n- Giving an informed consent\n\nWhile the patient meets the age inclusion criterion, there is no information provided about his ASA physical status, nor is there any indication that he is undergoing or has recently undergone scheduled surgery, which are required criteria for this clinical trial. Additionally, the patient's current state with a decreased level of consciousness may impair his ability to give informed consent.\n\nGiven the lack of information regarding scheduled surgery and ASA status, as well as the inability to give informed consent due to the decreased level of consciousness, the patient does not meet the inclusion criteria as stated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "409": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess this patient's eligibility for the trial.\n\nPatient note assessment:\n- The patient is an 85-year-old man.\n- His current health status includes a gradual decrease in the level of consciousness and an inability to walk or eat by himself.\n- There is no mention of him being an athlete or involved in regular running activities.\n- The patient's recent health decline does not suggest that he is \"apparently healthy\" as classified by A-1, A-2, or A-3 according to the American Heart Association.\n\nClinical trial inclusion criteria assessment:\n- Healthy, non-pregnant subjects between 18 and 55 years of age.\n- Classified as A-1, A-2, or A-3 according to the American Heart Association.\n- Capable of running a 5-km race within the specified age-graded time.\n- Willing to abstain from taking any nutritional supplements for the duration of the study, with the exception of certain specified supplements.\n\nThe patient does not meet the inclusion criteria based on his age (85 years old, which is above the maximum age of 55 years for the trial) and current health status (not apparently healthy as per AHA classification). Additionally, there is no indication that the patient is capable of running a 5-km race, which is a requirement for the trial.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "410": {
        "output": "",
        "label": 0
    },
    "411": {
        "output": "",
        "label": 0
    },
    "412": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself over the past 3 days.\n- He has no recent fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior and had a normal head CT at that time.\n- There is no mention of the patient undergoing surgery or planning to undergo non-cardiac surgery.\n\nClinical Trial:\n- The study concerns factors affecting the incidence of postoperative delirium in frail elderly patients.\n- The inclusion criteria specify patients who are elderly (over 65 years), frail, and undergoing non-cardiac surgery under anesthesia lasting more than 60 minutes.\n- The patient must be willing and able to complete the study requirements.\n\nAssessment:\n- The patient is elderly (85 years old) which fits the age criteria.\n- There is no information provided that suggests the patient is frail or that he is scheduled to undergo non-cardiac surgery. Thus, we cannot confirm whether he meets the criteria of being frail or the requirement of undergoing surgery which is key for this clinical trial.\n- Since the patient's current condition is related to a decline in consciousness and there is no mention of surgery, we cannot assume he will undergo surgery, which is a requirement for the trial.\n- The patient's willingness and ability to complete the study requirements cannot be assessed from the information given, particularly due to his decreased level of consciousness.\n\nGiven the lack of information on the patient's frailty status, upcoming surgery, and ability to participate in the study, we cannot definitively conclude that he is eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "413": {
        "output": "Considering the patient note and the clinical trial's inclusion and exclusion criteria, let's determine the patient's eligibility:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself\n- No mention of PTSD or a diagnosis related to PTSD\n- Involved in a car accident 3 weeks prior, but no mention of trauma-related stress symptoms\n\nClinical Trial Inclusion Criteria for PTSD Patients:\n- Age 18-55 years old\n- Currently diagnosed with PTSD and symptomatic with a CAPS score > 50\n\nThe patient does not meet the age criteria as he is 85 years old, which is outside the specified age range of 18-55 years old for the trial. Also, there is no information provided in the patient note that the patient has been diagnosed with PTSD or is experiencing any symptoms of PTSD.\n\nTherefore, based on the available information, the patient would not be eligible for this clinical trial focused on PTSD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "414": {
        "output": "Based on the information provided:\n\nThe patient is an 85-year-old man who presented to the ER with a gradual decrease in his level of consciousness, stopped walking and eating by himself, and has no fever, cough, rash, or diarrhea. The patient had been involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nThe clinical trial is looking for:\n\n- Males between 40 to 85 years of age\n- Individuals who participated in contact sports or other activities that could lead to concussions and have a memory or cognitive complaint\n- Individuals with Mild Cognitive Impairment (MCI) and no history of concussion or TBI\n- Healthy controls with no history of head injury and no current cognitive or memory problems\n- All participants require a study partner\n\nThe patient is within the age range required by the study (85 years old). However, the patient note does not mention participation in contact sports or other activities that could lead to concussions, nor does it mention any memory or cognitive complaints. It only mentions a recent car accident. Additionally, the presence of MCI or healthy control status is not clarified in the patient note.\n\nGiven the information provided, there is insufficient evidence to determine whether the patient fits the study's specific inclusion criteria regarding history of concussions and cognitive complaints or MCI status. Therefore, a more detailed investigation into the patient's medical history and current cognitive status would be necessary before considering a referral to this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "415": {
        "output": "Based on the information provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and recent history of cessation of walking and eating by himself does not fit the inclusion criteria of the clinical trial titled \"Dexmedetomidine and Delirium in Patients After Cardiac Surgery.\" The inclusion criteria specifically require patients who are 60 years or older and are planning to receive cardiac surgery (CABG and/or valve replacement surgery). There is no mention of the patient having undergone or planning to undergo cardiac surgery. Therefore, he would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "416": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess the patient's eligibility for the trial based on the inclusion criteria.\n\nPatient Note:\n- An 85-year-old man\n- Brought to the ER because of a gradual decrease in his level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Was involved in a car accident 3 weeks prior\n- Had a normal head CT at that time\n\nClinical Trial:\nTitle: Postoperative Delirium in Hip Arthroplasty Patients\nInclusion Criteria:\n- Male or female, between 30 and 80 years of age\n- ASA I, II, or III\n- Capable and willing to consent\n- Participants literate in English language\n\nAssessment:\nThe patient does not meet the age criterion for the trial, as he is 85 years old and the trial requires participants to be between 30 and 80 years of age. Additionally, there is no information provided that indicates the patient is undergoing or has undergone hip arthroplasty, which is the context in which the study of delirium is being conducted.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "417": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the two:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea reported.\n- Involved in a car accident 3 weeks prior with a normal head CT at that time.\n- There is no mention of acute abdominal pain.\n\nClinical Trial Inclusion Criteria:\n- Elderly patients aged 75 years old and older.\n- Admitted to the emergency department with acute abdominal pain.\n- Able to provide informed consent.\n\nThe patient in the note is within the appropriate age range for the trial (85 years old) and has been admitted to the emergency department. However, the patient does not present with acute abdominal pain, which is a requirement for the trial. Additionally, the patient has had a decrease in the level of consciousness, which may impair his ability to give informed consent.\n\nConsidering the information provided, the patient does not meet all of the inclusion criteria for the clinical trial, particularly the presence of acute abdominal pain and the ability to provide informed consent. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "418": {
        "output": "Based on the patient note provided, the 85-year-old man was brought to the ER because of a gradual decrease in his level of consciousness and has stopped walking and eating by himself. There is no mention of delirium or any symptoms that would specifically indicate delirium, such as changes in attention, cognition, or a fluctuating course of mental status. Additionally, there is no indication that the patient has been diagnosed with delirium or is exhibiting signs of delirium. The clinical trial is specifically looking for patients with delirium as part of the inclusion criteria.\n\nSince the patient note does not explicitly mention delirium, it is not possible to determine if the patient fits the inclusion criteria of the clinical trial without further information. Therefore, I would consider referring this patient to the clinical trial upon further investigation to determine if the decreased level of consciousness is due to delirium. This would potentially involve a clinical assessment for delirium using tools such as the CAM-ICU scale mentioned in the summary of the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "419": {
        "output": "",
        "label": 0
    },
    "420": {
        "output": "The patient in the note is an 85-year-old man who has experienced a gradual decrease in his level of consciousness. He has stopped walking and eating by himself, but there is no mention of fever, cough, rash, or diarrhea. His recent history includes a car accident three weeks prior to admission, after which he had a normal head CT.\n\nThe clinical trial in question is focused on validating an EEG-based delirium monitor in frail elderly patients who are undergoing elective surgery and are expected to remain admitted for at least two postoperative days. The inclusion criteria are as follows:\n1. 60 years and older\n2. Frail\n3. Undergoing elective surgery\n4. Expected to remain admitted for at least 2 postoperative days\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n- There is no indication that the patient is frail as defined by the study's requirements.\n- The patient has not undergone elective surgery, nor is there any mention of an upcoming surgery.\n- The patient's current admission to the ER does not seem to be related to an elective surgery, and thus, the requirement of remaining admitted post-surgery is not applicable.\n\nGiven these discrepancies, the patient would not meet the specific inclusion criteria set by the clinical trial. Therefore, he would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "421": {
        "output": "Based on the patient note, the 85-year-old man has been brought to the ER due to a gradual decrease in his level of consciousness, stopped walking, and stopped eating by himself. There is no mention of him being admitted to the Intensive Care Unit (ICU); however, the circumstances suggest he may require critical care given his acute change in status.\n\nThe clinical trial in question is targeting ICU patients to test the feasibility of a delirium detection system. The inclusion criteria for ICU patients are straightforward: the patient must be in the ICU, 18 years of age or older, and able to wear a motion sensor watch (ActiGraph). There are no specific exclusion criteria that would immediately disqualify the patient based on the note provided.\n\nSince the patient appears to be a candidate for ICU admission given his decreased level of consciousness and the recent decline in his functional status, he would potentially meet the age criteria (>18 years old) and could possibly be able to wear a motion sensor watch unless there are contraindications not mentioned in the note.\n\nHowever, without explicit confirmation of the patient's admission to the ICU or further clinical details, there is some uncertainty. Therefore, further investigation would be required to confirm the patient's ICU status and his ability to participate in the trial (e.g., whether he is able to wear the ActiGraph watch).\n\nGiven this information, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "422": {
        "output": "Based on the provided patient note and the clinical trial information, the patient would not meet the inclusion criteria for the clinical trial. The key reasons are:\n\n1. The patient is 85 years old, which is outside the age range of the inclusion criteria, which specify children aged 2 through 17 years.\n2. The clinical trial is specifically for cases of suspected long bone fractures requiring morphine analgesia within the first 12 hours after the injury. The patient note does not mention a long bone fracture or the need for morphine analgesia.\n3. The patient's presentation is a decrease in the level of consciousness and not related to an acute injury that would be treated in an emergency department for pain management, as the trial is investigating.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "423": {
        "output": "Based on the information provided:\n\nPatient note:\n- An 85-year-old man with a decrease in the level of consciousness.\n- No recent fever, cough, rash, or diarrhea.\n- Past car accident with normal head CT.\n\nClinical trial:\n- Focuses on young children with disabilities utilizing modified ride-on cars.\n- Aims to advance mobility and socialization.\n- Inclusion criteria include children aged 12 to 36 months with motor delays and specific motor impairments.\n\nThe patient in the note is an 85-year-old man, which does not meet the age criterion of the clinical trial that targets children between 12 to 36 months old. Additionally, the patient's condition as described does not match the focus of the clinical trial, which is on motor delays in young children.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "424": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial \"Clinical Relevance of Microbleeds In Stroke,\" we need to determine if the patient is eligible for the clinical trial.\n\nPatient Note:\n- An 85-year-old man\n- Brought to the ER because of a gradual decrease in his level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial Inclusion Criteria (Study I: CROMIS-2 (AF)):\n- Adult (\u226518y; no upper limit) patients\n- Clinical diagnosis of non-valvular AF (verified by ECG)\n- Intention to treat with best practice oral anticoagulants (e.g., warfarin)\n- Previous ischemic stroke or TIA diagnosed by treating clinician\n- Must be able to have GRE MRI before (or within 1 week) of starting best practice oral anticoagulant\n\nThe patient note does not mention a diagnosis of non-valvular atrial fibrillation (AF), nor does it indicate that the patient has had a previous ischemic stroke or transient ischemic attack (TIA). The note also does not mention if the patient has the intention to be treated with oral anticoagulants or the ability to have a GRE MRI.\n\nSince the patient's condition described in the note does not meet the specific inclusion criteria of having AF and a history of ischemic stroke or TIA, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "425": {
        "output": "",
        "label": 1
    },
    "426": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question would not be eligible for the clinical trial.\n\nThe patient is an 85-year-old man with a recent decrease in level of consciousness and mobility, which is not consistent with the population targeted by the clinical trial. The clinical trial is specifically looking for toddlers aged between 12 months to 36 months old with motor delays that prevent functional independent mobility and who are able to tolerate sitting with support for 30 minutes and able to reach for objects with one or both hands.\n\nThe inclusion criteria for the clinical trial clearly do not match the patient's age or clinical condition. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "427": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- The patient is an 85-year-old man, which meets the age criterion of \u2265 75 years.\n- He was brought to the ER because of a gradual decrease in his level of consciousness and has stopped walking and eating by himself.\n- No mention is made of acute dyspnoea, breathe rate, PaO2, SpO2, PacO2, pH level, or the state of the electrocardiogram at admission.\n\nClinical trial inclusion criteria:\n- Admission to the Emergency Department\n- Age \u2265 75 years\n- Criteria of acute dyspnoea (one of the following):\n  - Breathe rate \u2265 25 cycles/minute\n  - PaO2 \u2264 70 mmHg\n  - SpO2 \u2264 92% in room air\n  - PacO2 \u2265 45 mmHg and pH \u2264 7.35\n- Electrocardiogram in sinus rhythm at admission\n\nThe patient's age and admission to the ER align with the trial's inclusion criteria. However, the note does not specify that the patient has acute dyspnoea, nor does it provide the specific respiratory or blood gas measurements required. Additionally, there is no information on the patient's cardiac rhythm.\n\nGiven the information provided, the patient's eligibility cannot be confirmed because the clinical information necessary to determine the presence of acute dyspnoea and corresponding criteria is not available in the patient note.\n\nTherefore, additional information would be needed to make a complete assessment. Without this information, I would consider referring this patient to this clinical trial upon further investigation to determine if the criteria for acute dyspnoea and electrocardiogram status are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "428": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nPatient Note Analysis:\n- An 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- History of a car accident 3 weeks prior with a normal head CT\n\nClinical Trial Inclusion Criteria:\n- Patients with an age equal or older than 65 years\n- Hospitalized at the Acute Geriatric Unit of the Complejo Hospitalario Universitario of Albacete\n- Valid signed informed consent by the patient or legal representative\n\nBased on this information, the patient meets the age criterion for the clinical trial. However, there is no mention of the patient being hospitalized in the Acute Geriatric Unit of the Complejo Hospitalario Universitario of Albacete, which is a specific requirement for the trial. Additionally, the patient's decreased level of consciousness may impact the ability to provide valid signed informed consent unless a legal representative is available to do so on his behalf.\n\nWithout further information regarding the hospitalization location or the patient's or legal representative's ability to consent, the assessment for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "429": {
        "output": "The patient note describes an 85-year-old man who has experienced a gradual decrease in his level of consciousness, stopping walking and eating by himself. There is no mention of fever, cough, rash, or diarrhea, and he had a normal head CT following a car accident three weeks prior to admission.\n\nThe clinical trial is a randomized controlled trial (RCT) focused on the prevention of delirium using ramelteon in hospitalized adults aged 65 and older.\n\nInclusion Criteria for the clinical trial:\n- Hospitalized adults aged 65 and older\n- Patients from designated nursing units\n\nBased on the information provided, the patient is 85 years old and has been brought to the ER, which aligns with the age requirement for the clinical trial. However, the inclusion criteria are not fully detailed. It mentions \"from designated nursing units\" but does not specify if being in the ER qualifies or if the patient needs to be admitted to a specific unit within the hospital.\n\nGiven the lack of specificity in the inclusion criteria regarding the nursing units and the current setting of the patient (ER), it would be prudent to seek further information about the trial's specific requirements for the nursing units involved.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "430": {
        "output": "Based on the presented patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note Summary:\n- 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior to admission\n- Normal head CT after the accident\n\nClinical Trial Inclusion Criteria Summary:\n- Severe Trauma Population\n- All adults (age \u226518 to 54) with specific trauma and injury conditions\n- All adults (age 55 and older) with specific trauma and injury conditions, including long bone or pelvic fractures, hemorrhagic shock, or ISS \u2265 15\n- Ability to obtain Informed Consent prior to OR repair of injury\n\nExclusion Criteria Summary:\n- Patients not expected to survive greater than 48 hours\n- Prisoners\n- Pregnancy\n- Chronic corticosteroids or immunosuppression therapies\n- Previous bone marrow transplantation\n- End Stage Renal Disease\n- Pre-existing hematological disease\n- Elective Hip Repair Population with its own specific criteria\n\nAssessment:\nThe patient is an 85-year-old man, which fits within the age range of \"55 and older\" for the clinical trial. However, there is no indication in the patient note that he has suffered long bone or pelvic fractures, hemorrhagic shock, or has an ISS \u2265 15, which are required trauma-related inclusion criteria for the trial. Additionally, the patient's decrease in consciousness and inability to walk or eat by himself do not seem related to a trauma that would qualify him for this trial.\n\nThere is no mention of the patient's ability to consent, and we are not informed about his injury severity score or specific trauma details. The car accident mentioned occurred 3 weeks prior, and the normal head CT suggests that it did not result in severe trauma requiring ORIF or CRPP, or meet the shock or ISS criteria listed.\n\nConclusion:\nThe patient does not appear to meet the trauma-related inclusion criteria for the clinical trial. Without evidence of severe trauma, specific types of injury, or the required severity measures, the patient is not a suitable candidate for this trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "431": {
        "output": "",
        "label": 0
    },
    "432": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself over the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial:\n- Title: Delirium at the Intensive Care Unit - a Retrospective Cohort Study\n- Seeks to describe the incidence of delirium in ICU patients and identify risk and preventive factors\n- Investigates if an imitated natural light/dark cycle influences the frequency of delirium\n- Inclusion Criteria: Patients >18 years of age admitted to the ICU at K\u00f8ge Hospital in the study period\n\nAssessment:\nThe patient is an 85-year-old man who has had a significant change in his level of consciousness and functional status, which could be indicative of delirium or another acute medical condition. Considering he's been brought to the ER and, given his symptoms, may be admitted to the ICU, he would potentially meet the age and admission criteria for the clinical trial.\n\nHowever, it is not explicitly stated that he is diagnosed with delirium or that he is admitted to the ICU at K\u00f8ge Hospital, which are necessary to determine his eligibility for this specific study.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "433": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's review the patient's eligibility:\n\nPatient note review:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No recent fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior with a normal head CT scan at that time.\n- There is no mention of the patient being scheduled for cardiac surgery.\n\nClinical trial inclusion criteria review:\n- Written informed consent.\n- Age \u2265 65 years.\n- Scheduled to undergo elective cardiac surgery with the use of cardiopulmonary bypass (CPB).\n- Both genders are eligible.\n\nEligibility assessment:\n- The patient meets the age criterion (\u2265 65 years).\n- There is no information about the patient's consent, but it is assumed that it could potentially be obtained.\n- The patient is not mentioned to be scheduled for elective cardiac surgery, which is a critical criterion for the study.\n\nSince the patient is not scheduled for elective cardiac surgery, he does not meet one of the key inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "434": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient for this specific clinical trial.\n\nPatient Note Analysis:\n- The patient is a 36-year-old woman with 12 weeks of amenorrhea and symptoms suggesting a possible molar pregnancy (enlarged uterus with multiple cystic areas, vaginal spotting, lower abdominal tenderness).\n- A negative pregnancy test and ultrasound findings raise the possibility of gestational trophoblastic neoplasia, which includes conditions like a hydatidiform mole and choriocarcinoma.\n- There is no mention of beta HCG levels or histological confirmation of the type of gestational trophoblastic neoplasia.\n- The patient's current health status, including blood count and biochemical profile, is normal.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with histologically proven low-risk gestational trophoblastic neoplasia.\n- Patients must have undergone at least one uterine curettage.\n- The trial requires specific beta HCG titer criteria to be met.\n- The patient must not be pregnant or nursing and must agree to use effective contraception.\n- The patient must not have had any prior chemotherapy for gestational trophoblastic neoplasia.\n\nComparison:\n- The patient's condition could potentially be gestational trophoblastic neoplasia, but there is no histological proof provided in the patient note.\n- There is no information about prior uterine curettage or specific beta HCG titer levels.\n- The patient's performance status is not mentioned, but given the presentation in the emergency department, she might not meet the required performance status (GOG 0-2).\n- The patient's organ function seems to be within the normal ranges based on the \"complete blood count and biochemical profile are normal\" statement, but specific values for WBC, granulocyte count, platelet count, bilirubin, SGPT, SGOT, alkaline phosphatase, and creatinine are not provided.\n- The patient's pregnancy status is uncertain due to the negative pregnancy test despite the enlarged uterus, which could be due to a molar pregnancy (part of the spectrum of gestational trophoblastic neoplasia).\n\nGiven the information provided, the patient may potentially have a condition relevant to the clinical trial (gestational trophoblastic neoplasia), but there is insufficient evidence (such as histological confirmation and specific beta HCG titer criteria) to definitively include her in the trial without further investigation. Therefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "435": {
        "output": "To determine the eligibility of the patient for the clinical trial, we must compare the patient's characteristics and medical history to the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 36-year-old woman\n- Presents with 12 weeks of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting\n- Physical exam reveals an 18-week sized uterus and cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound reports an enlarged uterus with multiple cystic areas\n- Differential diagnosis includes vesicular mole vs fibroid degeneration\n\nClinical Trial Inclusion Criteria:\n- Female gender\n- In good health, chronic medication use is acceptable except for glucocorticoids\n- Menstrual cycles of 24 - 35 days (no information provided about this)\n- Hemoglobin greater than 10 g/dL (no information on hemoglobin level)\n- Willing and able to comply with study requirements\n- Age 33 to 50\n- Using mechanical contraception, sterilization, or abstinence\n- Negative pregnancy test\n- BMI less than or equal to 33 (no information on BMI)\n- Fluent in English\n- Normal glomerular filtration rate (no information provided)\n- Liver function tests within 130% of upper limit (no information provided)\n- History of uterine leiomyoma causing symptoms\n- Uterine leiomyoma(ta) of at least 2 cm size\n- No desire for fertility; willing to undergo hysterectomy\n\nClinical Trial Exclusion Criteria:\n- Significant abnormalities in history, physical or laboratory examination (possible due to differential diagnosis)\n- Pregnancy or lactation\n- Use of oral, injectable or inhaled glucocorticoids or megesterol within the last year\n- Unexplained vaginal bleeding (patient has vaginal spotting)\n- History of malignancy within the past 5 years\n- Use of estrogen or progesterone-containing compounds within 8 weeks of study entry\n- Use of agents known to induct hepatic P450 enzymes; use of imidazoles\n- Current use of GnRH analogs or other compounds that affect menstrual cyclicity\n- FSH greater than 20 IU/mL (no information provided)\n- Significant medical disorders (no clear indication beyond the presenting symptoms)\n- Cervical dysplasia (no information provided)\n- Need for interval use of narcotics (no information provided)\n- Abnormal adnexal/ovarian mass (no information provided)\n- Intrauterine device (no information provided)\n- Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months (no information provided)\n- Contraindication to anesthesia (no information provided)\n- Genetic causes of leiomyomata (no information provided)\n- Previous participation in the study (no information provided)\n- Known recent rapid growth of fibroids (no information provided)\n\nBased on the patient note and the clinical trial criteria:\n- The patient is the correct gender and age for the trial.\n- She presents with a negative pregnancy test, which is required.\n- The patient has an enlarged uterus with cystic areas, which could indicate fibroids, but this is part of a differential diagnosis, and a confirmed diagnosis of uterine leiomyomata causing symptoms is necessary for inclusion.\n- No information is provided about the patient's menstrual cycle regularity, hemoglobin levels, BMI, glomerular filtration rate, liver function tests, FSH levels, or desire for fertility.\n- The patient has vaginal spotting, which could be considered unexplained bleeding, potentially excluding her from the trial.\n- The patient's willingness to undergo a hysterectomy is not stated.\n- It is not clear if the patient fulfills the health criteria or if she is taking any excluded medications.\n\nGiven the information available, the patient could potentially have fibroids, which is the condition the trial is studying. However, there is not enough information to confirm her eligibility based on the inclusion criteria, and there are potential concerns regarding the exclusion criteria (such as unexplained vaginal bleeding).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "436": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- 36-year-old premenopausal woman\n- 12 weeks of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting\n- Physical exam reveals tender abdomen, 18-week sized uterus, cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound reports enlarged uterus with multiple cystic areas\n\nClinical trial inclusion criteria:\n- Premenopausal women, at least 18 years of age \u2713 (Patient is 36 years old and presumed premenopausal)\n- Diagnosis of uterine fibroid(s), confirmed by ultrasound ? (Differential diagnosis includes uterine fibroids, but not confirmed)\n- History of menstrual cycles between 17 and 42 days ? (Not enough information)\n- Otherwise in good health ? (The patient presents with several health issues, but it is not clear if they are related to a condition other than the uterine issue)\n- Scheduled for a hysterectomy at the end of the treatment period ? (Not mentioned whether a hysterectomy is scheduled)\n- Negative pregnancy test \u2713 (Patient has a negative pregnancy test)\n- Agrees to double barrier method of contraception ? (Not mentioned if the patient agrees)\n- Pap test with no evidence of malignancy or pre-malignant changes ? (No information provided)\n- Endometrial biopsy with no significant histological disorder ? (No information provided)\n\nThe patient's diagnosis of uterine fibroids is not confirmed, as the differential diagnosis includes vesicular mole vs fibroid degeneration. The clinical trial requires a confirmed diagnosis of fibroids by ultrasound for inclusion. Additionally, there is no information regarding her history of menstrual cycles, whether she is scheduled for a hysterectomy, her willingness to use contraception, or the results of a Pap test or endometrial biopsy.\n\nGiven the lack of confirmatory diagnosis and incomplete information on several other criteria, it is not possible to determine with certainty if the patient would be eligible for the trial based on the provided note.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "437": {
        "output": "Given the provided patient note and the inclusion criteria for the clinical trial, let's assess the eligibility of the patient:\n\nPatient characteristics:\n- A 36-year-old woman\n- Presents with 12 weeks of amenorrhea and vaginal spotting\n- Lower abdominal tenderness, nausea, and vomiting\n- Physical exam shows tender abdomen, 18-week sized uterus, cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound shows an enlarged uterus with multiple cystic areas\n- Differential diagnosis includes vesicular mole vs fibroid degeneration\n\nClinical trial inclusion criteria:\n- Women that have completed 6 months of treatment in study C02-037 with no more than a 7-day interruption in their treatment\n- Otherwise good health\n- Premenopausal based on Estrogen and Follicle Stimulating Hormone levels\n- Agrees to double-barrier method of contraception\n- Adequate endometrial biopsy with no significant histological disorder\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial as there is no mention of her having completed the 6-month study C02-037, which is a prerequisite for participation. Furthermore, the patient's current health condition (amenorrhea, vaginal spotting, and the presence of a possibly enlarged uterus due to either a vesicular mole or fibroid degeneration) does not clearly indicate that she is in otherwise good health as required by the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on the safety of treatment of uterine fibroids with Asoprisnil.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "438": {
        "output": "Based on the patient note provided, the patient is presenting with signs and symptoms that could be indicative of a gestational trophoblastic disease (GTD), such as a vesicular mole, given the 12 weeks of amenorrhea, vaginal spotting, and an ultrasound report of an enlarged uterus with multiple cystic areas. The differential diagnosis includes a vesicular mole, which is a type of GTD. However, the patient's Beta-HCG test is negative, which is not typically expected in active GTD, as these conditions are usually associated with high levels of hCG.\n\nThe clinical trial in question is focused on the detection of human chorionic gonadotropin (hCG) by Dual Polarisation Interferometry (DPI) in cases of gestational trophoblastic disease. The inclusion criteria for this clinical trial are specific to individuals with a diagnosis of GTD, including hydatidiform mole, choriocarcinoma, and gestational trophoblastic neoplasms.\n\nGiven that the patient's Beta-HCG is negative and there is no confirmed diagnosis of GTD (only a differential diagnosis that includes vesicular mole), further investigation would be needed to confirm the presence of a GTD before considering referral to the clinical trial. As such, the patient's eligibility for this trial is not clear cut based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "439": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 36-year-old woman presents with 12 weeks of amenorrhea and vaginal spotting.\n- The physical exam reveals a tender abdomen and an 18-week sized uterus with cervical dilation.\n- The point of care pregnancy test is negative.\n- Ultrasound reports an enlarged uterus with multiple cystic areas, with a differential diagnosis of vesicular mole vs. fibroid degeneration.\n\nClinical Trial Inclusion Criteria:\n1. Subject with uterine fibroids, who desire pregnancy within 12 months and has the one of the following criteria:\n   - Women 20-40 age.\n   - Women age < 46 years old who plan to have egg donation.\n   - Women above 38 should test for normal ovarian function as judged by endocrinological evaluation.\n   - If the couple has failed to conceive for more than 1 year, the woman should test for normal ovarian function, and the male must have adequate sperm test.\n   - Women undergoing fertility treatment or plan to have sperm donation.\n2. Use or non-use of non-steroidal treatments for excessive vaginal bleeding maintained for the three months prior to the study procedure.\n3. Clinically normal PAP smear within the timing of National Guidelines in the country of the clinical site.\n4. Able and willing to give consent and able to attend all study visits.\n5. Able to communicate sensations during the MRgFUS procedure.\n6. Having uterine fibroids that are device accessible.\n7. Tumors are clearly visible on non-contrast MRI.\n8. Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH.\n\nComparison:\n- The patient's age (36 years) falls within the age range specified in the inclusion criteria.\n- The patient has not expressed a desire for pregnancy within 12 months, which is not stated in the patient note but could be inferred given the concern over amenorrhea.\n- The enlarged uterus and cystic areas on ultrasound suggest the possibility of fibroids, which is part of the differential diagnosis.\n- The trial requires the fibroids to be visible on non-contrast MRI, and while the patient has had an ultrasound, MRI visibility is not mentioned.\n- It is not indicated whether or not the patient meets the other specific criteria such as the use of non-steroidal treatments, a normal PAP smear, or the ability to communicate sensations during the MRgFUS procedure.\n\nGiven this information, the patient may potentially have uterine fibroids and is within the age range, but there is insufficient information to determine her complete eligibility. Further investigation would be needed to clarify her desire for future pregnancy, the exact diagnosis of her condition, and other relevant inclusion criteria details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "440": {
        "output": "",
        "label": 2
    },
    "441": {
        "output": "Based on the provided information, the patient is a 36-year-old woman, which meets the age criterion of the clinical trial (age \u2265 18 years). However, the clinical trial in question is focused on skin self-examination and the use of mole mapping diagrams to increase accuracy in detecting changes in moles on the skin.\n\nThe patient presents with symptoms related to gynecological issues (amenorrhea, vaginal spotting, lower abdominal tenderness, and an enlarged uterus with multiple cystic areas). There is no mention of skin-related concerns or the need for mole mapping in the patient's note. The patient's condition does not seem to be relevant to the objectives of the skin examination clinical trial.\n\nTherefore, the patient does not meet the specific inclusion criteria related to the clinical trial's focus on skin health and mole mapping.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "442": {
        "output": "The patient in the provided note is a 36-year-old woman presenting with symptoms consistent with a gynecological issue (amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting). The ultrasound suggests a differential diagnosis of vesicular mole vs fibroid degeneration. There is no mention of herpes labialis, which is the focus of the clinical trial.\n\nThe inclusion criteria for the clinical trial are specific to adult patients with a history of recurrent herpes labialis, which is not indicated in the patient's note. The patient's current medical issues seem unrelated to herpes labialis or the effectiveness of famciclovir in treating it.\n\nTo evaluate the eligibility of the patient for the clinical trial on famciclovir for the treatment of recurrent herpes labialis, we have to compare the patient's condition with the trial's inclusion criteria:\n\n- The patient is 18 years or older (meets criteria).\n- There is no indication in the patient note of a history typical for recurrent herpes labialis (does not meet criteria).\n- General good health status is not clearly stated, and the patient appears to be experiencing a serious gynecological condition (unclear but likely does not meet criteria).\n- The patient's renal and hepatic function is not mentioned (unclear).\n- The patient's birth control methods are not discussed (unclear).\n- A negative pregnancy test is required, and the patient's pregnancy test is negative (meets criteria).\n- The informed consent document is not mentioned (unclear).\n\nAlthough the patient meets the age criteria and has a negative pregnancy test, the primary condition under investigation for the clinical trial (recurrent herpes labialis) is not mentioned in the patient note. Therefore, based on the information provided, the patient does not meet the specific disease-related inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "443": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient is a 36-year-old woman presenting with symptoms of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea and vomiting, and an enlarged uterus with multiple cystic areas, which may indicate the presence of uterine fibroids or a vesicular mole. The differential diagnosis includes vesicular mole vs. fibroid degeneration.\n\nThe clinical trial is looking to enroll women with symptomatic uterine fibroids. The primary endpoint of the study is menstrual bleeding reduction six months after treatment, with secondary endpoints such as symptom relief and volume reduction of fibroids.\n\nThe patient's negative pregnancy test and the presence of an enlarged uterus with cystic areas might suggest that she has uterine fibroids. However, since the diagnosis is not confirmed, and there is a differential diagnosis that includes a vesicular mole, which is not related to uterine fibroids, this creates uncertainty regarding her eligibility for the trial.\n\nGiven that the patient's diagnosis is not definitive for uterine fibroids and that further investigation (e.g., histopathological examination) would be needed to confirm the diagnosis, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "444": {
        "output": "",
        "label": 0
    },
    "445": {
        "output": "The patient is a 36-year-old woman who presents with symptoms suggestive of a gynecological condition, specifically with ultrasound findings of an enlarged uterus with multiple cystic areas and a differential diagnosis that includes vesicular mole vs fibroid degeneration. Importantly, her pregnancy test is negative.\n\nNow, comparing this patient's information with the inclusion criteria of the \"Fibroid Growth Study\" clinical trial, we find the following:\n\n- The patient is at least 18 years of age and is premenopausal, which meets the age and menopausal status criteria.\n- She speaks English (although not explicitly stated, this is often assumed in case studies unless otherwise noted).\n- The ultrasound report suggests an enlarged uterus, which is consistent with the requirement of the uterus being enlarged to the size typical during the 8th week of pregnancy.\n- There is a suspicion of uterine leiomyomas (fibroids) based on the ultrasound report, although it is not confirmed and is part of a differential diagnosis including vesicular mole. The trial requires a confirmed diagnosis of leiomyoma.\n\nGiven that the patient has not been confirmed to have a diagnosis of leiomyoma by ultrasound but is being considered for such a diagnosis, there is potential for her to be eligible for the trial. However, further investigation is required to confirm the diagnosis of leiomyomas before she can be definitively referred to the trial.\n\nTherefore, the assessment of the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "446": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's go through the factors one by one:\n\n1. The patient is a 36-year-old woman, which fits within the age range of 30 to 50 years specified by the trial inclusion criteria.\n   \n2. The patient presents with symptoms that could potentially be caused by uterine fibroids, such as lower abdominal tenderness and an enlarged uterus, which fits the criterion of symptoms caused by uterine fibroids. However, the trial specifically mentions symptoms like heavy bleeding (menorrhagia) and/or bulk-related complaints, which are not explicitly mentioned in the patient note.\n\n3. A differential diagnosis of vesicular mole vs fibroid degeneration is mentioned. This indicates that uterine fibroids are a consideration in her diagnosis, but it is not confirmed. The inclusion criterion requires fibroids confirmed by MRI, which is not yet established in this patient.\n\n4. The patient's kidney function isn't mentioned, but the biochemical profile is noted as normal, which may suggest normal kidney function. However, this would need to be explicitly confirmed to meet the trial's inclusion criteria.\n\n5. It is not clear if the patient has chosen to participate, signed informed consent, or is willing and able to undergo follow-up imaging as required by the trial.\n\nConsidering the information provided, there is potential for the patient to be eligible for the clinical trial, but further investigation is required to confirm fibroid presence via MRI, obtain patient consent, and establish her willingness and ability to comply with follow-up procedures. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "447": {
        "output": "Based on the information provided, the 28-year-old female patient is experiencing a range of symptoms including neck and shoulder pain, paresthesias, slight tremors, spasticity, and various other acute symptoms leading to hospitalization. It is not clear from the patient note whether the patient has an underlying disease affecting her movement, or if her symptoms are transient or part of an acute condition. Moreover, the symptoms such as difficulty swallowing, hydrophobia, and marked agitation suggest a potentially serious and acute neurological condition that requires immediate attention, which could be outside the scope of the clinical trial's intent to collect data on normal and adaptive movements.\n\nThe clinical trial in question is looking to develop a database on normal movements and adaptive movements of people with diseases that affect the way they move. The inclusion criteria for the trial are broad, allowing for any volunteer of any age who is medically fit to participate and willing to provide informed consent.\n\nGiven the patient's recent onset of symptoms and the fact that they have been hospitalized, we cannot determine from the information provided if she is medically fit to participate in the study, as her acute symptoms might preclude her from engaging in the movement tasks safely or as intended by the study. Moreover, since she is hospitalized, obtaining informed consent might be challenging, especially if her cognitive function is impaired due to her current condition.\n\nTherefore, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be required to assess the patient's medical fitness for participation, her ability to provide informed consent, and whether her movement issues are related to an underlying disease that affects movement in a way that is relevant to the study's aims.",
        "label": 2
    },
    "448": {
        "output": "The patient note describes a 28-year-old female presenting with neck and shoulder pain and paresthesias, along with symptoms that include tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia, and spastic arm movements. These symptoms are not directly related to voice disorders; rather, they suggest a neurological condition, potentially severe, considering the hydrophobia and difficulty swallowing (which could suggest something like rabies given her recent history with stray animals, although this is not explicitly stated).\n\nThe clinical trial is specifically looking for participants with idiopathic familial voice disorders, such as spasmodic dysphonia and vocal fold paralysis, with a genetic component. The inclusion criteria are focused on symptoms related to speech and voice, and the exclusion criteria rule out structural abnormalities of the larynx, history of airway obstruction, smokers, and individuals with certain psychiatric disorders.\n\nThe patient described does not exhibit symptoms that primarily relate to voice disorders. There is no mention of voice-related issues, familial history of voice disorders, or any other symptom that aligns with the focus of the clinical trial. Additionally, the patient's condition appears acute and possibly life-threatening, which would likely require immediate and specific treatment not related to the objectives of the voice disorder study.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial on idiopathic familial voice disorders, and none of the symptoms or history provided suggest eligibility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "449": {
        "output": "Reviewing the patient note and the inclusion criteria for the clinical trial titled \"1-Octanol to Treat Essential Tremor,\" let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 28-year-old female\n- Neck and shoulder pain, left-hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Prescribed NSAIDs and a topical muscle relaxant\n- Symptoms escalated to spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia\n\nClinical Trial Inclusion Criteria:\n- Patients with essential tremor affecting the upper limbs\n- 21 years of age or older\n- Not on medications for essential tremor or any other medical condition for at least 2 weeks\n- Not consumed alcohol or cold medications containing alcohol for at least 24 hours prior to the study\n- Not pregnant or lactating, with birth control for women of childbearing age\n- No neurological disease other than tremor\n- No evidence of thyroid, liver, kidney, or chronic lung disease\n\nEligibility Assessment:\n- The patient is within the age range (21 years or older).\n- The patient does have tremors, but it is not clear if these are diagnosed as essential tremors.\n- There is no information on the patient's use of medications, alcohol, or birth control which could impact the assessment.\n- The patient has been hospitalized with severe symptoms that might not align with essential tremor, including difficulty swallowing and hydrophobia, which are not typical for essential tremors and may suggest another neurological condition.\n\nGiven the information provided, it's not clear if the patient's tremors are diagnosed as essential tremor, and the patient's severe symptoms may suggest another neurological condition, which would disqualify her from the trial. Therefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "450": {
        "output": "Upon reviewing the given patient note and the inclusion criteria for the clinical trial on Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy, it is clear that the patient does not meet the specified criteria for this trial.\n\nThe patient is a 28-year-old female presenting with symptoms such as neck and shoulder pain, paresthesias, tremors, spasticity, and various other symptoms after a trip. These symptoms do not align with the diagnosis of hemiparetic cerebral palsy, which is a requirement for the clinical trial. Additionally, the trial is specifically designed for children with cerebral palsy, and the patient in question is an adult.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "451": {
        "output": "Given the patient note and the clinical trial information provided, let's determine the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- Recent hospitalization due to severe symptoms\n\nClinical Trial:\n- Title: Octanol to Treat Essential Tremor\n- Target disease: Essential tremor\n- Inclusion Criteria for the trial:\n  - Clinical diagnosis of essential tremor\n  - History of ethanol responsiveness\n  - Must be off any medications used to treat essential tremor for at least 2 weeks\n  - Must withhold ethanol and caffeine 24 hours prior to starting the treatment periods\n  - Age 21 years or older\n- Exclusion Criteria for the trial:\n  - Abnormalities on neurologic exam other than tremor\n  - History of chronic alcohol dependence\n  - Chronic medical conditions such as renal failure, hepatic failure, and chronic lung disease\n  - On medications that cannot be temporarily discontinued\n  - Women who are pregnant or lactating\n  - Patients under the age of 21\n  - Asians and Pacific Islanders\n\nAssessment:\n- The patient's age (28) fits within the age criterion of the trial.\n- The patient's symptoms include \"slight tremors,\" which may suggest the possibility of essential tremor, but this is not clear-cut as the patient also presents with other neurological symptoms that are not characteristic of essential tremor alone.\n- There is no information given about the patient's history of ethanol responsiveness.\n- The patient's recent hospitalization suggests that they may have a more complex neurological condition than just essential tremor.\n- It's also not stated whether the patient is on any medications to treat essential tremor, or whether she can withhold ethanol and caffeine as required.\n\nGiven that the patient's symptoms are not clearly indicative of essential tremor, and the lack of information on ethanol responsiveness, it is not possible to confidently refer this patient to the clinical trial based solely on the information provided. \n\nFurther investigation would be needed to determine if the tremors are indeed due to essential tremor and if the patient has a history of ethanol responsiveness. If further evaluation confirms essential tremor and ethanol responsiveness, and the other inclusion and exclusion criteria are met, the patient may become eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "452": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient's eligibility for the trial can be assessed as follows:\n\nThe patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, and subsequent neurological symptoms including spastic arm movements and difficulty swallowing. There is no mention of Essential Tremor (ET) in the patient's condition. Instead, the patient's symptoms, particularly hydrophobia and difficulty swallowing, are more suggestive of a possible neurological condition that could be unrelated to ET, such as an infection or other acute neurological issues.\n\nThe clinical trial is specific to adults with ethanol-responsive Essential Tremor. The inclusion criteria for the trial require patients to have a diagnosis of alcohol-responsive ET, with limb involvement being a prominent feature.\n\nBased on the patient note, the following points can be considered:\n- The patient\u2019s symptoms do not align with the characteristics of Essential Tremor.\n- There is no mention of the patient's tremors being responsive to alcohol, which is a specific requirement for the trial.\n- The patient's current symptoms of spastic arm movements and difficulty swallowing could indicate an exclusion criterion: \"Patients with abnormalities other than tremor on neurological exam.\"\n- The patient does not meet the specific inclusion criteria of having alcohol-responsive ET with limb involvement.\n\nGiven that the patient does not meet the core inclusion criteria of having alcohol-responsive Essential Tremor and presents with symptoms suggesting a different or more severe neurological condition, the patient would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "453": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, and various other symptoms including difficulty swallowing and marked hydrophobia.\n- The patient's symptoms started after a trip and there is no mention of a stroke, which is required for the clinical trial in question.\n- The note indicates recent onset of symptoms rather than a chronic or post-stroke condition.\n\nClinical Trial Inclusion Criteria:\n- Must be at least six months post-stroke.\n- 18 years of age or older with a clinical diagnosis of hemiparesis.\n- Voluntary control with a low to medium range of motion function.\n- Functionally stable with no significant changes in motor function over a week.\n- Able to tolerate being seated upright for 90 minutes.\n- No excessive pain in the impaired arm.\n- No severe left neglect or spasticity that interferes with task completion or wheel turning.\n- Not participating in other experimental therapies.\n- Not recently received chemical injections for spasticity.\n- Must have driven prior to stroke.\n- Not clinically depressed.\n\nThe patient in the note does not meet several key inclusion criteria:\n- There is no mention of the patient being post-stroke, which is a primary requirement for the trial.\n- The symptoms described do not align with hemiparesis, which is typically a result of stroke.\n- The patient's recent and acute symptoms suggest a condition other than stroke.\n\nGiven the information provided, the patient does not appear to have had a stroke, which is a fundamental inclusion criterion for the clinical trial. Therefore, the patient is not eligible for the trial based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "454": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 28 years old\n- Presenting symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, increased agitation, and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- No mention of a stroke, which is a specific condition required by the clinical trial for post-stroke spasticity\n\nClinical Trial Inclusion Criteria:\n- Male or female patients \u2265 18 years\n- \u2265 6 months since the last stroke, diagnosed by an appropriate health care professional\n- Focal spasticity with \u2265 2 points on the Ashworth Scale in the wrist and finger flexors\n- Specific patterns of spasticity (Flexed Wrist and Clenched Fist) are required\n\nClinical Trial Exclusion Criteria:\n- Spasticity of any other origin than stroke\n\nAssessment:\nThe patient's symptoms seem to be acute and potentially related to an infection (e.g., hydrophobia could suggest rabies) or other neurological issues, rather than post-stroke spasticity. There is no mention of a stroke in the patient's history, which is a critical inclusion criterion for the clinical trial. Since the origin of the patient's condition does not appear to be post-stroke, the patient does not meet the inclusion criteria for the trial.\n\nTherefore, the patient is not eligible for the clinical trial titled \"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "455": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 28-year-old female.\n- She is experiencing neck and shoulder pain, left hand and arm paresthesias, slight tremors, and almost imperceptible spasticity.\n- She has recently exhibited spastic arm movements and other symptoms suggestive of a serious condition that required hospitalization.\n\nClinical Trial:\n- The study is looking at the efficacy of Functional Electrical Stimulation (FES) in persons with upper extremity spasticity who receive Botulinum Neurotoxin (Botox\u00ae).\n- It requires participants to be at least 6 months post injury/insult with unilateral upper limb spasticity.\n- Participants need to have certain levels of spasticity as measured by the Modified Ashworth scores and CMA Hand Impairment Scale.\n- Participants must have received at least two prior doses of Botulinum toxin A, with the first dose occurring at least 6 months prior to study enrollment.\n- The trial requires the ability to answer yes/no questions and follow 1-step instructions, as well as providing written informed consent.\n- Female participants of childbearing age must agree to use adequate birth control measures.\n\nThe patient in the note does not clearly meet the specific criteria related to upper extremity spasticity as defined by the Modified Ashworth scores or the CMA Hand Impairment Scale. Additionally, there's no indication that the patient has had an injury/insult to the brain or spinal cord that is at least 6 months old, nor is there any information suggesting that she has received prior doses of Botulinum toxin A. Furthermore, the patient's symptoms may suggest an acute condition, possibly related to rabies given the hydrophobia mentioned, rather than a chronic neurological issue that has been present for over six months.\n\nGiven the lack of information confirming the patient's alignment with the trial's inclusion criteria, it would not be appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "456": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- Recently hospitalized\n\nClinical trial inclusion criteria:\n- 18 to 70 years of age\n- Written informed consent\n- Medically stable condition\n- History of stroke (hemorrhagic or ischemic) that resulted in a unilateral, upper-limb focal spasticity pattern of the wrist and fingers\n- EMG evidence of volitional activation of wrist and finger extensor and flexor muscles\n- Active range of motion capabilities as defined\n- MMSE >24\n- Stable anti-spasticity medication regimen 1 month prior to enrollment\n- Ability to follow study instructions and likely to complete all required visits\n\nThe patient's age falls within the trial's age range. However, there is no mention of a history of stroke, which is a critical inclusion criterion for the trial. The patient's symptoms seem to be related to a different medical issue rather than post-stroke spasticity. There's no mention of EMG evidence or assessment of active range of motion that aligns with the trial's requirements. There's also no information about the patient's MMSE score or medication regimen.\n\nGiven the information provided, the patient does not meet the key inclusion criteria related to the history of stroke and associated spasticity patterns. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "457": {
        "output": "Based on the patient note, the 28-year-old female patient is presenting with neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia, and was hospitalized. There is no mention of alcohol use or withdrawal, and her symptoms do not clearly align with alcohol withdrawal syndrome (AWS). The symptoms described could be indicative of another neurological disorder.\n\nThe clinical trial in question is focused on treating alcohol withdrawal with oral Baclofen in addition to standard benzodiazepine therapy. The inclusion criteria for the trial specify that participants must meet the DSM-IV criteria for alcohol withdrawal syndrome, be an inpatient at specific medical centers at the time of study enrollment, have a measurable alcohol withdrawal score triggering benzodiazepine therapy, agree to abstain from alcohol for the duration of the study, and be able to provide informed consent.\n\nThe patient note does not provide evidence that this patient is experiencing alcohol withdrawal or meets the DSM-IV criteria for AWS. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "458": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- A 28-year-old female (meets age criteria of \u226519 to \u226465 years)\n- Experiencing health problems (neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia)\n\nClinical Trial Inclusion Criteria:\n- Subjects free of obvious health-problems or with stable condition\n- Male or female subjects aged \u226519 to \u226465 years\n- BMI between \u226518 and \u226430 kg/m2\n\nThe patient's current health problems (spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing and marked hydrophobia) suggest that she is not free of obvious health-problems nor in a stable condition, especially considering that she was hospitalized.\n\nGiven the acute presentation and hospitalization, the patient does not meet the criterion of being free of obvious health problems or in a stable condition. Therefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "459": {
        "output": "After reviewing the patient note and the clinical trial information, the patient does not meet the inclusion criteria for the clinical trial. The trial is specifically looking for toddlers aged 12-18 months, while the patient is a 28-year-old female. Additionally, the patient's symptoms suggest a possible rabies exposure, which is not the focus of the trial. The trial is for pre-exposure rabies immunization and Japanese Encephalitis vaccination in healthy toddlers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "460": {
        "output": "Based on the information provided about the patient and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the Malaria Vaccine for Children in Mali clinical trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Males or females aged greater than or equal to 1 to less than 4 years.\n- Known residents of the village of Bancoumana, Mali, or its surrounding area.\n- Good general health as determined by means of the screening procedure.\n- Available for the duration of the trial (24 months from enrollment).\n- Willingness to have the child participate in the study as evidenced by parents/legal guardians signing or fingerprinting the informed consent document.\n\nThe patient note describes a 28-year-old female with various symptoms that led to hospitalization. This patient does not meet the age requirement (as she is 28, not between 1 and 4 years old), nor is there any indication that she is a resident of Bancoumana, Mali, or its surrounding area. Furthermore, the trial is specifically for children and requires parental consent, which is not applicable to this adult patient.\n\nTherefore, the patient is not eligible for the clinical trial based on age, residency, and the nature of the trial being for children.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "461": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, the patient does not match the profile for this particular study. The patient is a 28-year-old female presenting with neurological symptoms such as tremors, spasticity, anxiety, difficulty swallowing, and hydrophobia. These symptoms do not align with the trial's focus on chronic functional constipation in children.\n\nThe inclusion criteria for the trial are specific to chronic functional constipation, which includes symptoms like less than two bowel movements per week, fecal incontinence, retentive behavior, pain at defecation, and hard stools. The patient's symptoms do not mention any of these gastrointestinal issues, nor is there any indication that the patient is a child, as the patient is clearly stated to be 28 years old.\n\nTherefore, based on the available information, this patient would not be eligible for the physiotherapeutic intervention trial for children with chronic functional constipation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "462": {
        "output": "Based on the patient note and the clinical trial inclusion and exclusion criteria provided, let's assess the patient's eligibility:\n\nPatient note:\n- 28-year-old female (meets age criterion: 18 to 60 years)\n- Neck and shoulder pain and left hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Hospitalized with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n\nClinical trial inclusion criteria:\n- Aged 18 to 60 years on the day of inclusion (patient meets this criterion)\n- Provision of a signed Informed Consent Form (assumed that the patient can provide if meeting other criteria)\n- Able to attend all scheduled visits and comply with all trial procedures (assumed that the patient can comply if meeting other criteria)\n- For a woman of child-bearing potential, use of an effective method of contraception or abstinence (assumed that the patient can comply if meeting other criteria)\n- Entitlement to national social security (not mentioned in patient note, assumed to be met)\n- No known pregnancy or breast-feeding (not mentioned in patient note, assumed to be met)\n- No participation in another clinical trial in the 4 weeks preceding or planned during the trial (not mentioned in patient note, assumed to be met)\n- No immunodeficiency, immunosuppressive therapy, or systemic hypersensitivity related to the trial (not mentioned in patient note, assumed to be met)\n- No chronic illness, alcohol abuse, drug addiction, or receipt of blood products that might interfere with the trial (not mentioned in patient note, assumed to be met)\n- No vaccination against rabies with any vaccine (in pre- or post-exposure regimen)\n\nHowever, the patient's symptoms (difficulty swallowing, marked hydrophobia) suggest a possible acute illness, potentially rabies given the recent contact with stray animals and the symptoms aligning with rabies infection. This would most likely exclude the patient from participating in the trial if confirmed to be rabies, as it would be a contraindication to receive a vaccine under these conditions.\n\nGiven the information provided, the patient's current symptoms may be indicative of a serious acute illness that could interfere with the trial. Without further information on the definitive diagnosis and the cause of her symptoms, there is uncertainty about her eligibility. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "463": {
        "output": "",
        "label": 0
    },
    "464": {
        "output": "After reviewing the provided patient note and comparing it to the inclusion criteria of the \"Positive Action for Today's Health\" clinical trial, we can determine the trial-level eligibility as follows:\n\nThe inclusion criteria for the clinical trial are:\n1. African American (must have 3 of 4 grandparents of African Descent)\n2. Lives in the designated census area\n3. No plans to move in the next two years\n4. Has no medical condition that would limit participation in moderate intensity exercise including life-threatening illness (e.g., immobile, severely disabled, or bedridden)\n5. Available and able to participate in measures and intervention activities over the next 2 years\n\nBased on the patient note, we do not have information about the following:\n- The patient's race or ethnicity (whether she is African American with 3 of 4 grandparents of African Descent)\n- Her residential status in the designated census area\n- Her plans regarding relocating in the next two years\n- Her availability and ability to participate in the study activities over the next 2 years\n\nHowever, we do know that the patient does not have a medical condition which would limit participation in moderate intensity exercise according to the note provided. The symptoms described (neck and shoulder pain, tremors, spasticity, agitation, and hydrophobia) do not indicate a life-threatening illness or a condition that would make the patient immobile, severely disabled, or bedridden.\n\nSince we lack information on several key inclusion criteria, we cannot definitely determine the patient's eligibility for the trial. Therefore, further investigation is required to ascertain the missing details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "465": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial titled \"Study of Intradermal Administration of PCEC Rabies Vaccine\":\n\nInclusion Criteria Breakdown:\n1. Laboratory personnel, epidemiologists, EISOs, veterinary students, interns, and other first responders at CDC; other CDC employees; and healthy volunteer adults.\n2. Persons who contact the study coordinator will be assessed for possible occupational exposure to rabies using the risk assessment form.\n3. Male or nonpregnant females (as indicated by a negative urine pregnancy test prior to the first dose of vaccine), aged 18 years and older.\n4. Women of childbearing potential must agree to practice adequate contraception for the entire study period.\n5. Be in good health, as determined by vital signs, medical history, and a targeted physical examination based on medical history.\n6. Able to understand and comply with planned study procedures.\n7. Provide informed consent prior to any study procedures and be available for all study visits.\n8. Have health insurance.\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which satisfies the age criterion.\n- The patient has presented with symptoms that could potentially be related to rabies exposure (difficulty swallowing, hydrophobia), and there is a mention of her returning from a trip where she attended a stray animal recovery campaign. This could imply a risk of rabies exposure, which might align with the study's focus on individuals with potential occupational exposure to rabies.\n- The patient's health status is not fully clear from the note, but she does have several health issues (spastic arm movements, increased agitation, anxiety, malaise, hydrophobia), which might be considered when determining \"good health.\"\n- There is no information about the patient's occupation, whether she is one of the specified professionals or first responders, or a CDC employee.\n- There is no information on her insurance status, understanding, and willingness to comply with the study procedures, or her consent availability.\n\nGiven the available information, it is not clear if the patient would meet all the inclusion criteria, particularly with respect to her occupation and her current health status. However, assuming she had potential occupational exposure to rabies and her symptoms could be assessed as part of the study's interest in rabies exposure, she might be a candidate for further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "466": {
        "output": "The patient in question is a 28-year-old female presenting with various neurological symptoms, including neck and shoulder pain, paresthesias, tremors, spasticity, and a range of symptoms that could suggest a serious neurological condition, such as difficultly swallowing, marked hydrophobia, and increased agitation. These symptoms are potentially severe, and no definitive diagnosis is mentioned in the patient note.\n\nThe clinical trial at hand is focused on the immunogenicity and safety of the Japanese Encephalitis Vaccine IC51 in children and adolescents in non-endemic countries. The inclusion criteria specify:\n\n1. Male or female healthy children and adolescents aged >=2 months to <18 years at the time of first vaccination\n2. Written informed consent by the subject's legal representative(s), and assent by the subject if applicable\n3. For female subjects, either no childbearing potential or a negative pregnancy test. For females after menarche, a willingness to practice a reliable method of contraception.\n4. The subject is planning to travel to an area where JE is endemic after completion of the vaccination schedule and can adhere to the study visit schedule.\n\nThe patient described does not meet the inclusion criteria for several reasons:\n\n1. Age: The patient is 28 years old, which is outside the specified age range for the trial of 2 months to <18 years.\n2. Health status: The trial requires healthy children and adolescents, while the patient is presenting with significant neurological symptoms that would likely exclude them from being considered healthy.\n3. Travel plans: There is no information about the patient planning to travel to JE endemic areas.\n\nBased on the above points, this patient does not meet the inclusion criteria for the described clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "467": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for the vaccine against Enterotoxigenic Escherichia coli (ETEC), we need to analyze whether the patient meets the criteria for the study. Let's review the patient's information and the trial's criteria:\n\nPatient note:\n- A 28-year-old female, which fits the age criterion of 18-50 years.\n- Presents with neck and shoulder pain, left hand and arm paresthesias, slight tremors, spasticity, increased agitation, anxiety, malaise, difficulty swallowing, and marked hydrophobia.\n- No direct mention of general good health or clinically significant medical history.\n- No information provided about pregnancy status or contraception use.\n- No information on willingness to participate, training session attendance, or availability for the study duration.\n- No mention of any significant medical or psychiatric condition that would preclude participation.\n- No details on recent vaccinations or receipt of an investigational product.\n- No mention of working as a food handler, in child-care, or as a healthcare worker with direct patient contact.\n- No household contacts information provided.\n- No details on stool pattern, medication, or allergies.\n- The patient recently returned from California, but no information on symptoms consistent with Traveler's Diarrhea or travel to ETEC endemic countries.\n- No information on ETEC, cholera, or LT toxin vaccinations or ingestion.\n- No mention of antibiotic or proton pump inhibitor use before dosing.\n\nGiven the patient's current symptoms, including spastic arm movements, and the lack of detailed information regarding her overall health status, we cannot confirm general good health as required by the trial's inclusion criteria. Moreover, the patient's symptoms suggest an acute health issue, which may be a significant medical condition that could preclude participation in the trial, as per the exclusion criteria.\n\nWithout additional information to confirm her eligibility, particularly regarding her general health status, contraceptive use, willingness to participate, and absence of significant medical or psychiatric conditions, we cannot definitively determine her suitability for the trial.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "468": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be a candidate for the trial. The patient note describes a 28-year-old female with symptoms that include neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia, and marked sweating. There is no mention of thyroid disease, let alone the specific conditions of follicular thyroid carcinoma or papillary thyroid carcinoma that are required for inclusion in the trial.\n\nThe clinical trial is specifically looking for candidates who have either:\n(a) a minimally invasive follicular thyroid carcinoma \u22644 cm in diameter, or\n(b) a papillary thyroid carcinoma \u22642 cm in diameter.\n\nSince the patient's symptoms and diagnosis do not match the inclusion criteria of the clinical trial, which is focused on thyroid carcinoma and surgical outcomes, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "469": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- 28-year-old female\n- Neck and shoulder pain, left hand and arm paresthesias\n- Recent spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia\n\nClinical trial inclusion criteria:\n- Diagnosis of non-relapsing multiple sclerosis (either primary progressive MS or secondary progressive MS)\n- Reduced use of one of the hands because of MS\n- Ability to pick up and release a small object with the more-affected hand when requested\n- Can travel to the treatment program at UAB\n- Can undergo treatment for 2 weeks (Monday-Friday), 3.5 hours per day\n- Can undergo MRI scan\n- Any medication for MS allowed except spasticity medicine\n\nAssessment:\n- The patient's symptoms do not clearly indicate a diagnosis of multiple sclerosis.\n- There is no mention of a diagnosis of MS in the patient note, let alone the specific type required by the trial (non-relapsing MS).\n- The symptoms described in the patient note could potentially be due to a number of conditions, and there is no explicit link to MS.\n- The symptoms started after a specific event (trip to California and participation in a stray animal recovery campaign), which could suggest other etiologies.\n- The severity of the patient's symptoms and the rapid progression to hydrophobia and difficulty swallowing are concerning and may suggest a more acute condition (such as rabies, given the hydrophobia and recent contact with stray animals).\n\nGiven the information in the patient note, there is no evidence that this patient has been diagnosed with multiple sclerosis, which is a primary inclusion criterion for the clinical trial. Therefore, the patient does not meet the eligibility criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "470": {
        "output": "Based on the patient note, the 28-year-old female is showing symptoms that could possibly be related to rabies, particularly given her recent contact with stray animals and symptoms like difficulty swallowing, hydrophobia, and spastic arm movements. The clinical trial in question is focused on the rabies virus neutralizing activity and safety of CL184, a monoclonal antibody cocktail, in simulated rabies post-exposure prophylaxis in healthy adults.\n\nTo determine the patient's eligibility for the clinical trial, let's review the inclusion criteria:\n- Male or female subject aged \u226518 to \u226455 years\n- Subjects free of obvious health-problems or with stable conditions or medications\n- Body mass index between \u226518 to \u226430 kg/m^2\n- Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90\n- Male subjects must agree that they will not donate sperm from the first check-in until Day 90\n- Subject signed written informed consent\n\nThe patient meets the age criterion (28 years old) and the gender criterion (female subject). However, the patient is not \"free of obvious health problems,\" as the symptoms presented are quite severe and indicative of a potential rabies infection, which is a serious and life-threatening condition.\n\nGiven the severity and acute nature of the patient's symptoms, she is not a healthy adult subject, which is a requirement for this clinical trial. Therefore, she would not be eligible to participate in this study focused on healthy adults in a simulated post-exposure prophylaxis scenario.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "471": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the criteria for participation in the trial. The patient is described as a 28-year-old female with symptoms that do not indicate a diagnosis of Angelman Syndrome (AS). Instead, she presents with neck and shoulder pain, paresthesias, tremors, spasticity, and other symptoms that seem unrelated to AS. Furthermore, there is no mention of a molecular confirmation of AS, which is a requirement for enrollment in the study.\n\nThe inclusion criteria for the clinical trial specifically require participants to be between 4 years and 12 years of age with a molecularly confirmed diagnosis of Angelman Syndrome and not on certain medications prior to participation. The patient in question is 28 years old, which is well outside the specified age range, and there is no evidence of an AS diagnosis.\n\nTherefore, this patient does not meet the age requirement, nor is there a confirmed diagnosis of AS, which are both critical inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "472": {
        "output": "Based on the patient note provided:\n\nA 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing and marked hydrophobia, and was immediately hospitalized.\n\nAnd the clinical trial's inclusion criteria:\n\n- HIV infected patients 18-60 years of age\n- Ever received primary rabies immunization\n\nThe patient note does not mention HIV infection or a history of rabies immunization. The patient's symptoms suggest a possible acute rabies infection, especially given the marked hydrophobia and recent contact with stray animals, but there is no information provided about their HIV status or whether they have ever received rabies vaccination (primary or booster).\n\nGiven the lack of information on two critical inclusion criteria (HIV status and history of rabies vaccination), we cannot refer this patient for the clinical trial based on the available data.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "473": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial:\n\nPatient Details:\n- 28-year-old female\n- Presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- No mention of malaria or travel to a malaria endemic area\n\nClinical Trial Details:\n- Title: AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area\n- Aim: Assess the safety and immunogenicity of candidate malaria vaccines\n- Inclusion Criteria: Consenting adult males aged 18-50 years in good health and healthy children aged 2-6 years with consenting parents\n\nAssessment:\n- The patient is an adult female, which does not match the gender specified in the inclusion criteria (male).\n- The health condition presented by the patient is not related to malaria, nor is there any information to suggest that she is a volunteer in a malaria-endemic region, or that she is in good health, as required by the trial's inclusion criteria.\n\nBased on the above, the patient does not meet the gender requirement and does not have a health condition relevant to the trial's focus on malaria vaccine evaluation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "474": {
        "output": "Given the information from the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for this specific trial:\n\nPatient Characteristics:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity\n- Additional symptoms upon ER visit: spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- No mention of a stroke\n\nClinical Trial Inclusion Criteria:\n- Adult patients with upper limb spasticity following a stroke\n- Eligible to receive botulinum toxin Type A\n- No previous botulinum toxin Type A therapy\n\nThe patient in the note does exhibit some spasticity; however, there is no mention of her spasticity being the result of a stroke, which is a specific requirement for the trial's inclusion criteria. Additionally, there is no information regarding her eligibility to receive botulinum toxin Type A or whether she has previously received botulinum toxin Type A therapy. Given the lack of evidence that her spasticity is post-stroke, we cannot consider her a strong candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "475": {
        "output": "After reviewing the patient note and the clinical trial information, the eligibility assessment can be determined as follows:\n\n- The patient is a 28-year-old female, which does not meet the age requirement of 40-80 years stated in the inclusion criteria for the clinical trial focused on upper limb stroke rehabilitation.\n- The patient's symptoms and diagnosis do not indicate that she has sustained a stroke, which is the primary condition under investigation in the clinical trial. The symptoms mentioned in the patient note, such as spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and hydrophobia, suggest a different medical condition.\n- The inclusion criteria specifically require a history of a single stroke leading to upper limb paresis, which is not present in the patient's condition as described.\n\nConsidering these points, the patient does not fit the inclusion criteria for the clinical trial focused on stroke rehabilitation. Therefore, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "476": {
        "output": "",
        "label": 0
    },
    "477": {
        "output": "Given the patient note:\n\n- A 28-year-old female with symptoms suggestive of rabies (neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia) following participation in a stray animal recovery campaign.\n\nAnd the clinical trial:\n\n- Title: Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV\n- Inclusion Criteria: Healthy individuals who can visit according to the protocol.\n\nThe patient described in the note shows signs of a possible rabies infection, which is a serious and life-threatening condition. The clinical trial is looking for healthy individuals, which is typically defined as not having any significant acute or chronic illnesses that could impact the study outcome or the health of the participant. Given the patient's symptoms, she does not meet the \"healthy\" criterion set by the trial.\n\nTherefore, the assessment of eligibility for this patient to participate in the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "478": {
        "output": "Based on the information provided:\n\nPatient note: A 28-year-old female with various symptoms possibly unrelated to malaria, including neck and shoulder pain, paresthesias, slight tremors, spasticity, and a series of other acute symptoms leading to hospitalization.\n\nClinical trial: A Phase 1/2b study of an investigational malaria vaccination strategy for infants and children aged 5-17 months in Burkina Faso.\n\nInclusion criteria: Healthy infant/child aged 5-17 months at the time of first study vaccination, with informed consent of parent/guardian, and residency in the study area villages with availability for follow-up.\n\nThe patient in the note does not meet the age requirement (5-17 months) as she is 28 years old. Additionally, the trial is specifically targeting healthy infants and children for a malaria vaccination study, and the patient's symptoms suggest an acute condition unrelated to malaria. Furthermore, the patient is not located in the study area of Burkina Faso.\n\nTherefore, the patient is not eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "479": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient does not appear to meet the specific requirements for the trial. The patient's symptoms include neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms do not clearly indicate that the patient has a spinal cord injury, which is a key requirement for the clinical trial. Additionally, the trial specifically targets individuals with incomplete traumatic spinal cord injury that occurred at least 18 months prior and has been stable for 6 months, with moderate to severe lower-limb spasticity.\n\nThe patient's condition does not mention a spinal cord injury, nor does it mention the duration or stability of any such injury. Furthermore, the spasticity mentioned is not described as moderate to severe lower-limb spasticity, which is a requirement for the trial. Therefore, based on the information provided, the patient does not meet the inclusion criteria and is not a suitable candidate for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "480": {
        "output": "Based on the provided patient note, the patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and various symptoms associated with increased agitation, difficulty swallowing, and hydrophobia. These symptoms and the timeline (three weeks after a trip) do not indicate a stroke; instead, they might suggest another neurological condition, possibly an infection given her recent exposure during a stray animal recovery campaign.\n\nThe clinical trial in question is focused on patients who have had a first episode of unilateral stroke within the past 3 months and have specific functional and cognitive criteria, including a motor part of the upper limb of FMA score ranging from 10 to 40 and no serious cognitive impairment.\n\nThe patient does not meet the inclusion criteria for the trial, as there is no information suggesting she has had a stroke, which is a critical requirement for participation in the trial. Furthermore, there is no provided FMA score or Mini Mental State Exam score, which are required to assess the severity of motor impairment and cognitive function, respectively.\n\nTherefore, the patient in the note does not match the inclusion criteria for the clinical trial focused on robot-assisted therapy in patients with subacute stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "481": {
        "output": "After reviewing the patient note and the clinical trial information, here is the assessment:\n\nPatient Note:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- Recent history: attended a stray animal recovery campaign in California\n\nClinical Trial:\n- Title: The Protection Effect of Speeda\u00ae Rabies Vaccine for Human Use\n- Summary: Post-marketing protective effect research of rabies vaccine\n- Inclusion Criteria:\n  - Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed\n  - Participant is considered to be in good health including the body and mental status based on reported medical history and limited physical examination and live in local area \u2265 12 months before injured\n  - The man-killer (animal) could be found and detect whether it carries the virus\n\nAssessment:\nThe patient presents with symptoms that are concerning for rabies (difficulty swallowing, hydrophobia, and history of potential exposure through a stray animal recovery campaign), although rabies is not explicitly mentioned. However, the clinical trial is for the post-marketing protective effect of a rabies vaccine, which generally would require participants to be vaccinated prior to any potential exposure to rabies. The presence of active symptoms suggests that the patient is already experiencing the disease and therefore would not be eligible for a preventative vaccine trial. Furthermore, the inclusion criteria specify that the participant should be in good health, which does not seem to align with the current medical condition of the patient.\n\nAdditionally, the trial requires that the man-killer animal can be found and tested for the virus, which is not mentioned in the patient note. Given this information, the patient does not meet the inclusion criteria for the clinical trial on the protective effect of the rabies vaccine.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "482": {
        "output": "After reviewing the patient note and the clinical trial information, it's clear that the patient does not meet the inclusion criteria for the clinical trial provided. The trial is specifically for children and adolescents aged 2 to 17 years as part of a pre-exposure regimen for rabies vaccination. The patient in the note is a 28-year-old female, which is outside the age range specified in the trial's inclusion criteria. Therefore, she is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "483": {
        "output": "Upon reviewing the patient's note and the inclusion criteria of the clinical trial, the following points are critical to determining eligibility:\n\nPatient Note:\n- The patient is a 28-year-old female.\n- She has neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and other non-specific symptoms like agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n- The symptoms started three weeks after returning from a trip.\n- There is no mention of a diagnosis of Essential Tremor (ET), nor is there any indication that the tremors are refractory to medications.\n\nClinical Trial Inclusion Criteria:\n- Men and women between 18 and 80 years, inclusive.\n- A diagnosis of ET confirmed by a movement disorder neurologist.\n- Tremor refractory to medication trials.\n- Specific targeting requirements for the thalamus on MRI.\n- A tremor severity score requirement.\n- Significant disability due to essential tremor despite medical treatment.\n\nComparison:\n- The patient's age falls within the specified range.\n- There is no confirmation of a diagnosis of ET by a movement disorder neurologist.\n- There are no details suggesting that the patient's tremors are refractory to medication trials.\n- There is no evidence of significant disability due to tremors, nor is there any scoring based on the CRST rating scale provided.\n- It's not clear if the tremors are postural or intention tremors, which is necessary for the diagnosis of ET.\n- The patient's symptoms may suggest other neurological issues rather than Essential Tremor, particularly given the acute onset after a trip.\n\nBased on the available information, the patient does not meet several key inclusion criteria for this clinical trial, most importantly, a confirmed diagnosis of Essential Tremor and evidence of tremors being refractory to specific medications. Therefore, the patient is not eligible for the ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "484": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 28-year-old female\n- Neck and shoulder pain and left hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Symptoms worsened to include spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- No mention of stroke or any history related to stroke\n\nClinical Trial:\n- Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke\n- Inclusion criteria focus on patients in the acute phase of stroke recovery (less than 12 months post-onset)\n- The patient must have experienced their first stroke episode\n- No history of peripheral nerve injury or musculoskeletal disease in the affected upper extremity\n- No contracture of the affected wrist or fingers\n- No history of invasive procedures for spasticity treatment\n- Differentiation between patients with residual active motion and those without\n\nThe patient in the note does not mention having had a stroke. Moreover, the symptoms described do not align with those typically associated with a post-stroke condition, but rather suggest some form of acute neurologic event or condition, which is not specified as a stroke. The clinical trial is specifically designed for patients who have had a stroke, which does not appear to apply to the patient described.\n\nBased on the information given, the patient does not meet the inclusion criteria for the clinical trial because there is no evidence of a recent stroke, which is a primary requirement for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "485": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the inclusion criteria for the \"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib\" trial. The trial is looking for healthy volunteers in general good health, while the patient is presenting with a number of symptoms (spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia). These symptoms suggest that the patient is not in general good health, which is a requirement for participation in the study.\n\nAdditionally, the trial is specific to malaria vaccine research, and there is no indication in the patient note that the patient has been exposed to malaria or is at risk for malaria, which could potentially be a focus of the Phase Ib criteria, despite that part being for African volunteers. The patient's current health issues do not seem to be related to malaria or the focus of the vaccine study.\n\nTherefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "486": {
        "output": "The patient in the note is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and a range of other symptoms including difficulty swallowing and marked hydrophobia. The patient was hospitalized after her symptoms escalated.\n\nThe clinical trial in question is looking at the safety and efficacy of BOTOX (botulinum toxin Type A) in patients in Korea for treating primary axillary hyperhidrosis, focal spasticity, or moderate to severe glabellar lines.\n\nBased on the given patient note, there is a mention of \"slight tremors and almost imperceptible spasticity,\" which could potentially align with the \"focal spasticity\" mentioned in the inclusion criteria for the clinical trial. However, the patient's symptoms seem to be part of a broader and more acute clinical presentation, possibly not directly related to the conditions targeted by the clinical trial (primary axillary hyperhidrosis, focal spasticity related to a chronic condition, or cosmetic use for glabellar lines). \n\nFurthermore, it is not clear whether the patient's spasticity is a chronic condition or a transient response to another underlying issue. The trial seems to be directed towards patients with established conditions of hyperhidrosis, spasticity, or cosmetic concerns. \n\nGiven the limited information on the chronicity and cause of the patient's spasticity and the absence of a clear diagnosis of primary axillary hyperhidrosis or a need for treatment of glabellar lines, I would lean towards further investigation before making a referral. Thus:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "487": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"ASIS for Botox in Upper Limb Spasticity,\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 28-year-old female who presents with neck and shoulder pain and paresthesias in the left hand and arm.\n- Physical exam shows slight tremors and almost imperceptible spasticity.\n- The patient's symptoms have escalated to include spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n\nClinical Trial Inclusion Criteria:\n- Adults with a history of stroke that resulted in unilateral, upper-limb focal spasticity.\n- Wrist flexor tone and finger flexor tone of more than 2 as measured by the Ashworth Scale.\n- Ability to understand and follow verbal directions.\n- At least 1 functional disability item with a rating of more than 2 on the Disability Assessment Scale (DAS).\n- At least 1 functional task score that meets specific criteria at Day 0.\n\nComparison:\n- There is no mention of the patient having a history of stroke, which is a required condition for the trial.\n- The level of spasticity as measured by the Ashworth Scale is not documented, nor is there any indication that the patient's spasticity is a result of a stroke.\n- The patient's ability to understand and follow verbal directions is not explicitly mentioned, but given her recent hospitalization for severe symptoms, her ability to participate in a trial may be compromised.\n- The note does not provide information about the patient's functional disability items or task scores as per the Disability Assessment Scale (DAS) and other functional criteria.\n\nGiven that the patient does not have a documented history of stroke and other necessary details are missing or do not match the trial's criteria, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "488": {
        "output": "After reviewing both the patient note and the clinical trial inclusion criteria, it is clear that the patient does not meet the inclusion criteria for this clinical trial.\n\nThe patient is a 28-year-old female, which does not meet the age requirement of \"over 40 years of age\" stated in the trial's inclusion criteria. Additionally, the patient's symptoms and conditions mentioned in the note do not indicate that she has Myopic Macular Degeneration (MMD). Instead, her symptoms suggest a neurological condition, possibly related to her recent trip and involvement in a stray animal recovery campaign.\n\nThe clinical trial is specifically targeting patients with MMD and has very specific requirements for visual acuity, axial myopia, and other ocular health parameters, none of which are mentioned in the patient's note. Therefore, based on the information provided, the patient does not qualify for referral to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "489": {
        "output": "",
        "label": 0
    },
    "490": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the assessment of eligibility is as follows:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which meets the age criterion of the clinical trial (aged sixteen or older).\n- The symptoms described (spastic arm movements, tremors, and almost imperceptible spasticity) could suggest a neurological disorder, but there is no specific mention of cerebral palsy, which is a requirement for the trial.\n- There is no information provided regarding the patient's intelligence quotient (I.Q), speech troubles, or psychiatric health, which are also part of the inclusion criteria.\n- The patient's symptoms appeared to arise after a trip and are acute in nature, which does not align with cerebral palsy being a lifelong condition that typically arises in early childhood.\n\nClinical Trial Criteria Analysis:\n- The clinical trial is specifically aimed at patients with spastic cerebral palsy with a stable condition, which is not mentioned in the patient's note.\n- The trial requires motor disability to be unilateral or predominantly unilateral, which is not specified in the patient note.\n- The trial requires clinically evident speech troubles and normal or slightly sub-normal I.Q., none of which are mentioned in the patient note.\n- The trial excludes patients with psychiatric disorders, which could potentially include severe agitation and anxiety, though these symptoms in the patient note may be due to an acute condition rather than a psychiatric disorder.\n\nGiven the information provided, there is no indication that the patient has cerebral palsy, let alone the specific type of spastic cerebral palsy with the characteristics required for the trial. The patient's symptoms seem to be acute and related to a recent event rather than a stable, long-term condition like cerebral palsy. Thus, the patient does not meet the necessary criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "491": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note summary:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Recent hospitalization\n\nClinical trial inclusion criteria:\n- Compliant with protocol procedures and availability for clinical follow-up\n- Physical examination and laboratory results without clinically significant findings\n- BMI between 18.0 and 32.0 kg/m^2\n- Reliable forms of contraception or true abstinence, and refrain from sperm donation during treatment and the follow-up period\n\nAssessment:\n- The patient's age fits the criteria of being over 18.\n- The patient's current medical condition, with symptoms such as difficulty swallowing and hydrophobia, suggests a possible acute neurological condition that may not be stable or without clinically significant findings. This would likely require further investigation before determining her eligibility.\n- The patient's BMI is not mentioned, so we do not have enough information to assess this criterion.\n- The patient's contraceptive use is not discussed in the note, but this is a criterion that could be easily assessed and managed if she were otherwise eligible.\n\nBased on the patient's current symptoms and the lack of information on some of the criteria, I would say that further investigation is needed to determine her eligibility for the clinical trial. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "492": {
        "output": "To determine the patient's eligibility for the RNActive\u00ae Rabies Vaccine (CV7201) in Healthy Adults clinical trial, we need to assess the patient's characteristics against the inclusion criteria provided.\n\nInclusion criteria for the trial:\n1. Healthy male and female volunteers aged 18 to 40 years inclusive\n2. Compliant with protocol procedures and available for clinical follow-up through the last planned visit (V9)\n3. Physical examination and laboratory results without clinically significant findings\n4. Body Mass Index (BMI) \u2265 18.0 and \u2264 32.0 kg/m2\n5. Females: Negative human chorionic gonadotropin (HCG) pregnancy test (serum) for women presumed to be of reproductive potential on the day of enrolment\n6. Females of childbearing potential must use acceptable methods of birth control during the trial and follow-up period\n7. Males must use reliable forms of contraception and must refrain from sperm donation during the trial and follow-up period\n\nPatient characteristics from the note:\n- 28-year-old female\n- Presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- Hospitalized after the onset of severe symptoms\n\nBased on the patient note, this individual is experiencing severe symptoms including spasticity, agitation, and marked hydrophobia, which may be indicative of a significant medical condition. The inclusion criteria specify that participants should not have clinically significant findings in their physical examination and laboratory results. Therefore, this patient does not meet the criteria of being a \"healthy volunteer\" due to her current medical state, and referring her to this clinical trial would not be appropriate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "493": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 28-year-old female presenting with symptoms that could suggest possible rabies exposure (e.g., difficulty swallowing, hydrophobia, anxiety). The clinical trial is focused on the immunogenicity and safety of a post-exposure rabies intradermal regimen in children.\n\nThe inclusion criteria for the clinical trial specify that participants must be:\n1. 1-15 years old healthy children\n2. Able to give signed informed consent from their parents\n3. Willing to participate in the study and able to receive the vaccination and collect blood samples as planned.\n\nThe patient in the note is 28 years old, which is outside the specified age range for the trial (1-15 years). Therefore, she would not meet the inclusion criteria based on her age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "494": {
        "output": "Based on the patient note provided, the 28-year-old female patient does not appear to be eligible for the clinical trial in question. The clinical trial is targeted towards individuals who have suffered a stroke and have specific sensorimotor impairments as a result. The inclusion criteria for the trial are:\n\n- First focal unilateral lesion, ischemic or hemorrhagic\n- Had a stroke 1-12 months prior to enrollment\n- Rated between stages 2-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Arm and Hand\n\nThe patient's symptoms of neck and shoulder pain, paresthesias in the left hand and arm, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia, and hospitalization do not indicate that she has had a stroke. Instead, her symptoms might suggest a different neurological condition, potentially related to an infection or other acute event, especially given the onset after a trip and exposure to stray animals. Her symptoms do not align with the inclusion criteria specified for the trial, which are specific to stroke recovery.\n\nTherefore, based on the information given in the patient note, this patient would not be referred for the clinical trial focused on robot-aided rehabilitation intervention for stroke patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "495": {
        "output": "Based on the patient note provided, the patient is a 28-year-old female who presented with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and later developed more severe symptoms including spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia. The patient was hospitalized after these symptoms developed.\n\nThe clinical trial in question is focused on the rehabilitation of sensory and motor impairments following a stroke. The inclusion criteria for the trial specify that participants must have had their first focal unilateral lesion, ischemic or hemorrhagic, less than a month prior to enrollment, and be rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory for both arm and hand recovery.\n\nThe patient's symptoms do not indicate that she has had a stroke. Instead, her symptoms could suggest another neurological condition. There is no mention of a stroke or focal unilateral lesion, which are critical for eligibility in this trial. Therefore, based on the information provided in the patient note, the patient does not meet the inclusion criteria of having had a stroke and the subsequent impairment ratings required for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "496": {
        "output": "Given the patient's symptoms of neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and severe symptoms including spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and marked hydrophobia after attending a stray animal recovery campaign, there's a high suspicion of rabies exposure especially considering the hydrophobia symptom which is characteristic of rabies infection.\n\nThe clinical trial in question is studying the immunogenicity of rabies vaccine for pre-exposure prophylaxis. The inclusion criteria for the trial are:\n- Male and non-pregnant females aged \u2265 18 to \u2264 60 years on the day of inclusion\n- Able to comprehend and give informed consent\n- Able to attend all scheduled visits and to comply with all trial procedures\n- Subject in good health, based on medical history and physical examination\n\nThe patient is a 28-year-old female, which fits the age criterion. There is no information provided about pregnancy, but assuming she is not pregnant based on the available information, she would meet the gender and age criteria. However, the trial is for pre-exposure prophylaxis, and the patient's symptoms suggest that she may have already been exposed to rabies, which could be considered post-exposure. Additionally, the presence of clinical symptoms would likely exclude her from being considered \"in good health\" as per the trial's requirements.\n\nTherefore, despite the patient's age and gender fitting the inclusion criteria, her current health status does not align with the \"good health\" requirement for the trial, which is focused on pre-exposure prophylaxis rather than post-exposure treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "497": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor,\" I will determine the patient's eligibility for referral.\n\nPatient Note Summary:\n- A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias.\n- Presented with slight tremors and almost imperceptible spasticity.\n- Symptoms worsened over time, leading to hospitalization with spastic arm movements and other severe symptoms such as hydrophobia.\n\nClinical Trial Inclusion Criteria:\n- Essential Tremor diagnosed by criteria listed in the Consensus statement of the Movement Disorders Society on Tremor\n- Age 18 - 85 years of age\n- Motor skills allowing for capability to complete evaluations\n- Medically cleared for undergoing anesthesia and DBS surgery\n\nAssessment:\nThe patient's symptoms include tremors, which could be relevant to the trial's focus on Essential Tremor (ET). However, the patient's diagnosis is not clear from the note provided. The severe symptoms and rapid progression, including hydrophobia and difficulty swallowing, are not typical of ET, which is generally characterized by action tremors and does not typically include hydrophobia or difficulty swallowing. These symptoms may suggest a different neurological condition or another acute medical issue.\n\nThe clinical trial specifically requires a diagnosis of Essential Tremor as per the Movement Disorders Society's criteria. Since the patient has not been diagnosed with Essential Tremor and the symptoms described do not clearly match the typical presentation of ET, she does not meet the inclusion criteria based on the information provided.\n\nBased on the information available, it is not appropriate to refer the patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "498": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which fits within the age range of the inclusion criteria (2-100 years).\n- The patient presents with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and later with spastic arm movements, among other symptoms.\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of cervical dystonia or spasmodic torticollis.\n- Age range 2-100 years.\n\nAssessment:\nWhile the patient's age fits the trial's inclusion criteria, the patient note does not mention a clinical diagnosis of cervical dystonia or spasmodic torticollis. Instead, the symptoms described indicate a potential neurological condition that could require immediate and possibly different medical attention (e.g., difficulty swallowing, marked hydrophobia could suggest something more acute like rabies, given the recent history of attending a stray animal recovery campaign).\n\nThere is not enough information to diagnose cervical dystonia or spasmodic torticollis based solely on the patient note provided. The slight tremors and spasticity noted could be related to a variety of neurological conditions and would require further investigation before confirming a diagnosis of cervical dystonia.\n\nTherefore, the patient would not currently be referred for this clinical trial based on the information provided. However, further investigation and a definitive diagnosis would be necessary to make a final determination.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "499": {
        "output": "The patient described in the note is a 28-year-old female presenting with symptoms such as neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia following a trip and involvement in a stray animal recovery campaign. Her symptoms do not seem to be related to pregnancy, childbirth, or perineal tears, which are the focus of the clinical trial in question.\n\nThe clinical trial titled \"Palestinian Perineum and Birth Complication Study\" is aimed at assessing complications associated with pregnancy and delivery, and interventions used during labor. The inclusion criteria are specifically targeting midwives and physicians working on the labor ward in the participating hospitals and all women giving birth in those hospitals. There is no mention of the patient's condition being relevant to the study.\n\nGiven these considerations, the patient described does not meet the inclusion criteria for the clinical trial, as her medical condition is unrelated to the focus of the study and she is not part of the specified groups (midwives, physicians, or women giving birth in the participating hospitals).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "500": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 28-year-old female\n- Recently developed neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Hospitalized with symptoms suggestive of a possible neurological or infectious condition\n\nClinical Trial:\n- A Phase 3 study for a rabies vaccine (Vero Cell) for human use\n- Healthy Chinese subjects aged 10-60 years\n- Subjects must be in good health, as judged from medical history after the investigator's inquiry\n- Subjects with a temperature <=37.0\u00b0C on axillary setting\n\nAssessment:\nThe patient's recent symptoms, particularly marked hydrophobia and difficulty swallowing, are consistent with symptoms of rabies, a severe and often fatal viral infection. Given that the patient has been hospitalized with these symptoms and is exhibiting neurological signs, she would not be considered a \"healthy subject,\" which is a requirement for participation in the rabies vaccine trial. Additionally, the trial specifically mentions \"healthy Chinese subjects,\" and there is no information provided about the patient's ethnicity or nationality; thus, we cannot assume she meets this criterion.\n\nTherefore, based on the information provided and the inclusion criteria of the clinical trial, the patient would not qualify for the rabies vaccine study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "501": {
        "output": "Based on the patient note provided, the 28-year-old female presented with symptoms that could potentially be related to rabies, given her recent contact with stray animals and the subsequent development of hydrophobia, difficulty swallowing, and neurological symptoms. However, there is no mention of her HIV status or previous rabies immunization history in the patient note, which are both required inclusion criteria for the clinical trial in question.\n\nThe clinical trial is specifically for HIV-infected adults who have received primary rabies immunization and is designed to study the immune responses after a four-site intradermal rabies booster vaccination. Since the patient's HIV status and rabies vaccination history are not provided, we cannot determine her eligibility based on the inclusion criteria.\n\nTherefore, without additional information regarding the patient's HIV status and rabies immunization history, the assessment of her eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "502": {
        "output": "Given the patient note:\n\nA 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.\n\nAnd the clinical trial:\n\nTitle: Immediate Effects Cervicothoracic Manipulation Versus Passive Upper Trapezius Stretch\n\nSummary: The proposed project seeks to evaluate the influence of cervicothoracic (CT) manipulation and passive stretching to the upper trapezius on pressure pain thresholds and range of motion (ROM) in individuals without recent complain of neck pain.\n\nInclusion criteria:\n1. No current history or past history of neck pain; able to lie on back or stomach without difficulty\n\nThe patient clearly does not meet the inclusion criteria as she has a current history of neck and shoulder pain, which disqualifies her from the trial which requires individuals without recent complaints of neck pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "503": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- 28-year-old female\n- Presenting with neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Recent possible exposure to rabies (symptoms suggestive of rabies such as hydrophobia and difficulty swallowing)\n- Hospitalized for the symptoms\n- No mention of malaria or travel to malaria-endemic areas\n\nClinical Trial Summary:\n- Exploratory trial evaluating the effect of antimalarial drugs on the immune response to rabies vaccine\n- Inclusion criteria include being 18 to 60 years old, in good general health, and willing to comply with study procedures\n\nThe patient meets the age criterion for the trial. However, the trial is focused on the interaction between antimalarial drugs and the rabies vaccine. There is no indication that the patient has been exposed to malaria or is in need of antimalarial chemoprophylaxis. The patient appears to be presenting symptoms of rabies exposure, which is the focus of the vaccine portion of the study, but the main aspect of the study is the interaction with antimalarial drugs, not just the response to the rabies vaccine.\n\nGiven that the patient's medical condition (suspected rabies exposure) is not related to the primary focus of the clinical trial (antimalarial drugs' effect on rabies vaccine response), and there is no mention of a need for antimalarial drugs in her case, it would not be appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "504": {
        "output": "Based on the information provided, the patient is a 28-year-old female with neck and shoulder pain and left hand and arm paresthesias that started after a trip. Her symptoms include tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. There is no mention of lateral elbow pain or tennis elbow (lateral epicondylitis), which is the specific condition being addressed in the clinical trial for Radial Extracorporeal Shockwave Therapy.\n\nThe inclusion criteria for the clinical trial are:\n- Aged > 18 years old\n- Lateral elbow pain lasting > 3 months\n- Pain induced by direct compression on the lateral epicondyle or common extensor tendon, resistant wrist extension and pronation in the elbow extension position, or static stretching of common extensor tendon through the palmer flexion in wrist pronation and elbow extension position\n\nThe patient does not appear to meet the inclusion criteria for lateral elbow pain lasting more than 3 months or specific pain induced by actions associated with tennis elbow. Therefore, based on the patient note and the inclusion criteria provided, this patient would not be eligible for the clinical trial focused on tennis elbow.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "505": {
        "output": "",
        "label": 2
    },
    "506": {
        "output": "Given the details provided in the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, tachycardia, hypotension, and was found to have a ruptured liver abscess that required surgical intervention.\n\nThe clinical trial in question is studying cystic hydatid disease in Peru, which is caused by the parasite Echinococcus granulosus. The inclusion criteria for the trial are quite broad, requiring participants to be living in the study area (Cooperative Tupac Amaru) and to be older than five years old.\n\nThe patient note does not mention cystic hydatid disease or Echinococcus granulosus infection; rather, it details an acute presentation of a ruptured liver abscess in a patient with CVID. Additionally, there is no information suggesting that the patient resides in the specific study area required for the trial (Cooperative Tupac Amaru).\n\nBased on the available information, there is no direct link between the patient's current medical condition and the focus of the clinical trial. Furthermore, the geographical requirement is not met unless additional information is provided confirming the patient's residence in the study area.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "507": {
        "output": "To determine the patient's eligibility for the STA-5326 Mesylate clinical trial based on the provided patient note, we need to compare the patient's information against the inclusion and exclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- He experienced acute abdominal pain, fever, dehydration, elevated heart rate, and low blood pressure.\n- The patient underwent exploratory laparotomy for a ruptured liver abscess and was taken to ICU post-surgery.\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 75 years.\n- Diagnosed with CVID.\n- Documented, unintended loss of greater than 5% of body weight over the last year OR chronic diarrhea OR nutritional supplements required to maintain body weight.\n- If on oral antibiotics, a stable dose for at least 2 weeks.\n\nClinical Trial Exclusion Criteria:\n- Clinically significant diseases that could make the subject unsuitable.\n- Use of potential CYP3A4 inhibitors/inducers.\n- Abnormal clinical chemistry values including AST, ALT, serum bilirubin, serum creatinine, and alkaline phosphatase.\n- Abnormal blood cell counts and certain infection histories.\n\nBased on the provided patient note, we can see the following:\n\n- The patient is within the age range for inclusion.\n- The patient has a diagnosis of CVID.\n- The patient note does not mention unintended weight loss or chronic diarrhea or the need for nutritional supplements. More information would be needed to confirm this criterion.\n- The note does not provide information on the use of oral antibiotics or any chronic medication.\n- The patient has had a recent surgical emergency for a ruptured liver abscess, which may not disqualify him but does indicate a significant acute illness that could influence trial eligibility.\n- Given the patient's recent surgery and ICU admission, his clinical chemistry values might be outside the normal range, but we do not have specific values to confirm this.\n\nBased on the available information, we cannot definitively determine the patient's eligibility for the trial because of the following reasons:\n\n- We lack information about weight loss, diarrhea, and nutritional supplements.\n- The recent severe medical event (ruptured liver abscess) and ICU stay may impact his eligibility due to the potential for clinically significant diseases or abnormal clinical chemistry values.\n- We do not have information about potential CYP3A4 inhibitors/inducers usage.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "508": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess, which required surgical intervention\n- No mention of hyper-IgM syndrome or other disorders of immunoglobulin production besides CVID\n\nClinical Trial:\n- Investigates gene abnormalities in Primary Immune Deficiency (PID), including CVID\n- Aims to improve the diagnosis and treatment of patients with these conditions\n- Inclusion criteria specify patients with a known or suspected immune defect with hyper-IgM syndrome and/or disorders of immunoglobulin production\n- No age, sex, race, or disability limitations for patients with immune defects\n- Normal volunteers must be healthy adults between the age of 18 and 70 years\n- Participants must agree to allow the Principal Investigator (PI) to store research samples\n- Exclusion criteria include acquired abnormalities leading to immune defects such as HIV, chemotherapy, and malignancy\n\nThe patient has a history of CVID, which is one of the specific disorders mentioned in the summary of the clinical trial. Given that the patient's condition (CVID) is a focus of the study, and considering that the inclusion criteria do not restrict participation based on the patient's current complications (surgical intervention for a ruptured liver abscess), the patient appears to be a match for the trial's inclusion criteria.\n\nThe only potential consideration is the patient's current acute condition and whether it could interfere with the evaluation or pose an added risk for the patient as a study participant, which would be at the discretion of the Principal Investigator (PI) according to the exclusion criteria. However, based on the information provided, this does not seem to be a factor that would automatically exclude the patient from the trial.\n\nTherefore, it is reasonable to refer the patient to the clinical trial for further evaluation by the research team.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "509": {
        "output": "Based on the information provided for the patient and the clinical trial's inclusion criteria, let's examine the compatibility:\n\nPatient information:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Findings: Tenderness and positive Murphy sign, hepatomegaly, ruptured liver abscess\n- Intervention: Exploratory laparotomy and drainage in ICU\n\nClinical trial inclusion criteria:\n- Female or male, aged between 18 and 90 years.\n- Written informed consent.\n- Abscess formation or abdominal cyst scheduled for drainage.\n- Plasma creatinine <1.5 mg/dL\n\nComparison:\n- Age: The patient is 48 years old, which falls within the trial's age range of 18 to 90 years.\n- Gender: The trial accepts both female and male participants, so the patient's gender is appropriate.\n- Medical condition: The patient has a ruptured liver abscess and has undergone surgical drainage, fitting the criterion for abscess formation scheduled for drainage.\n- Plasma creatinine: The patient note does not mention the level of plasma creatinine. This would need to be confirmed to ensure it is below the <1.5 mg/dL required by the study.\n\nThe patient seems to match the majority of the inclusion criteria for the clinical trial. However, the plasma creatinine level is not mentioned, which is a necessary parameter to ascertain eligibility. Given this information, the patient would be considered for referral to the clinical trial upon confirmation of the plasma creatinine level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "510": {
        "output": "Based on the provided patient note and the clinical trial information, we must assess the patient's eligibility for the clinical trial concerning biliary tract cancer treatment.\n\nPatient Note Summary:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Physical examination: tenderness and positive Murphy sign\n- Abdominal ultrasound: hepatomegaly and free intraperitoneal fluid\n- Diagnosis: ruptured liver abscess, surgically drained\n- Postoperative care in ICU\n\nClinical Trial Inclusion Criteria Summary:\n- Nonmetastatic biliary tract cancer diagnosis, confirmed histologically or by imaging (MRI, CT scan, or ECHO)\n- Unresectable disease amenable to radiotherapy\n- No visceral metastases by imaging\n- Hepatic adenopathies within radiation field allowed\n- No ampulla of Vater or pancreatic cancer involving the biliary tract\n- WHO performance status 0-2\n- Creatinine < 1.5 mg/dL\n- Absolute neutrophil count \u2265 1,500/mm^3\n- Platelet count \u2265 75,000/mm^3\n- Prothrombin time > 70%\n- Bilirubin \u2264 2.9 mg/dL (after hepatic draining if needed)\n- No significant comorbidities that would preclude study therapy\n- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix\n- Not pregnant or nursing\n- No recent biliary surgery\n- No hepatic intra-arterial chemotherapy\n- No prior anticancer therapy\n\nComparison:\n- The patient has a history of CVID and a current diagnosis of a ruptured liver abscess, not biliary tract cancer.\n- There is no information regarding nonmetastatic biliary tract cancer or the patient's WHO performance status, creatinine levels, blood counts, prothrombin time, or bilirubin levels.\n- The patient has had recent abdominal surgery, which could potentially exclude him from the trial as per the \"No recent biliary surgery\" criterion, depending on the timeframe considered as \"recent\" by the trial.\n- The patient's current condition (ruptured liver abscess) is not related to biliary tract cancer and does not meet the disease characteristics required for the trial.\n\nBased on the information provided, the patient does not meet the disease criteria for the clinical trial, as he has no diagnosis of biliary tract cancer, and he has recently undergone abdominal surgery. Therefore, he would not be eligible for the clinical trial focused on treating nonmetastatic biliary tract cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "511": {
        "output": "",
        "label": 0
    },
    "512": {
        "output": "Upon reviewing the patient note and the clinical trial information provided, let's determine the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 48 years\n- Gender: Male\n- Medical condition: Common variable immunodeficiency (CVID), acute abdominal pain, fever, dehydration, ruptured liver abscess\n- History of receiving treatment: The patient has undergone surgery (exploratory laparotomy and drainage of a ruptured liver abscess) and is currently in the ICU.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent, age-adapted\n- Male or female aged 1 to 70 years\n- Diagnosis of primary humoral immunodeficiency\n- No prior immunoglobulin substitution therapy\n- IgG level of <5 g/L at screening\n- Women of childbearing potential must use medically approved contraception and must have a negative urine pregnancy test at screening\n\nClinical Trial Exclusion Criteria:\n- Evidence of serious infection between screening and first treatment\n- Bleeding disorders that require medical treatments\n- Any medical disorder causing secondary immune disorders, autoimmune neutropenia, or a clinically significant defect in cell-mediated immunity\n- Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial\n\nAssessment:\n- The patient is within the age range required by the trial (48 years old).\n- The patient has a diagnosis of primary humoral immunodeficiency, which meets one of the trial's inclusion criteria.\n- No information is provided regarding previous immunoglobulin substitution therapy, so we cannot determine if the patient has had this treatment before. This will require further investigation.\n- The patient's IgG level is not mentioned; this would need to be confirmed to meet the inclusion criteria.\n- The patient has just undergone surgery for a ruptured liver abscess, which could be considered a serious infection. This might place the patient under the exclusion criteria due to the recent serious infection.\n\nBased on the available information, the patient's eligibility is uncertain due to the lack of detail on their previous immunoglobulin therapy and IgG levels. Moreover, the recent surgery for a ruptured liver abscess might exclude the patient from participation. Therefore, further investigation is needed to determine if the patient has had prior immunoglobulin therapy and to confirm their IgG levels. Additionally, the impact of the recent surgery and current ICU stay on the patient's eligibility needs careful consideration.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "513": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's examine the patient's eligibility for the clinical trial.\n\nPatient note:\n- 48-year-old white male (within age criteria of 18 to 75 years)\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, tachycardia, and hypotension\n- Abdominal ultrasound showed hepatomegaly and abundant free intraperitoneal fluid\n- Exploratory laparotomy revealed a ruptured liver abscess, which was drained surgically\n\nClinical trial inclusion criteria:\n- Patients between 18 and 75 years of age inclusive (patient meets this criterion)\n- Patients with at least one focal liver lesion, either identified or suspected by various imaging techniques within 2 months before entering the study (the patient had a ruptured liver abscess, which is one of the listed pathologies under 'focal liver lesions')\n- Patients willing to undergo study procedures including safety follow-up (not mentioned in the patient note but typically expected if a patient is referred for a trial)\n- Patients who have undergone or who are scheduled to undergo the defined procedure for SOR within one month before or after the study MRI (patient has undergone surgery for the liver abscess, which might be considered a procedure in the context of the study)\n- Women of child-bearing potential with negative urine pregnancy test result within 24 hours before contrast medium injection (not applicable to the patient as he is male)\n- Patients who are fully informed about the study and have signed the informed consent form (not mentioned in the patient note but is a standard procedure for trial enrollment)\n\nGiven that the patient is within the age range, has a focal liver lesion (ruptured liver abscess), and there's no information suggesting that they are unwilling to undergo study procedures or unable to consent, it seems that the patient could potentially be eligible for the clinical trial.\n\nHowever, there are a few considerations to take into account:\n- The study is specific to Chinese patients, and it is not mentioned if the patient is Chinese or not.\n- The patient's current medical stability post-surgery and ICU admission is not clarified, which might affect his immediate eligibility for MRI procedures.\n\nSince the key inclusion criteria appear to be met but there are still some uncertainties that would need to be clarified (such as the patient's current medical stability and whether the study's ethnic focus applies to the patient), I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "514": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presents with acute abdominal pain, fever, dehydration\n- Physical examination: tenderness, positive Murphy sign\n- Exploratory laparotomy reveals a ruptured liver abscess, which is surgically drained\n- Patient is taken to the ICU post-surgery\n\nClinical Trial Inclusion Criteria:\n- Adult patients (>18 years)\n- Surgical intervention within 24 hours of diagnosis for localized intra-abdominal infection (IAI) of mild to moderate severity\n- Specific conditions include:\n  - Acute appendicitis: Ruptured or perforated with abscess\n  - Acute diverticulitis with perforation and/or abscess\n  - Acute cholecystitis with either rupture or perforation\n  - Acute gastric and duodenal (>24 hours) perforation\n  - Traumatic (>12 hours) perforation of the intestines\n  - Secondary peritonitis due to perforated viscus\n  - Intra-abdominal abscess (including of liver and spleen)\n\nMatching Points:\n- The patient is an adult over 18 years of age.\n- The patient required surgical intervention due to a ruptured liver abscess, which matches the criteria for \"Intra-abdominal abscess (including of liver and spleen).\"\n- The trial requires intervention within 24 hours of diagnosis, which is not specified in the patient note but can be inferred as likely given the nature of the condition and immediate surgical intervention.\n\nBased on the information provided, the patient matches the trial's inclusion criteria regarding age, the requirement for surgical intervention, and the specific condition of intra-abdominal abscess. However, the severity of the infection (mild to moderate) and the timeline of intervention (within 24 hours of diagnosis) are not explicitly detailed in the patient note, which could influence eligibility.\n\nWithout further information, the patient seems to fit the trial's criteria, but we cannot be certain without additional details on the severity of the infection and the timing of the surgical intervention.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "515": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 48-year-old white male (meets age criterion)\n- History of common variable immunodeficiency (CVID)\n- Presentation with acute abdominal pain, fever, dehydration\n- Positive Murphy sign, hepatomegaly, and free intraperitoneal fluid on ultrasound\n- Ruptured liver abscess surgically drained (indicates that the patient had a liver abscess)\n\nClinical Trial Inclusion Criteria:\n- Clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess\n- Both genders\n- Older than 15 years\n\nThe patient is a 48-year-old male which fulfills the age and gender criteria. However, the patient note does not specify that the liver abscess is amebic in nature, nor does it mention if serologic testing (ELISA) for amebiasis has been performed.\n\nGiven the patient has had a liver abscess, it would be reasonable to consider further investigation to determine if the abscess was caused by an amebic infection. If serologic testing confirms the diagnosis of an amebic liver abscess, the patient would meet the clinical trial's inclusion criteria.\n\nAs the information stands, there is not enough information to confirm the patient's eligibility for the clinical trial without further testing.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "516": {
        "output": "The patient described in the note is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, a rapid heart rate (HR of 132 bpm), and low blood pressure (BP 80/40). The physical examination showed tenderness and a positive Murphy sign, which often indicates gallbladder inflammation. However, an abdominal ultrasound revealed hepatomegaly and free intraperitoneal fluid, and exploratory laparotomy confirmed a ruptured liver abscess that was surgically drained.\n\nThe clinical trial in question is focused on determining the correlation between the region of abdominal tenderness as determined by a physical examination and the location of acute pathology diagnosed on abdominal CT in emergency department patients with non-traumatic abdominal pain and tenderness.\n\nBased on the inclusion criteria provided for the clinical trial, all consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled. The key requirement is that the abdominal pain and tenderness must be to direct palpation in the region anterior to the mid-axillary line bilaterally, and extending from the costal margins to the inguinal ligaments.\n\nGiven that the patient in the note was taken to the ICU after surgery for a ruptured liver abscess, it is unclear whether an abdominal CT for non-traumatic abdominal pain was performed or planned. However, the patient's clinical presentation and the findings from the ultrasound and surgery suggest that he would likely have met the criteria for abdominal pain and tenderness as defined by the trial.\n\nTherefore, I would consider referring this patient to the clinical trial upon further investigation into whether an abdominal CT was performed or indicated as part of the patient's evaluation in the emergency department. If the patient did undergo an abdominal CT for the evaluation of his abdominal pain and tenderness, he would meet the inclusion criteria for the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "517": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 48-year-old white male.\n- The patient has a history of common variable immunodeficiency (CVID).\n- The patient presented with acute abdominal pain, fever, dehydration, a high heart rate, and low blood pressure.\n- Physical examination showed tenderness and a positive Murphy sign, which is typically indicative of gallbladder inflammation.\n- Abdominal ultrasound showed hepatomegaly and free intraperitoneal fluid.\n- The patient had a ruptured liver abscess, not appendicitis, which was surgically drained.\n\nClinical Trial Inclusion Criteria:\n- The trial is studying laparoscopic operation for perforated appendicitis.\n- Patients admitted with pain other than the right lower abdominal quadrant, favoring the diagnosis of perforated acute appendicitis.\n- Clinical examination and abdominal computed tomography results must reveal signs of acute appendicitis and intra-abdominal fluid accumulation.\n- Perforated appendicitis must remain as the most likely diagnosis.\n- Age between 12 and 80 years old with informed consent.\n\nComparison:\n- The patient's age falls within the range specified by the trial (12 to 80 years old).\n- The patient's condition (ruptured liver abscess) is not consistent with the condition being studied (perforated appendicitis).\n- The diagnosis of the patient does not match the required diagnosis for the trial (perforated appendicitis).\n\nConclusion:\nThe patient's condition does not match the specific disease and condition that the clinical trial is investigating. The trial is focused on perforated appendicitis, and this patient has a ruptured liver abscess, which is a different condition. Therefore, based on the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "518": {
        "output": "Based on the information provided, the patient in the note has a history of common variable immunodeficiency (CVID) and has undergone surgery for a ruptured liver abscess. The clinical trial in question is investigating the effect of intraperitoneal local anaesthetic application on postoperative pain and fatigue in patients undergoing open colonic resection as part of an Enhanced Recovery After Surgery (ERAS) program.\n\nThe inclusion criteria for the clinical trial specifically mention \"Consecutive patients undergoing open colonic resection at MSC under the ERAS program.\"\n\nThe patient in the note does not fit the inclusion criteria because:\n- The patient underwent surgery for a ruptured liver abscess, not open colonic resection.\n- There is no indication that the patient's surgery was part of the ERAS program or that it was an open colonic resection.\n\nGiven this information, it would not be appropriate to refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "519": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient described does not appear to match the specific requirements for the clinical trial in question. The patient note describes a 48-year-old white male with a history of common variable immunodeficiency (CVID) and complications arising from a ruptured liver abscess, which was surgically drained. The clinical trial, however, is focused on patients who have had a laparoscopic cholecystectomy for gallbladder stones and is investigating the clinical impact of routine abdominal drainage after such surgery.\n\nThe patient in the note has not been described as having gallbladder stones or having undergone a laparoscopic cholecystectomy (surgery to remove the gallbladder). Instead, the patient had surgery for a ruptured liver abscess. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires patients who are undergoing or have undergone a laparoscopic cholecystectomy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "520": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the clinical trial. The trial is specifically looking for patients with gastric cancer to study the ultra-structure of the peritoneal surface by electronic microscopy. The patient described has a history of common variable immunodeficiency (CVID) and recently experienced a ruptured liver abscess, which is not related to gastric cancer.\n\nThe inclusion criteria for the trial are:\n- Patients with operable local gastric adenocarcinoma\n\nThe patient note does not mention gastric adenocarcinoma or any type of gastric cancer; instead, it describes a different medical condition involving a liver abscess and CVID. Hence, this patient would not meet the inclusion criteria for the trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "521": {
        "output": "The patient in the note has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, and signs of a ruptured liver abscess, which was surgically drained. The patient does not have a confirmed diagnosis of liver cirrhosis or a mention of symptomatic gall bladder stones, which are critical for inclusion in the clinical trial mentioned.\n\nThe clinical trial is specifically looking to include patients with liver cirrhosis who have symptomatic gall bladder stones for a study on clipless laparoscopic cholecystectomy using a harmonic scalpel. Since the patient's condition does not match the inclusion criteria of having liver cirrhosis and symptomatic gall bladder stones, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "522": {
        "output": "Based on the information provided:\n\nThe patient in the note is a 48-year-old white male with a history of common variable immunodeficiency (CVID). He presented with acute abdominal pain, fever, dehydration, tachycardia, hypotension, and signs consistent with a ruptured liver abscess, which was confirmed and treated surgically.\n\nThe clinical trial is focused on the prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without bleeding.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Age \u2265 21 years\n- Probable or confirmed dengue\n    - Confirmed dengue: laboratory confirmation of acute dengue by either positive PCR for viral RNA or positive NS1 antigen test with a compatible clinical syndrome\n    - Probable dengue: Positive acute dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 criteria for probable dengue.\n- Platelets \u2264 20x10^3/\u03bcL\n\nComparing the patient's condition to the trial's inclusion criteria:\n- The patient is 48 years old, which meets the age criterion.\n- There is no mention of dengue or related symptoms, laboratory tests, or diagnostic criteria that would suggest probable or confirmed dengue.\n- The platelet count is not mentioned, so we cannot assess if the patient has severe thrombocytopenia as defined by the trial's inclusion criteria.\n\nGiven that the patient does not have a confirmed or probable diagnosis of dengue, which is a critical inclusion criterion for the trial, the patient does not appear to meet the trial's eligibility requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "523": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- The patient presented with acute abdominal pain, fever, dehydration, tachycardia (HR of 132 bpm), and hypotension (BP 80/40).\n- The physical examination showed tenderness and a positive Murphy sign.\n- Abdominal ultrasound demonstrated hepatomegaly and free intraperitoneal fluid.\n- Exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained.\n- The patient was taken to the ICU post-surgery.\n\nClinical Trial:\n- The trial targets children with a delayed diagnosis of perforated appendicitis.\n- Inclusion criteria specify that participants must be children with symptoms of perforated appendicitis for 4 or more days.\n- The diagnosis must be confirmed with diagnostic imaging (CT scan or ultrasound) showing an established appendiceal abscess or phlegmon.\n- Consent to participate is required.\n\nAssessment:\n- The patient in question is not a child, therefore does not meet the age demographic targeted by the study.\n- The patient's diagnosis is a ruptured liver abscess, not perforated appendicitis.\n- There is no indication that the patient had appendicitis, delayed or otherwise.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial since the trial specifically targets children with perforated appendicitis and the patient has a different diagnosis. Therefore, it would not be appropriate to refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "524": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male, which fits the age criterion of the clinical trial (18 to 90 years of age).\n- The patient has had a ruptured liver abscess requiring surgical drainage, which aligns with one of the diagnoses specified in the inclusion criteria (intraabdominal abscess including liver).\n- The patient required surgical intervention (exploratory laparotomy and drainage), which fits the surgical intervention requirement within 24 hours of the first dose of the study drug.\n- There is no information provided that the patient would be unwilling or unable to comply with study procedures and restrictions, or that they would be unwilling or unable to provide written informed consent.\n\nClinical Trial Inclusion Criteria Review:\n- Age: 18 to 90 years (Patient is 48 years old)\n- Diagnoses: Intraperitoneal infection, including intraabdominal abscess (Patient had a ruptured liver abscess)\n- Surgical intervention required within 24 hours of the first dose of study drug (Patient had exploratory laparotomy)\n- Willingness and ability to comply with study procedures and to provide informed consent (Assumed, as there is no information suggesting otherwise)\n\nBased on the information given, the patient meets the age requirement, has a diagnosis that fits the inclusion criteria, and required surgical intervention in line with the trial's requirements. There is no clear information on renal function, but since this is not mentioned in the patient note, we will assume normal renal function unless otherwise indicated.\n\nGiven the above points, the patient appears to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "525": {
        "output": "Based on the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who has recently undergone surgery for a ruptured liver abscess. The patient has been in the ICU after the surgery.\n\nComparing this patient's situation to the inclusion criteria of the clinical trial, it is clear that the trial is specifically looking for adult recipients of kidney transplants from deceased donors. The patient note does not mention that the patient has received a kidney transplant, nor is there any indication that the patient is an eligible recipient for a kidney transplant. Thus, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "526": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria Assessment:\nA) The patient does not have a history of histologically-proven colorectal adenocarcinoma, nor is there any indication of peritoneal carcinomatosis, ovarian metastases, or rupture of a primary colorectal tumor.\nB) The patient has not received the specified chemotherapy regimen (Folfox 4) for colorectal adenocarcinoma, as there is no mention of colorectal cancer or such treatment in the patient's note.\nC) Since the patient does not have colorectal adenocarcinoma, the criterion regarding the absence of tumor recurrence does not apply.\nD) The patient's age fits within the specified range (18-70 years), but there is no information on the patient's Performance Status, blood counts, liver and renal function, peripheral neuropathy, or operability to determine eligibility based on these points.\nE) The trial-specific procedures, including informed consent, are not relevant to assessing eligibility at this point since the patient does not meet the primary disease-related criteria.\n\nGiven the information provided in the patient note, the patient does not meet the core disease-related inclusion criteria for the clinical trial. The patient's condition (CVID with ruptured liver abscess) is not related to colorectal adenocarcinoma or the specific risk factors for peritoneal carcinomatosis mentioned in the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "527": {
        "output": "Given the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), acute abdominal pain, fever, dehydration, and a ruptured liver abscess that was surgically drained. He does not meet the inclusion criteria for the clinical trial described, as the trial is specifically for pregnant women aged 14 years and over at \u2265 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans. Since the patient is male and not pregnant, he is not eligible for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "528": {
        "output": "Upon reviewing the patient's notes and the clinical trial's inclusion criteria, it is clear that this patient does not meet several of the specified criteria for the clinical trial on once-daily therapy for streptococcal pharyngitis.\n\nThe inclusion criteria for the trial are:\n- Age of 6 to 15 years old.\n- Clinical examination signs such as fever, erythema or exudate of tonsils, enlarged lymph nodes, sore throat, neck tenderness, abdominal pain, and pharynx petechiae.\n- No antibiotic use in the week before.\n- Positive throat culture for Group A \u03b2-hemolytic Streptococcus (GABHS).\n- No previous history of allergy to penicillin.\n\nThe patient in question is a 48-year-old male, which is outside the age range of 6 to 15 years old required by the trial. Furthermore, the patient's condition (common variable immunodeficiency with complications of a ruptured liver abscess) is not related to streptococcal pharyngitis, and there is no mention of a sore throat, fever, or any signs suggesting streptococcal infection. There is also no information on a throat culture being performed or results indicating GABHS.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial on once-daily therapy for streptococcal pharyngitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "529": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient does not appear to meet the criteria for the Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease study. The inclusion criteria specifically require a patient to have polycystic liver disease with a liver volume of \u2265 4 liters and \u2265 20 liver cysts. The patient must also exhibit at least two out of five listed symptoms related to mass effect and be diagnosed with either ADPKD (Autosomal Dominant Polycystic Kidney Disease) or ADPLD (Autosomal Dominant Polycystic Liver Disease).\n\nThe provided patient note describes a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and signs of sepsis (tachycardia and hypotension). An abdominal ultrasound showed hepatomegaly and intraperitoneal fluid, and an exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained. There is no mention of polycystic liver disease, liver cysts, or any of the other specific symptoms required by the study's inclusion criteria.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "530": {
        "output": "Based on the provided patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who presented with acute abdominal pain, fever, dehydration, and was found to have a ruptured liver abscess on exploratory laparotomy. The clinical trial in question is investigating the use of contrast-enhanced ultrasound for the evaluation of de novo focal liver lesions.\n\nComparing the patient's situation with the inclusion criteria for the clinical trial, the trial is specifically looking for:\n\n1. Patients diagnosed with de novo focal liver lesions (FLL) at standard ultrasound.\n2. Age > 18 years, male and female gender.\n3. Informed consent for the contrast-enhanced study.\n\nThe patient has a ruptured liver abscess, which is not described as a de novo focal liver lesion. However, since the patient has hepatomegaly, which could be related to his underlying condition (CVID), it is possible that focal liver lesions could be present or develop, but this has not been specifically mentioned in the patient note.\n\nGiven the information provided, the patient does not strictly meet the inclusion criteria as he is not described to have a de novo focal liver lesion that has been diagnosed at standard ultrasound. However, it is not clear whether the hepatomegaly observed might be related to such lesions, or if further ultrasound evaluation post-surgery could reveal de novo FLL.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "531": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- Age: 48 years old (meets age criterion of >18 years)\n- Condition: Ruptured liver abscess leading to severe intra-abdominal sepsis, managed with exploratory laparotomy and ICU care\n- Gender: Male (no gender-specific criteria mentioned)\n\nClinical Trial:\n- Title: Assessment of peritoneal immune response in patients with severe intra-abdominal sepsis managed with laparostomy and Vacuum Assisted Closure (VAC)\n- Inclusion Criteria: Patient > 18 years old, patients with severe abdominal sepsis, and informed consent\n\nThe patient in the note is a 48-year-old male who has severe intra-abdominal sepsis as a result of a ruptured liver abscess, which aligns with the clinical trial's patient population of interest (severe intra-abdominal sepsis). The clinical trial does not specify exclusions based on the type of sepsis or the origin (liver abscess), and the patient meets the age requirement. Additionally, there is no mention that the patient or relatives are unable or unwilling to sign the informed consent, which can be further investigated to ensure compliance with this criterion. Therefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "532": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 48-year-old white male (meets age criteria)\n- Ruptured liver abscess (condition is not liver cirrhosis as specified in the trial criteria)\n- No mention of liver cirrhosis diagnosis or MELD score\n- No information on whether the patient has been refused by a liver transplant program or not a transplant candidate\n\nClinical Trial Inclusion Criteria:\n- Age >18 years (patient meets this criterion)\n- Clinically diagnosed liver cirrhosis by any of the following: ultrasound/MRI/CT + tissue biopsy (no evidence in patient note)\n- MELD score \u2265 18 and <35 (no MELD score provided in patient note)\n- Ability to sign an informed consent (assumed capable unless stated otherwise)\n- Refused by liver transplant program or labeled as not a liver transplant candidate, decided by at least 3 transplant physicians (no information provided)\n\nBased on the information provided, the patient does not meet the specific diagnosis of liver cirrhosis required for the clinical trial, nor is there any evidence of a MELD score or liver transplant candidacy status. Therefore, the patient would not be eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "533": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 48-year-old white male with a history of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Physical examination showing tenderness and positive Murphy sign\n- Abdominal ultrasound indicating hepatomegaly and free intraperitoneal fluid\n- Exploratory laparotomy revealing a ruptured liver abscess, managed surgically\n\nClinical Trial:\n- Title: Antibiotics Versus Surgery in Acute Appendicitis\n- Target condition: Acute Appendicitis (AA)\n- Inclusion criteria:\n  - Patients between 18 and 65 years old\n  - First episode of suspected AA diagnosed by Andersson's score or combination with abdominal ultrasound\n\nAssessment:\nThe patient does not have acute appendicitis; instead, he has a ruptured liver abscess. The inclusion criteria for the clinical trial specify participants with a first episode of suspected acute appendicitis, which does not apply to this patient. Therefore, this patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "534": {
        "output": "Given the patient note:\n\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration, etc.\n- Underwent surgery for a ruptured liver abscess\n\nAnd the clinical trial's inclusion criteria:\n\n- Female patients only\n- Patients undergoing controlled ovarian hyperstimulation (COH), transvaginal oocyte aspiration (TVA), and Saline Infused Sonography (SIS) with UL collection\n- Age <35 y/o at the time of in vitro fertilization (IVF) cycle\n- Various criteria related to ovarian function and menstrual cycles or PCOS diagnosis and BMI\n\nThe patient in the provided note is a 48-year-old male, and the clinical trial's inclusion criteria specify that only female patients are eligible. Furthermore, the trial is focused on ovarian function and fertility issues, which are not applicable to the male patient. Thus, the patient does not meet the basic demographic and gender requirements for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "535": {
        "output": "To determine if the patient is eligible for the clinical trial of Bilhvax, a vaccine candidate against schistosomiasis, we must compare the patient's characteristics and condition with the inclusion criteria provided.\n\nThe inclusion criteria for the clinical trial are:\n1. Caucasian volunteers\n2. No smoker\n3. Biological parameters (haematological, biochemical, renal and hepatic) in normal range\n4. Health Insurance\n5. Sign informed consent\n\nThe patient note provides the following information:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- The patient has recently undergone surgery for a ruptured liver abscess and is taken to the ICU.\n\nFrom the patient note, we can infer the following:\n- The patient is a Caucasian male, which matches the first criterion regarding ethnicity.\n- There is no information on whether the patient is a smoker or not.\n- Given the patient has a ruptured liver abscess and is in the ICU, it is unlikely that his biological parameters are within the normal range, especially considering the acute presentation with fever, dehydration, and unstable vital signs.\n- There is no information regarding the patient's health insurance status.\n- Whether the patient can sign informed consent is uncertain due to his acute condition and potential ICU stay.\n\nBased on the available information, the patient does not meet at least one of the key inclusion criteria (biological parameters in normal range) due to his recent surgery and current critical condition. Additionally, the trial seeks healthy volunteers, which the patient is not, given his acute illness and CVID history.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "536": {
        "output": "Based on the information provided, the patient in the note has a history of common variable immunodeficiency (CVID), and the recent medical issue is related to a ruptured liver abscess. This patient does not have gastric cancer, which is the disease of interest for the clinical trial.\n\nThe inclusion criteria for the clinical trial specify that participants must be gastric cancer patients eligible for curative surgery. Since the patient in question does not have a diagnosis of gastric cancer, they do not meet the inclusion criteria for the clinical trial.\n\nTherefore, I would not refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "537": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Ruptured liver abscess, treated with surgery and taken to ICU\n\nClinical Trial Inclusion Criteria:\n- Patients of both sexes aged \u2265 18 years\n- Standard analytical parameters within certain ranges\n- Patients with liver space occupying lesion (LOE) that require extended hepatic resection\n- Different types of liver damage requiring specific interventions\n- Patients must give written informed consent\n\nComparison:\n- Age: The patient is 48 years old, which meets the age criterion (\u2265 18 years).\n- Sex: The trial includes patients of both sexes, so being male is not a disqualifying factor.\n- Standard analytical parameters: The patient's complete blood count and liver function tests are not provided, so we cannot assess this criterion.\n- Specific liver condition: The patient has a history of a ruptured liver abscess, which is not listed as one of the liver conditions for which the trial is recruiting (the trial mentions metastatic disease, hepatocarcinoma, and other specific liver lesions requiring resection).\n- Informed consent: The patient's ability to give informed consent is not clear from the note, as he is in the ICU after surgery, which may affect his capacity to consent.\n\nBased on the information provided, the patient does not appear to meet the inclusion criteria related to the specific liver conditions the trial is targeting. While he does have a liver-related issue (ruptured liver abscess), this is not the same as the liver space occupying lesions (LOE) that require extended hepatic resection mentioned in the inclusion criteria.\n\nTherefore, referring this patient to the clinical trial does not seem appropriate based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "538": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, it is clear that the patient does not meet the criteria for this endometriosis study. The patient is a 48-year-old male with a history of common variable immunodeficiency (CVID) and a recent medical event involving a ruptured liver abscess. The clinical trial is specifically focused on patients with endometriosis, which is a condition exclusive to individuals with a uterus, typically females. Furthermore, the trial is looking for participants with adnexal findings or those requiring laparoscopic sterilization, which are also not applicable to the male patient in question.\n\nSince the patient's condition and gender do not match any of the inclusion criteria for the endometriosis trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "539": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease\" involves matching the patient's characteristics and medical history with the inclusion and exclusion criteria provided for the trial.\n\nPatient characteristics:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Physical examination showed tenderness and positive Murphy sign\n- Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid\n- Exploratory laparotomy reveals a ruptured liver abscess, surgically drained\n- Patient was in the ICU post-surgery\n\nClinical trial inclusion criteria:\n- Has documented chronic granulomatous disease (CGD)\n- Age 18 - 75\n- Has a liver abscess infected with Staphylococcus aureus or other microorganism susceptible to RFA\n- Not an optimal candidate for curative surgical resection\n- Willing to return for imaging scans\n- Willing to undergo testing or procedures associated with the protocol\n- Has failed long term antibiotic treatment and abscess drainage if applicable\n\nClinical trial exclusion criteria:\n- Positive results for toxin-producing bacteria from liver biopsy\n- Good candidate for liver-curative open surgical resection\n- Not a candidate for RFA therapy due to lesion size or location\n- PT or PTT >1.5 times normal\n- Platelet count <50,000/mm(3)\n- Pregnancy\n- Any condition placing the patient at undue risk\n\nThe patient has a history of common variable immunodeficiency (CVID), not chronic granulomatous disease (CGD), which is a primary requirement for inclusion in the trial. Therefore, the patient does not meet one of the key inclusion criteria of having documented CGD. Additionally, there is no information about the patient refusing surgery or having failed long-term antibiotic treatment, which are other points of consideration in the inclusion criteria.\n\nBased on the information provided, the patient does not align with the specific disease and treatment history requirements for the clinical trial. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "540": {
        "output": "Based on the information provided, the patient in question has undergone exploratory laparotomy due to a ruptured liver abscess, which is different from an acutely inflamed gallbladder. The clinical trial is specifically interested in patients who have had a laparoscopic cholecystectomy for an acutely inflamed gallbladder. \n\nSince the patient did not have a laparoscopic cholecystectomy for an acutely inflamed gallbladder, but rather surgery for a ruptured liver abscess, they do not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "541": {
        "output": "Based on the patient note provided, the 48-year-old white male has a history of common variable immunodeficiency (CVID) and was diagnosed with a ruptured liver abscess, which was surgically drained. The inclusion criteria for the clinical trial are a radiologically and bacteriologically diagnosed pyogenic liver abscess.\n\nThe patient note confirms the presence of a liver abscess as it mentions a ruptured liver abscess found during exploratory laparotomy. However, the note does not specify whether the abscess is pyogenic, nor does it mention the results of any radiological or bacteriological tests that would confirm this diagnosis according to the trial's inclusion criteria.\n\nGiven the information provided, the patient has a liver abscess, which is relevant to the trial's focus. However, further investigation is required to determine whether the abscess is pyogenic and meets the trial's specific diagnostic criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "542": {
        "output": "Given the patient's note and the clinical trial inclusion criteria, we must determine if the patient is eligible for the trial. The patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess. The clinical trial is investigating the efficacy of combining Pasireotide with aspiration sclerotherapy to improve the volume reduction of hepatic cysts.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Age 18 - 70 years.\n2. Diagnosis of a dominant liver cyst with an indication for aspiration and sclerotherapy.\n3. Providing informed consent.\n\nThe patient note indicates a ruptured liver abscess rather than a simple or dominant liver cyst, which is the focus of the clinical trial. Therefore, based on the information provided, the patient does not meet the specific diagnosis required for the clinical trial, which is a dominant liver cyst needing aspiration and sclerotherapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "543": {
        "output": "The patient described in the note has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, tachycardia (heart rate of 132 bpm), hypotension (blood pressure 80/40), and positive Murphy sign, indicative of gallbladder inflammation. An abdominal ultrasound showed hepatomegaly and free intraperitoneal fluid. During exploratory laparotomy, a ruptured liver abscess was found and surgically drained, and the patient was then taken to the ICU.\n\nThe clinical trial in question is examining the significance of peritoneal washing cytology before and after neoadjuvant chemotherapy in patients with esophagogastric-junction (GEJ) cancer. The eligibility criteria for this trial are:\n\n- Patients with biopsy-verified GEJ-cancer referred to the department of surgical gastroenterology at Rigshospitalet, which is considered resectable at the multidisciplinary conference.\n- Patients must be over 18 years old.\n- Patients must provide informed consent.\n\nThe patient in the note does not have GEJ-cancer, nor is there any indication that they have been diagnosed with or treated for this type of cancer. Instead, the patient has been treated for a ruptured liver abscess. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which is specifically looking for patients with GEJ-cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "544": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, tachycardia, and hypotension\n- Physical examination: tenderness and positive Murphy sign\n- Abdominal ultrasound: hepatomegaly and free intraperitoneal fluid\n- Exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained\n- Post-surgery, the patient is in the ICU\n\nClinical trial:\n- Focused on gastric cancer patients\n- Requires T3 or T4 stage gastric cancer, any N staging, and M0 (no distant metastasis)\n- Open or laparoscopic gastrectomy with curative intent\n- Age limit of 21 to 80 years old\n- Ability to provide informed consent\n\nThe patient has a history of CVID and presented with a ruptured liver abscess, not gastric cancer. The trial is specific to patients with gastric cancer undergoing gastrectomy, and there is no information to suggest that the patient has gastric cancer or is undergoing gastrectomy. Therefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "545": {
        "output": "Based on the patient note provided, the 48-year-old white male patient has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, and signs consistent with a ruptured liver abscess, which was confirmed by exploratory laparotomy and subsequently drained. The patient was then taken to the ICU.\n\nThe clinical trial in question is focused on the management of hypersplenism in patients with liver cirrhosis and aims to compare the effectiveness of microwave thermal coagulation and partial splenic embolization.\n\nThe inclusion criteria for the clinical trial are:\n1. Liver Cirrhosis\n2. Hypersplenism\n\nFrom the patient note, there is no mention of liver cirrhosis or hypersplenism. The patient does have a liver-related condition (ruptured liver abscess), but this is not the same as liver cirrhosis, and there is no indication of splenomegaly or hypersplenism. Therefore, based on the information given, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "546": {
        "output": "",
        "label": 2
    },
    "547": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the eligibility as follows:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Surgical intervention for a ruptured liver abscess\n- No mention of breast cancer or oligometastatic disease\n\nClinical Trial:\n- Requires patients with histologically or cytologically confirmed breast cancer\n- Patients must have evidence of 1 to 5 metastases, suitable for SABR treatment\n- Requires a certain level of performance status and adequate organ function\n- Life expectancy > 12 months\n- Specific requirements for reproductive health and consent\n\nThe patient in the note does not have a diagnosis of breast cancer or any mention of metastatic disease. The trial specifically targets individuals with oligometastatic breast cancer and requires confirmation of this diagnosis. Therefore, the patient does not meet the trial's inclusion criteria based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "548": {
        "output": "Given the patient's condition and the clinical trial's specifics, the patient does not meet the inclusion criteria for the trial. The trial is focused on the use of Buckypaper for surgical procedures and treatment of solid cancers and hematopoietic system tumors, as well as abdominal wall hernias in humans. Furthermore, the inclusion criteria specifically mention an animal model using New Zealand female rabbits.\n\nThe patient in the provided note has a history of common variable immunodeficiency (CVID) and recently experienced a ruptured liver abscess, treated surgically. There is no mention of solid cancer, hematopoietic system tumors, or abdominal wall hernias, and certainly, the patient is not a New Zealand female rabbit.\n\nTherefore, it is clear that the patient does not fit the criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "549": {
        "output": "",
        "label": 0
    },
    "550": {
        "output": "Based on the provided patient note, the patient has a history of common variable immunodeficiency (CVID) and has been treated for a ruptured liver abscess. There is no mention of an intracranial aneurysm, which is a requirement for eligibility in the clinical trial for the Codman Enterprise\u00ae 2 Vascular Reconstruction Device.\n\nThe inclusion criteria for the clinical trial are:\n1. Subject \u2265 18 years old.\n2. Subjects with non-ruptured or ruptured intracranial aneurysm that is referred for endovascular treatment.\n3. Parent vessel with a diameter of \u2265 2.0 mm and \u2264 4 mm.\n4. Subject understands the nature of the procedure and provides voluntary written informed consent in accordance with the requirements of this study protocol.\n5. Subject is willing to participate in the telephone follow-ups and to return to the investigational site for the post-procedure follow-up evaluations.\n\nThe patient in the note does not meet the second key inclusion criterion as there is no indication of an intracranial aneurysm needing endovascular treatment. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "551": {
        "output": "After reviewing the patient note and the clinical trial details, here's the assessment:\n\nThe patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and signs of a ruptured liver abscess, which was surgically drained.\n\nThe clinical trial in question is studying the natural history of Noncirrhotic Portal Hypertension (NCPH). The inclusion criteria for this trial state that participants should be age 12 years or above and have a known diagnosis of NCPH or be at risk for NCPH due to underlying disease processes such as CVID. The patient in the note has CVID, which is specifically listed in the inclusion criteria as an underlying disease that puts him at risk for NCPH.\n\nWhile the patient has not been explicitly diagnosed with NCPH in the provided note, his condition of CVID makes him eligible to be considered at risk for NCPH, which is one of the criteria for inclusion in the study.\n\nNone of the exclusion criteria listed in the clinical trial seem to apply to this patient based on the information provided in the patient note. However, further investigation would be needed to confirm that none of the exclusion criteria apply, such as ensuring there are no other forms of liver disease that typically result in cirrhosis, no evidence of active chronic hepatitis B or C, and no evidence of hepatocellular carcinoma, among others.\n\nGiven the information available, the patient's CVID status places him at risk for NCPH, making him a potential candidate for the clinical trial upon further investigation to rule out any exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "552": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy,\" let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- He presented with acute abdominal pain, fever, dehydration, hepatomegaly, and a ruptured liver abscess.\n- He underwent exploratory laparotomy and surgical drainage.\n- He is currently in the ICU.\n\nClinical Trial Inclusion Criteria Analysis:\n- Aged > 18 years old (Patient is 48, meets this criterion)\n- Capable of providing informed consent (No information provided about the patient's ability to consent)\n- Histologically confirmed peritoneal carcinomatosis from specific origins, with no systemic metastases (The patient has a history of CVID and a ruptured liver abscess; there's no mention of peritoneal carcinomatosis or its origin)\n- Evidence of low-volume peritoneal disease (No information provided about peritoneal disease)\n- ECOG performance status of 0-2 (Patient is in the ICU, which suggests a performance status higher than 2)\n- Medically fit for surgery with specific requirements including no hepatic metastases, no biliary obstruction, no significant small bowel involvement, and no distant metastasis (Patient has a ruptured liver abscess, which could complicate surgical fitness)\n- Certain lab values and adequate hepatic and renal function (No lab values provided)\n- Satisfactory cardiopulmonary function (No information on cardiopulmonary function)\n- No significant history of a medical problem or co-morbidity that would preclude surgery (The patient has CVID, which may affect his eligibility)\n- No concurrent second malignancy or psychiatric/addictive disorders (No information provided on these aspects)\n\nGiven the provided information, the patient does not meet the inclusion criteria for the clinical trial. The trial is looking for patients with specific types of peritoneal carcinomatosis and the patient's current medical issues do not align with the trial's focus. Furthermore, the patient's current condition in the ICU suggests a performance status that would likely exclude him from the trial. There is no indication that the patient has peritoneal carcinomatosis or that he would be medically fit for the surgical procedure described in the trial, given his recent surgery and ICU stay.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "553": {
        "output": "Based on the patient note provided, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and complications including a ruptured liver abscess which required surgical intervention and ICU care.\n\nThe clinical trial in question is focused on the consequences of DNA Repair and Telomere Defects on the Function of the Immune System with a specific application to CVID and immune deficiencies with dysmorphic syndromes. Given that the patient has a documented history of CVID, he meets one of the key inclusion criteria for the trial, which is having a diagnosis of Common Variable Immunodeficiency (CVID).\n\nThe trial does not specify additional inclusion criteria such as age limits or specific stages of CVID. Therefore, based on the information provided, the patient appears to be a good candidate for the clinical trial because he has a diagnosis that is directly relevant to the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "554": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient note:\n- The patient is a 48-year-old white male, which meets the age criterion (\u226518 yrs old).\n- The patient has been diagnosed with a ruptured liver abscess, not a perianal abscess.\n- No information is provided about any perianal abscess or its characteristics.\n\nClinical trial:\n- The trial is focused on the treatment of perianal abscesses.\n- Inclusion criteria specify the patient must have a perianal abscess larger than 2 cm in diameter that has not spontaneously ruptured.\n- Patient must provide signed informed consent.\n\nSince the patient has a ruptured liver abscess, not a perianal abscess, he does not meet the specific condition criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "555": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Cyclophosphamide and Fludarabine to Treat Lupus Nephritis,\" we can determine the following:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient is post-major surgery with low urine output, generalized edema, and abnormal kidney function tests (blood urea nitrogen and serum creatinine levels).\n- The initial urinalysis shows RBC and granular casts, pointing towards renal involvement.\n\nClinical Trial Analysis:\n- This trial is designed for patients who are 18 years of age or older.\n- Patients must meet at least 4 criteria for Systemic Lupus Erythematosus (SLE) as defined by the American Rheumatism Association.\n- The trial is specifically for patients with active glomerulonephritis due to lupus nephritis with a renal biopsy within 1 year showing class III or class IV active lupus nephritis.\n- There are specific requirements for abnormal urine analysis and proteinuria levels, as well as exclusion criteria regarding previous treatments and other health conditions.\n\nThe patient in the note is a 6-month-old infant, which immediately disqualifies him from the clinical trial as the inclusion criteria specify that participants must be 18 years or older. Additionally, there is no mention of the patient having SLE, nor is there any indication that the patient meets the other specific criteria required for the study, such as having lupus nephritis.\n\nTherefore, based on the patient note and the clinical trial inclusion criteria, this patient would not be eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "556": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure\", let's evaluate the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery and is experiencing a reduced urine output of less than 0.2 mL/kg/hr.\n- The patient has generalized edema.\n- Blood pressure, pulse, and respirations are listed, with elevated blood pressure for an infant.\n- Laboratory results indicate a blood urea nitrogen of 33 mg/dL and a serum creatinine of 1.3 mg/dL.\n- Urinalysis shows specific gravity of 1.017 with some white and red blood cells, and granular casts present.\n- The patient's fractional excretion of sodium is 3.3%.\n\nClinical Trial Inclusion Criteria Analysis:\n- Group 3 criteria seem the most relevant to the patient, as they address acute renal failure (ARF) due to surgery or trauma.\n- Group 3 inclusion criteria specify:\n  - ARF severity index 20-60%\n  - Creatinine clearance 12-14 mL/min\n  - Rising creatinine of at least 0.5 mg/dL per day for 2 days without evidence of recovery despite standard supportive care\n  - No drug or contrast-induced renal failure\n  - Baseline creatinine greater than 2.5 mg/dL (males) or 2.0 mg/dL (females)\n\nEligibility Assessment:\n- The patient is an infant, which may not align with the typical demographic considered for this study (this is not explicitly stated in the inclusion criteria, but the baseline creatinine levels suggest adult participants).\n- The patient's current creatinine level is 1.3 mg/dL, which is below the specified baseline level for inclusion in the study.\n- The patient does not meet the creatinine clearance specified for Group 3, and there is no information on a rising creatinine level or ARF severity index.\n- It is unclear if the patient's condition is due to hypotension, surgery, or trauma as required by Group 3.\n- The patient does not appear to have chronic renal failure or other exclusions mentioned for Group 3.\n\nGiven the above analysis, the patient does not meet the specific inclusion criteria outlined for Group 3 participants, especially concerning age, baseline creatinine level, and creatinine clearance rate. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "557": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Study of Morphine in Postoperative Infants to Allow Normal Ventilation,\" let's compare the patient's characteristics and condition with the inclusion criteria provided:\n\nInclusion Criteria:\n1. Infants scheduled for surgery with postoperative inpatient care.\n2. Must be born after 35 weeks or more gestational age.\n3. No prenatal opiate exposure.\n4. Part I patients: Less than 12 months of age undergoing surgeries involving major thoracic, abdominal, or cardiac procedures.\n5. No pneumonectomy, tracheal or bronchial stenosis reconstruction, diaphragmatic hernia repair, or surgeries resulting in high intraabdominal pressure.\n6. No hepatic or renal transplantation.\n7. Age: Part I: Less than 12 months. Part II: Less than 3 months.\n8. Normal hepatic function tests.\n9. Normal renal function tests.\n10. No pulmonary disease causing baseline hypercarbia.\n11. No pulmonary hypertension contraindicating the use of 5% CO2 in rebreathing studies.\n12. No allergy to morphine.\n13. No severe developmental delay that precludes analgesia scoring.\n\nPatient Characteristics:\n- Age: 6-month-old male infant, which fits within the age range for Part I of the study.\n- Underwent major surgery, which aligns with the requirement for postoperative inpatient care.\n- Urine output of less than 0.2 mL/kg/hr shortly after surgery may suggest renal impairment.\n- Generalized edema.\n- Blood pressure is 115/80 mm Hg, pulse 141/min, respirations 18/min.\n- Blood urea nitrogen is 33 mg/dL, and serum creatinine is 1.3 mg/dL, which may indicate abnormal renal function.\n- Specific gravity of urine is 1.017, with some RBCs and granular casts present in urinalysis.\n\nBased on the patient note, while the patient's age and the fact that they underwent major surgery fit the inclusion criteria, the note indicates potential renal impairment as evidenced by low urine output, elevated blood urea nitrogen, and serum creatinine levels. The inclusion criteria specifically require normal renal function tests, which the patient does not seem to meet.\n\nGiven this mismatch, the patient's eligibility for the clinical trial in question is not supported. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "558": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility:\n\nPatient Note:\n- 6-month-old male infant\n- Post major surgery with low urine output\n- Generalized edema, elevated blood pressure, and high pulse\n- Blood urea nitrogen and serum creatinine levels elevated\n- Urinalysis shows specific gravity, WBCs, RBCs, and granular casts\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed IgA nephropathy, diagnosed within the past 3 years\n- Clinical presentation of either isolated hematuria/proteinuria for less than 3 years OR acute nephritic or nephrotic syndrome\n- No secondary forms of IgA nephropathy\n- No end stage renal failure\n- No systemic lupus erythematosus or systemic vasculitis\n- Healthy volunteers as control group\n- No concurrent medical or psychiatric illness that would preclude study\n\nThe patient note does not mention IgA nephropathy, which is a primary inclusion criterion for the clinical trial. The patient is a 6-month-old infant, whereas the inclusion criteria do not specify an age limit, but the diagnosis and clinical presentation specific to IgA nephropathy are critical for eligibility. Additionally, the patient has just undergone major surgery which could be considered a concurrent medical condition that may preclude study participation, although the trial does not specify post-surgical patients as an exclusion.\n\nGiven the information provided, the patient does not meet the key inclusion criterion of a confirmed diagnosis of IgA nephropathy. Therefore, this patient would not be eligible for the clinical trial based on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "559": {
        "output": "The patient is a 6-month-old male infant who has recently undergone major surgery. The clinical trial in question is studying the safety and efficacy of Triostat in infants with congenital heart disease during cardiopulmonary bypass surgery.\n\nTo determine trial-level eligibility, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n- Diagnosis of one of the following:\n  - Ventricular septal defect (VSD)\n  - Infant coarctation of the aorta\n  - Transposition of the great arteries\n  - Tetralogy of Fallot\n  - Complete atrioventricular canal defect\n  - Hypoplastic left heart, including patients who undergo a Norwood type procedure for aortic or mitral atresia\n- Patient must be scheduled for surgery.\n\nThe patient note does not mention any congenital heart disease or specify that the infant has any of the listed conditions that qualify for inclusion in the clinical trial. Additionally, the note does not indicate whether the infant is scheduled for heart surgery, which is a requirement for the trial.\n\nGiven the information provided, the patient does not meet the specified inclusion criteria, as there is no mention of a congenital heart defect or a scheduled surgery relevant to the study's focus.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "560": {
        "output": "Upon reviewing the patient's details and the inclusion criteria for the clinical trial titled \"Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery,\" we can determine the patient's eligibility as follows:\n\nThe inclusion criteria for the clinical trial are:\n1) Scheduled cardiac surgery with hypothermic CPB to repair certain congenital heart defects or to palliate certain heart conditions.\n2) Age 1-45 days at surgery.\n3) Birth weight > 2.3 kg.\n4) A cranial ultrasound < 1 week prior to enrollment showing at most grade II hemorrhage in high-risk patients.\n\nThe patient is a 6-month-old infant, which translates to approximately 180 days old. This is beyond the age range specified in the inclusion criteria, which is 1-45 days at surgery. Therefore, based solely on the age criterion, the patient does not meet the eligibility requirements for the clinical trial.\n\nFurthermore, the patient note does not mention any congenital heart defects or conditions that would qualify for the trial's specific cardiac surgical interventions. The patient's condition appears to be related to renal issues following major surgery, not cardiac issues that would require hypothermic cardiopulmonary bypass.\n\nTherefore, this patient would not be a candidate for the clinical trial based on both age and the condition not matching the specified inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "561": {
        "output": "Based on the information provided, the patient in question is a 6-month-old male infant, which does not meet the age requirement of the clinical trial. The clinical trial's inclusion criteria specify that participants must be children aged 8-12 years.\n\nTherefore, given that the patient's age does not fall within the specified range for the clinical trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "562": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient in question would not be eligible for this trial. The trial is focused on healthy infants aged 0 to 3 years, who are free of medication. The patient described is a 6-month-old male infant who has undergone major surgery, has generalized edema, and is showing signs of renal impairment, as indicated by low urine output, elevated blood urea nitrogen, and serum creatinine levels. This patient is not healthy and free of medication as required by the trial's inclusion criteria.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "563": {
        "output": "Assessing the patient note against the inclusion criteria for the clinical trial:\n\nPatient Note:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery.\n- The patient has oliguria (urine output of less than 0.2 mL/kg/hr).\n- The patient is not currently described as being on hemofiltration.\n- There is no mention of mechanical ventilation or written informed consent.\n\nClinical Trial Inclusion Criteria:\n- Cessation of hemofiltration.\n- Mechanical ventilation.\n- Written informed consent.\n\nBased on the patient note and the inclusion criteria provided for the clinical trial:\n\n- The infant is not currently described as being on hemofiltration, which is a requirement to meet the inclusion criteria.\n- There is no mention of the infant requiring mechanical ventilation.\n- It is not possible for an infant to provide written informed consent, and the note does not mention consent provided by a guardian or parent.\n\nGiven the information provided, the 6-month-old patient does not meet the explicit inclusion criteria for the clinical trial. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "564": {
        "output": "Given the patient note and the clinical trial information, we can evaluate the eligibility of the 6-month-old male infant for the clinical trial.\n\nPatient Note Details:\n- Age: 6-month-old male infant\n- Condition: Post-major surgery with low urine output, generalized edema, and changes in blood urea nitrogen and serum creatinine levels\n- Other Relevant Information: Blood pressure, pulse, respirations, urinalysis results\n\nClinical Trial Inclusion Criteria:\n- Age: Greater than 18 years of age\n- Referral for coronary angiography\n- Type 1 or type 2 diabetic requiring insulin or oral hypoglycemic agents\n- Specific serum creatinine concentration parameters for diabetics and non-diabetics\n- Stable renal function\n\nUpon comparing the patient's characteristics with the inclusion criteria of the clinical trial, it is clear that the patient does not meet the age criterion (greater than 18 years of age) as he is only a 6-month-old infant. Additionally, the trial is focused on patients referred for coronary angiography, which is not applicable to the infant. There is also no mention of diabetes, which is a requirement for the trial participants.\n\nTherefore, the 6-month-old patient does not fulfill the inclusion criteria for this clinical trial, and the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "565": {
        "output": "In assessing the eligibility of the 6-month-old male infant for the clinical trial involving Enteroaggregative E. coli (EAEC), we must compare the patient's characteristics to the inclusion criteria of the study.\n\nThe inclusion criteria for the EAEC study are as follows:\n1. Age between 18 and 40 years at the time of enrollment.\n2. Otherwise healthy individuals with a stable address and telephone.\n3. Ability to read and write English.\n4. Possession of a social security number.\n5. Negative serum pregnancy test for females and use of effective birth control.\n6. Seronegative for antibodies to dispersin.\n7. Normal laboratory screening values including WBC count, hemoglobin, hematocrit, platelets, BUN, glucose, creatinine, ALT, AST, quantitative immunoglobulins, T cell subsets (CD4 and CD8), urinalysis.\n8. Normal chest x-ray and electrocardiogram.\n9. Negative serologies for HIV, HBV, HCV, and a negative RPR.\n10. Negative stool examination for pathogenic ova and parasites, and bacterial enteropathogens (EAEC, Salmonella, Shigella, Campylobacter).\n11. Having the -251 AA IL-8 genotype.\n\nThe patient note describes a 6-month-old male infant, which immediately disqualifies him based on the age criterion alone, as the study requires participants to be at least 18 years of age. Moreover, the patient does not meet the criterion of being otherwise healthy, as he is currently experiencing medical issues (low urine output, generalized edema, abnormal blood urea nitrogen and serum creatinine levels) shortly after undergoing major surgery.\n\nGiven that the patient does not meet the age requirement and is not in a healthy state as required by the study, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "566": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the 6-month-old male infant does not meet the inclusion criteria for the trial on \"Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis.\" The inclusion criteria specify that the trial is for infants diagnosed with Gastroschisis, which is not a condition mentioned in the patient note. Instead, the patient note describes an infant with post-surgical complications related to urine output and kidney function, which is unrelated to Gastroschisis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "567": {
        "output": "The patient note presents a 6-month-old male infant who has undergone major surgery and is experiencing a low urine output, generalized edema, and abnormal laboratory findings including increased blood urea nitrogen and serum creatinine levels, alongside urinary findings indicative of renal impairment or injury.\n\nThe clinical trial in question is investigating the prophylactic use of Levosimendan versus Milrinone in open heart surgery in infants. The inclusion criteria for this trial are specifically:\n\n- Age younger than one year\n- Corrective open heart surgery with biventricular repair, except tetralogy of Fallot\n\nWhile the patient note does indicate that the infant is of the appropriate age for the clinical trial (younger than one year), there is no mention in the patient note of the infant having undergone open heart surgery or requiring biventricular repair. Without information confirming that the infant meets the surgical criteria for this clinical trial, it is not possible to determine eligibility based on the provided patient note.\n\nGiven the lack of information on the type of major surgery the infant underwent, we cannot assume it was open heart surgery with biventricular repair. Therefore, based on the available information, we cannot refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "568": {
        "output": "Considering the patient note and the inclusion criteria of the clinical trial for belatacept in liver transplant recipients, we can determine the following:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- He has undergone major surgery and now has low urine output, generalized edema, and abnormal values in blood urea nitrogen and serum creatinine.\n- The patient has not been described as a liver transplant recipient.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for first-time recipients of a deceased donor liver transplant.\n- Age range for participants is 18-70 years.\n- Participants must be Hepatitis C virus (HCV) positive recipients.\n- Certain exclusion criteria apply, including known intrinsic renal disease with a GFR < 40 ml/min/1.73 m^2 BSA.\n\nBased on the patient note, it is clear that the infant does not meet the age criteria for the clinical trial (the infant is 6 months old, while the trial requires participants to be aged between 18 and 70 years). Additionally, there is no mention of the infant being a liver transplant recipient or being HCV positive, both of which are required for participation in the trial.\n\nGiven these discrepancies between the patient's characteristics and the trial's inclusion criteria, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "569": {
        "output": "Given the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 6-month-old male infant\n- Underwent major surgery\n- Low urine output\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Pulse 141/min\n- Respirations 18/min\n- Blood urea nitrogen 33 mg/dL\n- Serum creatinine 1.3 mg/dL\n- Initial urinalysis shows specific gravity of 1.017, 1 WBC/HPF, 18 RBCs/HPF, and 5 granular casts/HPF\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial Inclusion Criteria:\n- Age over 18 years\n- Planned CABG or valvular surgery with cardiopulmonary bypass\n- Serum creatinine available (within 30 days)\n- Estimated GFR 15-90 ml/min using the abbreviated MDRD formula (CKD stages 2-4)\n\nThe patient in question is a 6-month-old infant, which does not meet the age criterion (over 18 years) of the clinical trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "570": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the following:\n\nThe patient is a 6-month-old male infant who has undergone major surgery and is experiencing a urine output of less than 0.2 mL/kg/hr, which indicates oliguria. The patient also presents with generalized edema, elevated blood pressure for an infant, tachycardia (pulse of 141/min), and abnormal laboratory findings indicative of renal impairment (blood urea nitrogen of 33 mg/dL and serum creatinine of 1.3 mg/dL).\n\nThe clinical trial in question is investigating the effect of fenoldopam and ketanserin on preventing acute kidney failure after cardiac surgery. The inclusion criteria for the clinical trial specify that participants must have undergone cardiac surgery and must exhibit at least one risk factor for acute renal failure, which includes oliguria < 0.5 ml/kg/hour for over 3 hours despite adequate blood volume and furosemide administration.\n\nThe patient note does not mention cardiac surgery specifically; it only mentions \"major surgery.\" Moreover, the patient note does not mention the administration of furosemide or the maintenance of diuresis at a rate greater than 1 ml/kg/hour.\n\nGiven the lack of specific information about the type of surgery the infant underwent and the absence of details regarding furosemide treatment, we cannot conclusively determine that the patient fits the inclusion criteria. However, the patient does exhibit a risk factor for acute renal failure (oliguria), which might make him a potential candidate for the trial if the surgery was indeed cardiac in nature and if other inclusion criteria are met upon further investigation.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "571": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Acute Kidney Injury in Neonates,\" we can evaluate the patient's eligibility.\n\nPatient Note Review:\n- The patient is a 6-month-old male infant, which fits the neonate category.\n- The patient has undergone major surgery and is experiencing a reduced urine output indicative of renal issues.\n- The patient has generalized edema, which can be associated with renal function impairment.\n- The laboratory results show elevated blood urea nitrogen and serum creatinine levels, as well as abnormal findings in the urinalysis, which may indicate acute kidney injury (AKI).\n\nClinical Trial Inclusion Criteria Review:\n- The trial is focused on infants in a neonatal intensive care unit.\n- The study aims to investigate acute kidney injury in neonates.\n- The inclusion criteria specify that families of infants with a birthweight over 1500g are to be asked to participate.\n\nThe patient appears to meet the trial's age range (neonate) and is experiencing renal issues, which is the focus of the study. However, the trial's inclusion criteria do not provide a detailed age range or specify the severity of renal dysfunction required for eligibility. The inclusion criteria also do not mention postoperative patients explicitly.\n\nGiven the information, the patient fits the general profile of the study population (neonates with potential acute kidney injury), but we lack some specifics such as birthweight and whether the study is looking at postoperative AKI cases exclusively or not. Therefore, further investigation would be required to determine the full eligibility of this patient for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "572": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant, which satisfies the age criterion (\u2265 18 years is not specified, so we can assume pediatric patients are eligible).\n- The patient is experiencing renal issues shortly after major surgery, with low urine output, generalized edema, high blood pressure, and abnormal blood and urine test results.\n- The patient's condition seems to be acute, given the context of recent surgery.\n\nClinical Trial Inclusion Criteria Analysis:\n- Proteinuria over 0.25 g/mmol of creatinine with hypoalbuminemia below 30g/L for the case: The patient note does not provide information on the proteinuria or albumin levels, so we cannot confirm if this criterion is met.\n- No history of renal disease: The patient note does not indicate a history of renal disease, but the current acute situation does not necessarily imply a history of chronic or idiopathic conditions.\n- Normal C3 and negativity for hepatitis B and C: The patient note does not provide information on C3 levels or hepatitis status.\n\nGiven that the patient note lacks information on proteinuria, albumin levels, C3, and hepatitis B and C status, we cannot definitively determine the patient's eligibility for the trial based on the information provided. Moreover, the trial seems to be focused on idiopathic nephrotic syndrome, which may not apply to the post-surgical acute condition of the patient.\n\nTherefore, the assessment of eligibility leans towards not referring this patient to the trial due to the lack of information and the acute context of the patient's condition, which does not clearly align with the idiopathic nature of the condition being studied in the trial. However, if additional information becomes available that aligns with the inclusion criteria, the assessment may change.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "573": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery.\n- The patient is experiencing a low urine output, generalized edema, and abnormal blood and urine test results.\n\nClinical trial inclusion criteria:\n- Infants aged 6 to 36 months.\n- Admitted to the Intensive Care-Sophia after craniofacial surgery.\n\nBased on the information provided, the patient is a 6-month-old infant, which fits the age range specified in the clinical trial's inclusion criteria. However, the trial specifically requires infants admitted to the Intensive Care-Sophia after craniofacial surgery. The patient note does not mention craniofacial surgery; instead, it refers to major surgery, with postoperative complications suggestive of renal issues.\n\nSince we do not have evidence that the patient underwent craniofacial surgery, we cannot definitively conclude that this patient meets the inclusion criteria based solely on the age match. Therefore, further investigation would be needed to determine if the patient's surgery was craniofacial and if they are admitted to the Intensive Care-Sophia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "574": {
        "output": "The patient in the note is a 6-month-old male infant with complications following major surgery, characterized by low urine output, generalized edema, and abnormal lab findings. The clinical trial in question is studying the absorption and excretion of zinc and copper in infants with ostomies, particularly focusing on those with ileostomies who are undergoing various nutritional support stages, including total parenteral nutrition (TPN) and enteral nutrition.\n\nThe inclusion criteria for the clinical trial are:\n1. Presence of ileostomy due to any disease or condition.\n2. Minimum birth weight of 500g.\n3. Likely to survive.\n\nThe patient note, however, does not mention the presence of an ileostomy or any related conditions such as necrotizing enterocolitis, intestinal atresias, gastroschisis, or intestinal perforations. Instead, the note focuses on the patient's postoperative state, with no information provided that would directly relate to the trial's focus on zinc and copper metabolism in the context of an ileostomy.\n\nGiven the available information, we cannot establish that this patient meets the inclusion criteria of the clinical trial. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "575": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant who has experienced a decrease in urine output following major surgery, along with other symptoms including generalized edema, elevated blood pressure, and changes in blood urea nitrogen and serum creatinine. The clinical trial in question is investigating the relationship of gestational age and urine concentration of S100B in preterm and term infants during the first week of life.\n\nThe inclusion criteria for the clinical trial specify that infants born at >28 weeks gestation are eligible for enrollment. However, the patient note does not provide any information about the gestational age at birth of the 6-month-old infant in question. Additionally, the study is focused on infants in their first week of life, which does not apply to the patient in the note who is already 6 months old.\n\nGiven this information, the 6-month-old patient does not meet the inclusion criteria based on the age requirement specified by the clinical trial, as the patient is well beyond the first week of life. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "576": {
        "output": "",
        "label": 0
    },
    "577": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, it appears that the patient is a 6-month-old male infant who has undergone major surgery and is now showing signs that could be indicative of acute kidney injury (AKI). The clinical trial is examining new diagnostic tests for AKI after heart surgery.\n\nThe inclusion criteria for children in the clinical trial state that the child must be undergoing open heart surgery. The patient note does not specify that the infant had open heart surgery; it only mentions \"major surgery.\" Without this specific information, it is not clear whether the child meets the inclusion criteria for the trial. Furthermore, the exclusion criteria for children mention pre-existing acute kidney failure (greater than 50% decline in creatinine clearance), but the patient note does not provide enough information to determine the percentage decline in creatinine clearance for this patient.\n\nGiven the information provided, and the lack of specifics regarding the type of surgery the infant underwent, I would consider further investigation to determine if the major surgery was in fact open heart surgery and to clarify whether the infant's current kidney condition meets the definition of pre-existing acute kidney failure as per the trial's exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "578": {
        "output": "",
        "label": 0
    },
    "579": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question is not eligible for referral to the clinical trial. The clinical trial is looking for healthy adult subjects between the ages of 18 and 45, while the patient is a 6-month-old male infant. Additionally, the trial requires subjects to be of normal health, and the infant is currently experiencing health issues following major surgery, as indicated by low urine output, generalized edema, and abnormal lab results.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "580": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 6-month-old male infant\n- Post-major surgery\n- Acute kidney injury indicators (low urine output, edema, elevated blood urea nitrogen, elevated serum creatinine)\n- No mention of heart surgery or cardiopulmonary bypass\n\nClinical trial:\n- Investigating the influence of remote ischemic preconditioning on acute kidney injury after cardiac surgery\n- Inclusion criteria specify patient undergoing heart surgery on cardiopulmonary bypass\n\nGiven that the patient is a 6-month-old infant who has undergone major surgery and there's no mention of the surgery being related to the heart or involving cardiopulmonary bypass, the patient does not meet the inclusion criteria specified for the clinical trial. The trial is specifically looking for patients who are undergoing heart surgery on cardiopulmonary bypass, which does not seem to apply to the infant described in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "581": {
        "output": "In this scenario, the patient is a 6-month-old male infant who recently underwent major surgery and is now presenting with a low urine output, generalized edema, and abnormal blood and urine test results. The clinical trial in question is studying the efficacy and safety of eltrombopag in pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).\n\nBased on the inclusion criteria provided for the clinical trial, the patient must meet several requirements to be eligible:\n\n1. Subjects between 1 year and <18 years of age at Day 1.\n2. Confirmed diagnosis of chronic ITP.\n3. Subjects who are refractory or have relapsed after at least one prior ITP therapy or are not eligible, for a medical reason, for other treatments.\n4. Day 1 (or within 48 hours prior) platelet count <30 Gi/L.\n5. Additional criteria related to previous treatments, stable doses of concomitant ITP medication, blood test results within a certain range, and specific criteria for kidney and liver function tests.\n\nThe patient note does not mention chronic ITP, instead it describes a post-surgical condition with complications related to kidney function, specifically mentioning findings of edema and abnormal blood and urine tests. There is no mention of thrombocytopenia or any previous treatment for ITP.\n\nGiven that the patient does not have a diagnosis of chronic ITP, and the fact that the patient is under 1 year of age, he does not meet the key inclusion criteria for the clinical trial. Therefore, this patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "582": {
        "output": "The patient described in the patient note is a 6-month-old male infant. According to the inclusion criteria stated for the clinical trial titled \"Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass,\" the participants must:\n\n- Be neonates aged \u2264 1 month\n- Be scheduled to undergo cardiac surgery involving Cardiopulmonary Bypass (CPB) (reparative or palliative procedures)\n- Have an inpatient status at MUSC a minimum of 8 hours prior to planned surgery\n\nThe patient in question does not meet the age criterion as he is 6 months old, and the trial specifically requires neonates who are 1 month old or younger. There is no information provided about whether the patient is scheduled to undergo cardiac surgery involving CPB or his inpatient status. However, the age criterion alone is sufficient to determine that this patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "583": {
        "output": "Considering the provided inclusion criteria for the clinical trial and the patient's information:\n\nInclusion Criteria Analysis:\n- The patient must be \u2265 18 years of age. The patient in the note is a 6-month-old infant, which does not meet this criterion.\n- The patient must be in general good health without a history of any of the conditions listed in exclusion criteria (not provided, but the infant has just undergone major surgery, indicating they are not in general good health).\n- Screening laboratory values must meet certain criteria. The patient's serum creatinine is 1.3 mg/dL, which is likely above the upper limit of normal (ULN) for an infant, and also does not meet the requirement of <1.1 x ULN for the study.\n- The study is designed for healthy adult volunteers, and this patient is a 6-month-old infant with health issues secondary to major surgery.\n\nGiven this information, the patient does not meet the age requirement, is not in general good health, and has laboratory values that do not meet the specified criteria for the clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "584": {
        "output": "In this scenario, we are given a patient note for a 6-month-old male infant and a clinical trial that is focused on preterm very low birth weight infants with shock.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Preterm infants born between 28 to 34 weeks gestation.\n- Very low birth weight infants with a birth weight of 750 to 1500 grams.\n- Infants who exhibit shock in the first week of life requiring vasopressor therapy or stable preterm infants matched for gestational age, birth weight, and postnatal age.\n\nThe patient note describes a 6-month-old male infant with a low urine output post-surgery, generalized edema, abnormal blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, and urinalysis findings. The infant does not fit the gestational age or birth weight criteria mentioned in the trial inclusion criteria. Furthermore, the patient's condition does not seem to be related to the trial's focus on relative adrenal insufficiency in the context of shock in the first week of life.\n\nGiven the information provided, this patient would not meet the inclusion criteria for the clinical trial because:\n- The patient is not within the 28 to 34 week gestation range.\n- The patient's current age is 6 months, which is beyond the first week of life.\n- The birth weight of the patient is not specified, but given the age, it is unlikely that the current weight would fall within the very low birth weight category.\n- There is no mention of shock requiring vasopressor therapy in the first week of life in the patient's history.\n\nTherefore, the assessment for this patient's eligibility for the clinical trial in question is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "585": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient is a 6-month-old male infant, which means he is beyond the neonatal period and does not fit the inclusion criteria of the clinical trial that specifically targets premature infants with a gestational age of less than 32 weeks. The trial aims to define normal citrulline levels as a diagnostic tool for gastrointestinal disease in the premature population. Since the patient is not a premature infant and does not fall within the specified gestational age range for the trial, he would not qualify for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "586": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the eligibility of the patient as follows:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery.\n- No mention of minimal change nephritic syndrome or a kidney biopsy.\n- Urine output, blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, and urinalysis results are provided.\n- Fractional excretion of sodium is 3.3%.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age from 18 years to 80 years.\n- Minimal change disease diagnosed by kidney biopsy.\n- Urine protein/creatinine ratio over 3.0.\n- Serum albumin below 3.0g/dL.\n- Consent form signed by the patient.\n\nComparing the two:\n- The patient is a 6-month-old male infant, which does not meet the age criterion of the clinical trial (18 to 80 years).\n- There is no mention of minimal change nephritic syndrome or evidence of a kidney biopsy.\n- The specific levels of urine protein/creatinine ratio and serum albumin are not provided in the patient note.\n- An infant cannot sign a consent form; a parent or guardian would have to provide consent.\n\nBased on the above, the patient does not meet the inclusion criteria for the clinical trial due to age, lack of diagnosis of minimal change disease, and no provided urine protein/creatinine ratio or serum albumin levels. The patient also cannot sign the consent form due to being an infant.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "587": {
        "output": "Considering the patient note and the clinical trial's inclusion criteria, the 6-month-old male infant does not meet the age criteria, as the trial requires participants to be 18 years or older. Since the patient is significantly younger, they are not eligible to participate in this clinical trial.\n\nTherefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "588": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery.\n- The patient has a urine output of less than 0.2 mL/kg/hr.\n- The patient has generalized edema, increased blood pressure, and altered renal function tests.\n- The patient does not have a diagnosis of cirrhosis or ascites mentioned.\n- The patient's serum creatinine is 1.3 mg/dL which is below the inclusion criterion of the trial.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent by subject or legally authorized representative.\n- At least 18 years of age.\n- Cirrhosis and ascites.\n- Rapidly progressive reduction in renal function characterized by a serum creatinine (SCr) \u2265 2.5 mg/dL and a doubling of SCr within 2 weeks.\n- No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion with albumin.\n\nThe patient does not meet the following inclusion criteria:\n- Age: The patient is 6 months old, whereas the study requires participants to be at least 18 years of age.\n- Diagnosis: The study is for patients with cirrhosis and ascites, which is not mentioned in the patient's note.\n- Serum creatinine: The patient's serum creatinine is 1.3 mg/dL, which does not meet the study's requirement of \u2265 2.5 mg/dL.\n\nGiven these discrepancies, the patient would not be eligible for the clinical trial aimed at evaluating the treatment of type 1 hepatorenal syndrome in participants with cirrhosis and ascites.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "589": {
        "output": "",
        "label": 0
    },
    "590": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 6-month-old male infant\n- Underwent major surgery\n- Postoperative findings suggesting acute kidney injury (AKI): low urine output, edema, elevated blood urea nitrogen and serum creatinine, abnormal urinalysis\n\nClinical Trial:\n- Title: NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants\n- Focus: Observational study on urinary NGAL as an early marker of AKI post-cardiac surgery\n- Inclusion Criteria: Term neonates and infants undergoing heart surgery with cardiopulmonary bypass, parental consent\n- Exclusion Criteria: Preoperative documented kidney injury, lack of parental consent\n\nThe patient is a 6-month-old infant, which aligns with the age group of the trial (neonates and infants). The patient has undergone major surgery, and the clinical trial specifically is looking at patients undergoing cardiac surgery with cardiopulmonary bypass. However, the patient note does not specify that the recent surgery was cardiac or involved cardiopulmonary bypass. Without this specific information, we cannot definitively say the patient meets all the inclusion criteria.\n\nThe trial aims to observe the postoperative kinetics of urinary NGAL in neonates and identify thresholds for predicting severe AKI requiring renal replacement therapy. The patient's condition suggests the possibility of AKI, which is relevant to the study's aim. However, the patient would only be eligible if the major surgery they underwent was indeed cardiac surgery with cardiopulmonary bypass.\n\nThe patient note does not mention any preoperative kidney injury, which is part of the exclusion criteria. It also does not mention whether the parents have been informed as required for inclusion.\n\nGiven the information provided, the patient might be eligible for the trial if the surgery was cardiac with cardiopulmonary bypass and parental consent can be obtained. However, since these details are missing, further investigation is required to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "591": {
        "output": "",
        "label": 0
    },
    "592": {
        "output": "Upon reviewing the patient note and comparing it with the inclusion and exclusion criteria of the clinical trial titled \"High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infants,\" the following observations are made:\n\nPatient note observations:\n- The patient is a 6-month-old male infant.\n- The patient has a urine output of less than 0.2 mL/kg/hr.\n- The patient's serum creatinine is 1.3 mg/dL.\n\nClinical trial inclusion criteria:\n- Gestational age <29 weeks.\n- Echocardiographic evidence of significant PDA.\n- Age of 12 to 24 hours.\n- RDS necessitating respiratory support.\n\nClinical trial exclusion criteria:\n- Major congenital anomalies.\n- Life-threatening infection or hydrops fetalis.\n- Pulmonary hypertension.\n- Death before the conclusion of the first course of ibuprofen.\n- Urine output below 1 ml per kilogram of body weight per hour during the preceding 12 hours (with the exception of the first dose).\n- A serum creatinine concentration of >1.5 mg/dL.\n- A platelet count of <50,000/mm3.\n- A tendency to bleed, as revealed by various clinical signs.\n\nBased on the patient note, the patient's age (6-month-old) does not meet the inclusion criteria, which specify an age of 12 to 24 hours. Additionally, the urine output of less than 0.2 mL/kg/hr is lower than the exclusion criteria threshold of 1 ml per kilogram of body weight per hour. Moreover, there is no information provided in the patient note about echocardiographic evidence of significant PDA or RDS necessitating respiratory support.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for the clinical trial, and it is not possible to determine if the patient would meet any of the exclusion criteria because some of the necessary information, such as platelet count and presence of major congenital anomalies, is not provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "593": {
        "output": "Based on the information provided, the patient is a 6-month-old male infant who recently underwent major surgery. The clinical trial is investigating the effects of Remote Ischemic Preconditioning (RIPC) on post-operative acute kidney, myocardial, and lung injury in patients undergoing cardiac surgery with planned cardiopulmonary bypass.\n\nThe inclusion criteria for the trial are:\n1. Age birth to 18 years\n2. Cardiac surgery with planned cardiopulmonary bypass\n\nThe patient note indicates that the infant is within the age range specified by the inclusion criteria (birth to 18 years). However, there is no mention of the infant undergoing cardiac surgery or having planned cardiopulmonary bypass. Therefore, we do not have sufficient information to determine if the infant meets all the inclusion criteria for the clinical trial.\n\nGiven the information provided, we cannot ascertain whether the infant has undergone cardiac surgery with planned cardiopulmonary bypass. Thus, at this point, further investigation is needed to determine if the infant meets the second inclusion criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "594": {
        "output": "Assessing eligibility based on the patient note and the clinical trial inclusion criteria:\n\nPatient note:\n- 6-month-old male infant\n- Post major surgery\n- Specific clinical findings (urine output, edema, blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, urinalysis results)\n\nClinical trial:\n- Title: Ketorolac in Postoperative Infants: Pharmacokinetics and Safety\n- Target population: Non-prematurely-born infants admitted to hospital following surgery ages 2-18 months, studied by age group 12-18 months, 6-12 months, < 6 months\n\nThe patient is a 6-month-old male infant which fits the age group for the clinical trial (6-12 months). The patient is also postoperative, a requirement for the trial. There is no indication that the patient was born prematurely, hence we would assume he meets this criterion as well.\n\nThe clinical trial is designed to analyze the pharmacokinetics and safety of ketorolac in infants, with a particular focus on kidney and liver function. The patient note indicates a concern for renal function (low urine output, elevated blood urea nitrogen and serum creatinine), which would be a particular point of interest for the safety aspect of the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "595": {
        "output": "",
        "label": 0
    },
    "596": {
        "output": "",
        "label": 1
    },
    "597": {
        "output": "",
        "label": 0
    },
    "598": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be a candidate for the clinical trial titled \"Plasma and Hemodynamic Markers During Hepatectomy.\" The inclusion criteria for the trial specify that the patient must have a neoplastic liver tumor and be undergoing elective hepatectomy. The patient note describes an infant who has developed renal issues post-major surgery, not specified as hepatectomy, nor is it mentioned that the patient has a neoplastic liver tumor.\n\nThe patient in question is a 6-month-old male infant with postoperative complications potentially related to acute kidney injury, as indicated by oliguria, increased blood urea nitrogen, and serum creatinine levels. The trial is assessing the impact of portal venous pressure on the kidney following liver resection and the effect of circulating growth factors on liver regeneration post-hepatectomy in patients with neoplastic liver tumors.\n\nSince the patient does not meet the critical inclusion criteria of having a neoplastic liver tumor and undergoing elective hepatectomy, they are not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "599": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant who has undergone major surgery and is experiencing issues with urine output and has generalized edema, among other symptoms.\n\nThe clinical trial in question is focused on the effects of sodium supplementation in very low birth weight infants, specifically those born at less than 32 weeks postmenstrual age.\n\nThe only inclusion criterion provided for this clinical trial is:\n\n- infants born at less than 32 weeks postmenstrual age\n\nThe patient's age (6 months old) is not directly relevant to the inclusion criterion, which is based on gestational age at birth rather than current age. There is no information provided in the patient note regarding the infant's gestational age at birth. Without this information, we cannot determine if the patient meets the inclusion criterion based on gestational age.\n\nGiven the lack of information on the birth gestational age of the patient, I cannot confirm eligibility. Further investigation would be needed to determine if the patient was born at less than 32 weeks postmenstrual age. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "600": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet several key eligibility requirements for the study:\n\n1. Age: The trial requires participants to be over 18 years of age, and the patient is a 6-month-old male infant.\n2. Health status: The trial is designed for healthy human subjects, and the patient has just undergone major surgery, indicating that he is currently not in a state of general health.\n3. Serum creatinine levels: The inclusion criteria specify normal clinical laboratory profiles with no clinically significant values. The patient's serum creatinine is elevated at 1.3 mg/dL, which may be considered clinically significant, especially for an infant.\n4. Urinalysis: The patient's urinalysis shows abnormalities (18 RBCs per HPF, and 5 granular casts per HPF), whereas the trial requires normal urinalysis with no clinically significant values.\n\nGiven the mismatch between the patient's profile and the trial's inclusion criteria, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "601": {
        "output": "Based on the information provided, the patient in question is a 6-month-old male infant who has undergone major surgery and is experiencing renal function issues. The clinical trial, however, is looking for adult deceased brain dead kidney donors and recipients scheduled for renal transplantation.\n\nThe patient does not meet the inclusion criteria for the clinical trial due to his age (infant vs. adult criteria) and the fact that he is not a deceased brain dead kidney donor or recipient. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "602": {
        "output": "Based on the provided patient note and the clinical trial information, the inclusion criteria for the clinical trial are:\n\n- Patients undergoing cardiac surgery (OPS 5-35 bis 5-37) between 2007 and 2011\n- Followed by postoperative observation on an ICU of the anaesthesiology department of the Charit\u00e9 hospital\n\nThe patient note describes a 6-month-old male infant who has recently undergone major surgery, not specifically cardiac surgery. Additionally, there is no mention of the surgery taking place between 2007 and 2011, nor is there any indication that the postoperative observation is taking place in the anaesthesiology department of the Charit\u00e9 hospital.\n\nGiven these mismatches between the patient's situation and the clinical trial's inclusion criteria, the patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "603": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the inclusion criteria for the study.\n\nThe inclusion criteria for the clinical trial specify that participants must be:\n1. Aged 18-65 years old.\n2. Comply with percutaneous nephrolithotomy lithotripsy indications for surgery (Group A/B) or have normal renal function and not associated with urinary calculi, or be cancer patients meeting radical nephrectomy indications for surgery, or be emergency trauma patients suffering from kidney resection surgical indications (Group C).\n\nThe patient in the provided note is a 6-month-old male infant, which does not meet the age requirement of 18-65 years old. Additionally, the patient's clinical presentation does not match any of the other criteria listed for the groups A, B, or C in the inclusion criteria.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "604": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant with a post-operative condition that includes reduced urine output, generalized edema, and laboratory findings suggestive of kidney injury (elevated blood urea nitrogen and serum creatinine levels, and the presence of granular casts in the urine).\n\nThe clinical trial in question is focused on the incidence and spectrum of acute kidney injury (AKI) in individuals with cirrhosis. The inclusion criteria specify two groups:\n\n- Group A: Patients with cirrhosis and normal baseline renal function\n- Group B: Patients who present with AKI\n\nHowever, the patient in the note does not have a diagnosis of cirrhosis; the condition described is acute kidney injury likely resulting from major surgery. Since cirrhosis is not mentioned as an underlying condition for the infant, the patient does not meet the specified inclusion criteria for the clinical trial.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "605": {
        "output": "",
        "label": 0
    },
    "606": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, it seems that the patient, a 6-month-old male infant, does not meet the specific inclusion criteria stated for the clinical trial. The clinical trial is focused on patients who underwent surgery for congenital heart disease, and there is no information in the patient note indicating that the infant's surgery was for congenital heart disease.\n\nTherefore, without additional information that connects the patient's surgery to a congenital heart disease, it would not be appropriate to refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "607": {
        "output": "Given the patient note and the clinical trial information provided, the patient in question is a 6-month-old male infant who has had major surgery and is now exhibiting signs that could be consistent with acute kidney injury (low urine output, edema, elevated blood urea nitrogen, and serum creatinine).\n\nThe clinical trial is focused on predicting acute kidney injury after coronary artery bypass graft surgery. However, the inclusion criteria for the trial are very specific: patients must have undergone coronary artery bypass surgery at the Samsung Medical Center between 2010 and 2012.\n\nThe patient in the note does not fit the inclusion criteria for several reasons:\n- The patient is a 6-month-old infant, and coronary artery bypass surgery is not a procedure typically performed on infants.\n- There is no mention of the patient having undergone coronary artery bypass surgery, only \"major surgery.\"\n- The timeframe during which the patient must have had surgery (between 2010 and 2012) does not align with the age of the patient (6 months old at the time of the note).\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "608": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 6-month-old male infant\n- Post-major surgery\n- Low urine output, generalized edema, high blood pressure for an infant, tachycardia, elevated blood urea nitrogen, and serum creatinine levels\n- Urinalysis with specific gravity, WBCs, RBCs, and granular casts\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial:\n- Evaluating the effect of tidal volume on clinical outcome in pediatric patients after congenital heart surgery\n- Inclusion Criteria: Pediatric patients who underwent surgery for congenital heart disease with cardiopulmonary bypass between 2009 and 2013 at Samsung Medical Center\n\nAssessment of Eligibility:\n- The patient is a 6-month-old infant, which fits the pediatric category.\n- The patient has undergone major surgery; however, there is no mention of congenital heart disease or use of cardiopulmonary bypass, which are specific requirements for the trial.\n- The surgery and patient care occurred after 2013, given the real-time knowledge cutoff.\n- The trial is specific to a time period and location (Samsung Medical Center), which is not mentioned in the patient note.\n\nConsidering the information provided, the patient does not meet the specified inclusion criteria for the clinical trial, as there is no evidence that the patient underwent surgery for congenital heart disease with cardiopulmonary bypass, nor is there evidence that the surgery took place between 2009 and 2013 at Samsung Medical Center. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "609": {
        "output": "",
        "label": 0
    },
    "610": {
        "output": "The patient in the provided note is a 6-month-old male infant, which immediately disqualifies him from the clinical trial mentioned, as the inclusion criteria specify that the patient must be 18 years of age or older. Additionally, there is no mention of a burn injury in the patient note, which is another requirement for the trial as the inclusion criteria state that the burn injury must be between 20% and 80% of total body surface area (TBSA).\n\nGiven these two critical discrepancies between the patient's characteristics and the trial's inclusion criteria, it is clear that this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "611": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the clinical trial.\n\nPatient note review:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery and is experiencing low urine output, generalized edema, and elevated blood urea nitrogen and serum creatinine levels.\n- The patient's urinalysis shows 18 RBCs per high-power field, which indicates the presence of blood in the urine (microscopic hematuria).\n\nClinical trial inclusion criteria review:\n- The trial is focused on post-menopausal women.\n- The participants must have asymptomatic microscopic hematuria.\n\nThe patient in the note is a 6-month-old male infant, which does not meet the age or gender criteria for the clinical trial, which is specifically looking for post-menopausal women. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "612": {
        "output": "",
        "label": 0
    },
    "613": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility step by step:\n\n1. Age: The patient is a 6-month-old male infant, which means he is less than 3 months postnatal age. This meets the first criterion of the clinical trial, which requires the patient to be a neonate less than 3 months postnatal age.\n\n2. Diagnosis: The patient note indicates that the infant has a urine output of less than 0.2 mL/kg/hr after surgery, generalized edema, elevated blood urea nitrogen, and elevated serum creatinine. These findings are consistent with acute kidney injury (AKI), which fits the second criterion of needing a diagnosis of AKI.\n\n3. Treatment: According to the trial criteria, the patient needs to be receiving aminophylline for AKI treatment as per local standard of care. The patient note does not specify if the infant is currently receiving aminophylline for AKI treatment.\n\nGiven the information available, the patient meets the age and diagnosis criteria but lacks specific information about the current treatment with aminophylline. To determine final eligibility, further investigation is required to confirm whether the infant is receiving aminophylline as part of the standard of care for AKI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "614": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics and condition:\n- 6-month-old male infant\n- Urine output of less than 0.2 mL/kg/hr post-surgery\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Blood urea nitrogen is 33 mg/dL\n- Serum creatinine is 1.3 mg/dL\n- Initial urinalysis shows specific gravity of 1.017, 1 WBC per HPF, 18 RBCs per HPF, 5 granular casts per HPF\n- Fractional excretion of sodium is 3.3%\n\nClinical trial inclusion criteria:\n- Proteinuria > 1000 mg/24h despite ACEi/ARB therapy and blood pressure control for > 3 months\n- Creatinine clearance > 30 ml/min/1.73m2\n- Blood pressure < 130/80 mmHg at > 75% of readings\n- Biopsy-proven IgA nephropathy with clinical features of HSP\n- Ability to receive injections\n- Kidney biopsy slide on file\n\nThe patient's characteristics do not align with the inclusion criteria. The patient is a 6-month-old infant and there is no mention of IgA nephropathy or proteinuria levels. Additionally, the trial seems to be targeting adults due to the mention of blood pressure requirements and previous treatments that are not typically applicable to infants.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, so:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "615": {
        "output": "The patient is a 6-month-old male infant who has recently undergone major surgery and is now presenting with symptoms consistent with acute kidney injury (AKI), such as low urine output, generalized edema, elevated blood urea nitrogen, and elevated serum creatinine. The clinical trial in question is focused on following up with neonates who experienced AKI during their stay in the NICU to learn more about the early signs of chronic kidney diseases in children who were born prematurely with low birth weight.\n\nThe inclusion criteria for the trial are:\n- Premature birth for Premature groups\n- UVA NICU admission prior to 2 days of life\n- Birth weight less than 1500 grams for premature groups\n- Premature AKI Study group: Acute Kidney Injury as defined by KDIGO modified criteria during NICU stay at UVA\n- Premature no AKI Control group: No AKI during NICU stay\n- Term no AKI Control group: No AKI and born at term\n- Parental or legal guardian consent obtained\n\nThe patient note does not specify that the infant was born prematurely or that he was admitted to the UVA NICU, nor does it provide information about the infant's birth weight or whether he meets the KDIGO criteria for AKI during his NICU stay. Without this information, we cannot definitively determine the infant's eligibility for the trial.\n\nGiven the lack of information on the patient's birth history, birth weight, and NICU stay at UVA, we cannot confidently refer this patient for the clinical trial based on the information provided. Additional information would be needed to determine if the patient meets the specific inclusion criteria related to prematurity, birth weight, and NICU admission. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "616": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant experiencing renal issues post-surgery, as indicated by low urine output, edema, and abnormalities in urinalysis. \n\nConsidering the inclusion criteria of the clinical trial, which are as follows:\n\n- Were in the age range of 18-45 years.\n- Were neither overweight nor underweight for their height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.\n- Had voluntarily given written informed consent to participate in this study.\n- Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.\n- Had a non-vegetarian diet habit.\n\nThe patient does not meet the age criteria since he is a 6-month-old infant, and the trial specifically requires subjects to be aged between 18-45 years. Additionally, the trial is looking for healthy adult male human subjects, while the patient in question is currently experiencing health issues related to renal function. Therefore, the patient is not eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "617": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 6 months old\n- Condition: Low urine output post-major surgery, not specified as a kidney transplant recipient\n- Other: Currently experiencing generalized edema, abnormal blood urea nitrogen and creatinine levels indicating renal dysfunction\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Patient with End-Stage Renal Disease (ESRD) on Renal Replacement Therapy (RRT)\n- Recipient of deceased donor kidney transplant\n- Urine output less than 0.5 mL/kg/h before transplant\n- Patient consents to the study\n- Patient is not allergic to furosemide or sulfa\n- English or Spanish speaking patient\n- Patient is oliguric or anuric in the first 6 hours post kidney transplant\n\nAssessment of Eligibility:\n- The patient is a 6-month-old infant, which does not meet the age requirement of \u2265 18 years.\n- There is no information suggesting that the patient has undergone a kidney transplant or has ESRD. The surgery mentioned is not specified as a kidney transplant.\n- The patient has low urine output, but this is post-major surgery, and there is no indication this was a kidney transplant.\n- No information is provided about the patient's ability to consent, language abilities, or allergies to furosemide or sulfa.\n\nGiven the patient's age and lack of information suggesting that they are a kidney transplant recipient with ESRD, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "618": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the clinical trial.\n\nThe patient is a 6-month-old male infant presenting with low urine output, generalized edema, and abnormal laboratory findings consistent with acute kidney injury post major surgery. This clinical presentation is not related to the focus of the clinical trial.\n\nThe clinical trial is specifically looking for patients undergoing flexible cystoscopy due to hematuria or a previous diagnosis of non-muscle invasive bladder cancer (NMIBC). The patient's age and clinical situation (post-operative pediatric patient with acute kidney injury) do not match the inclusion criteria, which are clearly targeted at an adult population with hematuria or a history of NMIBC.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "619": {
        "output": "Based on the provided patient note and the clinical trial information, we can determine the patient's eligibility for the trial by comparing the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nPatient Note Summary:\n- 6-month-old male infant\n- Post-major surgery\n- Oliguria (urine output < 0.2 mL/kg/hr)\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Pulse 141/min\n- Respiratory rate 18/min\n- Blood urea nitrogen 33 mg/dL\n- Serum creatinine 1.3 mg/dL\n- Urinalysis: Specific gravity 1.017, 1 WBC/HPF, 18 RBCs/HPF, 5 granular casts/HPF\n- Fractional excretion of sodium 3.3%\n\nClinical Trial Summary:\n- Title: Algorithm for Oliguria in Septic Shock\n- Focus: Acute Kidney Injury (AKI) in critically ill patients with shock, oliguria, and intervention with a goal-directed ultrasonographic protocol\n- Sample: Adult patients\n- Inclusion Criteria: Critically ill, adult patients with acute oliguric renal failure within 6 hours of presentation\n\nThe key inclusion criteria for the clinical trial are being critically ill, an adult patient with acute oliguric renal failure, and presentation within 6 hours. The patient described in the note does not meet the age criterion, as he is a 6-month-old infant, and the trial specifically states \"adult patients.\"\n\nTherefore, the patient is not eligible for the clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "620": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 6-month-old male infant would not be eligible for the trial which is focused on old patients undergoing orthopaedic surgery. The patient does not meet the age criteria, nor the clinical scenario as he is post-major surgery, not specifically orthopaedic surgery, and the trial is looking for old patients with normal renal function.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "621": {
        "output": "Based on the provided patient note, the 6-month-old male infant has recently undergone major surgery and is experiencing a low urine output with generalized edema. There are no indications in the note that the infant has been diagnosed with pyloric stenosis or that the infant will undergo pyloromyotomy.\n\nThe clinical trial in question is focused on assessing optimal postoperative feeding regimens following pyloromyotomy, and the inclusion criteria specify that subjects must be infants with a diagnosis of pyloric stenosis who will undergo pyloromyotomy.\n\nSince the infant in the patient note does not fit the inclusion criteria of having a diagnosis of pyloric stenosis and there is no mention of an upcoming pyloromyotomy procedure, the infant would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "622": {
        "output": "Based on the information provided, the 6-month-old male infant appears to meet the inclusion criteria for the clinical trial titled \"Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates.\" The trial is focused on neonates admitted to NICU who develop acute kidney injury and the patient note indicates that the infant has signs consistent with AKI (low urine output, generalized edema, elevated blood urea nitrogen, and serum creatinine levels). Additionally, the infant would have received intravenous fluids post-surgery, likely for more than 48 hours, which fits the second inclusion criterion.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "623": {
        "output": "The patient note describes a 6-month-old male infant with low urine output, generalized edema, and elevated blood urea nitrogen and serum creatinine levels. This suggests the infant is experiencing some form of renal impairment, possibly acute kidney injury (AKI), following major surgery.\n\nThe clinical trial in question is the REMEDIAL III trial, focused on the prevention of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing chronic kidney disease (CKD) who are undergoing imaging procedures that require contrast media. The trial is comparing two different hydration strategies to prevent CI-AKI.\n\nTo determine the patient's eligibility for this clinical trial, we need to compare the patient's characteristics to the trial's inclusion criteria:\n\nInclusion criteria for the trial:\n- Patients with chronic kidney disease (CKD) scheduled for coronary and/or peripheral angiography and/or angioplasty\n- An estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m^2\n- High risk for CI-AKI according to Mehran's score \u226511 and/or Gurm's score >7\n\nThe patient's note does not indicate that the infant has chronic kidney disease, nor is the infant scheduled for coronary or peripheral angiography/angioplasty procedures. The patient's eGFR is not provided, but given the age and the current medical problem (post-surgery), it is likely not a chronic condition but an acute one. Mehran's score and Gurm's score are specific to adults undergoing procedures with contrast media and do not apply to this infant.\n\nBased on the provided information, this 6-month-old infant does not meet the inclusion criteria for the REMEDIAL III trial, primarily because he does not have chronic kidney disease, is not scheduled for a procedure that involves contrast media, and is not within the age range typically studied for these scores or interventions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "624": {
        "output": "Based on the information provided, the patient is a 6-month-old male infant, which fits within the age range specified in the inclusion criteria (1-12 months). The patient has recently undergone major surgery, but it is not specified whether this surgery is related to cataract surgery. However, since the inclusion criteria specifically mention infants undergoing elective cataract surgery, and there is no mention of the infant having cataracts or requiring cataract surgery, it is unlikely that this patient would be eligible for the trial focused on postoperative analgesia in infantile cataract surgery.\n\nThe patient's current condition involves low urine output and generalized edema, suggesting a focus on renal function rather than ophthalmic issues, which are not relevant to the clinical trial's focus on analgesia for cataract surgery.\n\nAdditionally, there is no mention of the infant's ASA physical status grade, which is a requirement for inclusion. Without this information, we cannot confirm that the patient meets the criteria of ASA physical status grade I or II.\n\nGiven the information provided, it is clear that the patient does not meet the specific requirements of the clinical trial in question. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "625": {
        "output": "",
        "label": 0
    },
    "626": {
        "output": "",
        "label": 0
    },
    "627": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 6-month-old male infant with post-surgical oliguria, generalized edema, and abnormal laboratory findings suggestive of kidney dysfunction or injury.\n\nClinical Trial:\n- The trial is focused on patients with bladder cancer in a surveillance setting, using blue light cystoscopy with Cysview.\n- Inclusion criteria specify patients with histologically confirmed bladder cancer at their first surveillance cystoscopy, with a history of multiple tumors, recurrent tumors, or high-grade tumors.\n\nAssessment:\n- The patient in the note is an infant with no mention of bladder cancer or any surveillance cystoscopy, let alone a histologically confirmed tumor.\n- The patient's age and condition do not match the inclusion criteria of the clinical trial, which is specifically for patients with a history of bladder cancer.\n\nBased on this information, it's clear that the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "628": {
        "output": "",
        "label": 1
    },
    "629": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial in question, we need to match the patient characteristics and history with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- Difficulty swallowing that progressed from solids to liquids\n- Weight loss of 25 pounds\n- Obstruction felt at the lower end of his sternum\n\nClinical Trial Inclusion Criteria Analysis:\n- Age: 18 and over (Patient is 52 years old, so meets this criterion)\n- Histologically confirmed epidermoid carcinoma or adenocarcinoma of the esophagus (The patient's note does not confirm a diagnosis of esophageal cancer; further investigation is needed to determine if the dysphagia is due to epidermoid carcinoma or adenocarcinoma of the esophagus)\n- Disease eligible for potentially curative radiotherapy (Not confirmed from the patient note)\n- Performance status: Karnofsky 60-100% (Not specified in the patient note)\n- Adequate hematopoietic, hepatic, renal, and cardiovascular function (Not specified in the patient note)\n- No severe uncontrolled diabetes, uncontrolled infection, or other medical condition precluding treatment (The patient note does not indicate any of these conditions)\n- No mental status abnormality precluding comprehension or compliance with treatment (Not specified in the patient note)\n- No active cancer at another primary site (Not specified in the patient note)\n- No prior chemotherapy or radiotherapy (The patient note does not indicate any prior chemotherapy or radiotherapy)\n\nGiven the available information, the patient shows signs that could be consistent with cancer of the esophagus, such as progressive dysphagia and significant weight loss. However, without a confirmed diagnosis of epidermoid carcinoma or adenocarcinoma of the esophagus, as well as other necessary medical information, we cannot definitively determine eligibility for the clinical trial.\n\nTherefore, the patient should undergo further investigation to confirm the diagnosis and to assess other health parameters as per the trial's inclusion criteria. Only after obtaining a confirmed diagnosis and additional medical information can we properly assess the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "630": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. These symptoms are highly suggestive of esophageal cancer, although the note does not provide a specific diagnosis or staging.\n\nThe clinical trial in question is targeting patients with stage II or III esophageal squamous cell cancer that is stage T2-3 Nx M0. The inclusion criteria specify that the cancer must be histologically confirmed and that there should be no prior chemotherapy or radiotherapy.\n\nSince the patient note does not confirm a diagnosis of esophageal squamous cell cancer, nor does it provide staging information, it is uncertain whether this patient's condition matches the trial's inclusion criteria. Furthermore, the note does not mention whether the patient has had any prior treatments which would also affect eligibility.\n\nBased on the information at hand, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis cautious approach is due to the absence of key diagnostic information and treatment history which are necessary to determine the patient's eligibility with certainty. Further investigation, such as a biopsy, would be needed to confirm the diagnosis and stage of cancer, as well as to determine any previous treatments before a definite referral could be made.",
        "label": 1
    },
    "631": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. These symptoms suggest that the patient may have esophageal cancer, but the note does not confirm a diagnosis of esophageal cancer nor does it mention any biopsy or histological confirmation.\n\nThe clinical trial in question is looking for patients with histologically confirmed esophageal or non-small cell lung carcinoma that is considered acceptable for curative esophageal resection or locally advanced lung cancer (Stages IA-IIIB, T(any)N(any)M0) without pleural effusion. The patient must be a candidate for induction chemotherapy followed by surgical resection.\n\nThe patient in the note does not have a confirmed diagnosis, which is a key inclusion criterion for the trial. However, the symptoms described are highly suggestive of esophageal carcinoma, and if this were confirmed with a biopsy, the patient could potentially be a candidate for the trial.\n\nGiven that we do not have confirmation of a histological diagnosis or information on whether the patient is considered acceptable for curative resection or if he is a candidate for induction chemotherapy followed by surgical resection, we cannot definitively assess his eligibility for the trial.\n\nTherefore, the most appropriate response would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "632": {
        "output": "",
        "label": 1
    },
    "633": {
        "output": "The patient note describes a 52-year-old African American man with a history of heavy smoking and drinking who is experiencing progressive dysphagia. He has noticed difficulty swallowing that has progressed from solids to liquids and has lost 25 pounds due to this condition.\n\nThe clinical trial in question is focused on smoking cessation or weight control programs. The inclusion criteria for the smoking cessation studies are:\n- between 18 and 60 years old,\n- a minimum 2-year history of smoking,\n- a current level of smoking > 10 cigarettes per day,\n- and agreement to participate in the study.\n\nThe patient fits the age range and has a history of heavy smoking, which likely indicates he meets the minimum 2-year history of smoking and the current level of smoking > 10 cigarettes per day. However, there is no direct information about the precise number of cigarettes the patient smokes per day, or if the patient agrees to participate in the study.\n\nThe exclusion criteria mention that smokers and overweight persons would be excluded if currently being treated by a physician for a serious physical or psychological disorder, such as heart disease, cancer, depression, etc. The patient's dysphagia and significant weight loss could be symptoms of a serious underlying condition, potentially cancer, given his history of heavy smoking and drinking, which are risk factors for esophageal cancer. This suspicion would need to be confirmed with further medical investigation.\n\nSince the patient's medical condition isn't clearly defined as serious in the note, but there is a potential for an underlying serious condition, this might warrant further investigation before determining eligibility.\n\nBased on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "634": {
        "output": "The patient note describes a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. The patient has noted difficulty swallowing that has progressed from solids to liquids and has localized the obstruction sensation to the lower end of his sternum. The patient has lost a significant amount of weight, which may suggest advanced disease.\n\nThe clinical trial is looking for patients with advanced oesophageal cancer to compare the treatment of gullet cancer with radiotherapy alone versus radiotherapy with the addition of chemotherapy. The trial's aim is to assess the relief of dysphagia and quality of life improvements.\n\nTo determine the patient's eligibility for this clinical trial, we need to compare the patient's condition with the inclusion criteria:\n\n1. Biopsy proven Carcinoma of the oesophagus: The patient note does not mention a biopsy or a confirmed diagnosis of carcinoma of the oesophagus.\n2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness: The patient note suggests advanced disease due to progressive dysphagia and weight loss, but without more information on the staging or presence of metastases, we cannot confirm this criterion.\n3. Symptomatic patients with dysphagia scores of \u2265 1: The patient has dysphagia, which has progressed from solids to liquids, indicating a dysphagia score of at least 1.\n4. Performance status ECOG \u2264 2: The patient's performance status is not mentioned, but given the progressive nature of his symptoms, it's possible he falls within this range.\n5. Patients must begin treatment within 2 weeks of randomization: This criterion is contingent upon acceptance into the trial.\n6. Patient is at least 18 years old: The patient is 52 years old.\n7. Adequate haematological function to undergo chemotherapy: The patient's haematological function is not mentioned.\n8. Adequate renal function: The patient's renal function is not mentioned.\n9. Patients capable of childbearing are using adequate contraception: Not applicable to this patient.\n10. Written informed consent of patient: This is obtainable if the patient agrees to participate.\n\nBased on the provided information, the patient appears to meet some of the inclusion criteria (age, dysphagia symptoms). However, there are several key pieces of information missing that are crucial to determine his eligibility fully, such as a confirmed diagnosis of carcinoma of the oesophagus through biopsy, performance status, haematological and renal function tests, and whether he is not a candidate for radical treatment. Therefore, further investigation is needed to determine if the patient is suitable for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "635": {
        "output": "Based on the inclusion criteria for the clinical trial, the 52-year-old African American man with a history of progressive dysphagia fits the profile of a potential participant. The criteria require patients aged 18-90 presenting with dysphagia or food impaction, and the ability to undergo esophagogastroduodenoscopy (EGD) with biopsies. There is no mention of exclusion due to a history of smoking and drinking, and the patient does not have significant cardiopulmonary disease or other contraindications to EGD as far as the information provided.\n\nGiven the information provided in the patient note, this patient meets the age requirement, is experiencing dysphagia, and there is no indication that he has contraindications to undergoing EGD and biopsies. Therefore, he appears to be eligible for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "636": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Volitional Swallowing in Stroke Patients With Chronic Dysphagia,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria provided for the study.\n\nPatient Note Analysis:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He experiences progressive dysphagia (difficulty swallowing) that has worsened over time.\n- The patient has lost 25 pounds, possibly due to his difficulty in swallowing.\n- There is no mention of a stroke or brain injury, which is pertinent to the clinical trial's inclusion criteria.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 20 to 90 years old.\n- History of brain injury (no specific localization or type required).\n- Evidence of pharyngeal phase dysphagia following brain injury that places the patient at risk for aspiration.\n- Duration of dysphagia of 4 months or greater post-onset of brain injury.\n- MMSE score greater than or equal to 23, indicating adequate cognitive skills.\n- Stable medical status.\n\nClinical Trial Exclusion Criteria Analysis:\n- History of epileptic seizure.\n- Certain cardiac conditions or pacemaker in place if participating in TMS.\n- History of progressive neurodegenerative disorders.\n- History of malignant brain tumor.\n- Severe oral phase swallowing deficits.\n- Esophageal motility disorder.\n- Current psychiatric disorder other than depression.\n- Presence of metal in the body incompatible with MRI/TMS.\n- Inability to coordinate button or switch press with swallow.\n\nBased on the patient note, the patient does not meet the main inclusion criteria for the study, which requires a history of brain injury and evidence of pharyngeal phase dysphagia due to brain injury. The patient's dysphagia could be related to other causes, such as esophageal conditions often associated with a history of heavy smoking and drinking, and not necessarily due to a brain injury.\n\nSince the patient's condition does not fit the criteria of chronic dysphagia due to brain injury, and there is no mention of a stroke or other brain injury, the patient would not be eligible for this clinical trial. Therefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "637": {
        "output": "The patient described in the note is a 52-year-old African American man with a history of progressive dysphagia and significant weight loss (25 pounds). \n\nComparing this patient's characteristics with the inclusion criteria of the clinical trial, which is aimed at evaluating the effect of a medicine on gastric functions in healthy volunteers, we can see the following discrepancies:\n\n1. Age: The trial is seeking participants between 18-45 years old, and the patient is 52 years old.\n2. Gender: The trial specifies non-pregnant, non-breastfeeding females, and the patient is male.\n3. No alarm indicators: One of the exclusion criteria for the trial is no alarm indicators like weight loss of more than 7kg, but the patient has lost 25 pounds, which is an alarm indicator for potential serious underlying conditions.\n4. Health status: The patient's history of heavy smoking and drinking, along with the progressive dysphagia, suggests that he may not be a \"healthy volunteer\" as required by the study.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient would not be referred for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "638": {
        "output": "The patient is a 52-year-old African American man with progressive dysphagia, which has worsened from difficulty swallowing meat to including other solid foods, soft foods, and then liquids. He has also experienced significant weight loss. These symptoms are indicative of esophageal obstruction, possibly due to esophageal cancer, although no specific diagnosis is mentioned in the patient note.\n\nThe clinical trial in question is an observational study looking at the risks and burden of mucositis in patients receiving chemotherapy and radiation therapy treatment for various cancer types.\n\nThe inclusion criteria for the clinical trial are:\n\n1. 18 years or older\n2. Ability to understand the protocol and willing to provide written informed consent\n3. Membership in one of the following sub-cohorts:\n   - Histologically proven oral cavity or oropharyngeal cancers planned to receive radiation therapy +/- chemotherapy\n   - Histologically proven laryngeal or hypopharyngeal cancers planned to receive radiation +/- chemotherapy\n   - Histologically proven adenocarcinoma of the colon or rectum planned to receive chemotherapy cycles\n   - Adenocarcinoma of the breast planned to receive chemotherapy cycles\n   - Histologically proven adenocarcinoma (any primary) planned to receive chemotherapy cycles\n   - Stage 3A or 3B non-small cell lung cancers planned to receive radiation +/- chemotherapy\n   - B-cell Non-Hodgkin's lymphoma (NHL) planned to receive chemotherapy cycles\n\nThe patient's symptoms are suggestive of an esophageal cancer, but there is no information provided about a histological diagnosis or planned treatment that matches the cancer types specified in the inclusion criteria. Without a matching diagnosis and planned treatment regimen, the patient does not meet the necessary criteria to be included in the mucositis study.\n\nTherefore, based on the information provided, the patient does not fit the trial's inclusion criteria as there is no indication of the patient having any of the specified cancers or planned treatments.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "639": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Assessment:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He describes progressive dysphagia (difficulty swallowing) that has progressed from meats to liquids.\n- The patient has lost 25 pounds, presumably due to his difficulty in swallowing.\n- There is no mention of any cancer diagnosis, stage, or treatment in the patient note.\n\nClinical Trial Inclusion Criteria Assessment:\n- Patients with either: \n  a) histologically proven stage I, II, IIIa NSCLC who have undergone a complete surgical resection of the primary tumor OR \n  b) stage I or II HNSCC who have undergone definitive local treatment (surgery or radiation therapy).\n- Definitive local treatment \u2264 12 months prior to trial enrollment for HNSCC patients. For NSCLC patients, surgery \u2264 12 months prior to trial enrollment.\n- No evidence of residual cancer.\n- Age \u2265 18 years.\n- Performance status of 0-2 (Zubrod).\n- No contraindications for undergoing bronchoscopy.\n- No active pulmonary infections.\n- Required blood levels (granulocyte count, platelet count, total bilirubin, creatinine).\n- Consent to bronchoscopy and endobronchial biopsy for biomarker studies.\n- Smoking history of at least 10 pack years. May be current or former smoker.\n- Legally capable of providing consent.\n- For HNSCC patients only: No contraindications for undergoing laryngoscopy.\n\nThe provided patient note does not indicate that the patient has been diagnosed with NSCLC or HNSCC, nor that they have undergone any treatment for such conditions. The patient's primary complaint is dysphagia, which can be associated with esophageal cancer or another non-cancerous condition, but there is no specific mention of lung or head and neck cancer, which are the target diseases for the clinical trial.\n\nGiven the lack of information regarding a cancer diagnosis or treatment, it would not be appropriate to refer this patient to the clinical trial based on the information provided. The patient does not meet the specific inclusion criteria relating to NSCLC or HNSCC diagnosis and treatment history.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "640": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the study.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. 18 years or older\n2. Diagnosed with head and neck cancer including the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid\n3. All histological types of cancer\n4. All tumor stages according to American Joint Committee for Cancer (AJCC) Staging\n5. All forms of RT including standard or investigational and/or concurrent standard or investigational chemotherapy for head and neck cancers\n6. Alert and mentally competent\n7. English speaking\n\nThe patient note contains the following information about the patient:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, soft foods, and liquids\n- Sensation of obstruction at the lower end of the sternum\n- Significant weight loss (25 pounds)\n\nWhile the patient has symptoms that could be suggestive of a head or neck cancer (e.g., progressive dysphagia, significant weight loss), there is no explicit diagnosis of head or neck cancer mentioned in the patient note. Before this patient can be considered for the clinical trial, a diagnosis that fits the inclusion criteria (such as cancer of the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, or thyroid) would need to be confirmed. \n\nGiven the current information:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "641": {
        "output": "Based on the information provided:\n\nThe patient is a 52-year-old African American man with progressive dysphagia, initially with solids and now including liquids. He reports obstruction at the lower end of his sternum and has experienced significant weight loss.\n\nThe clinical trial aims to assess the analgesic effectiveness of celecoxib in patients with painful pharyngitis (sore throat).\n\nThe inclusion criteria for the clinical trial are:\n- The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis.\n- The patient is willing to abstain from taking anything by mouth except trial medication during specified times.\n\nThe patient described in the note does not have a diagnosis of pharyngitis; rather, he has dysphagia, which is difficulty swallowing and may indicate an esophageal disorder rather than a sore throat. Since the patient's symptoms and condition do not match the target condition for the clinical trial, which is pharyngitis, this patient would not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "642": {
        "output": "The patient described in the note has progressive dysphagia with a history of heavy smoking and drinking, and has experienced significant weight loss. There is no mention of ovarian cancer or primary peritoneal cancer, which are the target diseases for the clinical trial.\n\nThe clinical trial in question is specifically for patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer who have been previously treated with platinum and taxol compounds. The patient described does not meet the disease criteria as there is no mention of ovarian or primary peritoneal cancer. Therefore, they are not eligible for this trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "643": {
        "output": "Given the patient note, the patient is a 52-year-old African American man with a history of heavy smoking and drinking, experiencing progressive dysphagia which has worsened over time to include difficulty swallowing solids, soft foods, and liquids. The patient notes an obstruction at the lower end of his sternum and has lost a total of 25 pounds.\n\nNow, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\n1. The patient is 52 years old, which satisfies the age criterion of being 18 years of age or older.\n2. The patient is able to communicate his symptoms, which likely means he can provide written informed consent.\n3. The clinical trial is looking for patients with a diagnosis of head and neck malignancy involving an oral cavity site. The patient's symptoms suggest a possible malignancy, but the location is not specified as an oral cavity site, and the symptoms could potentially indicate an esophageal rather than an oral cavity cancer.\n4. The patient has not been described as having undergone any previous treatment for his condition, which fits the criteria of no previous treatment.\n5. The trial requires the current treatment plan to include a surgical intervention, but we don't have information about the treatment plan for this patient.\n6. The patient note does not specify whether the patient is English speaking, but if the patient interaction took place in an English-speaking country, it is likely that he speaks English.\n\nThe patient appears to potentially meet some of the inclusion criteria. However, there are uncertainties regarding the exact diagnosis, the treatment plan, and the patient's ability to speak English. This patient might be eligible for the trial if further investigation confirms the diagnosis of a malignancy involving an oral cavity site and if his treatment plan includes surgery. \n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "644": {
        "output": "",
        "label": 1
    },
    "645": {
        "output": "The patient note describes a 52-year-old African American man with a history of heavy smoking and drinking, who has progressive dysphagia to solids and liquids, with weight loss and localization of the obstruction at the lower end of his sternum. This clinical presentation is suggestive of esophageal pathology, which may include esophageal cancer given his risk factors; however, there is no specific mention of a cancer diagnosis or staging in the provided note.\n\nThe clinical trial in question is studying the effects of intensity-modulated radiotherapy (IMRT) on swallowing in patients with previously untreated Stage III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx, or larynx, or unknown primary.\n\nBased on the information provided, the patient does not meet the inclusion criteria as stated for the clinical trial. The inclusion criteria specifically mention stages III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx or larynx, or unknown primary. The patient's symptoms are suggestive of an esophageal pathology, and there is no indication that he has been diagnosed with the type of cancer specified in the trial's inclusion criteria.\n\nTherefore, based on the available patient note and the clinical trial inclusion criteria:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "646": {
        "output": "",
        "label": 0
    },
    "647": {
        "output": "Considering the information provided in the patient note and the clinical trial inclusion criteria, the patient described is a 52-year-old African American man with progressive dysphagia associated with weight loss. This patient's medical issues seem related to his swallowing difficulties, potentially due to an underlying esophageal condition.\n\nThe clinical trial in question is focused on smoking cessation interventions in dental clinic smokers. The inclusion criteria for the trial are:\n\n1. Patient seeking routine dental care at NYU College of Dentistry and meets medical clearance for routine care.\n2. Active smokers (active smoking as self-reported regular use of at least 10 cigarettes per day).\n3. Able to provide a telephone number or collateral contact information where they can be reached over the subsequent 12 months.\n4. Fluent in English or Spanish.\n\nThe patient note indicates a history of heavy smoking, which suggests that the patient might be an active smoker, fitting one of the inclusion criteria. However, there is no mention of the patient seeking dental care or being able to speak English or Spanish. To determine if the patient meets all inclusion criteria, further investigation is required to confirm:\n\n- If the patient is seeking routine dental care at NYU College of Dentistry.\n- If the patient meets the medical clearance for routine dental care.\n- If the patient is currently smoking at least 10 cigarettes per day.\n- If the patient is fluent in English or Spanish.\n\nBased on the available information and the need to confirm these points, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "648": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to assess the patient's characteristics against the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Difficulty swallowing solid foods and liquids\n- Weight loss of 25 pounds\n- The obstruction point is felt at the lower end of his sternum\n- No explicit mention of cancer diagnosis or stage\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx\n- No other histologic diagnosis than squamous cell carcinoma\n- Identifiable primary site\n- Locoregionally confined stage III (excluding T1-2, N1) or stage IV disease\n- No evidence of nodal disease below the clavicles or distant metastases (M0)\n- No stage IVC disease (stage IVB allowed)\n- Appropriate for non-operative management with curative intent\n- Resectable disease is not required\n- No primary cancer of the nasopharynx, paranasal sinus, or salivary gland\n- ECOG performance status 0-1\n- Adequate blood counts and organ function\n- Not pregnant or nursing, with a negative pregnancy test for females\n- Fertile patients must use effective contraception\n- No unstable/uncontrolled angina, clinically apparent jaundice, or active infection\n- No history of malignancy (with exceptions) unless disease-free for at least 5 years\n- No prior definitive surgery, radiotherapy, chemotherapy, immunotherapy, or EGF receptor inhibitors for this malignancy\n\nBased on the patient note, we do not have information regarding a confirmed histological diagnosis of squamous cell carcinoma or the stage of any cancer the patient may have. The symptoms described, such as progressive dysphagia and weight loss, could potentially be associated with head and neck cancer, but without a confirmed diagnosis and staging, we cannot definitively match the patient to the inclusion criteria.\n\nGiven the lack of explicit information on a cancer diagnosis and stage, we cannot determine with certainty that the patient would be eligible for the trial. The patient note does not provide enough details to satisfy the inclusion criteria that require histological confirmation and specific staging. Therefore, further investigation is needed to acquire more detailed patient information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "649": {
        "output": "The patient in the provided note is a 52-year-old African American male with progressive dysphagia, significant weight loss, and a history of heavy smoking and drinking. While the note does not explicitly state a diagnosis of esophageal cancer, the symptoms described are highly suggestive of such a condition, particularly with the localization of the obstruction at the lower end of the sternum and the progressive difficulty swallowing various textures of food.\n\nThe clinical trial in question is focused on biological factors in predicting response to treatment in patients with esophageal cancer or rectal cancer who are planning to receive neoadjuvant treatment.\n\nThe inclusion criteria for the trial are:\n1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum.\n2. Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy.\n3. Not pregnant or nursing.\n4. No blood disorder.\n5. Not deprived of freedom or protected by law.\n\nBased on the patient note, the individual has not yet been confirmed to have esophageal cancer through histological examination, which is a key requirement for eligibility. Although the patient's symptoms strongly suggest esophageal cancer, without histological confirmation, we cannot assume the diagnosis. Furthermore, there is no information regarding the patient's treatment plan, specifically whether they are planning to receive neoadjuvant treatment.\n\nTherefore, the patient might be eligible for referral based on the strong clinical suspicion of esophageal cancer, but further investigation is required to confirm the diagnosis histologically and to ascertain the planned treatment approach. The patient would need a biopsy to confirm adenocarcinoma or squamous cell carcinoma of the esophagus and a treatment plan that includes neoadjuvant therapy to meet the trial's disease characteristics criteria.\n\nGiven the need for additional information, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "650": {
        "output": "Based on the patient note provided, the 52-year-old African American man has progressive dysphagia and has experienced significant weight loss due to difficulty swallowing, which escalated from solids to liquids. The location of the obstruction is identified at the lower end of his sternum. This clinical presentation is suggestive of a possible esophageal disorder, which may include esophageal cancer or other structural abnormalities, and is not consistent with a sore throat.\n\nThe clinical trial in question is aimed at evaluating the efficacy of valdecoxib in patients with moderately to severely painful symptomatic sore throat. The inclusion criteria specify that the participants should have moderate to severe pain as measured by the Sore Throat Pain Intensity Scale (STPIS) on swallowing and meet certain criteria on the Tonsillo-Pharyngitis Score (TPS), among other things.\n\nSince the patient's primary complaint is progressive dysphagia with no mention of sore throat pain or related symptoms, he does not meet the inclusion criteria for the clinical trial, which is focused on sore throat pain and its treatment.\n\nTherefore, the patient's symptoms and history do not align with the focus of the clinical trial, and he would not be suitable for referral to this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "651": {
        "output": "Based on the patient note provided:\n\nA 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.\n\nAnd the clinical trial's inclusion criteria:\n\nPatients with newly diagnosed, previously untreated squamous cell carcinoma of the head and neck (SCCHN) who are candidates for the molecular epidemiology study LAB00-062 of head and neck cancer.\nMust have the ability to understand and provide informed consent.\nPatients must be 18 years and older.\nAbility to read, write, and speak English.\nResident of the United States.\nAgrees to have tumor tissue, if available, tested for HPV. No additional biopsy will be requested.\n\nThe patient note does not mention a diagnosis of squamous cell carcinoma of the head and neck (SCCHN), nor does it specify whether the patient has been previously untreated for this condition. The symptoms described (progressive dysphagia, weight loss) could be indicative of a number of conditions, including head and neck cancers, but without a confirmed diagnosis stated in the patient note, we cannot reliably assess eligibility based on the trial's inclusion criteria.\n\nTherefore, based on the information provided in the patient note, we cannot conclude that the patient meets the specific inclusion criteria for the clinical trial. However, if the patient were to be diagnosed with SCCHN, they might become eligible. Thus, further investigation into the patient's medical condition would be necessary before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "652": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 52-year-old African American man, which meets the age criterion (>18 years).\n- The patient has a history of heavy smoking and drinking.\n- The patient describes progressive dysphagia, which has worsened over time, indicating a possible esophageal obstruction.\n- He locates the obstruction at the lower end of his sternum and has experienced significant weight loss (25 pounds), which may suggest advanced disease.\n\nClinical Trial Inclusion Criteria:\n- 18 years of age and older (Patient meets this criterion).\n- Willing and able to provide informed consent (Unknown based on the patient note).\n- Willing to comply with follow-up requirements (Unknown based on the patient note).\n- Biopsy-confirmed esophageal cancer (adenocarcinoma or squamous cell carcinoma) in mid or distal esophagus (clinical stage 3 or less) (The patient's symptoms suggest esophageal cancer, but there is no confirmation of a biopsy in the note).\n- Indicated for chemotherapy and/or radiation therapy (Unknown based on the patient note).\n- Ability to dilate stricture to 15mm diameter at extent of disease evaluation (Unknown based on the patient note).\n- Placement of at least 18 x 23mm diameter and 120mm length PolyFlex stent (Unknown based on the patient note).\n\nThe patient's age fits the criteria, and his symptoms are suggestive of esophageal cancer, which is the disease targeted by the clinical trial. However, the patient note does not confirm a diagnosis of esophageal cancer through a biopsy, nor does it provide information about the clinical stage of the disease. Additionally, the patient's willingness and ability to consent, as well as compliance with follow-up, are not mentioned, and there's no information on the technical feasibility of stent placement or the patient's indication for chemotherapy and/or radiation therapy.\n\nTherefore, based on the information provided, we would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis and other missing details. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "653": {
        "output": "",
        "label": 0
    },
    "654": {
        "output": "",
        "label": 1
    },
    "655": {
        "output": "Based on the information provided, the patient is a 52-year-old African American man with a history of heavy smoking and drinking, who presents with progressive dysphagia that began several months ago. The dysphagia has progressed from difficulty swallowing meat to other solid foods, soft foods, and then liquids. The patient also reports weight loss of 25 pounds.\n\nThe clinical trial in question is targeting patients with advanced esophageal cancer, aiming to evaluate the effectiveness of a novel esophageal stent loaded with 125I seeds to relieve dysphagia and improve quality of life.\n\nThe inclusion criteria for the clinical trial are:\n1. Histologically confirmed primary cancer of the esophagus,\n2. Must be dysphagia caused by esophageal cancer,\n3. Without esophageal fistulas,\n4. Must be an inpatient,\n5. Life expectancy is over 6 months.\n\nWhile the patient note suggests the presence of dysphagia, there is no confirmation that the patient has esophageal cancer. A histological confirmation of primary cancer of the esophagus is necessary to satisfy the first inclusion criterion. Furthermore, there is no information provided about the presence of esophageal fistulas, whether the patient is an inpatient, or about their life expectancy.\n\nGiven the lack of specific information confirming the diagnosis of esophageal cancer and other inclusion criteria, I would consider this patient for the clinical trial upon further investigation to confirm the diagnosis and other eligibility requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "656": {
        "output": "To determine the patient's eligibility for the clinical trial, let's assess the inclusion criteria against the patient's clinical presentation:\n\n1. Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction - The patient note does not mention a histological diagnosis, only symptoms suggestive of esophageal obstruction.\n2. Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region - There is no information provided on the staging of the patient's condition.\n3. Age >18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained - The patient is 52 years old, which meets the age criterion.\n4. Weight loss < 10% in 0.5 yr - The patient has experienced a significant weight loss of 25 pounds, but without knowing the patient's initial weight, it is not possible to assess if this meets the criterion.\n5. WHO performance status 0-1 - The performance status of the patient is not mentioned, but progressive dysphagia might indicate a performance status worse than 1.\n6. No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus - There is no mention of prior treatment, suggesting the patient has not had any.\n\nGiven the information available, the patient has progressive dysphagia, which is a symptom that could be associated with esophageal adenocarcinoma, but without histological confirmation or staging, we cannot conclusively determine eligibility. The significant weight loss is concerning and could potentially disqualify the patient depending on the patient's initial weight. The lack of detailed medical information requires further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "657": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer,\" we need to compare the patient's characteristics and history with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids, weight loss of 25 pounds\n- Food obstruction sensation at the lower end of his sternum\n\nClinical trial inclusion criteria:\n- Adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus (requires histological proof)\n- Locally advanced disease (any T, N0 or N1, M0 or M1a)\n- No metastatic disease beyond specified in criteria\n- Inoperable disease OR surgery is contraindicated\n- ECOG performance status 0-2\n- Life expectancy \u2265 3 months\n- Adequate blood cell counts (ANC, platelet count, hemoglobin)\n- Adequate organ function (creatinine, total bilirubin, ALT/AST, prothrombin time)\n- Not pregnant or nursing, must use effective contraception\n- Sufficient caloric intake\n- No weight loss > 20% normal body weight within the past 3 months\n- No complete dysphagia\n- No exclusive requirement for parenteral nutrition\n- No prior treatment for esophageal cancer\n- No severe comorbidities that would preclude participation\n\nBased on the patient note, we cannot confirm if the patient has histologically proven carcinoma of the esophagus or the specific subtype. The patient does have dysphagia and weight loss, which are consistent with esophageal cancer symptoms, but the weight loss does not exceed the >20% threshold within the past 3 months as per the criteria. The trial also excludes patients with complete dysphagia, which our patient does not have since he can still swallow to some extent. The patient's history of no prior treatment for esophageal cancer is a match with the trial requirements.\n\nHowever, without further information on the histological diagnosis, stage of cancer, ECOG performance status, life expectancy, blood counts, organ function tests, and whether the disease is operable or not, we cannot definitively determine eligibility.\n\nGiven the available information, the patient's history suggests a possibility of esophageal cancer, but there is insufficient information to make a full assessment. Therefore, the patient should be considered for referral upon further investigation to confirm the diagnosis and other relevant clinical details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "658": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nThe patient is:\n- A 52-year-old African American man\n- With a history of heavy smoking and drinking\n- Describes progressive dysphagia\n\nThe clinical trial is seeking:\n- Heavy smokers and/or heavy drinkers\n- Treatment-seeking smokers between the ages of 18 to 65 years\n- Individuals who smoke \u2265 10 cigarettes per day\n- Individuals with a Fagerstrom Test of Nicotine Dependence score > 3\n- Individuals with an Alcohol Use Disorders Identification Test (AUDIT) score > 8 for heavy drinkers or < 8 for social drinkers\n- Males who drink > 25 drinks per week for heavy drinkers or < 14 drinks per week for social drinkers\n- Individuals able to provide written informed consent\n\nExclusion criteria for heavy smokers/heavy drinkers include:\n- Any medical condition requiring immediate investigation or treatment\n- Beck Depression Inventory score >16\n- Insulin-dependent diabetes\n- Drinking > 70 standard alcoholic drinks per week for males\n- Pregnancy or lactation\n- Current DSM-IV Axis 1 psychiatric disorder\n- Regular use of any therapeutic or recreational psychoactive drug use during the last three months or other substance use disorder, with the exception of tobacco and alcohol\n\nBased on the patient note, the patient is a heavy smoker and drinker, which fits the inclusion criteria for heavy smokers/heavy drinkers. However, the patient note does not provide information on the Fagerstrom Test of Nicotine Dependence score, AUDIT score, exact number of cigarettes smoked per day, or exact number of alcoholic drinks consumed per week. There is also no information on whether the patient is seeking treatment for his smoking and drinking habits, or if any of the exclusion criteria apply to the patient.\n\nGiven the lack of detailed information about the patient's smoking and drinking habits, as well as missing information on other inclusion and exclusion criteria, further investigation would be necessary to determine the patient's eligibility for the clinical trial. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "659": {
        "output": "",
        "label": 0
    },
    "660": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers,\" here are the key points to consider:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking.\n- The patient describes progressive dysphagia, which has worsened over several months.\n- He has experienced significant weight loss.\n\nClinical Trial Inclusion Criteria:\n- Adults > 45 years of age.\n- Non-smoking controls >50 years of age (not applicable to this patient as he is a heavy smoker).\n- Current smokers with > 30 pack years, no airflow obstruction (FEV1 > 90% predicted), or lung cancer, >50 years of age.\n- No prior history of head and neck or bronchogenic carcinoma.\n- Patients must understand the investigational nature of this study and sign an informed consent.\n\nAssessment:\n- The patient is over 45 years of age, which meets the age criterion.\n- The patient has a history of heavy smoking, which potentially meets the pack-year criterion, though this is not quantified in the patient note.\n- There is no mention of the patient having airflow obstruction or lung cancer, which aligns with the study's criteria.\n- There is no indication of a prior history of head and neck or bronchogenic carcinoma in the patient note.\n\nGiven that the patient's smoking history likely meets the > 30 pack years requirement, and assuming the patient does not have airflow obstruction or lung cancer, he may be a candidate for the study. However, further information would be needed to fully confirm eligibility (e.g., exact pack years, confirmation of no airflow obstruction or lung cancer). Therefore, the patient could potentially be eligible, but this determination would require additional information and assessments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "661": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 52-year-old African American man with a history of progressive dysphagia, weight loss, and difficulty swallowing, which are symptoms that could be associated with esophageal cancer. However, there is no direct mention of a diagnosis of adenocarcinoma of the esophagus or any treatment, including cisplatin-based treatment, that the patient has received.\n\nThe inclusion criteria for the clinical trial specify that the patient must have a diagnosis of adenocarcinoma of the esophagus, be at any stage I-IV of the disease, and must have received cisplatin-based treatment on clinical trial ECOG-1201.\n\nGiven that the patient note does not confirm a diagnosis of adenocarcinoma of the esophagus or any treatment received, we cannot definitively determine the patient's eligibility for the clinical trial without additional information. Therefore, the patient may warrant further investigation to confirm the diagnosis and treatment history before considering referral to the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "662": {
        "output": "To determine the trial-level eligibility of the patient for the given clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- Age: 52 years old\n- Gender: Male\n- Medical History: Progressive dysphagia, heavy smoking and drinking, significant weight loss, difficulty swallowing which has progressed from solids to liquids, and localization of obstruction at the lower end of his sternum.\n\nClinical Trial Inclusion Criteria for Inoculated Volunteers:\n- Healthy 18-54 years old (male or female) with no chronic medical conditions except well-controlled hypertension\n- Availability for study visits over the next 1 month\n- Normal hemoglobin, white blood cell count, creatinine, alanine aminotransferase (ALT), platelet count\n- Negative for HIV, hepatitis C, and hepatitis B\n- Negative urine protein and glucose by dipstick\n- Willingness to be housed in the clinical research unit for the first 3 nights of the inoculation period\n- For females of childbearing potential, a negative pregnancy test and agreement to use acceptable contraception\n\nAssessment:\nThe patient's age falls within the specified range (18-54 years old). However, the patient does not meet the criterion of being in good health, as progressive dysphagia and significant weight loss are indicative of underlying medical issues, which are likely related to his history of heavy smoking and drinking. These symptoms suggest that the patient could have a serious condition such as esophageal cancer or another esophageal disorder, which would not classify him as a healthy volunteer. Additionally, the trial requires that the volunteers have no chronic medical conditions (with the exception of well-controlled hypertension), which does not align with the patient's current health status.\n\nSince the patient does not meet the health status criteria of being a healthy individual without chronic medical conditions, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "663": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Review:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He experiences progressive dysphagia and has lost 25 pounds.\n\nClinical Trial Inclusion Criteria Review:\n- ASA (American Society of Anesthesiologists) physical status I-II.\n- Aged between 20 and 70 years.\n- Scheduled for elective laparoscopic cholecystectomy under general anesthesia with endotracheal intubation.\n\nComparison:\n- The patient's age (52 years) falls within the trial's age range of 20 to 70 years.\n- The trial requires patients to have an ASA physical status of I-II, which typically denotes patients who are healthy or have only mild systemic disease. The patient's history of heavy smoking and drinking and significant weight loss due to progressive dysphagia may indicate a more severe systemic condition, which might not align with ASA I-II status. However, the ASA status itself is not explicitly stated in the patient note.\n- The patient's clinical presentation (progressive dysphagia and weight loss) does not suggest he is scheduled for an elective laparoscopic cholecystectomy, which is a surgery for gallbladder removal. Instead, his symptoms suggest a possible esophageal disorder.\n\nGiven that the patient does not seem to be scheduled for the specific procedure required by the trial (elective laparoscopic cholecystectomy), and there is no mention of the need for general anesthesia with endotracheal intubation for his current condition, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "664": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking\n- Progressive dysphagia\n- Difficulty swallowing various types of food\n- Significant weight loss\n\nClinical Trial:\n- Efficacy and Safety of Varenicline Among HIV-infected Patients\n- Inclusion Criteria:\n  - HIV-infected patients\n  - Adults\n  - Regular smokers (at least 10 cigarettes a day during the last year)\n  - Motivated to stop smoking\n  - Followed in one of the participating clinical ward\n  - Signed written informed consent\n\nThe patient in the note is a heavy smoker, which aligns with the criteria for smoking habits. However, there is no mention of the patient being HIV-infected, which is a primary inclusion criterion for the clinical trial. Without confirmation that the patient is HIV-positive, we cannot assume eligibility based on the provided information.\n\nTherefore, the patient does not meet the primary inclusion criterion of being HIV-infected as specified by the trial. The trial is looking specifically for HIV-infected patients who are regular smokers and who are motivated to stop smoking.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "665": {
        "output": "Based on the patient note provided, the 52-year-old African American man with a history of progressive dysphagia and significant weight loss due to difficulty swallowing is not a candidate for the clinical trial for several reasons:\n\n1. The clinical trial is assessing the safety and tolerability of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in healthy volunteers. The patient described does not meet the criteria for \"general good health\" due to his significant medical symptoms, which are indicative of an underlying health condition.\n2. The age criteria for the clinical trial is 18-50 years, inclusive, and the patient is 52 years old, which exceeds the upper age limit.\n3. The trial requires the ability to ingest the study drug dissolved in cow's milk or soy milk orally. Given the patient's progressive dysphagia, even to liquids, he may not be able to ingest the study drug as required.\n\nBecause the patient does not meet the age and health criteria and likely cannot ingest the study drug orally due to his dysphagia, he is not suitable for referral to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "666": {
        "output": "Based on the patient note, the 52-year-old African American man presents with progressive dysphagia and significant weight loss. However, there is no mention of a diagnosis of non-small cell lung cancer (NSCLC), which is a requirement for the clinical trial in question. Despite the patient's history of heavy smoking, which is a risk factor for NSCLC, there is no information provided that confirms he has been diagnosed with NSCLC, particularly at an advanced stage (IIIB/IV), nor is there any mention of the availability of tumor tissue required for the study.\n\nGiven the lack of information confirming an NSCLC diagnosis and stage, as well as the absence of details on the availability of tumor tissue for analysis, this patient does not meet the clearly stated inclusion criteria for the clinical trial focused on K-RAS oncogene mutation in patients with advanced NSCLC associated with exposure to wood smoke and tobacco smoking.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "667": {
        "output": "Given the patient note, the patient is a 52-year-old African American man with a history of progressive dysphagia and significant weight loss. The clinical trial in question is investigating the effects of dexamethasone on post-operative sore throat in patients undergoing outpatient laparoscopic gynecologic surgery.\n\nThe inclusion criteria for the trial specify:\n\n1. Female patients undergoing outpatient laparoscopic gynecologic surgery\n2. ASA PS I and II\n3. Age between 18 and 64 years\n4. Fluent in English\n\nThe patient described in the note is a male with swallowing issues, which is unrelated to the focus of the clinical trial on post-operative sore throat in female patients after gynecologic surgery. Moreover, he does not meet the gender requirement which is a critical inclusion criterion for this study.\n\nTherefore, this patient is not eligible for the clinical trial based on the provided inclusion criteria and patient information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "668": {
        "output": "",
        "label": 1
    },
    "669": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, which is difficulty swallowing that has progressed from solids to liquids, and he has experienced significant weight loss. The main concern for this patient appears to be a potential esophageal obstruction or other serious condition related to his smoking and drinking history.\n\nThe clinical trial provided is a comparison between two methods of throat swabbing in the diagnosis of strep pharyngitis, which is a bacterial infection of the throat. The inclusion criteria for the trial are patients with a sore throat, classified 2-3 according to Cantor's criteria, which is likely a scale that assesses the severity of throat symptoms.\n\nThe patient's symptoms do not align with the trial's target condition (strep pharyngitis) and inclusion criteria. There is no mention of a sore throat or a diagnosis that would fit Cantor's criteria, nor is there any indication that the patient is suffering from an infection that would require throat swabbing.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial due to the absence of the specified condition (sore throat) and because the patient's primary health issue seems to be unrelated to the purpose of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "670": {
        "output": "The patient note describes a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. There is no mention of lung adenocarcinoma or any cancer diagnosis, nor is there any information about EGFR mutations or the stage of any potential cancer.\n\nThe clinical trial's inclusion criteria require the patient to have a diagnosis of stage IIIB/IV lung adenocarcinoma with EGFR mutations and to be previously untreated for lung adenocarcinoma. Furthermore, the patient must have an ECOG performance status of 0-2, at least one measurable lesion according to RECIST, and a life expectancy of at least 12 weeks.\n\nBased on the provided patient note, we do not have enough information to determine if this patient has lung adenocarcinoma with EGFR mutations or his ECOG performance status. The only matching criterion is that the patient is male and over 18 years old. Given the lack of information on a lung adenocarcinoma diagnosis, EGFR mutations, clinical stage, performance status, and prior treatments, we cannot assume the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "671": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the clinical trial titled \"Improve the Treatment of Thoracic Esophageal Cancer\":\n\nPatient Note Analysis:\n- The patient is a 52-year-old African American man.\n- He has a history of progressive dysphagia with difficulty swallowing that has progressed from meats to liquids.\n- He reports that the obstruction is felt at the lower end of his sternum.\n- He has experienced a significant weight loss of 25 pounds.\n- There is no explicit mention of a diagnosis, but symptoms are suggestive of esophageal cancer.\n- There is no information about the patient's performance status (Karnofsky Performance Status), clinical staging, or laboratory results.\n\nClinical Trial Inclusion Criteria:\n- Age \u2264 70 years old (the patient is 52 years old, so he meets this criterion).\n- Karnofsky Performance Status (KPS) \u2265 80 (not mentioned in the patient note).\n- Pathological diagnosis is squamous cell carcinoma of thoracic esophagus which is treated initially (not confirmed in the patient note).\n- Clinical stage is c T1-3 N0-1 (not provided in the patient note).\n- The preoperative evaluation of organ function is tolerant of surgery and chemotherapy (not provided in the patient note).\n- The subject can understand and sign the informed consent form (ICF) (assuming the patient is competent, he should be able to meet this criterion).\n- Laboratory tests within specific ranges (not provided in the patient note).\n\nBased on the available information in the patient note, while the patient's age meets the criteria, there is insufficient information to determine whether the other criteria are met, such as the KPS score, clinical staging, pathological diagnosis, organ function evaluation, and laboratory test results. Therefore, further investigation would be needed to determine if this patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "672": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- Describes progressive dysphagia and significant weight loss (25 pounds).\n\nClinical Trial Inclusion Criteria:\n- Ages 18 to 35 years old\n- BMI > 22 kg/m2 (not provided in the patient note)\n- Self-report smoking > 10 cigarettes each day\n- Have access to a telephone and the internet\n- Demonstrate ability to access a specific website\n- Demonstrate ability to receive and respond to email\n- Willing to accept random assignment\n- Intending to be available for a 24-month intervention\n- At risk for weight gain (e.g., plan to quit smoking)\n\nThe patient does not meet the age criterion for the clinical trial, as he is 52 years old, and the trial requires participants to be between 18 to 35 years old. Additionally, the trial focuses on individuals who are at risk for weight gain, particularly in the context of quitting smoking. The patient note does not indicate that the patient is planning to quit smoking or that he is at risk for weight gain; in fact, he has experienced significant weight loss.\n\nTherefore, the patient does not meet the key inclusion criteria for age and the context of weight gain associated with quitting smoking. There is no indication that the patient intends to quit smoking or that he is at risk for weight gain, as he has already lost weight due to dysphagia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "673": {
        "output": "Based on the information provided:\n\nPatient Characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Weight loss of 25 pounds\n- Possible obstruction at the lower end of sternum (suggestive of esophageal involvement)\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed esophageal cancer or gastroesophageal junction tumor (including adenocarcinoma, squamous cell cancer, poorly differentiated epithelial malignancy, Siewert type I or II tumors)\n- Failure after no more than 2 prior chemotherapy regimens and 1 chemoradiation course\n- Measurable or evaluable disease by CT scan\n- Stable brain metastases, if present, after cranial irradiation\n- WHO performance status 0-2\n- Specific blood test requirements (bilirubin, AST/ALT)\n- Ability to take oral tablets\n- No clinically active interstitial lung disease\n- No severe hypersensitivity to gefitinib or excipients\n- No prior other malignancy that could confound results or interfere with therapy\n- No medical condition that interferes with safe trial participation\n- Not pregnant and using effective contraception if fertile\n- No chemotherapy within the past 6 weeks\n- No radiotherapy to the site of measurable or evaluable disease within the past 4 weeks\n- No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy, or experimental medications\n\nThe patient note does not provide enough information to confirm the histological diagnosis of esophageal cancer or specify the patient's WHO performance status. There is also no information on prior treatments that the patient may have received. The symptoms described are indicative of esophageal involvement, which is relevant to the trial, but without a confirmed histological diagnosis of esophageal cancer or gastroesophageal junction tumor, and without knowledge of any prior treatments, we cannot definitively establish eligibility.\n\nTherefore, based on the available information from the patient note, we would need further investigation to determine if the patient has a confirmed diagnosis and meets the other inclusion criteria, especially regarding previous treatments and performance status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "674": {
        "output": "Based on the patient note provided, the 52-year-old African American man has a history of progressive dysphagia, which is difficulty in swallowing, and has experienced significant weight loss. There is no mention of a cough, whether chronic or otherwise, in the note. The clinical trial is investigating the effect of Lidocaine as a treatment for chronic cough.\n\nTo match the patient to the trial, we must assess the inclusion criteria of the trial against the patient's medical condition:\n\n1. Male and female subjects, age 18 years and over - The patient is a 52-year-old man, which meets this criterion.\n2. History of cough for more than 8 weeks - There is no mention of a cough in the patient's history.\n3. Normal chest x-ray - There is no information provided regarding chest x-ray results.\n4. Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers - The patient note does not describe any cough symptoms, let alone a chronic cough.\n\nSince the patient's primary complaint is dysphagia and there is no indication of chronic cough, which is the focus of the clinical trial, the patient does not appear to meet the specific inclusion criteria regarding the condition being studied. Therefore, it is appropriate to conclude:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "675": {
        "output": "Upon reviewing the patient's condition and the inclusion criteria for the clinical trial titled \"Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing,\" it is clear that this patient does not meet the criteria required for participation in the study.\n\nThe patient note describes a 52-year-old African American man with progressive dysphagia associated with weight loss, which began with difficulty swallowing meat and progressed to include other solid foods, soft foods, and then liquids. The patient's symptoms point towards a possible esophageal disorder, potentially related to his history of heavy smoking and drinking. The point of obstruction is felt at the lower end of his sternum, which suggests an esophageal rather than oropharyngeal origin.\n\nThe clinical trial's inclusion criteria specifically list:\n- Stroke identified by neurological and radiological examination\n- Oropharyngeal dysphagia as confirmed by clinical and radiological examination\n- No prior history of oropharyngeal dysphagia by patient and/or caregiver report\n- No previous head/neck surgery or trauma that may impact swallowing ability\n- No other/concomitant neurological disorders (e.g., Parkinson's disease) that would impact oropharyngeal swallowing ability\n- Physician and patient/family agreement to participate\n\nThe patient in question has not been identified as having suffered a stroke, nor is there any indication of oropharyngeal dysphagia, which is a requirement for the trial. Instead, the patient's symptoms suggest a different etiology for his dysphagia. Therefore, this patient does not match the specific inclusion criteria needed for participation in the trial, which is focused on the rehabilitation of swallowing post-stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "676": {
        "output": "",
        "label": 0
    },
    "677": {
        "output": "Given the patient's history of progressive dysphagia, trouble swallowing various types of food, and weight loss, there is a suggestion of an underlying malignancy, possibly esophageal carcinoma, which is mentioned specifically as one of the categories in the clinical trial's inclusion criteria. The patient has located the obstruction sensation at the lower end of his sternum, which is consistent with the location of the esophagus and further implies esophageal involvement. However, the note does not confirm a diagnosis of advanced or metastatic non-hematologic malignancy, nor does it mention any prior treatments or imaging studies.\n\nFor the patient to be eligible for the clinical trial in question, the following criteria need to be met according to the trial description:\n\n1. Confirmed diagnosis of advanced, measurable or evaluable, nonresectable, and/or metastatic non-hematologic malignancy.\n2. The malignancy must have been progressive in the last 6 months as demonstrated by serial imaging.\n3. The patient must have failed conventional treatment or for whom no therapy of proven efficacy exists or who is not amenable to established treatment options, or tumor tissue must be available for determination of E-cadherin expression.\n4. Recovery from reversible toxicities of prior anti-cancer therapies.\n5. Age \u2265 18 years (the patient is 52 years old).\n6. Life expectancy \u2265 3 months.\n7. Written informed consent.\n8. ECOG performance score 0-1.\n9. Willingness to provide paired tumor biopsies for pharmacodynamic determination.\n\nGiven that the patient note does not confirm a diagnosis of cancer, the status of progressive disease, or any prior treatment, more information would be required to determine if the patient fits the specific criteria for esophageal carcinoma (III) mentioned in the trial inclusion criteria. The patient would need a confirmed diagnosis and information on any previous treatments before a referral could be made. Therefore, based on the information provided in the patient note:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "678": {
        "output": "Given the information provided in the patient note:\n\n- The patient is a 52-year-old African American man with progressive dysphagia, significant weight loss, and a history of heavy smoking and drinking.\n- The patient has difficulty swallowing which has progressed from solids to liquids and locates the obstruction at the lower end of his sternum.\n- There's no specific mention of a diagnosis of gastric cancer or adenocarcinoma of the gastro-oesophageal junction, but the symptoms could be indicative of such conditions. Further investigation is needed to confirm the diagnosis histologically.\n\nThe clinical trial's inclusion criteria are:\n\n- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease not amenable to curative therapy.\n- Measurable disease according to RECIST assessed using imaging techniques.\n- ECOG Performance status 0, 1, or 2.\n- Life expectancy of at least 3 months.\n- Male or female age \u2265 18 years.\n- Signed informed consent.\n- Assessment of HER2 status by the central laboratory prior to initiation of study treatment.\n- Able to swallow and retain oral medication.\n- LVEF \u2265 50% assessed by MUGA or cardiac ultrasound.\n\nThis patient's symptoms suggest that he could potentially have a gastric or gastro-oesophageal junction cancer, but without a histological confirmation, we cannot be certain. Furthermore, we do not have information regarding his ECOG Performance status, life expectancy, HER2 status, ability to swallow and retain oral medication, or LVEF status. \n\nGiven the lack of specific diagnostic information and other essential eligibility criteria, the best course of action would be to consider referring the patient to this clinical trial upon further investigation to confirm the diagnosis and other relevant clinical details. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "679": {
        "output": "Based on the patient note provided, here is the assessment:\n\nPatient note details:\n- The patient is a 52-year-old African American man.\n- History of heavy smoking and drinking.\n- Progressive dysphagia to solids, soft foods, and liquids.\n- Point of obstruction felt at the lower end of his sternum.\n- Weight loss of 25 pounds.\n\nClinical trial inclusion criteria:\n- Age \u226518 years.\n- Confirmed esophageal/gastroesophageal (GEJ) cancer (Siewert Type I and Type II only) on biopsy.\n- Dysphagia score \u22652.\n- Stage IV cancer/Metastatic disease.\n\nComparison:\n- The patient is over 18 years old, which meets the age criteria.\n- The patient has progressive dysphagia, which suggests a potential for esophageal cancer, and his dysphagia is severe as it has progressed to include liquids, indicating a possible Dysphagia score \u22652.\n- The location where the patient feels the obstruction (lower end of the sternum) could be indicative of esophageal or GEJ cancer.\n\nHowever, the patient note lacks specific information that confirms a diagnosis of esophageal or GEJ cancer, the dysphagia score, and whether the patient has Stage IV or metastatic disease. Therefore, further investigation is required to determine if the patient truly meets the clinical trial criteria:\n\n- Confirmation of esophageal/GEJ cancer through biopsy.\n- Determination of the dysphagia score.\n- Assessment of cancer staging to confirm if it is Stage IV or metastatic.\n\nWithout this information, we cannot definitively refer the patient but should consider further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "680": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia starting with solid foods and progressing to liquids\n- Weight loss of 25 pounds\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction\n- Inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy\n- Measurable disease according to RECIST\n- HER2 positive tumor\n- ECOG Performance status 0, 1, or 2\n- Life expectancy of at least 3 months\n- Age over 20 years\n- Signed informed consent\n\nAssessment:\n- The patient's age meets the trial's age criterion (over 20 years).\n- The patient has symptoms that could be suggestive of an advanced gastric problem, which could align with the trial's target population (adenocarcinoma of the stomach or gastro-oesophageal junction).\n\nHowever, several critical pieces of information are missing to determine if the patient fulfills the other inclusion criteria:\n- There is no mention of a histologically confirmed diagnosis of adenocarcinoma of the stomach or gastro-oesophageal junction.\n- The HER2 status of any tumor (if present) is not provided.\n- The patient's ECOG Performance status is not mentioned.\n- There is no confirmation of inoperable locally advanced or recurrent and/or metastatic disease, nor is there any mention of measurable disease according to RECIST.\n\nGiven these gaps in information, we cannot conclude that the patient is definitively eligible for this trial. Additional investigations, such as histological confirmation, HER2 status assessment, ECOG performance evaluation, and imaging studies, would be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "681": {
        "output": "Given the information provided in the patient note, we have a 52-year-old African American man presenting with progressive dysphagia that has progressed over several months from difficulty in swallowing solid foods to liquids. He also has a significant weight loss of 25 pounds, which could be a result of his dysphagia. However, there is no mention of symptoms such as hoarseness, throat clearing, throat pain, globus sensation, or chronic cough, nor is there any mention of a diagnosis of laryngopharyngeal reflux (LPR) or any related investigations such as a laryngoscopic examination or reflux symptom index score.\n\nLet's compare the patient's information to the clinical trial's inclusion criteria:\n\n- Patients with age of 12-75 years old (inclusive): The patient is 52 years old, which fits within the age range.\n- Patients with at least one symptom consistent with LPR, including hoarseness, throat clearing, throat pain, globus sensation in the throat, or chronic cough \u2267 4 weeks before entering study: The patient note does not mention any of these symptoms.\n- Patients with a total reflux symptom index (RSI) >10: There is no RSI score provided in the patient note.\n- Patients with a total reflux finding score (RFS) >5: There is no RFS provided in the patient note.\n- Patients or their legal representatives have signed the informed consent form: This is a procedural criterion that could be fulfilled if the patient agrees to participate.\n\nBased on the information provided, the patient does not clearly meet the symptomatic criteria for LPR as outlined in the trial's inclusion criteria. Given the lack of information on LPR-specific symptoms or any diagnostic scores related to LPR, it is not possible to definitively determine the patient's eligibility without further evaluation.\n\nTherefore, the assessment for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "682": {
        "output": "In this case, the patient is a 52-year-old African American man with a history of progressive dysphagia, weight loss, and difficulty swallowing various consistencies of food, which he feels are obstructed at the lower end of his sternum. The clinical trial in question is seeking healthy, ambulatory subjects with sore throat pain due to an upper respiratory tract infection (URTI), and the pain must have started within six days of the screening period.\n\nThe patient's symptoms of dysphagia and weight loss are not consistent with the typical symptoms of an upper respiratory tract infection, nor does the patient note mention a sore throat or any related symptoms. Additionally, the patient's difficulty swallowing and obstruction at the lower end of the sternum suggest a potential esophageal disorder, which is not relevant to the clinical trial's focus on sore throat pain relief.\n\nGiven that the patient's primary complaint is unrelated to the inclusion criteria of the clinical trial (which specifically requires sore throat pain due to URTI), he would not be an appropriate candidate for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "683": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, soft foods, and liquids\n- Obstruction at the lower end of the sternum\n- Weight loss of 25 pounds\n\nClinical Trial:\n- Title: Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer\n- Summary: Evaluate impact of stent insertion for palliative care in patients with malignant dysphagia due to end-stage inoperable esophageal cancer\n- Inclusion Criteria: Patients with end-stage inoperable esophageal cancer deemed candidates for intraluminal esophageal palliative stent insertions\n\nComparison:\n- The patient presents with progressive dysphagia and significant weight loss, which are common symptoms in esophageal cancer, particularly in the context of a history of heavy smoking and drinking.\n- The clinical trial is specifically looking to enroll patients with end-stage inoperable esophageal cancer for stent insertion.\n\nTo accurately assess the patient's eligibility, we would need a confirmed diagnosis of esophageal cancer, specifically end-stage and inoperable, as stated in the inclusion criteria of the clinical trial. The patient's symptoms are suggestive of esophageal cancer, but without a confirmed diagnosis, we cannot proceed with certainty.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "684": {
        "output": "Based on the patient note provided and the inclusion and exclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- Describes progressive dysphagia, difficulty swallowing various consistencies of food, and significant weight loss.\n- Points to obstruction at the lower end of the sternum.\n\nClinical Trial Inclusion Criteria:\n- Submit to a 24-hour urine cotinine test to determine smoking status.\n- Must be a non-smoker or a smoker meeting specific criteria.\n- Agree to consume a standardized vitamin and mineral supplement and avoid other supplements for the duration of the study.\n- No history of malabsorptive, gastrointestinal, or other metabolic disorders requiring special diet recommendations.\n- Body mass index (BMI) between 20 and 35 kg/m2.\n- Abstain from purple and red colored foods and beverages.\n- Abstain from the use of ANY mouthwashes during the 6-week study period.\n\nClinical Trial Exclusion Criteria:\n- Known allergy to strawberries, corn, and wheat products.\n- Active metabolic or digestive illnesses.\n- History of pituitary hormone diseases requiring hormonal administration.\n- Significant loss of gastrointestinal organs.\n- Altered immunity including cancer.\n- Heavy alcohol consumers defined as >15 glasses/week.\n- Antibiotic use in the last 6 months or on medications that affect bowel motility.\n- Are receiving or in need of dental treatment during the study period.\n- Noticeable open lesions, sores, active oral lesions, or history of leukoplakia or tumors.\n- Difficulty swallowing (dysphagia), pain with swallowing (odynophagia), salivary gland dysfunction, or xerostomia (dry mouth).\n\nEligibility Assessment:\n- The patient is a heavy smoker, which could potentially meet the smoker inclusion criteria if he smokes at least 10 cigarettes per day and has a urine cotinine level of >1000 ng/mL.\n- The patient has progressive dysphagia, which is a direct exclusion criterion for the trial since participants with difficulty swallowing are not eligible.\n\nBased on the information given, the patient would not be eligible for the clinical trial because he has difficulty swallowing, which is listed explicitly as an exclusion criterion. Even though he may meet the criteria for a smoker, the presence of dysphagia rules out his participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "685": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- Weight loss of 25 pounds\n\nClinical Trial:\n- Title: Tumor Markers in Lung Cancer: DCAMLK-1LK-1\n- Inclusion Criteria: >45 years of age\n\nThe inclusion criteria for the clinical trial are limited in detail but mention an age criterion of being over 45 years old. The patient is 52 years old, which meets the age criterion. However, the trial is focused on lung cancer and the patient's symptoms suggest a possible esophageal issue rather than lung cancer (dysphagia and pinpointing obstruction near the sternum are more indicative of esophageal than lung pathology). There is no mention of the patient having lung cancer or a suspected lung condition, nor is there any mention of other inclusion criteria that may be relevant (such as suspected malignant or benign lung diseases).\n\nTherefore, based solely on the information given and the age criterion, the patient meets the age requirement but there is no clear indication that the patient has a condition relevant to the trial's focus on lung cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "686": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient's symptoms do not align with the requirements for participation in the trial. The patient has a history of progressive dysphagia with significant weight loss, which is suggestive of an esophageal disorder or other gastrointestinal tract issue rather than an upper respiratory tract infection (URTI) for which the clinical trial is designed.\n\nThe inclusion criteria for the clinical trial specifically require subjects to have symptoms of an upper respiratory tract infection (URTI), such as nasal congestion associated with colds and flu symptoms like pain, headache, fever, or sore throat, none of which are mentioned in the patient note.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial as the symptoms described in the patient note are not indicative of an upper respiratory tract infection.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "687": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Evaluation of Two Different Thickening Products in Patients With Dysphagia,\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 52-year-old man, which meets the age criterion of being over 18 years old.\n- He has a history of progressive dysphagia, initially with solids and progressing to liquids, indicating a history of dysphagia.\n- The patient notes a specific location where food is obstructed, suggesting a physical manifestation of dysphagia.\n- There is no mention of the patient's ability to complete a dynamic fluoroscopic swallow study, but given the detailed description of the dysphagia, it is plausible that he would be able to undergo such a study.\n- The patient's ability to provide informed consent is not mentioned, but there is no indication that he would be unable to do so.\n\nClinical Trial Inclusion Criteria:\n- History of dysphagia necessitating a dynamic fluoroscopic swallow study.\n- Age > 18 years.\n- Ability to complete a comprehensive dynamic fluoroscopic swallow study.\n- Ability to provide informed consent for study participation.\n\nThe patient meets the age requirement and has a history of dysphagia. However, the inclusion criteria specifically mention the need for a history of dysphagia necessitating a dynamic fluoroscopic swallow study, and it is not clear from the patient note whether such a study is indicated or has been performed.\n\nBased on the available information, the patient appears to meet most of the inclusion criteria, but further investigation is required to confirm the necessity of a dynamic fluoroscopic swallow study and the patient's capacity to provide informed consent. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "688": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. The key clinical information needed to assess eligibility for the clinical trial is not explicitly provided, such as the histological diagnosis of esophageal squamous cell carcinoma and staging of the disease.\n\nThe inclusion criteria for the clinical trial require a histological or cytologic diagnosis of Esophageal squamous cell carcinoma, among other specific medical and laboratory requirements. While the patient's symptoms of dysphagia and weight loss are consistent with esophageal cancer, there is no confirmation of a histological or cytologic diagnosis of Esophageal squamous cell carcinoma, and no information is provided on cancer staging, ECOG performance status, prior anticancer therapy, and specific organ function parameters.\n\nGiven the lack of detailed information in the patient note, I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis, cancer staging, and other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "689": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids\n- Point of obstruction felt at the lower end of the sternum\n- Significant weight loss (25 pounds)\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed diagnosis of esophageal cancer\n- No prior palliative treatment or at least 6 months from the last operation, adjuvant radiation therapy, and adjuvant chemotherapy\n- Age between 18 to 75 years\n- Measurable or evaluable disease with specified tumor mass size requirements\n- Expected life expectancy of \u2265 3 months\n- Performance status of \u2265 80 on the Karnofsky scale\n- Normal marrow function and specific blood test results\n- Normal electrocardiogram results and no history of congestive heart failure\n- Good compliance and agreement for follow-up\n- Written informed consent\n\nAssessment:\n- The patient's age falls within the required range (18 to 75 years).\n- The patient has progressive dysphagia with weight loss, which may indicate advanced esophageal cancer, although this is not confirmed histologically in the note.\n- There is no indication in the patient note about prior treatments, performance status, blood tests, ECG results, or life expectancy, which are required to determine eligibility fully.\n\nGiven that the patient has symptoms that are suggestive of esophageal cancer, he could potentially meet the criteria if further medical evaluation (e.g., histological confirmation, imaging, performance status assessment) supports it. However, without confirmation of a histologically confirmed diagnosis of esophageal cancer and other required details, we cannot definitively determine his eligibility.\n\nTherefore, I would rate this as:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "690": {
        "output": "",
        "label": 0
    },
    "691": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Satiety Innovation- Study 793. University of Aberdeen,\" we need to compare the patient's characteristics to the inclusion criteria of the study.\n\nThe inclusion criteria for the clinical trial are:\n- Males and females\n- 18-65 years old\n- Body Mass Index (BMI) 27-35kg/m^2\n- Overall healthy\n- Weight Stable (<3 kg change in the past 4 months, before the trial).\n\nThe patient's characteristics from the patient note:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids\n- Significant weight loss (25 pounds)\n\nFrom the given information:\n\n- The patient is a 52-year-old man, which fits within the 18-65 years age range specified in the inclusion criteria.\n- However, there is no information provided about the patient's BMI. The patient has experienced significant weight loss, which could affect BMI, but we do not have the patient's current or previous weight to calculate it.\n- The patient's history of heavy smoking and drinking, along with progressive dysphagia and significant weight loss, suggests he may not be \"overall healthy,\" as required by the trial.\n- The patient has lost 25 pounds, which indicates he has not been weight-stable in the past 4 months, violating one of the criteria.\n- The clinical trial is focused on appetite, satiety, and gut health in overweight and obese volunteers, whereas the patient has issues with dysphagia and weight loss, which are not related to the study's focus.\n\nBased on the information provided, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the patient's health issues and significant weight loss are not aligned with the characteristics of the target population for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "692": {
        "output": "After reviewing the patient's note and the clinical trial inclusion criteria, here are the assessments:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids, weight loss of 25 pounds\n- Obstruction sensation at the lower end of the sternum\n\nClinical Trial Inclusion Criteria:\n- Age between 20-85 years old\n- First-time stroke confirmed by computed tomography or magnetic resonance imaging\n- Dysphagia > 3 weeks, with preservation of the swallowing reflex\n- Currently on a restricted diet, with a Functional Oral Intake Scale (FOIS) score of 5 or less\n- Mini-Mental State Examination (MMSE)> 21\n- No obvious mental depression, receptive aphasia or cognitive impairment\n\nThe patient's description of progressive dysphagia does not indicate that he has had a stroke, which is a requirement for this clinical trial. The trial specifically targets stroke-related dysphagia, and there is no mention of a stroke in the patient's history. Therefore, the patient does not meet the key inclusion criteria of having had a stroke with resulting dysphagia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "693": {
        "output": "",
        "label": 1
    },
    "694": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the relevant points:\n\nPatient note:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia beginning several months ago\n- Difficulty swallowing that has progressed to liquids\n- Weight loss of 25 pounds\n\nClinical trial:\n- Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma\n- Stage T2-3N0M0 disease of thoracic esophageal squamous cell carcinoma (TESCC) confirmed by pathology studies\n- Patients who received R0 operations in Cancer Institute & Hospital, CAMS\n- KPS\u226570 before radiotherapy\n- Did not receive neoadjuvant or adjuvant treatment\n- No clear recurrent or metastatic lesions before radiotherapy\n- IMRT is accepted\n- Regular follow-up\n\nFrom the patient note, we do not have information that confirms a diagnosis of esophageal carcinoma, the stage of disease, or whether the patient has undergone any surgery (R0 resection) or other treatments related to esophageal carcinoma. The patient does have symptoms that could be suggestive of esophageal disease (e.g., progressive dysphagia, weight loss), but without more specific information, such as results from pathology studies or details on prior treatments, we cannot definitively determine if he meets the inclusion criteria for the clinical trial.\n\nAt this point, we would need additional information to confirm the patient's diagnosis, staging, and treatment history. The patient would need to be evaluated further to confirm eligibility for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "695": {
        "output": "",
        "label": 1
    },
    "696": {
        "output": "",
        "label": 0
    },
    "697": {
        "output": "",
        "label": 0
    },
    "698": {
        "output": "",
        "label": 0
    },
    "699": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Financial Incentives for Maintenance of Weight Loss,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the study:\n\nInclusion Criteria for the Clinical Trial:\n- Adults age 30-80\n- BMI between 30 and 45 prior to starting Weight Watchers\n- Have a documented weight loss of at least 5kg in the past 4-6 months before enrolling\n- Stable health\n\nPatient Characteristics:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Difficulty swallowing that progressed from solids to liquids\n- Sensation of obstruction at the lower end of the sternum\n- Weight loss of 25 pounds (unspecified time frame)\n\nAssessment:\n- The patient is within the age range required (30-80 years old).\n- There is no information about the patient's BMI prior to the onset of symptoms or prior to starting Weight Watchers.\n- The patient has experienced significant weight loss; however, it is not specified whether this loss is documented or occurred within the specified 4-6 months before enrolling.\n- The patient's health cannot be considered stable due to progressive dysphagia and significant weight loss, which are concerning for an underlying medical condition, potentially esophageal cancer given his symptoms and risk factors.\n\nGiven that the patient's significant weight loss is likely due to progressive dysphagia rather than a structured weight loss program like Weight Watchers, and considering the absence of BMI information and concerns about the stability of the patient's health, the patient does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "700": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for this trial.\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia (difficulty swallowing)\n- Weight loss (25 pounds)\n\nClinical Trial Inclusion Criteria:\n- ASA I-II patients\n- Aged between 20 and 65 years\n- Undergoing 1 or 2 level posterior spinal fusion in prone position with tracheal intubation\n\nThe trial is focused on patients who are undergoing spinal surgery in the prone position with tracheal intubation and aims to compare the effects of magnesium sulfate and dexamethasone on postoperative sore throat.\n\nThe patient in the note is experiencing progressive dysphagia, likely related to his history of smoking and drinking, and there is no indication that he is undergoing spinal surgery. Additionally, the patient's symptoms appear to be related to an esophageal condition rather than a condition requiring spinal surgery.\n\nGiven that the patient does not meet the specific requirement of needing spinal surgery, nor is there any indication that he is scheduled for such a procedure, he does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "701": {
        "output": "The patient in question is a 52-year-old African American man with progressive dysphagia, history of heavy smoking, and drinking. He has experienced significant weight loss due to his condition.\n\nThe clinical trial aims to determine the effectiveness of anti-smoking messages and is looking for participants who are either never smokers or former smokers aged 18-25 years who are part of the Survey Sampling International (SSI) panel.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the following reasons:\n\n1. Age: The patient is 52 years old, which is outside the specified age range of 18-25 years for the clinical trial.\n2. Smoking Status: The patient has a history of heavy smoking, and there is no indication that he is a never smoker or a former smoker who has not smoked in the past 30 days.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "702": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial. The patient presents with progressive dysphagia, weight loss, and difficulty swallowing that is consistent with esophageal obstruction rather than pharyngitis. The clinical trial is focused on the onset of action of flurbiprofen in patients with pharyngitis, and the inclusion criteria specifically mention a primary diagnosis of pharyngitis confirmed by a Tonsillo-Pharyngitis Assessment, a complaint of sore throat with an onset \u2264 4 days prior to randomization, and other symptoms of upper respiratory tract infection.\n\nThe patient's symptoms do not align with those specified in the inclusion criteria for the clinical trial, as there is no mention of a sore throat, recent onset of symptoms, or other signs of an upper respiratory tract infection. Moreover, the primary issue seems to be related to the esophagus rather than the pharynx or tonsils.\n\nTherefore, the patient's condition does not match the target of the clinical trial, which is pharyngitis and related symptoms. Consequently, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "703": {
        "output": "",
        "label": 0
    },
    "704": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient, a 52-year-old African American man with a history of progressive dysphagia and significant weight loss, does not appear to meet the inclusion criteria for the study on Colflex, which is testing the safety and efficacy of an oral spray on subjects experiencing colds or sore throats. The patient's symptoms and medical condition (dysphagia and weight loss) are unrelated to the conditions being studied (colds and sore throats), and there is no indication that the patient is in good health as required by the trial's inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "705": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He has progressive dysphagia (difficulty swallowing) that has worsened over time.\n- He has notable weight loss.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focusing on the natural history of head and neck cancer precursors in Taiwan.\n- Participants must be adults aged 21 years and older.\n- Participants can be some with abnormal growths in the mouth, some without any, and some with head and neck cancer.\n- The study targets individuals who chew betel-quid or smoke, screened through visual inspection for the presence of precursor lesions or cancer.\n\nExclusion Criteria Analysis:\n- Participants younger than 21 years are excluded.\n- Individuals with a history of head and neck cancer are excluded.\n\nComparison:\n- The patient meets the age criterion.\n- The patient has a history of heavy smoking, which is relevant to the study's interest in individuals who smoke.\n- There is no mention of abnormal growths in the mouth or previous head and neck cancer, so we cannot confirm if the patient has precursor lesions or invasive cancer. Further investigation would be needed to determine if the dysphagia is related to such conditions.\n\nHowever, the trial is location-specific (Taiwan), and it is not clear if the patient is in Taiwan or can travel there for the study. Additionally, the trial specifically mentions an interest in individuals who chew betel-quid, which is not mentioned in the patient's history.\n\nGiven the available information, the patient could potentially be of interest for the study if his dysphagia is related to the head and neck cancer precursors the trial is investigating. However, there is uncertainty regarding the patient's location and whether his condition is related to the study focus. Therefore, further investigation is needed before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "706": {
        "output": "The patient in question is a 52-year-old African American man with progressive dysphagia, a history of heavy smoking and drinking, and significant weight loss. The clinical trial is investigating the effects of a carbohydrate drink on cognitive function and exercise performance in adults and includes measures of mental function, appetite, and metabolism. \n\nThe inclusion criteria for the clinical trial are quite specific: healthy men or women aged 18 to 35 years old. \n\nGiven the patient's age, which is 52 years old, he falls outside of the specified age range for the trial (18-35 years old). Additionally, the patient's health status is not described as \"healthy,\" given his complaints of progressive dysphagia and significant weight loss, which are concerning symptoms that could indicate an underlying health condition. Thus, he does not meet the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "707": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose,\" we need to evaluate the patient's condition against the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n1. Histologically proven adenocarcinoma of the gastro-oesophageal junction\n2. Age 18 years or older\n3. International Union Against Cancer (UICC) T2-4 N0-2 M0, potentially resectable disease treated by the CROSS regimen\n4. WHO 0-2\n\nFrom the patient note, we know that:\n- The patient is a 52-year-old African American man, which meets the age criterion.\n- He has a history of heavy smoking and drinking and describes progressive dysphagia, with trouble swallowing that progressed to the point of obstruction at the lower end of his sternum and significant weight loss. \n\nHowever, the patient note does not provide information on:\n- Whether the dysphagia is due to histologically proven adenocarcinoma of the gastro-oesophageal junction.\n- The UICC stage of the disease, if it is indeed cancer.\n- Whether the patient is being treated by the CROSS regimen or is eligible for it.\n- The patient's WHO performance status.\n\nGiven the lack of information, we cannot conclusively determine the patient's eligibility for the trial based on the provided patient note. The symptoms described could be suggestive of an esophageal cancer, and the patient\u2019s age fits the criteria, but without further diagnostic information confirming the diagnosis, staging, treatment regimen, and performance status, we cannot confidently refer the patient for the trial.\n\nTherefore, the patient should be considered for referral to the clinical trial upon further investigation to confirm the diagnosis and other relevant details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "708": {
        "output": "",
        "label": 0
    },
    "709": {
        "output": "The patient is a 52-year-old African American man with a history of heavy smoking. His symptoms include progressive dysphagia, weight loss, and the sensation of food obstruction at the lower end of his sternum. \n\nThe clinical trial in question is focused on providing feedback to light smokers regarding their health and exposure to tobacco-related chemicals. The inclusion criteria for this trial are as follows:\n\n1. Male or female cigarette smokers, 18-75 years old.\n2. Smoked an average of less than 10 cigarettes per day during the past month.\n3. A personally signed and dated informed consent document.\n\nWhile the patient is a smoker within the age range of the trial's inclusion criteria, there is no information provided about how many cigarettes per day he smokes. The patient's history of heavy smoking might suggest that he smokes more than 10 cigarettes per day, which would make him ineligible for the trial. However, without specific information on the number of cigarettes he smokes, we cannot definitively determine his eligibility.\n\nGiven the lack of detailed information about his smoking habits, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "710": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility:\n\nPatient note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia that began several months ago\n- Difficulty swallowing solids to liquids\n- Weight loss of 25 pounds\n- Obstruction feeling at the lower end of the sternum\n\nClinical trial inclusion criteria:\n- Profound oropharyngeal feeding tube dependent dysphagia of greater than 12 months duration, with aspiration documented on fluoroscopic swallow study\n- Receiving 100% of nutritional requirements by enterogastric tube\n- 18 years of age and older\n- Diminished upper esophageal sphincter opening as defined in the criteria\n- Failure of > 3 months of dysphagia therapy within 3 months of study enrollment\n- No history of noncompliance with feeding recommendations\n- Cognition within normal limits (AMTS score > 6)\n- Normal manual dexterity (BBT)\n- Physical strength to pull the SED (able to lift a 5 lb weight)\n- Ability to understand informed consent and comply with follow-up (normal AMTS score)\n- Bilateral vocal fold mobility or unilateral immobility with complete glottic closure\n\nAssessment:\n- The patient has progressive dysphagia, but the duration is not specified as greater than 12 months.\n- There is no mention of the patient being feeding tube dependent or receiving 100% of nutritional requirements by enterogastric tube.\n- The patient's upper esophageal sphincter opening dimensions have not been provided.\n- There is no information on the patient having failed dysphagia therapy for more than 3 months within the last 3 months.\n- The patient's cognitive and physical abilities have not been assessed as per the trial's requirements.\n\nGiven the information we have, the patient does not meet several key inclusion criteria (dependent on feeding tube, duration of dysphagia, documented aspiration, therapy failure, and specific measurements and assessments). There is not enough information to consider referring the patient without further investigation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "711": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 52-year-old African American man with a history of heavy smoking and drinking, and progressive dysphagia. The patient describes difficulty swallowing which progressively worsened from solids to liquids, and he experiences obstruction at the lower end of his sternum, along with significant weight loss.\n\nThe inclusion criteria for the clinical trial are for patients undergoing an elective total thyroidectomy or hemithyroidectomy with lymphadenectomy for thyroid cancer. The trial is focused on the effects of dexamethasone on wound healing after thyroid surgery.\n\nThe patient's symptoms and history given in the note do not indicate that he is scheduled for or has a diagnosis that would lead to a total thyroidectomy or hemithyroidectomy for thyroid cancer. The patient's symptoms suggest a possible esophageal disorder, which is unrelated to the focus of the clinical trial.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial, as there is no mention of thyroid cancer or planned thyroid surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "712": {
        "output": "Based on the patient note provided, the 52-year-old African American man has a history of heavy smoking and drinking and describes progressive dysphagia. His trouble swallowing has progressed from difficulty with solids to liquids, and he has experienced significant weight loss.\n\nThe clinical trial in question is studying the effects of Oropharyngeal Strengthening on Dysphagia in Patients Post-stroke. Its inclusion criteria specify that participants must have a clinical diagnosis of unilateral ischemic stroke within 6 months of the diagnosis, among other criteria related to the severity of dysphagia, age, and ability to participate in the intervention.\n\nThe patient in the note does not meet the key inclusion criterion of having a unilateral ischemic stroke. Since the study is specifically targeting post-stroke patients, and there is no mention of a stroke in the patient's history, he would not be eligible for this particular clinical trial.\n\nTherefore, the assessment of eligibility for this patient for the clinical trial in question is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "713": {
        "output": "",
        "label": 0
    },
    "714": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, soft foods, and liquids\n- Weight loss of 25 pounds\n- Obstruction sensation at the lower end of the sternum\n\nClinical Trial Inclusion Criteria:\n- Pathologically confirmed esophageal carcinoma\n- Stage I to IVa by EUS and CT/MRI, without contraindication for radical radiotherapy\n- Aged \u2265 70 and < 85 years\n- ECOG scores 0-2\n- Specific blood count and serum chemistry parameters within a certain range\n- Signed informed consent and good compliance\n\nThe patient's age (52 years) does not meet the age criterion for the clinical trial, which requires participants to be aged \u2265 70 and < 85 years. Therefore, despite the patient's symptoms being suggestive of esophageal cancer, which could potentially align with the trial's target condition, the age discrepancy is a clear exclusion factor. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "715": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we can analyze the patient's eligibility for the trial:\n\nThe patient note describes:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- Weight loss of 25 pounds\n\nThe clinical trial's inclusion criteria state:\n- Men and women ages 18 and older\n- American Society of Anesthesiologists physical status classification system I and II\n- Patient coming for elective surgery (except head and neck) requiring general anesthesia\n- Patients staying for at least 24 hours postoperatively\n- Patients provide informed consent\n- Patients presenting for surgery >1 hour in length and <6 hours\n\nThe patient note does not provide information indicating that the patient is scheduled for elective surgery or that he would require general anesthesia, which are necessary conditions for inclusion in the trial.\n\nThe patient is experiencing progressive dysphagia and weight loss, which may indicate underlying health issues that are not related to postoperative sore throat, the focus of the study. Additionally, the presence of heavy smoking and drinking could contribute to his dysphagia and weight loss, suggesting the patient may have more complex medical needs than what the trial is addressing.\n\nWithout information about the patient's ASA physical status classification or any upcoming elective surgery, we cannot establish their eligibility for the trial. Based on the current information, there is no indication that this patient would be coming for elective surgery, which is a requirement for the clinical trial.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "716": {
        "output": "Based on the patient note provided, the 52-year-old African American man has a history of progressive dysphagia, weight loss, and difficulty swallowing that has progressed from solids to liquids. He locates the obstruction at the lower end of his sternum, which could be suggestive of an issue at the gastroesophageal junction. However, there is no explicit mention of a diagnosis of gastric or gastroesophageal junction adenocarcinoma, nor confirmation of HER2-negative status, which are required as per the clinical trial's inclusion criteria.\n\nThe inclusion criteria for the clinical trial are:\n\n- Patients \u2265 18 years\n- Histologically confirmed inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction\n- ECOG performance status 0-2\n- Adequate renal, hepatic, and hematologic function\n- Measurable or nonmeasurable disease according to RECIST\n\nGiven that the patient's diagnosis and HER2 status are not provided in the note, we cannot confirm if he meets the specific inclusion criteria regarding the type and status of cancer. However, the symptoms he is experiencing are worrisome for a possible cancer at the gastroesophageal junction, and further investigation such as a biopsy would be needed to confirm this.\n\nTherefore, based on the information available, the patient does not clearly meet the inclusion criteria without further diagnostic confirmation. However, given his symptoms, there is a possibility that he could meet the criteria once additional diagnostic information is obtained.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "717": {
        "output": "Based on the information provided, the patient in question is a 52-year-old African American man with a history of heavy smoking and drinking and progressive dysphagia, which has led to significant weight loss. There is no mention of the patient having a twin, which is a requirement for participation in the \"Brain Regulation of Appetite in Twins\" clinical trial. Furthermore, the patient's medical issues do not seem directly related to appetite or obesity, which are the main focus of the study.\n\nThe inclusion criteria for the clinical trial specifically require that participants must be able to come with their twin to the University of Washington, suggesting that only twin pairs are eligible. The patient's note does not indicate that he has a twin, nor does it provide any information about his body mass index (BMI) or whether he would fit into any of the specific aims of the study.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial, as there is no indication that he has a twin or that the specific aims of the study pertain to his condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "718": {
        "output": "Considering the provided patient note and the inclusion criteria for the clinical trial titled \"Effect of Saline Lubrication on Post-intubation Complications,\" let's compare the details:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia, difficulty swallowing various textures, weight loss\n\nClinical Trial Inclusion Criteria:\n- Patients aged between 20-80 years\n- Scheduled for surgery under general anesthesia requiring orotracheal intubation\n\nBased on the information given in the patient note, the patient is within the age range required for the clinical trial. However, there is no indication that the patient is scheduled for surgery under general anesthesia or that he would require orotracheal intubation. The patient's symptoms suggest a possible esophageal condition like esophageal cancer or stricture, which is not related to the focus of the clinical trial.\n\nGiven that the patient's current medical issue does not involve a surgery requiring orotracheal intubation, he does not meet the specific inclusion criteria regarding the need for general anesthesia and intubation. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "719": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Brief Tobacco Cessation Intervention,\" we will evaluate the patient's characteristics against the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- No indication that the patient is a Chinese resident or can communicate in Chinese\n\nClinical Trial Inclusion Criteria:\n- Outpatients aged 18 years or above\n- Smoke on at least 1 day in the past 30 days\n- Chinese residents able to communicate in Chinese (Mandarin or Cantonese)\n- Has a telephone\n\nThe patient meets the age criterion and is a smoker, which aligns with two of the inclusion criteria. However, there is no indication that the patient is a Chinese resident or that he can communicate in Chinese. This information is essential for inclusion in the trial, as the study is being conducted in Guangdong province, China, and requires participants to communicate in Chinese.\n\nTherefore, based on the information provided in the patient note, the patient does not meet all the inclusion criteria for the clinical trial. Specifically, the criteria that he does not meet are being a Chinese resident and the ability to communicate in Chinese.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "720": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the following:\n\n- The patient is a 52-year-old African American man, which meets the age requirement of \u226518 years.\n- The patient has a history of progressive dysphagia and weight loss, which may suggest esophageal cancer, but there is no specific mention of a histologically verified diagnosis of adenocarcinoma of the esophagus according to the UICC definition (TNM7).\n- There is no information provided about the staging of the patient's condition (e.g., cT1N+, M0 or cT2-4a, N0/+, M0), which is necessary to determine eligibility based on the inclusion criteria.\n- The patient's note does not provide information on prior abdominal or thoracic radiotherapy, ECOG Performance status, adequate cardiac, bone marrow, respiratory, renal, or liver function, or if the patient has provided written informed consent.\n\nSince the diagnosis of adenocarcinoma of the esophagus is not confirmed in the patient's history, and other required medical information is missing, we cannot determine with certainty if the patient meets the inclusion criteria for the trial. Further investigation would be required to obtain a histological verification of the cancer, staging information, and additional medical assessments.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "721": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, then soft foods, and liquids\n- Weight loss of 25 pounds\n- Obstruction sensation at the lower end of his sternum\n\nClinical Trial Inclusion Criteria:\n- Pathologically or cytologically diagnosed phase II-III esophageal carcinoma or IV thoracic segments carcinoma with supraclavicular lymph nodes metastasis\n- Measurable lesion of newly diagnosed esophageal carcinoma\n- Age 18-75 years old\n- ECOG performance status \u22642\n- Expected survival date \u22653 months\n- No serious diseases of important organs\n- Signed informed consent\n\nThe patient has progressive dysphagia and weight loss, which are common symptoms of esophageal cancer, and he locates the obstruction at the lower end of his sternum, which could correspond to the location of esophageal carcinoma. However, we don't have information confirming a diagnosis of esophageal cancer, nor do we have details about the stage of disease, performance status, or whether the patient has a measurable lesion or metastasis.\n\nThe patient's age fits the trial's criteria. However, without further medical evaluation and diagnostic confirmation (pathological or cytological) of esophageal carcinoma, we cannot definitively say that the patient is eligible for the trial.\n\nGiven the symptoms that could be suggestive of esophageal cancer and the patient's age, which aligns with the trial's criteria, the patient could potentially be eligible for the trial upon further medical evaluation and diagnostic confirmation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "722": {
        "output": "The patient note describes an 8-year-old male presenting with fever, dyspnea, cough, and bilateral lung infiltrates. There is no mention of the patient being HIV-positive, which is a crucial inclusion criterion for the clinical trial.\n\nThe clinical trial is looking for HIV-positive patients who are 13 years of age or older, with specific treatment experience criteria.\n\nGiven the information provided:\n\n- The patient is 8 years old, which does not meet the age criterion of being 13 years or older.\n- There is no indication that the patient is HIV-positive.\n\nThus, based on the information in the patient note, this patient does not meet the age requirement, nor is there any information about an HIV-positive status, which is essential for participation in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "723": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial as follows:\n\nPatient Note:\n- The patient is an 8-year-old male.\n- Presents with fever, dyspnea, cough, and a history of loose stools.\n- Recently returned from vacation in Colorado.\n- In respiratory distress with bronchial respiratory sounds on the left.\n- Chest x-ray shows bilateral lung infiltrates.\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically confirmed glioblastoma multiforme.\n- Recurrent disease documented by MRI after prior radiotherapy.\n- Age over 18.\n- Performance status Karnofsky 70-100%.\n- Specific hematopoietic, hepatic, renal, and cardiovascular requirements.\n- No history of pulmonary disease that would affect pulmonary function.\n- Not pregnant or nursing, with effective contraception required for fertile patients.\n- No other malignancy except specified conditions.\n- Specific prior therapy requirements, including timeframes for chemotherapy and radiotherapy.\n\nThe patient is an 8-year-old male with respiratory issues and no mention of glioblastoma multiforme. The trial is specifically for adult patients (over 18 years of age) with recurrent glioblastoma multiforme. This patient does not meet the age criterion nor is there any indication that they have the specific type of brain tumor the trial is addressing.\n\nTherefore, the patient is not eligible for the clinical trial based on the age requirement and the lack of a glioblastoma multiforme diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "724": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises.\"\n\nPatient note key points:\n- 8-year-old male\n- Presents with fever, dyspnea, cough, and bilateral lung infiltrates\n- No mention of sickle cell disease (SCD) or pain crisis\n\nClinical trial key points:\n- Patients must be 10 years of age or older\n- Must have a diagnosis of SCD (specific types mentioned, with exclusion of Hgb SC)\n- Must present in vaso-occlusive crisis (VOC)\n- Requires written informed consent/assent\n\nThe patient in the note is 8 years old, which is below the minimum age requirement of 10 years for the clinical trial. Furthermore, there is no information provided in the patient note to suggest that the patient has a diagnosis of sickle cell disease or that he is presenting in vaso-occlusive crisis. Therefore, based on the information given, the patient would not meet the inclusion criteria of the clinical trial due to age and lack of a sickle cell disease diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "725": {
        "output": "",
        "label": 0
    },
    "726": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 8-year-old male with symptoms consistent with a respiratory infection after a vacation in Colorado.\n\nClinical Trial:\n- The study is collecting blood samples from HIV infected individuals.\n- Inclusion criteria mention participation in a qualifying CPCRA clinical trial and signed informed consent.\n\nAssessment:\nThe patient note does not mention HIV infection, nor does it indicate that the patient has been or is currently enrolled in a CPCRA clinical trial. Furthermore, the patient is an 8-year-old child, and the inclusion criteria do not specify any age restrictions, but typically clinical trials involving blood collection would have an age limit due to ethical considerations for minors. Without any information to suggest this patient is HIV positive or involved in a CPCRA trial, it is not appropriate to refer the patient to this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "727": {
        "output": "",
        "label": 0
    },
    "728": {
        "output": "Based on the patient note provided, the patient is an 8-year-old male who presents with fever, dyspnea, cough, and bilateral lung infiltrates. This suggests he is currently unwell and suffering from respiratory distress, possibly due to an infection or other acute condition.\n\nThe clinical trial in question is investigating the safety and immunogenicity of a TBE vaccine in healthy children aged 1 to 6 years. The inclusion criteria specify that participants must be clinically healthy and between 1 year (from the 1st birthday) to the last day before the 6th birthday.\n\nThe patient presented does not meet the criteria for the following reasons:\n\n1. Age: The patient is 8 years old, which is beyond the specified age range of 1 to 6 years for the clinical trial.\n2. Current Health Status: The patient is not clinically healthy as he is experiencing fever, dyspnea, cough, and has been diagnosed with bilateral lung infiltrates.\n\nTherefore, the patient is not eligible for this clinical trial based on the age and health status requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "729": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient note:\n- An 8-year-old male\n- Presents with fever, dyspnea, and cough\n- Recent travel history to Colorado\n- Symptoms of respiratory distress and lung infiltrates observed on chest x-ray\n\nClinical trial inclusion criteria:\n- Male and female children aged 6 to 16 years\n- Must be clinically healthy\n- Legal representative (and the volunteer, if older than 8 years) must understand the study and give written informed consent\n- Legal representative must agree to keep a Volunteer Diary\n\nThe patient in the note is 8 years old, which meets the age requirement of the clinical trial. However, the trial requires participants to be clinically healthy, and the patient is currently presenting with symptoms of respiratory distress and has bilateral lung infiltrates, indicating that he is not clinically healthy at the moment.\n\nSince the patient's current health condition does not meet the criteria of being \"clinically healthy,\" he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "730": {
        "output": "Assessing the eligibility of the 8-year-old male patient for the clinical trial titled \"Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR\", the following points are relevant:\n\n1. The patient is 8 years old, which is below the required age range of 16 to 65 years.\n2. No information is provided on the patient's overall health status, but the current presentation with fever, dyspnea, and cough suggests he may not be clinically healthy at the moment, which is a requirement for the trial.\n3. The trial requires written informed consent, and while it is mentioned that for volunteers under 18 years of age, written informed consent of the parents/guardian is available, the patient's current health issue is not related to the study's focus on vaccination safety.\n4. The patient's current medical condition does not seem to be related to the focus of the clinical trial, which is to assess the safety of a vaccination schedule for tick-borne encephalitis (TBE).\n\nGiven the information provided, the most crucial disqualifying factor is the patient's age, which does not fall within the specified range for the clinical trial. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "731": {
        "output": "Patient Note Analysis:\n- 8-year-old male\n- Presents with fever, dyspnea, cough, and recent loose stools\n- Recently returned from vacation\n- In respiratory distress with bronchial respiratory sounds on the left\n- Bilateral lung infiltrates on chest x-ray\n\nClinical Trial Analysis:\n- Title: Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years\n- Purpose: To investigate the safety of FSME-IMMUN NEW vaccine\n- Age criteria: 1 year to < 16 years\n- Health status criteria: Clinically healthy (physician would have no reservations vaccinating with FSME-IMMUN NEW outside of a clinical trial)\n- Consent criteria: Written informed consent from both parents/legal guardians (and additional consent for children older than 8 years in Germany/Austria)\n- Diary criteria: Agreement to keep a volunteer diary\n\nComparison:\n- Age: The patient fits the age criteria (1 year to < 16 years).\n- Health Status: The patient is not clinically healthy as he presents with fever, respiratory distress, and bilateral lung infiltrates, which indicates an acute illness.\n- Consent: No information is provided about consent, but assuming it can be obtained.\n- Diary: No information is provided, but this is a minor point and can potentially be agreed upon.\n\nConclusion:\nThe patient does not meet the health status inclusion criterion of being clinically healthy for the trial, as he is currently experiencing symptoms of an acute respiratory illness. Therefore, the patient would not be eligible for the trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "732": {
        "output": "Based on the information provided:\n\nThe patient is an 8-year-old male who presents with symptoms of fever, dyspnea, cough, and a history of loose stools. He has bilateral lung infiltrates evident from a chest x-ray.\n\nThe clinical trial in question is a follow-up study assessing the seropersistence of TBE antibodies in children and adolescents who participated in Baxter study 209. The study also looks at the immune response to a booster vaccination administered after the primary immunization.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Participation in Baxter study 209.\n2. Understanding of the study and agreement to its provisions by the child/adolescent and their parents/legal guardians.\n3. Written informed consent from the parents/legal guardians and written informed assent from the child/adolescent.\n4. Receipt of the third vaccination with FSME-IMMUN 0.25 ml during Baxter study 209.\n5. A blood sample taken after the third vaccination during Baxter study 209.\n6. An ELISA concentration > 126 VIE U/ml and/or a NT titer >=10 after the third vaccination in Baxter study 209.\n7. Agreement to keep a Subject Diary.\n\nThe patient note does not mention any previous participation in Baxter study 209, nor does it provide information on TBE antibody levels or vaccinations received. Without this specific information, it cannot be determined if the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, based on the available information, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "733": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the 8-year-old male patient does not meet the inclusion criteria for the trial. The inclusion criteria specify that participants must have received two vaccinations with FSME-IMMUN 0.5 ml during Study 225 and must be clinically healthy, among other requirements. The patient in question does not mention receiving these vaccinations, and he is currently presenting with symptoms (fever, dyspnea, cough, and bilateral lung infiltrates) that indicate he is not clinically healthy at the moment.\n\nTherefore, I would not refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "734": {
        "output": "Based on the patient note provided, the 8-year-old male patient does not meet the inclusion criteria for the clinical trial in question. The inclusion criteria for the trial specifically require that the children must have participated in Study 146A, received a complete 3-immunization primary vaccination series with either 0.5 ml or 0.25 ml TicoVac in that study, and received FSME-IMMUN 0.25 ml Junior for their first booster vaccination approximately 3 to 4 years after their third vaccination in Study IMAG-146A.\n\nThe patient's note does not mention any participation in Study 146A, nor does it specify that he has received the TBE booster vaccination as required. Instead, the patient note discusses an acute presentation with fever, dyspnea, cough, and bilateral lung infiltrates, which is not related to the TBE vaccination history.\n\nTherefore, the patient does not meet the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "735": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate whether the patient would be eligible for the trial.\n\nPatient note:\n- An 8-year-old male\n- Presents with fever, dyspnea, and cough\n- Recent vacation in Colorado\n- Loose stools prior to onset of fever and cough\n- Respiratory distress and bronchial respiratory sounds on the left\n- Bilateral lung infiltrates on chest x-ray\n\nClinical trial:\n- Title: Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever\n- Focus: Tick-Borne Relapsing Fever (TBRF)\n- Inclusion criteria:\n  - Suspected exposure to tick-borne relapsing fever\n  - After returning from field exercise in a tick-borne relapsing fever infected area\n  - Having a tick bite or staying in field in close proximity to a subject with tick bite sign\n\nThe patient has presented with symptoms that could be suggestive of a respiratory infection, possibly tick-borne given the recent travel, but the inclusion criteria specifically mention \"suspected exposure to tick-borne relapsing fever\" and returning from an area known for TBRF or having a tick bite or close contact to someone with a tick bite. There is no mention in the patient's history of a tick bite or direct exposure to an area where TBRF is known to be endemic. Moreover, the patient was on vacation in Colorado, and there is no specific mention that this area is a known TBRF infected area. Therefore, without more evidence of tick exposure or a confirmed area with TBRF prevalence, the patient's symptoms alone would not be sufficient to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "736": {
        "output": "Given the patient note and the inclusion criteria from the clinical trial, let's compare the patient's characteristics to the trial's requirements:\n\nPatient Characteristics:\n- 8-year-old male\n- Presents with fever, dyspnea, cough, and previous loose stools\n- Recently returned from vacation\n- In respiratory distress with bronchial respiratory sounds on the left\n- Chest x-ray shows bilateral lung infiltrates\n\nClinical Trial Inclusion Criteria:\n- Healthy male and female children\n- 1 to 10 years of age\n\nThe patient is an 8-year-old male, which fits within the age range specified in the trial's inclusion criteria. However, the trial explicitly requires healthy children, and the patient is currently presenting with symptoms of illness (fever, dyspnea, cough, respiratory distress, and lung infiltrates). Therefore, based on the information provided, the patient does not meet the health status requirement for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "737": {
        "output": "Given the patient note:\n\n- The patient is an 8-year-old male.\n- He presents with fever, dyspnea, cough, and recently had loose stools.\n- He has bilateral lung infiltrates as shown by a chest x-ray.\n\nAnd the clinical trial criteria:\n\n- The study is focused on anti-HIV drug regimens.\n- Participants must be coenrolled in the SMART study.\n- A parent or guardian must be willing to provide informed consent, if applicable.\n\nBased on the information provided, there is no mention of the patient being HIV-positive or being a participant in the SMART study. Additionally, the patient's current medical issues (fever, dyspnea, cough, and bilateral lung infiltrates) do not seem to be related to HIV or its treatment. Without evidence of the patient's involvement in the SMART study or an HIV diagnosis, there is no basis for referring this patient to the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "738": {
        "output": "Based on the patient note and the clinical trial information provided, the 8-year-old male patient does not meet the inclusion criteria of the clinical trial. The patient presents with symptoms suggestive of a respiratory infection and possibly a gastrointestinal issue, as indicated by fever, dyspnea, cough, and loose stools. In contrast, the clinical trial is focused on the effects of anti-HIV drug regimens on HIV transmission risk behavior among SMART study participants.\n\nThe inclusion criteria for the trial require coenrollment in the SMART study and the ability of a parent or guardian to provide informed consent, if applicable. There is no indication in the patient note that the child is coenrolled in the SMART study or has HIV, which is the primary focus of the SMART study and the trial in question.\n\nTherefore, this patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "739": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is clear that the patient is not eligible for the trial. The patient is described as an 8-year-old male presenting with fever, dyspnea, cough, and bilateral lung infiltrates, with no mention of HIV status or current anti-HIV therapy. Additionally, the inclusion criteria specify that participants must be coenrolled in the SMART study, which is a specific requirement not met by the information given about this patient.\n\nGiven these considerations, the patient does not meet the age requirement (as no age is specified, but the context implies adults due to the mention of anti-HIV therapy which is usually not tested in children), there is no indication of HIV infection, and there is no mention of coenrollment in the SMART study.\n\nTherefore, the assessment of eligibility for this patient for the clinical trial described is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "740": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- 8-year-old male\n- Presents with fever up to 39 C, dyspnea, and cough for 2 days\n- History of recent travel\n- Bronchial respiratory sounds on the left\n- Bilateral lung infiltrates on chest x-ray\n\nClinical Trial Inclusion Criteria:\n- Age: 2 to 59 months (approximately 0.16 to 4.92 years)\n- Both boys and girls\n- Severe pneumonia according to WHO criteria\n- Attend the Radda Clinic and ICHSH during specified hours\n- Written informed consent by respective parents/guardians\n\nAnalysis:\n- The patient is 8 years old, which is equivalent to 96 months. This is outside the age range of 2 to 59 months specified by the clinical trial.\n- The patient does have signs of severe pneumonia, which is part of the clinical trial's target condition.\n\nSince the patient does not meet the age criteria for the clinical trial, he is not eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "741": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient would not be eligible for the clinical trial for the following reasons:\n\n1. Age Requirement: The inclusion criteria specify that participants must be aged >= 16 years at screening. The patient is an 8-year-old male, which does not meet the age requirement.\n\n2. Health Status: While the trial requires that subjects are clinically healthy, the patient presents with fever, dyspnea, cough, and bilateral lung infiltrates, indicating that he is currently unwell and experiencing acute symptoms.\n\nConsidering these points, the patient does not meet the key inclusion criteria for the clinical trial. Therefore, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "742": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for the Typhoid Fever Vaccine (Ty800), the patient does not meet the criteria for the following reasons:\n\n1. The patient is an 8-year-old male, which does not fall within the age range of 18 to 55 years required by the trial.\n2. There is no information suggesting that the patient is healthy, as he presents with fever, dyspnea, cough, and bilateral lung infiltrates, indicating an acute illness.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "743": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223),\" we can evaluate the eligibility of the 8-year-old male patient.\n\nPatient note summary:\n- 8-year-old male\n- Fever, dyspnea, cough, and loose stools\n- Recently returned from vacation\n- Respiratory distress with bronchial respiratory sounds on the left\n- Bilateral lung infiltrates on chest x-ray\n\nClinical trial inclusion criteria:\n- Must have participated in Study 223\n- Must understand the nature of the study and provide written informed consent\n- Must have received the first booster vaccination with FSME-IMMUN 0.5ml during Study 223\n- Must have had blood drawn after their first booster vaccination in Study 223\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial because:\n- The patient's age is not specified in the inclusion criteria, but the trial seems to be focused on adults while the patient is a child (8 years old).\n- There is no information given that suggests the patient participated in Study 223 or received a first booster vaccination of FSME-IMMUN 0.5ml during that study.\n- The patient's current clinical presentation (respiratory distress and fever) is unrelated to the TBE antibody persistence and booster vaccination study.\n\nTherefore, the 8-year-old male patient is not eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "744": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, we need to assess whether the 8-year-old male patient is eligible for the trial titled \"Transmission and the Respiratory Tract in Cryptosporidiosis.\"\n\nThe inclusion criteria for the trial are as follows:\n1. Male and female children aged 9-36 months at the time of enrollment\n2. Presence of acute or persistent diarrhea (diarrhea defined as 3 or more loose stool in the previous 24 hours AND not considered normal for that child if the child is exclusively breast fed OR any number of bloody stools in the previous 24 hours; less than or equal to 14 days duration for acute diarrhea; >14 days duration for persistent diarrhea)\n3. Child's parent/guardian speaks English or Luganda\n4. Parent/guardian provides full and free informed consent for child to participate in study\n\nAssessment of the 8-year-old male patient against the inclusion criteria:\n1. The patient is 8 years old, which is older than the specified age range of 9-36 months.\n2. The patient presents with fever, dyspnea, and cough, but there is no mention of diarrhea in the patient note.\n3. There is no information provided about the language spoken by the child's parent/guardian.\n4. There is no information provided about consent.\n\nThe primary reason for ineligibility is the patient's age, which is outside the specified range for the study (the patient is older). Even if other criteria might be met, the age criterion is a strict disqualifier.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "745": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note Summary:\n- 8-year-old male\n- Symptoms: fever up to 39 C, dyspnea, cough for 2 days\n- Recent travel history to Colorado\n- Loose stools before onset of fever and cough\n- Respiratory distress and bronchial respiratory sounds on the left upon examination\n- Chest x-ray shows bilateral lung infiltrates\n\nClinical Trial Inclusion Criteria:\n- Age between 6 months and 5 years\n- Present with history of fever or reported fever\n- Present with cough or difficult breathing\n\nAssessment:\nThe patient is an 8-year-old male, which does not meet the age inclusion criteria of the clinical trial, which specifies participants should be between 6 months and 5 years of age. Although the patient presents with symptoms relevant to the study (fever, cough, and difficult breathing), the age criterion is a strict requirement for the study. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "746": {
        "output": "Assessing the patient note against the inclusion criteria for the clinical trial:\n\nPatient note:\n- An 8-year-old male presenting with fever, dyspnea, and cough.\n\nClinical trial inclusion criteria:\n- Healthy individuals, as determined by medical history, clinical examination, and biological safety parameters.\n- Aged 18 to 45 years on the day of inclusion.\n- Provision of informed consent signed by the participant.\n- For women of childbearing potential, use of effective contraception or abstinence.\n- Able to attend all scheduled visits and comply with all trial procedures.\n\nThe patient in the note is an 8-year-old male, which does not meet the age criterion of the clinical trial (18 to 45 years). Therefore, regardless of any other information in the patient's note, this patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "747": {
        "output": "Based on the patient note provided, the patient is an 8-year-old male who presents with fever, dyspnea, cough, and has just returned from vacation. The clinical trial in question is focused on chronic gastrointestinal illness in Persian Gulf (PG) veterans, specifically those with symptoms related to Small Bowel Bacterial Overgrowth (SBBO).\n\nThe inclusion criteria for the clinical trial are as follows:\n- Men and women age 32-75 years\n- Rome III criteria for diarrhea-predominant IBS\n- Symptom onset after an apparent episode of acute gastroenteritis\n- Symptoms of > 3 months duration\n- Normal endoscopic appearance of the colonic mucosa\n- Negative markers for celiac disease and inflammatory bowel disease\n- Normal thyroid function and serum calcium levels\n- Must have served in the military or reserves during the time of Operation Desert Storm (August 1990 to May 1991)\n\nThe patient does not meet the following inclusion criteria:\n- The patient's age is not within the 32-75 years range.\n- There is no indication that the patient meets the Rome III criteria for diarrhea-predominant IBS.\n- There is no mention of the patient having symptoms for more than 3 months.\n- The patient's military service status is not applicable, as he is only 8 years old and could not have possibly served during Operation Desert Storm.\n\nGiven these points, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "748": {
        "output": "Based on the patient note provided, the patient is an 8-year-old male, which directly conflicts with the inclusion criteria of the clinical trial that requires participants to be aged 18-45 years. Therefore, this patient would not be eligible for the trial based on age criteria alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "749": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided:\n\nPatient Note:\n- An 8-year-old male with fever, dyspnea, and cough.\n- Recent travel history with onset of symptoms including loose stools.\n- Respiratory distress observed with bronchial respiratory sounds on the left.\n- Bilateral lung infiltrates shown on chest x-ray.\n\nClinical Trial Inclusion Criteria:\n- Patient and/or parents/guardian signed informed consent.\n- Patients with cough or shortness of breath.\n\nThe patient in the note has symptoms of cough and respiratory distress, which align with the inclusion criteria of cough or shortness of breath for the clinical trial. Additionally, as the patient is a minor, the parents or guardians can provide informed consent.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "750": {
        "output": "Given the patient note for the 8-year-old male and the inclusion criteria of the clinical trial for the Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Na\u00efve Adults, we can determine the patient's eligibility for the trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Healthy as determined by medical history, clinical examination, and biological safety parameters\n- Aged 18 to 45 years on the day of inclusion\n- Informed consent form signed\n- Able to attend all scheduled visits and to comply with all trial procedures\n- For women of child-bearing potential, use of an effective method of contraception or abstinence\n\nThe patient is described as an 8-year-old male, which does not meet the age criterion of being 18 to 45 years old. Therefore, based on the information provided, the patient is not eligible for the clinical trial solely due to age restrictions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "751": {
        "output": "The patient in question is an 8-year-old male, which places him within the age range specified by the clinical trial's inclusion criteria (1 to 11 years). The trial is for the assessment of immunogenicity, safety, and interchangeability of two different TBE vaccines. The inclusion criteria also require that the child's parents or legal guardians provide written informed consent, that the children provide written assent to the study according to age and capacity of understanding, and that the parents/guardians understand the nature of the clinical study and will comply with the requirements of the protocol.\n\nThe patient note does not mention any contraindications to vaccination, such as being immunocompromised or having a known allergy to vaccine components. The note also does not mention any chronic illness that would prevent vaccination. The patient is described as having fever, dyspnea, cough, and bilateral lung infiltrates, which suggest an acute illness, but this does not necessarily exclude him from future participation in the vaccine study once he recovers.\n\nGiven the information provided, the patient is within the age range for the study, and no information has been provided that would exclude him based on health status. However, further investigation would be required to ensure that the child is generally healthy (as per the inclusion criteria) once he recovers from his current acute illness, and that all consent and assent requirements are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "752": {
        "output": "Based on the information given, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient characteristics:\n- 8-year-old male\n- Presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray\n\nClinical trial inclusion criteria:\n- Children aged 2 to 59 months (which is equivalent to 2 to 4 years and 11 months old)\n- WHO defined non-severe pneumonia\n- Accessibility for follow-up\n- Written informed consent by a parent or legal guardian\n\nThe patient is 8 years old, which exceeds the upper age limit of the inclusion criteria for the clinical trial (59 months or just under 5 years of age). Therefore, the patient does not meet the age requirement for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "753": {
        "output": "Based on the information provided:\n\nThe patient is an 8-year-old male presenting with fever, dyspnea, cough, and bilateral lung infiltrates. This patient does not have any information provided that would indicate they have been previously enrolled in a precursor study (Study 700401) or have received a booster vaccination for Tick-Borne Encephalitis (TBE) as part of that study.\n\nThe clinical trial in question is specifically looking to assess seropersistence in individuals who participated in Study 700401 and who have received a booster vaccination with FSME-IMMUN as part of that study.\n\nSince there is no information suggesting that the patient was a part of the precursor Study 700401 or received the booster vaccination, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "754": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nInclusion Criteria for the Clinical Trial:\n- Children aged 1 to 12 years\n- With acute community-acquired pneumonia (cough, tachypnea, fever)\n- Chest radiography with lobar, segmental, or bronchopneumonia within the first 48 hours\n\nPatient Note Analysis:\n- The patient is an 8-year-old male, which fits the age criterion (1 to 12 years).\n- He presents with fever up to 39 C, dyspnea, and cough, indicating symptoms consistent with pneumonia.\n- A chest x-ray shows bilateral lung infiltrates, which is consistent with pneumonia.\n\nBased on the provided information, the patient meets the age requirement, has symptoms of pneumonia (cough, tachypnea, fever), and has evidence of pneumonia on a chest x-ray taken likely within the first 48 hours since the patient presents in March to the ER with symptoms for 2 days.\n\nTherefore, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "755": {
        "output": "Based on the information provided, the patient does not meet the age criterion for the clinical trial. The inclusion criteria specify that participants must be aged 18 years or older, and the patient in question is only 8 years old.\n\nTherefore, the patient is not eligible for the clinical trial, and the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "756": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient, an 8-year-old male, does not meet the age requirement of \"Adults, equal to or more than 18 years years of age\" for the Clarithromycin Modified Release Observational Study. Therefore, the patient would not be eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "757": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not meet several of the key criteria for inclusion in the study:\n\n1. Age: The patient is an 8-year-old male, while the inclusion criteria specify patients must be above 55 years of age.\n2. Antibiotic use: While the patient presents with symptoms that may require antibiotics (fever, dyspnea, cough), there is no mention in the note of the patient currently receiving antibiotics.\n3. Ability to take medication orally: This is not specified in the patient note, but given the patient's age, it is likely not an issue.\n4. Consent: There is no mention of the patient or guardians providing written informed consent/assent to take part in the study.\n\nThe primary disqualifying factor is the patient's age, as the trial is specifically looking for participants above 55 years of age. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "758": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in the note is an 8-year-old male who presents with fever, dyspnea, cough, and bilateral lung infiltrates, indicating a respiratory infection or possibly pneumonia. The clinical trial in question is focused on reducing inappropriate antibiotic prescribing by primary care clinicians and includes tracking patient records for various infectious conditions.\n\nThe inclusion criteria for the clinical trial are specific to clinic practices within certain healthcare systems and locations (Denver Health's Webb Center for Primary Care, University of Colorado - Anschutz Campus: General Internal Medicine Clinic, Clinic practices within the High Plains Network, and Clinical practices within the Wilmington Health Associates System). It also requires that these practices be willing to assist in tracking patient records for conditions related to certain ICD-9 codes associated with common infectious conditions and 30-day events such as hospitalizations, ED visits, or grade 3 or grade 4 abnormalities.\n\nThe patient note does not mention the healthcare system or the location of the clinic where the patient is being treated. Moreover, the trial seems to be targeting primary care practices rather than individual patients. Therefore, there is not enough information to determine if the patient's primary care clinic is participating in the trial or is located within the specified healthcare systems.\n\nGiven the available information, we cannot confidently refer this patient for the clinical trial based on the patient's individual clinical presentation alone. The trial is more focused on the practices' participation and their antibiotic prescribing patterns rather than on individual patient treatments.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "759": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- An 8-year-old male with fever, dyspnea, cough, and bilateral lung infiltrates after returning from vacation. \n\nClinical trial inclusion criteria:\n- Male or female ages 18-45, inclusive.\n- Healthy as judged by the PI and determined by medical history, physical examination, and medication history.\n- Must meet certain laboratory criteria.\n- Must demonstrate comprehension of the protocol procedures and knowledge of the study.\n- Capable of understanding, consenting, and complying with the entire study protocol.\n- Reproductive status requirements for males and females.\n- Agreement not to participate in another clinical trial during the study period.\n- Agreement not to donate blood to a blood bank for 12 months after receiving the vaccine.\n\nThe patient is a male, which meets the gender requirement of the clinical trial. However, the patient is 8 years old, which is below the age range of 18-45 years required by the study. Additionally, the patient is currently presenting with symptoms of an infection (fever, dyspnea, cough, bilateral lung infiltrates), which suggests that he is not healthy as judged by the PI, a requirement for the study.\n\nGiven that the patient does not meet the age and health status requirements, he would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "760": {
        "output": "Let's review the patient's information and the inclusion criteria of the clinical trial step by step.\n\nPatient information:\n- 8-year-old male\n- Presents with fever, dyspnea, and cough\n- Recently returned from vacation\n- Had loose stools prior to onset of fever and cough\n- Admitted to the ER with respiratory distress and bilateral lung infiltrates\n\nClinical trial inclusion criteria for cases:\n- Male or female child born after 6 March 2006 and at least 12 weeks of age\n- Admitted to the study clinics/hospitals for severe gastroenteritis during the study period\n- Onset of severe gastroenteritis \u2264 14 days prior to admission\n- Laboratory confirmed rotavirus positive stool sample at hospital admission or during the first 48 hours of hospitalization\n- Written informed consent obtained from the parent or guardian\n\nConsidering the information given:\n\n- The patient is 8 years old, which fits the age criterion if born after 6 March 2006.\n- The patient was admitted to the ER with respiratory distress, which is not gastroenteritis.\n- The patient had loose stools, which could be a symptom of gastroenteritis, but it is not confirmed that the patient's condition is severe gastroenteritis.\n- The patient's eligibility depends on whether the loose stools were due to rotavirus infection, which requires a laboratory-confirmed rotavirus positive stool sample. This information is not provided.\n- The patient presents with respiratory symptoms, which seem to be the primary concern rather than gastroenteritis.\n\nBased on the information provided, it is unclear whether the patient's symptoms are due to severe gastroenteritis, specifically rotavirus, as no laboratory confirmation is mentioned. Without this key piece of information, it is not possible to definitively determine eligibility. However, since the primary issue seems to be respiratory rather than gastroenteritis, and given that the patient is admitted to the ER for respiratory distress rather than severe gastroenteritis, it is unlikely that this patient would be eligible for the trial focused on rotavirus severe gastroenteritis.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "761": {
        "output": "The patient note describes an 8-year-old male who presents with fever, dyspnea, and cough, as well as a recent history of loose stools, which may suggest acute gastroenteritis. Given that the clinical trial is specifically looking to study the disease burden of acute rotavirus gastroenteritis in children under 5 years of age in the United Arab Emirates, we can assess the patient's eligibility based on the inclusion criteria provided.\n\nThe inclusion criteria for the clinical trial are:\n1. A male or female < 5 years of age at the time of admission to the study hospital for acute gastroenteritis.\n2. Written informed consent obtained from the parent or guardian of the subject.\n\nThe patient in question is 8 years old, which exceeds the age limit specified in the inclusion criteria of the clinical trial. This patient does not meet the age requirement for the study, which is focused on children under 5 years of age. Therefore, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "762": {
        "output": "",
        "label": 0
    },
    "763": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, the following points stand out:\n\n1. Age: The patient is an 8-year-old male, while the trial requires participants to be males aged between 21 and 40 years.\n2. Health Status: The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates, which does not align with the requirement of being healthy as assessed by a health and lifestyle questionnaire, physical examination, and pre-study laboratory tests.\n3. Other Criteria: The trial has additional specific criteria such as BMI range, normal Dutch eating habits, and a willingness to comply with study procedures, including an ETEC challenge, none of which are mentioned in the patient note. Moreover, the patient is a minor and therefore cannot provide informed consent, which is a requirement for the trial.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the clinical trial. The patient's age is not within the specified range, and the patient's current health status does not meet the criteria of being healthy. Additionally, there are no indications that the patient has normal Dutch eating habits or has given informed consent, which are both required for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "764": {
        "output": "",
        "label": 0
    },
    "765": {
        "output": "Based on the patient note provided, the 8-year-old male patient presents with fever, dyspnea, cough, and bilateral lung infiltrates. However, there is no mention of paraffin (kerosene) ingestion, which is a critical inclusion criterion for the clinical trial in question. Additionally, the trial requires that the patient have respiratory symptoms/signs following paraffin ingestion, and informed consent from a parent or legal guardian is necessary. The patient must also be a resident within a specific hospital's drainage area and able to attend two follow-up appointments.\n\nGiven that the patient note does not indicate paraffin ingestion or any connection to the Red Cross Hospital drainage area, we cannot assume that this patient meets the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "766": {
        "output": "The patient note describes an 8-year-old male who presents with fever, dyspnea, cough, and a recent history of loose stools following a vacation. The clinical trial in question is focused on the etiology of diarrhea in both Guinea-Bissau and Finland, looking at both patients with diarrhea and healthy volunteers as controls.\n\nThe inclusion criteria for the trial are as follows:\n- Accepting to participate and willing to deliver 2 stool samples.\n- With diarrhea: the first 10 children and 10 adults presenting each month at the health facility\n- Without diarrhea: In Bissau matched controls drawn from the registration system at Bandim Health Project. In Finland, controls selected at the health facilities participating.\n\nThe patient note indicates that the child had loose stools prior to the onset of fever and cough, which suggests that he may fit the criteria for those with diarrhea. However, the study specifies that it is collecting samples from volunteers in Guinea-Bissau and Finland, and there is no mention of the study being open to individuals from other locations. Since the child has just returned from a vacation in Colorado, it is unclear whether he would be eligible based on his geographic location.\n\nFurthermore, there is a limitation on the number of participants with diarrhea that the study is enrolling each month (the first 10 children and 10 adults). It is not specified whether the 8-year-old patient is within this limit.\n\nGiven these considerations, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if the patient's geographic location would be acceptable for the study and if the monthly quota for participants with diarrhea had been met.",
        "label": 1
    },
    "767": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can evaluate the patient's eligibility for the trial.\n\nThe patient is an 8-year-old male with fever, dyspnea, and cough. The inclusion criteria for the clinical trial are:\n\n- Male and female children aged 06 months to 06 years old\n- Weight above 5 kilos\n- Axillary temperature above 37.5 Celsius degrees\n\nThe patient does not meet the age criterion, as he is 8 years old and the trial includes children aged 6 months to 6 years old.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "768": {
        "output": "Based on the information provided, the 8-year-old male patient does not meet the inclusion criteria for the clinical trial focused on the treatment of Blastocystis hominis infection. The inclusion criteria specify that participants must be \u2265 18 years old, have gastrointestinal symptoms for more than 10 days, have B. hominis in any quantity in at least one stool specimen out of 3 examined, and have no other pathogenic micro-organism identified.\n\nThe patient in question is only 8 years old, which is below the minimum age requirement of 18 years. Furthermore, the patient's symptoms have been present for only 2 days, rather than the required 10 days. There is also no mention of B. hominis being identified in stool specimens or any stool specimens being examined at all.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "769": {
        "output": "The patient note describes an 8-year-old male who presents with fever, dyspnea, cough, and bilateral lung infiltrates on a chest x-ray. There is no mention of sickle cell disease or any of the specific hemoglobinopathies listed in the inclusion criteria (Hemoglobin SS, Hemoglobin SC, Hemoglobin sickle beta-zero thalassemia, or Hemoglobin sickle thalassemia).\n\nThe clinical trial is specifically for patients with a diagnosis of sickle cell disease who are experiencing Acute Chest Syndrome, as evidenced by the inclusion criteria which require a diagnosis of one of the specified sickle cell disease types and clinical criteria for ACS.\n\nSince there is no information provided in the patient note to suggest that the 8-year-old has sickle cell disease or meets the clinical criteria for ACS as detailed in the trial's inclusion criteria, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "770": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient Note:\n- 8-year-old male\n- Presents with fever, dyspnea, and cough\n- Recent travel history\n- Left-sided bronchial respiratory sounds and bilateral lung infiltrates on chest x-ray\n\nClinical Trial Inclusion Criteria:\n- Signed and dated written informed consent\n- Male or females \u2265 40 years of age\n- Clinical history of COPD by ATS/ERS definition\n- Spirometry criteria: FEV1/FVC ratio \u2264 0.70 and FEV1 \u226530 to \u2264 70% of predicted normal\n- Former or current smoker \u226510 pack years\n- History of or risk for cardiovascular disease\n\nThe patient is an 8-year-old male, which does not meet the age requirement of \u2265 40 years for the clinical trial. Furthermore, there is no indication of COPD or a history of smoking. The patient's symptoms are suggestive of an acute respiratory infection, likely unrelated to COPD. Therefore, this patient does not fit the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "771": {
        "output": "Based on the patient note presented, the patient is an 8-year-old male with symptoms of fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray. This is suggestive of a respiratory infection or other acute pediatric condition rather than a chronic condition like lung cancer.\n\nThe clinical trial in question focuses on lung cancer screening in individuals who are 40-75 years old and have a significant smoking history, with or without a family history of lung cancer or diagnosis of COPD. The inclusion criteria specifically require participants to be within this age range and to have a smoking history that meets the pack-year criteria outlined.\n\nThe patient described in the note does not meet the inclusion criteria for this trial on multiple counts:\n1. Age: The patient is 8 years old, which is well below the minimum age requirement of 40 years.\n2. Smoking history: Given the patient's age, it is highly unlikely that they have a smoking history, let alone one that meets the specified pack-year criteria.\n3. The trial is specifically for lung cancer screening, and there is no indication that the 8-year-old patient is at risk for lung cancer or is being considered for lung cancer screening.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "772": {
        "output": "The patient in question is an 8-year-old male, which immediately does not meet the age inclusion criteria of the clinical trial that requires participants to be aged 18 and over. Additionally, there is no information provided in the patient note that indicates a diagnosis of Clostridium difficile associated diarrhoea (CDAD), which is the condition being targeted by the clinical trial.\n\nGiven these points, the patient would not meet the inclusion criteria based on age and the lack of a specified diagnosis of CDAD. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "773": {
        "output": "It appears that the clinical trial details are incomplete as the title and inclusion criteria are not provided. Without this information, it's not possible to accurately assess the patient's eligibility for the clinical trial. To proceed, I would need the full details of the clinical trial, including its objectives, target diseases or conditions, interventions, and the specific inclusion and exclusion criteria.\n\nSince the necessary information to make an eligibility assessment is missing, I will have to consider this patient as not referable for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "774": {
        "output": "",
        "label": 0
    },
    "775": {
        "output": "Given the patient note and the clinical trial inclusion criteria, the patient is an 8-year-old male, which does not meet the age requirement of the clinical trial, which is 18 to 45 years old. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "776": {
        "output": "Based on the information provided:\n\nPatient note:\n- An 8-year-old male presents with fever, dyspnea, and cough.\n- He has bilateral lung infiltrates on a chest x-ray.\n\nClinical trial inclusion criteria:\n- Age \u2265 18\n- Infiltrate on chest x-ray\n- Cough or production of purulent sputum or pathologic lung auscultation (crackles) or fever\n\nThe patient does meet some of the criteria: he has an infiltrate on chest x-ray, cough, and fever. However, the patient is 8 years old, which does not meet the age criterion of the trial, which requires participants to be at least 18 years old.\n\nTherefore, based on the age requirement alone, the patient is ineligible for the clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "777": {
        "output": "Based on the patient note, the 8-year-old male patient presents with symptoms that include fever, dyspnea, cough, and recent history of loose stools. He is in respiratory distress and has bronchial respiratory sounds on the left, with a chest x-ray showing bilateral lung infiltrates. These symptoms align with the inclusion criteria for the clinical trial, which requires patients presenting to the Emergency Department with cough, wheezing, and/or dyspnea (shortness of breath), and who are referred for CXR and/or CT scan. The patient's chest x-ray findings and his symptoms of dyspnea and cough would likely make him a candidate for further evaluation with lung ultrasound as per the objectives of the study.\n\nThere are no exclusion criteria presented, and the patient's age is not specified as a factor in the inclusion criteria. Therefore, the patient's age should not preclude him from participating in the study based on the information provided.\n\nGiven this information, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "778": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is an 8-year-old male, fitting the age range of 6 months to 10 years for the clinical trial.\n- The patient presents with fever up to 39 C, which meets the fever criteria for the trial.\n- The patient has cough and dyspnea, which meets the criteria for respiratory symptoms.\n- The patient is in respiratory distress with bronchial respiratory sounds on the left, which could be consistent with auscultatory findings of pneumonia.\n- The chest x-ray shows bilateral lung infiltrates, which is consistent with bacterial CAP as required by the trial.\n- There is no mention of the patient being treated with systemic steroids, which is consistent with the exclusion criteria related to primary asthma exacerbation.\n- The patient's ability to be treated as an outpatient and other criteria (adequate volume status, ability to tolerate oral medication, oxygen saturation, no evidence of impending respiratory failure, no evidence of empyaema or necrotizing pneumonia on chest radiograph) are not explicitly stated, so it is assumed that the patient meets these criteria unless otherwise indicated.\n\nBased on the information in the patient note, the patient appears to meet all the stated inclusion criteria for the clinical trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "779": {
        "output": "Based on the patient note provided, the 8-year-old male patient does not meet the age requirement for the clinical trial, which specifies that participants must be between \u226518 years to <60 years of age. Without considering any other factors, this alone disqualifies the patient from participating in the trial.\n\nTherefore, the assessment of eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "780": {
        "output": "Based on the patient note, the patient is an 8-year-old male with symptoms of fever, dyspnea, and cough, as well as a recent history of loose stools and travel to Colorado. Upon examination, he shows signs of respiratory distress and has bilateral lung infiltrates on a chest x-ray.\n\nWhen comparing this patient's information to the inclusion criteria of the clinical trial:\n\n- The patient is 8 years old, which does not meet the age requirement of being 18 years or older at the time of dosing.\n- The trial is for healthy adult male and female travelers, and the patient is currently not healthy due to his respiratory symptoms and fever.\n- The trial is specific to individuals attending travelers' vaccination clinics for typhoid vaccination, and there's no information provided about the patient seeking typhoid vaccination.\n- The patient is a minor and cannot provide written informed consent independently. Consent would need to be provided by his parents or guardians.\n\nGiven the patient does not meet several of the key inclusion criteria for the clinical trial, particularly the age and current health status, the patient is not eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "781": {
        "output": "Given the patient note, we have an 8-year-old male who presents with fever, dyspnea, cough, and a history of loose stools after returning from a vacation. This patient exhibits respiratory distress and bilateral lung infiltrates as seen on a chest x-ray.\n\nThe clinical trial in question is assessing the health impact of a water and sanitation intervention in rural India. The inclusion criteria for the trial specify that households in participating villages are eligible if they have at least one child under 5 years of age.\n\nSince the patient in the note is 8 years old, he does not meet the age criterion for the trial, which is specifically looking for households with children under 5 years of age. Thus, the patient is not eligible for this clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "782": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we can assess the patient's eligibility for the trial as follows:\n\n1. The patient is an 8-year-old male, which satisfies the age requirement (age \u2265 18 years) is not specified in this trial's inclusion criteria.\n2. The patient presents with acute fever up to 39 C, which aligns with the inclusion criteria for fever.\n3. The duration of fever as per the patient note is 2 days, which does not meet the inclusion criteria of having fever for more than one week.\n4. The patient's temperature is higher than 38\u2103 Celsius degree, which meets the inclusion criteria regarding temperature.\n5. There is no information provided about whether a full physical and laboratory examination has been carried out for over one week without a definite diagnosis. However, the presentation to the ER seems to be recent, implying that the investigations may not have extended over a week.\n\nSince the inclusion criteria specifically require the patient to have had a fever for more than one week and the patient only presents with a 2-day history of fever, the patient does not meet this key inclusion criterion. Therefore, even though some criteria are met (such as the acute fever), the patient would not yet be eligible for referral based on the duration of symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "783": {
        "output": "Based on the information provided:\n\nPatient note:\n- An 8-year-old male\n- Presents with fever, dyspnea, and cough\n- Recently returned from vacation in Colorado\n- Had loose stools prior to the onset of fever and cough\n- In respiratory distress and has bronchial respiratory sounds on the left\n- Chest x-ray shows bilateral lung infiltrates\n\nClinical trial:\n- Title: Effectiveness of and Satisfaction With a Pharmacist-managed Travel Medicine Clinic\n- Evaluates the clinical effectiveness and patient satisfaction with pre-travel consultations\n- Inclusion Criteria: Receiving a pre-travel consultation at the Travel Health Network clinic in St. Albert, Alberta, Canada\n\nThe clinical trial is looking for participants who are receiving a pre-travel consultation at a specific clinic. The patient in question is an 8-year-old male who has already traveled and is currently presenting with symptoms post-travel, suggesting that he is in need of medical attention rather than a pre-travel consultation. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "784": {
        "output": "",
        "label": 0
    },
    "785": {
        "output": "Based on the information provided:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She was the driver involved in the accident.\n\nThe clinical trial is aiming to recruit drivers admitted as a result of motor vehicle accidents to ascertain the prevalence of sleep disorders in this group. The inclusion criteria for the clinical trial are drivers admitted as a result of motor vehicle accidents. There is no mention of excluding individuals based on their injuries or medical status following the accident.\n\nSince the patient fits the inclusion criteria of being a driver admitted as a result of a motor vehicle accident and there are no other exclusion criteria that would disqualify her, she is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "786": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient does not meet the criteria for the trial. The trial is specifically looking for individuals who screen positive for a drinking problem in the emergency department (ED). The patient note does not mention a drinking problem or any indication that the patient was screened for such an issue during her ED visit. The patient was admitted to the ER following a car accident, and there is no evidence in the patient note to suggest that alcohol was a factor in the accident. Thus, there is no indication to refer this patient to the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "787": {
        "output": "Based on the patient note, the 32-year-old woman was admitted to the ER following a car accident and has sustained multiple injuries, including upper and lower extremity fractures. She is fully awake and alert. There is no information provided about her chronic pain status, driving performance, or cognition.\n\nThe clinical trial in question is studying the effects of pain on driving performance and cognition. The inclusion criteria for this trial are:\n\n- Age\n- Driving license\n- Driving experience\n- Normal vision\n- Right-handed\n- Fluently Dutch speaking\n\nThe patient note does not provide information on whether she meets all these criteria. Specifically, there is no mention of her driving license status, driving experience, whether she is right-handed, or if she speaks Dutch fluently. However, given that she is currently in the ER following an accident and has sustained multiple injuries, it is unlikely that she would be an appropriate candidate for a trial focused on chronic pain and driving performance, at least until she has recovered from her acute injuries.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "788": {
        "output": "",
        "label": 0
    },
    "789": {
        "output": "Given the information from the patient note and the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- Age: 32 years old\n- Current condition: Admitted to the ER following a car accident, multiple injuries including fractures, tender abdomen with guarding and rebound.\n\nClinical trial inclusion criteria:\n- Age 21 - 75\n\nClinical trial exclusion criteria:\n- Height greater than 6'2\n- BMI greater than 45\n- Specified acute or chronic medical conditions\n\nThe patient's age falls within the inclusion criteria of 21 to 75 years. However, there is no information provided regarding the patient's height, BMI, or specific acute conditions that might be considered exclusionary for the trial. Since the patient is currently dealing with acute trauma from a car accident, it's reasonable to assume that she might have acute medical conditions that could exclude her from a trial focused on passenger comfort and discomfort during flight, which is unrelated to her current medical needs. The trial does not seem to be designed for patients recovering from recent trauma and hospitalization due to an accident.\n\nBased on the provided information, the patient's acute medical condition (multiple injuries from a car accident) does not align with the focus of the clinical trial, which is about hypoxia at altitude and its effects on comfort and well-being in a non-emergency setting.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "790": {
        "output": "Based on the information provided, the patient in the note is a 32-year-old woman who has sustained multiple injuries from a car accident. She does not meet the inclusion criteria for the Michigan Driver Education Study, as the study specifically requires teens between the ages of 15 years 0 months and 16 years 6 months who are enrolled in a licensed driver education course. \n\nSince the patient is 32 years old, she is well beyond the age limit set by the study's inclusion criteria. Therefore, she would not be eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "791": {
        "output": "Given the patient note and the clinical trial information, we can determine the following:\n\n- The patient is a 32-year-old woman.\n- She has been admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures.\n- There is no mention of her driving history, experience, or whether she has a driver's license.\n\nThe inclusion criteria for the clinical trial are:\n\n- Potential participants should be aged 16 or 17 who have held their driver's license for one month or less.\n- Teen participants will be recruited by arrangement with local driving schools in Montgomery County, VA.\n- Experienced adult drivers will be recruited via recruitment flyers in the Blacksburg, VA area.\n\nThe patient does not meet the inclusion criteria for the clinical trial since:\n\n- She is 32 years old, which is outside the 16 to 17 years age range specified for new teenage drivers.\n- There is no information supporting that she is a newly licensed teenage driver or an experienced driver in the 30 to 50 years age range.\n- The trial specifically requires potential participants to be able to legally drive in the Commonwealth of Virginia, and there is no information indicating that the patient meets this requirement.\n- The trial seems to be location-specific, requiring participants from Montgomery County, VA or the Blacksburg, VA area, and there is no information about the patient's location.\n\nBased on the information provided, the patient does not meet the age or potentially the location requirements, and there is no information on her driving status. Thus, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "792": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, it is clear that the patient does not meet the criteria for participation in the study. The clinical trial is focused on interventions for severe postpartum hemorrhage (PPH) in the immediate postpartum period, and the participants must be women who have delivered at a gestational age greater than 22 weeks in one of the participating maternity units during the study period.\n\nThe patient in the note is a 32-year-old woman who has been admitted to the ER following a car accident, with no mention of her being in the postpartum period or having delivered a child. Therefore, she does not meet the study's inclusion criteria, which are specifically for women who have recently given birth and are experiencing complications related to severe PPH.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "793": {
        "output": "Given the patient note and the clinical trial information provided, we can determine the patient's eligibility for the trial based on the inclusion criteria specified for the trial.\n\nPatient note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Multiple injuries including upper and lower extremity fractures\n\nClinical trial:\n- Title: Intra Ocular Pressure During Robotic Prostatectomy\n- Goal: Study the relationship between intraocular pressure during robotic prostatectomy surgery and visual deficiencies/vision loss after surgery\n- Inclusion criteria:\n  - Male, aged 18 or older\n  - Scheduled for Robotic Prostatectomy Surgery\n  - ASA Classification of I, II, or III\n  - Good comprehension of written and spoken English\n\nThe patient in the note is a 32-year-old woman, which immediately disqualifies her from the clinical trial as the inclusion criteria specify that participants must be male. Additionally, the trial is specific to patients scheduled for Robotic Prostatectomy Surgery, which would not be appropriate for a female patient.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "794": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to meet the eligibility requirements for the clinical trial on Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation. The trial is specifically targeting individuals with vasomotor rhinitis, which is characterized by chronic or recurrent nasal symptoms in response to changes in temperature, humidity, or nonspecific irritant triggers such as perfumes, cleaning products, and others. \n\nThe patient note describes a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries and no mention of chronic or recurrent nasal symptoms or any history of vasomotor rhinitis. Therefore, there is no indication that this patient would qualify for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "795": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem,\" we can assess the eligibility of the 32-year-old woman for the trial.\n\nThe inclusion criteria for the trial are:\n1. Hospitalized men or women \u226518 years of age\n2. Expected duration of treatment with intravenous antibiotics anticipated to be \u22655 full days but not exceeding 14 days\n3. Ability to provide documented and signed written informed consent\n4. Confirmed or suspected intra-abdominal infection, which for a confirmed infection requires a surgical procedure performed within 24 hours prior to enrollment and for a suspected infection requires radiological evidence and the presence of certain signs, symptoms, and SIRS criteria\n5. The subject must be scheduled for a surgical procedure within 24 hours of enrollment in the study\n\nConsidering the patient's condition as described in the note:\n- The patient is a 32-year-old woman (meets age criterion).\n- She was admitted to the ER following a car accident with multiple injuries, including a tender abdomen with guarding and rebound, which could indicate an intra-abdominal injury or infection (potential to meet the infection criterion).\n- Her vital signs show that she is awake and alert, but the note does not mention fever, heart rate, or white blood cell count relative to SIRS criteria.\n- There's no information provided about the expected duration of antibiotic treatment or whether she is scheduled for a surgical procedure within 24 hours of enrollment.\n\nBased on the available information, the patient could potentially have a confirmed or suspected intra-abdominal infection, indicated by a tender abdomen with guarding and rebound. To fully determine eligibility, further information would be needed, such as confirmation of the intra-abdominal infection, the patient's consent ability, the anticipated duration of antibiotic treatment, and whether she is scheduled for surgery within the specified timeframe.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "796": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the key points:\n\nPatient Note:\n- A 32-year-old woman admitted to the ER following a car accident.\n- Multiple injuries including fractures.\n- No mention of ADHD diagnosis.\n- No information on whether she has a driver's license or a history of driving collisions/citations.\n- No information on medication for ADHD or responsiveness to methylphenidate.\n\nClinical Trial Inclusion Criteria:\n- ADHD diagnosis.\n- Valid driver's license.\n- Not taking any medication for their ADHD.\n- Access to a car of which they are the primary driver.\n- A history of approximately two driving collisions or citations.\n- A history of responsiveness to methylphenidate.\n\nThe patient's note does not mention an ADHD diagnosis or any other criteria related to the clinical trial's inclusion requirements such as having a valid driver's license, not taking any ADHD medication, having access to a car, having a history of driving incidents, or a history of responsiveness to methylphenidate.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "797": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient in question does not appear to be eligible for the clinical trial focused on the effects of phenytoin on driving performance.\n\nThe patient is a 32-year-old woman who has been admitted to the ER following a car accident, with multiple injuries including upper and lower extremity fractures. The clinical trial is seeking neurologically normal subjects who are legally licensed to drive, have been actively driving for at least 5 years, and do not have chronic medical or psychiatric conditions that could alter driving performance independently of phenytoin.\n\nThe patient's recent car accident and resultant injuries, particularly the fractures and the tender abdomen with guarding and rebound, suggest that she is currently not in a state that would allow her to safely operate a vehicle, especially in a driving simulator for the study. Additionally, her injuries could be considered chronic medical conditions that might alter driving performance, which is an exclusion for the trial.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial on phenytoin and driving safety, mainly because she is not neurologically normal at this moment due to the recent trauma, and her ability to drive is likely impaired by her injuries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "798": {
        "output": "The patient in question is a 32-year-old woman who has been admitted to the ER following a car accident, presenting with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert but exhibits a tender abdomen with guarding and rebound in all four quadrants and no bowel sounds.\n\nThe clinical trial is investigating the correlation between the location of abdominal tenderness and acute pathology on abdominal CT scans in emergency department patients with non-traumatic abdominal pain and tenderness.\n\nTo determine the trial-level eligibility of the patient for the clinical trial, we need to assess the inclusion criteria against the patient's conditions.\n\nThe inclusion criteria for the clinical trial are as follows:\n- All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness.\n- Abdominal pain and tenderness is defined as pain and tenderness to direct palpation in the region anterior to the mid-axillary line bilaterally, extending from the costal margins to the inguinal ligaments.\n\nExclusion from the study includes CT scans for indications such as isolated vomiting, fever without source, staging of malignancies, isolated flank pain or suspected renal colic, or other indications that do not meet the definition of abdominal pain and tenderness.\n\nThe patient has abdominal tenderness with guarding and rebound in all four quadrants, which aligns with the study's definition of abdominal pain and tenderness. However, the patient's pain is the result of a traumatic event (car accident), which may or may not fit the non-traumatic abdominal pain and tenderness criterion depending on the interpretation of \"non-traumatic\" in this context. If \"non-traumatic\" is interpreted strictly as non-injury related, she would not meet the criteria. If it's interpreted as non-trauma in terms of not related to chronic or systemic medical conditions, she might be considered.\n\nGiven this ambiguity, the most appropriate course of action would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "799": {
        "output": "Based on the patient note provided, the 32-year-old woman has sustained multiple injuries including upper and lower extremity fractures from a car accident. The clinical trial in question is interested in patients who have had acute diaphyseal fractures of the humerus treated with open reduction and internal fixation (ORIF), and for whom the fracture has healed.\n\nThe patient's eligibility for the clinical trial would depend on whether one of her upper extremity fractures is a humeral shaft fracture and if it has been or will be treated with ORIF. Additionally, the fracture must have healed for the patient to be eligible, which is not the case here since she has just been admitted to the ER following the accident. Therefore, based on the available information, the patient does not meet the inclusion criteria of having a healed humeral shaft fracture treated with ORIF.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "800": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, the 32-year-old woman does not meet several key inclusion criteria:\n\n1. The patient's age is 32, while the trial requires participants to be 50 years or older.\n2. The fractures in the patient are due to a car accident, which is a traumatic cause, whereas the trial specifies non-traumatic vertebral fractures of osteoporotic origin.\n3. The fractures are acute, occurring as a result of a recent car accident, while the trial is looking for subacute fractures (older than 6 weeks).\n4. There is no mention of osteoporosis or the vertebral fractures being of osteoporotic origin in the patient note.\n5. The trial requires persistent pain despite medical treatment according to VAS \u2265 5 or last resort to morphine treatment, but there is no information given on the pain level or treatment of the patient's fractures.\n\nGiven these mismatches, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "801": {
        "output": "",
        "label": 0
    },
    "802": {
        "output": "",
        "label": 0
    },
    "803": {
        "output": "Based on the information provided in the patient note and the specified inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Has sustained multiple injuries including upper and lower extremity fractures\n- Fully awake and alert\n- Reports not wearing a seat belt\n- Physical examination reveals a tender abdomen with guarding and rebound in all four quadrants\n- No bowel sounds\n\nClinical Trial Inclusion Criteria:\n- Age 16-60 years\n- Onset of ankle sprain at least 2 weeks prior to enrollment\n- Foot and Ankle Ability Measure Activity of Daily Living subscale score less than or equal to 80%\n\nAssessment:\n- The patient's age (32 years) falls within the trial's inclusion age range (16-60 years).\n- The patient has multiple injuries from a car accident, but there is no specific mention of an ankle sprain.\n- The onset of any potential ankle sprain is not at least 2 weeks prior to enrollment since the patient is currently in the ER following a recent car accident.\n- There is no information provided regarding the Foot and Ankle Ability Measure Activity of Daily Living subscale score.\n\nGiven the lack of information about an ankle sprain and the recentness of the accident, the patient does not meet all the specified inclusion criteria for the clinical trial on ankle manual therapy for ankle sprains. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "804": {
        "output": "Based on the patient note, the 32-year-old woman has sustained multiple injuries from a car accident, including upper and lower extremity fractures. The clinical examination reveals a tender abdomen with guarding and rebound, indicating possible abdominal trauma, but there is no mention of rib fractures or chest wall injuries that would meet the specific inclusion criteria for the clinical trial focused on chest wall repair of rib fractures after trauma.\n\nThe inclusion criteria for the clinical trial are:\n1. Subjects must be at least >18 years of age\n2. Subjects must have one of the following clinical indications:\n   - >3 rib flail segments with paradoxical chest wall movement\n   - Non-repair of defect may result in pulmonary hernia\n   - Minimal associated injuries\n   - Severely displaced fractures are significantly impeding lung expansion.\n   - Failure of narcotics or epidural pain catheter to control pain\n\nSince there is no mention of rib fractures, flail chest, or any specific chest wall injury in the patient note, the patient does not meet the inclusion criteria based on the provided information. Therefore, the patient would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "805": {
        "output": "Based on the patient note, the 32-year-old woman was admitted to the ER following a car accident and has sustained multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, which could mean she might be able to give consent and participate in studies. However, there is no specific mention of neck injury or neck pain, which are common indicators of a whiplash injury. The study in question is specifically targeting patients with whiplash injuries, as indicated by the study's title and summary, which focuses on the range of motion in the cervical spine after such trauma.\n\nThe inclusion criteria for the clinical trial are very specific in that the patients must have had a measurement of the cervical range of motion following a whiplash trauma. Since the patient note does not mention any whiplash injury or measurement of cervical range of motion, there is no clear indication that this patient would meet the inclusion criteria based on the information provided.\n\nTherefore, based on the available information from the patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "806": {
        "output": "Considering the information provided for the patient and the inclusion criteria of the clinical trial titled \"Energy Drinks & Driving Ability,\" let's assess the patient's eligibility:\n\nPatient note assessment:\n- The patient is a 32-year-old woman, which fits within the 21-35 years age range required by the trial.\n- There is no information provided about the patient's BMI or body weight, so we can't confirm eligibility based on these criteria.\n- The patient's smoking status is not mentioned.\n- There is no information provided regarding the patient's visual acuity or hearing status.\n- The patient's possession of a valid driver's license and driving experience are not mentioned.\n- The patient's ability to provide written informed consent is assumed possible as she is fully awake and alert, but this would need to be confirmed.\n- The reliability and mental capability of the patient to adhere to the protocol should be further investigated, especially considering the recent trauma from a car accident which could potentially affect her short-term participation.\n\nClinical trial inclusion criteria:\n- Age between 21 and 35 years old (the patient meets this criterion).\n- BMI between 21 and 30 (information not provided).\n- 55-85 kg body weight (information not provided).\n- Non-smoker (information not provided).\n- Written informed consent (assumed possible but needs confirmation).\n- Normal static binocular acuity, corrected or uncorrected (information not provided).\n- Normal hearing (information not provided).\n- Possession of a valid driver's license for at least 3 years (information not provided).\n- Regular driver (> 5000 km/year) (information not provided).\n- Reliable and mentally capable of adhering to the protocol (needs further investigation).\n\nGiven the lack of information on several inclusion criteria and the patient's recent involvement in a car accident, which could impact her immediate ability to participate in a driving-related study, I would consider referring this patient to the clinical trial upon further investigation to confirm the missing information and her current condition post-accident.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "807": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it seems that the patient could potentially be eligible for the trial.\n\nThe patient note indicates that the patient is a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, which implies that she could give consent if required. Her physical examination reveals a tender abdomen with guarding and rebound in all four quadrants, and no bowel sounds, which could suggest the need for a laparotomy, potentially leading to an open abdomen situation.\n\nThe clinical trial's inclusion criteria are:\n- Trauma patients with open abdomen after initial laparotomy\n- Emergency surgery patients with open abdomen after initial laparotomy\n- Able to obtain consent from patient or LAR before any research initiated\n\nSince the patient has sustained trauma and may require a laparotomy, which could result in an open abdomen, she fits the trauma patient category. Additionally, she is alert and could provide consent for participation in the trial.\n\nGiven the information provided, and assuming that the patient will undergo a laparotomy resulting in an open abdomen, this patient could be considered for the trial. However, confirmation of the laparotomy and open abdomen is needed before a definitive referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "808": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial based on the inclusion criteria.\n\nPatient note summary:\n- 32-year-old woman\n- Admitted to the ER following a car accident\n- Sustained multiple injuries including fractures\n- Awake and alert, not wearing a seat belt during the accident\n- Blood pressure and pulse within normal ranges\n- Physical examination reveals a tender abdomen with guarding and rebound, and no bowel sounds\n\nClinical trial inclusion criteria:\n- Postoperative period of abdominal surgery (elective surgery of the colon-rectum, ileum, stomach, and pancreas)\n- Postoperative period after Urgent laparotomy for both traumatic and/or non-traumatic acute abdomen\n- Patients with signs of sepsis in the postoperative period\n- Patients with signs of systemic hypoperfusion in the postoperative period\n\nEligibility assessment:\nThe patient has been admitted to the ER following a car accident and has sustained multiple injuries, including abdominal tenderness with guarding and rebound, which could indicate an acute abdomen that may require urgent laparotomy. However, the patient note does not explicitly state that the patient has undergone abdominal surgery or that they are in the postoperative period. Additionally, there is no direct mention of signs of sepsis or systemic hypoperfusion.\n\nGiven the lack of information regarding whether the patient has undergone or will undergo an abdominal surgery, as well as the absence of explicit signs of sepsis or systemic hypoperfusion in the note, the patient's eligibility for the clinical trial is uncertain at this point.\n\nHowever, considering that the patient has a tender abdomen with guarding and rebound, which are suggestive of an acute abdominal condition that might require surgery, and the clinical trial includes patients in the postoperative period after urgent laparotomy for traumatic acute abdomen, it is reasonable to consider that this patient could potentially meet the inclusion criteria after further investigation such as confirming an actual surgery and postoperative status.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "809": {
        "output": "The patient is a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries including upper and lower extremity fractures. She is awake, alert, and her physical examination reveals a tender abdomen with guarding and rebound in all four quadrants, but there is no mention of a spinal cord injury, nor any details that would classify her injury on the ASIA Impairment Scale. The clinical trial in question is for patients with spinal cord injuries specifically between the C4 and T12 neurological levels and requires patients to be categorized in terms of the ASIA Impairment Scale.\n\nGiven that there is no information provided about the patient having a spinal cord injury, despite the trauma from the car accident, we cannot assume that she meets the specific inclusion criteria for the trial. Furthermore, the inclusion criteria require the injury to have occurred at least 6 months prior for chronic patients, less than 2 weeks for acute patients, and 2-8 weeks for subacute patients; there is no information provided about the timing of the injury relative to the onset of the patient's condition. The patient does meet the age requirement of being between 20-55 years old.\n\nBased on the available information, the patient does not meet the specific inclusion criteria related to the nature and details of the spinal cord injury. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "810": {
        "output": "Based on the information provided, the patient in the note is a 32-year-old woman who was admitted to the ER following a car accident, which makes her a road traffic accident victim. She has sustained multiple injuries and is fully awake and alert. According to the inclusion criteria for the DEPITAC clinical trial, participants must be road traffic accident victims hospitalized in a surgical department less than 2 weeks and able to be called by phone.\n\nThe patient meets the criteria as she is within the time frame of less than 2 weeks since her accident, given that she is described as being currently in the ER following the accident. There is no information provided that would exclude her from being able to be called by phone.\n\nTherefore, the patient appears to meet the inclusion criteria for the DEPITAC clinical trial, which aims to screen for PTSD in patients who have been in a motor vehicle accident and are hospitalized in a surgical department.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "811": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Lactated Ringer's Solution in Neonates With Feeding Intolerance, the 32-year-old woman would not be eligible for this clinical trial. The trial is specifically targeting preterm infants with a birth gestational age between 25 and 32 weeks and a corrected gestational age of less than 34 weeks who are experiencing severe feeding intolerance.\n\nThe patient in question is an adult and her medical issues are related to injuries from a car accident, not feeding intolerance in the neonatal period. Therefore, she does not meet any of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "812": {
        "output": "",
        "label": 2
    },
    "813": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet several of the specified criteria:\n\n1. Gender: The patient is a woman, and the trial specifies that participants must be male.\n2. Ethnicity: There is no information about the patient's ethnicity, so we cannot confirm if she is Caucasian, as required by the trial.\n3. Injuries: The patient has sustained multiple injuries and is currently in a medical emergency situation following a car accident. The trial is looking for healthy volunteers.\n\nGiven these discrepancies, the patient would not be eligible for the clinical trial on the effects of Zopiclone on driving simulator performance. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "814": {
        "output": "Based on the patient note provided and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- 32-year-old woman\n- Admitted to ER following a car accident\n- Multiple injuries, including fractures\n- Awake and alert\n- Not reported: Loss of consciousness, dazed, confused, saw stars, headache, dizziness, irritability, memory gap, visual loss, or specific mention of a diagnosis of mild traumatic brain injury (m-TBI) or post-traumatic stress disorder (PTSD)\n\nClinical Trial Inclusion Criteria Analysis:\n- Children age 6 to 18 (The patient is 32, not within this age range)\n- Language spoken: Hebrew, Arabic (Language proficiency not mentioned in the patient note)\n- DSM- IV R diagnosis: PTSD (PTSD diagnosis not mentioned in the patient note)\n- Car accident event within past 3 years (The patient's accident seems recent, so this condition is met)\n- Any of the following symptoms or experiences occurring during or shortly after the accident for the m-TBI group...\n- Diagnosis of mTBI within 3 years as confirmed by imaging\n- Glasgow coma scale; GCS<15 (Not mentioned in the patient note)\n\nGiven the information available, the patient does not meet the age criterion for the clinical trial. Moreover, there is no indication that the patient has been diagnosed with PTSD or m-TBI, which are required for inclusion in the trial. Therefore, we cannot conclude that the patient is eligible for this trial based on the current information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "815": {
        "output": "Given the patient note for a 32-year-old woman who was admitted to the ER following a car accident, we need to compare her profile with the inclusion criteria of the Teenage Driving Safety Study.\n\nThe inclusion criteria for the Teenage Driving Safety Study are:\n1. Teenagers perceived to be students driving near school property.\n2. Teenagers perceived to be of driving age.\n3. Teens in 10th, 11th, and 12th grades attending Phillipsburg, Southern Lehigh, Freedom, and Liberty High Schools.\n4. Any driver driving near school property, which is perceived to be older than of high school age.\n\nThe patient is 32 years old, which means she is not a teenager and does not fit the description of the participants that the study is aiming to include, which are specifically teenagers and individuals who are of high school age or perceived to be such. Furthermore, there is no indication that she is a student or affiliated with the high schools mentioned in the criteria.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the Teenage Driving Safety Study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "816": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient is a 32-year-old woman who was admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. \n\nThe inclusion criteria for the clinical trial are:\n1. 18 years of age or older\n2. Radiographic evidence of tibial plateau fracture\n\nThe patient note does not mention whether the fractures sustained by the patient include a tibial plateau fracture. To determine trial eligibility, we would need radiographic evidence confirming the presence of an intraarticular tibial plateau fracture.\n\nSince we do not have the specific information about the type of fractures, this patient cannot be directly referred to the trial based on the information provided. However, if further investigation (such as radiographs) reveals a tibial plateau fracture, she could potentially be eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "817": {
        "output": "To assess the eligibility of the patient for the \"WalkMore Walking Interventions for Overweight/Obese Postmenopausal Women\" trial, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient characteristics:\n- 32-year-old woman\n- Recently involved in a car accident with multiple injuries including upper and lower extremity fractures\n- Fully awake and alert\n- Not wearing a seat belt during the accident\n- Tender abdomen with guarding and rebound\n- No bowel sounds\n\nClinical trial inclusion criteria:\n- Woman between 45-74 years of age\n- Have not had a menstrual period for at least 12 months (postmenopausal)\n- Are not regularly physically active (self-reported non-exerciser for previous 6 months)\n- Have a body mass index (BMI) between 25-45 kg/m^2\n- Have high normal blood pressure or (systolic pressure of 130-179 mmHg or a diastolic pressure of 85-99 mmHg)\n- Not limited in your ability to walk\n- Understand these criteria\n- Are willing to provide informed consent\n- Willing to be randomized to either type of walking intervention or a control group being studied, and are willing to follow the protocol for the group to which they have been assigned\n\nBased on the information provided in the patient note:\n\n- The patient is a 32-year-old woman, which does not meet the age criterion of 45-74 years.\n- There is no information regarding her menopausal status, but given her age, it is less likely that she is postmenopausal.\n- There is no information about her physical activity levels, BMI, or willingness to participate.\n- The patient has sustained multiple injuries, including extremity fractures, which may limit her ability to walk, conflicting with the criteria of not being limited in the ability to walk.\n- The patient's blood pressure is 134/74 mm Hg, which does meet the blood pressure criterion.\n\nGiven that the patient does not meet the age criterion and potentially the postmenopausal status, and considering her recent injuries that may limit her ability to walk, it is clear that she is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "818": {
        "output": "",
        "label": 2
    },
    "819": {
        "output": "Based on the patient note provided, the patient is a 32-year-old woman who has been admitted to the ER following a car accident. The clinical trial in question is focused on drivers with Type 1 diabetes and aims to reduce hypoglycemia-related driving collisions through Internet interventions.\n\nTo determine trial-level eligibility, we must compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\n1. Have been diagnosed with Type 1 diabetes for at least one year - The patient note does not mention a diagnosis of Type 1 diabetes.\n2. Started taking insulin less than a year after being diagnosed with Type 1 diabetes - The patient note does not provide any information on diabetes or insulin use.\n3. Measure blood glucose at least twice a day - Again, there is no information on blood glucose measurement in the patient note.\n4. Legal and valid driver's license - The patient note does not mention whether the patient has a driver's license.\n5. Drives greater than 5,000 per year - The note does not provide information regarding the patient's driving habits.\n6. Regular access to the Internet, either through family computer or another readily accessible computer - There is no information provided about the patient's access to the Internet.\n7. Age 18 - 70 years - The patient meets this criterion as she is 32 years old.\n8. English speaker - The patient note does not specify the language spoken by the patient.\n\nGiven the information in the patient note, we do not have enough evidence to confirm that the patient meets any of the inclusion criteria specifically related to Type 1 diabetes, which is a critical aspect of this clinical trial. Therefore, without any indication that the patient has Type 1 diabetes, it is not appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "820": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients,\" we can proceed with the eligibility assessment.\n\nThe patient note describes a 32-year-old woman admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, with a tender abdomen with guarding and rebound in all four quadrants, indicating potential intra-abdominal injury, which may necessitate an open abdomen approach.\n\nThe inclusion criteria for the clinical trial are:\n- Trauma patients undergoing DC/OA (Damage Control/Open Abdomen) management for traumatic injury\n- Age 18+\n- Life expectancy longer than 48 hours\n\nThe patient is 32 years old, which meets the age criterion. Given that she has sustained traumatic injuries and may require DC/OA management based on the physical examination findings, she could potentially meet the first criterion as well. However, the patient note does not explicitly state that she is undergoing or will undergo DC/OA management. Lastly, there is no information on her life expectancy, but given that she is fully awake and alert, there is no immediate indication that her life expectancy would be less than 48 hours.\n\nConsidering the provided information, the patient appears to meet some of the inclusion criteria, but there is insufficient detail to confirm her eligibility fully. Therefore, further investigation is required to determine if she will receive DC/OA management and to assess her life expectancy based on her injuries and overall condition.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "821": {
        "output": "The patient note describes a 32-year-old woman who has been admitted to the ER following a car accident, with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, and her current condition is related to the accident.\n\nThe clinical trial is focused on the individualized fortification of breast milk for preterm infants, with specific inclusion criteria related to the gestational age (<32 weeks), enteral intake, and the expected duration of receiving the intervention.\n\nThe patient in the note does not fit the criteria for this clinical trial for several reasons:\n\n1. The trial is designed for preterm infants with specific gestational age and feeding requirements, while the patient is a 32-year-old woman.\n2. The trial requires written informed consent from an infant's legal representative, implying the study subjects are infants, not adults.\n3. The patient's condition (injuries from a car accident) is unrelated to the subject of the trial, which is breast milk fortification for preterm infants.\n\nGiven these points, it is clear that the patient does not meet the inclusion criteria for the clinical trial described. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "822": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial:\n\nPatient note:\n- A 32-year-old woman admitted to the ER\n- Following a car accident\n- Sustained multiple injuries, including extremity fractures\n- Fully awake and alert\n- Blood pressure 134/74 mm Hg, pulse 87/min\n- Tender abdomen with guarding and rebound\n- No bowel sounds\n\nClinical trial:\n- Title: Physical Activity for Campus Employees\n- Effects of a worksite wellness program on physical activity and cardiovascular disease risk factors\n- Inclusion Criteria: employee of Washington University in St. Louis\n\nThe only inclusion criterion provided for the clinical trial is being an employee of Washington University in St. Louis. There is no information in the patient note regarding her employment at Washington University in St. Louis. Therefore, based on the available information, we cannot establish her eligibility for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "823": {
        "output": "Given the patient note:\n\n- A 32-year-old woman is admitted to the ER following a car accident.\n- She has sustained multiple injuries including upper and lower extremity fractures.\n- She is fully awake and alert.\n- She reports that she was not wearing a seat belt.\n- Her blood pressure is 134/74 mm Hg, and her pulse is 87/min.\n- Physical examination reveals a tender abdomen with guarding and rebound in all four quadrants.\n- She has no bowel sounds.\n\nAnd the clinical trial inclusion criteria:\n\n- Both sex of Age > 65\n- Traumatic non-pathological fracture neck of femur or trochanteric or subtrochanteric fracture having operative intervention\n\nThe patient does not meet the inclusion criteria for the clinical trial based on the information provided. The patient is 32 years old, which is below the age threshold of 65 years required for the trial. Additionally, there is no specific mention that the patient has sustained a hip fracture (fracture neck of femur or trochanteric or subtrochanteric fracture) which is required for the trial. The patient's fractures are described as involving upper and lower extremities, but without further specifics, we cannot assume a hip fracture is among them.\n\nTherefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "824": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial \"Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy,\" let's assess the eligibility of the patient for the trial:\n\nPatient Note Assessment:\n- The patient is a 32-year-old woman, which fits within the age range of 19-65 years required by the trial.\n- The patient was admitted to the ER following a car accident with multiple injuries and tender abdomen with guarding and rebound, which may not correlate with an ASA PS 1-2 status. ASA PS 1 indicates a normal healthy patient, while ASA PS 2 indicates a patient with mild systemic disease. A patient with multiple injuries from a car accident likely exceeds the criteria for ASA PS 1-2, suggesting a more severe systemic condition.\n- The patient's current condition is an emergency, not an elective situation, and it is not specified that she is scheduled for an elective colonoscopy.\n- There is no information provided about whether the patient has signed written informed consent for this specific clinical trial.\n\nBased on the provided information:\n\n- The patient's age aligns with the trial's inclusion criteria.\n- The patient's ASA physical status is likely not within the 1-2 range due to the severity of the injuries.\n- The patient is not scheduled for an elective colonoscopy under Monitored Anesthesia Care, as she is admitted to the ER for acute injuries.\n- There is no confirmation of written informed consent for this trial.\n\nGiven these points, the patient does not meet several key inclusion criteria for the trial. Therefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "825": {
        "output": "Given the information provided about the patient and the clinical trial, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient note:\n- A 32-year-old woman admitted to the ER following a car accident with multiple injuries.\n- The patient has sustained upper and lower extremity fractures and has a tender abdomen with guarding and rebound.\n- She is awake and alert.\n\nClinical trial:\n- Title: Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis.\n- Inclusion Criteria: Consecutive patients recruited for the study who presented to the Yonsei University Medical Center with variable symptom or cause for ERCP, older than 20 years.\n\nThe patient has been admitted following a car accident and there is no mention of her needing an ERCP (Endoscopic Retrograde Cholangiopancreatography) procedure or having pancreatitis. The clinical trial is specifically looking for patients who are presenting for ERCP, which is not indicated in the patient's note. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial focused on the prevention of post-ERCP pancreatitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "826": {
        "output": "Based on the patient note and the clinical trial description, the 32-year-old woman who is admitted to the ER following a car accident with multiple injuries including upper and lower extremity fractures meets the inclusion criteria for the clinical trial titled \"Examination of Microcirculation of the Caput Humeri After Proximal Humerus Fracture.\" \n\nThe inclusion criteria for the clinical trial are:\n1. Traumatic fractures of the proximal humerus\n2. Surgical treatment\n3. Over eighteen years of age\n\nThe patient note indicates that the woman has sustained multiple injuries, which could include a proximal humerus fracture, although this is not explicitly stated. However, given the nature of her accident and injuries, it is quite possible that she has a humerus fracture that would require surgical treatment.\n\nAs the patient is 32 years old, she meets the age criterion. Given that the patient is already in the emergency room and given the nature of her accident, it is plausible that she could be assessed for a proximal humerus fracture and might require surgical treatment, which would make her a potential candidate for the clinical trial.\n\nTherefore, the assessment of eligibility would be:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "827": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient does not seem to be a suitable candidate for the clinical trial in question. \n\nThe patient is a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures, and she is displaying signs of an acute abdomen, which could suggest internal injuries. The trial, however, is specifically looking for patients with TMJ (temporomandibular joint) arthralgia, masticatory myalgia, TMJ sounds, and a history of at least 6 weeks of use of occlusal appliance therapy.\n\nThe patient's condition described in the note has no mention of TMJ issues or any history of TMJ treatment. Furthermore, the patient's current acute condition and injuries from the car accident are not related to the focus of the clinical trial, which is pain management associated with TMJ disorders.\n\nAs such, the eligibility for this clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "828": {
        "output": "The provided patient note describes a 32-year-old woman who was admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, with a blood pressure of 134/74 mm Hg and a pulse of 87/min. She exhibits signs of potential intra-abdominal injury with a tender abdomen showing guarding and rebound in all four quadrants and absent bowel sounds.\n\nThe clinical trial in question is investigating the use of abdominopelvic CT (CTap) imaging in stable, blunt trauma patients without suspected pelvis or hip fractures. The inclusion criteria for the clinical trial are:\n\n- Age between 3-60 years.\n- Evaluated for blunt trauma with a Glasgow Coma Scale (GCS) of >14.\n- Order for CT abdomen and pelvis imaging.\n\nThe patient meets the age criterion (32 years old) and is evaluated for blunt trauma with a GCS above 14, indicating she is alert and awake. Given her physical examination findings, it is likely that a CT abdomen and pelvis would be clinically indicated by the treating clinician to assess for intra-abdominal injury, thus meeting the third inclusion criterion for the study.\n\nBased on the patient note and the clinical trial's inclusion criteria, it seems that this patient could be a candidate for the trial. However, without explicit information regarding an order for CT abdomen and pelvis imaging, we can only assume it would be considered based on the clinical presentation. Therefore, I would assign the following trial-level eligibility score:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "829": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 32-year-old woman who was admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. The physical examination findings suggest a possible abdominal injury with tender abdomen, guarding, rebound tenderness, and absence of bowel sounds, which may be indicative of a traumatic bowel injury.\n\nThe clinical trial in question aims to determine the impact of Enteral Feeding (EN) in patients with a traumatic bowel injury requiring an open abdomen. The inclusion criteria for this trial are quite broad, stating simply \"All patients with a post-injury open abdomen.\"\n\nGiven that the patient has signs suggestive of an abdominal injury, it is possible that she may require an open abdomen treatment approach, which would make her a potential candidate for the trial. However, the patient note does not explicitly confirm that the patient has a bowel injury or that an open abdomen procedure is planned or has been performed. Therefore, while there is potential for eligibility, additional information is required to confirm the patient's condition and planned treatment approach.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "830": {
        "output": "Based on the patient note provided, the 32-year-old woman was admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures, and signs of abdominal trauma indicated by tenderness, guarding, and rebound tenderness in all four quadrants. There is no mention of an open abdomen or the requirement for surgical intervention leading to an open abdomen at this point in time.\n\nThe clinical trial in question is specifically looking to compare different management strategies for patients with an open abdomen, which is a condition where the abdomen has been surgically left open, usually due to trauma or infection.\n\nAs the patient note does not mention that the patient has an open abdomen or has undergone a procedure resulting in an open abdomen, she does not currently meet the inclusion criteria for this clinical trial, which specifically requires participants to have an open abdomen.\n\nTherefore, based on the information provided, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "831": {
        "output": "",
        "label": 0
    },
    "832": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the clinical trial titled \"Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol.\"\n\nPatient Note Assessment:\n- The patient is a 32-year-old woman, which fits the age range of 20 to 85 years required by the trial.\n- She has sustained multiple injuries, including fractures, from a car accident.\n- The patient note does not mention glucocorticoid use, which is a requirement for the trial.\n- The patient is able to walk without assistance, but this is not mentioned. However, given her multiple fractures, it is possible she may not be able to walk without assistance currently.\n- The note does not provide information about the patient's bone mineral density (%YAM) or any existing insufficiency fracture.\n- It is unknown if the patient has provided consent or would be willing to participate in the study.\n\nClinical Trial Inclusion Criteria:\n- The trial requires patients who are taking or plan to take oral glucocorticoids for 3 months or longer.\n- Patients must either have an insufficiency fracture, a %YAM <80, or be on a daily glucocorticoid dose >= 5 mg prednisolone equivalent.\n- The patient must be able to walk without assistance.\n- The patient must provide consent to participate in the study.\n\nBased on the patient note and the inclusion criteria for the clinical trial, we do not have enough information to determine if the patient is taking or plans to take oral glucocorticoids, nor do we know if she has an insufficiency fracture or meets the other bone condition requirements.\n\nGiven the lack of information on glucocorticoid use and the current injuries that may impair her ability to walk without assistance, it is not possible to confidently refer this patient for the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "833": {
        "output": "Based on the patient note provided, the 32-year-old woman was admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. There is no mention of any trauma to her eyes or visual impairment related to the car accident or any pre-existing condition such as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) or Multiple Sclerosis (MS) associated with visual loss.\n\nThe inclusion criteria for the clinical trial require that the participant:\n\n1. Is 18 years or older, which the patient satisfies.\n2. Has sustained trauma more than 3 months before this study or has been diagnosed with NAION more than 6 months before this study or has been diagnosed with MS and suffered visual loss more than 3 months before this study, which the patient does not satisfy as the trauma was recent (she is currently in the ER following the accident) and there is no mention of NAION or MS with visual loss in her history.\n3. Is willing and able to give written informed consent, which cannot be determined from the information provided.\n4. Is able to commit to enrolling in the study during the full time period of up to 6 months, which also cannot be determined from the information provided.\n\nGiven that the patient does not meet the specific criteria related to the reason for the study (trauma to the eye/visual loss or diagnosis of NAION/MS with visual loss), and the trauma was recent, not more than 3 months before the study as required, she would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "834": {
        "output": "",
        "label": 0
    },
    "835": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock,\" the patient appears to be potentially eligible for the trial. Here is the evaluation against the inclusion criteria:\n\nInclusion Criteria Evaluation:\n\n- Age \u226516 years of age or estimated weight \u226550kgs if age is unknown: The patient is 32 years old, which meets the age requirement.\n- Victim of blunt or penetrating trauma: The patient was involved in a car accident, which qualifies as blunt trauma.\n- Hemorrhagic shock defined as one or more episodes of systolic blood pressure \u226490mmHg at any time prior to enrollment into the study: The patient's blood pressure is provided as 134/74 mm Hg, which does not indicate hemorrhagic shock. However, it's possible that she could have experienced a lower blood pressure at the scene of the accident or later in the ER.\n- An identified source of blood loss (abdomen, chest, pelvis/retroperitoneum, extremities, external) or blood products (RBC, Platelets, Plasma, etc.) has been ordered to the trauma room: The patient has multiple injuries including fractures and a tender abdomen with guarding and rebound, which suggests a potential for internal bleeding, but there is no specific mention of an identified source of blood loss or orders for blood products.\n- Admitted to St. Michael's Hospital directly from the scene of injury within 3 hours of the injury: This information is not provided in the patient note.\n- Application and completion of Remote Ischemic Conditioning (RIC) within 4 hours of the injury: The patient is in the ER following the accident, but we do not have information on the timing of the RIC relative to the injury.\n\nThe patient meets some of the inclusion criteria, but crucial information regarding the presence of hemorrhagic shock, the specific source of blood loss, orders for blood products, and whether the patient was admitted to the specified hospital within the required timeframe is missing. Therefore, further information would be needed to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "836": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 32-year-old woman appears to be a suitable candidate for the study. She was admitted to the ER following a car accident, which is the population the study is looking to enroll.\n\nThe inclusion criteria for the clinical trial are:\n- Victims of motor vehicle accidents\n- Signed informed consent\n\nThe patient in question has sustained injuries from a motor vehicle accident. There are no additional specific requirements mentioned in the inclusion criteria, such as the need for a diagnosis of whiplash syndrome or post-traumatic stress disorder prior to enrollment. Based on the provided information, the patient meets the inclusion criteria as long as she is capable and willing to provide signed informed consent.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "837": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, we can analyze the eligibility of the patient for the trial.\n\nPatient Note Analysis:\n- The patient is a 32-year-old woman.\n- She is admitted to the ER following a car accident.\n- She has sustained multiple injuries, including upper and lower extremity fractures.\n- She is fully awake and alert.\n- Physical examination reveals a tender abdomen with guarding and rebound in all four quadrants, indicating possible internal injuries.\n- There is no mention of the patient's understanding of Danish or the ability to give informed consent in the provided note.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must be 18 years or older.\n- Patients must be scheduled for internal fixation of an ankle fracture.\n- Patients must have the ability to read and understand Danish and give informed oral and written consent.\n\nComparison:\n- The patient is above 18 years of age, which meets the age criterion.\n- The patient has sustained multiple injuries, including lower extremity fractures, which may include an ankle fracture, but this is not explicitly stated in the patient note.\n- The ability to read and understand Danish, as well as the ability to give informed consent, are not addressed in the patient note.\n\nGiven the information provided, there is insufficient evidence to determine if the patient's injuries include an ankle fracture that requires internal fixation, and there is no information on the patient's ability to understand Danish or provide consent. Due to these unknowns, further investigation is needed before referring this patient.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "838": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient described would not be eligible for the clinical trial mentioned. The clinical trial is focused on the effects of withholding feeds during red blood cell transfusion on the development of TRAGI in premature babies who are less than 32 weeks of gestational age or weigh less than 1500 grams and are more than 7 days old. \n\nThe patient in the note is a 32-year-old woman who has been admitted to the ER following a car accident. She has multiple injuries and is not a premature baby, which is the population of interest for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "839": {
        "output": "Based on the patient note provided, the 32-year-old woman was admitted to the ER following a car accident and has sustained multiple injuries including fractures and presents with a tender abdomen with guarding and rebound. There is no information provided that suggests she has end-stage renal disease (ESRD) or that she is undergoing hemodialysis, which are key inclusion criteria for the clinical trial in question.\n\nThe clinical trial \"Abdominal Compression Elastic Support (ACES)\" is specifically looking to recruit patients with end-stage renal disease who are on hemodialysis and have had at least two episodes of intra-dialytic hypotension (IDH) in the last month. The patient in the ER does not fit these criteria as there is no mention of her having ESRD, requiring hemodialysis, or experiencing IDH. Therefore, based on the information provided, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "840": {
        "output": "",
        "label": 0
    },
    "841": {
        "output": "",
        "label": 1
    },
    "842": {
        "output": "Given the patient's condition as described in the patient note, she has sustained multiple injuries including fractures after a car accident. The clinical trial in question is investigating the use of early fibrinogen concentrate as a therapy to prevent excessive bleeding in trauma patients. \n\nThe inclusion criteria for the clinical trial are:\n1. Injured trauma (penetrating or blunt) patients who are at risk of significant bleeding, defined as:\n   i. Systolic blood pressure (SBP) \u2264 100mmHg at any time from the injury scene until 30min after hospital admission AND\n   ii. Red blood cell transfusion has been ordered by the trauma team leader (or delegate)\n\nThe patient note indicates that the patient has a systolic blood pressure of 134/74 mm Hg, which is above the \u2264100mmHg threshold outlined in the inclusion criteria. Additionally, there is no mention that a red blood cell transfusion was ordered for the patient.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the trial as her systolic blood pressure is not within the specified range and there is no indication that a red blood cell transfusion has been ordered. Therefore, she would not be eligible for this clinical trial based on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "843": {
        "output": "",
        "label": 1
    },
    "844": {
        "output": "",
        "label": 0
    },
    "845": {
        "output": "Assessing the given patient information against the clinical trial inclusion criteria:\n\nPatient Information:\n- 32-year-old woman\n- Multiple injuries from a car accident including upper and lower extremity fractures\n- Fully awake and alert\n- Not currently receiving treatment for her fractures (based on provided information)\n\nClinical Trial Inclusion Criteria:\n- Patients at least 18 years old\n- Male or Female\n- All racial and ethnic groups\n- Fractures and fracture/dislocations of the foot, ankle, tibia, fibula, elbow, forearm, wrist, and hand\n- Patients who opt for surgical treatment of their fractures\n- Patients who consent to be randomized\n- Patients who are willing to follow up for a minimum of 52 weeks\n\nComparison:\n- The patient is 32 years old, meeting the age criterion.\n- The patient has fractures, which could potentially include the areas specified (foot, ankle, tibia, fibula, elbow, forearm, wrist, and hand).\n- There is no information provided that the patient would not opt for surgical treatment or would be unwilling to consent to be randomized or follow up for the necessary time period.\n\nGiven that the patient has sustained fractures and the trial is specifically looking at pain control after orthopedic surgery for extremity fractures, it is very likely that she may be opting for surgical treatment of her fractures. The patient would need to consent to be randomized and agree to the follow-up period, but there is no information suggesting she would not be amenable to these conditions.\n\nTherefore, based on the information provided, it seems:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "846": {
        "output": "",
        "label": 0
    },
    "847": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Multiple injuries, including extremity fractures\n- Fully awake and alert\n\nClinical Trial:\n- Title: Safety in Seconds 2.0: An App to Increase Car Seat Use\n- Focus: Tailored injury prevention education for car seat use via a smartphone app\n- Inclusion Criteria:\n  - Visiting the Pediatric Emergency Department (PED) at Johns Hopkins Hospital or Arkansas Children's Hospital\n  - Parent or guardian of child 4-7 years\n  - English speaking\n  - Have an Android or iPhone smartphone\n  - Drive with the child in a car at least once per week in a car that the parent owns, borrows, or gets a ride round-trip\n  - Resident of Baltimore City, MD or Little Rock, AR and surrounding area.\n\nThe patient note does not mention if the woman is a parent or guardian of a child aged 4-7 years, if she owns a smartphone, if she drives with a child at least once per week, or if she is a resident of the specified areas. Without this information, we cannot determine her eligibility based on the provided criteria.\n\nTherefore, based on the information given:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "848": {
        "output": "Given the patient note, the patient is a 32-year-old woman. The clinical trial in question is looking for individuals who are between the ages of 13-18 years old and have an appointment to see a provider at a participating clinic.\n\nSince the patient is 32 years old, she does not meet the age criterion for the clinical trial, which is specifically targeting adolescents.\n\nTherefore, on the scale of eligibility:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "849": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- 32-year-old woman (meets age criterion of at least 18 years of age)\n- Admitted to the ER following a car accident\n- Multiple injuries including fractures (not mentioned as exclusion criteria)\n- Fully awake and alert (meets inclusion criterion of being awake and alert)\n- Tender abdomen with guarding and rebound in all four quadrants (could suggest an abdominal injury or condition such as diffuse peritonitis)\n- No bowel sounds (could indicate ileus, but it is not clearly stated as \"severe or prolonged ileus\")\n\nClinical Trial Inclusion Criteria:\n- Awake and alert (met)\n- Not on a regular diet (likely met due to hospital admission)\n- Able to access the gut for enteral feeding (not explicitly mentioned, but no indication of inability)\n- At least 18 years of age (met)\n\nPotential Concerns:\n- The patient has a tender abdomen with guarding and rebound, which could suggest an underlying condition that would not meet some of the other criteria, such as diffuse peritonitis, or could develop into a condition such as abdominal compartment syndrome or severe ileus.\n\nGiven these considerations, the patient is awake and alert, not on a regular diet, and of age. However, the physical examination findings could potentially indicate a severe underlying abdominal condition that might exclude her from participation in the trial. Since the patient's current ailments might contraindicate the application of the trial's intervention or could evolve into an exclusion condition, further investigations would be necessary to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "850": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for this specific trial. The inclusion criteria for the trial are:\n\n- High school student\n- 16 or 17 at the start of the study\n- Have a valid driver's license\n- Lives in parent's/guardian's home\n- Drives to school\n- Primarily drive one car\n- Has their own iPhone 4S or newer or Android 4.3 or newer smartphone with data plan\n- Parent/guardian is willing to assist with installation\n- Admit to texting while driving >1 time in the last 30 days\n\nThe patient described in the note is a 32-year-old woman who is admitted to the ER following a car accident. Based on the provided information, this patient does not meet several of the inclusion criteria for the trial:\n\n- The patient is not a high school student.\n- The patient is not 16 or 17 years old.\n- There is no information suggesting that she lives in her parent's/guardian's home or drives to school.\n- There is no information about her owning a compatible smartphone or her texting habits while driving.\n\nGiven that the patient does not meet the age requirement and educational status, and the lack of information on the other criteria, it is clear that she is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "851": {
        "output": "The patient note describes a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures. She is fully awake and alert, which suggests that she does not have a severe traumatic brain injury, as her Glasgow Coma Scale (GCS) score is not mentioned to be 8 or less. There is also no mention of craniofacial fractures, only extremity fractures and a tender abdomen with guarding and rebound, which suggests possible abdominal injury but no direct indication of craniofacial or skull fractures.\n\nGiven the information provided, we do not have evidence that this patient meets the inclusion criteria for the clinical trial, which specifically requires a severe traumatic brain injury (GCS 8 or less) and/or craniofacial fracture.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "852": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 32-year-old woman who was admitted to the ER following a car accident does not fit the inclusion criteria for the clinical trial in question. The trial is focused on evaluating a neck strengthening program to reduce the risk of sport-related concussion in youth contact and collision sport athletes. The patient's situation does not indicate that she is an athlete involved in any contact or collision sports, nor is there any information suggesting she is seeking intervention for concussion prevention.\n\nThe inclusion criteria specifically mention contact/collision sport athletes and the trial is aimed at reducing the risk of sport-related concussion, which is not relevant to the patient's current condition of being involved in a car accident with multiple injuries, including extremity fractures and abdominal tenderness with guarding and rebound.\n\nTherefore, based on the information provided, it would not be appropriate to refer this patient to the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "853": {
        "output": "Based on the patient note, the 32-year-old woman was admitted to the ER following a car accident with multiple injuries, including a tender abdomen with guarding and rebound in all four quadrants and no bowel sounds. While these symptoms could be consistent with acute appendicitis, they are also indicative of trauma from the car accident. There is no specific mention of right lower abdominal pain, which is a requirement according to the trial's inclusion criteria.\n\nGiven the lack of specific information regarding right lower abdominal pain and considering the context of multiple injuries from a car accident, it is not clear whether the patient's symptoms are due to acute appendicitis or due to the trauma sustained in the accident. Therefore, further investigation would be needed to assess whether the patient's symptoms are indeed due to suspected acute appendicitis before considering referral to this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "854": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Multiple injuries including upper and lower extremity fractures\n- Fully awake and alert\n- Blood pressure: 134/74 mm Hg\n- Pulse: 87/min\n- Physical examination: tender abdomen with guarding and rebound in all four quadrants, no bowel sounds\n\nClinical trial:\n- Title: Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children\n- Inclusion criteria: \n  - Children aged 2 through 17 years (17 years included)\n  - Suspected fracture of a long bone requiring morphine analgesia (VAS \u2265 60/100 or Evendol \u2265 7/15 at the arrival at emergency department)\n  - Within the first 12 hours after the injury\n  - At least one signed parental informed consent\n  - Affiliated to health insurance\n\nThe patient in question is a 32-year-old woman, which does not fall within the age range specified in the inclusion criteria for the clinical trial (children aged 2 through 17 years). Therefore, based on the age criterion alone, she is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "855": {
        "output": "Given the patient note and the clinical trial information, we can assess the eligibility based on the provided inclusion criteria.\n\nPatient note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Multiple injuries including extremity fractures\n- Fully awake and alert\n- Tender abdomen with guarding and rebound\n- No bowel sounds\n\nClinical trial:\n- Title: The Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section\n- Inclusion criteria: Patients set for planned cesarean section under general or spinal anesthesia, age from 18 to 37 years, full term (37-41 weeks), singleton pregnancy, hemoglobin level more than 11 gm/dl.\n\nAssessment:\nThe patient in the note is a 32-year-old woman, which fits the age criterion. However, the patient has been admitted following a car accident and there is no indication of her being pregnant or requiring a cesarean section. Since the clinical trial specifically targets patients set for a planned cesarean section with additional criteria such as being full term in their pregnancy and having a singleton pregnancy, this patient does not meet these crucial inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "856": {
        "output": "Based on the information provided, the 32-year-old woman admitted to the ER following a car accident does not meet the inclusion criteria for the clinical trial entitled \"The Effects of Combining Modified Ride-On Cars With Bimanual Training on Enhancing Mobility, Socialization, Motor Function and Participation in Toddlers With Disabilities.\" The inclusion criteria for the trial specify that participants must be toddlers aged between 12 months to 36 months old with motor delays resulting in impairments that prevent functional independent mobility. The patient's age and her condition (injuries from a car accident) do not align with the study's focus on toddlers with developmental motor delays.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "857": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 32-year-old woman\n- Admitted to the ER following a car accident\n- Sustained multiple injuries including upper and lower extremity fractures\n- Fully awake and alert\n- Had a car accident without wearing a seat belt\n- Blood pressure: 134/74 mm Hg\n- Pulse: 87/min\n- Physical examination: tender abdomen with guarding and rebound in all four quadrants, no bowel sounds\n\nClinical Trial:\n- Title: Abdomen CT and Open Appendicectomy: New Diagnostic and Surgical Procedures\n- Focus: Evaluating new diagnostic and surgical procedures for acute appendicitis\n- Inclusion Criteria: patients with a clinical diagnosis of acute appendicitis\n\nThe patient in the note does not mention a diagnosis of acute appendicitis; instead, she has sustained injuries from a car accident and has a tender abdomen, which could have multiple causes that are trauma-related. The physical symptoms do not specifically indicate acute appendicitis, and there is no explicit mention of appendicitis or related symptoms.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial focused on acute appendicitis because there is no clinical diagnosis of acute appendicitis provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "858": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 32-year-old woman who was admitted to the ER following a car accident. The clinical trial is targeting adolescents aged 13-18 years old who are moderate to high risk alcohol users and will be assessing the effectiveness of an electronic personalized health screening app.\n\nThe patient in question does not fit the age criterion for the clinical trial, which specifically includes adolescents aged 13-18 years old. Additionally, there is no information provided about the patient's alcohol use, which is another inclusion criterion for the trial.\n\nGiven the information provided, the patient does not meet the age inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "859": {
        "output": "",
        "label": 1
    },
    "860": {
        "output": "Based on the patient note provided, the 21-year-old female patient presents with symptoms indicative of systemic lupus erythematosus (SLE), including arthralgias, alopecia, a characteristic rash, purpura, joint swelling, normocytic anemia, thrombocytopenia, and laboratory evidence of autoimmunity with positive ANA and anti-dsDNA, along with renal involvement indicated by proteinuria and RBC casts.\n\nThe clinical trial in question is studying the incidence, pathogenesis, and risk factors for thrombotic events and coronary artery disease in patients with SLE. The inclusion criteria for the clinical trial are not explicitly stated other than it involves patients with systemic lupus erythematosus.\n\nAs the patient's presentation is consistent with SLE, and there are no specific inclusion criteria provided other than the condition being studied (SLE), the patient appears to fit the population that the study is intending to investigate.\n\nTherefore, based on the information provided, it is highly likely the patient would be a candidate for this clinical trial, as they have a diagnosis aligned with the focus of the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "861": {
        "output": "Based on the patient note provided, the 21-year-old female patient is being evaluated for symptoms that suggest systemic lupus erythematosus (SLE), including arthralgias, alopecia, a characteristic rash, non-palpable purpura, swelling and tenderness of wrists and ankles, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts. The patient's presentation aligns with the inclusion criteria for SLE under the clinical trial titled \"Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases.\"\n\nThe inclusion criteria for SLE in this clinical trial are as follows:\n- Malar rash\n- Discoid rash\n- Photosensitivity\n- Oral ulcers\n- Arthritis\n- Serositis\n- Renal disorder\n- Neurologic disorder\n- Hematologic disorder\n- Immunologic disorder\n- Antinuclear antibody\n\nThe patient must have at least 4 of these manifestations, which the patient note suggests she does. Additionally, the patient must have evidence of potential life-threatening involvement of at least one internal organ system and be refractory to conventional therapy after attempts to control the disease with at least two drugs, including prednisone and one of the following: azathioprine, cyclophosphamide, or cyclosporine, or be controlled on conventional therapy but at the price of unacceptable toxicity.\n\nWhile the patient note does not detail the extent of organ involvement or provide a complete treatment history, the severity of the symptoms and presence of multiple SLE-related symptoms suggest that the patient could potentially meet the inclusion criteria for SLE in the trial. However, additional information on the patient's treatment history and the severity of organ involvement would be necessary to make a definitive assessment.\n\nConsidering the potential match of the disease and the symptoms presented, but acknowledging the need for more detailed information to ensure all specific inclusion criteria are met, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "862": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided:\n\nPatient Note Summary:\n- The patient is a 21-year-old female\n- Symptoms include progressive arthralgias, malaise, alopecia, a characteristic rash, purpura, swollen and tender wrists and ankles\n- Lab findings include normocytic anemia, thrombocytopenia, a positive ANA, anti-dsDNA, and urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- A diagnosis of systemic lupus erythematosus (SLE)\n\nThe patient's symptoms and lab findings (such as a positive ANA and anti-dsDNA, and characteristic rash) are indicative of systemic lupus erythematosus (SLE), which matches the inclusion criterion for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "863": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Anti-CD20 in Systemic Lupus Erythematosus,\" we will compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 21-year-old female\n- Symptoms consistent with systemic lupus erythematosus (SLE): arthralgias, malaise, alopecia, rash, purpura, swelling and tenderness of wrists and ankles\n- Laboratory results: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine\n\nClinical Trial Inclusion Criteria:\n- Age 18 to 70 years old\n- Willing to use reliable birth control during treatment and for 6 months after\n- Have SLE by the American College of Rheumatology criteria\n- Have had SLE for at least 6 months prior to screening\n- Have active SLE disease at the screening visit\n- Have organ disease (lung, stomach, intestinal, blood, kidney, and/or heart)\n- Have failed standard therapy or experienced side effects requiring discontinuation\n- Meet blood, liver, and kidney laboratory value criteria\n- Not on an immunosuppressive agent for 2 weeks prior to the first treatment\n- On a stable dose of oral corticosteroids for 4 weeks before the visit, if taking them\n- At least 1 elevated autoantibody level at the screening visit\n\nClinical Trial Exclusion Criteria:\n- Pregnant or breastfeeding\n- Diseases that may pose a risk during the trial\n- Cranial neuropathy\n- On blood-thinning agents\n- Serious skin disease\n- Certain class of heart disease\n- History of cancer (except certain types)\n- Serious infectious disease that is active or was active within 2 years of the baseline visit\n- HIV infection or immunosuppression\n- Experimental drug within 30 days of baseline visit\n- Monoclonal antibody or similar medication within 3 months of the baseline visit\n- Intravenous, joint, or muscle injection of corticosteroids within 4 weeks of the baseline visit\n- Alcohol or drug abuse\n- Unwilling or unable to follow the protocol\n- Poor veins for receiving injections\n\nBased on the patient's note, the following can be determined:\n- The patient is within the age range.\n- The patient has SLE, which is indicated by the symptoms and lab results.\n- The patient's active SLE disease is implied by the ongoing symptoms and lab findings.\n- The patient likely has organ involvement (kidney) as indicated by the presence of proteinuria and RBC casts.\n- The patient has elevated autoantibodies (ANA and anti-dsDNA).\n\nThe note does not provide information on birth control use, the duration of the patient's SLE diagnosis, whether the patient has failed standard therapy or had side effects requiring discontinuation, if they are on immunosuppressive agents, or if they are on a stable dose of oral corticosteroids. Also, it doesn't mention any of the exclusion criteria.\n\nGiven that the patient meets several key inclusion criteria and there is no information suggesting they meet any exclusion criteria, the patient could be considered for this clinical trial. However, further investigation is required to ascertain additional details such as duration of SLE diagnosis, medication history, and current treatments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "864": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE),\" we need to compare the patient's characteristics to the inclusion criteria listed for the trial.\n\nPatient characteristics:\n- 21-year-old female\n- Symptoms consistent with systemic lupus erythematosus (SLE): progressive arthralgias, malaise, alopecia, rash, purpura on calves, wrist and ankle swelling and tenderness\n- Laboratory findings: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, urine positive for protein and RBC casts\n\nClinical trial inclusion criteria:\n- Meets American College of Rheumatology (ACR) revised diagnostic guidelines for SLE\n- Weight of 25 kg (55 lbs) or more\n- Outpatient\n- Ability to complete self-report questionnaires in either English or Spanish\n- Willingness to comply with recommended diet\n- Acceptable methods of contraception\n\nBased on the patient's note, the patient exhibits signs and symptoms that are consistent with SLE and would likely meet the ACR revised diagnostic guidelines for SLE. The patient's age falls within the range that could be considered pediatric or young adult, which aligns with the study's focus on children and young adults. Additional information about the patient's weight, outpatient status, language abilities, dietary compliance, and use of contraception would be required to definitively determine eligibility.\n\nSince the patient demonstrates several key symptoms of SLE and the primary diagnostic criteria, it is reasonable to consider referring this patient to the clinical trial upon further investigation of the remaining inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "865": {
        "output": "Assessing the eligibility of the patient for the Lupus Genetics Studies clinical trial:\n\nPatient characteristics:\n- 21-year-old female\n- Symptoms consistent with systemic lupus erythematosus (SLE), such as progressive arthralgias, malaise, alopecia, a malar rash, non-palpable purpura, joint swelling and tenderness\n- Laboratory findings supportive of SLE diagnosis: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine\n\nClinical trial inclusion criteria:\n- Families in which one or more living members have been diagnosed with systemic lupus erythematosus (SLE)\n\nGiven the patient's symptoms, lab findings, and the clinical picture presented, it is highly suggestive of a diagnosis of SLE. The trial is looking for families with one or more living members diagnosed with SLE. Therefore, if this patient has been formally diagnosed with SLE, she and her family would potentially be eligible for this study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "866": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 21-year-old female.\n- She presents with progressive arthralgias and malaise, alopecia, a characteristic rash, non-palpable purpura, and swelling and tenderness of her wrists and ankles.\n- Laboratory findings include normocytic anemia, thrombocytopenia, positive ANA, and anti-dsDNA, and urine positive for protein and RBC casts.\n- These findings are consistent with a clinical diagnosis of systemic lupus erythematosus (SLE).\n\nClinical Trial Inclusion Criteria Analysis:\n- Clinical diagnosis of SLE: The patient has a clinical diagnosis of SLE based on her symptoms and laboratory findings.\n- Active SLE disease: The patient's symptoms and lab results suggest active disease.\n- On a stable SLE treatment regimen: The patient note does not specify if she is on a treatment regimen or if it is stable. Further investigation would be needed here.\n- History of measurable autoantibodies: The patient has a positive ANA and anti-dsDNA, which are measurable autoantibodies.\n\nClinical Trial Exclusion Criteria Analysis:\n- The patient note does not mention any use of non-FDA approved investigational agents, cyclosporin, IVIG, or plasmapheresis, no mention of active lupus nephritis requiring specific treatments, active CNS lupus, history of renal transplant, chronic infections, herpes zoster, infections requiring hospitalization or IV medication, hypogammaglobulinemia, IgA deficiency, HIV, or hepatitis B/C.\n\nGiven the information provided, the patient appears to meet the inclusion criteria for the clinical trial. However, the stability of her SLE treatment regimen is not clear from the patient note. Therefore, further investigation would be necessary to confirm her treatment status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "867": {
        "output": "Based on the patient note, the 21-year-old female has signs and symptoms indicative of lupus, such as alopecia, a characteristic rash, arthralgias, and laboratory findings including normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, as well as urine positive for protein and RBC casts. However, the clinical trial in question is focused on the Research Registry for Neonatal Lupus, which is looking for mothers with antibodies to SSA/Ro, SSB/La, or ribonucleoproteins (RNP), or their children who have neonatal lupus, or other family members related to such cases.\n\nThe patient note does not indicate that the patient is pregnant or has a child affected by neonatal lupus, nor does it mention the presence of the specific antibodies SSA/Ro, SSB/La, or RNP that are required for inclusion in the study. Additionally, the trial is specifically for the registry of neonatal lupus, which does not align with the patient's current presentation. \n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the Research Registry for Neonatal Lupus clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "868": {
        "output": "The patient note indicates that the 21-year-old female patient is experiencing symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, a rash on her face, purpura, swelling and tenderness of wrists and ankles, as well as laboratory findings of normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and urine positive for protein and RBC casts. These symptoms and lab results suggest an active SLE flare, particularly with the involvement of the skin and joints.\n\nThe clinical trial is seeking participants with a diagnosis of SLE who are experiencing an active lupus flare in at least one of three organ systems: skin, heart, or lung, or with arthritis (inflammation of more than 4 joints) within 14 days of a screening visit. Additionally, participants must be on a stable dose of prednisone (<30mg) for at least one month.\n\nBased on the patient note, the patient appears to meet the criteria for the clinical trial:\n\n1. The patient has been diagnosed with SLE.\n2. The patient is experiencing an active lupus flare, as evidenced by the rash on her skin and arthritis symptoms (swelling and tenderness of wrists and ankles, which are more than 4 joints).\n3. The eligibility criteria do not mention the need for the patient to be on a stable dose of prednisone, but this is a point that would need to be confirmed.\n\nSince the patient has active SLE flares in the skin and joints, which are among the organ systems specified in the inclusion criteria, she is a potential candidate for the study. However, the patient's current treatment regimen, including whether she is on prednisone and if so, the dose and duration, is not mentioned in the patient note. If the patient is not currently on prednisone or not on a stable dose for at least one month, this would need to be addressed before she could participate in the trial.\n\nAssuming that the patient is eligible based on the prednisone criteria, or could be made eligible with slight modifications to her treatment regimen, I would consider her a candidate for the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "869": {
        "output": "Based on the patient note provided:\n\n- The patient is a 21-year-old female, meeting the age criterion of being over 18 with the ability to provide informed consent.\n- The patient has symptoms suggestive of systemic lupus erythematosus (SLE), such as arthralgias, rash, alopecia, and non-palpable purpura, alongside laboratory findings of normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, which are consistent with SLE.\n- The patient's urine analysis is positive for protein and RBC casts, indicating possible kidney involvement, which could be consistent with membranous nephritis secondary to SLE.\n\nHowever, the inclusion criteria for the clinical trial specifically require:\n\n- Fulfillment of the revised American College of Rheumatology criteria for SLE.\n- Biopsy-proven membranous nephropathy secondary to SLE.\n- Nephrotic syndrome with proteinuria (> 3 g/day) and serum albumin < 30 g/dl, with or without active urinary sediments despite steroid therapy (with or without cytotoxic agents).\n\nWhile the patient shows signs of SLE and kidney involvement, the information provided does not confirm whether the patient has biopsy-proven membranous nephropathy, the extent of proteinuria, or serum albumin levels. Moreover, there is no information on whether the patient has received steroid therapy or any other treatments for SLE.\n\nGiven the lack of specific information on some of the key inclusion criteria, further investigation would be needed to determine if the patient has biopsy-proven membranous nephropathy, the extent of her proteinuria, and serum albumin levels, as well as to confirm past and current treatments.\n\nTherefore, the patient could be considered for referral to the clinical trial upon further investigation to confirm these details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "870": {
        "output": "",
        "label": 2
    },
    "871": {
        "output": "Based on the information provided, the patient described in the note has a clinical diagnosis consistent with Systemic Lupus Erythematosus (SLE), as evidenced by symptoms such as alopecia, a characteristic malar rash, joint swelling and tenderness (arthralgias), and laboratory findings including normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, and urine positive for protein and RBC casts. These are all typical findings in SLE.\n\nThe clinical trial is investigating the use of memantine in patients with SLE, specifically targeting those with neuropsychiatric manifestations, including cognitive dysfunction. The inclusion criteria for the trial are a clinical diagnosis of SLE and self-reported cognitive impairment.\n\nHowever, the patient note does not mention any neuropsychiatric symptoms or specifically cognitive impairment, which is an inclusion criterion for the trial. Without evidence of cognitive impairment, we cannot conclusively determine that the patient would be eligible for this trial based on the information provided. Therefore, further investigation would be required to assess the presence of cognitive dysfunction in this patient before a referral could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "872": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 21-year-old female, which fits the age range of >18 years old, <60 years old specified in the trial's inclusion criteria.\n- There is no mention of the patient's pregnancy status, contraceptive use, or childbearing potential, so we cannot fully assess this criterion.\n- The patient's condition is not specifically described as Chronic Fatigue Syndrome (CFS), as required by the trial. Instead, the patient presents with symptoms indicative of an autoimmune disorder with findings such as alopecia, a malar rash, arthralgias, and laboratory evidence of an autoimmune process (positive ANA and anti-dsDNA, proteinuria, and RBC casts).\n- The patient's ability to walk on a treadmill is not mentioned, nor is there information about a Karnofsky Performance Status (KPS).\n- The patient has laboratory documentation of a positive ANA and anti-dsDNA, which directly conflicts with the requirement for a negative ANA and anti-dsDNA in the trial's inclusion criteria.\n- There is no information provided regarding the patient's thyroid status or if they have a documented euthyroid state.\n\nClinical Trial Inclusion Criteria Analysis:\n- A diagnosis of CFS for >12 months.\n- Age between >18 years and <60 years.\n- Males or non-pregnant, non-lactating females who meet certain requirements regarding childbearing potential and use of contraception.\n- A documented KPS of 40 to 60 on three occasions within the preceding 12 weeks.\n- The ability to walk on a treadmill as specified.\n- Negative ANA, negative anti-dsDNA, negative Rheumatoid Factor, and a normal ESR.\n- Euthyroid status, with a stable dose for patients on thyroid replacement therapy during the washout period.\n- Ability to provide written informed consent.\n\nBased on the information provided, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the patient does not have a diagnosis of CFS, has a positive ANA and anti-dsDNA, and there is no information about her KPS or thyroid status. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "873": {
        "output": "Based on the patient note provided:\n\n- The patient is a 21-year-old female presenting with symptoms consistent with lupus, including arthralgias, malaise, alopecia, a rash on her cheeks and nose (malar rash), purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and signs of nephritis (proteinuria and RBC casts).\n\nGiven the inclusion criteria for the clinical trial:\n\n- Female and male patients aged 18-65 years (the patient fits within this age range).\n- Patients with histologically defined discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE) - the patient presents with a rash that may be indicative of lupus erythematosus, but the note does not specify if it is dLE or scLE, nor is there any mention of a histological confirmation.\n- The test sites must be on the face only (the patient has a rash on the bridge of her nose and cheeks, which fits this criterion).\n- The test sites must have a total sign score of 4 or more and must be the same within a given patient (there is no information provided about the sign score or the size of the test sites).\n- The patients must receive baseline medication with chloroquine (there is no information on the patient's current medications).\n- Patients must have been informed about the study procedures and medication and have given their written informed consent (this can be addressed if the patient is considered for the trial).\n- Patients expected to be available for the duration of the study and able to comply with the study visits (unknown based on the note provided).\n\nThe patient's symptoms suggest lupus, and while she has some features that meet the inclusion criteria (age, gender, facial rash), there is insufficient information to definitively determine if she has dLE or scLE, whether a biopsy has been performed, the severity of her rash, and whether she is on chloroquine treatment. Therefore, further investigation would be required to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "874": {
        "output": "The patient is a 21-year-old female with symptoms and lab findings consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, as well as urine positive for protein and RBC casts. These findings suggest that she meets at least 4 of the 11 American College of Rheumatology (ACR) Revised Classification Criteria for SLE, which is one of the inclusion criteria for the clinical trial.\n\nThe inclusion criteria for the trial are:\n1. Male or female subjects between the ages of 18 and 60 years, inclusive.\n2. Meeting at least 4 of 11 ACR Revised Classification Criteria for SLE.\n3. Having severe steroid-refractory disease, which is described in detail within the criteria.\n4. Ability and willingness to provide written informed consent.\n5. Must be ANA positive.\n\nThe patient meets the age criterion (21 years old), she appears to meet at least 4 of the ACR criteria for SLE based on the information provided (e.g., rash, arthralgias, positive ANA and anti-dsDNA, hematological abnormalities), and she is ANA positive. However, the patient note does not provide enough information to assess whether she has severe steroid-refractory disease as defined by the trial's specific requirements or her willingness and ability to provide informed consent.\n\nGiven that the patient meets some of the inclusion criteria but lacks information on the severity of her condition and treatment history, I would consider referring this patient to this clinical trial upon further investigation to confirm the severity and refractoriness of her disease to standard treatments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "875": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 21-year-old female with symptoms suggestive of systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic malar rash, purpura, swollen and tender wrists and ankles, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts.\n\nClinical Trial:\n- Studying the role of DcR3 in T cell activation in SLE and RA.\n- Inclusion criteria: Patients diagnosed with SLE or RA.\n\nThe patient's symptoms and lab findings are indicative of SLE, which aligns with one of the diseases specified in the inclusion criteria of the clinical trial. Therefore, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "876": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- A 21-year-old female\n- Symptoms consistent with systemic lupus erythematosus (SLE): arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, swelling and tenderness of wrists and ankles\n- Laboratory findings: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of SLE according to current ACR criteria\n- Diagnosis of ISN/RPS 2003 Class III or IV lupus nephritis\n- Proteinuria\n- Age 16-75 years\n\nThe patient's clinical presentation and lab findings (positive ANA and anti-dsDNA, proteinuria, and RBC casts) are consistent with a diagnosis of SLE and suggest lupus nephritis. However, the specific class of lupus nephritis (Class III or IV) cannot be confirmed without further information such as a kidney biopsy. The patient meets the age criterion and has evidence of proteinuria.\n\nGiven the information in the patient note, it is likely that the patient has lupus nephritis, and therefore would be considered for the clinical trial. However, additional information is needed to confirm the classification of lupus nephritis to ensure it meets the trial's specific ISN/RPS 2003 Class III or IV requirement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "877": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil,\" let's compare the patient note with the inclusion criteria step by step.\n\nPatient Note:\n- 21-year-old female\n- Symptoms: progressive arthralgias, malaise, alopecia, rash, purpura, wrist and ankle swelling, and tenderness\n- Lab findings: normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, proteinuria, and RBC casts\n\nThese findings and symptoms are suggestive of systemic lupus erythematosus (SLE), which aligns with the target condition for the clinical trial.\n\nInclusion Criteria for the Clinical Trial:\n1. Fulfill ACR Classification Criteria for SLE - The patient's symptoms and lab findings suggest she likely meets this criterion.\n2. >18 and < 60 years old - The patient is 21 years old, so she meets this age criterion.\n3. English-speaking/reading - There is no information given about the patient's language abilities.\n4. Has a treating rheumatologist at the Hospital for Special Surgery - This information is not provided.\n5. Estimated premorbid verbal I.Q. >80 measured by the North American Adult Reading Test - There is no information about the patient's IQ.\n6. Functional difficulties due to cognitive dysfunction defined as positive endorsement of \u22656 items on the Cognitive Symptoms Inventory (CSI) - There is no information given about cognitive dysfunction or CSI endorsement.\n7. No physical or mental disabilities that would preclude or confound the results of the neuropsychological testing - The patient's physical state is not described in terms of disabilities that could affect testing.\n8. Able to read normal newsprint and hear a normal speaking voice - There is no information on the patient's ability to read or hear.\n9. Normotensive at the time of enrollment with or without medication - There is no information about the patient's blood pressure.\n10. No arrhythmia or left ventricular hypertrophy on ECG - There is no information about an ECG.\n11. Adequate contraception (barrier method) - There is no information about the patient's use of contraception.\n\nGiven the information provided in the patient note, the patient meets the age and likely the SLE classification criteria for the clinical trial. However, there is a lack of information regarding the other inclusion criteria, particularly regarding cognitive impairment and functional difficulties, which are central to the study's focus on cognitive dysfunction in lupus patients.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation to confirm her cognitive symptoms and other eligibility criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "878": {
        "output": "Based on the patient note, the 21-year-old female has signs and symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, swollen and tender wrists and ankles, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and urine positive for protein and RBC casts, which are indicative of possible lupus nephritis.\n\nThe clinical trial is focused on lupus nephritis, specifically looking at the role of environmental and occupational exposures in its etiology. To be included in the trial, patients must meet the following inclusion criteria:\n\n1. Have renal biopsy-proven Lupus Nephritis (with the biopsy-based diagnosis date no earlier than January 1, 1995).\n2. Reside within designated counties of eastern North Carolina and South Carolina.\n\nWhile the patient's symptoms highly suggest lupus nephritis, there is no explicit mention of a renal biopsy being performed, which is a requirement for inclusion in the study. Additionally, the patient note does not provide information on her residence to confirm whether she lives within the specified counties of eastern North Carolina or South Carolina.\n\nWithout confirmation of a renal biopsy and the patient's residency, we cannot definitively include the patient in the trial. Therefore, further investigation would be needed to determine if the patient has had a renal biopsy confirming lupus nephritis and if she resides within the designated areas.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "879": {
        "output": "",
        "label": 0
    },
    "880": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the assessment of eligibility can be made as follows:\n\nPatient Note Assessment:\n- The patient is a 21-year-old female presenting with symptoms consistent with an autoimmune disorder.\n- The clinical findings include alopecia, a malar rash, arthralgias, and hematological abnormalities (normocytic anemia, thrombocytopenia).\n- The patient has a positive ANA and anti-dsDNA, which are indicative of systemic lupus erythematosus (SLE).\n- The patient's urine analysis is positive for protein and RBC casts, which can be associated with lupus nephritis, a common complication of SLE.\n\nClinical Trial Inclusion Criteria:\n- The clinical trial is focusing on efferocytosis and genomic polymorphism in autoimmune diseases.\n- The inclusion criteria for the clinical trial are patients with SLE, RA (rheumatoid arthritis), or healthy individuals.\n\nPatient Eligibility Assessment:\n- The patient appears to have SLE based on the clinical presentation and laboratory findings, which aligns with one of the conditions listed in the inclusion criteria for the clinical trial.\n\nBased on the information provided, this patient has characteristics that match the inclusion criteria for the clinical trial on efferocytosis and genomic polymorphism in autoimmune diseases.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "881": {
        "output": "To assess the eligibility of the 21-year-old female patient for the clinical trial titled \"Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus\", we need to examine the patient's characteristics against the inclusion criteria of the trial.\n\nInclusion Criteria Checklist:\n- Age > 18 years: The patient is 21 years old, so she meets this criterion.\n- Fulfillment of at least 4 of the American College of Rheumatology (ACR) criteria for SLE: The patient has alopecia, a typical malar rash, positive ANA and anti-dsDNA, and evidence of renal involvement (protein and RBC casts in urine), which likely fulfills at least 4 ACR criteria for SLE.\n- Presence of any two of the following risk factors:\n  - SLE duration of >= 5 years: Not specified in the patient note.\n  - Postmenopausal: Unlikely given the patient's age of 21 years.\n  - Age >= 40 years: The patient does not meet this criterion.\n  - Diabetes mellitus: Not specified in the patient note.\n  - Hypertension (140/90 mmHg): Not specified in the patient note.\n  - Serum low density lipoprotein (LDL) level >= 2.6 mmol/L or total cholesterol >= 5.5 mmol/L: Not specified in the patient note.\n  - Obesity (body mass index >= 27 kg/m2): Not specified in the patient note.\n  - Chronic current smoker: Not specified in the patient note.\n  - Positive antiphospholipid antibodies: Not specified in the patient note.\n  - Renal function impairment: The patient's urine is positive for protein and RBC casts which may indicate renal involvement, but the extent of impairment is not specified.\n  - Persistent proteinuria >= 1 gm/day for >= 6 months: Not specified in the patient note.\n- Informed consent obtained: This is a procedural criterion that can be fulfilled if the patient agrees to participate.\n\nBased on the information provided, the patient meets the age criterion and likely fulfills the ACR criteria for SLE. However, there is no detailed information about the risk factors required by the trial. We would need more information to assess whether she meets at least two of the specified risk factors.\n\nGiven this information, the patient might be eligible upon further investigation into the specified risk factors and obtaining informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "882": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient, a 21-year-old female, does not meet the eligibility criteria for the clinical trial on the Effect of Hormone Replacement Therapy on Lupus Activity. The inclusion criteria specifically require participants to be menopausal women, as indicated by either amenorrhea of 6 months or more, serum follicle-stimulating hormone (FSH) level of 30 IU/L or more, menopausal symptoms, or being 48 years or older. The patient in question is only 21 years old and there is no mention of her being menopausal or having any menopausal symptoms.\n\nTherefore, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "883": {
        "output": "Based on the provided patient note and the inclusion criteria of the Study PLUS clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- A 21-year-old female with symptoms indicative of Systemic Lupus Erythematosus (SLE), which includes arthralgias, malaise, alopecia, a malar rash, purpura, swollen and tender wrists and ankles, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts.\n\nClinical trial inclusion criteria:\n- Age of 18 and above (patient is 21, meets criteria)\n- Diagnosis of SLE according to the ACR Classification Criteria (patient's symptoms and lab results are suggestive of SLE, but the note does not confirm a formal diagnosis according to the ACR criteria)\n- Treatment with HCQ for at least 6 months, without modification of HCQ dosage for 2 months (not specified in patient note)\n- Stable dosage of HCQ (not specified in patient note)\n- No increase in the steroids dosage during the 3 previous weeks (not specified in patient note)\n- Steroids dosage lower or equal to 0.5 mg/kg/day of prednisone equivalent (not specified in patient note)\n- No modifications of a possible immunosuppressor during the 2 previous months (not specified in patient note)\n- SELENA-SLEDAI \u2264 12 (not specified in patient note)\n- Signature of the consent of participation (assumed possible if patient is willing)\n\nGiven the information provided, the patient seems to have SLE, which is required for the clinical trial. However, there is no information about her current treatment (specifically with hydroxychloroquine), steroid dosage, immunosuppressant use, or SELENA-SLEDAI score. Because these details are critical for determining her eligibility and are not provided in the patient note, further investigation is needed to determine if she meets the rest of the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "884": {
        "output": "Based on the patient's note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia, a rash on the bridge of the nose and cheeks\n- Delicate non-palpable purpura on calves\n- Swelling and tenderness of wrists and ankles\n- Lab findings: normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, proteinuria, and RBC casts in urine\n\nClinical trial inclusion criteria:\n- Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11 American College of Rheumatology criteria, either sequentially or coincidently (the 4 criteria need not be present at study entry)\n- Renal biopsy within 12 months prior to screening visit indicating active proliferative lupus glomerulonephritis (ISN/RPS Class III or IV, excluding certain subcategories, or WHO Class III or IV, excluding certain subcategories)\n- At least one abnormal serology if the biopsy was performed >3 months but \u226412 months prior to screening: low complement (C3 or C4) level or anti-dsDNA >upper limit of normal range\n- A stable serum creatinine \u22643 mg/dL\n\nAssessment:\n- The patient has multiple symptoms consistent with SLE, including alopecia, a characteristic rash, arthralgias, and lab findings (positive ANA, anti-dsDNA, proteinuria, and RBC casts) that suggest the presence of lupus nephritis.\n- However, it is not explicitly stated that the patient meets at least 4 of the 11 ACR criteria for SLE, although the symptoms and lab findings strongly suggest this could be the case.\n- There is no information about a renal biopsy, which is a requirement for trial inclusion to determine the class of lupus nephritis.\n- The patient's serum creatinine level is not provided, which is necessary to ensure it is within the required range for trial eligibility.\n\nBased on the information given, the patient appears to have clinical features consistent with SLE and possible lupus nephritis. However, critical information such as the confirmation of meeting the ACR criteria for SLE, details of a renal biopsy, and serum creatinine levels are missing. Therefore, further investigation would be needed to determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "885": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Study of Methotrexate in Lupus Erythematosus,\" we must match the patient's characteristics and condition against the inclusion criteria of the trial.\n\nPatient's characteristics and condition:\n- A 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia\n- Rash on the bridge of her nose and cheeks\n- Non-palpable purpura on her calves\n- Swelling and tenderness of her wrists and ankles\n- Lab results indicating normocytic anemia, thrombocytopenia, positive ANA, and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical trial inclusion criteria:\n- Men and women with a diagnosis of SLE (systemic lupus erythematosus)\n- 18 years and above\n- Negative pregnancy test for female subjects of childbearing age and must not attempt to get pregnant during the study\n- Active disease as defined by SLAM of at least 8\n- SLICC/ACR damage index of less than or equal to 15\n- On a stable dose of NSAIDs, prednisone, or antimalarials for at least 4 weeks preceding the study\n- Can be under other medications as long as the condition or treatment will not interfere with the experimental medications and assessments\n- Must understand either French or English and can give written informed consent\n\nThe patient is a 21-year-old female with a diagnosis that fits the description of SLE (evidenced by symptoms such as arthralgias, rash, alopecia, anemia, thrombocytopenia, and positive ANA and anti-dsDNA). There is no mention of her understanding of French or English, pregnancy status, or current medications, but it can be reasonably assumed that she meets these criteria based on standard clinical practice (excluding language, which may need to be confirmed).\n\nGiven the information provided, the patient seems to meet the inclusion criteria for the study, as she has symptoms and laboratory findings consistent with active SLE. There is no information to suggest she would not meet the other criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "886": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Myfortic Versus Azathioprine in Systemic Lupus Erythematosus,\" let us determine the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 21-year-old female, which meets the age criterion of being 18 years and over.\n- The patient exhibits symptoms consistent with systemic lupus erythematosus (SLE), such as arthralgias, malaise, alopecia, a characteristic malar rash, and non-palpable purpura.\n- Lab tests show normocytic anemia, thrombocytopenia, positive ANA, and anti-dsDNA, which align with the ACR guidelines for an SLE diagnosis.\n- The patient's urine is positive for protein and RBC casts, which indicates renal involvement, a common manifestation of SLE.\n- There is no explicit mention of the patient's SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score. However, the presence of multiple clinical symptoms and lab abnormalities might suggest that the patient could have an SLEDAI score greater than 6, indicating active disease.\n- There is no information on whether the patient is currently being treated with maintenance therapy that includes azathioprine.\n\nClinical Trial Inclusion Criteria Match:\n- Age \u2265 18 years: Matched\n- Diagnosis of SLE according to ACR guidelines with positive anti-dsDNA: Matched\n- SLEDAI > 6: Potentially matched (further investigation required)\n- Patients treated with maintenance therapy including azathioprine: Unclear (further investigation required)\n- Written informed consent: Presumed to be obtainable if the patient agrees to participate\n\nGiven the information available, the patient appears to meet several of the key inclusion criteria for the clinical trial. However, there are two points that require further investigation: confirmation of the patient's SLEDAI score and whether the patient is currently on maintenance therapy with azathioprine. \n\nTherefore, based on the information provided and the need for further investigation regarding the patient's SLEDAI score and current treatment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "887": {
        "output": "Based on the patient note provided, the 21-year-old female patient presents with symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, swelling and tenderness of the wrists and ankles, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and urine positive for protein and RBC casts. These clinical findings align with a diagnosis of lupus.\n\nThe clinical trial in question is the Duke Lupus Registry, which aims to collect information and blood samples from patients with lupus seen in the Duke Rheumatology clinics. The inclusion criteria are a diagnosis of Systemic Lupus Erythematosus or Cutaneous Lupus and being a patient of a rheumatologist at Duke University Medical Center.\n\nAssuming the patient is being evaluated at or can be referred to the Duke Rheumatology clinics, she meets the diagnostic criteria for SLE. However, her eligibility would depend on whether she is a patient under the care of a rheumatologist at Duke University Medical Center, which the patient note does not provide information on.\n\nSince we don't have information about whether the patient is already a patient of a rheumatologist at Duke or can become one, I would rate the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include confirming the patient's ability to become a patient at Duke Rheumatology clinics and to be registered in the Duke Lupus Registry.",
        "label": 1
    },
    "888": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 21-year-old female\n- Symptoms and lab findings suggestive of systemic lupus erythematosus (SLE): arthralgias, malaise, alopecia, malar rash, non-palpable purpura, wrist and ankle swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine.\n\nClinical Trial Inclusion Criteria:\n1. Age at least 18 years\n2. Diagnosis of SLE by ACR criteria\n3. Diagnosis of proliferative lupus nephritis (ISN/RPS class III or IV)\n4. Currently on prednisolone (5 to 20 mg/day)\n5. In partial or complete remission for at least 3 months\n\nThe patient is 21 years old, which meets the age criterion. The symptoms and lab findings are consistent with SLE, and the positive ANA and anti-dsDNA suggest that the patient would likely meet the ACR criteria for SLE diagnosis. However, there is no information provided that confirms a diagnosis of proliferative lupus nephritis (ISN/RPS class III or IV), whether the patient is currently on prednisolone or any other treatment, and if the patient is in remission or not.\n\nBecause the patient potentially meets some of the inclusion criteria but lacks specific information about their nephritis classification, current medications, and remission status, we cannot definitively determine eligibility for the trial. Further investigation is needed to obtain these details and assess the patient's full eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "889": {
        "output": "The patient note indicates that the individual is a 21-year-old female with symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash (malar rash), non-palpable purpura, swelling and tenderness of her wrists and ankles, normocytic anemia, thrombocytopenia, a positive ANA, anti-dsDNA, and urine positive for protein and RBC casts.\n\nThe clinical trial is focused on the long-term outcome of children and adolescents with anti-phospholipid antibodies (aPL) and includes various diagnostic categories related to SLE and aPL.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Age: Less than 21 years at baseline exam\n- Diagnosis: patients must meet criteria for one of the following five diagnostic categories:\n  1. SLE with no aPL\n  2. SLE with aPL, but without manifestations of APS\n  3. SLE-like APS\n  4. SLE with APS\n  5. Primary APS\n\nThe patient meets the age criterion, being 21 years old. However, the patient note does not mention the presence of anti-phospholipid antibodies (aPL) or associated complications like antiphospholipid syndrome (APS). To be eligible for this study, the patient must meet the criteria for one of the five diagnostic categories, which are based on aPL positivity, APS criteria, and SLE criteria.\n\nGiven that the patient note does not provide information on the presence of aPL or APS, further testing would be required to determine if the patient fits one of the specified diagnostic categories. Thus, on the basis of the information provided, we would consider referring this patient to this clinical trial upon further investigation to determine aPL positivity and whether APS manifestations are present.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "890": {
        "output": "The given patient note describes a 21-year-old female with symptoms and lab findings consistent with Systemic Lupus Erythematosus (SLE), including arthralgias, malaise, alopecia, a malar rash, purpura, swelling and tenderness of wrists and ankles, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, along with proteinuria and RBC casts in her urine. These findings meet more than 4 of the 11 American College of Rheumatology criteria for SLE, which is one of the inclusion criteria for the clinical trial.\n\nThe clinical trial is looking to evaluate the natural history of osteoporosis in children and adolescents with Systemic Lupus Erythematosus (SLE). The inclusion criteria for the clinical trial are subjects with SLE who meet at least 4 of the 11 American College of Rheumatology criteria for SLE and are less than 22 years of age.\n\nConsidering the patient's age and diagnosis, she fits the inclusion criteria for the clinical trial as she is under 22 years old and has been evaluated with SLE, meeting the necessary ACR criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "891": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can conduct an eligibility assessment for the clinical trial titled \"Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus.\"\n\nThe patient note details:\n- A 21-year-old female (meets the age criterion of 18 to 65 years)\n- Evaluation for symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, alopecia, rash, purpura, joint swelling, and tenderness\n- Laboratory findings supporting an SLE diagnosis: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts\n\nThe clinical trial inclusion criteria:\n- Age 18 to 65 years (the patient is 21 years old, so this criterion is met)\n- SLE as defined by the ACR classification (the patient's symptoms and lab findings suggest SLE, but ACR classification confirmation is needed)\n- Stable SLE (treatment not modified during the 2 months preceding the inclusion date W0; this information is not provided)\n- SLE treated by immunosuppressant only or systemic corticosteroids at a dose \u2265 5 mg/j or systemic corticosteroids at any dose associated with one or more immunosuppressive drugs (treatment details are not provided)\n- SLE treated by hydroxychloroquine only (treatment details are not provided)\n- Females must have an effective method of contraception during the first 7 months of the study and with a negative serum or urinary pregnancy test (contraception and pregnancy status are not provided)\n- Females not wishing to have a child during the 7 months following W0 (intentions regarding pregnancy are not provided)\n- Physical examination (the patient has undergone a physical examination)\n- Signed written and informed consent (not applicable at this stage of eligibility assessment)\n\nThe patient's age and symptoms are consistent with SLE, which meets some of the trial's inclusion criteria. However, further information is needed to fully determine her eligibility. Specifically, we require confirmation of the SLE diagnosis per the ACR classification, details on the patient's current SLE treatment and stability, and information on contraception and pregnancy intentions/status.\n\nGiven the need for additional information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "892": {
        "output": "Based on the patient note, the 21-year-old female presents with symptoms and lab findings consistent with Systemic Lupus Erythematosus (SLE): arthralgias, malaise, alopecia, a characteristic malar rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urinary abnormalities (proteinuria and RBC casts). \n\nThe clinical trial in question is seeking participants with SLE who fulfill the revised American College of Rheumatology (ACR) criteria for SLE and have evidence of active disease as indicated by the SLE Disease Activity Index (SLEDAI). \n\nGiven the information provided in the patient note, the patient appears to fulfill the ACR criteria for SLE and has evidence of active disease, which would likely be reflected in a SLEDAI score, although the exact SLEDAI score is not provided in the patient note. \n\nAs the patient seems to match the inclusion criteria of active SLE, which can be inferred from the symptoms and lab findings, the patient would be highly likely to be referred to the trial, provided no other exclusion criteria apply that have not been disclosed in the provided information.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "893": {
        "output": "",
        "label": 1
    },
    "894": {
        "output": "",
        "label": 0
    },
    "895": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria for SLE Subjects:\n1. SLE patients who exhibit ongoing disease activity by SLEDAI greater or equal to 4.\n2. SLE patients whose disease activity is controlled by administration of corticosteroids, most commonly, at least 10 mg/day of prednisone.\n3. 18 years of age or older.\n4. Updated vaccinations prior to study entry.\n5. Use of effective contraception for male patients before, during and up to 12 weeks after sirolimus therapy.\n\nPatient's Characteristics:\n1. The patient is a 21-year-old female with symptoms consistent with SLE, including alopecia, a rash on the nose and cheeks, non-palpable purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, proteinuria, and RBC casts in the urine.\n2. The patient's ongoing disease activity is indicated by the presence of multiple clinical findings and laboratory abnormalities, although the exact SLEDAI score is not provided.\n3. The patient's age fits the criteria (21 years old).\n4. There is no information given about the patient's vaccination status or use of corticosteroids.\n\nConsidering that the patient appears to have active SLE and meets the age requirement, and assuming the SLEDAI score would be greater or equal to 4 based on the symptoms presented, the patient could be eligible for the trial. However, information on vaccinations and current treatments, such as corticosteroids, is missing. Without confirmation of these criteria, it is not possible to definitively determine eligibility.\n\nBased on the information provided, I would rate the patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "896": {
        "output": "Based on the patient note provided, the 21-year-old female patient is evaluated for symptoms that are consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, purpura, and swelling and tenderness of the joints. The laboratory findings of normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts further support the diagnosis of SLE.\n\nThe clinical trial in question is focused on the efficacy and adverse effects of simvastatin compared to rosuvastatin in SLE patients who are on corticosteroid therapy with high LDL cholesterol levels.\n\nTo determine if this patient is eligible for the clinical trial, we need to compare the patient's information against the trial's inclusion criteria:\n\n1. SLE patients that on prednisolone more than 30 mg/day\n2. Normal liver function: AST and ALT < 80 mg/dl\n3. Normal muscle enzyme: CPK < 100 U/L\n4. LDL cholesterol level > 100 mg/dl\n\nThe patient note does not mention the use of prednisolone or any corticosteroid, nor does it provide specific values for liver function tests, muscle enzyme levels, or LDL cholesterol. Without this information, we cannot conclusively determine whether the patient meets all the necessary inclusion criteria for the trial.\n\nTherefore, the patient may need further evaluation to assess these specific criteria. Given the lack of information regarding her current treatment and laboratory results related to the inclusion criteria, I would consider her for the trial upon further investigation:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "897": {
        "output": "To determine the trial-level eligibility for the 21-year-old female patient with the described symptoms and lab findings, we need to align her condition and characteristics with the inclusion criteria of the given clinical trial for eltrombopag in pediatric patients with thrombocytopenia from Chronic Idiopathic Thrombocytopenic Purpura (ITP).\n\nPatient characteristics:\n- 21 years old\n- Female\n- Symptoms: Arthralgias, malaise, alopecia, rash, purpura, swelling and tenderness of wrists and ankles\n- Lab findings: Normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, urine positive for protein and RBC casts\n\nClinical trial inclusion criteria:\n- Subjects between 1 year and <18 years of age at Day 1\n- Confirmed diagnosis of chronic ITP\n- Refractory or relapsed after at least one prior ITP therapy or not eligible for other treatments\n- Platelet count <30 Gi/L\n- Stable dose for any concomitant ITP medication for at least 4 weeks prior to Day 1\n- No other causes of thrombocytopenia suggested by blood smear or bone marrow examination\n- Normal PT/INR and aPTT\n- Certain clinical chemistries within specific ranges\n- For those of child-bearing potential, adherence to acceptable contraception methods\n\nThe patient in this instance is 21 years old, which is beyond the age range of <18 years required for the clinical trial. Furthermore, the patient's diagnosis and symptoms are suggestive of systemic lupus erythematosus (SLE), particularly given the presence of alopecia, a malar rash, arthritis, anemia, thrombocytopenia, and a positive ANA and anti-dsDNA, which are not consistent with the diagnosis of chronic ITP as required by the trial's inclusion criteria.\n\nBased on the patient's age and diagnosis that do not meet the clinical trial's inclusion criteria, the patient would not be eligible for the trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "898": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the clinical trial in question. The clinical trial is focused on individuals with a diagnosis of Posttraumatic Stress Disorder (PTSD), while the patient is being evaluated for symptoms that suggest an autoimmune disorder, possibly systemic lupus erythematosus (SLE), given the presence of alopecia, a malar rash, arthralgias, purpura, and laboratory findings including a positive ANA and anti-dsDNA, proteinuria, and RBC casts.\n\nThe patient in question does not meet the inclusion criteria for the clinical trial, which specifically requires participants to have a diagnosis of PTSD. Since there is no mention of PTSD or related symptoms in the patient's note, it is clear that the patient does not qualify for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "899": {
        "output": "Based on the patient note, the 21-year-old female patient is presenting with symptoms and laboratory findings suggestive of systemic lupus erythematosus (SLE): alopecia, a malar rash, non-palpable purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts. These are consistent with the diagnostic criteria for SLE as outlined by the American College of Rheumatology.\n\nThe clinical trial in question is studying the metabolic syndrome in patients with systemic lupus erythematosus. The inclusion criteria for the trial are persons aged 18 and above who fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus.\n\nGiven that the patient fulfills the age requirement and appears to meet the diagnostic criteria for SLE, she would be a suitable candidate for the clinical trial. Therefore, it is highly likely that this patient would be referred for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "900": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Evaluation:\n- The patient is a 21-year-old female, which satisfies the age criterion of >18 years.\n- She presents with symptoms consistent with SLE, including arthralgias, alopecia, a rash on the nose and cheeks (which could be considered an inflammatory-type skin rash), and swelling and tenderness of the wrists and ankles (which could be considered arthritis).\n- The patient has laboratory findings of normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and urine positive for protein and RBC casts. These findings support the diagnosis of SLE and meet at least 4 criteria as defined by the ACR.\n- The patient has active disease with symptoms from joints and skin, which are among the symptoms listed in the inclusion criteria.\n\nClinical Trial Inclusion Criteria Checklist:\n- Age > 18 years at the time of signing the informed consent form \u2714\n- Fulfil at least 4 criteria for SLE as defined by the ACR \u2714\n- Present with active SLE disease with at least one of the following symptoms: \u2714\n  i) Arthritis - > 2 joints with pain and signs of inflammation \u2714\n  ii) Inflammatory-type skin rash \u2714\n  iii) Oral ulcers (not mentioned in the patient note)\n- Laboratory values as follows:\n  Hemoglobin \u2265 100 g/L (not specified in the patient note)\n  Absolute neutrophil count \u2265 1.0 x 10^9/L (not specified in the patient note)\n  Total bilirubin \u2264 1.5 x upper limit of normal (ULN) (not specified in the patient note)\n  AST (SGOT) / ALT (SGPT) \u2264 2.5 x ULN (not specified in the patient note)\n- Ability to take and retain oral medication (not specified in the patient note, but no contraindications mentioned)\n- Ability to sign and date a written informed consent prior to entering the study (assumed able unless otherwise noted)\n- Willingness and ability to comply with the protocol for the duration of the study (assumed able unless otherwise noted)\n\nGiven the information provided, the patient appears to meet the age and diagnostic criteria for SLE, as well as presenting with active symptoms qualifying her for the study. However, there are some laboratory values that are not provided in the patient note. These values are necessary to fully determine eligibility. \n\nTherefore, based on the available information, we:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "901": {
        "output": "The patient note describes a 21-year-old female with symptoms and laboratory findings consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, swelling and tenderness of wrists and ankles, normocytic anemia, thrombocytopenia, a positive antinuclear antibody (ANA), anti-dsDNA, and evidence of renal involvement (proteinuria and RBC casts in urine).\n\nThe clinical trial is investigating a medication for subjects with SLE and has the following inclusion criteria:\n\n1. Diagnosis of systemic lupus erythematosus (SLE)\n2. Disease duration: 6 months or longer\n3. Stable, mild to moderately active systemic lupus erythematosus (SLE)\n4. Receiving stable maintenance therapy\n\nBased on the patient note, the patient has a diagnosis of SLE, fulfilling the first inclusion criterion. However, the patient note does not provide information on the duration of the disease, the current activity level of SLE, or whether the patient is receiving any stable maintenance therapy. All these factors are necessary to determine eligibility according to the trial's inclusion criteria.\n\nGiven the information available, the patient seems to fit the diagnosis criterion for SLE but lacks specific information to satisfy all the trial's inclusion criteria. Therefore, further investigation is required to determine the patient's disease duration, activity level, and any ongoing therapies.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "902": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can evaluate the patient's eligibility for the trial:\n\nThe patient is a 21-year-old female with symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a malar rash, non-palpable purpura, and joint swelling and tenderness. The lab findings indicate normocytic anemia, thrombocytopenia, a positive ANA, anti-dsDNA, proteinuria, and RBC casts in the urine. These findings suggest active SLE.\n\nThe clinical trial is investigating QT dispersion in patients with SLE and recommends cardiovascular evaluation for SLE patients with an active disease (SLEDAI higher than 10). However, the inclusion criteria for the trial do not mention a required SLEDAI score. The inclusion criteria do specify that the patient should not be taking drugs that could potentially influence QT duration except for hydroxychloroquine, should not have a history of certain heart conditions or abnormal serum electrolytes, and must have a normal resting ECG and a good-quality ECG recording to measure the QT interval.\n\nThe patient note does not provide information on the following:\n- Whether the patient is taking medications that could influence QT duration (other than hydroxychloroquine).\n- If the patient has any history of heart disease, atrial fibrillation, or other specified conditions.\n- The patient's electrolyte levels or ECG results.\n\nGiven that the patient note lacks information on the specific inclusion criteria related to cardiac health and medication, we cannot conclusively determine the patient's eligibility for the clinical trial. However, the presence of active SLE symptoms might make the patient a candidate for further investigation regarding their QT interval as part of the study on cardiac involvement in SLE patients.\n\nTherefore, based on the given information, we would consider referring this patient to this clinical trial upon further investigation to ensure that none of the inclusion criteria are violated.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "903": {
        "output": "The patient note describes a 21-year-old female presenting with symptoms that are highly suggestive of systemic lupus erythematosus (SLE), including arthralgias, alopecia, a characteristic rash, non-palpable purpura, joint swelling and tenderness, as well as laboratory findings such as normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA antibodies, and evidence of kidney involvement (proteinuria and RBC casts in the urine).\n\nThe clinical trial in question is focusing on the autoimmunity in sisters of lupus patients. According to the inclusion criteria, to be eligible for the trial, the proband (the patient in this case, if she has SLE) must have a documented diagnosis of SLE that meets ACR criteria and must be diagnosed by age 40. Furthermore, the proband must have at least one biological sister between 10 and 45 years of age who is willing to participate in the study.\n\nIn the given patient note, there is no mention of a sister, either affected or unaffected by SLE. Therefore, we cannot determine if there is a potential participant (a sister) for this clinical trial based on the information provided. The patient herself does seem to have SLE, but the trial is not enrolling the patients with SLE; it is enrolling their sisters.\n\nGiven these considerations, the patient does not meet the specified inclusion criteria for the clinical trial because there is no information regarding a sister who could participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "904": {
        "output": "Based on the patient note provided and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 21-year-old female\n- Symptoms and lab results consistent with systemic lupus erythematosus (SLE): arthralgias, malaise, alopecia, rash, non-palpable purpura, wrist and ankle swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine.\n\nClinical Trial Inclusion Criteria:\n- Female SLE patients\n- Age 18-60 years\n- If premenopausal, using a reliable method of contraception\n- Clinically stable disease\n- Taking hydroxychloroquine and up to 15 mg of prednisolone daily\n\nComparison:\n- The patient is a female with SLE, which matches the trial's disease focus.\n- The patient's age is within the trial's age range (18-60 years).\n- There is no information about the patient's use of contraception, but this is something that could be addressed during further discussions with the patient.\n- There is no information provided on the stability of the patient's disease or her current medications (hydroxychloroquine and prednisolone), which would need to be confirmed to ensure trial eligibility.\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria for the clinical trial; however, we would need further information about the stability of her disease, her current medications, and her use of contraception. Therefore, my assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "905": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nPatient Note Analysis:\n- Patient is a 21-year-old female, which meets the age criteria of 18-65 years.\n- The patient's symptoms and lab findings (alopecia, rash on the nose and cheeks, non-palpable purpura, arthralgias, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, proteinuria, and RBC casts in urine) are indicative of Systemic Lupus Erythematosus (SLE).\n- The patient's diagnosis of SLE based on the note aligns with the American College of Rheumatology (ACR) criteria for SLE, which is a requirement for the study.\n\nClinical Trial Inclusion Criteria:\n- Age 18-65 (patient meets this criterion)\n- Diagnosis of SLE based on ACR criteria (patient meets this criterion)\n\nAssessment of Eligibility:\nGiven the information provided in the patient note, the patient appears to meet all the inclusion criteria outlined for the clinical trial on modified yoga in Systemic Lupus Erythematosus (SLE). Therefore, the patient is highly likely to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "906": {
        "output": "",
        "label": 2
    },
    "907": {
        "output": "Comparing the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia\n- Rash on the bridge of her nose and cheeks\n- Delicate non-palpable purpura on her calves\n- Swelling and tenderness of wrists and ankles\n- Normocytic anemia\n- Thrombocytopenia\n- Positive ANA and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of Juvenile Idiopathic Arthritis (JIA) must have been before the patient's 16th birthday\n- Disease duration of at least 6 months before study entry\n- Must have 5 or more joints with active arthritis\n- Must be taking a stable dose of methotrexate 10-30 mg/m^2 (patients with BSA 1.67 m^2 or more must be taking a minimum of 15 mg/week of methotrexate)\n- May take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of NSAIDs 2 weeks prior to entry\n- Must have qualifying laboratory values at the first visit\n\nBased on the patient note, it is not clear if the patient's diagnosis is Juvenile Idiopathic Arthritis; the symptoms described could be indicative of another autoimmune disorder, such as systemic lupus erythematosus (SLE), given the presence of alopecia, a malar rash, and serological findings (positive ANA and anti-dsDNA). The patient's symptoms and lab results do not clearly align with the diagnostic criteria for JIA. Additionally, there is no mention of the patient's medication history regarding methotrexate or other treatments. Without further information to confirm a diagnosis of JIA and the patient's treatment history, we cannot assume that they meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "908": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient appears to be a candidate for the Cutaneous Lupus Registry. The patient's symptoms and lab findings, such as alopecia, a rash on the nose and cheeks (which is characteristic of the malar rash associated with lupus), and positive ANA and anti-dsDNA, are consistent with systemic lupus erythematosus (SLE), and the patient has also shown skin manifestations that could be related to cutaneous lupus erythematosus.\n\nThe clinical trial's inclusion criteria specify that participants must be diagnosed with cutaneous lupus erythematosus and/or systemic lupus erythematosus by clinical, laboratory, and histopathological findings. The patient note provides clinical and laboratory evidence that is suggestive of SLE, which often includes cutaneous lupus erythematosus. Additionally, the trial requires that participants have the ability to speak and read English or Spanish at a 6th-grade reading level and be able to give written informed consent. While the patient note does not explicitly state the patient's language abilities or consent capacity, these are typical expectations for patients being evaluated in a clinical setting.\n\nGiven that the patient's presentation aligns with the inclusion criteria for the Cutaneous Lupus Registry clinical trial, it is reasonable to consider this patient a potential candidate for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "909": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, we can assess the eligibility of the patient for the trial.\n\nPatient Note Analysis:\n- The patient is a 21-year-old female.\n- She has symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a malar rash, purpura, swollen and tender wrists and ankles, and positive immunologic markers (ANA and anti-dsDNA).\n- The patient also has lab findings of normocytic anemia, thrombocytopenia, and urine positive for protein and RBC casts.\n\nClinical Trial Analysis:\n- The trial is looking to enroll pregnant women with SLE aged 18-45 before 14 weeks of gestation who have autoimmune thyroid antibodies.\n- The trial aims to study the impact of levothyroxine on pregnant SLE patients with autoimmune thyroid disease.\n\nComparison:\n- The patient's age falls within the range specified by the trial (18-45 years).\n- The patient displays signs and symptoms of SLE.\n- The inclusion criteria specifically require the patient to be pregnant before 14 weeks of gestation and have autoimmune thyroid antibodies.\n\nSince the patient note does not mention pregnancy, gestational age, or the presence of autoimmune thyroid antibodies, we cannot confirm if the patient meets all the inclusion criteria for the trial. Therefore, further investigation is needed to determine her pregnancy status and whether she has autoimmune thyroid antibodies.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "910": {
        "output": "Based on the patient note provided, the 21-year-old female patient has been evaluated and found to have symptoms and laboratory findings consistent with systemic lupus erythematosus (SLE), which include arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and urinary findings indicative of renal involvement.\n\nThe clinical trial in question aims to compare healthy children to children with SLE in terms of bone mass and the risk of vertebral compression fractures using Spine Quantitative Computed Tomography (QCT).\n\nThe inclusion criteria for SLE subjects in the trial are as follows:\n- Subjects age 5-21 drawn from the rheumatology clinic at Children's Hospital of Philadelphia diagnosed with SLE for at least 1 month.\n- Subjects with no known vertebral compression fracture of L2.\n\nGiven that the patient note describes a patient who is within the age range specified (21 years old), has been evaluated for SLE, and there is no mention of known vertebral compression fractures, it seems that the patient could be eligible for the SLE arm of the study. However, to be certain, additional information would be required to confirm the diagnosis duration (at least 1 month as per the criteria) and to ensure there are no known vertebral compression fractures.\n\nTherefore, while the patient appears to meet some of the inclusion criteria, there is not enough information to make a definitive referral without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "911": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we can assess the patient's eligibility for the trial as follows:\n\n1. Age: The inclusion criteria specify that subjects must be at least 20 years of age at the screening visit. The patient is 21 years old, which meets this criterion.\n\n2. Diagnosis: The patient must have a clinical diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) classification criteria, with 4 or more of the 11 ACR criteria present. The patient note indicates the presence of alopecia, a rash (malar rash), arthralgias, and a positive test for ANA and anti-dsDNA, which are all consistent with the ACR criteria for SLE. This meets the criterion.\n\n3. Medication: The patient must be on no SLE medication or a stable SLE treatment regimen for at least 2 months prior to the Screening visit. The patient note does not provide information about the patient's current medication regimen, so we cannot confirm this criterion without further information.\n\n4. Pregnancy and Birth Control: The patient is female, and the criteria require that female subjects must not be pregnant or nursing, and those of childbearing potential must agree to specific contraceptive measures. The patient note does not provide information about her pregnancy status or use of contraception, so we cannot confirm this criterion without further information.\n\n5. ANA or anti-dsDNA positivity: The patient must test positive for anti-nuclear antibody (ANA) or anti-dsDNA antibody in serum. The patient note confirms a positive test for ANA and anti-dsDNA.\n\nThe patient meets the age and diagnosis criteria and is positive for ANA and anti-dsDNA. However, without information on her medication regimen and pregnancy or contraception status, we cannot fully determine her eligibility. Therefore, further investigation is required to determine if the patient is on a stable SLE treatment regimen and to confirm her pregnancy and contraception status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "912": {
        "output": "The patient note describes a 21-year-old female with symptoms and laboratory findings consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a malar rash, purpura, joint swelling, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and evidence of kidney involvement (proteinuria and RBC casts). \n\nThe clinical trial provided is for systemic scleroderma (SSc) and involves a treatment approach using cyclophosphamide, anti-thymocyte globulin, and peripheral blood stem cell transplant (PBSCT), followed by mycophenolate mofetil as maintenance therapy. \n\nTo determine eligibility, we need to compare the patient's condition and history with the inclusion criteria of the STAT Study. The inclusion criteria specify that patients need to have systemic scleroderma with diffuse cutaneous disease, meet specific criteria related to the duration of SSc and organ involvement, and have failed a prior course of either MMF/Myfortic or cyclophosphamide.\n\nThe patient in the note has no mention of systemic scleroderma, and the clinical presentation is more indicative of SLE rather than SSc. There is no information provided that this patient has SSc, diffuse cutaneous disease, or any of the specific organ involvement required by the six groups listed in the inclusion criteria for the STAT Study.\n\nBased on the information given, the patient does not meet the inclusion criteria for the STAT Study, as her diagnosis and clinical presentation do not align with the target disease or the specific requirements detailed in the trial's inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "913": {
        "output": "Based on the provided patient note and clinical trial information, the patient is a 21-year-old female with symptoms and lab findings consistent with Systemic Lupus Erythematosus (SLE). The clinical trial in question is investigating the effects of vitamin D supplementation in patients with SLE. The inclusion criteria for the trial are:\n\n1. Diagnosis of Systemic lupus erythematosus (SLE)\n2. Age > 18 years\n3. Serum vitamin D levels [25(OH)D] < 30 ng/mL\n4. Low to moderate active disease without modification of associated treatments\n\nThe patient note indicates that the patient has SLE, is over 18 years of age, and is experiencing active disease symptoms. However, there is no information provided about the patient's serum vitamin D levels or the current status of her disease activity in terms of treatment modifications. To determine eligibility, we would need to confirm her vitamin D levels and ensure that her disease activity is low to moderate without recent changes in her treatment regimen.\n\nGiven the information provided, there is a potential match based on the diagnosis of SLE and the patient's age. However, without the serum vitamin D levels and more detail on the disease activity and treatment status, we cannot definitively determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "914": {
        "output": "Based on the provided patient note, the 21-year-old female patient is evaluated for symptoms that are indicative of a connective tissue disease, likely systemic lupus erythematosus (SLE), given the presence of alopecia, rash, purpura, arthralgias, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urinary findings of proteinuria and RBC casts.\n\nThe clinical trial in question is focused on patients with cancer who have developed brain metastases and are undergoing whole brain radiotherapy. The inclusion criteria specify the need for the patient to have brain metastases, be aged 18 years or older, have signed informed consent, and meet certain criteria related to the Recursive Partitioning Analysis (RPA) classification or have small cell lung cancer with extended disease.\n\nThe patient described in the note does not meet the inclusion criteria for this trial as there is no mention of cancer or brain metastases. Instead, the patient's symptoms and lab findings are consistent with a rheumatologic condition, not metastatic cancer. Therefore, this patient would not be eligible for the trial focused on hair-sparing whole brain radiotherapy in patients with brain metastases.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "915": {
        "output": "To determine the patient's eligibility for the clinical trial, let's compare the patient note with the inclusion criteria of the trial:\n\nPatient Note:\n- A 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia, a rash on the bridge of her nose and cheeks, purpura on calves\n- Swelling and tenderness of wrists and ankles\n- Lab findings: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- Male or female of \u226518 years of age\n- Written informed consent\n- Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of their illness\n- Disease duration of at least 6 months\n- SLEDAI-2K score \u2265 6 at screening\n- Positive test results for antinuclear antibody (ANA) (HEp-2 ANA \u22651:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (\u226530 IU/mL) at screening\n- Negative serum pregnancy test and a highly effective method of contraception for women of childbearing potential\n\nThe patient is a 21-year-old female, which meets the age requirement. She has a diagnosis of SLE, as indicated by her symptoms and lab results showing a positive ANA and anti-dsDNA, which aligns with the trial's need for a diagnosis satisfying at least 4 of the 11 ACR criteria. Although not all details of her disease duration and SLEDAI-2K score are provided, the presence of multiple symptoms and lab findings indicative of SLE suggest that her disease activity may likely meet the severity required by the trial (SLEDAI-2K score \u2265 6). Additionally, the patient would need to provide written informed consent and, if of childbearing potential, confirm a negative pregnancy test and agree to use highly effective contraception.\n\nBased on the information provided, it appears that the patient is a good candidate for the clinical trial. However, additional information, such as disease duration, SLEDAI-2K score, and confirmation of understanding and consent to trial participation, would be needed for a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "916": {
        "output": "Reviewing the patient's note and the clinical trial inclusion criteria, here is the comparison:\n\nPatient Note:\n- 21-year-old female with systemic symptoms suggestive of an autoimmune condition, specifically findings consistent with lupus (arthralgias, malaise, alopecia, rash, purpura, swollen and tender joints, normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, proteinuria, and RBC casts).\n\nClinical Trial Inclusion Criteria:\n- Caucasian volunteers\n- Non-smoker\n- Biological parameters (hematological, biochemical, renal and hepatic) within normal range\n- Health Insurance\n- Signed informed consent\n\nThe patient's note does not provide information about her race, smoking status, exact biological parameters, or health insurance status. However, it is noted that she has abnormalities in her biological parameters, namely hematological issues like anemia and thrombocytopenia, and renal involvement indicated by proteinuria and RBC casts. These abnormalities suggest that her biological parameters are not within the normal range, which is one of the inclusion criteria for the clinical trial.\n\nTherefore, based on the available information and the mismatch regarding the biological parameters, the patient does not meet the inclusion criteria for the clinical trial on Bilhvax, a vaccine candidate against schistosomiasis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "917": {
        "output": "Based on the provided information, the patient in the note is a 21-year-old female evaluated for symptoms consistent with systemic lupus erythematosus (SLE). She has arthralgias, malaise, alopecia, a characteristic malar rash, non-palpable purpura, swelling and tenderness of her wrists and ankles, normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA, and her urine is positive for protein and RBC casts. These clinical findings are highly suggestive of SLE.\n\nThe clinical trial in question is the CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE), which aims to identify increased cardiovascular risk in patients with systemic lupus erythematosus.\n\nThe inclusion criteria for the CASTLE study are patients with systemic Lupus erythematosus. The patient note provides sufficient evidence that the patient has SLE, making her a potential candidate for the study.\n\nTherefore, the patient's condition aligns with the inclusion criteria of the clinical trial, and she would likely be eligible for participation.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "918": {
        "output": "Based on the information provided in the patient note, the patient is a 21-year-old female with symptoms and laboratory findings suggestive of an autoimmune condition, likely systemic lupus erythematosus (SLE), given the presence of alopecia, a malar rash, arthralgias, normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, and urine positive for protein and RBC casts.\n\nThe clinical trial is looking for patients with immune thrombocytopenia (ITP), which is a condition where the immune system attacks and destroys platelets, leading to low platelet counts and an increased risk of bleeding. The inclusion criteria for the trial are:\n\n1. Patients older than 18 years old\n2. Immune Thrombopenia according to the American Society of Hematology (ASH) guidelines 2011\n3. Positive antinuclear antibodies > 1/160e on Hep2 cells\n\nWhile the patient does exhibit thrombocytopenia and positive antinuclear antibodies, the clinical context suggests that the thrombocytopenia is part of a broader autoimmune syndrome (SLE) rather than primary immune thrombocytopenia (ITP). The diagnosis of ITP is typically made in the absence of other underlying autoimmune diseases. Therefore, the patient does not strictly meet the second inclusion criterion of the trial, which specifies ITP as defined by ASH guidelines.\n\nGiven the discrepancy between the patient's likely diagnosis of SLE and the specific focus of the trial on ITP, the patient may not be the best fit for the trial's research objectives. However, if there is a possibility that the patient could be diagnosed with ITP in the context of SLE or if there are additional considerations that could be clarified with further investigation (such as the patient meeting ASH guidelines for ITP), then the patient could be considered for referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "919": {
        "output": "Given the patient note, the patient displays symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, and swelling and tenderness of the wrists and ankles. The lab findings of normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, and urine positive for protein and RBC casts support the diagnosis of SLE. The patient also has active skin manifestations, which is a requirement for the clinical trial in question.\n\nThe clinical trial is assessing the efficacy and safety of hydroxychloroquine sulfate in patients with either cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with active skin manifestation. The inclusion criteria specifically mention patients diagnosed with CLE, but given that the trial also aims to investigate efficacy on systemic symptoms in SLE patients and the patient has active skin manifestations, it is reasonable to consider that the patient could potentially be eligible.\n\nHowever, the trial's exclusion criteria state that patients receiving more than 15mg/day of the equivalent dose of prednisolone are excluded. The patient's note does not specify whether the patient is on corticosteroids or the dosage, which is critical information for determining eligibility. Additionally, the trial requires a dermatology specialist to evaluate the CLASI activity scores, and this is not provided in the note.\n\nGiven the incomplete information regarding the patient's current treatment with corticosteroids and the lack of a CLASI activity score, it is not possible to accurately assess the patient's eligibility without further investigation. While the patient does have SLE with skin manifestations which aligns with the study's patient population, these missing pieces of information are critical for a definitive eligibility determination.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "920": {
        "output": "Based on the information provided, the patient note describes a 21-year-old female with symptoms suggestive of systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a malar rash, purpura, swelling and tenderness of the wrists and ankles, as well as laboratory findings consistent with SLE (normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts).\n\nThe clinical trial titled \"BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115\" has inclusion criteria that are specific to participants who have completed previous studies (BEL113750 or C1115). There is no information provided that this patient has participated in either of those studies.\n\nGiven the fact that the patient does not meet the essential inclusion criteria of having completed the previous studies mentioned, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "921": {
        "output": "To assess whether the patient is eligible for the clinical trial based on the inclusion criteria provided, let's examine the patient's characteristics and medical condition:\n\n- The patient is a 21-year-old female, which meets the age criterion of at least 18 years of age.\n- The patient's race is not specified, but the trial requires self-identified black race participants.\n- The patient has a clinical diagnosis of SLE, as indicated by symptoms such as alopecia, rash, purpura, arthralgias, and positive lab results for ANA and anti-dsDNA. This meets the requirement of having a clinical diagnosis of SLE according to the ACR criteria.\n- The patient has active SLE disease, as suggested by the symptoms and lab results, but the SELENA SLEDAI score is not provided in the patient note. The trial requires a score of >= 8 at screening.\n- The patient has 2 unequivocally positive autoantibody test results (a 4/4 positive ANA and anti-dsDNA), which aligns with the trial's criteria for autoantibody test results.\n- The patient's current treatment regimen is not mentioned, so it's unclear whether she has been on a stable SLE treatment regimen for at least 30 days prior to Day 0.\n- The trial has specific criteria for females of child-bearing potential, but the patient's status regarding pregnancy or contraception is not provided.\n- The patient's ability to understand the requirements of the study and provide informed consent is assumed but not explicitly stated.\n\nGiven the information provided, the patient appears to meet several of the inclusion criteria: age, diagnosis of SLE, and positive autoantibody test results. However, there are critical pieces of information missing, such as the patient's race, SELENA SLEDAI score, details about her current treatment regimen, and reproductive status. Without this information, we cannot definitively determine her eligibility.\n\nTherefore, based on the available information, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "922": {
        "output": "The patient described in the note is a 21-year-old female with symptoms consistent with systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, purpura, joint swelling, normocytic anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, as well as urinary findings suggestive of lupus nephritis.\n\nThe clinical trial in question is targeting pediatric patients with active systemic lupus erythematosus and aims to evaluate the safety and efficacy of belimumab intravenous (IV) in patients aged 5 to 17 years.\n\nComparing the patient note to the clinical trial's inclusion criteria:\n\n- The age criterion for the trial is 5 to 17 years at enrollment, and the patient in the note is 21 years old, which falls outside the specified age range.\n- The patient does have a clinical diagnosis of SLE, which is consistent with the trial's requirement.\n- The trial requires an active SLE disease with a SELENA SLEDAI score \u2265 6, but the patient's SLEDAI score is not provided in the note.\n- The patient has a positive ANA test result, which meets one of the trial's criteria.\n- There is no information on whether the patient has been on a stable SLE treatment regimen for at least 30 days prior to consideration for the trial.\n- The patient is female and of childbearing age, but there is no mention of her willingness to use appropriate contraception.\n\nThe primary disqualifying factor here is the patient's age, which does not fall within the specified range for the trial. Therefore, the patient is not eligible for this pediatric lupus trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "923": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia, rash on the face, non-palpable purpura on calves\n- Swelling and tenderness of wrists and ankles\n- Normocytic anemia, thrombocytopenia\n- Positive ANA and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical trial inclusion criteria:\n- Men and women (not pregnant and not nursing)\n- Subjects with SLE meeting the ACR criteria, with a disease duration of at least 6 months\n- Subjects with clinically active SLE defined as a SELENA-SLEDAI score of at least 6 and positive for ANA and/or anti-dsDNA\n- If taken, background medication must be stable\n\nThe patient in the note has symptoms and lab findings that are consistent with SLE (Systemic Lupus Erythematosus), including a positive ANA and anti-dsDNA, which are specific for the disease. However, the information provided does not specify the duration of the disease or the current SELENA-SLEDAI score, which are required to determine eligibility for the clinical trial.\n\nGiven the information available, the patient seems to meet some of the inclusion criteria (such as a positive ANA and anti-dsDNA and symptoms consistent with SLE), but we lack some specific information required by the trial (disease duration and SELENA-SLEDAI score). Thus, further investigation is needed to determine the patient's SLEDAI score and disease duration to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "924": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the patient's characteristics and the requirements for the study:\n\nPatient's Characteristics:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia\n- Rash on the bridge of the nose and cheeks (malar rash)\n- Non-palpable purpura on calves\n- Swelling and tenderness of wrists and ankles (arthritis)\n- Normocytic anemia and thrombocytopenia (blood-hematologic disorder)\n- 4/4 positive ANA and anti-dsDNA (immunologic disorder)\n- Urine positive for protein and RBC casts (renal disorder)\n\nClinical Trial Inclusion Criteria:\n- The American College of Rheumatology criteria for SLE\n- Presence of at least 4 out of the 11 SLE symptoms simultaneously or serially on two separate occasions\n- HIV (-)\n- Signed the informed consent\n- Taking contraceptive measures during the treatment period\n\nThe patient appears to meet the following American College of Rheumatology criteria for SLE:\n1. Malar rash\n2. Arthritis\n3. Blood-hematologic disorder\n4. Renal disorder\n5. Antinuclear antibody test positive\n6. Immunologic disorder (positive anti-ds DNA)\n\nSince the patient has at least 4 of the 11 symptoms, they meet the criteria for SLE identification in clinical studies. The patient note does not mention the patient's HIV status, but for the purpose of this exercise, we will assume it is negative given no mention of it being positive. The patient would also need to sign the informed consent and be taking contraceptive measures during the treatment period to be included in the trial.\n\nGiven the information presented, the patient seems to fit the criteria for the clinical trial on Systemic Lupus Erythematosus (SLE) treatment. Therefore:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "925": {
        "output": "Based on the patient note provided, the patient is a 21-year-old female with symptoms and lab findings consistent with active systemic lupus erythematosus (SLE). She has arthralgias, malaise, alopecia, a malar rash, purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab work shows normocytic anemia, thrombocytopenia, a positive ANA, and anti-dsDNA antibodies. Additionally, she has proteinuria and RBC casts in her urine, which are common in lupus nephritis.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.\n2. Active SLE disease.\n3. Autoantibody-positive.\n4. On stable SLE treatment regimen, which may include corticosteroids, antimalarials, and/or immunosuppressants.\n\nThe patient appears to meet these criteria:\n\n- She has a clinical diagnosis of SLE indicated by her symptoms and positive lab findings for ANA and anti-dsDNA, which are part of the ACR criteria for SLE.\n- She has active disease evidenced by her symptoms and positive lab findings.\n- She is autoantibody-positive, as indicated by her positive ANA and anti-dsDNA.\n- The note does not mention her current treatment regimen, so we do not have information on whether she is on a stable SLE treatment regimen. However, this information could be obtained with further investigation.\n\nThe key exclusion criteria include:\n\n- Pregnant or nursing.\n- Treatment with belimumab, B cell targeted therapy, or any biological agent within specified time frames.\n- Received a live vaccine within the past 30 days.\n- Severe active lupus kidney disease.\n- Severe active central nervous system (CNS) lupus.\n- Positive for HIV, hepatitis B, or hepatitis C.\n\nThe patient note does not provide information on the following exclusion criteria:\n\n- Pregnancy or nursing status.\n- Previous treatments with excluded medications.\n- Whether she received a live vaccine recently.\n- The severity of her lupus kidney disease (if present).\n- Whether she has severe active CNS lupus.\n- Her HIV, hepatitis B, or hepatitis C status.\n\nGiven the information available in the patient note and the trial's inclusion criteria, the patient appears to be a potential candidate for the clinical trial. However, further investigation is needed to gather information regarding the exclusion criteria and her current treatment regimen. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "926": {
        "output": "Based on the patient note provided, the 21-year-old female patient has a clinical presentation consistent with systemic lupus erythematosus (SLE). The patient exhibits symptoms such as arthralgias, malaise, alopecia, a characteristic rash, purpura, joint swelling, and tenderness, along with laboratory findings including normocytic anemia, thrombocytopenia, positive ANA, anti-dsDNA, and evidence of renal involvement (proteinuria and RBC casts in urine). These clinical features and laboratory findings are indicative of active, autoantibody-positive SLE.\n\nThe clinical trial in question is an observational cohort study evaluating the safety and effectiveness of BENLYSTA (belimumab) in participants with active, autoantibody-positive SLE. The inclusion criteria for the trial are:\n\n1. Males or females age 18 years or older.\n2. Have a clinical diagnosis of active SLE.\n3. Current or history of autoantibody-positive SLE.\n4. Must be treated with SLE therapy including BENLYSTA and/or immunosuppressants.\n5. Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures.\n\nThe patient in the note meets the age criterion (21 years old) and has a clinical diagnosis of active SLE, as well as a current or history of autoantibody-positive SLE. The note does not specify the current treatment regimen, but the patient's condition would typically require treatment with SLE therapy, which may include immunosuppressants as mentioned in the inclusion criteria. Assuming the patient is capable of understanding the requirements of the study and can provide consent, she would meet the remaining inclusion criteria.\n\nConsidering the information provided, there is a high likelihood that this patient would be eligible for the clinical trial provided she is being treated for SLE and is willing to participate. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "927": {
        "output": "",
        "label": 1
    },
    "928": {
        "output": "",
        "label": 2
    },
    "929": {
        "output": "Based on the patient note, the 21-year-old female patient is presenting with symptoms consistent with an autoimmune condition, likely systemic lupus erythematosus (SLE), as indicated by arthralgias, malaise, alopecia, a characteristic malar rash, purpura, joint swelling, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, as well as evidence of kidney involvement with proteinuria and RBC casts in the urine.\n\nThe clinical trial in question is investigating the efficacy and safety of minoxidil 1% in the enhancement of eyebrows for individuals with hypotrichosis of the eyebrows.\n\nThe inclusion criteria for the trial are:\n- Male or female aged 18-60 years\n- Hypotrichosis of the eyebrows\n- Healthy\n- Informed consent obtained\n\nThe patient note does not mention hypotrichosis of the eyebrows specifically, nor does it state that the patient is otherwise healthy, as she is presenting with symptoms of a systemic disease. Additionally, there is no information to confirm whether the patient has given informed consent for the trial.\n\nGiven this information, the patient does not clearly meet all the inclusion criteria, particularly the criterion of being \"healthy,\" as she appears to have an active and untreated autoimmune disease. Therefore, further investigation would be needed to determine if her systemic condition would exclude her from participation, as the term \"healthy\" might be interpreted differently in various clinical trial contexts.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "930": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- The patient is a 21-year-old female with symptoms indicative of an autoimmune condition, likely lupus given the alopecia, rash, arthralgias, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urinary findings of protein and RBC casts.\n\nClinical Trial:\n- The study is looking at the prophylactic use of topical dapsone 5% gel versus moisturizer for the prevention or reduction of cetuximab-induced papulopustular rash in patients with metastatic colorectal cancer (mCRC) or head and neck squamous cell carcinoma (HNSCC) who are anticipated to initiate cetuximab treatment.\n\nInclusion Criteria for the Trial:\n- Patients must be 18 years or older.\n- Patients must have an underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma.\n- Patients must be newly diagnosed or existing patients who are anticipated to initiate cetuximab treatment.\n- Patients must be able to self-administer topical interventions or have someone to apply them.\n\nThe patient in the note does not have a diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma. Instead, the patient's symptoms are suggestive of lupus, an autoimmune condition not related to the trial's target diseases. Additionally, there is no mention of cetuximab treatment for the patient, which is a requirement for the clinical trial. Therefore, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "931": {
        "output": "Given the patient's note and the clinical trial criteria, let's assess the eligibility:\n\nPatient Note Assessment:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia, a rash mainly distributed on the bridge of her nose and cheeks, a delicate non-palpable purpura on calves, and swelling and tenderness of wrists and ankles\n- Lab results indicating normocytic anemia, thrombocytopenia, a positive ANA and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- Age 18 - 70 years, inclusive, at randomization\n- Diagnosis of SLE, per the ACR criteria\n- m-SLEDAI score < 4 at screening visit (SLEDAI score without serologies)\n- Physician Global Assessment (0-3) score of 1 or less at screening visit\n- On a stable dose of MMF (1000-3000 mg/day) for at least 12 weeks prior to randomization\n- Total duration of stable or decreasing MMF therapy must be at least:\n  - Two years for subjects initiating MMF for renal indications\n  - One year for subjects initiating MMF for extra-renal indications\n- If on corticosteroid, the dose may not exceed 10 mg/day for the 12 weeks prior to randomization\n- If the subject has a history of B cell depleting therapy within the past 3 years, presence of CD19 positive cells must be documented\n- On maintenance HCQ or chloroquine at a stable dose for at least 12 weeks prior to randomization\n\nComparison:\n- The patient is within the age range specified by the trial (18 - 70 years).\n- The patient has a diagnosis of SLE, which matches the trial's disease focus.\n\nHowever, there are multiple inclusion criteria for which we do not have sufficient information from the patient note:\n- The m-SLEDAI score is not provided.\n- The Physician Global Assessment score is not provided.\n- There is no mention of the patient being on MMF therapy, let alone the duration or dosage.\n- There is no mention of corticosteroid usage or dosage.\n- There is no mention of HCQ or chloroquine usage.\n\nWithout this information, we cannot confidently state that the patient meets the trial's inclusion criteria. Therefore, the patient may not be eligible based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "932": {
        "output": "The patient note describes a 21-year-old female with progressive arthralgias, malaise, alopecia, a malar rash, purpura, and wrist and ankle swelling. Laboratory findings include normocytic anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, as well as proteinuria and RBC casts in the urine. These clinical features and laboratory findings are consistent with a diagnosis of systemic lupus erythematosus (SLE), not alopecia areata. While the patient does have alopecia, it is not specified that it is of the patch type characteristic of alopecia areata, and there's no information about the extent of scalp hair loss.\n\nThe clinical trial is a pilot study to evaluate the efficacy of Ruxolitinib in alopecia areata, which is an autoimmune condition characterized by patchy hair loss. The inclusion criteria for this trial specifically require:\n\n1. Patients between 18 to 75 years of age.\n2. Diagnosis of patch type alopecia areata.\n3. >30% and <95% total scalp hair loss at baseline as measured using the SALT score.\n4. Duration of hair loss greater than 3 months.\n5. No evidence of regrowth present at baseline.\n6. Patients may be na\u00efve to treatment or unresponsive to previous treatments for alopecia areata.\n\nGiven the information in the patient note, we cannot confirm that this patient has patch type alopecia areata, nor do we have the SALT score to assess the extent of hair loss or details about the duration of hair loss and lack of regrowth. Furthermore, the patient's primary condition seems to be SLE, which is not the focus of the clinical trial.\n\nTherefore, based on the information provided and the mismatch between the patient's condition and the focus of the clinical trial, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "933": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Symptoms including alopecia, a characteristic rash (malar rash), purpura on calves, and swelling/tenderness of wrists and ankles\n- Lab results indicate normocytic anemia, thrombocytopenia, positive ANA, and anti-dsDNA, proteinuria, and RBC casts in urine\n\nClinical Trial Inclusion Criteria Summary:\n- Male or female subject with SLE (according to the ACR criteria)\n- Onset pediatric (<18 years) OR syndromic lupus OR lupus in context with familial consanguinity OR familial cases (2 cases of SLE related first-degree relative) OR related to a lupus patient participant OR parent of a lupus patient\n- Person entitled to a social security scheme or similar\n- Informed consent signed\n\nAssessment:\n- The patient is female, meeting the gender criterion.\n- She has been evaluated for symptoms and lab results that are consistent with SLE, fulfilling the requirement for SLE as defined by the ACR criteria.\n- The patient is 21 years old, which is not pediatric onset, but the trial includes adults with SLE as well.\n- There is no mention of syndromic lupus, familial consanguinity, or familial cases in the patient note.\n- The patient's eligibility regarding social security scheme or similar is not mentioned, but this is generally assumed unless otherwise stated.\n- The patient can provide informed consent.\n\nGiven the information provided, the patient appears to meet the trial's inclusion criteria for having SLE as per ACR criteria. There is no information contradicting her eligibility, such as exclusion criteria or lack of informed consent capacity.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "934": {
        "output": "",
        "label": 0
    },
    "935": {
        "output": "The patient note presents a 21-year-old female with symptoms and lab findings consistent with Systemic Lupus Erythematosus (SLE): alopecia, a malar rash, arthralgias, normocytic anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, as well as urine positive for protein and RBC casts. She also has a rash on her cheeks and the bridge of her nose, which could be indicative of cutaneous lupus lesions.\n\nThe clinical trial in question is seeking participants with active cutaneous lupus lesions, either Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE), with or without a diagnosis of Systemic Lupus Erythematosus (SLE). In addition, it requires a confirmed diagnosis of SLE using American College of Rheumatology criteria and current or historical positive ANA or anti-dsDNA for participants with DLE or SCLE with SLE.\n\nThe patient fulfills several inclusion criteria for the clinical trial:\n- She has a confirmed diagnosis of SLE with positive ANA and anti-dsDNA.\n- She presents with symptoms that could be indicative of active skin lesions that are typical in lupus patients, although a biopsy would be required to confirm the presence of DLE or SCLE.\n\nHowever, the note does not specify if she has been diagnosed with DLE or SCLE, nor does it confirm that the rash observed is an active skin lesion that can be biopsied according to the trial criteria.\n\nBased on the information provided, it suggests that the patient could potentially be eligible for the clinical trial; however, a histological analysis to confirm active DLE or SCLE would be necessary. Therefore, the patient would be considered for referral to the clinical trial upon further investigation to confirm these specific aspects.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "936": {
        "output": "",
        "label": 0
    },
    "937": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- A 21-year-old female\n- Exhibits signs and symptoms indicative of systemic lupus erythematosus (SLE):\n  - Progressive arthralgias and malaise\n  - Alopecia\n  - Rash on the nose and cheeks\n  - Non-palpable purpura on calves\n  - Swelling and tenderness of wrists and ankles\n- Laboratory findings:\n  - Normocytic anemia\n  - Thrombocytopenia\n  - Positive ANA and anti-dsDNA\n  - Urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- Four or more ACR criteria for the classification of SLE or 4 or more of the SLICE criteria\n- Involvement of one or more of the following organ systems: renal, neurologic, hematologic, cardiac, pulmonary, gastrointestinal\n- A lack of response to corticosteroids in moderate-to-high doses, and to either an equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin, tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other treatment\n- Patients should be eligible for transplantation according to the BMT Policy Manual\n\nPatient vs. Clinical Trial Criteria Match:\n- The patient exhibits multiple symptoms that match the ACR criteria for SLE classification (arthralgias, rash, alopecia, hematologic abnormalities, renal involvement indicated by urine protein, and RBC casts).\n- The patient has hematologic (anemia, thrombocytopenia) and renal involvement, which meets the organ system involvement requirement.\n- It is not explicitly stated whether the patient has tried and failed to respond to corticosteroids or other immunosuppressive therapies, which is necessary to meet the trial criteria.\n\nGiven the information provided, the patient appears to meet several criteria for SLE and has organ system involvement. However, the lack of information about treatment history is a critical factor in determining eligibility for the trial. Therefore, further investigation is required to ascertain the patient's previous treatments and response to those treatments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "938": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Profile:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Symptoms consistent with systemic lupus erythematosus (SLE): alopecia, malar rash, non-palpable purpura, wrist and ankle swelling and tenderness\n- Laboratory findings: normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, urine positive for protein and RBC casts\n\nClinical Trial Inclusion Criteria:\n- Received a minimum of 6 months therapy with belimumab 10 mg/kg in their current SLE belimumab continuation study\n- Be 18 years of age at the Day 0 visit\n- Non-pregnant, non-lactating females willing to comply with specific birth control requirements\n- Able to provide written informed consent to participate\n- SELENA SLEDAI score of 3 or less after the minimum of 6 months belimumab therapy\n- C3 and C4 complement levels at or above the lower limit of the central laboratory reference range\n- On a stable SLE treatment regimen during the 30 day screening period prior to Day 0\n- Subjects in the long-term discontinuation group have voluntarily withdrawn from their continuation studies\n\nAssessment:\nThe patient note does not mention any previous treatment with belimumab, which is a key inclusion criterion for the trial. The patient appears to have active lupus symptoms with no indication of being on a stable SLE treatment regimen, nor is there any mention of having a SELENA SLEDAI score of 3 or less. The patient's complement levels are also not provided. Based on the information given, we do not have evidence that this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "939": {
        "output": "",
        "label": 0
    },
    "940": {
        "output": "After reviewing the patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nPatient Note Review:\n- The patient is a 21-year-old female with symptoms indicative of an autoimmune condition, likely lupus erythematosus, given the presence of arthralgias, malaise, alopecia, a malar rash, purpura, swollen and tender joints, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts.\n\nClinical Trial Review:\n- The trial is evaluating the safety, tolerability, and efficacy of Doxycycline Foam for the prevention of epidermal growth factor receptor inhibitor (EGFRI) skin toxicity in cancer patients receiving Cetuximab or Panitumumab.\n\nInclusion Criteria for the Trial:\n- Age 18 years and older\n- Subjects with any cancer receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis\n- Scheduled to start Cetuximab or Panitumumab treatment\n- ECOG performance status 0-2\n- Other criteria related to reproductive status, informed consent, ability to apply the foam, and willingness to minimize sun exposure\n\nEligibility Assessment:\n- The patient is 21 years old, which meets the age criterion.\n- However, there is no indication in the patient's note that she has cancer or that she is scheduled to start Cetuximab or Panitumumab treatment.\n- The patient's condition does not seem to relate to the purpose of the study, which is focused on cancer patients and the prevention of a specific medication-induced skin toxicity.\n\nGiven that the key criteria related to the patient's cancer status and the specific treatment with Cetuximab or Panitumumab are not met, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "941": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 21-year-old female (meets age criterion of \u226518 years).\n- The patient is experiencing symptoms consistent with Systemic Lupus Erythematosus (SLE), which include alopecia, a characteristic malar rash, arthralgias, and non-palpable purpura.\n- Laboratory findings show normocytic anemia, thrombocytopenia, a 4/4 positive ANA, and anti-dsDNA, which are indicative of SLE and meet the diagnostic criteria.\n- The patient's urine is positive for protein and RBC casts, suggesting active renal involvement.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of SLE by ACR criteria.\n- Positive ANA or anti-ds DNA test results.\n- Active proliferative lupus nephritis, as evidenced by a kidney biopsy or active urinary sediment.\n- Urine protein-to-creatinine ratio (UPCR) >1 at study entry.\n- Ability to provide informed consent.\n\nAssessment:\n- The patient has a diagnosis consistent with SLE and positive ANA and anti-dsDNA tests, meeting the first two inclusion criteria.\n- The presence of protein and RBC casts in the urine suggests active nephritis, which is consistent with the clinical trial's requirement for active proliferative lupus nephritis.\n- However, the patient note does not provide details regarding a kidney biopsy or the specific class of lupus nephritis, which is necessary to confirm the type of nephritis and ensure it meets the trial criteria.\n- The note does not specify the urine protein-to-creatinine ratio, which is needed to confirm eligibility based on the trial's criteria.\n- We can assume the patient has the ability to provide informed consent, given there is no information suggesting otherwise.\n\nGiven that the patient appears to meet several of the key inclusion criteria but lacks specific information on the class of lupus nephritis and the UPCR, further investigation would be necessary to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "942": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Synergetic B-cell Immodulation in SLE,\" we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial. Here's a breakdown of the patient's condition versus the trial's inclusion criteria:\n\n1. Age 18 years: The patient is 21 years old, which meets the age criterion.\n2. American College of Rheumatology (ACR) diagnosis of SLE: The patient exhibits symptoms such as alopecia, a rash on the nose and cheeks (malar rash), arthritis, anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, all of which are indicative of SLE.\n3. Severe SLE flare at screening, according to one or more listed criteria:\n   - Increase in SLEDAI with 12 or more points: Specific SLEDAI score not provided in the patient note.\n   - New or worse SLE-related activity of major organs: The patient has protein and RBC casts in the urine, suggesting lupus nephritis.\n   - Refractory disease: There is no information on previous treatments or their failures.\n4. ANA seropositivity: The patient has a 4/4 positive ANA.\n5. Anti-DNA seropositivity: The patient has a positive anti-dsDNA.\n6. Immune-complex mediated complement usage: No information on C3 or C4 levels is provided.\n7. Use of effective contraception: No information provided.\n\nBased on the patient note, the patient meets several of the inclusion criteria for the trial, such as age, ANA and anti-dsDNA seropositivity, and symptoms suggestive of SLE. However, some criteria cannot be assessed due to missing information (e.g., specific SLEDAI score, complement levels, and use of contraception).\n\nGiven that the patient shows significant signs of SLE and potential lupus nephritis, which could align with the severe SLE flare criterion, and meets several of the other inclusion criteria, it is reasonable to consider this patient for the clinical trial. However, further investigation is required to obtain the missing details and confirm other aspects of the patient's condition in relation to the trial requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "943": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient note:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia\n- Rash on the bridge of the nose and cheeks (malar rash)\n- Delicate non-palpable purpura on calves\n- Swelling and tenderness of wrists and ankles\n- Normocytic anemia\n- Thrombocytopenia\n- Positive ANA and anti-dsDNA\n- Urine positive for protein and RBC casts\n\nClinical trial inclusion criteria:\n- Patients must fulfill the 1997 ACR modified or SLICC classification criteria of SLE\n- New onset thrombocytopenia: platelet count <30X10^9/L (by both routine test and citric acid anti-coagulated blood count test) within 3 months\n\nThe patient note suggests that the patient has symptoms that are consistent with systemic lupus erythematosus (SLE), including a malar rash, alopecia, arthralgias, and positive ANA and anti-dsDNA, which could potentially meet the classification criteria for SLE. However, the specific platelet count needed to determine the severity of thrombocytopenia is not provided in the patient note. To meet the inclusion criteria for the clinical trial, the patient would need a confirmed diagnosis of SLE and a platelet count of less than 30X10^9/L.\n\nBecause the patient note does not provide the exact platelet count, further investigation would be needed to determine if the patient's thrombocytopenia is severe enough (platelet count <30X10^9/L) to qualify for the trial. Therefore, based on the information given:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "944": {
        "output": "The patient note presents a 21-year-old female with symptoms and laboratory findings that are indicative of Systemic Lupus Erythematosus (SLE), including arthralgias, malaise, alopecia, a characteristic rash, non-palpable purpura, swelling and tenderness of wrists and ankles, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts.\n\nThe clinical trial is seeking men and women over 18 years old who are suffering from SLE, have not had an SLE flare for 3 months, and can provide signed consent and social security affiliation.\n\nBased on the information given in the patient note, the patient appears to meet the following inclusion criteria for the clinical trial:\n\n- Age \u2265 18 years old (the patient is 21 years old).\n- Suffering from SLE (the patient's symptoms and lab findings align with SLE).\n- The patient's consent and social security affiliation can be assumed to be obtainable if the patient agrees to participate.\n\nThe only unclear factor from the patient note is whether the patient has been without an SLE flare for 3 months, which is a specific requirement of the trial's inclusion criteria. This information is not provided in the patient note.\n\nGiven that the patient meets the age and diagnosis criteria for SLE and the only missing information is the duration since the last flare, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "945": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 21-year-old female\n- Symptoms and lab findings consistent with SLE (Systemic Lupus Erythematosus), including arthralgias, malaise, alopecia, rash, purpura, swollen and tender wrists and ankles, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine positive for protein and RBC casts.\n\nClinical Trial Inclusion Criteria:\n- SLE patients\n- Female patients aged 18-35 years\n- Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE\n- Having participated in the investigators' original HPV study in 2010\n- Able to give written informed consent\n\nComparison:\n- The patient is female and aged 21 years, which fits within the 18-35 years age range required by the trial.\n- The patient presents with symptoms and lab findings consistent with SLE and likely fulfills the ACR criteria for SLE based on the information given.\n- There is no information provided as to whether the patient participated in the original HPV study in 2010.\n\nGiven that the patient's participation in the original HPV study in 2010 is a critical piece of information not available in the patient note, we cannot conclusively determine her eligibility. Therefore, further investigation is needed to verify this particular inclusion criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "946": {
        "output": "Given the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial titled \"Web-based Genetic Research on Lupus.\"\n\nHere's the breakdown:\n\n- The patient has been evaluated and shows symptoms consistent with lupus, including alopecia, a rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, as well as urine positive for protein and RBC casts. This suggests a diagnosis of lupus by a qualified physician.\n- There are no details provided about the patient's consent to contact the physician or willingness to submit a saliva sample and complete online surveys, but these are actions the patient can decide to take if they agree to participate in the study.\n- The patient is 21 years old, which is above the minimum age requirement of 6 years.\n- There is no information about the patient's access to the internet or residency in the United States, but these criteria can easily be confirmed with the patient.\n\nSince the patient appears to meet the disease diagnosis criterion and other criteria are actionable by the patient (providing consent, submitting a sample, completing surveys) or easily verifiable (internet access, US residency), it is reasonable to assume that the patient could be eligible for the study upon confirming these details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "947": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's go through the eligibility factors step by step:\n\n1. Age \u2265 18 and \u2264 75 years: The patient is 21 years old, which meets the age criterion.\n2. Diagnosed SLE (defined by \u2265 4 of the 11 American College of Rheumatology (ACR) classification criteria for SLE) for at least 3 months before screening: The patient has alopecia, a rash on the bridge of her nose and cheeks (malar rash), non-palpable purpura, arthralgia, anemia, thrombocytopenia, a positive ANA, and anti-dsDNA, and urine positive for protein and RBC casts. This suggests a diagnosis of SLE as per the ACR classification criteria.\n3. Moderate to severe SLE disease activity demonstrated by SLEDAI-2K total score \u2265 6, including skin and joint involvement: The patient has skin (rash, alopecia, purpura) and joint involvement (swelling and tenderness of wrists and ankles), which likely indicates a SLEDAI-2K score \u2265 6.\n4. CLASI Activity score \u2265 5 or at least 5 of 66/68 joints with pain and signs of inflammation: The patient has skin and joint symptoms that could meet this criterion, but we do not have a CLASI Activity score or a specific joint count.\n5. Positive anti-nuclear antibodies (ANA) test at screening: The patient's lab shows a positive ANA.\n6. No change in concomitant medication for SLE activity maintenance and symptom control regarding type of medication and dose level for at least 8 weeks prior to baseline (for steroids and NSAIDs/pain medication 2 weeks): The patient note does not provide information about medication stability.\n7. Normal electrocardiogram (ECG): The patient note does not provide information about the ECG.\n\nGiven that the patient meets most of the inclusion criteria based on the available information, except for the two points where information is not provided (medication stability and ECG), I would consider referring this patient to the clinical trial upon further investigation to confirm medication stability and normal ECG results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "948": {
        "output": "",
        "label": 0
    },
    "949": {
        "output": "The patient is a 21-year-old female being evaluated for progressive arthralgias, malaise, alopecia, rash, purpura, joint swelling, and tenderness. The lab findings are indicative of an autoimmune process, likely systemic lupus erythematosus (SLE), given the positive ANA and anti-dsDNA, as well as the presence of protein and RBC casts in the urine.\n\nThe clinical trial in question is evaluating the clinical effectiveness of RegenKit Platelet-rich Plasma (PRP) in the treatment of androgenetic alopecia (AGA).\n\nThe inclusion criteria for this trial are:\n- Men and women, age 18-60 with AGA\n- Completed informed consent form\n- Ludwig stage 1-2 for women\n- Norwood Hamilton Stage 3 to 5 for men\n\nTo determine the eligibility of the patient for this trial, we must assess whether her alopecia fits the diagnosis of AGA, which is a specific type of hair loss pattern that is typically genetically determined and affects both men and women, but is more commonly referred to as male-pattern baldness.\n\nThe patient\u2019s alopecia in the context of the patient note seems to be associated with the described autoimmune condition rather than AGA. While the patient does fall within the age range of the inclusion criteria, the trial specifically targets AGA, which is not indicated in the patient note. Therefore, based on the information provided, this patient's alopecia might not be due to AGA but rather to an autoimmune etiology, making her not a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "950": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n- Age: The patient is 21 years old, which fits within the 18 to 65 years age range required by the trial.\n- Diagnosis: The patient's symptoms and lab results (alopecia, rash, arthralgias, non-palpable purpura, normocytic anemia, thrombocytopenia, positive ANA, and anti-dsDNA, proteinuria, and RBC casts in urine) suggest a diagnosis of systemic lupus erythematosus (SLE), which is the target condition for the trial.\n- ACR Classification Criteria: The patient has alopecia, rash, arthralgias, hematological disorders (anemia and thrombocytopenia), and renal involvement (proteinuria and RBC casts), which are part of the ACR Classification Criteria for SLE. Although the exact number of criteria met is not provided, the note strongly suggests the presence of at least 4 out of 11 criteria.\n- Positive ANA or dsDNA: The patient has a positive ANA and anti-dsDNA, meeting this requirement.\n- SLEDAI score and BILAG Assessment: The patient note does not provide the SLEDAI score or BILAG assessment, so it's unclear whether the patient has clinically active SLE as defined by the trial's criteria. Further investigation would be needed.\n- Renal organ system therapy: The patient note does not mention the specific treatments the patient has undergone for nephritis, if any, so it's not possible to confirm eligibility based on this criterion without additional information.\n\nGiven the information provided, the patient seems to meet many of the inclusion criteria for the clinical trial. However, there is insufficient information regarding the SLEDAI score, BILAG assessment, and details of renal therapy to make a definitive eligibility determination. Therefore, further investigation into the patient's clinical status and treatment history is warranted.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "951": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, the patient appears to meet the criteria for the study. The patient is a 15-year-old girl presenting with symptoms consistent with appendicitis and an abdominal ultrasound confirming an edematous appendix. The clinical trial is seeking to collect data on patients with appendicitis who are not receiving surgical treatment. The patient note does not mention that the patient has undergone an operation, which aligns with the trial's focus on non-operative management.\n\nGiven that the patient has appendicitis and there is no mention of surgical intervention, she meets the inclusion criteria for the clinical trial. The trial does not specify any age restrictions, and the patient has a confirmed diagnosis of appendicitis. There are no exclusion criteria mentioned that would disqualify the patient.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "952": {
        "output": "",
        "label": 2
    },
    "953": {
        "output": "Based on the patient note provided, the patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis, which is supported by an abdominal ultrasound showing a markedly edematous appendix.\n\nThe clinical trial's inclusion criteria are:\n\n1. Patients with acute appendicitis\n2. Patients with acute gastroenteritis\n3. Patients older than 15 years of age\n\nThe patient in question meets the first criterion, as she presents with symptoms and ultrasound findings consistent with acute appendicitis. However, she does not meet the third criterion because she is exactly 15 years old, and the inclusion criteria specify patients older than 15 years of age.\n\nSince the patient does not meet all the inclusion criteria due to her age, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "954": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 15-year-old girl.\n- She presents with abdominal pain, initially periumbilical, now localized to the right lower quadrant.\n- She denies diarrhea and has no sexual partners.\n- Examination shows localized rebound tenderness in the right lower quadrant.\n- Abdominal ultrasound indicates a markedly edematous appendix, which is consistent with appendicitis.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients admitted with pain other than the right lower abdominal quadrant (the patient has pain in the right lower quadrant, which is typical for appendicitis).\n- Clinical examination that favors the diagnosis of perforated acute appendicitis.\n- Abdominal computed tomography (CT) showing signs of acute appendicitis with intra-abdominal fluid accumulation (the patient had an ultrasound, not a CT).\n- Patients between 12 and 80 years old with informed consent (the patient falls within the age range).\n- Perforated appendicitis remains the most likely diagnosis (based on the information provided, the patient likely has appendicitis, but it is not explicitly stated that it is perforated).\n\nThe patient note indicates that the patient has appendicitis, which is consistent with the trial's focus on appendicitis. However, the trial specifically requires the diagnosis of perforated appendicitis, which is not confirmed in the patient note. Additionally, the trial asks for CT evidence of perforation and intra-abdominal fluid, and the patient was diagnosed with ultrasound instead.\n\nGiven the unconfirmed diagnosis of perforated appendicitis and the lack of a CT scan as required by the trial, the patient would not be immediately eligible based on the information provided. However, if further investigation (such as a CT scan) confirms perforated appendicitis, the patient could potentially become eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "955": {
        "output": "",
        "label": 2
    },
    "956": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, let's review the factors one by one:\n\n- Age: The patient is 15 years old. The inclusion criteria specify \"age over 15 years.\" Since the patient is exactly 15, this could potentially be a point of ambiguity as \"over 15 years\" might typically mean 15 years and some amount of additional time. However, if we interpret it as \"15 years and older,\" then the patient meets this criterion.\n- Suspected acute appendicitis: The patient presents with symptoms suggestive of acute appendicitis (abdominal pain localizing to the right lower quadrant, no appetite, localized rebound tenderness, and ultrasound findings of a markedly edematous appendix), which matches the inclusion criteria.\n- Suitability for laparoscopy: The patient note does not provide specific information about the patient's suitability for laparoscopy. However, given that the patient has a clear indication for appendectomy and there is no information to suggest that she wouldn't be a candidate for laparoscopy, it is reasonable to consider her potentially suitable.\n\nThe primary point of uncertainty here is the interpretation of \"age over 15 years.\" If the trial's intention for the age criterion is to include those who are 15 years old, then the patient meets all the listed inclusion criteria. If the intention was to exclude those who are exactly 15 years old, then the patient would not meet the age criterion.\n\nGiven the ambiguity around the age criterion, I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "957": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 15-year-old girl who presents with symptoms suggestive of acute appendicitis. The clinical trial in question is focused on adult patients with acute appendicitis, comparing two techniques of wound closure post-appendicectomy.\n\nThe inclusion criteria for the clinical trial specify that participants must be adult patients. Since the patient is 15 years old, she does not meet the age requirement to be considered an adult (which is typically 18 years or older). Therefore, she is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "958": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 15-year-old girl presents with acute appendicitis symptoms.\n\nClinical Trial:\n- Inclusion criteria specify an age range of 18 to 60 years and a CT scan diagnosed uncomplicated acute appendicitis.\n\nSince the patient is 15 years old, she does not meet the age criterion for this clinical trial, which requires participants to be between 18 and 60 years old.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "959": {
        "output": "Based on the information provided, the patient is a 15-year-old girl presenting with symptoms consistent with acute appendicitis. The clinical trial in question is testing the efficacy of single incision laparoscopic surgery (SILS) for appendectomy compared to the conventional three incisions method.\n\nThe inclusion criteria for the trial are:\n- Patients will be at least 18 years of age.\n- Male or female (excluding pregnant females).\n- Patients with ASA \u2264 3.\n- Patients informed about the study, and will have read; understood and signed the patient informed consent. Patients will be willing and able to submit to postoperative follow-up evaluations.\n\nThe patient in question does not meet the age requirement, as she is only 15 years old, while the inclusion criteria specify that patients must be at least 18 years of age.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "960": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 15-year-old girl with acute appendicitis.\n\nClinical trial:\n- Title: Warm Humid Gas Insufflation for Appendix Removal by Minimally Invasive Surgery (WARMIST)\n- Inclusion criteria: Healthy volunteers aged 8-14 years presenting to Starship Children's Hospital (Auckland, New Zealand) within the study period diagnosed clinically with acute appendicitis requiring diagnostic laparoscopy +/- appendicectomy.\n\nThe patient is a 15-year-old girl, which exceeds the age range specified in the clinical trial's inclusion criteria (8-14 years). Therefore, she is not eligible for the trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "961": {
        "output": "",
        "label": 0
    },
    "962": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the trial:\n\n- Age >14 years: The patient is a 15-year-old girl, which meets this criterion.\n- Lower / RIF Abdominal Pain: The patient presents with abdominal pain that was periumbilical and then localized to the right lower quadrant, which is consistent with the location for appendicitis pain.\n- Clinical Suspicion of Acute Appendicitis: The patient note indicates the presence of rebound tenderness in the right lower quadrant and a markedly edematous appendix on ultrasound, which supports a clinical suspicion of acute appendicitis.\n\nThe trial also requires an Alvarado Score, which is not explicitly provided in the patient note. The Alvarado Score is a clinical scoring system used to assess the likelihood of appendicitis. However, the patient's symptoms and the ultrasound findings suggest that the patient would likely score within the required range (5-10) for the trial, but a complete score would be needed to confirm this.\n\nInformed consent: The patient is under the age of 18, so consent from a parent or legal guardian would be required, which is aligned with the trial's criteria.\n\nBased on the information provided, the patient appears to meet the trial's inclusion criteria. However, a complete Alvarado Score is necessary to fully determine eligibility. Therefore, the patient would be considered for referral to the clinical trial upon further investigation to determine her Alvarado Score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "963": {
        "output": "Based on the patient note, the 15-year-old girl presents with symptoms indicative of acute appendicitis, which has been confirmed by an abdominal ultrasound showing a markedly edematous appendix. However, the inclusion criteria for the clinical trial require patients with a diagnosis of acute appendicitis with an intraoperative finding of a gangrenous appendix.\n\nAt this moment, the patient has not undergone surgery to confirm the presence of a gangrenous appendix; therefore, we cannot definitively say she meets the inclusion criteria. Moreover, the trial specifies the need for an intraoperative finding, which means eligibility can only be determined after surgical intervention.\n\nIn this case, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation. \n\nThis is because if the patient undergoes surgery and a gangrenous appendix is found intraoperatively, she may then meet the criteria for inclusion in the study. Further investigation (i.e., surgical findings) is required before a definitive referral can be made.",
        "label": 1
    },
    "964": {
        "output": "Based on the information provided, the 15-year-old girl presents with symptoms that are highly suggestive of appendicitis: abdominal pain that began around the umbilicus and localized to the right lower quadrant, lack of appetite, and localized rebound tenderness in the right lower quadrant. The abdominal ultrasound showing a markedly edematous appendix further supports the diagnosis of appendicitis.\n\nThe clinical trial in question is focused on evaluating a standardized approach for diagnosing appendicitis in children in the emergency department, and the inclusion criteria specifically mention a chief complaint of acute appendicitis.\n\nGiven that the patient's presentation aligns closely with the clinical trial's focus and inclusion criteria, it is highly likely that this patient would be considered for referral to the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "965": {
        "output": "Based on the patient's presentation and the inclusion criteria of the clinical trial, this patient does not meet the age requirement specified in the trial. The trial requires participants to be over 18 years of age, while the patient is only 15 years old. Despite the fact that her clinical presentation is consistent with suspicion of acute appendicitis, which aligns with the study's focus on pancreatic stone protein in predicting appendicitis, the age criterion is a strict one that cannot be overlooked.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "966": {
        "output": "The patient note describes a 15-year-old girl who presents with symptoms suggestive of appendicitis, specifically localized pain in the right lower quadrant and rebound tenderness on examination. An abdominal ultrasound revealed a markedly edematous appendix, which is consistent with appendicitis.\n\nThe clinical trial in question is looking for children younger than 14 years with complicated appendicitis, as defined by ultrasound or CT findings of appendix perforation, peri-appendicular abscess, free fluid, and signs of diffuse peritoneal irritation in the right lower quadrant. \n\nThe patient in the note is 15 years old, which is outside the age range specified in the inclusion criteria of the clinical trial (1-14 years). Therefore, despite her symptoms and ultrasound findings possibly fitting the clinical picture the trial is interested in, she would not be eligible due to her age.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "967": {
        "output": "Based on the patient note, the 15-year-old girl presents with symptoms that are highly suggestive of appendicitis. The clinical trial in question is investigating the diagnostic accuracy of serum bilirubin levels in discriminating between perforated and simple/no appendicitis in patients undergoing appendectomy for suspected appendicitis.\n\nThe inclusion criteria for the clinical trial are:\n- All patients undergoing appendectomy for suspected appendicitis.\n\nSince the patient note indicates that the girl has symptoms of appendicitis and there is an ultrasound finding of a markedly edematous appendix, it is likely that she would be considered for an appendectomy. \n\nGiven that if she were to undergo an appendectomy, she would indeed fit the inclusion criteria of the trial, which does not specify any age restrictions or other exclusionary factors based on the provided information.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "968": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Inflammatory Response in Appendicitis,\" the patient is a 15-year-old girl presenting with symptoms consistent with appendicitis, including abdominal pain that has localized to the right lower quadrant, absence of appetite, and findings on an abdominal ultrasound that indicate a markedly edematous appendix. \n\nThe inclusion criteria for the clinical trial are:\n- Patients with appendicitis\n\nThe patient note clearly describes a case of appendicitis, which is the condition being studied in the clinical trial. Therefore, the patient meets the inclusion criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "969": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial:\n\nPatient Information:\n- 15-year-old girl\n- Presenting with abdominal pain consistent with acute appendicitis\n- Diagnosis supported by abdominal ultrasound showing edematous appendix\n\nClinical Trial Inclusion Criteria:\n- Age above 18 years\n- Patients undergoing diagnostic laparoscopy for acute appendicitis\n- American Society of Anaesthesiology group 1-3\n- General Anaesthesia\n\nThe patient's age is 15 years, which does not meet the specified age criterion of being above 18 years. Therefore, solely based on the age criterion, the patient would be ineligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "970": {
        "output": "The patient in question is a 15-year-old girl presenting to the ER with symptoms that are highly suggestive of acute appendicitis, including gradual abdominal pain that localized to the right lower quadrant, lack of appetite, and localized rebound tenderness in the right lower quadrant. An abdominal ultrasound confirmed a markedly edematous appendix.\n\nThe clinical trial in question is seeking to determine the efficacy of low-dose CT compared to standard-dose CT in adolescents and young adults with suspected acute appendicitis.\n\nThe inclusion criteria for the clinical trial are:\n1. Emergency department visit with suspected symptoms and signs of acute appendicitis\n2. Intravenous contrast-enhanced computed tomography examination requested due to suspicion of appendicitis\n3. Willing to provide telephone or cell phone numbers for follow-up\n4. Signed informed consent provided prior to study entry\n\nThe patient meets the first criterion, as she has visited the ER with symptoms and signs that suggest acute appendicitis. The second criterion would likely be met as well, since the next step after an ultrasound might be an intravenous contrast-enhanced computed tomography examination if the diagnosis needs to be confirmed or if the surgical team requires further evaluation before proceeding with treatment. The third criterion is not mentioned, but it is usually possible to obtain contact information for follow-up. The fourth criterion, informed consent, can be obtained if the patient and/or her guardians agree to participate in the study.\n\nGiven the information provided, this patient appears to meet the inclusion criteria for the clinical trial. However, since obtaining informed consent is a critical step that has not yet been completed, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "971": {
        "output": "Based on the patient note provided, the 15-year-old girl presents with symptoms that are indicative of appendicitis, including gradual abdominal pain that localized to the right lower quadrant, lack of appetite, and localized rebound tenderness in the right lower quadrant. The abdominal ultrasound showing a markedly edematous appendix is consistent with a diagnosis of appendicitis.\n\nThe clinical trial in question is focused on the importance of peritoneal free fluid cultures in acute appendicitis and includes patients who have either perforated or non-perforated appendicitis, with free fluid present, and are between the ages of 6 and 90 years old.\n\nThe patient's age falls within the specified range, and there is an indication of appendicitis which is a requirement for inclusion in the trial. However, the trial specifically mentions the evaluation of free fluid cultures, and the patient note does not explicitly state that free fluid was present, only that an edematous appendix was seen on ultrasound.\n\nSince the presence of free fluid is a criterion for the trial and this information is not available in the patient note, further investigation would be needed to determine if free fluid is present before referring the patient.\n\nTherefore, the assessment of eligibility for this patient to be referred to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "972": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the 15-year-old girl with a markedly edematous appendix on ultrasound is not eligible for the clinical trial focused on rectal cancer surgery. The trial is specifically looking for patients with a diagnosis of rectal cancer confirmed by endoscopy and pathology. Additionally, the trial is looking at the effects of preserving the left colic artery during rectal cancer surgery, which is unrelated to the patient's condition of appendicitis.\n\nThe patient in the note is presenting with symptoms indicative of appendicitis, not rectal cancer, and there is no mention of a cancer diagnosis. Furthermore, the patient's age of 15 years would also potentially exclude her from many adult clinical trials unless specified otherwise. Therefore, it would not be appropriate to refer this patient for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "973": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the age requirement for the study. The inclusion criteria state that participants must be between the ages of 18 and 75, and the patient in question is only 15 years old. Therefore, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "974": {
        "output": "Based on the information provided, the patient is a 15-year-old girl who presents with symptoms consistent with appendicitis and has had an ultrasound confirming a markedly edematous appendix. The clinical trial in question is looking at outcomes following appendicectomy in Scotland, with specific interest in how geographic factors might influence these outcomes.\n\nThe inclusion criteria for the clinical trial are:\n- All patients, of all ages, undergoing appendicectomy (OPCS code H01) during the time period January 2001 - December 2010.\n\nGiven that the patient's presentation is consistent with appendicitis and she would likely undergo an appendectomy, she meets the clinical trial's inclusion criteria of being a patient undergoing appendicectomy. However, the clinical trial specifies a time period of January 2001 to December 2010. Since the patient note does not specify the current date or the date of presentation, we cannot confirm that the patient's situation falls within the specified time frame of the study.\n\nAssuming the current date is beyond December 2010 and since the clinical trial is retrospective, this patient would not qualify for inclusion based on the specified date range. Therefore, the patient would not be eligible for referral to the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "975": {
        "output": "Given the patient's note and the clinical trial details, we can compare the two to determine trial-level eligibility.\n\nPatient note:\n- A 15-year-old girl with abdominal pain localizing to the right lower quadrant.\n- Diagnosis of appendicitis based on clinical examination and ultrasound findings.\n\nClinical trial:\n- Title: The Hospital Volume Relationship in Appendicectomy Outcomes\n- Inclusion criteria: All patients, of all ages, undergoing appendicectomy during the time period January 2001 - December 2010.\n\nIn this case, the patient's condition (appendicitis) directly relates to the clinical trial's focus (appendicectomy outcomes). The inclusion criteria are very broad and include all ages, making the 15-year-old patient eligible based on her diagnosis and the requirement of undergoing an appendicectomy.\n\nHowever, one critical element is the time period specified in the inclusion criteria. The trial is retrospective and includes patients who underwent appendicectomy between January 2001 and December 2010. Since the patient note does not specify when the patient presented to the ER, if it is outside the specified date range, she would not be eligible.\n\nGiven the available information and assuming the patient's condition aligns with the trial's time period requirement (which we cannot confirm from the information provided), the patient could be potentially eligible for the study. If the current year is beyond December 2010, she would not be eligible due to the retrospective nature of the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "976": {
        "output": "Upon reviewing the patient note and the clinical trial information, we can determine the patient's eligibility based on the inclusion criteria provided:\n\nThe inclusion criteria for the clinical trial are:\n1. Patients operated for the clinical suspicion of acute appendicitis that will undergo a diagnostic laparoscopy.\n2. Age \u2265 18 years.\n3. Written informed consent.\n\nThe patient note describes a 15-year-old girl presenting with symptoms that are suggestive of appendicitis, such as abdominal pain that has localized to the right lower quadrant and rebound tenderness in the same area, along with an ultrasound that indicates an edematous appendix.\n\nThe first inclusion criterion is met, as the patient has a clinical suspicion of acute appendicitis and may require a diagnostic laparoscopy. However, the patient does not meet the second inclusion criterion, which requires patients to be aged 18 years or older. The patient's age of 15 years disqualifies her from participating in this study. The third criterion regarding informed consent is not applicable since the patient is not eligible due to age.\n\nTherefore, the patient is not eligible for the clinical trial based on the second inclusion criterion of age.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "977": {
        "output": "The inclusion criteria for the clinical trial mention that all patients aged 2 - 12 years old who, within the 10-year period of January 2001 - December 2010, are entered on the SMR01 database as having a code for appendicectomy are eligible to participate.\n\nThe patient note describes a 15-year-old girl presenting with symptoms indicative of appendicitis, which suggests she may require an appendectomy. However, she does not meet the age criterion specified in the clinical trial, as she is older than 12 years. Additionally, there is no mention of the current date or whether the patient's treatment would fall within the specified 10-year period of the study (January 2001 - December 2010). \n\nGiven the information provided, the patient does not meet the age criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "978": {
        "output": "Based on the patient note provided, the 15-year-old girl is presenting with symptoms that are consistent with acute appendicitis, specifically abdominal pain localized to the right lower quadrant and rebound tenderness in the same area, along with an ultrasound finding of a markedly edematous appendix. There is no mention of fever or any symptoms related to dengue fever, such as rash, headache, pain behind the eyes, fatigue, nausea, vomiting, or evidence of hemorrhage (such as petechiae, bleeding gums, or nosebleeds).\n\nThe clinical trial in question is focused on the use of bedside ultrasound to predict the severity of disease in children during a dengue fever outbreak. The inclusion criteria specify that participants should be between the ages of >3 months and <16 years, have a clinical suspicion of dengue hemorrhagic fever based on the Revised WHO Classification System, not be a prisoner or ward of the state, and have parents or guardians able and willing to give consent, with children older than 7 able to give assent.\n\nGiven that the patient in question does not have clinical suspicion of dengue fever and instead has symptoms of appendicitis, she does not meet the inclusion criteria for the clinical trial. Therefore, she would not be eligible for the trial focused on dengue fever.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "979": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- 15-year-old girl\n- Presents with abdominal pain, localized to the right lower quadrant\n- No appetite, denies diarrhea\n- No sexual partners, regular menses\n- Localized rebound tenderness over the right lower quadrant on examination\n- Abdominal ultrasound shows markedly edematous appendix, indicative of appendicitis\n\nClinical Trial Inclusion Criteria:\n- Pediatric patients aged 5-18\n- Diagnosis of appendicitis and scheduled for appendectomy during the hours of 0600-1800\n- Intraoperative findings of suppurative appendicitis\n\nBased on the patient note, the 15-year-old girl fits the age range required for the clinical trial. The symptoms and ultrasound findings are consistent with a diagnosis of appendicitis. However, it is not specified whether she is scheduled for appendectomy during the hours of 0600-1800, nor can we confirm intraoperative findings of suppurative appendicitis without the surgery being performed.\n\nSince the patient meets most of the inclusion criteria but some information is missing or cannot be confirmed until surgery (scheduled time and intraoperative findings), the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "980": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 15-year-old girl presents with abdominal pain, initially periumbilical, now localized to the right lower quadrant.\n- She has had no appetite since yesterday but denies diarrhea.\n- She has had no sexual partners and her menses are regular.\n- On examination, she has localized rebound tenderness over the right lower quadrant.\n- An abdominal ultrasound shows a markedly edematous appendix, suggesting appendicitis.\n\nClinical Trial:\n- Title: Improvement of Appendix Identification and Appendicitis Diagnosis in us After Administration of Oral Contrast Medium\n- Summary: A study to improve the localization of the appendix on ultrasound using oral iodinated contrast material.\n- Inclusion Criteria: Patients in the emergency department with right lower quadrant pain.\n\nAssessment:\nThe clinical trial is aimed at patients who present with right lower quadrant pain, which is consistent with the patient's presentation. Given that the patient's ultrasound has already shown an edematous appendix, she fits the profile of individuals that the study is designed to investigate.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "981": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the information:\n\nPatient Information:\n- A 15-year-old girl with abdominal pain\n- The pain was periumbilical, later localizing to the right lower quadrant\n- No appetite since yesterday but denies diarrhea\n- No sexual partners; regular menses\n- Localized rebound tenderness over the right lower quadrant\n- Abdominal ultrasound showing a markedly edematous appendix\n\nClinical Trial Inclusion Criteria:\n- English and non-English speaking patients\n- Age: 8-17 years\n- US or CT confirmed early appendicitis with specific characteristics (hyperemia, \u2264 1.1 cm in diameter, compressible or non-compressible, no abscess, no fecalith, no phlegmon)\n- White Blood Cell count > 5,000/\u00b5L and \u2264 18,000/\u00b5L\n- Abdominal pain \u2264 48 hours prior to receiving antibiotics\n\nThe patient note indicates that the girl fits within the age range (8-17 years) and presents with symptoms and ultrasound findings consistent with appendicitis. However, the note does not provide details on the diameter of the appendix, the presence of hyperemia, or the white blood cell count, which are specific inclusion criteria for the trial. Additionally, we lack information regarding the duration of her abdominal pain in relation to when she would potentially receive antibiotics.\n\nGiven the information presented, we know that the patient is age-eligible, has appendicitis, and there is no mention of an abscess, fecalith, or phlegmon, which would exclude her from the trial. Yet, due to the incomplete details regarding the full inclusion criteria, further investigation is necessary to determine her eligibility fully.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "982": {
        "output": "Based on the patient note, the 15-year-old girl presents with symptoms indicative of acute appendicitis, not cholelithiasis (gallstones), which is the condition being studied in the clinical trial. Furthermore, the inclusion criteria for the trial specify that participants must be between the ages of 18 and 80, and this patient is only 15 years old. Therefore, she does not meet the age requirement for the clinical trial.\n\nGiven this information, the patient is not eligible for the clinical trial on Single Incision Versus Four Ports Laparoscopic Cholecystectomy, as her condition (acute appendicitis) does not match the target condition for the trial (symptomatic gallstones), and she does not meet the specified age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "983": {
        "output": "Comparing the provided patient note with the inclusion criteria of the clinical trial for locally advanced pancreatic cancer (LAPC), let's consider the key points:\n\nPatient Note:\n- The patient is a 15-year-old girl.\n- She presents with abdominal pain and has a diagnosis of a markedly edematous appendix, indicating appendicitis.\n\nClinical Trial Inclusion Criteria:\n- Age: 18 to 80 years.\n- Diagnosis: Locally advanced pancreatic cancer with specific criteria regarding the extent of the tumor and the involvement of surrounding structures.\n- ECOG performance scale 0 and 1.\n- No evidence of any distant metastasis.\n- Specific requirements for kidney, liver, and bone marrow functionality.\n- Requirement for a negative pregnancy test in females of childbearing potential and not being lactating.\n- Other criteria related to the absence of psychological, familial, sociological, or geographical conditions that could affect compliance with the study protocol.\n\nBased on the information provided, the patient does not meet multiple critical inclusion criteria for the clinical trial:\n\n1. Age: The patient is 15 years old, which is below the minimum age requirement of 18 years.\n2. Diagnosis: The patient has an edematous appendix, suggestive of appendicitis, and there is no mention of pancreatic cancer, let alone locally advanced pancreatic cancer.\n3. The patient's ECOG performance scale is not mentioned, but given she is presenting with acute symptoms, it is unlikely to be relevant to the trial's requirements for patients with pancreatic cancer.\n4. Other specific criteria related to pancreatic cancer and its treatment are not applicable to this patient.\n\nTherefore, the patient is not eligible for this clinical trial based on the mismatch of diagnosis, age, and the specific medical criteria required for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "984": {
        "output": "The patient is a 15-year-old girl presenting with symptoms of acute appendicitis, which has been confirmed by an abdominal ultrasound showing a markedly edematous appendix. This fits the diagnosis of acute uncomplicated appendicitis, which is part of the inclusion criteria for the clinical trial.\n\nThe inclusion criteria for the clinical trial state that both adults and children ages \u22655 years with a diagnosis of acute uncomplicated appendicitis confirmed by imaging and surgical consultation are eligible. The patient also seems to be able to provide assent and her parent or guardian can provide consent on her behalf, as required for subjects ages 5-17.\n\nSince the patient is not of childbearing potential or there is no information regarding a pregnancy test, we would consider that aspect as non-applicable in this scenario.\n\nBased on the information provided in the patient note, the patient meets the age requirement, has a diagnosis of acute uncomplicated appendicitis, and is capable of providing assent with parental consent. Therefore, the patient appears to fit the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "985": {
        "output": "",
        "label": 0
    },
    "986": {
        "output": "The patient note describes a 15-year-old girl presenting to the ER with symptoms consistent with appendicitis: gradual onset of abdominal pain that localized to the right lower quadrant, lack of appetite, and localized rebound tenderness in the right lower quadrant. The abdominal ultrasound confirmed a markedly edematous appendix, which supports the suspicion of appendicitis.\n\nThe clinical trial is a pilot study focusing on the feasibility of rapid acquisition of point of care 3D ultrasound for pediatric appendicitis. The study is designed for patients 18 years and younger with suspected appendicitis, which matches the age and symptoms of the patient described in the note. The inclusion criteria further specify that potential subjects must be presenting to the pediatric emergency department for evaluation of right lower abdominal pain and suspected appendicitis, and the clinical diagnostic plan must include abdominal ultrasound and/or abdominal CT.\n\nGiven that the patient meets the age requirement (0-18 years), is presenting with right lower abdominal pain suggestive of appendicitis, and has already undergone an abdominal ultrasound as part of her evaluation, this patient fits the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "987": {
        "output": "Based on the information provided, the patient is a 15-year-old girl presenting with symptoms that are suggestive of acute appendicitis, not PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis). Furthermore, the inclusion criteria for the clinical trial explicitly mention that participants must be diagnosed or confirmed to have PFAPA by Dr. Bennett and must be between the ages of 1 and 12 years.\n\nThe patient does not meet the age criterion, and there is no indication that she has PFAPA or is undergoing treatment for it at CCMC. Therefore, this patient would not be eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "988": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient appears to be eligible for the clinical trial. The patient is a 15-year-old girl who presents with symptoms consistent with acute appendicitis, which is the condition under investigation in the trial. The trial's inclusion criteria specify patients with a clinical diagnosis of acute appendicitis, which matches the patient's presentation. However, it is important to note that the patient's age is not explicitly mentioned in the inclusion criteria; thus, it is unclear if there are any age restrictions for the trial.\n\nAssuming there are no age restrictions, the patient's clinical diagnosis of acute appendicitis makes her a potential candidate for the trial that investigates diagnostic and surgical procedures for appendicitis. Therefore, I would consider referring this patient to the clinical trial upon further investigation, particularly to clarify any age-related eligibility requirements that may not be included in the provided criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "989": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient note:\n- 15-year-old girl presents with abdominal pain.\n- Right lower quadrant pain, no appetite, denies diarrhea, no sexual partners, regular menses.\n- Localized rebound tenderness over the right lower quadrant.\n- Abdominal ultrasound shows a markedly edematous appendix.\n\nClinical trial inclusion criteria:\n- Children and adolescents aged 7-18 years old.\n- ASA Score I or II.\n- Scheduled for laparoscopic appendectomy surgery.\n- Uncomplicated appendicitis.\n- Hemodynamically stable patient.\n- No evidence of appendiceal perforation based on preoperative clinical and imaging assessment.\n- Diagnosed to have simple acute appendicitis by intraoperative laparoscopy.\n- Written informed assent by the patient.\n- Written informed consent by the caregivers.\n\nThe patient falls within the age range of 7-18 years and is scheduled for laparoscopic appendectomy surgery for what appears to be uncomplicated appendicitis, as there is no mention of perforation or systemic illness that could suggest a complicated case. The patient appears to be hemodynamically stable, as there is no mention of instability, and the condition is diagnosed by imaging which suggests an edematous appendix typically associated with acute appendicitis, although a definitive diagnosis would be confirmed intraoperatively.\n\nSince the patient meets the age criteria, has a diagnosis consistent with uncomplicated appendicitis, and there is no indication of contraindications, she would likely be eligible for the trial pending the formal diagnosis of simple acute appendicitis by intraoperative laparoscopy, as well as the provision of written informed assent and consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "990": {
        "output": "Given the patient note, we have a 15-year-old girl presenting to the ER with symptoms highly suggestive of appendicitis. The clinical trial in question is focused on pediatric acute abdominal pain in emergency care, specifically with the aim of using EHR technology to improve the diagnosis of appendicitis among other conditions.\n\nThe inclusion criteria for the clinical trial are:\n- Children and adolescents ages 5-20 years with abdominal pain\n- Internal med, family med, or emergency med trained providers at participating EDs\n\nThe patient in the note fits within the age range specified (15 years old) and presents with abdominal pain, which is consistent with the conditions under investigation in the trial. Since the trial is designed for EDs and aims at improving the diagnosis and care for patients like the one described, she would be a suitable candidate for the study.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "991": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's evaluate the patient's eligibility:\n\nPatient note analysis:\n- The patient is a 63-year-old man, which meets the age criteria of the clinical trial (Age greater than or equal to 40 years).\n- The patient has a history of heavy smoking, but the exact pack years are not specified in the note. We would need to confirm whether his smoking history meets or exceeds the 30 pack years required by the trial.\n- The patient presents with cough and shortness of breath. These symptoms, along with the mention of using home oxygen and hyperinflation on the chest x-ray, suggest the possibility of COPD, which could meet the \"Obstructive Spirometry\" criterion. However, spirometry results are not provided, so we cannot definitively confirm this.\n- The patient has a family history of early-onset dementia, but there is no mention of a first-degree relative with a smoking history willing to participate, which is one of the trial's criteria.\n\nGiven these observations, the patient appears to meet some of the inclusion criteria, but further information is needed to confirm others. Specifically, we need to know the patient's pack-year smoking history, results from spirometry tests, and whether a first-degree relative with a smoking history is willing to participate in the study.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "992": {
        "output": "",
        "label": 0
    },
    "993": {
        "output": "",
        "label": 1
    },
    "994": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the clinical trial as follows:\n\nThe patient is a 63-year-old man presenting with symptoms of respiratory distress, which include cough, shortness of breath, cyanosis, tachypnea, and diffuse rales over his lungs. The patient has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\nThe clinical trial in question is assessing the use of heliox-driven racemic epinephrine in the treatment of bronchiolitis in pediatric emergency department patients. The inclusion criteria for the trial are:\n\n1. Any child 2-12 months old seen in the emergency department.\n2. A clinical bronchiolitis score > 3 by modified Wood's Clinical Bronchiolitis Score (M-WCBS).\n3. Diagnostic criteria of bronchiolitis include tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. Confirmation of respiratory syncytial virus (RSV) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions.\n\nConsidering the inclusion criteria, the 63-year-old man does not meet the age requirement of 2-12 months old for the pediatric clinical trial. Additionally, the description of his condition does not match bronchiolitis, which is a condition typically seen in infants and young children, nor is there any mention of RSV infection, which is commonly associated with bronchiolitis.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial based on his age and the clinical presentation of his condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "995": {
        "output": "Based on the patient's presentation with cough, shortness of breath, and a history of heavy smoking, along with clinical findings of cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over the lungs, and the use of home oxygen, this patient is likely experiencing an acute exacerbation of chronic obstructive pulmonary disease (COPD). The chest x-ray showing hyperinflation without consolidation supports this diagnosis, although an explicit diagnosis of COPD is not provided.\n\nThe clinical trial in question is investigating the efficacy of antibiotic treatment versus placebo in acute exacerbations of COPD. The inclusion criteria for the trial are:\n\n1. Acute exacerbation of COPD type I or II according to GOLD\n2. Ability to perform lung function tests\n3. Ability to take oral medication\n\nThe patient note suggests that this individual may have an acute exacerbation of COPD given his symptoms and history of heavy smoking, which is a leading risk factor for COPD. However, the GOLD classification of COPD has not been explicitly mentioned, and it's not clear whether the patient is able to perform lung function tests or take oral medication from the information provided. These details are crucial to determine the patient's eligibility for the trial.\n\nSince the note does not provide sufficient information to confirm the patient's COPD GOLD classification or his ability to perform lung function tests or take oral medication, this patient would require further assessment to determine if he meets the specific inclusion criteria of the clinical trial. Therefore, my assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "996": {
        "output": "Based on the patient note provided, here are the key points relevant to the trial's inclusion criteria:\n\n- The patient is a 63-year-old man.\n- He presents with cough and shortness of breath.\n- He has a past medical history of heavy smoking, which is a risk factor for COPD.\n- His symptoms include a productive cough, purulent sputum, and difficulty breathing.\n- He has been using home oxygen, which suggests the severity of his respiratory issues.\n- Physical examination findings include cyanosis, tachypnea, a barrel-shaped chest, and diffuse rales over his lungs, which are consistent with obstructive lung disease.\n- The chest x-ray shows hyperinflation but no consolidation.\n\nNow, let's match these points to the trial inclusion criteria:\n\n- The trial is looking for patients with a physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation.\n- The patient must be admitted to the inpatient medical service at a specified institution, which is not mentioned in the patient note.\n- There should be evidence of airflow obstruction on spirometry (FEV1/FVC<70%).\n- The age requirement is 18 years or older, which the patient meets.\n\nGiven that the patient has symptoms suggestive of COPD and a history of heavy smoking, it is possible he may have COPD exacerbation or undifferentiated asthma/COPD exacerbation. However, we do not have a physician's diagnosis from the note, nor do we know if he has been admitted to one of the specified hospitals. Additionally, we do not have spirometry results to confirm airflow obstruction.\n\nWith the current information, further investigation is needed to confirm the patient's diagnosis, ensure the presence of airflow obstruction via spirometry, and determine if he is admitted to the required hospital.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "997": {
        "output": "",
        "label": 1
    },
    "998": {
        "output": "",
        "label": 2
    },
    "999": {
        "output": "Based on the patient note provided, the patient is a 63-year-old man with a history of heavy smoking, which aligns with the inclusion criteria of clinical COPD and smoking stated in the clinical trial. The age of the patient is also over 40 years, which fits the age criteria for the trial. Although clinical COPD is not explicitly mentioned in the patient's history, the symptoms described (cough, shortness of breath, use of home oxygen, cyanosis, tachypneic, and chest x-ray findings of hyperinflation without consolidation) are indicative of COPD, especially in a heavy smoker.\n\nWhile the patient note does not provide a definitive diagnosis of COPD, the symptoms and history of heavy smoking are highly suggestive of this condition. Before referring this patient, a confirmed diagnosis of COPD would be necessary to meet the clinical trial's inclusion criteria fully. Therefore, the patient would be considered for referral to the clinical trial upon further investigation, such as spirometry or other pulmonary function tests, to confirm COPD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1000": {
        "output": "Based on the patient note, the patient is a 63-year-old man with a history of heavy smoking, which may suggest a diagnosis of COPD, especially given his symptoms of cough, shortness of breath, and the need to use home oxygen. However, the note does not explicitly confirm that the patient has been diagnosed with COPD. The clinical trial in question is specifically targeting patients who have been admitted for an acute exacerbation of COPD.\n\nGiven that the patient presents with symptoms consistent with an acute exacerbation, and considering the history of heavy smoking and respiratory symptoms, it is plausible that the patient could have COPD. However, without a confirmed diagnosis of COPD, it would be premature to refer the patient directly to the trial. Additional information would be needed to confirm the diagnosis of COPD.\n\nTherefore, the appropriate trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1001": {
        "output": "The patient in question is a 63-year-old man presenting with cough and shortness of breath. His past medical history includes heavy smoking, which is relevant to the clinical trial criteria for COPD patients. Additionally, hyperinflation noted on the chest x-ray could be indicative of COPD, although this has not been explicitly diagnosed in the patient note.\n\nThe inclusion criteria for the clinical trial are:\n- Smoker or ex-smoker of at least 10 pack years\n- Age 40 or above\n- Prior and current use of inhaled corticosteroids for at least 6 months duration\n- FEV1 <80% of predicted, FEV1/FVC ratio <70%\n- Less than 15% change and <200 mls change in FEV1 after nebulised salbutamol\n- Must have had a previous exacerbation of COPD in the last year\n\nBased on the provided patient note, it is not clear whether this patient has been diagnosed with COPD, although his heavy smoking history and symptoms could be suggestive. There is no mention of his use of inhaled corticosteroids, nor is there any information on his lung function tests such as FEV1 and FEV1/FVC ratio. There is also no information provided regarding previous COPD exacerbations.\n\nGiven the lack of explicit information matching the inclusion criteria, it is not possible to confidently refer this patient for the trial at this point. However, given his smoking history and symptoms, it might be worth investigating further to see if he has a clinical and spirometric diagnosis of COPD, if he has been on inhaled corticosteroids, and to assess his lung function.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1002": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, the 63-year-old man does not meet the eligibility requirements for the specified trial. The trial is focused on treating children with attention deficit hyperactivity disorder (ADHD) and Tourette syndrome, while the patient's medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis, and respiratory issues, but there is no mention of either ADHD or Tourette syndrome. Additionally, the patient's age is not within the typical pediatric range, which is another reason he does not match the trial's population of interest.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1003": {
        "output": "Based on the information provided, the patient is a 63-year-old man presenting with symptoms of cough and shortness of breath, and a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. His symptoms are not consistent with severe pneumonia as defined by the WHO criteria, and his age does not fall within the 2 to 59 months age range that the clinical trial is targeting.\n\nThe clinical trial in question is specifically designed for children with severe pneumonia and clearly states the inclusion criteria regarding age, which is between 2 to 59 months. Furthermore, the trial is looking to enroll patients with severe pneumonia, which is a specific condition with defined clinical signs such as lower chest wall in drawing and a certain respiratory rate that is not described in the patient's note.\n\nGiven this information, the patient does not meet the age criterion nor the disease condition for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1004": {
        "output": "Given the patient's presentation with cough, shortness of breath, cyanosis, tachypnea, and a barrel-shaped chest, along with the use of home oxygen and a history of heavy smoking, the patient likely has chronic obstructive pulmonary disease (COPD), which fits with the target population for the described clinical trial. The clinical trial is looking for patients aged 45-70 with moderate COPD, according to the GOLD classification, and who are being treated with inhaled steroids and long-acting beta agonists.\n\nThe patient note does not explicitly mention the diagnosis of COPD or the current treatment regimen that would confirm the use of inhaled steroids and long-acting beta agonists. Before making a referral, we would need confirmation that the patient has moderate COPD and is on the specified treatment. Without this information, we cannot conclusively determine the patient's eligibility for the trial.\n\nTherefore, this patient could potentially be a candidate for the trial, but additional information is required to confirm their eligibility. Consequently, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1005": {
        "output": "To assess the patient's eligibility for the clinical trial on \"Causes, Characteristics and Mechanisms of Infective Exacerbations in Subjects With Asthma and Chronic Obstructive Pulmonary Disease (COPD),\" we need to carefully compare the patient's note with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 63-year-old man, fitting within the age range of 18 - 80 years required by the trial.\n- The patient presents with cough and shortness of breath, which could be indicative of an exacerbation of obstructive airway disease, thus potentially meeting the criteria.\n- The patient has a history of heavy smoking, which is a risk factor for COPD.\n- The note does not specify a diagnosis of asthma or COPD, but the symptoms and history suggest a potential for COPD.\n- The patient is using home oxygen, indicating a possible chronic respiratory issue.\n- The patient has a history of at least one recent exacerbation (the current one), but the trial requires at least two exacerbations in the past 12 months.\n\nClinical Trial Inclusion Criteria:\n- Male or female subjects between 18 - 80 years.\n- Any severity of exacerbation of obstructive airway disease attending the outpatient clinic.\n- History of at least two exacerbations in the past 12 months.\n- Signed written informed consent.\n\nBased on the available information, while the patient is within the correct age range and is experiencing respiratory symptoms, there is not enough information to confirm a diagnosis of asthma or COPD or to determine if the patient has had at least two exacerbations in the past 12 months. Therefore, further investigation is required to establish the patient's diagnosis and exacerbation history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1006": {
        "output": "In this scenario, we need to assess the patient's eligibility for a clinical trial focused on the association between increased oxidative stress, anti-inflammatory fatty acid formation, and airway infection in people with asthma and chronic obstructive pulmonary disease (COPD).\n\nThe inclusion criteria for the trial are not explicitly provided in the information given, but it is mentioned that there is \"No change from the MIA and LEUKO trials.\" Without specific details about the MIA and LEUKO trials' inclusion criteria, we cannot make a definitive judgment on the patient's eligibility based solely on the information about the current trial.\n\nHowever, we can make some inferences based on the patient note and the summary of the trial:\n\nThe patient note mentions:\n- The patient is a 63-year-old man.\n- He has a history of heavy smoking (a risk factor for COPD).\n- He presents with cough and shortness of breath.\n- A chest x-ray shows hyperinflation but no consolidation (hyperinflation can be associated with COPD).\n\nThe trial summary mentions:\n- The study targets individuals with asthma and COPD.\n- It aims to investigate airway infection and inflammation in these individuals.\n\nBased on the information given, it is reasonable to suspect that this patient may be experiencing an exacerbation of COPD, particularly given his history of heavy smoking and his current respiratory symptoms. If the MIA and LEUKO trials included patients with COPD and the patient does indeed have COPD (which would need to be confirmed), he might meet the inclusion criteria for this trial.\n\nGiven the lack of explicit inclusion criteria and assuming the MIA and LEUKO trials' criteria would be applicable here, I would suggest:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis is because there is a potential fit between the patient's symptoms and the disease of interest for the trial, but the exact nature of his respiratory condition would need to be confirmed, and the specific inclusion criteria of the MIA and LEUKO trials would need to be reviewed to make a definitive assessment.",
        "label": 1
    },
    "1007": {
        "output": "Based on the information provided:\n\nThe patient note describes a 63-year-old man with symptoms that are consistent with an exacerbation of chronic obstructive pulmonary disease (COPD), given his cough, shortness of breath, use of home oxygen, cyanosis, tachypnea, and a barrel-shaped chest. The chest x-ray findings of hyperinflation without consolidation further support this clinical picture.\n\nThe clinical trial is investigating the impact of corticosteroid-induced hyperglycemia on clinical outcomes in patients with COPD who have been admitted with a COPD exacerbation.\n\nThe inclusion criteria for the clinical trial are patients admitted with COPD exacerbation.\n\nThe patient described in the note has symptoms and signs that could be consistent with a COPD exacerbation, and if confirmed by his medical records and admission diagnosis, he would meet the inclusion criteria for the study.\n\nTherefore, assuming that the patient's condition is diagnosed as a COPD exacerbation upon admission, I would consider him eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1008": {
        "output": "To assess the eligibility of the patient for the Smoking Cessation in Patients With COPD (SMOCC) clinical trial, let's review the inclusion criteria and the patient details:\n\nInclusion Criteria for the Trial:\n- Age >35 years\n- Diagnosis recorded as COPD or ICPC code R95/96\n- Prescription of at least three times of bronchodilators (ATC code R03a/bc) and/or prescription at least two times of inhaled anti-inflammatory medication in the past year (ATC code R03)\n- Current smoking status\n- Suffering from COPD according to the GP's diagnosis\n- In command of the Dutch language\n\nPatient Details:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- Heavy smoker\n- Past medical history includes spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Uses home oxygen\n- Chest x-ray shows hyperinflation, no consolidation (consistent with COPD)\n\nBased on the patient's age, heavy smoking history, and symptoms that are consistent with COPD, he may be eligible for the trial. However, there are some pieces of information missing that are necessary to confirm his eligibility:\n\n1. We do not have confirmation that the patient has been diagnosed with COPD by a General Practitioner (GP).\n2. We do not know if the patient has been prescribed bronchodilators or inhaled anti-inflammatory medications, as per the inclusion criteria.\n3. There is no information on whether the patient is in command of the Dutch language.\n\nWithout confirmation of a COPD diagnosis by a GP and the patient's prescription history, we cannot definitively say that the patient meets all the inclusion criteria. However, given the patient's symptoms and history, it is reasonable to consider further investigation to determine if he meets the criteria for COPD as defined by the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1009": {
        "output": "Based on the patient note provided:\n\n- The patient is 63 years old, which satisfies the age inclusion criterion of being \u2265 18 years.\n- The patient presents with cough and shortness of breath, has a history of heavy smoking, and requires home oxygen, which could indicate a COPD exacerbation.\n- There is a history of heavy smoking, which aligns with the criterion of being a current or former smoker with a \u2265 20 pack-year smoking history.\n- The patient is currently using home oxygen, which meets one of the additional criteria for Phase 1 & 2 of the clinical trial.\n- No specific FEV1 or FEV1/FVC ratios are mentioned, but given the symptoms and history of smoking, COPD is likely, and further investigation into lung function tests would be necessary to confirm this criterion.\n\nSince most of the available information aligns with the inclusion criteria of the clinical trial, and the patient seems to be experiencing an exacerbation of a condition compatible with COPD, the patient could be potentially eligible for the trial. However, the actual FEV1 and FEV1/FVC values are not provided, and these are necessary to confirm COPD diagnosis and severity according to the trial criteria. Therefore, further investigation is needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1010": {
        "output": "Given the patient note, the patient is a 63-year-old man with a history of heavy smoking, presenting with symptoms including cough, shortness of breath, and requiring home oxygen, which could be indicative of a chronic lung condition such as COPD. However, the patient note does not explicitly state that the patient has been diagnosed with COPD.\n\nThe clinical trial in question is looking for current or former smokers with a diagnosis of COPD and impaired lung function as measured by spirometry. Since the patient is a heavy smoker and presents with respiratory symptoms, it is possible that he has COPD, but without a confirmed diagnosis and spirometry results, we cannot be certain of his eligibility for the trial.\n\nTherefore, further investigation would be required to confirm the diagnosis of COPD and assess lung function before this patient could be considered for referral to the clinical trial. This would include obtaining a detailed medical history, conducting a physical examination, and performing diagnostic tests such as spirometry.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1011": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 63-year-old man with symptoms of cough and shortness of breath.\n- Past medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n- Presenting symptoms include productive cough, purulent sputum, and difficulty breathing.\n- The patient has been using home oxygen for the past 24 hours.\n- No mention of fever.\n- Physical examination findings: cyanosis, tachypnea, barrel-shaped chest, diffuse rales over the lungs.\n- Chest x-ray: hyperinflation with no consolidation.\n- There is no explicit mention of a COPD diagnosis, but the patient's symptoms and history of heavy smoking suggest a strong possibility of COPD.\n\nClinical Trial Inclusion Criteria:\n- Patients with a COPD diagnosis according to the American Thoracic Society.\n- Acute exacerbation of COPD leading to acute respiratory failure.\n- Requirement for ICU admission and mechanical ventilation.\n- Increased frequency of cough, volume and purulence of expectoration, and increased baseline dyspnea.\n- Respiratory rate >30 cycles/min.\n- Blood gas criteria: PaCO2 > 6kPa and arterial pH <7.30 before initiation of mechanical ventilation.\n\nAssessment:\n- The patient note does not confirm a diagnosis of COPD, which is required by the trial inclusion criteria. However, given the patient's symptoms and heavy smoking history, COPD is a possibility.\n- The patient is using home oxygen and presents with symptoms that could indicate an acute exacerbation of COPD.\n- The note does not mention whether the patient requires ICU admission or mechanical ventilation, which are necessary for inclusion in the trial.\n- The patient's respiratory rate is not given, nor are the required blood gas values.\n\nWithout confirmation of a COPD diagnosis and the need for mechanical ventilation, as well as missing respiratory rate and blood gas values, we cannot definitively determine that this patient would be eligible for the trial. However, given the patient's presentation and history, it is possible that he could have COPD with an acute exacerbation. It would be prudent to gather more information to confirm a diagnosis and the severity of the condition before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1012": {
        "output": "Given the patient's history and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- 63-year-old man, which fits within the age range of 18-75 years required by the study.\n- History of heavy smoking, which is relevant for the study on smoking and COPD.\n- Presents with cough and shortness of breath, which may be indicative of COPD.\n- No explicit mention of a COPD diagnosis, but symptoms and history are suggestive.\n\nClinical Trial Inclusion Criteria:\n- Age 18-75 years: The patient is 63 years old, which meets this criterion.\n- Age, pack years, FEV1/FVC, and FEV1% predicted must fit in one of the 5 groups described above: Specific groups are not provided in the summary, but the patient's heavy smoking history may fit the criteria.\n- Able to stop smoking for 10 days and start smoking 3-4 cigarettes within 1 hour: The patient's current smoking status is unknown, but given the heavy smoking history, it is possible he could comply if he is currently a smoker.\n- Physically and mentally able to undergo the total study protocol: The patient is using home oxygen and has difficulty breathing, which could potentially limit his ability to participate, depending on the severity of these issues.\n- Written informed consent: Presumably, the patient could give this if he agrees to participate.\n\nGiven the information presented, the patient seems to have characteristics that could potentially make him eligible for the study. However, there are uncertainties regarding his current smoking status, specific respiratory function measurements, and his physical capacity to adhere to the study protocol due to his respiratory symptoms.\n\nTherefore, the patient might be considered for referral upon further investigation to determine specific lung function (FEV1/FVC, FEV1% predicted) and to assess whether his current health status allows him to safely participate in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1013": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, it appears that the patient does not meet the specific requirements outlined for the trial. The clinical trial is focused on subjects with specific allergies and mild asthma, as determined by certain lung function tests and a history of nasal allergy or asthma symptoms.\n\nThe patient in question presents with cough and shortness of breath, with a past medical history notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. There is no mention of the patient having a specific allergy or mild asthma, which are key inclusion criteria for the trial. The patient's respiratory symptoms seem more likely to be associated with his heavy smoking history rather than allergic asthma. Additionally, there is no information about the patient having had lung function tests or a history of episodic wheezing, chest tightness, or shortness of breath consistent with asthma. \n\nTherefore, based on the information provided, the patient does not match the inclusion criteria for the clinical trial that focuses on allergic and mildly asthmatic adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1014": {
        "output": "Based on the patient note provided, the patient has a history of heavy smoking and presents with symptoms consistent with chronic obstructive pulmonary disease (COPD), such as cough, shortness of breath, cyanosis, tachypnea, and a barrel-shaped chest. The chest x-ray findings of hyperinflation also support the likelihood of COPD.\n\nHowever, the inclusion criteria for the clinical trial require specific spirometric values: FEV1/FVC < 70% and FEV1 % predicted > 60%. There is no information in the patient note about spirometric testing or the patient's FEV1/FVC ratio and FEV1 % predicted values.\n\nWithout this spirometric data, it is not possible to confirm if the patient meets the respiratory function criteria for the trial. Therefore, further investigation would be needed to obtain this information before a referral could be considered.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1015": {
        "output": "The patient in the note is a 63-year-old man presenting with symptoms of cough, shortness of breath, and other signs that might be indicative of an exacerbation of a chronic respiratory condition. He has a history of heavy smoking, which is a risk factor for COPD. The clinical findings on examination, such as cyanosis, tachypnea, a barrel-shaped chest, and diffuse rales, are consistent with COPD, although the diagnosis is not explicitly stated.\n\nThe clinical trial is specifically looking for COPD patients who are experiencing an exacerbation of their condition. To be included in the study, patients must satisfy the following criteria:\n\n1. COPD diagnosis according to the GOLD Consensus Statement\n2. Initiation of symptoms diagnostic for COPD exacerbation in the past 72 hours\n3. Abstention from any new therapeutic intervention\n4. Absence of any signs suggestive of severe exacerbation requiring hospitalization\n\nThe patient has not been explicitly diagnosed with COPD in the note provided. However, the symptoms and history are suggestive of a possible COPD exacerbation. To determine if this patient is eligible for the trial, a clear diagnosis of COPD would need to be confirmed.\n\nGiven the information provided, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include confirming the COPD diagnosis according to the GOLD Consensus Statement and ensuring that the patient meets the other inclusion criteria, particularly the initiation of symptoms within the past 72 hours and the absence of any signs of severe exacerbation requiring hospitalization.",
        "label": 1
    },
    "1016": {
        "output": "Based on the patient note provided, the 63-year-old man presents with symptoms consistent with COPD, including a chronic productive cough, shortness of breath, and a history of heavy smoking. His physical examination findings of cyanosis, tachypnea, a barrel-shaped chest, and diffuse rales, along with a chest x-ray showing hyperinflation without consolidation, are also indicative of COPD.\n\nThe clinical trial in question is investigating the effect of theophylline on patients with moderate to severe COPD who are already being treated with inhaled steroids and long-acting beta-agonists. The inclusion criteria for the trial specify patients with stable stage II and III (GOLD) COPD, diagnosed at least 2 years prior.\n\nWhile the patient's note suggests he is likely suffering from COPD, the information provided does not confirm the stage of his COPD or whether his condition has been diagnosed for a minimum of 2 years as required by the trial's inclusion criteria. Therefore, additional information would be needed to determine his eligibility for the trial.\n\nGiven the information at hand, the patient might be eligible for the trial if his COPD is indeed at a stable stage II or III and has been diagnosed for at least 2 years. However, since this information is not explicitly stated, further investigation is needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1017": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to review the patient's characteristics and medical history against the trial's inclusion criteria for each group.\n\nThe patient is a 63-year-old man with a medical history that includes heavy smoking. He is currently experiencing respiratory symptoms, which could suggest a respiratory disease such as COPD, although COPD is not specifically mentioned in his diagnosis. The patient's condition does not seem to be stable as he is cyanotic and tachypneic, which could indicate respiratory distress. \n\nThe clinical trial has several groups with different inclusion criteria:\n\n- Group A is for healthy nonsmokers, which the patient does not qualify for as he is a heavy smoker and is currently experiencing respiratory symptoms.\n- Group B is for healthy current smokers, but the patient does not appear to be \"healthy\" given his respiratory symptoms.\n- Group C is for current smokers willing to stop smoking, but there is no indication that the patient is willing to stop smoking.\n- Group D is for current smokers with COPD. The patient may qualify for this group if his respiratory symptoms are due to COPD, but there is no definitive diagnosis of COPD in the patient's note.\n- Group E is for current smokers with COPD who are willing to stop smoking, which, as with Group C, we do not have information on the patient's willingness to quit smoking.\n\nThe patient's eligibility is uncertain because while he is a heavy smoker, which fits some of the inclusion criteria for groups B, C, D, and E, we do not have confirmation of a COPD diagnosis nor information about his willingness to quit smoking. Additionally, his current health status may not meet the \"healthy\" requirement for groups B and C, and his ability to participate in the study (e.g., repeated bronchoscopies) is not clear from the information provided.\n\nGiven the lack of clear evidence that the patient meets all the necessary inclusion criteria for any of the groups, particularly regarding his health status and willingness to quit smoking, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1018": {
        "output": "Based on the patient note provided:\n\n- The patient is a 63-year-old man with symptoms suggestive of a respiratory condition (cough, shortness of breath, cyanosis, tachypnea, and diffuse rales over his lungs), which could be consistent with Chronic Obstructive Pulmonary Disease (COPD), especially considering his history of heavy smoking.\n- The patient has a past medical history of spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. However, the clinical trial in question is focused on COPD patients.\n- The patient's use of home oxygen and presentation with cyanosis and tachypnea may indicate a chronic respiratory condition like COPD, but the stage of COPD is not mentioned in the patient note.\n- The clinical trial requires participants to currently smoke cigarettes. The patient note does not specify whether the patient currently smokes, only that he has a history of heavy smoking.\n- The patient must be willing to provide written informed consent, refrain from smoking and bronchodilators for a specific time before the test, and be registered in one of the recruitment institutes. The patient note does not provide information on these points.\n\nGiven the lack of specific information on the patient's current smoking status, COPD stage, and whether he is registered at a recruitment institute or willing to provide informed consent and abstain from smoking and bronchodilators before the test, I cannot conclusively determine the patient's eligibility for the clinical trial.\n\nTherefore, the patient may require further investigation to determine his COPD status, current smoking habits, and willingness to adhere to the study protocols. As such, I would consider this patient for the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1019": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the relevant details:\n\nPatient Note:\n- 63-year-old man\n- Symptoms: cough, shortness of breath, productive cough, purulent sputum, difficulty breathing, using home oxygen, cyanotic, tachypneic, barrel-shaped chest, diffuse rales over lungs\n- Past medical history: heavy smoking (risk factor for COPD), spinal stenosis, diabetes, hypothyroidism, mild psoriasis, family history of early-onset dementia\n- Recent condition: No fever, chest x-ray shows hyperinflation but no consolidation\n\nClinical Trial:\n- Title: Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease\n- Inclusion Criteria:\n  - Diagnosis of COPD according to GOLD criteria (FEV1/FVC < 70%)\n  - Age \u2265 18 years\n  - Three or more exacerbations of COPD in one year requiring prednisone and/or antibiotic therapy\n  - Clinically stable during 1 month prior to the study\n  - Informed consent\n\nAssessment:\n- The patient's symptoms and heavy smoking history suggest COPD, but there is no explicit mention of a COPD diagnosis or FEV1/FVC results in the patient note to confirm that he meets the GOLD criteria.\n- The patient is 63 years old, which meets the age criterion.\n- There is no information about the number of COPD exacerbations in the past year, nor about treatments with prednisone or antibiotics for such exacerbations.\n- The patient is currently symptomatic and using home oxygen, which may indicate that he is not clinically stable and has had a recent exacerbation or respiratory infection.\n\nConsidering the points above, we do not have sufficient information to conclusively determine whether the patient meets the GOLD criteria for COPD or has had the required number of exacerbations. Furthermore, the lack of clinical stability is a concern.\n\nTherefore, the patient's eligibility for the trial is uncertain based on the available information. Further investigation into the patient's medical records, particularly regarding COPD diagnosis and history of exacerbations, would be necessary before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1020": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- Symptoms: productive cough, purulent sputum, difficulty breathing, using home oxygen\n- Physical exam: cyanotic, tachypneic, barrel-shaped chest, diffuse rales over lungs\n- Chest x-ray: hyperinflation, no consolidation\n\nClinical Trial Inclusion Criteria:\n- COPD diagnosis according to GOLD guidelines\n- Hospitalization for any acute exacerbation of chronic obstructive pulmonary disease\n- Failure of outpatient treatment\n- Increasing of dyspnea in the last days\n- Comorbidity that causes detriment of respiratory function\n\nAnalysis:\n- The patient presents with respiratory symptoms consistent with an exacerbation of a possible chronic respiratory condition.\n- The patient's smoking history and clinical presentation could suggest a diagnosis of COPD, but the patient note does not explicitly state that the patient has been diagnosed with COPD.\n- The patient has been using home oxygen and has not responded to outpatient treatment, which implies a failure of outpatient treatment.\n- The patient has a comorbidity (spinal stenosis) that could potentially detriment respiratory function.\n- The patient does not have a confirmed diagnosis of COPD in the note, which is a key inclusion criterion for the trial.\n\nGiven that the patient's COPD diagnosis is not explicitly mentioned, but there are several indicators that could suggest he has COPD, and he meets several other inclusion criteria (failure of outpatient treatment, increasing dyspnea, comorbidity affecting respiratory function), I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis of COPD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1021": {
        "output": "",
        "label": 1
    },
    "1022": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we will assess the patient's eligibility:\n\nPatient note assessment:\n- The patient is a 63-year-old man, which meets the age criterion of 40 or over.\n- He presents with symptoms of cough and shortness of breath, which may align with an exacerbation of COPD according to the GOLD guideline (although COPD is not explicitly mentioned, the symptoms and the presence of hyperinflation on the chest X-ray are suggestive).\n- The patient is a heavy smoker, which likely meets the minimum smoking history of 10 pack years.\n- He is currently using home oxygen and experiencing difficulty breathing, which could indicate the need for hospital admission according to the GOLD guideline criteria.\n- There is no information about the patient's ability to ingest oral medication or his mental capacity to participate in the study, but there is also no information that suggests he is incapable.\n- The patient's life expectancy is not mentioned, but there is no indication that it is less than 30 days.\n\nClinical trial inclusion criteria:\n- Age 40 or over.\n- Written informed consent obtained.\n- AECOPD according to the GOLD guideline.\n- Criteria for hospital admission according to the GOLD.\n- Former or current smoker with a minimum smoking history of 10 pack years.\n- Capability to ingest oral medication.\n- Mentally capable of participating in the study.\n- Life expectancy \u2265 30 days.\n\nThe patient appears to meet most of the inclusion criteria based on the information provided. However, the diagnosis of COPD is not explicitly confirmed in the patient note, and it is unclear whether the patient has been formally diagnosed with AECOPD. Also, we lack information on his ability to provide consent, take oral medication, participate in study procedures, and his life expectancy.\n\nGiven the information we have, the patient seems to align with many of the criteria, but we would need further information to confirm his eligibility fully. Therefore, I would consider referring this patient to the clinical trial upon further investigation:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1023": {
        "output": "Patient note assessment:\n- The patient is a 63-year-old man, which meets the age criterion of \u2265 40 years.\n- The patient has a history of heavy smoking, which likely meets the criteria of smokers or ex-smokers of at least 10 pack-years.\n- The patient presents with symptoms of cough, shortness of breath, and use of home oxygen, which could be indicative of COPD, but the diagnosis of COPD according to the GOLD stage I or higher is not explicitly mentioned.\n- The patient shows signs that could be associated with an acute exacerbation of COPD (AECOPD), such as increased use of home oxygen and difficulty breathing, but there is no explicit mention of an increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics, or both.\n\nSince the diagnosis of COPD is not explicitly confirmed in the patient's note and there is no clear indication that the patient is currently experiencing an AECOPD as defined in the inclusion criteria, further investigation would be needed to confirm these details before referring the patient to the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1024": {
        "output": "Given the patient's symptoms of cough and shortness of breath, along with their history of heavy smoking and a chest x-ray showing hyperinflation without consolidation, they appear to have a chronic respiratory condition. However, the patient does not have a confirmed diagnosis of chronic idiopathic cough or chronic cough resistant to treatment of specific triggers, which are part of the clinical trial's inclusion criteria. Additionally, the chest x-ray finding does not indicate a 'normal' chest x-ray, which is another inclusion criterion for the trial.\n\nSince the patient presents with symptoms that could be related to chronic cough but does not meet all the specified inclusion criteria, further evaluation would be needed to determine if the cough is chronic (lasting more than 8 weeks) and idiopathic or resistant to treatment. Until such information is available, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1025": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the clinical trial:\n\n1. Age: The patient is 63 years old, which meets the trial's age criterion of being 40 years of age or older.\n2. Diagnosis: The patient presents with symptoms suggestive of COPD (cough, shortness of breath, cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over the lungs), but the diagnosis of COPD has not been explicitly stated in the patient note.\n3. COPD diagnosis confirmation: The trial requires a documented diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.7. There is no information provided about spirometry results or a confirmed diagnosis according to the GOLD guidelines.\n4. History of exacerbations: The patient's note does not mention a history of COPD exacerbations, nor does it specify any additional treatments for such exacerbations in the last 12 months.\n5. Tobacco use: The patient has a history of heavy smoking, which is likely to meet the smoking history requirement of more than 10 pack years.\n\nGiven that the patient's diagnosis of COPD is not confirmed and there is no information about a history of COPD exacerbations, further investigation would be needed to determine if the patient truly has COPD according to the GOLD guidelines and whether they have had exacerbations requiring additional treatment. Therefore, the patient might be eligible for the trial upon further investigation to confirm these details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1026": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Symptoms: productive cough, purulent sputum, difficulty breathing, and has been using home oxygen\n- No mention of asthma in the medical history\n\nClinical Trial Inclusion Criteria:\n- Male or female patients, age 12 through 65 years at the time of screening\n- Written informed consent obtained from the patient\n- Documented clinical history of chronic persistent asthma requiring controller therapy\n- Able to complete the study period of up to approximately 2 years\n- Willing to forego other forms of experimental treatment and study procedures during the study and for 30 days after the follow-up period is completed\n\nComparison:\n- The patient's age (63 years) falls within the age range specified by the trial (12 through 65 years).\n- There is no mention of asthma in the patient's history, which is a key inclusion criterion for the clinical trial. The patient's respiratory symptoms are not clearly linked to asthma and could be due to other respiratory conditions, especially considering his history of heavy smoking.\n- Other inclusion criteria such as written informed consent, ability to complete the study period, and willingness to forego other forms of experimental treatment cannot be determined from the patient note but are standard requirements for participation.\n\nConclusion:\nSince the patient does not have a documented clinical history of chronic persistent asthma requiring controller therapy, he does not meet a critical inclusion criterion for this asthma-related clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1027": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Cough Responses to Tussive Agents in Health and Disease,\" we need to compare the patient's characteristics with the inclusion criteria specified by the trial.\n\nPatient Characteristics:\n- 63-year-old man\n- Heavy smoking history\n- Respiratory symptoms: cough, shortness of breath, productive cough with purulent sputum\n- Oxygen use for the past 24 hours\n- Cyanosis, tachypnea, and diffuse rales on examination\n- Chest x-ray: hyperinflation, no consolidation\n- Other medical history: spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- No mention of spirometry results\n\nClinical Trial Inclusion Criteria:\n- Adult subjects aged 18 years and over\n- Subject groups:\n  - Healthy volunteers (non-smokers, no respiratory disease)\n  - Healthy smokers (current smokers, \u226510 pack years, normal spirometry)\n  - Asthma (physician diagnosis, hyperresponsiveness, non/ex-smokers with \u226410 pack years)\n  - COPD (physician diagnosis, ex-smokers with \u226520 pack years, airflow obstruction with FEV1/FVC ratio <70%)\n  - Chronic Cough (dry cough >8 weeks, normal CXR, non/ex-smokers with \u226410 pack years)\n\nAssessment:\nThe patient is a heavy smoker with a significant history of respiratory symptoms, but there is no explicit mention of a physician diagnosis of COPD, nor are there spirometry results provided to confirm airflow obstruction. Additionally, the cough is described as productive with purulent sputum, which does not align with the \"dry cough\" described in the chronic cough criteria.\n\nGiven the lack of diagnostic confirmation of COPD or chronic cough as defined by the trial's criteria and the presence of productive cough (which is not consistent with the \"dry cough\" required for the chronic cough group), the patient does not clearly meet any of the specified subject group criteria. Furthermore, the patient has a history of heavy smoking, but the exact pack years are not provided, and there's no mention of spirometry results.\n\nTherefore, as the patient does not clearly meet the inclusion criteria for any of the defined subject groups, the eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1028": {
        "output": "Given the patient's note and the clinical trial's inclusion criteria, let's compare the relevant data:\n\nPatient Note:\n- 63-year-old man\n- Symptoms: Cough, shortness of breath, productive cough, purulent sputum, difficulty breathing, cyanosis, tachypnea, barrel-shaped chest, diffuse rales over lungs\n- Past medical history: Heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- Family history: Early onset dementia\n- Chest x-ray: Hyperinflation with no consolidation\n\nClinical Trial Inclusion Criteria:\n- Age 40-80 years old\n- Cases:\n  - Spirometry (post-bronchodilator) based diagnosis of COPD (GOLD criteria)\n  - Smoking history of at least 10 pack-years\n  - Active smoking behavior till at least 10 years from the moment of enrollment\n\nThe patient is 63 years old, which fits within the age criterion of the trial (40-80 years). The patient presents with respiratory symptoms and has a heavy smoking history, which could potentially indicate COPD, although the diagnosis of COPD is not explicitly mentioned in the patient's note. The inclusion criteria require a spirometry-based diagnosis of COPD, which we do not have information on from the patient's note. However, given the patient's symptoms and heavy smoking history, it is plausible that the patient could have COPD, and further investigation with spirometry would be necessary to confirm.\n\nBased on the information provided, it is reasonable to consider referring this patient to the clinical trial upon further investigation to confirm if the patient meets the spirometry-based diagnosis of COPD according to GOLD criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1029": {
        "output": "Given the information from the patient note and the clinical trial's inclusion criteria, we need to assess if the patient is eligible for the trial.\n\nThe inclusion criteria for the clinical trial are:\n- Diagnosis of COPD in any field in the pre-index period and 60 days after the index date\n- Diagnosis of depression/anxiety in any field and a medication for treating depression/anxiety in the pre-index period and 60 days after the index date\n- Index date occurs during identification period\n- Patients must be continuously eligible during the 1-year pre and 1-year post-index date and be of at least 40 years of age\n\nThe patient note provides the following relevant information:\n- The patient is a 63-year-old man, which meets the age criterion.\n- The patient presents with symptoms indicative of a respiratory issue, possibly COPD (cough, shortness of breath, cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over his lungs, along with hyperinflation noted on a chest x-ray). This suggests a potential diagnosis of COPD. However, the note does not confirm a diagnosis of COPD.\n- There is no mention of depression or anxiety diagnosis, nor any mention of medication for treating depression or anxiety in the patient's history.\n- There is no information provided about the index date or the patient's eligibility during the 1-year pre and 1-year post-index date period.\n\nBased on the information provided, the patient potentially meets the age requirement and possibly has COPD, though COPD is not explicitly diagnosed in the patient note. However, there is no evidence of a comorbid diagnosis of depression/anxiety or a medication regimen for such conditions. Therefore, we cannot confirm that the patient meets all the inclusion criteria.\n\nGiven the lack of a confirmed diagnosis of both COPD and depression/anxiety, as well as incomplete information regarding the patient's medical history, medication, and eligibility period, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1030": {
        "output": "The patient is a 63-year-old man who presents with symptoms including a cough and shortness of breath. He is a heavy smoker, which matches the criteria for the clinical trial focused on smokers with chest symptoms who are older than 60 years. According to the patient note, he has productive cough and difficulty breathing, but it is not mentioned that he has hemoptysis or unexplained or persistent signs or symptoms lasting more than 3 weeks. Additionally, since he has a cough and increased breathlessness, he meets the criteria for symptoms reported to primary care that are included in the trial's disease characteristics.\n\nHowever, he has had a chest x-ray that showed hyperinflation without consolidation, which would need to be considered with respect to the trial's exclusion of patients who had a chest x-ray within the past 3 months. If the patient's most recent chest x-ray was within this time frame, he would not be eligible for the trial. \n\nThe patient note does not provide the exact timing of the chest x-ray relative to the current date. Further investigation is required to determine the date of the chest x-ray to ensure compliance with the trial's inclusion criteria.\n\nBased on the information provided, and pending verification of the timing of the chest x-ray, the patient appears to meet the symptom and age criteria for the clinical trial but potentially fails the prior chest x-ray criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1031": {
        "output": "First, let's compare the patient's characteristics and medical history to the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- Age: 63 years old\n- Heavy smoking history\n- Diagnosis: Presents with cough, shortness of breath, and other symptoms related to respiratory issues\n- Other medical history: Spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- Imaging: Chest X-ray notable for hyperinflation with no consolidation\n\nClinical Trial Inclusion Criteria:\n- No previous vaccination with PPSV23\n- A clinical diagnosis of severe COPD defined as FEV1/FVC < 70%, FEV1 reversibility test < 200 ml, and FEV1 < 50% of predicted\n- Current or past exposure to smoking\n- No exacerbation in the month prior to enrollment\n- Age < 65 years\n- Using high daily dose of ICS (budesonide > 800-1600 mcg/day or fluticasone > 500-1000 mcg/day)\n- Providing written informed consent\n\nAnalysis:\n- The patient is a heavy smoker, which aligns with the trial criterion of current or past smoking exposure.\n- The patient's age of 63 falls within the age limit (<65 years) for the trial.\n- The patient presents with respiratory symptoms, which could suggest COPD, but the patient note does not explicitly confirm a diagnosis of severe COPD as defined by the GOLD 2006 guideline.\n- It is not mentioned whether the patient is using high daily doses of ICS or whether there has been an exacerbation in the month prior to enrollment.\n- The patient's chest X-ray findings of hyperinflation are consistent with COPD, but without pulmonary function test results, it's unclear if the patient meets the specific COPD severity criteria.\n- There is no mention of prior vaccination status concerning PPSV23.\n\nGiven the information provided, there is a possibility that this patient could have COPD and align with the trial's criteria. However, further investigation is needed to confirm the diagnosis of COPD, severity of the disease, current use of ICS therapy, recent exacerbations, and vaccination history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1032": {
        "output": "To determine the trial-level eligibility for the patient with the provided note, we need to examine the inclusion and exclusion criteria of the clinical trial and compare them to the patient's characteristics and medical condition.\n\nPatient Note Summary:\n- 63-year-old man\n- Symptoms: cough, shortness of breath, productive cough, purulent sputum, difficulty breathing\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- Family history: early-onset dementia\n- Physical examination: cyanotic, tachypneic, barrel-shaped chest, diffuse rales over lungs\n- Diagnostic: chest x-ray shows hyperinflation, no consolidation\n\nClinical Trial Inclusion Criteria:\n- Minimum age 40 years at index\n- Continuously enrolled in a health plan\n- Diagnosis of COPD (ICD-9 codes of 491, 492, 496)\n- At least one moderate exacerbation event as defined previously\n\nClinical Trial Exclusion Criteria:\n- Exclusionary comorbid conditions of respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis (TB), bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, or sarcoidosis\n- Patients excluded if they did not receive treatment within the treatment assessment period following moderate exacerbation\n- Receipt of maintenance medication in the pre-period\n- Presence of treatment switch, discontinuation of index drug, or any COPD-related exacerbation during the treatment assessment period\n\nAnalysis:\n- The patient's age (63 years) meets the inclusion criteria (minimum age 40 years).\n- The patient shows symptoms consistent with a respiratory condition and possible COPD, given the history of heavy smoking and current respiratory symptoms.\n- The patient's chest x-ray indicates hyperinflation but no consolidation, which could be consistent with COPD.\n- The patient note does not provide information on the patient's health plan enrollment, COPD diagnosis confirmation, or moderate exacerbation events. We also lack information about any previous COPD maintenance medication, which is relevant for the exclusion criteria.\n\nGiven the information provided, the patient seems to potentially meet the age and symptom criteria for COPD, but there is insufficient data to confirm a COPD diagnosis or to determine whether the patient meets the other specific criteria for the study. Further investigation is required to confirm the COPD diagnosis and to assess other inclusion and exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1033": {
        "output": "Given the patient note:\n\nA 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum, and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination, he is cyanotic, tachypneic, with a barrel-shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.\n\nAnd the clinical trial:\n\nTitle: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.\n\nSummary: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Acutely Ill Children in a High Prevalent Setting: The Paediatric Accidents & Emergencies through prospective observational data collection concerning specific items from the clinical and technical examination in diagnosing serious infections, such as meningitis, sepsis, pneumonia, pyelonephritis, bronchiolitis with hypoxia. Eventually, we will attempt to validate a vital signs and symptoms rule derived from multiple low to high prevalent settings of acutely ill children.\n\nInclusion criteria: \n- Children aged 1 month to 16 years\n- Acute illness episode of maximum 5 days\n\nThe patient described in the note is a 63-year-old man, which does not meet the age inclusion criteria of the clinical trial that requires children aged 1 month to 16 years. Therefore, he is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1034": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 63-year-old man, which meets the age criterion of being at least 40 years of age.\n- The patient presents with symptoms of cough and shortness of breath, and a chest x-ray indicates hyperinflation, which could be consistent with a diagnosis of COPD. However, the diagnosis of COPD is not explicitly stated in the patient note.\n- The patient has a history of heavy smoking, which is a known risk factor for COPD.\n- The patient is using home oxygen, which suggests a more severe respiratory condition that may align with COPD management.\n- The patient's medical history includes conditions like spinal stenosis and diabetes, but these are not relevant to the COPD diagnosis.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must be at least 40 years of age. The patient is 63 years old, so this criterion is met.\n- The patient must be continuously enrolled for medical and pharmacy benefits during their pre- and post-period. This information is not provided in the patient note.\n- The patient must have a diagnosis of COPD (ICD 491.xx, 492.xx, 496.xx). The patient note suggests symptoms that could be associated with COPD but does not confirm the diagnosis.\n\nThe patient's age meets the inclusion criteria, and his symptoms are suggestive of COPD, but without confirmation of a COPD diagnosis and information about his enrollment for medical and pharmacy benefits, we cannot be certain of his eligibility. Therefore, further investigation is required to confirm the diagnosis of COPD and to gather additional relevant information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1035": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 63-year-old man, which meets the age criterion of being over 40 years.\n- The patient presents with symptoms of cough, shortness of breath, and has been using home oxygen, which may suggest an acute exacerbation of a respiratory condition.\n- The patient has a history of heavy smoking, which is a risk factor for COPD.\n- The patient has a notable chest x-ray showing hyperinflation, but no consolidation, which could be consistent with COPD.\n\nClinical Trial Inclusion Criteria Analysis:\n- Presence of COPD according to standard criteria.\n- Acute exacerbation of COPD according to recommended international criteria.\n- Over 40 years of age.\n- History of at least 10 pack-years of smoking.\n\nComparison:\n- The patient\u2019s age meets the clinical trial\u2019s inclusion criteria.\n- The patient's history of heavy smoking likely meets the history of at least 10 pack-years of smoking.\n- While the patient shows signs that could suggest COPD, there is no explicit mention in the patient note that the patient has been previously diagnosed with COPD, which is necessary to meet the trial criteria.\n\nGiven that the patient's clinical presentation could align with COPD and there is a history of heavy smoking, there is a possibility that the patient could have COPD. However, without a confirmed diagnosis of COPD, we cannot definitively refer the patient for the trial based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1036": {
        "output": "The patient in this case is a 63-year-old man presenting with cough and shortness of breath. His past medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis, and a family history of early onset dementia. The patient is experiencing respiratory symptoms consistent with a respiratory illness, but there is no indication that the patient has sickle cell disease or any of its variants (Hemoglobin SS, Hemoglobin SC, Hemoglobin sickle beta-zero thalassemia, or Hemoglobin sickle thalassemia), which is a key requirement for the clinical trial in question.\n\nThe clinical trial outlined is specifically for patients with sickle cell disease who are experiencing Acute Chest Syndrome (ACS), as indicated by the inclusion criteria which specifies types of sickle cell disease and clinical criteria for ACS including respiratory symptoms, fever, or chest pain in conjunction with findings on a chest x-ray.\n\nThe patient's symptoms do not appear to be related to sickle cell disease or ACS but rather to another form of respiratory illness, possibly exacerbated by his heavy smoking history. The patient's chest x-ray shows hyperinflation but no consolidation, which does not meet the criteria for ACS as defined in the clinical trial. Furthermore, there is no mention of the patient's hemoglobin levels or pulse oximetry readings, which are part of the clinical criteria for ACS.\n\nGiven that the patient does not meet the key inclusion criteria for the clinical trial, which is having a diagnosis of sickle cell disease and meeting the clinical criteria for Acute Chest Syndrome, this patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1037": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided inclusion criteria and patient note:\n\nPatient Note Analysis:\n- The patient is a 63-year-old man, which fits within the age range of 55-92 years required by the trial.\n- He has a history of heavy smoking, which is a potential issue as the trial requires participants who have not smoked for at least 10 years and have consumed no more than 10 pack years.\n- The patient is currently experiencing respiratory complaints, including cough and shortness of breath.\n- He shows signs of respiratory disease, with cyanosis and diffuse rales on examination and hyperinflation on chest x-ray.\n\nClinical Trial Inclusion Criteria:\n- Men aged 55-92 years old (the patient meets this criterion).\n- Must not currently be a cigarette smoker and if an ex-smoker then has not smoked for at least 10 years with no more than 10 pack years (the patient's smoking history is not compatible with this criterion).\n- Must volunteer for the study and be willing to sign the informed consent form (we do not have information about the patient's willingness, but this is assumed if he were considering participating in a trial).\n- Negative/normal screening tests for respiratory diseases and no current respiratory complaints (the patient does not meet this criterion).\n- Normal spirometry measurements and impedance oscillometry (we do not have this data for the patient).\n- Negative physical examination of the chest (the patient does not meet this criterion, as he has diffuse rales and is cyanotic).\n- Exhaled nitric oxide concentration within specified limits (we do not have this data for the patient).\n\nBased on the above points, the patient does not meet several of the key inclusion criteria for the clinical trial, particularly with respect to his smoking history and current respiratory complaints and diseases. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1038": {
        "output": "Based on the patient note provided, the patient is a 63-year-old man presenting with cough and shortness of breath, with a past medical history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. There is no mention of the patient having cystic fibrosis, which is a key inclusion criterion for the clinical trial in question.\n\nThe clinical trial is specifically aiming to treat patients with cystic fibrosis who are experiencing a pulmonary exacerbation and have a chronic or intermittent infection with Pseudomonas aeruginosa. The patient in the note shows no indication of having cystic fibrosis or an infection with Pseudomonas aeruginosa, which are both required according to the inclusion criteria of the clinical trial.\n\nTherefore, based on the information provided, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1039": {
        "output": "",
        "label": 1
    },
    "1040": {
        "output": "To assess the patient's eligibility for the clinical trial based on the provided information, let's compare the patient's characteristics and symptoms with the inclusion criteria of the trial:\n\nInclusion Criteria for the Clinical Trial:\n- Presence of purulent sputum documented by colorimetric assay, plus at least two of the following signs-symptoms:\n  - Increased cough\n  - Increased dyspnea\n  - Increase in sputum volume appeared at least 3 days\n- Previous antibiotic treatment with any medication (e.g., amoxicillin, amoxicillin/clavulanate, cephalosporins, or macrolides) with the exception of quinolones, conducted for at least 3 days with persistence or worsening of symptoms and subsequent use of hospital\n- Age \u2265 60 years\n- FEV1 <80% and \u2265 30% and ratio FEV1/FVC <70%\n- Chest x-ray negative for inflammatory infiltrates\n- Informed consent\n\nPatient Characteristics:\n- A 63-year-old man\n- Presents with cough (increased cough) and shortness of breath (increased dyspnea)\n- His symptoms began about a week prior to admission, with productive cough (increase in sputum volume) and purulent sputum\n- Denies fever (not directly relevant to the inclusion criteria)\n- Cyanotic, tachypneic, with a barrel-shaped chest and diffuse rales over his lungs on examination\n- Chest x-ray notable for hyperinflation but no mention of inflammatory infiltrates\n- Past medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis (not directly relevant to the inclusion criteria)\n\nBased on the patient's information:\n\n- The patient is 63 years old, meeting the age criterion.\n- The patient presents with increased cough, increased dyspnea, and an increase in sputum volume, which are symptoms consistent with the criteria.\n- There is no information regarding previous antibiotic treatment, FEV1/FVC ratio, or whether informed consent can be obtained.\n- The chest x-ray shows hyperinflation but no clear mention of inflammatory infiltrates, which could suggest that the criterion is met, but further investigation is needed to confirm the absence of inflammatory infiltrates.\n\nGiven that the patient meets several of the inclusion criteria but there is insufficient information on some criteria (previous antibiotic treatment, FEV1/FVC ratio, informed consent, and definitive exclusion of inflammatory infiltrates on the chest x-ray), I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1041": {
        "output": "",
        "label": 1
    },
    "1042": {
        "output": "Based on the information provided, the patient is a 63-year-old man with a history of heavy smoking, which is a risk factor for COPD. He presents with symptoms consistent with a COPD exacerbation, such as cough, shortness of breath, and the use of home oxygen. Additionally, he has a history of diabetes. The clinical trial is looking for diabetic patients with COPD exacerbation.\n\nThe inclusion criteria for the clinical trial are diabetic patients with COPD exacerbation. The patient note indicates that the patient has diabetes and is experiencing symptoms indicative of a COPD exacerbation (although COPD is not explicitly diagnosed in the patient note). Given this information, it appears that the patient could potentially meet the inclusion criteria for this clinical trial.\n\nTo confirm the patient's eligibility, we would need further investigation to verify a diagnosis of COPD and to ensure that the current symptoms are indeed due to a COPD exacerbation. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1043": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient note:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Symptoms: productive cough, purulent sputum, difficulty breathing, using home oxygen\n- Physical examination: cyanotic, tachypneic, barrel shaped chest, diffuse rales over lungs\n- Chest x-ray: hyperinflation with no consolidation\n\nClinical trial:\n- Title: The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults\n- Inclusion criteria:\n  - Age \u2265 18 years\n  - HRCT-diagnosed Bronchiectasis\n  - Capable of providing written informed consent\n\nThe patient's age qualifies him for the clinical trial (he is over 18 years old), and he is capable of providing written informed consent. However, there is no specific mention of HRCT-diagnosed bronchiectasis in the patient's note. While the patient does present with respiratory symptoms, a diagnosis of bronchiectasis cannot be assumed without the appropriate imaging and diagnostic criteria being met.\n\nTherefore, as there is no information confirming that the patient has been diagnosed with bronchiectasis via HRCT, which is a specific inclusion criterion for the trial, we cannot immediately refer this patient for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1044": {
        "output": "",
        "label": 0
    },
    "1045": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nThe patient is:\n- A 63-year-old man, which meets the age criterion of being older than or equal to 40 years of age.\n- Not specified as having COPD, but presents with symptoms that could be suggestive of an acute exacerbation of COPD, such as cough, shortness of breath, and use of home oxygen.\n- A heavy smoker, which may meet the smoking history requirement of at least 10 Pack Years or more.\n- Experiencing symptoms of less than 7 days' duration, as required by the trial criteria for the acute onset of moderate exacerbation.\n- Not specified as having pneumonia or infiltrates on chest x-ray, which is consistent with the trial's exclusion of such conditions.\n\nHowever, the patient's diagnosis of COPD is not explicitly stated in the note, which is a crucial part of the trial's inclusion criteria. While the symptoms and smoking history suggest a possibility of COPD, a definitive diagnosis is not provided.\n\nGiven the information available, the patient could potentially be eligible for the trial if further investigation confirms a diagnosis of COPD. However, based on the current information, we cannot conclusively determine eligibility without additional medical information, specifically regarding the diagnosis of COPD.\n\nTherefore, my assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1046": {
        "output": "The patient in question is a 63-year-old man presenting with cough and shortness of breath. His medical history includes heavy smoking, which is a risk factor for Chronic Obstructive Pulmonary Disease (COPD), in addition to other unrelated conditions such as spinal stenosis, diabetes, hypothyroidism, and psoriasis. The patient's symptoms of coughing, sputum production, and difficulty breathing, which have escalated to the use of home oxygen, suggest an acute exacerbation of a potential underlying COPD. The absence of fever and the presence of diffuse rales on examination also align with COPD exacerbations rather than pneumonia.\n\nThe clinical trial in question is seeking patients with confirmed or suspected COPD who are hospitalized for an exacerbation of the condition. The inclusion criteria are as follows:\n1. Confirmed or suspected COPD.\n2. Hospitalized with COPD exacerbation.\n3. Patients must be adults (more than 18 years) and of age.\n4. There must be a signed informed consent.\n5. Patients included only on weekdays.\n\nGiven the patient's presentation and history, there is a strong possibility that he is suffering from a COPD exacerbation, and thus, he meets the criteria for the clinical trial. However, it is not specifically stated in the patient note that COPD has been confirmed or suspected by a healthcare professional. Therefore, confirmation of COPD diagnosis would be necessary to fully establish eligibility.\n\nBased on the information provided and assuming that the patient can provide informed consent, he meets the preliminary criteria for the trial. However, the need for confirmation of a COPD diagnosis means that further investigation is required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1047": {
        "output": "The patient in question is a 63-year-old man presenting with symptoms of respiratory distress, notably cough and shortness of breath. His medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. His current presentation does not indicate a fever, but he exhibits cyanosis, tachypnea, and has a chest X-ray showing hyperinflation without consolidation.\n\nThe clinical trial under consideration is focused on diagnosing pneumonia under low-resource conditions, primarily targeting children. The inclusion criteria for the trial are explicitly stated as \"All children below 5 exceeding WHO age-dependent tachypnea criteria.\"\n\nSince the patient is a 63-year-old man and the inclusion criteria for the trial specify children below the age of 5, the patient does not meet the age criterion for the trial. Therefore, he is not eligible for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1048": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- History of heavy smoking\n- Past medical history includes spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Symptoms began a week prior, with productive cough, purulent sputum, and difficulty breathing\n- Using home oxygen for the past 24 hours\n- Cyanotic, tachypneic, with a barrel-shaped chest and diffuse rales over lungs on examination\n- Chest x-ray shows hyperinflation with no consolidation\n\nClinical trial inclusion criteria:\n- COPD patients in stable condition (without exacerbation min 1 months ago)\n- Over 40 years\n- History of at least 10 pack-years of smoking\n\nAnalysis:\n- The patient is over 40 years old, which meets the age criterion.\n- The patient has a history of heavy smoking, which could potentially meet the \"at least 10 pack-years of smoking\" criterion, though \"heavy smoking\" would need to be quantified to ensure it meets the 10 pack-year threshold.\n- The patient's symptoms, cyanosis, and hyperinflated chest on x-ray suggest a possible diagnosis of COPD, but COPD is not specifically mentioned in the patient note. Therefore, a confirmed diagnosis of COPD is required to meet the trial's criteria.\n- The patient appears to be experiencing an acute exacerbation (as indicated by the use of home oxygen and recent onset of symptoms), which might not meet the \"stable condition\" criterion requiring no exacerbations in the past month.\n\nBased on the above, without further information confirming a COPD diagnosis and stability of the condition, the patient may not be eligible for the clinical trial. However, if the patient's heavy smoking history equates to at least 10 pack-years, and if a confirmed diagnosis of COPD in a stable condition is obtained, the patient could potentially meet the inclusion criteria. Therefore, further investigation is required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1049": {
        "output": "To determine the patient's eligibility for the clinical trial, let's compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial:\n\nPatient characteristics:\n- 63-year-old man\n- Cough and shortness of breath\n- History of heavy smoking\n- Diagnosed conditions: spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Family history of early-onset dementia\n- Use of home oxygen for the past 24 hours\n- Cyanotic, tachypneic, with a barrel-shaped chest and diffuse rales over his lungs\n- Chest x-ray: hyperinflation with no consolidation\n\nClinical trial inclusion criteria:\n- Diagnosis of stable COPD\n- 40 years or older\n- Smoking history of at least 10 pack-years\n- FEV1 \u2264 70 % of predicted value and FEV1 / FVC < 0.70\n- Dyspnea \u2265 2 on the MRC scale\n- At least 2 exacerbations requiring prednisone treatment in the past 3 years\n- Using a written action plan and having demonstrated adequate use of the self-administered antibiotic & prednisone\n- Already on Advair BID as a maintenance therapy or able to switch over to Advair\n\nAssessment:\n- The patient's age and smoking history match the inclusion criteria.\n- The patient presents with symptoms that could indicate a COPD exacerbation (cough, shortness of breath, use of home oxygen, cyanosis, and tachypnea).\n\nHowever, there is no explicit mention of a COPD diagnosis in the patient's note, nor is there information about previous COPD exacerbations, use of a written action plan, or current maintenance therapy for COPD. Without this information, we cannot assume the patient has stable COPD or meets the specific COPD-related inclusion criteria for the trial.\n\nBased on the available information, it is not clear if the patient has stable COPD or meets other specific requirements such as the FEV1 values, MRC scale score, past exacerbations, or current use of Advair. Further investigation is required to determine the presence of COPD and other eligibility criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1050": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 63-year-old man\n- Presents with cough and shortness of breath\n- Heavy smoking history\n- Past medical history of spinal stenosis, diabetes, hypothyroidism, and mild psoriasis\n- Symptoms: productive cough, purulent sputum, difficulty breathing, using home oxygen\n- Examination: cyanotic, tachypneic, barrel-shaped chest, diffuse rales over lungs\n- Chest x-ray: hyperinflation with no consolidation\n\nClinical Trial Inclusion Criteria:\n- Signature of informed consent\n- COPD patients with age ranging from 50 to 85 years old\n- Patients with at least a history of COPD of one year\n- COPD patients clinically stable in the last three months\n- COPD subjects with Forced Expiratory Volume at one second (FEV1) < 50% of predicted value\n- COPD subjects with Residual Volume (RV) > 125% predicted value\n- FEV1/Forced Vital Capacity (FVC) < 88% (males) or < 89% (females) of Low Levels of Normality (LLN)\n- COPD former or active smokers with at least a smoking history of 20 pack years\n\nAssessment of Eligibility:\n- The patient falls within the age range (50-85 years old).\n- The patient has a heavy smoking history, which may indicate a smoking history of at least 20 pack-years.\n- The patient's symptoms and chest x-ray findings suggest COPD, which is characterized by hyperinflation and flow limitation.\n- The note does not mention a confirmed diagnosis of COPD, nor does it provide FEV1, RV, or FEV1/FVC values.\n\nGiven the information, the patient's history of heavy smoking and symptoms suggestive of COPD, along with the age requirement being met, indicate that he might be eligible for the trial. However, a confirmed diagnosis of COPD and specific pulmonary function test results are necessary to definitively determine eligibility.\n\nTherefore, without additional information to confirm the diagnosis of COPD and the specific pulmonary function test results, the patient's eligibility for this clinical trial is uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1051": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can proceed with the following assessment:\n\nThe patient is a 63-year-old man with a history of heavy smoking, which is suggestive of a possible diagnosis of COPD, especially given his symptoms of cough, shortness of breath, and the use of home oxygen. The chest x-ray findings of hyperinflation without consolidation could also be consistent with COPD. However, the diagnosis of COPD is not explicitly stated in the patient note.\n\nThe inclusion criteria for the clinical trial are for ex-smokers with moderate to severe COPD. While the patient has a significant smoking history, which could meet the \"ex-smokers (> 10 packets-year)\" part of the criteria, there is no clear indication of a COPD diagnosis, nor is there an assessment of the severity of the disease (moderate to severe) in the patient note.\n\nTherefore, before referring the patient for the clinical trial, further investigation would be needed to confirm the diagnosis of COPD and to determine the severity of the condition. If the patient is indeed found to have moderate to severe COPD, he may then meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1052": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease,\" we will compare the patient's clinical notes with the inclusion criteria of the trial.\n\nPatient note assessment:\n- The patient is a 63-year-old man, which fits the age criterion of \u226540 years old.\n- The patient presents with cough, shortness of breath, and has been using home oxygen for the past 24 hours, which could indicate an acute exacerbation of a respiratory condition.\n- The patient has a history of heavy smoking, which is a risk factor for chronic obstructive pulmonary disease (COPD).\n- The patient's chest x-ray shows hyperinflation but no consolidation, which is consistent with COPD rather than pneumonia.\n- The patient is cyanotic and tachypneic, which are signs that could be associated with an acute exacerbation of COPD.\n\nClinical trial inclusion criteria:\n- Hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease\n- Age \u2265 40 years old\n\nBased on the information provided in the patient note, the patient has symptoms that are consistent with an acute exacerbation of COPD, he is within the correct age range, and the note implies that his condition has worsened, potentially requiring hospitalization. However, the patient note does not explicitly confirm a diagnosis of COPD.\n\nGiven that the patient's symptoms and history are highly suggestive of COPD and he meets the age criterion, the next step would typically be to confirm the diagnosis of COPD. If the patient is indeed experiencing an acute exacerbation of COPD and requires hospitalization, he would be a candidate for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1053": {
        "output": "Assessing the patient's eligibility for the clinical trial involves matching the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 63-year-old man\n- Symptoms: cough and shortness of breath\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, mild psoriasis\n- Family history: early onset dementia\n- Current condition: cyanotic, tachypneic, hyperinflation noted on chest x-ray\n\nClinical trial inclusion criteria:\n- Post-bronchodilator FEV1/FVC ratio less than 0.7\n- Stable phase of COPD\n- Specific exposures (either to silica dust or polycyclic aromatic hydrocarbons exhaust for non-smokers or a history of tobacco smoking without occupational exposure)\n- COPD risk factor exposure duration not less than 12 months\n- Male\n- Caucasian\n- Age of 40 - 75 years old\n\nThe patient's age (63) and gender (male) match the inclusion criteria. The patient's history of heavy smoking is consistent with the inclusion criteria for a history of tobacco smoke exposure. The patient's shortness of breath and cough, along with the use of home oxygen, suggest the possibility of COPD, but we do not have evidence of a post-bronchodilator FEV1/FVC ratio less than 0.7 nor confirmation of the stable phase of COPD. \n\nHowever, we lack specific information on whether the patient is in a stable phase of COPD and the actual FEV1/FVC ratio. Furthermore, we would need to confirm his racial background (Caucasian) to ensure full compliance with the criteria.\n\nGiven the information provided, the patient has a history of tobacco smoke exposure, which is a risk factor for COPD and is within the correct age range, but we do not have enough information regarding his diagnosis and the specific criteria related to lung function and disease stability.\n\nTherefore, the patient may potentially be eligible for the trial, but further medical evaluation and specific diagnostic information would be required before a definitive decision can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1054": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion and exclusion criteria, let's assess the patient's eligibility:\n\nPatient note review:\n- The patient is a 63-year-old man.\n- Presenting with cough and shortness of breath.\n- Past medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n- Symptoms consistent with a respiratory infection.\n- No clear indication of COPD (Chronic Obstructive Pulmonary Disease) diagnosis from the patient note.\n\nClinical trial inclusion criteria review:\n- Clinical and spirometric diagnosis of COPD.\n- For the study group: clinical symptoms of exacerbation and infection of the lower airway.\n- Signed informed consent.\n\nClinical trial exclusion criteria review:\n- Treatment with antibiotic more than 2 days before consultation.\n- Another known pulmonology entity other than COPD.\n- Chronic treatment with oral corticosteroids or immunosuppressive drug.\n- Severe organ comorbidity such as advanced or terminal phase cancer, significant pulmonary tuberculosis, severe pneumoconiosis.\n- Severe alteration of nutritional status.\n- Evolved heart disease.\n- Limitation for understanding the study.\n\nGiven that the patient does not have a documented diagnosis of COPD, which is a primary requirement for inclusion in the trial, the patient does not meet the inclusion criteria. There is no mention of spirometric testing or a clinical diagnosis of COPD in the patient's note, which are necessary to establish eligibility for this trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1055": {
        "output": "Considering the patient note and the inclusion criteria for the clinical trial titled \"A P3 Comparator Trial in Community Acquired Bacterial Pneumonia,\" let's go through the criteria one by one:\n\n1. Adults aged 18 to 85, inclusive: The patient is 63 years old, so he meets this criterion.\n2. Has given written, informed consent: This is not mentioned in the patient note, but it's a procedural step that could be fulfilled if the patient agrees.\n3. Has acute illness with onset within previous 7 days: The patient's symptoms began about a week prior, which meets this criterion.\n4. Has at least 2 of the following symptoms: The patient has difficulty breathing and cough, meeting this requirement.\n5. Has at least 2 vital sign abnormalities:\n   - The patient is tachypneic, which meets one of the criteria.\n   - The patient is cyanotic, which could indicate hypoxemia (room air SaO2 < 90%); however, specific vital signs like temperature, blood pressure, heart rate, and oxygen saturation are not provided. We would need to confirm these details.\n6. Has at least one other clinical or laboratory abnormalities: The patient has diffuse rales, which could indicate pulmonary consolidation, but a definitive consolidation is not mentioned. The patient's chest x-ray shows hyperinflation but no consolidation.\n7. Has new lobar or multi-lobar infiltrates on chest radiograph: The chest x-ray note does not mention new lobar or multi-lobar infiltrates; it only mentions hyperinflation.\n8. Has CURB-65 risk category 1 to 4: The CURB-65 score is not calculated in the patient note, and we lack specific information required to calculate it (like confusion status, urea level, respiratory rate, blood pressure, and age). The patient's age gives him 1 point, but other data points are missing.\n\nBased on the patient note and the inclusion criteria provided, there are some criteria that the patient appears to meet, but there are uncertainties and missing information regarding vital sign abnormalities, specific chest x-ray findings, and CURB-65 risk category. Therefore, further investigation would be needed to accurately determine the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1056": {
        "output": "The patient is a 63-year-old man presenting with a cough and shortness of breath. His medical history includes heavy smoking, which is relevant to the clinical trial's target condition, COPD. The patient shows symptoms consistent with an acute exacerbation of a chronic respiratory condition (productive cough, purulent sputum, difficulty breathing, use of home oxygen, cyanosis, tachypneic, barrel-shaped chest, diffuse rales, and hyperinflation on chest x-ray).\n\nNow, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\n1. Age: The patient is 63 years old, which fits within the trial's age criteria of 50 to 75 years old.\n2. Gender: The patient is male, and the trial includes both male and female participants.\n3. Diagnosis: The patient's symptoms suggest an acute exacerbation of a chronic respiratory condition, likely COPD, although COPD is not explicitly mentioned in the patient's note.\n4. Smoking status: The patient has a history of heavy smoking. The clinical trial specifies a \"non-smoker\" criterion; however, it does not clarify if it refers to current smokers or includes past smokers as well.\n5. FEV1: There is no information provided about the patient's FEV1.\n6. Acute exacerbation of COPD: The patient appears to be experiencing an acute exacerbation, as indicated by difficulty breathing and the need to use home oxygen. However, the timing of the onset is not specified as within 24-48 hours before treatment, which is required by the trial criteria.\n\nThe primary concern here is the lack of explicit diagnosis of COPD in the patient's note and the unclear definition of \"non-smoker\" in the trial's criteria. Additionally, without the FEV1 values and specific onset timing of the exacerbation, we cannot conclusively determine the patient's eligibility.\n\nGiven these points, further investigation would be needed to determine if the patient's chronic respiratory condition is indeed COPD, to clarify the smoking status requirement, to measure the patient's FEV1, and to confirm the timing of the exacerbation onset. \n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1057": {
        "output": "To determine the patient's eligibility for the clinical trial, let's review the inclusion criteria against the patient's clinical information:\n\nInclusion Criteria:\n1. Post-bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7\n2. Stable phase of COPD\n3. History of exposure to respirable silica dust, nonsmokers with no of passive exposure to tobacco smoke or history of exposure to aromatic hydrocarbons, nonsmokers with no of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure\n4. COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months\n5. Male\n6. Caucasian\n7. Age of 40 - 75 years old\n\nPatient Information:\n- 63-year-old Caucasian male\n- Presents with cough and shortness of breath\n- History of heavy smoking\n- No explicit mention of a COPD diagnosis or FEV1/FVC ratio\n\nWhile the patient's history of heavy smoking aligns with one of the risk factors described in the trial's inclusion criteria, and the patient's age, gender, and ethnicity fit the demographic requirements, there is no explicit mention of a COPD diagnosis or FEV1/FVC ratio. Moreover, the patient is currently experiencing acute symptoms (cough, shortness of breath), which may not align with the \"stable phase of COPD\" required. Since there is a lack of specific information regarding a COPD diagnosis and the stability of the condition, further investigation would be needed to determine eligibility.\n\nTherefore, based on the available information, the trial-level eligibility for the patient would be:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1058": {
        "output": "Considering the patient's note and the inclusion criteria for the clinical trial, let's evaluate the eligibility:\n\n1. COPD diagnosis and severity:\n   - The patient presents with symptoms that could be indicative of COPD, such as cough, shortness of breath, and a history of heavy smoking. However, there is no explicit mention of a COPD diagnosis or evidence of airflow obstruction in the patient's note.\n\n2. Exacerbation History:\n   - The patient's note does not mention a history of COPD exacerbations resulting in prescription for antibiotics and/or oral corticosteroids or hospitalisation.\n\n3. Existing COPD maintenance treatment:\n   - There is no information on the patient receiving daily maintenance treatment for COPD.\n\n4. Tobacco use:\n   - The patient has a notable history of heavy smoking which meets the criteria for tobacco use.\n\n5. Sex and Age:\n   - The patient is a 63-year-old man, which fits the age criterion for inclusion.\n\n6. Ability to give consent:\n   - There is no information in the patient's note that suggests he is unable to give consent, but this would need to be confirmed.\n\n7. Corrected ECG QT interval:\n   - The patient's note does not provide information about ECG QT intervals.\n\nBased on the information provided, the patient's eligibility for the trial is uncertain due to the lack of explicit mention of a COPD diagnosis, the absence of a documented exacerbation history, and no indication of receiving COPD maintenance treatment. The patient would not be referred to this clinical trial based on the information available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1059": {
        "output": "",
        "label": 2
    },
    "1060": {
        "output": "",
        "label": 1
    },
    "1061": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers,\" we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 63-year-old man\n- Symptoms: cough, shortness of breath, productive cough with purulent sputum, difficulty breathing, using home oxygen\n- Medical history: heavy smoking, spinal stenosis, diabetes, hypothyroidism, psoriasis\n- No fever reported\n- Physical examination: cyanosis, tachypnea, barrel-shaped chest, diffuse rales over lungs\n- Chest x-ray: hyperinflation with no consolidation\n\nClinical Trial Inclusion Criteria for COPD Subjects:\n- Aged between 40 and 75 years at the time of signing the informed consent (patient meets this criterion)\n- Diagnosis of COPD as defined by ATS/ERS guidelines (patient likely meets this criterion given his symptoms and smoking history, but COPD diagnosis is not explicitly stated in the patient note)\n- Symptoms compatible with COPD for at least 1 year prior to screening (patient likely meets this criterion)\n- Post-bronchodilator spirometry readings required for COPD diagnosis (FEV1/FVC ratio <0.7 and FEV1 \u226540 % and \u226480 % of predicted; not provided in patient note)\n- If a smoker, must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of \u2265 5 pack years (patient likely meets this criterion)\n\nClinical Trial Exclusion Criteria for COPD Subjects:\n- Upper or lower respiratory tract infection within 4 weeks of the screening visit (patient does not seem to meet this criterion as no infection is mentioned)\n- Positive test for alcohol at screening (not applicable as alcohol use is not mentioned)\n- Unable to produce a total weight of at least 0.1g of selected sputum at screening (cannot be determined from the patient note)\n- Mentally or legally incapacitated (patient does not seem to meet this criterion)\n- Employee of the Sponsor or CRO, or a relative (not applicable as no employment information is provided)\n- History of life-threatening COPD including ICU admission and/or requiring intubation (not stated in the patient note)\n- Taking theophylline, oral steroids, or change in COPD medication in the 28 days before screening (not stated in the patient note)\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria for COPD subjects (age, likely diagnosis of COPD, and history of heavy smoking). However, the actual diagnosis of COPD and the required spirometry results are not explicitly confirmed in the patient note. Additionally, the patient is currently experiencing respiratory symptoms that may or may not be related to an infection, which could potentially exclude him if confirmed.\n\nSince there is insufficient information to definitively determine the patient's COPD status and other relevant details, further investigation would be needed before referring this patient to the clinical trial. However, the patient's symptoms and history of heavy smoking suggest a high possibility of COPD, which aligns with the trial's target population.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1062": {
        "output": "Based on the information provided, the patient note describes a 63-year-old man with symptoms consistent with Chronic Obstructive Pulmonary Disease (COPD), such as cough, shortness of breath, cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over his lungs, along with a history of heavy smoking which is a risk factor for COPD.\n\nThe clinical trial titled \"MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD\" is seeking to evaluate a new service delivery model for COPD care. The inclusion criteria for the trial are fairly broad:\n\n- Male or Female, aged 18 years or above.\n- Attended the MISSION clinic as a patient.\n- Participant is willing and able to give informed consent for participation in the study.\n\nThe patient in the note appears to meet the age requirement and is presenting with a condition (COPD) that is the focus of the study. The inclusion criteria do not specify the need for a formal diagnosis of COPD by a healthcare provider, nor do they mention any specific symptoms or severity of disease required for participation. Given that the patient's symptoms are highly suggestive of COPD and there are no exclusion criteria that would disqualify him based on the information given, he appears to be a suitable candidate for the clinical trial, assuming he has attended or will attend the MISSION clinic and is willing to give informed consent.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1063": {
        "output": "",
        "label": 0
    },
    "1064": {
        "output": "",
        "label": 1
    },
    "1065": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 63-year-old man, which satisfies the age criterion of \u2265 18 years.\n- The patient's medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. There is no mention of Multiple Sclerosis (MS).\n- The patient presents with respiratory symptoms indicative of a pulmonary issue, not an MS exacerbation.\n\nClinical Trial Inclusion Criteria:\n- Male or Female \u2265 18 years of age.\n- Patient has a clinically definite relapsing form of Multiple Sclerosis according to McDonald Criteria (2010 revision).\n- Patient with an acute MS exacerbation as determined by their treating clinician.\n- Patient planning to initiate Acthar Gel for the treatment of an acute MS exacerbation.\n- Patient capable of providing informed consent.\n\nComparison:\n- The patient meets the age criterion.\n- There is no evidence in the patient note that suggests he has been diagnosed with Multiple Sclerosis, let alone a relapsing form as required by the McDonald Criteria.\n- The patient is currently experiencing respiratory issues, not an acute MS exacerbation.\n- There is no mention of the patient planning to initiate Acthar Gel treatment.\n\nBased on the comparison, the patient does not meet the critical inclusion criteria related to having a clinically definite relapsing form of Multiple Sclerosis and experiencing an acute MS exacerbation. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1066": {
        "output": "The patient is a 33-year-old male who presented with acute abdominal pain due to a spleen rupture, which is an emergency medical condition and requires immediate treatment. The clinical trial in question is for the mobilization of Peripheral Blood Progenitor Cells (PBPC) in normal donors using filgrastim.\n\nFor the clinical trial, the inclusion criteria are as follows:\n- Eligible to be PBPC donor for allogeneic transplantation as determined by local institution\n\nAnd the exclusion criteria are:\n- History of splenectomy\n- Previous PBPC mobilization attempts\n- Previous treatment with GCSF or GMCSF\n\nGiven the patient's current medical emergency (spleen rupture), he is not in a condition to be considered a \"normal donor\" for PBPC mobilization. Additionally, the trial aims to evaluate the spleen during PBPC mobilization, and since the patient has a ruptured spleen, he would not be able to participate in the study. Furthermore, he might require a splenectomy as part of his treatment, which would also exclude him from the trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, and the emergency nature of his condition makes him unsuitable as a trial participant. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1067": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the criteria for participation in the \"Tenecteplase Pulmonary Embolism Italian Study.\"\n\nThe patient presented with acute abdominal pain due to a spleen rupture from a bike accident, which is unrelated to pulmonary embolism (PE) and right ventricular dysfunction (RVD). Furthermore, the inclusion criteria for the trial specify that patients must have symptomatic PE confirmed by specific diagnostic tests, normal blood pressure (SBP >100mmHg), and RVD at echocardiography. The patient's current health issues do not align with these requirements, notably their low blood pressure (BP: 60/30 mmHg) and the absence of any mention of PE or RVD.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1068": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 33-year-old male athlete.\n- Presented with acute abdominal pain.\n- Suffered blunt trauma to the abdomen from a bike accident a week prior.\n- Has had mild abdominal pain since the day of the accident.\n- Current vital signs indicate a state of shock (BP: 60/30 mmHg, HR: 140/min).\n- Physical examination shows muscle contraction and resistance in the abdomen.\n- Emergency ultrasound and CT scan reveal extended intraperitoneal hemorrhage due to spleen rupture.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients with life-threatening vital problems (respiratory, circulatory, or neurologically compromised).\n- Circulatory criteria include a pulse > 120/min and blood pressure < 100 mmHg, which the patient meets.\n- Patients with a revised trauma score under 12.\n- Patients with signs of fractures from at least two long bones.\n- Patients with clinical signs of flail chest/multiple rib fractures.\n- Patients with a clinically evident pelvic rim fracture.\n- Patients with signs of unstable vertebral fractures or signs of neural cord compression.\n- Patients involved in a high-energy injury mechanism, such as a fall from height (> 3 m) or as declared by prehospital emergency medical services.\n\nThe patient has life-threatening circulatory problems, as indicated by the very low blood pressure and high heart rate, and was involved in a high-energy injury mechanism (bicycle accident). While the patient does not specifically meet the criteria of a fall from height, the circumstances of the bike accident leading to blunt trauma could be interpreted as a high-energy injury mechanism.\n\nGiven that the patient's condition aligns with multiple inclusion criteria, particularly life-threatening vital problems and involvement in a high-energy injury mechanism, the patient would be a candidate for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1069": {
        "output": "Based on the patient note and the clinical trial information provided, we can assess the patient's eligibility for the trial titled \"Rituximab as Second Line Treatment for ITP\" by comparing the patient's characteristics and situation with the inclusion and exclusion criteria of the trial.\n\nPatient Note Summary:\n- 33-year-old male athlete\n- Presented with acute abdominal pain after a bike accident\n- Suffered blunt trauma to the left hemi-abdomen a week earlier\n- Extended intraperitoneal hemorrhage due to spleen rupture\n- No mention of Immune thrombocytopenic purpura (ITP) or any treatment with prednisolone\n- There is also no mention of the patient's platelet count\n\nClinical Trial Inclusion Criteria Summary:\n- Patients diagnosed with ITP\n- Platelet count <30 x 10^9/L after 2 weeks of treatment with prednisolone, or during the tapering period, with some exceptions for counts between 30-50\n- Subject is over 18 years of age\n- Informed consent provided\n- Ability to understand and comply with protocol\n- If female and of fertile age, willingness to use contraceptive methods for 6 months following the study drug administration\n\nClinical Trial Exclusion Criteria Summary:\n- Previous splenectomy, among other treatments\n- Underlying or past malignancy (except skin carcinoma)\n- Pregnancy or lactation\n- Short expected survival\n- Intolerance to murine antibodies\n- Unwillingness to use contraception by fertile females\n- Certain infections and immune deficiencies\n- Involvement in another drug treatment trial\n- Certain severe medical conditions\n\nThe patient in the note has suffered a spleen rupture, which is not related to having ITP or being treated for it. There is no indication that the patient has ITP or has been treated with prednisolone. Therefore, the patient does not meet the key inclusion criteria for the clinical trial regarding the diagnosis of ITP and the specific treatment requirements.\n\nGiven that the patient does not have the disease of interest (ITP) and does not meet the inclusion criteria, we would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1070": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, the patient in question does not meet the criteria for the following reasons:\n\n1. The clinical trial is focused on asymptomatic pediatric trauma patients, where \"pediatric\" is typically defined as patients who are 0 to 15 years old.\n2. The patient described in the note is a 33-year-old male, which exceeds the age limit for the pediatric definition.\n3. The patient is symptomatic, presenting with acute abdominal pain and other signs of distress such as low blood pressure and high heart rate, as well as findings of intraperitoneal hemorrhage due to spleen rupture on imaging. This does not align with the trial's focus on asymptomatic patients.\n\nGiven these points of disqualification, the patient is not eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1071": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Nicotine Patch as an Analgesic Adjuvant After Surgery,\" we must examine the provided patient note against the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n- Adult ASA 1-2\n\nThe ASA physical status classification system is a system for assessing the fitness of patients before surgery. In general terms:\n- ASA 1: A normal healthy patient.\n- ASA 2: A patient with mild systemic disease.\n\nThe patient note describes:\n- A 33-year-old male athlete with acute abdominal pain due to a spleen rupture following a bike accident.\n- The patient's history is negative for smoking, drugs, and alcohol.\n- The patient is in a critical state, indicated by low blood pressure (BP: 60/30 mmHg) and high heart rate (HR: 140/min), which suggests hemodynamic instability.\n\nGiven the acute nature of the patient's condition, the description of the patient's current state (hemodynamically unstable due to spleen rupture and extended intraperitoneal hemorrhage), they would not be classified as ASA 1 or 2. Patients with such acute conditions are likely to be ASA 3 or higher, indicating severe systemic disease or a life-threatening condition.\n\nTherefore, based on the provided information, this patient would not meet the inclusion criteria for the clinical trial, which is looking for patients who are classified as ASA 1-2 and presumably stable enough to undergo surgery and receive a nicotine patch as an analgesic adjuvant.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1072": {
        "output": "The patient in the note is a 33-year-old male athlete who presented to the ER with acute abdominal pain following a fall from his bike, which caused blunt trauma to the abdomen. The patient's condition has led to a spleen rupture causing intraperitoneal hemorrhage. There is no indication in the patient note of diabetes, familial pancreatic cancer, Peutz-Jeghers syndrome, or any suspicion of pancreatic cancer that would qualify him for the clinical trial in question.\n\nThe clinical trial is looking for participants who are at high risk for pancreatic adenocarcinoma, with specific inclusion criteria that do not match the patient's condition. The inclusion criteria for the trial are:\n\n1. Persons 50 years or older with recently diagnosed diabetes (within 2 years), with at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum CA 19-9, or those undergoing EUS with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.\n2. Persons 35 years old or older with familial pancreatic cancer with 2 or more first-degree relatives with pancreatic cancer.\n3. Persons 35 years old or older with Peutz-Jeghers syndrome.\n4. Persons 35 years old or older with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.\n\nThe patient does not meet any of the above criteria. He is not over 50 years old, there is no mention of recent diabetes diagnosis or pancreatic cancer risk factors, and the condition he presents with (spleen rupture) is unrelated to the focus of the trial, which is pancreatic adenocarcinoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1073": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Functional Outcome After Incisional Hernia Repair: Open Versus Laparoscopic Repair,\" the patient does not appear to be eligible for this clinical trial. The inclusion criteria specifically mention the study is for male patients aged over 18 years with a diagnosis of reducible incisional hernias up to 200 cm\u00b2 who are medically fit for general anesthesia. \n\nThe patient in question presented with acute abdominal pain due to a spleen rupture following a blunt trauma, which is not related to an incisional hernia. Furthermore, there is no mention of the patient having an incisional hernia or being a candidate for elective surgery for hernia repair. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1074": {
        "output": "Reviewing the patient note and the clinical trial inclusion and exclusion criteria provided:\n\nPatient note:\n- A 33-year-old male athlete with acute abdominal pain due to spleen rupture following blunt trauma\n- No history of smoking, drugs, or alcohol\n- Suffering from extended intraperitoneal hemorrhage\n\nClinical trial:\n- Focuses on hyperthermic intraperitoneal oxaliplatin for peritoneal malignancies\n- Requires histologic proof of peritoneal metastases\n- Allows previous chemotherapy and/or immunotherapy but not peritoneal chemotherapy\n- Requires complete tumor resection to be possible\n- Karnofsky performance score of \u2265 80%\n- Adequate hematologic, renal, and hepatic function\n- Must be at least 18 years of age\n- Ability to provide informed consent\n- Excludes patients with metastatic disease outside the peritoneal cavity, diagnosis of mesothelioma, sensory neuropathy, allergic reaction to platinum compounds, pregnant or lactating women, previous peritoneal chemotherapy, uncontrolled concurrent medical problems, or history of uncontrolled cardiovascular disease\n\nThe patient described in the note does not have peritoneal malignancies but is suffering from an acute condition due to a spleen rupture. The clinical trial is specifically for patients with peritoneal cancer, and thus, this patient does not meet the inclusion criteria.\n\nBased on the information provided, the patient is not eligible for the clinical trial mentioned. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1075": {
        "output": "Based on the information provided, the 33-year-old male athlete presents with acute abdominal pain due to a spleen rupture caused by blunt trauma. The clinical trial in question is focused on comparing the efficacy and safety of Ertapenem versus Ampicillin-Sulbactam in patients with community-acquired intra-abdominal infections (IAI) of mild to moderate severity that require surgical intervention within 24 hours of diagnosis.\n\nThe inclusion criteria specify various types of IAI, including intra-abdominal abscess (including of liver and spleen). Since the patient has a spleen rupture with extended intraperitoneal hemorrhage, which can be classified under intra-abdominal abscess due to the spleen injury, he fulfills the criteria that require the patient to have a localized IAI infection, mild to moderate in severity, and needing surgical intervention within 24 hours.\n\nGiven this information, the patient appears to meet the inclusion criteria of the clinical trial. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1076": {
        "output": "Upon reviewing the patient's information and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient's condition:\n- 33-year-old male\n- Acute abdominal pain due to trauma (fall off his bike)\n- Spleen rupture with extended intraperitoneal hemorrhage\n- No mention of thrombocytopenia, microangiopathic hemolytic anemia, or any other indication of thrombotic microangiopathy (TMA)\n- The patient's symptoms are acute and related to a physical injury rather than a systemic disease process like TMA\n\nClinical trial inclusion criteria:\n- Male or female; 18 to 75 years of age\n- Diagnosis of TMA based on the presence of thrombocytopenia, microangiopathic hemolytic anemia, and absence of other causes for these conditions\n- No use of unlicensed investigational agent 30 days prior to randomization\n- Must be capable of understanding and complying with the protocol\n\nThe patient does not meet the clinical trial inclusion criteria as there is no indication of TMA based on the information provided. The patient's acute condition is a result of physical trauma leading to spleen rupture, not thrombotic microangiopathy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1077": {
        "output": "",
        "label": 0
    },
    "1078": {
        "output": "The patient note describes a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture following a bike accident. The patient requires emergency intervention for the spleen rupture, which could potentially lead to a splenectomy.\n\nThe clinical trial in question is investigating the use of anticoagulation therapy post laparoscopic splenectomy to prevent splenic/portal vein thrombosis. The inclusion criteria for this trial are:\n\n1. Scheduled to undergo laparoscopic splenectomy at The University of Alberta or Grey Nun's Community Hospitals\n2. Capable of understanding the purpose and risks of the study and willing/able to sign a statement of informed consent\n3. Willing to undergo daily subcutaneous injections of Lovenox\u00ae\n\nBased on the information provided in the patient note, the patient has not yet undergone a splenectomy, but given the severity of their condition (extended intraperitoneal hemorrhage due to spleen rupture), it is possible that a splenectomy could be in their immediate treatment plan. However, the trial is specific to laparoscopic splenectomy conducted at The University of Alberta or Grey Nun's Community Hospitals, and there is no information about where this patient is being treated or whether they will be undergoing a laparoscopic splenectomy specifically.\n\nGiven that the patient's treatment details are not entirely clear from the note, and we don't have confirmation that the patient will have a laparoscopic splenectomy or that it would be at the specified hospitals, I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1079": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, it's clear that the patient does not meet the eligibility requirements for the clinical trial in question. The trial is specifically targeted at patients with Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis, whereas the patient in the note is an adult with a traumatic spleen rupture unrelated to Cystic Fibrosis. Additionally, the age range for the trial is 1 month to 6 years, which does not match the patient's age of 33 years. Therefore, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1080": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient in the note does not seem to be eligible for the clinical trial. The trial is specifically targeting patients who have undergone a splenectomy at National Taiwan University Hospital in the last 20 years. The patient in question presented with acute abdominal pain due to a spleen rupture from a recent trauma, and there is no indication that the patient underwent a splenectomy or that the procedure was performed at National Taiwan University Hospital. Additionally, the trial seems to be focused on the long-term follow-up of patients who have had a splenectomy, rather than acute trauma cases.\n\nTherefore, the assessment of the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1081": {
        "output": "Given the patient note, we have a 33-year-old male presenting with acute abdominal pain following a bike accident that resulted in blunt trauma to the abdomen and a spleen rupture. The patient's condition meets the following inclusion criteria of the clinical trial:\n\n- Age > 18\n- Abdominal pain > 2h and < 7 days (the patient has had mild abdominal pain since the accident, which occurred a week earlier; however, the acute presentation to the ER suggests that the severity may have increased within the threshold for the trial)\n\nConsidering the patient meets both age and timing criteria for the CT trial of the acute abdomen, and his acute presentation is related to the abdomen with a confirmed pathology via imaging (spleen rupture), the patient appears to be a suitable candidate for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1082": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient would not be eligible for the clinical trial in question. The patient presented with acute abdominal pain due to a spleen rupture caused by a biking accident, while the clinical trial is focused on pain management after laparoscopic cholecystectomy in patients with symptomatic gallstones.\n\nThe inclusion criteria for the trial are:\n\n1. Diagnosis of symptomatic gallstones requiring laparoscopic cholecystectomy.\n2. Elective surgical procedure.\n3. American Society of Anesthesiologists class I and II.\n\nThe patient note does not indicate that the patient has symptomatic gallstones or that they are undergoing an elective laparoscopic cholecystectomy. Additionally, the patient's current condition (acute abdominal pain due to spleen rupture) is not related to the condition being studied in the trial (postoperative pain after laparoscopic cholecystectomy).\n\nTherefore, the patient does not meet any of the inclusion criteria for the clinical trial, and I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1083": {
        "output": "Based on the information provided, the patient is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture following a bicycle accident. There is no mention of liver cirrhosis, portal hypertension, or secondary hypersplenism in the patient's history. The clinical trial in question is specifically looking for patients with liver cirrhosis accompanied by portal hypertension and secondary hypersplenism who are undergoing elective azygoportal disconnection and splenectomy.\n\nSince the patient's condition (spleen rupture due to trauma) does not align with the inclusion criteria of the clinical trial (liver cirrhosis with portal hypertension and secondary hypersplenism), the patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1084": {
        "output": "Based on the patient note provided, the 33-year-old male athlete does not meet the inclusion criteria for the clinical trial titled \"Laparoscopic or Conventional Mesh Repair of Incisional and Umbilical Hernia.\" The patient presented with acute abdominal pain due to a spleen rupture from blunt trauma, but there is no mention of an incisional or umbilical hernia, which is a requirement for the study.\n\nThe inclusion criteria for the trial are:\n\n1. Age > 18\n2. Incisional or umbilical hernia over 2 cm and less than 6 cm in diameter\n\nThe patient's condition (spleen rupture) does not match the conditions being studied in the trial (incisional and umbilical hernia).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1085": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 33-year-old male athlete does not appear to be a candidate for the trial. The trial is focused on patients who have undergone cytoreductive surgery and are receiving intraperitoneal chemotherapy, with the intent of using Single-Photon Emission Computed Tomography (SPECT) to predict the feasibility of sequential postoperative intraperitoneal chemotherapy.\n\nThe patient presented with acute abdominal pain due to spleen rupture from a biking accident, which is unrelated to the conditions being studied in the trial (i.e., not a case where cytoreductive surgery and intraperitoneal chemotherapy are applicable). Therefore, it does not seem appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1086": {
        "output": "In this scenario, the patient is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture following blunt trauma from a bike accident. The patient's condition does not involve a traumatic rupture of the FDP-tendon in Zone II, which is the specific injury of interest in the clinical trial.\n\nThe clinical trial is specifically looking to assess the healing process of profound flexor tendon following suture due to traumatic rupture of FDP-tendon in Zone II. Since the patient's condition is unrelated to the injury required by the trial's inclusion criteria, they would not be eligible for participation in this study.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1087": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 33-year-old male, which meets the age criterion of being > 18 years old.\n- The patient has presented with nontraumatic acute abdomen due to an intraperitoneal hemorrhage from spleen rupture caused by a blunt trauma from a bicycle accident a week prior. This aligns with the requirement of nontraumatic acute abdomen.\n- The patient's weight is not mentioned, but given he is an athlete, there is no direct indication that he exceeds the weight limit of < 120kg.\n- The patient is capable of giving informed consent, assuming no other conditions are impairing his ability to understand and consent.\n- The ability to keep apnoea for 15s is not stated, but given his athletic background, it is possible that he could meet this requirement.\n- The fitness of the patient for participation in the study is to be determined by the surgeon in charge. The patient's current state (BP: 60/30 mmHg, HR: 140/min) indicates hemodynamic instability, which may make the surgeon consider him unfit for participation at this time.\n\nGiven the patient's critical condition, particularly the instability indicated by his vital signs, it is likely the surgeon may not consider the patient fit for participation in the study at this moment. As such, the decision to refer the patient would depend on his stabilization and the surgeon's assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1088": {
        "output": "",
        "label": 0
    },
    "1089": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussillon,\" the patient appears to be a match for the trial:\n\n1. The patient presented to the ER with acute abdominal pain following a bike accident with blunt trauma to the abdomen, which aligns with the trauma aspect of the inclusion criteria.\n2. The patient has a diagnosis of splenic contusion confirmed by CT scan, which meets the diagnostic criteria.\n3. The patient is hospitalized for abdominal trauma, which is part of the inclusion criteria.\n4. There is no information provided about the patient's consent or social security program status, which are also part of the inclusion criteria.\n\nHowever, assuming the patient can provide consent and is a beneficiary of or affiliated with a social security program, the patient would meet the inclusion criteria. Since there is no information to the contrary, it is reasonable to assume these conditions could potentially be met.\n\nTherefore, the patient would likely be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1090": {
        "output": "The patient in question is a 33-year-old male who presented with acute abdominal pain due to spleen rupture following blunt trauma from a bicycle accident. This patient's medical situation involves emergency care related to internal bleeding and spleen injury, which is not related to the conditions required for the clinical trial in question.\n\nThe clinical trial is focused on studying the impact of cranioplasty on cerebral perfusion in patients who have previously received a decompressive craniectomy due to severe head injuries, subarachnoid hemorrhage, intra-cerebral hemorrhage, cerebral dural sinus thrombosis, or malignant middle cerebral artery stroke.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients over 18 years of age up to 65 years.\n2. Patients receiving a decompressive craniectomy for the specified cerebral conditions.\n3. Patients informed about the study and giving consent.\n\nThe patient does not meet the inclusion criteria for the clinical trial as there is no mention of head injuries, cerebral conditions, or a decompressive craniectomy being performed or required. The patient's condition (spleen rupture) is not related to the cerebral conditions being studied in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1091": {
        "output": "",
        "label": 0
    },
    "1092": {
        "output": "Given the patient note and the clinical trial information provided, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- 33-year-old male\n- Acute abdominal pain due to spleen rupture from blunt trauma\n- No mention of Achilles tendon issues\n\nClinical trial inclusion criteria:\n- Acute rupture of the Achilles tendon\n- Older than 18 years of age\n- Firmed letter of approval\n- Patient speaks/understands German\n- Planned surgical treatment\n- No more than 48h after rupture\n\nThis patient does not fit the inclusion criteria for the clinical trial, as the patient's medical issue is related to a spleen rupture and not an Achilles tendon rupture. There is no indication in the patient's history or presentation that they have experienced an Achilles tendon rupture.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1093": {
        "output": "",
        "label": 2
    },
    "1094": {
        "output": "Given the patient note and the clinical trial information provided, the 33-year-old male patient does not meet the inclusion criteria for the trial. The clinical trial is specifically looking at pregnant patients with minor maternal trauma to determine if fetal fibronectin can predict delivery due to abruptio placenta. The patient in the note is a male and not pregnant, which immediately disqualifies him from participation in the study focused on pregnancy-related conditions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1095": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient in question is a 33-year-old male athlete who presented with acute abdominal pain due to spleen rupture following blunt trauma. This clinical trial is specifically looking for women who are having a caesarean section for the first time, who have not had previous lower abdominal surgery, who speak and understand Danish, and who can give informed consent.\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n\n1. The patient is male, and the study is specifically for women.\n2. The trial relates to caesarean sections, which are not applicable to this patient.\n3. There is no indication that the patient speaks and understands Danish or that he can provide informed consent at this time due to his medical condition.\n\nTherefore, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1096": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the clinical trial. The patient presented with acute abdominal pain due to spleen rupture from a blunt trauma accident, which is unrelated to the trial's focus on distal bicep tendon ruptures. The clinical trial is specifically interested in patients with a complete rupture of the distal bicep tendon, and there is no mention of this condition in the patient's note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1097": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for the clinical trial investigating the impact of CT on the diagnosis of acute appendicitis. The patient presented with acute abdominal pain due to spleen rupture, not acute appendicitis. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1098": {
        "output": "Given the patient's presentation with acute abdominal pain due to a spleen rupture following blunt trauma, and the clinical trial's focus on the surgical treatment of splenic artery aneurysms, the two are not directly related. The patient has suffered an acute injury leading to a spleen rupture, while the clinical trial is specifically looking at the treatment of splenic artery aneurysms, which is a different condition.\n\nThe inclusion criteria for the clinical trial specify that participants must have a splenic artery aneurysm of a certain size or associated risk factors. There is no indication in the patient's note that he has a splenic artery aneurysm; he has an intraperitoneal hemorrhage due to spleen rupture from trauma. Therefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1099": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 33-year-old male athlete\n- Presented with acute abdominal pain due to blunt trauma\n- History of spleen rupture\n- Negative history for smoking, drugs, and alcohol\n- Currently in a critical condition with low BP and high HR\n\nClinical Trial:\n- Focuses on distal pancreatectomy with partial splenectomy for pancreatic tumors\n- Patients must have solid or cystic neoplasms of the pancreas\n- No evidence of metastatic disease\n- No evidence of local invasion into surrounding organs\n- ECOG performance status <3\n- Age 18 years or greater\n- Participants will provide written informed consent\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial because:\n\n- The patient does not have a solid or cystic neoplasm of the pancreas; instead, he has an injury-related spleen rupture.\n- The clinical trial is specific to patients undergoing surgery for pancreatic tumors, not trauma-induced spleen injuries.\n\nTherefore, this patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1100": {
        "output": "Based on the provided patient note, the 33-year-old male athlete is suffering from acute abdominal pain due to a spleen rupture following blunt trauma. The clinical trial in question is studying pancreatectomy with and without the use of routine intraperitoneal drainage. The inclusion criteria for the clinical trial are:\n\n1. The subject has a surgical indication for distal pancreatectomy.\n2. In the opinion of the surgeon, the subject has no medical contraindications to pancreatectomy.\n3. At least 18 years of age.\n4. The subject is willing to consent to randomization to the intraperitoneal drain vs. no drain group.\n5. The subject is willing to comply with 90-day follow-up and answer quality-of-life questionnaires per protocol.\n\nThe patient's current medical issue is related to an emergency condition (spleen rupture) and not a condition that requires a distal pancreatectomy. Therefore, the patient does not meet the primary inclusion criteria for the trial, which specifically requires a surgical indication for distal pancreatectomy.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial, as the trial is focused on a different surgical procedure than the one the patient would be indicated for due to their spleen rupture.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1101": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note Summary:\n- 33-year-old male\n- Presented with acute abdominal pain after falling off a bike a week earlier\n- Current vital signs indicate a state of shock (BP: 60/30 mmHg, HR: 140/min)\n- Abdominal examination suggests muscle contraction and resistance\n- Ultrasound and CT scan show extended intraperitoneal hemorrhage due to spleen rupture\n\nClinical Trial Inclusion Criteria:\n- Men or women aged \u226518 but <76 years presenting with acute renal colic\n- Emergency department physician highly suspects a primary diagnosis of kidney stones, or the patient requires imaging to rule out kidney stones\n\nComparison:\n- The patient is within the age range for the trial (33 years old).\n- The patient presented with acute abdominal pain, but this is not related to renal colic; it's due to a traumatic spleen rupture.\n- There is no indication that the emergency department physician suspects kidney stones as the cause of this patient's symptoms.\n\nTherefore, the patient does not meet the specific inclusion criteria related to the primary diagnosis for the clinical trial, which is focused on kidney stones (renal colic).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1102": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient, a 33-year-old male athlete with acute abdominal pain due to spleen rupture, does not meet the criteria for the clinical trial in question. The clinical trial is assessing the role of serum total antioxidant level in preterm labor, which is specifically for pregnant individuals between the 28th and 37th week of pregnancy with intact amnion membranes. Since the patient is a male and not pregnant, he is clearly ineligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1103": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient appears to meet the criteria for the trial:\n\n1. The patient is a trauma patient (suffered blunt trauma with spleen rupture).\n2. The patient is undergoing management for a traumatic injury (presented to the ER with acute abdominal pain due to spleen rupture, requiring urgent care).\n3. The patient is 33 years old, which is above the age of 18, as required by the trial.\n4. The patient's life expectancy is not mentioned, but given that he is receiving emergency care in the ER, it is reasonable to assume that there is an intention to manage his injuries with an expectation of survival beyond 48 hours, unless otherwise stated.\n\nGiven this information, it would be reasonable to refer this patient for the clinical trial investigating the use of Seprafilm in open abdomen damage control management for trauma patients, as the patient fits the inclusion criteria provided.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1104": {
        "output": "Given the patient's presentation and the clinical trial's focus, let's assess the eligibility:\n\nPatient note analysis:\n- The patient is a 33-year-old male who has suffered blunt trauma leading to splenic rupture, not aortic rupture.\n- The patient is currently in an emergency situation with critical vital signs indicating hemorrhagic shock.\n- There is no mention of a thoracic aorta injury.\n\nClinical trial analysis:\n- The trial is focused on blunt traumatic rupture of the thoracic aorta.\n- The inclusion criteria specify cases with traumatic rupture of the thoracic aorta.\n- The patient in question has a ruptured spleen, not a ruptured thoracic aorta.\n\nConclusion:\nThe patient does not meet the inclusion criteria for the clinical trial as the trial is specific to traumatic rupture of the thoracic aorta, and the patient has a spleen rupture. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1105": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial.\n\nPatient note:\n- A 33-year-old male athlete with acute abdominal pain.\n- History of blunt trauma to the abdomen from a bike accident.\n- Spleen rupture causing extended intraperitoneal hemorrhage.\n- No history of smoking, drugs, or alcohol.\n\nClinical trial:\n- The trial is for Chinese chronic primary immune thrombocytopenia (ITP) patients.\n- Eligibility includes being diagnosed with ITP for at least 12 months and having a platelet count of <30 X109/L.\n- Patients must have had no response or relapsed after prior ITP therapy, including splenectomy.\n- No recent cardiac disease or arrhythmia.\n- No history of clotting disorder, other than ITP.\n- Certain blood count and chemistry range requirements.\n\nThe patient in the note does not mention having ITP or any related blood platelet count issues. The patient's acute condition relates to trauma from an accident, which is not related to ITP or the study's focus. There is no indication that the patient meets any of the specific inclusion criteria for the clinical trial.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial on eltrombopag for chronic ITP patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1106": {
        "output": "Based on the provided patient note, the 33-year-old male athlete who presented to the ER with acute abdominal pain due to a spleen rupture following a bike accident would be a candidate for the clinical trial titled \"Evaluation of Trauma Team Activation Criteria.\" The trial is focused on patients admitted with the trauma team and those with an Injury Severity Score (ISS) greater than 15. While the note does not specifically mention the ISS, the patient's condition involving a spleen rupture and the need for emergency intervention suggests a high likelihood of an ISS greater than 15.\n\nTherefore, this patient's situation aligns with the inclusion criteria of the clinical trial, which is concerned with trauma and the efficiency and effectiveness of trauma team activation. The patient was admitted with a trauma team, as indicated by the ER presentation and the severity of the injury. This assessment is based on the information provided and the assumption that the patient's condition warrants a high ISS.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1107": {
        "output": "The patient note describes a 33-year-old male athlete who presented to the ER with acute abdominal pain after falling off his bike, resulting in a spleen rupture with intraperitoneal hemorrhage. There is no mention of the patient having any form of myeloproliferative neoplasm (MPN), which includes polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The clinical trial's inclusion criteria specifically require a diagnosis of one of the three classical Philadelphia negative MPNs according to WHO or IWG-MRT criteria, as well as a palpable spleen of a certain size depending on the type of MPN.\n\nSince the patient in the note does not have a documented diagnosis of any of the MPNs required for the clinical trial, and the spleen rupture was due to trauma rather than an underlying hematological condition, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1108": {
        "output": "The patient is a 33-year-old male who presented with acute abdominal pain and a history of falling off his bike, resulting in blunt trauma to the left hemi-abdomen. The physical examination and imaging studies (ultrasound and CT scan) reveal an extended intraperitoneal hemorrhage due to spleen rupture. \n\nThe clinical trial is investigating the utility of pelvic CT imaging in blunt abdominal trauma patients. The inclusion criteria for the trial are:\n\n1. Age 3-60 years old\n2. Evaluated for blunt trauma with a GCS (Glasgow Coma Scale) of >14\n3. Order for CT abdomen and pelvis imaging\n\nThe patient note indicates that the patient is within the age range for the trial and has been evaluated for blunt trauma. The patient's GCS score is not explicitly stated, but the fact that he presented to the ER and underwent an emergency ultrasound and CT scan implies that he was alert and likely had a GCS score greater than 14. Given that the patient has already undergone CT imaging as part of his emergency evaluation, he meets the criteria for inclusion in the study.\n\nTherefore, it appears that the patient is eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1109": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- 33-year-old male athlete\n- Presented with acute abdominal pain after blunt trauma from a bike fall\n- Suffered blunt trauma to the left hemi-abdomen with subsequent mild abdominal pain\n- Found to have extended intraperitoneal hemorrhage due to spleen rupture\n- No mention of blunt aortic injury (BAI)\n\nClinical Trial Inclusion Criteria Analysis:\n- Clinical diagnosis of blunt aortic injury (BAI)\n\nThe patient presented with acute abdominal pain and spleen rupture due to a biking accident, which is not consistent with the clinical diagnosis of blunt aortic injury. There is no mention of aortic injury in the patient's note. Therefore, based on the information given, the patient does not meet the inclusion criteria for the clinical trial that is focused on patients with a clinical diagnosis of blunt aortic injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1110": {
        "output": "Based on the patient note, the 33-year-old male athlete who presented with acute abdominal pain due to spleen rupture following a bicycle accident does not meet the inclusion criteria for the clinical trial titled \"The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia\". The clinical trial is specifically for patients with primary immune thrombocytopenia (ITP), a condition characterized by low platelet counts and a risk of bleeding, not trauma-induced spleen rupture. The trial includes patients with persistently low platelet counts and specific responses to treatment for ITP. Since there is no indication that the patient has ITP or meets any of the platelet count criteria outlined in the trial, he would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1111": {
        "output": "Based on the information provided, the patient is a 33-year-old male who presented with acute abdominal pain due to spleen rupture from a bicycle accident. The clinical trial in question is examining the impacts of intraperitoneal pressure and CO2 gas on the surgical peritoneal environment during laparoscopic surgery, specifically laparoscopic hysterectomy with promontofixation for uterine prolapse in menopausal patients.\n\nThe inclusion criteria for the clinical trial are:\n- Age 45-75 years old\n- Patients undergoing laparoscopic hysterectomy with promontofixation for uterine prolapse\n- Menopausal\n- ASA class I or II\n\nThe patient in the note does not meet several of the inclusion criteria:\n- The patient is a 33-year-old male, not within the 45-75 years age range.\n- The patient is male and therefore cannot undergo a laparoscopic hysterectomy, which is a procedure specific to females.\n- The patient cannot be menopausal as this is a condition that applies to females.\n- The ASA (American Society of Anesthesiologists) class is not mentioned, but given the patient's acute condition, it might be higher than II.\n\nConsidering these points, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1112": {
        "output": "Based on the provided patient note and the criteria of the clinical trial, the patient would not be eligible for the clinical trial in question. The trial is focused on the efficacy and safety of eculizumab for the treatment of antibody-mediated rejection following renal transplantation. The patient described in the note presented with acute abdominal pain due to a spleen rupture from a biking accident, with no mention of renal transplantation or antibody-mediated rejection. Therefore, this patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1113": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient note summary:\n- 33-year-old male athlete\n- Presented with acute abdominal pain\n- History of trauma from falling off a bike a week earlier\n- Suffered a spleen rupture with extended intraperitoneal hemorrhage\n- Hemodynamic instability (BP: 60/30 mmHg, HR: 140/min)\n- Negative history for smoking, drugs, and alcohol\n- Emergency condition requiring immediate medical attention\n\nClinical trial inclusion criteria:\n- All patients with acute abdomen undergoing abdominal surgery under emergency\n- Presenting on arrival in ICU at least a sign of bad perfusion\n\nThe patient clearly matches the inclusion criteria for the clinical trial. He has an acute abdomen condition due to spleen rupture, which is likely to require emergency abdominal surgery. Additionally, the patient presents with signs of bad perfusion, indicated by his very low blood pressure (BP: 60/30 mmHg) and high heart rate (HR: 140/min), which align with the trial's requirement for patients presenting in the ICU with at least one sign of bad perfusion.\n\nGiven the information provided, the patient is a suitable candidate for the clinical trial titled \"Different Fluidic Strategy in Patients With Acute Abdomen: The Sure Volume.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1114": {
        "output": "Based on the information provided, the patient in question is a 33-year-old male athlete who presented with acute abdominal pain due to spleen rupture after a biking accident. There is no indication in the patient note that the patient has been diagnosed with atrial fibrillation (AF), which is a key inclusion criterion for the clinical trial.\n\nThe clinical trial is focused on patients with a coded diagnosis for atrial fibrillation, and there is no mention of this condition in the patient's history or presentation. Thus, the patient does not meet the primary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1115": {
        "output": "Based on the provided information, the patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain due to a spleen rupture caused by blunt trauma. There is no mention of intra-abdominal infection, open abdomen (OA) management, or vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM) being currently required or utilized for his treatment. The clinical trial in question is looking for patients with complicated intra-abdominal infections who need open abdomen treatment and are suitable for a specific treatment involving continuous topical instillation.\n\nThe patient presented does not match the inclusion criteria of the clinical trial, as there is no indication that he has a complicated intra-abdominal infection, nor is there any mention of him requiring open abdomen management or being treated with VAWCM. Thus, he would not be eligible for the clinical trial based on the information available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1116": {
        "output": "The patient in the note suffered an injury from a bicycle accident, which caused blunt trauma to the abdomen, leading to spleen rupture. There is no mention of traumatic subarachnoid hemorrhage (tSAH) or any brain injury. The clinical trial in question is specifically looking to enroll patients who have suffered a traumatic subarachnoid hemorrhage.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria of the clinical trial because there is no indication of a tSAH. Therefore, the trial-level eligibility for referring this patient to the clinical trial mentioned would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1117": {
        "output": "Based on the information provided, the patient in question is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture following a biking accident. This patient does not meet the inclusion criteria for the clinical trial, which specifically states that the trial is for premature infants with a birthweight of 1500 grams or less.\n\nThe clinical trial is investigating the impact of visceral osteopathic treatment on meconium evacuation in preterm infants, which is not applicable to the adult patient described in the patient note.\n\nTherefore, the assessment of eligibility for this patient for the clinical trial mentioned is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1118": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the key inclusion criteria for the trial. The patient is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture from a blunt trauma incident. This clinical scenario is not related to the focus of the clinical trial.\n\nThe clinical trial is specifically looking at major obstetric haemorrhage (MOH) in pregnant women with a gestation age of more than 24 weeks. Since the patient is male and the condition being studied is exclusively applicable to pregnant women, the patient is not eligible for the trial.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1119": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient for eligibility:\n\nPatient Note:\n- 33-year-old male\n- Presented with acute abdominal pain after a bike accident (blunt trauma to left hemi-abdomen)\n- Suffered spleen rupture with intraperitoneal hemorrhage\n- No history of smoking, drugs, or alcohol\n- Vital signs indicate hemodynamic instability (BP: 60/30 mmHg, HR: 140/min)\n- Requires emergency care\n\nClinical Trial Inclusion Criteria:\n- Patient is 18 years of age or older\n- Patient presenting with blunt or penetrating trauma to the thorax or abdomen\n- Patient transported by MD Ambulance to Royal University Hospital\n- Patient being transported by a paramedic who has received training in the above ultrasound system\n- Patient has a NanoMaxx Ultrasound System (SonoSite) in connection with the RP-Xpress (InTouch Technologies)\n- Patient will take longer than 10 minutes to transport to hospital\n- Patient's care will not be compromised in completing a FAST exam - opinion of paramedic\n- Patient's care will not be compromised in completing a FAST exam - opinion of ER physician\n\nThe patient is a 33-year-old male, which meets the age requirement. He is presenting with blunt trauma to the abdomen due to a bike accident, which aligns with the trial's focus on thoracoabdominal trauma. It is not specified whether he is being transported by MD Ambulance to the Royal University Hospital or if the paramedic has the required ultrasound system and training, so these criteria would need further verification. However, given the patient's critical condition (BP: 60/30 mmHg, HR: 140/min) and the fact that immediate intervention is required due to the spleen rupture and intraperitoneal hemorrhage, it may be that performing a FAST exam could be considered to compromise the patient's care, depending on the paramedic's and ER physician's opinion.\n\nSince there's insufficient information to fully determine the patient's eligibility based on the trial's inclusion criteria, and given the patient's critical condition, it is prudent to exercise caution. Therefore, I would rate the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1120": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient does not seem to be eligible for the clinical trial in question. The patient is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture from a bicycle accident. The patient's condition is not related to ovarian, tube, or peritoneal primary adenocarcinoma, which is the focus of the clinical trial.\n\nThe clinical trial is specifically for patients with Stage IIIC unresectable ovarian, tubes, or peritoneal primitive adenocarcinoma that have been previously treated with neoadjuvant chemotherapy. The patient in the note does not have a diagnosis of any of these conditions nor a history of the required treatments.\n\nTherefore, given the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1121": {
        "output": "Based on the patient note, we have a 33-year-old male athlete who presented to the ER with acute abdominal pain due to spleen rupture from a biking accident. He underwent emergency imaging and likely requires surgical intervention.\n\nThe clinical trial in question is looking to include adult patients over 18 years old who are undergoing emergency laparotomy and will have a temporary abdominal closure.\n\nGiven that the patient has sustained trauma that has led to intraperitoneal hemorrhage due to spleen rupture, it is highly likely that he will undergo an emergency laparotomy. Since the trial is interested in patients who will have their abdominal wall closed at the end of surgery by a temporary closure technique, and this patient's condition may warrant such a procedure, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1122": {
        "output": "Based on the patient note provided, the 33-year-old male patient presented to the ER with acute abdominal pain due to spleen rupture sustained from a bike accident. The patient's condition seems acute and requires immediate medical attention, including potentially a splenectomy or other treatment modalities for the splenic injury.\n\nThe clinical trial in question is investigating the immunologic response to the pneumococcal polysaccharide vaccine in splenic injury patients. The inclusion criteria for the trial specify that adult trauma patients aged 18 to 65 years old who have sustained a splenic injury are eligible.\n\nThis patient fits the age range and has sustained a splenic injury, making him a potential candidate for the clinical trial. The patient's emergency situation aligns with the interests of the clinical trial, which is focused on the antibody response to pneumococcal vaccine in patients undergoing different modes of therapy for splenic injury.\n\nTherefore, given the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1123": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 33-year-old male athlete who presented with acute abdominal pain due to spleen rupture following blunt trauma from a bike accident. The clinical trial in question is focused on comparing two mesh/fixation concepts for laparoscopic ventral and incisional hernia repair. \n\nThe inclusion criteria for the trial are:\n- Informed Consent Form (ICF) signed by the patient or his/her legal representative\n- Primary or secondary ventral hernia less than 20 cm in length and less than 11 cm in width requiring elective surgical repair\n- Recurrence after former abdominal hernia repair WITH MESH\n- Recurrence after suture abdominal hernia repair CAN be included\n\nThe patient in question does not have a hernia but rather a spleen rupture. Therefore, he does not meet the inclusion criteria for the hernia repair study. The patient's condition is not related to the purpose of the clinical trial, which is focused on hernia repair and not on acute care management of traumatic injuries such as spleen rupture.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1124": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the necessary conditions for participation in the study. The trial is focused on patients with malignant pleural mesothelioma who are undergoing first-line chemotherapy with platinum-based agents. The patient in the note is an athlete who presented to the ER with acute abdominal pain due to a spleen rupture from blunt trauma, and there is no indication that the patient has malignant pleural mesothelioma or is receiving platinum-based chemotherapy.\n\nTherefore, this patient would not be eligible for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1125": {
        "output": "Based on the provided patient note and the inclusion criteria for the PATH-2 clinical trial, we can make the following observations:\n\nThe patient is:\n- A 33-year-old male, which meets the age criterion (\u226518 years).\n- An athlete who was ambulatory prior to injury, which meets the criterion of being ambulatory without the use of walking aids or assistance.\n- Suffering from acute abdominal pain due to blunt trauma and spleen rupture, not an Achilles tendon rupture.\n\nThe clinical trial PATH-2 is focused on:\n- Patients diagnosed with an acute, complete, Achilles tendon rupture.\n- Patients who present and receive study treatment within 12 days post injury.\n- Patients in whom the decision has been made for non-operative treatment of Achilles tendon rupture.\n- Participants able to attend follow-up at a PATH-2 study hospital site for the 24-week follow-up.\n\nThe patient does not meet the inclusion criteria for the PATH-2 clinical trial because:\n- The injury is a spleen rupture due to trauma, not an Achilles tendon rupture.\n- The trial is specific to Achilles tendon injuries, and there is no mention of this type of injury in the patient's note.\n\nTherefore, the patient is not eligible for the PATH-2 clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1126": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 33-year-old male athlete, which fits within the age bracket of 18 to 30 years required by the trial.\n- The patient presented with acute abdominal pain due to an accident involving blunt trauma, not an ACL injury.\n- There is no mention of the patient having a ruptured anterior cruciate ligament (ACL), which is the injury of interest in the clinical trial.\n- The patient's condition (spleen rupture) is unrelated to the subject of the trial (ACL rupture).\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on patients with a primary rupture of the ACL, evidenced by specific symptoms and confirmed by MRI and physical examination tests.\n- The patient must have a Tegner score of 5 or more, indicating a sportive, active lifestyle.\n- The age range is above 18 until 30 years at the time of inclusion.\n- No associated ligamentous disorder of the knee.\n- The time span between ACL rupture and operation should be no longer than 21 days.\n- The patient must be willing to comply with a rehabilitation protocol.\n\nComparison:\n- The age of the patient fits the criteria.\n- The patient is described as an athlete, which suggests a potentially active lifestyle, but there is no Tegner score provided.\n- The injury sustained by the patient is to the spleen as a result of blunt trauma, not an ACL rupture.\n- Since the trial is specifically looking for patients with an ACL rupture, which is not mentioned in the patient note, the patient's medical condition does not align with the trial's target condition.\n\nBased on the information provided, the patient does not meet the key inclusion criteria for the clinical trial, which is centered around an ACL rupture. Therefore, the patient is not eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1127": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility.\n\nPatient Note:\n- 33-year-old male athlete\n- Presented with acute abdominal pain after a fall off his bike\n- Suffered blunt trauma to the abdomen\n- Negative history for smoking, drugs, and alcohol\n- Emergency ultrasound and CT scan reveal extended intraperitoneal hemorrhage due to spleen rupture\n\nClinical Trial Inclusion Criteria:\n- Biopsy proven incurable melanoma or incurable head and neck squamous cell cancer (HNSCC)\n- Age \u2265 21 years old per NCI/NIH guidelines\n- ECOG performance status of 0, 1, or 2\n- Adequate bone marrow, hepatic and renal function (specific lab values listed)\n- Measurable disease according to RECIST version 1.1.\n- O2 saturation \u2265 93% on room air\n- Ability to understand and willingness to sign a written informed consent document\n\nThe clinical trial is specifically recruiting participants with biopsy-proven incurable melanoma or HNSCC. The patient in the note is an athlete with an acute injury due to trauma (spleen rupture) and no mention of melanoma or HNSCC. Therefore, the patient does not meet the disease-specific inclusion criteria for this trial. All other inclusion criteria are not relevant as the primary condition for inclusion is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1128": {
        "output": "The patient in question is a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture following a biking accident. This patient's condition and circumstances are not related to the clinical trial's focus.\n\nThe clinical trial in question is looking at maternal microcirculation in pregnant women undergoing a cesarean delivery. The inclusion criteria for the trial are very specific and include being of American Society of Anesthesiologists (ASA) Physical Status I-II, having a singleton pregnancy, being at 36-42 weeks gestation, non-labouring, scheduled for cesarean delivery, English speaking, and aged 18-45 years.\n\nSince the patient is male, not pregnant, and is not undergoing a cesarean delivery, he does not meet any of the inclusion criteria for this clinical trial. Therefore, he would not be eligible for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1129": {
        "output": "Given the patient note, the 33-year-old male patient presented with acute abdominal pain due to a spleen rupture following a bicycle accident. The clinical trial in question is focusing on injuries related to handlebar grips, specifically in children aged 0-15 years who are injured during non-motorized bicycle, tricycle, or kick scooter incidents. \n\nThe patient in this case does not meet the age criteria for the trial, which is specifically for children 0-15 years old. Additionally, the study is looking at incidents involving handlebar grip conditions, and there is no mention of the handlebar grip condition in the patient's accident description. \n\nBased on the provided information, the patient's situation does not align with the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1130": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note assessment:\n- The patient is a 33-year-old male who presents with acute abdominal pain.\n- The cause of the pain is established as a spleen rupture due to a bicycle accident, which is a surgical emergency.\n- The patient has no exclusionary factors mentioned in the note such as pregnancy, homelessness, or lack of social insurance.\n\nClinical trial inclusion criteria:\n- Presentation at the Emergency Department with acute abdominal pain.\n- The patient must be at least 18 years old.\n\nBased on the information provided, the patient meets the inclusion criteria:\n- He is over 18 years old.\n- He presented to the ED with acute abdominal pain, which is the primary requirement for the clinical trial.\n\nThe patient's situation aligns with the purpose of the clinical trial, which is to evaluate stress biomarkers in patients presenting with acute abdominal pain. Since the patient has acute abdominal pain due to a traumatic injury resulting in spleen rupture, he is a suitable candidate for this trial, which seeks to include patients with various causes of acute abdominal pain.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1131": {
        "output": "The patient described in the note is a 33-year-old male athlete who has been admitted to the emergency room with acute abdominal pain, following a bike accident that resulted in blunt trauma to the left hemi-abdomen a week prior. The patient has a ruptured spleen causing an extended intraperitoneal hemorrhage. His vital signs are indicative of hemodynamic instability (BP: 60/30 mmHg, HR: 140/min), which is a serious condition requiring immediate attention.\n\nThe clinical trial in question is investigating the emergency management of minor blunt thoracic trauma. The inclusion criteria for this trial are:\n- Glasgow Coma Scale (GCS) of 15\n- Stable vital signs\n- Admitted within the first 6 hours after injury\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial:\n- The patient's vital signs are not stable, as indicated by the very low blood pressure and high heart rate, which suggests he is in a state of shock, likely secondary to internal hemorrhage.\n- The patient has sustained an abdominal injury with spleen rupture, which is beyond the scope of minor blunt thoracic trauma.\n- The patient is being admitted a week after the injury, which is well beyond the 6-hour window specified in the inclusion criteria for the clinical trial.\n\nGiven these discrepancies, the patient is not a suitable candidate for the trial investigating minor blunt thoracic trauma. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1132": {
        "output": "The patient is a 33-year-old male athlete who presented with acute abdominal pain due to spleen rupture following blunt trauma. He does not have a distal biceps rupture or tear, which is the focus of the clinical trial in question.\n\nThe clinical trial is investigating early functional return to work following distal biceps repair (DBTR). The inclusion criteria for this trial are:\n\n1. Male subjects between 18 and 65 years of age\n2. Patient has had a DBTR amenable to surgical repair\n3. Surgeon must be able to obtain a tension-free repair using an endobutton\n4. Participants must have been working prior to the injury\n5. Patient must be expected to return to work post-injury\n\nThe patient's current medical issue is unrelated to the distal biceps and therefore does not meet the inclusion criteria for the clinical trial. As a result, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1133": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Clinical Relevance of Microbleeds In Stroke,\" the patient does not meet the eligibility requirements for participation in the trial.\n\nThe patient in the note is a 33-year-old male who presented to the ER with acute abdominal pain due to a spleen rupture following a bike accident. The clinical trial in question is focused on patients who have been anticoagulated after a cardioembolic stroke due to non-valvular atrial fibrillation (AF) and are being followed up for the occurrence of intracerebral hemorrhage (ICH) and ischemic stroke. The inclusion criteria specifically require:\n\n1. Adult patients (\u226518 years; no upper limit) with a clinical diagnosis of non-valvular AF verified by ECG.\n2. Intention to treat with best practice oral anticoagulants (e.g., warfarin) after a previous ischemic stroke or TIA diagnosed by a treating clinician.\n3. The ability to have GRE MRI before (or within 1 week) of starting best practice oral anticoagulant.\n\nThe patient does not have a history or diagnosis of non-valvular AF, has not had a previous ischemic stroke or TIA, and there is no mention of being a candidate for anticoagulant therapy. The patient's condition (acute abdominal pain and spleen rupture) is unrelated to the conditions being studied in the trial, which are cardioembolic stroke and ICH.\n\nTherefore, the patient does not meet the inclusion criteria for the \"Clinical Relevance of Microbleeds In Stroke\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1134": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we find the following:\n\nPatient Note:\n- The patient is a 33-year-old male athlete.\n- He suffered from an acute abdominal pain due to a spleen rupture after falling off his bike.\n- There is no mention of cardiac arrest or refractory cardiac arrest.\n\nClinical Trial Inclusion Criteria:\n- Adults over 18 years of age and under 65 years of age.\n- Refractory cardiac arrest (defined by the failure of professionals to resuscitate at the 20th minute of cardiac arrest with a minimum of 3 AED or equivalent analyze).\n- Beginning of external cardiac massage within the first 5 minutes after cardiac arrest (no flow < 5 min.) with shockable rhythm or the presence of signs of life during resuscitation.\n- Medical cause of the cardiac arrest.\n- ETCO2 above 10 mm Hg at the time of inclusion.\n- Absence of major co-morbidity.\n- ECMO team available and on-site before the 40th minute.\n\nThe patient in the note does not meet the criteria for the clinical trial as there is no mention of cardiac arrest, let alone refractory cardiac arrest. Furthermore, the trial is specifically looking for patients who have experienced refractory cardiac arrest and are eligible for a circulatory support strategy involving ECMO. The patient's condition (spleen rupture due to trauma) does not align with the trial's focus on cardiac arrest.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1135": {
        "output": "The patient described in the note is a 33-year-old male athlete who presented to the ER with acute abdominal pain due to a spleen rupture following a biking accident. There is no mention of the patient having myelofibrosis or related conditions.\n\nThe clinical trial in question is for pacritinib, a treatment for myelofibrosis, which includes primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). The inclusion criteria for the trial require a diagnosis of one of these types of myelofibrosis, among other specific medical and treatment-related conditions.\n\nGiven that the patient's condition (spleen rupture due to trauma) does not align with the target disease of the clinical trial (myelofibrosis), and there is no mention of the patient having myelofibrosis or being evaluated for it, the patient would not meet the inclusion criteria for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1136": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 33-year-old male, which fits into the age range of 7-18 years old required by the trial.\n- The patient suffered acute abdominal pain due to a spleen rupture, not appendicitis.\n- The patient is hemodynamically unstable with BP: 60/30 mmHg and HR: 140/min, which does not meet the \"hemodynamically stable patient\" criterion.\n- The patient has extended intraperitoneal hemorrhage, which is not an uncomplicated appendicitis case and likely indicates the presence of a severe systemic disease (not ASA Score I or II).\n- The patient is not scheduled for laparoscopic appendectomy surgery, which is a requirement for the trial.\n- There is no mention of appendicitis, let alone simple acute appendicitis diagnosed by intraoperative laparoscopy.\n- There is no information provided about the patient or caregivers having given written informed assent or consent.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age 7-18 years old (the patient is 33 years old, so does not meet this criterion)\n- ASA Score I or II (the patient's current state suggests a condition more severe than ASA Score II)\n- Patients scheduled for laparoscopic appendectomy (the patient is not scheduled for this procedure)\n- Uncomplicated appendicitis (the patient does not have appendicitis)\n- Hemodynamically stable (the patient is not stable)\n- No evidence of appendiceal perforation (irrelevant as the patient does not have appendicitis)\n- Diagnosed to have simple acute appendicitis by intraoperative laparoscopy (the patient does not have appendicitis)\n- Informed assent and consent (no information provided)\n\nBased on the above analysis, the patient does not meet the inclusion criteria for the clinical trial:\n\n- The age is outside the specified range.\n- The patient's condition does not align with the ASA Scores mentioned.\n- The patient is not scheduled for the specific surgery required by the trial.\n- The patient has a different medical condition (spleen rupture) that is not related to appendicitis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1137": {
        "output": "Given the patient note, the child has experienced a traumatic brain injury (TBI) as evidenced by the fall, subsequent drowsiness, vomiting, changes in heart rate and blood pressure, a low Glasgow Coma Scale (GCS) score, and impaired movement, which are indicative of a moderate to severe TBI. This aligns with the inclusion criteria for the clinical trial, which is looking for children with moderate to severe traumatic brain injury to assess the effects of methylphenidate on early recovery.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1138": {
        "output": "To determine the trial-level eligibility for the 8-year-old boy with a severe brain injury for the hypothermia treatment clinical trial, I will compare the patient's characteristics and condition against the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n- GCS 3-8 on initial evaluation or deteriorates during transport\n- Mechanism of injury consistent with blunt, non-penetrating trauma to head\n- Systolic blood pressure > 110 mm Hg\n- Diastolic blood pressure > 60 mm Hg\n- Heart rate (pulse) < 120 beats per minute\n- Estimated or known age 16-45\n- No suspicion of pregnancy\n- Esophageal/rectal probe temperature > 35.5\u00b0C (Pre-hospital cooling only)\n- Injured < 2 hours prior to arrival of pre-hospital providers\n- No evidence of severe chest trauma (unilaterally absent breath sounds with tracheal deviation or distended neck veins or requiring thoracentesis).\n\nPatient Characteristics:\n- 8-year-old boy (Age)\n- Fell from a bike and struck his head (Mechanism of injury)\n- GCS was 6/15 after the event (GCS)\n- Systolic blood pressure 155 mm Hg (Systolic BP)\n- Diastolic blood pressure 98 mm Hg (Diastolic BP)\n- Heart rate was 52/min (Heart rate)\n- No mention of pregnancy (irrelevant due to gender)\n- No information on body temperature or time since injury provided (Temperature, Injured < 2 hours)\n- No information on severe chest trauma provided (Chest trauma)\n\nThe patient does not meet the age criterion, which is a critical inclusion factor:\n\n- Age: The trial requires participants to be aged between 16-45, while the patient is an 8-year-old boy.\n\nGiven that the patient does not meet the age criterion, which is a strict inclusion requirement, this patient would not be eligible for the trial. All other inclusion criteria, while met, are not considered since the age criterion disqualifies the patient on its own.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1139": {
        "output": "To determine the trial-level eligibility of the patient described in the note for the clinical trial provided, we should compare the patient's characteristics and condition with the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- An 8-year-old boy\n- Experienced a traumatic brain injury (TBI) after falling from his bike\n- Glasgow Coma Scale (GCS) was 6/15 post-injury\n- No mention of epilepsy, mental retardation, developmental dysfunction, autism, major psychiatric disorder, pervasive developmental delay, meningitis, encephalitis, child abuse, or chronic serious physical disorders\n\nClinical Trial Inclusion Criteria:\n- English speaker\n- Minimum birth weight of 2500 grams (5.5 lbs) and 37 weeks' gestation\n- TBI resulting in a post-resuscitation Glasgow Coma Scale score of 13 to 15 or 3 to 8\n- No evidence of hypoxic injury\n\nClinical Trial Exclusion Criteria:\n- History of epilepsy, mental retardation, or documented evidence of developmental dysfunction\n- Previous hospitalization for head injury involving loss of consciousness or post-concussional symptoms\n- History of autism, major psychiatric disorder, or pervasive developmental delay\n- History of meningitis or encephalitis\n- History of child abuse\n- History of chronic or uncontrolled serious physical disorders (cancer, uncontrolled diabetes, cystic fibrosis, etc.)\n\nAssessment:\n- The patient is an English speaker (assumed as there is no information provided to the contrary).\n- There is no indication that the patient does not meet the birth weight and gestation criteria.\n- The patient has a TBI with a GCS of 6/15, which falls within the specified range for the clinical trial (3 to 8).\n- There is no mention of hypoxic injury in the patient note.\n- There is no information suggesting that the patient meets any of the exclusion criteria.\n\nBased on the information provided, the patient appears to meet the inclusion criteria and none of the exclusion criteria have been indicated. Therefore, the patient is likely eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1140": {
        "output": "Based on the information provided:\n\nThe patient is an 8-year-old boy who suffered a traumatic brain injury (TBI) after falling from his bike. The patient's Glasgow Coma Scale (GCS) was 6/15, which falls under the severe head injury category as per the inclusion criteria of the clinical trial.\n\nHowever, the clinical trial's inclusion criteria also specify that participants must be aged between 17 and 70 years. Since the patient is only 8 years old, he does not meet the age requirement for the trial.\n\nGiven this, the patient is not eligible for the clinical trial due to the age criteria, despite meeting the requirement for a severe head injury based on the GCS score.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1141": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Study of Oxycyte in Severe Closed Head Injury,\" let's assess the patient's eligibility:\n\nThe patient note describes:\n- An 8-year-old boy with a closed head injury following a fall from his bike.\n- Glasgow Coma Scale (GCS) was 6/15, indicating severe head injury.\n- The patient presented with asymmetrical pupils and impaired movement in the right extremities.\n- There is no mention of any life-threatening disease prior to trauma.\n- The patient is undergoing immediate treatment, but there is no information on brain oxygen monitoring or ventriculostomy/ICP monitor placement.\n\nThe clinical trial inclusion criteria state that participants must:\n- Have a severe closed head injury or a GCS of 3-9 and receive brain oxygen monitoring.\n- Have a ventriculostomy/ICP monitor.\n- Have at least one reactive pupil.\n- Have no known life-threatening disease prior to trauma.\n- Be between 18-70 years old.\n- Provide consent for microdialysis/brain O2 monitoring.\n- Have a legal family representative present that can give informed consent for perfluorocarbon administration.\n\nComparing these details, the patient does not meet the following inclusion criteria:\n- Age 18-70 years old: The patient is 8 years old, which is below the minimum age requirement.\n- Legal family representative present for consent: There is no information provided about the presence of a legal family representative for consent.\n\nGiven these discrepancies, specifically the age requirement, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1142": {
        "output": "Based on the patient note and the clinical trial information provided, we can assess the patient's eligibility for the clinical trial with the following considerations:\n\n1. Age: The inclusion criteria specify that the patient must be over 16 and under 45 years old. The patient in the note is 8 years old, which does not meet the age requirement.\n\n2. Type of Injury: The clinical trial is focused on non-penetrating brain injury with a post-resuscitation Glasgow Coma Score (GCS) < 8. While the patient has a traumatic brain injury, the GCS was noted to be 6/15, which fits within the required score range.\n\n3. Time of Injury: The clinical trial inclusion criteria require that the time of injury be within 2.5 hours of arrival at the hospital. There is no information provided in the patient note regarding the exact timing of the injury relative to the arrival at the hospital.\n\nDespite the patient having a GCS that would fit the criteria, the patient is disqualified from the clinical trial based on age alone. Therefore, we would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1143": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Hypothermia in Children After Trauma,\" let's assess the patient's eligibility.\n\nInclusion Criteria Assessment:\n- Patients with a GCS \u2264 8: The patient has a GCS of 6/15, which meets this criterion.\n- Glasgow Motor Score < 6: The patient has impaired movement in the right upper and lower extremities, which may indicate a Glasgow Motor Score < 6, although the exact score isn't provided.\n- Closed head injury: The patient fell from his bike and struck his head, which suggests a closed head injury.\n- Age 0 < 18 y: The patient is an 8-year-old boy, which is within the specified age range.\n\nExclusion Criteria Assessment:\n- The patient note does not provide information on some exclusion criteria, such as the time to initiate cooling, abnormal brainstem function, initial CT scan results, penetrating brain injury, mechanism and time of injury, coagulopathy, hypotension, hypoxia, or pregnancy.\n\nGiven the information provided, the patient meets the inclusion criteria for age, GCS score, and likely Glasgow Motor Score. However, there is insufficient information regarding the exclusion criteria, such as details on the initial CT scan, brainstem function, and the ability to initiate cooling within the specified timeframe.\n\nSince the patient fits the inclusion criteria but there is insufficient information to rule out the exclusion criteria, further investigation would be necessary to determine if the patient is truly eligible for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1144": {
        "output": "Based on the information provided, the patient is an 8-year-old boy who has suffered a traumatic brain injury (TBI) with a Glasgow Coma Scale (GCS) of 6/15, which indicates severe TBI. The patient is within the age range specified by the trial (1 to 16 years). The clinical trial is investigating the effects of hypothermia treatment on children with severe TBI.\n\nThe inclusion criteria for the clinical trial are:\n1. Severe traumatic brain injury as defined by a GCS \u2264 8 and an abnormal CT scan or a motor score \u2264 3 and normal CT scan.\n2. Aged between 1 and 16 years.\n3. Mechanically ventilated.\n\nThe patient note indicates that the child has a GCS of 6/15, which meets the first criterion of a severe traumatic brain injury with a GCS \u2264 8. While the patient note does not mention whether the patient is mechanically ventilated, the severity of the injury (implied by a GCS of 6/15 and the involvement of the neurosurgical team) suggests that mechanical ventilation is likely or imminent, especially in the context of an emergency department setting for a patient with impaired consciousness and movement.\n\nAlthough the CT scan results are not provided, the clinical context and the neurosurgical team's involvement suggest that the TBI is likely to be severe enough to potentially meet the inclusion criteria which includes an abnormal CT scan.\n\nGiven the information available and assuming that the patient is or will be mechanically ventilated, the patient appears to meet the inclusion criteria for the clinical trial. However, the eligibility would be contingent on the abnormal CT scan criterion being met, which is a detail not provided in the patient note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1145": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Risk Factors of Minor Head Injury,\" let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is an 8-year-old boy.\n- He fell from his bike and struck his head.\n- No immediate loss of consciousness was reported.\n- Symptoms developed half an hour after the fall, which included drowsiness, paleness, and vomiting.\n- Upon arrival at the emergency department, the patient presented with bradycardia (heart rate of 52/min), hypertension (blood pressure of 155/98), and a low Glasgow Coma Scale score (GCS of 6/15).\n- The patient had asymmetrical pupils and impaired movement in the right extremities.\n- The note mentions a head injury.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking at patients with minor head injury.\n- Symptoms of interest include dizziness, nausea, and vomiting.\n\nComparison:\n- The patient did experience vomiting, which aligns with the inclusion criteria.\n- The trial is looking at risk factors for minor head injury. However, the patient's condition seems to be more severe than a minor head injury, given the low GCS score and neurological deficits (such as impaired movement and asymmetrical pupils).\n\nGiven these points, the patient's injury might be too severe for this trial focused on minor head injuries, despite having some overlapping symptoms (vomiting). Therefore, this patient is not an ideal candidate for a study on minor head injuries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1146": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the 8-year-old boy does not meet the requirements for the clinical trial. The trial is specifically looking for healthy pediatric emergency patients with isolated extremity injury requiring reduction, while the patient presented here has a significant head injury with neurological symptoms (indicated by the GCS of 6/15, asymmetric pupils, and impaired movement of extremities), which is not the focus of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1147": {
        "output": "The patient in question is an 8-year-old boy who has experienced a traumatic event, resulting in a Glasgow Coma Scale (GCS) of 6/15, which indicates a severe level of impairment in consciousness. However, the clinical trial focuses on pediatric patients who have experienced cardiac arrest and are comatose post-cardiac arrest.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Informed consent by parent or legal guardian\n2. Age \u2265 38 weeks gestation up to and including 17 years\n3. Patient admitted with a diagnosis of a cardiac arrest requiring compressions \u22653 minutes\n4. Remain comatose i.e. have Glasgow Coma Score less than or equal to 10 assessed at the tertiary level pediatric hospital at least 1 hour post-cardiac arrest\n5. Invasive mechanical ventilation\n\nConsidering the information provided in the patient note:\n\n- The patient is 8 years old, which fits within the age range of the inclusion criteria.\n- There is no mention of cardiac arrest or requirement of compressions, which is a critical inclusion criterion for the clinical trial.\n- The patient's GCS is less than or equal to 10, which aligns with the inclusion criteria for being comatose.\n- There is no information regarding invasive mechanical ventilation, but the severity of the patient's condition as described may imply that such intervention could be necessary or already in place.\n\nThe key disqualifying factor here is that the patient did not experience a cardiac arrest, which is explicitly required by the clinical trial's inclusion criteria. While other aspects of the patient's condition may seem to fit the trial criteria, the lack of a cardiac arrest diagnosis means that this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1148": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, the patient's eligibility assessment would be as follows:\n\n- The clinical trial is for patients with a diagnosis of traumatic brain injury (TBI) with a Glasgow Coma Scale (GCS) of 4-8.\n- The patient in the note is an 8-year-old boy who has sustained a head injury with a GCS of 6/15, which fits the GCS range specified.\n- However, the clinical trial has an age inclusion criterion of 16-70 years.\n\nSince the patient does not meet the age criterion for the clinical trial, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1149": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI),\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is an 8-year-old boy, which is below the age criterion of 18 years.\n- The patient had a traumatic injury, which seems to align with the trial's focus on traumatic brain injury (TBI).\n- The patient shows signs of severe TBI (GCS of 6/15, asymmetrical pupils, and impaired movement of extremities).\n\nClinical Trial Inclusion Criteria:\n- Age 18 - 70 years at the time of study entry.\n- Weight \u226545 kg (not mentioned in the patient note but not likely met due to the patient's age).\n- Able to begin the infusion of study drug within 12 hours of injury.\n- Evidence of severe non-penetrating TBI.\n- GCS assessment of 4-8 prior to randomization.\n- At least one reactive pupil at screening.\n\nThe patient does not meet at least two of the key inclusion criteria for the clinical trial: age and weight. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1150": {
        "output": "Based on the information provided, the patient in question is an 8-year-old boy who sustained a head injury from falling off his bike. The clinical trial is focused on patients with chronic subdural hematoma that requires surgical evacuation and specifically includes patients who are over the age of 18. \n\nGiven that the patient is only 8 years old, he does not meet the age criterion for the trial. The trial specifies an age requirement of \"Age > 18 year,\" which excludes this patient. Additionally, there is no indication in the patient note that the boy has been diagnosed with chronic subdural hematoma or that he requires surgical evacuation.\n\nTherefore, based on the provided inclusion criteria and the patient's age, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1151": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) I-InTERACT,\" let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is an 8-year-old boy, which meets the unstated age criterion since the trial is for young children.\n- The patient has experienced a traumatic brain injury (TBI), as evidenced by the symptoms following a fall (drowsiness, vomiting, change in heart rate and blood pressure, low Glasgow Coma Scale score, impaired movement, and asymmetrical pupils).\n- The severity of the injury (GCS of 6/15 and neurosurgical advice for immediate treatment) suggests a moderate to severe TBI.\n- There is no information regarding an overnight hospital stay, but given the severity of the symptoms, an overnight stay is highly probable.\n- There is no information about language, but typically, clinical trials are designed to accommodate patients in the region where the trial is conducted, which often implies the prevalent language. We might assume the patient and family speak English unless otherwise stated.\n- There is no information on whether the parent is willing to provide informed consent, but this is something that can be sought after the initial screening.\n\nInclusion Criteria:\n- Moderate to severe TBI that occurred within the last 24 months (the patient note does not specify the timing of the injury, but immediate treatment implies recentness).\n- Overnight hospital stay (likely given the severity of the injury).\n- English-speaking (unknown, but likely if the patient is in an English-speaking region).\n- Parent must be willing to provide informed consent (unknown, but can be determined upon contact).\n\nAssessment:\nThe patient appears to meet the criteria for TBI severity and the age group targeted by the trial. However, there are a few details that are not confirmed in the patient note, such as the timing of the TBI, the overnight hospital stay, and the language and consent requirements. These factors would need to be confirmed before a full referral could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1152": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided:\n\nPatient Note:\n- An 8-year-old boy\n- Fell and hit his head, with subsequent changes in consciousness and vomiting\n- No mention of type 1 diabetes mellitus\n\nClinical Trial Inclusion Criteria:\n- 8-18 years old\n- Have a diagnosis of type 1 diabetes mellitus\n\nThe patient note indicates that the boy is the correct age for the trial (8 years old); however, there is no indication that he has a diagnosis of type 1 diabetes mellitus, which is a requirement for the trial. Therefore, the patient does not meet all of the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1153": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial:\n\nPatient Note:\n- An 8-year-old boy had a fall from his bike, striking his left temple.\n- Presented drowsy, pale, and vomited half an hour after the fall.\n- Heart rate was 52/min, blood pressure was 155/98.\n- Glasgow Coma Scale (GCS) was 6/15 upon arrival at the emergency department, indicating a decreased level of consciousness.\n- Asymmetrical pupils and impaired movement of the right extremities were noted.\n- The patient was advised to receive immediate treatment instead of a CT scan.\n\nClinical Trial Inclusion Criteria:\n- Children aged 6 to 18.\n- Language spoken: Hebrew, Arabic.\n- DSM-IV R diagnosis: PTSD due to a motor vehicle accident within the past 3 years.\n- For the m-TBI group: symptoms or experiences such as loss of consciousness, confusion, etc., during or shortly after the accident.\n- Diagnosis of mTBI within 3 years, confirmed by CT/MRI/fMRI.\n- Glasgow Coma Scale (GCS) < 15.\n\nAssessment:\n- The patient is an 8-year-old boy, which fits the age criterion (6 to 18 years old).\n- GCS of 6/15, which meets the criterion of a GCS < 15 for the m-TBI group.\n- The patient had a traumatic event, although it was due to a bicycle accident rather than a motor vehicle accident.\n- The trial specifically mentions PTSD diagnosis due to a motor vehicle accident, and there is no indication that the boy has PTSD or that the traumatic event was a car accident.\n- The language spoken by the patient is not specified, and it's unclear if it matches the inclusion criterion.\n- The diagnosis of mTBI has not been confirmed by CT/MRI/fMRI as per the clinical note, and the patient was advised to receive immediate treatment instead.\n\nGiven the information provided, the patient does not fully meet the inclusion criteria for the clinical trial due to the cause of the injury (bicycle accident, not a motor vehicle accident), and there is no indication of PTSD or the required language spoken. However, he does meet the age and GCS criteria. Therefore, he would not be referred for this clinical trial based on the current information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1154": {
        "output": "",
        "label": 0
    },
    "1155": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial for the vaccine candidate against schistosomiasis named Bilhvax, it is evident that the patient does not meet the necessary criteria for the following reasons:\n\n1. Age: The patient is an 8-year-old boy, and the inclusion criteria do not specify an age range, but it refers to \"adult healthy volunteers,\" which typically would not include children.\n2. Health Status: The patient has suffered a significant traumatic injury with a current medical emergency, which does not align with the requirement for \"healthy volunteers.\"\n3. Race: The inclusion criteria specify \"Caucasian volunteers,\" and there is no information provided about the race of the patient.\n4. Smoking Status: While it is not explicitly mentioned whether the child smokes, it is highly unlikely given his age, and this criterion is generally not applicable to children.\n5. Biological Parameters: Given the patient's current medical emergency, it is unlikely that all biological parameters are within the normal range as required.\n6. Health Insurance: There is no information provided about the patient's health insurance status.\n7. Informed Consent: The patient is a minor and would not be able to sign informed consent; this would need to be done by a parent or legal guardian.\n\nGiven these points, the patient is clearly not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1156": {
        "output": "Assessing the eligibility of the 8-year-old boy for the clinical trial titled \"The Affect of a Ventilated Helmet on Physiological Load\" based on the provided inclusion criteria:\n\n- The trial is looking for healthy civilian volunteers.\n- The age range specified for participants is 21-28 years old.\n- Participants should be without known medical illnesses or medication use.\n\nThe patient note describes an 8-year-old boy who has suffered a head injury and is showing signs of significant physiological stress (low heart rate, high blood pressure, low GCS, etc.), indicating that he is not healthy at the moment due to the accident.\n\nGiven the provided inclusion criteria and the patient's current medical state, the 8-year-old boy does not meet any of the criteria. He is not within the age range, he is not healthy due to his recent injury, and he is not a volunteer but a patient in need of medical care.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1157": {
        "output": "",
        "label": 0
    },
    "1158": {
        "output": "The patient described in the patient note is an 8-year-old boy who suffered a head injury after falling from his bike. He exhibited symptoms such as drowsiness, paleness, vomiting, a heart rate of 52/min, high blood pressure, a Glasgow Coma Scale (GCS) score of 6/15, asymmetrical pupils, and impaired movement of the right upper and lower extremities.\n\nAccording to the inclusion criteria of the clinical trial, eligible patients must have experienced a blunt trauma to the head within 24 hours with a GCS of 13 to 15 and possess at least one of the specified risk factors.\n\nThe patient in question does not meet the GCS requirement of 13 to 15, as his GCS is noted to be 6/15, indicating a more severe injury than what the study is targeting (mild head injury). Therefore, the patient would not be eligible for this clinical trial based on the GCS criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1159": {
        "output": "After comparing the patient note with the inclusion criteria of the Leuven Growing Into Deficit Follow-up Study, it is clear that the patient does not meet the criteria for the following reasons:\n\n- The patient is described as an 8-year-old boy, whereas the inclusion criteria specifically require seven-year-old children.\n- The patient fell from his bike, which is not related to having a congenital heart disease (CHD), nor is there any indication that the patient has CHD or underwent cardiac surgery as an infant, which are requirements for the CHD-group in the study.\n- The patient note does not indicate that this child has previously participated in the specified Paediatric ICU follow-up study at the age of four, which is a prerequisite for inclusion.\n\nGiven these discrepancies, the patient is not eligible for the Leuven Growing Into Deficit Follow-up Study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1160": {
        "output": "Given the patient's note, we have an 8-year-old boy who suffered a traumatic injury from falling off his bike and striking his head, leading to concerning symptoms such as drowsiness, paleness, vomiting, and a Glasgow Coma Scale score of 6/15. He requires immediate medical attention, which aligns with the nature of the clinical trial that is focused on pediatric trauma patients.\n\nNow, reviewing the clinical trial's inclusion criteria:\n\n1. Pediatric trauma patients with Injury Severity Score greater than 12\n2. Age 1-17 years\n3. Trauma within 8 hours\n\nThe patient fits the age criterion (2), being an 8-year-old boy. The trauma occurred within the required timeframe (3), as the symptoms developed half an hour after the fall, and he was transferred to the emergency department, which suggests that the treatment initiation is within 8 hours of the injury.\n\nHowever, the Injury Severity Score (ISS) is not explicitly mentioned in the patient note (1). Since the ISS is a medical score to assess trauma severity, and given the severity of the symptoms described (e.g., GCS of 6/15, asymmetrical pupils, impaired movement, and the need for immediate treatment without CT), it can be inferred that the boy likely has a significant injury that may correspond with an ISS greater than 12.\n\nBased on the information provided and the alignment with the inclusion criteria of the clinical trial, it is reasonable to consider that this patient might be eligible for the trial. However, the exact ISS would need to be confirmed for definitive eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1161": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the age criterion for the study. The inclusion criteria specifically state that participants must be 18 years or older, and the patient in question is only 8 years old.\n\nTherefore, despite the patient having a traumatic brain injury (TBI) which is relevant to the study, the age exclusion is a strict criterion that cannot be overlooked. Consequently, the patient is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1162": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria provided, it is clear that the patient does not meet the required criteria for the clinical trial. The patient is an 8-year-old boy, which is below the age range specified in the trial's inclusion criteria, which requires participants to be between the ages of 10 and less than 17 years old. Furthermore, the patient does not have a diagnosis of diabetes or diabetic ketoacidosis, which is another requirement for the clinical trial.\n\nThe patient's condition, described as a head injury resulting from a fall from a bike, is not related to the focus of the clinical trial, which is to understand the effects of diabetic ketoacidosis on brain compliance, learning, and behavior.\n\nTherefore, based on the available information, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1163": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, it appears that the 8-year-old boy who suffered a traumatic brain injury (TBI) from a bike accident could be a candidate for the clinical trial titled \"Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI).\"\n\nLet's review the inclusion criteria for the trial and match them with the patient's characteristics:\n\n1. TBI patients admitted to the pediatric intensive care service (PICU) or pediatric progressive care unit: The patient note does not explicitly mention the child being admitted to PICU or progressive care unit, but given the severity of the symptoms (GCS of 6/15 and asymmetrical pupils), it is highly likely that he would be admitted to one of these units.\n\n2. Range in age from birth to 15 years: The patient is 8 years old, which fits within the required age range.\n\n3. TBI with a Glasgow Coma Scale of 3-15: The patient has a GCS of 6/15, which is within the specified range.\n\n4. Acoustic window for adequate transcranial doppler (TCD) ultrasound: There is no information in the patient note regarding the availability of an acoustic window for TCD ultrasound; however, this is typically assessed after admission, and there is no indication that the patient would not have this.\n\n5. English or Spanish speaking or understanding parent/legal guardian to consent: The patient note does not mention the language spoken by the parent or legal guardian, but this is a simple criterion that can be confirmed upon further investigation.\n\n6. Access for a buccal swab for genotyping: The patient note does not mention any issues that would prevent a buccal swab from being taken for genotyping.\n\nGiven that the patient meets the age, GCS score criteria, and likely the admission criteria for TBI, and there is no information to suggest the other criteria can't be met, it is reasonable to:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1164": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, the patient does not meet the following eligibility criteria:\n\n1. Age \u2265 60 years old: The patient is an 8-year-old boy.\n2. Ethnic Chinese: There is no information provided about the patient's ethnicity.\n3. Diagnosed with symptomatic chronic subdural haematoma: The patient had a recent fall and symptoms suggesting an acute neurological event, but there is no mention of a chronic subdural haematoma diagnosis.\n\nGiven the information provided, the patient does not meet the age and potential diagnosis criteria for the trial. Thus, the patient would not be eligible for the clinical trial focused on chronic subdural haematoma in patients who are 60 years old or above and of ethnic Chinese.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1165": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- An 8-year-old boy\n- Fell from his bike with a head injury\n- Presented with a Glasgow Coma Scale (GCS) of 6/15, indicating a severe brain injury\n- There are signs of neurological deterioration, such as asymmetrical pupils and impaired movement of extremities\n\nClinical Trial Inclusion Criteria:\n- Subjects of 18 or more years old\n- Patients with disorders of consciousness (Glasgow Coma Scale < 9) requiring hourly pupillary surveillance in neurosurgical intensive care\n- Acute brain injury due to various potential causes\n- Admission to intensive care within the first 48 hours of the injury\n\nThe major disqualifying factor for this clinical trial is the age of the patient. The clinical trial requires participants to be 18 years or older, and the patient in question is only 8 years old. Therefore, despite the relevance of his brain injury and the need for intensive care, he does not meet the age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1166": {
        "output": "",
        "label": 0
    },
    "1167": {
        "output": "Given the patient note, the key details are:\n\n- The patient is an 8-year-old boy.\n- He experienced a head injury from falling off his bike.\n- He showed signs of neurological impairment after the accident.\n\nThe clinical trial in question has the following inclusion criteria:\n\n- Patients must be at least 18 years of age.\n- They must be presenting with a symptomatic chronic subdural hematoma.\n- The presence of chronic subdural hematoma must be verified on cranial CT or MRI.\n\nBased on the provided information, the 8-year-old boy does not meet the age criterion for the clinical trial, which requires patients to be at least 18 years old. Additionally, it is not specified in the patient note whether the boy has a chronic subdural hematoma, which is a requirement for inclusion in the study.\n\nTherefore, the patient would not be eligible for this clinical trial due to the age restriction and the lack of specified diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1168": {
        "output": "To determine the eligibility of the 8-year-old boy for the clinical trial titled \"Methylphenidate for Attention Problems After Pediatric TBI,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nInclusion Criteria for the Clinical Trial:\n1. Between ages of 6-17 (the boy is 8 years old, so this criterion is met)\n2. Sustained Moderate to Severe TBI\n3. TBI occurred at least 6 months prior to beginning the study\n4. TBI occurred no earlier than 5 years of age\n5. Positive endorsement of 6 out of 9 items on the Vanderbilt ADHD inattention or hyperactivity scale\n\nBased on the patient note:\n- The boy is 8 years old, which meets the age criterion.\n- He has sustained a head injury which is indicative of a TBI, but there is no information to classify it as moderate or severe at this point.\n- The TBI occurred very recently (\"half an hour after the fall\"), so this does not meet the criterion of having occurred at least 6 months prior to beginning the study.\n- The injury did occur after the age of 5, which meets another criterion.\n- There is no information provided regarding symptoms of attention or hyperactivity problems, nor is there mention of the Vanderbilt ADHD scale being administered.\n\nGiven the information provided, the boy does not meet all of the inclusion criteria, particularly the one stating that the TBI must have occurred at least 6 months prior to beginning the study. Therefore, he is not eligible to participate in the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1169": {
        "output": "Based on the inclusion criteria of the HIPP Study, the patient in question does not meet several key eligibility requirements:\n\n- Age: The patient is 8 years old, while the study requires participants to be 18 years or older.\n- Time since injury: The patient's injury is very recent, and the study requires the head injury to have occurred at least 6 months prior.\n- TBI severity: The study specifies a mild TBI (Traumatic Brain Injury) with a score of 2 or 3 on the OSU-TBI ID Survey, but there is not enough information to determine the TBI severity of the patient using this survey. Additionally, the patient's GCS score of 6/15 suggests a more severe injury than mild TBI.\n- Visual acuity: There is no information provided about the patient's visual acuity.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1170": {
        "output": "Based on the information provided, the patient is an 8-year-old boy. The inclusion criteria for the clinical trial specify that participants must be of an estimated age of 15 years or older (or have an estimated weight > 50 kg if age is unknown). Since the patient's age is known and is below the minimum age requirement for the trial, he would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1171": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the age requirement specified in the trial's inclusion criteria. The trial requires participants to be aged between 18 and 90 years old, and the patient in question is an 8-year-old boy. Therefore, regardless of other factors, this patient is not eligible for the clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1172": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet the specified criteria for the clinical trial in question. The patient is an 8-year-old boy, which is below the age range specified in the inclusion criteria (18-85 years of age). Additionally, the patient note does not specify that the child has experienced a spontaneous intracranial or intraparenchymal hemorrhage, which is a requirement for the trial. Instead, the patient has suffered a trauma from a fall, which is not mentioned as a qualifying event for this study.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1173": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the 8-year-old boy for the study titled \"To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients.\"\n\nPatient Note:\n- The patient is an 8-year-old boy.\n- He has a traumatic injury due to falling from a bike and striking his head.\n- There is no mention of an acute subdural hematoma, but his clinical symptoms suggest a serious brain injury (dropped GCS, asymmetrical pupils, impaired movement in extremities).\n- The Glasgow Coma Scale (GCS) upon arrival at the emergency department is 6/15.\n\nClinical Trial Inclusion Criteria:\n- Non-penetrating traumatic brain injury: The patient seems to meet this criterion.\n- Glasgow Coma Scale (GCS) motor score \u22645 (not following commands): The patient's overall GCS is 6/15, but the motor score component is not specifically mentioned.\n- Estimated or known age 22-65 years: The patient does not meet this age criterion as he is 8 years old.\n- Acute subdural hematoma requiring emergent craniotomy within 6 hours of initial injury: There is no mention of an acute subdural hematoma or requirement for craniotomy in the patient note, though the symptoms suggest a serious brain injury.\n- Estimated time of injury to time to reach temp of 35\u00b0C<6 hrs: There is no information provided about the time of injury or temperature management.\n\nThe critical factor that disqualifies the patient from the clinical trial is his age, which is outside the specified range of 22-65 years. Additionally, there is insufficient information to confirm other criteria such as the presence of an acute subdural hematoma, the need for craniotomy, and the specifics of the GCS motor score and temperature management timeline.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1174": {
        "output": "Reviewing the patient note and the inclusion criteria for the clinical trial titled \"Concussion and Post Traumatic Stress in Traumatic Brain Injury,\" we can determine the patient's eligibility.\n\nPatient note:\n- An 8-year-old boy with a traumatic event (fell from bike, struck left temple)\n- No immediate loss of consciousness but developed symptoms within half an hour (drowsiness, pallor, vomiting)\n- Vital signs: heart rate 52/min, blood pressure 155/98\n- Glasgow Coma Scale (GCS) was 6/15, indicating severe injury\n- Asymmetrical pupils and impaired movement of right upper and lower extremities\n- Immediate treatment was initiated without a CT scan\n\nClinical trial inclusion criteria:\n- Recruitment from Bellevue Hospital Emergency Services or inpatient populations\n- Consentable and able/willing to participate\n- Fitting into one of the three subject populations:\n  1. mild to moderate structural TBI with evidence on CT scan\n  2. non-structural TBI (concussion) with no structural injury on imaging but with symptoms\n  3. Non-brain injured subjects with other types of injuries\n\nThe patient in the note is an 8-year-old who has suffered a significant brain injury, as indicated by the low GCS score of 6/15, which is suggestive of a severe brain injury rather than a mild or moderate TBI. The clinical trial is looking for subjects with mild to moderate TBI or non-structural TBI (concussion), not severe TBI. Furthermore, the patient is underage, and the trial does not specify inclusion of pediatric patients.\n\nGiven that the patient's condition seems more severe than what the trial is aiming to study and considering the patient's age, which is not explicitly addressed in the inclusion criteria, it is unlikely that this patient would be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1175": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet several critical inclusion criteria for the trial:\n\n1. Age \u226518 and <90 years old: The patient is an 8-year-old boy, which does not meet the age criterion of being 18 years or older.\n2. The inclusion criteria specify that the patient should have a coagulation disorder due to long-term antiplatelet and anticoagulant drugs, which is not mentioned in the patient note.\n3. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma: The patient note does not mention a chronic subdural hematoma diagnosis, nor does it indicate that a CT scan has been completed to confirm such a diagnosis.\n\nGiven these discrepancies, it is clear that the patient does not meet the necessary inclusion criteria to participate in the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1176": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)\", the patient does not meet the specified inclusion criteria for the following reasons:\n\n1. The inclusion criteria require that the patients must be trauma patients at risk of significant bleeding, defined by specific hemodynamic criteria and the need for red blood cell transfusion.\n\n2. Although the patient experienced trauma from falling off a bike and presented with a serious condition indicated by a low Glasgow Coma Scale (GCS) score, asymmetrical pupils, and hemodynamic instability, it's not clearly stated that the patient is at risk of significant bleeding, nor is there a mention of a red blood cell transfusion being ordered.\n\n3. The patient's blood pressure is noted as 155/98, which is above the threshold of \u2264100mmHg systolic blood pressure as defined in the inclusion criteria.\n\nBased on this information, the patient does not clearly meet the specified inclusion criteria for the clinical trial. However, given the serious condition of the patient and the potential for significant bleeding due to the nature of the head injury, further investigation may be warranted to determine if the patient could be at risk of significant bleeding and if the trauma team leader considers ordering a red blood cell transfusion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1177": {
        "output": "Given the patient note and the clinical trial inclusion criteria, we can determine the trial-level eligibility as follows:\n\n- The patient is an 8-year-old boy, which does not meet the age requirement of the clinical trial that requires participants to be \u2265 18 years of age.\n- The Glasgow Coma Scale (GCS) for the boy is 6/15, indicating a severe level of impaired consciousness. The clinical trial requires that the patient be able to have a normal conversation and understand the information about the study, which corresponds to a Glasgow Coma Scale (Verbal Response) of 5. The boy's condition does not allow for this level of communication.\n- The patient note does not mention chronic subdural hematoma, nor does it mention that the patient has been admitted for surgery of chronic subdural hematoma, which is a requirement for the clinical trial.\n- The trial requires that a CT scan of the patient has been performed within the latest 96 hours. The patient note indicates that the neurosurgical team deferred the CT scan in favor of initiating immediate treatment, meaning this criterion is also not met.\n- There is no information provided about informed consent, but given the age and condition of the patient, it is unlikely that informed consent could be appropriately obtained.\n\nBased on these points, the 8-year-old boy does not meet the inclusion criteria for the clinical trial evaluating the sensitivity and specificity of microwave-based technology to detect chronic subdural hematoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1178": {
        "output": "Based on the patient note and the clinical trial's inclusion and exclusion criteria provided, the patient's eligibility can be assessed as follows:\n\nThe patient note describes an 8-year-old boy who suffered a head injury after falling from his bike. The clinical trial is looking for patients who have had a spontaneous subarachnoid hemorrhage (SAH), and the inclusion criteria specify that the patients must be 18 years or older and have a Glasgow Coma Scale (GCS) of 12 or less.\n\nThe patient in question does not meet the inclusion criteria for several reasons:\n\n1. The patient's age is 8 years, which is below the minimum age requirement of 18 years.\n2. The patient's injury is related to trauma (fall from a bike), whereas the trial is specifically for spontaneous SAH, not trauma-induced.\n3. The patient's GCS is 6/15, which would normally fit the inclusion criteria for GCS; however, because the SAH is not spontaneous, this point is moot.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1179": {
        "output": "Based on the patient note provided, the patient is an 8-year-old boy who suffered a head injury from a fall. There is no indication in the patient note that he is a survivor of bone or soft tissue sarcomas, nor is there any mention of him receiving any chemotherapy, let alone specific protocols listed in the inclusion criteria of the clinical trial. Furthermore, the trial is retrospective, meaning it is looking back at patients who have already received treatment.\n\nThe inclusion criteria for the clinical trial specify that participants must be survivors of pediatric bone or soft tissue sarcomas who were treated with specific treatment protocols. Since the patient in question does not meet these criteria, he would not be eligible for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1180": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the 8-year-old boy does not meet the primary inclusion criteria for the clinical trial focused on opioid withdrawal syndrome in critically ill adult patients. The inclusion criteria specify that the study is for adult patients who have been on intermittent use or continuous infusion of opioids for at least 96 hours. The patient note does not indicate that the boy has been on opioids, nor is he an adult patient, as he is only 8 years old.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1181": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nPatient note summary:\n- The patient is an 8-year-old boy.\n- He experienced a head injury from falling off his bike and hitting his temple.\n- There are signs of neurological impairment post-injury (drowsiness, vomiting, asymmetrical pupils, impaired movement, GCS of 6/15).\n- No mention of subdural hematoma or conservative treatment with dexamethasone.\n\nClinical trial inclusion criteria:\n- 18 years and older.\n- Evidence of subacute or chronic supratentorial subdural hematoma by CT/MRI.\n- Classified between 0 and 2 using the Markwalder grading scale.\n\nThe patient does not meet the inclusion criteria for the clinical trial for the following reasons:\n1. The patient is 8 years old, which is below the minimum age requirement of 18 years.\n2. There is no mention of a confirmed subacute or chronic subdural hematoma diagnosis by CT/MRI.\n3. There is no information provided to classify the patient using the Markwalder grading scale.\n\nGiven the discrepancies between the patient's condition and the trial's inclusion criteria, it is clear that the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1182": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility for the \"Handlebar Grip Related Injury Prevention (GRIP) Study\":\n\n- The patient is an 8-year-old boy.\n- The patient fell from his bike and sustained an injury (striking his left temple on the pavement).\n- The patient presented to the emergency department for assessment/treatment following the injury.\n- The incident involved a non-motorized bicycle.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n- Children 0-15 years inclusive (the patient is 8 years old, which meets this criterion).\n- Presenting to either of the study hospitals for assessment or treatment (the patient was transferred to the emergency department for treatment).\n- Sustained an injury or suspected to have sustained an injury (i.e. AIS >=0) (the patient sustained an injury due to the fall).\n- Due to an incident involving any non-motorized bicycle, tricycle or kick scooter (the patient's injury was due to a bicycle incident).\n\nGiven the information provided, the patient meets all the inclusion criteria for the GRIP Study. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1183": {
        "output": "Based on the information provided, the patient is an 8-year-old boy who has suffered a traumatic brain injury (TBI) due to a fall from his bike. This patient would meet the general condition of having a TBI for which a head CT scan is indicated.\n\nHowever, the inclusion criteria for the clinical trial specify that the trial is for children less than 72 months old (6 years) who present to the Children's Hospital Colorado (CHCO) Emergency Department (ED) or inpatient wards. Since the patient in the note is 8 years old, which is 96 months old, he exceeds the age limit set by the clinical trial's inclusion criteria.\n\nTherefore, despite the patient's condition aligning with the focus of the study, he is not eligible to participate due to not meeting the age requirement. Since this is a clear exclusion based on age, there is no need for further investigation, and the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1184": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient would not be eligible for the trial. The inclusion criteria specify that participants must have a vestibular schwannoma advised for surgical treatment with no measurable remaining vestibular function. The patient note describes an 8-year-old boy with a head injury from a biking accident, which is unrelated to vestibular schwannoma or its treatment. \n\nTherefore, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1185": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the criteria for the trial in question.\n\nThe patient is an 8-year-old boy who experienced trauma from a fall, resulting in acute neurological symptoms. This clinical scenario is unrelated to the study's focus, which involves adult patients undergoing elective head and neck surgery and the effects of remifentanil on post-operative recovery. Additionally, the patient's condition is emergent, and he is not scheduled for elective surgery, let alone head and neck surgery.\n\nThe inclusion criteria for the trial specify:\n1. Patients with ASA I to II, which refers to the American Society of Anesthesiologists' physical status classification system for assessing the fitness of patients before surgery. ASA I indicates a normal healthy patient, while ASA II indicates a patient with mild systemic disease.\n2. Scheduled for elective head and neck surgery with a minimum expected duration of 2 hours.\n3. Requiring general anesthesia.\n\nThe patient in question fails to meet these criteria since he is:\n- Underage (8 years old, whereas the trial does not specify including children).\n- Not scheduled for elective surgery, much less head and neck surgery.\n- Currently in an emergency situation, not a controlled surgical setting.\n\nTherefore, this patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1186": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 8-year-old boy who fell from his bike and experienced traumatic brain injury (evidenced by drowsiness, vomiting, and a GCS of 6/15) would be eligible for the study. The trial is looking for patients who have been treated in the ICU for traumatic or nontraumatic brain damage and have stayed for more than 24 hours. The patient note indicates that the child required immediate treatment, which likely includes ICU care, although it is not explicitly stated.\n\nHowever, it is important to note that while the child's condition aligns with the study's focus on brain damage, there is no specific mention of the duration of the ICU stay in the patient note. Since the trial requires a more than 24-hour stay, we would need additional information to confirm the child's eligibility based on the duration of their ICU stay.\n\nGiven the information we have, it seems that the patient fits the general profile of the study's target, but more information would be needed to ensure all criteria are met, specifically regarding the length of the ICU stay.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1187": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial titled \"Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children.\"\n\nPatient note details:\n- The patient is an 8-year-old boy, which fits within the age range of 2 to 17 years required by the trial.\n- The patient fell from his bike and struck his head, not a mention of a long-bone fracture.\n- There's no information provided about any suspected fracture, nor about any analgesia requirement such as a VAS score or an Evendol score.\n- The patient is experiencing neurological symptoms (drowsiness, vomiting, GCS 6/15, asymmetrical pupils, and impaired movement of extremities) which are not directly indicative of a long-bone fracture.\n- The trial requires that the child has a suspected fracture of a long bone requiring morphine analgesia, and this information is not available in the patient note. The symptoms described are more indicative of a head injury rather than a long-bone fracture.\n\nInclusion criteria of the clinical trial:\n- Children aged 2 through 17 years.\n- Suspected fracture of a long bone requiring morphine analgesia.\n- Within the first 12 hours after the injury.\n- At least one signed parental informed consent.\n- Affiliated to health insurance.\n\nBased on the available information, the patient does not meet the specific criteria of having a suspected fracture of a long bone that requires morphine analgesia. The patient seems to have sustained a head injury, which is not the focus of this particular clinical trial. Therefore, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1188": {
        "output": "",
        "label": 0
    },
    "1189": {
        "output": "Based on the information provided:\n\nThe patient is an 8-year-old boy who has suffered a head injury due to a fall from his bike. He presented with symptoms indicative of an acute neurological issue, including drowsiness, vomiting, a Glasgow Coma Scale (GCS) of 6/15, asymmetrical pupils, and impaired movement of the right extremities.\n\nThe clinical trial in question is investigating the use of Tranexamic Acid (TXA) in patients with Chronic Subdural Hematomas (CSDH). The inclusion criteria for the trial are a CT scan demonstrating the existence of a subdural hematoma containing a chronic component and a diagnosis within the last 14 days.\n\nThe patient note does not mention a diagnosis of chronic subdural hematoma; instead, it suggests an acute neurosurgical emergency given the recent trauma and rapid onset of symptoms. Additionally, the trial is likely looking for adult patients given the typical context in which TXA is used and the dosages mentioned, although it's not explicitly stated in the inclusion criteria provided.\n\nTherefore, without evidence of a chronic component to the hematoma and considering the acute presentation of the patient's condition and his young age, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1190": {
        "output": "Based on the information provided, the group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil and requires malaria chemoprophylaxis. However, the clinical trial in question is aiming to determine the efficacy of azithromycin in combination with chloroquine versus chloroquine alone in eradicating P. falciparum asexual parasitemia in asymptomatic, semi-immune adults in Western Kenya.\n\nThe inclusion criteria for the trial require participants to be healthy adults, asymptomatic with a specific range of P. falciparum parasitemia, aged between 18 and 60, and willing and able to consent and return for follow-up visits.\n\nThe patient note does not mention any of the individuals being infected with P. falciparum or having parasitemia within the specified range. Without this information, we cannot assume that any of the humanitarian service workers meet the trial's infection criteria. Additionally, the trial location is in Western Kenya, which may not align with the plans of the service workers traveling to Brazil.\n\nFurthermore, the fact that three of the women are in different stages of pregnancy would require careful consideration, as pregnancy may be a contraindication for participation in such trials due to potential risks to the fetus from the study medications.\n\nGiven the lack of information on parasitemia and the geographical mismatch, along with pregnancy concerns, I would conclude:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1191": {
        "output": "",
        "label": 0
    },
    "1192": {
        "output": "",
        "label": 0
    },
    "1193": {
        "output": "",
        "label": 1
    },
    "1194": {
        "output": "Based on the patient note provided and comparing it to the inclusion criteria of the clinical trial:\n\nPatient Note:\n- A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil.\n- All members have up-to-date vaccine certificates.\n- Malaria Chemoprophylaxis is indicated.\n- Three of the women are in different stages of pregnancy.\n\nClinical Trial Inclusion Criteria:\n- Age > 1 year\n- Axillary temperature \u2265 37.5\u00baC and/or history of fever in the previous 48 hours without any other evident cause\n- Unmixed infection with P. falciparum of between 250 and 100,000 asexual parasites/mm3 as determined by microscopic exam\n- An informed consent obtained from the patient or his/her guardian (in case of patients \u2264 18 years old) and assent for children (8-18 years old)\n- Willingness to come to the health facility for the following 28 days\n\nThe information provided in the patient note does not indicate that any of the 14 humanitarian service workers have a confirmed diagnosis of uncomplicated malaria due to P. falciparum, nor does it mention any clinical signs such as fever that would meet the trial's inclusion criteria. Additionally, for the three pregnant women, the trial does not specify whether pregnant women are eligible or not, but typically, special considerations are required for including pregnant women in clinical trials due to potential risks to the fetus.\n\nGiven the lack of information suggesting that any of the service workers have malaria and the specific needs of the pregnant women, it is not appropriate to refer this group to this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1195": {
        "output": "The patient note mentions three women in different stages of pregnancy who are part of a group preparing for a trip to the Amazon Rainforest region in Brazil. They have up-to-date vaccine certificates and require malaria chemoprophylaxis.\n\nThe clinical trial is assessing the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travelers. However, an important point in the inclusion criteria specifies that female patients are eligible to participate in the study only if they are of non-childbearing potential or have a negative pregnancy test and are using an acceptable contraceptive method.\n\nSince the patient note explicitly states that there are three women who are pregnant, these individuals do not meet the inclusion criteria for the clinical trial, which requires female participants to not be of childbearing potential or have a negative pregnancy test and be using contraception. Therefore, the three pregnant women would not be eligible for participation in this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1196": {
        "output": "Based on the patient note, we have a group of 14 humanitarian service workers, among which three are pregnant women preparing to travel to the Amazon Rainforest region in Brazil. Malaria chemoprophylaxis is indicated for these individuals.\n\nThe clinical trial in question is focused on the control of pregnancy-associated malaria with intermittent preventive treatment in Ghana. It is looking for women in their first and second pregnancies who are permanent residents in the study area. \n\nThe inclusion criteria for the clinical trial are:\n\n1. Primigravida (first pregnancy)\n2. Secundigravida (second pregnancy)\n3. Permanent resident of the study area\n4. Hemoglobin (Hb) level above 7 g/dl\n\nSince the patient note indicates that the pregnant women are preparing for travel and not permanent residents of the study area in Ghana, they do not meet the inclusion criteria related to residency. Additionally, the note does not provide specific information about whether these women are in their first or second pregnancies, nor does it provide hemoglobin levels, which are also necessary to determine eligibility.\n\nGiven the information provided, the pregnant women do not meet the residency criteria and lack specific information on their gravidity and hemoglobin levels. Therefore, they are not eligible for this clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1197": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the group of humanitarian service workers, including the three pregnant women, are not eligible for the clinical trial titled \"Early Childhood Malaria Prevention With Maloprim in The Gambia.\" The trial is specifically focused on children who were part of the original trial in the 1980s and were aged 3-59 months at that time. \n\nThe humanitarian service workers and the pregnant women do not meet the age criteria as they are adults, and there is no indication that any of them were part of the original trial as children. Furthermore, the follow-up of the trial involves participants who were in the original trial for at least one year, and there is no information to suggest that this applies to the humanitarian service workers.\n\nTherefore, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1198": {
        "output": "Given the patient note, the group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil are not suitable for the clinical trial described, which is focused on HIV-1 individuals who are also permanent residents of the Luanshya district in Zambia. Additionally, the trial specifies that participants must be non-pregnant adults between 18 and 50 years old and have a CD4 cell count of at least 350 per \u00b5L at enrolment, with their HIV sero-status determined at the VCT of the health center.\n\nThe patient note does not provide information on the HIV status or CD4 cell counts of the individuals, nor do they meet the residency requirement as they are preparing to travel and are not indicated as permanent residents of the Luanshya district. Furthermore, the trial explicitly excludes pregnant women, and it is mentioned that three of the women in the group are in different stages of pregnancy.\n\nBased on these discrepancies between the patient note and the inclusion criteria of the clinical trial, it is clear that the group of humanitarian service workers is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1199": {
        "output": "The patient note describes a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil, all of whom have up-to-date vaccine certificates. Malaria chemoprophylaxis is indicated, and three of the women in the group are pregnant.\n\nThe clinical trial is investigating the efficacy and safety of Dihydroartemisinin/Piperaquine (Artekin\u00ae) for the treatment of uncomplicated malaria in Peru. The trial includes individuals aged 5 - 60 years old who have a fever or a history of fever in the previous 24 hours and a monoinfection with P. falciparum, with parasitic density within a specified range. The trial requires informed consent to be provided by the patient or their parent/legal tutor.\n\nImportantly, the exclusion criteria for the clinical trial include pregnancy. Since three of the women in the group are pregnant, they would be excluded from participation based on this criterion alone.\n\nGiven this information, the three pregnant women would not be eligible for this clinical trial due to the explicit exclusion of pregnant individuals. There is no mention of malaria infection or fever in the patient note for the other members of the group; therefore, there is insufficient information to determine their eligibility based solely on the provided patient note.\n\nHowever, if we assume that the other members of the group may be at risk of malaria due to their travel to an endemic area and could potentially meet the other inclusion criteria, we could consider a tentative assessment of eligibility upon further investigation of their individual health statuses.\n\nFor the three pregnant women:\nTrial-level eligibility: 0) Would not refer these patients for this clinical trial.\n\nFor the other members of the group:\nTrial-level eligibility: 1) Would consider referring these patients to this clinical trial upon further investigation.",
        "label": 0
    },
    "1200": {
        "output": "Given the patient note:\n\n- A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil.\n- All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates.\n- Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.\n\nAnd the clinical trial details:\n\n- Title: Study to Investigate the Induction of a Protective Immune Response to Malaria\n- Inclusion Criteria: Age > 18 and < 45 years healthy volunteers (males or females), general good health based on history and clinical examination, all volunteers have to sign the informed consent form, negative pregnancy test, use of adequate contraception for females, reachable by phone during the whole study period, volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the trial.\n\nComparing the patient note with the inclusion criteria of the clinical trial, the following observations can be made:\n\n- The humanitarian service workers are likely older than 18 years and potentially younger than 45, but their exact ages are not specified.\n- They all have up-to-date vaccine certificates, which could imply general good health, but their individual health statuses are not detailed.\n- Three of the women are pregnant, which means they would not have a negative pregnancy test and are not using adequate contraception, as required by the trial's inclusion criteria.\n\nBased on the inclusion criteria and the patient note, the three pregnant women would clearly be ineligible for the trial due to the pregnancy exclusion. There isn't enough information about the other individuals in the group to make a comprehensive assessment of their eligibility. However, if any of the remaining group members are within the age range and meet the other health criteria, they might be considered for the trial.\n\nConsidering the above, the trial-level eligibility for the entire group would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1201": {
        "output": "Based on the provided patient note and the clinical trial information, the patient note indicates that there are three women in different stages of pregnancy who require Malaria Chemoprophylaxis for their trip to the Amazon Rainforest region in Brazil. The clinical trial is focused on pregnant women in Burkina Faso and looks at different approaches for the delivery of Intermittent Preventive Treatment in Pregnancy (IPT/SP).\n\nThe inclusion criteria for the clinical trial are:\n- Pregnant women of all parities\n- Second trimester\n\nThe patient note does not provide enough information about the specific trimesters of the pregnant women; it only states that they are in \"different stages of pregnancy.\" Without knowing if any of the three pregnant women are specifically in their second trimester, it is not possible to determine if they meet the inclusion criteria based on the information given.\n\nTherefore, based on the current information, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need to confirm the gestational ages of the pregnant women to see if any are in their second trimester and thus eligible for the trial.",
        "label": 0
    },
    "1202": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the eligibility of the group of humanitarian service workers for the clinical trial.\n\nPatient Note Summary:\n- A group of 14 humanitarian service workers.\n- All have up-to-date vaccine certificates.\n- Malaria Chemoprophylaxis is indicated.\n- Three of the women are pregnant.\n\nClinical Trial Summary:\n- The trial is focused on infants in Tanzania.\n- It evaluates the efficacy of weekly iron supplementation and malaria chemoprophylaxis from 2 to 12 months of age.\n- Participants must be born in San Francis Designated District Hospital of Ifakara.\n\nBased on the information provided, the group of humanitarian service workers does not meet the inclusion criteria for the clinical trial, as the trial specifically requires participants to be infants born in a particular hospital in Tanzania. The group preparing for a trip to the Amazon Rainforest is not eligible for this trial focused on infants in a different continent.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1203": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can analyze the eligibility of the three pregnant women among the group of humanitarian service workers preparing a trip to the Amazon Rainforest.\n\nPatient Note:\n- There are three women who are in different stages of pregnancy.\n\nClinical Trial Inclusion Criteria:\n- All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7 weeks gestation.\n- Preterm labor will be defined by regular contractions and/or cervical change from the last documented exam.\n- Cervical exam 4 cm or greater.\n- Intact membranes.\n\nThe patient note does not provide specific information on whether any of the three pregnant women are experiencing preterm labor, their gestational weeks, cervical exam measurements, or the status of their membranes. Without this information, we cannot definitively determine if any of the women meet the inclusion criteria for the clinical trial.\n\nGiven the lack of detailed information on the gestational status and labor status of the pregnant women, it is not possible to make a referral for the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1204": {
        "output": "Based on the patient note and the clinical trial provided, it seems there is a mismatch between the patient profile and the clinical trial's focus:\n\nThe patient note describes a group of humanitarian service workers preparing for a trip and needing malaria chemoprophylaxis, with three of the women being in different stages of pregnancy.\n\nThe clinical trial is focused on functional outcome measures in orthopedic surgery using advanced tracking technologies and does not mention anything related to malaria, travel medicine, or pregnancy.\n\nFurthermore, the inclusion criteria listed for the clinical trial is \"Unwillingness to sign informed consent,\" which is unusual as clinical trials typically require willingness to sign informed consent as an inclusion criterion. It's possible there's an error in the provided information.\n\nGiven the information at hand and assuming there is no additional context that aligns the patient group's situation with the clinical trial's objectives, I would determine the following:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1205": {
        "output": "Given the patient note, we are looking at a group of 14 humanitarian service workers, among which three are pregnant women preparing to travel to the Amazon Rainforest region in Brazil. They are considering malaria chemoprophylaxis for their trip.\n\nThe clinical trial in question is investigating new approaches to improve the coverage and compliance of antimalarial treatment for pregnant women, but it is specifically set in rural Africa and focuses on women in their first or second trimester of pregnancy and those who are in their first or second pregnancy. Additionally, the women need to be residents in the study area.\n\nThe women in the patient note do not meet the geographic criteria since they are planning to travel to Brazil, not residing in rural Africa where the study is being conducted. Furthermore, there is no information provided about which trimester of pregnancy the women are in or whether this is their first or second pregnancy.\n\nBased on the information given, these women do not meet the inclusion criteria of the clinical trial specified. Hence, the trial-level eligibility for referring these patients to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1206": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the eligibility of the three pregnant women for the clinical trial titled \"Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine.\"\n\nThe patient note indicates that three of the women are in different stages of pregnancy, which meets one of the inclusion criteria of the clinical trial. However, the trial specifically requires participants to be HIV-infected, and there is no mention of HIV status in the patient note. Additionally, the other inclusion criteria such as permanent residency in the study catchment's area, Karnofsky index \u226580, willingness to deliver at the hospital, and written informed consent cannot be confirmed from the patient note.\n\nSince the HIV status of the women is not provided and other necessary information is missing, we cannot determine with certainty if they meet all the inclusion criteria. Therefore, further investigation would be needed to assess their eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1207": {
        "output": "Based on the given clinical trial inclusion criteria and the patient note, we can determine the eligibility of the group of humanitarian service workers for the clinical trial on Weekly Dosing of Malarone\u00ae for Prevention of Malaria.\n\nInclusion Criteria for the clinical trial include:\n- A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening\n- Free of clinically significant health problems\n- Baseline ECG before entering into the study\n- Available to participate for the duration of the study (approximately 4 months, not including the screening period)\n- If the participant is female, not pregnant or lactating and willing to use contraception to prevent pregnancy\n- BMI between 19 and 30\n\nFrom the patient note, we know that:\n- The group consists of humanitarian service workers\n- All members have up-to-date vaccine certificates\n- There are three women who are in different stages of pregnancy\n\nGiven this information, the three pregnant women would not meet the inclusion criteria for the trial, as pregnant females are specifically excluded from participating.\n\nHowever, the note does not provide information about the other members of the group, such as their age, BMI, health status, or willingness to undergo a baseline ECG. Assuming that among the remaining members, there might be eligible individuals who are within the age range, not pregnant, not lactating, with a BMI between 19 and 30, and without clinically significant health problems, they could potentially be considered for the trial.\n\nSince we lack complete information on the rest of the group, we cannot definitively determine their eligibility. Therefore, the trial-level eligibility for the group, as a whole, based on the available information, would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1208": {
        "output": "",
        "label": 0
    },
    "1209": {
        "output": "In the given patient note, we have a group of humanitarian service workers, with three of the women being at different stages of pregnancy. They are preparing for a trip to the Amazon Rainforest region in Brazil and require Malaria Chemoprophylaxis.\n\nThe clinical trial in question is titled \"The Chloroquine for Influenza Prevention Trial,\" which aims to determine the efficacy of chloroquine for the prevention of influenza. The inclusion criteria for this trial are:\n\n1. Age 18 -65\n2. Have the ability to provide informed consent\n3. If a woman of child-bearing potential, willing to use contraception for the period of the trial\n\nBased on the inclusion criteria provided, the three pregnant women would not be eligible for the trial as they would not be able to comply with the requirement to use contraception during the trial period, due to their current pregnancies.\n\nFor the rest of the group, assuming they all meet the age criterion and have the ability to provide informed consent, they could potentially be eligible for the trial. However, the patient note does not specify if the group is seeking preventative treatment for influenza or for malaria. Since the trial is specifically for the prevention of influenza, it would not be suitable for individuals seeking malaria chemoprophylaxis.\n\nGiven the information provided, and the specific focus on the pregnant women in the context of the patient note, the trial-level eligibility for referring the specific subgroup mentioned (the three pregnant women) would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1210": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note:\n- A group of 14 humanitarian service workers\n- All members have traveled on multiple occasions and have up-to-date vaccine certificates\n- Malaria Chemoprophylaxis is indicated\n- Three of the women are in different stages of pregnancy\n\nClinical Trial Inclusion Criteria:\n- Age > 18 and < 35 years healthy volunteers (males or females)\n- Good health based on history and clinical examination\n- Negative pregnancy test\n- Use of adequate contraception for females\n- All volunteers must sign the informed consent form\n- Volunteer agrees to inform the general practitioner\n- Willingness to undergo a Pf mosquito challenge\n- For volunteers not living in Leiden: agreement to stay in a hotel room close to the trial center during a part of the study\n- Reachable by mobile phone during the whole study period\n- Living with a third party that could contact the clinicians or agreement to stay in a hotel room close to the trial center\n- Available to attend all study visits\n- Agreement to refrain from blood donation during the study period\n- Willingness to undergo HIV, hepatitis B and C tests\n- Negative urine toxicology screening test at screening visit and day before challenge\n- Willingness to take a prophylactic regime of chloroquine and curative regimen of Malarone\u00ae\n\nFrom the patient note, we can determine:\n- The group is planning a trip, which may interfere with the requirement to attend all study visits and agreement to stay in a hotel room close to the trial center during a part of the study.\n- Three of the women are pregnant, which directly conflicts with the requirement for a negative pregnancy test and the use of adequate contraception.\n\nBased on the information provided, the three pregnant women would be ineligible for the trial due to the pregnancy. For the rest of the group, there is not enough information provided to determine their exact ages, their health status, or their availability and willingness to meet all the study requirements. Therefore, the eligibility of the remaining group members cannot be fully assessed without further information.\n\nHowever, given the clear ineligibility of the pregnant women and the potential issues with the group's travel plans, the overall assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1211": {
        "output": "Given the patient note, we have a group of 14 humanitarian service workers, among which three are pregnant women, preparing to travel to the Amazon Rainforest region in Brazil. They require malaria chemoprophylaxis.\n\nNow, let's assess the eligibility of the pregnant women for the clinical trial based on the inclusion criteria provided:\n\n- Age > 18 and < 35 years: The patient note does not provide age information for the pregnant women.\n- Healthy volunteers (males or females): Pregnancy is not typically considered a state of ill health, but it does come with physiological changes and potential complications.\n- Good health based on history and clinical examination: The health status of the women, aside from being pregnant, is not provided.\n- Negative pregnancy test: The three women are confirmed to be pregnant, which is a direct exclusion criterion.\n- Use of adequate contraception for females: As they are already pregnant, this point is not applicable.\n- All volunteers must sign the informed consent form: This is feasible if the other criteria are met.\n- Volunteer agrees to inform the general practitioner and agrees to sign a request to release medical information: This is feasible if the other criteria are met.\n- Willingness to undergo a Pf mosquito or blood stage challenge: The willingness of the individuals is not mentioned, but given the pregnancy, undergoing such a challenge could be unethical and risky.\n- For volunteers not living in Nijmegen: This is logistically dependent and not relevant to the immediate health eligibility criteria.\n- Reachable by mobile phone during the whole study period: This is logistically feasible.\n- Living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial center: This is logistically dependent.\n- Available to attend all study visits: This is feasible if the other criteria are met.\n- Agreement to refrain from blood donation: This is feasible if the other criteria are met.\n- Willingness to undergo HIV, hepatitis B and hepatitis C tests: This is feasible if the other criteria are met.\n- Negative urine toxicology screening test at screening visit and day before challenge: The ability to meet this criterion is not provided in the patient note.\n- Willingness to take a prophylactic regime of chloroquine and curative regimen of Malarone\u00ae: This is feasible if the other criteria are met, but the use of these medications during pregnancy would need to be carefully considered.\n\nThe most critical exclusion criterion for these patients is the confirmed pregnancy, which directly conflicts with the requirement for a negative pregnancy test and the use of adequate contraception. Therefore, these pregnant women would not be eligible for the clinical trial as stated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1212": {
        "output": "Given the patient note, we have a group of 14 humanitarian service workers, three of whom are women in different stages of pregnancy. The clinical trial in question is testing immunization with Plasmodium falciparum sporozoites under chloroquine versus mefloquine prophylaxis, and it is specifically seeking healthy volunteers who are not pregnant, as one of the inclusion criteria is a negative pregnancy test.\n\nSince three of the women are pregnant, they would automatically be excluded from this clinical trial based on the requirement for a negative pregnancy test and the use of adequate contraception. The trial is seeking healthy volunteers, which the remaining members of the group might qualify for, but the note does not specify the age, health status, or consent of the remaining individuals to meet the trial's criteria. Without this specific information, it is not possible to determine if the non-pregnant members of the group are eligible.\n\nConsidering the information provided and focusing on the three pregnant women, they do not meet the inclusion criteria due to their pregnancy status. Therefore, for the pregnant women:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1213": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nThe patient note mentions a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest. In this group, three of the women are at different stages of pregnancy and require malaria chemoprophylaxis. However, there is no information indicating that any of the women have microscopically confirmed uncomplicated P.vivax malaria, which is a requirement for inclusion in the clinical trial. Additionally, there is no information about the gestational ages of the pregnant women or whether they meet the other specific criteria listed.\n\nThe clinical trial is specifically looking to evaluate the pharmacokinetics of chloroquine in pregnant women in their 2nd or 3rd trimester who have P.vivax malaria and then compare it to the pharmacokinetics post-partum. The inclusion criteria are quite specific and include:\n\n1. Age 18-50 years\n2. Gestational age (ultrasound confirmed) > 13.0 weeks\n3. Viable fetus as assessed by ultrasound scanning\n4. Microscopically confirmed uncomplicated P.vivax malaria\n5. Willingness and ability to comply with the study protocol for the duration of the trial\n6. Written informed consent provided\n7. No signs of labour\n\nWithout additional information confirming that any of the pregnant women in the group meet these criteria, particularly the confirmed P.vivax malaria, we cannot assume they are eligible for the trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1214": {
        "output": "Based on the patient note provided, the group consists of humanitarian service workers preparing for a trip to the Amazon Rainforest in Brazil. There is no mention of any of the group members being HIV positive or requiring antiretroviral therapy (ART). The clinical trial in question is focused on predicting and understanding the Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV infected patients who are starting on ART.\n\nThe inclusion criteria for the clinical trial are:\n1. Age > 18 years\n2. Informed consent\n3. ART naive (patients who have not yet started antiretroviral therapy)\n\nSince the patient note does not indicate that any of the humanitarian service workers are HIV positive or starting on ART, they do not meet the specific inclusion criteria for the clinical trial. Therefore, none of the members of the group mentioned in the patient note would be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1215": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the group of humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil are not suitable candidates for the clinical trial titled \"Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis.\" Specifically, three of the women are in different stages of pregnancy, which directly conflicts with the inclusion criteria stating a requirement for a negative pregnancy test and the use of adequate contraception for females.\n\nGiven this information, we can conclude the following for the group of 14 humanitarian service workers:\n\n- Age: Not specified, but assumed to be \u2265 18 years.\n- Health status: Presumably good health, but no specific individual clinical examination or laboratory screening is mentioned.\n- Pregnancy: At least three women are pregnant, which is a direct exclusion criterion.\n- Use of adequate contraception: Not applicable for the pregnant women.\n- Willingness to undergo various study requirements: Not mentioned, but pregnancy is a disqualifying factor.\n\nTherefore, the pregnant women in the group are ineligible to participate in the clinical trial due to the specific requirement for non-pregnant participants. While the note does not provide individual information on other members of the group, it is reasonable to assume that some may meet the age and health criteria. However, the information provided does not allow us to adequately assess their eligibility.\n\nGiven the disqualification based on the pregnancy status of at least three women in the group and the lack of detailed information on the remaining individuals, the trial-level eligibility for referring this group of patients to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1216": {
        "output": "Based on the information provided, the patient note describes a group of humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. The specific concern mentioned is that three of the women in the group are in different stages of pregnancy and require malaria chemoprophylaxis.\n\nThe clinical trial in question is focused on venous thromboembolic (VTE) prophylaxis in trauma patients, comparing the effectiveness of unfractionated heparin given three times a day versus enoxaparin given twice a day. The inclusion criteria for the trial specifically require that patients be admitted to the Scripps Mercy Trauma Service, be \u226518 years old, and be stratified as Significant or Highest risk of VTE by ACCP guidelines.\n\nThe patient group described does not match the criteria for the clinical trial. There is no mention of the individuals being trauma patients or being admitted to Scripps Mercy Trauma Service, nor is there any indication that they have been stratified for VTE risk. Instead, the focus for the group of service workers is on malaria chemoprophylaxis, which is unrelated to the study's focus on venous thromboembolic prophylaxis.\n\nTherefore, the group of humanitarian service workers, including the pregnant women needing malaria prophylaxis, are not eligible for the clinical trial regarding VTE prophylaxis in trauma patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1217": {
        "output": "Based on the patient note, we are informed that three of the women in the group of humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil are in different stages of pregnancy. However, there is no mention of these women being HIV-positive, which is a critical inclusion criterion for the clinical trial.\n\nThe inclusion criteria for the clinical trial titled \"Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum\" are as follows:\n- Age \u2265 18 years\n- HIV positivity\n- Gestational age between 16 and 28 weeks\n- CD4+ count > 350 cells/mm3 and no sign of WHO stage 2, 3, or 4\n- Agreement to attend all the antenatal consultations for the study\n- Willingness to adhere to all requirements of the study (including HIV-1 voluntary counseling and testing)\n- Signed informed consent\n\nSince the patient note does not provide any information about the HIV status of the pregnant women, we cannot assume they meet the HIV positivity criterion. Without this key piece of information, we cannot determine if they meet the other specific criteria related to HIV and gestational age.\n\nTherefore, based on the provided information, we cannot refer these patients for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1218": {
        "output": "Given the provided patient note and the clinical trial inclusion criteria, we need to assess the eligibility of the group of humanitarian service workers for the malaria vaccine study.\n\nPatient note indicates:\n- A group of 14 humanitarian service workers.\n- All members have up-to-date vaccine certificates.\n- Malaria chemoprophylaxis is required for the trip.\n- Three of the women are in different stages of pregnancy.\n\nClinical trial inclusion criteria:\n- Subject is aged \u2265 18 and \u2264 35 years and in good health.\n- Subject has adequate understanding of the procedures of the study and agrees to abide thereby.\n- Subject is able to communicate well with the investigator, is available to attend all study visits, lives in proximity to the trial center or is willing to stay in a hotel close to the trial center during part of the study (day 5 post-infection until three days post-treatment).\n- The subject will remain within the Netherlands during the challenge period, not travel to a malaria-endemic area during the study period, and is reachable (24/7) by mobile telephone throughout the entire study period.\n- Subject agrees to inform his/her general practitioner (GP) about participation in the study and to sign a request to release by the GP any relevant medical information concerning possible contra-indications for participation.\n- Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period and for a defined period thereafter according to Sanquin guidelines.\n- For female subjects: agrees to use adequate contraception and not to breastfeed for the duration of the study.\n- Subject has signed informed consent.\n\nBased on the clinical trial inclusion criteria, the group of humanitarian service workers would not be suitable for the following reasons:\n- The workers are preparing a trip to the Amazon Rainforest region in Brazil, which is a malaria-endemic area. This contradicts the trial requirement of not traveling to a malaria-endemic area during the study period.\n- There is no information regarding the age of the group members, but the restriction on travel to a malaria-endemic area during the study period already disqualifies them.\n- Three of the female workers are pregnant, which likely conflicts with the requirement to use adequate contraception and not to breastfeed during the study.\n\nWithout even considering other potential exclusion factors, such as the age of the subjects, the fact that the group is traveling to a malaria-endemic area and the presence of pregnant women in the group mean they do not meet the inclusion criteria of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1219": {
        "output": "The patient note describes a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. The relevant information for clinical trial eligibility is that three of the women are in different stages of pregnancy.\n\nThe clinical trial in question is assessing the efficacy of artesunate/mefloquine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Peruvian Amazon. The inclusion criteria for this trial are specific to individuals who:\n\n1. Are aged between 5 and 65 years old.\n2. Have a monoinfection of P. falciparum confirmed by microscopy.\n3. Have a documented fever, or history of fever, due to malaria and not other causes.\n4. Have a certain range of parasite density in their blood.\n5. Provide informed consent, and assent for minors.\n6. Are willing to return for follow-up and agree to transfer to a hospital for treatment.\n\nThe clinical trial does not specifically mention pregnancy as an exclusion criterion. However, in the context of a clinical trial, the safety of the intervention for pregnant women is a critical consideration. Generally, unless a trial is specifically designed to include pregnant women\u2014often with additional safety measures in place\u2014it is standard to exclude pregnant women due to potential risks to both the fetus and the mother, unless explicitly stated otherwise.\n\nBased on the information provided, the three pregnant women from the group of humanitarian service workers would not typically be eligible for this trial, as it does not mention including pregnant women and the safety profile for this population is not addressed in the summary provided.\n\nFor the remaining members of the group, if they meet the other inclusion criteria (which is not clear from the patient note), they could potentially be eligible.\n\nHowever, for a definitive assessment of the three pregnant women's eligibility, more information would be required, including specific guidance from the trial regarding the inclusion of pregnant women.\n\nGiven the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1220": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess the eligibility of the group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil, specifically focusing on the three women who are in different stages of pregnancy.\n\nThe clinical trial \"Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection\" has the following pertinent inclusion criteria:\n\n1. Subject is aged \u2265 18 and \u2264 35 years and in good health.\n2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.\n3. Subject is able to communicate well with the investigator, is available to attend all study visits, and lives in proximity to the trial center or is willing to stay in a hotel close to the trial center during part of the study.\n4. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of the study.\n\nFrom the patient note, we know that the three women are pregnant. Pregnancy is typically a strict exclusion criterion for many clinical trials due to potential risks to both the mother and the fetus. Although the inclusion criteria provided for this specific trial do not explicitly mention pregnancy as an exclusion criterion, the requirement for female subjects to agree to use adequate contraception and not to breastfeed suggests that pregnant women would not be eligible.\n\nSince the three pregnant women would not meet the contraception requirement due to their current condition, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer these patients for this clinical trial.",
        "label": 0
    },
    "1221": {
        "output": "",
        "label": 0
    },
    "1222": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion and exclusion criteria, it is clear that the three pregnant women in the group of humanitarian service workers do not meet the criteria for participation in the malaria vaccine trial.\n\nThe exclusion criteria for the trial specifically state that a subject will be excluded from participating if they are currently breastfeeding or if pregnancy is determined by a positive urine or serum human choriogonadotropin (beta-hCG) test at any point during the study. This directly applies to the three pregnant women, making them ineligible for the trial.\n\nThe remaining members of the group, if they meet the other inclusion criteria (such as being in good general health, having reliable access to the clinical trial center, availability to participate for the duration of the study, not having traveled to a malaria endemic area within the last 5 years, and not being diagnosed with malaria in the past), may be eligible for the trial. However, this information is not provided in the patient note.\n\nGiven the available information and the specific exclusion of pregnant women from the trial, the eligibility assessment for the three pregnant women is:\n\nTrial-level eligibility: 0) Would not refer these patients for this clinical trial.",
        "label": 0
    },
    "1223": {
        "output": "Based on the information provided, the patient note describes a group of 14 humanitarian service workers who are preparing for a trip to the Amazon Rainforest region in Brazil, which includes three pregnant women requiring malaria chemoprophylaxis.\n\nThe clinical trial in question (PROTECT Study) is looking at the impact of malaria in pregnancy on childhood neurodevelopmental outcomes. To participate in this study, individuals must meet the following inclusion criteria:\n\n1. Enrolled in the Makerere University-UCSF PROMOTE II study.\n2. HIV-uninfected.\n3. 12 months of age at the time of enrollment.\n4. Within 30 km of the clinic in Uganda.\n\nThe group of humanitarian service workers, including the pregnant women, do not meet any of the inclusion criteria for the PROTECT Study. Specifically, they are not enrolled in the PROMOTE II study, they are not within the age range or geographical location required, and there is no information regarding their HIV status.\n\nTherefore, none of the individuals from the patient note would be eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1224": {
        "output": "Given the patient note and the clinical trial information, it appears that the trial is investigating the effects of antimalarial drugs on the immune response to the rabies vaccine in individuals who are receiving post-exposure prophylaxis for rabies. The inclusion criteria for the trial are as follows:\n\n1. Provide signed and dated informed consent form.\n2. Willing to comply with all study procedures and be available for the duration of the study.\n3. Male or female, aged \u2265 18 to \u2264 60 years on day of inclusion.\n4. In good general health based on medical history and physical exam.\n\nThe patient note mentions a group of 14 humanitarian service workers who are preparing a trip to the Amazon Rainforest and are considering malaria chemoprophylaxis. Among the group, there are three pregnant women. However, there is no mention of rabies vaccine post-exposure prophylaxis, nor is there information that any of the individuals in the group have been exposed to rabies or are in need of such a vaccine.\n\nSince the trial is specific to the interaction between antimalarial drugs and the rabies vaccine post-exposure prophylaxis, and the patient note does not indicate that any of the service workers require rabies post-exposure prophylaxis or are participating in a situation relevant to the study's aim, it is unlikely that any of the members of the group would be eligible for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1225": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility:\n\nPatient characteristics:\n- A 21-year-old college student with a family history of multiple polyps.\n- His siblings had total proctocolectomy due to familial adenomatous polyposis.\n- The patient has dozens of small colonic polyps within rectosigmoid, all benign adenomas.\n\nClinical trial inclusion criteria:\n- Diagnosis of familial adenomatous polyposis (FAP) or related conditions.\n- Age between 18 to 80 years.\n- Specific hematologic, hepatic, and renal function criteria.\n- Not pregnant or nursing, and willing to use effective contraception if fertile.\n- No active peptic ulcer disease or serious underlying medical or psychiatric illness.\n- No prisoners or institutionalized patients.\n- No known allergy to sulindac or related compounds.\n- No active internal malignancy within the past 5 years.\n- No alcohol or drug abuse within the past 5 years.\n- No prior NSAIDs or salicylates more than 10 days a month for the past 3 months.\n- No concurrent NSAIDs (some exceptions apply).\n\nThe patient is 21 years old, which fits the age criterion. The patient has a family history of familial adenomatous polyposis and is found to have polyps, which could likely lead to a diagnosis of FAP. However, the patient note does not provide information about hematologic, hepatic, and renal function, pregnancy status, or recent NSAID use, which are necessary to fully assess eligibility. Also, there is no information on any serious underlying medical or psychiatric illness, allergy to sulindac or related compounds, active internal malignancy, or substance abuse history.\n\nBased on the information provided and assuming that the patient would meet the other clinical and laboratory criteria upon further investigation (which is not confirmed in the patient note), the patient may be a candidate for this clinical trial due to the likely diagnosis of familial adenomatous polyposis and the presence of colonic polyps. The assessment would be contingent on confirming the patient's full medical history aligning with the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1226": {
        "output": "Assessing the patient note against the clinical trial inclusion criteria:\n\n1. Diagnosis of colon cancer or polyps at age 70 or under:\n   - The patient has been found to have dozens of small colonic polyps and is 21 years old, which fits within the age criterion.\n\n2. Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under:\n   - The patient has both a brother and sister who had multiple colonic adenomas and underwent surgery, indicating a family history that meets this criterion.\n\n3. No history of familial adenomatous polyposis syndrome:\n   - The patient note does not indicate a diagnosis of familial adenomatous polyposis syndrome.\n\n4. No hereditary nonpolyposis colon cancer, according to Amsterdam criteria:\n   - There is no mention of hereditary nonpolyposis colon cancer in the patient note.\n\n5. No known I1370K adenomatous polyposis of the colon susceptibility variant:\n   - The patient note does not mention any genetic testing for this specific mutation.\n\n6. Enrolled on one of the following clinical trials (CLB-9581, CLB-89803, CLB-80001):\n   - The patient note does not indicate enrollment in any clinical trials, and this criterion is a bit unclear because it mentions that patients do not need to be receiving protocol therapy and that those outside the treatment protocol's follow-up range are eligible.\n\n7. Age 70 and under at diagnosis:\n   - The patient is 21 years old, which meets the age criterion.\n\n8. No significant psychiatric illness that would preclude giving informed consent:\n   - There is no information provided in the patient note about psychiatric illness.\n\n9. No inflammatory bowel disease (in patient or sibling):\n   - The patient note does not indicate the presence of inflammatory bowel disease in the patient or his siblings.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the genetic study of familial factors in patients with colon cancer, except for the unclear requirement about enrollment in other clinical trials. Since there is no information regarding those specific trials, further investigation would be needed to clarify this point.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1227": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient appears to be eligible for the clinical trial. The patient is a 21-year-old college student who has undergone sigmoidoscopy and has been found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and determined to be benign adenomas. This fits the description of Familial Adenomatous Polyposis (FAP) due to the family history of multiple polyps and proctocolectomies in siblings, which is consistent with the pattern of inheritance for FAP.\n\nThe inclusion criteria for the clinical trial specify:\n\n1. Males or females at least 18 years of age with familial adenomatous polyposis.\n\nThe patient meets the age criterion (21 years old) and has a condition (FAP) that aligns with the study's focus. Therefore, the patient is a suitable candidate for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1228": {
        "output": "Based on the patient note and the inclusion criteria for the APACC Study, the 21-year-old college student appears to be a potential candidate for the clinical trial. The inclusion criteria for the trial are:\n\n1. Patients aged between 18 and 75 years.\n2. At least 3 adenomas irrespective of size or at least one measuring 6mm or more.\n3. All subjects had a clean colon at the study entry.\n\nThe patient note indicates that the 21-year-old has a family history of multiple polyps, and during a sigmoidoscopy, he was found to have dozens of small colonic polyps, which are benign adenomas. Although the exact size of the polyps is not mentioned, the presence of \"dozens of small colonic polyps\" suggests that it is highly likely the patient has at least 3 adenomas, meeting one of the key inclusion criteria.\n\nHowever, the note does not specify whether the patient had a clean colon at the study entry, which is one of the inclusion criteria. Assuming that \"clean colon\" means that any polyps found were removed and there are no remaining lesions, additional information would be required to confirm this.\n\nGiven this information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1229": {
        "output": "Based on the information provided, the patient is a 21-year-old college student who has undergone colonoscopy due to a family history of multiple polyps, with both siblings undergoing total proctocolectomy after being found to have hundreds of colonic adenomas. During his sigmoidoscopy, the patient is found to have dozens of small colonic polyps within the rectosigmoid, which are biopsied and determined to be benign adenomas.\n\nThe clinical trial in question is focused on establishing the effectiveness of new techniques for increasing adenoma detection rates during sigmoidoscopy compared to standard sigmoidoscopy alone. The inclusion criteria for this trial specify that patients must have Familial adenomatous polyposis (FAP), have had an ileo-rectal anastomosis, and had 20 or fewer adenomas at the previous surveillance examination.\n\nThe patient note does not specifically mention a diagnosis of Familial adenomatous polyposis (FAP) nor does it state that the patient has undergone an ileo-rectal anastomosis. However, the family history of multiple polyps and the presence of dozens of small colonic polyps in the patient suggest that he may have FAP. Before referring the patient, it would be important to confirm the diagnosis of FAP and whether the patient has had an ileo-rectal anastomosis, as well as the number of adenomas found in previous examinations.\n\nGiven the potential alignment with the familial history and the findings of polyps but lacking specific confirmation of FAP diagnosis and previous surgical procedures, the patient might be considered for the trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1230": {
        "output": "In the given patient note, we have a 21-year-old college student who underwent sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid, and these were biopsied to be benign adenomas. This indicates that the patient has a family history of multiple polyps and potentially familial adenomatous polyposis (FAP), which is further supported by the history of his siblings undergoing total proctocolectomy due to hundreds of colonic adenomas.\n\nThe clinical trial in question is focused on patients with familial adenomatous polyposis and aims to determine the effectiveness of sulindac and probiotics in treating or preventing adenoma development in the ileal anal pouch post-restorative proctocolectomy with ileal pouch anal anastomosis.\n\nThe inclusion criteria for the trial are:\n1. Clinically or genetically proven familial adenomatous polyposis.\n2. Restorative proctocolectomy with ileal pouch anal anastomosis.\n\nWhile the patient likely has familial adenomatous polyposis given the family history and personal findings of adenomas, there is no information provided that the patient has undergone restorative proctocolectomy with ileal pouch anal anastomosis. Therefore, based on the available information, the patient does not meet all the inclusion criteria of the trial.\n\nHowever, if the patient is clinically or genetically diagnosed with FAP in the future and undergoes the specified surgery, they may become eligible. Thus, further investigation is necessary to determine the patient's full clinical picture and potential eligibility in the future.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1231": {
        "output": "The patient note describes a 21-year-old college student with a family history of multiple polyps and a finding of dozens of small colonic polyps within the rectosigmoid area that are benign adenomas.\n\nThe clinical trial provided is for a Phase 4 study of Ropinirole Hydrochloride, which is a treatment for Parkinson's Disease (PD). The inclusion criteria for the trial are:\n\n- Patients with a diagnosis of PD (including juvenile parkinsonism) with Modified Hoehn & Yahr Stages I to IV.\n- Patients who have been receiving another dopamine agonist for at least 4 weeks prior to the start of the screening phase and are expected to benefit from conversion to Ropinirole Hydrochloride.\n- Age: 20 years (at the time of written informed consent).\n- Informed consent: Patients who are able to give written informed consent in person.\n- Gender: Male or female.\n\nThe patient described in the patient note has no mention of Parkinson's Disease or any symptoms or treatments related to it. Instead, the patient has a gastrointestinal issue that is unrelated to the focus of the clinical trial.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this particular clinical trial, as the trial is specifically targeting patients with Parkinson's Disease and the patient in question has no indication of having this condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1232": {
        "output": "",
        "label": 2
    },
    "1233": {
        "output": "The patient in question is a 21-year-old college student with a family history of multiple polyps and siblings who have undergone total proctocolectomies due to the presence of hundreds of colonic adenomas. The patient himself has been found to have dozens of small colonic polyps within the rectosigmoid area, which are benign adenomas.\n\nThe clinical trial is for unprepped CT Colonography (CTC) with the aim to improve the performance of CTC for the detection of colorectal neoplasia. The inclusion criteria for this trial are:\n\n- Average risk or higher for colorectal cancer and scheduled for colonoscopy with any of the following indications: Prior colorectal cancer, prior colorectal adenoma, strong family history of colorectal neoplasia, iron deficiency.\n- Age \u2265 40 -100 years\n- Known or highly suspected primary colorectal neoplasms > 10 mm\n\nThe patient has a strong family history of colorectal neoplasia, which is one of the listed indications for the trial. However, the age criteria for the trial is \u2265 40 years, and the patient is only 21 years old. Therefore, the patient does not meet the age inclusion criterion for this clinical trial.\n\nBased on this information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1234": {
        "output": "",
        "label": 0
    },
    "1235": {
        "output": "Based on the patient note provided, the 21-year-old college student has a family history of multiple polyps and his siblings underwent total proctocolectomy after being found to have hundreds of colonic adenomas. The patient himself has been found to have dozens of small colonic polyps within rectosigmoid, which are benign adenomas.\n\nThe clinical trial in question is looking at the outcomes of colorectal, coloanal, and ileoanal anastomoses reinforced with a bioabsorbable staple line reinforcement material. The inclusion criteria for the clinical trial are:\n\n1. Subjects who will undergo restorative proctectomy or proctocolectomy (<10 cm from anal verge) with a low circular stapled colorectal, coloanal, or ileoanal anastomosis with or without a reservoir, for various conditions including rectal cancer, ulcerative colitis, familial adenomatous polyposis, diverticulitis, perforation of the bowel/trauma.\n2. Subjects undergoing Hartmann's reversal with restorative proctectomy.\n3. Subjects may or may not have a diverting loop ileostomy as a part of their initial surgery.\n4. Subjects treated for rectal cancer may or may not have preoperative chemoradiation therapy.\n\nThe patient note does not mention any immediate plans for restorative proctectomy or proctocolectomy, which is a key inclusion criterion for the trial. The conditions listed in the trial include familial adenomatous polyposis, which the patient might have given their family history and presentation, but this has not been explicitly stated in the patient note, and there is no indication that surgery is imminent or planned.\n\nGiven that the information provided does not confirm that the patient will undergo the surgical procedures mentioned in the inclusion criteria, nor that the patient has been diagnosed with one of the specific conditions listed (despite the suggestion of familial adenomatous polyposis), I would consider referring this patient to the clinical trial upon further investigation to clarify their diagnosis and treatment plan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1236": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, we can evaluate the patient's eligibility as follows:\n\nThe patient note indicates:\n- The patient is a 21-year-old college student.\n- There is a family history of multiple polyps and familial adenomatous polyposis (FAP).\n- The patient himself has been found to have dozens of small colonic polyps within the rectosigmoid area, which are benign adenomas.\n\nThe clinical trial inclusion criteria specify:\n- Diagnosis of familial adenomatous polyposis (FAP) based on genetic predisposition testing.\n- Genotype-positive FAP (pathologic APC mutation).\n- Has an intact colon and no requirement for colectomy.\n- Colorectal adenoma burden as assessed by baseline colonoscopy.\n- Other specific health criteria regarding blood counts and organ function tests.\n- No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs, or salicylates.\n- No significant medical or psychiatric problems that would make the patient a poor candidate for the study.\n\nThe patient note does not mention a genetic test confirming FAP, but the history of multiple polyps in his siblings and the finding of polyps in the patient suggest a strong likelihood of FAP. The patient appears to have an intact colon and no mention is made of a requirement for colectomy or any history of hypersensitivity or significant medical or psychiatric problems.\n\nHowever, it is not clear if the patient meets all the specific health criteria such as blood counts, organ function tests, and there is no information provided regarding recent use of NSAIDs or other exclusionary drugs. This information is necessary to confirm eligibility.\n\nWithout a confirmed genotype-positive FAP diagnosis and without the complete health status and medication history, it is not possible to definitively determine the patient's eligibility for the trial. Therefore, further investigation would be needed to obtain genetic testing results and a full health evaluation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1237": {
        "output": "The patient note describes a 21-year-old college student who underwent sigmoidoscopy and was found to have multiple benign colonic adenomas. This finding seems to be indicative of a familial tendency to develop polyps, as evidenced by the procedures undergone by the patient's siblings.\n\nThe clinical trial in question is looking at autonomic profiles in pediatric patients with a variety of gastrointestinal and autonomic disorders, including Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS), Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP), or Chronic Nausea.\n\nThe inclusion criteria for the clinical trial are not fully detailed in the provided information, but it does specify that the study is a retrospective chart review of children who had certain autonomic function tests completed at the Children's Hospital of Wisconsin and received outpatient services.\n\nBased on the information given:\n\n- The patient is 21 years old, which may or may not fall under \"pediatric\" depending on the specific age range the study is considering, but typically \"pediatric\" refers to patients under the age of 18.\n- The patient does not appear to have any of the conditions listed in the title of the study (CVS, IBS, POTS, FAP, or Chronic Nausea).\n- The patient note does not mention any autonomic function tests that have been completed, which are required for inclusion in the study.\n\nGiven this information, the patient does not meet the described conditions for the clinical trial, nor is there any indication they have undergone the necessary autonomic function tests. Therefore, it is unlikely that this patient would be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1238": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient is a 21-year-old college student undergoing colonoscopy due to a family history of multiple polyps, with both of his older siblings having undergone total proctocolectomy. The patient himself was found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and determined to be benign adenomas.\n\nThe clinical trial in question is interested in \"Colonography Versus Colonoscopy in High-Risk Patients\" and specifies two main categories for inclusion related to colorectal cancer (CRC):\n\n1. Surveillance of patients with a personal history of advanced adenoma or CRC, with additional sub-criteria.\n2. Screening of patients with a Family history of CRC at high risk, with additional sub-criteria.\n\nThe patient fits the second category for the following reasons:\n- The patient is within the age range of 18 to 80 years old.\n- The patient has a family history of CRC, as indicated by multiple polyps found in his siblings, which required total proctocolectomy.\n- The patient has undergone a previous medical examination (sigmoidoscopy).\n\nGiven that the patient's siblings had surgeries at ages 22 and 28, and assuming this falls within the last five years, the patient meets the criteria for the trial. However, the trial criteria specify a family history of \"colorectal cancer diagnosed <60yrs during the five previous years,\" and the patient note does not explicitly mention CRC but refers to adenomas. Therefore, assuming that the siblings' conditions are considered a high risk for CRC due to the presence of adenomas, which can be precursors to cancer, the patient may be eligible.\n\nHowever, there is a need for further investigation to confirm whether the siblings' conditions meet the criteria of a high-risk family history of CRC as defined by the trial. The patient's eligibility would depend on the interpretation of \"high risk of colorectal cancer\" and whether the siblings' adenomas are considered to fall under this category.\n\nThus, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1239": {
        "output": "Based on the patient note provided, the 21-year-old college student has a family history of multiple polyps, with both siblings having undergone total proctocolectomy after being diagnosed with hundreds of colonic adenomas. The patient himself has been found to have dozens of small colonic polyps within the rectosigmoid region during a sigmoidoscopy, and the biopsies of these polyps have shown them to be benign adenomas.\n\nThe inclusion criteria for the clinical trial titled \"Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)\" are:\n\n1. Diagnosis of familial adenomatous polyposis with at least 5 rectal polyps which are greater than or equal to 2 mm on baseline colonoscopy\n2. Have an endoscopically assessable rectal segment\n3. Have not taken NSAIDs or selective COX-2 inhibitors for two months prior to the study and willing to remain off NSAIDs for the study duration.\n\nThe patient's diagnosis aligns with the trial's target condition of familial adenomatous polyposis, and he has rectal polyps as required by the trial's inclusion criteria. However, the size of the polyps is not specified in the patient note; therefore, it is not clear whether they meet the size criteria of being greater than or equal to 2 mm. Furthermore, there is no information provided about the patient's use of NSAIDs or selective COX-2 inhibitors.\n\nWith the information provided, it seems that the patient could potentially be eligible for the trial, but there is insufficient information to make a definitive decision. Therefore, further investigation would be required to determine the size of the polyps and the patient's NSAID use before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1240": {
        "output": "Based on the patient note provided, the patient is a 21-year-old college student with a family history of multiple colonic polyps and has undergone a sigmoidoscopy revealing dozens of small colonic polyps within the rectosigmoid area. The biopsies of these polyps have shown them to be benign adenomas.\n\nThe clinical trial in question is focused on the prevention of progression of duodenal adenomas in patients with Familial Adenomatous Polyposis (FAP), assessing the effectiveness of celecoxib combined with ursodeoxycholic acid as a chemoprevention strategy.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients with Familial Adenomatous Polyposis (APC-mutation identified or more than 100 colorectal polyps on diagnosis).\n2. Spigelman score of duodenal adenoma equal to II or III.\n\nFrom the patient note, we can identify that the patient likely meets the first inclusion criterion, as they have a family history of multiple polyps and have been found to have dozens of small colonic polyps, suggesting the possibility of FAP. However, it is not specified whether the patient has an APC-mutation identified or if the number of polyps exceeds 100, which are the conditions specified in the criteria. Moreover, there is no mention of a Spigelman score, which is necessary to assess the severity of duodenal adenomas.\n\nGiven that the patient has a family history consistent with FAP and has been found to have multiple polyps, they could potentially be a candidate for the trial if further investigation confirms an APC mutation or if the number of polyps meets the threshold. However, without confirmation of these factors and the Spigelman score, we cannot conclusively determine their eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1241": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, the 21-year-old college student does not meet the inclusion criteria for the study on Ropinirole PR/XR tablets for adjunctive therapy to L-dopa in subjects with advanced Parkinson's Disease. The patient's medical issue pertains to a family history of multiple colonic polyps and the presence of benign adenomas in the patient himself, not Parkinson's Disease. The clinical trial is specifically for patients with advanced Parkinson's Disease experiencing lack of control with L-dopa therapy.\n\nThe inclusion criteria for the trial require a diagnosis of advanced Parkinson's Disease with severity corresponding to the modified Hoehn & Yahr criteria Stages II-IV, subjects receiving a stable dose of L-dopa, and specific QTc intervals on ECG, among other requirements. None of these criteria are applicable to the patient described in the note.\n\nTherefore, based on the information provided, the assessment of eligibility for this patient to the specified clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1242": {
        "output": "",
        "label": 0
    },
    "1243": {
        "output": "Based on the information provided, the patient is a 21-year-old college student found to have dozens of small colonic polyps within rectosigmoid, with the polyps biopsied and identified as benign adenomas. There is no mention of pancreatic cancer or any suspicion of a pancreatic mass.\n\nThe clinical trial in question is focused on patients with biopsy-proven adenocarcinoma of the pancreas or a pancreatic mass suspicious for pancreatic cancer, who are scheduled to undergo a resection or exploration of their pancreatic tumor.\n\nSince the patient's medical condition does not match the disease characteristics required for the clinical trial (i.e., they do not have pancreatic cancer or a suspicious pancreatic mass), the patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1244": {
        "output": "Given the patient note, the 21-year-old college student has a family history of multiple colonic polyps and has himself been found to have dozens of small colonic polyps which are benign adenomas. The clinical trial in question is focused on individuals with Lynch Syndrome (LS) and involves a chromoendoscopy technique to decrease the risk of colorectal neoplasia.\n\nThe inclusion criteria for the clinical trial are:\n- Proven carrier of a MLH1, MSH2, or MSH6 mutation\n- Age between 20 and 70 years\n- Written informed consent\n\nWhile the patient fits the age criterion (21 years old), there is no information provided that indicates the patient is a proven carrier of a MLH1, MSH2, or MSH6 mutation, which are specific to Lynch Syndrome. The patient's history of adenomas and family history of polyps suggest a predisposition to colorectal issues, but without confirmation of Lynch Syndrome, we cannot determine the patient's eligibility based solely on the information given.\n\nTherefore, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm whether the patient is indeed a carrier of the relevant mutation associated with Lynch Syndrome.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1245": {
        "output": "Based on the information provided, the patient is a 21-year-old college student with a family history of multiple polyps and has undergone sigmoidoscopy, revealing dozens of small colonic polyps that are benign adenomas. \n\nThe clinical trial in question is focused on patients who have undergone or are undergoing total proctocolectomy with ileal pouch anal anastomosis, which is a surgical operation typically for management of ulcerative colitis and familial adenomatous polyposis. The trial aims to evaluate whether diverting ileostomy is necessary in patients with stapled ileoanal pouch.\n\nThe patient note does not mention that the patient has undergone a total proctocolectomy with ileal pouch anal anastomosis or that they have ulcerative colitis or familial adenomatous polyposis, which are the typical indications for such a surgery. The patient has only been described as having multiple benign adenomas.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria of having had a total proctocolectomy with ileal pouch anal anastomosis. As such, they would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1246": {
        "output": "",
        "label": 2
    },
    "1247": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's medical history and condition with the inclusion criteria listed for the trial.\n\nPatient Note Analysis:\n- The patient is a 21-year-old college student with a family history of multiple polyps.\n- The patient's brother and sister both had total proctocolectomies due to multiple colonic adenomas and are diagnosed with FAP.\n- The patient has been found to have dozens of small colonic polyps within the rectosigmoid during a sigmoidoscopy.\n- The biopsies of these polyps are all benign adenomas.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with a diagnosis of phenotypic Familial Adenomatous Polyposis (FAP).\n- Group 1 requires greater than 100 adenomatous colorectal polyps prior to age 40.\n- Group 2 requires greater than 10 adenomatous polyps and age <40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype.\n- Specific requirements for no colorectal surgery or prior colon surgery for polyposis at least 1 year prior.\n- Baseline endoscopy with polyps measurement specifics.\n- Hematopoietic, hepatic, renal, and hearing function requirements.\n- Fertility, pregnancy, and contraception requirements.\n- No invasive malignancy within the past 5 years, except certain treated cancers.\n- No significant medical or psychiatric problems that would preclude study participation.\n- No chronic adrenocorticosteroids or prior pelvic irradiation.\n- No concurrent medication that would conflict with the study.\n\nBased on the patient note, the patient seems to meet the following relevant criteria:\n- The patient has a family history of FAP (siblings with multiple polyps and surgeries).\n- The patient has multiple polyps of adenomatous nature.\n- The patient is under the age of 40, which falls into Group 2 criteria.\n\nHowever, we do not have information on the following, which is critical to determining eligibility:\n- The exact number of polyps the patient has (whether it is greater than 10 or 25).\n- The patient's hematopoietic, hepatic, renal, and hearing functions.\n- Information on pregnancy or contraception is not relevant as the patient is male.\n- The patient's medical history in terms of invasive malignancy, significant medical or psychiatric problems, and medication use.\n\nGiven the patient's diagnosis of multiple colonic polyps and a strong family history of FAP, along with the age criteria, it is reasonable to consider that the patient may meet the phenotypic criteria for FAP as outlined in Group 2. However, since we lack some information, particularly the exact number of polyps and the detailed medical history required by the trial, further investigation would be necessary to fully determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1248": {
        "output": "In this scenario, the patient is a 21-year-old college student with a family history of multiple colonic adenomas, with both siblings undergoing total proctocolectomy due to numerous adenomas found through colonoscopy. The patient himself is found to have dozens of small colonic polyps within the rectosigmoid, which are biopsied and are all benign adenomas.\n\nComparing this patient's information to the clinical trial's inclusion criteria, we can determine the following:\n\n- The patient is undergoing screening for colonic polyps due to family history, which is a form of screening colonoscopy.\n- The patient is younger than the required age > 40.\n- The patient is not average risk due to family history of multiple polyps, indicating a possible genetic predisposition such as Familial Adenomatous Polyposis (FAP), which is an exclusion criterion.\n- The patient's ability to provide written consent is not mentioned, but we might assume he can give consent unless otherwise indicated.\n\nGiven the information provided, the patient does not meet the age criteria and has a family history that potentially disqualifies him as an average risk subject. Therefore, this patient would not be eligible for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1249": {
        "output": "Based on the clinical trial inclusion criteria provided and the patient note, we need to determine if the 21-year-old college student with a family history of multiple polyps and personal history of dozens of small colonic polyps that are benign adenomas would be eligible for the trial.\n\nInclusion criteria for the clinical trial include:\n\n1. Diagnosis of phenotypic classical Familial Adenomatous Polyposis (FAP) with disease involvement of the duodenum and/or colon/rectum/pouch.\n2. APC mutation (with or without family history) required.\n3. Classical FAP Phenotype: 100's to 1,000's of colorectal adenomatous polyps, usually appearing in teenage years.\n4. UGI/LGI endoscopy performed within 30 days of randomization.\n5. Specific criteria for rectal/pouch polyposis and duodenal polyposis.\n6. Hematopoietic, hepatic, and renal status requirements.\n7. No clinically significant hearing loss.\n8. If female, not pregnant or lactating, and negative pregnancy test if of child-bearing potential.\n9. Absence of gross blood in stool.\n10. No invasive malignancy within the past 5 years except specified conditions.\n11. No other significant medical or psychiatric problems.\n12. Willingness to forego certain medications and supplements.\n13. Able to provide informed consent and follow protocol requirements.\n\nThe patient note indicates that the 21-year-old has dozens of small colonic polyps, which are benign adenomas. Although the patient appears to have a family history consistent with FAP (siblings with hundreds of colonic adenomas and total proctocolectomies), the note does not explicitly confirm that the patient has been diagnosed with classical FAP, nor does it mention a genotype confirmation of an APC mutation. \n\nThe criteria for classical FAP phenotype mention \"100's to 1,000's of colorectal adenomatous polyps, usually appearing in teenage years,\" and the patient note only indicates \"dozens of small colonic polyps.\" Therefore, the patient may not meet the quantitative criteria for classical FAP phenotype.\n\nWithout more information confirming the diagnosis of FAP, APC mutation status, and that the patient fulfills all other inclusion criteria, we cannot confidently refer this patient to the clinical trial. However, given the family history and the presence of multiple polyps, it is plausible that the patient could have FAP and further investigations might reveal eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1250": {
        "output": "Based on the patient note provided, the 21-year-old college student is undergoing colonoscopy due to a family history of multiple polyps and has been found to have dozens of small colonic polyps within the rectosigmoid. Several biopsies were taken, and all were benign adenomas. There is no mention of abdominal pain-related functional gastrointestinal disorders (FAPD), such as functional dyspepsia, irritable bowel syndrome, or functional abdominal pain (FAPS), which are diagnosed according to Rome III criteria.\n\nThe clinical trial in question is specifically targeting children with FAPD and is testing the efficacy and safety of glucomannan for treating these conditions. Since the patient's condition does not match the inclusion criteria, which specifically require a diagnosis of an abdominal pain-related disorder as per the Rome III criteria, the patient would not be eligible for this trial. The patient's condition and the clinical trial's focus do not overlap.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1251": {
        "output": "The patient in question is a 21-year-old college student who has undergone sigmoidoscopy and has been found to have dozens of small colonic polyps within the rectosigmoid, which are benign adenomas. The patient has a family history of multiple polyps, with both his brother and sister undergoing total proctocolectomy after being diagnosed with hundreds of colonic adenomas.\n\nThe clinical trial is focused on screening and risk factors of colon neoplasia, proposing a screening population-based study for sDNA testing as an alternative to colonoscopy and a genetic epidemiological study of the relationship between colon polyps and risk factors for colon cancer.\n\nThe inclusion criteria for the clinical trial are patients undergoing routine colonoscopy at University Hospitals, Cleveland Ohio. \n\nGiven that the patient has undergone sigmoidoscopy and has a family history of colonic adenomas, which could indicate a predisposition to colon neoplasia, the patient appears to meet the general scope of the clinical trial. However, the inclusion criteria specifically mention \"patients undergoing routine colonoscopy,\" and it is not clear if the patient's sigmoidoscopy would qualify as a \"routine colonoscopy\" or if they are planning to undergo one. Assuming the patient is eligible for or planning to undergo routine colonoscopy at the specified location, they would meet the inclusion criteria based on the information provided. \n\nHowever, without confirmation that the patient will undergo routine colonoscopy at University Hospitals, Cleveland Ohio, or that the trial accepts candidates with recent sigmoidoscopy findings, we would need further investigation to determine their eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1252": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, we can assess the eligibility of the 21-year-old college student for the clinical trial titled \"Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations.\"\n\nPatient Note:\n- The patient is 21 years old.\n- The patient has a family history of multiple polyps.\n- The patient's siblings underwent total proctocolectomy due to the presence of hundreds of colonic adenomas.\n- The patient underwent sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and determined to be benign adenomas.\n\nClinical Trial Inclusion Criteria:\n- Any adenoma found on screening/surveillance colonoscopy (ICD9-211.3, Procedure code 45385 or 45380)\n- Greater than 18 years old\n\nAssessment:\n- The patient is older than 18 years of age, which meets the age criterion of the clinical trial.\n- The patient has been found to have adenomas on a sigmoidoscopy, which is consistent with the requirement of having adenomas found on a screening/surveillance colonoscopy.\n\nGiven that the patient's condition aligns with the inclusion criteria of having adenomas and being over 18 years old, and considering that the clinical trial is retrospective in nature, it is highly likely that the patient's data would be relevant for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1253": {
        "output": "",
        "label": 0
    },
    "1254": {
        "output": "Based on the patient note provided, the 21-year-old college student has a family history of multiple polyps with both siblings undergoing total proctocolectomy after being found to have hundreds of colonic adenomas. The patient himself has undergone sigmoidoscopy and was found to have dozens of small colonic polyps which are benign adenomas. \n\nComparing this to the inclusion criteria of the clinical trial:\n\n- Patients with familial adenomatous polyposis (FAP) who are 20 to 65 years of age.\n- FAP patients who have colonic or duodenal polyp.\n- FAP patients who have five or more polyps 2mm or more in diameter in endoscopic examination.\n\nThe patient fits all of the inclusion criteria: he is within the age range of 20 to 65 years, has a diagnosis consistent with FAP (as suggested by the presence of multiple adenomas and a family history), and has more than five polyps as required by the trial's inclusion criteria.\n\nTherefore, the patient appears to be a suitable candidate for the clinical trial on the chemopreventive effect of metformin in patients with familial adenomatous polyposis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1255": {
        "output": "Based on the given information:\n\nThe patient is a 21-year-old college student with a family history of multiple polyps. Siblings had total proctocolectomies due to hundreds of colonic adenomas. The patient has dozens of small colonic polyps within rectosigmoid, biopsied and found to be benign adenomas.\n\nThe clinical trial is seeking participants for a study to determine if screening colonoscopy performed with the water exchange method has a higher adenoma detection rate than the air method.\n\nThe inclusion criteria for the clinical trial are:\n\n- Age \u226550 years\n- Individuals able to provide informed consent\n- Individuals presenting for average-risk colorectal cancer screening by colonoscopy\n- Individuals presenting for surveillance of adenomatous/sessile serrated colon polyps as per the US multi-society taskforce on colorectal cancer\n\nThe patient in question is 21 years old, which does not meet the age criterion of \u226550 years for the clinical trial. Therefore, the patient is not eligible for this clinical trial based on the age restriction alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1256": {
        "output": "",
        "label": 0
    },
    "1257": {
        "output": "Based on the patient note, the 21-year-old college student was found to have dozens of small colonic polyps within rectosigmoid during a sigmoidoscopy. The clinical trial in question is focused on evaluating small colonic polyps using a high definition endoscopy with i-Scan technology. The inclusion criteria for the trial specify that patients must be found to have colonic polyps up to 10mm in size.\n\nThe patient note confirms that the individual has small colonic polyps, although the exact size of the polyps is not mentioned. Given that they are described as \"dozens of small colonic polyps,\" it is reasonable to assume that at least some of these polyps could be 10mm or smaller in size, fitting within the inclusion criteria of the clinical trial.\n\nTherefore, based on the information provided and the compatibility with the trial's inclusion criteria, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation. \n\nThe \"further investigation\" would be to confirm the size of the polyps to ensure they meet the trial's specification of being up to 10mm in size.",
        "label": 2
    },
    "1258": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient in question is a 21-year-old college student. The clinical trial's inclusion criteria specify that participants must be asymptomatic subjects aged 45 - 75 years who will give written consent.\n\nThe patient does not meet the age criteria for the clinical trial, as they are only 21 years old and the trial requires participants to be between the ages of 45 and 75. Therefore, this patient would not be eligible for the clinical trial based on their age.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1259": {
        "output": "Based on the patient note provided and the inclusion criteria for the APOLLO clinical trial, it appears that the patient does not meet the specific disease criteria required for the trial. The APOLLO study focuses on patients with transthyretin (TTR) mediated amyloidosis, specifically familial amyloid polyneuropathy (FAP), which is not mentioned in the patient's note. Instead, the patient has a family history of multiple polyps and has been found to have benign colonic adenomas, which is unrelated to TTR-mediated amyloidosis.\n\nSince the patient does not have a diagnosis of TTR-mediated amyloidosis, they would not qualify for this clinical trial. Therefore, the patient would not be referred for this study based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1260": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial.\n\nThe patient note describes a 21-year-old college student who has undergone sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid area. The polyps biopsied were all benign adenomas. This patient has a family history of multiple polyps, with both his brother and sister undergoing total proctocolectomy after being found to have hundreds of colonic adenomas.\n\nThe clinical trial is assessing the effectiveness of I-Scan during colonoscopy in increasing the yield of adenomas among a population at increased risk for colorectal cancer (CRC). The inclusion criteria for this trial are all increased risk patients referred for a screening colonoscopy. Increased risk is defined as patients with a family history or personal history of colon polyps or colon cancer and those with FOBT positive results.\n\nGiven that the patient has a family history of multiple polyps and has been found to have multiple benign adenomas himself, he fits the description of an increased risk patient. Therefore, he would be considered eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1261": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)\", the patient does not meet the eligibility criteria for the following reasons:\n\n- The patient is 21 years old, which is below the age range of 50-69 years specified in the trial's inclusion criteria.\n- The patient does not have a positive fecal immunochemical test (FIT), which is a requirement for inclusion.\n- The trial specifies that it is targeting individuals with no known risk factors, but this patient has a family history of multiple polyps and direct relatives who underwent total proctocolectomy for colonic adenomas. This may imply that the patient has a higher risk for colorectal cancer due to genetic factors, which does not align with the study's focus on an intermediate-risk population.\n\nGiven these discrepancies between the patient's profile and the study's requirements, the patient would not be eligible to participate in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1262": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 21-year-old college student.\n- The patient has a family history of multiple polyps and siblings who have undergone total proctocolectomy due to the presence of hundreds of colonic adenomas.\n- The patient was found to have dozens of small colonic polyps within the rectosigmoid colon, which were biopsied and found to be benign adenomas.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients with genetically or clinically proven Familial Adenomatous Polyposis (FAP).\n- Age 18 to 70 years.\n- Written informed consent.\n- Adequate potential for follow-up.\n\nComparison:\n- The patient's age (21 years) meets the trial's age criterion (18 to 70 years).\n- The patient has a family history consistent with FAP (multiple polyps in siblings and dozens of small colonic polyps within rectosigmoid) and could potentially have clinically proven FAP given the number of polyps and family history, although the exact number of polyps (more than 100 at diagnosis) is not confirmed in the note.\n- Written informed consent and potential for follow-up are not mentioned in the patient note but are assumed to be obtainable if the patient agrees to participate.\n\nThe patient appears to meet the criteria for FAP based on the clinical presentation and family history, although genetic testing or further clinical investigation would be necessary to confirm the diagnosis of FAP. Since the family history is suggestive and the patient has dozens of polyps, it is reasonable to consider this patient for the trial upon further investigation to confirm the diagnosis of FAP.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1263": {
        "output": "The patient note describes a 21-year-old college student who underwent a sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid area. These polyps were biopsied and determined to be benign adenomas. This patient has a family history of multiple polyps, as both his brother and sister underwent total proctocolectomy after being found to have hundreds of colonic adenomas.\n\nThe clinical trial in question is investigating the prevalence of small bowel polyps in patients with sporadic duodenal/ampullary adenomas. The inclusion criteria specify two groups of participants:\n\n1. Cases - Patients who were diagnosed with or underwent resection of a duodenal adenoma/ampulloma at Westmead hospital between the years 2005-2014.\n2. Controls - Patients undergoing VCE procedure for the evaluation of obscure gastrointestinal bleeding (OGIB) or Iron deficiency anemia (IDA).\n\nThe patient does not meet the inclusion criteria for the clinical trial as there is no mention of duodenal adenoma/ampulloma or the patient undergoing a VCE procedure for OGIB or IDA. The patient's polyps are located in the colon, specifically within the rectosigmoid region, which does not align with the focus areas of the trial (small bowel, duodenal/ampullary polyps). Additionally, the patient's situation does not match the circumstances described for control patients.\n\nTherefore, based on the information provided, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1264": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's compare the details to assess eligibility.\n\nPatient note details:\n- The patient is a 21-year-old college student.\n- The patient has a family history of multiple polyps, with both siblings having undergone total proctocolectomy for hundreds of colonic adenomas.\n- The patient himself was found to have dozens of small colonic polyps within rectosigmoid, which were biopsied and are all benign adenomas.\n\nClinical trial inclusion criteria:\n- First-degree relatives (aged 40 to 70 years) of individuals diagnosed with non-advanced adenoma on screening colonoscopy as Cases\n- FDR of patients with negative findings on colonoscopy identified during the same study period, who are of the same age group as the studied as Cohort\n\nThe patient is a first-degree relative (FDR) of individuals (his siblings) with non-advanced adenomas, fitting part of the criteria for the clinical trial. However, the inclusion criteria specify that the FDRs must be aged between 40 to 70 years. The patient is only 21 years old, which does not meet the age criterion for the trial.\n\nTherefore, based on the age criterion alone, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1265": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 21-year-old college student undergoing sigmoidoscopy due to a family history of multiple polyps. His siblings had numerous adenomas and underwent total proctocolectomy. The patient himself has been found to have dozens of small colonic polyps within the rectosigmoid area, all of which are benign adenomas.\n\nThe clinical trial in question is focusing on the utility of segmental withdrawal time during screening colonoscopy to increase adenoma detection rate. The inclusion criteria for the trial specify that adult patients aged 18-80 years who are undergoing colonoscopy for screening or surveillance purposes are eligible.\n\nThe patient fits the age requirement of the inclusion criteria, and since he has been found to have colonic polyps, he would likely be undergoing further colonoscopy for screening or surveillance of polyps. Therefore, he meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1266": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Calcium and Bone Mass in Young Females,\" here are the main points to consider:\n\nPatient Note:\n- The patient is a 51-year-old woman.\n- She has a past medical history of significant hypertension and diet-controlled diabetes mellitus.\n- She is in menopause and is concerned about osteoporosis.\n\nClinical Trial Inclusion Criteria:\n- Pubertal stage II (indicating a young female who is in the early stages of puberty).\n- Calcium intake below a threshold level.\n- Caucasian ethnicity.\n- Normal health.\n\nThe patient in the note does not meet the following inclusion criteria:\n- She is not in Pubertal stage II; she is a postmenopausal 51-year-old woman.\n- There is no information regarding her calcium intake, but the study is specifically targeting young females with low calcium intake.\n- The health status of the patient includes significant hypertension and diabetes mellitus, which may not be considered \"normal health\" as required by the study.\n\nGiven these discrepancies, it is clear that the patient does not match the demographic or health status requirements for the clinical trial. Therefore, she would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1267": {
        "output": "Given the information from the patient note and the clinical trial, let's assess the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria for the clinical trial:\n1. Women at least 60 years of age.\n2. Good general health.\n3. Willingness to participate in this 3.5 year study.\n4. Ability to give informed consent.\n5. Ability to live independently and travel to the research center for visits (transportation provided on a limited basis).\n6. Spine bone mineral density (BMD) (L1-4) T-score between -1.0 and -2.5, or a hip T-score between -1.0 and -2.5.\n\nPatient's characteristics from the note:\n- 51-year-old woman (does not meet the age requirement of at least 60 years).\n- In menopause within the last year.\n- Seeking advice on osteoporosis prevention.\n\nBased on the information provided, the patient does not meet the age criterion of the study, which is a critical inclusion factor. No information is provided regarding the patient's bone mineral density (BMD) scores, but even if they fall within the required range, the age criterion is not met.\n\nTherefore, the patient is not eligible for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1268": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the clinical trial.\n\nPatient Note:\n- A 51-year-old woman\n- Concerned about osteoporosis prevention\n- Past medical history of hypertension and diabetes mellitus\n- Menopausal within the last year\n\nClinical Trial Inclusion Criteria:\n- Chronological age: 6.0 - 17.0 years\n- AP Lumbar spine bone mineral density less than or equal to -2 standard deviations for age-matched controls (z-score)\n- Patients with Idiopathic Juvenile Osteoporosis, or osteoporosis with no identifiable etiology in a child\n- Other specific criteria related to the ability to comply with the study, certain medical conditions, and treatments.\n\nClearly, the patient does not meet the inclusion criteria for the clinical trial. The trial is specifically for children aged 6 to 17 years with idiopathic juvenile osteoporosis, whereas the patient is a 51-year-old woman concerned about osteoporosis prevention in her later years.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1269": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the inclusion and exclusion criteria provided.\n\nInclusion Criteria:\n1. Patients with karyotypically normal spontaneous premature ovarian failure diagnosed prior to the age of 40.\n2. Patients who are between the age of 18 and 42 years.\n\nExclusion Criteria (relevant to the patient note):\n1. Smokers (more than 2 cigarettes per day).\n\nPatient Note Analysis:\n1. The patient is a 51-year-old woman, which is beyond the age limit of 42 years stated in the inclusion criteria.\n2. The patient currently smokes 1 pack of cigarettes per day, which exceeds the exclusion criterion for smokers.\n\nGiven the information provided in the patient note:\n- The patient's age does not meet the inclusion criteria as she is older than the maximum age of 42 years.\n- The patient is a smoker, which is explicitly listed as an exclusion criterion.\n\nTherefore, the patient is not eligible for the clinical trial based on both her age and smoking status.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1270": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Dietary Phytoestrogens and Bone Metabolism,\" we need to compare the patient's characteristics to the inclusion criteria of the study:\n\nInclusion Criteria for the Trial:\n- Postmenopausal\n- Weight within 90% to 120% of ideal body weight\n- 12 or more months since last menstrual period\n- New York Metro Area resident\n\nPatient Characteristics:\n- A 51-year-old woman\n- Documented by previous LH and FSH levels to be in menopause within the last year\n- Concern about osteoporosis prevention\n- Significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n\nThe patient note indicates that the woman is postmenopausal, as she has been documented to be in menopause within the last year. However, to determine her eligibility, we also need to consider her weight in comparison to the ideal body weight and confirm whether she has been postmenopausal for 12 or more months. Additionally, it's necessary to know if she is a New York Metro Area resident.\n\nThe patient note does not provide information about her weight relative to the ideal body weight or her residency. Therefore, based on the available information, we cannot definitively determine her eligibility.\n\nTaking into account the missing information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need to gather more information about her weight and place of residency to make a final determination.",
        "label": 0
    },
    "1271": {
        "output": "The patient is a 51-year-old woman seeking advice on osteoporosis and is documented to be in menopause within the last year. To determine the patient's eligibility for the clinical trial titled \"Effects of Black Cohosh on Menopausal Hot Flashes,\" we need to compare the patient's characteristics with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n1. Resident of the New York Metro Area\n2. Postmenopausal\n3. Weight within 90% to 120% of ideal body weight\n\nFrom the patient note, we know that:\n1. The patient is postmenopausal, as indicated by her LH and FSH levels documented within the last year.\n2. There is no information about her residency, so we cannot confirm whether she is a resident of the New York Metro Area.\n3. There is no information provided about her weight or ideal body weight to determine if she falls within the 90% to 120% range.\n\nBased on the information given, the patient does meet the postmenopausal criterion, but we lack information on her residency and weight to fully assess her eligibility. Therefore, without additional information, we would consider referring this patient to the clinical trial upon further investigation to determine if she meets the remaining criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1272": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, here are the relevant points for determining eligibility:\n\nPatient Information:\n- The patient is a 51-year-old woman.\n- She is seeking advice on osteoporosis.\n- She has hypertension and diabetes mellitus.\n- She smokes cigarettes.\n- She is in menopause.\n\nClinical Trial Information:\n- The trial is focused on determining risk factors associated with osteoporosis in men.\n- Inclusion criteria specify veterans aged 50 and older from two existing VA cohorts.\n\nThe patient in the note is a 51-year-old woman, which does not meet the inclusion criteria of the clinical trial, as the trial is specifically looking for male veterans. Therefore, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1273": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility.\n\nPatient note analysis:\n- 51-year-old woman (matches the age criteria of 50-75 years)\n- Past medical history of hypertension and diabetes mellitus\n- Currently smokes cigarettes (not mentioned in the inclusion or exclusion criteria)\n- Documented to be in menopause within the last year (qualifies as postmenopausal)\n- Concerned about osteoporosis (reason for seeking advice on prevention, which may imply low bone mineral density)\n\nClinical trial inclusion criteria analysis:\n- Healthy Caucasian postmenopausal females between 50-75 years of age (patient is within the age range and is postmenopausal)\n- Low bone mineral density at the lumbar spine or hip as measured using DXA (not explicitly mentioned in the patient note, but the concern about osteoporosis could suggest this)\n- On estrogen replacement treatment for at least three years (not mentioned in the patient note, the patient's hormone levels were tested, but no indication of estrogen treatment)\n\nThe patient seems to meet some of the criteria (age, postmenopausal status), but there are gaps in the information provided. Specifically, there is no mention of her being on estrogen replacement treatment, which is a requirement, nor is there a confirmed low bone mineral density via DXA. Without additional information regarding her bone mineral density and estrogen replacement treatment history, we cannot confidently refer her for the trial. \n\nTherefore, the eligibility assessment would be:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1274": {
        "output": "In assessing the patient's eligibility for the clinical trial titled \"Patient- and Physician-Based Osteoporosis Education,\" we need to cross-reference the patient's characteristics with the specified inclusion criteria:\n\nThe patient note provides the following information:\n- The patient is a 51-year-old woman.\n- She has a past medical history of significant hypertension and diet-controlled diabetes mellitus.\n- She is currently a smoker.\n- She is in menopause, as indicated by previous LH and FSH levels within the last year.\n- She is seeking advice on osteoporosis prevention.\n\nThe inclusion criteria for the clinical trial are:\n- PACE beneficiaries who filled at least one prescription for a drug of any type in the year prior to the study.\n- At high risk for osteoporosis: women and men 75 years or older, patients taking glucocorticoids or psychoactive medications, patients diagnosed with rheumatoid arthritis, and patients with a past fracture.\n- Have had an outpatient visit with a participating doctor based on Medicare outpatient claims.\n\nBased on the provided information, the patient does not meet the age criterion as she is not 75 years or older. There is no mention of her being a PACE beneficiary, taking glucocorticoids or psychoactive medications, having rheumatoid arthritis, or having a past fracture. The patient note does not indicate that she has had an outpatient visit with a participating doctor or that she has filled a prescription for a drug in the past year.\n\nWithout additional information confirming any of the inclusion criteria such as PACE beneficiary status, prescription history, or outpatient visits, we cannot confidently refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1275": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the study.\n\nPatient characteristics:\n- 51-year-old woman\n- Postmenopausal within the last year\n- Significant hypertension (condition to consider regarding exclusion criteria)\n- Diet-controlled diabetes mellitus\n- Current smoker\n- Concerned about osteoporosis\n\nClinical trial inclusion criteria:\n- Postmenopausal for at least 3 years\n- With osteoporosis at specified sites (BMD > 2.0 standard deviations below young normal mean)\n- Willing to take study-supplied calcium and vitamin D supplement\n\nClinical trial exclusion criteria:\n- Pregnant or lactating, or of childbearing potential\n- Participated in another therapeutic trial within 30 days\n- History of hypersensitivity to ibandronate or certain hereditary problems\n- Esophageal abnormalities\n- Unable to stand or sit upright for at least 60 minutes\n- Current use of illicit drugs, or history of drug or alcohol abuse within 5 years\n- Certain medical conditions (hypocalcemia, severe malabsorption, moderate or severe uncontrolled hypertension, recent cardiovascular events, impaired renal function, organ transplantation, significant end organ diseases, metabolic bone disease other than postmenopausal bone loss, clinical fracture in the past year)\n- Treatment that influences bone turnover prior to randomization\n- Medications that alter bone or calcium metabolism during the study\n\nBased on the information provided, the patient is postmenopausal but it has been only within the last year, not the required 3 years as per the trial inclusion criteria. Additionally, her hypertension must be considered; if it's moderate or severe and uncontrolled, it could be a disqualifying factor.\n\nGiven these points, the patient does not meet the inclusion criteria for the duration of postmenopausal status. The hypertension status needs further clarification to ensure it's not a disqualifying condition.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1276": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether the patient meets the inclusion criteria for the clinical trial.\n\nPatient Note:\n- 51-year-old woman\n- Concerned about osteoporosis\n- Past medical history includes hypertension and diabetes mellitus\n- Current smoker\n- Postmenopausal within the last year\n\nClinical Trial Inclusion Criteria:\n- Women age 50-64 years at high risk for osteoporosis\n- Members of the Harvard Pilgrim Health Plan\n\nThe patient note indicates that the patient is a 51-year-old woman concerned about osteoporosis, which aligns with the age and concern targeted by the clinical trial. However, we lack information about whether she is a member of the Harvard Pilgrim Health Plan, which is a specific inclusion criterion for this trial. Without this information, we cannot conclusively determine her eligibility.\n\nTherefore, the assessment of eligibility, given the available information, is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1277": {
        "output": "After reviewing the provided patient note and the clinical trial's inclusion criteria, it is clear that the patient does not meet the necessary requirements to be eligible for this clinical trial. The key points to consider are:\n\n- The patient is a 51-year-old woman. The clinical trial specifically requires male participants.\n- The clinical trial is studying male methadone-maintained patients, and there is no indication that the patient is undergoing methadone maintenance therapy.\n- The age range for the trial is 18 to 50 years, and the patient is 51 years old.\n\nTherefore, based on these mismatches between the patient's characteristics and the trial's inclusion criteria, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1278": {
        "output": "Assessment:\n\n- The patient is a 51-year-old woman, which meets the age criterion of being fifty years or more of age.\n- She is seeking advice on osteoporosis prevention, which indicates a concern about the condition but does not confirm she currently has osteoporosis or a fracture caused by it.\n- The inclusion criteria specifically require a fracture caused by osteoporosis for participation.\n- The patient's note does not mention a history of fracture or diagnosis of osteoporosis, only a concern for future risk.\n- There is no mention of mental or physical state preventing participation, so we cannot assess the exclusion criteria fully.\n\nGiven the information provided, the patient does not meet the specific inclusion criterion of having a fracture caused by osteoporosis. However, since she is concerned about osteoporosis and is within the age group of interest, it is conceivable that with further investigation (e.g., bone density tests), she could potentially be found to have osteoporosis and may then meet the inclusion criteria if a fracture is present or occurs. Therefore, based on the current information, she is not immediately eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1279": {
        "output": "The patient in question is a 51-year-old woman who is postmenopausal, as indicated by documented LH and FSH levels within the last year. She is concerned about osteoporosis and is seeking advice on prevention, particularly with regard to hip fracture risk as she ages.\n\nThe clinical trial is targeting postmenopausal women and aims to evaluate the effectiveness of interventions in improving osteoporosis follow-up care after wrist fractures. The inclusion criteria specifically mention postmenopausal women who have had a low trauma distal radius fracture (wrist fracture), confirmed by x-ray.\n\nThe patient's note does not indicate that she has had a wrist fracture, only that she is seeking advice on osteoporosis prevention. There is no mention of a recent fracture or any treatment related to osteoporosis, such as Didrocal, Miacalcin, or hormone replacement therapy.\n\nGiven the information provided, this patient does not meet the inclusion criteria for the clinical trial, as there is no indication of a wrist fracture. Therefore, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1280": {
        "output": "Given the patient's age as 51 years old, she does not meet the age inclusion criterion for the clinical trial which requires women to be between 25 and 44 years of age. Therefore, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1281": {
        "output": "Based on the patient note and the provided information on the clinical trial, the patient does not appear to meet the inclusion criteria for the trial. The clinical trial is focused on secondary prevention of osteoporotic fractures in residents of long-term care facilities, and specifically requires participants from North Carolina long-term care facilities with ten residents who had had a hip fracture or osteoporosis diagnosis.\n\nThe patient in question is a 51-year-old woman seeking advice on osteoporosis prevention, and there is no mention of her being a resident in a long-term care facility or having a history of a hip fracture or osteoporosis diagnosis. Moreover, the inclusion criteria specify a very particular population from long-term care facilities in North Carolina, which does not seem to apply to this patient based on the information provided.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1282": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women,\" we need to consider the inclusion criteria provided and compare them to the patient's characteristics.\n\nInclusion Criteria Checklist:\n1. Healthy as assessed by the health and lifestyle questionnaire, physical examination, and results of the pre-study laboratory tests.\n2. Caucasian women.\n3. Postmenopausal (\u226512 - \u226460 months since last menses), determined by interview and FSH level \u2265 20 IU/l.\n4. Body Mass Index (BMI) \u226522 - \u226429 kg/m2.\n5. Voluntary participation.\n6. Having given their written informed consent.\n7. Willing to comply with the study procedures.\n8. Willing to accept use of all nameless data, including publication and the confidential use and storage of all data.\n9. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.\n\nPatient Characteristics:\n- 51-year-old woman (satisfies the postmenopausal age range).\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus.\n- Currently smokes 1 pack of cigarettes per day.\n- Documented by previous LH and FSH levels to be in menopause within the last year (satisfies the postmenopausal time frame and likely the FSH level criteria).\n- Concerned about osteoporosis prevention.\n\nThe patient's note indicates that she is a postmenopausal woman, which matches the trial's requirement. However, there are several pieces of information not provided in the patient note that are necessary to fully assess her eligibility, such as her ethnicity (to confirm she is Caucasian), her BMI, and her overall health status as determined by a health and lifestyle questionnaire and physical examination. Additionally, there is no information on whether the patient is willing to comply with the study procedures and other consent-related criteria.\n\nGiven the missing information, the assessment cannot be definitive. However, there are no immediate disqualifications based on the information provided. Therefore, the patient could potentially be eligible for the clinical trial upon further investigation to confirm the missing details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1283": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 51-year-old woman\n- Seeking advice on osteoporosis prevention\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented to be in menopause within the last year\n\nClinical Trial Inclusion Criteria:\n- Women who have been newly diagnosed with post-menopausal osteoporosis, requiring treatment\n- Naive to bisphosphonate treatment, or had bisphosphonate treatment for a maximum of 3 months, at least 5 years before screening\n\nAssessment:\n- The patient is post-menopausal, which is a requirement for the clinical trial.\n- The patient note does not specify whether the patient has been diagnosed with osteoporosis or whether she has previously received any bisphosphonate treatment.\n\nGiven the information available, the patient is a potential candidate for the clinical trial since she is post-menopausal and is seeking advice on osteoporosis prevention. However, further investigation is needed to confirm a diagnosis of osteoporosis and to ensure she has not previously been treated with bisphosphonates (or if treated, it was within the allowed criteria). Without this information, we cannot definitively determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1284": {
        "output": "Based on the provided patient note and clinical trial criteria, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- Age: 51 years old\n- Gender: Female\n- Medical history: Significant hypertension, diet-controlled diabetes mellitus, menopause within the last year\n- Lifestyle: Smoker (1 pack of cigarettes per day)\n- Concern: Osteoporosis prevention\n\nClinical Trial Inclusion Criteria:\n- Healthy African-American and Caucasian adults aged 18-65 years.\n\nThe patient is within the age range specified by the study. However, the trial is seeking healthy adults, and the patient has significant hypertension and diet-controlled diabetes mellitus, which might exclude her from being considered \"healthy\" as per the study's likely definition. Moreover, the patient is seeking advice on osteoporosis prevention, which is not the focus of the vitamin D nutrition study.\n\nGiven this information, the patient does not clearly meet the inclusion criteria, as her medical conditions may disqualify her from being considered a healthy adult for the purposes of this trial. Additionally, the study's aim does not align with her primary concern of osteoporosis prevention. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1285": {
        "output": "Assessing the eligibility of the patient for the clinical trial based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 51-year-old woman.\n- She has a past medical history of significant hypertension and diet-controlled diabetes mellitus.\n- She is a current smoker.\n- She has recently been documented to be in menopause.\n- She is seeking advice on osteoporosis prevention.\n\nClinical Trial Inclusion Criteria:\n- Postmenopausal women and men over the age of 40.\n- Patients who are starting therapy with teriparatide.\n\nThe patient in the note is a 51-year-old woman who has been documented to be in menopause. This matches the inclusion criteria of being a postmenopausal woman over the age of 40. However, the clinical trial specifically includes individuals who are starting therapy with teriparatide, and there is no information in the patient note indicating that the patient is starting or has been prescribed teriparatide therapy.\n\nGiven the information provided, the patient meets the age and menopausal status criteria for the trial. However, without confirmation that she is starting teriparatide therapy, we cannot fully determine her eligibility. Therefore, further investigation would be needed to ascertain whether she is a candidate for teriparatide therapy and thus for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1286": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- 51-year-old woman\n- Postmenopausal (documented by LH and FSH levels within the last year)\n- Significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Seeking advice on osteoporosis prevention\n\nClinical trial inclusion criteria:\n- Postmenopausal\n- Asthmatic outpatients under 60 years of age\n- On long-term oral or inhaled glucocorticoid treatment for at least one year\n\nThe patient meets some of the inclusion criteria for the clinical trial: she is a postmenopausal woman under 60 years of age. However, there is no mention of her having asthma or being on long-term oral or inhaled glucocorticoid treatment for at least one year. These are key inclusion criteria for the trial, which are related to the primary focus of the study \u2013 osteoporosis and fractures in asthmatics receiving glucocorticoids.\n\nSince the patient does not have a documented history of asthma or glucocorticoid treatment, she does not meet the crucial inclusion criteria for this clinical trial. Therefore, she would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1287": {
        "output": "Upon reviewing the patient's note and the inclusion criteria for the clinical trial titled \"The Effects of Aging and Estrogen on the Pituitary,\" we can compare the details to determine trial-level eligibility.\n\nPatient's characteristics:\n- 51-year-old woman (within the 45-55 age range specified by the trial)\n- History of natural menopause confirmed by previous LH and FSH levels within the last year (meets criteria)\n- Currently smokes 1 pack of cigarettes per day (does not meet the non-smoker or <10 cigarettes/day criteria)\n- Concerned about osteoporosis (not relevant to the trial's focus)\n\nInclusion criteria for the trial:\n- 45-55 or 70-80 years old (the patient is eligible)\n- History of natural menopause defined by the absence of menses for at least 12 months and a FSH level >26 IU/L (the patient is eligible)\n- On no hormonal medication or herbal supplements and/or over the counter menopause therapy for a minimum of 2 months prior to study (no information provided about the patient's medication or supplement use)\n- Normal thyroid stimulating hormone, prolactin, factor V Leiden, and complete blood count (no information provided about the patient's levels)\n- Normal blood urea nitrogen and creatinine (< 2 times the upper limit of normal) (no information provided)\n- Basal metabolic index \u2264 30 (no information provided about the patient's BMI)\n- Non-smokers or smoke less than 10 cigarettes/day (the patient does not meet this criterion)\n\nBased on the information available, the patient meets some of the inclusion criteria but fails to meet the smoking requirement. Additionally, we lack information on some other criteria, such as her medication/supplement use, specific blood test results, and BMI. Therefore, further investigation would be required to assess other criteria definitively. However, because the patient is a smoker and the criteria explicitly exclude smokers or limit to those who smoke less than 10 cigarettes per day, the patient would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1288": {
        "output": "Patient Note Analysis:\n- The patient is a 51-year-old woman.\n- She is in menopause.\n- She has hypertension and diabetes mellitus.\n- She smokes cigarettes.\n- She is seeking advice on osteoporosis prevention.\n\nClinical Trial Analysis:\n- The trial is focused on falls prevention in people with osteoporosis.\n- The inclusion criteria are: \n  1. osteoporosis (DXA T-score < -2.5 in hip and/or vertebrae)\n  2. able to walk at least 15 minutes without a helping device\n  3. 65 years or older\n  4. community-dwelling\n  5. at least one fall in the prior year\n\nBased on the provided information, the patient does not meet several of the inclusion criteria for the clinical trial:\n- There is no information to suggest she has osteoporosis with a DXA T-score < -2.5.\n- She is not 65 years or older.\n- There is no mention of her having experienced a fall in the prior year.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the clinical trial on falls prevention in people with osteoporosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1289": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient in question does not appear to be eligible for the clinical trial.\n\nThe clinical trial is specifically looking to evaluate the prevalence of bone mineral density in male patients with schizophrenia who also have a history of alcohol abuse.\n\nThe patient in question is a 51-year-old woman with a concern for osteoporosis and a past medical history of significant hypertension and diet-controlled diabetes mellitus. She does not have a diagnosis of schizophrenia or a history of alcohol abuse as defined by the trial's inclusion criteria.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial which requires a DSM-IV diagnosis of schizophrenia and an onset of illness more than 5 years.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1290": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, we can analyze the patient's eligibility.\n\nPatient Characteristics:\n- 51-year-old woman\n- Postmenopausal within the last year\n- Concerned about osteoporosis prevention\n\nClinical Trial Inclusion Criteria:\n- Postmenopausal women\n- >=3 months daily or weekly alendronate or risedronate for treatment or prevention of postmenopausal osteoporosis\n\nThe patient is postmenopausal and concerned about osteoporosis prevention, which aligns with the target population for the clinical trial. However, the inclusion criteria specifically require that participants must have been on daily or weekly bisphosphonate therapy with alendronate or risedronate for at least 3 months. The patient note does not mention that the patient has been on such therapy. Therefore, based on the information provided, there is no evidence that the patient meets one of the key inclusion criteria for the study.\n\nGiven this information, the patient does not currently meet the inclusion criteria for the BONCURE Study as there is no indication that she has been treated with bisphosphonates for osteoporosis. Therefore, she would not be referred to the clinical trial based on the information available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1291": {
        "output": "Based on the patient note, the 51-year-old woman has a history of significant hypertension, diet-controlled diabetes mellitus, is currently a smoker, and has been documented to be in menopause within the last year. She is seeking advice on osteoporosis prevention and is concerned about breaking her hip as she gets older.\n\nThe clinical trial in question is focused on education for osteoporosis in persons with existing fractures and aims to investigate the impact of different durations of osteoporosis education on various outcomes in people aged over 50 years who have already had a bone fracture.\n\nThe inclusion criteria for the clinical trial are:\n- Presented to Modbury Hospital's Accident and Emergency Department with a new bone fracture.\n\nThe patient note does not indicate that the woman has had a bone fracture; her concern is about future risk of fracture due to osteoporosis. Therefore, she does not meet the inclusion criteria for the clinical trial, which specifically requires participants to have already experienced a bone fracture.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1292": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 51-year-old woman\n- Postmenopausal (indicated by previous LH and FSH levels)\n- Concerned about osteoporosis and seeking advice on prevention\n\nClinical Trial Inclusion Criteria:\n- Female, post-menopausal women aged 50 to 90\n- Have a bone mineral density (BMD) evaluation resulting in a T-Score of <-1.0\n- Have a follow-up appointment with a provider in the areas of Family Medicine (FM), Primary Care Internal Medicine (PCIM), or POM (Preventive, Occupational, and Aerospace Medicine)\n- Have no major barriers to participation in shared decision-making\n\nComparison:\n- The patient is within the age range required by the trial (50 to 90 years old).\n- The patient is postmenopausal, which fits the criteria.\n- The patient's BMD score is not mentioned, so we do not know if she has a T-Score of <-1.0.\n- It is not stated whether she has a follow-up appointment with a provider in the specified areas.\n- There is no indication of the patient having major barriers to participation in shared decision-making.\n\nGiven that the patient's BMD score is not provided in the note, and we do not have information about a scheduled follow-up appointment with a provider in the specified areas, we cannot definitively determine her eligibility. However, based on her age and menopausal status, she could potentially be a candidate for the trial if her BMD score meets the criteria and she has a follow-up appointment with the right provider.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1293": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"GIOP Prevention Among People With Rheumatoid Arthritis,\" the patient in the note does not meet the inclusion criteria for the trial. The inclusion criteria specify that participants must:\n\n1. Meet the American College of Rheumatology criteria for rheumatoid arthritis.\n2. Be taking an oral glucocorticoid equivalent to 5 mg/day of prednisone for at least one month prior to study entry.\n3. Be 18 years of age or older.\n\nThe patient note describes a 51-year-old woman concerned about osteoporosis prevention, with a past medical history of hypertension and diabetes mellitus, and currently smoking. She is in menopause but does not have a diagnosis of rheumatoid arthritis nor is she described as taking glucocorticoids.\n\nTherefore, since the patient does not meet the necessary criteria related to rheumatoid arthritis and glucocorticoid use, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1294": {
        "output": "Let's review the patient's details against the inclusion criteria of the clinical trial:\n\nPatient's Characteristics:\n- Female\n- Age: 51 years old\n- Smoker: 1 pack per day\n- Postmenopausal status: within the last year\n- Significant hypertension and diet-controlled diabetes mellitus\n- Seeking advice on osteoporosis prevention\n\nClinical Trial Inclusion Criteria:\n- Female\n- Age 45 to 55 years (inclusive)\n- Race: Caucasian (not specified in the patient note)\n- Non-smokers / Smokers up to 10 cigarettes/day (patient exceeds this limit)\n- Postmenopausal hormone status: 1-3 years since the last spontaneous menstrual bleeding and a follicle-stimulating hormone concentration (FSH) >75 IU/ml and 17-estradiol (E2) of < 20 ng/L (patient's exact FSH and E2 levels are not provided; however, she is at the lower end of the 1-3 years postmenopausal criteria)\n- Years since menopause between 1-3 years (meets this criterion)\n- Natural menopause or total hysterectomy with bilateral salpingo-oophorectomy (not specified in the patient note)\n- Assessed as age-related healthy, based on a pre-study examination (the patient has hypertension and diabetes, which may affect this assessment)\n- Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements (assumed to be met)\n- Ability to understand, speak, read and write the English language (assumed to be met)\n\nBased on the information provided, the patient meets some of the inclusion criteria such as age, female gender, and being postmenopausal within the specified time frame. However, she exceeds the smoking limit set by the trial and her health status regarding hypertension and diabetes may affect her classification as \"age-related healthy.\" Furthermore, we lack information on her race, exact FSH and E2 levels, and whether her menopause was natural or the result of surgery.\n\nGiven the discrepancies and missing information, particularly the fact that she is a heavy smoker which clearly violates the trial criteria, I would assign the following:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1295": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note Summary:\n- The patient is a 51-year-old woman\n- Concerned about osteoporosis\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Current smoker\n- Documented menopause within the last year\n\nClinical Trial Inclusion Criteria Summary:\n- Postmenopausal female, 55-75 years old\n- History of Type II diabetes for more than 5 years, requiring insulin or treated with oral therapies\n- BMI of 19-35\n- Able to move without walkers, no history of long inactivity periods\n- For fracture participants: low energy trauma fractures after diabetes onset, verified by radiographs\n\nComparing the details:\n\n- Age: The patient is 51 years old, which is below the trial's age range of 55-75 years.\n- Diabetes: The patient has diet-controlled diabetes mellitus, but the trial specifies diabetes requiring insulin or treated with oral therapies for more than 5 years.\n- BMI: There is no information provided about the patient's BMI.\n- Mobility: There is no indication that the patient is unable to move without walkers or has a history of long periods of inactivity, but this is not explicitly confirmed.\n- Fractures: There is no mention of the patient having any fractures, which is a part of the criteria for some participants in the trial.\n\nGiven the information provided, the patient does not meet the age and diabetes treatment criteria for the clinical trial. Therefore, the patient is not eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1296": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 51-year-old woman who is postmenopausal as evidenced by documented LH and FSH levels within the last year. This aligns with the inclusion criteria of the trial, which requires healthy women aged 45 and above who have been menopausal for at least 1 year. However, the inclusion criteria also specify that participants should be \"healthy,\" which could be subjective. The patient has a history of significant hypertension and diet-controlled diabetes mellitus, and she is currently a smoker. These factors may impact her eligibility depending on the specific definitions of \"healthy\" used by the clinical trial.\n\nConsidering the information provided, the patient meets the age and menopausal status criteria, but there are potential concerns regarding her overall health status due to her medical history and smoking habit. More information would be needed to fully assess her health status in the context of the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1297": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the clinical trial.\n\nPatient note:\n- 51-year-old woman\n- Seeking advice on osteoporosis prevention\n- Past medical history includes significant hypertension and diet-controlled diabetes mellitus\n- Current smoker\n- Documented to be in menopause within the last year\n\nClinical trial:\n- Observational study on post-menopausal osteoporosis\n- Inclusion criteria: Women between the age of 18-55, pre-menopausal by history or documented FSH <10, no current estrogen therapy, undergoing hysterectomy with or without ovariectomy for benign gynecologic disease or for prophylaxis against ovarian cancer\n\nThe patient is outside of the specified age range of 18-55 years and is not pre-menopausal as she has been documented to be in menopause within the last year. Additionally, there is no mention of her undergoing hysterectomy for any of the listed conditions or for prophylaxis against ovarian cancer. Therefore, she does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1298": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess whether the patient is eligible for the trial.\n\nPatient Note Analysis:\n- The patient is a 51-year-old woman.\n- She has hypertension, which is one of the conditions listed in the trial's inclusion criteria.\n- She has diabetes mellitus, which is also listed in the inclusion criteria.\n- She is seeking advice on osteoporosis prevention, and osteoporosis is one of the conditions that the trial aims to address.\n- The patient is in menopause as indicated by previous LH and FSH levels.\n- The patient is a smoker, but smoking is not mentioned in the exclusion criteria.\n- There is no mention of the patient currently receiving treatment for alcohol or drug problems or suffering from substance-related medical illness.\n- There is no indication that the patient is experiencing physical dependence on alcohol, requiring medically supervised detoxification.\n- There is no mention of the patient currently abusing or being physically dependent on opiates, cocaine, or other illicit drugs.\n- The patient is not currently pregnant or nursing.\n- The patient appears to be able to complete study measures, as she is seeking advice in a clinic and there is no indication of any cognitive or physical impairments that would prevent her from doing so.\n\nClinical Trial Inclusion Criteria Checklist:\n- Has diabetes, hypertension, osteoporosis, or infertility: Yes (hypertension and diabetes)\n- Not currently receiving treatment for alcohol or drug problems or substance-related medical illness: No information provided, but nothing in the patient note suggests otherwise.\n- Not currently experiencing physical dependence on alcohol, requiring medically supervised detoxification: No information provided, but nothing in the patient note suggests otherwise.\n- Not currently abusing or physically dependent on opiates, cocaine, or other illicit drugs: No information provided, but nothing in the patient note suggests otherwise.\n- Not currently pregnant: Not mentioned, but since she is in menopause, it is highly unlikely.\n- Not currently nursing: No information provided, but nothing in the patient note suggests otherwise.\n- Able to complete study measures: Yes, as the patient is actively seeking medical advice.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial. There is no information to suggest that the patient would not be eligible based on the criteria provided. Therefore, the patient is highly likely to be referred for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1299": {
        "output": "Based on the information provided, the 51-year-old woman patient meets several of the inclusion criteria for the clinical trial studying the prevention and treatment of postmenopausal osteoporosis in Chinese women:\n\n- She is within the age range of 45-60 years old for early postmenopause criteria.\n- She has documented evidence of being in menopause within the last year, which fits the criterion of spontaneous amenorrhea for more than six months and less than 5 years.\n\nHowever, there are some pieces of information that are not provided in the patient note that would be necessary to determine full eligibility, such as:\n\n- Bone mineral density between -1 and -2.5 standard deviations compared with normal young women (required for the early postmenopause criteria).\n- Confirmation of physical and mental health status.\n- Whether she is of Chinese descent, as the trial specifies \"in Chinese women.\"\n\nGiven the information available, the patient appears to meet some of the critical eligibility criteria, but further investigation is required to confirm bone mineral density and other health qualifications.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1300": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient's characteristics:\n- Female\n- 51 years old\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Current smoker\n- Documented menopausal status within the last year\n\nClinical trial inclusion criteria:\n- Female\n- \u2265 65 years old\n- Postmenopausal for > 5 years\n\nThe patient is female and postmenopausal, which matches two of the criteria. However, she is 51 years old, which does not meet the age criterion of being 65 years or older. Additionally, she has been documented to be in menopause within the last year, not for more than 5 years as required by the trial.\n\nGiven this information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1301": {
        "output": "Based on the patient note and the clinical trial's inclusion and exclusion criteria, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient characteristics:\n- 51-year-old woman\n- Concerned about osteoporosis\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented menopause within the last year\n- Seeking advice on osteoporosis prevention\n\nClinical trial criteria for cases (patients with hip fracture):\n- Women with hip fracture\n- Aged 60 years and more\n- Clinical suspicion of osteoporosis\n- Availability of proximal femur radiographs\n- Signature of informed consent\n\nClinical trial criteria for controls (women without hip fracture):\n- Women aged 60 years and more\n- Signature of informed consent\n\nThe patient in question is a 51-year-old woman seeking advice on osteoporosis prevention, but she does not meet the age criteria of 60 years and more required for both cases and controls in the clinical trial. Furthermore, she does not have a hip fracture, which means she does not qualify as a case for the study.\n\nGiven that the patient does not meet the essential age criterion for the clinical trial, she would not be eligible to participate either as a case or as a control. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1302": {
        "output": "Based on the information provided:\n\n- The patient is a 51-year-old woman, which fits the adult category.\n- She is postmenopausal, as indicated by her LH and FSH levels documented within the last year.\n- She has concerns about osteoporosis, which is the focus of the clinical trial.\n\nHowever, the inclusion criteria for the clinical trial specify that patients must be 55 years of age or older. Since the patient is only 51 years old, she does not meet the age criterion for this trial.\n\nAll other factors seem compatible with the trial's focus, but the age criterion is a clear stipulation. Therefore, despite the other matching factors, the patient is not eligible for this trial due to not meeting the age requirement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1303": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition,\" we need to assess whether the patient meets the inclusion criteria as stated:\n\n- Women in late menopausal transition or early menopause\n- Age 40-55\n- BMI >25 kg/m2\n- Suffer from menopausal symptoms\n- Change in previously regular cycles consisting of at least \u22652 skipped cycles and an interval of amenorrhea (\u226560 days) in the last year\n- Negative pregnancy test\n- Vitamin D insufficiency (<30 ng/ml)\n- Weight stability (+/- 5%) for 3 months\n\nThe patient note indicates:\n\n- The patient is a 51-year-old woman, which matches the age criterion.\n- She is documented to be in menopause within the last year, which may satisfy the requirement for early menopause status.\n- She is seeking advice on osteoporosis prevention, which might indicate she suffers from menopausal symptoms, although this is not clearly stated.\n- Her BMI is not mentioned, so we cannot assess this criterion.\n- There is no mention of menstrual cycle changes, but since she is in menopause, it is implied there have been changes.\n- We do not have information on her pregnancy status, but given her age and menopausal status, it is likely she is not pregnant.\n- Vitamin D levels are not provided, so we cannot assess vitamin D insufficiency.\n- There is no information on her weight stability.\n\nGiven the information provided, the patient meets some of the criteria (age and being in menopause), but there is insufficient information to fully assess her eligibility based on BMI, menopausal symptoms, Vitamin D levels, and weight stability. Thus, further investigation would be needed to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1304": {
        "output": "In reviewing the patient note and the clinical trial information provided, let's assess the eligibility based on the inclusion criteria:\n\nPatient Note:\n- A 51-year-old woman\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented by previous LH and FSH levels to be in menopause within the last year\n- Concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention\n\nClinical Trial Inclusion Criteria:\n- Perimenopausal women\n- Willingness to participate in the 6-month study\n- Willingness to undergo testing of bone turnover markers before and after the drug therapies\n- Willingness to provide a self-assessment on quality of life and sleep throughout the program\n- Subjects must be willing to take their treatments right before bed and to not consume alcohol with this medication\n\nComparison:\n- The patient is a woman who was documented to be in menopause within the last year, which may still fall within the perimenopausal period depending on the study's definition.\n- The patient is seeking advice on osteoporosis prevention, which indicates a potential willingness to participate in a study related to this condition.\n- The note does not mention any unwillingness to undergo testing or provide self-assessment, which can be inferred as a potential willingness to participate.\n- There are no mentions of alcohol use that could interfere with the criteria of not consuming alcohol with the medication.\n\nBased on the information given, the patient appears to meet the criteria of being a perimenopausal woman concerned about osteoporosis, which is the focus of the study. The patient's willingness to participate and comply with study requirements, however, is not explicitly stated but can be inferred. There is no clear contraindication or exclusion mentioned. Therefore, I would consider referring this patient to the clinical trial upon further investigation to confirm her willingness and ability to comply with the study's protocols, including abstaining from alcohol and taking treatments as prescribed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1305": {
        "output": "Based on the patient note provided, the patient is a 51-year-old woman who is in menopause, has a history of significant hypertension, diabetes mellitus, and is a current smoker. She is seeking advice on osteoporosis prevention due to concerns about breaking her hip as she gets older.\n\nThe clinical trial is focused on developing an intervention model for osteoporosis and fall prevention in Taiwan. The inclusion criteria for the trial are simply stated as \"the risk of osteoporosis\" and \"the risk of falls.\"\n\nGiven the patient's age, menopausal status, and her concern for osteoporosis, she appears to have a risk for osteoporosis. As the trial seeks participants who are at risk for osteoporosis, this patient meets that criterion. However, there is no mention of the patient having a history of falls or conditions that significantly increase her risk of falling, which is also part of the inclusion criteria.\n\nDespite the lack of explicit information regarding the patient's risk of falls, menopausal women are generally at increased risk for osteoporosis and falls due to decreased bone density. Additionally, the patient's active search for osteoporosis prevention information may make her a good candidate for an intervention aimed at prevention.\n\nTherefore, the patient seems to meet at least one part of the inclusion criteria (risk of osteoporosis) and could potentially benefit from osteoporosis prevention strategies which could also serve to reduce her risk of falls.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1306": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 51-year-old woman.\n- She is postmenopausal (as indicated by previous LH and FSH levels).\n- She has a past medical history of significant hypertension and diet-controlled diabetes mellitus.\n- She is a current smoker.\n- She is seeking advice on osteoporosis prevention but there is no indication that she has been diagnosed with osteoporosis or that she is currently being treated with bisphosphonates.\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with postmenopausal osteoporosis by a physician.\n- Received any oral bisphosphonates (weekly or monthly) at least for 2 months.\n- Provide informed consent for study participation.\n\nComparing the patient's information with the trial's inclusion criteria:\n- The patient is postmenopausal, which is relevant to the trial.\n- There is no indication in the patient note that she has been diagnosed with osteoporosis or that she has been treated with bisphosphonates, which are both required for the trial.\n\nGiven the information provided, the patient does not meet all of the inclusion criteria for the clinical trial, specifically the diagnosis of osteoporosis and treatment with bisphosphonates. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1307": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to assess whether the patient is a good candidate for the trial. Let's evaluate the patient against the inclusion criteria step by step:\n\n1. **Ambulatory post-menopausal women aged between 55-85 years**: The patient is a 51-year-old woman, which makes her younger than the specified age range for the trial.\n\n2. **Post-menopausal osteoporosis**: The patient was documented to be in menopause within the last year. However, there is no mention of her having osteoporosis or a history of fragility fractures, nor is there any mention of bone mineral density (BMD) evidence.\n\n3. **Treatment with a bisphosphonate and calcium/vitamin D supplements for at least 12 months**: There is no information provided about the patient's current treatment for osteoporosis, if any.\n\n4. **Informed written consent**: This is a procedural step that the patient would need to complete if she meets the other criteria.\n\n5. **eGFR >30 ml/min**: There is no information on the patient's estimated glomerular filtration rate (eGFR).\n\n6. **Normocalcaemia**: There is no information on the patient's calcium levels.\n\nGiven the patient is not within the age range specified by the trial and there is no information on her having osteoporosis, treatment with bisphosphonate and calcium/vitamin D supplements, or related blood measures, she does not meet the key inclusion criteria for the randomized controlled trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1308": {
        "output": "After reviewing the patient note and the clinical trial information, we can compare the patient's characteristics with the inclusion criteria for the trial:\n\nPatient Characteristics:\n- 51-year-old woman\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Current smoker (1 pack per day)\n- Recently postmenopausal\n- Concerned about osteoporosis\n\nClinical Trial Inclusion Criteria:\n- Age 40-80 years old\n- Cases: Spirometry (post-bronchodilator) based diagnosis of COPD (GOLD criteria) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment\n- Smoking controls: No COPD (spirometry-based) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment\n- Non-smoking controls: No COPD (spirometry-based) + < 1 pack-year\n\nThe patient's current age and smoking history fit within the inclusion criteria of being 40-80 years old and having a significant smoking history (at least 10 pack-years). However, there is no information provided about whether the patient has COPD or the results of any spirometry tests. The trial specifically seeks to investigate patients with COPD or control subjects without COPD but with a smoking history. Since we do not have information regarding the patient's COPD status or spirometry results, we cannot definitively include or exclude her from the trial.\n\nTherefore, we would consider referring this patient to the clinical trial upon further investigation to determine if she has COPD or if spirometry results are available.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1309": {
        "output": "To determine if the patient is eligible for the clinical trial, we need to match the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 51-year-old woman\n- Has a past medical history of hypertension and diet-controlled diabetes mellitus\n- Currently smokes cigarettes\n- Documented menopause within the last year\n- Seeking advice on osteoporosis prevention\n\nClinical trial inclusion criteria:\n- Diagnosed with type 2 diabetes mellitus\n- HgbA1c value \u2265 7% and \u2264 17%\n- On basal insulin, with or without oral agents\n- Not on basal bolus insulin therapy\n- No severe hypoglycemic episodes in the 6 months prior to enrollment\n- No known allergy to medical tape or sensors\n- Capable of and willing to test their blood glucose (BG) on average 4 times per day\n- Willing to not use Acetaminophen while enrolled in the study\n- Willing not to undergo an MRI procedure while wearing the CGM sensor\n- Willing and capable of performing self insertions of the device sensor\n- Women of childbearing potential must be willing to use an approved form of birth control\n- Women of childbearing potential must be willing to perform pregnancy tests monthly\n- Can understand and speak English fluently\n\nClinical trial exclusion criteria:\n- On pump therapy in the 6 months prior to enrollment\n- Receiving basal-bolus insulin therapy\n- Taking any medication not approved to be taken with insulin\n- Pregnant or intentions of becoming pregnant during the study\n- Any skin condition that would inhibit the proper wearing of the CGM sensor\n- Hematocrit \u2264 30% or \u2265 55%\n- Currently enrolled in another clinical study\n- Employed by a company that manufactures or is developing a CGM device\n- Deemed incapable of participating in the study by the Primary Investigator for any reason\n\nBased on the patient note, the following points are relevant to the clinical trial criteria:\n\n- The patient has diabetes mellitus, which is not specified as type 1 or type 2 in the patient note. However, the fact that it is diet-controlled may suggest type 2 diabetes, which is a point for inclusion.\n- There is no information on the patient's HgbA1c levels.\n- There is no indication that the patient is currently using insulin, either basal or bolus.\n- There is no mention of severe hypoglycemic episodes.\n- We have no information about allergies to medical tape or sensors.\n- The patient's willingness and capability to perform BG testing or sensor insertion are not mentioned.\n- The patient's willingness to avoid Acetaminophen, MRI procedures while wearing the sensor, and to use birth control or perform pregnancy tests is not stated.\n- The patient can presumably understand and speak English fluently, as she is seen in the clinic for advice.\n\nGiven that the only clear matching criterion is the diagnosis of diabetes, which is not explicitly stated as type 2, and the lack of information on many of the other criteria, the patient's eligibility for this clinical trial is not clear. Therefore, further investigation would be necessary to determine if the patient has type 2 diabetes, her HgbA1c levels, and her treatment regimen, among other factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1310": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note Assessment:\n\n- The patient is a 51-year-old woman which meets the age criterion (\u2265 18 years).\n- She has a concern about osteoporosis and is seeking advice on prevention, which suggests she may have or be at risk for osteoporosis.\n- She has menopause within the last year, which can be associated with an increased risk for osteoporosis due to changes in hormone levels.\n- There is no mention of inherited low-turnover osteoporosis in her medical history.\n- There is no mention of her bone mineral density (BMD) T-score.\n\nClinical Trial Inclusion Criteria:\n\n- The trial is looking for patients with inherited low-turnover osteoporosis.\n- Patients must have a lumbar spine or hip BMD T-score \u2264 -2.5.\n- Patients must provide written informed consent.\n\nGiven the information in the patient note, we cannot confirm if this patient has inherited low-turnover osteoporosis or what her BMD T-score is. While the patient is concerned about osteoporosis, there is no indication that her condition is specifically the inherited low-turnover type required for the trial, nor do we have BMD scores to determine the severity of her bone density.\n\nTherefore, based on the provided information, the patient does not meet the specific inclusion criteria for the clinical trial as there is no evidence of inherited low-turnover osteoporosis or a BMD T-score provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1311": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, we can determine the eligibility of the 51-year-old woman for the clinical trial titled \"Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women.\"\n\nPatient Note Analysis:\n- The patient is a 51-year-old woman who is postmenopausal, as indicated by previous LH and FSH levels documented within the last year.\n- She has significant hypertension and diet-controlled diabetes mellitus.\n- She is currently a smoker.\n- She is seeking advice on osteoporosis prevention and is concerned about hip fractures as she ages.\n\nClinical Trial Inclusion Criteria Analysis:\n- Premenopausal women aged 20-45 with regular menses and no secondary cause of osteoporosis.\n- Documented adult fractures judged to be low-trauma for women aged 20-35 years (with at least one major osteoporotic fracture and low BMD) or women above the age of 35 years (with a history of fracture and/or low BMD).\n- Willingness to use effective contraception throughout the period of study drug administration.\n\nComparing the patient note with the inclusion criteria:\n- The patient is 51 years old, which is above the age range of 20-45 years specified in the inclusion criteria.\n- The patient is postmenopausal, which does not fit the requirement of being premenopausal with regular menses.\n- There is no mention of documented adult fractures or low BMD in the patient note.\n- The trial is specifically looking to enroll premenopausal women, which the patient is not.\n\nBased on the information provided, the patient does not meet the age or menopausal status requirements of the clinical trial. Therefore, she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1312": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note:\n- The patient is a 51-year-old woman.\n- She has hypertension and diabetes mellitus, which are controlled.\n- She is a current smoker.\n- She is in menopause as documented by LH and FSH levels within the last year.\n- She is seeking advice on osteoporosis prevention.\n\nClinical Trial Inclusion Criteria:\n- Aged over 65 years with normal renal function.\n- Normal transaminase levels.\n- Normal calcium blood levels.\n- Not homebound (not immobilized) nor in socio-healthcare institutions.\n\nThe patient does not meet the age criterion as she is 51 years old and the trial requires participants to be over 65 years old. Therefore, she would not be eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1313": {
        "output": "To determine the patient's eligibility for the clinical trial, let's assess the patient information against the inclusion criteria provided by the clinical trial:\n\nInclusion Criteria for the Clinical Trial:\n1. Postmenopausal women or men > 60 years\n2. DXA T-Score at lumbar spine, total hip, or femur neck <-2.0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral density\n3. Pretreatment with bisphosphonates for at least four years\n4. Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009\n5. Signed informed consent\n\nPatient Information:\n- 51-year-old woman (not > 60 years)\n- Past medical history includes significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented by previous LH and FSH levels to be in menopause within the last year\n- Concerned about breaking her hip as she gets older and seeking advice on osteoporosis prevention\n\nBased on the information provided:\n- The patient is postmenopausal, which meets the first part of criterion 1, but she is not over 60 years old, which does not meet the second part of criterion 1.\n- There is no information provided on the patient's DXA T-Score or history of low trauma vertebral fractures, which is necessary to meet criterion 2.\n- There is no information regarding pretreatment with bisphosphonates, which is necessary to meet criterion 3.\n- There is no information on the patient's risk for hip and vertebral fractures according to DVO-guideline for osteoporosis 2009, which is necessary to meet criterion 4.\n- Although the patient can provide signed informed consent, this alone does not qualify her for the study.\n\nGiven that the patient does not meet the age criterion and there is a lack of information on the other critical inclusion criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1314": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine if the 51-year-old woman seeking advice on osteoporosis prevention is eligible for the clinical trial regarding PMMA- versus PEEK-cages in cervical spine pathology.\n\nThe inclusion criteria for the clinical trial are:\n- Virgin spines\n- No emergency operation\n- Age above 18\n- Sufficient knowledge of the German language\n- Indication for anterior cervical discectomy and fusion\n- Absence of concomitant spinal disease\n\nThe patient in the note is a 51-year-old woman with a past medical history of significant hypertension and diet-controlled diabetes mellitus. She is in menopause and is concerned about osteoporosis, specifically breaking her hip as she gets older. There is no mention of cervical spine pathology, requirement for anterior cervical discectomy and fusion, or any issues related to the spine. Furthermore, there is no information given about her knowledge of the German language or if her spine can be considered \"virgin\" (meaning no previous spinal surgeries).\n\nSince the patient's concerns are related to osteoporosis and not cervical spine pathology, and there is no indication that she would need an anterior cervical discectomy and fusion, she does not meet the inclusion criteria for the clinical trial. Therefore, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1315": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient:\n\n- Is a 51-year-old woman (meets the age criterion of being over 45 years)\n- Has been documented to be in menopause within the last year (meets the criterion of being postmenopausal)\n- Is seeking advice on osteoporosis prevention (implies she could be an outpatient screened for osteoporosis, which is part of the trial's scope)\n\nThe patient appears to meet all the specified inclusion criteria for the Osteoporosis Screening Trial. However, it's important to note that her willingness to participate and giving consent to be measured is a prerequisite for eligibility as per the trial's inclusion criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1316": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the eligibility of the patient based on the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 51-year-old woman\n- Concerned about osteoporosis\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Smokes 1 pack of cigarettes per day\n- Documented menopause within the last year\n- Concerned about breaking her hip as she gets older\n\nClinical Trial Inclusion Criteria:\n- Age 65 or older\n- Patient of the Centre for Family Medicine Family Health Team (CFFM FHT)\n- Have at least one of the following: \n  - 2 or more falls in the past 12 months\n  - Age 75 or older\n  - High risk of fracture based on the CAROC\n  - Difficulty with walking or balance as determined by attending physician\n  - Acute fall\n  - History of a fragility fracture after the age of 50\n\nBased on the clinical trial inclusion criteria, the patient does not meet the age requirement of being 65 or older. Additionally, there is no indication that she is a patient of the CFFM FHT or that she has experienced multiple falls, difficulty with walking or balance, an acute fall, or a history of fragility fracture after the age of 50. Furthermore, the high risk of fracture would need to be assessed by the CAROC, which is not mentioned in the patient note.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1317": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial as follows:\n\nPatient Characteristics:\n- 51-year-old woman\n- Currently smokes 1 pack of cigarettes per day\n- In menopause within the last year\n- Seeking advice on osteoporosis prevention\n- No mention of a COPD diagnosis\n\nClinical Trial Inclusion Criteria:\n- Active smokers over 40 years and more than 10 pack-years\n\nThe patient in question meets the age criteria (over 40 years) and is an active smoker with a history of smoking 1 pack per day. However, there is no information provided in the patient note about the total duration of her smoking habit to calculate the pack-years. A pack-year is defined as twenty cigarettes smoked every day for one year. To meet the inclusion criteria of more than 10 pack-years, the patient would have to have smoked for at least 10 years. Given that this information is not provided, we cannot definitively ascertain her eligibility.\n\nTherefore, the assessment of eligibility for this patient for the given clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1318": {
        "output": "Based on the information provided, the patient is a 51-year-old woman with a medical history of significant hypertension and diabetes mellitus, which is specified as being diet-controlled. This implies that the patient has diabetes, and since no type is specified, it could be type 2 diabetes, which is the most common form, especially in the context of diet control. The patient is seeking advice on osteoporosis prevention and has concerns about her bone health as she ages. \n\nThe clinical trial in question is looking at osteoporosis in type 2 diabetic patients. The inclusion criteria for the trial are:\n\n1. Age 40-99 years old\n2. With type 2 diabetes mellitus\n\nSince the patient is within the age range and has diabetes mellitus, which we are assuming to be type 2 based on the typical context of diet control, she could potentially be eligible for the clinical trial. However, the patient's exact type of diabetes (whether it is type 1 or type 2) is not clearly stated in the note. Therefore, before referring, it would be important to confirm that the patient indeed has type 2 diabetes.\n\nGiven that the only potential barrier to eligibility is confirmation of the type of diabetes, the patient could be considered for the clinical trial upon further investigation into her diabetes type.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1319": {
        "output": "The patient is a 51-year-old woman, which meets the first inclusion criterion of being postmenopausal. The patient is seeking advice on osteoporosis prevention and was documented by previous LH and FSH levels to be in menopause within the last year, which supports the postmenopausal status.\n\nHowever, the patient note does not specifically state that the patient has a diagnosis of osteoporosis in her medical record, which is the second inclusion criterion. It only mentions that she is seeking advice on osteoporosis prevention. There is a distinction between seeking advice on prevention and actually having a diagnosis of osteoporosis.\n\nThe third criterion is having at least one prescription drug to treat osteoporosis in the last 5 years. The patient note does not provide any information about the patient having been prescribed or having taken any drug therapy for osteoporosis.\n\nThe fourth criterion is being insured by Clalit Health Services. The patient note does not mention any information about the patient's health insurance provider.\n\nThe fifth criterion is Hebrew-speaking capability and readiness to answer a questionnaire. The patient note does not provide any information about the patient's language capabilities or willingness to participate in the study by answering a questionnaire.\n\nGiven the information provided in the patient note, it is not clear whether the patient has a diagnosis of osteoporosis or has been under any treatment for it in the past 5 years. Furthermore, there is no information about her health insurance provider or her language capabilities. Thus, we would need additional information to determine her eligibility based on the second, third, fourth, and fifth criteria.\n\nTherefore, the patient could be considered for referral to the clinical trial upon further investigation to determine if she meets the other inclusion criteria. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1320": {
        "output": "Based on the information provided, we will assess the patient's eligibility for the clinical trial titled \"Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)\" by comparing the patient's characteristics to the trial's inclusion criteria:\n\nInclusion Criteria for the trial:\n1. Type 1 or type 2 diabetes.\n2. Age \u2265 50 years.\n3. Unaltered treatment of diabetes during the previous six months (no changes in drugs, but an increase or decrease in dose is accepted) and HbA1c is stable with a level of \u00b1 1 in the same period.\n4. HbA1c level \u2265 7 % through the previous six months.\n5. BMI between 19 and 35.\n6. Specific inclusion criteria for type 2 diabetes:\n   - Either treatment with metformin, sulfonylureas, DPP IV inhibitors or GLP-1 analogs.\n   - Treatment with insulin and insulin in combination with metformin, sulfonylureas, DPP IV inhibitors or GLP-1 analogs.\n\nPatient's characteristics:\n- 51-year-old woman\n- Diet-controlled diabetes mellitus (implies type 2 diabetes)\n- Seeking advice on osteoporosis prevention\n\nBased on the patient's characteristics, she meets the following criteria:\n- She has type 2 diabetes.\n- She is over 50 years old.\n\nHowever, the available information does not allow us to verify the following:\n- Whether her treatment for diabetes has remained unaltered during the previous six months.\n- Her HbA1c levels in the previous six months.\n- Her BMI.\n- Specific information regarding her diabetes medication.\n\nGiven the information provided, the patient meets some of the inclusion criteria (age and type of diabetes), but we lack details about her treatment stability, HbA1c levels, BMI, and specific diabetes medications. Therefore, we cannot definitively determine her eligibility without further information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1321": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- A 51-year-old woman (meets age criteria)\n- Concerned about osteoporosis\n- Past medical history of hypertension and diabetes\n- Currently smokes\n- Documented to be in menopause\n\nClinical Trial Inclusion Criteria:\n- Men and non-pregnant women at least 20 years and under 75 years of age (patient meets this criterion)\n- Female subjects cannot be pregnant or breastfeeding (the patient is in menopause, so she meets this criterion)\n- Able to comply with the requirements of the study (not enough information to assess this, but no indication the patient couldn't comply)\n- Adequately informed and given written informed consent (this is a process requirement that can be fulfilled if the patient agrees to participate)\n\nThe patient is within the correct age range and is not pregnant or breastfeeding, which are two key inclusion criteria for this trial. Regarding the patient's ability to comply with the requirements and providing informed consent, these are actions the patient could complete if she chose to participate.\n\nThe clinical trial is focused on the efficacy of Vitamin K2 in human osteoporosis, which is relevant to the patient's concern about preventing osteoporosis. While there is no explicit requirement that the patient must have a diagnosis of osteoporosis or be at a specific risk level for osteoporosis, her concerns and her menopausal status (which is a risk factor for osteoporosis) make it a pertinent study for her.\n\nGiven the information, the patient seems to be a suitable candidate for the trial. However, the final determination would likely require further discussion with the patient about the study requirements and her willingness and ability to comply with the study protocol.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1322": {
        "output": "The patient is a 51-year-old woman presenting for advice on osteoporosis. She has a history of significant hypertension and diet-controlled diabetes mellitus, is currently a smoker, and has been documented to be in menopause within the last year. She is specifically concerned about the risk of breaking her hip as she gets older and is looking for information on osteoporosis prevention.\n\nThe clinical trial is focused on increasing osteoporosis awareness and fall prevention among the elderly in the northern region of Taiwan. It includes educational programs and assessments for fracture risk.\n\nNow, let's compare the patient\u2019s characteristics with the inclusion criteria for the clinical trial:\n\n1. Adults between the ages of 40 to 90: The patient is 51 years old, which fits within the age range.\n2. Adults who been fractures prior to assessment: There is no information provided about the patient having any prior fractures.\n3. Adults who have the ability, well conscious to complete the questionnaires: The patient appears to be seeking information and advice, which suggests she is well conscious and likely able to complete questionnaires.\n\nWhile the patient's note does not mention any previous fractures, she is still within the age range and appears to have the cognitive ability to participate in educational programs and complete questionnaires. The patient is seeking advice on osteoporosis prevention, which aligns with the educational aspect of the clinical trial. There is no explicit requirement in the inclusion criteria that the participants must have had a previous fracture, only that they fit within the age range and are capable of completing questionnaires.\n\nGiven this information, the patient seems to be a potential candidate for the educational aspect of the clinical trial related to osteoporosis and fall prevention.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1323": {
        "output": "The patient is a 51-year-old woman in menopause seeking advice on osteoporosis prevention. The clinical trial in question is focusing on the validation of a novel ultrasound device (Bindex\u00ae) for osteoporosis diagnostics in a postmenopausal population.\n\nThe inclusion criteria for the clinical trial specify that participants should be postmenopausal women (and men) referred for a bone density examination. The patient in the note is a postmenopausal woman concerned about osteoporosis, which likely makes her a candidate for a bone density examination.\n\nGiven the patient is a postmenopausal woman, which is the target demographic of the clinical trial, and her concern about osteoporosis indicates that she could indeed be referred for a bone density examination, she fits the inclusion criteria of the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1324": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient appears to be a suitable candidate. The patient is a 51-year-old woman, which fits the age range of 50 to 89 years required by the trial. Additionally, the clinical trial is looking for female participants, and the patient is a woman. The study aims to validate a novel ultrasound device for the diagnosis of osteoporosis, and the patient is concerned about osteoporosis prevention, which is relevant to the trial's focus.\n\nThe trial does not specify additional inclusion criteria such as the presence of osteoporosis, past medical history, or lifestyle factors like smoking, which are mentioned in the patient note. Since the inclusion criteria provided are very broad and the patient fits the gender and age requirements, it is reasonable to consider this patient eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1325": {
        "output": "Let's analyze the patient's eligibility based on the inclusion criteria provided:\n\nPatient Information:\n- 51-year-old woman\n- Concerned about osteoporosis\n- Past medical history of significant hypertension\n- Diet-controlled diabetes mellitus\n- Current smoker (1 pack per day)\n- Documented menopause within the last year\n\nClinical Trial Inclusion Criteria:\n- Osteoporosis suspicion\n- Age: 50 - 59 years\n- Post-menopausal status\n- At least one clinical risk factor for fracture:\n  - Low body mass index (< 19kg/m2)\n  - Previous fragility fracture\n  - Parental history of hip fracture\n  - Glucocorticoid treatment (\u2265 5mg prednisolone daily or equivalent for 3 months or more)\n  - Current smoking\n  - Alcohol intake 3 or more units daily\n  - Causes of secondary osteoporosis:\n    - Untreated hypogonadism\n    - Inflammatory bowel disease\n    - Prolonged immobility\n    - Organ transplantation\n    - Type 1 and type 2 diabetes\n    - Thyroid disorders\n    - Chronic obstructive pulmonary disease\n\nThe patient meets several of the inclusion criteria:\n- She is within the age range of 50 - 59 years.\n- She is post-menopausal.\n- She is a current smoker, which is a clinical risk factor for fracture.\n- She has type 2 diabetes, which is listed as a cause of secondary osteoporosis.\n\nGiven this information, the patient seems to be eligible for the clinical trial based on her age, menopausal status, and having at least one clinical risk factor for fracture (current smoking) and a cause for secondary osteoporosis (type 2 diabetes). The clinical trial does not require a referral for axial DXA investigation as part of the inclusion criteria, so we can disregard the last statement about the physician's referral.\n\nTherefore, this patient is a good candidate for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1326": {
        "output": "The patient note presents a 51-year-old woman seeking advice on osteoporosis prevention. She has a history of hypertension, diabetes mellitus, and is postmenopausal. She is concerned about the risk of hip fracture as she ages. \n\nThe clinical trial is focused on improving the screening for osteoporosis in women hospitalized in various departments, aged 50 to 80 years, who are able to respond to a questionnaire and consent to participate in the study. \n\nAccording to the inclusion criteria, the patient appears to meet the following relevant criteria:\n- She is a woman.\n- She is within the age range of 50 to 80 years.\n- She is capable of responding to an easy questionnaire.\n- She is capable of giving her agreement to participate in the study.\n\nHowever, the clinical trial specifically includes women who are hospitalized in medical services, orthopedics, gynecology, or surgery. There is no indication in the patient note that the woman is currently hospitalized or has been hospitalized recently in the relevant departments.\n\nGiven the lack of information regarding hospitalization, which is a key requirement for this clinical trial, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1327": {
        "output": "Based on the patient note, the 51-year-old woman has a past medical history of significant hypertension and diet-controlled diabetes mellitus, and she currently smokes 1 pack of cigarettes per day. These medical conditions align with the cardiovascular risk factors specified in the inclusion criteria for the clinical trial: hypertension, diabetes mellitus, and tobacco use.\n\nThe inclusion criteria for the clinical trial also specify that participants must be between the ages of 35 and 70, which the patient meets. Additionally, the patient resides in the area allotted to the community health worker (CHW), as the trial is community-based and requires participants from the urban community in the town of Dalkhola, Uttar Dinajpur district, West Bengal, India.\n\nGiven that the patient meets the age requirement and has at least one cardiovascular risk factor (in fact, she has three: hypertension, diabetes, and smoking), she would be eligible to participate in the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1328": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to be eligible for the clinical trial in question.\n\nThe patient note indicates:\n- A 51-year-old woman\n- Concerned about osteoporosis\n- Has hypertension and diet-controlled diabetes mellitus\n- Currently smokes\n- Recently confirmed to be in menopause\n\nThe clinical trial inclusion criteria require:\n- PCOS diagnosis to include three of the Rotterdam criteria\n\nSince the patient does not have a diagnosis of Polycystic Ovary Syndrome (PCOS) mentioned in their note, and the clinical trial is specifically looking for participants with PCOS, this patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1329": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Periodontal Disease and Post-menopausal Osteoporosis,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nPatient characteristics:\n- 51-year-old woman\n- Past medical history of significant hypertension\n- Diet-controlled diabetes mellitus\n- Current smoker (1 pack per day)\n- Recently documented to be in menopause\n- Concerned about osteoporosis and seeking prevention advice\n\nClinical trial inclusion criteria:\n- Women between 45-70 years\n- Underwent Absorptiometry Dual Energy X-ray (DEXA)\n- Post-menopausal women with periodontal disease\n- Study group includes women with osteoporosis/osteopenia\n- With and without bisphosphonate treatment for longer than 3 months before the study\n\nThe patient in the note is a 51-year-old woman, which fits the age criterion. She is post-menopausal as confirmed by LH and FSH levels within the last year. However, there is no mention of periodontal disease or a diagnosis of osteoporosis/osteopenia, nor is there any information provided about whether she has had a DEXA scan or if she has been treated with bisphosphonates.\n\nBased on the information provided, we cannot confirm whether the patient has periodontal disease or osteoporosis/osteopenia, which are key inclusion criteria for the clinical trial. Without further information regarding these specific conditions and treatments, we cannot definitively refer her to the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1330": {
        "output": "The patient noted is a 51-year-old woman seeking advice on osteoporosis prevention. She has a history of significant hypertension, diet-controlled diabetes mellitus, and is documented to be menopausal. Her concerns are primarily about the risk of osteoporosis, specifically the risk of breaking her hip as she ages.\n\nThe clinical trial in question is aiming to assess disturbances in the calcitonin gene in patients with gum disease and osteoporosis. The inclusion criteria specify that candidates should be male or female, aged between 35 and 60 years old, and diagnosed with osteoporosis and chronic periodontitis.\n\nBased on the information provided, the patient appears to meet some of the age criteria and is concerned about osteoporosis; however, there is no mention of her having been diagnosed with osteoporosis or having chronic periodontitis. Furthermore, the trial is looking to enroll patients who have both osteoporosis and periodontitis. As such, we do not have enough information to determine whether she meets these specific diagnoses, so she may not be eligible for the trial based on the given information.\n\nTrial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation. \n\nFurther investigation would be required to confirm a diagnosis of osteoporosis and chronic periodontitis before a definitive referral could be made.",
        "label": 0
    },
    "1331": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility.\n\nPatient note:\n- 51-year-old woman\n- Concerns about osteoporosis\n- Postmenopausal as indicated by LH and FSH levels within the last year\n- Significant hypertension and diet-controlled diabetes mellitus\n- Current smoker\n- Seeking advice on osteoporosis prevention\n\nClinical trial inclusion criteria:\n- Postmenopausal women with osteoporosis\n- Decision has been made to treat with Prolia in the last 4 weeks\n- Received their first prescription of Prolia in the last 4 weeks\n- Patient has provided informed consent before enrolling in the study\n\nThe patient in the note is postmenopausal and concerned about osteoporosis. However, the clinical trial specifically requires women who have already been diagnosed with osteoporosis and have decided to be treated with Prolia in the last 4 weeks, including those who have already received their first prescription of Prolia. There is no information provided in the patient note indicating that this patient has been diagnosed with osteoporosis, has been prescribed Prolia, or has started treatment with Prolia within the specified timeframe.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial because there is no mention of a diagnosis of osteoporosis nor any treatment with Prolia. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1332": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 51-year-old woman\n- Postmenopausal (documented by previous LH and FSH levels)\n- Has significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Seeking advice on osteoporosis prevention\n\nClinical trial inclusion criteria:\n- Postmenopausal women\n- Age 50 years or greater\n\nThe patient's age (51 years old) and menopausal status align with the inclusion criteria for the clinical trial, which requires participants to be postmenopausal women aged 50 years or greater. Therefore, the patient meets the inclusion criteria specified for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1333": {
        "output": "To assess the eligibility of the patient for the clinical trial, we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient characteristics from the note:\n- 51-year-old woman\n- Past medical history of significant hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented to be in menopause within the last year\n- Concerned about osteoporosis prevention\n\nClinical trial inclusion criteria:\n- Female patients with postmenopausal osteoporosis (T-score \u2264-2.5 SD at any skeletal site)\n- Under osteoporosis treatment (except teriparatide) for at least one year\n- History of \u2265 low-energy fracture during the last 10 years prior to the study\n\nThe patient is a postmenopausal woman, which aligns with the first part of the inclusion criteria. However, the note does not indicate that the patient has been diagnosed with osteoporosis (T-score \u2264-2.5 SD) nor that she is currently under osteoporosis treatment. Additionally, there is no mention of the patient having a history of low-energy fractures in the last 10 years.\n\nSince the patient does not meet the key inclusion criteria for the clinical trial, she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1334": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not meet the specified conditions for participation. The trial is specifically looking for patients who are 50 years old or older and have undergone spinal fusion surgery performed by Dr. Daniel Fassett, MD, MBA, Neurosurgeon at OSF-INI between November 1, 2012, and October 31, 2014. The patient in question is seeking advice on osteoporosis prevention and there is no mention of her undergoing spinal fusion surgery, nor is there any indication that she was treated by the specified neurosurgeon within the stated timeframe.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1335": {
        "output": "The patient in question is a 51-year-old woman who has diet-controlled diabetes mellitus. The clinical trial is looking to assess bone differences in individuals with type 2 diabetes mellitus (T2DM) with and without fragility fractures.\n\nThe inclusion criteria for the trial specify the need for a presence of type 2 diabetes for at least 3 years, and it is not stated how long the patient has had diabetes. Since the trial requires a history of treatment for type 2 diabetes and the patient note only mentions \"diet-controlled diabetes mellitus,\" it is unclear whether the patient has been on any medication for her diabetes, which is a common treatment method alongside diet control.\n\nGiven the information provided in the patient note, it is not possible to definitively say that this patient has had type 2 diabetes for at least 3 years or has received treatment for it. Therefore, further investigation would be needed to determine if the patient meets the trial's inclusion criteria regarding her diabetes history and treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1336": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient appears to meet the requirements for participation. The patient is a 51-year-old woman, which satisfies the age criterion of at least 20 years. She is able to read and fill out a questionnaire, as implied by her seeking advice in a clinic setting. Additionally, there is no mention of unwillingness to participate. Although her specific interest is in osteoporosis prevention advice, and not explicitly in participation in a clinical study, there is no information suggesting she would be unwilling to participate in such a study. \n\nTherefore, the patient does meet the age requirement, can likely read and fill out a questionnaire, and there is no indication of her unwillingness to participate. Hence, she could be considered for referral to the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1337": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, the patient appears to be potentially eligible for the clinical trial. The patient has a solitary mass in the right frontal lobe, which could correspond with the inclusion criteria of \"Patients with frontal lobe lesions.\"\n\nHowever, there are a few considerations to address before a final decision can be made:\n\n1. The trial is looking for patients with frontal lobe lesions, and the patient has a solitary mass in the right frontal lobe. This could potentially qualify as a frontal lobe lesion, but it would require confirmation from a medical professional that the mass is indeed considered a lesion that would be relevant for the study.\n\n2. The patient's age fits within the 18-65 years old range of the inclusion criteria.\n\n3. The patient's neurologic examination is described as unremarkable, which might indicate that the patient does not have severe neurological deficits that could exclude them from participation.\n\n4. There is no information provided about the patient's handedness, which is relevant since the inclusion criteria specify \"Right-handed normal volunteers.\"\n\n5. The patient note does not mention any of the exclusion criteria, such as a personal or family history of seizures, presence of metal in the cranium, intracardiac lines, increased intracranial pressure, cardiac pacemakers, or intake of neuroleptics.\n\nGiven the available information, the patient might be eligible for the clinical trial, but additional details are required to make a definitive assessment. Specifically, clarification on the nature of the frontal lobe mass and confirmation of the patient's handedness are needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1338": {
        "output": "",
        "label": 0
    },
    "1339": {
        "output": "",
        "label": 1
    },
    "1340": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient appears to be ineligible for the trial. The clinical trial is focused on patients with primitive neuroectodermal tumors of the CNS and has specific age criteria (3 to 16 years old). The patient described is a 58-year-old female, which is well outside the specified age range for trial participants. Additionally, the patient's diagnosis is not mentioned as a primitive neuroectodermal tumor but rather a solitary mass in the right frontal lobe, which may or may not be the same type of tumor. Without a histological confirmation that the tumor is indeed a primitive neuroectodermal tumor, we cannot assume eligibility.\n\nGiven the information, the patient does not meet the age criterion, and there is no confirmation that the mass is a primitive neuroectodermal tumor; thus, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1341": {
        "output": "The patient in question is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough, found to have a left lung mass on chest x-ray, and a solitary mass in the right frontal lobe on a CT scan of the head. \n\nThe clinical trial is seeking patients with inoperable non-small cell lung cancer (NSCLC) for a study to explore the utility of anatometabolic imaging for radiation treatment planning.\n\nInclusion Criteria for the Clinical Trial:\n- Histologically confirmed locally advanced NSCLC (squamous, large cell undifferentiated or adenocarcinoma).\n- Disease limited to the thorax, adjacent mediastinum and neurovascular structures, and supraclavicular or scalene lymph node area, as defined by the AJCC Staging System. This includes patients with Stage IIIA and IIIB disease.\n- Performance status of 0-2 by Southwest Oncology Group criteria.\n- Medically inoperable patients (Stage I or II)\n- Locoregional recurrent tumor following surgery will be eligible provided they meet other eligibility criteria.\n\nBased on the patient note, the patient has a left lung mass, which is suggestive of lung cancer, but it has not been specified to be NSCLC, nor has it been histologically confirmed. Additionally, the patient has a solitary brain mass, which may or may not be related to the lung mass. There is no mention of the patient having a performance status as required by the criteria, nor is there information confirming that the disease is limited to the thorax or related structures as detailed by the inclusion criteria.\n\nGiven the lack of detailed information on the histological type of lung cancer, the stage of the disease, the performance status of the patient, and the absence of a histological confirmation of NSCLC, it is not possible to determine with high certainty that the patient would meet the criteria for this clinical trial.\n\nTherefore, the patient might require further investigation to confirm the diagnosis and determine the stage of the disease. Only with additional information confirming that the patient's condition matches the trial's inclusion criteria would a referral be appropriate.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1342": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 58-year-old white female\n- Nonsmoker\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- Neurologic examination unremarkable\n\nClinical Trial Inclusion Criteria:\n- Age: 40 to 70\n- High risk for the development of lung cancer defined by:\n  - At least 40 pack years of smoking (may have stopped smoking within the past 10 years) at the time of study entry\n  - FEV-1/FVC ratio less than 70% predicted OR FEV-1 less than 80% predicted obtained from 3 serial performances with less than 5% difference\n  - Normal or stable current chest x-ray\n- Performance status: Not specified\n- Life expectancy: At least 5 years\n- No other comorbidity that limits life span to less than 5 years\n- No prior cancer except nonmelanomatous skin cancer or carcinoma in situ of the cervix\n- Not pregnant, with a negative pregnancy test for women of childbearing potential\n- Fertile patients must use effective contraception\n\nComparing the patient's information with the trial's inclusion criteria:\n\n- The patient's age (58) falls within the required age range (40 to 70).\n- The patient is a nonsmoker, and the trial specifically requires a history of heavy smoking (at least 40 pack years).\n- There is no information on the patient's FEV-1/FVC ratio or other pulmonary function tests.\n- There is no information on the patient's life expectancy, performance status, or other comorbidities.\n- There is no information provided about the patient's history of cancer other than the lung mass and brain mass mentioned.\n\nThe key disqualifying factor here is the patient's nonsmoking status, which does not meet the trial's requirement for a significant smoking history. Based on the information provided, the patient does not meet the smoking-related inclusion criteria for this trial. Therefore, she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1343": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility step by step:\n\n1. **Diagnosis and Condition**: The patient has a left lung mass and a solitary mass in the right frontal lobe. The clinical trial is looking for patients with central nervous system (CNS) disorders with lesions localization verified by CT or MRI scanning, which the patient appears to have.\n\n2. **Type of Lesions**: The trial specifically mentions an interest in patients with focal or degenerative lesions of the human prefrontal cortex (HPFC), non-frontal lesions, basal ganglia disorders, limbic system lesions, penetrating head injuries, frontotemporal dementia, and specific cases with unique behavioral presentations. The patient's right frontal lobe mass could potentially fall under the category of \"focal lesions\" of interest to the trial.\n\n3. **Requirement for Verification**: The trial requires that lesions localization be verified by CT or MRI scanning, which the patient has undergone, as per the patient note.\n\n4. **Neurological and Neuropsychological Evidence**: The patient must have evidence compatible with one of the recruited diagnoses. This seems likely given the patient's CT scan results showing a brain mass.\n\n5. **Ability to Cooperate**: The patient must be able to cooperate with neuropsychological testing. There is no information in the patient note suggesting the patient cannot cooperate.\n\n6. **Age**: The trial does not specify an age range for the adult patients, and the patient is 58 years old, which does not exclude her.\n\n7. **Exclusion Criteria**: Individuals with a neurological or psychiatric history or medical condition that would compromise the interpretation of the test results will not be included. There is no information provided about the patient's psychiatric history or other medical conditions that might compromise test results.\n\nGiven the information provided, the patient appears to meet several of the key inclusion criteria: having a CNS disorder with a verified lesion in the brain, specifically in the right frontal lobe, which could be indicative of a focal lesion of the HPFC. Without additional details on the exact nature of the brain mass or further medical history, a definitive assessment cannot be made, but there is reasonable ground to consider this patient for the trial.\n\nHowever, since we do not have a complete confirmation that the mass in the right frontal lobe would be classified as a \"focal or degenerative lesion of the HPFC,\" and because other subtle details might affect eligibility that are not disclosed in the patient note, a cautious approach would be to consider referring this patient to this clinical trial upon further investigation to ensure a precise match to the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1344": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial.\n\nPatient's characteristics:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan\n- No other symptoms or conditions mentioned\n\nClinical trial inclusion criteria:\n- Histologically confirmed non-small cell bronchogenic carcinoma\n- Stage IV or Stage IIIB\n- Progressed during or after first-line therapies with platinum-containing regimens in the advanced or metastatic treatment regimen\n- At least 18 years of age\n- Good performance status (ECOG 0 to 1)\n- Adequate liver, renal, and bone marrow function\n\nClinical trial exclusion criteria:\n- Pregnant or lactating women\n- Treatment with more than one cytotoxic therapy\n- Prior radiation to the whole pelvis\n- Unstable medical conditions such as uncontrolled cardiac arrhythmia\n- Patients with known history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80\n\nThe patient's note does not provide sufficient information to definitively confirm the patient's eligibility for the trial:\n\n- It is not clearly stated whether the patient has a histologically confirmed diagnosis of non-small cell bronchogenic carcinoma.\n- The stage of the lung cancer is not mentioned (IV or IIIB are required).\n- There is no information indicating whether the lung cancer has progressed during or after platinum-containing regimens, which is a requirement for the trial.\n- The patient's performance status is not described, nor is there information about liver, renal, and bone marrow function.\n- There's no indication that the patient meets any of the exclusion criteria.\n\nGiven the lack of information in several critical areas, we cannot confirm that the patient is eligible for the clinical trial without further investigation. Therefore, the appropriate response would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1345": {
        "output": "To assess the patient's trial-level eligibility, we must compare the patient's characteristics and condition to the inclusion criteria of the clinical trial:\n\nPatient characteristics:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of surgical removal of lung mass\n- No mention of staging of lung cancer\n- No information on post-operative status or mediastinal lymph node resection/sampling\n- No information on performance status (ECOG)\n- No laboratory results provided (leukocytes, granulocyte count, platelets, etc.)\n- No information on time elapsed since surgery (if surgery was performed)\n- No details on consent for tumor tissue provision or understanding and willingness to sign a written informed consent document\n- No information on potential receipt of post-operative adjuvant platinum-based chemotherapy\n\nClinical trial inclusion criteria:\n- Histological proof of primary non-small cell lung cancer\n- Post-operative stage IB, II, or IIIA based on pathologic criteria\n- Complete mediastinal lymph node resection or sampling at time of resection\n- Surgery must have consisted of specific types of resections and all gross disease must have been removed\n- Certain timeframes must be met between surgery and randomization\n- Patients must consent to provide a tumor tissue block\n- ECOG performance status of 0, 1, or 2\n- Specific laboratory values\n- Chest x-ray and CT/MRI scans within specified timeframes\n- Agreement to use adequate contraception\n- May have received post-operative radiation therapy or adjuvant chemotherapy with specific recovery timeframes\n- Ability to understand and willingness to sign a written informed consent document\n- Must be accessible for treatment and follow-up\n\nBased on the patient note provided, there is not enough information to determine if the patient meets many of the inclusion criteria for the clinical trial. The patient does have a lung mass, which could potentially be non-small cell lung cancer, but there is no confirmation of histological proof, staging, or surgical status, among other missing details. Without this information, we cannot ascertain that the patient would be eligible for the trial.\n\nTherefore, the patient would need further evaluation to gather the missing information and determine if they meet the inclusion criteria. At this point, the patient might be considered for the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1346": {
        "output": "The patient in question is a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe, as indicated by a CT scan. This patient has a history of a disorder of the central nervous system (a brain mass), which likely disqualifies her from participating in the clinical trial that requires participants without a history of any disorder of the central nervous system.\n\nThe clinical trial aims to test the effects of direct current polarization on brain function in healthy volunteers. The inclusion criteria specifically state that participants should not have a history of any disorder of the central nervous system. The patient's solitary brain mass is indicative of a central nervous system disorder, which is a disqualifying factor according to the trial's exclusion criteria.\n\nAdditionally, the trial is looking for right-handed volunteers aged 20 to 70 without any history of significant trauma or medical condition affecting the brain or skull. The patient note does not specify the patient's handedness, but the presence of a brain mass alone is sufficient to deem her ineligible.\n\nBased on the provided information, this patient does not meet the inclusion criteria for the clinical trial due to the presence of a brain mass. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1347": {
        "output": "",
        "label": 2
    },
    "1348": {
        "output": "",
        "label": 0
    },
    "1349": {
        "output": "The patient presented is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough. She has a left lung mass on chest x-ray, and a CT scan of the head shows a solitary mass in the right frontal lobe. \n\nThe clinical trial in question is looking to enroll patients who have solitary pulmonary nodules as identified in a CT scan. The trial aims to differentiate benign from malignant solitary pulmonary nodules and to see if the perfusion parameters from DCE MRI can predict patient outcomes and survival.\n\nBased on the information provided in the patient note, the patient has a solitary mass in the left lung, which corresponds to the inclusion criteria of having a solitary pulmonary nodule in a CT scan. However, the presence of a solitary mass in the right frontal lobe of the brain indicates that the patient may have metastasis or a secondary tumor, which complicates the assessment. The trial information provided does not specify whether the presence of a secondary mass outside the lungs would exclude a patient from participation. \n\nAs such, further investigation would be necessary to determine if the patient's brain mass is related to the lung mass (such as in the case of metastasis) or if it is a separate issue. If it is a separate issue and the lung mass is indeed a solitary pulmonary nodule, the patient could potentially be eligible for the trial. If the brain mass is metastatic from the lung mass, it could indicate that the lung nodule is not solitary, and thus the patient might not meet the inclusion criteria. \n\nGiven this information, the patient's eligibility is not clear-cut, and further investigation would be needed to clarify the nature of the lung and brain masses before a referral could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1350": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility.\n\nPatient Note:\n- 58-year-old white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan\n- Nonsmoker\n- No mention of asthma or COPD diagnosis\n- Neurologic examination unremarkable\n- No information about hospital admission or spirometry results\n\nClinical Trial Inclusion Criteria:\n- Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation\n- Admitted to the inpatient medical service at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center\n- Evidence of airflow obstruction on spirometry (FEV1/FVC<70%)\n- Age 18 years or older\n\nAssessment:\nThe patient is 58 years old, which meets the age criterion. However, there is no information provided that the patient has a physician-diagnosed asthma or COPD. The symptoms described (mild exertional dyspnea and occasional cough) could be related to many other conditions, including the lung mass that was found. There is also no mention of an exacerbation of asthma or COPD, no evidence of being admitted for such a condition, and no spirometry results to indicate airflow obstruction.\n\nGiven the information provided, it does not appear that the patient has been diagnosed with asthma or COPD, nor is there evidence of an exacerbation or airflow obstruction which are required to meet the inclusion criteria for this clinical trial. Additionally, the presence of a lung mass and a brain mass may indicate a different underlying pathology that is not addressed by the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1351": {
        "output": "Based on the information provided, the patient is a 58-year-old woman with a history of a left lung mass and a solitary mass in the right frontal lobe. The clinical trial in question is focused on follow-up in patients with resected lung carcinoma using minimum dose computed tomography (CT) of the thorax.\n\nThe inclusion criteria for the clinical trial are:\n- Lung cancer patients undergoing resection with intent to cure\n\nFrom the patient note, we do not have information that confirms if the lung mass has been diagnosed as carcinoma, nor do we have information about any planned or completed resection with the intent to cure. The patient is found to have a left lung mass, which may suggest the possibility of lung cancer, but without a confirmed diagnosis and a treatment plan that includes resection, we cannot determine if the patient fits the inclusion criteria.\n\nTherefore, additional information regarding the diagnosis of the lung mass and whether a resection with intent to cure is planned or has been performed would be necessary to establish eligibility. As such, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1352": {
        "output": "Based on the provided patient note and the clinical trial details:\n\nThe patient note describes a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough who is found to have a left lung mass on chest x-ray. Additionally, a CT scan of the head reveals a solitary mass in the right frontal lobe. This information indicates the presence of a lung mass and a brain mass, but it does not specifically mention an acute pulmonary embolus or the patient being admitted for investigation of acute pulmonary embolus.\n\nThe clinical trial is focused on patients admitted for investigation of an acute pulmonary embolus, comparing the efficacy of chest x-ray (CXR) and Minimum dose CT (MnDCT) in detecting acute findings.\n\nSince the patient is not described as being admitted for the investigation of an acute pulmonary embolus, nor is there any indication that this is the concern leading to her medical imaging, this patient does not meet the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1353": {
        "output": "The patient described is a 58-year-old non-smoker white female with a left lung mass and a solitary brain mass in the right frontal lobe. This patient's cancer is not described as squamous cell carcinoma of the oral cavity, but rather a lung mass with potential metastasis to the brain. \n\nThe clinical trial in question is specifically for patients with early-stage (T1 or T2), node-negative (N0), metastasis-free (M0) squamous cell carcinoma of specific regions within the oral cavity (buccal mucosa, lower alveolus, oral tongue, and floor of mouth).\n\nComparing the patient's characteristics with the inclusion criteria of the clinical trial:\n\n- The patient's cancer type does not match the required squamous cell carcinoma of the oral cavity.\n- The location of the patient's cancer (lung and brain) does not match the specified locations in the oral cavity.\n- There is no mention of histological proof of T1 or T2 N0 M0 squamous cell carcinoma of the oral cavity.\n- There is no information provided to assess if surgery is the preferred treatment for the patient's lung mass.\n- The patient has a history of a prior malignancy (lung mass with brain metastasis), which is outside of the head and neck region.\n- The patient's age fits within the trial criteria (age > 18 years and < 75 years).\n- There is no information on the patient's co-morbid conditions or ASA grade, nor on the reliability for follow-up or understanding of the protocol for informed consent.\n\nThe patient's diagnosis does not match the specific cancer type and location required by the trial. Therefore, the patient does not fulfill the essential inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1354": {
        "output": "The patient note describes a 58-year-old nonsmoker white female with symptoms of mild exertional dyspnea and an occasional cough. She has a left lung mass on a chest x-ray and a solitary mass in the right frontal lobe on a CT scan of the head. The neurologic examination is unremarkable, which suggests that the neurological symptoms are not prominent in her presentation.\n\nConsidering the clinical trial's inclusion criteria, we are looking for:\n\n1. Diagnosis of mild COPD OR healthy control subjects\n2. Participants aged 40-80 years old\n3. Participants able to perform all study procedures\n4. Smoking history of > 10 pack years for mild COPD or < 10 pack years for healthy control subjects\n\nThe patient is within the age range of 40-80 years old required by the study. However, the patient note does not confirm a diagnosis of mild COPD; it only mentions symptoms that could be associated with COPD but are not definitive for the condition. Additionally, the patient is a nonsmoker, which does not meet the specific smoking history criteria detailed for COPD patients in the trial (i.e., > 10 pack years). It is possible that she could be considered as a healthy control subject, but the presence of a lung mass and the lack of information on her ability to perform all study procedures make it unclear whether she would be eligible under this category.\n\nGiven the information provided, the patient's eligibility for this clinical trial is uncertain. Further investigations, including confirmation of a mild COPD diagnosis and clarification on the patient's ability to perform study procedures, would be necessary before a referral could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1355": {
        "output": "",
        "label": 1
    },
    "1356": {
        "output": "Based on the patient note provided, the 58-year-old female patient has a left lung mass and a solitary mass in the right frontal lobe found through diagnostic imaging. There is no mention of depression or any psychiatric evaluation, which is necessary to determine eligibility for the clinical trial in question. The patient's neurologic examination is unremarkable, but no further details are provided about her mental status or if she meets the criteria for major depressive disorder (MDD) as per DSM-IV, nor are there any scores for the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) or the Mini Mental State Examination (MMSE) provided.\n\nTo consider her for the clinical trial titled \"Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression,\" the following inclusion criteria must be met:\n\n1. Diagnosis of major depressive disorder (MDD) according to DSM-IV.\n2. MADRS score greater than 20 (or greater than 17 for atypical depression).\n3. MMSE score greater than 20.\n\nWithout information on her psychiatric status and these specific scores, we cannot ascertain her eligibility based on the inclusion criteria provided for the clinical trial.\n\nTherefore, the trial-level eligibility for referring the patient to the clinical trial described would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1357": {
        "output": "",
        "label": 0
    },
    "1358": {
        "output": "Based on the provided patient note, the patient in question has a left lung mass with a solitary mass in the right frontal lobe, as identified by a chest x-ray and a CT scan of the head. There is no mention of renal cell carcinoma, which is the specific type of cancer being targeted in the clinical trial for Cediranib.\n\nThe inclusion criteria for the clinical trial are clear: participants must have confirmation of metastatic or recurrent renal cell carcinoma. Since the patient's note does not indicate a diagnosis of renal cell carcinoma, but instead suggests the presence of a lung mass and a brain mass, the patient does not meet the essential inclusion criterion for this trial.\n\nTherefore, the patient would not be eligible for referral to this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1359": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 58-year-old nonsmoker white female with a left lung mass and a solitary brain mass. This patient does not fit the inclusion criteria for the COMPAS study, which is focused on healthy children less than 3 years old and aims to measure the efficacy of a pneumococcal conjugate vaccine to prevent pneumonia and acute otitis media. The patient is neither in the specified age range nor suffering from the conditions being studied in the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1360": {
        "output": "Upon reviewing the patient note and the clinical trial criteria, we can assess the patient's eligibility as follows:\n\nPatient note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe as per CT scan of the head\n\nClinical trial criteria:\n- Patients with primary intracranial tumors such as low-grade glioma, meningioma, craniopharyngiomas, ependymomas, and other benign tumors considered for radical focal radiotherapy\n- Tumors measuring up to 7 cms on maximum dimension on the CT/MRI\n- Age 3 to 25 years\n- NPS of 0-3\n- Informed consent from patients or parents as appropriate\n- Long-term follow up expected\n\nBased on the provided information, the patient is not suitable for the clinical trial due to the following reasons:\n\n1. The patient's age (58 years) is outside of the specified range for the trial (3 to 25 years).\n2. The type of tumor (lung mass and brain mass) is not specified in the patient note as one of the tumor types listed in the inclusion criteria for the trial.\n\nGiven these discrepancies, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1361": {
        "output": "",
        "label": 2
    },
    "1362": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial:\n\nPatient note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Neurologic examination unremarkable\n- CT scan of the head shows a solitary mass in the right frontal lobe\n\nClinical trial inclusion criteria:\n- Pathologically confirmed non-small cell lung cancer (NSCLC)\n- Measurable primary pulmonary tumors \u2265 1cm\n- Plans for a clinically indicated non-contrast CT scan of the chest\n- All patients must be \u2265 18 years old\n\nComparison:\n- The patient has a left lung mass, which could potentially be NSCLC, but it is not yet pathologically confirmed.\n- There is no information on the size of the lung mass, but it was detected on a chest x-ray, which could imply it is measurable and likely \u2265 1cm.\n- The patient has had a CT scan of the head, but there is no mention of planned non-contrast CT scans of the chest.\n- The patient is 58 years old, which meets the age requirement.\n\nConclusion:\nThe patient appears to potentially meet some of the inclusion criteria, particularly age and the presence of a lung mass. However, without pathological confirmation of NSCLC and more information on the planned chest CT scans, we cannot definitively determine eligibility. Therefore, the patient may be considered for referral to the clinical trial upon further investigation to confirm the diagnosis and establish that a chest CT scan is planned or can be incorporated into their care.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1363": {
        "output": "To determine the patient's eligibility, let's compare the patient's information to the inclusion criteria of the clinical trial:\n\nPatient Information:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray, otherwise asymptomatic\n- Neurologic examination unremarkable\n- CT scan of the head shows a solitary mass in the right frontal lobe\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed non-small cell lung cancer by biopsy or cytology\n- AJCC Stage I or II (T1, N0, M0; T2 (<=7cm), N0, M0; T3 (<=7cm), N0, M0)\n- Primary tumor in central chest locations as specified\n- Hilar or mediastinal lymph nodes <=1cm and no abnormal uptake on PET considered N0\n- Tumor must be technically resectable, but patient inoperable due to medical issues or refuses surgery\n- Age >=18\n- Zubrod performance status 0-2\n- No metastases after appropriate staging\n- No previous lung or mediastinal radiation therapy\n- No concomitant antineoplastic therapy, except at progression\n- No active infection\n- Not pregnant or lactating\n- Required pre-study tests (including CT, PET, brain MRI or CT, PFTs)\n\nBased on the information provided, the patient has a lung mass and a brain mass. The clinical trial is specific to non-small cell lung cancer, and the patient does have a lung mass that could potentially be non-small cell lung cancer; however, the presence of a brain mass raises the possibility of metastatic disease, which would typically be staged as M1, excluding the patient from this trial based on the provided inclusion criteria.\n\nHowever, the patient would need a confirmed histological diagnosis of non-small cell lung cancer and further staging to determine if the lung mass meets the T and N criteria and to rule out metastases (M0). Moreover, the patient would need to undergo all the required pre-study tests and assessments, including a PET scan to evaluate for metastases and a biopsy to confirm the type of lung cancer.\n\nGiven that the patient note does not confirm histology, does not provide staging, and the presence of a brain mass suggests potential metastatic disease, I would say:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1364": {
        "output": "",
        "label": 0
    },
    "1365": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Unremarkable neurologic examination\n- Solitary mass in the right frontal lobe on CT scan of the head\n\nClinical Trial Inclusion Criteria:\n- Participant has a known or clinically suspected solid malignancy (excluding brain tumor)\n- Nodule must be discovered at the time of diagnosis of the primary malignancy or after the completion of therapy\n\nAssessment:\n- The patient does have a suspected solid malignancy, as indicated by the left lung mass found on the chest x-ray.\n- However, there is a solitary mass in the right frontal lobe, which appears to be a brain tumor. Since the trial specifically excludes patients with brain tumors, this patient would not be eligible.\n- There is no information on whether the lung mass was discovered at the time of diagnosis or after completion of therapy, which is also required for inclusion; however, the exclusion of brain tumors takes precedence.\n\nConclusion:\nThe patient is not eligible for the clinical trial because they have a brain tumor, which is excluded from the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1366": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, it appears that the patient does not meet the key inclusion criteria specified by the trial. The trial is seeking to enroll patients who have been admitted to the Neurosurgical Intensive Care Unit within 24 hours after neurosurgery with ventilator support.\n\nThe patient in the note has a lung mass and a solitary mass in the right frontal lobe, identified through a chest x-ray and a CT scan of the head, respectively. However, there is no mention of the patient having undergone neurosurgery or being on ventilator support, nor is there any indication that the patient is within the 24-hour post-neurosurgery window required for the trial.\n\nBased on this information, the patient would not be eligible for the clinical trial focused on stress ulcer prophylaxis in the neurosurgical ICU setting. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1367": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial on CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer, we need to compare the patient's characteristics and medical condition with the inclusion criteria provided by the trial.\n\nHere's a summary of the inclusion criteria for the trial:\n1. Patient must be over the age of 18 years.\n2. Pulmonary nodule with maximum diameter \u2264 5 cm.\n3. Histological confirmation of primary NSCLC.\n4. Eligible stages of NSCLC: Stage I or Stage II (specific conditions apply).\n5. ECOG/Zubrod status of 0, 1, or 2.\n6. Determined to be not a surgical candidate by a Board Certified Thoracic surgeon and a radiation oncologist.\n7. Medically inoperable based on major or minor criteria listed.\n8. Females of child-bearing age must be using reliable birth control.\n9. PET-CT scan within 8 weeks of registration.\n10. Signed and dated written informed consent.\n\nNow, let's consider the patient's information:\n- The patient is a 58-year-old nonsmoker white female (age criteria met).\n- The patient has a left lung mass (potential primary NSCLC, but size not specified).\n- No information on histological confirmation is provided (necessary for eligibility).\n- No information on the ECOG/Zubrod status is provided.\n- No information on the stage of NSCLC is provided.\n- The patient does not appear to have been determined inoperable by a thoracic surgeon and radiation oncologist (as per the note).\n- The patient's medical operability based on major or minor criteria is unknown.\n- The patient is of child-bearing age but use of birth control is not mentioned.\n- No information on a PET-CT scan is provided.\n- No information on informed consent is provided.\n\nBased on the information provided, it is not clear if the patient has a histological confirmation of NSCLC, what the stage of the disease is, or if they have been deemed inoperable by a thoracic surgeon and a radiation oncologist. Additionally, other criteria such as ECOG/Zubrod status, specific medical inoperability criteria, and procedural requirements like PET-CT scan and informed consent are not mentioned.\n\nTherefore, at this stage, the patient does not meet all known inclusion criteria for the trial. However, since some of the needed information is missing or requires confirmation (such as histological confirmation and the stage of NSCLC), further investigation is needed before a final determination can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1368": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the study on \"Biomarkers and Genetic Factors Related to Emphysema.\"\n\nHere is the patient note:\n- The patient is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough.\n- She has a left lung mass on chest x-ray.\n- A CT scan of the head shows a solitary mass in the right frontal lobe.\n- There is no mention of a smoking history or a diagnosis of emphysema.\n\nInclusion criteria for the clinical trial:\n- Able to read and write English.\n- At least 30 pack-year smoking history.\n- Able to participate in the informed consent process.\n- Relatively stable clinical status for the past six weeks.\n- For participants with emphysema: GOLD class II, III, or IV COPD or more than minimal emphysema on a chest CT scan.\n- For participants without emphysema: GOLD class I COPD or GOLD class 0 and no or minimal emphysema on a chest CT scan.\n\nThe patient note does not provide any information that the patient has a smoking history, let alone a 30 pack-year history, which is a requirement for all participants in the study. Additionally, the note does not indicate that the patient has been diagnosed with COPD or emphysema, which are the main focus of the study.\n\nGiven that the patient does not meet the key inclusion criteria related to smoking history and emphysema, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1369": {
        "output": "After reviewing the patient note and the clinical trial information, it is apparent that the patient does not meet the inclusion criteria for the clinical trial.\n\nThe patient note describes a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe. There is no mention of major abdominal surgery, which is a specific requirement for the clinical trial in question.\n\nThe clinical trial is focused on the comparison of intravenous Pantoprazole and Famotidine for stress ulcer prophylaxis in patients who have received major abdominal surgery and are admitted to the surgical ICU.\n\nThe inclusion criteria for the clinical trial are quite clear:\n- Patients that have received major abdominal surgery (estimated admission to surgical ICU more than 7 days)\n- Patients must give written consent and be randomized within 24 hours of admission.\n\nSince the patient has not undergone major abdominal surgery and there is no indication that she would be admitted to a surgical ICU for such a procedure, she does not qualify for the clinical trial.\n\nTherefore, the assessment of eligibility is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1370": {
        "output": "To determine the patient's eligibility for the clinical trial, we must match the patient's characteristics and condition against the inclusion criteria of the trial.\n\nPatient Characteristics:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed non-small cell lung cancer\n- Stage I or II disease (T1-3, N0, M0)\n- T2 or T3 tumor \u2264 5 cm\n- No T3 tumors involving the central chest or mediastinum (only chest wall involvement allowed)\n- Tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, AND patient deemed medically inoperable\n- Patients with FDG-avidity in mediastinal lymph nodes are eligible provided they can undergo mediastinoscopy to confirm N0 status\n- ECOG performance status 0-2\n- Not pregnant or nursing\n- Fertile patients must use effective contraception\n\nBased on the patient note, the patient has a left lung mass, which could potentially be non-small cell lung cancer, and a solitary mass in the right frontal lobe. However, there is no histological confirmation of non-small cell lung cancer, and it is not clear if the lung cancer is stage I or II. Furthermore, there is no information on the size of the tumor, whether the tumor involves the central chest or mediastinum, or whether the patient is medically inoperable. Additionally, there is no information about the patient's ECOG performance status, or whether the patient is able or willing to undergo mediastinoscopy to confirm N0 status.\n\nGiven the lack of specific information confirming the patient's cancer stage, the histological type of the lung mass, and the patient's performance status, we cannot conclude that the patient is eligible for the clinical trial. Thus, further investigation is required to determine if the lung mass meets the criteria for stage I or II non-small cell lung cancer, and other relevant factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1371": {
        "output": "The patient note describes a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial in question is targeting patients with carcinoma of unknown-primary (CUP) and is evaluating the efficacy of adding cetuximab to a carboplatin/paclitaxel regimen.\n\nTo assess the patient's eligibility for the trial based on the provided inclusion criteria, let's go through them systematically:\n\n1. Histologic or cytologic proven, non-resectable carcinoma of unknown primary (adenocarcinoma or non-differentiated carcinoma): The patient note does not specify the histology or cytology of the mass in the lung or brain, nor does it mention that the carcinoma is of unknown primary. Further investigation is needed to confirm this.\n\n2. Measurable tumor lesion(s) according to RECIST criteria: The patient has a left lung mass and a brain mass, which could potentially meet this criterion if they are measurable according to RECIST criteria.\n\n3. WHO PS 0 to 1: The WHO Performance Status (PS) ranges from 0 (fully active) to 5 (dead). The patient note describes the patient as having mild symptoms (exertional dyspnea and occasional cough), suggesting that the patient could potentially fit this criterion, but a formal assessment of PS is needed.\n\n4. Signed written informed consent: This is a procedural step that the patient would need to complete if they were otherwise eligible.\n\n5. \u2265 18 years of age: The patient is 58 years old, which meets this criterion.\n\n6. Effective contraception for both male and female subjects if the risk of conception exists: This is not directly addressed in the patient note but is a standard requirement for patients of childbearing potential.\n\n7. Adequate bone marrow function: Specific blood counts are not provided in the patient note, so this cannot be assessed without further testing.\n\n8. Adequate liver and renal function: Similarly, liver and renal function tests are not mentioned in the patient note and would need to be assessed.\n\nGiven the information provided, it is not possible to definitively determine whether the patient's carcinoma is of unknown primary, which is a critical element of the trial's inclusion criteria. Additionally, there is insufficient information regarding the patient's performance status, tumor measurability, and lab values to assess bone marrow, liver, and renal function.\n\nTherefore, based on the available data:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1372": {
        "output": "Based on the provided patient note and the clinical trial information, we can determine the patient's eligibility for the clinical trial as follows:\n\nPatient characteristics:\n- Age: 58 years old\n- Diagnosis: Left lung mass found on chest x-ray, solitary mass in the right frontal lobe on CT scan of the head\n- Other: Nonsmoker, mild exertional dyspnea, occasional cough, unremarkable neurologic examination\n\nClinical trial inclusion criteria:\n- Diagnosis of suspected lung cancer or lung cancer\n\nThe patient note indicates that the patient has a mass in the left lung, which on a chest x-ray could be indicative of lung cancer. Furthermore, the patient also has a solitary mass in the right frontal lobe, which could be metastasis from the lung cancer, although this would need to be confirmed. The clinical trial is looking for patients with a diagnosis of suspected lung cancer or lung cancer, which seems to align with the patient's condition as suggested by the chest x-ray findings.\n\nHowever, it is important to note that the patient has not been explicitly diagnosed with lung cancer in the patient note provided. The presence of a lung mass on imaging is highly suggestive but not definitive without a biopsy or further diagnostic confirmation. The trial inclusion criteria specify a diagnosis of suspected lung cancer or confirmed lung cancer.\n\nGiven this information, the patient appears to match the inclusion criteria based on the suspicion of lung cancer. However, further investigation to confirm the diagnosis of lung cancer would be necessary before a definitive referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1373": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Symptoms: mild exertional dyspnea and occasional cough\n- Findings: left lung mass on chest x-ray, solitary mass in the right frontal lobe on a CT scan of the head\n- Diagnosis: Not specifically mentioned, but the presence of a lung mass and a solitary brain mass could indicate a primary lung cancer with possible brain metastasis.\n\nClinical Trial Inclusion Criteria:\n- Histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (> 20 cm from the incisors) or gastroesophageal junction.\n- No distant metastases (M0).\n- Patients will be stratified by stage (clinical N0 versus clinical N1), and surgeon.\n- Patients with tumors within 3 cm distal spread into gastric cardia as detected by esophagogastroscopy.\n- Resectable mediastinal nodes are eligible.\n- No prior chemotherapy for this malignancy.\n- No prior radiotherapy that would overlap the field(s) treated in this study.\n- Patients with other malignancies are eligible only if > 5 years without evidence of disease or completely resected or treated non-melanoma skin cancer.\n- Age > 18 years and able to tolerate tri-modality therapy at the discretion of the treating thoracic surgeon, medical and radiation oncologists.\n- Tumors must be resectable after assessment by the thoracic surgeon.\n\nThe patient's lung mass and brain mass do not align with the trial's requirement for esophageal or gastroesophageal junction cancer, and there is no mention of esophageal cancer in the patient's note. Additionally, the presence of a brain mass in the patient suggests possible metastasis, which would not meet the \"No distant metastases (M0)\" criterion.\n\nGiven this information, the patient does not meet the disease-specific inclusion criteria for this clinical trial on esophageal cancer, as the patient's diagnosis does not match the required diagnosis for the trial, and there is a possibility of distant metastases, which is an exclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1374": {
        "output": "",
        "label": 2
    },
    "1375": {
        "output": "Based on the patient note and the inclusion criteria provided for the GE Healthcare VolumeRAD Lung Nodule Detection Study, the patient appears to meet several of the specified criteria:\n\n- The patient has a left lung mass on chest x-ray, which is relevant to the study's focus on detecting lung nodules.\n- The patient is 58 years old, which satisfies the age criterion of being 18 years of age or older.\n- The patient is scheduled for a CT scan as part of their medical care, which aligns with the requirement for participants to be scheduled for chest CT.\n- The patient note does not specify any inability to stand motionless or hold their breath, suggesting that they could potentially comply with the image acquisition procedures.\n\nHowever, there is no explicit mention of the patient's physical condition to confirm they are in good enough physical condition to stand motionless and hold their breath during the image acquisition procedures. Additionally, the information provided does not detail whether the patient has had previous imaging beyond the chest x-ray and CT scan of the head.\n\nGiven the information available, the patient seems to fit the inclusion criteria, but we would require confirmation of their ability to comply with the imaging procedures and possibly review previous imaging if available to ensure they fulfill the needs of the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1376": {
        "output": "Based on the inclusion criteria provided for the clinical trial titled \"Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms,\" the patient in the note does not meet the necessary requirements for several reasons:\n\n1. Age: The trial specifies that participants must be children in the age range of 3-18 years. The patient is 58 years old.\n\n2. Consent: The trial requires the subject's parent or legal guardian to provide informed consent, which is not applicable to an adult patient.\n\n3. Acute symptoms: The patient's respiratory symptoms are described as \"mild exertional dyspnea and occasional cough,\" which does not clearly indicate acute respiratory complaints as required by the trial.\n\nGiven these points, the patient does not meet the age criterion, consent requirement, or the symptom criteria for the clinical trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1377": {
        "output": "The patient in question is a 58-year-old nonsmoker white female with a left lung mass found on chest x-ray, and a solitary mass in the right frontal lobe on a CT scan of the head. The clinical trial is focused on patients with small lung nodules < 1cm that require excision with no history of prior ipsilateral thoracotomy, and these nodules must be amenable to thoracoscopic wedge excision.\n\nThe inclusion criteria for the clinical trial are:\n1. Newly diagnosed patients with small lung nodules < 1cm that require excision.\n2. No history of prior ipsilateral thoracotomy.\n3. Nodules must be located in parts of the lung that are amenable to thoracoscopic wedge excision.\n4. The external surface of the lesion must be at least 2 cm from the major pulmonary arteries, veins, and main bronchi.\n5. Patients must be mentally competent to give written, informed consent.\n6. Patients must be capable of independently completing standard English-language QOL instruments.\n\nBased on the patient note provided, the following can be assessed:\n- The patient has a left lung mass, but it is not specified whether this mass is < 1cm in size, which is a requirement for the trial.\n- There is no history provided suggesting a prior ipsilateral thoracotomy.\n- There is no information on whether the nodule is amenable to thoracoscopic wedge excision or its proximity to major pulmonary structures.\n- The patient is assumed to be mentally competent as there is no indication otherwise.\n- The patient's ability to complete English-language QOL instruments is not mentioned but is generally assumed unless otherwise stated.\n\nGiven this information, the patient could potentially match some of the inclusion criteria for the clinical trial but crucial information is missing, specifically the size of the lung mass and its location relative to the pulmonary structures. Therefore, further investigation would be needed to determine if the lung mass meets the trial's specific requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1378": {
        "output": "",
        "label": 1
    },
    "1379": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the criteria for this schizophrenia-focused study. The patient is a 58-year-old female with a left lung mass and solitary brain mass, which are not related to schizophrenia, and there is no mention of her being stabilized on antipsychotic medication or a diagnosis of schizophrenia by DSM IV. Moreover, the age and medical condition do not align with the study requirements.\n\nThe inclusion criteria specifically state that candidates should be between 18 to 45 years of age and must have a diagnosis of schizophrenia. The patient's age exceeds this range, and there is no indication of a schizophrenia diagnosis. Additionally, the trial seeks individuals who are right-handed, and there is no information about the handedness of the patient. \n\nGiven these discrepancies, the patient does not fulfill the necessary inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1380": {
        "output": "",
        "label": 1
    },
    "1381": {
        "output": "Based on the patient note, the patient is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough and has been found to have a left lung mass on a chest x-ray. Additionally, a CT scan of the head shows a solitary mass in the right frontal lobe.\n\nThe clinical trial in question is investigating the usefulness of interferon-gamma release assays in diagnosing pulmonary nodules, specifically in patients who have had a percutaneous needle biopsy for diagnosis of a lung nodule.\n\nThe inclusion criteria for the clinical trial are:\n- Age > 18 years\n- Patients with a solitary pulmonary nodule\n- Patients who had percutaneous needle biopsy for diagnosis of lung nodule\n\nThe patient's age fits the criteria. However, there is no information in the patient note indicating that the patient has had a percutaneous needle biopsy performed for the diagnosis of the lung nodule. Furthermore, the presence of a solitary mass in the brain could potentially be related or unrelated to the lung mass; this information is not specified in the trial's inclusion criteria as a factor.\n\nSince we lack information about whether the patient has undergone a percutaneous needle biopsy, further investigation is needed to determine if the patient has had this procedure as part of her diagnostic work-up for the lung nodule. If the biopsy has been performed and the lung nodule is indeed solitary, the patient may be eligible for the trial. However, without confirmation of the biopsy, we cannot assume eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1382": {
        "output": "",
        "label": 1
    },
    "1383": {
        "output": "",
        "label": 0
    },
    "1384": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can deduce the following:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of pulmonary nodules being not visualizable during VATS or that the patient is a candidate for VATS resection\n\nClinical Trial:\n- Title: Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound\n- Focus: Identification and localization of pulmonary nodules using intracavitary ultrasound during VATS procedures\n- Inclusion Criteria: All patients with CT identified pulmonary nodules not deemed to be visualizable during VATS who are candidates for VATS resection\n\nThe patient does have a pulmonary nodule (left lung mass) identified on a chest x-ray, which is further supported by findings from a CT scan. However, the clinical trial specifically requires patients with pulmonary nodules that are not deemed to be visualizable during VATS and who are candidates for VATS resection. The patient note does not provide information about whether the nodule is not visualizable during VATS or if the patient is specifically being considered for VATS resection. Further information is required to determine if the patient's pulmonary nodule meets the visibility criteria and if they are a candidate for VATS resection.\n\nTherefore, based on the information provided, the patient could potentially be eligible for the clinical trial, but more information is needed to make a definitive decision. The assessment of eligibility, in this case, would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1385": {
        "output": "The patient in the note has a left lung mass, which could potentially be considered a \"solitary pulmonary nodule\" as described in the inclusion criteria of the clinical trial if it meets the size requirement of being less than 4 cm. There is no mention of an endobronchial lesion in the patient note, which aligns with the absence of endobronchial lesion as an inclusion criterion. Additionally, the patient's finding of a lung mass on a chest x-ray could warrant further diagnostic investigation through bronchoscopy, which is another inclusion criterion for the clinical trial.\n\nHowever, we do not have information on the exact size of the patient's left lung mass to determine if it meets the \"less than 4 cm\" requirement. It is also not explicit in the patient note whether there is an indication for bronchoscopy other than the presence of the mass. Without this information, we cannot conclusively say that the patient would certainly be eligible for the trial.\n\nBased on the available information, I would consider referring this patient to this clinical trial upon further investigation to confirm the size of the lung mass and the indication for bronchoscopy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1386": {
        "output": "Based on the provided patient note and clinical trial information:\n\nPatient Note:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan\n\nClinical Trial:\n- Prospective study of children and adolescents with craniopharyngioma\n- Inclusion criteria:\n  - Diagnosed with craniopharyngioma for the first time\n  - Age at diagnosis 18 years or less of age\n  - Agreement from patient's parents or legal guardian as well as the patient\n  - Additional criteria for randomization study include age at primary surgery over 5 years, incomplete primary resection, and histological diagnosis of craniopharyngioma\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial. The patient has a mass in the right frontal lobe, which is not specified as craniopharyngioma, and the patient is 58 years old, which is well above the age limit of 18 years or less for the trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1387": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can make the following assessment:\n\nPatient note:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of an incisional hernia\n\nClinical trial:\n- Title: Watchful Waiting Versus Repair of Oligosymptomatic Incisional Hernias\n- Inclusion criteria:\n  - Age \u226518 years\n  - Asymptomatic/oligosymptomatic incisional hernia\n\nSince the patient note does not mention an incisional hernia, the patient does not meet the specific inclusion criteria for the clinical trial, which is focused on the condition of incisional hernias. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1388": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nPatient's characteristics and condition:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Unremarkable neurologic examination\n- A solitary mass in the right frontal lobe on a CT scan of the head\n\nClinical trial inclusion criteria:\n- Age at diagnosis at least 4 years and less than 22 years\n- Histologically proven medulloblastoma\n- No CNS metastasis on MRI\n- No clinical evidence of extra-CNS metastasis\n- No tumour cells on the cytospin of lumbar CSF\n- Radiotherapy to start no more than 40 days after surgery\n- Ability to receive twice daily radiotherapy\n- Vital functions within normal range for their age group\n- CTC grades < 2 for liver, renal, haematological and audiological function\n- No medical contraindication to radiotherapy or chemotherapy\n- Written informed consent (and patient assent where appropriate)\n- National and local ethical committee approval\n\nComparison:\n- The patient's age (58 years old) does not meet the age criterion (between 4 or 5 years and less than 22 years) of the trial.\n- The patient has a solitary mass in the right frontal lobe, which is not specified as medulloblastoma, and thus does not meet the histological diagnosis requirement.\n- The trial is specific to patients with medulloblastoma, and there is no mention of this diagnosis in the patient's note.\n\nGiven the patient's age and the lack of a medulloblastoma diagnosis, this patient does not meet the key inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1389": {
        "output": "Based on the patient note, the 58-year-old nonsmoker white female presents with a left lung mass and a solitary mass in the right frontal lobe. There is no mention of bronchiectasis or bronchiolitis in the patient's record. The inclusion criteria for the clinical trial specify that all patients must have bronchiectasis or bronchiolitis.\n\nSince the patient's note does not indicate the presence of bilateral bronchiectasis or bronchiolitis, which are required for eligibility in the clinical trial, the patient would not be considered a match for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1390": {
        "output": "Given the information provided:\n\nPatient note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of a lung cancer diagnosis, but the presence of a lung mass may suggest it\n\nClinical trial:\n- Title: A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer\n- Inclusion criteria: Participant is a lung cancer patient\n\nBased on the patient note, the patient has a lung mass that could potentially be lung cancer, but there is no definitive diagnosis mentioned in the note. The clinical trial's inclusion criteria are very broad and only require the participant to be a lung cancer patient.\n\nSince the patient has a lung mass, which is highly indicative of lung cancer, but without a confirmed diagnosis, further investigation would be needed to determine if the mass is indeed cancerous. If the lung mass is confirmed to be lung cancer, the patient would meet the inclusion criteria.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1391": {
        "output": "The patient note describes a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial is investigating extracolonic findings on computed tomography colonography (CTC), specifically examining the incidence of diagnostic imaging, hospitalization, and interventional procedures associated with extracolonic findings reported from a previous CT colonography trial.\n\nThe inclusion criteria for the clinical trial are broad, stating that no participant sub-populations will be excluded prior to selection. The trial involves different cohorts, including one specifically for cases with indeterminate but potentially significant extracolonic findings other than pulmonary nodules, and another cohort for cases with extracolonic findings characterized as pulmonary nodules.\n\nGiven the patient has a left lung mass and a brain mass, which could be considered extracolonic findings, the patient may potentially fit the cohort for cases with pulmonary nodules or other significant extracolonic findings. However, the clinical trial does not explicitly mention brain masses as part of its focus.\n\nThe lack of specific exclusion criteria for the patient in question and the broad nature of the inclusion criteria suggest that the patient could potentially be included in the study, but it is not entirely clear whether the study's focus on extracolonic findings would consider a brain mass as relevant to the study's aims. Therefore, further investigation into the relevance of the patient's specific findings to the clinical trial's objectives would be necessary before making a definitive decision.\n\nBased on the available information, I would place this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1392": {
        "output": "Based on the patient note provided, the patient is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough, who has a left lung mass on chest x-ray and a solitary mass in the right frontal lobe on a CT scan of the head. There is no mention of the patient requiring placement of a nasogastric or orogastric tube, which is a requirement for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Patients 18 years and older\n2. Patient or proxy willing to provide informed consent\n3. Patients who require placement of a nasogastric/orogastric tube, in the ED or ICU, as standard of care\n4. The presence of a study staff member during NG/OG tube placement\n5. The anticipation that the patient will remain in the ED/ICU to obtain a RightSpot pH Indicator reading and verifying CXR\n\nThe patient described does not fit the inclusion criteria as there is no stated need for a nasogastric/orogastric tube placement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1393": {
        "output": "",
        "label": 1
    },
    "1394": {
        "output": "The patient note describes a 58-year-old woman with a left lung mass and a solitary mass in the right frontal lobe. She presents with mild exertional dyspnea and an occasional cough but does not have any mention of hypotension or the associated symptoms listed in the clinical trial's inclusion criteria.\n\nThe clinical trial is focused on evaluating the use of ultrasound in patients who present with symptomatic undifferentiated hypotension, with specific criteria including an arterial pressure of less than 100 mm/Hg at presentation and at least one of the following symptoms: unresponsiveness, syncope, impaired mental status, respiratory distress, or severe malaise and fatigue.\n\nSince the patient does not present with hypotension or the symptoms listed in the inclusion criteria, she would not be eligible for the trial. There is no mention of her arterial pressure or any of the symptoms that would qualify her for inclusion in the study based on the patient note provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1395": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- 58-year-old white female with mild exertional dyspnea and occasional cough\n- Left lung mass found on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n\nClinical Trial:\n- Title: Lung Ultrasound in the Evaluation of Pneumothorax Size\n- Inclusion Criteria:\n  - Radiologic diagnosis of pneumothorax\n  - Clinical need to perform a CT scan\n  - Ability to perform the lung ultrasound imaging within 20 minutes from the CT study\n\nThe patient in the note does not have a diagnosis of pneumothorax; instead, she has a left lung mass and a solitary mass in the right frontal lobe. The clinical trial is specifically looking for patients with a radiologic diagnosis of pneumothorax, which the patient does not have. Therefore, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1396": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's assess the patient's eligibility:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of pancreatic cancer or metastatic pancreatic adenocarcinoma\n- No mention of prior treatments or systemic therapy\n\nClinical Trial Inclusion Criteria:\n- Histologically documented metastatic pancreatic adenocarcinoma not previously treated with palliative systemic therapy\n- Metastatic disease based on the presence of clinically and/or radiologically documents Measurable disease base on RECIST.\n- Adequate tissue available for IHC testing of hENT1\n- ECOG performance status of 0 - 1\n- Age \u2265 18 years\n- Life expectancy of at least 3 months\n- Adequate hematologic, hepatic, and renal function\n- Prior chemotherapy or radiation, if part of initial curative therapy, completed at least 6 months prior to study start date\n- Prior palliative radiotherapy, if applicable, \u2265 4 weeks before study entry with recovery from toxic effects\n- Prior surgery, if applicable, \u2265 4 weeks before study entry with recovery from toxic effects\n- Ability to give informed consent and comply with study requirements\n\nThe patient presented has a solitary mass in the right frontal lobe, which is indicative of brain cancer, not pancreatic cancer. There is no mention of metastatic pancreatic adenocarcinoma in the patient's note, which is a key inclusion criterion for the clinical trial. Since the patient's diagnosis does not match the specific cancer type required for the study (metastatic pancreatic adenocarcinoma), the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1397": {
        "output": "",
        "label": 0
    },
    "1398": {
        "output": "Given the patient note: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.\n\nAnd the clinical trial inclusion criteria:\n- ICSI candidates with repeated implantation failure and history of development of good embryos in previous ICSI cycles.\n- Advanced maternal age above 38 years.\n- Poor endometrial response to ovulation induction drugs.\n- Endometrial atrophy.\n\nThe patient in question does not meet any of the specific inclusion criteria for this clinical trial. The patient is not described as an ICSI candidate, there is no mention of repeated implantation failure or a history of developing good embryos in previous ICSI cycles. Additionally, there is no information about poor endometrial response to ovulation induction drugs or endometrial atrophy. Instead, the patient presents with a left lung mass and a brain mass, which are not relevant to the clinical trial's focus on implantation rates in ICSI patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1399": {
        "output": "Based on the provided patient note, the patient is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough who has been found to have a left lung mass on chest x-ray. Additionally, a CT scan of the head reveals a solitary mass in the right frontal lobe.\n\nNow, looking at the inclusion criteria for the clinical trial titled \"A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department,\" the trial seeks:\n\n1. All patients who present to the ED with respiratory symptoms suspicious for pneumonia.\n2. Patients in whom the treating physician believes would benefit from diagnostic imaging.\n\nThe patient in the note does present with respiratory symptoms (mild exertional dyspnea and occasional cough), and there is a finding of a left lung mass on chest x-ray, which could potentially be pneumonia, a reason for diagnostic imaging.\n\nHowever, the presence of a solitary mass in the right frontal lobe on the CT scan might indicate a different or additional pathology that is not related to pneumonia. This could affect the patient's eligibility if the lung mass is not pneumonia or if the trial investigators are specifically looking for uncomplicated cases of suspected pneumonia.\n\nGiven the information, the patient has symptoms that could be suspicious for pneumonia and would benefit from diagnostic imaging, which aligns with the inclusion criteria for the clinical trial. However, the trial's objective is to evaluate the effectiveness of lung ultrasound (LUS) compared to chest x-ray for diagnosing pneumonia. Therefore, it is essential to determine if the treating physician suspects pneumonia as the diagnosis for the lung mass. If the physician suspects pneumonia, the patient could be considered for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1400": {
        "output": "Considering the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nThe patient is a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe. \n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. Age 40-75 years - The patient meets this criterion, as she is 58 years old.\n2. The patient must be a current or ex-smoker with a significant smoking history to meet the criteria for ages 40-59 or 60-75. However, the patient is described as a nonsmoker, and there is no mention of a family history of lung cancer or COPD.\n3. Subject is able to return to Cleveland Clinic for annual follow-up screening - There is no information provided about the patient's ability or willingness to return to the clinic for follow-up.\n4. Subject is willing to sign a medical release form - There is no information provided about the patient's willingness to sign a release form.\n\nSince the patient does not meet the smoking history criteria, which are a requirement for eligibility in this clinical trial, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1401": {
        "output": "Based on the patient note provided, the 58-year-old nonsmoker white female has a left lung mass and a solitary mass in the right frontal lobe. There is no clear indication that she has Transitional Cell Carcinoma (TCC) of the bladder or upper urinary tracts. Additionally, there is no mention of prior platinum-based chemotherapy or progression of disease within 12 months of such treatment. Moreover, her specific performance status is not mentioned, and there is no indication of histological or cytological confirmation of TCC.\n\nGiven the lack of information confirming a diagnosis of TCC, prior platinum-based chemotherapy, progression of disease within 12 months, and measurable disease as per RECIST Criteria 1.1, we do not have sufficient evidence to conclude that this patient meets the inclusion criteria for the clinical trial concerning the treatment of Transitional Cell Carcinoma with Cabazitaxel.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1402": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan\n\nClinical trial:\n- Title: Spinal Anesthesia for Cesarean Delivery is Associated With Decreases in Regional Cerebral Oxygen Saturation as Assessed by Near-Infrared Spectroscopy\n- Inclusion criteria: Term healthy parturients\n\nThe term \"parturients\" refers to women who are about to give birth or have just given birth. Since the clinical trial is specifically focused on parturients undergoing cesarean delivery and assessing cerebral oxygen saturation in this context, the patient in question does not fit the criteria. The patient does not appear to be pregnant, and nothing in the patient note suggests that she is a candidate for cesarean delivery. \n\nTherefore, the patient is not eligible for this clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1403": {
        "output": "",
        "label": 0
    },
    "1404": {
        "output": "After reviewing the patient note and the clinical trial information provided, let's determine the patient's eligibility for the trial:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- Asymptomatic otherwise\n\nClinical Trial Inclusion Criteria:\n- Men and women who at the time of randomization are less than 55 or greater than or equal to 75 years of age are excluded\n- Individuals undergoing treatment for cancer at this time are excluded\n- Individuals with known prior cancer of the colon, rectum, lung, prostate (men only), or ovary (women only) are excluded\n- Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate (men only) are excluded\n- Other specific exclusions not directly related to the patient note\n\nBased on the information provided, the patient does not meet the age criterion as she is 58 years old and the trial excludes individuals who are less than 55 or greater than or equal to 75 years of age. Additionally, the presence of a lung mass as well as a solitary mass in the brain may indicate active cancer, which is another exclusion criterion.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1405": {
        "output": "Given the patient note, we have a 58-year-old nonsmoking white female who is experiencing mild exertional dyspnea and an occasional cough. She has a left lung mass observed on chest x-ray and a solitary mass in the right frontal lobe found via a CT scan of the head. \n\nThe clinical trial in question is looking to enroll individuals for a Lung Cancer Screening Study with Low-dose CT Scan and Blood Biomarker. The inclusion criteria for the trial are:\n\n1. Smokers or former smokers\n2. At least 20 pack-year history of smoking\n3. Ages 50 - 75\n\nThe patient described in the note is within the age range of 50-75, which matches one of the inclusion criteria. However, the patient is noted to be a nonsmoker, and there is no mention of a smoking history that would meet the requirement of at least a 20 pack-year history of smoking. This information is critical because the study specifically targets smokers or former smokers with significant smoking history, which is a known risk factor for lung cancer.\n\nSince the patient does not meet all of the inclusion criteria due to the absence of a smoking history, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1406": {
        "output": "Based on the information provided, the patient is a 58-year-old nonsmoker white female with a left lung mass on chest x-ray and a solitary mass in the right frontal lobe found on a CT scan of the head. The clinical trial is aimed at evaluating pulmonary nodules with imaging and biomarkers, specifically looking at patients with suspected lung cancer.\n\nThe inclusion criteria for the clinical trial are:\n- All patients aged above 21 years\n- Capable of giving consent\n- Suspected of lung cancer with radiological lung nodules and masses\n\nThe patient in question meets the age requirement and presumably is capable of giving consent. The presence of a lung mass on chest x-ray and accompanying symptoms such as mild exertional dyspnea and occasional cough suggest a suspicion of lung cancer. However, further diagnostic workup, such as biopsy, would be needed to confirm the suspicion of lung cancer.\n\nGiven the information provided and assuming the patient can give consent, there is a high likelihood of referring this patient for the clinical trial because the patient has a lung mass on chest x-ray, which aligns with the trial's focus on patients with radiological lung nodules and masses.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1407": {
        "output": "Based on the patient note, we have a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe. The neurologic examination is unremarkable, which suggests that the primary concern at this moment is the lung mass and potential brain involvement, as indicated by the CT scan.\n\nThe clinical trial in question is looking for patients with undifferentiated sarcomas. The inclusion criteria specify that it is looking for 49 cases of undifferentiated sarcomas from a specific previous study (ARST0332).\n\nThe patient note does not mention sarcoma or the specific study ARST0332. Instead, it mentions a lung mass, which is not necessarily a sarcoma, and a mass in the brain, which is also not explicitly stated to be sarcoma.\n\nWithout any indication that the patient has an undifferentiated sarcoma or is connected to the ARST0332 study, there is no basis to refer this patient to the clinical trial described. Therefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1408": {
        "output": "Assessing the patient's eligibility based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- 58-year-old nonsmoker white female\n- Symptoms: mild exertional dyspnea and occasional cough\n- Findings: left lung mass on chest x-ray, solitary mass in the right frontal lobe on CT scan\n- No mention of histological confirmation of malignancy or staging studies\n- No mention of the lung mass being non-metastatic NSCLC or metastatic from a non-lung primary\n- No information on the number of lung lesions\n- No information on lymph node status (N0) or the function of the other lung\n- No information on other potential malignancies or expected prognosis\n- Adequate lung function to tolerate SBRT not explicitly stated\n- No mention of previous radiation therapy to the mediastinum/lung\n- The patient's Zubrod performance status is not provided\n- No data on reproductive status or willingness to use contraception\n- Willingness and ability to give informed consent is not stated\n\nClinical Trial Inclusion Criteria Analysis:\n- Histological confirmation of malignancy or acceptable alternative evidence\n- Staging studies completed\n- Criteria based on the stage and location of the lung cancer or metastasis\n- Number of lung lesions specified\n- Lymph node status (N0)\n- Co-existing malignancy prognosis consideration\n- Adequate lung function for SBRT\n- Previous radiation therapy considerations\n- Age \u2265 18 years\n- Zubrod performance status between 0 and 3\n- Contraception for participants of childbearing potential\n- Informed consent\n\nBased on the information provided, the patient's eligibility for the trial cannot be determined conclusively from the patient note as several key inclusion criteria are not addressed. Therefore, further investigation is required to obtain missing information such as histological confirmation, staging studies, lymph node status, lung function, and other factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1409": {
        "output": "Based on the patient note, the patient is a 58-year-old white female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe on a CT scan. The clinical trial is aimed at patients who have peripheral lung nodules of less than 3 cm in size and who are surgical candidates.\n\nThe patient note does not provide information on the size of the lung mass or whether the patient is a surgical candidate. However, the presence of a solitary mass in the right frontal lobe suggests a possible metastasis from the lung mass, which might complicate the patient's eligibility as a surgical candidate for lung lesion resection, depending on the specifics of the trial protocol and whether the trial is targeting primary lung lesions versus metastatic conditions.\n\nGiven the lack of detailed information on the size of the lung mass and the absence of a clear statement about the patient being a surgical candidate, I would consider referring this patient to the clinical trial upon further investigation to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1410": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Avonex\u00ae: Safety, Blood Levels and Effects\", let's evaluate the patient's eligibility:\n\nPatient Note:\n- Age: 58 years old\n- Key medical findings: Mild exertional dyspnea, occasional cough, left lung mass, solitary mass in the right frontal lobe\n- No mention of BMI or body weight\n- Other data: Nonsmoker, white female, neurologic examination unremarkable\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 45 years\n- BMI of 19 to 28 kg/m2\n- Minimum body weight of 50 kilograms\n- Written informed consent\n\nAssessment:\n- The patient's age (58 years old) exceeds the specified age range for the trial (18 to 45 years).\n- There is no information about the patient's BMI or body weight, but even if these criteria were met, the age criterion alone is sufficient to make the patient ineligible.\n- The trial does not mention specific medical conditions or diagnoses as part of its criteria, but the patient's diagnosis does not seem to align with the trial's focus on interferon beta-1a, which is commonly used to treat multiple sclerosis, not lung masses or brain tumors.\n\nGiven that the patient does not meet the age criterion, which is a mandatory inclusion criterion, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1411": {
        "output": "The patient note describes a 58-year-old nonsmoking white female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial in question is focused on subjects with advanced melanoma treated with TH-302.\n\nTo determine if the patient is eligible for the clinical trial, we need to review the inclusion criteria:\n\n1. **At least 18 years of age:** The patient is 58, so she meets this criterion.\n2. **Ability to understand the purposes and risks of the study:** Since the patient\u2019s neurologic examination is unremarkable, we can assume she has the capacity to understand the study, assuming no other cognitive impairments are present.\n3. **Histologically documented cutaneous or mucosal malignant melanoma:** The patient\u2019s diagnosis is not specified as melanoma; she has a left lung mass and a brain mass. Without evidence that she has melanoma, she does not meet this criterion.\n4. **Adequate tumor tissue available:** We do not have information on the availability of tumor tissue.\n5. **Ability to complete all prescribed biomarker studies:** We do not have information regarding her ability or availability for this.\n6. **Recovered to Grade 1 from reversible toxicities of prior therapy:** There is no mention of prior therapy, so we cannot assess this.\n7. **Presence of clinically and/or radiologically documented disease:** The patient does have a radiologically documented disease, but it is not specified as melanoma.\n8. **ECOG performance status of 0 - 1:** We do not have specific information about her ECOG performance status, but she is described as otherwise asymptomatic, which may suggest a good performance status.\n9. **Prior treatment with immunotherapies, targeted therapies, or no more than one chemotherapy:** We have no information on prior treatments.\n10. **Acceptable liver function, renal function, hematologic status, and normal 12-lead ECG:** We do not have this information.\n11. **Female subjects of childbearing age must have a negative urine HCG test:** We do not have information on her menopausal status, but given her age, she may be perimenopausal or postmenopausal.\n12. **Effective birth control for sexually active subjects:** This would require her agreement if she is of childbearing potential.\n\nThe primary issue here is that the patient does not have a documented diagnosis of melanoma, which is a key inclusion criterion for the trial. Without this diagnosis, she does not meet the eligibility criteria for the study. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1412": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's potential eligibility:\n\nPatient note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n- No mention of emphysema or any pulmonary function tests\n\nClinical trial inclusion criteria:\n- Willing and able to provide informed consent and to participate in the study\n- Age \u2265 40 years at the time of screening\n- Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan\n- Minimum of 2 subsegments appropriate for treatment\n- MRCD questionnaire score of 2 or greater at screening\n- Failure of medical therapy to provide relief of symptoms\n- Specific spirometry and lung volume measurements\n- Oxygen saturation (SpO2) > 90 % on \u2264 4 L/min supplemental O2, at rest\n- Six-Minute Walk Test distance \u2265 150 m\n- Abstinence from smoking for at least 16 weeks prior to screening\n\nGiven that the patient in the note has a lung mass and a brain mass, but there is no mention of emphysema or the specific pulmonary function test results needed for the inclusion criteria, we do not have enough information to determine if the patient has emphysema or meets the specific respiratory function requirements of the trial.\n\nThe patient does not appear to meet the criteria for the trial as there is no evidence of emphysema, which is a key requirement for the trial. The mass in the lung is not enough to suggest emphysema without further diagnostic information such as spirometry or CT scan evidence of emphysema. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1413": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n- The patient has a confirmed diagnosis of a solid tumour, as indicated by the presence of a left lung mass on chest x-ray and a solitary mass in the right frontal lobe on a CT scan. This meets the criterion for having a \"confirmed diagnosis of advanced, non-resectable and / or metastatic solid tumours.\"\n- There is no mention of the patient failing conventional treatment, not being amenable to established forms of treatment, or no therapy of proven efficacy existing. However, since the patient is otherwise asymptomatic and presenting with only mild exertional dyspnea and an occasional cough, it might be inferred that they have not yet undergone treatment. This would need to be clarified.\n- The presence of the tumour can be evaluated by techniques such as X-ray and CT, which meets the criterion of \"evaluable tumour deposits by one or more techniques.\"\n- The patient is 58 years old, satisfying the \"age 18 years or older\" criterion.\n- There is no mention of the life expectancy of the patient. This would need to be estimated by a physician to meet the \"life expectancy of at least three months\" criterion.\n- It's assumed that the patient can give written informed consent, as there are no indications otherwise.\n- The patient's performance status is not explicitly stated, but the neurologic examination being unremarkable and the patient being otherwise asymptomatic could suggest an ECOG performance score < 2. This would need to be confirmed.\n- There is no information on the patient's recovery from prior treatments since it's not clear if the patient has undergone any treatments at all.\n\nGiven the information available, the patient appears to potentially meet several of the inclusion criteria, but further information is needed to fully assess eligibility. Therefore, I would consider referring this patient to the clinical trial upon further investigation to clarify the missing information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1414": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the relevant details:\n\nPatient Details:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on a CT scan of the head\n\nClinical Trial Inclusion Criteria:\n- A soft tissue solitary dominant pulmonary nodule of \u2265 8mm and \u226430mm on axial plane\n- Measured on lung window using conventional CT scan\n- No other ancillary evidence strongly indicative of malignancy (e.g. distant metastases or unequivocal local invasion)\n- If clinicians and reporting radiologists believe the patient is being treated as having a single pulmonary nodule and there are other small lesions <4mm that would normally be disregarded, the patient should be included in the trial\n- Nodules already under surveillance can be included provided they have a recent or scheduled FDG-PET/CT\n- 18 years of age or over at the time of providing consent\n- Able and willing to consent to study\n\nThe patient note indicates the presence of a left lung mass, which could potentially be a solitary pulmonary nodule that fits the trial's criteria. The presence of a solitary mass in the right frontal lobe on a CT scan of the head suggests a possible metastasis, but the information given doesn't confirm whether it is related to the lung mass or if it's indicative of a separate pathology. However, the clinical trial requires that there be no ancillary evidence strongly indicative of malignancy, such as distant metastases.\n\nGiven that the trial is investigating solitary pulmonary nodules without strong evidence of malignancy, and we have only limited information about the nature of the lung mass and the separate brain mass, it is not possible to definitively determine the patient's eligibility without further investigation to clarify the nature of both masses.\n\nTherefore, the patient's eligibility for the trial would require more detailed information regarding the characteristics of the lung mass and the brain mass to ensure they meet the trial criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1415": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient in question is a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial is focused on prostate cancer genomic heterogeneity and is looking to enroll men with prostate cancer or suspicion of prostate cancer either treatment-na\u00efve or post-treatment with suspicion of recurrence.\n\nThe inclusion criteria for the clinical trial are:\n- Treatment na\u00efve group\n  - Men with no prior diagnosis of prostate cancer undergoing prostate biopsy based on identified lesions on imaging\n  - Men with a raised PSA above 15ng/ml\n  - Men giving informed consent\n- Treated men\n  - Men undergoing tissue biopsy for suspicion of prostate cancer recurrence following previous local or systemic therapy based on identified lesions in multi-parametric MRI, bone-scan, choline PET/CT, or PET/MRI\n\nSince the patient is a female with a lung mass and brain mass, and the clinical trial is specifically for men with prostate cancer or suspicion of prostate cancer, this patient does not meet the gender or disease requirements for the clinical trial. Therefore, this patient is not eligible to participate in the prostate cancer genomic heterogeneity study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1416": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided:\n\nPatient note:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Neurologic examination unremarkable\n- CT scan of the head shows a solitary mass in the right frontal lobe\n\nClinical trial inclusion criteria:\n- Age over 18 years\n- Planned thoracoscopic surgery of a pulmonary nodule\n- Informed consent\n\nThe patient is over 18 years old and has a pulmonary nodule (left lung mass), which may require thoracoscopic surgery. While the trial does not specify the need for a solitary nodule or the stage of lung disease, based on the information given, this patient could potentially be eligible for the trial as they might be planning for thoracoscopic surgery to address the lung mass.\n\nFurther investigation would be needed to confirm that thoracoscopic surgery is indeed planned for this patient's pulmonary nodule, and to ensure that the patient is informed and willing to consent to the trial's procedures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1417": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided patient note and the inclusion/exclusion criteria of the trial:\n\nPatient Note:\n- 58-year-old white female.\n- Non-smoker.\n- Mild exertional dyspnea and occasional cough.\n- Left lung mass on chest x-ray.\n- Neurologic examination unremarkable.\n- CT scan of the head shows a solitary mass in the right frontal lobe.\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus.\n- Age \u226518 years.\n- ECOG Performance status \u22642.\n- Measurable disease according to RECIST criteria version 1.1.\n- Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus.\n- HIV+ patients will be considered eligible with a CD4 count of \u2265200.\n- Adequate organ function (specified by blood counts and chemistries).\n- Fertile men and women must agree to contraceptive precautions.\n- Life expectancy of at least 3 months.\n\nClinical Trial Exclusion Criteria:\n- Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded.\n- Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus.\n- Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.\n- Surgery or palliative radiotherapy within 28 days of randomisation.\n- Clinically significant cardiac disease, interstitial lung disease, malabsorption syndrome, active hepatitis, serious active infection requiring i.v. antibiotics, other malignancy within the last 5 years, clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment, hypersensitivity to study drugs, peripheral neuropathy \u2265 grade 1, pre-existing hearing impairment, planning for a live vaccine, pregnant or lactating females.\n\nAssessment:\n- The patient has a solitary mass in the right frontal lobe and a left lung mass, with no mention of anal cancer.\n- The trial is specific to squamous cell carcinoma of the anus, which does not align with the patient's diagnosis.\n- The patient's neurologic examination is described as unremarkable, which seems to contradict the exclusion criterion of documented or symptomatic brain metastases.\n- However, the presence of a solitary mass in the right frontal lobe could potentially be a brain metastasis, which would exclude the patient if it were symptomatic or documented as a metastasis.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial, as the patient's diagnosis is not squamous cell carcinoma of the anus. Furthermore, the potential brain metastasis could be an excluding factor if confirmed to be symptomatic or documented metastasis related to the patient's lung mass.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1418": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility of the patient:\n\nPatient Note:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on a CT scan of the head\n- Otherwise asymptomatic\n- Neurologic examination is unremarkable\n\nClinical Trial Inclusion Criteria:\n- Intubation and mechanical ventilation in the ICU\n- Ramsay score 6 under sedation and analgesia\n- ICU respirator implemented with pressure-volume curve device\n- Age equal to or greater than 18 years\n- ARDS defined from the Berlin criteria\n- Absence of pneumothorax on the CXR before the study\n- Absence of pleural effusion greater than 500 ml estimated from ultrasonography\n- No child-bearing woman\n- Written informed consent signed by the next of kin\n\nAssessment:\n- The patient is a 58-year-old woman, satisfying the age criterion.\n- There is no information provided that the patient is intubated, on mechanical ventilation, or in the ICU.\n- The patient has a left lung mass, but there is no mention of ARDS per the Berlin criteria.\n- There is no information about pneumothorax or pleural effusion regarding the patient.\n- The patient is not described as being sedated or having a Ramsay score of 6.\n- Informed consent capability cannot be determined from the note.\n\nGiven the available information, the patient does not meet several key inclusion criteria such as being on mechanical ventilation or having ARDS. Furthermore, the patient has a brain mass, which is not related to the study's focus on lung recruitment in ARDS patients. Therefore, the patient does not appear to be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1419": {
        "output": "Based on the information provided, the patient is a 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough, and a left lung mass observed on chest x-ray. Additionally, a solitary mass in the right frontal lobe is evidenced by a CT scan of the head.\n\nThe clinical trial is focused on the use of MRI to evaluate solitary pulmonary nodules (mass in the lung smaller than 3 centimeters) and the metabolic pathways these nodules use. The inclusion criteria for the trial are:\n\n- Subjects of all races and ethnic origins over 18 years of age will be recruited.\n- Patients must have a suspicious or known to be malignant solitary pulmonary nodule, 5cm or less in size.\n\nThe patient note indicates the presence of a left lung mass, which could potentially qualify as a \"suspicious or known to be malignant solitary pulmonary nodule.\" However, the size of this mass is not specified in the patient note. If the lung mass is indeed 5cm or less in size, the patient could be eligible for the trial. Furthermore, there is no mention of contraindicating factors that would automatically exclude the patient from the trial.\n\nGiven that the information provided does not include the size of the lung mass, further investigation would be needed to determine if the patient meets the specific inclusion criterion regarding nodule size. Therefore, based on the current information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1420": {
        "output": "Based on the information given in the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe (on CT scan of the head)\n\nClinical Trial Inclusion Criteria:\n- Age between 18-90 years old\n- Hemisyndrome (central paralysis of the upper extremity, and all degrees of weakness: M0 - M5 on the paresis scale) as a result of a first stroke\n- Sub-acute lesion not more than 6 weeks post ictus\n\nThe patient has a mass in the right frontal lobe, which may suggest a brain lesion, but there is no indication that this lesion is a result of a stroke or that the patient has a hemisyndrome (central paralysis of the upper extremity). Moreover, the trial specifies that the lesion should be sub-acute and not more than 6 weeks post ictus, and there's no information provided regarding the timing of the lesion noted in the patient.\n\nTherefore, without further information to suggest that the patient's condition is a result of a stroke and meets the specific criteria of hemisyndrome within the required time frame, the patient is not a clear match for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1421": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Unremarkable neurologic examination\n- Solitary mass in the right frontal lobe on a CT scan of the head\n\nClinical Trial:\n- Title: IPg2 Study: Left-sided Lung Isolation\n- Focus: Comparing lung collapse in left VATS using different lung isolation devices\n- Inclusion Criteria:\n  - Signed informed consent\n  - Elective left video-assisted thoracoscopy\n  - One lung ventilation\n\nThe patient note indicates that the patient has a left lung mass, which could potentially make her a candidate for a left video-assisted thoracoscopy (VATS), assuming that such a procedure might be indicated for her condition. However, the patient note does not specifically mention if she is scheduled for an elective left VATS, only that a mass has been found. Furthermore, the patient also has a solitary mass in the right frontal lobe, which is not related to the thoracic surgery but is worth considering in the overall assessment of patient care.\n\nGiven the available information, the patient might be a candidate for the clinical trial if she is scheduled for an elective left VATS where one lung ventilation is required. However, this information is not explicitly stated in the patient note. Therefore, additional information would be needed to determine if the patient is scheduled for this specific procedure and if she meets all other eligibility criteria, such as providing informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1422": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 58-year-old white female.\n- She has a lung mass and a solitary mass in the right frontal lobe.\n- She is experiencing mild exertional dyspnea and occasional cough.\n- She is a nonsmoker.\n- No mention of asthma or severe asthma diagnosis.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with severe asthma.\n- Patients must be between 18 and 65 years old.\n- The diagnosis of asthma must be confirmed through specific respiratory function tests or medication response.\n- Patients must be on regular maintenance medication for severe asthma.\n- There are specific requirements for lung function (FEV1) and asthma control (ACQ score).\n- Patients must be nonsmokers or have a limited smoking history.\n- Ability to undergo bronchoscopy and Bronchial Thermoplasty (BT).\n- Women of childbearing potential must agree to adequate birth control methods.\n\nComparison:\n- The patient falls within the age range required for the trial.\n- The patient is a nonsmoker, which fits one of the inclusion criteria.\n- However, the patient note does not mention a diagnosis of asthma, nor does it indicate that the patient is suffering from severe asthma or is on maintenance medication for asthma.\n- There is no information provided on the patient's lung function (FEV1), asthma control (ACQ score), or the presence of bronchial hyper-responsiveness.\n- The primary health concern for the patient appears to be related to the lung mass and brain mass, which is not related to asthma.\n\nBased on the information given, the patient does not fit the profile of someone suffering from severe asthma, which is a critical inclusion criterion for the clinical trial. There is no mention of asthma in the patient's note, and thus the patient does not meet the necessary diagnostic criteria for asthma required for participation in the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1423": {
        "output": "In assessing the eligibility of the patient for the clinical trial titled \"Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer,\" we should compare the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient Characteristics:\n- 58-year-old nonsmoker white female\n- Presenting with mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Unremarkable neurologic examination\n- Solitary mass in the right frontal lobe on a CT scan of the head\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer with mutation in the ALK gene or other ALK abnormalities as detected by approved tests.\n- No other curative therapeutic option available.\n- WHO performance status 0-2.\n- Age \u2265 18 years.\n- Recovery from all toxicities related to prior anticancer therapies to \u2264 Grade 2, except alopecia.\n- Adequate organ function as defined by specific laboratory criteria.\n- Written informed consent for the protocol.\n- Willingness and ability to comply with the trial's procedures.\n\nComparison:\n- The patient has a lung mass and a brain mass, but there is no information about thyroid cancer or ALK gene abnormalities. The trial specifically targets anaplastic thyroid cancer or undifferentiated thyroid cancer with certain genetic characteristics.\n- The patient's WHO performance status is not provided, but given the mild symptoms described, it could potentially be within the 0-2 range.\n- The patient meets the age criterion.\n- There is no information on the patient's recovery from prior toxicities or whether any previous anticancer therapies were administered.\n- No details are provided on the patient's organ function or laboratory values.\n- Willingness and ability to comply, along with informed consent, are not mentioned but are standard requirements for all trial participants.\n\nGiven the available information, the primary disqualifying factor is that the patient does not have a confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer, which is a key inclusion criterion for this trial. Additionally, there is no mention of ALK gene abnormalities, which is another crucial eligibility requirement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1424": {
        "output": "Patient Note Analysis:\n- The patient is a 58-year-old nonsmoker white female.\n- She has a left lung mass and a solitary mass in the right frontal lobe.\n- The neurologic examination is unremarkable.\n- No mention of melanoma diagnosis.\n\nClinical Trial Analysis:\n- The trial is for patients with melanoma brain metastases.\n- The patient must be 18 years or above.\n- The patient must have stage IV melanoma or unknown primary melanoma with brain metastasis that is measurable.\n- The patient should not have had prior treatment for brain metastases.\n- The patient needs to be neurologically asymptomatic from brain metastases.\n- Other specific criteria include ECOG Performance Status of 0-2 and adequate organ function.\n\nComparison:\n- The patient's age fits the inclusion criteria.\n- There is no information given that confirms the patient has melanoma; the note only mentions a lung mass and a brain mass.\n- There is no indication of prior treatments for brain metastases, which matches the trial criteria.\n- Neurological status is asymptomatic according to the trial's requirement.\n- There is no information provided on the patient's ECOG Performance Status or organ function.\n\nDue to the lack of information confirming the diagnosis of melanoma, as well as incomplete information regarding other inclusion criteria, there is not enough evidence to refer this patient for this clinical trial without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1425": {
        "output": "Based on the given patient note and the inclusion criteria of the provided clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient Note:\n- The patient is a 58-year-old nonsmoker white female.\n- She presents with mild exertional dyspnea and occasional cough.\n- A left lung mass is found on chest x-ray.\n- A CT scan of the head shows a solitary mass in the right frontal lobe.\n- The note does not mention melanoma or the presence of metastases in the sentinel node.\n\nClinical Trial Inclusion Criteria:\n- Cutaneous melanoma with a tumour thickness of at least 1.00mm.\n- Positive sentinel node with micro metastases of max. 2mm in diameter.\n\nComparison:\n- The patient note does not mention a diagnosis of cutaneous melanoma, which is a key requirement for the clinical trial.\n- There is no information about the presence of micro metastases in a sentinel node, another critical inclusion criterion for the trial.\n\nGiven the available information, the patient does not meet the inclusion criteria for the clinical trial focused on malignant melanoma with evidence of micro metastases in the sentinel node. Instead, the patient has a lung mass and a brain mass, with no mention of melanoma or sentinel node involvement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1426": {
        "output": "Based on the patient note provided, the patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial in question is focused on patients with locally advanced rectal cancer and is investigating the efficacy of 18F-FDG-PET-CT and texture analysis of MRI in predicting response to neoadjuvant therapy.\n\nThe inclusion criteria for the trial are:\n- Patients with biopsy-proven confirmed rectal cancer\n- MRI stage: T3/T4 and/or N1/N0\n- No contraindication to MRI and PET-CT\n\nThe patient described in the note has no mention of rectal cancer or any indication that they have been diagnosed with or treated for rectal cancer. Instead, the patient has a lung mass and a brain mass, which are not relevant to the clinical trial's focus on rectal cancer.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial on rectal cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1427": {
        "output": "Based on the patient note:\n\n- The patient is a 58-year-old nonsmoker white female.\n- The patient has mild exertional dyspnea and occasional cough.\n- A left lung mass is present.\n- Neurological examination is unremarkable.\n- CT scan of the head shows a solitary mass in the right frontal lobe.\n\nAnd comparing it to the clinical trial:\n\n- The trial is studying cooperative behavior and decision-making in frontal lobe epilepsy.\n- The inclusion criteria for patients are:\n  - Age between 18 and 50\n  - Diagnosis of frontal lobe epilepsy\n  - Written consent to participate\n  - Right-handed\n  - Hospital Anxiety and Depression Scale Score under 10\n  - Obsessive Compulsive Inventory Score under 40\n  - Sufficient language skills\n  - Social insurance\n- Exclusion criteria for patients include:\n  - Seizures types other than epileptic (psychogenic etc.)\n  - Mental retardation\n  - Epilepsies other than FLE\n  - Other known neurological diseases\n  - Hospital Anxiety and Depression Scale Score over 10\n  - Obsessive Compulsive Inventory Score over 40\n  - Pregnancy\n  - Non-MRI suitable transplants (cardiac pacemaker etc.), claustrophobia, orthopedic diseases that prevent lying in the scanner\n  - During exclusion period of other studies\n  - No social insurance\n\nThe patient does not meet the inclusion criteria for several reasons:\n\n- The patient's age exceeds the specified range (18-50 years old).\n- There is no information provided suggesting a diagnosis of frontal lobe epilepsy; the presence of a solitary mass in the right frontal lobe does not equate to epilepsy.\n- Even if the mass was indicative of frontal lobe epilepsy, the age criterion alone would be disqualifying.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1428": {
        "output": "To determine the trial-level eligibility for the given patient, we need to assess whether the patient meets the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 58-year-old nonsmoker white female\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Solitary mass in the right frontal lobe on CT scan of the head\n\nClinical Trial (COPDGene/Lung Cancer Center Database) Inclusion Criteria:\n1. Be enrolled in COPDGene\u00ae Phase 1 with or without enrollment in Phase 2 with newly diagnosed, non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC).\n2. Documented GOLD stage 1-4 COPD or a history of smoking with no COPD\n3. Signed HIPAA Research Authorization and a Release of Protected Health Information form to collect and review medical records regarding lung cancer diagnosis, treatment, and outcome\n\nBased on the information provided in the patient note, the patient has a left lung mass that could potentially be lung cancer, but there is no information indicating that she has been diagnosed with lung cancer (NSCLC or SCLC). Additionally, there is no mention of COPD or a history of smoking, which are required for the trial. Moreover, there is no information indicating that the patient is enrolled in COPDGene\u00ae Phase 1 or Phase 2.\n\nSince the patient does not meet the key inclusion criteria of having a documented diagnosis of lung cancer or COPD, and there is no evidence of them being enrolled in the COPDGene\u00ae study, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1429": {
        "output": "Based on the information provided, the patient is a 58-year-old nonsmoking white female who has a left lung mass shown on chest x-ray. She also has a solitary mass in the right frontal lobe of the brain, as evidenced by a CT scan. The clinical trial in question is for patients with newly diagnosed lung cancer or indeterminate pulmonary nodules, using 18F-FSPG PET/CT imaging.\n\nThe patient's condition appears to meet the inclusion criteria for the clinical trial, which requires an untreated indeterminate pulmonary nodule or lung mass, without prior exams establishing lesion stability for two or more years, or a newly diagnosed, untreated primary lung cancer.\n\nThe patient has an indeterminate lung mass and no information is given regarding prior examinations of the lesion's stability or prior treatment. There is also no mention of a lung cancer diagnosis, but the presence of a mass and the need for further imaging suggest that the patient may be in the process of diagnosis.\n\nGiven this information, the patient may be a good candidate for the trial because she has an untreated lung mass and a possible need for further diagnosis through imaging, which is what the trial is investigating.\n\nHowever, it is important to clarify whether the mass has been stable for two or more years and whether the patient is willing to undergo the necessary informed consent, biopsy, or follow-up as required by the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1430": {
        "output": "Based on the information provided, the patient has a solitary mass in the right frontal lobe and a left lung mass on chest x-ray. The clinical trial is investigating the use of ultrathin bronchoscopy (UB) for solitary pulmonary nodules (SPN) that are beyond the visible range of standard-size bronchoscopy (SB).\n\nThe inclusion criteria for the clinical trial are:\n1. Pulmonary nodule on a recent CT\n2. Non-visible on standard-size bronchoscopy\n\nThe patient note indicates that there is a left lung mass, which could be consistent with a pulmonary nodule. However, the information provided does not specify whether the mass is beyond the visible range of standard-size bronchoscopy or if a CT scan has been done to confirm this. The patient would need a CT scan of the chest to further evaluate the pulmonary nodule and determine if it is non-visible on standard-size bronchoscopy.\n\nGiven the information available, I would consider referring this patient to the clinical trial upon further investigation to confirm that the pulmonary nodule meets the specific criteria of being non-visible on standard-size bronchoscopy and is present on a recent CT scan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1431": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we have the following:\n\nPatient Note:\n- 58-year-old white female\n- Has a left lung mass on chest x-ray\n- Mild exertional dyspnea and occasional cough\n- Solitary mass in the right frontal lobe on a CT scan of the head\n- No mention of interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF)\n\nClinical Trial:\n- Title: The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease\n- Evaluating the prevalence of lung cancer in ILD and IPF patients\n- Inclusion criteria: Patients equal to or above 40 years old with ILD, IPF, connective tissue disorder (CTD), or COPD\n\nThe patient's age fits the inclusion criterion of being above 40 years old. However, there is no mention in the patient note of the patient having interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), a connective tissue disorder (CTD), or chronic obstructive pulmonary disease (COPD). The clinical trial specifically seeks to study patients with ILD or IPF, and there is no indication that the patient has been diagnosed with these conditions based solely on the patient note provided.\n\nTherefore, without further information confirming the patient has ILD or IPF, we cannot assume the patient is eligible for the trial. It would be necessary to investigate whether the lung mass and symptoms are related to ILD or IPF before referring this patient to the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1432": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient is a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe. The clinical trial is focused on early rectal adenocarcinoma and the intervention involves neoadjuvant chemoradiotherapy with a radiotherapy boost.\n\nThe inclusion criteria for the clinical trial include:\n- Adenocarcinoma of the rectum classified clinically as T2, T3a, or T3b by TNM classification, < 5 cm largest diameter, less than half rectal circumference, N0-N1, M0\n- Operable patient\n- Tumor accessible to endocavitary contact X-Ray Brachytherapy with a distance from the lower tumor border to the anal verge \u2264 10cm\n- Age 18 years or above\n- No comorbidity preventing treatment\n- Adequate birth control\n- Patient having read the information note and having signed the informed consent\n- Health care insurance available\n- Follow-up possible\n\nThe patient described does not have rectal adenocarcinoma but rather a lung mass and a brain mass, which do not meet the specific diagnosis required for inclusion in the trial. Therefore, the patient is not eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1433": {
        "output": "The patient in the note is a 58-year-old white female with a left lung mass on chest x-ray. She also has a solitary mass in the right frontal lobe as revealed by a CT scan. She presents with mild exertional dyspnea and an occasional cough.\n\nThe clinical trial in question is focused on low-dose computed tomography (LDCT) screening for lung cancer in relatives with a family history of lung cancer.\n\nTo determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics to the inclusion criteria of the trial:\n\n1. Relatives of lung cancer patients: The patient note does not mention a family history of lung cancer. This is a critical piece of information required for eligibility.\n2. Age older than 55 years old or age older than the age of onset of lung cancer proband if the family members were less than 55 years old: The patient is 58 years old, which meets the age criterion.\n3. Compulsory signing the consent agreement after understanding the purpose of the study and the exposure to radiation: This criterion is procedural and can be fulfilled if the patient agrees to participate.\n\nThe key missing piece of information is whether the patient has a family history of lung cancer, as this is a specific requirement for the trial. Since this information is not provided in the patient note, we cannot definitively determine whether the patient is eligible.\n\nBased on the information given, I would rate the patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would specifically need to clarify the patient's family history regarding lung cancer to determine if the trial's inclusion criteria are met.",
        "label": 2
    },
    "1434": {
        "output": "",
        "label": 0
    },
    "1435": {
        "output": "Given the patient note, we have a 58-year-old female who is a nonsmoker with mild exertional dyspnea and occasional cough. She has been found to have a left lung mass on chest x-ray. Additionally, a CT scan of the head reveals a solitary mass in the right frontal lobe. \n\nNow, let's consider the inclusion criteria for \"The Watch the Spot Trial\":\n\n1. Adults aged \u226535 years\n2. At least one nodule measuring \u226415 mm in average diameter on chest CT\n\nThe patient is 58 years old, which satisfies the age criterion of being 35 years or older. However, the patient note does not provide information on the size of the lung nodule found on the chest x-ray. The clinical trial specifically requires the lung nodule to be \u226415 mm in average diameter on chest CT. To determine eligibility, we would need additional information on the size of the lung nodule found in this patient.\n\nWithout this crucial information, we cannot definitively conclude that the patient meets all the inclusion criteria. \n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1436": {
        "output": "Given the information provided:\n\nThe patient is a 72-year-old man with a history of cardiovascular issues, including a myocardial infarction and a transient ischemic attack. He is experiencing calf pain when walking uphill and has had worsening blood pressure despite medication. He also has a right carotid bruit and diminished pulses in the lower extremities, which are indicative of vascular issues.\n\nThe clinical trial titled \"Strong Heart Study\" aims to determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas.\n\nThe inclusion criteria for the clinical trial are not specified, which implies that there may be no restrictions on who can participate based on the information provided. However, it is important to note that the study specifically mentions a focus on American Indians.\n\nSince the patient in the note is not described as being American Indian, and because the focus of the study is very specific to that population, it might suggest that the patient may not be the target participant for this trial. However, without explicit exclusion criteria stating that non-American Indians cannot participate, this cannot be determined with certainty.\n\nTherefore, based on the information given and the absence of specific eligibility criteria, it is not possible to make a definitive assessment of the patient's eligibility. However, if the study is intended only for American Indians, as implied, the patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1437": {
        "output": "",
        "label": 0
    },
    "1438": {
        "output": "Given that the clinical trial in question does not have any specified inclusion criteria, there are no particular patient characteristics required for eligibility. This means that if the trial is investigating peripheral vascular disease (PVD) and its relation to plasma homocysteine, the patient's symptoms of calf pain when walking uphill and the history of cardiovascular issues could potentially make him a candidate for the study.\n\nHowever, without clear inclusion criteria, it is impossible to definitively determine the patient's eligibility based solely on the provided patient note. The decision to refer the patient would likely require direct communication with the trial's investigators to clarify the aims of the study and whether the patient's clinical profile matches the research interests.\n\nGiven the lack of explicit inclusion criteria and assuming the trial's relevance to the patient's condition of peripheral vascular disease, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1439": {
        "output": "In order to assess the patient's eligibility for the clinical trial titled \"Exercise Training for Patients With Poor Leg Circulation,\" we need to compare the patient note with the inclusion criteria provided for the trial. Let's examine the criteria step by step:\n\n1. **Diagnosis of PAD (peripheral artery disease)**:\n   - The patient's complaint of increasing calf pain when walking uphill and the symptoms worsening over the past 3 months suggest intermittent claudication, which is a symptom of PAD. Additionally, the physical examination findings of cool extremities and diminished pulses are consistent with PAD. However, a formal diagnosis of PAD is not stated in the patient note.\n\n2. **Positive Edinburgh Claudication Questionnaire**:\n   - The patient note does not mention the Edinburgh Claudication Questionnaire, so we cannot confirm if this criterion is met.\n\n3. **Fontaine stage IIa only (mild claudication, walking distance > 200 feet)**:\n   - The patient's symptoms are consistent with claudication, but the exact walking distance that causes pain is not provided, so we cannot confirm if the patient fits into Fontaine stage IIa.\n\n4. **Ambulatory, without assistive devices**:\n   - The patient note does not indicate the use of any assistive devices for walking.\n\n5. **Calf muscle claudication within 10 minutes of treadmill walking and calf muscle exercise**:\n   - The patient complains of calf pain when walking uphill, which may suggest calf muscle claudication, but the time frame (within 10 minutes) is not specified in the patient note.\n\nBased on the provided patient note, we have some indications that the patient might have PAD given his symptoms and the physical examination findings. However, we lack specific confirmations regarding a formal diagnosis of PAD, positive Edinburgh Claudication Questionnaire results, the exact walking distance that elicits symptoms, and the time frame of onset of claudication during exercise.\n\nGiven the information we have, it is possible that this patient could be eligible for the clinical trial after further investigation to confirm the diagnosis of PAD and other specific criteria. Therefore, the patient should be referred for further assessment and potential participation in the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1440": {
        "output": "After reviewing the patient note and the clinical trial information, we can determine the patient's eligibility based on the inclusion criteria provided for the clinical trial:\n\n- The inclusion criteria specifically state that the trial is for postmenopausal women.\n- The patient in the note is a 72-year-old man.\n- Additionally, the patient needs to have mild to moderate hypertension and be on statin therapy or have an LDL level \u2264 4.1 mmol/L. While the patient does have hypertension, there is no information provided about statin therapy or LDL levels.\n\nGiven that the patient is male and the trial is specifically for postmenopausal women, the patient does not meet the gender requirement for the trial. Therefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1441": {
        "output": "Based on the information provided, the patient in the note is a 72-year-old man with symptoms that suggest peripheral artery disease, such as calf pain when walking uphill and diminished pulses in the lower extremities. He also has a history of cardiovascular issues, including myocardial infarction and transient ischemic attack.\n\nThe clinical trial is focused on evaluating the burden of peripheral artery occlusion disease in Taiwan peritoneal dialysis patients. The inclusion criteria for the trial require that participants be stable peritoneal dialysis patients for more than 3 months.\n\nThe patient in the note does not mention undergoing peritoneal dialysis or having chronic kidney disease that would necessitate such treatment. Without this information, there is no indication that the patient is on peritoneal dialysis, which is a key inclusion criterion for the trial.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1442": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's assess the patient's eligibility:\n\nPatient's characteristics:\n- 72 years old\n- Male\n- History of myocardial infarction and transient ischemic attack\n- Hypertension that is not well controlled with current medication\n- No indication of stage II systolic hypertension in the note\n\nClinical trial inclusion criteria:\n1. 18 years of age or older\n2. Patients with stage II systolic hypertension\n3. If female, must have a negative serum pregnancy test and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent, or if of childbearing potential, must practice approved measures of birth control throughout the study.\n\nThe patient is male and over 18 years of age, which satisfies the first and third criteria (the third being irrelevant for male patients). However, the patient note does not specify that the patient has stage II systolic hypertension. Stage II systolic hypertension is typically defined as having a systolic blood pressure (the top number) of 140 mm Hg or higher. The patient's blood pressure is elevated at 151/91 mm Hg, which suggests that he might have stage II systolic hypertension, but this information is not explicitly stated in the patient note.\n\nConsidering the information provided, the patient potentially meets the age requirement and likely has a form of hypertension that may or may not qualify as stage II systolic hypertension. There is insufficient information to make a definitive conclusion about the patient's eligibility based on the hypertension criteria without further investigation. The patient's hypertension status should be clarified before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1443": {
        "output": "",
        "label": 1
    },
    "1444": {
        "output": "",
        "label": 0
    },
    "1445": {
        "output": "",
        "label": 0
    },
    "1446": {
        "output": "Based on the patient note provided, the 72-year-old man has a history of myocardial infarction and transient ischemic attack, which are related to cerebrovascular-cardiovascular disease. Additionally, he is currently experiencing worsening blood pressure despite medication, which could be indicative of hypertension\u2014one of the components of metabolic syndrome. The Rajavithi Health Promotion Project is interested in patients who have metabolic syndrome or are at high risk of developing serious complications from it.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Age 16 years or more\n2. Informed consent\n3. Living in selected community (Health Promotion area of Rajavithi Hospital)\n\nThe patient meets the age requirement (72 years old) and potentially has components of metabolic syndrome, which is the focus of the study. However, the provided patient note does not mention whether the patient is capable of giving informed consent or whether he lives in the selected community (Health Promotion area of Rajavithi Hospital).\n\nGiven the information provided, the patient seems to align with the health focus of the trial but lacks specific information regarding his location and ability to consent. With the available information, I would consider that further investigation is needed to determine if the patient lives in the required area and can provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1447": {
        "output": "To assess the eligibility of the 72-year-old male patient for the clinical trial titled \"PTA and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia\", we need to compare the patient's condition and history with the inclusion criteria provided for the trial.\n\nThe patient's symptoms suggest peripheral artery disease (PAD), manifesting as calf pain when walking uphill, which is characteristic of claudication. The presence of a carotid bruit, high blood pressure, cool extremities, and diminished pulses suggest vascular disease, which is consistent with PAD. However, the trial is specific to critical limb ischemia, which corresponds to Fontaine stages III and IV or Rutherford categories 4, 5, and 6. The patient's symptoms do not clearly indicate critical limb ischemia, such as ischemic rest pain, ulcers, or gangrene.\n\nGiven the information provided:\n- The patient is a male, so the criterion regarding pregnancy does not apply.\n- He is over 18 years old.\n- There is no mention of the patient's willingness or ability to comply with follow-up evaluations, but this could potentially be clarified with further investigation.\n- The patient's condition is not clearly defined as critical limb ischemia, which is necessary for eligibility.\n- There is no detailed data provided on the specific arterial lesions required by the trial (stenotic or occluded infrapopliteal artery with a lesion length \u2264 60 mm, and artery diameter requirements).\n\nConsidering the above points, the patient does not clearly meet the criteria of having critical limb ischemia or the specific arterial lesion characteristics. Therefore, there is not enough information to definitively refer this patient to the trial without further diagnostic information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1448": {
        "output": "Based on the patient note provided, the patient is a 72-year-old man who has symptoms consistent with peripheral arterial disease, as indicated by calf pain while walking uphill (claudication), a history of cardiovascular events (myocardial infarction and transient ischemic attack), and physical examination findings (cooler lower extremities and diminished pulses). He has not undergone any percutaneous coronary or peripheral vascular intervention as mentioned in the note, which is one of the inclusion criteria for the clinical trial. \n\nThe clinical trial in question is focused on the use of the SafeSeal(TM) Hemostasis Patch following percutaneous coronary artery and peripheral vascular interventions. To be eligible for the trial, a patient must meet the following inclusion criteria:\n\n1. Patient \u2265 18 years old\n2. Coronary or peripheral vascular intervention\n3. 6 French arterial sheath used\n4. Overnight hospitalization following the procedure\n\nThe patient does not meet the inclusion criteria of having undergone a percutaneous coronary or peripheral vascular intervention. Therefore, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1449": {
        "output": "Based on the information provided in the patient note, the 72-year-old man is experiencing calf pain when walking uphill, which suggests a potential vascular issue, such as peripheral artery disease (PAD). The patient's history includes myocardial infarction and transient ischemic attack. His physical examination notes high blood pressure, a carotid bruit, and cool extremities with diminished pulses, but there is no mention of chronic venous ulcers or the presence of necrotic tissue, which are required for the clinical trial in question.\n\nThe clinical trial is seeking participants with chronic venous ulcers for evaluating the DermastreamTM - EnzystreamTM system. The inclusion criteria for the trial are specific to individuals with venous leg ulcers and other criteria related to the characteristics and duration of the wound.\n\nComparing the patient's condition to the trial inclusion criteria:\n\n- The patient has no mention of venous leg ulcers.\n- The patient's age fits within the 18-85 years range.\n- There is no information provided on the clinical presentation of venous insufficiency by Doppler or Ankle-Brachial Index values.\n- The status of palpable pulses in the arteries mentioned is unclear; the note says they are diminished, which might not meet the criterion for \"good palpable pulses.\"\n- There's no mention of wound presence for at least 6 weeks or the specifics regarding wound size or necrotic tissue area.\n- The San Antonio classification of the wound is not provided.\n- There is no indication that the patient has a wound on the foot or calf where the device could be attached.\n\nGiven the lack of information on chronic venous ulcers and other necessary criteria, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1450": {
        "output": "",
        "label": 1
    },
    "1451": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's evaluate the patient's eligibility for the clinical trial titled \"Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia\":\n\nPatient Note Analysis:\n- The patient is a 72-year-old man, which meets the age criterion of being older than 18 years.\n- He complains of increasing calf pain when walking uphill, which is consistent with claudication symptoms.\n- The patient has a history of cardiovascular issues, including myocardial infarction and transient ischemic attack.\n- His blood pressure is elevated, and he has diminished pulses at the dorsalis pedis, which may indicate poor blood circulation in the extremities.\n- There is no mention of Ankle-Brachial Index (ABI) values, which is a specific measurement required by the trial's inclusion criteria.\n- It is not specified if the patient's condition is not amenable to surgical or percutaneous revascularization.\n\nClinical Trial Inclusion Criteria:\n- Males or females older than 18 years of age. (The patient is 72 years old, so this criterion is met.)\n- Limb ischemia with ABI of < 0.7 in the index lower extremity on two consecutive examinations at least 1 week apart. (Information on ABI is not provided in the patient note.)\n- Limb ischemia with resting ischemic pain and/or claudication at 100 meters and/or non-healing ulcers. (The patient has claudication symptoms, which meets this criterion.)\n- Patients not considered candidates for surgical or percutaneous revascularization. (The patient note does not provide information on whether the patient is a candidate for revascularization.)\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria, such as age and symptoms of claudication, but there is insufficient information to determine whether all criteria are met, particularly ABI values and candidacy for revascularization procedures. Therefore, additional information is required to make a final determination.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1452": {
        "output": "Considering the patient's characteristics and the inclusion criteria of the clinical trial, let's compare them:\n\nPatient's Characteristics:\n- 72-year-old man\n- Increasing calf pain when walking uphill for the past 3 months\n- History of myocardial infarction and transient ischemic attack\n- Hypertension with recent worsening\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination: Right carotid bruit, lower extremities slightly cool with diminished pulses at the dorsalis pedis\n\nClinical Trial Inclusion Criteria:\n- Aged 40 or older, male or female\n- 6-month history of walking limitation or symptoms of intermittent claudication in at least 1 lower limb\n- Diagnosis of PAD secondary to atherosclerosis\n- If ABI > 1.3 or cannot be measured, TBI \u2264 0.7 in at least 1 leg\n- Claudication severity and medications for CAD, PAD, and IC stable for 3 months prior to screening\n- On ETT, PWT of at least 1 min but no more than 12 min at Baseline\n- Willing to discontinue Pletal or Trental for 21 days before screening\n- Stable antihypertensive, cholesterol-lowering, chronic oral nitrates, and diabetic therapy for 30 days prior to screening\n- Willing and able to comply with all study-related procedures\n- Acceptable method of contraception if sexually active\n- Negative pregnancy test for females of childbearing potential\n\nThe patient's age and symptoms are consistent with the inclusion criteria. The patient has a history of walking limitation due to calf pain when walking uphill, which could be related to intermittent claudication. However, there is no explicit mention of a diagnosis of PAD secondary to atherosclerosis, nor is there information about the patient's ankle-brachial index (ABI) or toe-brachial index (TBI) results. Additionally, there is no information on whether the patient's medications for coronary artery disease and related conditions have been stable, which is required for the trial.\n\nGiven this information, the patient might potentially be eligible, but further investigation is needed to confirm details such as the diagnosis of PAD secondary to atherosclerosis, stability of symptoms and medications, and the results of ABI or TBI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1453": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient described does not fit the specific demographic requirement of being African American, which is a key inclusion criterion for the clinical trial. Additionally, the patient's hypertension is currently not described as Stage 2, which requires a mean sitting systolic blood pressure (MSSBP) \u2265 160 mmHg and < 200 mmHg. The patient's current blood pressure is 151/91 mm Hg, which is below the threshold for Stage 2 hypertension as specified in the trial's inclusion criteria.\n\nTherefore, the patient would not be eligible for this clinical trial based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1454": {
        "output": "",
        "label": 0
    },
    "1455": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- Age: 72 years old (meets age criteria of 18 to 90 years)\n- Gender: Male (gender is not a limiting factor in the criteria)\n- Condition: Patient complains of increasing calf pain when walking uphill, which is consistent with claudication pain typical of PAD.\n\nClinical information:\n- Patient has a history of myocardial infarction and transient ischemic attack, which are not exclusion criteria per se.\n- Symptoms of PAD appear to be present for more than 3 months but less than a year, which aligns with the criteria.\n- The patient is using isosorbide dinitrate, hydrochlorothiazide, and aspirin, with aspirin being mentioned in the trial criteria.\n- The patient has not been confirmed to have PAD by Doppler Ultrasound and Ankle-Brachial Pressure Index (ABPI \u2264 0.9 in one leg), which is a requirement for the trial.\n- There is no information provided on whether the patient has a stable PAD Fontaine Stage II or initial claudication distance as measured by a treadmill test.\n- There is no information about the state of the aortoiliac vessels or recent (<30 days) clinical examination to confirm no significant hemodynamic disturbances.\n- The patient's willingness to participate and undergo standardized walking exercise is not mentioned but can be ascertained upon further conversation with the patient.\n\nGiven that several key pieces of information are missing or not confirmed (such as diagnosis of PAD by Doppler Ultrasound and ABPI, PAD Fontaine Stage II status, aortoiliac vessel status, and initial claudication distance), the patient cannot be immediately referred for the trial.\n\nHowever, considering the patient's age, symptoms, aspirin treatment, and the absence of information that directly excludes him, further investigation is warranted to confirm PAD diagnosis and other criteria. Thus, the assessment will be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1456": {
        "output": "Based on the patient note, the patient is a 72-year-old man with symptoms consistent with lower limb ischemia, given his calf pain when walking uphill and the gradual increase in symptoms over the past three months. The presence of diminished pulses at the dorsalis pedis and slightly cool extremities further supports this. He also has a history of cardiovascular disease, as indicated by a previous myocardial infarction and a transient ischemic attack.\n\nThe clinical trial in question is focused on collecting tissue oxygenation data via hyperspectral imaging before and after endovascular procedures in patients with an established diagnosis of lower limb ischemia based on symptoms and vascular laboratory tests. The patient fits the age criterion of being between 50-85 years of age and is male, which aligns with the gender criteria.\n\nGiven that the patient's symptoms and the physical examination findings are suggestive of lower limb ischemia and the patient's age falls within the required range, he appears to meet the key inclusion criteria for the trial. However, to be certain of his eligibility, further vascular laboratory tests would be needed to establish the diagnosis officially as per the trial's inclusion criteria.\n\nGiven this information, the patient seems to be a good candidate for the trial, pending confirmation of the diagnosis of lower limb ischemia with appropriate tests.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1457": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease,\" we should compare the patient's characteristics and medical history with the inclusion criteria of the study.\n\nPatient Characteristics:\n- 72-year-old man\n- Experiencing calf pain when walking uphill, symptoms worsening over 3 months\n- History of myocardial infarction 2 years prior\n- Transient ischemic attack 6 months ago\n- Blood pressure recently worsened despite medication\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination findings: high blood pressure (151/91 mm Hg), pulse 67/min, right carotid bruit, cool extremities, diminished pulses at dorsalis pedis\n\nClinical Trial Inclusion Criteria:\n- Subjects with peripheral arterial disease for more than 6 months\n- Male or female with claudication secondary to lower extremity atherosclerotic arterial disease confirmed with ankle/brachial pressures \u2264 0.9 in one or both legs or who have had a previous intervention for peripheral arterial disease\n- Over 40 years old\n- Able to comply with protocol requirements\n- Able to provide informed consent\n- Subjects taking anti-platelet therapy medication must be on a stable dose for 3 months prior to as well as during the study\n- Subjects taking lipid-lowering medication must be on a stable dose for 3 months prior to as well as during the study\n\nBased on the patient's age (72 years old) and symptoms (calf pain when walking uphill, which is suggestive of claudication), it appears the patient may have peripheral arterial disease (PAD). However, there is no explicit mention of a diagnosis of PAD or results from an ankle-brachial index test to confirm the presence of the disease. The patient is also taking anti-platelet therapy (aspirin) and has a history of cardiovascular events, which aligns with the trial's focus on cardiovascular disease.\n\nHowever, because we do not have definitive evidence of PAD or the results of an ankle-brachial index test, it would be premature to refer the patient without further investigation to confirm PAD. Therefore, the patient may be eligible for the trial upon confirmation of PAD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1458": {
        "output": "Based on the patient note provided, the 72-year-old man is experiencing symptoms indicative of peripheral arterial disease (PAD), such as calf pain when walking uphill, a history of cardiovascular issues (myocardial infarction and transient ischemic attack), worsened blood pressure, and physical findings like a right carotid bruit, cool extremities, and diminished pulses in the lower extremities. These symptoms and findings could potentially align with a Rutherford Clinical Category Score of 1 - 6, which is part of the inclusion criteria for the clinical trial.\n\nHowever, no specific information about the degree of stenosis or occlusion in the target vessels, confirmation by angiography, or details about the lesion length, reference vessel diameter, or other specific criteria listed under the inclusion criteria for the study of SilverHawk\u00ae/TurboHawk\u00ae in Lower Extremity Vessels (DEFINITIVE\u2122 LE) have been provided.\n\nGiven that the symptoms and history suggest PAD and could potentially meet a Rutherford score of 1 - 6, the patient could be a candidate for the trial upon further investigation. Therefore, additional information, particularly an angiogram confirming the degree of stenosis and other detailed vascular assessments, would be necessary to fully determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1459": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 72-year-old man with cardiovascular issues, including a history of myocardial infarction and transient ischemic attack. He has symptoms suggestive of peripheral arterial disease as evidenced by calf pain when walking and diminished pulses in the lower extremities.\n\nThe clinical trial in question is focused on preterm infants with peripheral artery catheters and investigates the effects of blood sampling on cerebral oxygenation and blood flow using near infrared spectroscopy.\n\nThe inclusion criteria for the trial are:\n- Preterm infant (Gestational Age <37+0)\n- Peripheral arterial catheter (ulnary or radial artery)\n\nThe patient in the note does not meet the inclusion criteria because he is not a preterm infant with a gestational age of less than 37 weeks, nor does he have a peripheral arterial catheter in place for the purposes of the study. \n\nTherefore, the patient is not eligible for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1460": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 72-year-old man.\n- Complains of increasing calf pain when walking uphill over the past 3 months.\n- History of myocardial infarction 2 years prior and transient ischemic attack 6 months prior.\n- Worsening blood pressure despite medication.\n- On physical examination, high blood pressure and diminished pulses at the dorsalis pedis, which can be indicative of peripheral arterial disease (PAD).\n- There is no explicit mention of the patient having undergone surgery for peripheral arterial disease.\n\nClinical Trial Inclusion Criteria:\n- Peripheral arterial disease post surgery > 1 month.\n- No discharge of surgical incision.\n- Intermittent claudication post invasive treatment.\n\nAssessment:\n- The patient's symptoms are consistent with peripheral arterial disease, specifically intermittent claudication.\n- However, there is no mention in the patient note of the patient having undergone surgery for PAD, which is a requirement for the trial.\n- We would need confirmation of the patient's surgical history to determine eligibility.\n\nGiven the information provided, we do not have enough evidence to confirm the patient's surgical history for PAD. Thus, the patient's eligibility for this trial is uncertain without further investigation into their medical history, particularly regarding any invasive treatments for PAD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1461": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient Note Assessment:\n- The patient is a 72-year-old man.\n- He has a history of myocardial infarction and transient ischemic attack.\n- The patient has worsening blood pressure despite antihypertensive therapy with diltiazem, hydrochlorothiazide, and propranolol.\n- The patient is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin.\n- The patient's blood pressure is measured at 151/91 mm Hg, which is below the threshold outlined in the trial's criteria.\n- There is no indication that the patient has essential hypertension as the primary condition; rather, he has a history of other cardiovascular events.\n\nClinical Trial Inclusion Criteria:\n- Requires treatment with antihypertensive therapy and has a mean sitting clinic systolic blood pressure \u2265 160 and \u2264 190 mm Hg.\n- Females of childbearing potential must use contraception, not applicable to this patient as he is male.\n- Clinical laboratory test results within the normal range or not considered clinically significant by the investigator.\n- Willing to discontinue current antihypertensive medications up to 3 weeks before enrollment.\n\nComparison:\n- The patient's systolic blood pressure is 151 mm Hg, which is below the trial's requirement of at least 160 mm Hg.\n- The patient's medical conditions are not detailed regarding essential hypertension, and it is unclear if his hypertension is the primary issue or secondary to other conditions.\n- There is no information about the patient's willingness to discontinue his current antihypertensive medications, which is a requirement for the trial.\n\nGiven the information, the patient does not meet the blood pressure criteria for the trial, as his systolic blood pressure is below 160 mm Hg. Additionally, there is no clear indication that the patient has essential hypertension as his primary diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1462": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Gene Therapy for Painful Diabetic Neuropathy,\" let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- Age: 72 years\n- Medical history: Myocardial infarction, transient ischemic attack, hypertension\n- Current symptoms: Calf pain when walking uphill, high blood pressure, right carotid bruit, cool extremities, diminished pulses\n- Medications: Isosorbide dinitrate, hydrochlorothiazide, aspirin\n- No mention of diabetes or diabetic neuropathy\n\nClinical Trial Inclusion Criteria:\n- Age: 18 to 75 years (patient meets this criterion)\n- Documented history of Type I or II diabetes (patient's history does not mention diabetes)\n- Diagnosis of painful diabetic peripheral neuropathy in both lower extremities (patient's symptoms do not indicate diabetic neuropathy)\n- MNSI Score \u2265 3 at Screening (no information provided)\n- VAS score \u2265 4 cm at Screening (no information provided)\n- Stable treatment of diabetes for at least 3 months (patient's history does not mention diabetes treatment)\n- Lower extremity pain for at least 6 months (patient mentions calf pain, but no information on whether it is due to diabetic neuropathy)\n- If female, negative pregnancy test and contraception (not applicable to this male patient)\n\nThe patient does not have a documented history of diabetes, nor does the note indicate that the patient has been diagnosed with diabetic peripheral neuropathy. While the patient's age falls within the inclusion criteria, the key medical conditions required for the trial (diabetes and diabetic neuropathy) are not present in the patient's history. Therefore, based on the information provided, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1463": {
        "output": "",
        "label": 1
    },
    "1464": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- The patient is a 72-year-old man.\n- He experiences calf pain when walking uphill, which has been worsening over 3 months.\n- He has a history of myocardial infarction and transient ischemic attack.\n- His blood pressure is elevated despite medication.\n- Physical examination notes include a right carotid bruit and cool extremities with diminished pulses, suggesting some form of peripheral arterial disease (PAD).\n\nClinical Trial Inclusion Criteria:\n- Patients diagnosed with Fontaine grade II peripheral arterial disease (PAD).\n- Diagnosis confirmed by hemodynamic evaluation (Doppler ultrasound).\n- Patients must be over 18 years old.\n\nThe patient's symptoms are suggestive of peripheral arterial disease, which aligns with the condition being studied in the clinical trial. However, the patient note does not explicitly mention a confirmed diagnosis of Fontaine grade II PAD nor the results of a hemodynamic evaluation (Doppler ultrasound) to confirm the diagnosis.\n\nGiven the symptoms that match the target condition of the clinical trial (PAD) but without explicit confirmation of a Fontaine grade II PAD diagnosis, the patient would be considered for referral to the clinical trial upon further investigation to confirm the diagnosis of PAD and its grade.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1465": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Screening DIVA - Diffuse Vascular Disease,\" let's assess the eligibility of the patient:\n\nPatient Note Assessment:\n- The patient is a 72-year-old man, which satisfies the age requirement as no specific age range is given in the inclusion criteria.\n- The patient had an uncomplicated myocardial infarction 2 years earlier, which qualifies as an acute coronary syndrome (ACS).\n- The patient had a transient ischemic attack (TIA) 6 months ago, which is also listed in the inclusion criteria.\n- The patient complains of increasing calf pain when walking uphill, which could suggest symptoms of peripheral arterial disease (PAD), although PAD is not clearly documented in the patient's note.\n\nClinical Trial Inclusion Criteria:\n- Documented acute coronary syndrome (ACS) or/and documented ischemic stroke/transient ischemic attack (IS/TIA).\n\nThe patient's history of myocardial infarction (MI) and transient ischemic attack (TIA) matches the inclusion criteria for documented ACS and IS/TIA. Therefore, the patient appears to be eligible for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1466": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the criteria for participation in the trial. The inclusion criteria specify that participants must be healthy volunteers aged 20-30 years old with no cardiac, hepatic or renal, or peripheral vascular diseases. The patient is a 72-year-old man with a history of cardiovascular issues, including an uncomplicated myocardial infarction and a transient ischemic attack, and is currently experiencing calf pain potentially indicative of peripheral vascular disease. Additionally, the patient's current health conditions and medications suggest that he is not a healthy volunteer.\n\nTherefore, the patient does not meet the age requirement, is not a healthy volunteer, and has a history of cardiac and potential peripheral vascular diseases, which disqualifies him from participating in the study focused on limb ischemic preconditioning in healthy individuals.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1467": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility:\n\nPatient attributes:\n- 72-year-old man\n- Increasing calf pain when walking uphill (suggestive of claudication)\n- History of myocardial infarction and transient ischemic attack\n- Recent worsening of blood pressure despite medication\n- Medications: isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination findings: high blood pressure (151/91 mm Hg), right carotid bruit, cool lower extremities with diminished pulses\n\nClinical trial inclusion criteria for peripheral arterial disease participants:\n- Male or female, > 40 years of age (patient is 72 years old)\n- Documented peripheral arterial disease (PAD) including those with claudication or asymptomatic carotid stenosis of >50%, or previous intervention for PAD (patient has symptoms suggestive of claudication and possible carotid stenosis indicated by bruit)\n- Stable medication profile for the past 3 months with no changes anticipated (the patient had worsening blood pressure recently, which might have led to medication changes)\n- Willing to comply with the protocol requirements and provide informed consent (assumed)\n- Not having completed another food study within the last 3 months (unknown)\n\nClinical trial exclusion criteria for peripheral arterial disease participants:\n- Currently smoking, or smoking within the last 6 months (unknown)\n- Renal failure requiring dialysis (unknown)\n- Ongoing cardiovascular event or medical illness within the last 3 months (patient had a transient ischemic attack 6 months ago, which does not disqualify him)\n- Hormone replacement therapy (not applicable)\n- Amputation of leg, foot, arm, or hand; post mastectomy or post lymphadenectomy (not applicable)\n- History of gastrointestinal reactions or allergies to dietary oils and banana bread ingredients (unknown)\n- Inability to adhere to a regular diet (unknown)\n- Daily consumption of omega-3 supplements (unknown)\n\nThe patient's symptoms of calf pain when walking uphill and the findings of high blood pressure, right carotid bruit, and cool lower extremities with diminished pulses suggest he may have peripheral arterial disease, which is one of the conditions being studied in the trial. However, there are several unknowns, including recent medication changes, smoking status, dietary restrictions, and omega-3 supplement use, that would need to be clarified to determine eligibility fully.\n\nGiven the information at hand, the patient seems to meet several of the inclusion criteria for the clinical trial but also presents uncertainty regarding medication stability and other exclusions that are not addressed in the patient note.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1468": {
        "output": "Given the patient note and the clinical trial information, we can assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 72-year-old man\n- Complains of increasing calf pain when walking uphill\n- History of myocardial infarction and transient ischemic attack\n- Worsening blood pressure\n- Current medications include isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination: high blood pressure, right carotid bruit, slightly cool lower extremities with diminished pulses\n\nClinical trial summary:\n- Title: Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation\n- Purpose: Investigate if lower limb ischaemic preconditioning can improve renal function in patients undergoing living donor kidney transplantation\n- Inclusion Criteria: Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation, living donors, compatible ABO blood type, PRA < 20%\n\nThe patient described in the note does not have end-stage kidney disease nor is there any indication that he is undergoing or is a candidate for kidney transplantation. He also is not described as a living donor. Therefore, based on the provided information, the patient does not meet the inclusion criteria for the clinical trial focused on renal function in patients undergoing living donor kidney transplantation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1469": {
        "output": "Considering the patient note and the clinical trial information provided, the patient is a 72-year-old man with cardiovascular issues including a history of myocardial infarction and a transient ischemic attack. The clinical trial is focused on improving awareness and knowledge of cardiovascular disease in the African American community and requires participants to be African American adults over 18 years old.\n\nThe patient's age qualifies him as an adult over 18 years old, which matches the age requirement in the inclusion criteria of the clinical trial. However, there is no information provided in the patient note regarding the patient's race or ethnicity. To determine eligibility based solely on the information given, it is not possible to confirm whether the patient is African American or not. Therefore, it is not possible to definitively refer this patient without further information on their race or ethnicity.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1470": {
        "output": "Based on the information provided for the patient and the clinical trial, let's compare the patient's characteristics with the inclusion criteria for the clinical trial:\n\nPatient Characteristics:\n- Age: 72 years old\n- Medical History: Myocardial infarction, transient ischemic attack, hypertension\n- Current Symptoms: Increasing calf pain when walking uphill\n- Current Medications: Isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical Examination Findings: High blood pressure (151/91 mm Hg), right carotid bruit, cool lower extremities, diminished pulses at the dorsalis pedis\n\nClinical Trial Inclusion Criteria:\n- Essential hypertensive patient no less than 18 years old\n- Patient who gave informed consent\n\nThe patient is above 18 years old and has a history of hypertension, which is consistent with the trial's inclusion criteria for essential hypertension. Assuming the patient gives informed consent, he meets the trial's inclusion criteria.\n\nTherefore, the patient appears to be a good candidate for this trial, provided he is willing to participate and provides informed consent.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1471": {
        "output": "The patient in question is a 72-year-old man who has a history of myocardial infarction, which occurred 2 years prior, and a transient ischemic attack 6 months ago. His symptoms are consistent with peripheral arterial disease (calf pain when walking uphill), and he also exhibits signs of uncontrolled hypertension. The patient is on medication for heart disease and has a history of significant cardiovascular events.\n\nThe clinical trial is evaluating the effect of Rosuvastatin on coronary atherosclerosis plaque volume in patients with coronary heart disease (CHD) and hyperlipidemia. The inclusion criteria for the trial are:\n\n- Written informed consent\n- Men or women, aged 18 -75\n- Diagnosed with CHD stable angina for more than 1 month or has a history of myocardial infarction, or CHD confirmed by coronary angiography, or exercise ECG positive for CHD or perfusion defect\n- One or more main branch of coronary artery stenosis \u2265 50% confirmed by CT scanning\n- Hyperlipidemia (LDL-C levels depending on whether the patient is treatment-na\u00efve or has received treatment)\n- The 64 slice CT shows at least one significant coronary artery stenosis \u226520% with the narrowest \u226460% and other specified criteria\n\nThe patient meets several of the inclusion criteria:\n- He is within the age range specified (18-75 years old).\n- He has a history of myocardial infarction, which satisfies the CHD condition.\n- He likely has hyperlipidemia given his history of heart disease, but LDL-C levels are not provided in the patient note.\n\nHowever, there is no information provided regarding:\n- The patient's willingness or provision of informed consent.\n- The results of a 64 slice CT scan to confirm coronary artery stenosis and plaque characteristics.\n- Specific LDL-C levels to confirm hyperlipidemia according to the trial's definition.\n- Whether the patient's coronary artery condition meets the specific stenosis and plaque criteria outlined.\n\nGiven the matching points (age, history of myocardial infarction), and the potential for hyperlipidemia, the patient could be a candidate for the trial. However, additional information is needed, particularly the results of a CT scan to assess coronary artery plaque, and LDL-C levels to confirm hyperlipidemia according to the trial's standards.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1472": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Peripheral Perfusion Targeted Fluid Management,\" the patient's eligibility can be assessed as follows:\n\nThe patient is a 72-year-old man with symptoms that suggest peripheral arterial disease (increasing calf pain when walking uphill, a history of myocardial infarction, transient ischemic attack, and worsening blood pressure). Additionally, the physical examination findings (cool extremities, diminished pulses) support this.\n\nThe clinical trial is targeting adult patients admitted to the intensive care unit with hemodynamic instability due to severe sepsis, a mean arterial pressure < 65 mmHg, and an arterial lactate concentration > 3.0 mmol/L.\n\nThe patient described does not meet the inclusion criteria for the clinical trial because:\n1. There is no mention of the patient being admitted to the intensive care unit.\n2. There is no indication that the patient has severe sepsis.\n3. The patient's blood pressure is not < 65 mmHg.\n4. There is no information about the patient's arterial lactate concentration.\n\nBased on the available information, the patient does not fulfill the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1473": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess the patient note against the inclusion and exclusion criteria of the trial.\n\nPatient note summary:\n- 72-year-old man\n- Calf pain when walking uphill, worsening over 3 months\n- History of myocardial infarction 2 years ago\n- Transient ischemic attack 6 months ago\n- Worsening blood pressure, currently 151/91 mm Hg despite medication\n- Medications: isosorbide dinitrate, hydrochlorothiazide, aspirin\n- Physical examination: right carotid bruit, cool lower extremities, diminished pulses at dorsalis pedis\n\nClinical trial inclusion criteria:\n- Male or female\n- 60-85 years\n- Femoro-popliteal stenosis\n- TASC B or C category\n- HBA1c <9%, if diabetic\n- Creatinine <130\u00b5g/ml\n- Blood pressure <160/95mmHg\n- Thrombocyte aggregation inhibitors or coumarine derivatives\n\nClinical trial exclusion criteria:\n- <60 or >85 years\n- Stenosis not in femoro-popliteal axis\n- TASC A or D category\n- HBA1c >9%, if diabetic\n- Creatinine >130\u00b5g/ml\n- Blood pressure >160/95mmHg\n- Major trauma\n- Malignancy\n- Anti-phospholipid syndrome\n- Relevant hepatic disease\n- Major operation within 1 month of enrolment\n\nBased on the given information:\n\n- The patient is a 72-year-old man, which fits the age criterion (60-85 years).\n- The patient has calf pain which could be indicative of peripheral arterial disease, but there is no specific mention of femoro-popliteal stenosis, nor is it stated which TASC category the condition falls under. Further investigation would be needed to confirm this.\n- The patient's blood pressure is currently above the trial's cut-off (151/91 mm Hg vs. <160/95 mm Hg), but it is not significantly higher. This might be controllable with medication adjustments or could be a temporary elevation.\n- The patient is on aspirin, which is a thrombocyte aggregation inhibitor, meeting that criterion.\n\nHowever, without more detailed information on the following points, we cannot confirm the patient's eligibility:\n\n- Whether the patient's calf pain is due to femoro-popliteal stenosis and what TASC category it is\n- The patient's creatinine level\n- More comprehensive current medical management for blood pressure control\n\nTherefore, based on the available information, the patient's eligibility cannot be confirmed, but he is a potential candidate for the trial pending further investigation into his condition.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1474": {
        "output": "Based on the patient note provided, the 72-year-old man is experiencing calf pain when walking uphill, which has been gradually increasing over the past 3 months. This symptom may suggest peripheral arterial disease (PAD), and the presence of a carotid bruit and diminished pulses at the dorsalis pedis are clinical findings that support this hypothesis. His history of myocardial infarction and transient ischemic attack indicates a cardiovascular disease background.\n\nNow, let's consider the inclusion criteria for the clinical trial:\n\n1. The subject is over 18 years old.\n2. Subjects are referred to undergo a peripheral arteriography as part of their routine clinical care.\n\nThe patient fits the age criterion as he is 72 years old. The information provided does not specify whether the patient is scheduled to undergo peripheral arteriography, but given his symptoms and clinical findings, it is reasonable to consider that he may be referred for this diagnostic procedure as part of his routine clinical care.\n\nTherefore, based on the available information and assuming that peripheral arteriography could be indicated for further evaluation of his symptoms, the patient may be eligible for the clinical trial. However, the final decision would depend on the recommendation from his healthcare provider to undergo arteriography.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1475": {
        "output": "The given patient is a 72-year-old man with a history of cardiovascular issues, including a myocardial infarction and a transient ischemic attack. He complains of calf pain when walking uphill, which has been worsening over the past 3 months. His current medications indicate management of hypertension and heart disease but do not indicate diabetes management.\n\nThe clinical trial in question is focused on the treatment of painful diabetic neuropathy in patients with a documented history of Type I or II diabetes. The trial has specific inclusion criteria related to diabetes and diabetic neuropathy, including a current glycosylated hemoglobin A1c of \u2264 10.0%, diagnosis of painful diabetic peripheral neuropathy, pain duration, VAS score, BPNS symptoms, MNSI score, and stable treatment for diabetes.\n\nBased on the information provided in the patient note, there is no indication that the patient has diabetes or diabetic neuropathy. Instead, his symptoms suggest peripheral arterial disease, which is not the focus of the clinical trial.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial on the treatment of painful diabetic neuropathy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1476": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 72-year-old man\n- History of myocardial infarction and transient ischemic attack\n- Increasing calf pain when walking uphill\n- Blood pressure of 151/91 mm Hg despite medication\n- Right carotid bruit\n- Lower extremities slightly cool to the touch with diminished pulses at the dorsalis pedis\n\nClinical Trial Inclusion Criteria:\n- Men and non-pregnant, non-lactating women 45 years of age or older\n- Able to give informed consent and complete scheduled visits\n- Mild-moderate bilateral lower extremity peripheral arterial disease as defined by an ankle-brachial index (ABI) measurement of 0.6-0.9. If a subject has baseline claudication symptoms, the symptoms must be stable for the 3 months preceding enrollment.\n- History of hypertension. Blood pressure at the screening visit must be \u2264160/100 mmHg and \u2265100/60 mmHg for all subjects. If a subject is currently prescribed beta-blocker therapy, BP at the screening visit must be \u2264140/90 mmHg. In addition, heart rate must be \u226555 beats per minute if currently prescribed a beta-blocker and \u226460 beats per minute if not currently prescribed a beta-blocker.\n- At least moderate risk for CAD.\n\nComparison:\n- Age: The patient is 72 years old, satisfying the age criterion of being 45 years of age or older.\n- Informed Consent: The patient note does not indicate any issues with the patient's ability to give informed consent and complete scheduled visits.\n- Lower Extremity PAD: The patient has symptoms suggestive of peripheral arterial disease (calf pain when walking uphill and diminished pulses), but an ABI measurement is needed to confirm a diagnosis of mild-moderate PAD and to see if it falls within the specified range.\n- Hypertension: The patient has a history of hypertension, which is an inclusion criterion. The current blood pressure is high and outside the specified range if the patient is on a beta-blocker, but within range if not currently prescribed a beta-blocker. The patient note does not mention a current beta-blocker prescription.\n- Risk for CAD: The patient has had a myocardial infarction and transient ischemic attack, indicating at least a moderate risk for CAD.\n\nBased on the information provided, the patient meets several of the inclusion criteria for age, hypertension history, and risk for CAD. However, there are uncertainties regarding the patient's use of beta-blockers, the specific measurement of the ABI, and the stability of claudication symptoms. Therefore, further investigation is needed to confirm these aspects before a final decision on eligibility can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1477": {
        "output": "Based on the patient note provided, the 72-year-old man is experiencing calf pain when walking uphill, which has been worsening over the past 3 months. He has a history of myocardial infarction and a transient ischemic attack. His current symptoms and medical history suggest vascular issues; however, there is no specific mention of him needing lower limb vascular bypass surgery at this moment.\n\nThe clinical trial in question is investigating the prevalence of bacteria in vascular surgery wounds perioperatively to see if it correlates with the incidence of wound infections postoperatively. The inclusion criteria specifically mention the need for lower limb vascular bypass surgery.\n\nGiven the information in the patient note, there is no indication that the patient is scheduled for or requires lower limb vascular bypass surgery, only that he has symptoms that could be associated with vascular issues. Without explicit information about a planned or needed bypass, we cannot definitively say that the patient meets the inclusion criteria based on the provided note.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1478": {
        "output": "Based on the patient note provided, the 72-year-old man does not meet the inclusion criteria for the clinical trial titled \"Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit.\" The patient is not currently admitted to the Intensive Care Unit (ICU), nor is there an indication that his treating clinicians have determined the need for both a central venous line and an arterial line, which are specified as requirements in the inclusion criteria.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1479": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 72-year-old man\n- Increasing calf pain when walking uphill, worsening over 3 months\n- Past medical history includes an uncomplicated myocardial infarction 2 years ago and a transient ischemic attack 6 months ago\n- Worsening blood pressure despite medication\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- On examination: high blood pressure, cool extremities, diminished pulses, right carotid bruit\n\nClinical Trial Inclusion Criteria:\n- Age > 17 years\n- Stable angina pectoris, patient electively referred for coronary angiography\n- Written informed consent to participate in the study\n\nClinical Trial Exclusion Criteria:\n- Acute coronary syndrome; unstable cardio-pulmonary conditions\n- Congestive heart failure NYHA III-IV\n- Previous coronary bypass surgery\n- Q-wave myocardial infarction in the area undergoing CFI measurement\n- Anatomical variants not allowing coronary sinus occlusion\n- Severe valvular heart disease\n- Severe hepatic or renal failure (creatinine clearance < 15ml/min)\n- Pregnancy\n\nAssessment:\n- The patient is over 17 years old, meeting the age criterion.\n- The patient has a history of myocardial infarction, but it was 2 years ago and is described as uncomplicated, so it does not necessarily indicate an acute coronary syndrome or unstable cardio-pulmonary condition at present.\n- The patient's calf pain when walking uphill could suggest claudication, which may be related to peripheral artery disease rather than stable angina pectoris. However, a detailed assessment would be necessary to determine if the patient's cardiac condition could be classified as stable angina pectoris.\n- The patient has not been stated to have previously undergone coronary bypass surgery or have severe valvular heart disease, severe hepatic or renal failure, or be pregnant, which helps to meet some of the exclusion criteria.\n- The description does not provide enough information to determine if the patient has congestive heart failure NYHA III-IV, anatomical variants, or a Q-wave myocardial infarction in the area undergoing CFI measurement.\n\nGiven that the patient's symptoms and medical history suggest a complexity that may not align perfectly with the trial's focus on stable angina pectoris and the lack of information on some exclusion criteria, further investigation would be required to determine trial eligibility. For instance, it would be essential to confirm whether the calf pain is indeed due to peripheral artery disease or possibly related to stable angina, and whether the patient's myocardial infarction or transient ischemic attack affects eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1480": {
        "output": "Patient Note Analysis:\n- The patient is a 72-year-old man, which meets the age criterion of being greater than 18 years.\n- He complains of calf pain when walking uphill, which has been worsening over the past 3 months.\n- The patient has a history of myocardial infarction and a transient ischemic attack, suggesting underlying vascular disease.\n- He has high blood pressure and diminished pulses in the lower extremities, which may indicate peripheral artery disease.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age greater than 18 years: The patient is 72 years old, which meets this criterion.\n- Patient willing to give full informed consent for participation: There is no information given about the patient's willingness, but we can assume that if informed, the patient could decide to consent.\n- Patients undergoing elective carotid endarterectomy or patients undergoing open abdominal aortic aneurysm repair or patients undergoing endovascular abdominal aneurysm repair or patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal): The patient note does not specify that the patient is currently scheduled for any of these procedures, but the presence of a right carotid bruit and the symptoms described may suggest that he could be a candidate for a carotid endarterectomy or other vascular surgery.\n\nBased on the information provided in the patient note, it seems that the patient could potentially be a candidate for vascular surgery due to his symptoms and history of vascular disease. However, without explicit mention of a scheduled surgery, we cannot be certain of the patient's eligibility for the clinical trial, which is specifically targeting patients scheduled for major vascular surgery.\n\nGiven the information available, the patient's eligibility is not clear-cut. Further investigation would be needed to determine whether the patient is scheduled for or could be considered for one of the surgeries mentioned in the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1481": {
        "output": "",
        "label": 0
    },
    "1482": {
        "output": "The patient in question is a 72-year-old man with a history of cardiovascular issues, including an uncomplicated myocardial infarction and a transient ischemic attack. His current symptoms are increasing calf pain when walking uphill, which could be related to peripheral arterial disease, given the cool extremities and diminished pulses at the dorsalis pedis. He is taking medications for his cardiovascular conditions.\n\nThe clinical trial in consideration is investigating the potential nephroprotective effects of remote ischemic preconditioning in patients undergoing contrast-enhanced abdomino-pelvic CT scanning. The inclusion criteria for this trial specify that participants must be hospital inpatients undergoing contrast-enhanced abdomino-pelvic CT scanning. There is no mention of any specific age, gender, or pre-existing conditions that would exclude a patient from participating.\n\nBased on the information provided, the patient seems to be an outpatient, and there is no indication that he is scheduled for or requires a contrast-enhanced abdomino-pelvic CT scan. Therefore, he does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1483": {
        "output": "Based on the patient note provided, the patient is a 72-year-old man who experiences increasing calf pain when walking uphill, which has been gradually worsening over the past 3 months. This indicates the possibility of intermittent claudication. Additionally, the patient has a history of cardiovascular issues, including an uncomplicated myocardial infarction and a transient ischemic attack.\n\nComparing this information with the inclusion criteria of the clinical trial titled \"Obstructive Sleep Apnoea in Patients With Intermittent Claudication,\" we can assess the following:\n\n1. The patient is older than 18 years old.\n2. The patient has symptoms suggestive of intermittent claudication.\n3. The patient is likely registered to social health insurance, as he is under medication for his conditions, although this is not explicitly stated.\n4. There is no information provided about his maximal walking distance, but given the description of his symptoms, it might be less than 750m.\n5. There is no indication the patient cannot understand the protocol of the study.\n\nGiven that the patient fits most of the inclusion criteria but we need more information regarding his maximal walking distance and his registration to social health insurance, the trial-level eligibility for referring the patient to this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1484": {
        "output": "The patient note describes a 72-year-old man with symptoms that suggest peripheral arterial disease (increasing calf pain when walking uphill, cool extremities, diminished pulses) and a history of cardiovascular events (myocardial infarction, transient ischemic attack). He is currently being treated for hypertension and had a previous issue with blood pressure control.\n\nThe clinical trial in question is retrospectively analyzing the relationship between traditional cardiovascular risk factors (hypertension, obesity, dyslipidemia, and diabetes) and hand or knee osteoarthritis, comparing these results to a control group with soft tissue disease.\n\nInclusion criteria for the clinical trial are:\n- Patients referred for symptomatic hand or knee osteoarthritis\n- All patients referred in the same period for soft tissue disease\n- Patients who are over 50 years old\n\nThe patient in the note does not mention having hand or knee osteoarthritis or soft tissue disease, which are key inclusion criteria for the clinical trial. Although the patient is over 50 years old and likely has cardiovascular risk factors (a criterion indirectly related to the study's focus), he does not fulfill the primary condition of having osteoarthritis or being a control patient with soft tissue disease. Therefore, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1485": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies,\" let's analyze the eligibility:\n\nPatient Note:\n- A 72-year-old man with increasing calf pain when walking uphill, symptoms have increased over the past 3 months.\n- History of myocardial infarction and transient ischemic attack.\n- Worsening blood pressure despite medication.\n- On examination, high blood pressure, right carotid bruit, cool extremities, and diminished pulses at the dorsalis pedis.\n\nClinical Trial Inclusion Criteria:\n- A positive history of chronic claudication.\n- Exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon.\n- An ankle/brachial index < 0.90 at rest.\n\nComparison:\n- The patient's symptoms of calf pain when walking, which could be indicative of claudication, align with the trial's focus on leg dysfunction due to claudication.\n- The patient's history of vascular issues and current symptoms suggest a likelihood of peripheral arterial disease (PAD), which is associated with claudication.\n- However, to confirm eligibility, the patient would need to undergo a screening walking test to establish exercise-limiting claudication and have an ankle/brachial index measurement taken to confirm it is < 0.90 at rest.\n\nGiven the patient's symptoms that suggest claudication and his vascular history, there is a good chance that he meets the criteria after further testing. Thus, the patient is potentially eligible for the trial pending the necessary clinical assessments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1486": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 72-year-old man.\n- He has experienced calf pain when walking uphill, which has increased over 3 months.\n- He had an uncomplicated myocardial infarction 2 years earlier.\n- He had a transient ischemic attack 6 months ago.\n- His hypertension has worsened despite medication.\n- He is currently on isosorbide dinitrate, hydrochlorothiazide, and aspirin.\n- Physical examination shows high blood pressure (151/91 mm Hg), a right carotid bruit, and cool extremities with diminished pulses, suggesting vascular disease.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on Korean patients at high risk for cardiovascular disease.\n- Inclusion criteria relevant to the patient could include:\n  - High risk hypertension patients with target organ damage (eGFR > 60 or eGFR <= 60 not specified for the patient).\n  - Atherosclerotic cardiovascular disease (presence of carotid bruit and symptoms suggestive of peripheral arterial disease could imply this, but specific tests like ankle-brachial index, carotid plaque/intima-media thickness measurement, or coronary artery stenosis are not mentioned).\n\nGiven the patient's history of myocardial infarction, transient ischemic attack, worsening hypertension, and physical signs suggestive of vascular disease, it appears he may have atherosclerotic cardiovascular disease, which is one of the inclusion criteria for the clinical trial. However, specific measurements like the ankle-brachial index, carotid plaque/intima-media thickness, or confirmation of stenosis in coronary arteries are not provided. There is also no mention of whether the patient is Korean, which seems to be a focus of the study.\n\nGiven these considerations, the patient could potentially be eligible for the trial, but further investigation to confirm the specifics of his atherosclerotic cardiovascular disease would be necessary before making a referral. Additionally, the focus on Korean patients may or may not be a limiting factor depending on the patient's ethnicity, which is not specified.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1487": {
        "output": "The patient note describes a 72-year-old man who presents with increasing calf pain when walking uphill, which has gradually worsened over the past 3 months. This symptom is characteristic of intermittent claudication, a common manifestation of Peripheral Arterial Disease (PAD). The patient also has a history of myocardial infarction, a transient ischemic attack, and worsening blood pressure despite medication, indicating cardiovascular issues that may be related to PAD. Physical examination findings such as a right carotid bruit and cool extremities with diminished pulses further support the suspicion of PAD.\n\nThe clinical trial in question is looking to recruit adults over the age of 18 with symptomatic PAD (either critical limb ischemia or intermittent claudication) caused by more than 50% stenosis or occlusion of infrainguinal arteries and who are eligible for endovascular treatment.\n\nGiven that the patient appears to have symptoms consistent with intermittent claudication and possible infrainguinal arterial disease (which would need to be confirmed with further diagnostics such as imaging), he meets the age criteria and has symptomatic PAD, which makes him a potential candidate for the SWEDEPAD 2 study, part of the Swedish Drug-elution Trial in Peripheral Arterial Disease. However, complete eligibility would need confirmation of the diagnosis with imaging to ensure that his PAD is due to >50% stenosis or occlusion of infrainguinal arteries and that he is eligible for endovascular treatment.\n\nTherefore, based on the information provided in the patient note, the patient is likely to be eligible for this clinical trial, pending confirmation of his PAD diagnosis and the specific arterial involvement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1488": {
        "output": "",
        "label": 0
    },
    "1489": {
        "output": "The patient in question is a 72-year-old man with a history of cardiovascular issues including an uncomplicated myocardial infarction and a transient ischemic attack. He presents with increasing calf pain when walking uphill, which has been worsening over the past 3 months. He has a right carotid bruit and diminished pulses at the dorsalis pedis, which could be indicative of peripheral arterial disease. The patient's symptoms suggest that he may have underlying vascular issues, which could potentially make him a candidate for vascular surgery.\n\nThe clinical trial is investigating the use of remote ischemic preconditioning (RIPC) to reduce complications from major vascular surgery. The inclusion criteria for the trial are:\n- Age greater than 18 years\n- Patient willing to give full informed consent for participation\n- Patients undergoing elective carotid endarterectomy or\n- Patients undergoing open abdominal aortic aneurysm repair or\n- Patients undergoing endovascular abdominal aneurysm repair or\n- Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)\n\nBased on the patient note, the patient has not yet been indicated for any of the specific surgical procedures listed in the inclusion criteria of the trial. However, given the patient's symptoms and history of cardiovascular issues, it is plausible that he may be evaluated for and potentially require one of the mentioned surgeries, particularly if further investigation reveals significant arterial disease that would necessitate intervention.\n\nAt this point, the patient has not been scheduled for any of the surgeries that would make him eligible for the trial. Therefore, it is not possible to highly likely refer him without further information regarding his treatment plan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1490": {
        "output": "Based on the patient note provided, the 72-year-old man is experiencing calf pain when walking uphill, which has been worsening over the past three months. He has a history of cardiovascular events, including an uncomplicated myocardial infarction and a transient ischemic attack. His current symptoms and the presence of a carotid bruit, as well as diminished pulses in the lower extremities, suggest peripheral arterial disease (PAD). The elevated blood pressure and the fact that his extremities are cool to the touch with diminished pulses further support this.\n\nThe clinical trial in question is investigating the effects of supervised exercise therapy with risk factor management and lifestyle coaching for patients with PAD, specifically for those at Rutherford stage 4 and 5. Rutherford stages 4 and 5 refer to patients with chronic limb-threatening ischemia, with stage 4 being characterized by pain at rest and stage 5 involving minor tissue loss.\n\nWhile the patient note does not explicitly state the Rutherford stage of the patient's PAD, the description of increasing calf pain during exertion (which may suggest claudication) and the absence of any mention of rest pain or tissue loss (which would be typical of stages 4 and 5) suggest that the patient might not be at the specific stages required for inclusion in the trial.\n\nHowever, given the patient's symptoms and history, further evaluation would be necessary to accurately determine the Rutherford stage and whether the patient's PAD could benefit from vascular intervention. As such, additional information such as imaging results and assessment by a vascular specialist would be required to make a definitive eligibility determination.\n\nBased on the information provided and the need for further investigation to ascertain the patient's Rutherford stage:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1491": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 72-year-old man with a history of myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Currently, he complains of increasing calf pain when walking uphill, which suggests symptoms of peripheral arterial disease rather than ongoing myocardial infarction. His current condition does not match the specific criteria for the clinical trial, which requires:\n\n- Male or non-pregnant female.\n- Age \u2265 18 years old and <80 years old (the patient meets this criterion).\n- Hospitalization with documented evidence of ST-Segment Elevation Myocardial Infarction (STEMI) receiving Percutaneous Coronary Intervention.\n- Persistent \u22650.2 Millivolt ST segment elevation in two or more contiguous precordial leads or \u22650.1 Millivolt ST elevation in two or more contiguous limb leads, with one of the following: persistent chest pain or elevation of biomarkers of myocardial necrosis.\n- Time from chest pain onset to receiving Percutaneous Coronary Intervention <12 hours.\n- Persistent chest pain <12 hours.\n- Provision of informed consent prior to any study-specific procedures.\n\nThe patient does not meet the criteria for an active or recent STEMI patient currently receiving percutaneous coronary intervention (PCI) nor does he exhibit persistent chest pain or recent chest pain onset. As such, the patient does not fit the inclusion criteria for the clinical trial on Ticagrelor and Clopidogrel.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1492": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- A 72-year-old man\n- Complains of calf pain when walking uphill\n- History of myocardial infarction and transient ischemic attack\n- Worsening blood pressure despite medication\n- Medications include isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination findings: high blood pressure, carotid bruit, cool extremities, diminished pulses\n\nClinical Trial Inclusion Criteria:\n- Established diagnosis of non-ischemic dilated cardiomyopathy\n- Ejection fraction (EF) < 35%\n- NYHA functional class (f.c.) II - IV\n- Optimal medical management for > 6 months\n- Age between 18 and 75 years\n\nThe patient's symptoms and history suggest vascular issues, potentially peripheral artery disease, given the calf pain when walking and the physical examination findings. There is no mention of dilated cardiomyopathy or heart failure symptoms that would be associated with NYHA functional class II - IV criteria. Additionally, the patient has a history of myocardial infarction, which points to ischemic heart disease rather than non-ischemic dilated cardiomyopathy.\n\nBased on the available information, the patient does not meet the inclusion criteria of having a diagnosis of non-ischemic dilated cardiomyopathy nor the NYHA functional class required. Although the patient's age falls within the required range, the other criteria are not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1493": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial.\n\nPatient note summary:\n- 72-year-old man\n- Increasing calf pain when walking uphill, worsening over 3 months\n- History of myocardial infarction 2 years earlier\n- Transient ischemic attack 6 months ago\n- Worsening blood pressure despite medication\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination: high blood pressure, carotid bruit, cool extremities, diminished pulses\n\nClinical trial inclusion criteria summary:\n- At least 18 years old\n- Documented symptomatic atherosclerotic disease in specific arteries\n- Undergone clinically indicated uncomplicated endovascular intervention\n- Estimated survival \u22651 year\n- Pre-index procedure use of ASA (aspirin), clopidogrel, or both\n\nComparison:\n- The patient is over 18 years old.\n- The patient has symptoms that could be suggestive of peripheral arterial disease (PAD), given the calf pain when walking and diminished pulses. However, it is not explicitly stated that the patient has a documented symptomatic atherosclerotic disease, which is a requirement for the trial.\n- There is no mention of the patient having undergone an endovascular intervention.\n- The patient is on aspirin, which aligns with the pre-index procedure use of ASA.\n- The patient's estimated survival is not discussed, but there are no immediate indicators that it would be less than a year.\n\nGiven the information available, the patient does not clearly meet all the inclusion criteria for the trial. Specifically, there is no documentation provided that he has symptomatic atherosclerotic disease as required by the trial, nor is there mention of him having undergone an endovascular intervention. Therefore, further investigation would be needed to determine if the patient's calf pain is indeed due to PAD and if he has had or is a candidate for an endovascular intervention.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1494": {
        "output": "Based on the patient note provided, the 72-year-old man is experiencing calf pain when walking uphill, which has been increasing over the past 3 months. He has a history of an uncomplicated myocardial infarction and a transient ischemic attack. His current symptoms, along with the physical examination findings of high blood pressure, a right carotid bruit, cool lower extremities, and diminished pulses at the dorsalis pedis, suggest that he may have peripheral arterial disease (PAD), which is characterized by symptoms like claudication and can be associated with diminished pulses in the extremities.\n\nThe clinical trial provided is a post-market study in Japan for the Zilver Flex device, which is intended for symptomatic peripheral arterial disease (PAD) involving the above-the-knee femoropopliteal arteries. The inclusion criteria specifically mention symptomatic PAD involving the above-the-knee femoropopliteal arteries.\n\nWhile the patient's symptoms are consistent with PAD, there are some considerations before determining his eligibility for the trial:\n\n1. The trial is a post-market study in Japan, and there is no indication that the patient is in Japan or has access to the study location.\n2. The symptoms described might be consistent with PAD, but there is no explicit confirmation that the PAD involves the above-the-knee femoropopliteal arteries as required by the trial's inclusion criteria.\n3. The patient has a history of cardiovascular issues, which may or may not be relevant to the study's inclusion criteria but would need to be considered in the context of the full study protocol.\n\nTherefore, this patient could be potentially eligible for the study, but further investigation is needed to confirm the specifics of his PAD diagnosis and whether he would have access to the trial location in Japan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1495": {
        "output": "",
        "label": 2
    },
    "1496": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient note summary:\n- 72-year-old man\n- Complains of increasing calf pain when walking uphill\n- History of myocardial infarction and transient ischemic attack\n- Worsening blood pressure despite medication\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical examination findings: high blood pressure, right carotid bruit, cool lower extremities, diminished pulses\n\nClinical trial summary:\n- Title: Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty\n- Investigates the effect of remote ischemic preconditioning (RIPC) on restenosis rate post angioplasty\n- Inclusion criteria: Patients planned for lower limb angioplasty\n- Exclusion criteria: Upper limb PVD, history of upper limb DVT, use of glibenclamide or nicorandil, Raynaud's Disease, intraoperative decision to use a graft\n\nThe patient's symptoms, especially the calf pain when walking uphill and diminished pulses in the lower extremities, may suggest peripheral arterial disease (PAD), which could potentially require lower limb angioplasty. However, the patient note does not explicitly mention that the patient is planned for lower limb angioplasty, which is a specific inclusion criterion for the clinical trial.\n\nAlso, there are no indications that the patient meets any of the exclusion criteria such as known upper limb PVD, previous history of upper limb DVT, being on glibenclamide or nicorandil, or having Raynaud's Disease.\n\nTherefore, this patient might be a candidate for referral to this clinical trial upon further investigation to confirm the need for lower limb angioplasty. The decision is not definitive without additional information regarding the patient's treatment plan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1497": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Phase 3 Gene Therapy for Painful Diabetic Neuropathy\" involves comparing the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nBased on the patient note provided, here are the relevant points to consider:\n\n- The patient is a 72-year-old man, which fits within the age range specified in the trial inclusion criteria (18 to \u2264 75 years).\n- There is no mention of type I or II diabetes in the patient's history, which is a requirement for the trial.\n- The patient's complaint is of calf pain when walking uphill, but there is no indication that this is due to diabetic peripheral neuropathy.\n- The patient has a history of myocardial infarction and transient ischemic attack, but there is no mention of diabetic complications.\n- The patient's medications include isosorbide dinitrate, hydrochlorothiazide, and aspirin, but there is no mention of medications specifically for diabetes, such as oral, injectable, or insulin treatments.\n- There is no information provided about the patient having painful diabetic peripheral neuropathy, lower extremity pain for at least 6 months, VAS score, BPNS, or MNSI Score.\n\nThe inclusion criteria specifically require a documented history of type I or II diabetes with current treatment control and a diagnosis of painful diabetic peripheral neuropathy in both lower extremities, among other details. Since the patient note does not provide any evidence that this patient has diabetes or diabetic neuropathy, he does not meet the essential criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1498": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Ischaemic PReconditioning In Non Cardiac surgEry,\" let's evaluate the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 72-year-old man, which meets the age criterion (age \u2265 18 years).\n- The patient has a history of myocardial infarction and transient ischemic attack, indicating he has a cardiac history but the trial is in a non-cardiac surgery setting.\n- The patient's symptoms of calf pain when walking uphill could suggest peripheral arterial disease, which may require surgery that could be classified as non-cardiac surgery.\n- The patient's medications include isosorbide dinitrate and aspirin, which are indicative of ongoing antiplatelet therapy.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent.\n- Intermediate and high-risk non-cardiac surgery.\n- General anesthesia.\n- Ongoing or recently suspended antiplatelet therapy.\n\nBased on the information given, the patient could potentially be eligible for the trial if:\n1. They provide written informed consent.\n2. They are scheduled for or may require intermediate or high-risk non-cardiac surgery.\n3. The surgery would involve general anesthesia.\n4. Their ongoing antiplatelet therapy aligns with the trial's criteria.\n\nIt is not explicitly stated that the patient is scheduled for non-cardiac surgery or that they would be undergoing general anesthesia, but given the patient's cardiovascular complications and the possibility of surgery for the calf pain, there is potential for eligibility upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1499": {
        "output": "Based on the patient note provided, the 72-year-old man has complaints that align with symptoms of peripheral arterial disease (PAD), such as increasing calf pain when walking uphill and diminished pulses at the dorsalis pedis, indicating poor arterial circulation to his lower extremities. His age is over 18, which meets one of the inclusion criteria for the clinical trial.\n\nHowever, the inclusion criteria for the clinical trial specifically require a patient to be suffering from PAD with a systolic pressure index between 0.60 and 0.75, along with moderate venous insufficiency or classified as C1s to C4 using the CEAP classification. The patient note does not provide specific information about the systolic pressure index or the CEAP classification of venous insufficiency for this patient. Therefore, we cannot definitively determine whether the patient meets these particular inclusion criteria based on the information given.\n\nAdditionally, the clinical trial requires the patient to have French health insurance and to have signed informed consent. There is no information provided regarding the patient's health insurance status or his willingness to sign informed consent.\n\nGiven the lack of specific information on some key inclusion criteria, the eligibility of this patient for the clinical trial cannot be confirmed without further investigation. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1500": {
        "output": "Based on the information provided, the patient is a 72-year-old man who presents with increasing calf pain when walking uphill, a history of myocardial infarction, a transient ischemic attack, and worsening blood pressure. The clinical trial in question is looking for adults with congenital heart disease to determine risk factors for acquired heart disease.\n\nThe inclusion criteria for the clinical trial are:\n1. Male or Female over 18 years of age\n2. Moderate or Complex Congenital Heart Disease\n3. Willingness to Consent\n\nThe patient's note does not mention any congenital heart disease. Instead, it describes a history of acquired cardiovascular events such as myocardial infarction and transient ischemic attack. Therefore, the patient does not meet the explicit inclusion criteria related to the type of heart disease required for the study (congenital heart disease).\n\nGiven the lack of information suggesting the patient has a moderate or complex congenital heart disease, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1501": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication, we can assess the patient's eligibility as follows:\n\n- The patient is a 72-year-old man, which meets the age criterion of being above the age of 18 years.\n- The patient complains of increasing calf pain when walking uphill, which could be indicative of mild intermittent claudication, although this would need to be confirmed with a diagnosis.\n- The patient's blood pressure is 151/91 mm Hg, which is considered under moderate control according to the trial's criteria of < 160/100 mmHg.\n- There is no mention of current foot ulceration in the patient's note, so we can assume the patient does not have this exclusionary condition.\n\nWhile the information provided suggests that this patient could potentially be eligible for the trial, the diagnosis of mild intermittent claudication needs to be confirmed. Hence, further investigation is required to determine the patient's suitability for the trial, particularly to verify the diagnosis of intermittent claudication.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1502": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 72-year-old man, which satisfies the age criterion of being over 21 years of age.\n- The patient has symptoms that could be indicative of peripheral arterial disease (PAD), such as calf pain when walking uphill and diminished pulses in the lower extremities. However, there is no explicit mention of PAD diagnosis or requirement for angiography or angioplasty in the note.\n- The patient has a history of cardiovascular issues, including myocardial infarction and transient ischemic attack. While patients with PAD often have comorbidities, there is no direct link made in the patient note between these conditions and PAD.\n- The patient note does not mention chronic kidney disease (CKD) or provide estimated glomerular filtration rate (eGFR) levels.\n\nClinical Trial Inclusion Criteria:\n- Elective intra-arterial peripheral angiography/angioplasty is required.\n- Patients must be over 21 years of age, which our patient satisfies.\n- Patients must have CKD as evidenced by specific eGFR levels.\n\nThe patient's age meets the trial's age criterion, but there is no information on whether the patient has CKD or what his eGFR levels might be. Additionally, while the patient might have symptoms suggestive of PAD, there is no confirmation of a PAD diagnosis or an indication that the patient is scheduled for elective intra-arterial peripheral angiography/angioplasty.\n\nGiven the lack of information regarding the patient's CKD status, eGFR levels, and the specific requirement for elective intra-arterial peripheral angiography/angioplasty, it does not seem appropriate to refer this patient to the clinical trial at this time. Further investigation would be needed to assess the patient's renal function and confirm a PAD diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1503": {
        "output": "",
        "label": 0
    },
    "1504": {
        "output": "",
        "label": 0
    },
    "1505": {
        "output": "Given the patient note and the clinical trial details, let's evaluate the patient's eligibility based on the inclusion criteria provided:\n\nInclusion Criteria for the Clinical Trial:\n1. Give informed consent, assent, and documentation of patient authorization for disclosure of study results.\n2. Assent from the patient must be obtained (as applicable following state regulations) and written informed consent obtained from the parent or legal guardian.\n3. Age > = 6 months -12 years.\n4. A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the clinical signs and symptoms compatible with tonsillitis and/or pharyngitis.\n5. A positive rapid screening test for S. pyogenes (enzyme immunoassay; SiGNIFY\u2122 Strep A Test).\n6. Patient is an appropriate candidate for oral antibiotic therapy and can swallow the study dosage forms.\n7. Females must be non-lactating and, if of childbearing potential and sexually active, must have a negative prestudy urine pregnancy test and be utilizing acceptable birth control methods throughout the study.\n\nAssessment Based on Patient Note:\n1. The patient is a 2-year-old boy, which satisfies the age criterion (6 months - 12 years).\n2. The patient has a high fever and irritability, which could be indicative of tonsillitis or pharyngitis.\n3. The patient exhibits signs of conjunctivitis, strawberry tongue, and cervical lymphadenopathy. Strawberry tongue is listed in the inclusion criteria.\n4. There is no mention of a positive rapid screening test for S. pyogenes in the patient note, which is required for inclusion.\n5. The symptoms described in the patient note, particularly the high fever, conjunctivitis, inflammation of the hands and feet, desquamation of the skin, and enlarged liver, suggest a diagnosis that is more consistent with Kawasaki disease rather than acute tonsillitis or pharyngitis.\n6. There is no indication that the patient is unable to swallow oral medication, but this would need to be confirmed.\n\nIn conclusion, although the patient falls within the correct age range and has some symptoms that overlap with those listed in the inclusion criteria, the overall clinical picture suggests a different diagnosis (possibly Kawasaki disease) rather than acute tonsillitis or pharyngitis. Moreover, the absence of a positive rapid screening test for S. pyogenes means this patient would not meet all of the inclusion criteria for the clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1506": {
        "output": "Based on the information provided, the patient is a 2-year-old boy showing symptoms consistent with Kawasaki Disease, which is relevant to the clinical trial in question. However, the inclusion criteria for the clinical trial specify that participants must be between the ages of 4 and 16. Since the patient is only 2 years old, he does not meet the age requirement for the trial.\n\nThe patient's symptoms and the presence of coronary artery changes on the echocardiogram are consistent with Kawasaki Disease, which is the focus of the clinical trial. However, eligibility cannot be established solely based on the disease presence due to the specific age range required by the trial's inclusion criteria.\n\nTherefore, despite the patient's condition aligning with the disease under study, the age requirement is a critical exclusionary factor. Based on this, the patient would not be eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1507": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it appears that the patient does not meet the necessary criteria for the study. The patient is a 2-year-old boy with symptoms consistent with Kawasaki disease, as suggested by the high fever, conjunctivitis, strawberry tongue, inflammation of the extremities, desquamation, and cervical lymphadenopathy. The trial in question is looking for participants with a DSM-IV Axis II diagnosis of mental retardation who have behavioral disorders that have not improved with psychological therapy and are learning disabled children.\n\nThe patient's presentation does not indicate a behavioral disorder, a diagnosis of mental retardation, or that he has been treated with behavioral and family therapy. Additionally, the patient's age falls outside of the typical school age, and there is no information suggesting that the patient has a score of >=8 on a hostility scale or that he is in school at least part-time.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1508": {
        "output": "The patient note describes a 2-year-old boy with symptoms and lab findings consistent with acute Kawasaki Disease (KD). The clinical trial is investigating the use of Infliximab (Remicade) for patients with acute Kawasaki Disease.\n\nLet's evaluate the patient's eligibility based on the inclusion criteria of the clinical trial:\n\n1. All eligible subjects, or legal representative, must provide written informed consent/assent - The patient is a minor, so the legal representative (parents) can consent.\n2. Eligible subjects will be infants and children, under 18 years old, with acute KD - The patient is 2 years old and has acute KD.\n3. Remain or become febrile after IVIG infusion - The patient's fever history is not clearly stated in relation to IVIG treatment.\n4. Persistent or reoccurrence of fever > 48 hours of observation - The patient's fever history is not clearly stated.\n5. Prior to IVIG treatment, patients must have been febrile for \u2265 3 days and have met 4/5 standard clinical criteria or have 3/5 criteria with a Z score of > 2 on echocardiogram - The patient has been febrile for 5 days and meets the clinical criteria, and the echocardiogram shows coronary artery anomalies.\n6. Present for initial diagnosis and IVIG treatment within the first 14 days after fever onset - The patient's timeline of fever onset to presentation is not provided.\n7. Females of childbearing potential and males must use adequate contraception - This is not applicable to the 2-year-old patient.\n8. Chest radiograph within one week prior to first infusion with no evidence of malignancy, infection, or fibrosis - This information is not provided.\n\nExclusion criteria to consider:\n\n- No evidence suggests the patient has been receiving corticosteroids at doses > 1 mg/kg prednisone equivalent daily, has a history of TB or TB exposure, has a history of histoplasmosis or coccidiomycosis, has received certain medications within 1 month prior to study drug administration, has any chronic disease other than those specified, has a history of certain infections or received a transplanted organ, has a known malignancy or history of malignancy, has multiple sclerosis, has received any previous treatment with infliximab or other monoclonal antibodies, has used any investigational drug within specified time frames, is participating in another investigative trial, has a history of substance abuse, is pregnant or nursing or planning pregnancy, has a known allergy to murine proteins or other chimeric proteins, or has ischemic congestive heart failure.\n\nBased on the available information:\n\n- The patient is a child under 18, with acute KD, which fits the primary inclusion criteria. \n- However, some details are missing, such as confirmation of fever after IVIG infusion, the timeline of fever onset to presentation, and a chest radiograph prior to the infusion. These missing pieces of information are crucial to fully determine the eligibility of the patient.\n\nGiven this, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1509": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- A 2-year-old boy with high fever and irritability for 5 days.\n- Symptoms include conjunctivitis, strawberry tongue, inflammation of hands and feet, desquamation of the skin of fingers and toes, and cervical lymphadenopathy.\n- Enlarged liver, elevated liver enzymes, high white blood cell count, low albumin, elevated C-reactive protein and erythrocyte sedimentation rate, mild normochromic, normocytic anemia, and leukocytes in urine.\n- Echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.\n\nClinical Trial Inclusion Criteria:\n- History of Kawasaki disease more than 12 months before enrollment.\n- Present age of 8 years or older.\n\nThe patient is a 2-year-old boy, which does not meet the age requirement of 8 years or older for the clinical trial. Furthermore, the inclusion criteria specify that the history of Kawasaki disease must be more than 12 months before enrollment. The patient's current symptoms and presentation suggest that he may be in the acute phase of Kawasaki disease, not having a history of the disease for more than 12 months.\n\nTherefore, based on the criteria provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1510": {
        "output": "Based on the information provided for the patient and the clinical trial:\n\nPatient Note:\n- A 2-year-old boy\n- High fever and irritability\n- Conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation, cervical lymphadenopathy, abdominal tenderness, enlarged liver\n- Elevated liver enzymes, white blood cell count, low albumin, high C-reactive protein and ESR, anemia, leukocytes in urine\n- Moderate dilation of the coronary arteries with possible coronary artery aneurysm on echocardiogram\n\nClinical Trial:\n- Title: New Treatment for Donor Sites\n- Inclusion Criteria:\n  - Ages 0-90 years\n  - Any patient admitted to the hospital with burn injury requiring grafting and a donor site\n\nThe patient presented does not fit the inclusion criteria for the clinical trial as there is no mention of a burn injury or the requirement for grafting and a donor site. The patient's symptoms and the medical situation described in the note do not align with the conditions being studied in the trial, which is focused on the treatment of donor sites in burn injury patients.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1511": {
        "output": "The patient presented is a 2-year-old boy with symptoms consistent with a systemic inflammatory condition, possibly Kawasaki disease, given the fever, conjunctivitis, strawberry tongue, skin desquamation, and enlarged liver. The patient's condition has no apparent relation to the focus of the clinical trial, which is studying the effects of omalizumab in individuals with cat allergies.\n\nLooking at the inclusion criteria for the clinical trial:\n\n- Ability to understand and provide informed consent: A 2-year-old cannot provide informed consent.\n- Male or Female (non-pregnant), age 18-50: The patient is 2 years old, which is below the required age range of 18-50 years.\n- Clinical history of seasonal or perennial allergic rhinitis for at least two years, with or without mild persistent asthma: There is no information provided about the patient having a history of allergic rhinitis or asthma.\n- Positive tests for cat allergen response (skin test, Immunocap, intranasal challenge, in vitro assay): There is no indication the patient has been tested for cat allergens, nor that allergies are a concern in this clinical picture.\n\nGiven the patient does not meet multiple critical inclusion criteria, specifically age and diagnosis, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1512": {
        "output": "Based on the information provided, the patient, a 2-year-old boy, presents with high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the fingers and toes, cervical lymphadenopathy, abdominal tenderness with an enlarged liver, and some abnormal laboratory findings including elevated liver enzymes, high white blood cell count, low albumin, elevated C-reactive protein, and erythrocyte sedimentation rate. The echocardiogram suggests possible coronary artery aneurysm. \n\nThe clinical trial in question is focused on the treatment of strep throat in children with a specific set of inclusion criteria. The patient must have evidence of acute pharyngitis/tonsillitis with specific accompanying symptoms and a positive test for Group A Beta-Hemolytic Streptococcus (GABHS).\n\nThe patient note does not describe symptoms specific to acute pharyngitis/tonsillitis or a positive test for GABHS, which are required for inclusion in the clinical trial. Instead, the symptoms and findings suggest a different clinical picture, which may be consistent with a condition such as Kawasaki disease, given the presence of fever, conjunctivitis, strawberry tongue, rash, and coronary artery dilation.\n\nTherefore, based on the provided information, the 2-year-old boy would not meet the inclusion criteria for the clinical trial on the treatment of strep throat in children.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1513": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, it's clear that the patient does not meet the requirements for participation in the study. The patient is a 2-year-old boy with symptoms that are not related to rheumatoid arthritis (RA), which is the focus of the trial. The trial is specifically looking to observe patients who are 18 years of age or older with a diagnosis of RA as per the ACR criteria, are eligible for anti-TNF therapy, na\u00efve to anti-TNF\u03b1 drugs, and have certain radiographic assessments. \n\nThe patient's symptoms suggest a diagnosis that is not RA, and he is significantly younger than the minimum age requirement for the trial. Therefore, the patient is not eligible for referral to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1514": {
        "output": "The patient note describes a 2-year-old boy with symptoms highly suggestive of Kawasaki Disease, including high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, tenderness and an enlarged liver, elevated alanine aminotransferase, white blood cell count, and other inflammatory markers. Furthermore, the echocardiogram findings of moderate dilation of the coronary arteries with possible coronary artery aneurysm are consistent with the cardiovascular complications often seen in Kawasaki Disease.\n\nComparing the patient's details with the inclusion criteria of the clinical trial:\n\n1. Age: The patient is a 2-year-old boy. The trial includes males aged from 2 months to 20 years. This patient falls within the age range specified.\n\n2. Gender: The trial includes both male and female participants fitting specific age criteria. Since the patient is male, he meets this criterion.\n\n3. Provision of Parental Consent: Although not explicitly stated, the fact that the patient is brought in by his parents implies that parental involvement is present, which would likely allow for parental consent to be provided.\n\n4. Kawasaki Disease Presentation: The patient's clinical presentation is highly suggestive of Kawasaki Disease, which fits the disease focus of the trial.\n\nGiven the provided information, the patient appears to meet all the inclusion criteria for the clinical trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1515": {
        "output": "The patient in the note provided is a 2-year-old boy with symptoms that suggest a diagnosis of Kawasaki disease, indicated by high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, skin desquamation, cervical lymphadenopathy, and changes in the coronary arteries.\n\nThe clinical trial in question is seeking to enroll hypertensive patients to collect data on the long-term safety and effectiveness of Micombi Tablets in Japan. The inclusion criteria are simply that the patients must be hypertensive and have never taken Micombi Tablets.\n\nGiven that the patient is a 2-year-old boy with no mention of hypertension and the trial is looking for hypertensive patients who have never taken Micombi Tablets, the patient does not meet the inclusion criteria for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1516": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 2-year-old boy with symptoms indicating a high fever, irritability, and signs consistent with Kawasaki disease (conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, tender abdomen with enlarged liver, elevated inflammatory markers, etc.). There is also mention of coronary artery involvement, which is a complication of Kawasaki disease.\n\nClinical Trial:\n- The clinical trial is focused on the prevention of major adverse cardiac events (MACE) in hypercholesterolemia patients with concomitant type 2 diabetes and hypertension.\n- Inclusion criteria include being 50 years of age or older, having hypercholesterolemia, type 2 diabetes, hypertension, and other specified risk factors.\n\nThe 2-year-old boy does not meet the inclusion criteria for the clinical trial. The patient is not within the age range required (50 years or older), nor is there any indication that he has type 2 diabetes, hypercholesterolemia, or hypertension, which are the primary conditions being studied in the clinical trial.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1517": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 2-year-old boy would not be eligible for the PALACE 3 clinical trial. The trial is specifically for patients with psoriatic arthritis, and participants must be at least 18 years of age. The patient in the note is 2 years old and there is no mention of psoriatic arthritis; instead, the symptoms described are more consistent with a condition like Kawasaki disease, given the high fever, conjunctivitis, strawberry tongue, desquamation of fingers and toes, and possible coronary artery aneurysm.\n\nTherefore, this patient does not meet the age requirement, does not have a diagnosis of psoriatic arthritis, and does not meet any of the other specific criteria outlined for the clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1518": {
        "output": "Based on the information provided, the patient is a 2-year-old boy, which fits within the age range (6 months through 11 years) specified in the inclusion criteria of the clinical trial. However, the patient presents with symptoms and laboratory findings consistent with a diagnosis that does not align with the condition being studied in the clinical trial, which is perennial allergic rhinitis (PAR). The patient's symptoms such as high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation, cervical lymphadenopathy, and echocardiographic findings suggest a diagnosis that is potentially Kawasaki disease, a condition characterized by inflammation of the blood vessels and not related to PAR.\n\nGiven the available information, there is no indication that the patient has perennial allergic rhinitis. Additionally, the trial requires patients specifically diagnosed with PAR, and there is no mention of allergic symptoms or diagnosis in the patient's note. Therefore, this patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1519": {
        "output": "The patient is a 2-year-old boy presenting with symptoms indicative of a serious condition, possibly Kawasaki disease, given the high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, and coronary artery changes. However, these symptoms do not align with the clinical trial's focus, which is on PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) and the use of IVIG for treatment.\n\nThe inclusion criteria for the clinical trial specify:\n\n1. Male and female children 4-13 years of age.\n2. Presence of DSM-IV TR OCD with or without a tic disorder.\n3. Moderate or greater severity of OCD symptoms.\n4. The acute onset of symptoms within the previous six months.\n5. Symptom onset or exacerbation preceded by a Group A streptococcal infection (GAS).\n6. Onset/exacerbation of OCD is accompanied by at least three of seven specified clinical signs and symptoms.\n\nThe patient is only 2 years old, which is below the minimum age of 4 years required by the trial. Additionally, there is no mention of OCD or tic disorder symptoms, or any indication of a preceding GAS infection that would be associated with PANDAS. Based on the provided patient note, the patient does not meet the critical inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1520": {
        "output": "The patient is a 2-year-old boy with symptoms and clinical findings suggestive of a systemic inflammatory condition, possibly Kawasaki disease, given the high fever, conjunctivitis, strawberry tongue, changes in extremities, cervical lymphadenopathy, elevated inflammatory markers, and changes in the coronary arteries.\n\nThe clinical trial in question is for the Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA). The inclusion criteria for this trial require subjects to be male or female, aged \u2265 18 years at the time of consent, have a documented diagnosis of Psoriatic Arthritis (PsA) of \u2265 3 months duration, meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at the time of screening, and have \u2265 3 swollen AND \u2265 3 tender joints, among other specific requirements.\n\nThe patient described does not meet the inclusion criteria for this clinical trial for several reasons:\n\n1. Age: The patient is 2 years old, whereas the trial requires participants to be \u2265 18 years old.\n2. Disease: The patient does not have a diagnosis of Psoriatic Arthritis. Instead, the patient's symptoms suggest a different inflammatory condition.\n3. Treatment History: The trial specifies criteria regarding previous treatments with disease-modifying antirheumatic drugs (DMARDs), which are not relevant to this patient's case.\n\nGiven these discrepancies, it is clear the patient does not fit the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1521": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 2-year-old boy does not meet the age requirement for the trial, which specifies participants should be aged between 20 and 80 years old. Additionally, the clinical condition described (high fever, irritability, conjunctivitis, strawberry tongue, inflammation of hands and feet, desquamation, cervical lymphadenopathy, liver enlargement, and possible coronary artery aneurysm) does not match the target condition for the trial, which is focused on proximal gastric cancer.\n\nThe patient's symptoms and clinical findings are suggestive of a condition unrelated to proximal gastric cancer, and the patient is far below the minimum required age. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1522": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient in question is a 2-year-old boy with symptoms consistent with Kawasaki disease (KD). The clinical trial is looking for adults who had a history of Kawasaki disease before the age of 18. The inclusion criteria specifically state that participants must be 18 years old or older at the time of the study.\n\nSince the patient in the note is only 2 years old, he does not meet the age requirement for the clinical trial. Therefore, he would not be eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1523": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 2-year-old boy\n- High fever and irritability for 5 days\n- Conjunctivitis, strawberry tongue, inflammation of hands and feet, desquamation of fingers and toes, cervical lymphadenopathy\n- Tender abdomen and enlarged liver\n- Elevated laboratory markers suggestive of inflammation and infection\n- Echocardiogram shows coronary artery changes\n\nClinical Trial Inclusion Criteria:\n- Male and Female subjects three (3) years of age or older\n- Patients exhibiting at least 3 of the following symptoms:\n  - Fever\n  - Sore throat\n  - Swollen lymph nodes in the neck\n  - Redness of the throat and tonsils\n  - White or yellow patches on the tonsils\n- Must be able to collect 2 throat swab samples from patient\n\nAssessment:\n- The patient is only 2 years old, which is below the minimum age requirement of 3 years for the clinical trial.\n- The patient's symptoms are not specifically described as a sore throat, redness of the throat and tonsils, or white or yellow patches on the tonsils, which are required for the trial.\n- The patient does have fever, but there is no mention of a sore throat or other specific throat-related symptoms that match the trial's inclusion criteria.\n- The patient's primary symptoms and diagnosis do not seem related to a Group A Streptococcus (Strep A) infection, which is what the trial is evaluating.\n\nBased on the above points, the patient does not meet the age requirement and does not exhibit enough of the specific symptoms that are listed in the inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1524": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the 2-year-old boy does not meet the specified inclusion criteria for the Sofia Strep A FIA Field Study. The inclusion criteria focus on symptoms related to Group A Streptococcus infection, particularly those affecting the throat such as sore throat, redness of the posterior pharyngeal wall, tonsillar exudate, tonsillar swelling, tender anterior cervical adenopathy, and fever.\n\nWhile the patient does present with fever and cervical lymphadenopathy, the other symptoms listed in the inclusion criteria, such as sore throat, redness of the posterior pharyngeal wall, tonsillar exudate, and tonsillar swelling, are not mentioned in the patient note. Moreover, additional symptoms provided in the patient's case, such as conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, and coronary artery anomalies, suggest a different medical condition, which is not targeted by the clinical trial in question.\n\nTherefore, the patient's overall presentation does not match the symptom profile being studied in the trial, and the patient is not a candidate for this specific research study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1525": {
        "output": "Based on the patient note provided, the 2-year-old boy appears to have Kawasaki disease, indicated by symptoms such as high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy. The patient also has signs of systemic inflammation with elevated acute phase reactants and normocytic anemia, which are consistent with this diagnosis.\n\nComparing the patient's characteristics to the inclusion criteria of the clinical trial titled \"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease\":\n\n1. The patient has been diagnosed with Kawasaki disease and presents with more than 5 of the 6 major symptoms of Kawasaki disease.\n2. There is no information provided on whether the patient is refractory to initial IVIG therapy, which is a key inclusion criterion for the trial.\n3. The patient has a high fever, which meets the fever criterion of the inclusion criteria.\n4. There is no information on the day of the disease the patient is currently on, which is relevant to determine if the study drug can be administered by day 8 of the disease.\n\nGiven that the patient meets some but not all known inclusion criteria, there are critical pieces of information missing that are needed to determine trial eligibility fully. Specifically, we need to know if the patient has received and is refractory to IVIG treatment and if it's still within the timeframe to administer the study drug (by day 8 of the disease).\n\nTherefore, the eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1526": {
        "output": "Given the details in the patient note, the 2-year-old boy has a presentation that is consistent with Kawasaki disease (KD), which includes symptoms like high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy. Additionally, the echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm, which is a complication associated with KD.\n\nThe clinical trial's inclusion criteria for the treatment arm include patients aged 1 month to 21 years with confirmed KD who meet certain criteria related to coronary artery dilation or aneurysms during the acute febrile phase of KD or who have refractory KD after initial treatment with IVIG and dilated coronary arteries during the first month of KD. The patient note indicates the presence of coronary artery dilation, which could meet the trial's criteria for coronary artery involvement during the acute febrile phase of KD.\n\nBased on the patient note and the trial's inclusion criteria, it appears that the 2-year-old boy could potentially be eligible for the clinical trial. However, the specific z-score of the coronary artery dilation is not mentioned, which is necessary to confirm eligibility according to the trial's specified inclusion criteria for coronary artery dilation beyond a z-score of +2.5.\n\nTherefore, with the information provided, it would be necessary to investigate further to obtain the exact measurements of the coronary artery dilation to confirm eligibility. The patient's age falls within the range specified by the trial, and the presence of coronary artery dilation during the acute phase of KD suggests that the patient may be a candidate for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1527": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Management of Drug Hypersensitivity in Children,\" the patient does not appear to meet the specific inclusion criteria for the trial. The patient note describes a case with symptoms that could be consistent with Kawasaki disease, given the high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation, cervical lymphadenopathy, elevated inflammatory markers, and changes in the coronary arteries. There are no indications in the patient note that the symptoms are related to drug hypersensitivity or that the patient has taken any drugs that could have caused such a reaction.\n\nThe inclusion criteria for the trial specify that participation will be proposed to children (0 to 16 years) who are receiving one or several drugs and have developed clinical manifestations linked to drug allergies such as urticaria, maculopapular rash, bullous eruption, flush, anaphylaxis, serum sickness-like disease, SJS, TEN, DRESS, or fever linked to drug intake. Since there is no mention of the child taking any medications or having symptoms specifically related to drug hypersensitivity, this patient would not meet the criteria for inclusion in this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1528": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, the 2-year-old boy would not be eligible for the clinical trial. The trial is specifically for patients with immune thrombocytopenia (ITP) who are aged 19 or older and have a platelet count below 20x10^9/L. The patient in the note is only 2 years old, does not have ITP (no mention of thrombocytopenia, and the symptoms are indicative of Kawasaki disease), and there is no information regarding his platelet count. \n\nTherefore, it is clear that this patient does not meet the age or disease criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1529": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, it becomes clear that the patient does not meet several of the specified requirements for the trial:\n\n- The patient is a 2-year-old boy, which is below the age range of 18-50 years required by the trial.\n- The trial specifies the need for a negative urine pregnancy test for females; however, this is not applicable to the patient as he is male.\n- The patient must have completed a physical exam, ECG, medical history, and blood test within the last year, but there is no information provided to confirm whether this patient has met these requirements.\n- The inclusion criteria also mention the need for the patient to meet specific demographic requirements for the device under study and to provide written informed consent. Given the patient's age, he would not be able to provide informed consent, and his parents or guardians would have to provide consent on his behalf.\n\nGiven the age discrepancy and lack of information regarding the other requirements, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1530": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the 2-year-old boy's clinical manifestations align closely with the diagnostic criteria for Kawasaki Disease (KD) as described for the clinical trial. The patient presents with a high fever for 5 days, conjunctivitis, strawberry tongue, changes in the extremities (inflammation of the hands and feet, desquamation of the skin of the fingers and toes), and cervical lymphadenopathy. Additionally, the echocardiogram shows coronary artery abnormalities, which are significant for KD.\n\nThe clinical trial's inclusion criteria specifically mention that cases were included if the patients had at least five of the six clinical manifestations or at least four signs together with coronary abnormalities documented by echocardiography or coronary angiography, which this patient has.\n\nTherefore, given that the patient's presentation is consistent with the inclusion criteria for the Kawasaki Disease clinical trial, the trial-level eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1531": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility step by step according to the inclusion criteria:\n\n1. Age and Weight: The inclusion criteria state that patients at any age \u2265 3 months (5 kg) of life can participate. The patient is a 2-year-old boy, which meets the age requirement. However, the patient's weight is not provided, but we can assume a 2-year-old boy would typically weigh more than 5 kg.\n\n2. Diagnosis: The patient must have Kawasaki Disease (KD) according to the American Heart Association definition for complete or incomplete KD. The patient note indicates symptoms consistent with Kawasaki Disease, such as fever, conjunctivitis, strawberry tongue, changes in extremities, and cervical lymphadenopathy.\n\n3. Clinical Signs: The patient has a fever for more than 5 days and at least 4 of the 5 main clinical signs, which is consistent with the trial's inclusion criteria for KD.\n\n4. Coronary Abnormalities: The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm, which suggests coronary abnormalities that can be associated with KD.\n\n5. Response to Standard Treatment: The inclusion criteria specify patients who failed to respond to standard therapy of KD. The patient note does not mention any previous treatment with intravenous immunoglobulins (IV Ig), so we cannot determine if the patient has failed standard treatment.\n\n6. Informed Consent: The patient is a minor, so informed consent must be provided by a parent or legal guardian. The patient note does not specify whether consent has been obtained.\n\n7. Health Insurance: The patient must have health insurance, which is not mentioned in the patient note.\n\n8. Contraception: Since the patient is a 2-year-old boy, the requirement for effective contraception does not apply.\n\nBased on the available information:\n\n- The patient meets the age criteria.\n- The patient shows symptoms consistent with KD.\n- The patient has coronary abnormalities suggestive of KD.\n- There is no information on treatment response or health insurance.\n\nDue to missing details about the patient's response to standard therapy and health insurance, the patient's eligibility cannot be fully determined without further investigation. Therefore, the trial-level eligibility will be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1532": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Different Doses of IVIG for Kawasaki Disease,\" let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 2-year-old boy, which fits within the 1 month to 12 years old age range required by the trial.\n- The symptoms described in the patient note (high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the fingers and toes, and cervical lymphadenopathy) are consistent with those of Kawasaki Disease.\n- There is no mention of previous treatment for Kawasaki Disease in the patient note, which aligns with the inclusion criterion that the patient should not have received treatment prior to the study.\n- The patient has laboratory findings and echocardiogram results that support the diagnosis of Kawasaki Disease (elevated inflammatory markers, coronary artery abnormalities).\n\nClinical Trial Inclusion Criteria Analysis:\n- Diagnosis of KD confirmed using the diagnostic criteria issued by the Japan Kawasaki Disease Research Committee.\n- The patient's age fits the criteria (1 month to 12 years old).\n- There is no mention of informed consent in the patient note, but this is typically obtained after the patient is considered for inclusion in a trial, so the absence of this information does not preclude eligibility.\n- The patient has not received treatment before, as per the inclusion criteria.\n\nGiven the information provided, the patient appears to meet all of the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1533": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for the trial. The patient is a 2-year-old boy, and the trial requires patients to be 18 years or older. Furthermore, there's no mention of the patient having clinically documented cirrhosis or being coagulopathic, nor is there any note of the patient undergoing an endoscopic or neurosurgical procedure. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1534": {
        "output": "Based on the information provided, the 2-year-old boy does not meet the inclusion criteria for the clinical trial focused on the effects of freeze dried strawberry powder supplementation on vascular function and blood markers of cardiovascular risk. The inclusion criteria specify that participants must be men and women aged 35-65 years, have a certain BMI range, specific levels of LDL cholesterol, total cholesterol, and triglycerides, be non-smokers, and have blood pressure within a certain range.\n\nThe patient in the note is a 2-year-old boy, which is well below the minimum age requirement of 35 years. Additionally, no information on the BMI, lipid levels, smoking status, or blood pressure of the boy is provided, but these criteria are irrelevant as the age criterion alone disqualifies him from participation.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1535": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to assess the following factors to determine the patient's eligibility for the trial:\n\n1. Age: The trial is for children 0-18 years, and the patient is a 2-year-old boy, so he meets this criterion.\n2. Condition: The trial is for group A streptococcal blistering distal dactylitis.\n3. Diagnostic test: The trial requires a positive rapid Group A Streptococcus test.\n4. Consent: Informed consent needs to be signed by the parents.\n\nThe patient note describes a 2-year-old boy with symptoms that do not clearly indicate blistering distal dactylitis. Instead, the symptoms described \u2013 high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, and possible coronary artery aneurysm \u2013 are more consistent with Kawasaki disease, which is a completely different condition.\n\nFurthermore, there is no mention of distal blistering dactylitis or a positive rapid Group A Streptococcus test in the patient note. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1536": {
        "output": "Based on the patient note, we have a 56-year-old female presenting with shortness of breath and malaise post-mastectomy. The physical examination and elevated D-dimer are suggestive of a possible pulmonary embolism (PE), which is a condition where one or more arteries in the lungs become blocked by a blood clot.\n\nThe clinical trial in question is the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), which aims to evaluate the diagnostic tools for pulmonary embolism. The inclusion criteria for this trial are men and women suspected of having a pulmonary embolism and who meet the criteria to undergo angiography.\n\nGiven that the patient's presenting symptoms and laboratory findings are suggestive of a pulmonary embolism, and there is a need to confirm this diagnosis, she appears to meet the criteria for the PIOPED clinical trial. Therefore, she would likely be considered for angiography to confirm the diagnosis of PE, which aligns with the trial's inclusion criteria.\n\nThus, my assessment would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1537": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria of the trial, we need to compare the patient's characteristics and condition with the criteria listed.\n\nPatient characteristics from the note:\n- 56-year-old female\n- Post-left mastectomy (20th-day post-operation)\n- Symptoms: Shortness of breath, malaise\n- Physical examination: Tenderness on the left upper thoracic wall and right calf\n- Laboratory tests: Elevated D-dimer\n- The patient is not explicitly stated to have advanced breast cancer that has failed prior chemotherapy or hormone therapy\n- There is no information provided about CNS metastases, performance status, life expectancy, hematopoietic, hepatic, or renal function values\n- No history of heparin-associated thrombocytopenia is mentioned\n- No information on thromboembolic phenomena unless the tenderness in the right calf and elevated D-dimer suggest a recent thromboembolic event such as a deep vein thrombosis (DVT)\n\nClinical trial inclusion criteria:\n- Advanced breast, lung, colorectal, or prostate cancer that has failed prior chemotherapy or hormone therapy\n- No active CNS metastases\n- Age 18 and over\n- Performance status: ECOG 0-2\n- Life expectancy: At least 12 weeks\n- Adequate hematopoietic, hepatic, and renal function\n- No history of heparin-associated thrombocytopenia\n- At least 1 year since prior thromboembolic phenomenon\n\nBased on the information provided, the patient does seem to have breast cancer, but there is no detail indicating that the cancer is advanced or has failed prior chemotherapy or hormone therapy. Additionally, the elevated D-dimer could suggest a possible thromboembolic event, which if recent, could disqualify the patient due to the criteria stating that there must be at least 1 year since a prior thromboembolic phenomenon.\n\nGiven the lack of detailed information and potential recent DVT suggested by the patient's symptoms and elevated D-dimer, the patient may not meet all the necessary inclusion criteria for the clinical trial. However, further investigation would be required to confirm the patient's cancer status, treatment history, and other eligibility criteria such as performance status, life expectancy, and laboratory values.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1538": {
        "output": "Given the patient's presentation of shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, as well as an elevated D-dimer, there is a concern for venous thromboembolism (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE). The clinical trial is focused on the incidence and outcomes of VTE in Olmsted County, Minnesota, from 1966 through 1990.\n\nThe inclusion criteria for the clinical trial are not specified in the information provided. This means that potentially any patient could be considered for inclusion in the study regardless of their specific medical condition, as long as the study's broader aim aligns with their diagnosis or suspicion thereof.\n\nGiven the lack of specific inclusion criteria and the patient's clinical presentation that is highly suggestive of VTE, I would assume that this patient could potentially be relevant to the clinical trial's aims. However, without explicit inclusion criteria, it is important to be cautious. It would be necessary to clarify with the trial organizers whether this patient's recent surgical history and clinical presentation match the populations they are looking to study.\n\nConsidering the information we have:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1539": {
        "output": "Based on the patient note, the 56-year-old female patient is presenting with symptoms suggestive of thromboembolic events (shortness of breath, malaise, tenderness in the calf, and elevated D-dimer), which are concerning for complications such as deep vein thrombosis or pulmonary embolism following a mastectomy.\n\nHowever, the inclusion criteria for the \"ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)\" specify that patients must be scheduled for primary elective unilateral total hip arthroplasty and must have given written informed consent to participate in the study.\n\nThe patient described in the note does not meet the inclusion criteria, as she is not scheduled for a hip arthroplasty but is rather presenting with symptoms post-mastectomy. Therefore, she is not eligible for this clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1540": {
        "output": "Given the information provided in the patient note and the inclusion criteria for the clinical trial, we can determine the patient's eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 56-year-old female, which satisfies the age criterion of the trial (age \u2265 18 years).\n- The patient presents with shortness of breath and malaise 20 days post-left mastectomy. There is no mention of small cell lung cancer (SCLC).\n- The patient is experiencing symptoms that could be associated with post-surgical complications, such as pulmonary embolism (suggested by elevated D-dimer and shortness of breath), rather than SCLC.\n- There is no indication that the patient has been diagnosed with extensive small cell lung cancer, which is a specific requirement for the trial.\n- There is no information about any prior chemotherapy for SCLC because there is no mention of SCLC at all.\n- The patient's recent surgery (mastectomy) is within the last 3 weeks, which could be a concern depending on the trial's definition of \"major surgery\" and the decision on what is in the best interest of the patient.\n- Laboratory values such as bone marrow reserve and kidney and liver function are not provided.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent.\n- Patients with confirmed extensive small cell lung cancer (SCLC).\n- No prior chemotherapy within 5 years of the diagnosis of SCLC.\n- Presence of either measurable or non-measurable SCLC by X-ray or physical examination.\n- At least 3 weeks since last major surgery (or a lesser period if deemed in the best interest of the patient).\n- At least 24 hours since prior radiotherapy with recovery from reversible side effects.\n- Adequate bone marrow reserve and adequate kidney and liver function.\n\nBased on the available information, the patient does not meet several key inclusion criteria for the clinical trial, namely the confirmed diagnosis of extensive small cell lung cancer and the specific requirements related to the disease's treatment history and measurable presence. Since the patient's current medical issues do not align with the focus of the trial, which is extensive small cell lung cancer treatment, there is no basis for considering a referral.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1541": {
        "output": "Based on the patient note provided, the 56-year-old female patient presents with symptoms that may suggest pulmonary complications post-mastectomy, such as shortness of breath and malaise, along with physical examination findings of tenderness and bilateral decreased breath sounds, especially at the right base. Elevated D-dimer levels could be indicative of a thromboembolic event, which is a common cause of pulmonary hypertension (PHTN). However, the patient note lacks specific information confirming a diagnosis of PHTN, such as results from Doppler Echocardiography.\n\nThe clinical trial in question is focused on assessing the effectiveness of nesiritide (Natrecor) in reducing pulmonary hypertension. The inclusion criteria for this trial are:\n\n1. Ages 18 to 85 years old.\n2. Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).\n3. PHTN documented by Doppler Echocardiography (Done within the last 30 days).\n4. Must be able to give an informed consent.\n\nThe patient meets the age criterion and likely has evidence of underlying lung disease given her symptoms and physical examination findings. However, the patient note does not provide evidence of PHTN documented by Doppler Echocardiography within the last 30 days, which is a specific inclusion criterion for the clinical trial.\n\nGiven the lack of documented PHTN, we cannot definitively determine the patient's eligibility for the trial based solely on the information provided in the patient note. However, if the patient has undergone recent Doppler Echocardiography and meets all other inclusion criteria, she could potentially be eligible. Therefore, further investigation is required to obtain Doppler Echocardiography results and confirm a diagnosis of PHTN.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1542": {
        "output": "Based on the patient note provided and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 56-year-old female (meets age criterion of 18 to 85 years old)\n- Post-left mastectomy (not relevant to heart failure)\n- Complaining of shortness of breath and malaise (could potentially align with symptoms of fatigue and shortness of breath related to heart failure)\n- Physical examination reveals tenderness on the left upper thoracic wall and right calf (not directly relevant to heart failure)\n- Elevated D-dimer (could indicate a clotting issue but is not a direct measure of heart failure)\n\nClinical Trial Inclusion Criteria:\n- Age 18 to 85 years old (patient meets this criterion)\n- Admitted with acute heart failure determined by symptoms of fatigue; shortness of breath; edema; physical evidence of volume overload; and/or pulmonary edema by CXR (the patient's shortness of breath could indicate heart failure, but this is not confirmed)\n- LVEF \u2265 40% on recent (\u2264 1 month) echo or MUGA (there is no information provided about the patient's LVEF)\n- NYHA class III or IV on admission (NYHA classification not provided)\n- Baseline systolic blood pressure > 90 mm Hg (blood pressure not provided)\n- Baseline BNP level > 100 pg/ml (BNP level not provided)\n- Able to sign informed consent and return for follow-up assessments (assuming the patient can provide this)\n\nThe patient does have symptoms that could be indicative of heart failure, such as shortness of breath, but there is insufficient information to determine whether she meets the specific criteria for acute congestive heart failure as defined by the trial. Key pieces of information such as left ventricular ejection fraction (LVEF), NYHA class, baseline blood pressure, and BNP level are missing. Without this information, we cannot definitively include or exclude the patient.\n\nHowever, the presence of shortness of breath, which is a symptom of heart failure, and the elevated D-dimer suggesting a possible cardiac issue, would warrant further investigation into the patient's cardiac function to determine the presence of heart failure and its classification.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1543": {
        "output": "Given the patient's presentation with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer, there is a suspicion of deep vein thrombosis (DVT). These symptoms, along with the elevated D-dimer, suggest a moderate to high pre-test probability for DVT. The clinical trial in question is looking for adults aged \u226518 years presenting with suspected lower-limb initial or recurrent DVT, which aligns with the patient's potential condition. The patient is a 56-year-old female, which meets the age criterion. There is no information provided on when the symptoms started, so it cannot be definitively said whether the onset of symptoms occurred within the last 7 days, which is a requirement for the trial. Assuming she has been in bed for the last two weeks with these symptoms, it is possible that her symptoms started more than 7 days ago, which could disqualify her from the trial. Additionally, there is no information on whether she has had a negative pregnancy test, but given her age, she may not be of childbearing potential. \n\nHowever, if her symptoms related to DVT began within the last 7 days and a pregnancy test is confirmed negative or not required, then she would meet the inclusion criteria. There is enough alignment with the inclusion criteria to consider referring the patient to the clinical trial upon further investigation to clarify the onset of symptoms and confirm pregnancy status (if applicable).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1544": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 56-year-old female.\n- The patient is post-left mastectomy and presenting with shortness of breath and malaise.\n- The patient has remained in bed for the last two weeks.\n- There is tenderness on the left upper thoracic wall and right calf.\n- Pulmonary auscultation reveals bilateral decreased breath sounds, especially at the right base.\n- Laboratory tests reveal an elevated D-dimer, which may suggest a thromboembolic event such as a pulmonary embolism or deep vein thrombosis.\n\nClinical Trial Inclusion Criteria:\n- Adult patient aged > 18 years.\n- Admitted to an ICU with an expected ICU length of stay > 72 hours.\n- Severe renal insufficiency, defined by a calculated CrCl < 30 mL/min/1.73m2.\n\nTrial Eligibility Assessment:\n- The patient is above 18 years old, meeting the age criterion.\n- There is no information provided about the patient's renal function (CrCl value).\n- There is no indication that the patient is admitted to an ICU or is expected to stay in ICU for > 72 hours.\n\nGiven the information provided, there is insufficient evidence to determine whether the patient meets all the inclusion criteria, particularly regarding renal insufficiency and ICU admission status. Therefore, further investigation would be required to determine the patient's renal function and whether they are or will be admitted to an ICU for the required duration.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1545": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- A 56-year-old female\n- Presents with shortness of breath\n- On the 20th day post-left mastectomy\n- Elevated D-dimer\n\nClinical Trial Inclusion Criteria:\n- Patients presenting to the ED with shortness of breath\n- Over 40 years old\n- Emergency department triage category of 3 or higher\n\nThe patient is over 40 years old and is presenting with shortness of breath, which matches the inclusion criteria of the clinical trial. However, the trial's inclusion criteria also require a triage category of 3 or higher, which is not mentioned in the patient note. Since we cannot confirm the patient's triage category without additional information, we cannot definitively determine if she meets all the inclusion criteria.\n\nGiven that the patient does meet the age requirement and presents with shortness of breath, I would consider her potentially eligible for the trial, pending confirmation of the triage category.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1546": {
        "output": "Based on the patient note provided:\n\nA 56-year-old female presents to the emergency department complaining of shortness of breath and malaise 20 days post-left mastectomy. She reports having remained in bed for the last two weeks. Physical examination reveals tenderness on the left upper thoracic wall and right calf, with bilateral decreased breath sounds, especially at the right base. Elevated D-dimer levels are noted in the laboratory tests.\n\nComparing these details with the inclusion criteria of the clinical trial titled \"Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis\":\n\nInclusion criteria:\n\n1. Presenting signs and symptoms sufficiently suspicious for lower extremity DVT to warrant a formal radiology study in the opinion of the treating physician.\n2. EITHER\n   a. Moderate or high pre-test clinical probability of DVT (Wells Criteria)\n   b. Low pre-test clinical probability of DVT with a positive D-dimer.\n\nThe patient presents with symptoms that could be suggestive of deep venous thrombosis (DVT), such as tenderness in the calf and shortness of breath, which are common symptoms in DVT cases post-surgery given the prolonged immobilization (remaining in bed for two weeks). Additionally, the patient has an elevated D-dimer, which is a common marker used to rule out DVT when negative but does not confirm DVT when positive due to its low specificity. However, a positive D-dimer in the context of clinical symptoms increases the suspicion of DVT.\n\nGiven the information provided, the patient does meet the inclusion criteria because she has symptoms suspicious of DVT and an elevated D-dimer. Therefore, it would be appropriate for the treating physician to consider her for inclusion in the trial to undergo a diagnostic ultrasound for DVT by the emergency physicians as part of the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1547": {
        "output": "Based on the information provided in the patient note, the patient is a 56-year-old female who is post-operative day 20 after a left mastectomy. She presents with shortness of breath and malaise and has been bedridden for the last two weeks. This clinical presentation is concerning for a possible thromboembolic event, given the elevated D-dimer and symptoms. However, the patient note does not explicitly state that the patient is admitted to the ICU or expected to remain in the ICU for greater than 72 hours, which are both inclusion criteria for the PROTECT Pilot clinical trial.\n\nConsidering the clinical scenario, which suggests a potential thromboembolic event, and the fact that such patients may require ICU admission for management, there might be a possibility that this patient could be admitted to the ICU. However, without confirmation of ICU admission and the expected duration of ICU stay, we cannot definitively conclude that the patient meets the inclusion criteria for the trial.\n\nTherefore, based on the current information provided in the patient note and the inclusion criteria for the clinical trial:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1548": {
        "output": "The patient described in the note is a 56-year-old female who is 20 days post-left mastectomy and presents with shortness of breath and malaise. The patient has remained in bed for the last two weeks, which may suggest a risk of thrombosis due to lack of mobility. The presence of tenderness on the left upper thoracic wall and right calf, along with an elevated D-dimer, could indicate a thromboembolic event such as deep vein thrombosis (DVT) or pulmonary embolism (PE), both of which would require thrombosis prophylaxis.\n\nThe HIT-TRAP Trial is a randomized, double-blind trial comparing unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in heparin-induced thrombocytopenia (HIT). The inclusion criteria for this trial are:\n- Trauma-surgical patient\n- Consent given\n- Minimum age 18\n- Expected inpatient period at least 7 days\n- Need for thrombosis prophylaxis with heparin\n\nThe patient is certainly over the minimum age of 18 and presents with a condition that may require thrombosis prophylaxis. However, the patient is not specifically described as a trauma-surgical patient, which is a requirement for the trial. Moreover, there is no information provided that indicates the patient has been diagnosed with HIT or has a need for thrombosis prophylaxis specifically with heparin, nor is there information about the expected inpatient period.\n\nGiven the information provided, the patient does not clearly meet all of the specified inclusion criteria for the HIT-TRAP Trial, particularly the requirement of being a trauma-surgical patient and the need for thrombosis prophylaxis with heparin. Therefore, it would be prudent to seek more information about the patient's condition, specifically whether they have HIT or require heparin, before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1549": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 56-year-old female\n- 20th day post-left mastectomy\n- Presenting with shortness of breath and malaise\n- Has remained in bed for the last two weeks (possible immobility risk factor for thrombosis)\n- Tenderness on the left upper thoracic wall and right calf (possible deep vein thrombosis signs)\n- Elevated D-dimer (laboratory marker indicating possible thrombosis)\n\nClinical Trial:\n- Title: Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services\n- Aim: To examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT)\n- Inclusion Criteria: Patients admitted to General Medicine Services with a primary or secondary diagnosis related to venous thromboembolism\n\nAssessment:\nThe patient presents with clinical signs and laboratory findings suggestive of venous thromboembolism, such as tenderness in the calf area and elevated D-dimer levels. Although the clinical trial is focused on the diffusion of the use of LMWH among medical professionals, the inclusion criteria specifically mention patients with a primary or secondary diagnosis related to venous thromboembolism.\n\nGiven that the patient is likely to be diagnosed with venous thromboembolism, such as DVT, due to the symptoms and findings, she fits the inclusion criteria for the clinical trial. The trial appears to be looking at the patterns of LMWH use in patients with conditions like the one the patient is presenting with.\n\nThus, the patient would be considered eligible for participation in the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1550": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 56-year-old female who presents with symptoms suggestive of a post-surgical complication, likely a pulmonary embolism, given her shortness of breath, malaise, tenderness on the thoracic wall and calf, decreased breath sounds, and elevated D-dimer level. There is no mention of type 2 diabetes or any related treatment in the patient's note.\n\nThe clinical trial is focused on patients with type 2 diabetes and involves comparing self-adjustment versus standard of care treatment in subjects using basal insulin therapy with insulin detemir. The inclusion criteria for the trial specifically require a diagnosis of type 2 diabetes with certain HbA1C and BMI parameters, and treatment involving basal insulin therapy.\n\nSince the patient note does not mention type 2 diabetes, HbA1C levels, BMI, or any ongoing treatment with basal insulin therapy, the patient does not meet the inclusion criteria specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1551": {
        "output": "",
        "label": 1
    },
    "1552": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, here is the evaluation:\n\nPatient Note Summary:\n- 56-year-old female\n- 20th day post-left mastectomy\n- Presenting with shortness of breath and malaise\n- Tenderness on the left upper thoracic wall and right calf\n- Decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nClinical Trial Inclusion Criteria:\n- Patients admitted to the ICU with pulmonary hypertension (mean PA > 35 mmHg)\n- Patients in ICU with postoperative pulmonary HTN (mean PA > 35 mm Hg)\n- Patients with ARDS (PaO2/FiO2 < 200, bilateral infiltrates on chest X-ray, a wedge < 20 mm Hg on swan ganz parameters) or signs of heart failure\n\nEvaluation:\nThe patient's presentation with shortness of breath, malaise, and the finding of decreased breath sounds could be indicative of a pulmonary condition. The elevated D-dimer may suggest a thromboembolic event such as a pulmonary embolism, which could potentially lead to pulmonary hypertension. However, it's not clear from the note whether the patient has been diagnosed with pulmonary hypertension or ARDS. Additionally, there is no information regarding the specific pressures (mean PA) or the presence of bilateral infiltrates on chest X-ray, which are necessary to confirm the patient's eligibility for the trial based on the inclusion criteria.\n\nGiven the information provided, further investigation would be needed to determine if the patient meets the specific trial inclusion criteria for pulmonary hypertension or ARDS. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1553": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 56-year-old female\n- 20th day post-left mastectomy\n- Presents with shortness of breath and malaise\n- Has remained in bed for the last two weeks\n- Elevated D-dimer\n\nClinical trial inclusion criteria:\n- Patient must be 18 years and older (The patient meets this criterion)\n- Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcinoma In Situ of the left breast. (The patient appears to have undergone a mastectomy for breast cancer, which may meet this criterion)\n- Patients must have undergone a segmental mastectomy (SM) or Mastectomy (The patient meets this criterion)\n- Patients must not have received prior radiation therapy to the breast at any time for any reason. (There's no information on prior radiation therapy)\n- Any patient with active local-regional disease prior to registration is not eligible. (There's no information on the current status of the disease)\n- Patients must not be pregnant due to the potential for fetal harm as a result of this treatment regimen. (There's no information on pregnancy status, but given her age, it\u2019s less likely)\n- Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. (There's no information on any serious medical or psychiatric illness)\n- All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.\n\nThe patient note indicates that the patient is experiencing shortness of breath and malaise, which might be due to complications such as a pulmonary embolism, suggested by an elevated D-dimer. The trial does not mention compatibility with post-surgical complications or ongoing medical conditions not related to the breast cancer itself.\n\nGiven that we do not have complete information on whether the patient had received prior radiation therapy, the status of her breast cancer (active or not), her pregnancy status, and any serious medical or psychiatric illness, there is an indication for further investigation to determine her eligibility for this trial. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1554": {
        "output": "Based on the patient note provided, the patient is a 56-year-old female who has recently undergone a left mastectomy and is now presenting with symptoms that could be indicative of deep venous thrombosis (DVT) or pulmonary embolism (PE), such as shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer.\n\nThe clinical trial in question is studying the effectiveness of desirudin compared to heparin in preventing vein clots after heart and lung surgery. The inclusion criteria for the clinical trial are patients who are scheduled for elective cardiac or thoracic surgery and are over 18 years of age.\n\nGiven that the patient has already undergone surgery (mastectomy) and is not scheduled for any elective cardiac or thoracic surgery, she does not meet the inclusion criteria for the clinical trial. The trial is specific to patients undergoing heart and lung surgery, and there is no indication that the patient in the note is scheduled for such procedures.\n\nTherefore, based on the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1555": {
        "output": "",
        "label": 0
    },
    "1556": {
        "output": "",
        "label": 2
    },
    "1557": {
        "output": "Given the patient's presentation with shortness of breath and malaise post-left mastectomy, and an elevated D-dimer, there is a clinical suspicion of pulmonary embolism (PE). The patient falls into the category that the trial is designed to investigate, as Phase II Inclusion Criteria include clinical suspicion of PE with signs or symptoms suggestive of PE within 24 hours of presentation.\n\nThe patient has not been described as having any of the exclusion criteria such as hemodynamic instability, severe respiratory distress, inability to breathe without exogenous oxygen, intubation, anatomic limitations preventing mouth breathing, incarceration, active tuberculosis, prior PE or DVT with noncompliance, active PE under treatment, pregnancy, or recent treatment with fibrinolytic agents.\n\nHowever, the patient does not match the Phase I Inclusion Criteria as the surgeries listed do not include mastectomy. Therefore, we are considering only the Phase II criteria for this assessment.\n\nThe Phase II Inclusion Criteria also require that a CTA of the pulmonary arteries be ordered by clinical care providers, and the patient must be 18 years or older with written informed consent. Assuming these conditions can be met, the patient would be eligible based on the information provided.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1558": {
        "output": "Based on the patient note provided, the patient is a 56-year-old female with recent post-surgical complications of a mastectomy. She presents with shortness of breath and malaise, which could suggest complications such as a pulmonary embolism, especially considering the elevated D-dimer and decreased breath sounds.\n\nThe clinical trial in question is targeting children with severe pneumonia, with the inclusion criteria specifying an age range of 2 to 59 months. This criterion alone disqualifies the patient from this clinical trial, as she is an adult and does not have a diagnosis of pneumonia.\n\nGiven the mismatch in both the target age range and the disease condition, the patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1559": {
        "output": "Based on the provided patient note, the patient is a 56-year-old female who is 20 days post-left mastectomy and presents with symptoms suggestive of possible venous thromboembolism (VTE), which includes shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer level. These symptoms and laboratory findings could potentially indicate a deep vein thrombosis (DVT) or pulmonary embolism (PE), which are components of VTE.\n\nThe clinical trial's inclusion criteria specifically require patients with ultrasound-confirmed DVT. At this point, the patient has not been confirmed to have DVT through ultrasound, but her symptoms and the elevated D-dimer suggest that she may be at risk or could possibly have DVT.\n\nGiven that the patient's current clinical findings are highly suggestive of DVT, it would be reasonable to perform an ultrasound to confirm the diagnosis. If confirmed, she would meet the inclusion criteria for the trial. Therefore, I would consider referring this patient for the clinical trial upon further investigation, specifically an ultrasound to confirm DVT.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1560": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient is a 56-year-old female who is postoperative from a left mastectomy and is presenting with symptoms suggestive of a possible postoperative complication such as a thromboembolic event (e.g., pulmonary embolism) given her shortness of breath, malaise, tenderness in the right calf, and an elevated D-dimer.\n\nThe clinical trial in question is looking for healthy male subjects between the ages of 18 to 45. The patient in the note does not meet several of the inclusion criteria: she is not male, she is older than 45 years, and she is currently not healthy as indicated by her postoperative status and current complaints. Additionally, based on her presentation, she could possibly have a cardiovascular or pulmonary disorder (which is an exclusion criterion), though this is not definitively diagnosed in the patient note.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial and also meets multiple exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1561": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\n1. The patient is a 56-year-old female, which means she does not meet the age \u2265 75 years risk factor.\n2. She is on the 20th day post-left mastectomy, which suggests she has recently undergone treatment for cancer. However, the note does not specify if she is currently under treatment for active cancer or if she has received treatment within the last 6 months.\n3. She presents with shortness of breath and malaise and has remained in bed for the last two weeks. This could potentially indicate an acute medical condition requiring bed rest.\n4. The physical examination reveals tenderness on the left upper thoracic wall and right calf. While these symptoms are not directly listed in the inclusion criteria, tenderness in the right calf could be suggestive of a deep vein thrombosis (DVT), which is a type of VTE.\n5. Laboratory tests reveal an elevated D-dimer, which is a potential indicator of VTE, though not diagnostic on its own.\n\nThe patient appears to have an acute medical condition requiring bed rest and has at least one additional risk factor for VTE (recent cancer treatment, if we assume the mastectomy was due to cancer and that she received treatment within the last 6 months). However, the patient note does not explicitly mention any of the specific medical conditions listed in the inclusion criteria (e.g., congestive heart failure, acute respiratory failure, acute infection, etc.).\n\nGiven the potential for the recent mastectomy to be related to active cancer treatment and the symptoms that could suggest an acute medical condition, I would consider this patient for the clinical trial upon further investigation to clarify the recent cancer treatment status and the underlying cause of her current symptoms and restricted mobility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1562": {
        "output": "The patient note indicates that the patient is a 56-year-old female who is experiencing shortness of breath and malaise post-mastectomy. The physical examination finding of bilateral decreased breath sounds, especially at the right base, along with an elevated D-dimer, suggests a pulmonary issue which might be of interest for the clinical trial on Vibration Response Imaging (VRI) in the diagnosis of pulmonary disease.\n\nThe inclusion criteria for the clinical trial are:\n\n- All adult (\u2265 21 years old) patients (inpatients and outpatients) under the care of the Department of Respiratory and Critical Care Medicine between specific dates.\n- Ability to provide informed consent.\n\nThe patient fits the age criterion and is presenting with symptoms that suggest a pulmonary condition, which is the focus of the study. However, it is not specified whether the patient is under the care of the Department of Respiratory and Critical Care Medicine, nor whether the trial's specified dates align with the patient's presentation date. Assuming the patient can provide informed consent and is under the appropriate care department within the specified dates, the trial could potentially be relevant to her condition.\n\nBased on the available information, the patient could be considered for referral to the clinical trial, pending confirmation of the care department and the alignment of the trial's recruitment dates with the patient's presentation. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1563": {
        "output": "",
        "label": 0
    },
    "1564": {
        "output": "The patient is a 56-year-old female presenting with symptoms that could suggest a recent development of deep vein thrombosis (DVT), such as shortness of breath and tenderness in the calf, accompanied by an elevated D-dimer which is a common marker for clotting disorders. The clinical trial in question is focused on ultrasound elasticity imaging of venous thrombi and is seeking:\n\n1. Male or female subjects with a diagnosis of chronic DVT that is at least 2 weeks old, without an acute DVT on top of the chronic DVT.\n2. Male and female patients diagnosed with an acute blood clot by the Diagnostic Vascular Lab with symptoms occurring within the previous 2 weeks.\n3. Patients under the age of 18 who give assent and whose parents give consent.\n4. Adult patients who give consent.\n\nThe patient's presentation aligns with the second point of the inclusion criteria: patients who have been diagnosed with an acute blood clot with symptoms occurring within the previous 2 weeks. However, the patient note does not confirm a diagnosis of acute DVT, only symptoms suggestive of it and an elevated D-dimer. A diagnosis would be necessary to determine eligibility definitively.\n\nBased on the available information, the patient could potentially be eligible for the clinical trial, provided that further diagnostic tests confirm the presence of an acute DVT. Therefore, further investigation is needed before a definitive referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1565": {
        "output": "Based on the information provided in the patient note, the 56-year-old female patient presents with symptoms that are suggestive of a postoperative complication, potentially a pulmonary embolism (given the shortness of breath, malaise, right calf tenderness, and elevated D-dimer), which does not seem to have any direct relation to the clinical trial in question.\n\nThe clinical trial is focused on the effects of fenoldopam in patients undergoing partial nephrectomy with a single functioning kidney or an atrophic minimally functioning kidney. The trial seeks to understand if fenoldopam can lessen injury to the kidney during surgery.\n\nThe patient note does not mention any issues with the patient's kidneys, nor does it state that the patient has a single kidney or is scheduled for a partial nephrectomy. Instead, the patient has recently undergone a mastectomy, which is unrelated to the clinical trial's focus on renal function and nephrectomy.\n\nGiven the lack of any mentioned kidney issues and the absence of any scheduled partial nephrectomy, the patient does not meet the inclusion criteria specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1566": {
        "output": "Based on the patient note, the patient is a 56-year-old female who is 20 days post-left mastectomy and presents with shortness of breath and malaise. She has tenderness on the left upper thoracic wall and right calf, with bilateral decreased breath sounds, especially at the right base. An elevated D-dimer is noted, which may suggest a thromboembolic event such as a pulmonary embolism, especially given her recent surgery and prolonged bed rest.\n\nThe clinical trial in question is studying the use of Low Molecular Weight Heparin (LMWH) in hemodiafiltration. The inclusion criteria for this clinical trial are:\n\n- Chronic kidney disease stage V treated with hemodiafiltration\n- Age > 18 years\n- Hematocrit > 30%\n\nThe patient described in the note does not mention having chronic kidney disease or being treated with hemodiafiltration. Therefore, she does not meet the inclusion criteria based on the information provided in the patient note. Additionally, there is no information regarding her hematocrit level.\n\nGiven the lack of information suggesting that the patient has chronic kidney disease stage V and is undergoing hemodiafiltration, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1567": {
        "output": "The provided patient note describes a 56-year-old female who is 20 days post-left mastectomy and presents with shortness of breath and malaise. The physical examination reveals tenderness on the left upper thoracic wall and right calf, and laboratory tests show an elevated D-dimer. There are no indications in the patient note that the patient has non-small cell lung cancer (NSCLC), which is the focus of the clinical trial.\n\nThe clinical trial is looking to recruit patients with locally advanced or metastatic NSCLC (stage IIIB or IV), patients who are not candidates for radical combined modality treatments or high-dose radiation therapy, those with at least one measurable lesion according to RECIST criteria, good performance status, adequate haematological, renal, and liver function, and who have provided written informed consent.\n\nSince the patient's condition (post-mastectomy complications) does not align with the inclusion criteria of the clinical trial (which is focused on NSCLC), the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1568": {
        "output": "In order to determine the patient's eligibility for the clinical trial, let's compare the patient note with the inclusion and exclusion criteria of the trial.\n\nPatient Note:\n- A 56-year-old female\n- 20th day post-left mastectomy\n- Presents with shortness of breath and malaise\n- Remained in bed for the last two weeks\n- Tenderness on the left upper thoracic wall and right calf\n- Elevated D-dimer\n\nClinical Trial:\n- Title: Efficacy of Preventive Dosing of Fondaparinux Sodium for the Prevention of VTE in Patients Undergoing Coronary Bypass Surgery\n- Inclusion Criteria:\n  - Consecutive patients undergoing isolated or redo isolated CABG\n  - Must provide written informed consent\n  - Must agree to comply with study procedures\n  - Must be 18 years old or greater\n\n- Exclusion Criteria (relevant ones to consider):\n  - Patients with medical history that requires chronic anticoagulation\n  - Patients with contraindications to anticoagulation\n  - Renal insufficiency\n  - Body weight < 50 kg\n  - Pregnancy\n  - Life expectancy < 6 months\n  - Platelet count below 100,000/mm\u00b3\n  - History of documented VTE within the last 3 months\n\nAssessment:\nThe patient in question has recently had a mastectomy and is presenting with symptoms that could indicate a venous thromboembolism (VTE), as suggested by the elevated D-dimer. However, the clinical trial is specifically for patients undergoing coronary artery bypass graft (CABG) surgery, which the patient has not had.\n\nThe patient does not meet the primary inclusion criterion for the trial, which is to be undergoing isolated or redo isolated CABG surgery. Therefore, the patient is not eligible for this clinical trial based on the mismatch of the medical condition and the target population of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1569": {
        "output": "Given the patient's presentation with shortness of breath and malaise post-mastectomy, as well as tenderness in the right calf and elevated D-dimer levels, there is a suspicion of deep vein thrombosis (DVT). The inclusion criteria for the clinical trial include suspected deep vein thrombosis of a leg and either intermediate/high pre-test clinical probability or high D-dimer levels.\n\nThe patient's elevated D-dimer and symptoms are consistent with a high pre-test clinical probability of DVT, which aligns with the trial's inclusion criteria. Although the trial's title specifically mentions isolated deep vein thrombosis of the calf, the inclusion criteria do not strictly limit to isolated calf DVT but to suspected DVT in general.\n\nBased on the information provided in the patient note, this patient seems to meet the criteria for the clinical trial in question, as they present with suspected DVT and have high D-dimer levels.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1570": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial titled \"Diaphragm Activity During Incentive Spirometry and Diaphragmatic Breathing\", we can determine the patient's eligibility based on the specified criteria:\n\nThe inclusion criteria for the trial are:\n- Being 18 to 40 years old\n- Having a normal body mass index\n- Being a non-smoker\n- Not knowing the DB and the IS techniques\n- Reporting the absence of respiratory diseases.\n\nAssessing the patient note:\n- The patient is a 56-year-old female, which is outside the specified age range of 18 to 40 years old in the inclusion criteria.\n- There is no information provided about her body mass index, smoking status, knowledge of DB and IS techniques, or the presence of respiratory diseases.\n- However, the patient is presenting with shortness of breath and has an elevated D-dimer, which could suggest a respiratory issue such as a pulmonary embolism, especially post-surgery. This could potentially be classified as a respiratory disease, making the patient ineligible.\n\nConsidering the information provided, the patient does not meet the age criterion, and there is a strong possibility of a respiratory issue based on the symptoms described, which would exclude her from the study. Therefore, we have enough information to determine that the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1571": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 56-year-old female\n- Post-left mastectomy (20 days)\n- Complaining of shortness of breath and malaise\n- In bed for two weeks\n- Tenderness on the left upper thoracic wall and right calf\n- Decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nClinical trial inclusion criteria:\n- Functioning central venous catheter in the upper or lower venous system\n- Cohort A: Asymptomatic patients having placement of a new central venous catheter in the last 40\u00b120 days\n- Cohort B: Subjects who have experienced symptoms for a CVC-related DVT with a CVC in place or subjects who have been incidentally identified by radiographic imaging as having a CVC-related DVT\n- Males and females from full-term newborns to < 18 years\n\nThe patient does not meet the clinical trial's inclusion criteria for several reasons:\n\n1. The patient is a 56-year-old female, which is outside the age range specified in the inclusion criteria (must be < 18 years).\n2. There is no indication from the patient note that the patient has a functioning central venous catheter or that she has a catheter-related DVT.\n3. The clinical trial is specific to pediatric patients, and this patient is an adult.\n\nBased on the information provided, the patient is not eligible for the pediatric catheter-related thrombosis imaging study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1572": {
        "output": "The patient is a 56-year-old female who presents with signs and symptoms suggestive of a pulmonary embolism (PE) or deep vein thrombosis (DVT), such as shortness of breath, malaise, and an elevated D-dimer. The patient is on the 20th day post-left mastectomy, suggesting a recent cancer treatment, but there is no information about ongoing cancer treatment or the presence of metastatic disease.\n\nThe clinical trial is seeking patients with cancer who have had a confirmed PE or DVT and have been treated for 6 to 12 months with anticoagulants. The patient must have an indication for long-term anticoagulant therapy, which could be due to metastasized disease or ongoing chemotherapy.\n\nBased on the information provided:\n\n1. The patient has a recent history of cancer treatment (mastectomy), but there is no specific mention of metastasized disease or ongoing chemotherapy.\n2. The patient is presenting with signs and symptoms suggestive of a VTE episode, but there is no confirmation of a PE or DVT diagnosis within the note.\n3. The patient has not been mentioned to have received 6 to 12 months of anticoagulant treatment, which is a requirement for the trial.\n\nTherefore, the patient does not meet the specific inclusion criteria based on the information available in the note. However, if the patient does have a confirmed PE or DVT and an indication for long-term anticoagulant therapy, they may potentially be eligible for the trial. Confirmation of the diagnosis and additional patient history would be required to adequately assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1573": {
        "output": "Given the information provided, the patient is a 56-year-old female presenting with symptoms that could be indicative of a pulmonary embolism (PE) \u2013 namely, shortness of breath and malaise following a period of immobilization (remaining in bed for two weeks post-mastectomy). The physical findings of tenderness in the calf, which may suggest deep vein thrombosis (DVT), and the presence of decreased breath sounds at the right base of the lungs, combined with an elevated D-dimer level, further support a clinical suspicion of PE.\n\nThe clinical trial in question is assessing the diagnostic performance of V/Q SPECT for the diagnosis of pulmonary embolism. The inclusion criterion is simply a suspicion of pulmonary embolism, which this patient certainly has based on her symptoms, physical examination findings, and laboratory results.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be a good candidate for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1574": {
        "output": "",
        "label": 0
    },
    "1575": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question appears to be a 56-year-old female who is post-operative from a left mastectomy and is presenting with symptoms that could suggest a pulmonary embolism (shortness of breath, malaise, elevated D-dimer, tenderness in the calf, and decreased breath sounds in the lungs). This patient's current medical condition does not align with the inclusion criteria of the clinical trial provided.\n\nThe clinical trial is focused on the uteroplacental and fetal pulmonary circulation in patients with severe idiopathic oligohydramnios during pregnancy. The inclusion criteria specify that participants should be pregnant women with a single pregnancy and a diagnosis of persistent oligohydramnios between 18 and 34 weeks of gestation.\n\nGiven that the patient note does not mention pregnancy, let alone oligohydramnios, and focuses instead on post-mastectomy complications, there is no indication that this patient would be eligible for the trial in question. Therefore, the assessment of the patient's eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1576": {
        "output": "The patient in the note is a 56-year-old female who is on the 20th day post-left mastectomy and presents with shortness of breath and malaise. There is no mention of atrial fibrillation or any associated symptoms such as palpitations or fatigue related to a heart rhythm disorder.\n\nThe clinical trial in question is specifically for patients with paroxysmal or persistent atrial fibrillation, and inclusion criteria require that the patient be symptomatic with their atrial fibrillation, affecting their ability to perform daily activities. Additionally, the patients must have a left atrium size of less than 6.1 cm (volume).\n\nGiven that the patient in the note does not present with symptoms of atrial fibrillation and there is no information about her left atrium size or any history of atrial fibrillation, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1577": {
        "output": "Based on the patient note provided, the 56-year-old female patient is presenting with symptoms that could be indicative of deep venous thrombosis (DVT), such as shortness of breath, malaise, tenderness in the calf, and an elevated D-dimer level. The clinical trial in question is investigating the incidence of perioperative deep venous thromboses of the lower extremities by performing duplex studies of the legs before and after surgery.\n\nThe inclusion criteria for the clinical trial are very broad, only stipulating that the subject must be 18 years or older and able to provide consent. The patient note does not mention whether the patient is consentable, but given that she presents to the emergency department and there is no mention of mental incapacity, it is reasonable to assume that she can consent.\n\nWhile the patient is postoperative, which aligns with the trial's focus on perioperative thromboses, the study seems to be aimed at patients who are scheduled for surgery, not those who have already undergone surgery. However, given that the patient's current condition might be relevant to the study's interests in DVTs associated with surgical procedures, and because she meets the minimal age requirement, she might be considered for inclusion upon further investigation. This would depend on the specifics of the study protocol, which might include or exclude patients with recent surgery. More information would be needed to make a definitive assessment.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1578": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Apremilast to treat active Psoriatic Arthritis (PsA), we can assess the eligibility of the patient for the trial.\n\nPatient Note Assessment:\n- The patient is a 56-year-old female, which satisfies the age requirement of being \u2265 18 years.\n- The patient presents with shortness of breath and malaise post-mastectomy, which is not relevant to Psoriatic Arthritis.\n- There is no mention of the patient having Psoriatic Arthritis or meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA.\n- The symptoms reported (shortness of breath, malaise, tenderness on the upper thoracic wall and calf, and elevated D-dimer) do not suggest Psoriatic Arthritis, which commonly involves joint pain and swelling.\n- The laboratory tests mentioned (elevated D-dimer) do not provide information on the specific laboratory criteria required by the trial.\n\nClinical Trial Inclusion Criteria Assessment:\n- The patient does not have a documented diagnosis of Psoriatic Arthritis.\n- There is no indication that the patient has \u2265 3 swollen AND \u2265 3 tender joints, as required by the trial.\n- The patient's current medical condition and treatment history are not related to Psoriatic Arthritis or its treatment with DMARDs.\n- No information is provided on the patient's use of corticosteroids, NSAIDs, or other medications relevant to the trial's criteria.\n- The patient's laboratory values required by the trial are not provided.\n\nConclusion:\nGiven the information in the patient note, the patient does not appear to have Psoriatic Arthritis, which is a critical criterion for inclusion in the clinical trial. Therefore, this patient would not be eligible for the trial based on the provided information. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1579": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 56-year-old female who has recently undergone a left mastectomy.\n- The patient presents with shortness of breath and malaise, having been in bed for two weeks.\n- Physical examination shows tenderness in the left upper thoracic wall and right calf.\n- There is an elevated D-dimer level, which could indicate a venous thromboembolism (VTE).\n\nClinical Trial Analysis:\n- The trial is investigating the effects of intermittent pneumatic compression (IPC) on venous thromboembolism (VTE) incidence and the healing of acute Achilles tendon ruptures.\n\nInclusion Criteria for the Clinical Trial:\n- Achilles tendon rupture operated on within 96 hours of diagnosis.\n\nComparison:\n- The clinical trial is specifically looking for patients with an Achilles tendon rupture.\n- The patient in question does not have an Achilles tendon rupture but has presented with symptoms that may suggest a VTE or pulmonary issue.\n\nThe patient's condition (post-mastectomy complications with possible VTE) is unrelated to the focus of the clinical trial (Achilles tendon rupture and healing). Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1580": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's evaluate the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 56-year-old female who is presenting with shortness of breath and malaise.\n- She is post-left mastectomy, which is unrelated to COPD.\n- The physical exam shows tenderness on the left upper thoracic wall and right calf, which could be a sign of a deep vein thrombosis leading to a pulmonary embolism.\n- The elevated D-dimer supports the suspicion of a pulmonary embolism.\n- There is no mention of Chronic Obstructive Pulmonary Disease (COPD) or a history of COPD exacerbations.\n\nClinical Trial Inclusion Criteria:\n- Known or suspected COPD\n- COPD-exacerbation\n\nThe patient does not meet the inclusion criteria for the clinical trial because there is no indication that she has COPD or that she is experiencing a COPD exacerbation. The symptoms she has could be related to a pulmonary embolism but without any connection to COPD, which is the focus of the clinical trial.\n\nTherefore, the patient is not eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1581": {
        "output": "Based on the information provided, the patient is a 56-year-old female who presents with shortness of breath and malaise on the 20th day post-left mastectomy. She has signs that may suggest a venous thromboembolic event (VTE), such as tenderness on the right calf and an elevated D-dimer, but there is no indication that she is undergoing or has recently undergone total hip replacement surgery.\n\nThe clinical trial in question is investigating the safety and efficacy of a medication for the prevention of VTE after total hip replacement surgery. While the patient meets some of the inclusion criteria such as being over 18 years of age and potentially being able to comply with the study procedures, the trial specifically targets subjects undergoing total hip replacement surgery, which does not apply to this patient.\n\nTherefore, the patient does not match the key inclusion criteria related to the specific surgical procedure, which is a core aspect of this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1582": {
        "output": "The patient note describes a 56-year-old female who is on the 20th day post-left mastectomy, presenting with symptoms that might suggest a postoperative complication such as a thromboembolic event, considering the elevated D-dimer and symptoms of shortness of breath and malaise. The patient is not mentioned to be pregnant, which is a key inclusion criterion for the clinical trial.\n\nThe clinical trial is aiming to evaluate the effect of thromboprophylactic doses of LMWH (Low Molecular Weight Heparin) on coagulation in pregnant women just before birth. The inclusion criteria for this trial are very specific: pregnant women undergoing a planned caesarean section in the 39th-40th week of pregnancy, aged 18-40 years.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial as she is not described as being pregnant, is post-mastectomy (which is not relevant to the trial), and is outside the age range specified in the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1583": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient Note:\n- 56-year-old female (meets age criterion)\n- On 20th day post-left mastectomy (indicates a cancer-related surgery)\n- Presents with shortness of breath and malaise, elevated D-dimer (these symptoms could suggest a VTE which is relevant to the study, but this is not a direct inclusion criterion)\n\nClinical Trial Inclusion Criteria:\n- Age 18 and older (patient meets this criterion)\n- At least one record of a primary inpatient discharge diagnosis of cancer (the note suggests the patient had a mastectomy due to cancer)\n- A procedure code for a cancer-related surgery during the index hospitalization (mastectomy is a cancer-related surgery)\n- A code for an anticoagulant treatment as thromboprophylaxis therapy during the day prior to or two days after cancer-related surgery during the index hospitalization (this information is not provided in the patient note)\n\nThe patient note indicates the patient had a cancer-related surgery (mastectomy) and is of the appropriate age, which aligns with the inclusion criteria. However, there is no information about whether the patient received anticoagulant treatment around the time of surgery, which is a specific requirement for the study.\n\nTherefore, the patient might be eligible for the clinical trial, but additional information is required to determine whether the patient received anticoagulant treatment as part of the thromboprophylaxis therapy around the time of surgery. If the patient did receive the appropriate anticoagulant treatment as specified, she could be a candidate for the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1584": {
        "output": "Based on the patient note provided, the 56-year-old female patient is presenting with shortness of breath and malaise post-mastectomy. Her condition is suggestive of a possible pulmonary embolism due to the elevated D-dimer and decreased breath sounds, but there is no indication that she is undergoing or has recently undergone an endoscopic retrograde cholangiopancreatography (ERCP) procedure. \n\nThe clinical trial in question is specifically looking to recruit subjects who are undergoing ERCP as part of their medical care, and the patient must be 19 years of age or older. The patient note does not mention ERCP, and her current medical issues do not seem to be related to the biliary or pancreatic systems, which are the focus of ERCP.\n\nGiven that the patient is not undergoing ERCP and the clinical trial is specifically looking for participants who are, this patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1585": {
        "output": "Based on the information provided in the patient note and the clinical trial details, the patient does not meet the inclusion criteria for the clinical trial titled \"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy.\" The inclusion criteria specifically mention the need for the patient to have undergone certain procedures such as meniscectomy, diagnostic arthroscopy, or removal of corpora libera, which all pertain to the knee. \n\nThe patient in the note is a 56-year-old female presenting with symptoms that may be suggestive of a post-surgical complication like a pulmonary embolism or deep vein thrombosis (elevated D-dimer, shortness of breath, tenderness in the calf), following a mastectomy for breast cancer. There is no mention of knee surgery or arthroscopy, which are the relevant procedures for eligibility in the clinical trial described.\n\nTherefore, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1586": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, it appears the patient does not meet the specific requirements for the clinical trial in question. The patient has presented post-mastectomy with symptoms potentially indicative of a thromboembolic event (shortness of breath, malaise, elevated D-dimer), whereas the clinical trial is focused on thrombosis prophylaxis during lower leg immobilization with a plaster cast.\n\nThe inclusion criteria for the trial specifically mention patients who require immobilization of the lower leg with a plaster cast due to trauma, surgery followed by immobilization, or non-traumatic indications of the lower leg. The patient in the note does not match these criteria as there is no indication of lower leg immobilization, trauma, or surgery of the lower leg that is mentioned.\n\nTherefore, based on the provided information, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1587": {
        "output": "Based on the provided patient note and the clinical trial information, we can assess the patient's eligibility for the trial as follows:\n\nThe clinical trial is focused on the frequency of vascular events with short-term thromboprophylaxis in patients undergoing fast-track hip and knee arthroplasty (THR/TKR or uni-KR). The inclusion criteria specify that participants must have undergone primary uni/bilateral THR/TKR, revision THR/TKR, or uni-KR in a fast-track setup and been discharged within 3 \u00b1 2 days.\n\nThe patient described in the note has presented with symptoms suggestive of a potential thromboembolic event (shortness of breath, malaise, elevated D-dimer) on the 20th day post-left mastectomy. There's no mention of the patient having undergone hip or knee arthroplasty, which is the primary requirement for inclusion in the clinical trial. Furthermore, the patient's current medical condition does not appear to be related to the focus of the trial, which is on thromboprophylaxis post-ortho surgery.\n\nTherefore, the patient described does not meet the inclusion criteria for the clinical trial as they have not undergone the specified surgeries (THR/TKR or uni-KR) in the context of a fast-track setup. Additionally, their medical issue (potential thromboembolic event post-mastectomy) is not the focus of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1588": {
        "output": "Based on the patient note provided, the patient is a 56-year-old female who has recently undergone a left mastectomy and is presenting with symptoms that may be suggestive of a deep vein thrombosis (DVT), such as shortness of breath, malaise, tenderness in the right calf, and an elevated D-dimer level.\n\nThe clinical trial in question is looking to analyze the influence of surgery duration and tourniquet time on the incidence of DVT in patients who have undergone total knee arthroplasty (TKA). The inclusion criteria specifically state that the trial is for patients who underwent cemented total knee arthroplasty.\n\nSince the patient described in the note did not undergo a total knee arthroplasty but rather a mastectomy, she does not meet the inclusion criteria for this clinical trial. Therefore, she would not be eligible to participate in this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1589": {
        "output": "Based on the provided patient note, the 56-year-old female patient presented to the emergency department with symptoms that are suggestive of a pulmonary embolism, such as shortness of breath and malaise, particularly after a period of immobilization (remaining in bed for two weeks). The tenderness in the upper thoracic wall and right calf, along with the decreased breath sounds in the pulmonary auscultation and an elevated D-dimer, further support the suspicion of pulmonary embolism.\n\nThe clinical trial in question is the Italian Pulmonary Embolism Registry - IPER, which aims to improve the knowledge of the epidemiology, management, and outcome of acute pulmonary embolism in Italy. The inclusion criteria for the trial are quite broad and only specify that the trial is looking to enroll \"consecutive patients with acute pulmonary embolism.\"\n\nGiven that the patient's presentation is highly suggestive of acute pulmonary embolism, she meets the inclusion criteria for the trial. Therefore, it would be appropriate to refer this patient to the clinical trial based on the provided information.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1590": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient appears to be eligible for the trial. The patient is a 56-year-old female who presents with shortness of breath, which aligns with the chief complaint of shortness of breath or dyspnea required for the trial. There is no mention of exclusion criteria that would disqualify the patient, and the age falls within the specified range of 18-89 years.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1591": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 56-year-old female who recently underwent a left mastectomy and is presenting with symptoms that could be suggestive of deep vein thrombosis (DVT), such as shortness of breath, malaise, and tenderness in the right calf, along with an elevated D-dimer level. \n\nHowever, the inclusion criteria for the clinical trial specifically require that the participants be pregnant women with clinically suspected DVT. Since there is no indication in the patient note that the patient is pregnant, she would not meet the inclusion criteria for this clinical trial.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1592": {
        "output": "Based on the patient note and the clinical trial information provided:\n\n- The patient is a 56-year-old female, which meets the age criterion of being over the age of 18 years.\n- The patient presents with shortness of breath and malaise. While the patient has tenderness on the left upper thoracic wall, it is not stated that chest pain is a leading symptom, which is a required inclusion criterion.\n- The patient is post-left mastectomy, which is a recent thoracic surgery, and according to the exclusion criteria, patients with recent thoracic surgery within 1 year are excluded.\n\nGiven the lack of explicit mention of acute chest pain as a leading symptom and the recent thoracic surgery (mastectomy), this patient would not meet the inclusion criteria and would meet the exclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1593": {
        "output": "Based on the patient note, the 56-year-old female patient is presenting with symptoms that could be indicative of a venous thromboembolic event (VTE), such as shortness of breath and tenderness on the right calf, along with an elevated D-dimer, which is a common marker for clotting disorders. The patient is post-operative from a mastectomy, which is a known risk factor for VTE due to immobility and surgical intervention.\n\nThe clinical trial in question is investigating venous thromboembolic prophylaxis in trauma patients who are at high risk for deep vein thrombosis and pulmonary embolism. The trial is comparing the effectiveness of unfractionated heparin administered every 8 hours versus low molecular weight heparin administered every 12 hours.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Admitted to Scripps Mercy Trauma Service\n2. \u226518 Years old\n3. Stratified to either Significant or Highest risk of VTE by ACCP guidelines\n\nThe patient in the note meets the age criterion (\u226518 years old). However, there is no information provided that suggests she is admitted to the Scripps Mercy Trauma Service or that she has been stratified by ACCP guidelines into a significant or highest risk category for VTE. The patient has undergone surgery, which is a risk factor for VTE, but the trial specifically mentions trauma service, and there is no indication that the patient's condition is a result of trauma.\n\nSince there is insufficient information to determine whether the patient meets the other two criteria (admission to Scripps Mercy Trauma Service and risk stratification by ACCP guidelines), I would consider further investigation to see if the patient fits the trial's risk stratification and admission criteria before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1594": {
        "output": "",
        "label": 0
    },
    "1595": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Note Assessment:\n- The patient is a 56-year-old female, which fits within the age range of 18-80 years required by the trial.\n- The patient presents with shortness of breath and malaise post-mastectomy, which is unrelated to TMJ disorders.\n- There is no mention of TMJ arthralgia, masticatory myalgia, or TMJ sounds in the patient note.\n- There is no mention of the patient having a history of occlusal appliance therapy for at least 6 weeks.\n\nClinical Trial Inclusion Criteria:\n- Female (the patient is female)\n- 18-80 years of age (the patient is 56 years old)\n- TMJ arthralgia (not mentioned in the patient's note)\n- Masticatory myalgia (not mentioned in the patient's note)\n- TMJ sounds (not mentioned in the patient's note)\n- History of at least 6 weeks use of occlusal appliance therapy (not mentioned in the patient's note)\n\nThe patient does not meet several of the inclusion criteria specific to TMJ disorders and there is no indication that she has been diagnosed with or is experiencing symptoms of TMJ disorders like arthralgia, myalgia, or TMJ sounds. Additionally, there is no information about a history of occlusal appliance therapy.\n\nTherefore, the patient does not appear to be eligible for this clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1596": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the necessary criteria to be eligible for the clinical trial. The clinical trial is focused on preventing venous insufficiency in pregnant women through the use of compression stockings, and the inclusion criteria specifically require that participants be pregnant women between 18-45 years of age, with a fetal gestation between 8-20 weeks.\n\nThe patient in the note is a 56-year-old female who is post-mastectomy, with no indication of being pregnant. She presents with symptoms that may suggest complications such as a deep venous thrombosis, but her current medical issue and demographic details do not align with the population targeted by the clinical trial.\n\nTherefore, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1597": {
        "output": "The patient in the note is a 56-year-old female presenting with symptoms consistent with possible post-surgical complications such as deep vein thrombosis or pulmonary embolism, as suggested by shortness of breath, malaise, and an elevated D-dimer. There is no mention of snoring or any related nasal or respiratory conditions that align with the clinical trial's focus.\n\nThe clinical trial is specifically investigating the effect of nasal steroids on snoring intensity. The inclusion criteria for this trial are:\n\n1. Every night snoring;\n2. No medication known to influence nasal resistance;\n3. No smoking for the last 6 months;\n4. No upper or lower respiratory tract disease;\n5. Written informed consent.\n\nThe patient's current medical condition does not seem related to the focus of the trial, which is snoring. Additionally, there's no information provided that confirms the patient meets the inclusion criteria regarding snoring, medication use, smoking status, or respiratory tract health. Therefore, based on the available information, this patient does not appear to be an appropriate candidate for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1598": {
        "output": "Based on the patient note provided, the 56-year-old female patient is presenting with shortness of breath and malaise post-mastectomy. There is no mention of her having pulmonary arteriovenous malformations (AVMs) or a diagnosis of hereditary hemorrhagic telangiectasia (HHT), which are required for the clinical trial in question.\n\nThe clinical trial aims to compare the success rate of embolization between two types of coils in patients with pulmonary AVMs. The inclusion criteria specifically require the presence of untreated pulmonary AVMs and a clinical or genetic diagnosis of HHT, neither of which are mentioned in the patient's note. Additionally, the patient's symptoms of shortness of breath and an elevated D-dimer could suggest a pulmonary embolism or another condition unrelated to pulmonary AVMs or HHT.\n\nGiven the lack of information connecting the patient's condition to the clinical trial's target disease and treatment, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1599": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 56-year-old female\n- 20th day post-left mastectomy\n- Complaining of shortness of breath and malaise\n- Has remained in bed for the last two weeks\n- Tenderness on the left upper thoracic wall and right calf\n- Decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nClinical Trial Inclusion Criteria:\n- Patients with acute (\u226414 days) symptomatic pulmonary embolism by CT Angiogram of the thorax\n- Embolus involving at least one main or lower lobe pulmonary artery\n- RV:LV ratio > 0.9\n\nAssessment:\n- The patient presents with symptoms that could be indicative of a pulmonary embolism (shortness of breath, malaise, tenderness in the calf which could be deep vein thrombosis, and elevated D-dimer).\n- However, the inclusion criteria specifically mention an acute pulmonary embolism that is symptomatic and confirmed by a CT Angiogram within 14 days. The patient is on the 20th day post-surgery, which exceeds the 14 days acute phase specified in the trial criteria.\n- There is no information provided about a CT Angiogram confirmation or RV:LV ratio in the patient note.\n\nBased on the information provided, the patient does not meet the specified inclusion criteria of having an acute pulmonary embolism within 14 days of symptom onset confirmed by CT Angiogram. However, given the symptoms described and the elevated D-dimer, further investigation (such as a CT Angiogram) could potentially confirm a diagnosis that would meet the clinical trial's inclusion criteria. Therefore, the patient is not currently eligible based on the available information, but further investigation is warranted to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1600": {
        "output": "",
        "label": 2
    },
    "1601": {
        "output": "The patient note describes a 56-year-old female who is post-left mastectomy and presents with shortness of breath and malaise. There are no specific indications that the patient has congestive heart failure (CHF); in fact, the clinical presentation of shortness of breath and malaise, along with an elevated D-dimer and recent surgery, may be more indicative of a pulmonary embolism or post-surgical complications rather than CHF. The patient does not clearly meet any of the inclusion criteria listed for the clinical trial focused on Doppler signals in left HF patients.\n\nThe inclusion criteria for the clinical trial require patients to belong to one of the following categories:\n\nA. Acute decompensated left HF: There is no clear indication that the patient has acute pulmonary congestion or pulmonary edema, and key pieces of evidence such as BNP levels and chest X-ray findings are not provided.\n\nB. Compensated left HF: There is no information provided that the patient has a history of stable left HF or that they are on medical treatment for CHF.\n\nC. Non-CHF controls: While there's no specific information stating the patient has CHF, the absence of uncontrolled hypertension is not documented, and their current condition does not necessarily exclude the possibility of CHF.\n\nGiven the lack of information to clearly place the patient in any of the defined categories for the clinical trial and the more likely differential diagnosis of a post-surgical complication such as pulmonary embolism, it is not appropriate to refer the patient to this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1602": {
        "output": "Based on the patient note, the patient is a 56-year-old female presenting with symptoms suggestive of a pulmonary embolism (PE), such as shortness of breath and malaise post-mastectomy, with an elevated D-dimer test. The clinical trial in question is investigating the efficacy and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) in combination with thrombolytic treatment in patients with acute massive pulmonary thromboembolism.\n\nMatching the patient's characteristics with the inclusion criteria for the clinical trial:\n\n1. Adults, age \u2265 18 years: The patient is 56 years old, which meets the age criterion.\n2. Patients who have signed the study informed consent form prior to initiation of any study-related procedure: This is an actionable item and not a current characteristic of the patient, so it does not affect eligibility at this stage.\n3. Acute massive PE patients who require thrombolytic treatment: The patient presents with symptoms that suggest PE and an elevated D-dimer, which indicates a possible acute PE. However, the term \"massive PE\" typically refers to a PE with hemodynamic instability, and there is no information provided regarding the patient's hemodynamic status.\n\nGiven that the patient presents with symptoms suggestive of a PE and no information contradicts the possibility of a \"massive PE,\" it is reasonable to consider further investigation to determine the severity of the PE and whether thrombolytic treatment is required. Thus, the patient could potentially be eligible for the trial pending confirmation of the diagnosis and severity of the PE.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1603": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- 56-year-old female\n- 20th day post-left mastectomy\n- Presents with shortness of breath and malaise\n- Has been bedridden for the last two weeks\n- Tenderness on the left upper thoracic wall and right calf\n- Decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nClinical Trial Inclusion Criteria:\n- Type 2 diabetes\n- Age above or equal to 50 years with predefined previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined cardiovascular risk factors\n- HbA1c (glycosylated haemoglobin) above or equal to 7.0% or HbA1c below 7.0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day\n- One or more oral or injectable antidiabetic agent(s)\n\nExclusion Criteria:\n- An acute coronary or cerebrovascular event in the previous 60 days\n- Planned coronary, carotid or peripheral artery revascularisation\n- Chronic heart failure NYHA (New York Heart Association) class IV\n- Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)\n\nAssessment:\nThe patient note does not mention the patient having type 2 diabetes or any related treatment, which is a primary inclusion criterion for the clinical trial. Without information indicating that the patient has type 2 diabetes, we cannot consider her for a trial focused on the cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes. \n\nMoreover, the exclusion criterion regarding malignant neoplasms (cancers) within the last 5 years might also apply, as the patient has recently undergone a mastectomy, commonly associated with breast cancer treatment. If the mastectomy was related to breast cancer, this would further exclude the patient from the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1604": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient, a 56-year-old female presenting with symptoms suggestive of a postoperative complication (likely a VTE given the elevated D-dimer and shortness of breath), does not meet the specific inclusion criteria for the clinical trial.\n\nThe clinical trial is evaluating anti-FXa levels under two different regimens of enoxaparin for VTE prophylaxis after sleeve gastrectomy for morbid obesity. The inclusion criteria state that the patient must be an adult undergoing laparoscopic sleeve gastrectomy, and the surgery must be performed in the surgical wing of the Tel-Aviv Sourasky Medical Center. Furthermore, the patient must have received full information regarding the study's nature, agreed to participate, and provided informed consent.\n\nThe patient in the note has undergone a left mastectomy, not bariatric surgery, and there is no indication that they are participating in a study at the Tel-Aviv Sourasky Medical Center or have provided informed consent for such a study.\n\nTherefore, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1605": {
        "output": "",
        "label": 0
    },
    "1606": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can assess the eligibility of the patient for the clinical trial titled \"Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty.\"\n\nPatient Note Analysis:\n- The patient is a 56-year-old female.\n- She is on the 20th day post-left mastectomy.\n- She presents with shortness of breath and malaise.\n- She has remained in bed for the last two weeks, which could suggest a risk of deep vein thrombosis (DVT).\n- Physical examination reveals tenderness on the left upper thoracic wall and right calf.\n- Pulmonary auscultation indicates bilateral decreased breath sounds, especially at the right base.\n- Elevated D-dimer, which is a common indicator for the presence of DVT.\n\nClinical Trial Inclusion Criteria Analysis:\n- TKA candidacy: The trial is specifically looking for candidates for total knee arthroplasty, which is a surgery for osteoarthritis of the knee.\n- Osteoarthritis: The trial is focused on patients with osteoarthritis as the primary condition.\n- Patients able to understand study intent and agree to study participation: This criterion is about the patient's ability to consent but provides no specific information about the patient's mental state or understanding.\n\nComparison:\n- The patient in the note does not fit the primary disease criteria for the clinical trial, which is osteoarthritis leading to TKA candidacy. The patient has presented with symptoms potentially indicative of DVT following a mastectomy, not knee problems.\n- The trial seeks to study the effectiveness of a mechanical compression device following knee surgery, which is not relevant to the patient's current medical issue.\n\nGiven the information, the patient does not meet the clinical trial's inclusion criteria as she is not a candidate for total knee arthroplasty, nor is she suffering from osteoarthritis, which the trial is specifically designed to address.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1607": {
        "output": "",
        "label": 0
    },
    "1608": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 56-year-old female\n- Presented with shortness of breath and malaise\n- Post-left mastectomy (20th day)\n- Tenderness on the left upper thoracic wall and right calf\n- Bilateral decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nClinical Trial Inclusion Criteria:\n- Concern for pulmonary embolism (PE) by attending physician\n- Computed tomography of the pulmonary arteries (CTPA) ordered\n\nThe patient presents with symptoms consistent with a potential pulmonary embolism, such as shortness of breath and an elevated D-dimer level. The physical findings and clinical concerns may lead the attending physician to suspect a PE. If the attending physician's concern results in a CTPA being ordered to rule out or confirm PE, this patient would meet the inclusion criteria for the clinical trial.\n\nGiven the information, it seems the patient's condition could lead to an order for a CTPA by the attending physician to investigate the possibility of PE.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1609": {
        "output": "Based on the patient note provided, the patient is a 56-year-old female who is 20 days post-left mastectomy and presents with shortness of breath and malaise. The physical examination findings of tenderness on the left upper thoracic wall and right calf, along with decreased breath sounds, particularly at the right base, and laboratory tests revealing an elevated D-dimer are suggestive of a possible Deep Vein Thrombosis (DVT).\n\nThe clinical trial in question is looking to enroll participants who are 18 or older and suspected of having DVT to investigate the accuracy and utility of bedside ultrasound for DVT in the ED.\n\nGiven that the patient is over 18 years of age and the clinical presentation along with the elevated D-dimer raises the suspicion of DVT, this patient meets the inclusion criteria for the clinical trial. Therefore, it is highly likely that this patient should be referred for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1610": {
        "output": "Based on the information provided, the 56-year-old female patient who presents with shortness of breath and malaise post-left mastectomy does not appear to meet the inclusion criteria for the clinical trial titled \"Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty.\" The inclusion criteria for the clinical trial are:\n\n- Patients with osteoarthritis\n- Scheduled for elective primary unilateral Total Hip Replacement (THR) or Total Knee Replacement (TKR)\n- Provided informed consent\n- Can read, write, and speak English\n\nThe patient note does not mention osteoarthritis, nor does it indicate that the patient is scheduled for THR or TKR. Instead, the note discusses a recent mastectomy and symptoms that might suggest complications such as a possible thromboembolic event (e.g., elevated D-dimer and shortness of breath).\n\nTherefore, the patient does not fit the target demographic for the study, which is focused on patients undergoing elective orthopedic surgery for osteoarthritis. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1611": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Apixaban Pharmacokinetics in Bariatric Patients (APB).\"\n\nPatient note:\n- The patient is a 56-year-old female presenting with shortness of breath and malaise post-left mastectomy.\n- The patient has been bedridden for the last two weeks.\n- Physical examination shows tenderness on the left upper thoracic wall and right calf, with bilateral decreased breath sounds, especially at the right base.\n- Laboratory tests reveal an elevated D-dimer.\n\nClinical trial inclusion criteria:\n- Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB).\n- Signed written informed consent.\n- Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of the study drug.\n- Women must not be breastfeeding.\n\nThe patient's current medical condition does not mention obesity, bariatric surgery, or a BMI of 35 kg/m2 or greater. The patient is also not reported to be undergoing bariatric surgery, which is a specific requirement for the clinical trial. Therefore, based on the provided information, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1612": {
        "output": "The patient is a 56-year-old female who is post-operative from a left mastectomy and is presenting with symptoms suggestive of a possible postoperative complication, such as a pulmonary embolism (shortness of breath, malaise, elevated D-dimer, and decreased breath sounds especially at the right base). The physical examination findings and elevated D-dimer are concerning and warrant further investigation.\n\nThe clinical trial in question is studying the effects of sound energy on pulmonary gas exchange and is seeking healthy volunteers. The patient's current health status does not meet the criteria of being a \"healthy volunteer\" due to her recent surgery and current symptoms that require medical attention.\n\nGiven the mismatch between the patient's current health condition and the inclusion criteria of the clinical trial, which requires healthy volunteers:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1613": {
        "output": "The patient is a 56-year-old female presenting with shortness of breath and malaise 20 days after a left mastectomy. Physical examination reveals tenderness on the left upper thoracic wall and right calf, and pulmonary auscultation indicates bilateral decreased breath sounds, particularly at the right base. An elevated D-dimer suggests the possibility of deep vein thrombosis (DVT).\n\nHowever, the clinical trial in question is specifically for unselected pregnant women with suspected acute symptomatic DVT. The patient's note does not mention pregnancy, and the symptoms and situation described do not align with the inclusion criteria, which require the patient to be pregnant and presenting with new leg swelling, edema, or pain with onset in the last month.\n\nGiven that the patient does not meet the key inclusion criteria of being pregnant, it is clear that this patient would not qualify for the trial. Therefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1614": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the assessment of the patient's eligibility for the trial is as follows:\n\nThe patient note describes a 56-year-old female presenting with shortness of breath and malaise post-mastectomy, with physical examination findings including tenderness on the left upper thoracic wall and right calf, and laboratory tests revealing an elevated D-dimer. The patient's condition does not indicate that she is intubated or suffering from conditions related to airway secretion accumulation or the need for airway clearance, which are the focus of the clinical trial.\n\nThe clinical trial is investigating the efficacy of breathing exercises using the BreatheMAX device on airway secretion clearance and lung function specifically in intubated patients, both with and without mechanical ventilation dependence. The inclusion criteria for the trial require the patient to be intubated, have a clinical and radiologic diagnosis of pulmonary infection or an acute or chronic airway inflammation disease, have stable cardiopulmonary function, stable hydration status, the ability to breathe or tolerate a spontaneous breathing trial, and good consciousness and cooperation.\n\nThe patient in the note does not meet the key inclusion criteria of being intubated with evidence of pulmonary infection or airway inflammation disease, nor is there any indication that she requires airway secretion clearance, which is the primary focus of the intervention being studied.\n\nGiven the information provided, the patient does not fit the inclusion criteria for the clinical trial as she is not intubated, does not have a diagnosis related to airway secretion issues, and there is no mention of her requiring mechanical ventilation support. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1615": {
        "output": "Given the patient note and the clinical trial information provided, it is evident that the patient does not meet the inclusion criteria for the clinical trial. The trial is specifically looking for patients undergoing primary unilateral total knee arthroplasty or primary unilateral total hip arthroplasty under spinal anesthesia. The patient in question is a 56-year-old female who is post-left mastectomy, presenting with shortness of breath and malaise, which is unrelated to the focus of the clinical trial on joint arthroplasty.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1616": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient in the note is a 64-year-old obese female with a diagnosis of diabetes mellitus. The clinical trial is focused on identifying and assessing therapy efficacy for type 2 diabetes in Hispanic patients, specifically in pediatric patients aged 10-18 with type 2 diabetes of youth (type 2Y).\n\nThe inclusion criteria for the clinical trial specify that participants must be pediatric patients (ages 10-18) diagnosed with type 2Y for at least one year. The patient in the note is 64 years old, which is well outside the specified age range for the clinical trial. Therefore, regardless of the patient's ethnicity, obesity, or diabetes status, she does not meet the age requirement for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1617": {
        "output": "The patient presented is a 64-year-old obese female with a diagnosis of diabetes mellitus and an elevated HbA1c level. She has a painful skin lesion on her lower leg that has not responded to topical treatments and is worsening.\n\nComparing the patient's condition to the inclusion criteria of the clinical trial:\n\n1. History of Diabetes Mellitus - The patient has diabetes, which meets this criterion.\n2. Limitation of dorsiflexion ankle range of motion to zero degrees or less \u2013 The patient's note does not mention any limitation in ankle dorsiflexion.\n3. Recurrent or nonhealing ulcer (Grade II, Wagner scale) \u2013 The patient has a skin lesion that is oozing and increasing in size, which may suggest a nonhealing ulcer. However, there is no specific information to determine if it is a foot ulcer or its Wagner grade.\n\nWhile the patient has diabetes, which is one of the inclusion criteria, there is insufficient information about the ankle dorsiflexion and the specific condition of the skin lesion to confidently assess its Wagner grade. Additional information is needed to determine if the patient's skin lesion qualifies as a Grade II ulcer and if there is a limitation in ankle dorsiflexion.\n\nGiven the lack of certain key details in the patient note, I would consider referring this patient to the clinical trial upon further investigation to determine if the skin lesion qualifies as a recurrent or nonhealing ulcer (Grade II, Wagner scale) and to assess the limitation of ankle dorsiflexion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1618": {
        "output": "Based on the patient note provided, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c. She presents with a painful skin lesion on her left lower leg that has increased in size and is now oozing, which seems indicative of a foot ulcer.\n\nThe clinical trial in question is seeking diabetic patients with foot ulcers, which appears to match the patient's condition. Therefore, given this information and the inclusion criteria of the trial, the patient seems to be a suitable candidate for this study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1619": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 64-year-old obese female.\n- She has a diagnosis of diabetes mellitus with persistently elevated HbA1c levels.\n- The patient is not compliant with diabetes medication or exercise.\n- She presents with a painful skin lesion on the lower leg, which may or may not be related to diabetes complications.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on preventing the complications of insulin resistance, including Type-2 diabetes.\n- It targets obese patients with a BMI > 27.\n- It also targets patients with complications of insulin resistance, such as acanthosis nigricans, dyslipidemia, elevated blood pressure, hyperandrogenism.\n- It includes siblings and parents of patients with insulin resistance, but only with documented insulin resistance through OGTT and/or IVGTT.\n- There is a consideration for patients with a family history of type II diabetes.\n\nThe patient is obese, which aligns with the inclusion criteria. Additionally, the patient has diabetes mellitus, which is a clinical manifestation of insulin resistance. However, there is no explicit mention of acanthosis nigricans, dyslipidemia, elevated blood pressure, or hyperandrogenism. Without these specific complications or a clear indication of insulin resistance other than diabetes, it is uncertain whether the patient would be eligible based on complications alone.\n\nThe patient note lacks information on her family history regarding type II diabetes, her exact BMI, and whether there is documented insulin resistance through OGTT or IVGTT.\n\nGiven the information provided, the patient could potentially be eligible due to obesity and the presence of diabetes mellitus (a form of insulin resistance), but additional information would be needed to confirm other aspects of the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1620": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg that is oozing and increasing in size\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of Type I or Type II diabetes mellitus and a glycohemoglobin A1c < 12%\n- Minimum of one neuropathic, diabetic ulcer stage III or IV, located on the distal lower extremity, between 1 and 15 square centimeters\n- No exposed bone at the ulcer site\n- No osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure\n- Adequate arterial circulation to the foot\n- New ulcers must be full-thickness (Stage III or IV), located on feet or ankles, with additional criteria as listed above\n- Recurrent ulcers must meet certain criteria as listed above\n- Female patients must meet specific reproductive criteria\n\nAssessment:\n- The patient has a diagnosis of diabetes mellitus. However, the HbA1c level is not provided in the note, which is a required criterion.\n- The patient complains of a painful skin lesion on the left lower leg, which might be a diabetic ulcer, but there is no information provided about the stage of the ulcer, its exact size, or whether there is exposed bone or osteomyelitis. \n- The note does not mention the patient's arterial circulation status.\n- Reproductive criteria for females in the trial are met as the patient is postmenopausal due to her age.\n\nGiven the information available, the patient has diabetes and a lower extremity skin lesion, which could potentially qualify as a diabetic ulcer appropriate for the study. However, there is insufficient information to confirm the patient's HbA1c level, the exact nature and stage of the ulcer, and her arterial circulation status. Without this information, we cannot definitively determine eligibility.\n\nTherefore, based on the information provided, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1621": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus, which indicates she has either Type 1 or Type 2 diabetes. The inclusion criteria for the clinical trial are:\n\n- People with Type I or Type II Diabetes\n- 18 Years or Older\n\nThe patient meets both inclusion criteria as she is over 18 years old and has been diagnosed with diabetes mellitus. There is no specification in the inclusion criteria regarding the patient's medication compliance or willingness to see a nutritionist, nor is there a mention of HbA1c levels as part of the criteria.\n\nTherefore, the patient appears to be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1622": {
        "output": "Given the patient note and the clinical trial information provided, here is the analysis:\n\nPatient Note Analysis:\n- The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c.\n- The patient is not compliant with her diabetes medication or exercise regimen.\n- She presents with a painful skin lesion on her left lower leg that is not responding to topical treatments and is worsening.\n\nClinical Trial Analysis:\n- The clinical trial is investigating the effect of SACCHACHITIN gel on chronic wound healing in humans.\n- The SACCHACHITIN gel has been shown to inhibit MMP activity and stimulate VEGF in animal models, which may enhance wound healing.\n- The trial is specifically looking to include patients with poorly healed wounds where a skin graft is clinically indicated.\n\nComparing Patient to Inclusion Criteria:\n- The patient has a chronic, non-healing wound that is worsening despite topical treatment, suggesting that more advanced interventions may be required.\n- The trial includes patients with poorly healed wounds that might need skin grafting, which could potentially apply to this patient since the wound is oozing and increasing in size.\n\nBased on the information provided, it seems that the patient could potentially be eligible for the clinical trial since she has a chronic wound that is not healing properly, which aligns with the patient population the trial is aiming to study. However, it is not explicitly stated that her wound requires a skin graft, which is the specific indication for inclusion in the trial. Therefore, further investigation would be needed to determine if the patient's wound meets the clinical criteria of requiring a skin graft.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1623": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- 64-year-old female\n- Diagnosed with diabetes mellitus\n- Non-compliant with diabetes medication\n- Complaints of a painful skin lesion on the left lower leg, which is increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Provision of written informed consent\n- Men or women above 30 years of age\n- Fertile women need to take contraceptives or be sterilized (not applicable here due to age)\n- Diagnosed with any diabetes mellitus type 1 or type 2\n- Present foot ulcer with an ulcer duration <= 12 months\n\nComparison:\n- The patient is above 30 years of age, satisfying the age criterion.\n- The patient has a diagnosis of diabetes mellitus, meeting the diabetes diagnosis criterion.\n- The patient has a painful skin lesion on the lower leg that could potentially be a foot ulcer, which is relevant for the study. However, the duration of the ulcer is not specified in the patient note.\n\nThe most critical piece of information that is missing here is the duration of the foot ulcer. If the ulcer has been present for 12 months or less, the patient would be eligible based on the information provided. Since the patient note does not specify the duration of the ulcer, we would need further investigation to determine eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1624": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility of the patient:\n\nPatient Note Analysis:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliant with diabetes medication and exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- 18 years of age or older\n- Ambulatory\n- Diagnosed Type 2 diabetic (not juvenile onset)\n- Have a diabetic foot ulcer (DFU) on the plantar surface of either foot\n- Have a DFU of >4 weeks but <6 months duration\n- Willing and capable of cooperating to the extent and degree required by the study protocol\n\nComparison:\n- The patient is 64 years old, which meets the age requirement.\n- The patient note does not mention mobility issues, so we might assume the patient is ambulatory.\n- The patient has a diagnosis of diabetes mellitus, which is likely to be Type 2 given the age and no mention of juvenile onset.\n- The skin lesion is described as on the lower leg, not specifically on the plantar surface of the foot, which does not meet the criteria for the location of the diabetic foot ulcer (DFU).\n- The duration of the skin lesion is not specified, so it is unclear if it meets the duration requirement for the DFU.\n- The patient note does not provide information on the patient's willingness and capability to cooperate with the study protocol.\n\nBased on the information provided, the most critical discrepancy is that the lesion is not specified to be on the plantar surface of the foot, which is a requirement for the study. Additionally, the lesion is oozing, which might indicate an infection or a more complicated state than what is described in the inclusion criteria.\n\nTherefore, the patient does not clearly meet the inclusion criteria for the clinical trial, especially due to the location of the skin lesion. The eligibility for referral would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1625": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Prevention of Bacteremia Induced by Debridement of Pressure Ulcer,\" we need to determine if the patient is a candidate for the study. \n\nPatient note summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Non-compliant with diabetes medication and exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical trial inclusion criteria:\n- Patient in the complex nursing department\n- With contaminated pressure ulcers\n- Going to have a debridement procedure\n\nThe patient note does not explicitly mention that the patient has a pressure ulcer; it refers to a painful skin lesion on the leg that is oozing. While this could potentially be a pressure ulcer, there is no definitive information stating this. Additionally, there is no information provided that the patient is in the complex nursing department or that they are scheduled to have a debridement procedure. Therefore, based on the information given, we cannot assume that this patient meets the specific inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1626": {
        "output": "Given the patient's note, we can see that the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus, which is characterized by persistently elevated HbA1c levels. She has a painful skin lesion on her lower leg that is oozing, but the trial is focused on the prevention of foot ulcers through temperature monitoring.\n\nComparing this to the inclusion criteria of the clinical trial, the patient fits the following criteria:\n- Diagnosis of diabetes by WHO criteria\n- Ability to provide informed consent\n- 18-80 years of age\n\nHowever, the clinical trial is specifically aimed at evaluating the effectiveness of a home infrared temperature probe in preventing foot ulcers in diabetic patients with neuropathy. There is no direct mention of the patient having foot ulcers or neuropathy, which are key concerns of the trial. The patient's skin lesion, while potentially related to diabetes, may not be indicative of the kind of foot complications the study is aiming to prevent or manage.\n\nGiven the information provided, the patient does seem to have diabetes, which is a primary condition for the trial, but there is not enough information about her foot health or presence of neuropathy to definitively determine her eligibility based on the trial's focus. Therefore, she may need further evaluation to determine if she is at high risk of foot complications and if she would benefit from the intervention being studied.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1627": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note Analysis:\n- The patient is a 64-year-old female with diagnosed diabetes mellitus.\n- There is a mention of a painful skin lesion on the left lower leg, which has increased in size and is now oozing. \n- There is no explicit mention of the skin lesion being an ulcer, nor is it classified according to the Wagner scale.\n- The patient is non-compliant with diabetes medication or exercise, which is not directly related to eligibility but may affect the patient's adherence to the trial protocol.\n- There is no mention of confirmed sensory neuropathy.\n\nClinical Trial Inclusion Criteria:\n- Confirmed diabetes (the patient has this).\n- Neuropathic ulcer grade 1/2 on the Wagner scale (not explicitly mentioned in the patient note).\n- Confirmed sensory neuropathy (not mentioned in the patient note).\n\nBased on the information provided, the patient has diabetes, which aligns with one of the trial's inclusion criteria. However, there is not enough information to determine if the skin lesion is a neuropathic ulcer grade 1/2 on the Wagner scale or if the patient has confirmed sensory neuropathy. Before referring the patient to the clinical trial, further investigation would be required to confirm the nature of the skin lesion and the presence of sensory neuropathy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1628": {
        "output": "Upon reviewing the patient's information and comparing it with the inclusion criteria for the clinical trial titled \"Improving Care for Patients With Diabetes and Poor Numeracy Skills,\" the patient appears to meet several of the specified criteria for eligibility:\n\n1. Clinical diagnosis of Type 1 or 2 Diabetes: The patient has been diagnosed with diabetes mellitus.\n2. Most recent A1C greater than or equal to 7.0%: The patient's HbA1c is described as persistently elevated, which likely meets or exceeds the 7.0% threshold.\n3. Referred to the Diabetes Improvement Program for diabetes care: There is no mention of a referral to a Diabetes Improvement Program in the patient note provided. This would require further investigation.\n4. Age 18-80: The patient is 64 years old, which falls within the specified age range.\n5. English Speaking: There is no information provided about the patient's language proficiency. This would require further investigation.\n\nGiven that the patient meets the age and diabetes diagnosis criteria, and likely meets the A1C level criterion, I would consider referring this patient to the clinical trial upon further investigation into whether they have been referred to a Diabetes Improvement Program and confirmation of their English language proficiency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1629": {
        "output": "After reviewing the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nThe patient is a 64-year-old obese female with a diagnosis of diabetes mellitus, which meets the inclusion criteria of having Type I or Type II Diabetes. Additionally, the patient has a painful skin lesion on the left lower leg, which is consistent with having a diabetic foot ulcer, also mentioned in the inclusion criteria.\n\nHowever, the trial requires the ulcer to be a plantar forefoot ulcer(s) beneath metatarsal head or toe ulcer, and there is no specific mention in the patient note that the lesion is located in this area or that it has been present for at least 4 weeks. The note does not provide information about the patient's arterial perfusion status, platelet count, whether infection or osteomyelitis have been ruled out or are being treated, or if an orthopedic assessment has been completed to rule out a mechanical source of ulceration. It also does not mention if the patient is appropriately offloaded.\n\nGiven the missing information, it is not clear if the patient meets all the inclusion criteria for the trial. Thus, further investigation would be needed to determine the exact nature and duration of the ulcer, as well as the other medical assessments required by the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1630": {
        "output": "Based on the information provided in the patient note, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c. She has a painful skin lesion on her left lower leg that is increasing in size and oozing, which may suggest a diabetic ulcer or another skin condition, but not necessarily ulcerative colitis (UC).\n\nThe clinical trial in question is seeking participants with active ulcerative colitis, with a CAI (Clinical Activity Index) greater than or equal to 4. There is no mention of ulcerative colitis in the patient's note, nor is there any indication that the skin lesion is related to UC. Therefore, the patient does not meet the specific inclusion criteria for the clinical trial provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1631": {
        "output": "",
        "label": 0
    },
    "1632": {
        "output": "Based on the information provided in the patient note, let's evaluate the patient's eligibility for the clinical trial regarding the use of bemiparin for chronic foot ulcers in diabetic patients.\n\nPatient note assessment:\n- Age: 64 years old (meets the criteria of age over 18 years)\n- Type of diabetes: Diabetes mellitus is mentioned, but it is not specified whether it is type I or II (further clarification needed)\n- Duration of diabetes: Not specified, but given the age and the mention of persistently elevated HbA1c, it is plausible that the patient has had diabetes for more than 3 years (likely meets criteria but requires confirmation)\n- Presence of a cutaneous ulcer: The patient has a painful skin lesion on the left lower leg, which has increased in size and is oozing. This could qualify as an ulcer, but it's not explicitly stated that it is an ulcer (further investigation needed)\n- Wagner's classification: The stage of the lesion is not provided. It needs to be determined if it fits the criteria of stages I or II (further clarification needed)\n- Duration of the ulcer: Not specified if the lesion has been present for at least three months (further clarification needed)\n- Informed Consent: The patient's willingness to give written informed consent cannot be determined from the note (further clarification needed)\n\nBased on the above points, the patient's eligibility for the clinical trial cannot be confirmed without additional information. The note suggests potential eligibility, but key details such as the specific type of diabetes, the duration of the lesion, its classification as an ulcer, and the patient's willingness to participate are missing.\n\nTherefore, the most appropriate assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1633": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, it seems that the patient does not match the specific requirements of the trial. The patient is described as having diabetes mellitus with an elevated HbA1c and a painful skin lesion, but there is no mention of the patient having end-stage renal disease (ESRD) or being treated by hemodialysis. Since having ESRD and being treated by hemodialysis are key inclusion criteria for the clinical trial, and these conditions are not indicated in the patient note, the patient would not be eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1634": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effectiveness of XCell on Autolytic Debridement of Venous Ulcers,\" we'll compare the patient's condition with the inclusion criteria provided for the trial.\n\nHere are the inclusion criteria for the trial:\n1. Patients of any race and are between 18 and 90 years of age.\n2. Patients that are able to understand and are willing to give written informed consent.\n3. Patients that have a non-healing open venous ulcer for at least one month.\n4. Patients that have greater than 50% of the ulcers surface area covered with non-viable tissue such as fibrin slough, dry crust, or a combination of both.\n5. Patients that have the clinical signs and symptoms of venous ulceration such as varicosities, hyper pigmentation, stasis dermatitis, lipodermatosclerosis, and edema.\n6. Patients that have a venous ulcer with a surface area of greater than or equal to 1.5 cm2.\n7. Patients that have an ankle to brachial index (ABI) > 0.70.\n\nNow let's look at the patient note:\n- 64-year-old obese female (meets age criterion)\n- Diagnosis of diabetes mellitus (not directly relevant to inclusion criteria)\n- Painful skin lesion on the left lower leg (could be a venous ulcer, needs further investigation)\n- The lesion has increased in size and is now oozing (suggests a non-healing open wound, potentially qualifying as a venous ulcer)\n- No mention of understanding and willingness to consent, duration of the ulcer, percentage of non-viable tissue, clinical signs and symptoms specific to venous ulceration, surface area of the ulcer, or ABI value.\n\nBased on the available information, the patient potentially has a venous ulcer, which is a criterion for the trial. However, there is insufficient information to determine if the patient fully meets the inclusion criteria (e.g., duration of the ulcer, percentage of non-viable tissue, clinical signs of venous ulceration, surface area, and ABI). Therefore, further investigation is required to assess these aspects.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1635": {
        "output": "Based on the patient note provided, let's assess the patient's eligibility against the inclusion criteria of the clinical trial.\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Not compliant with diabetes medication or exercise\n- Painful skin lesion, not the focus of the diabetes trial\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of Type 2 Diabetes\n- Most recent A1C >= 7.5%\n- Referred to the Diabetes Care Program for diabetes care\n- Age 18-85\n- English Speaking\n\nAssessment:\n- The patient has a clinical diagnosis of type 2 diabetes.\n- The patient has an elevated HbA1c, which is likely to be above 7.5% given the description of persistently elevated levels.\n- The patient's non-compliance with medication suggests a need for improved diabetes care, which aligns with the aim of the trial to teach self-management skills.\n- The patient is within the age range of 18-85.\n- There is no information on the patient's language skills, but we might assume she is English speaking unless otherwise stated.\n\nThe provided patient note does not indicate whether the patient has been referred to the Diabetes Care Program, which is a requirement for the trial. Without this information, we cannot definitively conclude the patient's eligibility. However, given the patient's diagnosis and elevated HbA1c, which meet some of the key inclusion criteria, the patient might be a candidate for referral to the Diabetes Care Program and subsequent participation in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1636": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"The Effects of Vacuum-Compression Therapy on the Healing of Diabetic Foot Ulcers,\" we need to consider the following:\n\nPatient Details:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliance with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, which is oozing\n\nClinical Trial Inclusion Criteria:\n- A diabetic foot ulcer corresponding to grade 2\n- No history of deep venous thrombosis\n- No hemorrhage in ulcer\n\nThe patient note indicates that the patient has a painful skin lesion on the left lower leg, which suggests the possibility of a diabetic foot ulcer. However, there is no specific mention of the ulcer being grade 2, nor is there mention of a history of deep venous thrombosis or hemorrhage in the ulcer. Without further information about the grade of the ulcer, it's challenging to determine whether the patient's skin lesion meets the specific requirements of a grade 2 diabetic foot ulcer. Additionally, the absence of history regarding deep venous thrombosis or hemorrhage is not indicated.\n\nTherefore, the patient may be a potential candidate for the trial but would require further investigation to confirm the specifics of the lesion and to ensure all inclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1637": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers,\" let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Noncompliant with diabetes medication and exercise regimen\n- Painful skin lesion on the left lower leg, which is oozing and has increased in size despite the use of topical lotions and creams\n\nInclusion Criteria for the Clinical Trial:\n- Diabetic ulcer of primarily neuropathic origin on the plantar region of the forefoot\n- Ulcer extending through the dermis but without sinus tract, tendon, capsule, or bone exposure\n- Ulcer present for at least 2 weeks and measuring 1-16 cm2\n- Diminished sensation on the target extremity/foot\n- Ulcer is not infected\n- Type 1 or 2 diabetes with adequate glycemic control\n- Adequate vascular supply to the target extremity\n\nAssessment:\n- The patient has diabetes, which aligns with the trial's target demographic.\n- The note does not specify the exact location of the lesion, so it's unclear if the ulcer is on the plantar region of the forefoot.\n- There is no information about the ulcer's duration, size, or whether there is sinus tract, tendon, capsule, or bone exposure.\n- The patient's compliance issues and elevated HbA1c suggest that her glycemic control may not be adequate, which is a requirement for the trial.\n- The patient's vascular supply status is not mentioned.\n- The presence of oozing might indicate infection, which would be an exclusion criterion if confirmed.\n\nGiven the information provided, the patient does not clearly meet several of the specified inclusion criteria, particularly regarding the ulcer's characteristics and the patient's glycemic control. Without further details about the ulcer and confirmation of the patient's vascular status and infection status, it would be premature to determine the patient's eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1638": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient Note Analysis:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliant with medication or exercise\n- Complains of a painful skin lesion on the left lower leg that is oozing\n\nClinical Trial Inclusion Criteria Analysis:\n- Male or females, in good health, and at least 12 years of age\n- Individuals with 2 or more keloids on the trunk, arm, leg, and neck between 0.5 and 2 cm in length\n- Individuals who are willing and able to participate in the requirements of the study, including signing the informed consent\n- In the opinion of the investigator, the 2 keloids can be excised in a similar manner and closed properly with the two techniques and will benefit from the procedure\n- In the opinion of the investigator, the keloid could benefit from surgical procedure\n\nComparison:\n- The patient is female and over 12 years of age, which meets the age and gender criteria.\n- The patient has a skin lesion, but there is no mention that it is a keloid, nor is there any indication that she has two or more keloids required by the study.\n- The health status of the patient is in question due to non-compliance with diabetes management and no indication that she is in 'good health' as required.\n- The study requires the individual to be willing and able to participate, which might be questionable given the patient's reluctance to see a nutritionist and non-compliance with diabetes management.\n- There is no information to suggest that the lesion is a keloid, nor that there are multiple lesions, which is a critical factor for inclusion.\n\nGiven that the patient's skin lesion is not confirmed to be a keloid and there is no mention of multiple keloids, along with the patient's questionable health status due to diabetes, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1639": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliant with diabetes medication\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- A current hemoglobin A1c (HbA1c) of >8.0%\n- An average HbA1c of >8.0% during the past year\n- Diagnosed with Type 1 diabetes for at least one year\n- Reside in the metro Detroit tri-county area\n\nThe patient has diabetes mellitus with persistently elevated HbA1c, which suggests the possibility of meeting the HbA1c-related criteria. However, the patient information does not specify the type of diabetes (Type 1 or Type 2), which is crucial for determining eligibility since the trial is specifically for those with Type 1 diabetes. Additionally, there is no information provided about the patient's residence to confirm if they live in the specified tri-county area.\n\nGiven the lack of specific information confirming the type of diabetes and the patient's residence, it would be necessary to further investigate these details to determine eligibility before considering referral. Therefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1640": {
        "output": "Given the patient note, we have a 64-year-old obese female with diabetes mellitus and an elevated HbA1c. She also has a painful skin lesion on the lower leg, which is oozing and increasing in size despite using topical lotions and creams. This suggests she may have a diabetic foot ulcer, which is a common complication of diabetes.\n\nNow let's compare this with the clinical trial inclusion criteria:\n\n1. Patients who are at least 18 years of age. (The patient is 64, so meets this criterion.)\n2. Males and females (provided they are not pregnant or, if of reproductive age, are using contraception). (The patient is female, and there is no information suggesting she is of reproductive age or pregnant.)\n3. Patients with a venous stasis, diabetic foot, or decubitus reference ulcer located between the tibia and foot. (The patient has a painful skin lesion on the left lower leg, which could be indicative of a diabetic foot ulcer, meeting this criterion.)\n4. Patients undergoing surgical debridement of their reference ulcer in the operating room (OR). (The patient's current condition may require surgical intervention, considering the increase in size and oozing.)\n5. Patients undergoing their first surgical debridement of the reference ulcer. (There is no information provided about previous surgical debridement, so it's not clear if this is the patient's first time.)\n6. Patients suitable for debridement of their reference ulcer with both VERSAJET\u2122 and conventional debridement techniques. (The patient's lesion seems to be in a condition that might require debridement, suggesting suitability.)\n7. Patients who are able to understand the evaluation and are willing and able to provide written consent to participate in the evaluation. (There is no information suggesting the patient is unable to understand the evaluation or provide consent.)\n\nBased on the information available, the patient appears to meet most of the inclusion criteria for the clinical trial, with the main uncertainty being whether her lesion is indeed a diabetic foot ulcer and whether this would be her first surgical debridement. However, since these details can be confirmed upon further investigation, the patient seems to be a potential candidate for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1641": {
        "output": "Based on the patient note provided, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus. She has a painful skin lesion on her lower leg that is not responding to topical treatments and has increased in size and is oozing. This could indicate a chronic wound, which is potentially suitable for the clinical trial in question.\n\nThe clinical trial is looking for participants who are over 18 years old, have Type 1 or Type 2 diabetes mellitus, and a Wagner grading of foot lesions 3 or 4 on the lower limb that have not healed for 4 weeks. While the patient note does not specifically mention the Wagner grade of the foot lesion, the fact that it is a non-healing and worsening lesion suggests that it could be severe enough to meet the criteria for Wagner grade 3 or 4.\n\nGiven the information provided, the patient appears to meet the age and diabetes diagnosis criteria. However, to accurately determine the Wagner grade of the lesion and confirm that the lesion has persisted for at least 4 weeks, further investigation is required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1642": {
        "output": "Based on the patient note provided, here are the key points that need to be compared with the clinical trial inclusion criteria:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliance with diabetes medication or exercise\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- Type 1 diabetes\n- Type 2 diabetes\n- Candidates of use of a basal insulin as part of their diabetes regimen\n\nComparison:\n- The patient has a diagnosis of diabetes mellitus. The type of diabetes is not specified, but both Type 1 and Type 2 diabetes are included in the trial.\n- The patient seems to be a candidate for basal insulin use as part of their regimen, given her non-compliance with her current diabetes medication.\n\nAssessment:\nSince the patient has diabetes and is potentially a candidate for a change in her diabetes management regimen to include basal insulin (like Levemir\u00ae), she could be considered for the clinical trial. However, there is no explicit mention of her current treatment regimen, so it is not absolutely clear whether Levemir\u00ae would be an appropriate addition or replacement. Further investigation into her current treatment and a discussion about the potential benefits and changes with Levemir\u00ae would be necessary.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1643": {
        "output": "To determine the patient's eligibility, let's compare the patient note with the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c (implies poor metabolic control)\n- Non-compliant with diabetes medication\n- No mention of dyslipidemia or LDL levels\n- No mention of health plan enrollment or medication dispensing history\n\nClinical Trial Inclusion Criteria:\n- At least 2 dispensings for oral medications used to treat diabetes and dyslipidemia in the last 18 months (not specified in the patient note)\n- At least one laboratory result for both glycated hemoglobin and LDL-cholesterol in the last 6 months (HbA1c is mentioned, but LDL-cholesterol is not)\n- Average HbA1c \u2265 7% OR an average LDL \u2265 100 mg/dL (HbA1c is implied to be elevated, but specific values are not provided)\n- Continuous health plan enrollment currently and in the previous calendar year with no more than a 1-month lapse of coverage, and benefits that include both medical and pharmacy coverage (not specified in the patient note)\n\nThe patient appears to have poorly controlled diabetes, which is a focus of the clinical trial. However, there is insufficient information provided in the note to confirm that all the inclusion criteria are met, specifically concerning medication dispensing history, LDL-cholesterol levels, and health plan enrollment.\n\nTherefore, given the information available, I would consider referring this patient to the clinical trial upon further investigation to confirm the missing details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1644": {
        "output": "Based on the patient note provided, the 64-year-old female patient has a diagnosis of diabetes mellitus with an elevated HbA1c level and has a painful skin lesion on the left lower leg that is oozing. This does not align with the inclusion criteria of the clinical trial, which is focused on patients with corneal ulcers that are diagnosed by an ophthalmologist and exhibit specific features related to the eye condition.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. The patient must be diagnosed with a corneal ulcer by an ophthalmologist.\n2. The corneal ulcer must have at least 2 of the following features:\n   - Corneal epithelial defect with stromal infiltration.\n   - Reaction in the anterior chamber.\n   - Positive for bacteria or fungus.\n3. The patient must have received a subconjunctival antibiotic injection at least twice.\n4. The patient must provide informed consent.\n\nThe patient's condition related to diabetes and a skin lesion does not meet the requirements of the clinical trial, which is focused on an entirely different medical issue (corneal ulcers). Therefore, this patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1645": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for Biatain Ag vs Biatain in the Treatment of Leg Ulcers, the patient appears to be a potential candidate for the trial. The patient is over 18 years old and has a painful skin lesion on the lower leg that has increased in size and is oozing, which may be indicative of a leg ulcer that is not healing properly despite the use of topical treatments. \n\nHowever, there are several specific criteria we would need to verify before referring the patient:\n\n1. Whether the leg ulcer is venous or predominantly venous (ankle-brachial index > 0.8). This would require a medical assessment.\n2. The size of the ulcer (between 2 cm and 13 cm in all directions).\n3. The level of exudate (moderately or severely exudating leg ulcer).\n4. Confirmation that the ulcer is in the phase of debridement or formation of granulation tissue.\n5. Evidence that the ulcer has not been healing properly despite suitable and well-conducted local treatment in the four weeks prior to inclusion.\n6. Confirmation that the patient has been treated with appropriate compression in the four weeks prior to inclusion.\n7. The patient's availability for monitoring for at least 10 weeks.\n\nGiven that the patient note indicates a persistently unhealing lesion but lacks specific details to confirm all the inclusion criteria, the appropriate action would be to consider referring this patient to the clinical trial upon further investigation to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1646": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria Summary:\n- Subject has had a brain injury at least 12 months prior to study enrollment\n- Subject is at least 18 years old\n- Etiology of brain injury: Stroke, anoxia, and trauma\n- Must be able to equalize ears, or have tympanostomy tubes\n- Willingness to complete outcome measures and complies with the research protocols\n- Commitment to pay the hospital for hyperbaric oxygen\n\nAssessment:\nThe clinical trial is focused on subjects with a history of chronic stable brain injury due to trauma, anoxia, or stroke. The patient in question does not have a reported history of brain injury; instead, she has diabetes with complications of a skin lesion. There is no mention of brain injury, stroke, anoxia, or trauma in her history. Therefore, she does not meet the key inclusion criteria for the trial related to the etiology of the condition being studied.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1647": {
        "output": "Based on the patient note provided, the 64-year-old female patient has a diagnosis of diabetes mellitus with a persistently elevated HbA1c. She has a painful skin lesion on her left lower leg, which has increased in size and is now oozing. This could potentially be indicative of a diabetic foot ulcer.\n\nComparing the patient's condition with the inclusion criteria of the clinical trial \"Trial of Herb Yuyang Ointment to Diabetic Foot Ulcer\":\n\n- The patient is over 18 years of age.\n- The patient has a diagnosis of diabetes mellitus.\n- The patient has a painful skin lesion on the lower leg, potentially a diabetic foot ulcer that has been present and worsening despite the use of topical treatments, suggesting it could have occurred more than 3 weeks ago.\n\nWhile the patient note does not explicitly state that the lesion is a diabetic foot ulcer, the description provided is consistent with such a diagnosis. However, to confirm trial eligibility, a clinical confirmation of a diabetic foot ulcer diagnosis would be necessary. Since the patient is non-compliant with diabetes management and the lesion seems to be persisting and worsening, it is reasonable to consider the patient for the clinical trial, pending confirmation of the ulcer diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1648": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial.\n\nThe patient is described as:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Reluctant to see a nutritionist\n- Non-compliant with diabetes medication or exercise\n- Complains of a painful skin lesion on the left lower leg\n\nThe clinical trial's inclusion criteria are:\n- Age 18-70\n- Primary trigeminal neuralgia (TN) patient (MRI examination support diagnosis)\n- Suffering from this pain for at least 3 months\n- VAS (Visual Analogue Scale for pain) > 40mm\n- Patient can assess pain intensity correctly\n\nComparison:\n- Age: The patient is 64 years old, which is within the trial's age range of 18-70 years.\n- Condition: However, the patient has a skin lesion related to diabetes, not trigeminal neuralgia. There is no mention of trigeminal neuralgia or facial pain in the patient note.\n- Pain duration: Not applicable since the patient does not have trigeminal neuralgia.\n- Pain assessment: Not applicable since the patient does not have trigeminal neuralgia.\n\nThe patient does not meet the essential inclusion criterion of having a diagnosis of primary trigeminal neuralgia. Therefore, she would not be eligible for the clinical trial focused on hyperbaric oxygen treatment for trigeminal neuralgia patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1649": {
        "output": "",
        "label": 0
    },
    "1650": {
        "output": "Based on the information provided in the patient note, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c, indicating poor diabetes control. She is non-compliant with her diabetes medication and exercise regimen. However, there is no mention of at-risk drinking in the past month, which is one of the inclusion criteria for the clinical trial.\n\nGiven the lack of information on the patient's alcohol consumption, we cannot determine if the patient meets the criterion of \"report at-risk drinking in past month.\" Therefore, we cannot conclude that the patient is eligible for the trial based solely on the information provided. However, since the patient does have poor diabetes treatment adherence, which is one of the inclusion criteria, it might be worth investigating further to ascertain her alcohol consumption habits.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1651": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's analyze the patient's eligibility:\n\n- Age from 40 to 70 years: The patient is 64 years old, which meets this criterion.\n- Type 2 diabetic patients: The patient has a diagnosis of diabetes mellitus.\n- Bilateral critical limb ischemia (ABI from 0.30 to 0.60): The patient note does not mention the ankle-brachial index (ABI) or confirm the presence of critical limb ischemia.\n- At least with one foot ulcer: The patient has a painful skin lesion on the left lower leg that is oozing, which may indicate an ulcer, but it is not specifically described as a foot ulcer, nor is it clearly indicated that the lesion is due to ischemia.\n\nThe patient meets some of the inclusion criteria (age and diagnosis of diabetes mellitus), but the note lacks specific details regarding the presence of bilateral critical limb ischemia and a confirmed foot ulcer. Without this information, it's unclear whether the skin lesion is due to critical limb ischemia, which is essential for the trial's focus.\n\nSince critical limb ischemia and a foot ulcer are required as part of the inclusion criteria, and the patient note does not confirm these conditions, further investigation would be needed to determine eligibility. Therefore, the patient may potentially be eligible, but more information is needed to make a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1652": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers, let's evaluate the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 64-year-old obese female.\n- She has a diagnosis of diabetes mellitus with persistently elevated HbA1c levels.\n- She is non-compliant with diabetes medication and exercise.\n- She complains of a painful skin lesion on the left lower leg that is oozing and has increased in size despite using topical lotions and creams.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients 18 years of age or older. (The patient is 64, so she meets this criterion.)\n- Able to give informed consent and follow the treatment procedure. (There is no information to suggest the patient cannot consent or follow procedures.)\n- Target ulcer area between 1 and 30 cm\u00b2. (The exact size of the lesion is not provided, but it is described as having increased in size, so further investigation would be needed to confirm.)\n- Leg ulcers diagnosed as hypertensive MARTORELL's ulcers. (The patient has a painful skin lesion on the leg; however, it is not specified if it is a hypertensive ulcer.)\n- Presence of arterial hypertension, treated or not. (Not mentioned in the patient note.)\n- Presence of diabetes treated by oral agent, insulin, or diet. (The patient has diabetes, which is being treated, although non-compliantly.)\n- Absence of clinical signs of chronic venous insufficiency. (Not mentioned in the patient note.)\n- Absence of significant peripheral arterial occlusive disease. (Not mentioned in the patient note.)\n- Absence of clinical sign of arterial insufficiency. (Not mentioned in the patient note.)\n- Superficial spreading necrotic ulcer. (The lesion is described as oozing but not specifically as necrotic.)\n- Presence of spontaneous pain. (The lesion is described as painful.)\n- Presence of a red purpuric margin. (Not mentioned in the patient note.)\n\nGiven the information provided, the patient meets some of the inclusion criteria (age, diabetes, painful lesion), but there are several critical details missing that are necessary to confirm eligibility, such as the specific diagnosis of the leg ulcer, presence of hypertension, and absence of venous and arterial issues. \n\nTherefore, further investigation would be necessary to determine if the patient's leg ulcer is indeed a hypertensive MARTORELL's ulcer and to assess other vascular aspects of her condition. Until these details are confirmed, the patient cannot be considered a definitive match for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1653": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we'll compare the patient note against the inclusion criteria of the trial:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg\n- Lesion has increased in size and is now oozing\n\nClinical Trial Inclusion Criteria:\n- Subject must have evidence of a full-thickness cutaneous wound of at least 30 days duration.\n- Subject must be at least 18 years of age.\n- Subject must have a minimum life expectancy of at least 1 year to be determined by the Investigator.\n- The study ulcer must be from 1 cm2 to 20 cm2 in size.\n- The study ulcer must have been present for at least 30 days at study Day -7.\n- The subject's Glycosylated hemoglobin (HbA1C) must be equal to or less than 10.0% for subjects with diagnosed diabetes at study Day 0.\n- The subject, legal guardian or authorized representative must have understood, signed and dated the IRB approved informed consent form.\n- The subject must be available for evaluation on a weekly basis for the twelve (12) weeks of the study. Visits at Week 13 and Week 14 are required for initial wound healing, which is achieved in study Week 11 or 12. The Investigator will evaluate both groups at Week 16. Subjects must be available for evaluation at Week 16.\n- The subject's TCpO2 must be equal to or greater than 25 mm of mercury in the periwound area and ABI greater than 0.7.\n\nAssessment:\n- The patient is of eligible age (\u226518 years).\n- The patient has a chronic skin lesion, which may satisfy the full-thickness cutaneous wound criterion if it is at least 30 days in duration.\n- There is no information about the size of the wound, life expectancy, TCpO2 levels, or ABI values, so we cannot confirm these criteria.\n- The patient's HbA1c is described as \"persistently elevated,\" but we do not have a specific value to confirm that it is equal to or less than 10.0%.\n\nGiven the information provided, the patient could potentially be eligible for the trial if the wound meets the specified criteria regarding size and duration, and if her HbA1c level is equal to or less than 10.0%. However, since there is insufficient information to conclusively determine her eligibility, the patient would require further investigation to assess these factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1654": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the clinical trial:\n\nPatient note:\n- 64-year-old obese female with a diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical trial criteria:\n- Diagnosed with Type 1 or 2 diabetes mellitus\n- Diagnosed with diabetic peripheral neuropathy\n- Palpable or biphasic pulses\n- Intact from lower limb vascular or neuropathic ulceration, scoring Grade 0 on the Wagner classification for foot ulcer\n- Able to walk a minimum of 10 meters unaided\n- Willing to comply with the requirements of the study\n\nComparison:\n- The patient has diabetes mellitus, which matches the trial criteria.\n- It is not explicitly mentioned if the patient has been diagnosed with diabetic peripheral neuropathy, which is a trial criterion.\n- The patient's leg lesion could be indicative of a complication from diabetes, possibly an ulcer, but we do not have information on its classification according to the Wagner scale.\n- There is no information on the patient's pulses, which is necessary to determine vascular status as per the trial criteria.\n- The patient's ability to walk unaided is not mentioned.\n- The patient is described as non-compliant with medication and exercise, which may affect their willingness to comply with the trial requirements.\n\nGiven the information available, the patient does have diabetes mellitus, which is one of the prerequisites for the trial. However, there is insufficient information to confirm eligibility based on the other criteria, such as the presence of diabetic peripheral neuropathy, the status of pulses, walking ability, and willingness to comply with the study. The skin lesion's description suggests the possibility of an ulcer, which might disqualify the patient if it does not score Grade 0 on the Wagner classification.\n\nDue to these uncertainties and potential non-compliance, the patient would need further assessment to determine trial eligibility. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1655": {
        "output": "Based on the provided patient note and clinical trial information:\n\nPatient Note:\n- 64-year-old obese female with a diagnosis of diabetes mellitus.\n- Persistently elevated HbA1c, non-compliance with medication and exercise.\n- Painful skin lesion on the left lower leg, which has increased in size and is now oozing.\n\nClinical Trial:\n- Title: Removable Walker for Neuropathic Ulcers\n- Objective: Evaluate the efficacy of removable cast walker vs. non-removable fiberglass off-bearing cast in treating diabetic plantar foot ulcer.\n- Inclusion Criteria:\n  - The presence of neuropathic plantar ulcer graded IA according to the Texas University classification.\n  - The presence of peripheral neuropathy, diagnosed by insensitivity to a 10-g Semmes-Weinstein monofilament and a vibration perception threshold > 25 volts at the malleolus.\n\nThe patient's eligibility for the trial hinges on whether her skin lesion is a neuropathic plantar ulcer graded IA and if she has peripheral neuropathy meeting the specified diagnostic criteria. While the patient has diabetes, which is commonly associated with neuropathic ulcers and peripheral neuropathy, we do not have enough information from the note to determine if her skin lesion is a neuropathic plantar ulcer or if she has been diagnosed with peripheral neuropathy as defined by the trial's criteria.\n\nTherefore, further investigation is needed to assess the type of ulcer and to perform the specific diagnostic tests for peripheral neuropathy. Only with this additional information would we know if she fits the trial's specific inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1656": {
        "output": "To determine the patient's eligibility for the clinical trial, we must evaluate the patient note against each of the inclusion criteria listed for the trial:\n\n1. Is the subject 18 years of age or older? - Yes, the patient is 64 years old.\n2. Does the subject have a chronic full thickness diabetic foot ulcer (DFU) inferior to the malleolus that has been present for a minimum of four (4) weeks? - The patient note indicates a painful skin lesion on the left lower leg, but there is no information about the duration or confirmation that it is a full thickness DFU.\n3. Does the diabetic foot ulcer measure greater than 1.0 cm2 and less than 25.0 cm2 after the wound is debrided? - There is no information provided about the size of the lesion.\n4. Does the subject show evidence of neuropathy? - Not specifically mentioned, but neuropathy is common in diabetic patients.\n5. Is the subject's wound free of tunneling and showing no exposed periosteum or bone and free of clinical infection defined as the presence of local signs and symptoms including purulence, warmth, tenderness, pain, induration, cellulitis, bullae, crepitus, abscess, fasciitis and osteomyelitis? - The lesion is oozing, which could indicate infection, but there is no detailed information on other signs of clinical infection or the presence of tunneling, exposed periosteum, or bone.\n6. Is the study wound able to be offloaded or achieve pressure relief and permit daily dressing changes? - There is no information provided.\n7. Is the subject willing to have three (3) wound biopsies taken (Visit 0, 4 and 8)? - There is no information provided about the patient's willingness.\n8. Is the subject willing to have photos taken of their wound and permit use of the photos in publications? - There is no information provided about the patient's willingness.\n9. Has the subject or their legally authorized representative signed an Institutional Review Board approved informed consent document and authorized the use and disclosure of protected health information? - There is no information provided.\n10. Does the subject have adequate circulation to the foot as evidenced by an Ankle Brachial Index (ABI) of 0.8 - 1.2; or if the ABI is greater than 1.2, does the subject show toe pressures >40 mmHg, or transcutaneous oximetry (TcPO2) > 40 mm Hg, or does the subject show adequate circulation on an arterial Doppler study? (ABI or Doppler results must be < 45 days old.) - There is no information provided about the patient's circulation.\n11. Is the subject able to comply with the protocol requirements? - The patient is not compliant with her diabetes medication or exercise, which may affect her ability to comply with the protocol.\n12. If the subject is a woman of childbearing potential is she practicing an acceptable form of birth control as determined by the Investigator, and is she willing to have a pregnancy test? - This is applicable only if the patient is of childbearing potential, which at 64 years old may not be the case.\n\nBased on the available information, there are many unknowns that prevent a clear determination of eligibility. The patient does have diabetes and a skin lesion, which could potentially qualify her for the study if it's confirmed to be a diabetic foot ulcer. However, the lack of information on several key inclusion criteria, particularly the specifics of the lesion, patient compliance, and willingness to participate in certain study procedures, makes it difficult to confidently refer the patient for the trial without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1657": {
        "output": "Patient note:\n64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.\n\nClinical trial (Part 2 relevant to patient):\nTitle: A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes\n\nInclusion criteria for trial part 2:\n- Gender: male or female of no childbearing potential\n- Age: 18-65 years\n- Type 1 diabetes: BMI (body mass index): 18-28 kg/m2\n- Type 2 diabetes: BMI (body mass index): 22-35 kg/m2\n- Type 1 or type 2 diabetes for at least 12 months\n- Type 1 diabetes: Treatment with insulin for at least 12 months\n- Type 2 diabetes: Treatment with insulin for at least 3 months\n\nAssessment:\n- The patient is within the age range (18-65 years).\n- The patient has type 2 diabetes, which is among the target conditions.\n- The patient\u2019s gender is female, which is acceptable provided she is of no childbearing potential.\n- The patient's BMI is not provided, but she is described as obese. The BMI range for type 2 diabetes inclusion is 22-35 kg/m2, and obesity could potentially place her outside this range (BMI \u2265 30 kg/m2).\n- There is no information about the duration of diabetes or insulin treatment. The patient is not compliant with her diabetes medication, which may or may not include insulin.\n\nGiven that the patient's exact BMI is not provided and we lack information about her diabetes medication compliance, particularly with respect to insulin treatment, further investigation would be needed to determine her eligibility based on these specific criteria. \n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1658": {
        "output": "To assess the trial-level eligibility of the patient for the clinical trial, we need to match the patient's characteristics and medical condition with the inclusion criteria of the study.\n\nPatient Characteristics:\n- 64-year-old female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliant with diabetes medication\n- No information provided about LDL levels\n- No information provided about cholesterol-lowering drug therapy duration\n- No information provided about the number of primary care visits\n\nClinical Trial Inclusion Criteria:\n- Adults with diabetes\n- LDL greater than or equal to 100\n- Cholesterol-lowering drug therapy for more than 6 months\n- A working telephone\n- At least 2 primary care visits in the past 1.5 years\n\nBased on the information provided, the patient clearly has diabetes, which meets one of the inclusion criteria. However, we do not have information on her LDL levels, the duration of cholesterol-lowering drug therapy, or the number of primary care visits in the past 1.5 years. To determine her eligibility, we would need to obtain this information. Since the patient has diabetes and poor adherence, which is a focus of the study, she could potentially benefit from the interventions being tested.\n\nGiven the information we have, we can't definitively determine her eligibility; therefore, further investigation is needed to gather additional relevant data, such as her LDL levels, duration of cholesterol-lowering drug therapy, and primary care visit history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1659": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- Adult with type 1 or 2 diabetes with or without neuropathy\n\nThe patient in the note meets the age requirement and has a diagnosis of diabetes mellitus, which are part of the inclusion criteria for the clinical trial. The clinical trial is focused on evaluating bone abnormalities in diabetic patients, and while the patient note does not explicitly mention neuropathy or bone issues, peripheral neuropathy can be a common complication in patients with long-standing, poorly controlled diabetes, which seems to be the case given the patient's non-compliance with medication and persistently elevated HbA1c.\n\nGiven the information provided, the patient could potentially have undiagnosed neuropathy or be at risk for bone density issues related to diabetes, which the trial aims to evaluate. Therefore, the patient could be considered for the clinical trial upon further investigation to confirm the presence of neuropathy or any signs of bone density issues.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1660": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers,\" we need to compare the patient's characteristics and conditions with the inclusion criteria provided:\n\n1. Patient is 18 years of age or older. \u2013 The patient is 64 years old, which meets this criterion.\n2. Patient has type I or II diabetes. \u2013 The patient has diabetes mellitus, which meets this criterion.\n3. Foot ulcer has been present for a minimum of 2 weeks under the current investigator's care. \u2013 The patient note does not specify the duration under the investigator's care, further information would be required.\n4. Foot ulcer is on the plantar surface of the forefoot or heel. \u2013 The patient note specifies a lesion on the lower leg, which does not meet this criterion.\n5. Ulcer size is >=1.0 cm2 at Day 0 (day of randomization). \u2013 The patient note does not provide the size of the lesion, further information would be required.\n6. Ulcer extends through the dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone, or joint capsule. \u2013 The patient note does not provide detailed information about the depth of the lesion, further information would be required.\n7. Ulcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made up of healthy vascularized tissue. \u2013 The patient notes that the lesion is oozing, which could indicate infection, further information would be required to confirm.\n8. Patient's Ankle-Arm Index by Doppler is >=0.7. \u2013 The patient note does not provide this information, further information would be required.\n9. Patient has adequate circulation to the foot as evidenced by a palpable pulse. \u2013 The patient note does not provide this information, further information would be required.\n10. Female patients of childbearing potential must not be pregnant and must use accepted means of birth control. \u2013 The patient note does not provide information about pregnancy or birth control, further information would be required if applicable.\n11. Patient and caregiver are willing to participate in the clinical study and can comply with the follow-up regimen. \u2013 The patient note indicates noncompliance with diabetes medication or exercise, which may raise concerns about the patient's ability to comply with the study requirements, further information would be needed.\n12. Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment. \u2013 This would be a procedural step if the patient were considered for the trial.\n13. Patient's study ulcer has been present (open) for at least 6 weeks at the time of the Screening visit. \u2013 The patient note does not provide the duration the ulcer has been present, further information would be required.\n\nBased on the provided information, the patient does not meet several key criteria (specific location of the ulcer, details about ulcer characteristics, and potential compliance issues). The patient requires further evaluation to determine if the other criteria are met, such as ulcer duration, size, depth, absence of infection, and adequate circulation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1661": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Maggot Therapy for Wound Debridement,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe patient's characteristics:\n- 64 years old (within the 18 to 90 years age range of the trial)\n- Complains of a painful skin lesion on the left lower leg which is oozing and increasing in size (possible non-healing fibrinous wound)\n\nThe inclusion criteria of the trial are:\n- Patient between 18 and 90 years old (the patient meets this criterion)\n- Patients with a non-healing fibrinous wound \u2264 40cm2 (the patient's wound could meet this criterion, but the exact size is not provided)\n- Pressure ulcers were less than 2cm-deep (no information on the depth of the patient's lesion is provided)\n- Limb wounds were venous ulcers with an ankle-brachial pressure (ABP) \u2265 0.8 (no information on whether the patient's wound is a venous ulcer or the patient's ABP is provided)\n- Signed informed consent (this can be obtained if the patient agrees to participate)\n\nBased on the information provided, the patient could potentially meet the criteria for the trial if the lesion is a non-healing fibrinous wound \u2264 40cm2 and less than 2cm-deep, and if the wound is a venous ulcer with an ABP \u2265 0.8. However, additional information is needed to confirm these points. Therefore, the patient's eligibility would require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1662": {
        "output": "To determine the trial-level eligibility of the patient for the described clinical trial, we must compare the patient\u2019s medical profile with the inclusion and exclusion criteria of the trial.\n\nPatient Profile:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Painful skin lesion on the left lower leg, which has increased in size and is now oozing\n- Non-compliance with diabetes medication and exercise\n- No other details provided that match the exclusion criteria\n\nClinical Trial Inclusion Criteria (must meet all to be eligible for randomization):\n- Age 18 years or older\n- Type 1 or 2 diabetes\n- A single full-thickness DFU present for at least 2 weeks\n- DFU wound surface area between 0.9 cm2 and 20 cm2 after a 2-week placebo run-in period\n- HbA1c below or equal to 10%\n- Neuropathy confirmed by monofilament test\n- No exposure of bone in the DFU\n- No predominant ischemia, with specific vascular assessments required\n- DFU of grade A1 or A2 on the University of Texas Wound Classification System or Grade 1 or 2 of the Wagner classification\n- DFU appropriately debrided\n\nClinical Trial Exclusion Criteria (must not meet any to be eligible):\n- Active or inadequately off-loadable inactive Charcot foot\n- Ulcers of non-neuropathic origin\n- Any infected ulcers requiring antibiotic treatment\n- Another wound on the same foot as the target DFU\n- Morbid obesity, defined as BMI \u2265 45kg/m2\n- Clinically significant conditions that could impair wound healing\n- Severe renal failure requiring dialysis\n- Pregnancy, breastfeeding, or inadequate contraception in women of childbearing potential\n- High-dose corticosteroids treatment\n- Participation in another clinical study within the previous 3 months\n- History of drug or alcohol abuse within the previous year\n- Severe psychiatric disease\n- Known intolerance to the IMP or its excipients\n- Known uncooperativeness or noncompliance\n- Inability to comply with daily spray application requirements\n- Any other condition making the patient unsuitable for the study, in the investigator's opinion\n\nThe patient\u2019s profile indicates she has diabetes, which is a requirement for the trial. However, there are several pieces of information missing that are necessary to confirm her eligibility, such as the presence of neuropathy confirmed by a monofilament test, vascular assessments, classification of the ulcer, and wound surface area measurement. Additionally, the patient is non-compliant with her diabetes medication, which could affect her eligibility given the requirement for good or acceptable compliance during the placebo run-in period.\n\nThe patient's obesity is noted, but without a specific BMI value, we cannot determine if she meets the exclusion criterion of morbid obesity. However, the patient\u2019s HbA1c is described as \"persistently elevated,\" which could be above the threshold of 10% set by the trial's inclusion criteria. \n\nGiven the information provided and the fact that several key inclusion criteria cannot be confirmed, as well as the potential issue with HbA1c levels, the patient does not clearly meet the eligibility requirements for this clinical trial. Further investigation would be needed to gather more information and to address the concerns about medication compliance and HbA1c levels.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1663": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliant with diabetes medication and exercise\n- Complains of a painful skin lesion on the left lower leg\n\nClinical Trial:\n- Title: Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section\n- Study to compare skin closure methods after caesarean section\n- Inclusion Criteria:\n  - Woman having elective or level III caesarean section\n  - Woman who speak and understand Danish\n  - Woman who can give informed consent\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial. The trial is specific to women who are having a caesarean section, which is not relevant to the patient's condition. Additionally, there is no indication that the patient speaks and understands Danish or is currently pregnant and requiring a caesarean section.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1664": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the relevant details:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg, which has increased in size and is oozing\n\nClinical Trial Inclusion Criteria:\n- Chronic wound needing debridement >3 cm2\n- Ulcer history >4mo\n- Adequate arterial blood flow (ABI>0.7)\n- Chronic wounds including Venous, Inflammatory, Pressure, Diabetic ulcers\n\nThe patient note indicates that the patient has diabetes mellitus, which often leads to chronic wounds such as diabetic ulcers. The note also mentions a skin lesion that could be consistent with a chronic wound, as it has been present for an unspecified duration, has increased in size, and is oozing. However, there are missing specifics to fully determine eligibility, including the size of the wound (>3 cm2), duration of the ulcer (>4 months), and the patient's arterial blood flow (ABI>0.7).\n\nGiven the diabetic condition and the presence of a skin lesion, it is possible that the patient could have a diabetic ulcer that meets the trial criteria. However, further investigation is necessary to confirm the chronic nature of the wound, its size, duration, and ABI measurement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1665": {
        "output": "Based on the patient note provided, the 64-year-old female patient has a diagnosis of diabetes mellitus and is obese, which aligns with the inclusion criteria of the clinical trial aimed at determining calcaneal spur incidence in obese subjects with and without type 2 diabetes mellitus.\n\nAlthough the patient note does not mention plantar fasciitis or calcaneal spur directly, the conditions specified in the inclusion criteria (diabetes mellitus and obesity) are met. However, the patient's non-compliance with diabetes management and the painful skin lesion mentioned in the patient note are not directly relevant to the study's focus on calcaneal spur incidence.\n\nBased on the information provided, the patient meets the primary inclusion criteria for the clinical trial, which are a clinical diagnosis of diabetes mellitus and obesity.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1666": {
        "output": "Based on the provided patient note and clinical trial information, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- Male and female between 18 - 50 years old\n- Immigrants with background from Middle East, Africa, and South Asia\n\nThe patient does not meet the age criterion (64 vs. 18-50 years old) and there is no mention of the patient's ethnic background, but the study specifically seeks immigrants from the Middle East, Africa, and South Asia, which may not be applicable to this patient. Additionally, the study focuses on the effects of vitamin D supplementation on muscular strength, musculoskeletal pain, and headache, which do not seem directly related to the patient's primary complaints of diabetes management and a skin lesion.\n\nBased on this information, the patient does not meet the inclusion criteria for age, and there is no indication that the other specific demographic requirement (immigrant background) is met. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1667": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Reluctant to see a nutritionist and non-compliant with medication or exercise\n- Painful skin lesion on the left lower leg that is oozing and has increased in size\n\nClinical Trial Inclusion Criteria:\n- Patient with a lower limb ulcer, regardless of origin, present for more than 6 months or large in size (> 10 cm\u00b2)\n- Surgeon has recommended that an Integra\u00ae matrix be implanted\n- Not eligible for skin flap surgery\n- The patient or patient's representative has agreed to sign the information letter\n\nAssessment:\n- The patient has a lower limb ulcer, which fits the general description of the trial's target condition.\n- The note does not specify the duration the ulcer has been present or its size, which are important details for eligibility.\n- The note does not mention if a surgeon has recommended an Integra\u00ae matrix be implanted.\n- There is no information on the patient's eligibility for skin flap surgery.\n- The patient's willingness to participate in the study or to sign the information letter is not discussed.\n\nGiven the incomplete information in the patient note regarding some of the specific inclusion criteria of the clinical trial (such as the duration and size of the ulcer, surgeon's recommendation, and patient consent), we cannot conclusively determine the patient's eligibility. Therefore, further investigation would be necessary to obtain this information and make a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1668": {
        "output": "The patient is a 64-year-old obese female with a diagnosis of diabetes mellitus, elevated HbA1c, non-compliance with diabetes medication and exercise, and a painful skin lesion on the left lower leg that is increasing in size and oozing. \n\nNow, let's compare the patient's condition with the inclusion criteria for the clinical trial:\n\n1. Subject > 18 years - The patient is 64 years old, so she meets this criterion.\n2. Subject is attending weekly office visits at SW Wound Care Center as an out-patient - There is no information given about the patient attending any wound care center.\n3. Subject has a moderately to highly exudative venous leg ulcer that would be indicated for treatment with Drawtex - The patient has a painful skin lesion which is oozing, but it is not specified if it is a venous leg ulcer.\n4. Subject is informed about the trial, understands its nature and provides written informed consent prior to study enrollment - This is a procedural step that can be fulfilled if the other criteria are met.\n5. Subject is willing and able to comply with all specified care and visit requirements - The patient's current non-compliance with diabetes treatment raises concerns about her willingness and ability to comply with the study requirements.\n\nGiven that the patient has an oozing skin lesion, which could potentially be a venous leg ulcer, there is a possibility that she meets some of the inclusion criteria. However, further investigation is needed to confirm the exact nature of the skin lesion and her current attendance at a wound care center (if any). Additionally, her non-compliance with treatment for diabetes might affect her eligibility. Therefore, a cautious approach would be taken.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1669": {
        "output": "To determine the eligibility of the 64-year-old female patient for the clinical trial \"Evaluation of Low Source of Signal in SCOUT DS\", we need to compare her characteristics and conditions to the inclusion criteria of the trial.\n\nBased on the patient note provided:\n- The patient is 64 years old, which satisfies the age criterion of being greater than or equal to 45 years.\n- The patient has diabetes mellitus, which is a condition associated with insulin resistance, and she presents with persistently elevated HbA1c.\n- The patient is described as obese, which could imply a BMI > 25 kg/m\u00b2, although the exact BMI is not given.\n- The patient note does not mention the patient's skin tone, which is a specific requirement for the trial (Von Luschan chromatic skin color > 35).\n\nGiven that there is no information about the patient's skin tone, we cannot conclusively determine her eligibility based on the information provided. Skin tone is a critical inclusion criterion for this trial, and without that information, we cannot proceed with a referral.\n\nTherefore, I would consider further investigation to determine the patient's skin tone and check if any other diabetes risk factors match the inclusion criteria. If the patient does have a dark skin tone (as required), and the other conditions are met, she might be eligible for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1670": {
        "output": "Based on the patient note provided, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and a painful, oozing skin lesion on the left lower leg. The clinical trial in question is focused on the prevention of pressure ulcers in trauma patients admitted to the ICU.\n\nThe inclusion criteria for the clinical trial are as follows:\n- ED and ICU admission for critical illness and/or major trauma\n- Over 18 years old\n\nThe patient note does not mention that the patient has been admitted to the ED or ICU for critical illness or major trauma, which are key requirements for inclusion in the trial. The only relevant information that matches the inclusion criteria is that the patient is over 18 years old. However, this alone is not sufficient for eligibility without the context of an ED or ICU admission due to critical illness or major trauma.\n\nTherefore, based on the information provided, the patient does not meet the specific inclusion criteria of the clinical trial focused on pressure ulcer prevention in the ICU setting.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1671": {
        "output": "Based on the patient note provided, the 64-year-old female patient has a diagnosis of diabetes mellitus, which is one of the diseases of interest for the clinical trial titled \"Neurogenic Inflammation in Diabetes.\" The trial is investigating the inflammatory response in patients with diabetes, specifically those with polyneuropathy and a history of Charcot's disease.\n\nThe inclusion criteria for the trial are:\n- Patients with type 2 diabetes with and without polyneuropathy.\n- Patients with type 2 diabetes with a history of Charcot's disease.\n- Healthy controls.\n- Signed informed consent.\n\nThe patient note does not mention polyneuropathy or Charcot's disease directly; however, the presence of a painful skin lesion that is not healing properly could be suggestive of complications related to diabetes, potentially including polyneuropathy. The information provided is not sufficient to determine definitively whether the patient has polyneuropathy or Charcot's disease, which would be necessary to establish eligibility for this trial.\n\nDue to the lack of specific information regarding polyneuropathy or Charcot's disease, it would be prudent to consider referring this patient for the clinical trial upon further investigation to determine if they meet the specific inclusion criteria related to these conditions.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1672": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate whether the patient qualifies for this clinical trial:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus and elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Is 18 years or older; male or female\n- Previous diagnosis of venous insufficiency proven by a positive venous duplex with reflux\n- Has a venous ulcer with a wound area between 5 cm2 - 40 cm2\n- Has an ankle brachial index (ABI) >0.8\n- Has a venous ulcer with duration less than 24 months\n- Has a venous ulcer which is critically colonized based on the Lazareth Study Model with at least three of the five signs: severe spontaneous pain, perilesional erythema, local edema, malodour, heavy exudation\n- Is currently using Profore as their standard of care\n- Has not received antibiotics for 6 weeks prior to enrollment\n\nThe patient note specifies a painful skin lesion, but it does not specifically mention venous insufficiency, venous ulcer, or any findings from a venous duplex. The lesion is described as oozing, which might not fulfill the criteria of critically colonized without infection. Additionally, there is no information on the patient's use of Profore or their ABI value.\n\nGiven the available information, the patient does not clearly meet the inclusion criteria of having a diagnosed venous ulcer with specific characteristics (such as size, duration, and critical colonization status) and other specific requirements such as the use of Profore and an ABI >0.8.\n\nFurthermore, since the patient is not compliant with her diabetes medication, this might affect her ability to comply with the study protocol, which is an indirect consideration for eligibility.\n\nTherefore, based on the provided patient note and the criteria for this clinical trial, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1673": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers,\" we need to compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nPatient Characteristics and Condition:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Subject is \u226518 years of age and has type 1 or 2 diabetes\n- Texas grade 1a or 2a wound located distal to the malleolus\n- Wound depth \u2264 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts\n- Ulcer size between 1 cm\u00b2 and 12 cm\u00b2 (post-debridement)\n- Ulcer duration of \u2265 30 days\n- Study ulcer separated from other ulcers by at least 2 cm\n- Ulcer or affected limb free of clinical signs of infection\n- Post-debridement, ulcer free of necrotic tissue\n- Adequate vascular perfusion of the affected limb\n- HbA1c \u2264 12.0%\n- Demonstrated adequate offloading regimen\n- Willingness to comply with the protocol, including having blood drawn to create the RD1\n- Use of acceptable form of contraception if applicable\n\nBased on the patient note:\n- The patient is above 18 years old and has diabetes, meeting the age and diabetes criteria.\n- The patient has a skin lesion on the lower leg, which may potentially be a Texas grade 1a or 2a wound, but further information is required to confirm the grade, size, depth, and duration of the ulcer.\n- The patient has elevated HbA1c levels, but the specific value is not given, so we cannot confirm if it is \u2264 12.0%.\n- The patient's willingness to comply with the protocol is questionable due to non-compliance with diabetes medication or exercise.\n- We do not have information about the patient's vascular perfusion status or whether they have demonstrated an adequate offloading regimen.\n- We also lack information on contraception use, which is relevant only if the patient is of childbearing potential.\n\nGiven the information provided, we do not have enough evidence to determine that the patient's wound meets the specific criteria of a Texas 1a or 2a wound, nor can we confirm the patient's HbA1c level, compliance with the protocol, and vascular perfusion status. Therefore, this patient would require further assessment before a definitive eligibility determination could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1674": {
        "output": "Given the patient's note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nThe patient note includes:\n- 64-year-old female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Painful skin lesion on the left lower leg that is oozing\n\nThe clinical trial's inclusion criteria are:\n- Patient has diabetic foot ulceration, venous ulcer, or mixed aetiology ulcer with a surface area <100 cm2 and <10 cm in widest diameter on lower extremity, but larger than 1 cm2\n- Wound present for >30 days\n- Wound is in a location amenable to creation of an airtight seal around wound using TNP dressings\n- Patient is able to comply with study protocol requirements\n- Patient is able to understand and provide written consent\n\nBased on the patient note, the patient does have a diagnosis of diabetes mellitus, which is consistent with one of the conditions (diabetic foot ulceration) listed in the trial's inclusion criteria. However, we do not have information on the duration of the skin lesion (whether it has been present for more than 30 days), its dimensions, or if it is amenable to the creation of an airtight seal using TNP dressings. Additionally, the patient's compliance with medication or exercise is not reported, which raises a question about her ability to comply with study protocol requirements.\n\nGiven the information provided, the patient potentially meets some of the inclusion criteria (diagnosis of diabetes and a lower extremity ulcer), but further information would be needed to fully determine eligibility. Therefore, the assessment of this patient's eligibility for referral to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1675": {
        "output": "The patient note describes a 64-year-old obese female with diabetes mellitus and a painful skin lesion on the left lower leg that is oozing. There is no mention of Buruli ulcer, which is the target disease for the clinical trial. Buruli ulcer is a specific condition caused by Mycobacterium ulcerans, and this patient has not been described as having this condition. Additionally, the trial seems to be geographically specific to certain districts in Benin, and there is no indication that the patient is from or located in these districts. Furthermore, the inclusion criteria require confirmation of Buruli ulcer disease by direct microscopy following acid-fast staining or PCR, which has not been described in the patient's note.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial focused on Buruli ulcer. Therefore, the assessment of eligibility for this patient for the given clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1676": {
        "output": "To determine the patient's eligibility for the clinical trial, we will compare the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient Characteristics:\n- 64-year-old female\n- Diagnosis: Diabetes mellitus\n- Elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg\n- The lesion is increasing in size and is now oozing\n\nClinical Trial Inclusion Criteria:\n- Patient over 18 years old who has provided his/her written informed consent\n- Patient who can be monitored by the same investigation team throughout the duration of the study\n- Patient who agrees to wear effective venous compression every day, associated with the trial dressing\n- Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3\n- Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2\n- Ulcer duration between 3 and 36 months\n- Ulcer where the surface area is 70% or more covered by fibrinous tissue\n- Ulcer at least 3 cm away from any other lesion\n- Ulcer moderately or strongly exudative justifying the use of an absorbent dressing\n\nAnalysis:\n- The patient is over 18 years old, satisfying one of the inclusion criteria.\n- There's no information provided about the patient's willingness to provide informed consent or to be monitored by the same team throughout the study, but these can potentially be achieved.\n- The patient has a painful skin lesion, which could be a leg ulcer, but the description does not provide enough detail to confirm this or to match the specific characteristics of the ulcer described in the inclusion criteria (such as size, duration, coverage by fibrinous tissue, distance from other lesions, and level of exudation). Further medical evaluation would be needed to determine these factors.\n- There is no mention of the patient's Ankle Brachial Pressure Index (ABPI), which is a criterion that needs to be met.\n\nGiven the information provided, the patient might have a condition that could potentially qualify for the study (a leg ulcer), but there is not enough detail in the patient note to determine if all the specific inclusion criteria are met. Therefore, further investigation is needed to assess the characteristics of the patient's skin lesion and other factors before a referral can be considered.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1677": {
        "output": "Based on the provided information, the patient is a 64-year-old obese female with diabetes mellitus and a persistent, non-healing skin lesion. The clinical trial in question is investigating risk factors of prolonged wound healing following primary arthroplasty.\n\nThe inclusion criteria for the trial are quite specific: all patients receiving primary hip or knee arthroplasty at Hvidovre Hospital from January 2012 to January 2014. The patient note does not mention the patient having undergone hip or knee arthroplasty, nor does it specify that the patient was treated at Hvidovre Hospital within the specified time frame.\n\nGiven the absence of any information suggesting that the patient meets the inclusion criteria for this clinical trial, it would not be appropriate to refer this patient for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1678": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 64 years old\n- Diagnosis: Diabetes mellitus with elevated HbA1c\n- Compliance: Not compliant with diabetes medication or exercise\n- Symptoms: Painful skin lesion on the left lower leg, oozing\n\nClinical Trial Inclusion Criteria:\n- Condition: Ischemic lower limb based on TASK guideline\n- Rutherford score: 2,3\n- ABI<0.6\n- Absolute ankle pressure < 60 mmHg\n- Both gender\n- Age: 20-62 years\n\nComparing the patient's characteristics with the inclusion criteria:\n\n- The patient is 64 years old, which is above the maximum age limit of 62 years specified in the trial's inclusion criteria.\n- There is no mention of ischemic lower limb, Rutherford score, ABI, or absolute ankle pressure in the patient's note.\n- The patient's main complaint is related to a painful skin lesion, not necessarily tied to ischemic lower limb.\n\nSince the patient's age exceeds the specified range and there is no indication that the patient has ischemic lower limb as required by the trial, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1679": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Reluctant to see a nutritionist\n- Non-compliant with diabetes medication or exercise regimen\n- Painful skin lesion on the left lower leg that is oozing\n\nClinical Trial Inclusion Criteria:\n- Adult diabetic foot syndrome subjects over 18 years of age of any sex\n- All stages of diabetic foot syndrome including Wagner stage 5 - Mid-foot gangrene only after appropriate surgical treatment\n- Patients suffering from type 1 or type 2 diabetes mellitus with diabetic foot syndrome\n- Stable metabolic and pharmacological control at recruitment and during the trial period\n- Adequate perfusion of lower limb as measured by Handheld Doppler (HHD) and confirmed by Ankle-Brachial Pressure Index (APSV)\n\nComparison:\n- The patient is over 18 years of age and has diabetes, which aligns with the trial's inclusion criteria.\n- The patient has a painful skin lesion on the left lower leg, which could potentially be a diabetic foot ulcer, but this is not explicitly confirmed in the patient note. If confirmed, this would align with the trial's focus on diabetic foot ulcers.\n- The lesion's current state is oozing, suggesting it may have not received proper surgical treatment yet, which is a requirement for the trial.\n- The patient note does not confirm the patient's metabolic and pharmacological control as being stable, which is a requirement for the trial.\n- The patient's perfusion status of the lower limb has not been provided, and this would need to be assessed to meet the trial's inclusion criteria.\n\nThe patient could potentially meet the inclusion criteria if the lesion is indeed a diabetic foot ulcer and if it has received or will receive proper surgical treatment. Additionally, the patient would need to demonstrate stable metabolic and pharmacological control and adequate lower limb perfusion.\n\nGiven the information provided, there are several items that would need further investigation before the patient could be referred to the clinical trial. The patient's eligibility is not clear from the patient note alone and would require additional information and assessments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1680": {
        "output": "The patient in question is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c levels. She is noncompliant with her diabetes medication and exercise regimen. The clinical trial in focus is evaluating the use of insulin detemir (Levemir\u00ae) in patients with type 1 or type 2 diabetes who have insufficiently controlled blood sugar levels under their previous therapy.\n\nGiven the information provided, the patient appears to meet the inclusion criteria for the clinical trial, which is specifically looking for patients with insufficiently controlled type 1 or type 2 diabetes. The patient's reluctance to see a nutritionist, noncompliance with medication, and persistently high HbA1c are indications of insufficient control over her diabetes.\n\nThe patient's painful skin lesion on the left lower leg is an additional medical issue, but it is not specified as an exclusion criterion in the clinical trial details provided. Therefore, it would not necessarily preclude the patient from participating in the study.\n\nBased on the patient's diagnosis and the specific inclusion criteria of the clinical trial, it seems the patient is a suitable candidate for referral to the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1681": {
        "output": "The patient in question is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c. The patient also has a painful skin lesion on her left lower leg, which could indicate a complication related to her diabetes, such as a diabetic ulcer. However, the provided patient note does not explicitly mention a history of diabetic neuropathic plantar ulcer, which is a specific requirement for the test subjects in the clinical trial's inclusion criteria.\n\nThe clinical trial is aiming to compare the microvascular response in the skin on the bottom of the big toe after applying a controlled load in diabetic subjects with a history of foot ulcer and healthy controls. The inclusion criteria for test subjects require a history of diabetic neuropathic plantar ulcer.\n\nBased on the information given, the patient does not clearly meet the specific inclusion criteria of having a history of diabetic neuropathic plantar ulcer. Thus, while the patient is within the age range and has diabetes, the absence of documented history of a plantar ulcer in the patient note suggests that the patient may not be eligible for this specific study. However, there is a possibility that the painful skin lesion on the lower leg could be related to such an ulcer, so further investigation would be necessary to determine the nature of the lesion and if it qualifies as a plantar ulcer.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1682": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient does not appear to be eligible for this clinical trial. The clinical trial is focused on patients undergoing primary total hip arthroplasty via the anterior supine intermuscular approach and is specifically looking at the efficacy of the Aquamantys\u00ae System in terms of blood loss, transfusion, and wound healing.\n\nThe patient note indicates that the patient is a 64-year-old obese female with diabetes mellitus, and no mention is made of her requiring or being scheduled for a total hip arthroplasty. The patient's chief complaint is a painful skin lesion on her left lower leg, which is unrelated to hip arthroplasty.\n\nSince the patient does not meet the specific inclusion criteria of undergoing primary unilateral total hip arthroplasty via the anterior supine intermuscular approach and there is no indication that the patient is willing and able to complete all follow-up visits at 6 weeks and 1 year, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1683": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the assessment of eligibility for this trial is as follows:\n\nThe trial is focused on improving the quality of bowel preparation for patients undergoing colonoscopy by providing repeated instruction via telephone on the day before the procedure. The only inclusion criterion listed is that participants must be patients undergoing a colonoscopy.\n\nThe patient note does not specifically mention the patient undergoing a colonoscopy or being scheduled for one. Therefore, there is no direct indication that the patient fits the inclusion criteria based solely on the information given in the note.\n\nAs the patient's current medical concerns (diabetes mellitus, elevated HbA1c, a painful skin lesion) do not pertain to the clinical trial, further investigation is needed to determine if the patient is scheduled for a colonoscopy. If the patient is scheduled for a colonoscopy, then she would be eligible for the trial. Without this information, we cannot definitively assess the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1684": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Off-Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Non-compliant with medication or exercise\n- Painful skin lesion on the left lower leg, which is oozing\n\nClinical trial inclusion criteria:\n- More than 18 years old man or woman\n- Type 1 or 2 Diabetes mellitus\n- A new plantar ulcer of the forefoot or the toes\n- GRADE 1A or 2 A of the University of Texas Classification\n- Neuropathy assessed by absence of sensation in 10g monofilament test\n\nClinical trial exclusion criteria:\n- Severe angiopathy (Grade 3 of the PEDIS classification)\n- Osteomyelitis or cellulitis of the foot\n- Transmetatarsal amputation\n- Other study in course\n- Immunosuppressive drugs, antibiotic therapy\n- Hepatic insufficiency\n- No possibility to follow the patients every 14 days\n- No state health insurance\n- Pregnancy\n\nFrom the information provided in the patient note, the patient does have diabetes mellitus and a skin lesion on the lower leg. However, the following points need to be clarified to determine eligibility:\n\n1. Whether the skin lesion is a new plantar ulcer of the forefoot or the toes.\n2. The classification of the ulcer according to the University of Texas Classification system.\n3. The presence of neuropathy assessed by a monofilament test.\n4. The absence of exclusion criteria such as severe angiopathy, osteomyelitis or cellulitis, current participation in another study, use of immunosuppressive drugs or antibiotic therapy, hepatic insufficiency, ability to follow up every 14 days, and having state health insurance.\n\nWithout additional information regarding the specifics of the patient's foot lesion, neuropathy status, and other potential exclusion criteria, it is not possible to definitively determine if the patient would be eligible for the clinical trial. However, since the patient has diabetes and a foot lesion, there is a possibility that she could meet the inclusion criteria upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1685": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial regarding olivamine-containing products in the management of patients with nonhealing lower extremity ulcers, let's evaluate the patient's eligibility:\n\nPatient Note Evaluation:\n- The patient is a 64-year-old obese female, which meets the age criterion of being 18 years old or older.\n- The patient has a painful skin lesion on the left lower leg that is increasing in size and oozing, which may indicate a nonhealing lower extremity ulcer.\n- The patient has a diagnosis of diabetes mellitus, and diabetic foot ulcers are one of the ulcer types mentioned in the inclusion criteria.\n\nClinical Trial Inclusion Criteria Checklist:\n- Patient is 18 years old or older. [Meets criteria]\n- Patient has a diagnosis of arterial, diabetic foot, venous insufficiency, or pressure ulcer or surgical and traumatic wound. [Potentially meets criteria, pending confirmation that the lesion is one of the specified ulcers]\n- Patient's target study ulcer/wound is a lower extremity full thickness ulcer/wound not involving tendon, capsule, or bone. [Needs confirmation]\n- Patient's target study ulcer/wound is \u22651.0 cm2 and \u2264 10.0 cm2 in size at the day of initial consult. [Needs confirmation]\n- Study ulcer/wound has been present for greater than 6 weeks prior to initial consult. [Needs confirmation]\n- Patient has adequate circulation to the lower extremity as evidenced by an ABI of \u2265 0.7. [Needs confirmation]\n- Patient must have adequate in-home support to comply with all protocol-mandated visits and procedures. [Needs confirmation]\n- Patient or his/her legal representative has read and signed the informed consent form before Screening. [Needs confirmation]\n\nSince the patient does have diabetes, which could be associated with a diabetic foot ulcer, it seems she could potentially meet the criteria. However, there are several points that need confirmation, such as the nature and size of the ulcer, the duration of the wound, circulatory status (ABI testing), and patient's support system for compliance.\n\nTherefore, the patient note suggests potential eligibility but requires further investigation to confirm the nature of the ulcer, its size, duration, and the patient's circulatory status, among other factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1686": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n- Lesion has not healed despite topical treatments\n\nClinical Trial Inclusion Criteria:\n- Patients need to be at least 18 years old\n- Admitted to the university hospitals of Geneva for a non-healing lower limb ulcer\n- Non-healing lower limb ulcers for more than 3 months\n- Hospitalized in the Dermatology inpatient clinic\n- Benefited from at least one thin skin autograft at the ulcer level in the past or during the index hospitalization\n- Complete angiological diagnostic work-up including ABI, toe pressure, tcPO2 measurements, and arterial imaging (angio-CT or angio-MRI)\n- Mild to moderate peripheral artery disease (PAD) without critical limb ischemia (CLI)\n\nAssessment:\n- The patient is over 18 years old.\n- The patient has a non-healing lower limb ulcer, which fits the condition being studied.\n- There is no mention of previous thin skin autografts or a complete angiological diagnostic work-up, which are required before inclusion.\n- There is no indication that the patient is admitted to or will be admitted to the university hospitals of Geneva, which is a requirement for the trial.\n\nGiven the information provided, we cannot confirm that the patient has had a thin skin autograft or the necessary diagnostic work-up to determine the severity of PAD. Additionally, the trial seems to be location-specific, requiring admission to a particular hospital, which is not indicated in the patient note.\n\nThe patient does have a non-healing ulcer which aligns with the trial's interest but lacks several key inclusion criteria details and the specified hospital admission requirement.\n\nTherefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1687": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Non-compliance with diabetes medication\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of spina bifida and neurogenic bladder\n- Performing clean intermittent catheterization (CIC)\n- Taking 0.3-0.4 mg/kg/day of oxybutynin for a poorly compliant bladder\n- Has not had previous bladder surgery\n- Has had a urodynamic or videourodynamic study done within the last 6 months\n- Upper motor neuron (UMN) type bladder demonstrated on last urodynamic study\n- Urodynamic study (UDS) showing specific bladder pressures and capacities\n- Able and willing to complete CIC Diaries and Quality of Life Questionnaires\n- Consent and assent given to participate in trial\n\nUpon reviewing the patient's information, it is clear that the patient does not meet the inclusion criteria for the clinical trial. The patient has diabetes mellitus, which is not related to the neurogenic bladder condition being studied, and there is no mention of spina bifida, neurogenic bladder, or any history of bladder issues in the patient note. Furthermore, the trial is specific to pediatric patients with neurogenic bladder due to spina bifida, and the patient is 64 years old. Therefore, this patient would not be eligible for the clinical trial focused on pediatric neurogenic bladder and spina bifida.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1688": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, we can assess the eligibility of the patient based on the specified factors.\n\nPatient Note Analysis:\n- The patient is a 64-year-old female.\n- She has a diagnosis of diabetes mellitus (type is not specified, but typically at her age it would be type 2 unless otherwise noted).\n- She has an elevated HbA1c, indicating poor glucose control.\n- There is no mention of her being English-speaking, but this is often assumed unless noted otherwise.\n- She has a painful skin lesion, which is not relevant to the trial's focus.\n\nClinical Trial Inclusion Criteria:\n- English-speaking patients.\n- Ages 10 to 18 years.\n- Diagnosed with type 1 diabetes for at least 12 months.\n- Poor diabetes control as defined by having a hemoglobin A1c value > 8%.\n\nComparison:\n- The patient's age (64 years) does not match the age range required for the trial (10 to 18 years).\n- The type of diabetes is not specified in the patient note, but the trial is specific to type 1 diabetes.\n- The trial specifies the need for poor glycemic control, which the patient does have, but this alone does not make her eligible.\n\nGiven these points, the patient does not meet the age and confirmed diagnosis criteria for the clinical trial. Therefore, she would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1689": {
        "output": "",
        "label": 0
    },
    "1690": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, it appears that the patient is not eligible for the clinical trial. The clinical trial is specifically looking to enroll patients with a diagnosis of fibromyalgia, as diagnosed by physical examination of pain sensitivity, by Dolorimeter and finger pressure. The patient in the note has diabetes mellitus with a skin lesion and no mention of fibromyalgia or chronic pain syndrome consistent with fibromyalgia. Therefore, this patient does not meet the inclusion criteria for the trial focused on fibromyalgia patients receiving hyperbaric oxygen therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1691": {
        "output": "The patient is a 64-year-old female with a diagnosis of diabetes mellitus and persistently elevated HbA1c, which suggests that she might have type 2 diabetes. She is not compliant with her diabetes medication, which could be relevant to her potential for adherence to the trial protocol.\n\nThe clinical trial is seeking participants with either type 1 or type 2 diabetes to compare the pharmacodynamics and pharmacokinetics of insulin degludec with insulin glargine. The inclusion criteria relevant to this patient are:\n\n1. Glycosylated haemoglobin (HbA1c) below or equal to 10 percent based on central laboratory results\n2. Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening\n3. Treated with insulin for the past 3 months prior to screening\n4. Body Mass Index (BMI) between 22.0 and 35.0 kg/m^2 (both inclusive)\n\nThe patient note does not provide the exact HbA1c value but mentions it as persistently elevated. Assuming it does not exceed 10 percent, this criterion could potentially be met. The patient is described as having diabetes mellitus, which could be type 2 given her age and obesity, and she has been diagnosed for an unspecified amount of time, likely more than 12 months. However, the note does not confirm that she has been treated with insulin for the past 3 months, as she is not compliant with medications. The patient's BMI is not provided but is described as obese, which could fall within the 22.0 to 35.0 kg/m^2 range for type 2 diabetes patients.\n\nGiven the provided information, the patient's eligibility is uncertain due to the lack of detail about her HbA1c level, her treatment with insulin, and her exact BMI. Thus, more information would be needed to fully assess her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1692": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial:\n- Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease\n- Efficacy comparison of MAL-PDT with/without Er:YAG AFL for Bowen's disease on the lower extremities\n- Inclusion Criteria: Korean patients aged \u2265 18 years who had biopsy-confirmed BD lesions on the lower extremities\n\nThe inclusion criteria for the clinical trial specify that participants must be Korean patients aged \u2265 18 years with biopsy-confirmed Bowen's Disease (BD) lesions on the lower extremities. There is no mention of the patient's ethnicity or if the skin lesion is biopsy-confirmed BD in the patient note. Therefore, without further information on the patient's ethnicity and a confirmed diagnosis of BD by biopsy, we cannot determine if the patient meets the inclusion criteria.\n\nGiven the patient has a skin lesion, it is possible, but not confirmed, that the lesion could be BD. However, without a biopsy confirming BD and without knowing if the patient is Korean, we cannot assume eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1693": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion and exclusion criteria:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Painful skin lesion on the left lower leg\n- Lesion has increased in size and is now oozing\n\nClinical Trial Inclusion Criteria:\n- Able to understand the evaluation and willing to consent and comply with all post-debridement visits and procedures\n- Age 18 years and older\n- Chronic wound(s) below the knee, acute wound(s), or diabetic foot ulcer(s)\n- Venous leg ulcers below the knee with failed medical therapy >30 days\n- Lab results within 30 days: serum albumin >20g/L, non-significant LFTs, serum glucose, CBC with differential\n- Braden Score \u226513-14\n- Adequate arterial blood flow (ABI >0.75)\n\nClinical Trial Exclusion Criteria:\n- Tunneling wounds\n- Active infection in the study wound (defined by purulence with fever and leukocytosis, or any two of malodor, pain, warmth, erythema, induration, swelling, lymphangitis)\n- Infected bone\n- Wound does not require debridement\n- Cardiac pacemaker or other electronic implants\n- Certain medical conditions (e.g., vasculitis, non-reconstructive peripheral vascular disease, etc.)\n- Uncontrolled bleeding disorder or coagulopathy\n- Certain treatments (e.g., systemic corticosteroids, immunosuppressive agents, etc.)\n- Terminally ill\n- Immunodeficiency disorders\n- Chronic skin conditions\n- Residing in a nursing home\n- Physically or mentally compromised\n- Pregnancy\n- History of drug/alcohol abuse within the last 12 months\n- Participation in another research study during the follow-up phase or 84 days after study completion\n\nBased on the patient's description, the patient has a diabetic foot ulcer which matches the inclusion criteria for the clinical trial. However, the patient's lesion is also described as \"oozing,\" which may suggest an active infection. The exclusion criteria specify that subjects with an active infection in the study wound, as defined by purulence and fever, leukocytosis, or any two of the following: malodor, pain, warmth, erythema, induration, swelling, lymphangitis, are excluded.\n\nGiven the information, it seems that the patient may have an active infection due to the oozing lesion, which would exclude her from the trial. However, without additional information on the presence of fever, leukocytosis, or other signs of infection, it is not possible to make a definitive assessment based on the note alone.\n\nTherefore, the patient may be considered for the trial upon further investigation to clarify the nature of the oozing lesion and to ensure that it does not meet the exclusion criteria for active infection.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1694": {
        "output": "The patient is a 64-year-old obese female with a diagnosis of diabetes mellitus. She has a lesion on her lower leg which is increasing in size and is oozing, indicative of an infection. The clinical trial is investigating the efficacy and safety of the Garamycin\u00ae Sponge in diabetic patients with moderate or severe foot ulcer infections.\n\nTo determine if the patient is eligible for the clinical trial, let's compare the patient's characteristics and condition with the trial's inclusion criteria:\n\n1. Is aged \u2265 18. \n   - The patient is 64 years old, which meets this criterion.\n\n2. Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.\n   - The patient has been diagnosed with diabetes mellitus, fulfilling this requirement.\n\n3. Has an open foot wound with visible inflammation, namely at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America (IDSA).\n   - The patient has a painful skin lesion on the lower leg that is oozing. While this suggests an infection, it is not explicitly stated that the lesion is an ulcer on or below the malleolus with moderate or severe infection according to IDSA guidelines. Further investigation is needed to determine if the lesion meets these specific criteria.\n\n4. Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis.\n   - There is no information provided about surgical intervention or a diagnosis of osteomyelitis for this patient. This would require further investigation.\n\n5. Meets certain minimal laboratory criteria.\n   - The patient's note does not provide specific laboratory results, so we cannot determine if the patient meets the laboratory criteria. Further investigation is necessary.\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria for the clinical trial, but there is insufficient information to definitively determine eligibility without further investigation, particularly regarding the specifics of the foot lesion and laboratory criteria. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1695": {
        "output": "Given the patient note, the patient is a 64-year-old obese female with diabetes mellitus and a painful skin lesion on the left lower leg, which has increased in size and is now oozing. This could potentially indicate a chronic wound such as a leg ulcer or diabetic foot ulcer, especially given the patient's non-compliance with diabetes management which can lead to complications such as leg ulcers.\n\nThe clinical trial is looking for participants with hard-to-heal wounds such as pressure ulcers, diabetic foot ulcers, and leg ulcers. The patient seems to fit the wound criteria based on the description of her leg lesion. Additionally, the inclusion criteria specify that the subject must be 18 years and above, which the patient meets, and must have signed an informed consent form, which is a standard procedure that can be completed if the patient agrees to participate.\n\nGiven the information provided, the patient appears to meet the age requirement and potentially has a qualifying wound type for the study. However, without further information on the duration and exact diagnosis of the wound (to confirm it is chronic and fits the specified wound types), the assessment cannot be definitive. Therefore, further investigation is needed to confirm the wound history and ensure it aligns with the study's criteria before referring the patient.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1696": {
        "output": "Based on the information provided:\n\nPatient Characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Non-compliance with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Adults, age 18-70 years, both men and women\n- Ability to speak and read English as the primary language\n- Ability and willingness to provide written informed consent for study participation\n- Ability and willingness to complete outcome assessments and provide blood and urine samples as required by the study protocol\n- Ability to tolerate the chamber environment and hood placement and to equalize middle ear pressure\n- Past history of at least one brain injury with persistent symptoms that meets all of the following criteria:\n  - Brain injury of non-stroke etiology that occurred at least 6 months but no more than 10 years prior to enrollment\n  - At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears\n  - Normal thyroid stimulating hormone and hematocrit value greater than 35% within the previous 6 months\n\nAssessment:\nThe patient note does not mention a brain injury of any sort or any symptoms related to a brain injury. The patient's primary concerns are related to unmanaged diabetes and a skin lesion, which are not relevant to the clinical trial's focus on brain injury and its persistent symptoms. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires a history of brain injury and associated symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1697": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let us assess the patient's eligibility:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg that is oozing\n\nClinical Trial Inclusion Criteria:\n- Male or female over the age of 18 years\n- Chronic venous ulceration - Defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85.\n- Ulceration present for at least four weeks.\n- Colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.\n\nAssessment:\n- The patient is a female over 18 years old, which meets the age and gender criteria.\n- The patient has a painful skin lesion on the lower leg, which could be consistent with chronic venous ulceration, but this is not confirmed in the note.\n- The duration of the ulceration is not specified, only that it has increased in size and is now oozing. For inclusion, the lesion should be present for at least four weeks.\n- There is no mention of an Ankle Brachial Pressure Index or colour venous duplex evidence to confirm chronic venous insufficiency with reflux or obstruction.\n\nGiven the information provided, the patient may potentially meet some of the inclusion criteria, but there is insufficient information to confirm eligibility. Specifically, we need to confirm the diagnosis of chronic venous ulceration, the duration of the ulceration, and the results of a venous duplex and Ankle Brachial Pressure Index. Therefore, further investigation is required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1698": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 64-year-old female, which fits the age criterion of being over 20 years of age.\n- She has a painful skin lesion on the left lower leg which is oozing, which may be indicative of a chronic wound.\n- There is no mention of previous treatments for the lesion other than topical lotions and creams, which suggests the wound could be untreated.\n- The size and stage of the wound are not specified in the patient note.\n\nClinical Trial Inclusion Criteria Analysis:\n- Over 20 years of age: The patient meets this criterion.\n- Subject who has untreated wounds: The patient has used lotions and creams, but it is not clear if these constitute \"treatment\" in the context of the trial. Further investigation is needed.\n- Subject who has wound size over 3cm x 3cm: The size of the patient's wound is not provided.\n- Subject who has wound over stage 2: The stage of the patient's wound is not provided.\n\nBased on the available information, the patient meets some of the inclusion criteria (age and potentially untreated wound), but crucial details regarding the size and stage of the wound are missing. Therefore, further investigation is needed to determine if the patient's wound meets the size and stage criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1699": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Noncompliant with diabetes medication or exercise\n- Complains of a painful skin lesion on the left lower leg, which is increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Men or women >18 years old\n- One or more foot ulcers without clinical evidence of osteomyelitis\n- Diagnosis of Diabetes Mellitus\n- University of Texas Grade 1A, 1C, 2A, or 2C ulcer\n- ABI >0.7 and Toe pressure >30mmHg\n\nThe patient meets the following inclusion criteria:\n- The patient is over 18 years old.\n- The patient has a diagnosis of diabetes mellitus.\n\nHowever, the information provided does not specify:\n- Whether the skin lesion on the patient's leg is indeed a foot ulcer.\n- If it is a foot ulcer, there is no information on whether it meets the University of Texas ulcer grading specified.\n- There are no ABI (Ankle-Brachial Index) or toe pressure values provided.\n- There is no indication that the ulcer is without clinical evidence of osteomyelitis.\n\nGiven the information available, the patient could potentially have a diabetic foot ulcer, but more information is needed to fully assess the ulcer and other clinical parameters. Therefore, further investigation is required before a referral can be considered.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1700": {
        "output": "Given the patient's note and the inclusion criteria of the clinical trial, let's evaluate the eligibility:\n\nPatient note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus (type not specified)\n- Elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg\n\nClinical trial inclusion criteria:\n- Type 1 diabetes\n- Males and females\n- Age between 14-24 years\n- Any diabetes duration\n- Cared for by the diabetes center for at least 1 year\n- HbA1c \u2265 8%\n- Basal bolus treatment (any insulin)\n- Poor compliance with Self-Monitoring of Blood Glucose\n- Written informed consent\n\nAssessment:\nThe patient is 64 years old, which is outside the age range of 14-24 years specified in the trial criteria. Additionally, the patient has a diagnosis of diabetes mellitus, but the type is not specified. The clinical trial is specifically for patients with Type 1 diabetes, and hence, the type of diabetes the patient has is crucial for determining eligibility. Since the patient's type of diabetes is not mentioned, and given the age mismatch, we cannot assume that she would be eligible based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1701": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Effect of Local Application of Boron on Diabetic Foot Ulcers\", we can evaluate the patient's eligibility.\n\nThe patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c. She has a skin lesion on the left lower leg, which is painful, increasing in size, and oozing. This could suggest a diabetic foot ulcer, which is a common complication of diabetes.\n\nThe inclusion criteria for the clinical trial are:\n- Diabetic foot ulcer classified by International Working Group of the Diabetic Foot (IWGDF) as grade 1 and 2.\n\nHowever, the patient note does not provide enough details to definitively classify the skin lesion as a diabetic foot ulcer, nor does it specify the IWGDF grade of the potential ulcer. A diabetic foot ulcer is typically defined by specific characteristics, and its classification into grades 1 and 2 involves certain criteria such as the presence of an open wound and the absence of infection or ischemia.\n\nGiven that the patient has diabetes and a potentially relevant wound, it suggests a possibility that she may qualify for the trial. However, further medical evaluation and confirmation of the ulcer's classification according to IWGDF criteria are necessary to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1702": {
        "output": "Assessment of the patient's eligibility based on the provided patient note and clinical trial inclusion criteria:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliance with diabetes medication and exercise\n- Painful skin lesion on the left lower leg\n\nClinical Trial Inclusion Criteria:\n- Age >19 years of age\n- Type 2 diabetes mellitus requiring at least one medication (oral hypoglycemic agent and/or insulin) to control diabetes\n- A1C \u22657% in past 1 year\n- Willingness/ability to attend the Diabetes education, dietician, and peer sessions and follow up assessments\n- Ability to provide informed consent\n- Self-identify as South Asian (from India, Pakistan, Sri Lanka, or Bangladesh) regardless of generational status or timing of immigration with the ability to speak in English or Punjabi.\n\nComparison:\n- The patient is above the age threshold of 19 years.\n- The patient has diabetes mellitus with an elevated HbA1c, suggesting she meets the criterion of a high A1C level.\n- There is no mention of the patient's willingness or ability to attend educational sessions, but her reluctance to see a nutritionist could be indicative of potential non-compliance.\n- The patient's ethnicity and language abilities are not mentioned, which is crucial for determining eligibility as the trial specifically requires participants to self-identify as South Asian and speak English or Punjabi.\n\nGiven the information, the patient meets some of the inclusion criteria such as age, diabetes diagnosis, and elevated HbA1c. However, without information about the patient's ethnicity and language abilities, as well as a clear indication of her willingness to attend the required sessions, it is not possible to definitively determine her eligibility. Therefore, further investigation is needed to determine her suitability for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1703": {
        "output": "Given the patient note:\n\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Painful skin lesion on left lower leg, increasing in size and oozing\n- No mention of atopic dermatitis or previous diagnosis\n\nAnd the clinical trial's inclusion criteria:\n\n- Male or female subjects who are not pregnant or lactating\n- 18-80 years of age\n- Diagnosis of atopic dermatitis for at least 6 months using the Hanifin and Rajka Diagnostic Criteria\n- Presence of lesional atopic dermatitis skin in both antecubital fossae\n- Positive S. aureus colonization based on skin culture from AD-affected antecubital fossa during screening\n\nThe patient does not meet the inclusion criteria for the clinical trial as there is no mention of atopic dermatitis, which is a specific requirement. The skin lesion described in the patient note does not necessarily indicate atopic dermatitis and could be related to other conditions, such as a complication of diabetes. Additionally, the trial requires a confirmed diagnosis of atopic dermatitis using specific criteria and positive S. aureus colonization, none of which is mentioned in the patient note.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1704": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess if this patient is eligible for the clinical trial titled \"Comparison of Resin Salve and Octenidine in Patients With Neuropathic Diabetic Foot Ulcers\":\n\nPatient Note:\n- 64-year-old female\n- Diagnosis of diabetes mellitus with elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Adult patient (18-80 years)\n- Suffering from infected neuropathic fore- or mid-foot ulceration originated from type I or II diabetes (PEDIS-classification \u2265 Grade II)\n\nAnalysis:\n- The patient fits the age criteria (64 years old).\n- The patient has a diagnosis of diabetes mellitus, which is consistent with the trial's target population.\n- The patient has a painful skin lesion, which could potentially be a neuropathic diabetic foot ulcer, though this has not been explicitly diagnosed as such.\n\nHowever, it is not clear from the patient note whether the skin lesion is located on the fore- or mid-foot, whether it is infected, or whether it meets the PEDIS-classification \u2265 Grade II requirement. Given the lack of information on the specific characteristics and location of the ulcer, as well as the absence of a confirmed diagnosis of a neuropathic diabetic foot ulcer, we cannot conclude with certainty that the patient would be eligible for the trial.\n\nTherefore, the patient would require further evaluation to determine the nature of the skin lesion and if it meets the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1705": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not meet the eligibility requirements for the trial. The patient is described as a 64-year-old obese female with a diagnosis of diabetes mellitus, which is not related to ulcerative colitis, the condition being studied in the trial. Additionally, the age range for the trial is 5 - 18 years, and the patient is 64 years old. The patient also has an unmanaged painful skin lesion, which is not related to the criteria of having mild to moderate active ulcerative colitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1706": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Effect of Topic Pirfenidone in Diabetic Ulcers,\" we can assess the patient's eligibility for the trial as follows:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and an elevated HbA1c level. She has a painful skin lesion on her left lower leg that has been increasing in size and is now oozing, which suggests a diabetic foot ulcer. She has tried using topical lotions and creams, indicating that the lesion is persistent and possibly chronic.\n\nThe inclusion criteria for the trial are:\n- Men or women\n- Type 1 or 2 diabetes\n- Age \u2265 18 years\n- Wagner 1 or 2 diabetic foot ulcer\n- Diabetic ulcer for more than 8 weeks duration\n- Willing to participate in the study with signed informed consent\n\nThe patient meets several of the inclusion criteria: she is a woman with type 2 diabetes and is over the age of 18. The information about the lesion on her lower leg suggests that it could be a diabetic foot ulcer, which is relevant to the trial. However, the note does not specify the Wagner grade of the ulcer or the exact duration of the ulcer, which are required to meet the inclusion criteria. Furthermore, the patient's willingness to participate in the study and provide informed consent cannot be determined from the note.\n\nGiven the information provided, the patient appears to meet some of the inclusion criteria, but further information is needed to fully determine eligibility. Specifically, the Wagner grade of the ulcer needs to be confirmed, as well as the ulcer's duration and the patient's willingness to consent to the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1707": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c. She complains of a painful skin lesion on the left lower leg, which has been increasing in size and is now oozing.\n\nThe clinical trial in question is examining the effect of hyperbaric chamber treatment on patients with diabetic retinopathy. The inclusion criteria for this trial are patients between the ages of 18-90 with Diabetes type I or II and diabetic retinopathy who are scheduled for hyperbaric treatment for other indications than diabetic retinopathy.\n\nGiven that the patient note does not mention diabetic retinopathy, nor does it indicate that the patient is scheduled for hyperbaric treatment for a separate indication, the patient does not meet the specific inclusion criteria outlined for this clinical trial. Therefore, based on the information available, the patient would not be eligible for referral to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1708": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to assess whether the 64-year-old female with a diagnosis of diabetes mellitus and a painful skin lesion on the left lower leg would be eligible for the clinical trial on Shockwave Therapy of Chronic Diabetic Foot Ulcers.\n\nPatient Note Analysis:\n- The patient is 64 years old and obese.\n- Diagnosed with diabetes mellitus.\n- Has persistently elevated HbA1c levels, indicating poorly managed diabetes.\n- The patient has a non-healing, oozing skin lesion on the left lower leg, which could be indicative of a diabetic foot ulcer.\n\nClinical Trial Inclusion Criteria:\n- Patients receiving care and treatment in OUH Wound Clinic (Odense University Hospital, Denmark) with a diabetic foot ulcer.\n- Wagner groups 1 and 2 (Wagner Ulcer Classification System).\n\nAssessment:\n- The patient has a diabetes-related skin lesion, which could potentially be a diabetic foot ulcer. However, it is not explicitly stated that the lesion is a foot ulcer, nor is there any mention of the Wagner group classification.\n- The patient is not specified to be receiving care at OUH Wound Clinic, which is a requirement for the trial.\n\nGiven the information provided, the patient appears to have a skin lesion consistent with a diabetic ulcer, which is the target condition for the clinical trial. However, the absence of specific information about the lesion being located on the foot and classified within Wagner groups 1 or 2, as well as the requirement of being a patient at OUH Wound Clinic, suggests that this patient does not meet all the necessary criteria for the clinical trial.\n\nTherefore, the assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1709": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliance with medication and exercise\n- Painful skin lesion on the left lower leg\n- Lesion has increased in size and is now oozing\n\nClinical Trial Inclusion Criteria:\n- Veterans over 21 years of age\n- With chronic lower extremity or diabetic foot ulcers (wound duration over 8 weeks)\n- Requires wound debridement (25% or more of wound bed covered with non-viable tissue)\n- Wound size 1.5 cm or larger in diameter\n\nComparison:\n- The patient is of the appropriate age (over 21 years).\n- The patient has diabetes, which is commonly associated with chronic lower extremity ulcers that could require debridement.\n- The patient has a lesion that is oozing and has increased in size despite treatment, which could indicate the need for debridement.\n- The trial specifically mentions \"Veterans,\" which the patient note does not address. If the patient is a veteran, she would meet this criterion. If not, she would not be eligible.\n- It is not explicitly stated that the wound is a diabetic foot ulcer, but given the patient's diabetes and description of the lesion, it is a reasonable assumption that it could be.\n- We do not have information about the duration of the wound (whether it is over 8 weeks old) or the exact size of the wound.\n\nGiven the information presented, the patient seems to meet some of the inclusion criteria but critical information is missing, particularly whether the patient is a veteran, the duration of the wound, and the size of the wound. Therefore, further investigation is needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1710": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the eligibility of the patient for the trial as follows:\n\n- The patient is a 64-year-old female, which meets the age requirement of \u2265 18.\n- She has a diagnosis of diabetes mellitus, which is consistent with the requirement of Type 2 Diabetes.\n- The patient has a painful skin lesion on the left lower leg. While the trial specifies a break in the skin on the foot, the lesion is described on the lower leg and not specifically on the foot. This may or may not meet the criteria depending on the exact location of the lesion.\n- The lesion is said to be oozing and has increased in size despite treatment, which might suggest a more advanced ulcer, but it is not clear if it meets the Grade 1 or 2 definition by the Wagner grading system without further information.\n- The patient has persistently elevated HbA1c, which likely meets the requirement of Hemoglobin A1c \u2265 5.9%.\n- There is no information about the patient's ability to provide written informed consent, but we can assume capacity unless otherwise stated.\n\nGiven the information provided, the patient seems to meet most of the inclusion criteria except for the specific location and grading of the skin lesion, which needs further clarification to ensure it meets the Grade 1 or 2 Wagner criteria. Therefore, I would consider referring this patient for the clinical trial upon further investigation to clarify the specifics of the skin lesion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1711": {
        "output": "",
        "label": 1
    },
    "1712": {
        "output": "",
        "label": 0
    },
    "1713": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increased in size and oozing\n\nClinical trial inclusion criteria:\n- Has diabetes mellitus, according to the ADA criteria\n- At least 1 skin ulcer located on or below the malleolus with clinical manifestations of a moderate or severe infection\n- \u2265 2 manifestations of inflammation\n- \u2265 1 characteristic suggesting deeper or more extensive infection\n- Adequate arterial perfusion in the affected limb\n- Appropriate surgical intervention if diagnosed with osteomyelitis\n- Appropriate surgical debridement to remove gangrenous tissue\n\nAssessment:\n- The patient has diabetes mellitus which meets the ADA criteria.\n- The patient complains of a painful skin lesion on the left lower leg that is oozing, which could meet the criteria for an infected ulcer with \u2265 2 manifestations of inflammation.\n- Additional information would be needed to confirm the severity of the infection and whether the lesion is indeed an ulcer that fits the specific criteria of the trial (e.g., erythema >2cm, deeper structure involvement).\n- There is no information provided regarding the patient's arterial perfusion in the affected limb, surgical interventions, or debridement, which are necessary to fully assess eligibility.\n\nGiven the information available in the patient note, the patient appears to have some characteristics that could potentially match the inclusion criteria of the trial. However, further investigation is required to determine the full extent of the ulcer's characteristics, severity of infection, and other criteria such as arterial perfusion and surgical interventions.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1714": {
        "output": "Based on the information provided in the patient note, let's compare it to the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 64-year-old obese female.\n- She has a diagnosis of diabetes mellitus.\n- Her HbA1c levels are persistently elevated.\n- She is not compliant with her diabetes medication.\n- She has not been confirmed as a patient in the Vanderbilt APPC or the Eskind Diabetes Clinic.\n- There is no information regarding her use of the \"My Health at Vanderbilt\" user portal.\n- She is currently being treated for diabetes, although she is non-compliant.\n\nClinical Trial Inclusion Criteria:\n- Adults 18 years and older.\n- Individuals who have received a diagnosis for type 2 diabetes mellitus (T2DM).\n- Enrolled as a patient in the Vanderbilt APPC or the Eskind Diabetes Clinic.\n- Registered My Health at Vanderbilt user.\n- Recent A1c of 7.0 or greater.\n- Individuals currently being treated with oral and/or injectable diabetes medication.\n\nThe patient meets some of the inclusion criteria: she is over 18 years old, has been diagnosed with diabetes mellitus (assuming type 2 since no type is specified), and has a recent HbA1c of 7.0 or greater. However, there is no information provided that confirms she is enrolled as a patient at the specified clinics or that she is a registered user of the My Health at Vanderbilt portal. Additionally, while she is being treated with diabetes medication, her non-compliance might be a factor to consider.\n\nGiven the missing information, this patient's eligibility cannot be confirmed without further investigation to determine if she is a patient in the specified clinics and a user of the health portal. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1715": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c (no specific value given)\n- Noncompliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n- Has tried topical lotions and creams without improvement\n\nClinical Trial Inclusion Criteria:\n- Signed and dated informed consent\n- Ability and willingness to comply with study procedures and weekly visits\n- Age 18 years or older\n- Presence of at least 50% or greater necrotic tissue in the wound bed and a wound surface area of >1cm2 to <64cm2\n- No current use of parenteral or oral antibiotics except for UTI\n- Diabetic subjects: HbA1c < 12.0% within 90 days preceding enrollment\n- Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment\n- If the subject has a pressure ulcer, they must be receiving adequate pressure redistribution\n- If the subject has a diabetic plantar surface ulcer, they must use an offloading boot if ambulatory\n- If the subject has a venous ulcer, they must be currently receiving and using compression therapy\n- Subject and caregiver are trainable and able to perform dressing changes\n- No allergies to collagenase or honey\n- No allergies to semi-occlusive or absorptive secondary dressing\n- If multiple wounds, the largest wound fitting the criteria will be selected\n\nAssessment:\n- The patient is 64 years old, which meets the age criterion.\n- The patient has a skin lesion that seems to require debridement, which may fit the wound criteria. However, it is not specified if the lesion has 50% or greater necrotic tissue.\n- The patient's HbA1c level is described as persistently elevated, but it is not specified if it is below the required 12.0%. This would need to be confirmed.\n- There is no information on whether the patient is using antibiotics, what her pre-albumin level is, or if she is receiving any specific therapy for the ulcer (such as pressure redistribution, offloading boot, or compression therapy).\n- The patient's noncompliance with her diabetes medication and exercise regimen might affect her ability to comply with study procedures, which is a concern for study enrollment.\n- The patient's willingness and ability to comply with weekly visits and perform dressing changes are not mentioned.\n\nGiven the information available, the patient may potentially meet some of the inclusion criteria, but there are several key pieces of information missing that are vital to determine eligibility. The patient's HbA1c level needs to be confirmed, and more details on the wound characteristics and current treatments are required.\n\nTherefore, I would categorize the assessment of eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1716": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical Trial Inclusion Criteria:\n- Patients with cutaneous leg ulcers due to diabetes mellitus, venous stasis, and arterial insufficiency\n- Patients of both sexes\n- Patients over 18 years\n- Patients that have basic laboratory at admission\n- Patients with comorbidities such as Diabetes Mellitus, Hypertension, stroke, heart disease, nephropathy, venous insufficiency, and arterial insufficiency, etc.\n\nThe patient has diabetes mellitus and a painful skin lesion on the lower leg that is oozing, which could be indicative of a cutaneous ulcer. The patient is also over 18 years old and of the appropriate sex, meeting those inclusion criteria. However, the patient note does not mention venous stasis or arterial insufficiency specifically. To ensure that the patient's condition aligns with the trial's focus, these additional diagnoses would need to be confirmed.\n\nGiven the information provided, the patient seems to meet several key inclusion criteria but requires further investigation to confirm the exact nature of the skin lesion and to ensure that all relevant comorbidities are documented, including the necessary basic laboratory tests at admission.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1717": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus with persistently elevated HbA1c\n- Non-compliant with diabetes medication or exercise regimen\n- Painful skin lesion on the left lower leg, increasing in size and oozing\n\nClinical trial summary:\n- Investigates the effectiveness of using an oil bath additive on skin barrier function\n- Participants must have an Overall Dry Skin score (ODS) of 1 to 2 at arms and lower legs\n- TEWL > 12 g/m2/h on the left mid volar forearm\n- General good and stable health condition, or clinically stable medical conditions\n- Accepts not to sunbathe or use a solarium during the study\n\nThe patient note indicates that the patient has a skin lesion, which might suggest dry skin or another dermatological issue. However, the clinical trial specifically requires participants to have an Overall Dry Skin score of 1 to 2 at arms and lower legs and TEWL measurements, which are not provided in the patient note. Additionally, the patient's health condition may not be considered \"good and stable\" or \"clinically stable\" due to her non-compliance with diabetes management, which could affect the skin's healing and barrier function.\n\nSince the patient's skin condition is not clearly defined as \"dry skin\" and specific measurements like TEWL are not provided, and her overall health condition might not meet the \"stable\" requirement due to poorly managed diabetes, it is not clear if she would be eligible for the trial. Therefore, further investigation would be needed to determine her skin's dryness level and TEWL, as well as an assessment of her overall health in relation to her diabetes management before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1718": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Elevated HbA1c\n- Non-compliance with diabetes medication or exercise\n- Painful skin lesion on the left lower leg that is oozing\n\nClinical Trial Inclusion Criteria:\n- Adult patients (ages 18-65)\n- Diabetes mellitus\n- Presenting for an anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications (e.g., diabetic lower extremity wounds or refractory osteomyelitis)\n- Current antibiotic use for active infection\n\nComparison:\n- The patient's age fits within the 18-65 range.\n- She has diabetes mellitus, which is a requirement.\n- The skin lesion on her leg could potentially be considered a \"diabetic lower extremity wound,\" which is one of the possible indications for the hyperbaric oxygen sessions mentioned in the trial.\n- There is no mention of the patient using antibiotics for an active infection, which is part of the inclusion criteria.\n\nGiven the information, the patient's age and diagnosis of diabetes align with the trial's inclusion criteria. However, there is no explicit mention of her using antibiotics for the leg lesion, which the trial specifies for active infection. Therefore, we must consider the possibility of the skin lesion being an active, chronic infection to determine her eligibility fully.\n\nAssuming the lesion is indeed an active, chronic infection and the patient is started on antibiotics, she would be eligible. However, since this is not confirmed from the patient note, further investigation is needed before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1719": {
        "output": "Based on the patient note provided, the 64-year-old obese female patient has a diagnosis of diabetes mellitus with a persistently elevated HbA1c level. She presents with a painful skin lesion on the left lower leg that is oozing and has increased in size despite the use of topical lotions and creams.\n\nComparing this patient's situation with the inclusion criteria for the clinical trial titled \"Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers,\" the following points are relevant:\n\n- The patient is over 18 years old and could provide written informed consent.\n- There is no information regarding whether the patient can be monitored by the same investigation team throughout the study or if she agrees to wear an effective venous compression system every day, associated with the trial dressing.\n- The patient has a leg ulcer, but there is no information on whether this ulcer is venous or mixed, as required by the trial.\n- No Ankle Brachial Pressure Index (ABPI) score is provided, which is necessary to determine eligibility based on the trial's criteria.\n- The size and duration of the ulcer are not specified, so compliance with the criteria of an ulcer area \u2265 5cm\u00b2 and duration \u2265 6 months cannot be confirmed.\n- The description of the wound bed and the level of exudation are not detailed enough to match the inclusion criteria, which require the ulcer to be covered with 50% or more by sloughy tissue and to be moderately or heavily exudative.\n\nGiven the lack of detailed information regarding the ulcer's type, ABPI score, size, duration, wound bed condition, and exudation level, and no indication that the patient agrees to the necessary treatment protocols of the trial, it is not possible to determine with certainty that this patient would be eligible for the clinical trial. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1720": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Pressure-Sensing Insoles in the Neuropathic Ulcer Treatment Pathway,\" we need to compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nInclusion Criteria for the trial:\n1. Diabetes (according to AAFP diagnostic criteria)\n2. Presence of neuropathy with Loss of Protective Sensation (LOPS), as defined by any loss of sensation as per the assessments included in the Modified Neuropathy Disability Score (MNDS)\n3. Active plantar diabetic foot ulcer (Grade 1A, according to the University of Texas Wound Classification System)\n4. A minimum size ulcer \u22650.5cm2 and \u2264 12 cm2 post debridement at the time of randomization\n5. If the subject has more than one ulcer, they should be identified and at least 2 cm apart\n6. Age >18\n7. At least one palpable foot pulse\n8. Ability to understand all of the study requirements\n9. Life expectancy greater than the duration of the study\n10. Subject or responsible caregiver is willing and able to maintain the required offloading (as applicable for the location of the ulcer) and applicable dressing changes\n11. Doppler Ultrasound positive for at least one pedal pulse in each foot\n\nPatient Characteristics:\n1. 64-year-old obese female (meets age criteria)\n2. Diagnosis of diabetes mellitus (meets diabetes criteria)\n3. Painful skin lesion on the left lower leg, which could be indicative of a diabetic foot ulcer, but it is not explicitly stated that it is an active plantar diabetic foot ulcer (further information required)\n4. The lesion is oozing, which could suggest an infection rather than an active ulcer (further information required)\n5. Noncompliance with diabetes medication or exercise (may affect the ability to maintain the required offloading and applicable dressing changes)\n6. No information provided on the presence of neuropathy with LOPS, ulcer size, ulcer grading, palpable foot pulse, understanding of study requirements, life expectancy, or Doppler Ultrasound results\n\nBased on the information provided, the patient appears to have diabetes, which is a primary requirement for the trial. However, there is insufficient information regarding the specifics of the diabetic foot ulcer, including its location, grading, size, and whether proper sensation is lost, which are critical for meeting the inclusion criteria. Moreover, the patient's reluctance to comply with medical advice and treatment may affect their ability to adhere to the study requirements.\n\nTherefore, the patient's eligibility is uncertain without further investigation to ascertain the specifics of her foot lesion and overall health status in relation to the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1721": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nPatient characteristics:\n- 64-year-old obese female\n- Diagnosis of diabetes mellitus\n- Persistently elevated HbA1c\n- Painful skin lesion on the left lower leg, oozing and increasing in size despite topical treatment\n\nClinical trial inclusion criteria:\n1. Patient is 18 years of age or older.\n2. Patient has one of the following difficult-to-treat chronic ulcers in the lower limb:\n   2.1. Neuropathic lower limb ulcer\n   2.2. Venous lower limb ulcer\n   2.3. Post traumatic lower limb ulcer\n   2.4. Post operative lower limb ulcer\n3. In case of Neuropathic foot grade according to University of Texas Classification 1A\n4. Wound area measurement ranging between 1-20cm2.\n5. Ulcer defined as grade \u2265E on the granulometer scale.\n6. Willing to adhere to the proper off-loading device (off loading cast, healing shoe) according to investigator recommendation.\n7. Female patients must meet certain criteria regarding pregnancy and birth control.\n8. Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study.\n\nBased on the patient note, the patient has a painful skin lesion on the lower leg which could potentially be a chronic ulcer. However, there is no specific information provided regarding the type of ulcer (neuropathic, venous, post-traumatic, or post-operative), its measurement, or the granulometer scale assessment. \n\nAlthough the patient is over 18 years old and has a chronic lower limb condition that may qualify as an ulcer, we lack detailed information about the ulcer's nature and classification to definitively match the trial's inclusion criteria. \n\nFurthermore, the note mentions the patient's non-compliance with medication and reluctance to see a nutritionist, which might raise concerns about her willingness to adhere to study procedures and the off-loading device as per criterion 6.\n\nGiven these uncertainties, it would be prudent to obtain further information about the nature of the skin lesion and the patient's willingness to comply with study requirements before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1722": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Characteristics:\n- 64-year-old female\n- Diagnosed with diabetes mellitus\n- Elevated HbA1c levels\n- Non-compliant with diabetes medication and exercise\n- Painful skin lesion on the left lower leg, which has increased in size and is oozing\n\nClinical Trial Inclusion Criteria:\n- Age between 18 years and 80 years\n- Diagnosed with Type I or Type II diabetes\n- Presence of a diabetic foot ulcer for more than 4 weeks at the screening visit\n- Ulcer located on the foot, and size is between 1 cm^2 and 25 cm^2\n- Ulcer extends into the dermis, subcutaneous tissue, tendon, or joint capsule (Wagner grade 1 or 2)\n- Ulcer is free of necrotic debris\n- Adequate circulation to the ulcer\n- Ability to give written informed consent and comply with study requirements\n\nComparison:\n- The patient's age is within the inclusion range.\n- The patient has diabetes, which is necessary for the trial.\n- The patient has a skin lesion, but it is located on the lower leg, not on the foot as required by the trial.\n- There is no information on the size of the lesion or its duration.\n- The status of the ulcer (whether it extends into the specified tissues and is free of necrotic debris) is not described.\n- There is no information provided about the circulation to the ulcer, nor any of the specific tests or measurements mentioned in the inclusion criteria.\n- The patient's willingness to comply may be questionable due to her non-compliance with diabetes management, but this is not definitive for her ability to consent or comply with the study itself.\n\nGiven the lack of specific information regarding the ulcer's location being on the foot, size, depth, duration, and circulation status, we cannot confirm that the patient meets all the necessary inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1723": {
        "output": "Based on the patient note, the patient is a 64-year-old female with a diagnosis of diabetes mellitus and persistently elevated HbA1c, indicating poor control of her diabetes. The note also mentions that she is not compliant with her diabetes medication, which fits the inclusion criteria of the clinical trial for patients considered to be poorly adherent to CVD risk factor medications. The inclusion criteria also specify that eligible patients must be users of CVD risk factor medications, which typically include oral antihyperglycemic therapies that the patient is likely prescribed given her diabetes diagnosis.\n\nThe trial aims to encourage the use of mail order pharmacy services among diabetes patients who are poorly adherent to their CVD risk factor medications, and the patient has not been described as using mail order pharmacy services to fill her prescriptions. This suggests that she could potentially benefit from the intervention being studied in the trial.\n\nHowever, the patient note does not explicitly state that she has not used mail order pharmacy services in the prior 12 months, which is one of the inclusion criteria for the trial. Assuming this information is obtained and confirms her eligibility, the patient would be a good candidate for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1724": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient appears to meet the following criteria for the trial:\n\n1. The patient has a history of bipolar disorder, which aligns with the trial's focus on Bipolar I disorder.\n2. The patient is experiencing symptoms of depression, which could be considered part of a depressed episode of Bipolar I disorder.\n3. The patient is currently taking lithium carbonate, which is required for the trial.\n\nHowever, the note does not explicitly state that the patient has been diagnosed with Bipolar I disorder, nor does it confirm that the patient is currently experiencing a manic or depressed episode as defined by the clinical trial criteria. Since the patient is experiencing depressive symptoms and is on lithium carbonate, it suggests the patient may be experiencing a depressed episode, but this would require further investigation to confirm.\n\nTherefore, the patient note suggests potential eligibility, but further information would be needed to confirm that the patient is experiencing a manic or depressed episode consistent with Bipolar I disorder at the time of study entry, as required by the clinical trial. The assessment of eligibility falls into the category of:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1725": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nThe patient:\n- Is a 26-year-old woman, which meets the age criteria of \u2265 18 years.\n- Has a history of bipolar disorder, which aligns with the trial's target population.\n- Is currently taking lithium carbonate, a mood stabilizer, which is mentioned in the inclusion criteria.\n- Is experiencing symptoms of major depression, as indicated by her depression and suicidal thoughts.\n\nClinical Trial Inclusion Criteria:\n- Free of manic symptoms for at least 4 weeks.\n- Must be treated with valproate or lithium for at least 4 weeks.\n- Meet criteria for major depression and bipolar disorder (BP-I, BP-II, or BP-NOS).\n- Not pregnant.\n\nWhile the patient is currently taking a mood stabilizer (lithium) and has bipolar disorder with depressive symptoms, there is no information provided about her being free of manic symptoms for at least 4 weeks. Additionally, there is no information about her pregnancy status. These are critical points that would need further clarification to determine her eligibility for the trial.\n\nConsidering the information at hand, the patient appears to meet some of the inclusion criteria for the clinical trial but further investigation is needed to verify other criteria such as duration of stability and pregnancy status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1726": {
        "output": "Based on the patient note provided, the 26-year-old woman does not mention a smoking habit. The clinical trial in question is specifically targeting women who smoke at least 10 cigarettes per day, are concerned about cessation-related weight gain, and are motivated to quit smoking.\n\nSince there is no indication the patient meets these key inclusion criteria related to smoking habits, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1727": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD),\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 26 years old\n- Health Condition: Bipolar disorder with recent struggles with weight and eating, depression, difficulty sleeping, excessive anxiety and agitation, suicidal thoughts, irritability.\n- Current Medications: Lithium carbonate and zolpidem\n- Other Factors: The patient is fidgety and unable to sit still for extended periods.\n\nClinical Trial Inclusion Criteria:\n- Current age 15 or older (Best Practice Pathway) or 18 years or older (Randomized Care Pathways)\n- Able to give informed consent for data to be harvested\n- Meet DSM-IV criteria for Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS, or Cyclothymic Disorder\n- Undergo a complete standard evaluation including clinical interview, self ratings, and laboratory studies\n- Meet with Clinical Specialist as scheduled\n- Able to complete all Study Registry Forms within 3 months of registration\n\nClinical Trial Exclusion Criteria:\n- Unwilling or unable to adhere to basic study requirements\n- Not competent to give informed consent in the opinion of the investigator (e.g., psychotic)\n\nBased on the information provided, the patient meets the following inclusion criteria:\n- She is over 18 years old.\n- She is able to give informed consent (there is no information suggesting otherwise).\n- She has a history of bipolar disorder, which is one of the conditions listed in the inclusion criteria.\n- There is no indication that she would be unwilling or unable to adhere to study requirements or that she is not competent to give informed consent.\n\nGiven that the patient's condition aligns with the focus of the clinical trial and she meets the inclusion criteria without evidence of meeting any exclusion criteria, it is likely that she would be eligible for the STEP-BD study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1728": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Clinical Trial of Mifepristone for Bipolar Depression,\" we need to assess the patient's characteristics against the stated inclusion and exclusion criteria.\n\nPatient characteristics from the note:\n- 26 years old\n- Female\n- History of bipolar disorder\n- Currently experiencing a depressive phase with difficulty sleeping, anxiety, agitation, thoughts of suicide, and irritability\n- Current medications: lithium carbonate and zolpidem\n\nClinical trial inclusion criteria for bipolar patients:\n- Male or female inpatients in need of treatment for severe bipolar depression\n- 18-75 years of age\n- Women of childbearing potential must be using an adequate form of contraception\n- DSM-IV diagnosis of bipolar depression I/II, severe, with or without psychotic features\n- A current major depressive episode of at least 6 weeks' duration\n- Score of \u226518 on the HAM-D at the prestudy visit and at the first baseline phase visit\n- Score of \u226515 on the HAM-D at the end of the baseline period(s)\n- Score of \u22654 on the CGI-BP scale at the prestudy and first visit and end of baseline phase\n- Judged to be in good physical health on the basis of medical history, physical examination, and laboratory screening\n- Able to understand procedures and agree to participate in the study by giving written informed consent\n- On lithium and/or valproate for at least 4 weeks\n- Able to come off of prior drugs and PRN zolpidem and lorazepam by the start of the baseline\n\nClinical trial exclusion criteria for bipolar patients:\n- Pregnant, intending to become pregnant, or breastfeeding\n- Recent treatment with certain therapies including Fluoxetine, MAOIs, other antidepressants\n- Contraindication or history of hypersensitivity to mifepristone and related compounds\n- Clinically significant organ system disease, infection, or severe liver, respiratory, or renal disease\n- Clinically significant cardiovascular disease\n- Anemia\n- Known clotting defect or receiving anticoagulants\n- Rapid cycling in the last year\n- History of porphyrias\n- Clinically significant abnormalities in physical exam, ECG, or laboratory assessments\n- Substance dependence not in sustained full remission\n- Other principal psychiatric diagnosis judged by the investigator to dominate the clinical presentation\n- History of nonresponse to >4 trials of antidepressants for the current episode\n\nBased on the patient note provided, the patient appears to meet many of the inclusion criteria for the clinical trial:\n- She is within the age range required.\n- She has a history of bipolar disorder and is currently experiencing a severe depressive phase.\n- She is currently taking lithium carbonate, which is one of the mood stabilizers mentioned in the inclusion criteria.\n\nHowever, there are some unknowns that would need to be clarified before referring the patient to the trial:\n- We do not have information regarding the length of the current depressive episode.\n- The patient's scores on the HAM-D and CGI-BP scales are not provided.\n- The patient's physical health status and laboratory screening results are not mentioned.\n- We do not have confirmation that she meets the contraception requirement.\n\nGiven the information provided and assuming the patient's willingness to participate, I would consider referring this patient to the clinical trial upon further investigation to clarify the unknowns and ensure all inclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1729": {
        "output": "To assess the eligibility of the patient for the clinical trial, we will compare the patient's characteristics and condition with the inclusion criteria specified by the trial:\n\nPatient Characteristics:\n- Age: 26 years old\n- Diagnosis: Bipolar disorder\n- Current medications: Lithium carbonate and zolpidem\n- Other symptoms: Obesity, difficulty sleeping, anxiety, agitation, suicidal thoughts, irritability\n\nClinical Trial Inclusion Criteria:\n- Age: Between 18 and 65 years\n- Diagnosis: Schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder\n- Medication: Must be taking olanzapine\n- Other: Ability to visit the doctor's office as scheduled for the next 4 months\n\nThe patient fits the age criterion and has a diagnosis of bipolar disorder, which is one of the conditions listed in the trial's inclusion criteria. However, the trial specifically requires patients to be taking olanzapine, which is not listed among the patient's current medications. The patient is taking lithium carbonate and zolpidem but not olanzapine.\n\nGiven that the patient is not currently taking olanzapine, which is a prerequisite for the trial, the patient does not meet one of the essential inclusion criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1730": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing depression, as indicated by her statement that she feels depressed.\n- She has difficulty sleeping and feels excessively anxious and agitated, which could be associated with an episode of bipolar disorder.\n- She mentions having thoughts of suicide and exhibits increased irritability.\n- She is on medication for bipolar disorder (lithium carbonate) and for sleep (zolpidem).\n\nClinical Trial Inclusion Criteria:\n- Bipolar I or II Disorder\n- Meet criteria for rapid cycling, defined as four or more episodes over the past 12 months\n- Meet criteria for a major depressive episode\n\nAssessment:\n- The patient has bipolar disorder, which matches the inclusion criterion of the clinical trial.\n- The patient seems to be experiencing a major depressive episode, which is another inclusion criterion.\n- However, there is no information provided about the number of episodes over the past 12 months to determine if she meets the rapid cycling criteria.\n\nGiven the information, the patient appears to meet some of the inclusion criteria for the clinical trial, specifically having bipolar disorder and experiencing a major depressive episode. However, due to the lack of information on the frequency of her episodes over the past year, we cannot definitively determine if she meets the rapid cycling criterion.\n\nTherefore, the patient's eligibility is not clear-cut, and further investigation into her episode frequency in the past year is needed to ascertain if she meets the rapid cycling criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1731": {
        "output": "Based on the provided patient note, we have a 26-year-old woman with a history of bipolar disorder experiencing symptoms that suggest she is currently struggling with depression, including difficulties with weight and eating, sleep disturbances, excessive anxiety and agitation, suicidal thoughts, fidgetiness, and irritability. Her current treatment includes lithium carbonate and zolpidem.\n\nThe clinical trial in question is focusing on reducing symptoms of depression in low-income mothers with young children enrolled in Early Head Start Programs. The inclusion criteria for the trial are:\n\n1. A score of 16 or higher on the Center for Epidemiological Studies Depression (CES-D) Scale.\n2. Having a child who is 6 weeks to 30 months old.\n3. Having a child who is enrolled in an Early Head Start program.\n\nThe patient note does not provide information about whether the patient has a young child enrolled in an Early Head Start program, nor does it mention her CES-D score. Without this information, we cannot definitively determine her eligibility for the clinical trial. Additionally, there is no indication that the woman is a low-income mother, which is the target population for this trial.\n\nGiven the lack of information on key inclusion criteria, I would classify this patient's eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1732": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Effect of Lithium and Divalproex in Alzheimer's Disease,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 26 years old\n- Diagnosis: Bipolar disorder with symptoms of depression, anxiety, agitation, suicidal thoughts, and difficulty sleeping\n- Current medications: Lithium carbonate and zolpidem\n- Other: Obese, fidgety, irritable\n\nClinical Trial Criteria:\n\nInclusion Criteria:\n- Patient is between the ages of 40 and 90 (inclusive).\n- Patient will have a diagnosis of Alzheimer's disease (AD); the study will be confined to patients who are able to provide consent (pass a capacity assessment).\n- The modified Hachinski Ischemia Score must be less than 4.\n- Brain MRI performed within 15 months of enrollment must be compatible with the diagnosis of AD.\n- Patient and/or caregiver are willing to adhere to protocol requirements as evidenced by written, informed consent.\n\nExclusion Criteria:\n- History of any medical condition that can reasonably be expected to subject the patient to unwarranted risk.\n- Clinically significant laboratory abnormalities that would preclude administration of lithium and divalproex.\n- Taking prohibited concomitant medication.\n- Not using an adequate contraceptive method, pregnant, or breastfeeding (if female).\n- Participated in a clinical study with an investigational drug within the last 30 days.\n- Condition that would interfere with compliance or safety.\n- Known hypersensitivity to lithium or divalproex.\n- Inability to swallow tablets or to comply with medication schedule.\n- No adequate caregiver.\n- Unwilling to sign an informed consent or to comply with protocol requirements.\n- Unwilling to have lumbar puncture.\n\nAssessment:\nThe patient is a 26-year-old woman with bipolar disorder, which does not meet the inclusion criteria for a diagnosis of Alzheimer's disease. Additionally, the patient does not fall within the required age range of 40 to 90 years. Since the patient does not meet key inclusion criteria and does not have the condition the clinical trial is investigating, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1733": {
        "output": "Based on the patient note provided, the patient is a 26-year-old obese woman with a history of bipolar disorder. She is currently experiencing depression, anxiety, agitation, difficulty sleeping, and has had thoughts of suicide. She is on medications that include lithium carbonate and zolpidem.\n\nNow, let's compare this to the inclusion criteria for the clinical trial:\n\n1. DSM-IV diagnosis of cannabis dependence with at least a three-month history.\n2. Seeking treatment for primary cannabis problem\n3. Withdrawal identified as a barrier to abstinence\n\nThe patient in question does not mention any use of cannabis, let alone dependence. There is no indication that the patient is seeking treatment for a primary cannabis problem or that she has identified withdrawal as a barrier to abstinence. Therefore, based on the information provided, this patient does not meet the inclusion criteria of having a cannabis dependence and seeking treatment for it, nor is there any mention of experiencing withdrawal symptoms as a barrier to achieving abstinence from cannabis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1734": {
        "output": "Given the patient note, the patient is a 26-year-old obese woman with a history of bipolar disorder. She is currently struggling with weight, depression, anxiety, agitation, and suicidal thoughts. She is also irritable and fidgety, which could be associated with symptoms of ADHD, but the note does not explicitly diagnose her with ADHD.\n\nThe clinical trial in question is for the efficacy of Aripiprazole in children and adolescents with bipolar disorder comorbid with ADHD. The inclusion criteria for the trial are:\n1. Age: 8-17\n2. BD type I or II comorbid with ADHD\n3. Baseline score in the YMRS (Young Mania Rating Scale) \u2265 20\n\nThe patient in the note is 26 years old, which is outside the age range of 8-17 years specified in the inclusion criteria. Therefore, based on the information provided, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1735": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the two:\n\nPatient Note:\n- 26-year-old woman (meets age criteria of 18-65 years)\n- History of bipolar disorder (relevant to the study)\n- Struggles with weight and eating, feeling depressed (possible symptoms of depressive episodes)\n- Difficulty sleeping, excessive anxiety, agitation, thoughts of suicide (could be part of depressive episodes)\n- Fidgety, unable to sit still, irritability (could indicate hypomanic episodes)\n- On current medications including lithium carbonate (a mood stabilizer) and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Aged 18-65 (patient meets this criterion)\n- Minimum two-year history of depressive and hypomanic episodes (the patient\u2019s history length is not specified)\n- Mood episodes occurring monthly (frequency is not specified in the patient note)\n- Meet DSM-IV criteria for Bipolar II Disorder (with exception of minimum 4-day period for hypomanic episodes) (patient has a history of bipolar disorder, but the subtype is not specified, nor is the duration of episodes)\n\nThe patient appears to have bipolar disorder and is within the age range for the trial. However, the patient note does not provide enough information to confirm a definitive diagnosis of Bipolar II Disorder as per DSM-IV criteria, nor does it specify the frequency or duration of the mood episodes. Additionally, the trial is investigating the efficacy of Escitalopram as a mood stabilizer, and the patient is already on a mood stabilizer (lithium carbonate), which could be a confounding factor in the study.\n\nGiven the information provided, we cannot confirm the patient's eligibility without further investigation into their bipolar disorder subtype, the history and pattern of their mood episodes, and their treatment history. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1736": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility of the patient:\n\nPatient characteristics:\n- Age: 26 years (fits the age criteria of 25 - 55)\n- Symptoms: Difficulty sleeping, depression, anxiety, agitation, suicidal thoughts, fidgetiness, and irritability\n\nClinical trial inclusion criteria:\n- Ages 25 - 55 (the patient meets this criterion)\n- A stable sleep/wake schedule with a preferred sleep phase between 10:00 p.m. and 8:00 a.m. (we do not have information about the patient's sleep schedule)\n- Patients with Primary Insomnia meeting diagnostic criteria for Psychophysiologic Insomnia (the patient has difficulty sleeping, but we do not have enough information to diagnose Primary Insomnia or Psychophysiologic Insomnia)\n- Complaint of disturbed sleep with specific characteristics (the patient has difficulty sleeping, but the exact characteristics of her sleep disturbance are not described in detail)\n\nThe patient note indicates that the 26-year-old woman has difficulty sleeping, which aligns with the age criteria and potentially with the sleep disturbance criteria of the trial. However, we do not have detailed information about her sleep patterns or whether her insomnia meets the specific diagnostic criteria for Psychophysiologic Insomnia according to the ICSD. Furthermore, her difficulty sleeping could be related to her bipolar disorder and the medications she is taking, rather than Primary Insomnia.\n\nGiven the lack of detailed information about the patient's sleep disorder and the necessity for a specific diagnosis of Psychophysiologic Insomnia, further assessment would be needed before considering referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1737": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"A Study of Risperidone Monotherapy in Bipolar Anxiety,\" we must match the patient's characteristics and condition with the inclusion criteria of the study.\n\nPatient's Characteristics:\n- 26-year-old woman\n- Diagnosed with bipolar disorder\n- Current symptoms: depression, difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, restlessness, irritability\n- Current medications: lithium carbonate (mood stabilizer) and zolpidem (sedative)\n\nClinical Trial Inclusion Criteria:\n- 18 years of age or older\n- Lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria\n- Lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria\n- Bipolar symptoms no more than moderately severe, defined as a CGI-BP < 4\n- Anxiety symptoms at least moderately severe, defined as a CGI-S > 4\n- Not receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline\n- If female, use of effective contraception\n\nThe patient is 26 years old and has a diagnosis of bipolar disorder, fulfilling two of the inclusion criteria. The patient also reports excessive anxiety and agitation, which could potentially meet the criteria for generalized anxiety disorder. However, there are several factors that hinder the patient's eligibility:\n\n1. The severity of the patient's bipolar symptoms is not clearly stated, but the mention of suicidal thoughts might suggest that the symptoms could be more than moderately severe, which would not meet the CGI-BP < 4 criterion.\n2. The patient is currently on lithium carbonate, which is a mood stabilizer, and zolpidem. The trial requires patients not to be receiving mood stabilizers or other specified medications for more than one week prior to baseline.\n3. It is not clear whether the patient's anxiety is a lifetime condition or if it meets the DSM-IV criteria for panic disorder or GAD, which is necessary for the trial.\n\nGiven these factors, particularly the current use of medication that does not align with the trial's requirements, the patient would not be immediately eligible for referral. However, if the patient's medications are discontinued for the required period and the severity of her bipolar and anxiety symptoms are clarified and fulfill the trial's criteria, she could potentially be considered for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1738": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 26-year-old woman\n- History of bipolar disorder\n- Struggles with weight and eating\n- Feels depressed, anxious, agitated\n- Thoughts of suicide\n- Fidgety and irritable\n- Medications: lithium carbonate and zolpidem\n\nClinical Trial:\n- Title: Aripiprazole as Augmentation for TRD (Treatment-Resistant Depression)\n- Inclusion Criteria:\n  - Males or females age 18 to 65 years\n  - DSM-IV episode of Major Depression non-psychotic\n  - \u226514 score on the 17-item HRSD (Hamilton Rating Scale for Depression)\n  - Adequate trial with two antidepressants\n  - Ability to receive and give informed consent\n  - If of child-bearing potential, use of an effective contraceptive and a negative pregnancy test for females upon entry into the study\n\nAssessment:\n- The patient is within the age range (18 to 65 years).\n- The patient has a history of bipolar disorder, which is not the same as major depression; patients with bipolar disorder can have depressive episodes, but the trial specifically mentions major depression non-psychotic.\n- There is no information provided on whether the patient has had an adequate trial with two antidepressants, which is a requirement for the trial.\n- The patient is on lithium carbonate (commonly used for bipolar disorder) and zolpidem (a sleep aid), but there's no mention of current or past use of an antidepressant specifically for major depression.\n- The patient's ability to give informed consent is not clear due to the mention of thoughts of suicide and potential severe depressive symptoms.\n\nGiven that the patient has a diagnosis of bipolar disorder rather than unipolar major depression and there is no clear indication that she has had an adequate trial with two antidepressants for major depression, it is unlikely that she would meet the specific inclusion criteria for this clinical trial focused on treatment-resistant major depression.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1739": {
        "output": "The patient in the note is a 26-year-old woman with a history of bipolar disorder, who is currently experiencing difficulty sleeping, feeling depressed, excessively anxious, agitated, and has thoughts of suicide. She is on lithium carbonate and zolpidem.\n\nThe clinical trial in question is investigating the characteristics of sleep patterns in young adults with and without insomnia. The inclusion criteria are that the participant must be physically healthy and meet the DSM-IV criteria for primary insomnia. Additionally, for subjects interested in a PET study, right-handedness is required.\n\nBased on the patient note, she does have difficulty sleeping, which could potentially align with insomnia. However, her sleep issues may be secondary to her bipolar disorder and the medications she is taking. The trial specifically mentions \"primary insomnia,\" which is insomnia not attributable to a medical, psychiatric, or environmental cause. Since the patient's insomnia symptoms could be related to her underlying bipolar disorder or the medications used for its management, she may not meet the criteria for primary insomnia as defined by the DSM-IV.\n\nFurthermore, there is no information provided on the patient's overall physical health or her hand dominance, which are required for the PET study part of the trial.\n\nGiven the information provided, while the patient does experience sleep difficulties, we cannot conclusively determine her eligibility without further assessment regarding the nature of her insomnia and her physical health status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1740": {
        "output": "Upon reviewing the patient note and the clinical trial details, here's my assessment:\n\nThe patient is a 26-year-old obese woman with bipolar disorder. She is experiencing depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, restlessness, and irritability. She is currently on lithium carbonate and zolpidem.\n\nThe clinical trial in question is looking for individuals who are 50 years or older with bipolar disorder, specifically those who have had a sub-optimal response to current psychotropic management. The trial aims to study the effectiveness and tolerability of aripiprazole (Abilify) in this population.\n\nBased on the inclusion criteria provided:\n- The patient has bipolar disorder, which matches one of the criteria.\n- However, the patient does not meet the age requirement as she is 26 years old and the trial requires participants to be 50 years or older.\n- There is no information provided regarding the patient's location, but even if she lives in the Northeast Ohio area, she would still be ineligible due to her age.\n\nGiven that the age requirement is a strict inclusion criterion that the patient does not meet, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1741": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics with the inclusion criteria of the trial:\n\nPatient Characteristics:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Currently feeling depressed, anxious, and agitated\n- Difficulty sleeping\n- Thoughts of suicide\n- Fidgetiness and irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Male and female patients aged 15 to 29\n- Experiencing a first episode psychosis\n- Meet DSM-IV criteria for bipolar either manic or mixed episode, or schizoaffective disorder manic episode\n- Minimum score of 20 on the YMRS\n- Written informed consent to participation\n\nComparing the two:\n\n- Age: The patient is 26 years old, which falls within the age range of 15 to 29 years required by the trial.\n- Experiencing a first episode psychosis: The patient note does not specify that this is the patient\u2019s first episode of psychosis.\n- Diagnosis: The patient has a history of bipolar disorder, which is one of the conditions listed in the trial's inclusion criteria.\n- YMRS Score: The patient note does not provide a Young Mania Rating Scale (YMRS) score, but this could potentially be assessed.\n- Informed Consent: Assuming the patient is capable of providing informed consent, this criterion could be met.\n\nThe eligibility of the patient for the clinical trial hinges on whether this is indeed her first episode of psychosis, which is not clear from the patient note, and whether she meets the required minimum score on the YMRS. These points would require further investigation.\n\nGiven the information provided, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1742": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial,\" we must evaluate the provided patient note against the inclusion criteria stated for the trial.\n\nHere are the key points from the patient note:\n\n- 26-year-old obese woman\n- History of bipolar disorder\n- Weight and eating struggles leading to depression\n- Difficulty sleeping, anxiety, and agitation\n- Thoughts of suicide\n- Fidgety, unable to sit still, and increasingly irritable\n- Current medications include lithium carbonate and zolpidem\n\nNow let's compare these points with the inclusion criteria of the trial:\n\n1. Are men or women, between the ages of 19 and 65, inclusive:\n   - The patient is 26 years old, which meets this criterion.\n   \n2. Have a diagnosis of any type of bipolar disorder or any type of psychotic disorder based on a structured diagnostic interview (MINI):\n   - The patient has a history of bipolar disorder, meeting this criterion.\n   \n3. Are currently outpatients or inpatients and taking a neuroleptic or mood stabilizer medication (listed below) for the past 6 months, and on a stable dose for the past 2 months:\n   - The patient is on lithium carbonate, which is a mood stabilizer medication listed in the inclusion criteria. However, we do not have information about the duration of use or stability of the dose.\n   \n4. Have a body mass index > 25:\n   - The patient is described as obese, which suggests a BMI > 25, meeting this criterion.\n   \n5. No substance use disorder in the past 2 months (except for nicotine or caffeine):\n   - There is no mention of substance use disorder in the patient note.\n   \n6. Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study:\n   - We do not have information about the patient's agreement to these terms.\n   \n7. Are able to swallow the capsules whole:\n   - There is no information provided regarding the patient's ability to swallow capsules.\n   \n8. Are willing and able to follow Investigator instructions and study procedures, and report adverse events:\n   - We do not have information about the patient's willingness or ability to comply with study procedures.\n   \n9. Not currently actively suicidal or homicidal:\n   - The patient has had thoughts of suicide, which may be a concern, although we do not know if she is actively suicidal.\n   \n10. No use of topiramate within the last 6 months:\n    - There is no mention of topiramate use in the patient's note.\n    \n11. No medical contraindication to the use of zonisamide:\n    - There is no information provided regarding any contraindications.\n\nBased on the information provided, the patient meets most of the inclusion criteria; however, there are uncertainties about the duration and stability of the mood stabilizer medication, the patient's agreement to birth control measures, her ability to swallow capsules, willingness to follow study procedures, and current suicidality status. Therefore, the patient may be eligible, but further investigation is required to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1743": {
        "output": "The patient note describes a 26-year-old obese woman with a history of bipolar disorder. She is experiencing symptoms that include depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, fidgetiness, irritability, and she is currently on lithium carbonate and zolpidem. However, there is no specific mention of binge eating disorder (BED) or behaviors that align with the DSM-IV criteria for BED, such as recurrent episodes of binge eating characterized by a sense of lack of control and the associated behaviors listed in the inclusion criteria of the clinical trial.\n\nThe clinical trial is looking for participants with BED associated with obesity. The inclusion criteria for the trial are quite specific and include: \n- Meeting DSM-IV criteria for BED for at least the last 6 months.\n- Binge eating episodes are associated with at least three of the specified behaviors.\n- Binge eating occurs, on average, at least two days a week for six months.\n- The binge eating does not occur exclusively during the course of bulimia nervosa and anorexia nervosa.\n- Obesity as defined by body mass index > 30 kg/m2.\n- Men or women, between the ages of 18 and 65.\n\nAlthough the patient is obese, which aligns with one of the criteria, there is no information given in the note that she meets the specific DSM-IV criteria for BED. Therefore, based on the information provided, we cannot confirm that the patient would meet the trial's inclusion criteria related to binge eating disorder.\n\nBased on this analysis, the patient does not clearly meet the inclusion criteria as there is no mention of binge eating behaviors. Thus, we cannot highly likely refer this patient for this clinical trial, nor can we consider referring her without further investigation into whether she meets the criteria for BED.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1744": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess whether the patient is eligible for the clinical trial titled \"Lamictal As Add on Treatment in Mixed States of Bipolar Disorder.\"\n\nPatient Note Assessment:\n- The patient is a 26-year-old woman, which fits the age criteria (E: Age 13 years to 75 years).\n- The patient has a history of bipolar disorder, which meets criterion A (A: Patients meeting DSM-IV diagnosis of bipolar disorder, I or II).\n- The patient's symptoms suggest she may be experiencing a mixed state of bipolar disorder, as she reports depression, difficulty sleeping, excessive anxiety, agitation, and thoughts of suicide, which could align with criteria B. However, specific DSM-IV criteria-based assessment is needed to confirm this.\n- The patient is currently taking mood stabilizers (lithium carbonate), which is relevant to the study's interest in adding Lamictal to an existing regimen of mood stabilizers (summary).\n- There is no information provided on the patient's MADRS (Montgomery\u2013\u00c5sberg Depression Rating Scale) or YMRS (Young Mania Rating Scale) scores, which are required to meet criteria C and D (C: MADRS of \u226514; D: YMRS of \u2265 14).\n- The patient is female, which meets criterion F (F: Male or female).\n- It is not specified whether the patient is an outpatient, which is required by criterion G (G: Outpatient).\n\nGiven the patient's age and gender meet the trial's inclusion criteria, and the patient's history of bipolar disorder aligns with the study's focus, there is a potential fit. However, the eligibility cannot be confirmed without further details, specifically the MADRS and YMRS scores, and confirmation of the patient's outpatient status. Additionally, a formal assessment to confirm that the patient's current state meets the specific DSM-IV criteria for a mixed episode as described in criterion B is necessary.\n\nTherefore, the referral decision for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1745": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 26-year-old woman (meets age criterion of age above 18)\n- History of bipolar disorder (relevant to the trial)\n- Recent struggles with weight and eating, feeling depressed (could be related to a depressive episode)\n- Difficulty sleeping, feeling excessively anxious and agitated, thoughts of suicide (symptoms that could be part of a depressive or mixed episode)\n- Fidgety and unable to sit still, increased irritability (could be signs of a manic or mixed episode)\n- Current medications include lithium carbonate (relevant to the trial as it's a comparison with lithium)\n\nClinical Trial Inclusion Criteria:\n- Age above 18 (patient meets this criterion)\n- Affective episode requiring hospitalization or outpatient drug treatment (index episode) which can be a manic, depressive, or mixed episode (patient appears to be in an affective episode, but it's not clear if it requires hospitalization or outpatient drug treatment)\n- No more than 12 months may pass between the onset of the index episode and the date of randomization (it's not clear when the patient's index episode started)\n- At least one previous episode within the last five years (not specified in the patient note)\n- At least one manic episode (or mixed manic episode) within the last 5 years (not specified in the patient note)\n\nClinical Trial Exclusion Criteria:\n- Contraindications to protocol drugs (not indicated in the patient note)\n- Severe somatic disease (not indicated in the patient note)\n- Pregnancy (not indicated in the patient note)\n- Prior adequate prophylactic treatment with lithium or lamotrigine without effect (patient is currently on lithium, but it is not clear if it was for prophylactic use and with a lack of effect)\n- An ICD-10 diagnosis of abuse within the last year (not indicated in the patient note)\n- Anticipated protocol violation (not indicated in the patient note)\n- No written informed consent (not applicable here)\n- Has previously been randomized in the study (not indicated in the patient note)\n\nThe patient meets some of the inclusion criteria but there are key details missing that would be necessary to determine her eligibility, such as the requirement of the index episode needing hospitalization or drug treatment, the timing of the index episode, and a history of at least one manic or mixed episode within the last five years. Therefore, I would consider referring this patient to the clinical trial upon further investigation to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1746": {
        "output": "The patient note describes a 26-year-old obese woman with a BMI that is presumably over 30 given the description of her as \"obese\". She has a history of bipolar disorder and is currently experiencing symptoms including depression, difficulty sleeping, agitation, and suicidal thoughts. She is taking lithium carbonate and zolpidem for her condition.\n\nThe clinical trial is looking to assess the weight loss efficacy of zonisamide in obese patients. The inclusion criteria for the clinical trial are straightforward: participants must be between the ages of 18-65 years and have a BMI of 30-50.\n\nBased on the information provided, the patient meets the age requirement (26 years old) and is described as obese, which likely means her BMI is over 30. However, the exact BMI is not provided. Assuming her BMI falls within the 30-50 range, she would be eligible based on the age and BMI criteria. There is no mention of bipolar disorder or the use of lithium carbonate and zolpidem as exclusion criteria for the trial.\n\nGiven this information, the patient appears to meet the inclusion criteria specified for the clinical trial. However, the patient's mental health status and current medications should be considered and discussed with the trial investigators to ensure her safety and the appropriateness of her participation in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1747": {
        "output": "Given the information provided in the patient note, the patient is a 26-year-old woman who is obese and has a history of bipolar disorder. She reports recent struggles with weight and eating, resulting in depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts. She exhibits symptoms like being fidgety and unable to sit still, which indicates a possibility of hyperactivity. However, there is no specific mention of binge eating disorder (BED) symptoms as defined by the DSM-IV-TR criteria.\n\nThe clinical trial is looking for patients with BED associated with obesity, with specific criteria including recurrent episodes of binge eating, marked distress regarding binge eating, binge eating occurring at least two days a week for six months, and not occurring exclusively during the course of bulimia nervosa and anorexia nervosa. Additionally, the patient must be obese, as defined by a body mass index (BMI) greater than 30 kg/m^2, and be between the ages of 18 and 65.\n\nAlthough the patient meets the age and obesity criteria, there is no clear evidence in the patient note of her meeting the DSM-IV-TR criteria for BED. To determine full eligibility, a clinical assessment specifically for BED would be necessary. Therefore, further investigation is needed to confirm her diagnosis of BED according to the clinical trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1748": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess the provided patient note against the inclusion criteria of the study:\n\nPatient Note Analysis:\n- The patient is a 26-year-old obese woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing depression, difficulty sleeping, excessive anxiety, agitation, and suicidal thoughts.\n- She is described as fidgety and irritable.\n- Her current medications include lithium carbonate and zolpidem.\n\nClinical Trial Inclusion Criteria Analysis:\n- Subjects must be 18 years of age or older. (The patient is 26 years old, so she meets this criterion.)\n- Subjects must have lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria. (The patient has a history of bipolar disorder, though the specific type is not mentioned in the patient note.)\n- Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria. (The patient complains of feeling excessively anxious and agitated, which may indicate an anxiety disorder, but we cannot confirm a diagnosis of panic disorder or GAD without further information.)\n- Subjects' bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4. (The patient note doesn't provide a CGI-BP score, so we cannot determine the severity of the bipolar symptoms.)\n- Subjects' anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4. (The patient's anxiety symptoms seem to be significantly impacting her life, but we do not have a CGI-S score to confirm the severity.)\n- Subjects must not be receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline. (The patient is currently on lithium carbonate, which is a mood stabilizer.)\n- Subjects or their legally authorized representative must sign the Informed Consent Document. (This is standard and can be assumed to be possible if the patient agrees to participate.)\n- If female, subjects must be postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception. (There's no information about this in the patient note, but it's a manageable criterion if the patient agrees to comply.)\n\nBased on the information provided in the patient note and the clinical trial's inclusion criteria, there is a potential match regarding age, diagnosis of bipolar disorder, and presence of anxiety symptoms. However, there are uncertainties surrounding the exact diagnosis of the anxiety disorder, the severity of the bipolar symptoms, and the patient's current use of a mood stabilizer, which is not allowed by the trial criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1749": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion and exclusion criteria, we can determine the patient's eligibility as follows:\n\nThe patient is:\n- A 26-year-old woman (fits the age criterion of 21-64 years)\n- Experiencing difficulty sleeping (may meet sleep disturbance criteria)\n- Diagnosed with bipolar disorder (does not meet major depressive disorder criteria and is an exclusion if considering bipolar as a history of mania or manic episode)\n- Currently taking lithium carbonate (long-term medication needs to be stable for at least 28 days, which we do not have information about)\n- Currently taking zolpidem (excluded if using benzodiazepines or more than 2 days of use within the 28 days preceding randomization; though zolpidem is not an SSRI or typical benzodiazepine, it is a sedative which could be a potential issue)\n- Expressing suicidal ideation (excluded due to history of suicidal ideation)\n- Possibly using contraception (we do not have information about this, but it is a requirement)\n\nGiven the information available:\n\n- The patient does not meet the diagnostic requirements for Major Depressive Disorder, as she has a history of bipolar disorder. The exclusion criteria explicitly exclude individuals with a history of mania, manic episode, or bipolar disease.\n- The patient has a history of suicidal ideation, which is a major exclusion criterion.\n- The patient is currently taking zolpidem, which may conflict with the exclusion criteria related to the use of sedative drugs for sleep induction.\n\nBased on these points, the patient does not meet the eligibility criteria for the clinical trial due to her bipolar diagnosis and history of suicidal ideation, and potential issues with her current medication. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1750": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro),\" we must examine the inclusion and exclusion criteria of the trial against the patient's note.\n\nInclusion Criteria Analysis:\n- Age: The patient is 26 years old, which falls within the 21-64 years age range required.\n- Gender: The study is open to both male and female participants, so there is no issue here.\n- Generalized Anxiety Disorder: The patient reports feeling excessively anxious, which could align with GAD, but a formal diagnosis is not mentioned.\n- HAM-A Score: Not mentioned in the patient's note, but she reports symptoms that suggest anxiety.\n- Newly diagnosed or relapse during no drug therapy: The patient is currently on medication, so this criterion is not clearly met.\n- Sleep disturbances: The patient has difficulty sleeping, which aligns with this criterion.\n- Stabilized on long-term medication: The patient is on lithium and zolpidem, but we don't know if it's been for at least one month.\n\nExclusion Criteria Analysis:\n- Bipolar Disorder: The patient has a history of bipolar disorder, which is listed as an exclusion criterion.\n- Concomitant medication: The patient is taking lithium carbonate, which is not explicitly mentioned in the exclusion criteria, but the use of an SSRI is. Since the patient is not currently on an SSRI, this might not be an exclusionary factor.\n- Other exclusion criteria such as history of PTSD, abnormal lab values, shift work, pregnancy, breastfeeding, drug addiction, alcoholism, drug abuse, sedative drugs use, untreated diseases, sleep apnea, myasthenia gravis, hypersensitivity to the drugs in question, or current participation in another clinical trial do not seem to be mentioned or implied in the patient note.\n\nGiven that the patient has bipolar disorder, which is specifically listed as an exclusion criterion, and there is no confirmation of a GAD diagnosis or HAM-A score, it appears that the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1751": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the clinical trial titled \"Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia\":\n\nPatient Note Assessment:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing depressive symptoms, anxiety, agitation, and sleep difficulties.\n- She is on medications including lithium carbonate and zolpidem.\n- There is no mention of ADHD diagnosis or ADHD-associated insomnia specifically.\n\nClinical Trial Inclusion Criteria:\n- Male or female between the ages of 6 and 17 years, inclusive.\n- Children with diagnosed ADHD.\n- Complaint of childhood insomnia not due to drug abuse or misuse of a prescribed medication.\n- Stabilized on all long-term therapy for at least one month.\n- If female of childbearing potential, must have a negative pregnancy test and be using effective birth control.\n\nComparison:\n- Age: The patient is 26 years old, which is outside the specified age range of 6 to 17 years.\n- Diagnosis: The patient has bipolar disorder, not ADHD. There is no mention of an ADHD diagnosis.\n- Insomnia: The patient does have sleep difficulties, but these are not specified to be ADHD-associated insomnia.\n- Therapy Stabilization: It is not clear if the patient's therapies are stabilized.\n- Birth Control: There is no information on the patient's use of birth control or pregnancy status.\n\nBased on the information provided, the patient does not meet the age criteria and does not have a diagnosis of ADHD, which are both critical inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1752": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 26-year-old woman\n- History of bipolar disorder\n- Recent weight and eating struggles leading to depression\n- Difficulty sleeping, excessive anxiety, agitation, thoughts of suicide\n- Fidgety and unable to sit still\n- Increasing irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Between the ages of 13 years, 0 months and 17 years, 11 months\n- Meets DSM-IV criteria for bipolar I or II disorder\n- Has had a manic, mixed, or hypomanic episode within 3 months of study entry; or a depressed episode within 3 months of study entry with a prior history of a manic, hypomanic, or mixed episode\n- Severe depression, hypomania, or mania symptoms for at least 1 week within the 3 months prior to study entry\n- Lives with at least one biological or step-parent who is willing to participate in treatment\n\nThe patient in question is 26 years old, which is outside the age range of the clinical trial's inclusion criteria, which specify participants must be between the ages of 13 and 17 years, 11 months. Therefore, the patient is not eligible for this clinical trial based solely on age, regardless of her bipolar disorder diagnosis and symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1753": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Group Intervention for Interpersonal Trauma,\" let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Recent weight and eating struggles leading to depression\n- Difficulty sleeping, excessive anxiety, and agitation\n- Thoughts of suicide\n- Restlessness and irritability\n- Current medications: lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Exposure to an interpersonal traumatic event\n- Diagnosis of depression or PTSD (threshold or subthreshold)\n- Functional literacy\n\nAnalysis:\n- The patient has symptoms of depression, which could potentially meet the depression criteria for the trial if it is confirmed to be related to an interpersonal traumatic event.\n- There is no explicit mention of exposure to an interpersonal traumatic event in the patient note.\n- There is no indication that the patient does not have functional literacy.\n\nBased on the information provided, the patient appears to have symptoms consistent with depression, but there is no information regarding exposure to interpersonal trauma or a diagnosis of PTSD. Therefore, further investigation would be needed to confirm the patient's exposure to an interpersonal traumatic event and to determine if her depression is related to this. Without this information, we cannot conclusively determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1754": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder,\" let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 26-year-old female\n- Diagnosed with bipolar disorder\n- Experiencing depression, difficulty sleeping, excessive anxiety, agitation, suicidal ideation, and restlessness\n- Current medications include lithium carbonate and zolpidem\n\nClinical trial inclusion criteria:\n- Male and female outpatients, aged 18 to 75 years (The patient meets this criterion)\n- Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II) (The patient meets this criterion)\n- Current diagnosis of Generalized Anxiety Disorder (GAD) (The patient reports excessive anxiety and agitation, which could be indicative of GAD, but a clear diagnosis of GAD is not mentioned in the note)\n- Participants must be on at least one mood stabilizer at a steady dose for at least 4 weeks prior to randomization (The patient is on lithium carbonate, but the blood levels are not mentioned)\n\nThe patient seems to meet most of the inclusion criteria except for the confirmed diagnosis of Generalized Anxiety Disorder and the specified blood levels for lithium. These two factors are crucial to determine full eligibility for the trial. Therefore, further investigation is needed to confirm the diagnosis of GAD and to ensure the blood levels of lithium are within the required range.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1755": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's go through the criteria one by one to determine the patient's eligibility:\n\n- **Insomnia as defined by DSM-IV criteria and supported by subject diary**: The patient mentions difficulty sleeping, which could potentially meet the DSM-IV criteria for insomnia.\n- **Male or female between the ages of 18-64 years**: The patient is a 26-year-old woman, which fits within the age range required.\n- **Body mass index (BMI) between 18-34 kg/m^2**: While the patient is described as obese, we do not have a specific BMI value to confirm whether she is within the required range. However, since \"obese\" typically implies a BMI of 30 or above, it's possible she meets this criterion.\n- **Females of childbearing potential must use a medically acceptable method of contraception**: There is no information provided about the patient's use of contraception, so this cannot be confirmed without further investigation.\n- **Capable of understanding and willing to comply with study procedures and has provided informed consent**: This is generally determined during the consent process, so we cannot confirm this without further information.\n\nGiven that the patient appears to meet most of the inclusion criteria but there are some details that would need to be confirmed (BMI range and use of contraception), I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1756": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\n1. Written informed consent is obtained: This is a procedural step that can be fulfilled by the patient if she agrees to participate.\n2. The patient is an outpatient, man or woman of any ethnic origin, 18-75 years of age (inclusive): The patient is a 26-year-old woman, which meets the age criterion.\n3. Patient reports insomnia for at least six months, and insomnia causes the patient distress: The patient note indicates difficulty sleeping but does not specify the duration. Further investigation is needed to confirm whether it has been for at least six months.\n4. The Investigator determines that the patient meets diagnostic criteria for Chronic Insomnia according to International Classification of Sleep Disorders (ICSD) criteria: Based on the patient note, she has difficulty sleeping but there's insufficient information to confirm a diagnosis of Chronic Insomnia as per ICSD criteria.\n5. Sleep diary based screening shows sleep onset latency >30 minutes, and/or wake after sleep onset >30 minutes per night at least 3 nights per week, with combined wake-time-in-bed _> 45 minutes: The patient note does not provide detailed information about sleep latency or wake-time-in-bed, so further investigation would be needed.\n6. The patient is in good health as determined by a medical and psychiatric history, and physical examination: The patient has a history of bipolar disorder, which may or may not impact her eligibility based on the definition of good health as per the trial's standards. Further investigation is needed here.\n7. Women must be surgically sterile, 2 years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control, and agree to continued use of this method for the duration of the study: There is no information provided about the patient's fertility status or birth control methods.\n8. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol: This criterion can only be assessed through direct communication with the patient.\n\nGiven the information provided, there are several aspects of the patient's condition and history that need further investigation to determine whether she meets the inclusion criteria for the clinical trial. The patient's insomnia and its duration would need to be confirmed, along with a diagnosis of Chronic Insomnia as per ICSD criteria, and her overall health status would need to be evaluated in the context of her bipolar disorder.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1757": {
        "output": "To determine the trial-level eligibility for the clinical trial titled \"Medication, Weight Gain and GI Hormones,\" let's compare the patient's characteristics to the inclusion criteria listed for the trial:\n\nPatient Characteristics:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Currently experiencing depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts\n- Fidgety and unable to sit still\n- Irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- A principal diagnosis of bipolar I or II disorder\n- Ages 18-60\n- Physically healthy\n- Outpatient status\n- Montgomery-Asberg Rating Scale (MADRS) Score greater than or equal to 15\n- BMI 23-30\n- Able and willing to give written informed consent\n\nBased on the information provided, the patient appears to meet the following inclusion criteria:\n- A principal diagnosis of bipolar disorder (assuming it is bipolar I or II as specified)\n- Age within the range of 18-60\n- Outpatient status (implied as there is no mention of hospitalization)\n\nHowever, the patient's eligibility cannot be fully determined without additional information on:\n- Whether the patient is physically healthy apart from obesity and bipolar disorder\n- The patient's current MADRS score to assess the severity of depression\n- The patient's exact BMI (Body Mass Index)\n\nGiven that the patient is described as \"obese,\" her BMI may be above the upper limit of 30 stipulated in the trial criteria.\n\nDue to the lack of information on the patient's MADRS score, physical health status, and exact BMI, we cannot confirm her eligibility. Therefore, further investigation is required to assess these factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1758": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania\", we need to compare the patient's characteristics and history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 26 years old\n- Obese\n- History of bipolar disorder\n- Current medications: lithium carbonate and zolpidem\n- Symptoms: difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, irritability, fidgetiness\n\nClinical Trial Inclusion Criteria:\n- 12 to 21 years of age, inclusive (Patient does not meet this criterion as she is 26 years old)\n- Diagnosis of bipolar I disorder in a current manic or mixed episode\n- Cannabis use disorder within 28 days prior to screening\n- Initial YMRS total score of >16 at screening and baselines\n- Cannabis use a minimum of twice per week on average during the 28 days prior to screening\n\nClinical Trial Exclusion Criteria (relevant ones to consider for this patient):\n- Significant suicidal ideation (Patient has thoughts of suicide, which could be considered significant)\n- Been diagnosed or treated for an eating disorder (No information provided about an eating disorder diagnosis or treatment)\n- Require concurrent treatment with mood stabilizers, anticonvulsants, or antidepressants (Patient is currently on lithium carbonate, a mood stabilizer)\n\nBased on the information provided, the patient does not meet the age requirement for the clinical trial, which is a primary inclusion criterion. Additionally, there is no mention of a cannabis use disorder that is necessary for inclusion. Furthermore, the patient is currently being treated with a mood stabilizer, which is listed as an exclusion criterion, and she has significant suicidal ideation, another exclusion criterion.\n\nConsidering these points, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1759": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, here are the important points to consider for eligibility assessment:\n\nPatient Note:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Current medications include lithium carbonate and zolpidem\n- Symptoms include depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, irritability\n\nClinical Trial Inclusion Criteria:\n- Male or female patients, ages 10-18 years\n- Female patients of menarche must be using contraception\n- Legal guardian consent and patient assent required\n- Diagnosis of DSM-IV-TR bipolar disorder, type I, with an acute manic or mixed episode\n- Young Mania Rating Scale score of at least 16\n- English fluency\n\nBased on the provided information, the patient does not meet the age criterion for the clinical trial, as she is 26 years old and the trial is for patients aged 10-18 years. Consequently, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1760": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Recent weight and eating struggles leading to depression\n- Difficulty sleeping, excessive anxiety and agitation, thoughts of suicide\n- Restlessness, irritability\n- Medications: lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of Bipolar I Disorder\n- Hospitalized or in the process of being hospitalized for a manic or mixed episode\n\nThe patient has a history of bipolar disorder and is currently on lithium carbonate, which suggests that her diagnosis aligns with Bipolar I Disorder. However, there is no indication that she is currently experiencing a manic or mixed episode or that she is hospitalized or in the process of being hospitalized for such an episode. Her symptoms suggest depression and anxiety rather than mania.\n\nBased on the information provided, the patient does not meet the specific inclusion criteria related to the state of a manic or mixed episode and hospitalization status. Therefore, she would not be eligible for this clinical trial focusing on acute mania in Bipolar I Disorder patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1761": {
        "output": "The patient is a 26-year-old obese woman with a history of bipolar disorder, currently experiencing depression, anxiety, agitation, sleep difficulties, suicidal thoughts, and irritability. Her current medications include lithium carbonate and zolpidem.\n\nThe clinical trial is looking for subjects aged 18 - 60 with chronic spinal cord injury, confirmed by MRI, with a neurological status of ASIA A, B, or C. They must be able to read, understand, and complete the VAS and sign an informed consent form. Subjects with significant psychiatric diseases are excluded from the trial.\n\nGiven that the patient does not have a spinal cord injury, she does not meet the inclusion criteria for the trial that specifically targets patients with chronic spinal cord injury. Her primary issue is related to bipolar disorder and its associated symptoms, not a spinal cord injury. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1762": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient is a 26-year-old woman with bipolar disorder, struggles with weight and eating, depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts. She is currently taking lithium carbonate and zolpidem.\n\nThe clinical trial is looking for adolescent patients with insomnia and is specifically focusing on the efficacy and safety of zolpidem in this population. The inclusion criteria for the trial are:\n\n1. Patients diagnosed as having nonorganic insomnia or nonorganic sleep disorder in ICD10.\n2. Patients whose age at the time of obtaining consent is 12 years or over and 18 years or below.\n\nThe patient in question is outside of the age range specified by the trial's inclusion criteria (26 years old versus the maximum age of 18 years for the trial). Therefore, she would not qualify for this clinical trial based on her age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1763": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial.\n\nPatient Characteristics:\n- 26-year-old woman\n- Diagnosis of bipolar disorder\n- Currently feels depressed with a recent increase in weight, difficulty sleeping, excessive anxiety and agitation, thoughts of suicide, restlessness, and irritability\n- Currently on lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Patients with bipolar disorder in a major depressive episode according to DSM-IV\n- MADRS score of at least 20 points at screening and baseline\n- 18-70 years of age\n- Unchanged dose of mood stabilising medication for at least six weeks prior to inclusion\n- Voluntary, informed, and written consent\n\nAssessment:\n- The patient has bipolar disorder and is currently experiencing depressive symptoms, which could suggest that she is in a major depressive episode as required by the trial.\n- The patient's exact MADRS score is not provided, but her symptoms suggest that she could have a score indicating a major depressive episode.\n- She is within the age range of 18-70 years as required by the trial.\n- Information about the duration of her current medication regimen (lithium carbonate and zolpidem) is not specified. We would need to confirm that the dose has remained unchanged for at least six weeks.\n- The patient would need to provide voluntary, informed, and written consent to participate.\n\nThe key piece of missing information is the MADRS score and the duration of the current medication regimen. If the MADRS score is 20 or above and the medications have been stable for six weeks, she would likely be eligible. However, without this confirmation, we cannot be certain of her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1764": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question could potentially be eligible for the clinical trial. \n\nThe patient note describes a 26-year-old woman who has difficulty sleeping, which aligns with the inclusion criteria of the clinical trial that is looking for adults with a history of sleeplessness. Additionally, the patient is already taking zolpidem, which is related to the medication being studied in the trial (zolpidem tartrate sublingual tablet).\n\nHowever, the patient also has other medical conditions, such as obesity, bipolar disorder, and reports of feeling depressed with thoughts of suicide, which may or may not be relevant to the trial. These factors may need to be considered to ensure the safety of the patient and the integrity of the trial results.\n\nGiven the information, the patient seems to meet the basic inclusion criteria of having a history of sleeplessness, but further investigation would be required to ensure that her other conditions and medications do not exclude her from participation or pose a risk to her safety.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1765": {
        "output": "After reviewing the provided patient note and the clinical trial inclusion criteria, it appears that the patient in question does not meet the specific requirements for the clinical trial. The trial is focused on patients with brain metastases from a primary cancer located outside of the brain, and there is no mention of such a diagnosis in the patient's history. The patient has a history of bipolar disorder and is currently struggling with weight, depression, anxiety, agitation, and thoughts of suicide, which are unrelated to the conditions under study in the trial.\n\nSince the patient does not have a diagnosed extracranial primary malignancy and there is no indication of brain metastases, she would not be eligible for this clinical trial focused on the effects of lithium during whole-brain radiotherapy for patients with brain metastases.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1766": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Olanzapine Versus Comparator in the Treatment of Bipolar Disorder,\" we must compare the patient's situation with the inclusion criteria provided for the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Male or female in- or out-patients at least 18 years of age\n2. Patient must have a diagnosis of bipolar I disorder and currently display acute manic or mixed episodes (with or without psychotic features) according to the DSM-IV based on clinical assessment\n3. Patients must have a level of understanding sufficient to agree to all tests and examinations required by the protocol\n4. Patients must have a Young Mania Rating Scale (Y-MRS) total score of greater than or equal to 20 at both visits 1 & 2\n5. Patients must be considered reliable\n\nNow, let's analyze the patient note:\n\n- The patient is a 26-year-old woman, which satisfies the first criterion (age \u2265 18 years).\n- She has a history of bipolar disorder, which meets part of the second criterion. However, it is not specified whether she has bipolar I disorder, nor is it clear if her current state is an acute manic or mixed episode. Further clinical assessment is required to confirm this.\n- The patient is on medication, which may imply some level of understanding of her condition, but the note does not explicitly state that she has the understanding required by the third criterion.\n- There is no information provided about the Y-MRS total score, so we cannot assess the fourth criterion.\n- The note does not provide information on the patient's reliability, so we cannot assess the fifth criterion.\n\nBased on the available information, the patient appears to potentially meet some of the inclusion criteria but further information and assessments are required to establish eligibility fully. Therefore, the patient may be a candidate for the trial, but additional investigation is needed before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1767": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria provided by the clinical trial.\n\nPatient Characteristics:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Taking lithium carbonate and zolpidem\n- Difficulty sleeping, feeling anxious, agitated, and having thoughts of suicide\n- Fidgety and irritable\n- Has been taking zolpidem\n\nClinical Trial Inclusion Criteria:\n- Chronic insomnia and taking greater than or equal to 10 mg zolpidem at least 4 times per week\n- Has been prescribed zolpidem for difficulty in initiating sleep\n- Chronic use of zolpidem greater than or equal to 10 mg therapy for a minimum of 3 months\n- Taken zolpidem greater than or equal to 10 mg at least 4 of 7 days each week of the 4 weeks immediately prior\n- Willingness to discontinue zolpidem therapy\n- Habitual bedtime between 9:00 PM and 1:00 AM\n- Negative tests for hepatitis B and C\n- Females must agree to use contraception and cannot be pregnant or lactating\n\nClinical Trial Exclusion Criteria:\n- Known hypersensitivity to ramelteon, zolpidem, or melatonin\n- Participation in investigational study or drug within 30 days prior\n- Shift work within 3 months prior\n- History of fibromyalgia, seizures, sleep apnea, restless leg syndrome, periodic leg syndrome, COPD, schizophrenia, **bipolar disorder**, mental retardation, or cognitive disorder\n- History of drug or alcohol abuse within the past 12 months\n- Significant diseases unless controlled and stable\n- BMI less than 18 or greater than 34\n- Clinically important abnormal findings\n- Positive hepatitis panel, known HIV\n- Taking disallowed medication\n\nBased on the information provided, the patient does match some of the inclusion criteria such as chronic insomnia and the use of zolpidem. However, the patient has a history of bipolar disorder, which is specifically listed under the exclusion criteria. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1768": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility criteria for the following reasons:\n\n1. Age: The patient is 26 years old, whereas the clinical trial is for children between the ages of 2 and 18 years.\n2. Diagnosis: The patient has a history of bipolar disorder with depressive symptoms, not primarily insomnia as determined by a physician or study investigator.\n3. Medication: Although the patient is currently taking zolpidem, which is the drug being studied, the primary reason for this medication does not seem to be insomnia, but rather mood stabilization and sleep issues related to her bipolar disorder.\n\nGiven these discrepancies, the patient does not fit the clinical trial's inclusion criteria. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1769": {
        "output": "",
        "label": 0
    },
    "1770": {
        "output": "Based on the provided patient note and the specified inclusion criteria for the clinical trial, the patient does not seem to be a suitable candidate for the trial. The patient's primary health concerns relate to bipolar disorder, obesity, depression, anxiety, agitation, and difficulty sleeping, none of which are mentioned in the inclusion criteria for the trial. The clinical trial is focused on patients with chronic hepatitis C genotype 1 and insulin resistance, which are not conditions mentioned in the patient's note.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1771": {
        "output": "Given the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder.\"\n\nFirst, let's compare the patient's characteristics against the inclusion criteria:\n\n- **Provision of written informed consent before initiation of any study-related procedures**: This is a prerequisite that the patient can fulfill if they agree to participate.\n- **Men and women aged 18 to 65 years**: The patient is 26 years old, which fits within the age range.\n- **A documented clinical diagnosis according to the DSM-IV**: The patient has a history of bipolar disorder. However, the specific type of bipolar disorder is not mentioned in the patient note. The inclusion criteria specify Bipolar I disorder with a specific recent episode type. This information is not provided in the patient note.\n- **PSQI total score of >=5**: The Pittsburgh Sleep Quality Index (PSQI) score is not provided in the patient note, but the patient does report difficulty sleeping, which suggests that she may meet this criterion upon formal assessment.\n- **MADRS total score of <=12**: The Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score is not provided. The patient does report feeling depressed, but the severity according to MADRS is unknown.\n- **YMRS total score of <= 12**: The Young Mania Rating Scale (YMRS) score is not provided. The patient reports irritability, agitation, and fidgetiness, which could be related to manic symptoms, but the severity according to YMRS is unknown.\n- **Female patients of childbearing potential must have a negative urine pregnancy test at enrollment and be willing to use a reliable method of birth control**: This criterion is applicable if the patient decides to participate and is willing to comply.\n- **Be able to understand and comply with the requirements of the study, as judged by the investigator**: Based on the information provided, there is no indication that the patient would not be able to understand and comply with study requirements.\n\nGiven the information provided, the patient appears to meet some of the inclusion criteria (age, gender, history of bipolar disorder) but there is insufficient information to determine whether she specifically has Bipolar I disorder and what her most recent episode type was. Additionally, there is insufficient information regarding her PSQI, MADRS, and YMRS scores.\n\nTherefore, I would categorize this patient as:\n\n`Trial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.`\n\nFurther information would be needed to fully assess her diagnosis and her scores on the relevant psychiatric scales to determine if she meets all the inclusion criteria.",
        "label": 1
    },
    "1772": {
        "output": "Based on the patient note provided, the patient is a 26-year-old woman with a history of bipolar disorder, who is currently experiencing depressive symptoms, including difficulty sleeping, excessive anxiety, agitation, and thoughts of suicide. She is also taking lithium carbonate, which is a mood stabilizer commonly used to treat bipolar disorder.\n\nComparing this patient's situation with the inclusion criteria of the clinical trial:\n\n1. Current major depressive episode or mixed episode: The patient has mentioned feeling depressed and having symptoms such as difficulty sleeping and agitation, which could be indicative of a current depressive episode.\n2. Bipolar disorder: The patient has a history of bipolar disorder, as mentioned in the patient note.\n3. History of suicidal behavior: The patient has expressed having thoughts of suicide.\n\nThe patient appears to meet all the inclusion criteria for the clinical trial \"Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder.\" Therefore, based on the information given, the patient is highly likely to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1773": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient characteristics:\n- Age: 26 years old\n- Condition: Bipolar disorder, with symptoms including depression, difficulty sleeping (insomnia), anxiety, agitation, suicidal thoughts, fidgetiness, and irritability.\n- Current medications: Lithium carbonate (commonly used for bipolar disorder) and zolpidem (used for insomnia).\n\nClinical trial inclusion criteria:\n- Persons with Bipolar Condition, Depression, Anxiety, Stress, and Insomnia\n\nThe patient's characteristics align well with the inclusion criteria for the clinical trial. She is within the appropriate age range and has a diagnosed Bipolar Condition along with depression, anxiety, and insomnia, all of which are specifically listed in the inclusion criteria.\n\nBased on this information, the patient appears to be a strong candidate for the clinical trial:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1774": {
        "output": "Considering the patient's note and the clinical trial's inclusion criteria, let's match the requirements:\n\n1. Age: The patient is 26 years old, which fits within the 18 to 65 years age range required.\n2. Diagnosis: The patient has a history of bipolar disorder. However, we do not have information about whether it is bipolar I, II, or NOS, as required by the study.\n3. Co-morbid Disorders: The patient has symptoms of anxiety and agitation, which could suggest a generalized anxiety disorder (GAD), but there is no clear mention of a lifetime panic disorder or GAD diagnosis.\n4. Severity of Bipolar Symptoms: The patient seems to exhibit signs of depression and agitation, but without a Clinical Global Impressions for Bipolar Disorder (CGI-BP) score provided, we can't confirm if the bipolar symptoms are \"no more than moderate in severity.\"\n5. Severity of Anxiety Symptoms: The patient reports feeling excessively anxious, which could be considered at least moderate in severity, but again, without a Clinical Global Impressions-Severity (CGI-S) score, this cannot be confirmed.\n6. Medication: The patient is currently on lithium carbonate and zolpidem, which does not comply with the trial's requirement for subjects to be off regular mood-stabilizing medication for at least one week prior to baseline.\n7. Informed Consent: There is no information about the patient's willingness or capacity to consent.\n8. Contraception: There is no information provided about the patient's status regarding the possibility of childbearing or contraception use.\n\nGiven this information, while the patient does fit some of the inclusion criteria (age and bipolar disorder), there are several areas where we do not have enough information (specific type of bipolar disorder, GAD/panic disorder diagnosis, and severity of symptoms) or where the patient does not meet the criteria (current use of mood stabilizers). Furthermore, the patient's current suicidal thoughts would likely require immediate clinical attention, which could be a contraindication for clinical trial enrollment at this time.\n\nBased on these points, my assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1775": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Current medications: lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria Analysis:\n- Histologically confirmed Medullary Thyroid Cancer (MTC) with signs of residual/persistent disease\n- Elevated neuroendocrine markers post-op\n- Disease progression is not a requirement\n- Certain time frame from completion of major surgery, chemotherapy, radiation therapy, or other systemic therapy\n- Specific laboratory values within normal ranges or specified limits\n- ECOG performance status of 2\n- Age \u2265 18 years\n- Not pregnant or lactating\n- Required use of effective contraception for women of childbearing potential and sexually active males\n- No known history of allergic reactions or adverse reactions to Lithium or its derivatives\n- Not on concurrent chemotherapy or radiation therapy\n\nThe patient in the note does not mention having Medullary Thyroid Cancer (MTC) or any related symptoms or treatments. The patient is being treated for bipolar disorder and currently takes lithium carbonate. There is no indication from the patient note that the patient has MTC or meets any of the other specific medical criteria outlined for the clinical trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial related to Medullary Thyroid Cancer, as there is no mention of MTC or related treatment and diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1776": {
        "output": "Based on the patient note provided:\n\n- The patient is a 26-year-old woman with a history of bipolar disorder, which aligns with the inclusion criteria of the clinical trial targeting patients with Bipolar Disorder.\n- The patient is currently experiencing symptoms associated with her bipolar disorder, including depression, anxiety, agitation, difficulties with sleep, and suicidal thoughts.\n- The patient is on medication for bipolar disorder, which is lithium carbonate, and for sleep issues, which is zolpidem.\n\nThe clinical trial is titled \"BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder\" and aims to assess the prevalence of Metabolic Syndrome in the Spanish population with Bipolar I or II Disorder, analyze clinical progress over 12 months, and evaluate health status, quality of life, and functioning/disability in patients.\n\nThe inclusion criteria for the trial are:\n- Patients with a diagnosis of Bipolar Disorder (DSM-IV TR)\n- Patients or their legal representatives have provided informed consent\n\nThe patient in the note meets the inclusion criteria as she has been diagnosed with bipolar disorder and is currently being treated for it. Since there is no mention of the patient's refusal or inability to consent, it is reasonable to assume that she or her legal representative could provide informed consent if required.\n\nTherefore, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1777": {
        "output": "",
        "label": 0
    },
    "1778": {
        "output": "Given the patient note:\n\n- The patient is a 26-year-old woman with a history of bipolar disorder.\n- She is currently experiencing depression, anxiety, agitation, and thoughts of suicide.\n- She is taking lithium carbonate and zolpidem.\n\nAnd the clinical trial:\n\n- Title: Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions.\n- The study aims to test the bioequivalence of two lithium carbonate 300 mg formulations.\n- Inclusion criteria require no clinically significant abnormal findings on physical examination, medical history, or clinical laboratory results during screening.\n\nThe patient is already taking lithium carbonate, which is the medication being studied in the trial. However, the trial's inclusion criteria specify that there should be no clinically significant abnormal findings in the patient's medical history. The patient's current psychiatric symptoms, including depression, anxiety, and suicidal ideation, could be considered clinically significant abnormal findings. Therefore, it is uncertain if the patient would be eligible for the trial without further information about the specific requirements related to psychiatric conditions in the trial's protocol.\n\nGiven the available information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1779": {
        "output": "Based on the information provided, the patient is a 26-year-old woman with bipolar disorder, currently taking lithium carbonate. The clinical trial in question is a bioequivalency study of 450 mg lithium carbonate under fed conditions.\n\nThe inclusion criteria for the clinical trial specify that there should be no clinically significant abnormal findings on physical examination, medical history, or clinical laboratory results during screening.\n\nThe patient note does not mention any clinically significant abnormal findings other than the psychiatric condition (bipolar disorder) for which she is already being treated, which includes the use of lithium carbonate, the medication under study for bioequivalence. The patient's other complaints regarding depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, fidgeting, and irritability appear to be related to her psychiatric condition rather than indicating clinically significant abnormal findings that would exclude her from a bioequivalence study.\n\nGiven the patient is already on lithium carbonate, which is the subject of the bioequivalence study, and assuming her bipolar disorder and related symptoms would not be considered clinically significant abnormal findings that would interfere with the study, she could potentially be eligible.\n\nHowever, her mental health status, including the reported thoughts of suicide, would need to be further evaluated to ensure safety and the ability to comply with study requirements. This consideration is especially important given that clinical trials typically involve close monitoring and adherence to protocol, and her current mental state may pose challenges to participation.\n\nTherefore, the patient might be eligible for the trial, but further investigation into her mental health status and overall well-being would be required before a final determination could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1780": {
        "output": "",
        "label": 0
    },
    "1781": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Antidepressant Therapy in Treating Bipolar Type II Major Depression,\" we need to compare the patient's characteristics and condition with the trial's inclusion criteria:\n\n1. Meets DSM-IV criteria for Axis I bipolar II disorder\n2. Meets DSM-IV criteria for Axis I major depressive episode\n3. Score of 16 on 17-item HAM-D rating scale\n4. Not taking monoamine oxidase inhibitors (MAOI) for more than 2 weeks prior to study entry\n5. Willing to use an effective form of birth control throughout the study\n\nThe patient note gives us the following information:\n\n- The patient is a 26-year-old woman, which meets the age criterion (age \u2265 18 years).\n- She has a history of bipolar disorder; however, it is not specified whether it is bipolar II disorder, which is required for the trial.\n- She reports feeling depressed, having difficulty sleeping, feeling excessively anxious and agitated, and having thoughts of suicide, which could indicate a major depressive episode, but this has not been formally diagnosed according to the DSM-IV criteria.\n- There's no mention of a HAM-D rating scale score, so we cannot verify if her score meets the required 16.\n- The patient is currently taking lithium carbonate (a mood stabilizer) and zolpidem (a sleep aid), and there is no mention of MAOI use.\n- There are no details provided about her willingness or practice to use an effective form of birth control throughout the study.\n\nBased on the information provided, the patient might potentially meet some of the inclusion criteria, but there is insufficient information to conclusively determine her eligibility. For example, we do not know if her bipolar disorder diagnosis is specifically bipolar II, or if she meets the DSM-IV criteria for a major depressive episode. Furthermore, we do not have a HAM-D score, and there's no information on her birth control practices.\n\nGiven these unknowns, further investigation is needed to determine if the patient meets all the inclusion criteria, especially the specific diagnosis of bipolar II disorder and the presence of a major depressive episode as defined by the DSM-IV.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1782": {
        "output": "To evaluate the patient's eligibility for the \"Weight Gain Prevention\" clinical trial, we need to consider the inclusion criteria mentioned:\n\n1. Age 18-35\n2. Body mass index (BMI) between 23 and 30\n3. Interested in preventing weight gain\n\nThe patient note provides the following information:\n\n- The patient is a 26-year-old woman.\n- She is described as obese, but her exact BMI is not provided.\n- She has a history of bipolar disorder and is experiencing depression, difficulty sleeping, anxiety, agitation, and thoughts of suicide.\n- The patient is on lithium carbonate and zolpidem.\n- There is no mention of her interest in preventing weight gain, but her struggles with weight and eating are causing her distress.\n\nBased on the information given:\n\n- The patient meets the age criteria (26 years old, within the 18-35 range).\n- The description of the patient as obese suggests that her BMI might be over 30, which would not meet the BMI criteria of 23 to 30. However, without exact BMI data, we cannot definitively determine her eligibility based on this criterion.\n- There is no explicit statement about the patient's interest in preventing weight gain, but given her concerns about her struggles with weight, it could be inferred that she might be interested.\n\nSince there is not enough information to make a definitive determination on her BMI and interest in preventing weight gain, further investigation would be needed to assess these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1783": {
        "output": "To determine if the patient described in the note is eligible for the clinical trial, we must compare the patient's characteristics and condition to the inclusion and exclusion criteria listed for the trial.\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman, which fits within the age range of 12 to 35 years specified in the trial's inclusion criteria.\n- She has a history of bipolar disorder and is currently experiencing depression, which is consistent with the requirement for depressed bipolar patients.\n- The patient is currently on lithium carbonate, which may not align with the requirement for patients to have been off medications for one week prior to study enrollment. However, it's not specified whether the patient can safely discontinue the medication for this period.\n- The patient expresses thoughts of suicide, which might be relevant to the exclusion criterion regarding significant suicidality.\n- It is not indicated that the patient has a chemical use disorder, a medical or neurological disorder, mental retardation, an IQ <85, an MRI contraindication, lives >100 miles from the University of Cincinnati, or meets criteria for a bipolar mixed episode.\n\nClinical Trial Inclusion Criteria Checklist:\n1. Depressed bipolar patients (meets criteria based on patient note).\n2. Patients will meet DSM-IV criteria for type I bipolar disorder, depressed (appears to meet criteria based on patient note).\n3. A maximum of three documented affective episodes (not specified in patient note).\n4. Off medications for one week prior to study enrollment (patient is currently on medication, further investigation needed).\n5. Hamilton Depression Rating Scale (HDRS) total score \u226520 (not specified in patient note).\n6. Age between 12 and 35 years (patient is 26 years old; meets criteria).\n\nClinical Trial Exclusion Criteria Checklist:\n1. Any chemical use disorder within 3 months (not specified, but nothing in the patient note suggests this).\n2. A history of significant suicidality (patient has thoughts of suicide, further investigation needed).\n3. Current score \u22653 on item 3 of the HDRS-17 (Suicide Item) (not specified in patient note).\n4. Any medical or neurological disorder that could influence fMRI results (not specified in patient note).\n5. A history of mental retardation or an estimated IQ total score <85 (not specified in patient note).\n6. MRI contraindication (not specified in patient note).\n7. Patient lives >100 miles from the University of Cincinnati or cannot attend follow-up visits (not specified in patient note).\n8. Meets DSM-IV criteria for a bipolar mixed episode (not specified in patient note).\n\nBased on the available information:\n- The patient meets some of the inclusion criteria, such as age and condition (depressed bipolar disorder).\n- There are areas that require further investigation, such as the number of documented affective episodes, the possibility of discontinuing current medications for one week, and the HDRS score.\n- The patient's mention of suicidal thoughts might be a concern for the exclusion criteria; however, without the HDRS score or further details on the severity of suicidality, it's difficult to make a final determination.\n\nGiven the incomplete information and potential concerns regarding the patient's suicidality and medication status, the patient would not be immediately referred for this clinical trial without further information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1784": {
        "output": "Assessing the eligibility of the patient for the clinical trial involves comparing the patient's condition and characteristics with the inclusion criteria of the study.\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently taking lithium carbonate and zolpidem.\n- She complains of weight struggles, depression, anxiety, agitation, sleep difficulties, and suicidal thoughts.\n- She exhibits restlessness and irritability.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is evaluating the hypnotic efficacy of zolpidem in patients with primary insomnia.\n- The inclusion criterion requires a diagnosis of primary insomnia based on DSM-IV criteria.\n\nComparison:\n- The patient is currently taking zolpidem, which is the medication being studied in the trial.\n- However, the patient's insomnia seems to be secondary to her bipolar disorder, rather than primary insomnia. Primary insomnia is a sleep disorder that is not attributable to a medical, psychiatric, or environmental cause.\n\nGiven that primary insomnia is a specific diagnosis and the patient's sleep difficulties may be secondary to her bipolar disorder, she does not clearly meet the inclusion criteria for the trial, which specifies \"primary insomnia.\"\n\nTherefore, the patient is not a clear fit for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1785": {
        "output": "Assessment of the patient's eligibility for the clinical trial titled \"Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression\" based on the provided inclusion criteria:\n\nInclusion Criteria:\n1. DSM-IV diagnosis of major depressive disorder (MDD)\n2. Drug naive from prior psychotropic medication for more than 6 months before study entry\n3. Hamilton-Depression (HAM-D) 17 score greater than or equal to 16\n4. Woman of childbearing age with a negative pregnancy test within 48 hours of scanning\n\nPatient Characteristics:\n- A 26-year-old obese woman\n- History of bipolar disorder, not explicitly diagnosed with MDD\n- Currently on psychotropic medication (lithium carbonate, zolpidem)\n- Symptoms include depression, anxiety, agitation, suicidal thoughts, fidgeting, irritability\n- No information on HAM-D 17 score\n- Woman of childbearing age (assuming she can provide a negative pregnancy test)\n\nBased on the information provided:\n\n- The patient has a history of bipolar disorder, not explicitly major depressive disorder (MDD). While symptoms of depression are present, without a clear diagnosis of MDD, this does not meet the first criterion.\n- The patient is currently on psychotropic medication, which does not align with the requirement to be drug naive from prior psychotropic medication for more than 6 months.\n- No information is provided regarding the HAM-D 17 score, which is necessary to assess the severity of depression.\n- As a woman of childbearing age, she could potentially meet the last criterion if she can provide a negative pregnancy test.\n\nGiven the current information, the patient does not meet at least two of the inclusion criteria (diagnosis of MDD and being drug naive). Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1786": {
        "output": "",
        "label": 0
    },
    "1787": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"The Role of Partial Reinforcement in the Long Term Management of Insomnia,\" we need to compare the patient's condition with the inclusion criteria provided for the trial.\n\nPatient note:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She reports depression, difficulty sleeping, excessive anxiety, agitation, and suicidal thoughts.\n- She is experiencing fidgetiness and irritability.\n- She is on lithium carbonate and zolpidem.\n\nClinical trial inclusion criteria:\n- Patients with insomnia meeting RDC criteria for psychophysiologic insomnia.\n- Complaints of disturbed sleep with characteristics such as:\n  > 30 minutes to fall asleep (Initial Insomnia)\n  2 awakenings per night of >15 minutes duration and/or wake after sleep onset time of > 30 minutes (Middle Insomnia)\n  An awakening of > 30 minutes prior to the desired wake up time (Late Insomnia)\n  Any two of the above complaints (Mixed Insomnia)\n- Total sleep time not exceeding 6 hours (unless sleep efficiency quotient is < 80%)\n- Problem frequency equal to or greater than 4 nights/week (severe insomnia)\n- Problem duration > 6 months (chronic insomnia)\n- This profile must be evident at both intake and as an average profile from two weeks of baseline diaries.\n\nThe patient note indicates that the patient is having difficulty sleeping, which aligns with the general theme of insomnia issues. However, the note does not provide specific details about the nature of her sleep disturbances, such as how long it takes to fall asleep, the number and duration of awakenings, early morning awakenings, total sleep time, sleep efficiency, frequency per week, and duration of the problem, which are necessary to meet the clinical trial's inclusion criteria.\n\nGiven that the patient is already using zolpidem, which is the medication being studied in the trial, this suggests that she may have insomnia. However, without clear evidence that the patient meets the specific insomnia criteria outlined for the trial, we cannot conclusively determine her eligibility.\n\nTherefore, based on the information provided, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1788": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman with bipolar disorder.\n- She is currently on lithium carbonate treatment.\n- She complains of depression, which can be part of a mixed episode in the context of bipolar disorder.\n- She is experiencing symptoms that may align with a manic or mixed episode: difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, restlessness, and irritability.\n- Her medication includes lithium carbonate, which is one of the treatments specified in the inclusion criteria.\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or without psychotic features.\n- Current ongoing lithium or valproate treatment.\n- Possibility of benefiting from adjunctive treatment with aripiprazole based on the investigator's judgment.\n- Therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score of 16 or higher at screening and baseline.\n\nThe patient appears to meet several of the key inclusion criteria for the clinical trial:\n- She has a diagnosis of bipolar disorder, though it is not explicitly stated as bipolar I disorder.\n- She is currently being treated with lithium carbonate.\n- She may benefit from adjunctive treatment with aripiprazole, pending clinical judgment.\n\nHowever, there are some uncertainties that need to be clarified:\n- The type of bipolar disorder (I or II) is not explicitly mentioned in the patient note.\n- The severity of her mania (as measured by the Young Mania Rating Total Score) is not provided.\n\nGiven the information provided, there are strong indications that this patient could be eligible for the trial. However, further investigation is needed to confirm the type of bipolar disorder and to assess the severity of her symptoms with the appropriate rating scale. Therefore, the patient's eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1789": {
        "output": "Assessing the eligibility of the patient for the clinical trial titled \"Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder\" involves comparing the patient's characteristics and condition with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n1. Provision of written informed consent before initiation of any study-related procedures.\n2. Documented clinical diagnosis meeting the DSM-IV criteria for:\n   - 296.4X Bipolar I Disorder, Most Recent Episode Manic\n   - 296.0X Bipolar I Disorder, Single Manic Episode\n3. Have a YMRS score of at least 20 and a score of at least 4 on 2 of the following 4 YMRS items both at enrolment and at randomization: Irritability, Speech, Content, and Disruptive/Aggressive Behaviour.\n4. Female patients of childbearing potential must have a negative urine pregnancy test at enrolment and be willing to use a reliable method of birth control during the study.\n5. Be able to understand and comply with the requirements of the study, as judged by the investigator.\n\nThe patient note indicates:\n- The patient is a 26-year-old woman, which meets the age requirement.\n- She has a history of bipolar disorder, which may align with the DSM-IV criteria required by the trial.\n- The patient exhibits symptoms that could correspond to a high YMRS score, such as irritability, difficulty sleeping, feeling anxious and agitated, and thoughts of suicide. However, the actual YMRS score is not provided in the note.\n- The patient is already on lithium carbonate, which aligns with the trial looking at quetiapine fumarate as mono-therapy or adjunct to lithium.\n- There is no information on whether she is capable of providing informed consent, her childbearing status, or her willingness to use birth control methods.\n\nGiven that the patient shows signs of acute mania and is already on lithium, she might be a candidate for the trial. However, further assessment is needed to confirm her YMRS score, ensure she meets the DSM-IV criteria precisely, and ensure other requirements such as informed consent and birth control are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1790": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien\u00ae Under Fasting Conditions,\" we must compare the patient's characteristics with the inclusion criteria provided for the trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Sex: Male or Female; similar proportions of each preferred\n2. Age: At least 18 years\n3. Weight: must be 15% of ideal weight for height and frame\n4. Subjects must be in good health and physical condition as determined by medical history\n5. Subjects must read and sign the Consent Form\n\nThe patient note provides the following information:\n- The patient is a 26-year-old obese woman.\n- She has a history of bipolar disorder.\n- Her current medications include lithium carbonate and zolpidem.\n\nBased on this information:\n1. The patient's sex is female, which meets the criteria regarding sex.\n2. The patient is 26 years old, which meets the age criterion.\n3. The patient is described as obese; however, the specific percentage over the ideal weight is not mentioned. Therefore, we cannot conclusively determine eligibility based on this criterion without further information.\n4. The patient is not in good health due to her struggle with bipolar disorder, which is causing her depression, anxiety, agitation, and thoughts of suicide. This does not align with the requirement for subjects to be in good health and physical condition.\n5. There is no information provided about whether the patient is willing to read and sign the Consent Form, but we typically assume that this is possible unless otherwise indicated.\n\nGiven the information provided, the patient does not seem to be in good health and physical condition due to her mental health issues, which is a requirement for the clinical trial. Therefore, based on the available information, it is unlikely that this patient would be eligible for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1791": {
        "output": "",
        "label": 0
    },
    "1792": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- Age: 26 years (matches the trial's age inclusion criteria of 18-55 years)\n- BMI: Obese (BMI > 30 kg/m2, which does not match the trial's inclusion criteria of BMI 18-30 kg/m2)\n- Current medications: Includes zolpidem (the trial is studying the effect of zolpidem)\n\nClinical trial inclusion criteria:\n- Age 18-55 (the patient is 26 years old, so this criterion is met)\n- BMI 18-30 kg/m2 (the patient is obese, which typically means a BMI over 30 kg/m2, so this criterion is not met)\n- Body weight > 50 kg (there is no information about the patient's weight, but given that she is obese, it is likely that she meets this criterion)\n\nThe critical factor for exclusion in this case is the patient's BMI, which is outside of the specified range for the clinical trial. Although the patient is within the age range and is currently taking zolpidem, which may be of interest for the study, the BMI criterion is not met, and thus the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1793": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 26-year-old woman\n- History of bipolar disorder\n- Not currently pregnant (no mention of pregnancy in the patient note)\n\nClinical Trial Inclusion Criteria:\n- Medically healthy (no information provided about her overall medical health)\n- Meets DSM-IV criteria for bipolar disorder of any subtype (the patient has a history of bipolar disorder, which potentially meets this criterion)\n- No more than 32 weeks gestation, dated by last menstrual period (no information provided about pregnancy status)\n\nThe patient note indicates that the woman has a history of bipolar disorder, which aligns with one of the inclusion criteria. However, there is no information regarding her pregnancy status, which is a critical component of the inclusion criteria. Therefore, we cannot assume the patient is eligible based on the information provided.\n\nGiven that pregnancy status is a key inclusion factor and there is no information about this in the patient note, we would need further investigation to determine the patient's eligibility for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1794": {
        "output": "Patient note assessment:\n- The patient is a 26-year-old woman, which meets the adult age requirement.\n- She has a history of bipolar disorder, relevant to the trial.\n- She is experiencing agitation, as evidenced by feeling excessively anxious and irritable, and having difficulty sitting still.\n\nClinical trial inclusion criteria:\n- The trial is for male and female adult patients.\n- Patients must have bipolar 1 disorder and acute agitation.\n\nComparison:\n- The patient is an adult female, which fits the gender and age criteria.\n- The patient has bipolar disorder, though the note specifies \"bipolar disorder\" without stating it is specifically \"bipolar 1 disorder.\" However, given that bipolar disorder is mentioned, it is reasonable to assume there could be a fit upon further clarification.\n- The patient is experiencing acute agitation, aligning with the trial's focus.\n\nGiven the information provided, the patient appears to match the inclusion criteria for the clinical trial, assuming her bipolar disorder is confirmed to be bipolar 1 disorder. Therefore, she would be a candidate for referral to the trial, pending further investigation to confirm the specifics of her bipolar diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1795": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing depressive symptoms, increased anxiety, agitation, suicidal thoughts, restlessness, and irritability.\n- Her current medications include lithium carbonate (typically used for bipolar disorder) and zolpidem.\n\nClinical Trial Inclusion Criteria:\n- Age 18-65, male or female.\n- Must meet DSM-IV criteria for bipolar I affective disorder.\n- Ability and willingness to sign informed consent for participation in the study.\n\nComparison:\n- The patient's age (26 years old) fits within the age range of 18-65 years required by the study.\n- The patient has a history of bipolar disorder, which aligns with the study's requirement for participants to meet DSM-IV criteria for bipolar I affective disorder.\n- There is no information provided about the patient's willingness or ability to sign informed consent, but this can typically be assessed during the screening process.\n\nThe patient meets the age requirement and has a diagnosis of bipolar disorder, which are key inclusion criteria for the clinical trial. However, there is no mention of tobacco smoking in the patient note, which is a focus of the study. Since it's not explicitly stated that the patient is a smoker or non-smoker, this information would need to be verified.\n\nTherefore, based on the information available, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1796": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, we can analyze the patient's eligibility for the trial:\n\n- The patient is a 26-year-old woman, which fits within the age range of 18-60 years specified by the trial.\n- The patient has a history of bipolar disorder, which is not directly relevant to the trial's focus on spinal cord injuries.\n- There is no mention in the patient note of a chronic spinal cord injury, which is a requirement for the trial.\n- The trial requires subjects with an ASIA classification of A, B, or C for at least 6 months unchanged, and there's no information provided on this in the patient note.\n- The vertebral level requirement for the spinal cord injury (between C4 and T10) is not met, as there is no mention of a spinal cord injury in the patient's history.\n- The ability to read, understand, and complete the Visual Analogue Scale (VAS) is required, but the patient's cognitive abilities are not questioned in the note.\n- The patient must have signed an informed consent, which is not relevant to the current eligibility assessment.\n\nGiven the lack of information regarding a spinal cord injury in the patient's history and the specific requirements related to spinal cord injury characteristics, this patient would not be eligible for the clinical trial focused on the efficacy and safety of lithium carbonate in the treatment of chronic spinal cord injuries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1797": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, we need to assess whether the 26-year-old woman is eligible for the trial titled \"Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem.\"\n\nThe inclusion criteria for the clinical trial are:\n- Healthy Males age 18 to 35 inclusive\n- Body Mass Index 18 to 30\n- Willing to adhere to prohibitions and restrictions specified in protocol\n- Must give informed consent.\n\nThe patient in question is a 26-year-old woman, which already does not meet the inclusion criteria, which specify males only. Additionally, the trial is looking for healthy individuals, while the patient has a history of bipolar disorder and is currently experiencing significant symptoms such as depression, anxiety, agitation, and suicidal thoughts. Furthermore, there is no information provided on her Body Mass Index (BMI), but since she is described as obese, it is likely that her BMI may be above 30, which would also exclude her from the trial.\n\nBased on the patient note and the inclusion criteria for the clinical trial, the patient would not be eligible to participate in the trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1798": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided patient note and inclusion criteria, let's review the requirements one by one:\n\n1. DSM diagnoses that have an FDA indication for atypical antipsychotic use for at least one agent in the respective pediatric or adult age group. \n   - The patient has a history of bipolar disorder, which is included in the Bipolar Spectrum category.\n\n2. Clinically stable on current treatment regimen for at least 30 days.\n   - The patient note does not specify the duration of the current treatment regimen, so this criterion cannot be confirmed.\n\n3. Current SGA treatment with specific antipsychotics for \u2265 8 weeks.\n   - The patient note does not mention the use of any second-generation antipsychotics (SGAs); therefore, this criterion is not met.\n\n4. Stable dose of current SGA and psychotropic co-medications for at least 30 days.\n   - As the use of SGAs is not mentioned, we cannot confirm that this criterion is met.\n\n5. Body mass index (BMI) at least in the 85th percentile for age and gender.\n   - The patient is described as obese, which suggests that her BMI might be in the 85th percentile or above.\n\n6. Substantial weight gain over the previous 3 years while taking a SGA.\n   - There is no mention of weight gain being associated with SGA use since SGAs are not listed in the patient's current medications.\n\n7. Agrees to use two effective forms of birth control or to remain abstinent.\n   - The patient note does not provide information regarding this criterion.\n\n8. Has a primary caretaker who has known the child well for at least 6 months before study entry.\n   - This criterion is not applicable as the patient is not a child.\n\n9. Primary caretaker is able to participate in study appointments as clinically indicated.\n   - This criterion is not applicable as the patient is an adult, and there's no information provided about a caretaker.\n\nBased on the patient note and the inclusion criteria of the clinical trial, it appears that the patient does not meet several key criteria, particularly the use of specific antipsychotic medications and the association of weight gain with SGA use. However, the patient does have a diagnosis within the Bipolar Spectrum and is described as obese, which partially aligns with some of the inclusion requirements.\n\nGiven the information provided, the patient does not clearly meet enough of the inclusion criteria to be considered eligible for the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1799": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can assess the eligibility of the patient for the trial as follows:\n\nPatient characteristics:\n- Age: 26 years old\n- Diagnosed with bipolar disorder\n- Experiencing weight issues, depression, anxiety, agitation, suicidal thoughts, restlessness, and irritability\n- Current medications: lithium carbonate and zolpidem\n\nClinical trial inclusion criteria:\n- Age between 60-99 years\n- Clinical diagnosis of Dementia of the Alzheimer's type or Vascular Dementia\n- Mini Mental Status Examination scores of greater or equal to 10\n\nThe patient in the note does not meet the inclusion criteria for age, as she is 26 years old, and the trial requires participants to be aged between 60-99 years. Furthermore, the patient does not have a diagnosis of Dementia of the Alzheimer's type or Vascular Dementia, which are required for the clinical trial.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1800": {
        "output": "Based on the information provided, the patient does not meet the inclusion criteria for the clinical trial. The inclusion criteria specify that participants must be healthy males and/or females, with an age range from 21 to 55 years old, and a BMI ranging from 18 to 30 kg/m^2.\n\nThe patient described is a 26-year-old woman, which fits the age criteria. However, she is not a healthy subject as she has a history of bipolar disorder, is currently experiencing depression with suicidal thoughts, and is under medication for her psychiatric condition (lithium carbonate and zolpidem). Furthermore, the patient is described as obese, which may suggest her BMI is above 30 kg/m^2, thus not fitting the BMI criterion as well.\n\nGiven that the patient does not meet the health status and potentially the BMI criteria, she would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1801": {
        "output": "",
        "label": 0
    },
    "1802": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults,\" we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Current feelings of depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts\n- Fidgetiness and irritability\n- Current medications: lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Ages 18 to 55 years old\n- Diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or Major Depressive Disorder (MDD)\n- YMRS score < 16 and MADRS score < 24 at screening and baseline visits\n- SAPS scores <2 on all subscales\n- Weight gain > 7% following treatment with olanzapine\n- BMI > 30 kg/m2\n- Informed consent\n- If female, appropriate contraception or postmenopausal status\n- Stable dose of olanzapine for at least 14 days, and on 5-30mg/day for at least 1 month\n\nClinical Trial Exclusion Criteria (relevant to the patient):\n- Clinically significant suicidal or homicidal ideation\n- Treatment with concurrent mood stabilizers (except lithium)\n- Current clinically significant depressive or manic symptoms (MADRS score >24 or YMRS score > 16)\n- Current clinically significant psychotic symptoms (any SAPS subscale score > 2)\n\nBased on the information provided in the patient note:\n\n- The patient is within the age range (26 years old).\n- The patient has a diagnosis of bipolar disorder, which is one of the conditions listed in the inclusion criteria.\n- The patient's current medication does not include olanzapine, and there is no mention of weight gain associated with olanzapine use.\n- The patient's BMI is not specified, but she is described as obese which suggests her BMI could be > 30 kg/m2.\n- There are no details about the patient's YMRS, MADRS, or SAPS scores, which are necessary to determine eligibility.\n- The patient has suicidal thoughts, which is an exclusion criterion.\n\nGiven that the patient has not been reported to use olanzapine, which is a requirement for the trial, and has suicidal thoughts, which is an exclusion criterion, she does not meet the inclusion criteria for the clinical trial. Therefore, despite some information being missing (such as specific scores for the required scales), the patient is not eligible for this trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1803": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- A 26-year-old woman\n- History of bipolar disorder\n- Current symptoms: depression, anxiety, agitation, suicidal thoughts, irritability\n- Current medications: lithium carbonate and zolpidem\n- Experiencing weight gain issues\n\nClinical Trial Inclusion Criteria:\n- Patients with bipolar disorders (I, II, NOS) diagnosed with DSM-IV criteria\n- Age between 18 and 65\n- Adequate decisional capacity to provide informed consent or has an authorized surrogate decision maker\n- In a syndromal remission state at least for 2 months: CGI - BP \u2264 3\n- Patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (i.e., >7% weight gain)\n\nAssessment:\n- The patient has a diagnosis of bipolar disorder which matches the trial's target condition.\n- The patient's age falls within the range specified by the trial.\n- There is no information on the patient's decisional capacity, but there is no indication that it is inadequate.\n- The patient does not appear to be in a syndromal remission state as she is currently experiencing significant symptoms.\n- The patient has weight gain issues which may or may not be due to her current medication, but this is not clearly stated as a >7% weight gain after starting an antipsychotic.\n\nGiven that the patient is not currently in a syndromal remission state, which is an inclusion criterion for the trial, it would be inappropriate to refer her to this clinical trial at this time. However, if further investigation reveals that her weight gain meets the specific criteria related to antipsychotic use, and her condition stabilizes into a remission state, she might become eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1804": {
        "output": "Based on the patient note provided:\n\n- The patient is a 26-year-old woman with a history of bipolar disorder.\n- She is experiencing symptoms of depression, anxiety, agitation, and has had thoughts of suicide.\n- She is currently on medication including lithium carbonate.\n\nThe clinical trial in question is evaluating the efficacy of quetiapine alone versus quetiapine in combination with lithium for the treatment of a major depressive episode in patients with bipolar disorder. The inclusion criteria are:\n\n- Outpatients that meet the diagnostic criteria for bipolar disorder I and bipolar disorder II with the most recent episode depressed.\n- The total score of the scale that's used for the evaluation of depression (HAM-D) should be \u226520.\n- The total score of the scale that's used for the evaluation of mania (YMRS) should be \u226412.\n\nThe patient's note indicates that she has bipolar disorder and is currently experiencing a depressive episode, which meets part of the inclusion criteria. However, the note does not provide specific HAM-D or YMRS scores, which are required to determine her exact eligibility for the study. Without this information, we cannot definitively determine her eligibility.\n\nGiven that the patient is diagnosed with bipolar disorder and is currently in a depressive state, there is potential suitability for the trial pending further assessment of her HAM-D and YMRS scores. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1805": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, let's consider the key points of eligibility:\n\n- The patient is a 26-year-old woman with a history of bipolar disorder.\n- She is currently taking lithium carbonate and zolpidem.\n- The patient does not mention taking Zyprexa\u00ae (olanzapine), which is a specific requirement for the clinical trial.\n- The trial is looking for patients who are starting therapy with Zyprexa\u00ae and aims to prevent weight gain associated with this medication.\n- There is no mention of her weight being stable for the last 2 weeks or participation in a weight loss program within the past 3 months.\n\nGiven this information, the patient does not meet the key inclusion criteria of being a patient who is concurrently taking Zyprexa\u00ae for a psychiatric indication. Therefore, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1806": {
        "output": "Based on the information provided, let's compare the patient's characteristics with the inclusion criteria of the clinical trial titled \"Sleep and Endometrial Cancer\":\n\nPatient's Characteristics:\n- 26-year-old woman\n- History of bipolar disorder\n- Current medications include lithium carbonate and zolpidem\n- Complaints of depression, difficulty sleeping, excessive anxiety, agitation, thoughts of suicide, fidgetiness, and irritability\n- Struggling with weight and eating\n\nClinical Trial Inclusion Criteria:\n- Women at least 18 years old\n- Clinical indications of primary endometrioid adenocarcinoma of the endometrium\n- Scheduled for staging surgery by laparotomy under standardized protocols\n- Ability to communicate in English sufficient for completion of study materials\n- No neuromuscular/movement disorders\n- No uncontrolled medical, sleep, endocrine, or psychiatric illness\n- No ongoing use of medication known to affect sleep or wake function\n\nThe patient does meet some of the inclusion criteria such as being a woman over 18 and being able to communicate in English. However, the trial specifically requires participants to have clinical indications of primary endometrioid adenocarcinoma of the endometrium and be scheduled for surgery. The patient does not have this diagnosis, nor is she scheduled for any surgery related to endometrial cancer. Additionally, the patient has a psychiatric illness (bipolar disorder) and is taking medication (lithium carbonate and zolpidem) that may affect sleep or wake function, which is a disqualifying factor for this trial.\n\nGiven this information, the patient does not meet the essential criteria related to the primary reason for the trial and also has disqualifying factors (ongoing psychiatric illness and use of medications affecting sleep/wake function). Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1807": {
        "output": "Based on the patient note provided, the 26-year-old woman has a history of bipolar disorder and is currently experiencing depressive symptoms, anxiety, agitation, and suicidal thoughts. She also reports difficulty sleeping, which could be related to her psychiatric condition or medication regimen. Her current medications include lithium carbonate, used for bipolar disorder, and zolpidem, which is used for the treatment of insomnia.\n\nThe clinical trial in question is evaluating the efficacy and safety of a zolpidem modified release formulation in patients with primary insomnia. The inclusion criteria specify that the patient must have a diagnosis of primary insomnia based on DSM-IV criteria and must have given written informed consent.\n\nIn the case of the patient described, her insomnia may be secondary to her bipolar disorder rather than primary insomnia. Primary insomnia is characterized by difficulty initiating or maintaining sleep that is not attributable to medical, psychiatric, or environmental causes.\n\nGiven that the patient's insomnia could be secondary to her bipolar disorder and not primary insomnia, she does not meet the specific inclusion criteria for the trial. Consequently, she would not be an appropriate candidate for the clinical trial focused on primary insomnia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1808": {
        "output": "Given the patient's note and the clinical trial's inclusion criteria, we can analyze whether this patient is eligible for the trial:\n\nPatient note analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder, not cancer.\n- She experiences depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts.\n- Her current medications include lithium carbonate and zolpidem.\n\nClinical trial inclusion criteria analysis:\n- Age between 18-76 (the patient meets this criterion).\n- Current or historical diagnosis of cancer (the patient does not meet this criterion).\n- Projected life expectancy of at least one year (not applicable as the patient does not have cancer).\n- DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder due to cancer, Adjustment Disorder with anxious features (the patient does not have a diagnosis related to cancer).\n\nBased on this information, the patient does not meet the key inclusion criteria for the clinical trial, specifically the requirement for a current or historical diagnosis of cancer, as well as the specific DSM-IV diagnoses related to cancer. Therefore, she would not be eligible for the psilocybin cancer anxiety study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1809": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess the inclusion criteria provided against the patient's characteristics:\n\nInclusion Criteria Assessment:\n1. Patients meeting DSM-IV criteria for either Bipolar I, Bipolar II, Cyclothymic Disorder, or Bipolar Disorder NOS\n   - The patient has a history of bipolar disorder, which meets this criterion.\n\n2. Patients on monotherapy treatment with lithium carbonate at steady state level for a minimum of two weeks prior to study treatment assignment\n   - The patient is currently on lithium carbonate, but the note does not specify the duration of the treatment or if it is at a steady state level. Further investigation is required to confirm this criterion.\n\n3. Women are postmenopausal for at least 1 year, or surgically incapable of childbearing, or practicing an acceptable method of birth control (hormonal contraception, intrauterine device, or barrier with spermicide were acceptable) and not pregnant at baseline\n   - The patient's note does not provide information about menopausal status, surgical history regarding childbearing, or birth control practices. Therefore, we do not know if the patient meets this criterion without further investigation.\n\nGiven the information from the patient note, we have a partial match with the inclusion criteria for the clinical trial. Specifically, the patient has a history of bipolar disorder. However, we lack information about the duration and stability of lithium carbonate use and the patient's reproductive status and birth control practices.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1810": {
        "output": "Based on the provided patient note and the clinical trial information, the patient appears to be a potential match for the trial. The patient has a history of bipolar disorder and is currently experiencing sleep disturbances, which are both inclusion criteria for the study. Additionally, the patient is taking medication for bipolar disorder, which is not an exclusion criterion for the trial. The patient also expresses distress related to significant sleep disturbance, which is another inclusion criterion. However, there is no explicit mention that the patient is inter-episode, which is required for the study. Further investigation would be needed to confirm the patient's current episode status.\n\nGiven that the patient meets several key inclusion criteria but requires further assessment regarding her inter-episode status, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1811": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing depression, anxiety, agitation, difficulty sleeping, and suicidal thoughts.\n- She is on lithium carbonate and zolpidem for her condition.\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of probable Multiple System Atrophy (MSA).\n- Age \u226518, <80.\n\nComparison:\n- The patient's age falls within the inclusion criteria of the clinical trial (age \u226518, <80).\n- However, the patient has been diagnosed with bipolar disorder, not Multiple System Atrophy (MSA), which is the condition under investigation in the clinical trial.\n\nSince the patient does not have a diagnosis of Multiple System Atrophy, she does not meet the specific condition requirement for the clinical trial. The use of lithium in her case is related to bipolar disorder, not MSA.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1812": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the essential inclusion criterion of having a molecular diagnosis of Spinocerebellar Ataxia 2 (SCA2). The patient note details a 26-year-old woman with bipolar disorder and associated symptoms, not SCA2. Therefore, she is not eligible for this clinical trial, which is specifically designed for individuals diagnosed with SCA2.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1813": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia\", we need to assess if the patient meets the inclusion criteria as listed below:\n\n1. Patient is diagnosed as a primary insomnia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)\n2. Patients complaining of insomnia continuously for 4 weeks or longer\n3. Patient's usual bedtime is between 9 p.m. and 12 a.m. for the 4 week period prior to initial screening\n4. Patient on most occasions sleeps for a total of \u22653 and <6.5 hours over the 4 week period prior to initial screening\n5. Patient's usual wake time after sleep onset in a single night is \u226545 minutes per night for the 4 week period prior to initial screening\n6. Patients have a body weight of \u226545 kg and \u226485 kg, a BMI of \u226518.5 and <30\n\nReviewing the patient note:\n\nThe patient is a 26-year-old woman who complains of recent struggles with her weight and feeling depressed. She has had difficulty sleeping, feels excessively anxious and agitated, and has had thoughts of suicide. She finds herself fidgety and has been increasingly irritable. She is currently taking lithium carbonate and zolpidem. From the information provided, there are a few points to consider:\n\n- The patient is currently taking zolpidem, which is relevant to the study drug.\n- The patient has a complaint of insomnia, however, it is not clear if this is diagnosed as primary insomnia according to DSM-IV criteria.\n- There are no specific details about the duration of her insomnia, her usual bedtime, total sleep time, or wake time after sleep onset.\n- The patient is described as obese, but there is no specific information on her weight or BMI to confirm if she falls within the required range.\n\nGiven the information provided in the patient note, we cannot definitively say that the patient meets all the inclusion criteria for the clinical trial. The patient does have insomnia and is taking zolpidem, which could be relevant, but more information would be needed to confirm her eligibility, such as her weight, BMI, specific sleep patterns, and confirmation of a primary insomnia diagnosis.\n\nBased on the information at hand, the eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1814": {
        "output": "Based on the patient note provided, we can assess the patient's eligibility for the clinical trial with the following considerations:\n\n- The patient is a 26-year-old woman, which fits within the age range specified by the clinical trial (21-70 years).\n- The patient is currently using zolpidem, which is the focus of the study on the safety and efficacy of chronic hypnotic use.\n- The patient has difficulty sleeping, as indicated by her recent struggles with sleep, although it is not specified if this difficulty meets the criteria of having more than 30 minutes of sleep latency, less than 6 hours of sleep, or nonrestorative sleep.\n- The patient does not specifically mention that she has been diagnosed with primary insomnia according to DSM-IV criteria. Instead, she reports feeling depressed and anxious, which could be contributing to her sleep issues.\n- The patient's use of lithium carbonate suggests that her primary diagnosis may be related to her bipolar disorder, and her sleep issues may be secondary to her mood disorder rather than primary insomnia.\n\nGiven that the patient does not clearly meet the specified criteria for chronic insomnia complaints and that her insomnia may not be primary but rather secondary to her bipolar disorder, further investigation would be needed to determine if her sleep issues align with the DSM-IV criteria for primary insomnia.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1815": {
        "output": "Given the patient note and the clinical trial information provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently experiencing symptoms related to her bipolar disorder, such as depression, anxiety, agitation, insomnia, and suicidal thoughts.\n- She is on medication for bipolar disorder (lithium carbonate) and insomnia (zolpidem).\n- There is no mention of the patient being a biological parent or the primary caretaker of a child.\n\nClinical Trial Inclusion Criteria Analysis:\n- Have a diagnosis of bipolar disorder (the patient meets this criterion).\n- Be 18 years or older (the patient meets this criterion).\n- Be a biological parent of a child who is younger than 30 years old (the patient note does not provide information about this).\n- Be willing to participate in the survey (the patient's willingness is not mentioned, but it's assumed that if the patient is being considered, consent can be sought).\n- The participant must be (or must have been) the primary caretaker for his or her child (the patient note does not provide information about this).\n\nBased on the information provided, the patient meets some of the inclusion criteria of the clinical trial (diagnosis of bipolar disorder and age). However, there is no information about whether the patient is a biological parent and the primary caretaker of a child, which are also part of the inclusion criteria. Without this information, we cannot definitively determine the patient's eligibility.\n\nTherefore, the assessment of eligibility for this patient is:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther information is required regarding the patient's parental status and caretaking responsibility to make a full assessment of eligibility.",
        "label": 1
    },
    "1816": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient note with the inclusion criteria provided for the clinical trial. Let's analyze the patient's information and the trial's criteria step by step:\n\n1. The patient has a diagnosis of bipolar I disorder according to DSM-IV-TR criteria and is currently experiencing a major depressive episode.\n   - The patient note indicates a history of bipolar disorder with current symptoms of depression, so this criterion appears to be met.\n\n2. Documentation that the patient has had at least 1 previous manic or mixed episode.\n   - The patient note does not provide information about previous manic or mixed episodes, so we cannot confirm this with the information given.\n\n3. The patient has had no more than 6 mood episodes in the last year.\n   - The patient note does not specify the number of mood episodes in the last year, so we cannot confirm this with the information given.\n\n4. The patient's current major depressive episode must have started no less than 2 weeks and no more than 12 months prior to the screening visit. The current depressive episode must have begun after the patient's current mood stabilizer regime began.\n   - The patient note does not specify when the current depressive episode began or when the current mood stabilizer regime began, so we cannot confirm this with the information given.\n\n5. The patient must have been taking 1 (or 2) of the following protocol-allowed mood stabilizers: lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, risperidone, or ziprasidone (only if taken in combination with lithium or valproic acid).\n   - The patient is currently taking lithium carbonate, which is one of the allowed mood stabilizers listed.\n\n6. Written informed consent is obtained.\n   - This is a process that would occur if the patient agreed to participate.\n\n7. The patient is a man or woman 18 through 65 years of age.\n   - The patient is 26 years old, which meets this criterion.\n\n8. The patient is in good health (except for diagnosis of bipolar I disorder) as judged by the investigator, based on medical and psychiatric history, medical examination, ECG, serum chemistry, hematology, and urinalysis.\n   - The patient is described as obese, which could be a consideration for overall health, but there is no information that would explicitly exclude her based on health, aside from her psychiatric diagnosis.\n\n9. Women of childbearing potential must use medically accepted contraception.\n   - The patient's contraceptive use is not mentioned, but this is actionable if the patient is eligible otherwise.\n\n10. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits.\n    - The patient note does not comment on the patient's willingness or ability to comply, but this is also actionable if the patient is eligible otherwise.\n\n11. The patient has permanent accommodations and means of being contacted by the study center.\n    - There is no information provided about the patient's living situation or contact means.\n\n12. The patient understands that they may enroll in this clinical study only once and may not enroll in any other clinical study while participating in this trial.\n    - There is no information provided about the patient's understanding of the study enrollment conditions.\n\nGiven the information provided, it seems that the patient meets several of the inclusion criteria: diagnosis of bipolar I disorder, age, and current treatment with an allowed mood stabilizer (lithium). However, there are several details not provided in the patient note that are required to confirm eligibility, such as documentation of previous manic or mixed episodes, details about the current depressive episode timeline, and the number of mood episodes in the last year.\n\nBecause of these missing pieces of information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1817": {
        "output": "Given the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform\n- Females must be unable to have children or willing to remain abstinent from Day -5 until 90 days after discharge\n- Males must be willing to remain sexually abstinent or use an effective method of birth control from Day -5 until 90 days after discharge\n- Able and agree to remain off of prior antipsychotic medication for the duration of the study\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial. The patient has a history of bipolar disorder, not schizophrenia, schizoaffective disorder, or schizophreniform. Therefore, the patient is not eligible for this trial that is focused on drug-drug interactions with a specific focus on patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1818": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Prevention of Weight Gain in Early Psychoses,\" we must compare the patient's characteristics to the inclusion criteria of the trial.\n\nPatient characteristics:\n- Age: 26 years\n- Gender: Female\n- Diagnosis: Bipolar disorder\n- Status: Appears to be outpatient (not explicitly stated but no evidence of inpatient status is provided)\n- Medications: Lithium carbonate and zolpidem (no mention of antipsychotics)\n- BMI: Described as obese (BMI above 30 is indicated by the term \"obese\")\n\nClinical trial inclusion criteria:\n- Age between 14 and 45 years (inclusive)\n- Male or Female gender\n- DSM-IV-TR diagnosis of several disorders, including Bipolar Disorder (Type I) and Bipolar Disorder (Type II)\n- Outpatient status at the time of randomization\n- Duration of antipsychotic treatment of less than 5 years\n- Ability to provide informed consent\n- Female patients of childbearing potential must be using a medically accepted means of contraception\n- Treatment with specific antipsychotics for less than 8 weeks duration at enrollment\n- BMI between 18.5 and 30\n\nBased on the information provided, the patient meets most of the inclusion criteria: the age is within the specified range, the patient is female, has a diagnosis of bipolar disorder, and appears to be an outpatient capable of providing informed consent. However, there are two potential disqualifying factors:\n\n1. The patient's BMI is described as obese, which usually indicates a BMI over 30. The inclusion criteria specify a BMI between 18.5 and 30.\n2. There is no mention of the patient being treated with the specified antipsychotics (olanzapine, clozapine, quetiapine, risperidone, or paliperidone), let alone for less than 8 weeks duration at enrollment.\n\nGiven the lack of information regarding the patient's exact BMI and the specific antipsychotic treatment, it is not possible to definitively determine eligibility without further investigation. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1819": {
        "output": "The patient note describes a 26-year-old woman with a history of bipolar disorder who is experiencing depression, anxiety, agitation, suicidal thoughts, irritability, and difficulty sitting still. She is currently on lithium carbonate and zolpidem.\n\nTo assess trial-level eligibility, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\n1. Structured Clinical Interview (SCID) derived DSM-IV diagnoses of Bipolar Disorder (Type I or II), and Nicotine Dependence: The patient has a history of bipolar disorder, but there is no mention of nicotine dependence or smoking habits.\n2. Young Mania Rating Scale Total Score <12 at study entry: We don't have information on her Young Mania Rating Scale score.\n3. HAM-D 17-Item Score >5 and <24 at study entry: We don't have information on her Hamilton Depression Rating Scale score.\n4. Fagerstrom Test for Nicotine Dependence (FTND) score of 5 or higher: There is no information provided on her FTND score or smoking habits.\n5. Be able to provide informed consent to participate in this study as judged by clinical evaluation, and scoring at least 80% on a post-consent test: We can't determine her ability to consent based on the note provided.\n6. Smoking at least 10 cigarettes per day (confirmed by an expired breath CO level >10 ppm and a plasma cotinine level >150 ng/ml at baseline): There is no information regarding her smoking habits or related test results.\n7. Be motivated to quit smoking within 30 days of initial evaluation, as assessed by a score of 7 or higher on the Contemplation Ladder assessment tool: Again, no information about her motivation to quit smoking or if she smokes at all.\n8. On a stable dose of a mood stabilizer for at least 1 month (e.g., lithium, valproate, carbamazepine, atypical antipsychotic): The patient is on lithium carbonate, which is a mood stabilizer.\n9. Judged by the study psychiatrists and/or trained psychiatric clinicians to be in remission from active manic, hypomanic, major depressive and psychotic symptoms based on a clinical interview and SCID-IV \u22651 month prior to study enrollment: The patient appears to be experiencing depressive symptoms, so it is not clear if she is in remission.\n\nBased on the provided information, the patient does not meet the inclusion criteria specifically related to nicotine dependence and smoking habits, which are critical for a trial on smoking cessation/reduction. Without this information, it is not possible to accurately assess her eligibility. However, given no evidence of smoking is provided, it is reasonable to conclude that she would not be eligible based on the information at hand.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1820": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not meet the criteria for the clinical trial in question. The trial is specifically targeting pregnant women who are less than 16 weeks gestation and is focused on promoting healthy weight gain during pregnancy. The patient is described as a 26-year-old obese woman with a history of bipolar disorder, but there is no mention of her being pregnant. Therefore, the patient does not fulfill the key inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1821": {
        "output": "Reviewing the patient's note and the clinical trial inclusion criteria:\n\nPatient note:\n- A 26-year-old obese woman.\n- History of bipolar disorder.\n- Experiencing depression, anxiety, agitation, and suicidal thoughts.\n- Reports difficulty sleeping and fidgetiness.\n- Currently on lithium carbonate and zolpidem.\n\nClinical trial inclusion criteria:\n- Male and female subjects who can provide informed consent.\n- Ages between 19-65 years.\n- DSM-IV diagnosis of Major Depressive Disorder (MDD) by MINI and confirmed by psychiatric interview.\n- Currently experiencing a depressive episode with suicidality.\n- Montgomery-Asberg Depression Rating Scale (MADRS) score > 25 and a suicidal sub-score > 4.\n\nThe patient is within the age range required for the trial and is experiencing suicidality, which is a focus of the trial. However, the patient has a history of bipolar disorder, not specifically a DSM-IV diagnosis of Major Depressive Disorder (MDD), as required by the trial. The patient is currently taking lithium, which is one of the treatments being studied, but the trial is looking for adjunctive therapy to standard of care antidepressants, which is not mentioned in the patient's current treatment.\n\nGiven that the patient does not have a confirmed DSM-IV diagnosis of MDD and the details of her current depressive episode and MADRS score are not provided, I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis and assess her current depressive symptoms and suicidality against the trial's specific requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1822": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient described does not appear to be eligible for the clinical trial. The inclusion criteria for the trial specify individuals between the ages of 18 to 50 years with no sleep complaints or problems, good sleep quality per questionnaire, and sufficient time in bed each night. However, the patient described is experiencing difficulty sleeping, is feeling excessively anxious and agitated, and is currently taking zolpidem, which suggests she has sleep complaints or problems, contrary to the trial's requirements for good sleep quality without sleep problems.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1823": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania,\" let's assess the eligibility:\n\nPatient Note:\n- A 26-year-old woman\n- History of bipolar disorder\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Participants aged 7 years to 17 years, 11 months old at the time of the first dose\n- Diagnosis of manic or mixed episodes in bipolar I disorder according to DSM-IV\n- Score of > 20 on the YMRS at screening and baseline\n- Consent requirements met\n- If female, must meet certain reproductive criteria\n- Negative pregnancy tests if female and capable of pregnancy\n- No substance abuse or agreement to abstain\n- Willingness to wash out of exclusion medications\n- No clinically significant abnormalities in ECG or bloodwork\n\nThe patient does not meet the age requirement for the clinical trial, as she is 26 years old and the trial requires participants to be between 7 and 17 years, 11 months old. Therefore, despite her diagnosis and current treatment with lithium, she is not eligible for the pediatric study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1824": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder (GAD),\" we should compare the patient's characteristics and condition with the inclusion criteria of the trial:\n\nInclusion Criteria Checklist:\n1. Age 18 to 65 years: The patient is 26 years old, which meets this criterion.\n2. Lifetime bipolar I, II, or NOS disorder as defined by DSM-IV TR criteria: The patient has a history of bipolar disorder, which meets this criterion.\n3. Lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria: The patient complains of feeling excessively anxious and agitated, but it is not specified whether she has been diagnosed with panic disorder or GAD. This would require further investigation.\n4. Bipolar symptoms must be no more than moderate in severity, defined as a CGI-BP < 4: The patient's current state of depression, anxiety, and suicidal thoughts suggests her symptoms may be severe; this needs to be confirmed with a CGI-BP score.\n5. Anxiety symptoms must be at least moderate in severity, defined as a CGI-S > 4: The patient reports excessive anxiety and agitation, which indicates her anxiety symptoms could be moderate to severe; this should be confirmed with a CGI-S score.\n6. Must not be receiving regular mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for at least one week prior to baseline: The patient is currently taking lithium carbonate, which is a mood stabilizer. This does not meet the criterion and would disqualify her unless there is a washout period.\n7. Informed consent: This can be obtained from the patient or her legally authorized representative.\n8. Female contraception requirements: There is no information regarding this, but it is a manageable criterion if the patient is eligible based on other factors.\n\nBased on the information provided, there are uncertainties regarding the exact diagnosis of the patient's anxiety disorder and the severity of her bipolar symptoms. Additionally, her current use of lithium carbonate disqualifies her unless there is a washout period. Therefore, further investigation is needed to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1825": {
        "output": "Based on the information provided, the patient in question is a 26-year-old obese woman with a history of bipolar disorder who is currently experiencing depression, anxiety, agitation, difficulty sleeping, and suicidal thoughts. She is taking lithium carbonate for her bipolar disorder and zolpidem, which is a medication commonly used for the treatment of insomnia.\n\nThe clinical trial in question is investigating the efficacy and safety of zolpidem modified release versus zolpidem immediate release in patients with primary insomnia. The inclusion criteria for the clinical trial are:\n\n- Diagnosis of primary insomnia based on DSM-IV criteria (307.42)\n- Written informed consent has been obtained\n\nConsidering that the patient is already on zolpidem and is experiencing difficulty sleeping, which could indicate insomnia, there is a possibility that she may meet the criteria for primary insomnia. However, the patient's difficulty sleeping may also be secondary to her bipolar disorder, and therefore, it is not clear if she has primary insomnia as defined by the DSM-IV.\n\nGiven this information, further investigation would be needed to establish whether the patient's insomnia is primary or secondary to her bipolar disorder. This would require an appropriate clinical assessment to determine if her insomnia meets the DSM-IV criteria for primary insomnia.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1826": {
        "output": "Based on the patient note provided, the patient is a 26-year-old woman with a history of bipolar disorder. She reports symptoms that could be indicative of depression, such as feeling depressed, having difficulty sleeping, feeling anxious and agitated, having suicidal thoughts, and being fidgety and irritable. She is on medication for her condition, including lithium carbonate for bipolar disorder and zolpidem, likely for sleep issues.\n\nThe clinical trial in question is focused on patients with a clinical diagnosis of Major Depressive Disorder and requires a score of 15 or more on the Montgomery-\u00c5sberg Depression Rating Scale - Self-report version (MADRS-S).\n\nThe patient in question does exhibit symptoms of depression; however, the patient note does not specify a clinical diagnosis of Major Depressive Disorder, nor is there information provided on her MADRS-S score. Furthermore, the patient has a known diagnosis of bipolar disorder, which can complicate the assessment of depressive episodes due to the cyclical nature of the disorder.\n\nGiven these considerations, the patient may potentially be eligible for the trial if she meets the specific diagnostic criteria for Major Depressive Disorder in addition to her bipolar disorder, and if her MADRS-S score is 15 or more. However, further investigation would be needed to determine these factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1827": {
        "output": "The patient in question is a 26-year-old woman with a history of bipolar disorder. She does not mention having an eating disorder such as Anorexia Nervosa (AN) or Eating Disorder Not Otherwise Specified (EDNOS), nor is it indicated that she meets the weight criteria of being less than or equal to 85% of her ideal body weight. Furthermore, she is not in the age range specified by the clinical trial's inclusion criteria, which is for male or female participants between 11 and 17 years old. Additionally, there is no mention of her being treated by a physician on the eating disorder team at the Children's Hospital of Eastern Ontario (CHEO).\n\nBased on the provided information, the patient does not meet the age, diagnosis, weight, or treatment provider requirements outlined in the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1828": {
        "output": "In assessing the eligibility of the 26-year-old female patient for the clinical trial titled \"A Pilot Study of Lithium in Progressive Multiple Sclerosis,\" we must compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are as follows:\n1. Diagnosis of a progressive subtype of multiple sclerosis by revised 2005 McDonald Criteria.\n2. EDSS (Expanded Disability Status Scale) of 3.0-6.5\n3. Ages 30-65\n4. Must be mentally capable of providing informed consent and following study guidelines.\n\nThe patient note provides the following information:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is currently taking lithium carbonate.\n- There is no mention of multiple sclerosis or an EDSS score in her patient note.\n\nBased on the information provided, the patient does not meet the age criterion for the trial (as she is 26 and the trial requires ages 30-65) and there is no indication that she has been diagnosed with a progressive subtype of multiple sclerosis. Therefore, she does not meet at least two of the inclusion criteria.\n\nGiven this information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1829": {
        "output": "Based on the patient note provided, we have a 26-year-old woman with a history of bipolar disorder who is currently experiencing weight-related issues, depression, anxiety, agitation, suicidal thoughts, and restlessness. She also has issues with irritability and is currently on lithium carbonate and zolpidem.\n\nNow let's evaluate her eligibility against the inclusion criteria for the clinical trial titled \"Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)\":\n\n1. Diagnosis of Type I or II BD for at least 6 months (confirmed with MINI): The patient note does not specify the duration of her bipolar disorder diagnosis or whether it has been confirmed using the MINI interview, but she is receiving treatment for bipolar disorder, which suggests the possibility of a confirmed diagnosis.\n\n2. On maintenance evidence-based treatment for BD (lithium, antipsychotic, anticonvulsant): The patient is on lithium carbonate, which is a maintenance treatment for bipolar disorder.\n\n3. Have weight gain concerns that individual believes are related to BD medication treatment: The patient's note explicitly states her struggles with weight and eating, which have contributed to her depression. This suggests a concern with weight gain related to her condition or treatment.\n\n4. Sub-optimal adherence as measured by the Tablet Routines Questionnaire (TRQ) and which the patient feels is related to weight gain concerns: The patient note does not provide information about her medication adherence, so we cannot ascertain whether she meets the criteria related to adherence issues.\n\nGiven that the patient has not been confirmed to have sub-optimal adherence due to weight gain concerns, we have an incomplete match with the inclusion criteria. However, given that she is on lithium (an evidence-based treatment for BD) and has concerns about weight gain, there is potential for her to fit the trial's profile after confirming her medication adherence and the duration and confirmation of her BD diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1830": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"The Quietude Study: Quetiapine Use for Agitated Depression,\" let's assess the eligibility:\n\nPatient Characteristics:\n- 26-year-old woman (meets age criteria of 18 to 65)\n- History of bipolar disorder (the trial specifies a diagnosis of major depressive disorder; this may or may not be considered equivalent depending on the trial's definitions and the patient's specific diagnosis)\n- Reports depression, agitation, irritability (consistent with significant agitation)\n- Difficult sleeping (could be related to depression/agitation)\n- Thoughts of suicide (indicates a severe level of mood disorder)\n- Current medications include lithium carbonate (commonly used in bipolar disorder) and zolpidem.\n\nClinical Trial Inclusion Criteria:\n- Male or female (patient is female)\n- Age 18 to 65 (patient is 26)\n- Outpatient at enrolment (patient status is not specified but there is no indication of hospitalization)\n- A diagnosis of major depressive disorder (patient has a history of bipolar disorder; unclear if patient also meets criteria for major depressive disorder)\n- Baseline HAMD-17 score > 20 and HAMD Item1 score > 2 both at enrolment and baseline (not provided in the patient note)\n- Significant agitation (patient reports feeling anxious and agitated)\n- CGI-S score > 4 at screening and baseline (not provided in the patient note)\n- Negative serum pregnancy test at enrolment and use of reliable birth control (not applicable as it's not mentioned in the patient note)\n- Able to understand and comply with the requirements of the study (not specified but there\u2019s no indication the patient wouldn't be able to comply)\n- Able and willing to give meaningful informed written consent (not specified but there\u2019s no indication the patient wouldn't be able to consent)\n\nThe main points of uncertainty here are whether the patient's bipolar disorder could be considered equivalent to or coexistent with major depressive disorder for the purposes of the trial, and whether the specific measures (HAMD-17 score, CGI-S score) meet the thresholds for inclusion. These details are crucial and not provided in the patient note.\n\nGiven this information, the patient could potentially be eligible if she also meets the criteria for major depressive disorder and the required scores on the specified scales. However, further investigation is necessary to confirm these details, especially her diagnosis in relation to major depressive disorder and the specific scores required for enrolment. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1831": {
        "output": "Given the inclusion criteria for the clinical trial in question and the patient note provided, the patient appears to be potentially eligible for the study. The inclusion criteria stipulate that participants must be female, aged between 18 and 40 years, and currently taking lithium or sertraline.\n\nThe patient described in the note is a 26-year-old woman who is currently taking lithium carbonate. This matches the age and medication requirements of the trial. Although the patient note does not specify the phase of the patient's menstrual cycle, this information can be obtained during the screening process.\n\nHowever, since the patient note mentions that the patient is struggling with her weight, feeling depressed, excessively anxious, agitated, and has had thoughts of suicide, it would be prudent to ensure that her current mental state would not interfere with her ability to participate in the trial or pose a risk to her safety. Therefore, further evaluation of her stability and suitability for the trial would be necessary.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1832": {
        "output": "Based on the information provided, the patient in question is a 26-year-old obese woman with a history of bipolar disorder. She is currently experiencing depression, anxiety, agitation, and has had thoughts of suicide. She is also on medications including lithium carbonate and zolpidem.\n\nThe clinical trial in question is focused on the development of the Fathers Supporting Success in Preschoolers (FSSP) Program, which is designed to engage fathers in improving parenting and child behavior. The inclusion criteria for this clinical trial are specifically:\n\n- Male Guardian\n- Child enrolled in partnering Head Start site\n\nGiven that the patient is a woman and there is no mention of her being a guardian of a child enrolled in a Head Start site, she does not meet the inclusion criteria for this clinical trial. Therefore, she would not be eligible for participation in this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1833": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the clinical trial titled \"Lithium Versus Paroxetine in Major Depression.\"\n\nPatient note review:\n\n- The patient is a 26-year-old woman, which satisfies the age criterion of being 18 years or older.\n- She has a history of bipolar disorder and is currently experiencing symptoms of depression, including feeling depressed, having difficulty sleeping, feeling excessively anxious and agitated, and having suicidal thoughts.\n- She is currently taking lithium carbonate, which is relevant to the study as it is comparing the effectiveness of lithium with paroxetine.\n\nClinical trial inclusion criteria review:\n\n- The patient must be a man or woman who is 18 years or older. The patient is a 26-year-old woman, which meets this criterion.\n- The patient must meet criteria for a major depressive episode. The patient's symptoms suggest she may be experiencing a major depressive episode.\n- The patient must have a family history of bipolar disorder or completed suicide. The patient note does not mention a family history of bipolar disorder or completed suicide, but the patient herself has a history of bipolar disorder, which may be considered relevant to the study's focus on patients with a background of bipolar disorder.\n\nGiven the information provided, the patient appears to meet most of the inclusion criteria for the clinical trial. However, the patient note does not explicitly mention a family history of bipolar disorder or completed suicide, which is a specific inclusion criterion for the trial. Due to this lack of information, further investigation would be needed to confirm the family history aspect. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1834": {
        "output": "",
        "label": 0
    },
    "1835": {
        "output": "The patient note describes a 26-year-old obese woman with a history of bipolar disorder, depression, anxiety, agitation, and suicidal thoughts, currently on lithium carbonate and zolpidem. The clinical trial is investigating the safety and efficacy of oral lithium, intraspinal umbilical cord blood mononuclear cell transplant, and the combination in the treatment of acute and subacute spinal cord injury.\n\nUpon reviewing the inclusion criteria for the clinical trial, we can determine the following:\n\n- The patient's age (26 years old) falls within the range of 18-65 years old specified by the trial.\n- The trial specifically targets individuals with acute or subacute traumatic spinal cord injury, which is not mentioned in the patient note.\n- The patient must have a neurological status of ASIA A and a neurological level between C5-T11, which is not applicable as there's no mention of any spinal cord injury in the patient's note.\n- An MRI showing the injury site is within 3 vertebral levels and a necrotic focus, if it exists, is less than 1/3 of the spinal cord diameter, is also required, which is not relevant to the patient's current condition.\n- The patient should be in need of a spinal decompression surgery, which again is not applicable here.\n- The patient should be able to complete a neurological examination, which is not relevant to the patient's psychiatric condition.\n- Finally, the patient must have voluntarily signed and dated an informed consent form, which is a procedural requirement that any patient would need to fulfill upon deciding to participate in a trial.\n\nBased on the information provided in the patient note and the specific inclusion criteria of the clinical trial, the patient does not have a spinal cord injury, which is the primary focus of the study. Therefore, this patient would not be eligible for the trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1836": {
        "output": "To assess this patient's eligibility for the clinical trial titled \"Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine,\" we need to match the patient's characteristics and circumstances with the inclusion criteria of the study:\n\nPatient Characteristics:\n- 26-year-old woman\n- History of bipolar disorder\n- Complaints of weight struggles, depression, anxiety, agitation, and suicidal thoughts\n- Fidgety and irritable\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Diagnosis (DSM-IV) of schizophrenia or functional psychosis including schizophreniform and acute psychosis with schizophrenia symptoms\n- Receiving olanzapine treatment for no more than 3 months\n- The dose of olanzapine is stable for at least 2 weeks prior to randomization and subject is willing to maintain a stable dose for the duration of the study\n- Evidence of weight gain in the last 3 months attributable to olanzapine, prior to screening\n- Further weight gain attributable to olanzapine in the baseline period no more than 5 months subsequent to commencement of olanzapine treatment\n- Willing to maintain a stable dose of any concomitant medications for a minimum of 6 weeks (with the exception of olanzapine)\n- No changes in diet or exercise for 6 weeks prior to screening and agrees to maintain stability for the duration of the study\n\nBased on the patient note, the patient does not meet the following inclusion criteria:\n- The patient does not have a diagnosis of schizophrenia or functional psychosis; she has a history of bipolar disorder.\n- There is no mention of the patient receiving olanzapine treatment, let alone for a specified period or with evidence of weight gain attributable to such treatment.\n\nSince the patient does not meet key inclusion criteria related to diagnosis and medication, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1837": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria:\n\nPatient note:\n- A 26-year-old obese woman\n- History of bipolar disorder\n- Current symptoms: depression, difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, restlessness, irritability\n- Current medications: lithium carbonate and zolpidem\n\nClinical trial:\n- Title: Gao Bipolar Spectrum Lithium/Quetiapine Study\n- Study on the safety, tolerability, and effectiveness of Lithium versus Quetiapine in patients with Bipolar disorder\n- Inclusion criteria:\n  - Able to provide informed consent\n  - Male and female patients at least 18 years of age\n  - Meets DSM-IV criteria for BPI, BP II, or sub-threshold BP, in need of medication adjustment(s)\n  - Willing to be randomized to either Lithium or Quetiapine\n  - If a sexually active female of childbearing potential, using reliable contraception\n  - Negative urine pregnancy test for women with reproductive potential\n\nThe patient is a woman who is at least 18 years old and has a history of bipolar disorder, which suggests she could meet the DSM-IV criteria for BPI, BP II, or sub-threshold BP. She is currently on lithium carbonate, indicating a need for medication adjustment, and she might be willing to be randomized to either Lithium or Quetiapine as per trial requirements. However, further information would be needed to confirm her diagnosis according to DSM-IV criteria, her willingness to participate and be randomized, and whether she meets the contraception requirement if she is of childbearing potential.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1838": {
        "output": "Given the patient note, the patient is a 26-year-old obese woman with a history of bipolar disorder, experiencing depression, anxiety, agitation, sleep difficulties, and suicidal thoughts. She is currently on lithium carbonate and zolpidem.\n\nThe clinical trial is focused on studying postoperative sleep disturbances after zolpidem treatment in patients who have undergone fast-track hip and knee replacement surgery.\n\nThe inclusion criteria for the clinical trial are:\n1. Total hip or knee replacement in a fast-track setup\n2. Age 60 years or above\n3. ASA class 1-3\n\nThe patient does not meet the inclusion criteria for the clinical trial as she has not undergone a hip or knee replacement surgery, which is a primary requirement for the study. Additionally, she is not within the specified age range of 60 years or above. There is also no mention of her being classified within ASA class 1-3.\n\nBased on the provided information, the patient in the note does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1839": {
        "output": "To assess the patient's eligibility for the trial titled \"Reducing Suicidal Ideation Through Insomnia Treatment,\" we need to compare the patient's characteristics and conditions with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- Age: 26 years old (meets the age criterion of 18-65 years)\n- Current Conditions: Bipolar disorder, insomnia, depression, suicidal ideation (potentially meets the DSM-IV diagnosis of MDE and Research Diagnostic Criteria diagnosis of insomnia)\n- Medications: Lithium carbonate and zolpidem (patient is not free of all psychotropic medications)\n\nClinical Trial Inclusion Criteria:\n- Age 18-65 years of age (patient meets this criterion)\n- Persons with confirmed DSM-IV diagnosis of MDE by SCID (patient likely meets this criterion, but confirmation with SCID is required)\n- Persons with Research Diagnostic Criteria diagnosis of insomnia (patient reports difficulty sleeping, but a formal diagnosis based on Research Diagnostic Criteria is needed)\n- Persons free of all psychotropic medications for one week before baseline assessment (patient does not meet this criterion; she is currently on lithium carbonate and zolpidem)\n- Persons with Scale for Suicide Ideation (SSI) scores >2 (patient has suicidal thoughts, but SSI score needs to be assessed)\n- Persons with Hamilton Rating Scale for Depression (HRSD24) score >20 (patient appears depressed but HRSD24 score needs to be assessed)\n- Persons with Mini Mental State Exam (MMSE) score >24 (MMSE score not provided)\n- Persons with Insomnia Severity Index (ISI) score >7 (patient has insomnia, but ISI score needs to be assessed)\n- Persons with habitual sleep latency > or = 30 minutes or wake time in the middle of the night of > or = 30 minutes, and sleep efficiency <85% (the patient reports difficulty sleeping, but specific measures need to be assessed)\n\nGiven that the patient is currently on psychotropic medications and there is no information provided about a one-week abstinence period from these medications before the baseline assessment, it is unlikely that she would be immediately eligible for this trial. Furthermore, while the patient does report symptoms that could potentially meet several of the inclusion criteria, formal assessments (such as SCID, SSI, HRSD24, MMSE, and ISI) would be required to determine her eligibility.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1840": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Cognitive Behavioral Therapy for Insomnia in Euthymic Bipolar Disorder,\" we must compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n1. Fulfilling criteria for SCID-1-verified bipolar I or II disorder.\n2. Euthymic, as defined by Montgomery \u00c5sberg Depression Rating Scale (MADRS) not higher than eleven, and Young Mania Rating scale (YMRS) not higher than five.\n3. Fulfilling DSM-IV criteria for primary insomnia or insomnia related to another mental disorder, as assessed by the Insomnia Interview Schedule (IIS).\n\nThe patient's characteristics are:\n- 26 years old, which meets the general adult age requirement.\n- Has a history of bipolar disorder, which is aligned with the first inclusion criterion.\n- Experiences insomnia, difficulty sleeping, which could meet the third inclusion criterion.\n- Describes symptoms of depression and anxiety, which could be related to bipolar disorder.\n\nHowever, to determine if the patient is euthymic (criterion 2), we would need specific scores from the MADRS and YMRS, which are not provided in the patient note. The patient does report feeling depressed and has had thoughts of suicide, which suggests that she may not be currently euthymic. Furthermore, the patient is currently experiencing symptoms that could indicate an active mood episode, such as increased irritability, agitation, and difficulty sleeping.\n\nGiven the available information, the patient does not clearly meet the second inclusion criterion of being euthymic. Therefore, we would not refer this patient for the clinical trial without further investigation into her current mood state and the specific ratings on MADRS and YMRS.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1841": {
        "output": "",
        "label": 0
    },
    "1842": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial \"Mindfulness Therapy on Disrupted Sleep in Bipolar Disorder,\" let's evaluate the patient's eligibility:\n\nThe inclusion criteria for the trial are:\n1. Men and women age 18-65\n2. DSM-IV diagnosis of bipolar I or II disorder\n3. HAM-D-17 score < 17 (i.e. low or no depressive symptoms)\n4. YMRS score < 8 (i.e. no or low manic symptoms)\n5. Optimized, stable maintenance pharmacotherapy at maximum tolerated dosages in accordance with the revised Texas Implementation of Medication Algorithm\n6. DSM-IV insomnia A and B criteria are met (i.e. difficulty initiating or maintaining sleep, for at least 1 month) as operationally defined by:\n   - Insomnia Severity Index score of > 15 (moderate clinical insomnia)\n   - M1 derived average actigraphic total sleep time < 6 hours, and < 40% average total sleep time in high frequency coupling, as measured with the M1 device over 5 days pre-randomization, corresponding to < 1SD below the mean of the M1 normative comparison sample of healthy control participants.\n\nThe patient note indicates:\n- The patient is a 26-year-old woman, which satisfies the age criteria (1).\n- She has a history of bipolar disorder, which may satisfy criterion (2) but does not specify whether it is bipolar I or II.\n- She complains of depression and difficulty sleeping, which may be indicative of DSM-IV insomnia A and B criteria (6), but there is no Insomnia Severity Index score provided or actigraphic sleep data.\n- There is no information regarding the HAM-D-17 score or YMRS score (3 and 4), so we can't confirm if she meets these criteria.\n- The patient is on lithium carbonate and zolpidem, suggesting she is on pharmacotherapy, but there is no information on whether this pharmacotherapy is optimized and stable at maximum tolerated dosages (5).\n\nGiven the current information, the patient appears to potentially meet several of the inclusion criteria, specifically age, bipolar disorder diagnosis, and sleep difficulties. However, further information would be necessary to determine if she meets all the required criteria including the severity of her depressive and manic symptoms, whether her pharmacotherapy is optimized and stable, and the specific measures of her sleep difficulties.\n\nTherefore, the assessment for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1843": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 26-year-old woman (fits the age criterion of 13 to 21)\n- History of bipolar disorder\n- Current symptoms include depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, restlessness, irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Age 13 to 21 (patient is 26, which is outside this range)\n- Experience a moderately elevated level of depressive symptoms on the CES-D scale (patient does show depressive symptoms but it\u2019s not stated that the CES-D scale has been used or what the score might be)\n- May or may not have had a past history of depression, anxiety and/or substance abuse (patient has a history of bipolar disorder, which includes symptoms of depression)\n\nThe patient does not meet the age criterion for the clinical trial, which is a fundamental inclusion requirement. While the patient does exhibit depressive symptoms, the specifics of her CES-D score are not provided, and she is older than the age range specified in the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1844": {
        "output": "To assess the patient's eligibility for the clinical trial \"Adjunctive Isradipine for the Treatment of Bipolar Depression,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial. Let's examine the patient's details and the trial criteria step by step:\n\nPatient's Characteristics:\n- Age: 26 years old (meets the age criterion of 18-65 years)\n- Current medications: lithium carbonate (meets the criterion for current treatment with a lithium preparation)\n- Condition: The patient has bipolar disorder and is experiencing depressive symptoms, which include difficulty sleeping, excessive anxiety and agitation, and thoughts of suicide.\n\nClinical Trial Inclusion Criteria:\n- Age 18-65 (Patient meets this criterion)\n- Written informed consent (Assumed obtainable if patient agrees to participate)\n- Meets DSM-IV criteria for bipolar I disorder, current episode depressed (Patient appears to meet this criterion based on their reported bipolar disorder and depressive symptoms)\n- Montgomery-Asberg Depression Scale (MADRS) score of at least 20 and no greater than 34 at screen and baseline visit (Patient's MADRS score is not provided, further assessment needed)\n- Young Mania Rating Scale (YMRS) score < 12 at screen and baseline visit (Patient's YMRS score is not provided, further assessment needed)\n- Currently treated with a lithium preparation at a stable dose for at least 4 weeks with level >0.6 and <1.0; and/or valproate at a stable dose for at least 4 weeks at level >60 and <110; and/or other atypical antipsychotic at stable dose for at least 4 weeks (Patient meets this criterion with lithium carbonate, assuming levels are within the specified range)\n- Caucasian by self-report (Patient's ethnicity is not provided, further assessment needed)\n\nBased on the information provided in the patient note, the patient is within the age range required, has bipolar disorder with a current depressive episode, and is currently being treated with lithium carbonate. However, we do not have information on the patient's MADRS and YMRS scores, nor do we know the patient's ethnicity, which is a specific inclusion criterion for the trial.\n\nTherefore, based on the information given, I would consider referring this patient to the clinical trial upon further investigation to determine MADRS and YMRS scores and to confirm the patient's ethnicity. This is necessary to fully establish the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1845": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility of the patient for the trial:\n\nPatient characteristics:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Experiencing depression, difficulty sleeping, excessive anxiety, agitation, and thoughts of suicide\n- Symptoms of restlessness and irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical trial inclusion criteria:\n- Primary insomnia or secondary insomnia\n- Requires sleep medication (Zolpidem) for a three-week trial\n- Active duty military service member stationed at Fort Carson\n\nThe patient does have difficulty sleeping, is feeling depressed, and is currently using zolpidem, which aligns with some of the inclusion criteria of the clinical trial (which targets individuals with sleep issues and requires the use of Zolpidem). However, the trial specifically requires participants to be active duty military service members stationed at Fort Carson. The patient note does not mention the patient being an active duty military service member, which is a critical inclusion criterion for the clinical study.\n\nTherefore, unless further information is provided about the patient\u2019s military service status, she would not meet all the inclusion criteria based on the information available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1846": {
        "output": "Based on the patient note provided:\n\n- The patient is a 26-year-old obese woman (meets age criterion of 18-65 years).\n- She has a history of bipolar disorder, not a traumatic spinal cord injury.\n- There is no mention of her experiencing neuropathic pain, which is a requirement for the clinical trial.\n- There is also no indication that her pain severity has been evaluated on an 11-point numeric rating scale, nor that she experiences pain regularly for at least 6 weeks before enrollment.\n- The patient is currently being treated with lithium carbonate, which is the medication under investigation in the trial, but for bipolar disorder, not for neuropathic pain due to spinal cord injury.\n\nThe inclusion criteria for the clinical trial are specific to individuals who have a diagnosis of traumatic spinal cord injury and are experiencing neuropathic pain. As the patient does not meet these critical criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1847": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman with a history of bipolar disorder.\n- She is currently experiencing depressive symptoms, which include difficulty sleeping, feeling excessively anxious and agitated, and having thoughts of suicide.\n- She experiences restlessness and irritability, which could potentially align with hypomania/mania symptoms or ADHD symptoms.\n- Her current medications include lithium carbonate, which is commonly used to treat bipolar disorder, and zolpidem, which is used for sleep problems.\n- The note does not mention any biological parents with bipolar disorder, which is a key inclusion criterion for the trial.\n\nClinical Trial Inclusion Criteria:\n- Have at least one biological parent diagnosed as bipolar disorder (bipolar I or II).\n- Have at least one of the following syndromes: hypomania/mania symptoms, major depressive symptoms, psychotic symptoms, or ADHD symptoms, with evidence of clinically significant impairment.\n\nComparison:\n- The patient has symptoms that could potentially align with the clinical definitions of hypomania/mania, major depressive symptoms, and ADHD symptoms.\n- However, there is no information provided about the patient\u2019s biological parents and whether they have been diagnosed with bipolar disorder.\n\nGiven the lack of information on the patient's parental history of bipolar disorder, we cannot definitively determine if she meets all of the inclusion criteria. Her current symptoms suggest that she could potentially be experiencing the prodromal stage of bipolar disorder, aligning with some of the criteria for the trial, but without confirmation of a biological parent with bipolar disorder, it's not clear if she would be eligible.\n\nTherefore, further investigation is necessary to determine if the patient has a biological parent with a diagnosis of bipolar disorder. If she does, she may very well meet the inclusion criteria and could be considered for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1848": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder,\" we need to compare the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient Characteristics:\n- Age: 26 years\n- Gender: Female\n- Diagnosed with bipolar disorder\n- Experiencing depression, anxiety, agitation, and suicidal thoughts\n- Currently on medication including lithium carbonate and zolpidem\n- Complains of difficulty sleeping and being fidgety and irritable\n\nClinical Trial Inclusion Criteria:\n- Men and women age 18-65\n- DSM-IV diagnosis of bipolar I disorder and at least one of three additional anxiety disorders: generalized anxiety disorder, panic disorder, or social phobia.\n- HAM-D-17 score <16 (indicating depressive symptoms that are not severe)\n- YMRS score < 12 (indicating no or very low manic symptoms)\n- Current, stabilized (> 3 months) pharmacotherapy treatment under the care of a psychiatrist consisting of optimized, stable maintenance pharmacotherapy at maximum tolerated dosages according to Texas Implementation of Medication Algorithm.\n\nAssessment:\n- The patient falls within the appropriate age range (18-65).\n- The patient has a diagnosis of bipolar disorder; however, it is not specified as bipolar I disorder, which is a requirement.\n- The patient is experiencing depressive symptoms, but we do not have a HAM-D-17 score to confirm that it is below 16.\n- The patient's level of manic symptoms is not specified, so we cannot confirm a YMRS score below 12.\n- The patient is currently on pharmacotherapy, but we lack information about the duration of stabilization on these medications (> 3 months) and whether the medications are optimized and at maximum tolerated dosages.\n\nGiven the available information, we cannot confirm that the patient meets the specific diagnostic criteria (bipolar I disorder), nor do we have the necessary scores (HAM-D-17 and YMRS) or complete details on the patient's pharmacotherapy treatment. Therefore, further investigation is required to determine if the patient has bipolar I disorder and meets the other specific criteria for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1849": {
        "output": "Based on the information provided, the patient in the note has a history of bipolar disorder, which aligns with the target condition for the clinical trial. The trial is looking for participants with a diagnosis of bipolar I disorder, manic or mixed phase, and requires participants to have a score of 18 or more on the Young Mania Rating Scale (YMRS).\n\nThe patient note indicates that the patient is experiencing symptoms such as feeling depressed, difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, being fidgety and unable to sit still, and increased irritability. These symptoms could be indicative of a manic or mixed phase of bipolar I disorder. However, the patient note does not provide a YMRS score, which is crucial for determining eligibility based on the inclusion criteria specified by the trial.\n\nGiven the absence of a YMRS score in the patient note, we cannot determine for certain if the patient would meet the specified threshold for the trial. Therefore, further investigation, such as obtaining a YMRS score, would be necessary before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1850": {
        "output": "Given the patient's note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 26-year-old woman\n- History of bipolar disorder\n- Current medications include lithium carbonate and zolpidem\n- Complaints of weight struggles, depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, restlessness, and irritability\n\nClinical trial inclusion criteria:\n- Age between 20 and 64 years\n- Diagnosis of primary insomnia according to DSM-IV criteria\n- Difficulty in maintaining sleep and waking up until 3 am\n- Not having used any psychoactive drug in the last 30 days prior to inclusion in the study\n- Signature of informed consent (IC)\n\nAssessment:\n- Age: The patient is 26 years old, which fits within the trial's age range of 20 to 64 years.\n- Diagnosis: The patient complains of difficulty sleeping, which might suggest insomnia. However, the patient has bipolar disorder and is currently taking lithium and zolpidem, which implies the sleep issues may be secondary to her psychiatric condition or medication, not primary insomnia.\n- Psychoactive drug use: The patient is currently on lithium carbonate, which is a mood stabilizer, and zolpidem, which is used to treat sleep problems. As per the inclusion criteria, candidates should not have used any psychoactive drug in the last 30 days. The patient does not meet this criterion.\n\nGiven that the patient's insomnia may not be classified as primary due to her bipolar disorder and current medication use, and she has used psychoactive drugs within the last 30 days, she would not meet the inclusion criteria for the clinical trial on the efficacy and safety of sublingual zolpidem for primary insomnia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1851": {
        "output": "Based on the patient note and the clinical trial information provided, here is the assessment:\n\nPatient Note:\n- A 26-year-old woman.\n- Has a history of bipolar disorder.\n- Is currently experiencing depression, anxiety, agitation, sleep difficulties, and suicidal thoughts.\n- Is on medication including lithium carbonate.\n- Is not specified as a Veteran of the United States Armed Forces.\n\nClinical Trial Inclusion Criteria:\n- Must be a Veteran of the United States Armed Forces.\n- Survived an episode of suicidal self-directed violence within six months of admission to the study, or admitted within the past six months to prevent suicide.\n- Have a diagnosis of an affective disorder meeting DSM-IV-TR criteria for Bipolar I Disorder, Bipolar II Disorder, or Major Depressive Disorder.\n- Able to provide informed consent and identify contacts.\n- Mental health provider concurrence and general medical provider awareness.\n\nThe patient meets several of the clinical trial's inclusion criteria, such as having bipolar disorder and being on lithium medication. However, the patient does not meet a key inclusion criterion of being a Veteran of the United States Armed Forces. This criterion is essential for eligibility, and since there is no indication that the patient is a veteran, she would not be eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1852": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's go through each criterion one by one:\n\nPatient Note Analysis:\n- The patient is a 26-year-old woman, which falls within the age range of 18-65 years required by the trial.\n- She has a history of bipolar disorder and is currently experiencing a major depressive episode (MDE) with suicidal ideation.\n- She is currently on medication (lithium carbonate and zolpidem) but is still struggling with depressive symptoms, indicating she may not be responding adequately to her current treatment.\n- She expresses moderate to severe suicidal ideation.\n- She is pre-menopausal and there is no indication that she is unwilling to use acceptable forms of birth control.\n- There is no information suggesting an inability to provide informed consent.\n- The patient note does not mention any unstable medical or neurological conditions, significant ECG abnormalities, pregnancy, lactation, current psychotic symptoms, contraindications to study treatments, insufficient understanding of English, prior ineffective trial of or adverse reaction to ketamine or midazolam, or opiate use.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 18-65 years: the patient is 26 years old, which fits the criterion.\n- Bipolar depression with the current MDE and suicidal ideation: the patient has bipolar disorder, is currently depressed, and has suicidal thoughts.\n- Willingness to be admitted to an inpatient research unit for the infusion phase of treatment: this willingness is not stated but could be assessed with further investigation.\n- Pre-menopausal female participants must use birth control: there is no indication she would not comply.\n- Ability to provide informed consent: there is no information to suggest she cannot.\n- Subjects 61-65 years old must score 25 or higher on the MMSE: this does not apply as the patient is 26 years old.\n\nGiven the information provided, the patient seems to meet all the explicit inclusion criteria for the clinical trial. However, the patient's willingness to be admitted to an inpatient research unit is not stated and would need to be confirmed. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1853": {
        "output": "Based on the information provided:\n\nPatient note:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Symptoms include depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, restlessness, and irritability\n- Current medications include lithium carbonate and zolpidem\n\nClinical trial:\n- Title: Retrain Your Brain in Children/Adolescents With Bipolar Disorder: A Pilot Study\n- Age Criteria: 7-17 years old\n- Disorder Criteria: bipolar disorder type I preferred (at least 1 week of mania)\n\nThe patient does not meet the age inclusion criteria for the clinical trial, as the trial is specifically targeting children and adolescents aged 7-17, and the patient is 26 years old. Additionally, while the patient has a history of bipolar disorder, the clinical trial specifies a preference for bipolar disorder type I with at least 1 week of mania, and there is no indication in the patient note that this specific criterion is met. \n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1854": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 26-year-old woman\n- History of bipolar disorder\n- Experiencing depression, anxiety, agitation, sleep difficulties, and suicidal thoughts\n- Current medications: lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n1) Age 12 years, 0 months to 18 years, 11 months\n2) A diagnosis of Bipolar Disorder (BP) I, II, or NOS with an acute manic, mixed, or depressive episode in the 3 months preceding study entry\n3) Willing to engage in pharmacotherapy treatment at the CABS specialty clinic\n4) At least one parent or guardian who is willing to participate in DBT skills training\n5) English language fluency and at minimum a 3rd grade literacy level\n6) Able and willing to give informed consent/assent to participate\n\nThe patient meets several of the inclusion criteria, such as having a diagnosis of bipolar disorder, experiencing symptoms such as depression and agitation, and potentially being able and willing to give informed consent to participate. However, the patient does not meet the age criterion as she is 26 years old, which is beyond the maximum age limit of 18 years, 11 months specified in the trial inclusion criteria.\n\nBased on the age criterion alone, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1855": {
        "output": "Based on the patient note and the clinical trial provided, the 26-year-old woman with a history of bipolar disorder, recent weight and eating struggles, depression, anxiety, agitation, suicidal thoughts, restlessness, and irritability is not a nurse, which is the key inclusion criteria for the clinical trial mentioned. The clinical trial is looking to recruit nurses who work in various wards to enhance their suicide risk assessment abilities. Since the patient does not meet the primary occupation-related inclusion criteria of being a nurse, she would not be eligible to participate in this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1856": {
        "output": "",
        "label": 0
    },
    "1857": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it appears that the patient in question does not meet the criteria for participation in the specified trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. 10-17 years old\n2. At least one parent with bipolar disorder\n3. Meets clinical criteria for a specific anxiety disorder\n4. PARS -5 item scale score > 10 at screening and baseline of initial study phase\n5. Fluent in English\n6. Provision of written informed consent/assent\n7. Agrees to participate in 75% of sessions\n\nThe patient described in the note is a 26-year-old woman, which does not meet the age requirement of 10-17 years old for the trial. Additionally, there is no mention of the patient having a parent with bipolar disorder or meeting clinical criteria for a specific anxiety disorder, nor is there information on a PARS score. Therefore, the patient does not fulfill the necessary inclusion criteria for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1858": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility.\n\nPatient Note Summary:\n- 26-year-old obese woman\n- History of bipolar disorder\n- Current medications: lithium carbonate and zolpidem\n- Symptoms: depression, difficulty sleeping, anxiety, agitation, suicidal thoughts, irritability, restlessness\n\nClinical Trial Summary:\n- Title: A Comparison of Midazolam and Zolpidem as Oral Premedication in Children\n- Population: Male and female children between 2 and 9 years of age\n- Inclusion Criteria: Pediatric patients ages 2-9 years, ASA class I-II, inpatient surgeries of at least 2 hours duration, requiring postoperative admission of at least 23 hours\n- The study aims to compare the efficacy of midazolam and zolpidem in preoperative sedation in children.\n\nAssessment:\nThe patient is a 26-year-old woman, which immediately disqualifies her from participating in a clinical trial with inclusion criteria specifically targeting pediatric patients aged 2-9 years. Therefore, the patient does not meet the age requirement for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1859": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient has a history of bipolar disorder.\n- The patient is currently experiencing symptoms of depression, anxiety, and agitation, which may suggest that she is not in a euthymic state.\n- The patient is currently taking lithium carbonate, which is a mood stabilizer that fits one of the inclusion criteria for the study.\n- There is no mention of a previous suicide attempt, only thoughts of suicide.\n\nClinical Trial Inclusion Criteria Assessment:\n- The patient must be informed about the study (not mentioned in the patient note).\n- The patient must have health insurance (not mentioned in the patient note).\n- The diagnosis of bipolar disorder must be confirmed, which is consistent with the patient's history.\n- The patient must be euthymic, as determined by a psychiatric interview and scoring \u2264 7 on both the HDRS (Hamilton Depression Rating Scale) and YMRS (Young Mania Rating Scale) questionnaires.\n- The patient must be prescribed a mood stabilizer based on lithium or divalproex, which aligns with the patient's current medication (lithium carbonate).\n\nGiven that the patient appears to be experiencing an acute depressive episode, they do not meet the criteria of being euthymic, which is a requirement for the trial. Additionally, while the patient is taking lithium carbonate, there is no explicit mention of a history of suicide attempt, only thoughts of suicide, which may or may not qualify depending on the specifics of the study's definition of \"suicidal.\" Therefore, further clarification on the patient's mood state and history of suicide attempts would be necessary to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1860": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial as follows:\n\nPatient characteristics:\n- A 26-year-old woman (meets age requirement)\n- Has a history of bipolar disorder (meets diagnosis requirement)\n- Experiencing significant mental health issues, including depression, anxiety, agitation, and suicidal thoughts (potentially meets the requirement for recent suicidal ideation and/or behavior)\n- Currently on medication for bipolar disorder (the trial does not exclude those on medication)\n\nClinical trial inclusion criteria:\n- Diagnosis of Bipolar Disorder I, II, or Not Otherwise Specified (patient has a history of bipolar disorder, but the type is not specified in the note)\n- Living with or in close contact with at least one parent who is willing to participate (not mentioned in the patient note)\n- Have had at least 1 week in the prior 3 months of significant suicidal ideation and/or at least one suicidal event in the 3 months prior to study intake (patient states having thoughts of suicide, which could meet this criterion)\n- Willing to be treated pharmacologically by a psychiatrist in the CHAMP clinic (not mentioned in the patient note but seems likely given current medication)\n\nThe patient appears to have a diagnosis of bipolar disorder and recent suicidal ideations, which align with the trial's inclusion criteria. However, the patient note does not mention the type of bipolar disorder, nor does it confirm the frequency or exact nature of the suicidal ideation or events. Additionally, it does not mention whether the patient is in close contact with a parent willing to participate, or her willingness to be treated at the CHAMP clinic. Therefore, further investigation would be required to determine if the patient meets all necessary criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1861": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility of the patient:\n\nPatient Characteristics:\n- A 26-year-old woman (meets age criterion of 18 to 69 years)\n- Has a history of bipolar disorder, currently experiencing depression, difficulty sleeping, anxiety, agitation, and suicidal thoughts\n- Currently taking lithium carbonate and zolpidem for her condition\n\nClinical Trial Inclusion Criteria:\n- Age between 18 years to 69 years (patient meets this criterion)\n- Fluent in German language (language proficiency not mentioned in the patient note)\n- Provide written informed consent (assumed capable unless otherwise noted)\n- Ability to understand the explanations and instructions given by the study physician and the investigator (assumed capable unless otherwise noted)\n\nThe patient meets the age criterion and is currently taking zolpidem, which is relevant to the study. However, there is no information regarding her fluency in the German language. This is a critical criterion for inclusion, as it is necessary for communication and understanding throughout the trial. Since we cannot assume language proficiency based on the patient note, we would need additional information to determine eligibility.\n\nGiven the information provided, the patient's eligibility is uncertain due to the lack of data regarding language fluency. Therefore, I would need further investigation to confirm her understanding of German before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1862": {
        "output": "",
        "label": 0
    },
    "1863": {
        "output": "The patient in the note is a 26-year-old obese woman with a history of bipolar disorder, who is currently taking lithium carbonate and zolpidem. The clinical trial in question is evaluating the effect of lithium on men with prostate cancer.\n\nBased on the inclusion criteria provided for the clinical trial, the patient does not meet several key requirements:\n\n1. The trial is specifically for subjects with histologically confirmed local adenocarcinoma of the prostate, which the patient does not have, as she is a woman.\n\n2. The trial requires subjects who have elected to proceed with radical prostatectomy as primary curative therapy, which is a treatment for prostate cancer, not applicable to the patient.\n\n3. The study is investigating effects in men, and the patient is a woman.\n\n4. The patient has been taking lithium carbonate, which is a consideration for the trial only if the subject has not received lithium or lithium-containing medications within 90 days prior to enrollment.\n\nGiven these points, the patient does not match the gender requirement, does not have the disease being studied (prostate cancer), and does not fit the treatment criteria outlined in the inclusion criteria. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1864": {
        "output": "",
        "label": 0
    },
    "1865": {
        "output": "Given the patient note, the patient is a 26-year-old woman with a history of bipolar disorder, currently experiencing symptoms of depression, anxiety, agitation, and suicidal thoughts. She is currently on lithium carbonate, which is relevant to the clinical trial in question.\n\nThe clinical trial is investigating the efficacy and tolerability of olanzapine versus lithium in the treatment of acute depression in patients with bipolar II or bipolar disorder not otherwise specified (NOS). The inclusion criteria for the trial include:\n\n1. A major depressive episode in type 2 bipolar disorder or bipolar disorder NOS, with a MADRS score of more than 20 points.\n2. Age between 18 and 65 years.\n3. Subjects who sign the informed consent document.\n\nThe patient appears to meet the age criteria (26 years old) and has a diagnosis of bipolar disorder, which could potentially be type 2 or NOS, although this specific detail is not provided in the patient note. The patient is already being treated with lithium carbonate, which is one of the medications being studied in the trial. Furthermore, her symptoms suggest that she could be experiencing a major depressive episode, although a MADRS score is not provided in the patient note to confirm the severity.\n\nGiven the information in the patient note and the inclusion criteria of the clinical trial, the patient seems to be a potential candidate for the trial. However, further investigation is needed to determine if her bipolar disorder diagnosis aligns with bipolar II or NOS, and if her current depressive episode meets the severity requirement (MADRS score > 20 points). Additionally, her willingness to provide informed consent would need to be confirmed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1866": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial.\n\nPatient's Characteristics:\n- Age: 26 years old, which meets the age criterion of being greater than 18 and less than 65 years.\n- Diagnosis: The patient has a history of bipolar disorder, which aligns with the requirement for the diagnosis of Bipolar Disorder (BD) I or II.\n- Current state: The patient is experiencing depression, anxiety, agitation, and has had thoughts of suicide, indicating a current depressive episode.\n- Consent: There is no information provided about the patient's willingness or ability to give written informed consent, but this is typically assessed during the recruitment process.\n- Suicidal ideation: The patient has had thoughts of suicide, but there is no information on the severity as measured by the MADRS suicide item score or a history of serious suicidal ideation that required hospitalization.\n- Sensory requirements: There is no information provided about the patient's hearing and vision, but these are relatively simple criteria to assess.\n\nThe patient seems to match several of the key inclusion criteria: age, diagnosis, and current depressive episode. However, we lack specific information regarding the severity of her suicidal ideation and whether she meets the criteria of a MADRS suicide item score of > 3 or a history that required hospitalization. Furthermore, we don't have explicit confirmation of her ability to give written informed consent, nor do we have information on her hearing and vision, although these are less likely to be barriers.\n\nGiven the information at hand, the patient appears to be a potential match for the clinical trial but requires further evaluation to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1867": {
        "output": "Given the patient's note and the clinical trial information provided, we can assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- A 26-year-old obese woman with a history of bipolar disorder.\n- Current medications include lithium carbonate and zolpidem.\n- The patient is struggling with weight, depression, excessive anxiety, agitation, and suicidal thoughts.\n- The patient is fidgety and irritable.\n\nClinical trial:\n- Title: Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers.\n- Inclusion criteria include being in good general health, having a normal sleep pattern without habitual daytime napping, an Epworth Sleepiness Scale score \u2264 10, the ability to understand and provide informed consent, and the ability to follow instructions in English.\n\nAssessment:\n- The patient does not meet the inclusion criteria for being in good general health due to her bipolar disorder, depression, and thoughts of suicide.\n- The study specifically calls for \"healthy volunteers,\" which typically means the absence of psychiatric or severe medical conditions.\n- The study is also specifically being conducted in male subjects, while the patient is female.\n- The patient is currently taking zolpidem, which is one of the drugs under investigation in the study, but her health condition and gender do not align with the study requirements.\n\nBased on the patient note and the clinical trial's inclusion criteria, this patient does not meet the requirements for the trial. Therefore, the assessment of eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1868": {
        "output": "",
        "label": 0
    },
    "1869": {
        "output": "Based on the information provided, the patient is a 26-year-old obese woman with a history of bipolar disorder, who is experiencing depression, difficulty sleeping, excessive anxiety, agitation, thoughts of suicide, fidgetiness, and irritability. Her current medications include lithium carbonate and zolpidem.\n\nThe clinical trial in question is focused on the spectrum of sleep disorders in cirrhotic patients and the efficacy of zolpidem in cirrhotic patients with insomnia. The inclusion criteria for the trial are as follows:\n\n- Age 18 to 70 years\n- Clinical, Biochemical, Radiological, Histological evidence of cirrhosis of all etiology\n- Child A and B cirrhosis (for the intervention part)\n- Cirrhosis patients giving a history of persistent sleep disturbances (PSQI\u22655)\n- Child A, B, and C cirrhosis (for the observational part)\n\nThe patient described does not appear to meet the inclusion criteria for the clinical trial because there is no mention of her having cirrhosis. Additionally, the trial specifically excludes individuals with psychiatric illnesses like depression and anxiety, which the patient has (as noted by her symptoms and the fact that she is being treated with lithium carbonate for bipolar disorder).\n\nTherefore, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1870": {
        "output": "Considering the patient note and the clinical trial information provided, let's assess the patient's eligibility based on the inclusion criteria:\n\n1. **Age 18 or older**: The patient is 26 years old, which meets this criterion.\n2. **If Pregnant, equal to or less than 26 weeks**: The patient note does not mention pregnancy, so this criterion cannot be assessed.\n3. **English-speaking**: The patient note does not provide information about language, but this is typically assumed if not otherwise noted.\n4. **DSM-IV Bipolar Disorder, any subtype, Major Depressive Disorder, or Mood Disorder Not Otherwise Specified**: The patient has a history of bipolar disorder, which meets this criterion.\n5. **Able to provide informed consent**: There is no information provided that suggests the patient is unable to provide informed consent.\n6. **Daily dosing of lithium**: The patient's current medications include lithium carbonate, indicating she is on a daily dosing regimen of lithium.\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria of the clinical trial, with the exception of details regarding pregnancy which is not applicable unless she is pregnant, and English-speaking, which is assumed by default. The patient has bipolar disorder and is taking lithium carbonate daily, which matches the trial's focus on lithium therapy in individuals with mood disorders.\n\nTherefore, it seems appropriate to refer this patient to the clinical trial for further screening regarding any additional unmentioned criteria and to determine pregnancy status if relevant.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1871": {
        "output": "The patient in the note is a 26-year-old woman with a history of bipolar disorder, which is a mood disorder. She is currently experiencing depression, anxiety, agitation, and has had thoughts of suicide. She is on medications that are consistent with the treatment of mood disorders, including lithium carbonate.\n\nThe clinical trial aims to evaluate the impact of a smartphone-based platform on patients with mood disorders and has specified a range of DSM-V codes for eligibility. The patient seems to meet the following inclusion criteria for the clinical trial:\n\n1. Age 18 or older: The patient is 26 years old.\n2. Experiencing mood disorders: The patient has a history of bipolar disorder and is currently experiencing symptoms consistent with this diagnosis.\n3. Possessing a smartphone with either an Android or iOS platform: Not specified, but given the prevalence of smartphones, this could be easily determined with a follow-up question.\n4. Able to read and write in English: Not directly specified, but the fact that she is under treatment and communicates with her family about her condition may suggest she can.\n5. Have a designated primary behavioral health care provider: Not specified, but she is currently on medication, which implies she is under some form of care.\n\nThe only information not stated in the patient note is whether she has a smartphone and if her behavioral health care provider is participating in the study either through the app (intervention) or surveys on paper (control). However, these are details that could be confirmed with further investigation.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, it seems likely that the patient could be eligible for participation in the study, pending confirmation of smartphone possession and the involvement of her behavioral health care provider in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1872": {
        "output": "",
        "label": 0
    },
    "1873": {
        "output": "Patient note analysis:\n- The patient is a 26-year-old woman.\n- She has a history of bipolar disorder.\n- She is experiencing insomnia, as indicated by her difficulty sleeping.\n- She is currently taking lithium carbonate, which is a mood stabilizer for bipolar disorder.\n- There is no explicit mention of her total sleep time, but given her difficulty sleeping, it can be inferred that she may not be getting sufficient sleep.\n\nClinical trial analysis:\n- The trial is studying the efficacy of Suvorexant for treatment-resistant insomnia in individuals with bipolar disorder.\n- Inclusion criteria require a diagnosis of bipolar I, II, or not otherwise specified, with concurrent insomnia related to bipolar disorder.\n- Participants must be currently taking \u2265 1 prescription psychotropic medication for the management of bipolar disorder.\n- Participants must have a subjective total sleep time (sTST) of less than 6 hours on \u2265 1 night during the prior week.\n\nBased on the available information, the patient seems to fit the inclusion criteria for the clinical trial. She is within the appropriate age range, has a history of bipolar disorder, is experiencing insomnia, and is currently taking a psychotropic medication (lithium carbonate) for the management of her bipolar disorder. However, to definitively determine eligibility, confirmation of her specific bipolar disorder diagnosis (I, II, or not otherwise specified) and verification that her subjective total sleep time is less than 6 hours on one or more nights during the prior week would be required.\n\nSince there is no explicit confirmation of her sleep time and the specific type of bipolar disorder, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1874": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression,\" we need to compare the patient's characteristics and medical history against the inclusion criteria of the trial.\n\nThe patient in question is a 26-year-old obese woman with a history of bipolar disorder. She reports depression, anxiety, agitation, suicidal thoughts, and sleep difficulties. She is currently on medication, which includes lithium carbonate (commonly prescribed for bipolar disorder) and zolpidem (typically prescribed for sleep disturbances).\n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. Provision of written informed consent - The patient note does not mention her willingness, but this is presumably obtainable if she agrees to participate.\n2. [MDD stream only] Diagnosis of major depressive disorder, currently depressed - Not applicable as the patient has bipolar disorder.\n3. [BD stream only] Diagnosis of bipolar disorder, type I or II, currently depressed as determined by DSM-IV diagnostic criteria - The patient has a history of bipolar disorder and is currently experiencing symptoms of depression, which meets this criterion.\n4. Both females and males, aged 18 to 65 years - The patient is 26 years old, which meets this criterion.\n5. Inpatient status - The patient note does not specify if she is an inpatient, so this requires further investigation.\n6. Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active - The patient's childbearing status and willingness to take birth control if sexually active need to be confirmed.\n7. The ability to understand and comply with the requirements of the study and capable of providing informed consent - Assuming the patient's mental state allows for this, she could potentially meet this criterion.\n8. Suffering from suicidal ideation/attempts as evidenced by a score of >0 on either of the SSI or CSSRS or both - The patient reports thoughts of suicide, which suggests she meets this criterion.\n\nBased on the information provided, the patient appears to meet several of the inclusion criteria: diagnosis of bipolar disorder type I or II currently depressed, age, and experiencing suicidal ideation. However, there are some details that need further investigation, such as her inpatient status and confirmation of a negative pregnancy test and birth control use if applicable.\n\nGiven the information provided and pending confirmation of the additional details, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1875": {
        "output": "Given the patient note, the patient is a 26-year-old woman with a history of bipolar disorder, which is clearly stated in the clinical trial inclusion criteria. She is currently experiencing depressive symptoms, anxiety, agitation, and suicidal thoughts, which are relevant to the study's focus on suicidality in patients with bipolar disorder. Additionally, she is on medication for bipolar disorder (lithium carbonate), which supports the diagnosis.\n\nThe clinical trial aims to identify treatments to reduce suicidal behavior and improve the quality of life in patients with bipolar disorder through a group-based intervention program. The patient's struggles with depression and suicidal thoughts would make her a relevant participant for the trial's objectives.\n\nThe inclusion criteria for the trial are:\n1. English speaking\n2. Diagnosis of Bipolar Disorder (BD)\n3. Able to provide written informed consent\n\nThe patient note does not mention the patient's language abilities, but given the absence of any indication otherwise, it is reasonable to assume that she is English speaking. She has a diagnosis of bipolar disorder and is currently being treated for it, which meets the second criterion. As for the third criterion, there is nothing in the patient note to suggest that she would be unable to provide written informed consent.\n\nTherefore, the patient appears to meet all the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1876": {
        "output": "To assess the patient's trial-level eligibility for the \"Pharmacokinetics of Zolpidem Orodispersible Tablet\" clinical trial, we need to evaluate the patient's characteristics against the trial's inclusion criteria:\n\nPatient Characteristics:\n- Age: 26 years old\n- Sex: Female\n- BMI: Obese (exact BMI not provided)\n- Current medical conditions: Bipolar disorder, depression, anxiety, difficulty sleeping, thoughts of suicide, agitation, irritability\n- Current medications: Lithium carbonate and zolpidem\n\nClinical Trial Inclusion Criteria:\n- Male or female participants, aged above 18 years old; women cannot be pregnant or breastfeeding\n- BMI greater than or equal to 19 and less than or equal to 28.75 Kg/m2\n- Good health conditions or without significant diseases, according to the best medical judgment, including medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG), and complementary laboratory tests\n- Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature\n\nAssessment:\n- The patient is above 18 years old, which meets the age requirement.\n- The patient is currently taking zolpidem, which is the investigational product in the trial.\n- The patient is female and there is no indication that she is pregnant or breastfeeding.\n- The patient is described as obese, which may imply a BMI higher than the specified maximum of 28.75 Kg/m2 for the trial.\n- The patient has several significant health issues including bipolar disorder, depression, anxiety, and suicidal thoughts, which do not align with the requirement of being in \"good health conditions or without significant diseases.\"\n\nGiven the information provided, the patient's obesity (with an implied BMI above the inclusion criteria) and significant mental health conditions suggest that she would not meet the health requirements of the trial. Therefore, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1877": {
        "output": "In comparing the patient's characteristics with the clinical trial's inclusion criteria, we must consider the following:\n\nPatient's Characteristics:\n- 62-year-old man\n- Progressive memory loss and jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial Inclusion Criteria:\n- HIV-positive status\n- At least 18 years old\n- Symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control\n- On stable anti-HIV drug therapy for the past 6 weeks if taking anti-HIV drugs\n\nThe patient note indicates a 62-year-old man with severe cognitive deficits, which could align with the symptoms of AIDS dementia required for the clinical trial. However, there is no mention of the patient's HIV status, which is a critical inclusion criterion for the trial. Since the trial is specific to HIV-infected patients with AIDS dementia, and there is no information provided about the patient's HIV status, we cannot assume the patient meets the inclusion criterion regarding HIV status.\n\nTherefore, without confirmation of the patient's HIV-positive status, it would not be appropriate to refer this patient for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1878": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the information:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss and jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy\n- Cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial Inclusion Criteria:\n- Men aged 18 and over\n- With motor neuron disease, i.e.:\n  - X-linked spinal and bulbar muscular atrophy (Kennedy's disease)\n  - Confirmed by androgen receptor, exon-1 mutation genotype\n  - Amyotrophic lateral sclerosis\n  - Spinal muscular atrophy\n- Significant muscle weakness on manual muscle testing\n- No prisoners\n- No mental disability\n\nThe patient presents with progressive memory loss, cognitive deficits, and jerking movements of the lower extremities. The EEG and neuroimaging findings, along with the cortical biopsy, suggest a neurological disorder, but there is no clear diagnosis of a motor neuron disease such as Kennedy's disease, ALS, or spinal muscular atrophy in the patient note. Additionally, the patient is showing signs of severe cognitive deficits, which could be interpreted as a mental disability, thus potentially excluding him from the trial based on one of the non-eligibility criteria.\n\nGiven the information, the patient does not clearly fit the inclusion criteria which specify motor neuron diseases and significant muscle weakness confirmed by manual muscle testing. Moreover, the presence of severe cognitive deficits might disqualify the patient due to the 'no mental disability' criterion.\n\nTherefore, the patient does not appear to meet the criteria for the clinical trial on motor neuron diseases.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1879": {
        "output": "The patient in question is a 62-year-old man with a neurologic condition characterized by progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The cause of his symptoms appears to be a neurodegenerative process, as indicated by the cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration. The neuroimaging studies also show moderately advanced cerebral atrophy. \n\nThe clinical trial in question is focused on investigating brain anatomy in patients with focal hand dystonia using high-resolution MRI. The inclusion criteria for patients are those with primary focal hand dystonia and for healthy volunteers, individuals who are matched for age, sex, handedness with the group of patients with primary focal hand dystonia. \n\nGiven the patient's conditions and the exclusion criteria of the trial that exclude participants with cognitive complaints, abnormal neurological exam or history of past neurological disease, and the presence of a second neurological disease or condition, this patient would not be eligible for the study. The patient's neurodegenerative disease with cognitive deficits would disqualify him from participation as a healthy volunteer or as a patient with primary focal hand dystonia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1880": {
        "output": "The patient described in the note is a 62-year-old man with severe cognitive deficits and memory dysfunction, with neuroimaging showing cerebral atrophy and a cortical biopsy revealing diffuse vacuolar changes of the gray matter with reactive astrocytosis. The patient does not have a diagnosis of Parkinson's disease (PD); instead, the symptoms and findings suggest a different neurodegenerative condition, which could be consistent with a prion disease like Creutzfeldt-Jakob disease due to the presence of periodic sharp waves on EEG and the described biopsy findings.\n\nThe clinical trial in question is focused on patients with Parkinson's disease and is investigating the effects of dopamine-loss and dopamine-restoring medicines on movement performance. The inclusion criteria specify that the trial is looking for PD patients who have a stable clinical response to L-DOPA and DAergic agents, with early or mild-to-moderate PD as defined by a score of less than 3 on the Hoehn & Yahr scale. Additionally, the trial seeks non-demented, non-depressed patients with primarily akineto-rigid parkinsonian symptoms and signs, and a mild or moderate tremor at most.\n\nGiven that the patient in the note does not have a diagnosis of Parkinson's disease, and instead has a neurodegenerative condition that is not PD, he does not meet the inclusion criteria for this clinical trial. Furthermore, the patient has severe cognitive deficits, which would likely exclude him from the trial based on the exclusion criteria regarding cognitive impairment.\n\nTherefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1881": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Direct Current Brain Polarization in Frontotemporal Dementia,\" we will compare the patient note to the inclusion and exclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 62-year-old man, which falls within the age range of 35 to 75 years specified in the inclusion criteria.\n- The patient has been diagnosed with severe cognitive deficits and memory dysfunction, which are consistent with frontotemporal dementia (FTD).\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration, which supports the diagnosis of a neurodegenerative condition like FTD.\n\nClinical Trial Inclusion Criteria:\n- Patients between 35 and 75 years of age with frontotemporal dementia.\n- Clinical diagnosis of FTD confirmed by neurological examination.\n- Six patients referred to the Cognitive Neuroscience Section, NINDS.\n\nClinical Trial Exclusion Criteria:\n- Greater than 75 years of age.\n- Presence of metal in the head other than dental hardware.\n- Broken skin in the area of the stimulating electrodes.\n- Any behavioral disorder that makes testing impossible.\n- Children are excluded, as FTD is not a childhood illness.\n\nAssessment:\n- The patient is within the age range required.\n- The patient has a diagnosis consistent with FTD, which is the target condition for the trial.\n- There is no indication of metal in the head, broken skin in the stimulation area, or behavioral disorders that would impede testing, as mentioned in the exclusion criteria.\n- We would need to confirm that the patient was referred to the Cognitive Neuroscience Section, NINDS, to fully meet the inclusion criteria, which is not stated in the patient note.\n\nBased on the information provided, the patient seems to meet the age and diagnosis criteria for the study. However, the patient's eligibility is contingent upon a referral to the Cognitive Neuroscience Section, NINDS, and confirmation of the diagnosis by the study team. Therefore, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1882": {
        "output": "Based on the patient note, the 62-year-old man presents with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves, and neuroimaging studies demonstrate moderately advanced cerebral atrophy. The cortical biopsy revealing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration is indicative of a prion disease.\n\nThe clinical trial in question is PRION-1, which is looking to assess the activity and safety of Quinacrine in human prion disease. The inclusion criteria for this trial are simply being aged 12 years or more and diagnosed with any type of human prion disease.\n\nThe patient's symptoms, alongside the EEG findings, neuroimaging, and histopathological findings from the cortical biopsy, are consistent with a prion disease, which would make him a candidate for the PRION-1 trial. Since the only inclusion criteria are age over 12 and a diagnosis of human prion disease, and the patient's presentation fits within these criteria, he would be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1883": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of the lower extremities\n- Severe cognitive deficits\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy\n- Diffuse vacuolar changes of the gray matter with reactive astrocytosis on cortical biopsy\n\nClinical Trial:\n- Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms\n- Conducted in North America\n- Aim: To determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis\n- Inclusion Criteria: Postmenopausal women whose last menstruation was at least two years previously\n\nThe patient in question is a 62-year-old man, which does not meet the inclusion criteria of the clinical trial that specifies postmenopausal women. Therefore, this patient would not be eligible for the trial based on gender and the specific condition under study (postmenopausal atrophic vaginitis).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1884": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria given, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- 62-year-old man\n- Progressive memory loss and jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial Inclusion Criteria Summary:\n- B-cell Lymphoma CD 20 positive: Mantle cell, Marginal zone, lymphocytic, follicular requiring treatment, or histological transformation from low grade to high grade, or diffuse large cell without adverse prognostic factors defined by the IPI\n- Aged from 18 to 80 years\n- Untreated with chemotherapy except with Chlorambucil or Cyclophosphamide per os alone less than 6 months\n- Previous radiotherapy allowed if localized\n- Performance status < 3\n- Signed informed consent\n\nThe patient's condition, as described in the note, does not mention B-cell lymphoma or any form of cancer. The patient has severe cognitive deficits, memory dysfunction, and neurological symptoms, but these do not align with the inclusion criteria for a B-cell lymphoma trial. The trial is specifically for patients with a diagnosis of certain types of B-cell lymphoma, which the patient does not appear to have.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial specified.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1885": {
        "output": "Based on the provided patient note and the inclusion criteria for the PRIME Study, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 62-year-old man with progressive memory loss and jerking movements of the lower extremities.\n- Neurologic examination confirms severe cognitive deficits and memory dysfunction.\n- An electroencephalogram shows generalized periodic sharp waves.\n- Neuroimaging studies show moderately advanced cerebral atrophy.\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of dementia under the DSM-IV criteria, or of Mild Cognitive Impairment, using the Peterson Criteria\n- Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week)\n- Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy\n- Availability of a caregiver willing to provide consent for required components of the study\n- Fluent in English\n- May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia\n\nAssessment:\n- The patient shows severe cognitive deficits and memory dysfunction, which could potentially meet the DSM-IV criteria for dementia.\n- The patient note does not specify the living situation of the patient, but there is no indication that the patient would not meet this criterion.\n- It is not clear if the patient can provide written informed consent due to severe cognitive deficits, but a legal guardian/proxy could potentially do so.\n- The patient note does not mention the availability of a caregiver, but this could be confirmed with further investigation.\n- The patient note does not specify if the patient is fluent in English.\n- There is no information provided about the patient's participation in any other clinical trials, such as a Phase IV study.\n\nGiven the potential diagnosis of dementia and the severity of cognitive deficits observed, it is possible that the patient could meet the diagnostic criteria required for the PRIME Study. However, since there is insufficient information on certain aspects, such as the patient's living situation, caregiver availability, language fluency, and informed consent capability, further investigation would be necessary to determine if all inclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1886": {
        "output": "Based on the provided patient note and the clinical trial's inclusion and exclusion criteria, we need to determine if the patient is eligible for the trial. Let's examine the patient's information and the trial criteria:\n\nPatient note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- EEG shows generalized periodic sharp waves\n- Neuroimaging shows moderately advanced cerebral atrophy\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis\n\nClinical trial inclusion criteria for patients with dementia:\n- Clinical diagnosis of AD (Alzheimer's Disease) or mild cognitive impairment\n- Primary language German\n\nExclusion criteria for the clinical trial:\n- Allergies to levodopa or tetrazine\n- History of medication/drug abuse\n- Acute nicotine withdrawal or heavy smoking\n- Heavy caffeine or alcohol consumption\n- Severe hypertension or arteriosclerosis\n- Diabetes, asthma, or glaucoma\n- Severe hearing disability\n- No focal brain lesions\n- Premorbid depression or psychosis\n- Medication with dopamine agonists or antagonists\n- Parkinsonian symptoms\n\nThe patient's note does not provide information on language proficiency, history of allergies, substance abuse, or other medical conditions that are part of the exclusion criteria. However, the patient does show signs of memory dysfunction and cognitive deficits, which could fit the diagnosis of dementia or mild cognitive impairment. The trial specifically looks at levodopa's effect on learning and memory in patients with dementia or mild cognitive impairment, which seems relevant to the patient's condition.\n\nThe details provided in the patient note do not explicitly diagnose the patient with Alzheimer's Disease or mild cognitive impairment, but the symptoms described (progressive memory loss, severe cognitive deficits) suggest the patient could potentially have one of these conditions. \n\nGiven the information provided, the patient may be a potential candidate for the trial if further investigation confirms a clinical diagnosis of AD or mild cognitive impairment. Additionally, we would need to ensure the patient meets all other inclusion and exclusion criteria, including language proficiency and no history of the listed exclusions.\n\nTherefore, I would consider the patient for this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1887": {
        "output": "",
        "label": 1
    },
    "1888": {
        "output": "",
        "label": 0
    },
    "1889": {
        "output": "",
        "label": 0
    },
    "1890": {
        "output": "The patient described in the note is a 62-year-old man with progressive memory loss and jerking movements of the lower extremities. Neurological examination confirms severe cognitive deficits and memory dysfunction, and a biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration. The diagnosis and presentation do not mention a stroke, but rather suggest a neurodegenerative process, which could be something like Creutzfeldt-Jakob disease given the EEG findings and the biopsy results.\n\nThe clinical trial in question is seeking participants who are 18 years of age or older who have had subacute thromboembolic or hemorrhagic stroke more than 3 months before enrolling. The trial is focused on brain reorganization after a stroke and requires participants to have impaired motor function in at least one limb but still be capable of performing certain motor tasks.\n\nThe patient described does not fit the inclusion criteria for several reasons:\n1. The patient's condition is not specified as a subacute thromboembolic or hemorrhagic stroke.\n2. The patient has severe cognitive deficits, which could be considered serious cognitive deficits as per the trial's exclusion criteria (equivalent to a mini-mental state exam score of 23 or less).\n3. There is no information indicating that the patient has impaired motor function due to a stroke or that he is capable of performing the required motor tasks for the trial.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the trial and meets at least one exclusion criterion (serious cognitive deficits). Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1891": {
        "output": "The patient being considered for the clinical trial is a 62-year-old man presenting with progressive memory loss and jerking movements of the lower extremities, severe cognitive deficits and memory dysfunction, generalized periodic sharp waves on EEG, moderately advanced cerebral atrophy on neuroimaging, and diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration on cortical biopsy.\n\nThe clinical trial in question is investigating cognitive impairment in Parkinson's disease (PD) and is looking to categorize these impairments according to motor symptoms and disease severity. The inclusion criteria for the trial are as follows:\n\n1. Idiopathic Parkinson's in accordance to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria\n2. Born and raised in Denmark\n3. Age over 50 years\n\nBased on the patient's note, there is no indication that the patient has been diagnosed with idiopathic Parkinson's disease. The symptoms described (progressive memory loss, jerking movements, severe cognitive deficits) could be associated with several neurological conditions, but without a specific diagnosis of Parkinson's disease, we cannot assume the patient fits the first inclusion criterion.\n\nFurthermore, there is no information provided regarding the patient's place of birth or upbringing, so we cannot determine eligibility based on the second criterion.\n\nThe patient does meet the age requirement, as he is 62 years old.\n\nGiven the lack of information confirming a diagnosis of idiopathic Parkinson's disease and the absence of data about the patient's place of birth and upbringing, we cannot consider the patient eligible for the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1892": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial:\n- Title: Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan\n- Focus: Childhood Acute Lymphoblastic Leukemia (ALL)\n- Inclusion Criteria: Patients with ALL, healthy individuals for control/comparison group\n\nThe clinical trial is focused on Childhood Acute Lymphoblastic Leukemia (ALL) and is seeking to establish better risk classifications and treatment responses for this specific disease. The patient described in the note is suffering from neurological issues with severe cognitive deficits, which are unrelated to ALL. As the patient does not have a diagnosis of ALL, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1893": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess whether the patient is eligible for the Women's Health Initiative Study of Cognitive Aging (WHISCA):\n\nPatient Note Analysis:\n- The patient is a 62-year-old man.\n- He has progressive memory loss and jerking movements of the lower extremities.\n- Severe cognitive deficits and memory dysfunction are confirmed.\n- Neuroimaging studies show cerebral atrophy.\n- A cortical biopsy shows changes consistent with a neurodegenerative condition.\n\nClinical Trial Inclusion Criteria:\n- Enrolled in WHIMS (Women's Health Initiative Memory Study).\n- At least 65 years old.\n- Not diagnosed with dementia.\n\nAssessment:\n- The patient is a man, whereas the clinical trial is focused on postmenopausal hormone therapy, which would only be applicable to women.\n- The patient is 62 years old, which is younger than the minimum age of 65 required for the trial.\n- The patient appears to have a neurodegenerative condition with severe cognitive deficits, which could be indicative of dementia, although not explicitly diagnosed. This might or might not meet the criteria of \"Not diagnosed with dementia,\" depending on whether the clinical trial would consider severe cognitive deficits as a form of dementia.\n\nGiven the gender and age criteria, the patient does not meet the key inclusion criteria for the clinical trial. The additional details about his neurodegenerative condition would not change this assessment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1894": {
        "output": "In this scenario, the patient described in the note is experiencing progressive memory loss and jerking movements of the lower extremities, with neurologic examination confirming severe cognitive deficits and memory dysfunction. The diagnosis is not clearly stated, but the symptoms and biopsy results suggesting diffuse vacuolar changes with reactive astrocytosis could be indicative of a prion disease like Creutzfeldt-Jakob disease or another neurodegenerative condition.\n\nThe clinical trial in question is specifically targeting ALS (Amyotrophic Lateral Sclerosis) patients to assess their satisfaction with hospital rooms equipped with assistive technology. The inclusion criteria for the trial are quite clear: patients must have probable or definite ALS and be between the ages of 18 and 90, staying on the neurology floor of Hahnemann Hospital.\n\nGiven the information provided, there is no indication that the patient described has ALS. Therefore, based on the available data, the patient does not meet the inclusion criteria for the ALS patient satisfaction survey clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1895": {
        "output": "Based on the provided patient note and clinical trial information, the patient is a 62-year-old man with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The patient's neuroimaging studies show moderately advanced cerebral atrophy, and a cortical biopsy reveals diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nThe clinical trial is focused on individuals with Amyotrophic Lateral Sclerosis (ALS) and aims to investigate the feasibility of using EEG-based Brain-Computer Interface (BCI) technology as a communication solution for individuals with ALS who have lost muscle control and face severe communication impairments.\n\nThe inclusion criteria for the medical subjects in the clinical trial are:\n- Be able to give consent themselves or via a legally authorized representative.\n- Diagnosed with a neuromuscular disease and have limited ability to communicate.\n- Be able to see visual cues such as targets or letters presented on the screen and/or ability to hear auditory cues.\n- Be able to understand and remember instructions concerning participation.\n\nThe patient in question does not have a diagnosis of ALS or a similar neuromuscular disease. Instead, the patient's symptoms and biopsy results are suggestive of a neurodegenerative condition that is not ALS. Since the trial specifically requires participants to have been diagnosed with a neuromuscular disease like ALS, this patient would not meet the inclusion criteria based on the current information provided.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1896": {
        "output": "Upon reviewing the patient note and the clinical trial criteria, it is clear that the patient does not meet the specific inclusion criteria of the clinical trial. The patient is described as having progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The electroencephalogram and neuroimaging findings, along with the biopsy results, do not suggest a spinal cord injury, which is a requirement for the clinical trial.\n\nThe clinical trial is specifically looking for participants with an incomplete C6 ASIA C (Central Cord) spinal cord injury, significant spasticity as measured by the Ashworth scale, the ability to ambulate with minimal assistance, and intact cognitive abilities. The patient note does not mention a spinal cord injury, nor does it describe the patient's spasticity level, mobility, or cognitive abilities in relation to the requirements of the trial.\n\nGiven the information provided, the patient does not seem to align with the inclusion criteria of the trial, particularly the requirement for a specific type of spinal cord injury and the associated conditions such as spasticity and limited mobility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1897": {
        "output": "To assess the eligibility of the patient for participation in the clinical trial titled \"A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,\" we must compare the patient's characteristics and condition with the inclusion criteria specified by the trial.\n\nPatient Characteristics:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Diffuse vacuolar changes of the gray matter with reactive astrocytosis on cortical biopsy\n\nClinical Trial Inclusion Criteria:\n- Veteran with El Escorial Lab Supported Probable or more definite diagnosis of ALS\n- Lost the ability to communicate either verbally or in writing (ALSFRS-R score of 0 for item 1 or item 4)\n- Adult (age >18)\n- Living at home\n- Living within 100 miles of the participating study site\n- Corrected visual acuity of at least 20/80\n- Ability to read and understand 6th grade English text on a computer screen\n- Able to indicate willingness and understanding of the consent form\n- Able to identify one significant other\n- Able to communicate non-verbally\n- Significant other, caregiver, and system operator willing to participate and be involved for at least one year\n- Life expectancy of at least one year\n- Home environment conducive to BCI operation\n- Demonstrate sufficient EEG interaction for BCI operation (classification rate of 70%)\n- Significant other, caregiver, and system operator able to manage the BCI\n\nThe patient's condition (progressive memory loss, jerking movements, severe cognitive deficits, and EEG findings) does not match the specific diagnosis required for the trial, which is amyotrophic lateral sclerosis (ALS). Furthermore, there is no mention of the patient being a veteran or having ALS. The patient's diagnosis seems to be different (likely a prion disease given the cortical biopsy findings), and therefore, he does not meet the primary diagnosis criterion for inclusion in the trial.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial because they do not have an ALS diagnosis, which is a critical criterion for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1898": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to be eligible for the trial. The patient note describes a 62-year-old man with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The diagnostic tests have shown generalized periodic sharp waves on an electroencephalogram and diffuse vacuolar changes of the gray matter with reactive astrocytosis on a cortical biopsy. The description is more consistent with a neurodegenerative process rather than Multiple Sclerosis (MS).\n\nThe clinical trial is specifically looking to include patients with established Secondary Progressive Multiple Sclerosis (SPMS) according to the McDonald criteria. Since the patient in the note does not have a diagnosis of Multiple Sclerosis, but rather symptoms suggestive of a different neurological disease, he does not meet the inclusion criteria for this Multiple Sclerosis-focused study.\n\nTherefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1899": {
        "output": "Based on the given patient note and the clinical trial information provided:\n\nPatient note:\n- 62-year-old man\n- Progressive memory loss and jerking movements\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis\n- No mention of atrophic vaginitis or any related symptoms\n\nClinical trial:\n- Evaluating efficacy of low dose vaginal estrogens in the treatment of atrophic vaginitis\n- Inclusion criteria include postmenopausal women, symptoms of atrophic vaginitis, and discontinuation of hormone therapy for at least 3 months\n\nThe patient is a 62-year-old man, which does not meet the inclusion criteria of being a postmenopausal woman. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1900": {
        "output": "Given the information provided:\n\nPatient note:\n- 62-year-old man with progressive memory loss and jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Electroencephalogram shows generalized periodic sharp waves\n- Neuroimaging studies show moderately advanced cerebral atrophy\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical trial:\n- Title: Gore Tex Implants in the Treatment of Atrophic Rhinitis\n- Study involving patients with atrophic rhinitis who underwent Gore Tex\u00ae implants in the nasal fossa\n- Inclusion criteria: Symptoms of atrophic rhinitis, with previous clinical treatment without good results\n\nThe patient's symptoms and diagnosis do not match the target condition for the clinical trial. The patient is seeing a neurologist for progressive memory loss and jerking movements, which are neurological issues, not atrophic rhinitis. The clinical trial seeks to include patients with atrophic rhinitis, a condition that affects the nasal passages and is not related to the patient's neurological symptoms.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial on Gore Tex Implants in the Treatment of Atrophic Rhinitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1901": {
        "output": "The patient in the note is a 62-year-old man who presents with progressive memory loss and jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The clinical trial in question is focused on identifying genes that predict recurrence in women with breast cancer treated with chemotherapy.\n\nBased on the provided inclusion criteria for the clinical trial, the patient must:\n\n- Have a diagnosis of breast cancer\n- Be node positive OR have high-risk node negative disease\n- Have a tumor > 1.0 cm in diameter\n- Not have locally advanced, inflammatory, or metastatic breast cancer\n- Have been previously treated with 4 courses of anthracycline-containing chemotherapy\n- Be enrolled on clinical trial ECOG-E2197\n- Have adequate tumor material available in ECOG Pathology Coordination Center\n- Have previously consented to future cancer-related research\n- Have known hormone receptor status\n- Be female\n\nThe patient from the note does not meet several of the key inclusion criteria:\n\n- The patient is male.\n- There is no mention of breast cancer; instead, the patient has neurologic issues.\n- There is no mention of the patient having been previously treated with chemotherapy, or being involved in the specific clinical trial ECOG-E2197.\n- There is no information provided regarding hormone receptor status or tumor size.\n\nGiven these discrepancies, the patient does not qualify for the breast cancer-related clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1902": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, the patient appears to be a potential candidate for the clinical trial. The patient note indicates the presence of neurologic symptoms, specifically severe cognitive deficits, memory dysfunction, and jerking movements of the lower extremities. The electroencephalogram (EEG) shows generalized periodic sharp waves, and neuroimaging studies show cerebral atrophy, which are findings that could be associated with general paresis.\n\nThe clinical trial is focused on the clinical and neuroimaging findings in general paresis, and the inclusion criteria simply state \"EEG MR.\" It seems that the clinical trial requires EEG and MR (presumably magnetic resonance imaging) findings as part of the inclusion criteria. Since the patient has had both an EEG with notable findings and neuroimaging studies showing cerebral atrophy, it is likely that he meets the criteria specified for the trial.\n\nHowever, the inclusion criteria provided are not detailed and do not specify the exact EEG and MR findings required, nor do they specify additional clinical characteristics or diagnostic criteria needed to qualify for the study. There may be more specific inclusion criteria not listed that could affect the patient's eligibility.\n\nGiven the information provided and the potential alignment with the inclusion criteria, the patient could be considered for referral to the clinical trial. However, further investigation would be necessary to clarify the exact EEG and MR findings required, as well as to obtain more detailed patient history and diagnostic information to ensure a proper match.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1903": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 62-year-old man\n- Progressive memory loss\n- Jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial:\n- Title: Quantitative Automated Lesion Detection of Traumatic Brain Injury\n- Inclusion Criteria: Control subjects from 18-50. Patients from 18-50 who have suffered TBI.\n\nThe patient described in the note is 62 years old, which is outside the specified age range for both control subjects and patients (18-50 years) in the clinical trial. Additionally, the patient's symptoms and diagnosis do not indicate a history of traumatic brain injury (TBI), which is the focus of the clinical trial.\n\nGiven these points, the patient would not meet the inclusion criteria for the clinical trial based on age and diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1904": {
        "output": "Based on the patient note provided:\n\n- The patient is a 62-year-old man with severe cognitive deficits, memory dysfunction, and jerking movements of the lower extremities. Neurological examination and diagnostic tests suggest a neurodegenerative disorder, with no mention of blood-borne diseases or a history of blood donation.\n\nThe inclusion criteria for the clinical trial are:\n\n- Deferred blood donor status due to a positive result of a routine blood test for HIV, hepatitis B, hepatitis C, HTLV, or having been identified as at risk of vCJD.\n- Deferral occurred in 2008 or 2009 (2007 for the pilot; 2005 for those at risk of vCJD).\n- Donor registered at one of the NHSBT centers (English Blood Service in England and Wales).\n\nBased on the available information, the patient does not meet any of the specific inclusion criteria for the clinical trial. The patient's condition and medical history do not indicate deferral from blood donation due to a positive test for any blood-borne diseases or being at risk of vCJD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1905": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, it appears that the patient does not meet the eligibility requirements for the clinical trial. The trial is aimed at women with a history of breast cancer who are currently taking an aromatase inhibitor and suffering from symptoms of atrophic vaginitis. The patient described in the note is a 62-year-old man with progressive memory loss and neurologic issues, which have no relevance to the trial's focus on atrophic vaginitis in women with breast cancer.\n\nTherefore, this patient would not be eligible for the trial based on gender, medical condition, and treatment history as specified in the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1906": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's analyze whether the patient could be eligible for the trial.\n\nPatient Note Analysis:\n- The patient is a 62-year-old man.\n- Presenting with progressive memory loss and jerking movements of the lower extremities.\n- Neurologic examination confirms severe cognitive deficits and memory dysfunction.\n- An electroencephalogram shows generalized periodic sharp waves.\n- Neuroimaging studies show moderately advanced cerebral atrophy.\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on patients with septic shock and includes a detailed list of criteria related to hemodynamic insufficiency, temperature, heart rate, respiratory rate, leukocyte count, kidney function, consciousness, clotting, skin perfusion, oxygenation, and lactate levels.\n- Specifically, it is looking for patients who have septic shock, which is characterized by a set of clinical signs as detailed in the inclusion criteria.\n\nComparison:\n- The patient's clinical presentation does not indicate septic shock or any of the specific symptoms or lab values listed in the inclusion criteria for the clinical trial.\n- The patient is being seen for neurological issues, not for symptoms or conditions related to septic shock.\n\nConclusion:\nThe patient described in the note does not meet the inclusion criteria for the clinical trial on septic shock. The patient's condition is neurological in nature and does not align with the clinical features of septic shock as specified in the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1907": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note Summary:\n- 62-year-old man\n- Progressive memory loss and jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Diffuse vacuolar changes of the gray matter with reactive astrocytosis on cortical biopsy\n- No mention of Parkinson's Disease (PD)\n\nClinical Trial Summary:\n- Study on the effects of Vitamin B6, B12, Folic Acid, and exercise in Parkinson's Disease (PD)\n- Outcome variables related to PD symptoms and quality of life\n- Inclusion Criteria: \n  - Medical clearance to perform an exercise tolerance test and training program.\n  - A diagnosis of PD at stage 2 on the Hoehn and Yahr scale.\n\nBased on the information provided, the patient does not have a diagnosis of Parkinson's Disease (PD) as required by the clinical trial's inclusion criteria. Instead, the patient's symptoms and diagnostic findings suggest a different neurologic condition (not specified as PD).\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires a diagnosis of Parkinson's Disease at stage 2 on the Hoehn and Yahr scale.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1908": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial for Alzheimer's Disease and Related Disorders, here is the assessment:\n\nPatient note assessment:\n- The patient is a 62-year-old man with progressive memory loss and jerking movements of the lower extremities, which suggests a neurodegenerative disorder.\n- Neurologic examination confirms severe cognitive deficits and memory dysfunction, which might align with dementia-related symptoms.\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration, which does not clearly diagnose Alzheimer's disease but indicates a neurodegenerative process.\n\nClinical trial inclusion criteria assessment:\n- The trial is for elderly patients at the University Memory Center of Angers University Hospital, with no specific age range given beyond \"elderly.\"\n- Patients must be able to walk without any walking aid on 15 meters. The patient note does not specify any walking impairment.\n- A Mini-Mental Status Examination score > 10 is required. The patient's MMSE score is not mentioned in the patient note provided.\n- Patients must be affiliated with a social security regime, which is not mentioned in the patient note.\n\nGiven the information provided, the patient does show signs of a neurodegenerative disorder that could be related to Alzheimer's disease or a related disorder, which is the focus of the study. However, there are missing details that are necessary to confirm eligibility, such as the MMSE score and the patient's affiliation to a social security regime. Additionally, it is not specified if the patient is a patient at the University Memory Center of Angers University Hospital.\n\nTherefore, based on the available information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1909": {
        "output": "",
        "label": 0
    },
    "1910": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Diffuse vacuolar changes of the gray matter with reactive astrocytosis (cortical biopsy)\n\nClinical Trial:\n- Title: Special Drug Use Investigation for Botox\u00ae (Botulinum) Spasticity\n- Objective: Collect safety, efficacy, and usage data on botulinum injection for upper or lower limb spasticity\n- Inclusion Criteria:\n  - Subjects with upper or lower limb spasticity\n  - Subjects must use botulinum injection for the first time\n\nThe patient's symptoms include jerking movements of the lower extremities, which could be consistent with some form of spasticity. However, the patient's primary diagnosis appears to be related to cognitive deficits and memory dysfunction, and there is no clear mention of a diagnosis of spasticity. Additionally, the patient's jerking movements could be myoclonus rather than spasticity, which is a different neurological condition.\n\nGiven that the patient's primary issues seem to be cognitive rather than motor-based spasticity and there is no clear indication that the patient has been diagnosed with spasticity that requires treatment with botulinum toxin, it is unlikely that this patient would meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1911": {
        "output": "",
        "label": 0
    },
    "1912": {
        "output": "",
        "label": 0
    },
    "1913": {
        "output": "",
        "label": 0
    },
    "1914": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 62-year-old man presenting with progressive memory loss and jerking movements of the lower extremities, with neurologic examination confirming severe cognitive deficits and memory dysfunction. The patient's condition is further supported by an EEG showing generalized periodic sharp waves, neuroimaging showing moderately advanced cerebral atrophy, and a cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis.\n\nThe clinical trial in question is focused on mild cognitive impairment in individuals with Parkinson's disease and is investigating the potential benefits of the Exelon (rivastigmine) Patch, which is FDA-approved for the treatment of mild to moderate dementia in Alzheimer's and Parkinson's disease patients.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Participants must be experiencing symptoms of mild cognitive impairment.\n2. Participants must be on a stable medication regimen for 2 months prior to starting the study.\n3. Participants are capable of giving informed consent supported by not meeting Parkinson's disease Dementia criteria.\n\nThe patient described in the note does exhibit cognitive deficits and memory dysfunction; however, there is no mention of Parkinson's disease or symptoms typically associated with it. Instead, the patient has symptoms that could suggest another neurological condition. Therefore, the patient does not meet the specific inclusion criteria related to Parkinson's disease diagnosis required for the trial.\n\nConsidering this information, the patient does not seem to be a good candidate for the clinical trial focused on mild cognitive impairment in Parkinson's disease as the patient's symptoms and diagnosis do not align with the specific population being studied (those with Parkinson's disease).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1915": {
        "output": "",
        "label": 0
    },
    "1916": {
        "output": "Based on the patient note provided, the 62-year-old man is seeing a neurologist for progressive memory loss and jerking movements of the lower extremities, with a diagnosis that includes severe cognitive deficits, memory dysfunction, and changes consistent with a neurodegenerative process. There is no mention of thyroid cancer or any thyroid-related issues.\n\nThe clinical trial in question is focused on diagnosing thyroid cancer using blood tests and is looking for participants who have thyroid cancer. The inclusion criteria specify that the patient must be over 18 years old, have thyroid cancer, and be capable of understanding the information sheet and giving informed consent.\n\nGiven that the patient note does not indicate that the patient has thyroid cancer, he does not meet the inclusion criteria for the study. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1917": {
        "output": "",
        "label": 0
    },
    "1918": {
        "output": "Based on the information provided, the patient in the note does not appear to meet the inclusion criteria specified for the clinical trial. The trial is focused on patients with early relapsing-remitting multiple sclerosis (RRMS) who were previously enrolled in the ASA study and have undergone MRI scans using a 1.5 T magnet. The patient note describes a 62-year-old man with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The neuroimaging studies show cerebral atrophy, and a cortical biopsy displays vacuolar changes and reactive astrocytosis, but there is no mention of multiple sclerosis or previous enrollment in the ASA study.\n\nGiven this information, the patient does not meet the key inclusion criteria (diagnosis of RRMS, prior enrollment in the ASA study, and specific MRI requirements). Therefore, the patient would not be eligible for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1919": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial in question. The clinical trial is focused on patients who are scheduled for a primary Total Knee Arthroplasty (TKA) using Trabecular Metal Technology (TMT) Zimmer NexGen\u00ae due to severe osteoarthrosis of the knee. The inclusion criteria specifically mention:\n\n1. Severe osteoarthrosis of the knee with indication for a TKA.\n2. Age between 40 and 70 years.\n\nThe patient note details a 62-year-old man with progressive memory loss and jerking movements of the lower extremities, severe cognitive and memory dysfunction, generalized periodic sharp waves on EEG, cerebral atrophy on neuroimaging, and diffuse vacuolar changes of the gray matter with reactive astrocytosis on brain biopsy. There is no indication that the patient has severe osteoarthrosis of the knee or that he is scheduled for a TKA. The patient's primary issues are neurological, not orthopedic.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial on TKA using TMT Zimmer NexGen\u00ae. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1920": {
        "output": "Based on the information provided, the patient in the note is a 62-year-old man with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, memory dysfunction, and a neuroimaging study showing moderately advanced cerebral atrophy. His cortical biopsy indicates diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nThe clinical trial in question is investigating the preventive effect of proprioceptive stimulation on muscle atrophy, specifically targeting patients confined to bed during a post-operative period after knee replacement surgery. The trial is looking to evaluate the efficiency of a device designed to stimulate foot and ankle proprioceptors and its effects on muscle force, muscle volume, and functional outcomes related to gait and balance.\n\nThe inclusion criteria for the trial are explicitly stated as patients waiting for knee replacement. The patient in the note does not fit this criterion, as there is no mention of knee problems or a pending knee replacement surgery. Instead, the patient exhibits neurological symptoms and conditions that are unrelated to the focus of the clinical trial.\n\nGiven that the patient's medical condition and history do not align with the specific inclusion criteria of the clinical trial (which is looking for patients in a post-operative period for knee replacement), the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1921": {
        "output": "Given the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 62-year-old man.\n- He presents with progressive memory loss and jerking movements of the lower extremities.\n- He has severe cognitive deficits and memory dysfunction.\n- EEG shows generalized periodic sharp waves.\n- Neuroimaging shows moderately advanced cerebral atrophy.\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is studying the developmental trajectory of brain structural connectivity and cognitive function.\n- It is focused on a younger age group, specifically from childhood to young adulthood.\n- Participants should be between the ages of 8 and 21.\n- Participants should not have a current or past history of any psychiatric disorder or autistic symptoms.\n\nComparison:\n- The patient is 62 years old, which is well beyond the upper age limit of 21 years set by the clinical trial.\n- The clinical trial is looking for participants without a history of psychiatric disorders, whereas the patient has significant neurological symptoms, including memory loss and cognitive deficits.\n\nBased on the information provided, the patient does not meet the age criteria for the clinical trial, and his neurological condition also likely disqualifies him from participation, as the trial specifies no current or past psychiatric disorders.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1922": {
        "output": "",
        "label": 0
    },
    "1923": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 62-year-old man, which fits within the 18 to 90 years old range required by the trial.\n- The patient presents progressive memory loss and jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction.\n- An electroencephalogram shows generalized periodic sharp waves.\n- Neuroimaging studies show moderately advanced cerebral atrophy.\n- A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients of 18 to 90 years old (the patient is 62 years old, so this criterion is met).\n- Subcortical stroke (the patient note does not mention a stroke, specifically not a subcortical stroke or infarction of the internal capsule).\n- Achievement of the internal capsule, according to MRI (the patient's neuroimaging studies do not mention internal capsule involvement).\n- Ability to perform MRI within 10 days after the onset of symptoms (the timing of the patient's symptoms onset is not specified).\n- NIHSS over or equal 2 and < 20 (the patient's NIHSS is not mentioned).\n- Rankin Score over or equal 1 and \u2264 5 (the patient's Rankin Score is not mentioned).\n- Written informed consent after information about the protocol, from patients or reliable person if the patient is in the incapacity to sign (it is not specified if the patient can provide consent).\n- Affiliation to a social security scheme (it is not specified).\n\nBased on the available information, the patient does not meet several key inclusion criteria for this clinical trial: there is no mention of a subcortical stroke or specific involvement of the internal capsule, and other required assessments like NIHSS and Rankin Score are not provided. Therefore, this patient would not be a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1924": {
        "output": "Based on the patient note provided, the 62-year-old man is experiencing progressive memory loss and jerking movements of the lower extremities, which are not necessarily indicative of spasticity after a stroke. The neurological examination confirms severe cognitive deficits and memory dysfunction, and neuroimaging shows cerebral atrophy. The cortical biopsy findings suggest a neurodegenerative process but do not mention a stroke or spasticity resulting from a stroke.\n\nThe clinical trial in question is seeking patients with lower limb spasticity after a stroke. The inclusion criteria also specify that the duration should be more than 6 months and the Modified Ashworth Scale of the ankle joint should be more than 2.\n\nGiven that the patient's condition does not clearly indicate he has suffered a stroke or has lower limb spasticity as a result of a stroke, the patient does not meet the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1925": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is a 62-year-old man.\n- Presenting with progressive memory loss and jerking movements of the lower extremities.\n- Exhibits severe cognitive deficits and memory dysfunction.\n- EEG shows generalized periodic sharp waves.\n- Neuroimaging indicates moderately advanced cerebral atrophy.\n- Cortical biopsy reveals diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial:\n- Title: The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer.\n- Purpose: To determine findings of PET and MRI in primary lesion and axillary metastasis of breast cancer, and to compare two imaging modalities in these patients.\n- Inclusion Criteria: Newly diagnosis of breast cancer for which surgical intervention is planned.\n\nThe patient in the note does not have a diagnosis of breast cancer, which is the primary inclusion criterion for this clinical trial. Instead, the patient has neurological symptoms and findings consistent with a neurodegenerative disorder or prion disease, which is unrelated to breast cancer.\n\nTherefore, this patient would not be eligible for the breast cancer imaging trial, as the patient's condition does not meet the inclusion criteria of a newly diagnosed breast cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1926": {
        "output": "The patient presented with progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction. The patient has been diagnosed with neurologic issues based on an electroencephalogram and a cortical biopsy, but there is no mention of atrial fibrillation (AF) or any cardiac issues.\n\nThe clinical trial in question is looking for patients with a diagnosis of atrial fibrillation, which this patient does not have, according to the provided information. Additionally, the inclusion criteria specify patients with a coded diagnosis for atrial fibrillation in their primary or secondary care record, and there is no mention of such a diagnosis in the patient's note.\n\nBased on the lack of information suggesting the patient has atrial fibrillation, which is the primary condition being studied in the clinical trial, this patient would not meet the inclusion criteria for the trial. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1927": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, here is the analysis:\n\nPatient Note Analysis:\n- 62-year-old man.\n- Progressive memory loss and jerking movements of the lower extremities.\n- Severe cognitive deficits and memory dysfunction.\n- Generalized periodic sharp waves on EEG.\n- Moderately advanced cerebral atrophy on neuroimaging.\n- Cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria:\n- Elderly.\n- Able to provide informed consent.\n- Definitive Idiopathic Parkinson's Disease diagnosed by a Neurologist.\n- Hoehn and Yahr Stage 1-3.\n- Able to ambulate without an assistive device.\n- On stable doses of Parkinson's medications prior to study onset.\n\nComparison:\n- The patient is elderly, which matches one of the trial criteria.\n- However, the patient's diagnosis is not clearly stated as Parkinson's Disease; instead, the symptoms and findings suggest a different neurodegenerative disorder, possibly a prion disease given the EEG findings and the cortical biopsy results.\n- There is no mention of Parkinson's Disease, Hoehn and Yahr Stage, or use of Parkinson's medications in the patient note.\n\nConclusion:\nThe patient's diagnosis does not meet the specific criteria for Idiopathic Parkinson's Disease required by the clinical trial. Additionally, there is no information on the patient's ability to ambulate without an assistive device or on the stability of Parkinson's medications, which are crucial criteria for inclusion in the trial.\n\nTherefore, the patient is not eligible for the Parkinson's Disease clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1928": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- A 62-year-old man\n- Severe cognitive deficits and memory dysfunction\n- Progressive memory loss\n- Jerking movements of lower extremities\n- Neurologic examination confirms severe cognitive deficits and memory dysfunction\n- EEG shows generalized periodic sharp waves\n- Neuroimaging shows moderately advanced cerebral atrophy\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial Inclusion Criteria:\n- Male and female subjects with normal cognition and >50 years of age\n- Subjects within normal limits on neurological and psychiatric examinations\n- Subjects must have a Clinical Dementia Rating = 0 and Global Deterioration Scale < 3\n- Subjects must have had a minimum of 12 years of education\n- An informed family member or life partner must be interviewed to confirm the reliability of the subject interview\n- Subjects must agree to MRI imaging, lumbar puncture, ApoE genotyping, and DNA banking\n\nAssessment:\nThe patient is not eligible for this clinical trial for several reasons:\n- The patient does not have normal cognition, which is required by the trial. The patient has severe cognitive deficits and memory dysfunction.\n- The patient's neurologic examination confirms severe cognitive deficits, indicating that the patient would not be within normal limits on neurological examinations.\n- Given the severe cognitive deficits, it is highly unlikely that the patient would have a Clinical Dementia Rating of 0 and a Global Deterioration Scale score of less than 3.\n\nBased on these discrepancies, the patient does not meet the inclusion criteria for the clinical trial titled \"Sleep, Aging and Risk for Alzheimer's Disease.\" Therefore, the patient would not be referred to this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1929": {
        "output": "",
        "label": 0
    },
    "1930": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's evaluate the patient's eligibility for the RELIEF Study.\n\nThe patient is a 62-year-old man with progressive memory loss and jerking movements of the lower extremities. The clinical examination confirms severe cognitive deficits and memory dysfunction, and a cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis. The electroencephalogram shows generalized periodic sharp waves, and neuroimaging studies show moderately advanced cerebral atrophy. The clinical presentation suggests a neurodegenerative disorder rather than post-stroke symptoms.\n\nThe RELIEF Study's inclusion criteria are as follows:\n- Men or women age 18 years and above (the patient meets this criterion)\n- Post-stroke lower-limb spasticity (there is no indication that the patient has had a stroke or suffers from lower-limb spasticity)\n- Prior agreement with the patient to inject BoNT-A (not mentioned in the patient note)\n- If previously treated with BoNT-A, (at least 3 months interval between last injection and inclusion) (not mentioned in the patient note)\n- Therapeutic goals agreed jointly with the patient (not mentioned in the patient note)\n- Functional Ambulation Classification (FAC) score 2-5 (not mentioned in the patient note, and the patient does not appear to have post-stroke spasticity)\n- Capacity to comply with the protocol (not mentioned in the patient note)\n- Written informed consent (not mentioned in the patient note)\n\nThe key criterion that the patient does not meet is the requirement for post-stroke lower-limb spasticity. There is no information suggesting that the patient's condition is related to a stroke or that he suffers from lower-limb spasticity. Therefore, based on the information provided, it appears that this patient would not qualify for the RELIEF Study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1931": {
        "output": "After reviewing the patient note and the clinical trial information, here is the assessment:\n\nPatient Characteristics:\n- Age: 62 years old\n- Condition: Progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits, memory dysfunction, generalized periodic sharp waves on EEG, moderately advanced cerebral atrophy, diffuse vacuolar changes of the gray matter with reactive astrocytosis on cortical biopsy.\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 65 years\n- Elective major surgery\n- Planned general anesthesia\n\nThe patient in question does not meet the age criterion of the clinical trial, which requires participants to be 65 years or older. Additionally, the patient is not described as being planned for elective major surgery under general anesthesia, which are also required criteria for the trial.\n\nTherefore, based on the available information, the patient does not fulfill the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1932": {
        "output": "Assessing the patient note against the inclusion and exclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 62-year-old man.\n- The patient presents with progressive memory loss and jerking movements of the lower extremities, severe cognitive deficits, and memory dysfunction.\n- EEG shows generalized periodic sharp waves.\n- Neuroimaging shows moderately advanced cerebral atrophy.\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria:\n- Be greater than or equal to 18 years of age.\n- Able to provide informed consent.\n- Meets the donation requirements established by AABB and FDA for allogeneic or autologous use with the exception of hemoglobin/hematocrit.\n\nClinical Trial Exclusion Criteria (relevant to the patient):\n- History of cancer.\n- At risk for the possible transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD).\n\nThe patient's age and ability to provide informed consent would initially seem to make him a potential candidate for the trial. However, the patient's neurological symptoms and the findings on EEG and neuroimaging, along with the biopsy results, strongly suggest a neurological condition that could potentially be Creutzfeldt-Jakob Disease (CJD), which is one of the exclusion criteria for the clinical trial.\n\nWhile the patient note does not explicitly diagnose CJD, the presence of \"generalized periodic sharp waves\" on EEG and \"diffuse vacuolar changes of the gray matter\" from a cortical biopsy are characteristic of CJD, which must be considered as a differential diagnosis here. Since individuals at risk for the transmission of CJD are excluded from the trial, it would be prudent to clarify the patient's diagnosis before making a referral.\n\nGiven the potential risk of CJD, the exclusion criteria for this trial would likely disqualify this patient unless further investigation ruled out CJD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1933": {
        "output": "Assessing the eligibility of the patient for the clinical trial based on the provided patient note and the clinical trial inclusion criteria:\n\nPatient Note Summary:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on electroencephalogram\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis\n\nClinical Trial Summary:\n- Title: Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease\n- Purpose: To compare the accuracy and comparability of forearm BMD measurements by DXA and SOS to standard DXA evaluations\n- Inclusion Criteria:\n  - Age: >18\n  - Gaucher disease type 1\n  - Able to undergo a DEXA test\n\nBased on the clinical trial's inclusion criteria, the patient does not meet the specific disease requirement as there is no mention of Gaucher disease in the patient's note. Instead, the patient presents with neurological symptoms and findings that are not related to Gaucher disease. Therefore, this patient would not be eligible for the clinical trial that is focused on patients with Gaucher disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1934": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the trial. The patient is described as having progressive memory loss, jerking movements of the lower extremities, severe cognitive deficits and memory dysfunction, generalized periodic sharp waves on EEG, and neuropathological findings consistent with diffuse vacuolar changes of the gray matter with reactive astrocytosis. These findings do not align with the diagnosis of amyotrophic lateral sclerosis (ALS), which is the target condition for the clinical trial.\n\nThe inclusion criteria for the clinical trial specifically require a diagnosis of ALS according to the Airlie House criteria, with a time between first symptoms and diagnosis of less than 18 months, and a specific pattern of loss on the ALSFRS-R rating scale. Since the patient's condition does not match the ALS diagnosis or the specified patterns of functional loss on the ALSFRS-R, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1935": {
        "output": "Assessing the eligibility of the 62-year-old man for the clinical trial titled \"Music Therapy to Restore Motor Deficits After Stroke\":\n\n- The patient is presenting with progressive memory loss and jerking movements of the lower extremities, with severe cognitive deficits and memory dysfunction.\n- The patient's neuroimaging studies show cerebral atrophy, and a biopsy indicates vacuolar changes of the gray matter with reactive astrocytosis.\n- The clinical trial is investigating the effectiveness of music-supported therapy (MST) to restore motor function in stroke patients.\n- The inclusion criteria for the trial are:\n  - Motor deficits of the upper limb after a first ever stroke\n  - A minimum score on specific motor function tests\n  - Less than 6 months from stroke\n  - Age between 30 and 75 years\n  - Right-handed\n\nBased on the information provided:\n- The patient's age (62 years) fits within the trial's age range.\n- There is no information suggesting that the patient has had a stroke, as the symptoms described do not directly indicate a stroke. Instead, the patient seems to have a different neurological condition.\n\nGiven the lack of evidence that the patient has had a stroke, which is a primary condition for inclusion in the trial, the patient does not meet the key inclusion criteria and therefore would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1936": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient note:\n- 62-year-old man\n- Neurologic examination confirms severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n- No mention of dependency on ADLs or specific dementia diagnosis\n\nClinical trial inclusion criteria:\n- Severe cognitive impairment (complete dependency in all activities of daily living (ADLs))\n- Diagnosis of Alzheimer's disease, vascular dementia, or frontotemporal dementia\n- Score > 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care\n\nAssessment:\n- The patient has severe cognitive deficits and memory dysfunction, which might suggest severe cognitive impairment.\n- There is no specific diagnosis of Alzheimer's disease, vascular dementia, or frontotemporal dementia provided in the patient note. The patient has a cortical biopsy showing changes consistent with some form of dementia, but it is not specified.\n- There is no information regarding the patient's dependency on ADLs or if he has paratonic rigidity with a score > 3 on the paratonic assessment instrument.\n\nSince the patient note does not provide sufficient information to determine whether the patient meets all the inclusion criteria of the trial, particularly concerning the specific type of dementia, dependency on ADLs, and paratonic rigidity, the patient would not be immediately referred to the clinical trial. However, further investigation, such as a more detailed medical history and assessments, could provide the necessary information to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1937": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 62-year-old man, which fits within the age criteria of \u2265 18-80 years specified by the clinical trial.\n- The patient presents with progressive memory loss and jerking movements of the lower extremities, which are not indicative of post-stroke limb spasticity.\n- The patient has severe cognitive deficits and memory dysfunction, with neuroimaging studies showing cerebral atrophy. This does not align with the condition of post-stroke spasticity.\n- The diagnosis of the patient, as per the cortical biopsy, does not suggest a stroke but rather a neurodegenerative disorder with vacuolar changes of the gray matter.\n\nClinical Trial Inclusion Criteria Analysis:\n- Men and women aged 18-80 years, which the patient meets.\n- Must have post-stroke limb spasticity, which the patient does not have (there is no mention of a stroke in the patient's history).\n- The stroke must have occurred in the previous 6 months, which is not applicable to the patient as there is no mention of a stroke.\n- The treatment goal must have been agreed upon with the patient or their legal representative, which we cannot confirm from the patient note.\n- The patient must have clinically significant poststroke upper/lower limb spasticity and it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation, which is not applicable to the patient.\n- No previous treatment with BoNT-A, which we cannot confirm from the patient note but is irrelevant due to the lack of diagnosis of post-stroke spasticity.\n- The patient must be able to follow the protocol, which is uncertain due to the patient's severe cognitive deficits.\n\nGiven the information provided, the patient does not meet the core inclusion criteria for the clinical trial, specifically the requirement of having post-stroke limb spasticity and the occurrence of a stroke within the previous 6 months. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1938": {
        "output": "Based on the patient note provided, the 62-year-old man is presenting with progressive memory loss, jerking movements of lower extremities, severe cognitive deficits, and memory dysfunction. The neuroimaging shows moderately advanced cerebral atrophy, and a cortical biopsy reveals diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nComparing this to the clinical trial's inclusion criteria, we have the following:\n\n- The patient is a 62-year-old man, which means he does not meet the age requirement of being 65 years or older.\n- There is no indication that the patient has been diagnosed with Major Depressive Disorder (MDD), as the symptoms described are more in line with a neurodegenerative disorder.\n- The patient's condition does not seem to be primarily related to depression, and there is no mention of depressive episodes or their duration.\n- The severity of depression has not been assessed using the Hamilton Depression Rating Scale (HDRS), and there is no information to suggest a score greater than 20.\n- The patient's general health status is not clearly mentioned, but the presence of severe cognitive deficits may suggest health concerns beyond depression.\n- There is no information on the patient's ability to give informed consent, although the severe cognitive deficits could impair this ability.\n\nGiven that the patient does not meet several key inclusion criteria (age, diagnosis, and depression severity), it is not appropriate to refer this patient to the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1939": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"INfusion VErsus STimulation in Parkinson's Disease,\" the patient does not appear to be eligible for the trial. The patient's symptoms include progressive memory loss and jerking movements of the lower extremities, with a neurologic examination confirming severe cognitive deficits and memory dysfunction. The diagnosis suggested by the patient's symptoms and the cortical biopsy results is not specified as Parkinson's disease, and the symptoms described do not match the typical motor symptoms of Parkinson's disease (bradykinesia, resting tremor, rigidity, and asymmetry).\n\nThe inclusion criteria for the clinical trial specifically require a diagnosis of idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs: resting tremor, rigidity, and asymmetry. Additionally, the patient must exhibit certain symptoms despite optimal pharmacological treatment, and have a life expectancy of at least two years.\n\nSince the patient note does not indicate a diagnosis of Parkinson's disease nor describe the specific motor symptoms required for the trial, the patient would not meet the inclusion criteria. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1940": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- EEG shows generalized periodic sharp waves\n- Neuroimaging shows moderately advanced cerebral atrophy\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial:\n- Study of neurological complications after radiotherapy for high-grade glioblastoma\n- Inclusion Criteria:\n  - Diagnosis of glioma (stage 3 to 4)\n  - Both genders\n  - Age > 18 years\n  - Treatment by radiotherapy and chemotherapy\n  - Clinical monitoring post radiotherapy in Neurology Department, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital and in the radiotherapy department of the Paul Strauss Institute\n\nThe patient's note does not mention a diagnosis of glioma or any treatment specifically for glioma such as radiotherapy and chemotherapy. Instead, the patient has severe cognitive deficits and memory dysfunction, which could be related to a variety of neurological conditions. The neuroimaging findings of cerebral atrophy and the cortical biopsy findings do not align with the inclusion criteria which specifically list glioma (stage 3 to 4) as a requirement. \n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, as there is no indication of a diagnosis of high-grade glioblastoma or treatment by radiotherapy and chemotherapy for such a condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1941": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss and jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration\n\nClinical Trial Inclusion Criteria:\n- Age 35 years or older\n- HIV infection for at least 1 year\n- Able to communicate in English or French\n- Capable of providing informed consent\n- Easy access to the internet\n- EEG and MRI compatible\n\nComparison:\n- The patient meets the age criterion (62 years old, where the minimum age is 35).\n- The patient note does not mention HIV infection, which is a specific requirement for the clinical trial.\n- The patient note does not describe the patient's ability to communicate in English or French, but since they are seeing a neurologist, it can be assumed they can communicate unless otherwise stated.\n- The patient note does not indicate whether the patient is capable of providing informed consent. However, severe cognitive deficits could impair this ability.\n- The patient note does not mention the patient's access to the internet.\n- The patient has had an EEG, which is compatible with the study requirements; however, we do not have information about MRI compatibility.\n\nThe critical missing information is whether the patient has HIV, as this is a specific requirement for the trial. Without this information, we cannot assume the patient is eligible based on the requirements given. The severe cognitive deficits may also preclude informed consent, which is a requirement for participation in the trial.\n\nGiven the information provided, the patient does not meet one of the key inclusion criteria (HIV infection), which is essential for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1942": {
        "output": "Based on the information provided in the patient note, the patient is a 62-year-old man with severe cognitive deficits and memory dysfunction, and there is no mention of colorectal cancer or any indication that the patient is undergoing or is scheduled for curative surgery for colorectal adenocarcinoma.\n\nThe clinical trial is specifically looking for patients who:\n\n1. Have a biopsy-confirmed colorectal adenocarcinoma.\n2. Are eligible for curative surgery.\n3. Have no metastatic disease on CT scan.\n4. Have completed a pre-operative staging scan within six weeks prior to surgery.\n5. Have provided written informed consent to participate in the study.\n6. Are aged 16 years or over.\n\nSince the patient's condition (progressive memory loss, jerking movements of the lower extremities, and cognitive deficits) does not align with the inclusion criteria of the clinical trial (no mention of colorectal adenocarcinoma or eligibility for curative surgery), the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1943": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the trial as follows:\n\nPatient Note Summary:\n- 62-year-old man\n- Progressive memory loss and jerking movements of the lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis\n- No mention of a diagnosis of relapsing multiple sclerosis (RRMS) or current use of Natalizumab (NTZ)\n\nClinical Trial Inclusion Criteria:\n- 18-55 years of age at the time of informed consent\n- Diagnosis of relapsing multiple sclerosis as defined by the 2010 revised McDonald criteria\n- Currently taking Tysabri (Natalizumab)\n\nEligibility Assessment:\n- The patient is 62 years old, which is outside the age range specified in the inclusion criteria (18-55 years).\n- There is no information in the patient note that indicates a diagnosis of relapsing multiple sclerosis (RRMS).\n- There is no mention of the patient currently taking Natalizumab (Tysabri).\n\nBased on this information, the patient does not meet the age criterion, there is no mention of an RRMS diagnosis, and no indication of current Natalizumab (Tysabri) therapy. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1944": {
        "output": "Based on the patient note provided, let's compare the patient's characteristics and condition with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- Age: 62 years old\n- Condition: Progressive memory loss, jerking movements of lower extremities, severe cognitive deficits and memory dysfunction, generalized periodic sharp waves on EEG, moderately advanced cerebral atrophy, cortical biopsy showing diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.\n\nClinical Trial Inclusion Criteria:\n- Age at the time of enrollment: 35 - 75 years.\n- Diagnosis of idiopathic Parkinson's disease (PD) with probable Parkinson's disease dementia (PDD) as defined by the MDS consensus guidelines.\n- Mild to moderately severe dementia as defined by a Mini-Mental State Examination (MMSE) score of 10 to 24.\n- Duration of bilateral idiopathic PD: \u22655 years of motor symptoms.\n- Severity of bilateral idiopathic PD in the meds off state: modified Hoehn and Yahr stage \u22652.\n- UPDRS subset III score of \u226530 in the meds off, stim off state.\n- Levodopa must improve PD symptoms by \u226530% in a levodopa challenge test, as measured by UPDRS subset III score.\n- PDD with a symptom onset at least 2 years after first symptoms of PD.\n- Willing and able to comply with all visits and study-related procedures.\n- Able to understand the study requirements and the treatment procedures and to provide written informed consent.\n\nAssessment:\nThe patient's age fits within the trial's age range. However, the patient does not have a diagnosis of idiopathic Parkinson's disease or Parkinson's disease dementia (PDD), as required by the trial. The patient's symptoms and biopsy results suggest a different neurological condition rather than PD or PDD. There is no mention of Parkinsonism, the use of levodopa, or responsiveness to levodopa in the patient note. The details provided do not suggest the presence of PD or PDD, which are critical for eligibility in this trial. Since the patient's condition does not meet the essential diagnostic criteria for the trial, they would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1945": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note:\n- 62-year-old man\n- Progressive memory loss\n- Jerking movements of lower extremities\n- Severe cognitive deficits and memory dysfunction\n- Generalized periodic sharp waves on EEG\n- Moderately advanced cerebral atrophy on neuroimaging\n- Diffuse vacuolar changes of the gray matter with reactive astrocytosis on cortical biopsy\n- No mention of Hereditary Spastic Paraplegia (HSP) or spasticity\n\nClinical Trial:\n- Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia (HSP)\n- Inclusion criteria:\n  - Age between 18 and 80 years\n  - Clinical diagnosis of Hereditary Spastic Paraplegia\n  - Ability to walk at least 10 meters, even with assistive devices\n\nAssessment:\nThe patient does not meet the inclusion criteria for the clinical trial as there is no mention of a clinical diagnosis of Hereditary Spastic Paraplegia, which is a key requirement for participation in the trial. The symptoms described (progressive memory loss, cognitive deficits, and jerking movements) do not align with the typical presentation of HSP, which is primarily characterized by spasticity and difficulty walking due to muscle stiffness and weakness.\n\nBased on the information provided, the patient does not fit the inclusion criteria for this specific clinical trial on Hereditary Spastic Paraplegia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1946": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, the patient in question would not be eligible for the clinical trial. The trial is focused on evaluating stool tagging protocols in patients undergoing colorectal evaluation and has an age requirement of 45 to 80 years old for routine screening colonoscopy. The patient note describes a 43-year-old woman with dermatological lesions, which is unrelated to the focus of the clinical trial, and she is also below the minimum age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1947": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Experience and Enhancement: Improving Colonoscopic Polyp Detection,\" the patient does not appear to be a candidate for this trial. The patient note describes a 43-year-old woman with multiple small soft, pedunculated lesions on her neck, varying in color. There is no mention of a clinical indication for colonoscopy or any issues related to colon health.\n\nThe inclusion criteria for the clinical trial specify patients over 18 years of age, with a clinical indication for colonoscopy who are considered by the endoscopist to be fit for the procedure. Since the patient in the note is seeing a dermatologist for skin lesions on the neck and there is no mention of gastrointestinal symptoms or need for colonoscopy, she does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1948": {
        "output": "",
        "label": 0
    },
    "1949": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nThe patient is a 43-year-old woman, which meets the age criterion of being over 18 years of age.\n\nThe patient is visiting the dermatologist for lesions on her neck, which means she is undergoing an examination of her skin. This meets the criterion of \"Patients undergoing an examination of their skin\".\n\nThe lesions described are small, soft, pedunculated, with the largest being about 4 mm in diameter and vary in color from flesh-colored to slightly hyperpigmented. While the lesions are not explicitly diagnosed as one of the five categories mentioned in the inclusion criteria (basal cell carcinoma, squamous cell carcinoma, pre-cancer lesions, pigmented lesions, and benign lesions), the description suggests they could potentially be benign lesions or pigmented lesions.\n\nThe inclusion criteria specify that the patient should have a lesion that warrants a biopsy. There is no information provided in the patient note to determine whether a biopsy is warranted for these lesions. However, the fact that they are being examined by a dermatologist suggests that a biopsy could be a possibility.\n\nThe patient note does not mention if a signed informed consent document has been provided, but this is a step that can typically be completed if the patient agrees to participate in the trial.\n\nBased on the information provided, it seems the patient could be eligible for the clinical trial, but additional information (specifically about the necessity of a biopsy for the lesions) is required to make a definitive determination. Therefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1950": {
        "output": "Assessing the provided patient note against the inclusion criteria of the clinical trial:\n\nPatient note:\n- A 43-year-old woman with multiple lesions on her neck that are small, soft, and pedunculated.\n\nClinical trial:\n- Title: Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation\n- Inclusion criteria: Patient receiving bone marrow transplant\n- Exclusion criteria: Not receiving other growth factors\n\nThe patient in the note is visiting a dermatologist for lesions on her neck. There is no mention of the patient undergoing a bone marrow transplant or receiving Palifermin. To be eligible for the clinical trial, the patient must be undergoing a bone marrow transplant. Since there's no information provided about the patient's bone marrow transplant status or her use of Palifermin, it would not be appropriate to refer this patient to the clinical trial based on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1951": {
        "output": "Based on the information provided, the patient is a 43-year-old woman with lesions on her neck. The lesions are described as small, soft, and pedunculated, with the largest being about 4 mm in diameter. The color of the lesions varies from flesh-colored to slightly hyperpigmented.\n\nNow, let's compare this patient's characteristics to the inclusion criteria of the clinical trial titled \"Feasibility Study of Cryotherapy for Chronic Venous Disorders\":\n\n1. Aged 45 years and older: The patient is 43 years old, which does not meet the age requirement of being at least 45 years old.\n\n2. CEAP classification: stage C4 (changes in skin and subcutaneous tissue secondary to CVDs)4a (pigmentation or eczema) 4b (lipodermatosclerosis or atrophie blanche) C5 (healed venous ulcers): The patient's note does not mention chronic venous disorders (CVDs) or any of the specific skin changes associated with CEAP classification stages C4 or C5.\n\n3. Ankle brachial index (ABI) 0.9 - 1.3mm Hg 0 absence of peripheral arterial disease: The patient's note does not provide information about ABI or the presence of peripheral arterial disease.\n\n4. Intact skin sensation measured with 10 gram monofilament: The patient's note does not provide information about skin sensation.\n\n5. Intact thermal sensation measured with thermal sensory tester at lower leg skin and foot surfaces: The patient's note does not provide information about thermal sensation.\n\n6. Agreement to wear compression garments such as wraps or stockings during waking hours: The patient's note does not mention any willingness or ability to wear compression garments.\n\n7. Phone, e-mail, or mail accessible: The patient's note does not provide information about contact accessibility.\n\n8. Working freezer: The patient's note does not provide information about the availability of a working freezer.\n\nConsidering the inclusion criteria and the information provided in the patient note, it is clear that the patient does not meet the age requirement and there is no indication that the patient has chronic venous disorders or meets any other specific criteria required for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1952": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient in the note does not meet the age criterion set by the trial. The trial is specifically recruiting participants aged between 5 and 10 years with a clinical diagnosis of molluscum contagiosum. The patient described is a 43-year-old woman, which makes her ineligible for this trial based solely on her age.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1953": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility needs to be assessed.\n\nPatient note:\n- 43-year-old woman\n- Lesions on her neck\n- Multiple small, soft, and pedunculated lesions, with varying color\n\nClinical trial inclusion criteria:\n- Histologically confirmed advanced or metastatic non-curable solid tumor\n- Completed \u22651 conventional therapy\n- Clinically indicated surgery or procedure to collect available tumor in sufficient quantity for vaccine processing\n- Subjects that have completed all acceptable therapies that are the current standard of care for their respective diseases\n- Recovered from all toxicities related to prior therapies\n- Subjects with brain metastases treated at least \u22652 months prior to enrollment\n- \u22651 measurable or evalailable lesion\n- Age \u226518 years\n- ECOG performance status (PS) 0-1\n- Normal organ and marrow function\n- Ability to understand and sign informed consent\n- Negative pregnancy test\n\nThe patient note does not provide evidence that the woman has an advanced or metastatic non-curable solid tumor; rather, it describes her visit to a dermatologist for lesions on her neck, which could potentially be benign. There is no mention of a histologically confirmed advanced cancer, previous conventional therapies, or any information regarding the need for or completion of surgery to collect a tumor for vaccine processing. Additionally, the patient's ECOG performance status is not provided, and there's no information on the patient's organ and marrow function or pregnancy status.\n\nGiven the lack of information suggesting that the patient has an advanced or metastatic non-curable solid tumor or any details that match the specific criteria for this trial, the patient does not appear to be a candidate for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1954": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question is a 43-year-old woman with multiple lesions on her neck which are small, soft, and pedunculated. The inclusion criteria for the clinical trial are patients receiving docetaxel as mono- or combination therapy, patients with no nail disorders at the start of treatment, and a life expectancy of at least 3 months.\n\nThe patient's dermatological condition described does not appear to be related to docetaxel-induced nail toxicities, and there is no mention of the patient receiving docetaxel or any chemotherapy treatment. Therefore, there is no indication that this patient would be eligible for a clinical trial focused on cryotherapy intervention for docetaxel-induced nail toxicities.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1955": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 43-year-old woman\n- Multiple lesions on her neck\n- Lesions are small, soft, and pedunculated\n- Largest lesion is about 4 mm in diameter\n- Color varies from flesh colored to slightly hyperpigmented\n\nClinical Trial:\n- Title: Pilot Study of Infrared Imaging of Cutaneous Melanoma\n- Inclusion Criteria:\n  - Patients or volunteers with or without a history of melanoma\n  - One or more palpable skin or subcutaneous lesions that meet certain criteria (tissue diagnosis made, will be made, or a clinical diagnosis with high confidence)\n  - Ability and willingness to give informed consent\n  - Age 18 years or older at the time of study entry\n\nThe patient is a 43-year-old woman, which meets the age criterion. She has multiple lesions, which could potentially meet the criterion of having palpable skin or subcutaneous lesions. However, from the description provided, there is no indication that these lesions are suspected or diagnosed as melanoma, nor is there an explicit mention of a prior history of melanoma or a plan to obtain a tissue diagnosis. The lesions are described with characteristics such as being soft and pedunculated, and varying in color, which may be indicative of skin tags or another benign condition rather than melanoma.\n\nTo determine eligibility, further information would be needed to clarify whether any of the lesions are suspected of melanoma or if there is a plan to obtain a tissue diagnosis for these lesions (which would put the patient into Category A2), or if there is a clinical diagnosis with a high degree of confidence that any of the lesions are melanoma or comparable to other cutaneous metastases of melanoma in the same patient (Category B).\n\nAs the information stands, it is not clear whether the patient's lesions are eligible for the study based on the inclusion criteria, especially regarding the specific criteria related to the diagnosis or suspicion of melanoma.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1956": {
        "output": "Based on the patient note, the 43-year-old woman has multiple lesions on her neck that are small, soft, and pedunculated, with the largest being about 4 mm in diameter and varying in color from flesh-colored to slightly hyperpigmented. The clinical trial in question is investigating the use of confocal microscopy in the diagnosis of benign and malignant skin tumors.\n\nThe inclusion criteria for this trial are:\n- Men and women over the age of 18\n- Skin lesion suspected to be Basal Cell Carcinoma (BCC) or Squamous Cell Carcinoma (SCC), etc.\n- Patient was referred for biopsy diagnostic/therapeutic beforehand, and regardless of confocal microscope examination, according to the clinical consideration of the physician\n\nThe patient's age meets the criteria (>18 years old). However, the patient note does not mention that the lesions are suspected to be BCC, SCC, or any other type of skin cancer, nor does it indicate that the patient was referred for a biopsy. The description of the lesions does not strongly suggest malignancy but rather benign skin growths. Therefore, based on the information provided, it is not clear that the patient's lesions are suspected of being cancerous, which is a key inclusion criterion for this clinical trial.\n\nGiven the lack of information suggesting a suspicion of malignancy or a referral for a biopsy, the patient would not initially be considered a clear fit for this clinical trial. However, further investigation, such as a consultation with the patient's dermatologist to clarify the nature of the lesions and whether they are suspected to be malignant, could potentially change this assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1957": {
        "output": "",
        "label": 2
    },
    "1958": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note:\n- A 43-year-old woman\n- Multiple lesions on her neck\n- Lesions are small, soft, and pedunculated\n- Largest lesion is about 4 mm in diameter\n- Varied color from flesh-colored to slightly hyperpigmented\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with a large non-pedunculated rectal adenoma (sessile or flat) with a largest diameter of \u22652 cm\n- The lower and upper borders of the adenoma are located at \u22652 cm and \u226415 cm from the anal verge, respectively\n- Biopsies of the lesion did not show malignant neoplastic tissue; only lesions with low or high-grade dysplasia are suitable for inclusion\n- No signs of endoscopic suspicion for submucosal invasive cancer\n- EUS to exclude invasion into the submucosal layer and pathological lymphadenopathy\n- Total colonoscopy to detect and remove all synchronous colonic adenomas or cancers\n- General health condition permits general anesthesia (ASA- classification I-III)\n- Absence of non-correctable coagulopathy\n- Patient age of 18 years or older\n\nComparison:\n- The patient is a 43-year-old woman, which meets the age criterion.\n- However, the patient has lesions on the neck, not rectal adenomas. The lesions described are also pedunculated and not the required non-pedunculated, large rectal adenomas specified in the trial criteria.\n- The size of the patient's largest lesion (4 mm in diameter) does not meet the size criterion for the trial (\u22652 cm).\n- There's no information indicating that the patient has been diagnosed with rectal adenomas or that the other specific rectal and endoscopic criteria have been met.\n\nConclusion:\nThe patient does not meet the specific disease and lesion criteria for the clinical trial, as the patient's condition pertains to neck lesions and the trial is focused on rectal adenomas. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1959": {
        "output": "Based on the patient note provided, the 43-year-old woman is visiting her dermatologist due to multiple small lesions on her neck. The lesions are described as small, soft, pedunculated, and vary in color. There is no mention of infantile hemangioma, which is the focus of the clinical trial in question.\n\nThe clinical trial's inclusion criteria specifically target patients who are:\n\n1. Patients with ages up to 2 years;\n2. Clinically diagnosed hemangioma, in proliferative or involutive phase, with relative indication for clinical treatment;\n3. Lesion causing alteration of regional anatomy with no systemic or functional damage and with a diameter greater than 1 centimeter, or lesion causing aesthetic deformity, or lesion causing local repetitive complications such as ulceration, bleeding or local infection, or lesion causing partial damage of orifices, or lesion causing psychological compromise;\n4. Absence of cardiopathy;\n5. Informed consent signed by responsible parties.\n\nThe patient in the note does not fit these criteria as she is not within the age range specified (up to 2 years old), nor is there any indication that she has a clinically diagnosed hemangioma. The lesions described do not meet the characteristics of hemangiomas as described in the trial's inclusion criteria.\n\nTherefore, based on the information given, this patient would not be eligible for the clinical trial on the treatment of infantile hemangioma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1960": {
        "output": "Based on the information provided, the patient is a 43-year-old woman presenting with multiple small, soft, pedunculated lesions on her neck, varying in color. To determine her eligibility for the clinical trial titled \"Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia,\" we need to compare her condition to the inclusion criteria listed for the trial.\n\nThe inclusion criteria for the trial are:\n1. Elevated fasting insulin level, indicating insulin resistance.\n2. Diagnosis of acanthosis nigricans, verified by a Dermatologist.\n3. Willingness to undergo treatment with Metformin.\n4. Agreement to abide by the investigator's guidelines.\n5. Ability to understand the study requirements and risks, and to sign the informed consent form.\n6. Agreement to follow and undergo all study-related procedures.\n\nFrom the patient note, we see that she has lesions that could be suggestive of acanthosis nigricans, but there is no mention of hyperinsulinemia or insulin resistance, nor is there a confirmed diagnosis of acanthosis nigricans by a dermatologist. Also, there is no information on whether the patient is willing to undergo treatment with Metformin or any other study-related procedures. \n\nTherefore, based on the information provided, we do not have enough evidence to confirm that she meets all of the inclusion criteria for the trial. She may potentially have acanthosis nigricans, but further investigation is required to determine her fasting insulin levels and to obtain a formal diagnosis from a dermatologist. If these conditions are met, she may be eligible for the trial. However, with the current information, the patient's eligibility is uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1961": {
        "output": "In this scenario, the patient is a 43-year-old woman with multiple lesions on her neck that are small, soft, and pedunculated. The largest lesion is about 4 mm in diameter, and they vary in color from flesh-colored to slightly hyperpigmented.\n\nThe clinical trial is studying the use of high frequency ultrasound with elastography in skin neoplasms to differentiate benign from cancerous skin lesions. The inclusion criteria for this trial specify that patients with skin lesions undergoing biopsy for diagnosis are eligible to participate.\n\nGiven that this patient has multiple lesions on her neck and there is no indication that a biopsy has been ruled out, it is reasonable to assume that a biopsy could be a next step for diagnosis, making her a potential candidate for the trial. While the information provided doesn't explicitly state the patient will be undergoing a biopsy, it is a common procedure for such lesions that require a diagnosis.\n\nSince the patient fits the age requirement and has skin lesions, which could potentially be undergoing biopsy, she is likely to be considered for referral to the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1962": {
        "output": "Based on the provided patient note, the 43-year-old woman is visiting her dermatologist for lesions on her neck that are described as small, soft, pedunculated, and vary in color. There is no indication that these lesions are malignant or that they are associated with lymphadenopathy. \n\nThe clinical trial in question is focused on patients with malignant cervical lymphadenopathies and compares the efficacy of ultrasound-guided needle biopsy methods. The inclusion criteria specifically state that patients must have malignant cervical lymphadenopathies and have had US-FNA or US-CNB evaluation before.\n\nGiven that the patient's description does not mention any malignancy or prior biopsy evaluation (US-FNA or US-CNB), she does not meet the inclusion criteria for the trial. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1963": {
        "output": "Given the patient note and the clinical trial information provided, the patient in question does not meet the inclusion criteria for the clinical trial. The trial is focused on mothers with healthy children between 6 and 24 months, while the patient is a 43-year-old woman presenting with lesions on her neck. There is no mention of her having a child within the specified age range, and her medical concern is unrelated to the study's focus on infant and young child feeding (IYCF).\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1964": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not seem to be eligible for the trial. The trial is specifically designed for patients with pedunculated colorectal polyps that are larger than 10 mm in head diameter and have a stalk larger than 5 mm in diameter. The patient's dermatological lesions on the neck, described as small soft, and pedunculated with the largest being about 4 mm in diameter, do not meet the criteria for colorectal polyps, nor do they meet the size requirements specified in the trial's inclusion criteria.\n\nTherefore, the patient's dermatological condition does not align with the focus of the clinical trial, which is on the prevention of postpolypectomy bleeding in large colonic polyps.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1965": {
        "output": "Based on the patient note provided, the 43-year-old woman has multiple lesions on her neck that are described as small, soft, and pedunculated, with variation in color from flesh-colored to slightly hyperpigmented. None of the information specifically identifies these lesions as actinic keratoses (AKs). Actinic keratoses are typically characterized by scaling or crusting in sun-damaged regions of the body, which is not mentioned in the patient's description.\n\nThe clinical trial in question is focused on the development and validation of a Quality of Life instrument for patients with actinic keratoses. The inclusion criteria for this trial are quite broad:\n- Male or female, age 18 years or older being seen in a dermatology clinic\n- Informed consent of participation must be given by subject\n\nThe patient in the note meets the age criterion and is being seen in a dermatology clinic, which aligns with the inclusion criteria. However, since the diagnosis of actinic keratoses has not been confirmed, we cannot categorically say that the patient is eligible for the trial based solely on the description provided.\n\nGiven that the lesions have not been explicitly identified as AKs by the dermatologist, further investigation would be necessary to confirm the diagnosis. If the lesions are found to be AKs, then the patient would meet the inclusion criteria. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1966": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the study.\n\nThe patient in the note is a 43-year-old woman visiting her dermatologist for lesions on her neck. The lesions are described as small, soft, pedunculated, and vary in color. There is no mention of acne vulgaris, which is a requirement for the clinical trial. \n\nThe inclusion criteria for the clinical trial are as follows:\n- Have Acne vulgaris, presenting at least one inflammatory lesion on the face\n- Body mass index between 18.0 and 30.0 kg/m2 (inclusive), and body weight not less than 50 kg (man) or 45 kg (woman)\n- Blood pressure between 90 and 140 mmHg systolic (inclusive), and no higher than 90 mmHg diastolic\n- Electrocardiogram (ECG) consistent with normal cardiac conduction and function\n- Non-smoker\n- Adequate contraception method for both men and women. If a woman, must have a negative pregnancy test\n- Signed an informed consent document\n\nThe patient note does not mention acne vulgaris, which is a key inclusion criterion. Instead, it describes lesions that do not appear to be related to acne vulgaris. Additionally, there is no information on the patient's BMI, blood pressure, ECG, smoking status, contraception use, or pregnancy status. Therefore, based on the available information, the patient does not meet the primary inclusion criterion of having acne vulgaris, and we cannot determine other criteria due to lack of information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1967": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it seems that the patient does not meet the specific requirements for the trial. The clinical trial is focused on patients with poor vein circulation in the lower legs, specifically those with Stage 4 and 5 venous insufficiency, and who have a history of venous leg ulcers (VLU). The patient in the note is visiting a dermatologist for lesions on her neck, which are described as small, soft, and pedunculated, with the largest being about 4 mm in diameter and varying in color. There is no mention of venous insufficiency, leg ulcers, or any related circulatory issues in the lower legs.\n\nThe inclusion criteria for the trial are quite specific and include requirements such as a history of healed VLU within the past 2 years, a certain range of ankle brachial index, intact skin and thermal sensation, and the requirement to wear compression during waking hours. The patient's note does not provide any information that would suggest she meets any of these criteria.\n\nTherefore, based on the information given, the patient does not appear to be eligible for the clinical trial on \"Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1968": {
        "output": "Based on the information provided, the patient is a 43-year-old woman visiting her dermatologist for multiple lesions on her neck. The lesions are described as small, soft, and pedunculated, with the largest being about 4 mm in diameter and varying in color.\n\nThe clinical trial in question is looking for participants for a study on the treatment of actinic keratosis (AK) on the face and scalp using a combination of cryotherapy and PEP005 Gel compared to cryotherapy alone.\n\nTo determine the patient's eligibility for the clinical trial, we must compare her situation with the inclusion criteria:\n\n1. Subjects must understand the nature of the trial and provide informed consent. (Not enough information provided, but this is generally assumable.)\n2. Subjects with 4 to 8 clinically typical, visible, and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp. (The patient's lesions are on the neck, not the face or scalp, and there is no mention of AKs.)\n3. Subject at least 18 years of age. (The patient meets this criterion.)\n4. Female subjects must be of either non-childbearing potential or, if of childbearing potential, must have a negative urine pregnancy test prior to study treatment and be willing to use effective contraception. (Not enough information provided.)\n\nThe crucial point here is that the clinical trial is specific to the treatment of AK on the face or scalp. The patient note does not mention AK but instead describes lesions on the neck. There is no indication that the lesions are actinic keratosis, nor are they in the specified treatment area for the trial (face or scalp).\n\nGiven this information, the patient does not meet the inclusion criteria based on the location and unspecified nature of the lesions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1969": {
        "output": "Based on the information provided, the patient is a 43-year-old woman with multiple lesions on her neck. Each lesion is described as small, soft, and pedunculated, with the largest being about 4 mm in diameter. The trial in question is focused on the use of prophylactic hemoclips in the endoscopic resection of large pedunculated polyps, specifically those with heads measuring more than 1 cm in diameter.\n\nThe patient's lesions do not meet the inclusion criteria for the trial, as the lesions are described as being considerably smaller than the 1 cm threshold set by the trial's inclusion criteria for pedunculated polyps. Additionally, the lesions are located on the patient's neck, and there is no mention of them requiring endoscopic resection, which is the focus of the clinical trial.\n\nTherefore, based on the provided information, the patient does not have the specific condition that the trial is studying, nor do her lesions meet the size criteria for inclusion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1970": {
        "output": "Based on the patient note provided, the 43-year-old woman has multiple small, soft, pedunculated lesions on her neck. These lesions vary in color from flesh-colored to slightly hyperpigmented, and the largest is about 4 mm in diameter.\n\nThe clinical trial under consideration is evaluating a Radiofrequency Identification (RFID) Localization System for marking and retrieving breast lesions.\n\nTo determine if the patient is eligible for the trial, we need to compare her case to the inclusion criteria listed for the trial:\n\n1. Have had stereotactic or ultrasound-guided biopsy with marker placement\n2. Have a lesion or biopsy marker that is visible under ultrasound\n3. Have surgical target < 6 cm from the skin when lying supine\n4. Have a discreet surgical target\n5. Have a lesion in which the center/focal area is defined\n6. Be at least 18 years of age or older\n\nThe patient's lesions are located on her neck, and there is no mention of them being in the breast or requiring surgical retrieval, nor is there any indication that she has had a biopsy with marker placement that would necessitate the use of the RFID Localization System. Furthermore, the trial is specifically for breast lesions, and the patient's dermatological condition does not seem to fit the surgical target described.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial focused on breast lesions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1971": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- Age: 43 years old\n- Gender: Female\n- Medical condition: Lesions on the neck, no mention of a tissue diagnosis of Basal Cell Carcinoma (BCC) or site of lesions being on the lower extremities\n- No mention of risk factors for surgical complications\n\nClinical Trial Inclusion Criteria:\n- Patients over 60 years old\n- BCC determined with tissue diagnosis in the lower extremity\n- One or more risk factors for surgical complications\n\nComparing the patient's characteristics with the clinical trial inclusion criteria:\n- The patient is 43 years old, which does not meet the trial's age criterion of being over 60 years old.\n- There is no information provided that the lesions are on the lower extremity or that they have been diagnosed as BCC through tissue diagnosis.\n- No risk factors for surgical complications have been mentioned in the patient's note.\n\nGiven this information, the patient does not meet the inclusion criteria for age, diagnosis, location of the lesions, or the presence of risk factors for surgical complications.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1972": {
        "output": "The patient note describes a 43-year-old woman with multiple small, soft, pedunculated lesions on her neck, varying in color. There is no mention of intracranial aneurysms or any related neurological conditions.\n\nThe clinical trial titled \"The Penumbra Liberty Trial\" is specifically targeting patients with wide-neck, saccular, intracranial aneurysms in the internal carotid artery. The inclusion criteria for the trial require the patient to have:\n\n1. At least 18 years old (the patient is 43 years old, so this criterion is met)\n2. A wide-neck intracranial saccular aneurysm with a neck \u2265 4mm or a dome to neck ratio <2 in the ICA from the cavernous segment to the carotid terminus (there is no information that the patient has an intracranial aneurysm)\n3. Life expectancy > 12 months (no information is provided regarding life expectancy)\n4. Signed Informed Consent (this is a procedural requirement that can be fulfilled if other criteria are met)\n\nSince the patient's dermatological condition does not align with the target disease of the clinical trial, which is focused on intracranial aneurysms, and there is no indication that the patient has an intracranial aneurysm, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1973": {
        "output": "Based on the patient note provided, the 43-year-old woman has multiple lesions on her neck that are described as small, soft, and pedunculated with the largest lesion being about 4 mm in diameter. The color of the lesions varies from flesh-colored to slightly hyperpigmented. There is no mention of the lesions being diagnosed as any of the conditions listed in the inclusion criteria for the clinical trial.\n\nThe clinical trial is focused on the use of Optical Coherence Tomography (OCT) imaging for the differentiation of benign and malignant skin lesions and specifically includes the following conditions in its inclusion criteria:\n\n- seborrheic warts\n- nevi\n- dermatofibroma\n- basal cell carcinoma\n- actinic keratosis\n- squamous cell carcinoma\n- Bowen's disease\n- Merkel cell carcinoma\n- malignant melanoma\n\nThe patient's lesions have not been diagnosed or identified as any of the listed conditions; therefore, based on the information given, the patient does not meet the inclusion criteria for this clinical trial. The lesions could potentially be benign, such as seborrheic keratoses (commonly known as seborrheic warts), but without a proper diagnosis, it is not possible to determine eligibility definitively.\n\nGiven this uncertainty and the lack of a specific diagnosis matching the inclusion criteria, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1974": {
        "output": "",
        "label": 1
    },
    "1975": {
        "output": "Based on the patient note, the 43-year-old woman has multiple small soft, pedunculated lesions on her neck. The largest lesion is about 4 mm in diameter, which does not meet the inclusion criteria for the clinical trial that specifies \"pedunculated colorectal polyps larger than 2cm in diameter\" for patients on long-term antiplatelet therapy. Additionally, there is no mention of the patient being on antiplatelet therapy or having colorectal polyps. Therefore, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1976": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 43-year-old woman\n- Multiple lesions on her neck, small, soft, and pedunculated\n- Largest lesion is about 4 mm in diameter\n- Lesions vary in color from flesh-colored to slightly hyperpigmented\n\nClinical Trial:\n- Title: Temperature Skin Check After Cryotherapy Application\n- Aim: To reheat the skin in different ethnic groups after application of cryotherapy\n- Inclusion Criteria: Belong to ethnic groups requested\n\nThe patient's eligibility for the clinical trial is not clear from the information provided. The trial's inclusion criteria specify that participants must belong to certain ethnic groups, but the patient's ethnic group is not mentioned in the patient note. Therefore, without additional information regarding the patient's ethnicity, we cannot determine if the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1977": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 43-year-old woman\n- Lesions on her neck, small, soft, and pedunculated\n- Largest lesion is about 4 mm in diameter\n- Lesions vary in color from flesh-colored to slightly hyperpigmented\n\nClinical Trial Inclusion Criteria:\n- Keloids or hypertrophic scars older than 12 months and insensitive to other treatments\n- A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks\n- Patients with all Fitzpatrick skin types\n- Patients older than 10 years of age\n\nComparing the patient note to the inclusion criteria:\n- The patient is 43 years old, which meets the age criterion (>10 years of age).\n- The inclusion criteria specify the need for keloids or hypertrophic scars, which are typically raised and proliferate beyond the original lesion site. The patient note does not specify the diagnosis of the lesions as keloids or hypertrophic scars; it only mentions \"lesions\" without further classification.\n- There is no mention of the lesions being older than 12 months or insensitive to other treatments.\n- There is no information on the duration since any previous treatment.\n- The patient's Fitzpatrick skin type is not mentioned, but the trial accepts all types.\n\nBased on the available information, the patient does not clearly meet the specific requirements for keloids or hypertrophic scars, their age, or their lack of response to previous treatments. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1978": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for the Bioavailability of Anthocyanins of Blue Potatoes as Compared With Bilberries, we can determine the patient's eligibility for referral to the clinical trial. \n\nThe inclusion criteria for the trial are as follows:\n- Age 18-45\n- Male\n- No regular medication\n- No participation in a drug trial or blood donation within 2 months\n- Non-smoker\n- Signs informed consent\n- Body mass index 18.5-27 kg/m^2\n- Fasting plasma cholesterol < 5.5 mmol/l\n- Fasting plasma triacylglycerols < 2.6 mmol/l\n- Fasting plasma glucose 4-6 mmol/l\n- Blood pressure <140/80 mmHg\n- Hemoglobin >130 g/l\n- Fasting plasma alanine amino transferase (ALAT) <60 U/l (normal liver function)\n- Fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function)\n- Fasting plasma creatinine <118 \u00b5mol/l (normal kidney function)\n\nThe patient note describes a 43-year-old woman with lesions on her neck. \n\nThe first and most significant mismatch with the inclusion criteria is gender; the trial specifies males, and the patient is female. This alone disqualifies her from the study. Additionally, no other information is provided that could potentially match the remaining criteria (e.g., BMI, fasting plasma values, etc.), but the gender criteria are definitive. \n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1979": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 43-year-old woman with lesions on her neck does not appear to be seeking treatment for a condition related to surgical sponges or the detection of foreign objects left in the body post-surgery. The clinical trial is specifically aimed at testing the visibility of micromachined tags for the detection of surgical sponges in healthy volunteers.\n\nThe inclusion criteria for the clinical trial are:\n\n- Healthy men and women\n- Ages 18 or older\n\nThe patient note does not indicate any health issues that would exclude the woman from being considered \"healthy,\" nor does it indicate any surgical intervention where surgical sponges could be a concern. However, there is also no indication that the woman is interested in participating in a study unrelated to her dermatological condition. Without additional information suggesting the patient's interest or suitability for this specific study, it would not be appropriate to refer her based solely on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1980": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can make the following assessment:\n\nPatient Note Analysis:\n- The patient is a 43-year-old woman with multiple lesions on her neck.\n- The lesions are described as small, soft, and pedunculated, with the largest being about 4 mm in diameter.\n- The color of the lesions varies from flesh-colored to slightly hyperpigmented.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is studying the effectiveness of Intralesional cryotherapy with an argon gas-based device for treating keloids and hypertrophic scars.\n- Inclusion criteria require that the scars be keloids or hypertrophic scars older than 12 months and insensitive to other treatments.\n- There should be a period of at least 12 weeks since the previous treatment.\n- Patients of all Fitzpatrick skin types are eligible.\n- Patients must be older than 10 years of age.\n\nAssessment of Eligibility:\nThe patient note does not provide enough information to determine whether the lesions are keloids or hypertrophic scars, which is a critical factor for eligibility in the clinical trial. Additionally, there is no mention of the lesions being insensitive to other treatments or the time since any previous treatment. Due to the lack of specific information on the type of scars and their treatment history, it is not possible to definitively conclude that the patient would be eligible for the clinical trial.\n\nGiven the information at hand, the patient's eligibility for the trial cannot be confirmed, and further investigation would be required to determine if the lesions are indeed keloids or hypertrophic scars and if other inclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1981": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Tolerance and Efficacy Evaluation of 3 Face Creams,\" let's assess the patient's eligibility:\n\nPatient characteristics:\n- A 43-year-old woman (meets age criterion)\n- Visits her dermatologist for lesions on her neck (does not specify any treatments that would disqualify her)\n- Multiple small, soft, and pedunculated lesions (does not conflict with the trial criteria)\n\nClinical trial inclusion criteria:\n- Female gender (the patient is female)\n- Age > 35 years old (the patient is 43 years old)\n- Good general state of health (not enough information, but no poor health is reported)\n- Woman who had already undergone Hyaluronic acid injections (not mentioned in the patient note)\n- Woman who have not applied any retinoid product in the last 3 months (not mentioned in the patient note)\n- Woman who are not in a recovery period after laser/peeling/acne treatment (no such treatments mentioned)\n- Accepting to return to the centre for the planned visits (not mentioned, but this is a standard requirement)\n- Accepting to follow the investigator's instructions during the entire study period (not mentioned, but this is a standard requirement)\n- Agreeing to present at each study visit without make-up (not mentioned, but this is a standard requirement)\n- Accepting to not change their habits regarding: food, physical activity, face cleansing, and make-up use (not mentioned, but this is a standard requirement)\n- Agreeing to not receive any drug able to change the skin characteristics during the entire duration of the study (not mentioned)\n- Accepting to not receive any cutaneous anti-age treatment during the entire duration of the study (not mentioned)\n- Accepting not to expose their face to strong UV irradiation (UV session or sunbathes) during the entire duration of the study (not mentioned)\n- Accepting to sign the Informed consent form (not mentioned, but this is a standard requirement)\n\nThe main question is whether the patient has previously undergone Hyaluronic acid injections, as this is a specific requirement mentioned in the inclusion criteria. This information is not provided in the patient note. All other inclusion criteria that can be assessed from the patient note are met or not specifically contradicted.\n\nGiven this information, and without knowledge of whether the patient meets all the specific requirements such as previous Hyaluronic acid injections, I would lean towards further investigation before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1982": {
        "output": "Based on the patient note provided, the 43-year-old woman is visiting her dermatologist for lesions on her neck. The lesions are described as soft, small, pedunculated, and vary in color. \n\nNow, let's compare this to the inclusion criteria of the clinical trial which is focused on the treatment of External Genital Warts (EGW) with cryotherapy and sinecatechins 15% ointment:\n\n1. Adults at least 18 years old with at least two visible EGWs.\n2. Subject must be in good general health as confirmed by the medical history.\n3. Subject must be able to read, sign, and understand the informed consent.\n4. Subject must be willing to forego any other treatments for his/her EGW lesions.\n5. Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions.\n6. If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study.\n\nThe patient's lesions are on her neck, not external genital warts, which is a different condition. There is no indication that the patient has external genital warts or meets the specific requirement of having at least two visible EGWs. Therefore, the patient does not meet the primary disease condition for which the study is being conducted. All other inclusion criteria are irrelevant if the primary condition of having EGWs is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1983": {
        "output": "Based on the information provided, the patient has visited a dermatologist for lesions on her neck, described as multiple, small, soft, and pedunculated. The largest lesion is about 4 mm in diameter. The clinical trial in question is looking for patients with pedunculated colorectal polyps that are larger than 10mm in head diameter and with stalks larger than 5 mm in diameter.\n\nGiven that the patient has skin lesions and not colorectal polyps, she does not meet the inclusion criteria for the clinical trial, which specifically targets patients with large pedunculated colorectal polyps.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1984": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial.\n\nThe patient is a 43-year-old woman who presents with multiple lesions on her neck. Each lesion is described as small, soft, and pedunculated, with the largest being about 4 mm in diameter. The color varies from flesh-colored to slightly hyperpigmented. \n\nThe clinical trial in question is looking for subjects with seborrheic keratosis (SK) lesions. Here are the key inclusion criteria to consider for this patient:\n\n1. Subject is at least 18 years of age. (The patient is 43, so she meets this criterion.)\n2. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis. (The patient note does not specify that the lesions are seborrheic keratosis.)\n3. Subject has 4 appropriate seborrheic keratosis target lesions with specific size and morphological characteristics. (The largest lesion mentioned in the patient note is 4mm in diameter, which is below the minimum size requirement of \u22657mm.)\n4. Not be pedunculated. (The patient's lesions are described as pedunculated, which does not meet this criterion.)\n5. If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an active form of birth control for the duration of the study. (There is no information provided about this for the patient.)\n6. Subject is non-pregnant and non-lactating. (There is no information provided about this for the patient.)\n7. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of any target lesion or which exposes the subject to an unacceptable risk by study participation. (The patient note does not provide any information that would suggest the patient does not meet this criterion.)\n8. Subject is willing and able to follow all study instructions and to attend all study visits. (There is no information provided about this for the patient.)\n9. Subject is able to comprehend and willing to sign an Informed Consent Form (ICF). (There is no information provided about this for the patient.)\n\nThe patient does not meet the size criterion for the SK lesions and her lesions are described as pedunculated, which is specifically excluded in the trial criteria. Without confirmation that the lesions are indeed seborrheic keratosis and given the mismatch in lesion description, it is not appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1985": {
        "output": "Based on the provided information, the patient is a 43-year-old woman visiting her dermatologist for lesions on her neck that are described as small, soft, and pedunculated, with the largest lesion being about 4 mm in diameter and varying in color from flesh-colored to slightly hyperpigmented. These lesions are not explicitly stated to be malignant or benign, but they are suspicious skin lesions, which is what the clinical trial is interested in.\n\nThe clinical trial titled \"Moletest Clinical Study in Scotland\" is looking to evaluate an iPad-based photoimage analysis system for distinguishing between benign and malignant suspicious skin lesions or moles. The inclusion criteria for the trial state that all patients referred to the Dermatology Department, Lanarkshire Hospitals, for assessment of suspicious skin lesions will be eligible. There are no age limits, although patients under the age of 18 require parental/guardian consent.\n\nGiven that the patient has suspicious skin lesions and is of eligible age (over 18), and assuming the dermatologist is within the Lanarkshire Hospitals or is referring to this Department, the patient meets the inclusion criteria for the clinical trial. Therefore, it would be appropriate to consider referring this patient to the clinical trial upon further investigation such as confirming the referral pathway to the Dermatology Department involved in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1986": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to meet the criteria for the trial. The patient has lesions on the neck, which are described as small, soft, and pedunculated, with varying colors. The largest lesion is about 4 mm in diameter. However, the clinical trial is specifically for adult patients with brain metastasis receiving Gamma Knife Radiosurgery (GKR). The lesions mentioned in the patient note do not appear to be brain metastases, and there is no mention of the patient having any primary tumor or brain metastasis. Therefore, the patient does not qualify for the clinical trial focused on treating brain micrometastases with GKR.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1987": {
        "output": "",
        "label": 0
    },
    "1988": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 43-year-old woman\n- Has multiple lesions on her neck, small soft, and pedunculated\n- Lesions vary in color, with the largest being about 4 mm in diameter\n\nClinical Trial Inclusion Criteria:\n- Subjects are Caucasian or Asian (not specified in the patient note)\n- Subjects who are between 18-65 years old (the patient is 43 years old, so this criterion is met)\n- Subjects have flat or macular seborrheic keratosis on the dorsum of the hands and wrists, extensor surfaces of the forearms (the patient has lesions on her neck)\n- The diagnosis of flat seborrheic keratosis is confirmed by two clinical dermatologists using routine clinical examination and dermoscopy (not enough information to confirm this)\n- Subjects have Fitzpatrick skin type I-III (not specified in the patient note)\n- Subjects are in good health (not specified in the patient note, but no health issues are mentioned)\n- Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator (not specified in the patient note)\n\nThe patient meets the age criterion but has lesions on her neck rather than on the dorsum of the hands and wrists or extensor surfaces of the forearms, as required by the trial. Since there is insufficient information to match other specific inclusion criteria, such as confirmation of flat seborrheic keratosis by two clinical dermatologists, the patient's Fitzpatrick skin type, and the patient's overall health status, it is unclear whether she would be eligible for the trial.\n\nGiven the information provided, it is unlikely that the patient would be referred to this clinical trial because the location of her lesions does not match the required location for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1989": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial in question. The trial is focused on radiofrequency-guided localization in patients with abnormal breast tissue undergoing lumpectomy. \n\nThe patient's note indicates that she has visited a dermatologist for lesions on her neck, which are described as small, soft, and pedunculated with varying color, but there's no mention of abnormal breast tissue or a requirement for lumpectomy.\n\nThe inclusion criteria for the clinical trial require:\n\n1. A history of stereotactic or ultrasound-guided biopsy with marker placement.\n2. A lesion or biopsy marker that is visible under ultrasound.\n3. A surgical target within 6 cm from the skin when lying supine.\n4. A discreet surgical target.\n5. A defined center/focal area of the lesion.\n6. The ability to understand and the willingness to sign a written informed consent document.\n\nThe patient's note does not mention any of these specific requirements, most importantly, there is no mention of abnormal breast tissue or prior biopsy with marker placement, indicating that the lesions are unrelated to the breast tissue. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1990": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient does not seem to meet the criteria for the clinical trial. The trial is focused on the treatment of small colon polyps using Cold Snare Polypectomy (CSP) or Endoscopic Mucosal Resection (EMR), with an inclusion criterion that the patient must have at least one polyp of eligible size (6-10 mm) in the colon.\n\nThe patient note describes a 43-year-old woman with multiple soft, pedunculated lesions on her neck, with the largest being about 4 mm in diameter. The lesions described are on the skin, not in the colon, and are smaller than the size specified for the clinical trial. Furthermore, there is no mention of colon polyps in the patient's note.\n\nGiven the mismatch between the patient's condition and the focus of the clinical trial, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1991": {
        "output": "",
        "label": 0
    },
    "1992": {
        "output": "",
        "label": 0
    },
    "1993": {
        "output": "Given the patient note and the clinical trial information, we need to determine the eligibility of the 43-year-old woman for the clinical trial based on the inclusion criteria provided.\n\nPatient Note:\n- 43-year-old woman\n- Lesions on her neck\n- Multiple, small, soft, and pedunculated lesions\n- Largest lesion about 4 mm in diameter\n- Lesions vary in color from flesh-colored to slightly hyperpigmented\n\nClinical Trial Inclusion Criteria:\n- Healthy Subjects\n- Fitzpatrick Skin Types I, II, or III\n\nTo assess eligibility, we must determine if the patient can be considered a \"healthy subject\" and if she has a Fitzpatrick Skin Type I, II, or III. The patient note does not provide information on her overall health status or her Fitzpatrick Skin Type. Fitzpatrick Skin Types are categorized based on how skin reacts to sun exposure and the likelihood of sunburn, which is not mentioned in the patient note.\n\nGiven the limited information provided, it is not clear if the lesions on the woman's neck would disqualify her from being considered a \"healthy subject.\" The term \"healthy subjects\" is often defined in the context of the study, and skin lesions may or may not be a disqualifying factor depending on the study's specific definition of health. However, without additional information on the patient's overall health status or Fitzpatrick Skin Type, it is not possible to definitively determine her eligibility.\n\nTherefore, the best course of action would be to gather more information before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1994": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to evaluate if the 44-year-old male patient is eligible for the HIV treatment study.\n\nThe patient note mentions:\n- A 44-year-old male with an emergency situation due to \"coffee ground\" vomiting.\n- He has a rapid heart rate and low blood pressure, indicative of a significant medical issue, likely related to gastrointestinal bleeding.\n- He was treated with fluids and a blood transfusion and admitted to the ICU for further care.\n- There is no mention of HIV infection or any antiretroviral treatment in the patient's note.\n\nThe inclusion criteria for the clinical trial are:\n- HIV infected\n- Specific antiretroviral treatment history\n- CD4 cell count of at least 50 cells/mm3 within 45 days prior to study entry\n- Viral load of 2000 copies/ml or more within 45 days prior to study entry\n- On current antiretroviral treatment regimen for at least 30 days prior to study entry\n- Willingness to use acceptable methods of contraception\n\nThe patient note does not provide any information regarding an HIV infection or any history of antiretroviral treatment. Thus, there is no evidence to suggest that this patient meets the inclusion criteria for the HIV treatment study. Without this information, we cannot assume that the patient is eligible.\n\nGiven the lack of information about the patient's HIV status and treatment history, we must conclude that the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1995": {
        "output": "Based on the patient note provided, the 44-year-old male patient presents with symptoms suggestive of upper gastrointestinal bleeding, indicated by \"coffee ground\" vomiting. He is hemodynamically unstable, as evidenced by a high heart rate and low blood pressure, and has received emergency treatment including rapid crystalloid infusion and a blood transfusion.\n\nThe clinical trial in question is evaluating the efficacy and safety of intravenous pantoprazole in preventing rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.\n\nTo determine this patient's eligibility for the clinical trial, let's compare the patient's characteristics with the inclusion criteria:\n\nInclusion Criteria:\n- Patients must be men or non-pregnant women at least 18 years of age.\n- Patients who present with a gastric or duodenal ulcer.\n\nPatient Characteristics:\n- 44-year-old male (meets age and gender criteria).\n- Presents with symptoms suggestive of upper gastrointestinal bleeding, but no explicit mention of a diagnosed gastric or duodenal ulcer.\n\nThe patient's age and gender align with the trial's inclusion criteria. However, while the symptoms are consistent with peptic ulcer disease, there is no definitive diagnosis provided in the note that confirms the presence of a gastric or duodenal ulcer. It is also not stated whether the patient has undergone endoscopic hemostatic therapy, which is a requirement for the trial.\n\nGiven the lack of specific information on a confirmed peptic ulcer diagnosis and endoscopic treatment, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther information, such as endoscopy results confirming a gastric or duodenal ulcer and successful hemostatic therapy, would be necessary to fully determine this patient's eligibility for the clinical trial.",
        "label": 2
    },
    "1996": {
        "output": "Based on the information provided for the patient and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the trial.\n\nThe patient is a 44-year-old male who presented to the emergency room with symptoms indicative of gastrointestinal bleeding (e.g., \"coffee ground\" vomiting) and hemodynamic instability (e.g., tachycardia with a heart rate of 135 bpm and hypotension with a blood pressure of 70/40 mmHg). The patient required rapid infusion of crystalloid solution and packed red blood cell transfusion and was admitted to the ICU for further care.\n\nThe TOBY clinical trial is focused on infants with perinatal asphyxial encephalopathy, assessing the efficacy of prolonged whole body cooling on survival without severe neurological or neurodevelopmental impairments at 18 months. The inclusion criteria for this trial are specifically for infants who are at least 36 completed weeks gestation and are admitted to the NICU with certain conditions related to perinatal asphyxia and encephalopathy.\n\nSince the patient in question is a 44-year-old male and not a term infant with perinatal asphyxial encephalopathy, he does not meet any of the inclusion criteria for the TOBY clinical trial. Therefore, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1997": {
        "output": "Given the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 44-year-old male patient\n- Presenting with multiple bouts of vomiting with a \"coffee ground\" appearance, indicative of upper gastrointestinal bleeding (UGIB)\n- Heart rate of 135 bpm and blood pressure of 70/40 mmHg, which suggests hypovolemic shock\n- Received rapid infusion of crystalloid solution and packed red blood cell transfusion\n- Admitted to the ICU, indicating the severity of the condition\n\nClinical Trial Inclusion Criteria:\n- Male or female non-cirrhotic patients at least 18 years old\n- Suspected to bleed from a peptic ulcer (PU)\n- Patients with hematemesis and/or hematochezia and/or melena observed by a clinical team\n- Documented signs of hypovolemia related to the current bleeding episode or, occurrence of symptoms of hypovolemia\n\nComparison:\n- The patient is a 44-year-old male, which meets the age and gender criteria.\n- The \"coffee ground\" appearance of the vomitus suggests bleeding from an upper GI source, which could be consistent with a peptic ulcer.\n- The vital signs and treatment received indicate that the patient has signs of hypovolemia related to the bleeding episode, meeting this part of the inclusion criteria.\n\nBased on the above comparison, the patient seems to meet the inclusion criteria for the clinical trial, as he is of the appropriate age, is experiencing an acute severe UGIB with documented signs of hypovolemia, and there is no mention of cirrhosis which would exclude him.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1998": {
        "output": "Based on the patient note, we have a 44-year-old male presenting with \"coffee ground\" vomiting, tachycardia, hypotension, and decreased mental status, all signs that are suggestive of an upper gastrointestinal bleed. He is being treated with a rapid infusion of crystalloid solution and packed red blood cells, and is admitted to the ICU for further care.\n\nThe clinical trial in question is studying the natural history of ulcer healing on proton pump inhibitors (PPI) and the ulcer recurrence without acid suppression therapy in patients with Non-steroidal Anti-inflammatory Drugs (NSAID) and non-Helicobacter pylori (HP) bleeding peptic ulcers.\n\nThe inclusion criteria for the trial are:\n1. Patient has a non-NSAID, non-Helicobacter pylori bleeding peptic ulcer\n2. Age > 18 years old\n3. Informed consent\n\nThe patient's age fits the inclusion criteria as he is over 18 years old. However, the patient note does not provide specific information about whether the cause of the bleeding ulcer is non-NSAID and non-Helicobacter pylori related, which is crucial to determine trial eligibility.\n\nGiven that there is insufficient information in the patient note to confirm the cause of the bleeding ulcer (whether it is non-NSAID and non-Helicobacter pylori), we would need further investigation to determine if this patient's condition aligns with the study's focus. Therefore, the patient could potentially be eligible, but additional information is required before a definitive referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1999": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note:\n- 44-year-old male with \"coffee ground\" vomiting (suggestive of upper gastrointestinal bleeding)\n- Heart rate of 135 bpm and blood pressure of 70/40 mmHg (indicative of hemodynamic instability)\n- Received rapid infusion of crystalloid solution followed by packed red blood cell transfusion\n- Admitted to the ICU for further care\n\nClinical Trial Inclusion Criteria:\n- Clean base ulcer with severe upper gastrointestinal bleeding (GIB), defined as melena, hematochezia, hematemesis, and/or gross blood in NG lavage\n- Any one of the following:\n  - SBP \u2264 90mmHg\n  - P of \u2265110 bpm\n  - Orthostatic changes with SBP drops 20mmHg or P increases 20 bpm\n  - Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission\n  - A documented hematocrit (HCT) drop of at least 6% from baseline\n- Endoscopically confirmed bleeding from gastric ulcer (GU), duodenal ulcer (DU), pyloric ulcer, or anastomotic ulcer\n- The patient can have either primary or secondary acute upper gastrointestinal hemorrhage\n\nThe patient's presentation is consistent with severe upper gastrointestinal bleeding, as evidenced by the \"coffee ground\" vomiting (which could be indicative of melena or hematemesis), and the hemodynamic instability shown by tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg). Additionally, the patient required transfusion, which aligns with the clinical trial's inclusion criteria.\n\nHowever, we do not have information on whether the bleeding is from a clean base ulcer or whether an endoscopic confirmation of the source of the bleeding has been done, as required by the trial. Despite the high likelihood that this patient may meet the inclusion criteria based on the severity of their presentation, we would need further information to confirm their eligibility, such as endoscopic findings.\n\nTherefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2000": {
        "output": "Based on the information provided in the patient note, the patient is a 44-year-old male with symptoms suggestive of gastrointestinal bleeding, as indicated by the \"coffee ground\" appearance of his vomit, tachycardia (heart rate of 135 bpm), hypotension (blood pressure of 70/40 mmHg), decreased mental status, and cool extremities. The patient has received initial stabilization with crystalloid solution and packed red blood cell transfusion and has been admitted to the ICU for further care.\n\nThe inclusion criteria for the clinical trial are:\n\n- All consecutive patients admitted for peptic ulcer bleeding with emergency endoscopy done within 24 hours after admission with Forrest classification types Ia, Ib, IIa, and IIb.\n- Age 15 - 90 years.\n- Written consent available.\n\nThe patient note suggests that the patient may have a bleeding peptic ulcer, which could fit the trial's condition if an emergency endoscopy confirms a Forrest classification type Ia, Ib, IIa, or IIb. However, to determine trial eligibility, the following would need to be confirmed:\n\n1. The diagnosis of peptic ulcer bleeding through emergency endoscopy and its classification according to the Forrest classification.\n2. The patient's ability to provide written consent.\n\nSince the patient is within the age range specified by the trial (44 years old) and presuming that the \"coffee ground\" vomiting is due to peptic ulcer bleeding, there is a potential match. However, confirmation of the Forrest classification and the patient's consent are required.\n\nTherefore, based on the information given and pending confirmation of the diagnosis and the patient's ability to consent:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2001": {
        "output": "Based on the patient note provided, the 44-year-old male patient presents with symptoms consistent with an upper gastrointestinal bleed, as evidenced by \"coffee ground\" vomiting. His heart rate of 135 bpm and blood pressure of 70/40 mmHg suggest hemodynamic instability, which is being acutely managed with a rapid infusion of crystalloid solution and packed red blood cell transfusion in the ICU.\n\nThe clinical trial in question is focused on comparing the efficacy of different endoscopic treatments for peptic ulcer bleeding. The inclusion criteria for the clinical trial are:\n\n1. Age >16\n2. Ability to obtain written consent\n3. Ulcers that require endoscopic therapy with stigmata of recent hemorrhage (SRH): Forrest I a, Ib, II a, and II b\n\nThe patient note does not specify whether the patient has a peptic ulcer or the Forrest classification of any such ulcer; however, the symptoms described could be consistent with peptic ulcer bleeding. Given the seriousness of the patient's condition and the fact that he is already in the ICU, it would be reasonable to investigate further to determine if the patient has a peptic ulcer with stigmata of recent hemorrhage that fits the inclusion criteria. If such an ulcer is present and classified as Forrest I a, Ib, II a, or II b, the patient may be eligible for the trial. Therefore, the next step would be to obtain an endoscopic evaluation to determine the nature of the bleeding.\n\nBased on the information available, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2002": {
        "output": "",
        "label": 0
    },
    "2003": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, here are the key points to consider:\n\nPatient note highlights:\n- The patient is a 44-year-old male.\n- The patient presents with signs of shock: tachycardia (heart rate of 135 bpm), hypotension (blood pressure of 70/40 mmHg), decreased mental status, and signs of poor perfusion (cool extremities).\n- The patient has evidence of gastrointestinal bleeding (\"coffee ground\" vomiting).\n- The patient has received a rapid infusion of crystalloid solution and packed red blood cells.\n\nClinical trial inclusion criteria:\n- Mean arterial pressure (MAP) less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading.\n- At least 1000 mL of crystalloid or 500 mL of colloid has been administered, unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated.\n\nComparing the patient's situation with the trial's inclusion criteria:\n- The patient's initial blood pressure of 70/40 mmHg indicates a MAP below 70 mmHg, which aligns with the trial's inclusion criteria for shock.\n- The patient has received a rapid infusion of crystalloid solution and blood transfusion, suggesting adequate fluid loading has been attempted.\n\nSince the trial's inclusion criteria do not specify the underlying cause of shock, and since the patient's current medical condition seems to align with the criteria for the study (shock state after fluid resuscitation), the patient appears to be a potential candidate for the trial.\n\nHowever, because the patient note does not specify the exact volume of crystalloid solution administered and does not provide CVP or PAOP values, there is a need for further investigation to ensure that these specific criteria are met. Therefore, the patient is potentially eligible but requires further assessment to confirm eligibility based on the precise details of the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2004": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 44-year-old male, which meets the age criterion of being 15 years of age or older.\n- The patient has presented with signs of shock, including a heart rate of 135 bpm and a blood pressure of 70/40 mmHg, which may indicate hypovolemia due to internal bleeding, possibly related to trauma.\n- The patient received a rapid infusion of crystalloid solution followed by a packed red blood cell transfusion, indicative of severe blood loss management.\n- There is no mention of the patient having suffered blunt or penetrating trauma, which is a necessary condition for the clinical trial.\n\nClinical Trial Inclusion Criteria:\n- Blunt or penetrating trauma\n- Prehospital Systolic Blood Pressure (SBP) <= 70; OR\n- Prehospital SBP 71-90 AND Heart Rate (HR) \u2265108\n- 15 years of age or older, or 50kg or more if age unknown\n\nComparison:\n- Age: The patient meets the age criterion.\n- Trauma: The patient note does not specify that the patient has suffered trauma.\n- Blood Pressure and Heart Rate: The patient's blood pressure and heart rate align with the criteria for shock as outlined in the trial, but without confirmation of trauma, it is unclear if this is due to traumatic injury.\n\nBased on the information provided, the key determining factor for eligibility is whether the patient's condition is a result of blunt or penetrating trauma, which is not specified in the patient note. If the vomiting with \"coffee ground\" appearance and signs of shock are due to a traumatic injury, then the patient may be eligible. However, without this information, we cannot assume eligibility based solely on the symptoms described.\n\nTherefore, without additional information confirming the cause of the patient's condition, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2005": {
        "output": "The patient note describes a 44-year-old male who presents to the emergency room with symptoms indicative of upper gastrointestinal bleeding, specifically the \"coffee ground\" appearance of vomit. He is hemodynamically unstable as evidenced by tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg), which are concerning for significant blood loss likely related to his gastrointestinal condition. The patient required resuscitation with a rapid infusion of crystalloid solution and packed red blood cells, indicating active management of suspected severe bleeding and subsequent admission to the ICU.\n\nThe clinical trial in question is focused on the use of high versus standard doses of Proton Pump Inhibitors (PPIs) in patients with peptic ulcer bleeding that has been successfully treated by endoscopic therapy. To be eligible for this trial, patients must be admitted for upper gastrointestinal bleeding secondary to peptic ulcers and must have been successfully treated with endoscopic therapy. \n\nGiven the information in the patient note, it appears that the patient could potentially be a candidate for this trial if his upper gastrointestinal bleeding is confirmed to be secondary to peptic ulcers, and he receives successful endoscopic therapy. However, the note does not specify whether the patient has peptic ulcers or if endoscopic therapy is planned or has been performed. Therefore, further investigation is required to determine if the patient meets the specific inclusion criteria regarding the cause of the bleeding and the treatment received.\n\nBased on the available information, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2006": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient does not appear to qualify for the ICEREA Study. The patient in the note has been brought to the emergency room for multiple bouts of vomiting with \"coffee ground\" appearance, which suggests gastrointestinal bleeding rather than a cardiac event. There is no mention of a cardiac arrest episode, which is a primary condition for inclusion in the trial. The trial specifically targets patients who have experienced out-of-hospital cardiac arrest due to a presumed cardiac etiology. Additionally, there are no details regarding the patient's return of spontaneous circulation (ROSC) or the delay between the cardiac arrest, ROSC, and the start of cooling, which are crucial for determining eligibility for the trial.\n\nGiven the lack of evidence that the patient has experienced a cardiac arrest and the absence of information regarding the specifics of ROSC and cooling, the patient would not meet the inclusion criteria for the ICEREA Study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2007": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the clinical trial. The clinical trial is specifically looking for pregnant individuals at term who are scheduled for an elective Cesarean section. The patient described in the note is a 44-year-old male who was brought to the emergency room for a completely different medical issue, unrelated to pregnancy or Cesarean sections.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2008": {
        "output": "Based on the patient note provided, the 44-year-old male patient has presented with symptoms suggestive of gastrointestinal bleeding (e.g., \"coffee ground\" vomiting), which has led to hemodynamic instability (evident from the heart rate of 135 bpm and blood pressure of 70/40 mmHg). The patient has been admitted to the ICU for further care, indicating a serious and acute medical condition.\n\nThe clinical trial in question is studying the effectiveness of esomeprazole in preventing peptic ulcers in subjects on continuous low-dose acetylsalicylic acid (ASA or Aspirin). The inclusion criteria for this clinical trial are specific to individuals who are on daily low-dose Aspirin therapy and meet additional age-related and medical history requirements. None of the inclusion criteria explicitly state that the trial is designed for patients with acute gastrointestinal bleeding or those who are critically ill, as is the case with the patient in the scenario provided.\n\nGiven the information in the patient note, there is no indication that the patient is on low-dose Aspirin therapy or meets any of the other specific inclusion criteria (such as having a documented history of uncomplicated peptic ulcer(s), being na\u00efve to low-dose ASA with the treatment started within 1 month prior to randomization, having stable coronary artery disease, or having upper GI symptoms requiring an EGD with findings of erosions).\n\nTherefore, based on the available information and the lack of alignment with the trial's inclusion criteria, the patient in the scenario would not be eligible for referral to the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2009": {
        "output": "Given the patient note, the patient is a 44-year-old male who has been brought into the emergency room with severe symptoms including \"coffee ground\" vomiting, a sign of possible gastrointestinal bleeding, tachycardia (heart rate of 135 bpm), and hypotension (blood pressure of 70/40 mmHg). The physical exam findings and the necessity for rapid infusion of fluids and blood transfusion indicate a critical condition requiring intensive care.\n\nThe clinical trial in question is a Phase I study assessing the safety and tolerability of TB-402, a monoclonal antibody directed against FVIII, in healthy male volunteers. The inclusion criteria specify:\n\n- Males 18 to 45 years of age (Groups 1-9) or 55 to 75 years of age (Group 10)\n- No clinically important abnormal physical, laboratory, ECG findings\n- Normal (or abnormal but not clinically significant) supine blood pressure and heart rate\n\nThe patient in question does not meet the inclusion criteria for several reasons:\n\n1. The patient is not healthy due to the current severe medical condition requiring ICU admission.\n2. The patient has clinically important abnormal physical findings (decreased mental status, cool extremities, severe hypotension).\n3. The patient's blood pressure and heart rate are not within normal limits or even abnormal but not clinically significant; they are indicative of a critical, life-threatening condition.\n\nTherefore, the patient would not be eligible for the clinical trial, and the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2010": {
        "output": "Based on the information provided in the patient note, the 44-year-old male presented to the emergency room with signs suggestive of an upper gastrointestinal bleed, as indicated by the \"coffee ground\" appearance of his vomit. He also exhibits signs of shock with a rapid heart rate and low blood pressure. He is receiving acute care, including rapid fluid resuscitation and blood transfusion.\n\nThe clinical trial in question is focusing on the perioperative course for patients surgically treated for benign peptic ulcer perforation. To determine eligibility for this trial, we need to establish whether the patient has been diagnosed and surgically treated for benign peptic ulcer perforation.\n\nThe patient note does not explicitly state that the patient has been diagnosed with a peptic ulcer or that he has had a perforation or any surgical treatment. Therefore, based on the information given, we cannot ascertain if the patient meets the inclusion criteria for the clinical trial.\n\nHowever, given the symptoms and emergency treatment, it is possible that further investigation could reveal a diagnosis consistent with peptic ulcer perforation, which would make the patient a candidate for the trial. Therefore, at this stage, with the information provided, we would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis and treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2011": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Helicobacter Pylori Empiric Treatment in Ulcer Bleeding,\" let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- 44-year-old male (meets age criterion)\n- Presented with \"coffee ground\" vomiting, which suggests upper gastrointestinal bleeding, a potential symptom of a peptic ulcer\n- No explicit mention of a diagnosis of a duodenal ulcer, erosive duodenitis, or gastric ulcer\n- No information on Helicobacter pylori status\n- No details on life expectancy, but no indication of a terminal condition\n- The patient is in a critical state, admitted to the ICU, which could affect his ability to attend further clinical controls\n\nClinical Trial Inclusion Criteria:\n- Patients older than 18 (the patient is 44, so this criterion is met)\n- Informed Consent signed (not mentioned, but potentially obtainable)\n- Diagnosis of non-variceal upper gastrointestinal bleeding secondary to a duodenal ulcer, erosive duodenitis, or gastric ulcer (the patient has upper gastrointestinal bleeding, but the exact cause is not specified)\n- Life expectancy longer than 6 months (not mentioned, but there is no indication the patient does not meet this criterion)\n- Able to attend further clinical controls (current critical condition could compromise this, but it's not a definitive exclusion)\n\nGiven the patient's current state and the lack of specific diagnostic information regarding the cause of the gastrointestinal bleeding, it is not possible to definitively determine eligibility for this clinical trial. Further investigation would be required to confirm the cause of the bleeding and ensure that the patient can meet all inclusion criteria, particularly regarding the diagnosis and the ability to attend further clinical controls. Hence, the patient's eligibility falls into the category of needing further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2012": {
        "output": "Based on the patient note provided, the 44-year-old male patient is presenting with symptoms of what appears to be gastrointestinal bleeding, given the \"coffee ground\" appearance of the vomit, a sign of digested blood. The patient also exhibits signs of shock, including tachycardia (heart rate of 135 bpm), hypotension (blood pressure of 70/40 mmHg), decreased mental status, and cool extremities. The patient is receiving treatment with rapid infusion of crystalloid solution and a packed red blood cell transfusion, and is admitted to the ICU for further care.\n\nThe clinical trial in question is focused on the genetic analysis of children with cyclic vomiting syndrome (CVS) and migraines.\n\nThe inclusion criteria for the clinical trial include:\n- Subjects age 0-21 years old with CVS (different phenotypes).\n- Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent.\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n- The patient is 44 years old, which is outside the specified age range of 0-21 years old.\n- There is no mention of the patient having cyclic vomiting syndrome (CVS) or migraines.\n- The current medical issue does not appear to be related to CVS.\n\nBased on these points, this patient would not be eligible for the clinical trial described. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2013": {
        "output": "The provided patient note describes a 44-year-old male who presented to the emergency room with multiple bouts of vomiting that has a \"coffee ground\" appearance, indicative of gastrointestinal bleeding. The patient has signs of shock, such as a high heart rate (135 bpm), low blood pressure (70/40 mmHg), decreased mental status, and cool extremities. These symptoms suggest an upper gastrointestinal bleed, which could be due to a peptic ulcer, among other causes.\n\nThe clinical trial in question is investigating the effectiveness of intravenous Proton Pump Inhibitors (PPIs) for peptic ulcer bleeding. The inclusion criteria for the trial specify that patients are eligible if they have a peptic ulcer with active bleeding, a non-bleeding visible vessel, or an adherent blood clot at the ulcer base observed within 24 hours of hospital admission.\n\nBased on the information given in the patient note, there is a possibility that this patient could have a peptic ulcer given the \"coffee ground\" vomit and instability, but there is no confirmation of a peptic ulcer nor a description of an endoscopy having been performed to visualize the ulcer and assess for active bleeding, NBVV, or an adherent blood clot. To determine whether the patient is eligible for the trial, an endoscopic evaluation would be needed.\n\nTherefore, without confirmation of these specific signs of peptic ulcer bleeding, the patient\u2019s eligibility for the trial is uncertain. Further investigation such as an endoscopy would be required to confirm the diagnosis and the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2014": {
        "output": "Based on the patient note provided, the patient is a 44-year-old male who was brought to the emergency room with symptoms suggestive of gastrointestinal bleeding (e.g., vomiting with a \"coffee ground\" appearance). His condition is critical, with signs of hypotension and tachycardia, indicating a possible shock state. He has received emergency treatment and has been admitted to the ICU for further care.\n\nThe clinical trial in question is focused on temperature control in central fever in the Neuro-ICU. Central fever is a specific type of fever that is due to central nervous system disturbances rather than an infectious cause.\n\nLooking at the inclusion criteria for the clinical trial:\n\n1. Two or more days with core temperature \u2265 100.4F\n2. Approval of the patient's primary attending physician\n3. Need for core temperature measurement independent of the study\n4. Admission to the Neuro-ICU for an underlying condition\n\nThe patient note does not mention a fever, central nervous system issues, or an admission to the Neuro-ICU specifically for a neurological condition. There is also no information on the patient having a core temperature above 100.4F for two or more days or any mention of central fever. Additionally, since the patient is currently in a critical state, their primary focus would likely be on stabilizing their condition rather than participating in a clinical trial.\n\nGiven the lack of information on a central fever or neurological condition and the current critical state of the patient, they do not meet the inclusion criteria specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2015": {
        "output": "Based on the information provided, the patient presents with \"coffee ground\" vomiting, tachycardia with a heart rate of 135 bpm, hypotension with a blood pressure of 70/40 mmHg, decreased mental status, and cool extremities. These symptoms are indicative of an upper gastrointestinal bleed rather than scorpion envenomation.\n\nThe clinical trial in question is for the treatment of scorpion envenomation and includes specific criteria related to symptoms of scorpion stings, such as sweating, pulse rate, respiratory rate, blood pressure, CNS effects, and priapism. The patient's presentation does not match these criteria, and there is no mention of a scorpion sting or related symptoms.\n\nMoreover, the inclusion criteria for the trial require the patient to have a composite score based on the scorpion sting symptoms, which cannot be computed for this patient due to the absence of these symptoms. Additionally, the trial specifies exclusion criteria for patients with other serious medical diseases, which could potentially include the current severe condition of the patient.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial on the treatment of scorpion envenomation, as the patient's symptoms and presentation are not related to a scorpion sting.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2016": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer (NSCLC), it appears that this particular patient does not meet the trial's inclusion criteria.\n\nThe patient note describes a 44-year-old male presenting with symptoms of what appears to be an upper gastrointestinal bleed, indicated by \"coffee ground\" vomiting, and hemodynamic instability as evidenced by tachycardia and hypotension. The patient has been admitted to the ICU for further care.\n\nHowever, the clinical trial is specifically for patients with locally advanced or metastatic NSCLC (stage IIIB or IV) who are not candidates for radical combined modality treatments or high-dose radiation therapy and who have at least one measurable lesion according to RECIST criteria, among other requirements.\n\nThere is no information in the patient note that suggests the patient has NSCLC or any type of cancer. Therefore, based on the available information, this patient does not meet the inclusion criteria for the clinical trial focused on NSCLC patients undergoing chemotherapy and would not be eligible for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2017": {
        "output": "Based on the patient note provided, the 44-year-old male patient has an overt non-variceal upper GI bleed as evidenced by coffee ground vomiting, which is consistent with the inclusion criteria listed for the European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) clinical trial. The patient's clinical presentation (vomiting with a \"coffee ground\" appearance) and the subsequent medical intervention (rapid infusion of crystalloid solution followed by packed red blood cell transfusion) suggest an acute blood loss from the upper GI tract, which meets the criteria of the study.\n\nFurthermore, the patient was admitted to the ICU for further care, which indicates that they are hospitalized, and it is likely that an upper GI endoscopy will be performed as part of the standard care for such a condition, meeting another criterion of the trial. Assuming that the complete medical record will be available, the patient appears to fulfill the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "2018": {
        "output": "",
        "label": 0
    },
    "2019": {
        "output": "Based on the patient note provided, the 44-year-old male patient presents with signs consistent with upper gastrointestinal bleeding, as indicated by vomiting with a \"coffee ground\" appearance. His critical state is further supported by a high heart rate of 135 bpm, low blood pressure of 70/40 mmHg, decreased mental status, and cool extremities. These symptoms, alongside the initiation of a rapid infusion of crystalloid solution and packed red blood cell transfusion, suggest an acute medical emergency likely related to a bleeding peptic ulcer.\n\nHowever, the inclusion criteria for the clinical trial requires:\n\n1. Bleeding peptic ulcer diagnosed based on hematemesis or melena, confirmed by upper GI endoscopy revealing active bleeding, non-bleeding visible vessels, or fresh blood clots, performed within 24 hours after hospitalization.\n2. Patients must have achieved primary hemostasis with an endoscopic hemostasis procedure via upper GI endoscopy.\n\nThe patient's initial presentation is consistent with upper GI bleeding, and he might undergo an upper GI endoscopy as part of his standard care to confirm a diagnosis of a bleeding peptic ulcer and potentially achieve primary hemostasis if an endoscopic hemostasis procedure is performed.\n\nHowever, there is no information in the note confirming that an endoscopy has already been performed, nor does it confirm that primary hemostasis has been achieved through an endoscopic procedure. Therefore, based on the current information, we cannot fully establish the patient's eligibility for the trial since key inclusion criteria have not been confirmed.\n\nConsequently, further investigation is needed to determine if the patient meets the specific inclusion criteria regarding diagnosis and treatment. Thus, the patient may be considered for the clinical trial upon further investigation, particularly if an endoscopy is performed and results confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2020": {
        "output": "Given the patient note and the clinical trial information provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note:\n- A 44-year-old male\n- Presented with vomiting of \"coffee ground\" appearance (suggestive of gastrointestinal bleeding)\n- Hemodynamic instability with a heart rate of 135 bpm and low blood pressure (70/40 mmHg)\n- Decreased mental status and cool extremities\n- Admitted to ICU for further care\n\nClinical Trial:\n- Examining the efficacy of famotidine vs. pantoprazole in preventing recurrent aspirin-induced peptic ulcer/erosion\n- Inclusion Criteria for the Trial:\n  - Upper gastrointestinal bleeding (GIB) or dyspepsia due to peptic ulcers/erosions while on low-dose aspirin (80-320 mg daily)\n  - Endoscopic confirmation of gastric or duodenal ulcers or erosions\n  - Continuous need for low-dose aspirin for secondary prevention of cardiovascular events\n  - Age 18 years or older\n\nAssessment:\n- The patient's age (44 years old) meets the trial age criterion.\n- The patient presents with what might be upper GIB, which could align with the trial's focus on peptic ulcers/erosions.\n- However, we do not have information on whether the patient is taking low-dose aspirin or if there is an endoscopic confirmation of ulcers or erosions.\n- The patient's current condition seems to be an acute emergency, which might prioritize stabilization over trial recruitment.\n\nBased on the information provided, the patient potentially has upper GIB, which could meet one of the trial's inclusion criteria, but we lack information on aspirin use and endoscopic findings. Additionally, the patient's acute condition and need for stabilization in the ICU must be considered before any trial recruitment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2021": {
        "output": "The patient note describes a 44-year-old male with symptoms indicative of upper gastrointestinal bleeding, as evidenced by the \"coffee ground\" appearance of his vomit. The patient's heart rate and blood pressure suggest that he is experiencing a significant bleed leading to hemodynamic instability. There is no mention of the patient's medication history, cardiovascular history, or whether he has had a percutaneous coronary intervention (PCI), nor is there any mention of a history of peptic ulcer disease (PUD).\n\nThe clinical trial in question is focused on patients who have ischemic heart disease, have undergone PCI, and are taking both aspirin and clopidogrel, with or without a proton pump inhibitor (PPI). The trial is investigating the effect of PPI use on ulcer complications in this specific patient group.\n\nSince the patient note does not provide information on the patient's history of cardiovascular disease, PCI, or his medication regimen including aspirin and clopidogrel, we cannot determine if the patient meets the inclusion criteria based on the information provided. Without this critical information, we cannot confidently refer the patient to the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2022": {
        "output": "",
        "label": 2
    },
    "2023": {
        "output": "Assessment of the patient's eligibility for the clinical trial titled \"Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer\" based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 44-year-old male, which fits within the age criteria (>18 and <75) of the trial.\n- The patient has presented with symptoms of what appears to be gastrointestinal bleeding (coffee ground vomiting), but there is no mention of esophageal cancer or any cancer diagnosis.\n- The patient's current condition (vomiting, hypotension, and decreased mental status) suggests an acute medical emergency, likely unrelated to cancer, and does not provide information on his ECOG performance status.\n- The note does not mention any histological confirmation of locally advanced esophageal cancer.\n\nClinical Trial Inclusion Criteria:\n- Informed consent form signed (Cannot be determined from the patient note).\n- ECOG performance status 0-2 (Cannot be determined from the patient note).\n- Age >18 and <75 (The patient meets this criterion).\n- Measurable disease by RECIST criteria (No information provided on this in the patient note).\n- Histologically confirmed diagnosis of locally advanced esophageal cancer (No diagnosis provided in the patient note).\n- Life expectancy of more than 3 months (Cannot be determined from the patient note).\n- Effective contraceptive use for patients of both sexes (Cannot be determined from the patient note).\n- No serious organ dysfunction or immuno-deficiency (Cannot be determined from the patient note, but the patient is in the ICU which could suggest possible organ dysfunction).\n- Neutrophils \u22653\u00d710^9/L, platelet count\u2265100\u00d710^9/L and hemoglobin\u22659g/dL, Creatinine \u2264 1.5 x NUL (No blood work results provided in the patient note).\n\nBased on the above analysis, the patient does not meet the necessary inclusion criteria of having a histologically confirmed diagnosis of locally advanced esophageal cancer. Additionally, the patient note does not provide enough information to assess other criteria such as ECOG performance status, measurable disease, life expectancy, organ function, or blood work results.\n\nTherefore, the patient does not appear to be eligible for the clinical trial titled \"Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2024": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we must determine if the patient is eligible for the trial. The inclusion criteria for the trial are:\n\n1. Patients status post laparoscopic Roux-en-Y gastric bypass (RYGB) surgery\n2. With active gastrointestinal hemorrhage secondary to marginal ulcer\n\nThe patient note describes a 44-year-old male with symptoms suggesting an upper gastrointestinal bleed, as indicated by \"coffee ground\" vomiting. However, there is no mention of the patient having undergone a Roux-en-Y gastric bypass surgery, nor is there any mention of a marginal ulcer being the confirmed source of the bleeding.\n\nGiven that the information provided does not confirm that the patient meets the specific inclusion criteria of the clinical trial (i.e., status post laparoscopic RYGB surgery and active gastrointestinal hemorrhage secondary to marginal ulcer), we cannot refer the patient for this clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2025": {
        "output": "Based on the patient note provided, the 44-year-old male patient presented to the emergency room with multiple bouts of vomiting that has a \"coffee ground\" appearance, tachycardia, hypotension, decreased mental status, and cool extremities. These symptoms are indicative of an upper gastrointestinal bleed rather than a perforated ulcer. There is no mention of the patient having a history of gastric bypass surgery or a perforated marginal ulcer.\n\nThe clinical trial in question is specifically looking to include patients who require laparoscopic repair of a perforated marginal ulcer after Roux-en-Y gastric bypass (RYGB). Since the patient note does not mention any history of gastric bypass or a diagnosis of a perforated marginal ulcer, this patient would not fit the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2026": {
        "output": "Based on the patient note provided, the 44-year-old male patient is brought to the emergency room with symptoms indicating a potential upper gastrointestinal bleed, as evidenced by \"coffee ground\" vomiting. There is no explicit mention of a perforated viscus or ulcer in the patient's note. However, his condition is severe, indicated by tachycardia and hypotension, and he has been admitted to the ICU for further care, which suggests an ongoing serious medical issue.\n\nComparing the patient's condition to the inclusion criteria of the clinical trial:\n\n1. The clinical trial is looking for patients with a clinical diagnosis of a perforated viscus who are scheduled to undergo surgical intervention.\n2. The patient must be a surgical candidate for endoscopic, laparoscopic, or open procedure.\n3. The age criterion is >21 years.\n4. Informed written consent is required.\n\nThe patient in the note appears to be critically ill and requires immediate care, which could potentially include surgery for a suspected gastrointestinal issue like a perforated viscus, although this has not been clearly diagnosed in the note. Given that the patient's condition might align with the trial's target of a perforated viscus and the patient seems to be of appropriate age and in need of surgical intervention, it's conceivable that he could meet the inclusion criteria upon further investigation and confirmation of his diagnosis.\n\nHowever, without a clear diagnosis of a perforated viscus and lacking information on whether the patient is a candidate for the specific surgical procedures mentioned (endoscopic, laparoscopic, or open procedure) or his ability to provide informed consent, there is a degree of uncertainty. Therefore, the patient could be considered for referral pending further diagnostic clarification and assessment of his condition.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2027": {
        "output": "Based on the information provided, the patient is a 44-year-old male who was brought to the emergency room with symptoms indicative of gastrointestinal bleeding, as suggested by \"coffee ground\" vomiting, and he is in a state of shock as evidenced by his high heart rate and low blood pressure. The patient required intensive care unit (ICU) admission for further management, which includes rapid fluid resuscitation and blood transfusion.\n\nThe clinical trial in question is focused on investigating the effect of intravenous (IV) dextrose on postoperative nausea and vomiting (PONV) in female patients who are undergoing urologic, gynecologic, or breast outpatient surgery. \n\nThe inclusion criteria for the clinical trial are as follows:\n1. ASA I or II - This refers to the American Society of Anesthesiologists (ASA) Physical Status Classification System where ASA I indicates a normal healthy patient and ASA II indicates a patient with mild systemic disease.\n2. Female urologic, gynecologic, and breast surgery patients undergoing scheduled same day procedures at LLUMC Heart and Surgical Hospital.\n\nGiven that the patient in question is male and is currently in the ICU for a condition unrelated to the outpatient surgeries mentioned in the trial criteria, he does not meet the gender requirement nor the surgery type requirement for the clinical trial. Therefore, this patient is not eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2028": {
        "output": "The patient presented is a 44-year-old male who has been brought to the emergency room with symptoms suggesting an upper gastrointestinal bleed, as indicated by \"coffee ground\" vomiting. He is hemodynamically unstable, as evidenced by his tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg), and he has received treatment with both a rapid infusion of crystalloid solution and a transfusion of packed red blood cells.\n\nThe clinical trial in question is investigating the efficacy of a Proton Pump Inhibitor (PPI) in the prevention of clopidogrel-related peptic ulcers. The trial aims to enroll clopidogrel users who do not have a baseline gastroduodenal ulcer at initial endoscopy. Patients in the trial will be given esomeprazole in addition to clopidogrel or clopidogrel alone for a period of 6 months.\n\nBased on the information provided, the patient's current condition does not clearly indicate that he is a user of clopidogrel or that he has a history of peptic ulcers. The inclusion criteria for the trial specifically require participants to be users of clopidogrel without a baseline gastroduodenal ulcer at the time of initial endoscopy. There is no evidence from the patient note that this individual is currently using clopidogrel or has been diagnosed with a peptic ulcer.\n\nGiven the lack of information regarding the patient's use of clopidogrel and his peptic ulcer history, the patient does not meet the inclusion criteria for the clinical trial as described. However, if further investigation reveals that the patient is indeed a user of clopidogrel and does not have a baseline gastroduodenal ulcer, he could potentially be considered for the trial. Therefore, based on the information provided in the patient note:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2029": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 44-year-old male.\n- He presents with multiple bouts of vomiting with \"coffee ground\" appearance, which indicates upper gastrointestinal bleeding, potentially from a peptic ulcer.\n- Heart rate is 135 bpm, and blood pressure is 70/40 mmHg, which suggests hypotension.\n- He has decreased mental status and cool extremities, which are signs of shock, likely due to the bleeding.\n- He received a rapid infusion of crystalloid solution and a red blood cell transfusion, suggesting that his condition is severe and that he likely has ongoing blood loss.\n- He is admitted to the ICU for further care, but there's no mention of endoscopic intervention yet.\n\nClinical Trial Inclusion Criteria Analysis:\n- Actively bleeding peptic ulcers (Forrest I), NBVV or Forrest IIa ulcer.\n- Successful endoscopic hemostasis achieved.\n- Presence of one of the following:\n  - Spurting hemorrhage during endoscopy.\n  - Ulcer >= 2 cm.\n  - Hemoglobin (Hb) on admission of < 9 g/dl.\n  - Hypotension prior to endoscopy defined by SBP of <90 mmHg AND HR of >110 bpm.\n\nComparing Patient to Criteria:\n- The patient's signs and symptoms suggest an upper gastrointestinal bleed, which could be due to a peptic ulcer (matching the target condition of the trial).\n- The patient does exhibit hypotension (SBP < 90 mmHg) and tachycardia (HR > 110 bpm), which meets one of the criteria for inclusion.\n- However, there is no information provided about the success of endoscopic hemostasis or the specific characteristics of the ulcer, such as size or the presence of spurting hemorrhage during endoscopy. Also, the hemoglobin level on admission is not provided.\n\nGiven that the patient meets some of the inclusion criteria (hypotension and tachycardia), but there is insufficient information on other critical criteria, such as the success of endoscopic hemostasis and specific characteristics of the ulcer, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2030": {
        "output": "Based on the patient note provided, the 44-year-old male patient has presented with \"coffee ground\" vomiting, indicative of gastrointestinal bleeding, and has been admitted to the ICU after receiving a rapid infusion of crystalloid solution and a packed red blood cell transfusion. The clinical trial in question is focused on the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy, specifically comparing the efficacy and safety of intravenous and oral Esomeprazole in such patients.\n\nTo assess the patient's eligibility for the clinical trial based on the inclusion criteria provided, we need to identify the following:\n\n1. Age \u2265 18: The patient is 44 years old, so this criterion is met.\n2. Confirmed ulcer bleeding with Forrest Ia, Ib, IIa, IIb: The patient note does not specify that the bleeding is from a confirmed peptic ulcer or the Forrest classification of the bleeding. This information is critical because the trial specifically targets patients who have confirmed ulcer bleeding with certain Forrest classifications, indicating active bleeding or a non-bleeding visible vessel, and who have achieved hemostasis.\n3. Endoscopic hemostasis achieved: The patient note does not mention that the patient has undergone endoscopic therapy or that hemostasis has been achieved.\n4. Informed consent obtained: This is a procedural criterion that could be fulfilled if the patient agrees to participate in the trial.\n\nGiven that the patient's note lacks specific information regarding the diagnosis of a peptic ulcer and the achievement of endoscopic hemostasis, we cannot confirm that the patient meets all the inclusion criteria. However, the clinical presentation suggests a high likelihood of a gastrointestinal bleed, which could potentially be from a peptic ulcer, and therefore the patient might be a candidate for endoscopic therapy.\n\nWithout confirmation of the diagnosis and treatment, I would consider further investigation to determine if the patient meets the specific criteria outlined in the trial. Therefore, my assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2031": {
        "output": "The patient in question is a 44-year-old male who presents with what appears to be acute upper gastrointestinal bleeding, as evidenced by multiple bouts of vomiting with a \"coffee ground\" appearance. This symptom is a classic sign of upper gastrointestinal bleeding and aligns with the inclusion criteria of the clinical trial, which specifically mentions \"coffee ground vomiting\" as one of the clinical evidences for acute upper gastrointestinal bleeding.\n\nIn addition to the presenting symptom, the patient's physiological responses (heart rate of 135 bpm and blood pressure of 70/40 mmHg) suggest a significant acute blood loss, which is consistent with the clinical picture of acute upper gastrointestinal bleeding. The patient is receiving appropriate initial treatment with rapid infusion of crystalloid solution followed by packed red blood cell transfusion, indicating the severity of the condition and the need for further care in the ICU.\n\nGiven that the patient's presentation matches the inclusion criteria for the clinical trial (established diagnosis of acute upper gastrointestinal bleeding confirmed by the presence of hematemesis/coffee ground vomiting and other clinical evidence of acute blood loss), and assuming that the patient or their legal representative can provide written informed consent, the patient appears to be a suitable candidate for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2032": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial on a three-point scale:\n\nPatient Note:\n- 44-year-old male\n- Brought to the emergency room with severe vomiting of \"coffee ground\" appearance\n- Heart rate of 135 bpm\n- Blood pressure of 70/40 mmHg\n- Decreased mental status\n- Cool extremities\n- Received crystalloid solution and packed red blood cell transfusion\n- Admitted to ICU\n\nClinical Trial Inclusion Criteria:\n- Acute gastroenteritis patients between 1-14 years\n- Presenting with diarrhea, persistent vomiting\n- Failed oral rehydration\n- Admitted to the observation unit for intravenous hydration\n\nAnalysis:\n- The patient is a 44-year-old male, which does not meet the age requirement of 1-14 years specified in the clinical trial's inclusion criteria.\n- The clinical trial is specifically for patients with acute gastroenteritis, and there is no mention in the patient note of a diagnosis of gastroenteritis.\n\nBased on the information provided, the patient does not meet the inclusion criteria for age and there is no clear diagnosis of gastroenteritis. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2033": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient note:\n- 44-year-old male\n- Presented with \"coffee ground\" vomiting\n- Signs of shock (tachycardia with a heart rate of 135 bpm, hypotension with blood pressure of 70/40 mmHg)\n- Decreased mental status and cool extremities\n- Received a rapid infusion of crystalloid solution followed by packed red blood cell transfusion\n- Admitted to the ICU\n\nClinical trial:\n- Title: PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers\n- Inclusion criteria:\n  - A history of H. pylori-negative idiopathic peptic ulcers\n  - No exposure to certain medications before hospitalization\n  - Negative biopsies for H. pylori in the absence of acid suppressive therapy\n  - Endoscopically confirmed ulcer healing\n  - Age >18 years old\n  - Informed consent\n\nThe patient presents with symptoms that suggest an upper gastrointestinal bleed given the \"coffee ground\" vomiting. However, the patient note does not provide information about the cause of the upper GI bleeding, whether he has a history of H. pylori-negative idiopathic peptic ulcers, whether he has been exposed to the listed medications, or whether he has undergone endoscopy to confirm ulcer healing. Without this information, it's impossible to determine definitively if the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include:\n- Confirmation of a history of H. pylori-negative idiopathic peptic ulcers\n- Review of medication history prior to hospitalization\n- Endoscopic evaluation to confirm ulcer healing and rule out other causes of ulceration\n- Ensuring the patient can provide informed consent once medically stable",
        "label": 1
    },
    "2034": {
        "output": "",
        "label": 2
    },
    "2035": {
        "output": "Based on the patient note provided, the patient is a 44-year-old male who presents with multiple bouts of \"coffee ground\" vomiting, which is indicative of upper gastrointestinal bleeding (UGIB). The patient's tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg) suggest a significant bleed and hemodynamic instability, which warrant emergent care and likely necessitate further diagnostic procedures, such as an upper GI endoscopy.\n\nThe clinical trial in question is surveying non-variceal upper gastrointestinal bleeding in Vietnamese patients. The inclusion criteria for this trial include adult patients (>=18 years) who are admitted to the hospital with overt non-variceal upper GI bleed, as evidenced by symptoms such as hematemesis, coffee ground vomiting, melena, or hematochezia, and who have had an upper GI endoscopy performed.\n\nGiven that the patient meets the age criterion and presents with symptoms consistent with non-variceal upper GI bleed (coffee ground vomiting), the next step to meet the trial inclusion criteria would be the performance of an upper GI endoscopy. Since the patient is admitted to the ICU for further care, it is reasonable to assume that an endoscopy may be part of the standard diagnostic workup to investigate the source of the bleeding.\n\nWhile we do not have information on whether the patient is Vietnamese or whether an endoscopy has been performed yet, the clinical presentation aligns well with the study's focus. Therefore, the assessment of eligibility for referring this patient to the clinical trial is as follows:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2036": {
        "output": "Based on the patient note provided, the 44-year-old male is presenting with symptoms that could be indicative of a gastrointestinal bleed, such as vomiting with a \"coffee ground\" appearance, tachycardia (heart rate of 135 bpm), hypotension (blood pressure of 70/40 mmHg), decreased mental status, and cool extremities. These symptoms necessitated his admission to the ICU for further care, which included a rapid infusion of crystalloid solution and packed red blood cell transfusion.\n\nThe clinical trial in question is focused on the treatment of aspirin-associated peptic ulcers, comparing the efficacy of esomeprazole plus aspirin with esomeprazole alone. The inclusion criterion for the trial is being an aspirin user with a peptic ulcer confirmed by endoscopy.\n\nGiven that the patient note does not mention the use of aspirin or the confirmation of a peptic ulcer by endoscopy, it is not possible to definitively determine whether the patient meets the inclusion criteria for the trial. To refer the patient for this clinical trial, it would be necessary to confirm that the patient's symptoms are due to an aspirin-associated peptic ulcer, which would require further investigation such as an endoscopy.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2037": {
        "output": "",
        "label": 2
    },
    "2038": {
        "output": "Based on the patient note, the 44-year-old male patient is presenting with \"coffee ground\" vomiting, which is indicative of upper gastrointestinal bleeding, and he has received packed red blood cell transfusion. This clinical presentation could be consistent with peptic ulcer bleeding, which is relevant to the clinical trial in question.\n\nHowever, there is no explicit confirmation in the patient note that the bleeding is due to a peptic ulcer, or that it is associated with low-dose ASA (aspirin) use. Furthermore, there is no information provided about the patient's use of ASA, history of peptic ulcer bleeding, H. pylori status, or whether they have provided written informed consent.\n\nGiven the lack of specific information connecting the patient's acute presentation to the inclusion criteria of the clinical trial (which focuses on recurrent upper gastrointestinal bleeding in high-risk users of low-dose ASA with documented peptic ulcer bleeding and management of H. pylori), we cannot confidently refer this patient for the clinical trial based solely on the information provided.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2039": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess the patient's condition against the inclusion and exclusion criteria provided for the trial.\n\nPatient note assessment:\n- The patient is a 44-year-old male, meeting the age criterion of \u226515 years.\n- The patient presents with symptoms that suggest hemorrhagic shock: \"coffee ground\" vomiting, tachycardia (heart rate of 135 bpm), hypotension (blood pressure of 70/40 mmHg), decreased mental status, and cool extremities.\n- The patient received rapid crystalloid infusion and packed red blood cell transfusion, indicating a response to presumed significant blood loss.\n- The nature of the patient's injury or the cause of the hemorrhagic shock is not specified in the note. We do not have information on whether it is due to blunt or penetrating injury.\n\nClinical trial inclusion criteria assessment:\n- Blunt or penetrating injury (not specified for the patient)\n- Age \u226515 years (patient is 44 years old)\n- Prehospital SBP \u2264 90 mmHg (patient has a blood pressure of 70/40 mmHg)\n- Weight is not specified, but the patient is an adult male, and it is reasonable to assume a weight \u226550kg\n\nExclusion criteria assessment:\n- We do not have information that the patient meets any of the specific exclusion criteria.\n\nGiven the information provided, the patient matches some of the inclusion criteria: age and prehospital SBP \u2264 90 mmHg. However, the cause of the hemorrhagic shock is not clear from the patient note. Since we cannot confirm whether the patient's condition is a result of blunt or penetrating trauma, we cannot immediately rule them in for the trial. Further investigation is required to determine the cause of the hemorrhagic shock and ensure none of the exclusion criteria apply.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2040": {
        "output": "",
        "label": 0
    },
    "2041": {
        "output": "Based on the patient note provided:\n\nA 44-year-old male is brought to the emergency room with symptoms of \"coffee ground\" vomiting, tachycardia, hypotension, decreased mental status, and cool extremities. He is treated with crystalloid solution and red blood cell transfusion, and admitted to the ICU for further care.\n\nAnd the clinical trial information:\n\nTitle: Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer\n\nInclusion criteria:\n- Cytologically or histologically confirmed esophageal carcinoma\n- Age of 20-80\n- Karnofsky performance status \u2265 70\n- No treatments prior to enrollment\n- At least one measurable lesion on CT, MRI or esophageal barium exam\n- Normal functions of heart, lung, liver, kidney, and bone marrow\n- Blood exams qualified for chemotherapy, which included hemoglobulin \u22659 g/dl, neutrophil \u22651.5\u00d710^9/L and platelet (PLT) \u2265100\u00d710^9/L, creatinine \u22641.5 UNL\n- Informed consent signed\n\nBased on the patient note, there is no information suggesting that the patient has esophageal cancer. The symptoms described are consistent with gastrointestinal bleeding rather than esophageal carcinoma. Furthermore, the patient is currently receiving acute treatment for a likely unrelated condition, which could also impact their eligibility for a trial that requires participants to have not received any prior treatments. There is also no mention of the patient's Karnofsky performance status or any diagnostic imaging confirming a measurable lesion related to esophageal cancer.\n\nGiven the lack of information connecting the patient's current medical issue to esophageal carcinoma and the explicit requirement for confirmed esophageal carcinoma as part of the inclusion criteria, this patient would not be considered eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2042": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility:\n\nPatient note:\n- 44-year-old male\n- Presented with multiple bouts of \"coffee ground\" vomiting\n- Vital signs indicate possible hypovolemic shock (heart rate of 135 bpm, blood pressure of 70/40 mmHg)\n- Received treatment including rapid infusion of crystalloid solution and packed red blood cell transfusion\n- Admitted to ICU for further care\n\nClinical trial:\n- Title: Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers\n- Target condition: Gastroduodenal ulcer with active bleeding\n- Inclusion criteria: All adult patients with gastroduodenal ulcer\n\nAssessment:\nThe patient's symptoms of \"coffee ground\" vomiting suggest upper gastrointestinal bleeding, which could be related to a gastroduodenal ulcer, although this is not explicitly confirmed in the patient note. The patient has been treated for what appears to be an acute bleed, which aligns with the clinical trial's focus on actively bleeding gastroduodenal ulcers.\n\nSince the inclusion criteria for the clinical trial are quite broad and simply require all adult patients with gastroduodenal ulcers, and the patient presents with symptoms that could be indicative of such an ulcer, it seems reasonable to consider referring this patient to the clinical trial. However, an explicit diagnosis of a gastroduodenal ulcer with active bleeding is necessary to confirm eligibility.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2043": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the eligibility:\n\nPatient Note Analysis:\n- The patient is a 44-year-old male, which satisfies the age criterion of \u226518 years.\n- The patient has presented with \"coffee ground\" vomiting, which is indicative of upper gastrointestinal bleeding, possibly related to peptic ulcer disease.\n- The patient's vital signs suggest hemodynamic instability, which is consistent with significant bleeding and would likely result in a higher Rockall score.\n\nClinical Trial Inclusion Criteria Analysis:\n1. Clinical presentations of melena, hematochezia, or hematemesis - The patient has hematemesis, as indicated by \"coffee ground\" vomiting.\n2. Gastroscopy confirmed peptic ulcers and major stigmata of recent hemorrhage - While the patient's symptoms are suggestive of peptic ulcer bleeding, there's no confirmation that a gastroscopy has been performed or that peptic ulcers with major stigmata of recent hemorrhage have been confirmed.\n3. A Rockall score \u2265 6 - The patient's condition (cool extremities, decreased mental status, tachycardia, hypotension, and ongoing bleeding) suggests a potentially high Rockall score, but the actual score is not provided.\n\nGiven that the patient's condition appears to align with the clinical manifestations required by the trial and the likely high Rockall score, but lacking confirmation of peptic ulcers via gastroscopy, the patient could be considered for referral to the clinical trial upon further investigation to confirm the diagnosis with a gastroscopy and determine the Rockall score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2044": {
        "output": "Based on the patient note provided, the 44-year-old male patient presented with \"coffee ground\" vomiting, a heart rate of 135 bpm, and a blood pressure of 70/40 mmHg. These symptoms suggest the patient is experiencing a major bleeding event, which is further supported by his need for rapid infusion of crystalloid solution and packed red blood cell transfusion. This patient was admitted to the ICU for further care, indicating the severity of his condition.\n\nComparing these details to the clinical trial titled \"Control of Major Bleeding After Trauma Study,\" the inclusion criteria are as follows:\n\n- Age >= 18 years\n- Acutely injured\n- SBP < 70 mmHg or SBP 71-90 mmHg with heart rate (HR) > 108 beats per minute\n\nThe patient meets the age criteria (44 years old), is acutely injured (as evidenced by the emergency situation and major bleeding), and has both a systolic blood pressure (SBP) less than 70 mmHg (70/40 mmHg) and a heart rate greater than 108 beats per minute (135 bpm). Therefore, this patient fits all the inclusion criteria outlined for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2045": {
        "output": "Given the patient note and the clinical trial information provided, the patient is a 44-year-old male presenting with symptoms indicative of gastrointestinal bleeding (e.g., vomiting with \"coffee ground\" appearance, hypotension, tachycardia, and decreased mental status). This patient is in need of immediate medical attention, as evidenced by his admission to the ICU.\n\nThe clinical trial in question is focused on the prevention of gastric ulcer bleeding by using a computer-alert system in general practice. It is aimed at general practitioners and involves the use of a decision-support tool to reduce the frequency of peptic ulcer bleeding related to the use of NSAIDs and aspirin.\n\nThe inclusion criteria for the clinical trial do not match the patient's condition. The study is designed for general practitioners in the Region of Southern Denmark who are linked to the Danish General Medical Database for at least 6 months. It does not include patients directly, but rather targets the healthcare providers who would use the decision-support tool in their practice.\n\nTherefore, the patient in the emergency room described in the note would not be eligible for this clinical trial, as it does not pertain to individual patient interventions but to a practice-based intervention for general practitioners.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2046": {
        "output": "The patient note describes a 44-year-old male with symptoms suggestive of gastrointestinal bleeding, indicated by \"coffee ground\" vomiting. He is experiencing a significant cardiovascular response to this event, with tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg). The patient required resuscitation with fluids and blood products and has been admitted to the ICU for further care.\n\nThe clinical trial in question is focused on the risk of uncomplicated symptomatic peptic ulcer in the general population and its relationship with the use of low dose aspirin, other anti-inflammatory drugs, and the effect of proton pump inhibitors. The inclusion criteria for this trial are quite specific: Patients aged 40-84 years in the period of 1997-2005.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, there are several factors to consider:\n\n1. The patient's age fits within the range of 40-84 years.\n2. The patient note does not provide any information regarding the use of low dose aspirin or other anti-inflammatory drugs, which are relevant to the study's focus.\n3. There is no information provided about the patient's history or diagnosis of peptic ulcer.\n4. The timeframe mentioned in the inclusion criteria (1997-2005) may imply that the study is retrospective and looking at a historical cohort. The patient's current medical event is outside of this period.\n\nGiven the lack of information on the patient's use of anti-inflammatory drugs and the timeframe discrepancy, it seems that the patient would not meet the inclusion criteria for the trial as the clinical trial is looking for data from 1997-2005 and the patient is being treated outside of this timeframe.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2047": {
        "output": "Based on the information provided:\n\nPatient note:\n- 44-year-old male\n- Presents with multiple bouts of vomiting with \"coffee ground\" appearance\n- Heart rate of 135 bpm\n- Blood pressure of 70/40 mmHg\n- Decreased mental status\n- Physical exam findings of cool extremities\n- Received rapid infusion of crystalloid solution and packed red blood cell transfusion\n- Admitted to the ICU for further care\n\nClinical trial inclusion criteria:\n- All patients with acute abdomen undergoing abdominal surgery under emergency and presenting on arrival in ICU at least a sign of bad perfusion.\n\nThe patient in the note presents with signs of bad perfusion, evidenced by the low blood pressure, increased heart rate, cool extremities, and decreased mental status. These are indicators that the patient may be experiencing shock, possibly due to an acute abdomen which could necessitate emergency abdominal surgery. Given that the patient has been admitted to the ICU, where further evaluation and management of acute abdomen may be considered, there is a possibility that the patient could fulfill the trial's inclusion criteria.\n\nHowever, there is no explicit mention of acute abdomen or the need for abdominal surgery from the patient note. Therefore, further investigation would be needed to confirm whether the patient's condition is indeed due to an acute abdomen and if they are undergoing or have undergone emergency abdominal surgery.\n\nBased on the available information, the assessment of eligibility for this patient for the clinical trial titled \"Different Fluidic Strategy in Patients With Acute Abdomen: The Sure Volume\" would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2048": {
        "output": "Based on the information provided, the patient is a 44-year-old male who has presented with symptoms consistent with upper gastrointestinal bleeding, as evidenced by \"coffee ground\" vomiting. His vital signs indicate possible hypovolemic shock with a heart rate of 135 bpm and low blood pressure (70/40 mmHg), which is a serious and life-threatening condition. The patient is receiving emergency treatment, including fluid resuscitation and packed red blood cell transfusion, and has been admitted to the ICU for further care.\n\nThe clinical trial in question is focused on comparing two different endoscopic injection materials for the treatment of gastric varices. The inclusion criteria for the trial are:\n\n1. Patients presented to the hospital with acute gastric variceal bleeding, with or without liver cirrhosis.\n2. Patients are between 18 and 80 years old.\n\nThe patient note indicates that the individual is within the age range specified by the trial (44 years old) and is presenting with what could be symptoms of acute gastric variceal bleeding (coffee ground vomiting). However, without additional information confirming the diagnosis of gastric varices or liver cirrhosis, we cannot definitively say that this patient is experiencing variceal bleeding as opposed to another cause of upper gastrointestinal bleeding.\n\nTherefore, based on the information provided and assuming that upon further investigation the patient's condition is confirmed to be acute gastric variceal bleeding, the patient may potentially be eligible for the clinical trial. However, further diagnostic confirmation would be needed before a referral could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2049": {
        "output": "Based on the information provided in the patient note, the patient is a 44-year-old male who presents with symptoms suggestive of an upper gastrointestinal bleed, indicated by \"coffee ground\" vomiting. He is hemodynamically unstable with a heart rate of 135 bpm and blood pressure of 70/40 mmHg, which suggests a serious condition that requires immediate and intensive care in the ICU.\n\nThe clinical trial in question is investigating the therapeutic effectiveness of proton pump inhibitors (PPIs) among different administration methods (PO, IV, and SL) in patients with peptic ulcer disease.\n\nTo determine the patient's eligibility for the clinical trial, let's compare the trial inclusion criteria with the patient's characteristics:\n\nInclusion Criteria:\n- Patients with peptic ulcer disease\n- Age: 20-75 years old\n- Patients who submitted informed consent\n\nPatient's Characteristics:\n- 44 years old male (fits the age criterion)\n- Symptoms suggestive of an upper gastrointestinal bleed, which could be related to peptic ulcer disease (possible fit, but the actual diagnosis of peptic ulcer disease is not confirmed in the patient note)\n- The patient's ability to provide informed consent is not clear due to decreased mental status (this could be a temporary issue due to his acute condition, but it is a concern for immediate participation)\n\nBased on the available information, it is not clear if this patient has a confirmed diagnosis of peptic ulcer disease, which is necessary for inclusion in the trial. Additionally, the patient's decreased mental status may prevent him from providing informed consent at this time. While the age criterion is met, the other criteria require further medical evaluation and information.\n\nGiven these considerations, the patient's eligibility for this clinical trial is uncertain without further information regarding his diagnosis and his capacity to consent. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2050": {
        "output": "Based on the information provided, the patient in question is a 44-year-old male who presented to the emergency room with symptoms indicative of gastrointestinal bleeding, demonstrated by \"coffee ground\" vomiting. He is in a state of shock, as evidenced by his rapid heart rate of 135 bpm, low blood pressure of 70/40 mmHg, decreased mental status, and cool extremities. He is treated with fluid resuscitation and blood transfusion and admitted to the ICU for further care.\n\nThe clinical trial in question is focused on comparing the safety and efficacy of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in combination with thrombolytic treatment in patients with acute massive pulmonary thromboembolism (PE). The inclusion criteria for the trial are:\n\n1. Adults, age \u2265 18 years\n2. Patients who have signed the study informed consent form prior to initiation of any study-related procedure.\n3. Acute massive PE patients who require thrombolytic treatment.\n\nThe patient described in the note does not have documented acute massive pulmonary embolism; instead, he has symptoms that suggest gastrointestinal bleeding and shock. There is no mention of pulmonary embolism or the requirement of thrombolytic treatment, which are necessary conditions for inclusion in the clinical trial.\n\nGiven that the patient's clinical presentation does not match the target condition of the clinical trial, which is acute massive pulmonary embolism, and there is no information suggesting that the patient requires thrombolytic treatment for PE, he does not meet the inclusion criteria for this particular study.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2051": {
        "output": "Based on the patient note provided, the 44-year-old male patient was brought to the emergency room with symptoms indicative of an acute medical condition, potentially gastrointestinal bleeding given the \"coffee ground\" appearance of the vomit. His current condition includes a rapid heart rate (tachycardia) and low blood pressure (hypotension), which necessitated rapid infusion of fluids and a blood transfusion, followed by admission to the ICU for further care.\n\nThe clinical trial in question is evaluating predictive risk factors for chemotherapy-induced nausea and vomiting. The inclusion criteria for the trial are:\n\n1. Minimum age of 18 years\n2. Histologically proven solid organ cancer\n3. Eastern Cooperative Oncology Group Performance status 0-2\n4. More than 3 months for life expectancy\n5. Patients scheduled to receive the first line, first cycle FOLFOX or FOLFIRI chemotherapy\n6. Patients must sign an informed consent\n\nThe patient note does not mention a diagnosis of solid organ cancer, nor does it indicate that the patient is scheduled to receive chemotherapy, specifically FOLFOX or FOLFIRI. The patient's current medical emergency is not related to chemotherapy but appears to be an acute condition requiring immediate intensive care.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not meet the criteria for the study, primarily due to the lack of any indication of solid organ cancer or pending chemotherapy treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2052": {
        "output": "Given the patient's presentation with \"coffee ground\" emesis, which is indicative of upper gastrointestinal (GI) bleeding, and the fact that he was admitted to the ICU for further care, he meets the inclusion criteria for the clinical trial that is investigating the effect of prokinetic drugs on endoscopy outcomes for upper GI bleed. The patient is an adult within the specified age range (18-80) and has been admitted to the ICU for a condition (coffee ground emesis) that is directly relevant to the trial's focus.\n\nBased on the information provided, the patient is a suitable candidate for the trial, as he fulfills the explicit inclusion criteria mentioned in the trial summary.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2053": {
        "output": "Assessing the information provided:\n\nPatient note:\n- 44-year-old male\n- Presented with multiple bouts of vomiting with \"coffee ground\" appearance\n- Vital signs: heart rate 135 bpm, blood pressure 70/40 mmHg\n- Clinical findings: decreased mental status, cool extremities\n- Intervention: received crystalloid solution and packed red blood cells, admitted to ICU\n\nClinical trial:\n- Title: Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting\n- Inclusion criteria: Must be undergoing elective orthognathic surgery, age 18-50 years old, must have signed informed consent\n\nThe patient in the note is not indicated to be undergoing elective orthognathic surgery, which is a specific type of surgery related to the jaws. The patient seems to be dealing with an acute medical issue, possibly gastrointestinal bleeding, indicated by \"coffee ground\" vomit, which is typically unrelated to orthognathic surgery. There is no mention of elective surgery, and the patient's current emergency condition makes it unlikely that he is a candidate for a study focused on an elective procedure.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial in question, specifically the requirement of undergoing elective orthognathic surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2054": {
        "output": "",
        "label": 2
    },
    "2055": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Transfusion in Gastrointestinal Bleeding,\" we can make an assessment of the patient's eligibility for the clinical trial.\n\nPatient Note Assessment:\n- The patient is a 44-year-old male, which meets the age criterion of being 18 years or over.\n- The patient presents with \"coffee ground\" vomiting, indicative of upper gastrointestinal bleeding, which aligns with the trial's focus on Acute Upper Gastrointestinal Bleeding (AUGIB).\n\nInclusion Criteria for the Clinical Trial:\n- Adults aged 18 or over years presenting with AUGIB, defined by haematemesis or melaena.\n\nThe patient's presentation of \"coffee ground\" vomiting is consistent with haematemesis, a symptom of AUGIB. His age also falls within the specified range for the trial. Therefore, it appears that the patient meets the inclusion criteria provided for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "2056": {
        "output": "",
        "label": 2
    },
    "2057": {
        "output": "Based on the patient note provided, the 44-year-old male patient presents with what appears to be upper gastrointestinal bleeding, as suggested by the \"coffee ground\" vomiting. He has a rapid heart rate and low blood pressure, indicative of a potential bleeding event or shock. He requires aggressive management with fluid resuscitation and blood transfusion and is admitted to the ICU for further care.\n\nThe clinical trial in question is evaluating the efficacy of a cytoprotective agent, Repamipide, for the prevention of peptic ulcers in patients who are taking dual antiplatelet agents (clopidogrel and aspirin).\n\nTo determine trial eligibility, let's examine the inclusion criteria against the patient's information:\n\n1. Age 18-70 year-old: The patient is 44 years old, which falls within the specified age range.\n2. Had cardiovascular disease which needed clopidogrel and aspirin: The patient note does not mention cardiovascular disease or the use of dual antiplatelet therapy. This information is critical to determine eligibility for this trial.\n3. Stable enough for gastroscopy: The patient is admitted to the ICU and is being stabilized, but without further information, we cannot ascertain if he is stable enough for gastroscopy at this time.\n\nGiven the information at hand, the patient's eligibility cannot be fully determined because the patient's history regarding cardiovascular disease and dual antiplatelet therapy use is not provided. Additionally, while the patient is being stabilized, we do not have confirmation that he is stable enough for gastroscopy, which is one of the inclusion criteria.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2058": {
        "output": "Based on the patient note provided, the 44-year-old male has presented with symptoms suggestive of an acute upper gastrointestinal bleed, as indicated by the \"coffee ground\" appearance of his vomit. The patient's vital signs indicate hemodynamic instability with tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg), which are concerning for significant blood loss. The patient's management with rapid crystalloid infusion and packed red blood cell transfusion is consistent with the treatment of an acute bleed.\n\nThe clinical trial in question is looking for patients with bleeding peptic ulcers who have major stigmata of recent hemorrhage (SRH) and who were treated with specific endoscopic hemostasis techniques.\n\nThe patient note does not explicitly mention a diagnosis of a peptic ulcer or describe the specific endoscopic treatment that the patient may have received. Without this information, we cannot confirm that the patient meets the inclusion criteria for the clinical trial.\n\nAs a result, the patient note lacks sufficient information to definitively include the patient in the clinical trial based on the given criteria. However, given the symptoms and the potential for a peptic ulcer being the cause of the bleeding, further investigation is warranted to determine whether the patient's condition aligns with the study's focus.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2059": {
        "output": "Based on the patient note provided, the patient is a 44-year-old male who presents with signs suggestive of gastrointestinal bleeding, as indicated by \"coffee ground\" vomiting, which is a symptom associated with peptic ulcer bleeding. The patient is also experiencing a severe episode, given the tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg), which required rapid fluid resuscitation and blood transfusion, indicating a significant or high-risk bleeding event.\n\nFor the clinical trial titled \"Argon Plasma Coagulation for Bleeding Peptic Ulcers,\" the inclusion criteria are:\n(i) over 20 years of age and\n(ii) patients with high-risk peptic ulcer bleeding.\n\nThe patient in the note is indeed over 20 years old and is displaying symptoms that could be consistent with high-risk peptic ulcer bleeding, which meets both inclusion criteria for the clinical trial. However, without confirmation of a diagnosis of a peptic ulcer via endoscopy or other diagnostic means, there is still some uncertainty regarding the patient's eligibility.\n\nGiven the information available and assuming that further investigation (such as endoscopic confirmation of a peptic ulcer) supports the initial assessment, the patient could potentially be a candidate for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2060": {
        "output": "Based on the patient note, the 44-year-old male patient presented to the emergency room with symptoms consistent with a bleeding peptic ulcer, as evidenced by \"coffee ground\" appearance vomiting, which is indicative of digested blood. The patient's vital signs (heart rate of 135 bpm and blood pressure of 70/40 mmHg) suggest hemodynamic instability likely due to the bleeding. The patient was treated with a rapid infusion of crystalloid solution and packed red blood cell transfusion, which is consistent with the management of significant blood loss due to an upper gastrointestinal bleed, like that from a peptic ulcer.\n\nThe clinical trial is focused on validating a prediction model for mortality in patients with high-risk bleeding peptic ulcers after therapeutic endoscopy. The inclusion criteria for the trial are:\n\n1. Patients presented with bleeding peptic ulcers.\n2. Age > 18 years old.\n3. Informed consent for the study and OGD (oesophagogastroduodenoscopy, commonly referred to as endoscopy).\n\nThe patient described in the note meets the age criterion (>18 years old) and presents with clinical signs of bleeding peptic ulcers. The only remaining requirement for eligibility is the patient's ability to provide informed consent for the study and undergo OGD, which is a standard diagnostic and therapeutic procedure for peptic ulcers.\n\nGiven this information, if the patient can provide informed consent, they would be a suitable candidate for the clinical trial. However, since the patient has decreased mental status, their ability to provide informed consent at this time may be compromised. This would require further evaluation or the involvement of a legally authorized representative to provide consent on the patient's behalf if permissible under the study protocol.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2061": {
        "output": "",
        "label": 0
    },
    "2062": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\n- The patient is a 44-year-old male, which aligns with the trial's inclusion criterion for age (over 19 years of age).\n- There is no mention of the patient's use of low-dose aspirin in the patient note, which is a requirement for the trial (continuous administration of low-dose aspirin is required).\n- The patient is presenting with \"coffee ground\" vomiting, indicative of upper gastrointestinal bleeding, which suggests the presence of a peptic ulcer; however, there is no information about whether the patient has a history of peptic ulcers or ulcer scars.\n- The patient's current condition includes an emergency situation with vomiting, hypotension (blood pressure 70/40 mmHg), and decreased mental status, which may not align with \"no digestive symptoms\" as required by the trial. The trial excludes patients with significant digestive symptoms except for mild physconia, abdominal pain, diarrhea, and vomit, nausea-vomiting.\n- There is no information provided on whether the patient fulfills the criteria of having an ulcer scar from a stomach or duodenal ulcer or if the patient has a Modified Lanza Score (MLS) of 0 according to endoscopic findings.\n\nDue to the lack of information on aspirin use, peptic ulcer history, and the current severe symptoms that the patient is exhibiting, it is not possible to definitively assess the patient's eligibility for the trial without further investigation. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2063": {
        "output": "In this scenario, we need to assess whether the 44-year-old male patient with a \"coffee ground\" appearance to his vomit, a heart rate of 135 bpm, and blood pressure of 70/40 mmHg who was admitted to the ICU after receiving a rapid infusion of crystalloid solution and packed red blood cell transfusion is eligible for the clinical trial titled \"Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes.\"\n\nThe inclusion criteria for this trial are:\n1. Age >= 18\n2. Informed consent obtained\n3. Successful endoscopic hemostasis\n4. Risk Score >= 5\n\nBased on the patient note, the patient meets the age criterion (1). However, there is no information provided about the patient having undergone endoscopic hemostasis, nor is there any indication that a risk score has been calculated or that the patient has peptic ulcers. Informed consent is also not mentioned, but this is typically obtained before participation in a clinical trial, so it is not an immediate disqualifying factor from the patient note.\n\nGiven the lack of information regarding endoscopic treatment and the specific risk score, it is not possible to determine with certainty whether the patient would be eligible for the trial. However, since the patient has a severe presentation that might be related to a gastrointestinal bleed, which could potentially involve peptic ulcers, there may be a possibility of the patient being eligible if further evaluation confirms the presence of a bleeding peptic ulcer and the patient undergoes successful endoscopic hemostasis with a risk score >= 5.\n\nTherefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2064": {
        "output": "",
        "label": 0
    },
    "2065": {
        "output": "",
        "label": 0
    },
    "2066": {
        "output": "Based on the patient note provided, the 44-year-old male patient presents with multiple bouts of \"coffee ground\" vomiting, which is a sign of upper gastrointestinal bleeding (UGIB). He also has a rapid heart rate and low blood pressure, which are consistent with acute blood loss. The patient required resuscitation with crystalloids and blood transfusion, indicating the severity of his condition and suggesting that he is experiencing an acute, overt UGIB event.\n\nThe inclusion criteria for the clinical trial state that individuals must be aged \u2265 18 years and presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena.\n\nThe patient clearly meets the age criterion (44 years old) and presents with acute, overt UGIB as evidenced by his \"coffee ground\" vomiting. Therefore, he fits the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2067": {
        "output": "The patient presented with \"coffee ground\" vomiting, which is a sign of upper gastrointestinal bleeding, possibly related to a peptic ulcer. The patient's condition appears to be acute, requiring immediate intervention as indicated by the rapid infusion of crystalloid solution and the packed red blood cell transfusion.\n\nThe clinical trial in question is looking for patients who have a history of bleeding peptic ulcers and have already undergone endoscopic therapy. The trial is specifically for long-term prevention of rebleeding in patients who are at high risk (Rockall score \u2265 6) after the ulcer has healed with an initial 16-week esomeprazole therapy.\n\nBased on the patient note, the patient may potentially meet the inclusion criteria for the clinical trial given that he shows evidence of upper gastrointestinal bleeding. However, several key pieces of information are missing:\n\n1. Confirmation of a bleeding peptic ulcer as the source of the vomiting via gastroscopy.\n2. Whether the patient has received endoscopic therapies classified as Forrest class Ia, Ib, IIa, and IIb.\n3. The patient's Rockall score which determines the risk of rebleeding and mortality.\n4. The healing status of the ulcer after the initial therapy, if applicable.\n\nWithout this information, it is not possible to definitively determine whether the patient would be eligible for the clinical trial. The patient does appear to be in a high-risk category that the trial targets, but further information and investigation are required to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2068": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for inclusion in the study. The patient in the note is experiencing a medical emergency likely related to gastrointestinal bleeding, as indicated by \"coffee ground\" vomiting, and is being treated in the ICU.\n\nThe inclusion criteria for the clinical trial specify that the patient must be scheduled for elective hip replacement surgery, be between the ages of 19-85 years, and have signed informed consent. The patient presented in the note does not meet the criteria as they are not scheduled for elective hip replacement surgery, and there is no indication that they have signed informed consent for this specific study.\n\nTherefore, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2069": {
        "output": "The patient described is a 44-year-old male who is brought to the emergency room with signs of gastrointestinal bleeding, evidenced by \"coffee ground\" vomiting, and hemodynamic instability indicated by a heart rate of 135 bpm and blood pressure of 70/40 mmHg. This patient is critically ill and requires intensive care unit admission for further management.\n\nThe clinical trial in question is investigating the efficacy of norepinephrine versus ephedrine infusion in preventing hypotension after spinal anesthesia for cesarean section. The inclusion criteria for this trial are very specific:\n\n- The American Society of Anesthesiologists (ASA) Physical Status classification 1 and 2\n- Pregnant women with singleton pregnancy\n- Gestational age greater than 36 weeks\n- Cesarean delivery under spinal anesthesia\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial. The patient is male and therefore cannot be pregnant or undergoing a cesarean delivery. Additionally, the patient is being treated for an acute condition unrelated to the focus of the study, which is on preventing hypotension during cesarean section in pregnant women.\n\nTherefore, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2070": {
        "output": "Based on the patient note provided, the patient is a 44-year-old male with symptoms suggesting an upper gastrointestinal bleed, as evidenced by \"coffee ground\" vomiting. He presents with tachycardia (heart rate of 135 bpm) and hypotension (blood pressure of 70/40 mmHg), indicative of hemodynamic instability. He received a rapid infusion of crystalloid solution and a transfusion of packed red blood cells, which is in line with the management of severe bleeding and subsequent admission to the ICU for further care.\n\nHowever, there is no mention of a pelvic fracture or multitrauma, nor is there any information provided about the patient's Injury Severity Score (ISS) or the type of pelvic fracture according to Tile classification. Hemodynamic instability in this patient appears related to an upper GI bleed rather than a pelvic fracture.\n\nThe clinical trial in question is looking for patients with specific criteria related to traumatic injury: multitrauma with an ISS > 17, dislocated pelvic fracture type B or C, and hemodynamic instability as defined by the trial's criteria.\n\nGiven that the patient's presentation does not match the trauma-related inclusion criteria specified for the trial, he would not be eligible for participation based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2071": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, I will compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial for Premenstrual Syndrome (PMS).\n\nPatient Note Analysis:\n- The patient is a 38-year-old woman.\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- She has a past medical history of infertility treatment and an ectopic pregnancy.\n- No information regarding her current mental health status, medication use, or other health conditions is provided.\n\nClinical Trial Inclusion Criteria Analysis:\n- Female patients aged 18-50.\n- History within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity.\n- Symptoms with sudden onset and offset.\n- Not currently pregnant and in good medical health.\n- Medication-free.\n- Prior participation in Protocol No. 81-M-0126 with a confirmed relationship between mood disorder and the premenstrual phase of the menstrual cycle.\n- Good physical health based on physical examination and laboratory tests.\n\nClinical Trial Exclusion Criteria Analysis:\n- Current Axis I psychiatric diagnosis.\n- Conditions such as endometriosis, undiagnosed ovarian enlargement, abnormal liver function tests, history of certain conditions (e.g., pulmonary embolism, phlebothrombosis), and others.\n- Any woman meeting the criteria for perimenopause.\n- Subjects taking certain medications (e.g., birth control pills, diuretics, psychotropic agents).\n\nBased on the patient note, the patient fits within the age range and complains of symptoms that could be related to PMS. However, there are several points that need clarification before determining eligibility:\n\n1. Confirmation that the patient's symptoms are indeed related to PMS and meet the criteria as specified in Protocol No. 81-M-0126.\n2. Verification of her participation in Protocol No. 81-M-0126, as required by the study.\n3. Assessment of her current mental health status, medication use, and general health to ensure she does not meet any of the exclusion criteria.\n\nGiven the information provided, the patient may potentially be eligible for the clinical trial, but further investigation is needed to confirm several critical points. Therefore, I would rate this:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2072": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks,\" we can evaluate the patient's eligibility.\n\nThe patient is a 38-year-old woman with complaints of severe pelvic pain premenstrually and during menstruation, heavy and irregular periods, and occasional spotting. She has a history of infertility treatments and an ectopic pregnancy.\n\nThe inclusion criteria for the trial are specific to women with acute porphyria experiencing cyclic attacks with severe abdominal pain and other symptoms during the luteal phase of their menstrual cycle that resolve within 5 days of the onset of menses. There must be a history of multiple such attacks, and the patient must have a normal pelvic exam, Pap smear, and menstrual cycle length. Additionally, the patient must not have a history of life-threatening porphyria attacks, no amenorrhea, no other menstrual or gynecologic abnormalities, and must agree to use medically approved contraception.\n\nThe patient note does not mention acute porphyria or cyclic attacks that are characteristic of acute porphyria. Instead, the symptoms described seem to be related to menstrual issues and not porphyria. There is no evidence in the patient note to suggest that the patient's symptoms are due to acute porphyria, which is a requirement for the clinical trial. Therefore, the patient does not meet the disease characteristic criteria for the clinical trial.\n\nBased on the available information, the patient's symptoms do not align with the specifics of the trial's focus on acute porphyria. Thus, it is unlikely that this patient would be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2073": {
        "output": "",
        "label": 0
    },
    "2074": {
        "output": "Given the patient's note and the inclusion criteria of the clinical trial titled \"Norplant and Irregular Bleeding/Spotting,\" we need to determine the eligibility of the 38-year-old woman for this trial. \n\nPatient Note Analysis:\n- The patient is a 38-year-old woman.\n- She experiences severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- She has a history of infertility treatments and had an ectopic pregnancy at age 26.\n\nClinical Trial Inclusion Criteria:\n- Regular menstrual periods for the last 2 cycles.\n- Not using hormonal contraceptives, including oral contraceptives, patch, ring, or Norplant in 2 months prior to study entry, or Depo-Provera in 12 months prior to study entry.\n- Not using tetracycline-class antibiotics.\n- A normal Pap smear.\n\nClinical Trial Exclusion Criteria:\n- Pregnancy or breastfeeding within 2 months of study entry.\n- Chronic migraine headaches.\n- Uncontrolled high blood pressure.\n- Untreated sexually transmitted diseases.\n- Alcoholism or drug abuse within 12 months of study entry.\n- Insulin dependent diabetes.\n- Liver, kidney, or gallbladder disease.\n- Participation in another clinical trial within 30 days of study entry.\n- History of cancer.\n- History of blood clots, strokes, or heart disease.\n\nAssessment:\nThe patient complains of \"heavy, irregular periods and occasional spotting between periods,\" which does not explicitly satisfy the requirement for \"regular menstrual periods for the last 2 cycles\" as stated in the inclusion criteria for the trial. Additionally, the patient's history of infertility treatment and an ectopic pregnancy may be relevant to her current menstrual irregularities, but there isn't enough information provided about her current use of hormonal contraceptives or recent Pap smear results.\n\nWithout clear information that the patient meets all the inclusion criteria and none of the exclusion criteria, we cannot confidently refer her to the clinical trial. However, it is possible that upon further investigation, such as confirming her contraceptive use history and the results of her latest Pap smear, she might qualify for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2075": {
        "output": "Based on the patient note provided, the 38-year-old woman is presenting with symptoms that are consistent with endometriosis, such as severe premenstrual and menstrual pelvic pain, heavy and irregular periods, and occasional spotting between periods. Although the note does not explicitly state that she has been diagnosed with endometriosis, her symptoms and past medical history of infertility treatment could be suggestive of endometriosis.\n\nThe clinical trial in question is looking for female patients with endometriosis-associated pelvic pain, which seems to align with the symptoms the patient is experiencing. However, without a confirmed diagnosis of endometriosis, it cannot be definitively stated that she meets the trial's inclusion criteria.\n\nTherefore, the patient may be considered for referral to the clinical trial upon further investigation, such as obtaining a confirmed diagnosis of endometriosis from her healthcare provider. A gynecological evaluation and possibly imaging or laparoscopic examination could confirm the diagnosis and determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2076": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Conventional Infertility Treatment vs. Fast Track to IVF,\" let's evaluate the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 38-year-old woman, which fits within the age range of 21 to under 40 years old as required by the trial.\n- She has a history of infertility treatments for two years, which meets the criterion of infertility defined as failure to conceive after one year of unprotected intercourse.\n- The patient has a history of an ectopic pregnancy, which may be relevant depending on which tube was affected and if there is at least one remaining patent fallopian tube.\n\nClinical Trial Inclusion Criteria Analysis:\n- Female partner age 21 up to 40th birthday at the time of recruitment (Patient is 38 years old, so she meets this criterion).\n- Infertility is defined as failure to conceive a recognized pregnancy after one year of unprotected intercourse (Patient has been undergoing infertility treatment for two years, so she meets this criterion).\n- Female patient has at least one ovary and at least one ipsilateral patent fallopian tube confirmed by HSG or laparoscopy; pelvic pathology amenable to operative laparoscopy (The patient note does not specify the condition of her fallopian tubes or ovaries, further investigation is required).\n- The open tube cannot have had a previous ectopic (tubal) pregnancy (The patient note mentions an ectopic pregnancy but does not specify which tube was affected, further investigation is required).\n- Normal uterine cavity demonstrated by HSG, Sonohysterogram (SHG), or hysteroscopy (The patient note does not provide information about the condition of her uterine cavity, further investigation is required).\n- Anovulatory patients criteria (The patient note does not mention ovulatory status, further investigation is required).\n- Normal ovarian reserve demonstrated in all patients i.e., cycle day 3 FSH/E2 values (The patient note does not provide information about ovarian reserve, further investigation is required).\n- Female body mass index \u2264 38 (The patient note does not provide information about her BMI, further investigation is required).\n\nGiven the information in the patient note, the patient seems to meet some of the inclusion criteria (age and history of infertility). However, there is insufficient information provided about the condition of her fallopian tubes post-ectopic pregnancy, the health of her ovaries, her ovulatory status, her uterine cavity, and her BMI. These are all critical factors that need to be confirmed before a definitive eligibility determination can be made.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2077": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914,\" we need to assess the patient's characteristics against the inclusion and exclusion criteria.\n\nFrom the patient note:\n- The patient is a 38-year-old woman.\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods.\n- Has a history of infertility treatment and an ectopic pregnancy.\n\nFrom the clinical trial inclusion criteria:\n- Female gender: The patient is female.\n- History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain: The patient note does not mention uterine leiomyomata (fibroids); it mentions pelvic pain and irregular periods which can be symptoms of other conditions, not necessarily fibroids.\n- Uterine leiomyoma(ta) of at least 2 cm size: Not mentioned in the patient note.\n- In good health: The patient note does not provide enough information to assess this.\n- Menstrual cycles of 24 - 35 days: The patient has irregular periods, but we do not have information on the exact cycle length.\n- Hemoglobin greater than 10 g/dL: Not mentioned in the patient note.\n- Willing and able to comply with study requirements: Not mentioned in the patient note.\n- Age 25 to 50: The patient is 38 years old, which fits the age requirement.\n- Using mechanical contraception or abstinence: Not mentioned in the patient note.\n- Negative urine pregnancy test: Not mentioned in the patient note, but the patient has a history of infertility treatment.\n- BMI \u2264 33 if surgical candidate or \u2264 35 if not a surgical candidate: Not mentioned in the patient note.\n- Creatinine less than 1.3 mg/dL: Not mentioned in the patient note.\n- Liver function tests within 130% of upper limit: Not mentioned in the patient note.\n- If interested in hysterectomy, no desire for fertility: The patient has a history of infertility treatment, which suggests a desire for fertility.\n- Exclusion criteria: There is no information provided in the patient note that would immediately exclude the patient based on the listed exclusion criteria.\n\nBased on the information provided, we do not have enough evidence to confirm that the patient has uterine leiomyoma, which is a key inclusion criterion for the trial. Furthermore, the patient's history of infertility treatment suggests she may have a desire for fertility, which could conflict with an interest in hysterectomy (if that were part of the study requirements).\n\nGiven the lack of confirmation of uterine fibroids and the potential desire for fertility, the patient does not clearly meet some of the key inclusion criteria. Therefore, I would not refer this patient for this clinical trial without further information confirming the presence of uterine leiomyomata and assessing her current fertility wishes and general health.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2078": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note Analysis:\n- The patient is a 38-year-old woman.\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- She has a history of infertility treatment and an ectopic pregnancy.\n- There is no mention of insomnia, depression, or anxiety symptoms.\n- There is no mention of perimenopausal or postmenopausal status.\n\nClinical Trial Inclusion Criteria Analysis:\n- Women 40+ years old.\n- Must have specific perimenopausal or postmenopausal signs and symptoms.\n- Must have insomnia symptoms for at least one month.\n- Must have mild depression and/or anxiety.\n- If on hormonal therapy or an antidepressant, must be on a stable dose for at least 2 months.\n- General good health.\n\nComparing the patient note with the inclusion criteria:\n\n- Age: The patient is 38 years old, which is below the required age of 40+.\n- Menopausal status: There is no information indicating that the patient is perimenopausal or postmenopausal.\n- Insomnia, depression, and anxiety: There is no mention of these symptoms in the patient note.\n- Stable medication doses and general good health: No information provided.\n\nBased on the comparison, the patient does not meet the age requirement, and there is no information suggesting that she has the specific menopausal status or symptoms required for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2079": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea,\" we can evaluate the patient's eligibility for the trial as follows:\n\nThe patient is a 38-year-old woman, which meets the first inclusion criterion of being 20 years or older at the time of informed consent.\n\nThe patient complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. The inclusion criteria require patients to have a normal menstrual cycle (25 to 38 days) in the latest two menses before final enrollment. The patient's note mentions irregular periods, which might suggest that her menstrual cycle does not fall within the 25 to 38 days range consistently. However, further investigation would be needed to confirm the regularity of her menstrual cycles over the past two months.\n\nRegarding the third inclusion criterion, the patient must have a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment. The patient note indicates severe premenstrual and menstrual pelvic pain, which suggests that the patient might meet the dysmenorrhea score requirement, but specific scores are not provided in the note.\n\nGiven the information in the patient note, there is an indication that the patient might meet some of the inclusion criteria, particularly her age and the presence of dysmenorrhea. However, the irregularity of her periods requires further clarification to evaluate her eligibility definitively. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2080": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we need to determine if the 38-year-old woman with severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods is eligible for the clinical trial titled \"Menstrual Effects On Mood Symptoms in Bipolar Disorder.\"\n\nThe inclusion criteria for the clinical trial are as follows:\n- Ages 18-45;\n- Bipolar Disorder (BD) I or II (DSM-IV criteria), must agree to communication between PI and Psychiatrist;\n- Healthy Control without Past or Current Major Depression, Psychotic Disorder, premenstrual syndrome or Premenstrual Dysphoric Disorder;\n- 25-31 day menstrual cycles;\n- Minimum 6 menstrual cycles per year.\n\nThe patient note mentions severe menstrual-related symptoms and a history of infertility treatment, but there is no mention of a diagnosis of Bipolar Disorder, which is a key inclusion criterion for participation in this study. Without confirmation of a Bipolar Disorder diagnosis, the patient does not meet the essential inclusion criteria of having BD I or II.\n\nBased on the available information, the patient does not appear to be eligible for the clinical trial because she does not meet the specified requirement of having a Bipolar Disorder diagnosis. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2081": {
        "output": "Based on the patient note provided, the 38-year-old woman is complaining of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. However, there is no mention of premenstrual mastalgia, which is a specific type of breast pain that typically occurs prior to menstruation and is the focus of the clinical trial's interest.\n\nThe clinical trial's inclusion criteria are as follows:\n1. Premenstrual mastalgia\n2. Age 20-45 years\n3. Reliable non-hormonal contraception\n\nThe patient falls within the age range specified in the inclusion criteria (20-45 years). However, the patient note does not mention premenstrual mastalgia, which is a required condition for participation in the study. It also does not provide information on whether the patient is using a reliable form of non-hormonal contraception.\n\nWithout any information on mastalgia or the use of non-hormonal contraception, it's not possible to determine with certainty whether the patient would be eligible for the trial. However, since the primary condition required for the study (premenstrual mastalgia) is not mentioned, it is unlikely that the patient would be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2082": {
        "output": "Based on the patient note provided, the 38-year-old woman is complaining of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. Her past medical history is notable for infertility treatment and an ectopic pregnancy. There is no mention of trichotillomania or ADHD, which are the conditions being targeted in the clinical trial for methylphenidate treatment.\n\nThe inclusion criteria for the clinical trial are as follows:\n- DSM-IV Diagnosis of trichotillomania\n- DSM-IV diagnosis of ADHD\n- Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study.\n\nSince the patient does not have a documented diagnosis of trichotillomania or ADHD as required by the trial's inclusion criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2083": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided:\n\nPatient Note:\n- A 38-year-old woman\n- Complains of severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- History of infertility treatment and an ectopic pregnancy\n\nClinical Trial Inclusion Criteria:\n- Women age 18 or older\n- Initiating Depo-Provera for contraception\n- English or Spanish-speaking\n- Have a negative urine pregnancy test\n\nThe patient in question is a 38-year-old woman, which meets the age criterion of the study. However, there is no information provided that she is initiating Depo-Provera for contraception. The patient's complaints are related to menstrual issues and past fertility treatments, not a current decision to begin using Depo-Provera. Additionally, language proficiency is not mentioned, though we might assume she speaks English since there's a patient note, and pregnancy status is not provided.\n\nSince the patient's intention to initiate Depo-Provera is not mentioned, and this is a critical inclusion criterion for the study, we do not have sufficient evidence to refer her to this clinical trial based solely on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2084": {
        "output": "Based on the information provided, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient's Characteristics:\n- 38-year-old woman\n- Severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- History of infertility treatment and an ectopic pregnancy\n\nClinical Trial Inclusion Criteria:\n- Meets DSM-IV criteria for PMDD by history\n- Regular menstrual cycles that are 25 to 35 days in length during the year prior to study entry\n- Willing to use barrier methods of birth control during the study if sexually active\n- If engaged in psychotherapy for at least 3 months before study entry, participation will be allowed if the intensity of psychotherapy remains the same during the study\n- Normal PAP and physical exam, including pelvic exam, within the 1 year prior to study entry\n\nThe patient complains of severe premenstrual and menstrual pelvic pain, which could be indicative of PMDD, but we do not have information confirming that she meets the DSM-IV criteria for PMDD. The patient also has heavy, irregular periods, and the study requires regular menstrual cycles. The information provided does not specify the length of her menstrual cycles or whether they fit the 25 to 35-day range required by the study. Additionally, there is no information regarding her willingness to use barrier methods of birth control, her engagement in psychotherapy, or the results of her PAP and physical exams.\n\nGiven the lack of detailed information to confirm that the patient meets all the inclusion criteria, particularly the DSM-IV diagnosis of PMDD and regular menstrual cycles, I would say:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2085": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"The Oral Contraceptive Pill for Premenstrual Worsening of Depression,\" let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 38-year-old woman (meets age criteria)\n- Severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting (possible indication of premenstrual syndrome or related issues)\n- History of infertility treatment and an ectopic pregnancy\n\nClinical trial inclusion criteria:\n- Women who are non-smokers between the ages of 18-45 years\n- Regular menstrual cycles for the past 6 months\n- Use of an antidepressant for at least 3 months with a stable dose for at least 2 months\n- Expected continued use of the same antidepressant at the same dose for the duration of the study\n- 30% increase of the mid-follicular phase MADRS score to the late-luteal phase MADRS required\n- Normal pelvic exam and PAP smear in the past 12 months\n- Normal TSH at screen\n- Negative serum HCG at baseline, and negative urine HCG at visits 3 and 5\n- Normal potassium levels at screen\n- Willingness to use barrier contraceptive methods during the study, if sexually active\n- Good general health\n\nAssessment:\n- The patient's smoking status is not mentioned.\n- The patient has irregular periods, which does not meet the requirement for regular menstrual cycles.\n- There is no information provided about the use of antidepressants or a diagnosed depressive disorder.\n- There is no mention of a 30% increase in the MADRS score during her menstrual cycle.\n- There is no information on a recent pelvic exam, PAP smear, TSH levels, HCG tests, or potassium levels.\n- The patient's willingness to use barrier contraceptive methods during the study and her general health status is not mentioned.\n\nGiven this information, the patient does not clearly meet several key inclusion criteria, such as having regular menstrual cycles and the required history and current use of antidepressants. Therefore, the patient would require further evaluation to determine if she meets the other criteria. However, the information provided suggests that she is unlikely to qualify based on the irregular menstrual cycles and lack of information on antidepressant use.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2086": {
        "output": "Based on the information provided, the 38-year-old woman is experiencing severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She has a past medical history of infertility treatment and an ectopic pregnancy.\n\nNow, let's compare this information to the inclusion criteria of the clinical trial:\n- Signed and dated informed consent: This would be obtained if the patient agrees to participate.\n- Age between 18 and 50 years: The patient is 38 years old, so she meets this criterion.\n- Otherwise healthy female subjects requesting contraception: The patient note does not specify if she is requesting contraception, but given her history of infertility treatment, it is possible she may be interested.\n- Currently using a LNG, NGM, or norethindrone/norethindrone acetate containing OC in a 21-day regimen and suffering from at least moderate pelvic pain: The patient complains of severe pelvic pain. However, there is no information about her current use of any oral contraceptive, so further investigation would be needed here.\n- Normal or clinically insignificant cervical smear not requiring further follow up: There is no information provided about her cervical smear status.\n- Able to tolerate ibuprofen and willing to use only ibuprofen supplied by the investigator: There is no information provided about her tolerance to ibuprofen.\n\nGiven the lack of information on her current contraceptive use, cervical smear status, and ibuprofen tolerance, I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2087": {
        "output": "",
        "label": 0
    },
    "2088": {
        "output": "Based on the information provided:\n\nPatient's characteristics:\n- 38-year-old premenopausal woman\n- Complains of severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- Past medical history of infertility treatment and an ectopic pregnancy\n- No mention of a previous diagnosis of endometriosis through surgery\n\nClinical trial's inclusion criteria:\n- Premenopausal female 18 to 45 years of age\n- Attending for her first diagnostic laparoscopy or for laparoscopy for tubal sterilization\n- Has no previous history of endometriosis diagnosis through surgery\n\nThe patient is a 38-year-old premenopausal woman, which fits within the age range of 18 to 45 years old required for the study. She has complaints that could be associated with endometriosis (pelvic pain, heavy and irregular periods), but there is no mention of a previous surgical diagnosis of endometriosis, which aligns with the inclusion criteria of not having had a prior diagnosis of endometriosis through surgery.\n\nGiven the patient's symptoms and the lack of a previous surgical diagnosis of endometriosis, she appears to meet the inclusion criteria for the clinical trial. However, we do not have information on whether she is attending for her first diagnostic laparoscopy or laparoscopy for tubal sterilization. If she is scheduled for one of these procedures and it is indeed her first diagnostic laparoscopy, she would be highly likely to be referred for this clinical trial.\n\nAssuming she meets all the inclusion criteria, including attending for her first diagnostic laparoscopy:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2089": {
        "output": "",
        "label": 0
    },
    "2090": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial.\n\nPatient Note:\n- 38-year-old woman\n- Severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- History of infertility treatment\n- History of an ectopic pregnancy\n\nClinical Trial Inclusion Criteria:\n- Age over 20 but not older than age 45\n- Willing to participate (informed consent)\n- Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10)\n- Other severe symptoms of PMS (level 7-10)\n- Symptoms causing reduction in productivity or inefficiency in daily routine\n- Symptoms causing avoidance of or less participation in social activities\n- Symptoms interfering with relationships\n- Symptoms timing: 14 days prior to menstrual flow up to 5 days during menstrual flow\n- Symptomatic period: minimum of 2 days, up to 14 days\n- Two out of last three consecutive menstrual cycles monitored\n- Asymptomatic phase: day 6 to at least day 10 of the menstrual cycle\n- Clear shift from no PMS symptoms to PMS symptoms (cyclicity)\n- Reliable non-hormonal contraception\n\nThe patient complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and spotting, which might be indicative of severe PMS. However, the trial requires a known dominant severe symptom of breast swelling and tenderness (level 7-10), which is not mentioned in the patient note.\n\nWhile the patient does experience severe symptoms associated with her menstrual cycle, the specific details required for the trial's inclusion\u2014such as the severity level of symptoms, impact on daily activities, relationship interference, the pattern of cyclicity, and the use of non-hormonal contraception\u2014are not all explicitly provided. Therefore, we cannot conclusively determine if she meets all of the inclusion criteria.\n\nGiven the information, the patient seems to have severe PMS symptoms, but without the specific details, we cannot guarantee that she fulfills all the inclusion criteria, particularly the dominant breast swelling and tenderness symptom.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2091": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided information:\n\nPatient's characteristics:\n- 38 years old woman\n- Complaints of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods\n- Past medical history of infertility treatment and an ectopic pregnancy\n- No mention of parity status (whether she has given birth to a child at gestational age >=28 weeks)\n\nClinical trial inclusion criteria:\n- Healthy female subjects in need of contraception\n- Age >=18 to <=40 years at screening\n- Must have given birth to at least one child (gestational age >=28 weeks)\n- Must have a uterus with a measured length between 6.0 and 9.0 cm from external os to fundus uteri\n\nBased on the information provided, the patient is within the age range for the clinical trial. However, there is insufficient information regarding her parity status (whether she has given birth before) and the size of her uterus. Both of these are essential criteria for inclusion in the trial. Therefore, until further information is obtained concerning these two criteria, the patient's eligibility remains uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2092": {
        "output": "Based on the patient note provided, the 38-year-old woman is complaining of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She has a history of infertility treatment and an ectopic pregnancy. There is no mention of hypertension or any blood pressure readings, which are necessary to meet the inclusion criteria for the clinical trial.\n\nThe clinical trial in question is focused on determining the best dose combination of S-Amlodipine and Telmisartan for patients with stage I or II essential hypertension. The inclusion criteria for the trial are:\n\n1. Age 18 years or older\n2. Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=115 mmHg\n3. Ability to provide written informed consent\n\nSince there is no information to suggest that the patient has hypertension or that her diastolic blood pressure falls within the specified range, she does not meet the inclusion criteria for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2093": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\n1. Age: The patient is 38 years old, which is below the age range of 40-55 years specified by the trial's inclusion criteria.\n2. Menopausal Status: The patient complains of severe premenstrual and menstrual pelvic pain, indicating that she is still experiencing menstrual cycles and is therefore not in late menopausal transition or early menopause.\n3. BMI: There is no information provided about the patient's BMI.\n4. Menopausal symptoms: Although the patient experiences menstrual-related symptoms, there is no indication that she suffers from menopausal symptoms.\n5. Menstrual cycle changes: The patient does not meet the criteria of having at least \u22652 skipped cycles and an interval of amenorrhea (\u226560 days) in the last year.\n6. Pregnancy: There is no information on a recent negative pregnancy test, although the patient's history of infertility treatment may imply she is not currently pregnant.\n7. Vitamin D levels: There is no information on the patient's Vitamin D levels.\n\nFrom the information provided, the patient does not meet several key inclusion criteria, specifically the age requirement and menopausal status. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2094": {
        "output": "",
        "label": 0
    },
    "2095": {
        "output": "",
        "label": 1
    },
    "2096": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome,\" we must compare the patient's characteristics and history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 38-year-old woman\n- Complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods\n- Past medical history includes two years of infertility treatment and an ectopic pregnancy at age 26\n\nClinical Trial Inclusion Criteria:\n- Females aged 18 to 45\n- History of cyclic mastodynia and premenstrual syndrome\n- Stable cycle duration of 25 to 35 days during the past 6 months\n- At screening, reporting at least one physical and one psychic premenstrual symptom rated moderate or severe\n- Total score of at least 15 in the late luteal phase using COPE\n- Specific requirements for visual analog scale scores and COPE scores during the run-in cycles\n\nClinical Trial Exclusion Criteria:\n- Pre-Menstrual Dysphoric Disorder\n- Intake of certain medications before treatment start and within 6 months prior to the screening visit\n\nBased on the available patient information:\n- The patient is within the eligible age range.\n- The patient reports symptoms that could be consistent with cyclic mastodynia and premenstrual syndrome.\n- There is no information on the stability of her menstrual cycle duration.\n- No data provided on the severity of symptoms using the COPE symptom list or visual analog scale.\n- There is no information on the intake of excluded medications.\n\nGiven the information provided, the patient seems to potentially meet some of the inclusion criteria based on age and symptoms reported. However, critical information regarding cycle stability, COPE scores, and medication history is missing. This means further investigation is required to determine eligibility. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2097": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- A 38-year-old woman\n- Complaints of severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- History of infertility treatment for two years\n- An ectopic pregnancy at age 26\n\nClinical trial's inclusion criteria:\n- Infertile females with preserved gonadal function\n- Ages 18 - 44 years old included\n- First oocyte donation cycle\n\nThe patient is within the age range specified by the trial (18-44 years old) and has a history of infertility treatment, which suggests that she may be infertile. However, it is not explicitly stated whether she is currently in her first oocyte donation cycle or if her gonadal function is preserved. Therefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2098": {
        "output": "In assessing the eligibility of the 38-year-old woman for the clinical trial titled \"Investigation of Tibolone and Escitalopram in Perimenopausal Depression,\" we need to compare her characteristics and situation with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n- Females who are currently physically well and between 45 and 55 years of age\n- Current DSM-IV diagnosis of depression disorder\n- Able to give informed consent\n- Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile\n\nThe patient note provides the following information:\n- The woman is 38 years old, which is below the age range specified in the inclusion criteria (45-55 years).\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- She has a past medical history of infertility treatment and ectopic pregnancy.\n- There is no mention of a current DSM-IV diagnosis of depression disorder.\n- There is no information provided about her being perimenopausal as determined by symptom profile or gonadal hormonal profile.\n\nBased on the information provided, the patient does not meet the age criteria and there is no indication that she has a DSM-IV diagnosis of depression disorder or is perimenopausal. Therefore, she is not eligible for the trial based on the criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2099": {
        "output": "Given the patient's complaints of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods, and a past medical history significant for infertility treatment and an ectopic pregnancy, we can consider the possibility of symptomatic uterine fibroids, which is a condition for which the clinical trial is recruiting participants.\n\nHowever, the patient note does not explicitly confirm the presence of uterine fibroids, which is a necessary inclusion criterion for the trial. Additionally, we do not have information on whether the fibroids, if present, are accessible for focused ultrasound treatment, or if the patient meets the other inclusion criteria such as being premenopausal and having fibroids that are not larger than 10 cm, non-enhancing with contrast, or adenomyosis. \n\nFurthermore, the exclusion criteria for the trial include the desire for future fertility, which might be relevant for this patient given her past infertility treatment, but we do not have current information on her fertility wishes. \n\nBecause the diagnosis of fibroids is not confirmed and other necessary information is missing, I would consider referring this patient to the clinical trial upon further investigation to confirm the presence and nature of uterine fibroids, as well as to gather additional relevant medical history and patient preferences.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2100": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we need to assess whether this 38-year-old woman is eligible for the trial on \"Somatic Stem Cells in Endometriosis.\"\n\nPatient Note Analysis:\n- The patient is a 38-year-old woman, fitting the age criterion of 20 to 40 years.\n- The patient complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. These symptoms are suggestive of a gynecological condition that could potentially be endometriosis.\n- There is no explicit mention of a diagnosis of endometriosis; however, the symptoms presented are consistent with those of the condition.\n- The patient has a history of infertility treatment and an ectopic pregnancy, which are not uncommon in patients with endometriosis.\n\nClinical Trial Inclusion Criteria:\n- Female patients with ovarian endometriosis, peritoneal, and recto-vaginal endometriosis are eligible.\n- Aged between 20 and 40.\n- Signing of informed consent for the collection and storage of biological samples.\n\nAssessment:\nWhile the patient's age fits the inclusion criteria, and her symptoms are suggestive of endometriosis, there is no confirmed diagnosis of endometriosis in the patient note provided. Infertility treatment and ectopic pregnancy history align with common endometriosis-related complications, but without confirmation, we cannot be sure.\n\nTherefore, the assessment for eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to confirm the diagnosis of endometriosis through medical records or additional diagnostic testing before a definite referral could be made.",
        "label": 2
    },
    "2101": {
        "output": "The patient note presents a 38-year-old woman who complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She has a history of infertility treatment and an ectopic pregnancy.\n\nThe clinical trial is investigating the efficacy of tranexamic acid (TA) versus combined oral contraceptive pills (COCP) for the treatment of menorrhagia or menometrorrhagia in menstruating females.\n\nNow, let's compare the patient's information with the inclusion criteria of the clinical trial:\n\n1. The patient is a menstruating female, which matches the gender requirement.\n2. The patient complains of heavy and irregular periods, which could be indicative of menorrhagia or menometrorrhagia.\n3. However, there is no mention of a PBAC (Pictorial Blood Assessment Chart) score in the patient note, which is required to be greater than 100 for 2 consecutive cycles for eligibility.\n4. There is no information provided about a pelvic ultrasound within the last 12 months, as required by the trial.\n5. There is no information about a normal external genitalia examination within the last 6 months.\n6. The patient's thyroid stimulating hormone (TSH) levels are not provided, which need to be normal within the last 6 months as per the trial criteria.\n7. There is no mention of a pregnancy test, which needs to be negative within 4 weeks prior to study participation.\n\nWhile the patient shows potential signs of the condition being studied (menorrhagia or menometrorrhagia), several pieces of information are missing that are necessary to fully assess her eligibility for the trial. Therefore, additional information would be needed to determine if she meets all the inclusion criteria.\n\nBased on the information provided, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2102": {
        "output": "Reviewing the patient's characteristics against the clinical trial's inclusion criteria:\n\nPatient Characteristics:\n- A 38-year-old woman\n- Complaints of premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods\n- History of infertility treatment and an ectopic pregnancy\n\nClinical Trial Inclusion Criteria:\n- Regularly menstruating women before Copper Intrauterine Device (CIUD) insertion\n- Age between 18 and 35 years\n- No hormonal treatment within at least two months before the study\n- No nonsteroidal anti-inflammatory drugs taken 24 hours before the examination\n\nThe patient does not meet the age criterion set by the clinical trial (18 to 35 years) since she is 38 years old. The other criteria cannot be confirmed from the given patient note, such as regular menstruation before CIUD insertion, hormonal treatment status, or use of NSAIDs.\n\nBased on the provided information, the patient is not eligible due to the age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2103": {
        "output": "The patient is a 38-year-old woman, which fits within the age range of 18 to 55 years specified in the inclusion criteria for the clinical trial. Her presenting complaints include severe premenstrual and menstrual pelvic pain, heavy and irregular periods, and occasional spotting between periods, which could be symptoms associated with uterine fibroids, although fibroids are not explicitly mentioned in the patient note.\n\nThe clinical trial is specifically for the treatment of uterine fibroids using Philips Sonalleve MR-HIFU. However, there is no direct mention of uterine fibroids in the patient's history. While the symptoms presented by the patient could be suggestive of fibroids, the diagnosis of uterine fibroids has not been established based on the provided patient note. Furthermore, other specific criteria such as the size of the uterus, cervical cell assessment results, number and size of fibroids, their perfusion characteristics, and MR-HIFU device accessibility have not been addressed in the patient history.\n\nGiven the information provided, we cannot confirm that the patient has uterine fibroids or that she meets the other detailed requirements of the trial. Therefore, further investigation would be needed to determine her actual diagnosis and whether it aligns with the fibroids criteria detailed in the trial, as well as additional details regarding her cervical health and potential imaging results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2104": {
        "output": "The patient is a 38-year-old woman who complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She has a history of infertility treatment and an ectopic pregnancy.\n\nTo assess her eligibility for the clinical trial \"LNG-IUS for Treatment of Dysmenorrhea\" which focuses on treating dysmenorrhea and chronic pelvic pain secondary to adenomyosis, we need to compare her situation to the inclusion criteria:\n\n1. Women have dysmenorrhea and/or chronic pelvic pain secondary to adenomyosis.\n2. Planning for birth spacing for at least 2 years.\n3. Patient aged between 20-45 years old.\n4. Ultrasonographic and Doppler examination suggestive of adenomyosis.\n5. Living in a nearby area to make follow-up reasonably possible.\n\nThe patient meets the criteria for age, as she is 38 years old. She reports symptoms that could be suggestive of dysmenorrhea. However, we do not have information regarding her plans for birth spacing, whether she has been diagnosed with adenomyosis, if she has had an ultrasonographic and Doppler examination suggesting adenomyosis, or if she lives near the clinical trial site.\n\nBased on the information provided, we know she has symptoms that align with the clinical trial's focus, but we lack specific diagnostic evidence and additional personal information. Therefore, further investigation would be necessary to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2105": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the clinical trial titled \"Uterine Leiomyoma Treatment With Radiofrequency Ablation,\" let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 38-year-old premenopausal woman with severe premenstrual and menstrual pelvic pain, heavy and irregular periods, and occasional spotting between periods.\n- The patient has a history of infertility treatment and an ectopic pregnancy.\n\nClinical Trial Inclusion Criteria:\n- Premenopausal (at least 1 menstrual period in the last 3 months)\n- Age >21 years\n- Fibroids associated with heavy bleeding, pelvic pressure or discomfort, urinary or bowel symptoms, or dyspareunia\n- Desires surgical management of fibroids\n- Uterus \u226416 weeks in size\n- All fibroids \u2264 10 cm in maximum diameter by ultrasound or MRI assessment within the last year\n- Total number of fibroids \u22646 by ultrasound or MRI assessment within the last year\n- Had a Pap smear within the last 3 years with appropriate follow-up and treatment for cellular abnormalities\n- Endometrial biopsy indicates no hyperplasia or cancer (biopsy only required if age >45 years and has anovulatory heavy bleeding)\n- Able to tolerate laparoscopic surgery\n- Able to give informed consent\n\nEligibility Assessment:\nThe patient's symptoms of heavy and irregular periods could be indicative of fibroids, but the patient note does not explicitly mention a diagnosis of uterine fibroids. The clinical trial specifically targets premenopausal women with symptomatic uterine fibroids who wish to undergo surgical management. Since the patient's diagnosis of fibroids is not confirmed in the note, further investigation (such as an ultrasound or MRI) would be required to determine if the patient has fibroids and their size and number, which are critical for determining eligibility for this trial.\n\nMoreover, the patient has a history of infertility treatment, which could potentially exclude her from the trial based on the exclusion criterion of planned treatment for infertility. However, it is not clear if the patient is currently planning infertility treatment, so this would also require additional clarification.\n\nBased on the information given and the need for further investigation to confirm the presence of fibroids and the patient's current infertility treatment status, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2106": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\nPatient's condition: The patient is a 38-year-old woman with severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She has a history of infertility treatment and an ectopic pregnancy.\n\nClinical trial's focus: The trial is investigating the effectiveness of radial extracorporeal shock wave therapy (ESWT) on chronic low back pain.\n\nInclusion criteria for the clinical trial:\n1. Symptom of low back pain during the last 4 weeks\n2. Low back pain history for more than 3 months\n\nThe patient note does not mention low back pain, which is the specific condition being studied in the clinical trial. The patient's complaints are related to menstrual and pelvic pain, which is different from low back pain. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2107": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Biologic Predictors of Leiomyoma Treatment Outcomes,\" let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 38-year-old woman.\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- She has a past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.\n\nClinical Trial Inclusion Criteria Analysis:\n- Able and willing to give consent\n- Age 18 or older\n- Presence of known uterine leiomyoma (fibroids)\n\nAssessment of Eligibility:\n- The patient is 38 years old, which satisfies the age criterion.\n- The inclusion criteria require the presence of known uterine leiomyoma. The patient's symptoms could be suggestive of uterine fibroids, but there is no explicit mention that she has been diagnosed with uterine leiomyoma.\n- The patient has not expressed an inability to give consent, so it is assumed she is able and willing to give consent if she has the condition being studied.\n\nThe patient's symptoms may suggest the possibility of uterine fibroids, but without a confirmed diagnosis of known uterine leiomyoma, we cannot be certain that she meets all the inclusion criteria for the trial. Therefore, further investigation such as medical records review or diagnostic testing to confirm the presence of uterine leiomyoma would be necessary before referring her to the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2108": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nPatient Characteristics:\n- 38 years old\n- Severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods\n- Occasional spotting between periods\n- History of infertility treatment\n- History of an ectopic pregnancy\n\nClinical Trial Inclusion Criteria:\n- Age 18-35 years of age\n- Written and signed informed consent by the patient to participate in the study\n- Patients with regular menses\n- Both ovaries\n- Serum TSH within normal range\n- BMI <30 kg/m^2\n- Normal sperm analysis of the husband\n\nAssessment:\n- The patient is 38 years old, which is outside the age range specified in the inclusion criteria (18-35 years).\n- There is no information provided about the regularity of her menses, the status of her ovaries, her serum TSH level, her BMI, or her husband's sperm analysis.\n\nGiven that the patient does not meet the age criterion, which is a fundamental eligibility requirement, she would not qualify for this trial regardless of other factors. Further investigation is unnecessary in this case due to the clear mismatch in age criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2109": {
        "output": "It appears that the clinical trial information is incomplete, as the title, interventions, summary, and full inclusion criteria are not provided. Without this information, I cannot accurately determine the patient's eligibility for the clinical trial.\n\nHowever, based on the limited information available from the patient note, we know that the patient is a 38-year-old woman with severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and a history of infertility treatment and an ectopic pregnancy. Without the specific trial criteria related to her condition, I cannot assess her suitability for the clinical trial.\n\nTherefore, given the incomplete information provided about the clinical trial, I would have to assign the following rating based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2110": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 38-year-old woman\n- Severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods\n- Occasional spotting between periods\n- History of infertility treatment\n- History of ectopic pregnancy\n\nClinical trial inclusion criteria:\n- Premenopausal women aged 20-45 years\n- Diagnosed with adenomyosis earlier\n- No other pathology of the uterus, regardless of clinical symptoms\n\nThe patient's age falls within the range required for the clinical trial (20-45 years). The patient's symptoms of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting could be consistent with adenomyosis, which is the focus of the clinical trial. However, the patient note does not explicitly mention a previous diagnosis of adenomyosis, which is a key inclusion criterion for the trial.\n\nGiven that adenomyosis is mentioned as a condition that could explain the patient's symptoms and the clinical trial is investigating uterine peristalsis in women with adenomyosis, there is a possibility that this patient could be suitable for the trial if adenomyosis has been diagnosed earlier. However, further investigation is necessary to confirm the diagnosis of adenomyosis as no such diagnosis is mentioned in the patient note provided.\n\nTherefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2111": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can see the following:\n\nPatient note:\n- 38-year-old premenopausal woman\n- Severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods\n- Occasional spotting between periods\n- History of infertility treatment and an ectopic pregnancy\n\nClinical trial inclusion criteria:\n- Premenopausal women aged 30 - 50 years old\n- Scheduled for vaginal, abdominal or laparoscopic total hysterectomy\n- One or more of the following clinical symptoms: bleeding disorders (menorrhagia, irregular bleeding, hypermenorrhoea), chronic pelvic pain, dysmenorrhoea, or dyspareunia\n- Junction zone definable\n\nThe patient is within the age range specified in the trial, is premenopausal, and suffers from symptoms that align with the inclusion criteria (heavy, irregular periods and severe pelvic pain). However, there is no information provided about whether she is scheduled for a hysterectomy or if her junction zone is definable, both of which are required for inclusion in the clinical trial.\n\nGiven that the patient shows symptoms relevant to the trial but lacks confirmation of all the necessary inclusion criteria, I would categorize this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2112": {
        "output": "Given the patient note:\n\n- The patient is a 38-year-old woman\n- She complains of severe premenstrual and menstrual pelvic pain\n- She has heavy, irregular periods and occasional spotting between periods\n- Her past medical history includes two years of infertility treatment and an ectopic pregnancy at age 26\n\nAnd the clinical trial inclusion criteria are:\n\n- Females complaining of pelvic congestion: dysmenorrhea, dyspareunia, chronic pelvic pain, menorrhagia, metrorrhagia\n\nThe patient's symptoms of severe premenstrual and menstrual pelvic pain, heavy and irregular periods, and spotting between periods align well with the inclusion criteria of dysmenorrhea (painful periods) and menorrhagia (heavy periods). Moreover, the study is focused on diagnosing adenomyosis, and the patient's symptoms could be suggestive of this condition. The patient's history of infertility treatment could also be relevant, as adenomyosis can be associated with infertility.\n\nBased on the available information, the patient seems to fit the inclusion criteria for the clinical trial, as she is a female with complaints that correspond to the symptoms outlined in the criteria (dysmenorrhea and menorrhagia).\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2113": {
        "output": "Based on the information provided, the patient is a 38-year-old female with severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. She also has a history of infertility treatment and an ectopic pregnancy. However, the note does not explicitly mention a diagnosis of endometriosis or its staging according to the AFSr classification.\n\nThe clinical trial in question is focused on women with endometriosis stages III or IV and involves assessing the effect of deep endometriosis surgery on ovarian reserve. The inclusion criteria for this trial are specifically:\n\n1. Female patient between 18 and 38 years\n2. Endometriosis stage III or IV in the AFSr classification\n3. Laparoscopy included deep endometriosis procedures\n4. Written informed consent\n\nThe patient's age fits within the specified range for the trial. However, without additional information confirming the diagnosis of endometriosis and its stage, or details about any prior laparoscopic deep endometriosis procedures, we cannot definitively state that she meets the inclusion criteria for the clinical trial. \n\nTherefore, based on the information provided, the patient might be eligible for the trial if she indeed has endometriosis, specifically stage III or IV. Additional information would be needed to confirm the diagnosis and stage of her condition, as well as any previous surgical interventions related to endometriosis. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2114": {
        "output": "Based on the information provided, the patient note discusses a 38-year-old woman with severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods. Additionally, she has a past medical history of infertility treatment and an ectopic pregnancy. There is no mention of constipation or a diagnosis of Parkinson's disease (PD).\n\nThe clinical trial's inclusion criteria are specific to individuals with a diagnosis of constipation according to Rome III criteria, with complete bowel movements per week less than 3 and total bowel movements per week less than 6, and who have provided written informed consent.\n\nSince the patient does not have constipation as described in the trial's inclusion criteria, nor is there any indication she has Parkinson's disease, she would not be an appropriate candidate for this clinical trial focusing on constipation in PD patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2115": {
        "output": "",
        "label": 1
    },
    "2116": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 38-year-old woman\n- Complains of severe premenstrual and menstrual pelvic pain\n- Heavy, irregular periods and occasional spotting between periods\n- Past medical history remarkable for two years of infertility treatment\n- History of an ectopic pregnancy at age 26\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years\n- Patients operated by laparoscopy for endometriosis in our department between 2006 and 2014\n\nThe patient is over 18 years old, which meets one of the inclusion criteria. However, there is no information provided in the patient note indicating that she has been operated on by laparoscopy for endometriosis, specifically in the department mentioned between 2006 and 2014. The patient does have symptoms suggestive of endometriosis (pelvic pain, heavy and irregular periods), and she has a history of infertility treatment, which is often associated with endometriosis. However, without confirmation that she has been operated on for endometriosis in the specified department and timeframe, we cannot definitively determine her eligibility.\n\nTherefore, based on the available information, the eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2117": {
        "output": "The patient in question is a 38-year-old woman suffering from severe premenstrual and menstrual pelvic pain, heavy and irregular periods, and occasional spotting between periods. She has a history of infertility treatment and an ectopic pregnancy.\n\nThe clinical trial is investigating the quality of life in women with endometriosis and is also including control groups: one with women who do not have endometriosis or chronic pain, and another with women who have chronic abdominal/pelvic pain but not endometriosis.\n\nInclusion criteria for the trial are:\n- Female >18 years old\n- Fluent in German\n- Cases: diagnosis of endometriosis\n- Control 1: no endometriosis, no chronic pain\n- Control 2: no endometriosis, chronic abdominal/pelvic pain\n\nBased on the patient note, we do not have a confirmed diagnosis of endometriosis; however, the patient's symptoms could be suggestive of endometriosis, which is often characterized by severe menstrual pain and can be associated with infertility issues. The patient falls within the age range and is presumably fluent in German (as this information is not provided, we would need to confirm this).\n\nSince the patient might be eligible as a control subject under Control 2 (no endometriosis, chronic abdominal/pelvic pain), provided that a diagnosis of endometriosis is ruled out, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis further investigation would include a medical examination to confirm or rule out the diagnosis of endometriosis and to establish the presence of chronic abdominal/pelvic pain not related to endometriosis, as well as confirming the patient's fluency in German.",
        "label": 2
    },
    "2118": {
        "output": "Based on the information provided:\n\n- The patient is a 38 year old woman, which meets the age inclusion criterion of being \u2265 18 years.\n- She complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods, and occasional spotting between periods.\n- Her past medical history is remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.\n\nHowever, the inclusion criteria for the clinical trial specify:\n\n- The patient must be able to give informed consent (which we can assume she can).\n- The patient must have a type 3 uterine fibroid (the patient note does not mention uterine fibroids).\n- The patient must be in sufficient physical condition to undergo deep sedation (which we do not have enough information to assess).\n- The patient must have a waist circumference that allows positioning on the HIFU table top inside the MR bore (which we do not have enough information to assess).\n\nSince the patient's complaint and medical history do not mention type 3 uterine fibroids, which is a key inclusion criterion of the clinical trial, we do not have a basis to refer her for this trial based on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2119": {
        "output": "The patient's symptoms include sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, and generalized slowness in movement and speech. These symptoms are suggestive of a hypothyroid state rather than Guillain-Barre syndrome (GBS), which is characterized by progressive weakness and areflexia, typically following an infectious event.\n\nThe clinical trial is focused on children with Guillain-Barre syndrome, requiring specific criteria such as progressive weakness of limbs, absence or reduced tendon reflexes, no atypical symptoms, no pure sensory neuropathy, no prior history of GBS, disability at least grade 3, no improvement before randomization, symptoms started not more than 14 days before randomization, no CNS involvement, and no prior treatment with plasmapheresis or IVIg. Additionally, patients must be under 18 years old, HIV negative, and have no other contraindications.\n\nGiven that the patient in the note is a 56-year-old female with symptoms not consistent with GBS, and the trial is designed for children under the age of 18 with GBS, she does not meet the age requirement, the disease criteria, or the neurological profile for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2120": {
        "output": "Based on the information provided, the inclusion criteria for the clinical trial focusing on the evaluation of two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines are not available. Without these criteria, it is impossible to make an informed decision regarding the patient's eligibility.\n\nThe patient note describes a 56-year-old Caucasian female with symptoms suggestive of hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and bradylalia (slow speech). These symptoms and signs do not appear to be directly related to Group B Streptococcus (GBS) infection or its prevention.\n\nSince the clinical trial is aimed at evaluating a vaccine for GBS, and typically, vaccine trials would target healthy individuals or those at risk for the infection the vaccine is designed to prevent, this patient does not seem to fit the typical profile for such a study based on her current symptoms. However, without the specific inclusion criteria, we cannot definitively determine the patient's eligibility.\n\nGiven the lack of inclusion criteria and the patient's current medical presentation, which does not evidently align with a vaccine trial for GBS prevention:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2121": {
        "output": "Based on the patient note provided, the 56-year-old Caucasian female displays symptoms that are highly suggestive of hypothyroidism: increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and slow movements and speech. These symptoms align well with the focus of the Thyroxine Titration Study, which aims to examine the effects of fine titration of thyroxine dosage on symptoms of hypothyroidism.\n\nLet's assess the inclusion criteria for the Thyroxine Titration Study:\n\n1. Male or female subjects >18 years of age: The patient is 56 years old, so she meets this criterion.\n2. Primary hypothyroidism \u22656 months duration arising from autoimmune hypothyroidism, thyroidectomy, or radioiodine treatment: The patient note suggests symptoms of hypothyroidism, but it does not specify the duration, cause, or any previous treatments.\n3. Thyroxine dose \u2265100 mcg/day: The patient note does not indicate whether the patient is currently being treated with thyroxine or the dosage.\n4. No change in thyroxine dose in past 2 months: Again, there is no information about any current thyroxine treatment.\n5. Serum TSH of 0.1-4.8 mU/L: There is no laboratory data provided in the patient note, so we cannot confirm if this requirement is met.\n6. Adequate contraceptive measures for women of childbearing age: The patient note does not provide any information regarding the use of contraceptive measures.\n\nWhile the patient's symptoms are suggestive of hypothyroidism, which is the focus of the clinical trial, there is not enough information in the patient note to determine if she meets all the inclusion criteria. Specifically, we lack details on the diagnosis, duration, treatment, and current medication dosage, as well as lab values and contraceptive measures.\n\nTherefore, based on the information available, I would consider referring this patient to the clinical trial upon further investigation to confirm her diagnosis, treatment history, and other criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2122": {
        "output": "Given the patient note and the clinical trial information, it appears that the patient in question does not fit the inclusion criteria for the specified clinical trial.\n\nThe patient is a 56-year-old Caucasian female with symptoms that suggest she may be experiencing hypothyroidism, as indicated by sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slow movement and speech.\n\nThe clinical trial is focused on evaluating the effectiveness of the FluMist influenza vaccination in a school-based intervention program. The inclusion criteria for the trial specify that participants should be healthy children enrolled in the target schools, and that written informed consent must be obtained from a child's parent(s) if they agree to participate.\n\nSince the patient in the note is not a child, not enrolled in a target school, and does not fit the description of \"healthy children\" due to her symptoms, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2123": {
        "output": "The patient in the provided note is a 56-year-old Caucasian female who presents with symptoms that are suggestive of hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slowed movement and speech.\n\nThe clinical trial in question is focused on studying the effects of growth hormone and GnRH Agonist in adolescents with acquired hypothyroidism to see if this combination along with thyroid hormone can improve final height.\n\nThe inclusion criteria for the trial are as follows:\n- Clinical and biochemical evidence of hypothyroidism (T4 < 5.0 ng/dl, fT4 < 1.0 mcg/dl, TSH > 10)\n- Patients with prolonged hypothyroidism should have growth failure and delayed bone age of at least 2 SD from the mean\n- Patients with short term hypothyroidism should have normal growth velocity and bone age\n- Females aged 8 to 16 years old\n- Males aged 9 to 17 years old\n- Patients without any chronic medical conditions\n- Availability of a parent or guardian to attend study visits with the patient\n- Written informed consent from the patient's parent or guardian\n\nBased on these criteria, the patient described would not be eligible for the trial for several reasons:\n- The patient is 56 years old, which is well beyond the age range specified in the criteria (8 to 16 years for females and 9 to 17 years for males).\n- The trial is specifically for adolescents, and the patient is an adult.\n- There is no mention of growth failure or delayed bone age in the patient note, which is a requirement for patients with prolonged hypothyroidism in the study.\n- The trial requires the availability of a parent or guardian to be actively involved in the treatment plan, which is not applicable for this adult patient.\n\nGiven these points, the patient does not meet the age, developmental stage, or other specified inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2124": {
        "output": "Based on the patient note provided, the patient is a 56-year-old Caucasian female showing symptoms that may be indicative of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and slowed movement and speech.\n\nThe clinical trial in question is focusing on infants with congenital chylothorax and is aiming to measure hormonal concentrations in chylothorax fluid.\n\nThe inclusion criteria for the clinical trial are specifically for infants with congenital chylothorax requiring a thorax drain. The patient described in the note does not fit this criterion as she is an adult and there is no mention of congenital chylothorax or the need for a thorax drain.\n\nGiven the discrepancy between the patient's condition and the specific inclusion criteria of the clinical trial, the patient would not be eligible for participation in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2125": {
        "output": "Based on the information provided, the patient is a 56-year-old Caucasian female who displays symptoms suggestive of hypothyroidism such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and bradylalia (slowness in speech and movements).\n\nThe clinical trial in question is focused on long-term observations of postpartum thyroiditis and its potential risk for developing hypothyroidism 20 years after partum. Eligibility for this trial requires women who either tested positive for postpartum thyroiditis in 1985 or those who were part of a control group randomly picked from those who tested negative.\n\nGiven that the patient note does not mention any history of postpartum thyroiditis, nor does it specify that the patient was part of the defined group of women from 1985 who tested positive for postpartum thyroiditis or the control group, it is not possible to determine the patient's eligibility based on the information provided. Hence, without further information confirming the patient's history related to the inclusion criteria of the trial, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2126": {
        "output": "",
        "label": 0
    },
    "2127": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- She is experiencing symptoms that may be indicative of hypothyroidism, such as increased cold sensitivity, fatigue, decreased appetite, constipation, hyporeflexia, delayed relaxation of reflexes, dry skin, and slow movement and speech.\n- There is no mention of cancer, opiate-induced sedation/drowsiness, or the use of strong opioids for cancer pain.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients who are experiencing drowsiness/sedation caused by opiates for more than 3 days and with an intensity of \u22653/10.\n- Patients must be receiving a regular dose of a strong opioid for the treatment of cancer pain.\n- Patients need to have relatively intact cognition as defined by the Mini Mental State Examination.\n- The trial involves follow-up visits and phone assessments.\n- Sexually active females at risk of pregnancy must have a negative urine pregnancy test.\n- Patients must be 18 years or older.\n- Concurrent radiation treatment and chemotherapy are permissible under certain conditions.\n\nComparison:\n- The patient in the note does not mention cancer or the use of opioid medication, which are key criteria for the clinical trial.\n- The symptoms described in the patient note do not align with the trial's focus on opiate-induced sedation/drowsiness in patients with stable cancer pain.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2128": {
        "output": "Based on the information provided in the patient note, the 56-year-old Caucasian female is experiencing symptoms that may be indicative of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, and slow movements and speech). These symptoms do not align with the inclusion criteria for the clinical trial, which is specifically looking for patients with bilateral treated moderate dry eye syndrome.\n\nThe inclusion criteria for the clinical trial require:\n\n1. Signed and dated informed consent.\n2. Male or female aged from 18 to 90 years old.\n3. Known treated bilateral dry eye.\n4. Dry eye syndrome confirmed by ocular examination with specific tests performed within the last 12 months.\n5. Bilateral symptomatology suggestive of dry eye with a specific score.\n6. Fulfilling criteria of dry eye syndrome in both eyes with specific test scores.\n\nThe patient note does not mention any ocular symptoms, dry eye diagnosis, or treatments related to dry eye syndrome. Therefore, there is no indication that this patient would meet the inclusion criteria for the dry eye syndrome clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2129": {
        "output": "Based on the provided patient note, the patient exhibits symptoms consistent with hypothyroidism: sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slow movement and speech. However, there is no explicit mention of hypopituitarism involving at least three axes, which is a requirement for the clinical trial.\n\nFurthermore, the patient note does not provide information on whether the patient has had surgical or radiation treatment for a pituitary tumor, nor does it mention the patient's BMI or smoking status. All of these are required inclusion criteria for the clinical trial.\n\nGiven the lack of specific information on the patient's condition that aligns with the inclusion criteria of the clinical trial, I would not immediately refer this patient for the clinical trial. However, further investigation would be necessary to determine if the patient meets the specific criteria of hypopituitarism, non-smoking status, and the appropriate BMI, as well as to verify the time since any pituitary treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2130": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, we need to determine if the patient could be eligible for a trial studying the combination of lapatinib and paclitaxel in patients with ErbB2 amplified advanced gastric cancer.\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- There is no mention of gastric carcinoma or any cancer diagnosis in the patient note.\n- The symptoms described (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, slow movement and speech) suggest an underlying condition that is not gastric cancer, possibly a thyroid disorder such as hypothyroidism.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial requires a histologically or cytologically confirmed gastric carcinoma with ErbB2 amplification.\n- The patient must have received one prior regimen for gastric carcinoma containing 5-fluoropyrimidine and/or cisplatin and shown progression or recurrence.\n- There are specific requirements for left ventricular ejection fraction, ECOG Performance Status, ability to swallow medication, etc.\n- The patient must have a life expectancy of at least 12 weeks and meet certain baseline laboratory values.\n\nBased on the available information, the patient does not meet the key inclusion criteria for the clinical trial, as there is no indication of a gastric carcinoma diagnosis or prior treatment for such cancer. Therefore, this patient would not be eligible for the trial focused on advanced gastric cancer and ErbB2 amplification.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2131": {
        "output": "Based on the patient note, the 56-year-old Caucasian female exhibits symptoms that are suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slowed movements and speech. However, there is no specific mention of congenital hypothyroidism or thyroglobulin defective synthesis.\n\nThe clinical trial in question is focused on identifying mutations in the thyroglobulin gene in patients with fetal goiter and congenital goiter hypothyroidism. The inclusion criteria specify that patients must have congenital hypothyroidism due to thyroglobulin defective synthesis.\n\nSince the patient has not been explicitly diagnosed with congenital hypothyroidism or identified as having thyroglobulin defective synthesis, and the symptoms presented could be due to other forms of hypothyroidism or different conditions entirely, she does not clearly meet the inclusion criteria for this clinical trial based on the information provided.\n\nWithout additional information confirming a diagnosis of congenital hypothyroidism due to thyroglobulin defective synthesis, the patient would not be a clear candidate for referral to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2132": {
        "output": "",
        "label": 1
    },
    "2133": {
        "output": "Based on the patient note provided, the 56-year-old Caucasian female exhibits symptoms that could be suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and a general slowing of movement and speech. These symptoms align with those commonly associated with hypothyroidism, but there is no explicit mention of either a clinical diagnosis of subclinical hypothyroidism or iron deficiency anemia.\n\nThe clinical trial's inclusion criteria require both a clinical diagnosis and laboratory confirmation of iron deficiency anemia and subclinical hypothyroidism. Since the patient note does not confirm these diagnoses, further investigation would be needed to determine if the patient has laboratory-confirmed iron deficiency anemia and subclinical hypothyroidism. Additionally, her ability to swallow tablets isn't mentioned, which is also a requirement for the trial.\n\nTherefore, it would be necessary to obtain more information about her condition and conduct appropriate tests to confirm the diagnoses before considering her for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2134": {
        "output": "Based on the given patient note, the 56-year old Caucasian female presents with symptoms suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, bradylalia, and bradykinesia). However, the clinical trial in question is focused on the treatment of benign nodular goiter with levothyroxine in a very specific patient population.\n\nThe inclusion criteria for the clinical trial are:\n1. Age between 20 to 90 years old\n2. Benign nodular goiter diagnosed with thyroid echo and fine-needle aspiration cytology\n\nThe patient note does not mention a diagnosis of benign nodular goiter, nor does it specify that the patient has undergone a thyroid echo or fine-needle aspiration cytology to diagnose such a condition. Because the patient\u2019s symptoms are not clearly linked to the trial's target condition (benign nodular goiter), and there is no mention of the necessary diagnostic tests having been performed, this patient does not meet the inclusion criteria as stated.\n\nTherefore, I would not refer this patient for this clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2135": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- She exhibits symptoms that may suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, delayed reflex relaxation, dry skin, slow movement, and speech).\n- No information is provided about birth weight, gestational age, serum free thyroxine level, serum thyrotropin level, or age in weeks post-birth.\n\nClinical Trial Inclusion Criteria:\n- Birth weight: less than 1500g (VLBW - Very Low Birth Weight)\n- Gestation: 22 weeks 0 day \u2264\n- Serum free thyroxine level lower than 0.8 ng/dl\n- Serum thyrotropin lower than 10 \u03bcU/ml\n- Age of between 2 and 4 weeks after birth\n- Informed consent\n\nThe clinical trial is focused on preterm infants with hypothyroxinemia and specifies very strict inclusion criteria related to birth weight, gestational age, specific thyroid hormone levels, and age in weeks after birth. The patient described in the note does not fit these criteria, as she is an adult and the trial is specifically for preterm infants within the first month of age.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2136": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, the following points are observed:\n\nPatient Note:\n- 56-year old Caucasian female\n- Symptoms suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, slow movements and speech)\n\nClinical Trial:\n- Title: PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections\n- Age range for inclusion: 2 to 6 years old\n- Suspected or diagnosed Gram-positive infection required\n- Other specific clinical and laboratory criteria\n\nThe patient described in the note does not meet the age criterion (she is 56 years old and the study is for children aged 2 to 6), nor is there any mention of a Gram-positive infection, which is a requirement for the clinical trial. Additionally, the symptoms described do not suggest a bacterial infection but rather a potential thyroid disorder. Therefore, the patient does not match the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2137": {
        "output": "",
        "label": 0
    },
    "2138": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Maternal Hypothyroidism in Pregnancy,\" the patient's eligibility for the trial needs to be assessed.\n\n**Patient Note**:\n- A 56-year-old Caucasian female.\n- Symptoms include: sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, slow movement, and speech.\n- No mention of pregnancy status.\n\n**Clinical Trial Inclusion Criteria**:\n- TSH value >98th centile in early pregnancy.\n\nThe patient note does not specify if the patient is currently pregnant, which is a critical factor for inclusion in a trial focused on maternal hypothyroidism in pregnancy. Furthermore, the inclusion criteria specifically require a TSH value above the 98th centile in early pregnancy, and no such value or indication of pregnancy is given in the patient note.\n\nGiven the lack of information on the patient's pregnancy status and TSH levels, I cannot refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2139": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- Symptoms include sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and slow movement and speech.\n\nClinical Trial Inclusion Criteria:\n- Non-diabetic\n- Schizophrenic or schizoaffective disorder\n- Currently prescribed olanzapine or ziprasidone\n- Age 18-80 years old\n\nComparison:\n- The patient's age falls within the required range (18-80 years old).\n- The patient note does not mention diabetes, schizophrenia, or schizoaffective disorder, nor does it indicate that the patient is currently prescribed olanzapine or ziprasidone.\n\nConclusion:\n- The patient's symptoms and medical condition, as described in the note, do not meet the specific inclusion criteria relating to diagnosis (schizophrenia or schizoaffective disorder) and current medication (olanzapine or ziprasidone). The symptoms described are more suggestive of hypothyroidism than a psychiatric disorder for which antipsychotic medications would be prescribed.\n\nTherefore, the patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2140": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- The patient shows symptoms that may suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, very dry skin, bradylalia, and bradykinesia).\n- There is no mention of Major Depressive Disorder (MDD) or a diagnosis according to the DSM-IV.\n\nClinical Trial Inclusion Criteria:\n- Age 18 - 80. (The patient meets this criterion.)\n- Written informed consent. (This is assumed to be obtainable if the patient is eligible and agrees to participate.)\n- Current MDD according to the DSM-IV. (The patient note does not mention MDD.)\n- Recently started to receive or about to start receiving treatment for MDD. (This is not applicable as there is no mention of MDD or treatment for it in the patient note.)\n- QIDS-C and QIDS-IVR scores equal or greater than 10 at baseline visit. (Since MDD is not mentioned, we cannot assume the patient has been assessed for this.)\n\nGiven that the patient's symptoms are more indicative of a potential thyroid disorder rather than MDD, and there is no evidence in the patient note to suggest a diagnosis of MDD as required by the inclusion criteria of the clinical trial, the patient would not appear to be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2141": {
        "output": "The patient described in the note is a 56-year-old female who is experiencing symptoms that are suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and generally slowed movements and speech. There is no mention of knee problems or that she is scheduled for total knee replacement or revision of total knee replacement.\n\nThe clinical trial in question is focused on the use of a combination of peripheral nerve block and DepoDur in patients undergoing total knee joint replacement or revision. To be eligible for this trial, patients must be scheduled for total knee replacement or revision, agree to have a regional technique including neuraxial analgesia for post-operative analgesia, be between 18 and 70 years old, and be classified as an ASA (American Society of Anesthesiologists) score I-III.\n\nBased on the information given, the patient does not meet the primary inclusion criteria of being scheduled for a total knee replacement or revision. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2142": {
        "output": "",
        "label": 0
    },
    "2143": {
        "output": "Based on the patient note provided, the 56-year-old Caucasian female has symptoms that could be suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and general slowing of movement and speech. These symptoms align with the interest of the clinical trial in subclinical hypothyroidism (SH) and its potential effects on cognitive abilities and other bodily functions in the elderly.\n\nHowever, the inclusion criteria for the clinical trial specifically require a TSH level between 4 and 10 mUI/L. The patient's TSH level is not provided in the patient note, which is a crucial piece of information needed to determine eligibility for this trial. Without this specific lab value, we cannot definitively say that the patient is eligible for the trial.\n\nGiven the patient's symptoms, which are highly suggestive of hypothyroidism, and the focus of the trial, it would be reasonable to consider this patient for referral to the clinical trial upon further investigation to determine her TSH levels. If her TSH levels fall within the required range, she would then meet the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2144": {
        "output": "Based on the patient note provided, the 56-year-old female patient presents with symptoms that suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and bradylalia). There is no mention of a fibromyalgia diagnosis by a rheumatologist or any indication that the patient meets the pain score criteria for fibromyalgia. Additionally, there is no information provided about her being on any fibromyalgia-related medications.\n\nThe clinical trial's inclusion criteria specify that participants must be female volunteers who have been diagnosed with fibromyalgia by a rheumatologist, have an overall body pain average score \u2265 4, be within the age range of 18 to 65 years old, be on stable doses of certain fibromyalgia-related medications for at least 4 weeks, and be willing to restrict any change in their fibromyalgia-related medication for 12 weeks.\n\nGiven that the patient note does not mention a diagnosis of fibromyalgia, pain scores, or any medications related to the treatment of fibromyalgia, it is not possible to determine if she meets the specific inclusion criteria for this clinical trial based on the information provided. Therefore, I would not refer this patient for this clinical trial based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2145": {
        "output": "",
        "label": 0
    },
    "2146": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 56-year-old Caucasian female\n- Symptoms suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, slow movement, and speech)\n\nClinical Trial Inclusion Criteria:\n- 18 years or older\n- Diagnosis of low or intermediate-1 risk Myelodysplastic Syndrome (MDS) without del 5q chromosome abnormality\n- Anemia requiring red blood cell transfusions\n- Resistant to erythropoiesis-stimulating agents (ESAs) or erythropoietin level > 500 mU/mL\n- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \u2264 2\n- Agree to follow pregnancy precautions as required by the protocol\n- Agree to receive counseling related to teratogenic and other risks of lenalidomide\n- Agree not to donate blood or semen\n- Willing to consent to two or more bone marrow aspirate procedures to be completed during study\n\nEligibility Assessment:\nThe patient's symptoms are indicative of hypothyroidism rather than MDS. There is no mention of anemia, transfusion dependency, or a diagnosis of MDS in the patient's note. Therefore, the patient does not meet the primary disease-related inclusion criteria for the clinical trial on lenalidomide versus placebo in subjects with transfusion-dependent anemia in lower-risk MDS without del 5q.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2147": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, we can analyze the patient's eligibility:\n\nPatient Note Summary:\n- 56-year-old Caucasian female\n- Symptoms: Sensitivity to cold, fatigue, decreased appetite, constipation\n- Physical exam: Hyporeflexia, delayed relaxation of reflexes, dry skin, slow movement, and speech\n\nClinical Trial Inclusion Criteria:\n- Men and women, ages of 18 or greater\n- Documented evidence of HIV-1 infection\n- Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain\n- Pain starts in the feet\n\nBased on the patient's symptoms, there is no mention of HIV-1 infection or neuropathic pain associated with HIV neuropathy. The symptoms described in the patient note (sensitivity to cold, fatigue, constipation, hyporeflexia, dry skin, slow movement, and speech) more closely resemble those of hypothyroidism rather than HIV-associated neuropathy. There is no mention of pain, specifically neuropathic pain starting in the feet, which is a requirement for this clinical trial.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on pregabalin in the treatment of neuropathic pain associated with HIV neuropathy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2148": {
        "output": "",
        "label": 0
    },
    "2149": {
        "output": "The patient described in the note is a 56-year-old Caucasian female with symptoms that are suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slow movements and speech. There is no mention of acute myeloid leukemia (AML) or any related hematologic condition.\n\nThe clinical trial is specifically for patients with acute myeloid leukemia (AML) and has very clear inclusion criteria, including a diagnosis of AML, bone marrow blasts >30%, age \u2265 65 years, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\nGiven the information provided in the patient note, this patient does not meet the key inclusion criteria for the clinical trial, which are focused on AML. The patient's age does not meet the minimum age requirement of 65 years, and there is no indication of an AML diagnosis or related condition.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2150": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not seem to be eligible for the clinical trial in question. The patient's symptoms suggest a possible thyroid disorder (marked sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and slow movement and speech), which are not related to Age-related Macular Degeneration (AMD), the focus of the study.\n\nThe inclusion criteria for the trial specifically require a clear diagnosis of Age-related Macular Degeneration for subjects and less than five small hard drusen for controls, neither of which is mentioned in the patient note. Furthermore, there is no indication that the patient has AMD or any related symptoms, nor is there any mention of the patient's vision or fundus health, which are relevant to the inclusion criteria of the study.\n\nTherefore, this patient would not meet the inclusion criteria for this clinical trial, and I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2151": {
        "output": "The patient note describes a 56-year-old Caucasian female presenting with symptoms that are suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and slowed movements and speech.\n\nThe clinical trial in question is an observational study focused on the initial treatment of hypothyroidism in France. The inclusion criteria for the trial are:\n\n1. Recently diagnosed hypothyroid subject (either during the inclusion period, or within the 6 previous months).\n2. Subject for whom data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor.\n3. Subject who has given his/her oral consent for participation.\n\nBased on the patient note provided, it appears the patient exhibits symptoms that could be indicative of hypothyroidism. However, there is no explicit mention of a recent hypothyroidism diagnosis within the last 6 months, which is a requirement for inclusion in the trial. Therefore, further investigation would be needed to confirm the diagnosis and the timing of it to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2152": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in the note does not meet the inclusion criteria for the specified clinical trial. The patient is described as a 56-year-old Caucasian female presenting with symptoms suggestive of hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and slow movements and speech. \n\nThe clinical trial in question is focused on the thermoregulation in preterm infants and is comparing the response of temperature adaptation using the polyethylene wrap with and without previous drying.\n\nThe inclusion criteria for the trial specify that the study is for preterm infants as defined by the Official Mexican Norm -007-SSA2-1993 (1995). Since the patient presented in the note is a 56-year-old adult, she does not qualify as a preterm infant and, therefore, does not meet the criteria for participation in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2153": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 56 years old\n- Gender: Female\n- Health concerns: Increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, slow movement and speech\n\nClinical Trial Inclusion Criteria:\n- Able to read and sign Informed Consent Form (ICF)\n- Male or female > 18 and < 49 years of age at the time the ICF is signed\n- Generally healthy, as determined by medical history and clinical assessment\n- Able to attend all scheduled visits and to comply with all trial procedures\n- If female of child-bearing potential, use of an acceptable method of contraception or abstinence\n- If female, postmenopausal, surgically sterile, or have a negative urine pregnancy test\n\nAssessment:\n- The patient is 56 years old, which is above the age limit of 49 years set by the clinical trial's inclusion criteria.\n- There is no information on the patient's ability to read and sign the ICF, but it is assumed that if a patient is participating in a clinical setting, they would be able to do so.\n- The patient's general health status is not clearly defined, but the presence of symptoms suggests that the patient may not be \"generally healthy.\"\n- There is no information regarding the patient's ability to attend all scheduled visits and comply with all trial procedures.\n- There is no information about the patient's reproductive status or contraceptive use.\n\nConclusion:\nThe patient does not meet the age criterion as they are older than the specified age range for the trial. Furthermore, the general health status of the patient is questionable due to the symptoms described, which may or may not disqualify them, but the age criterion alone is sufficient to determine ineligibility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2154": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, the patient in question does not appear to be a candidate for the clinical trial. The trial is specifically designed for preterm newborns less than 32 weeks of gestation with hypothyroxinemia, and the inclusion criteria require a gestational age of less than 32 weeks, specific thyroid function test results within a certain timeframe after birth, and written consent from the parents.\n\nThe patient described in the note is a 56-year-old Caucasian female who is showing signs and symptoms that may be indicative of hypothyroidism, given her sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, and slowed movements and speech. However, she is not a preterm newborn, nor does the patient note mention any thyroid function test results that would apply to the clinical trial's criteria.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2155": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- A 56-year old Caucasian female\n- Symptoms: More sensitive to the cold, fatigue, decreased appetite, constipation\n- Physical examination: Hyporeflexia, delayed relaxation of knee and ankle reflexes, dry skin, slow movement and speech\n\nThese symptoms and physical exam findings are suggestive of hypothyroidism. However, there is no explicit mention of a diagnosis of hypothyroidism, subclinical or otherwise, and no lab values provided (such as serum TSH and FT4) to confirm the condition.\n\nClinical trial inclusion criteria:\n- Patients >18 years old\n- With Subclinical hypothyroidism defined as serum TSH concentration above 5.0 IU/mL when serum FT4 level is within the reference range\n- With OSA defined by specific AHI scores\n- With confirmed sustained subclinical hypothyroidism, and measurements of TSH and FT4 conducted within four weeks before randomization\n\nGiven that the patient note does not confirm the diagnosis of subclinical hypothyroidism nor provides the required lab values (TSH and FT4), and there is no mention of obstructive sleep apnea (OSA) or its severity through an Apnea Hypopnea Index (AHI) score, we cannot confirm the patient's eligibility for the trial solely based on the information provided.\n\nAt this stage, further investigation would be needed to determine if the patient has subclinical hypothyroidism and OSA as per the trial's requirements. This would involve lab tests for TSH and FT4 levels, as well as a sleep study to diagnose OSA and determine the AHI score.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2156": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the study. The trial is specifically for pediatric solid organ transplant (SOT) patients between the ages of 3-17 years old, and the patient in question is a 56-year old female with no mention of having undergone a solid organ transplant. Additionally, the patient's symptoms suggest a possible thyroid issue rather than issues related to post-transplant care.\n\nTherefore, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2157": {
        "output": "Based on the patient note provided, the patient exhibits symptoms consistent with hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and bradylalia (slow speech and movement). The clinical trial in question is looking at patients with central hypothyroidism, specifically those with pituitary insufficiency, and their cardiovascular risk.\n\nThe patient note does not explicitly mention central hypothyroidism or pituitary insufficiency, which are the key inclusion criteria for the trial. However, the symptoms described in the patient note could suggest an underlying hypothyroid condition, possibly central in nature, given the presence of hyporeflexia and delayed relaxation of reflexes, which could point to a more systemic issue involving the pituitary gland.\n\nBefore referring this patient, further investigation would be needed to confirm a diagnosis of central hypothyroidism and pituitary insufficiency. This would likely involve endocrine evaluation, including specific hormonal testing (e.g., thyroid-stimulating hormone (TSH) and free T4 levels), pituitary function tests, and possibly brain imaging to evaluate the pituitary gland.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2158": {
        "output": "",
        "label": 0
    },
    "2159": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the 56-year-old Caucasian female patient does not meet the specified criteria for the clinical trial. The trial is focused on pregnant women with positive Group B Streptococcus (GBS) screening culture at 35-37 weeks of gestation. There is no indication in the patient note that the woman is pregnant, and the symptoms described (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, slowed movement, and speech) are suggestive of hypothyroidism rather than issues related to GBS colonization in pregnancy.\n\nTherefore, the patient does not fit the inclusion criteria for the trial, which require participants to be pregnant, GBS-positive, and at a specific point in their gestation period.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2160": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, I will evaluate the patient's eligibility for the clinical trial:\n\nPatient Note Review:\n- The patient is a 56-year-old Caucasian female.\n- The patient exhibits symptoms suggestive of hypothyroidism: increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and slowed movement and speech.\n- There is no mention of the patient's living situation or if she is living independently.\n- There is no information about the patient's thyroid-stimulating hormone (TSH) levels.\n- There is no indication that the patient has been diagnosed with hypothyroidism or that she has been treated with levothyroxine for at least 6 months.\n- There is no information about the patient's written informed consent for participation.\n\nClinical Trial's Inclusion Criteria:\n- Males and Females aged 80 years or older.\n- Diagnosed with hypothyroidism and treated with levothyroxine for at least 6 months.\n- Living independently in the community.\n- All TSH results within the range 0.4 - 4mU/L in the 3 months before commencing the study.\n- Participant has provided written informed consent for participation in the study, prior to any study-specific procedures.\n\nComparison:\n- The patient is 56 years old, which does not meet the age criterion of being 80 years or older.\n- There is not enough information to determine if the patient meets the other inclusion criteria regarding hypothyroidism diagnosis, treatment duration, living situation, TSH levels, and written informed consent.\n\nDue to the patient's age not meeting the age requirement of 80 years or older for the clinical trial, the patient would not be eligible for this specific study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2161": {
        "output": "The patient note describes a 56-year-old Caucasian female with symptoms that are suggestive of hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and slow movement and speech. These symptoms do not align with the condition being studied in the clinical trial, which is focused on preventing acute mountain sickness (AMS) in healthy adults who are traveling to high altitudes.\n\nThe inclusion criteria for the clinical trial specifies \"Healthy adults\" as the population of interest. The patient's presentation does not suggest that she is currently a \"healthy adult\" due to her symptoms, which likely indicate an underlying medical condition that requires investigation and treatment.\n\nTherefore, based on the information provided, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2162": {
        "output": "Based on the patient note provided:\n\n- A 56-year old Caucasian female complains of being markedly more sensitive to the cold than most people. She also gets tired easily, has decreased appetite, and has recently tried home remedies for her constipation. Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.\n\nThis clinical presentation is suggestive of hypothyroidism, which is not mentioned as a non-hematologic malignancy. Furthermore, there is no information provided that suggests the patient has a non-hematologic malignancy or that she is scheduled to receive cytotoxic chemotherapy.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n1. Patients must have biopsy-confirmed non-hematological malignancy.\n2. Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic setting), excluding immunotherapy.\n3. Patients must be of age >=18 years.\n4. Patients must have an absolute lymphocyte count >= 1,000/mcL immediately prior to influenza vaccination.\n5. Ability of the patient (or legally authorized representative if applicable) to understand and the willingness to sign a written informed consent document.\n\nThe patient in question meets the age criterion (3); however, there is no indication that she meets the other criteria, specifically having a biopsy-confirmed non-hematologic malignancy (1) and being scheduled to receive cytotoxic chemotherapy (2). The other criteria cannot be assessed without further information.\n\nGiven the information provided, this patient does not seem to meet the key inclusion criteria for the clinical trial concerning the type of illness and treatment plan. Therefore, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2163": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility.\n\nPatient note:\n- 56-year-old Caucasian female\n- Sensitive to cold, fatigue, decreased appetite, constipation\n- Physical examination: hyporeflexia, delayed relaxation of knee and ankle reflexes, very dry skin\n- Moves and talks slowly\n\nClinical trial:\n- Title: The Using of NEurocryostimulation in Military Ankle Sprains\n- Target population: Military patients 40 years old or younger with acute ankle sprains\n- Inclusion criteria: Age equal or less than 40 years-old, military subject, acute ankle injury, signed informed consent\n\nAssessment:\n- The patient is 56 years old, which is above the age limit of 40 years set by the trial's inclusion criteria.\n- The patient is not described as a military subject, which is another requirement for the trial.\n- The patient's symptoms do not suggest an acute ankle injury, which is the condition being studied in the trial.\n- The patient's symptoms suggest a possible thyroid dysfunction, which is unrelated to the focus of the trial on ankle sprains and cryotherapy.\n\nGiven that the patient does not meet the age, occupation, and medical condition requirements of the clinical trial, the patient is not eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2164": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial in question. The patient described in the note is a 56-year-old Caucasian female with symptoms that are suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, dry skin, slow movement, and slow speech). \n\nThe clinical trial is focused on the detection of the hyper-virulent clone ST17 of Group B Strep (GBS) for the prevention of neonatal GBS meningitis. The inclusion criteria for the clinical trial specify:\n\n- Patient having a positive vaginal swab for GBS at the end of pregnancy (PCR +).\n- Patient aged over 18 years.\n- Patient who received information and agreeing to sign informed consent.\n- Patient affiliated or beneficiary of an insurance.\n\nThe patient described does not meet the key inclusion criteria of having a positive vaginal swab for GBS at the end of pregnancy. There is no mention of pregnancy, GBS, or neonatal considerations in the patient note. Therefore, the patient is not suitable for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2165": {
        "output": "The patient described in the patient note exhibits symptoms that are commonly associated with hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and general slowness in movement and speech. These symptoms align with the condition being studied in the clinical trial, which is focused on the treatment of hypothyroidism with Desiccated Thyroid Extract (DTE) and Levothyroxine (L-T4).\n\nThe inclusion criteria for the clinical trial specify that patients must be between the ages of 18 to 65 and have been on levothyroxine for primary hypothyroidism for at least 6 months. The patient note does not provide information on whether the patient is currently being treated for hypothyroidism, nor does it mention the duration of any such treatment. This lack of information means we cannot conclusively determine whether the patient meets the clinical trial's inclusion criteria.\n\nGiven that the patient's symptoms are suggestive of hypothyroidism and the patient's age falls within the specified range (56 years old), it would be reasonable to consider referring this patient for the clinical trial upon further investigation into their treatment history to confirm if they meet the criteria of being on levothyroxine for at least 6 months.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2166": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility step by step.\n\nPatient Note Assessment:\n- The patient is a 56-year-old Caucasian female.\n- The symptoms described (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia, delayed relaxation of reflexes, dry skin, slow movement, and speech) are indicative of hypothyroidism.\n- There is no mention of Down syndrome in the patient's note.\n- There is no information provided about the patient's TSH or T4 levels.\n- The patient's age is outside the specified range for the trial (8 - 20 years).\n\nClinical Trial Inclusion Criteria:\n- Males and females, ages 8 - 20 years.\n- Diagnosis of Down syndrome.\n- Subclinical hypothyroidism: TSH level between 5 - 10 mIU/L, normal T4.\n- Parental/guardian permission (informed consent) and, if appropriate, child assent.\n- Females who are at least 11 years of age or who are menarchal must have a negative urine/serum pregnancy test.\n- Committed to adherence to levothyroxine treatment and study completion.\n\nComparing the patient note with the inclusion criteria, the patient does not meet the following essential criteria:\n- The patient is not within the age range of 8 - 20 years.\n- There is no indication that the patient has Down syndrome.\n- Lack of TSH and T4 levels to confirm subclinical hypothyroidism.\n\nGiven this information, the patient does not meet the critical inclusion criteria for the clinical trial, specifically the age range, diagnosis of Down syndrome, and specified thyroid function levels.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2167": {
        "output": "The patient note indicates a 56-year-old Caucasian female presenting symptoms that are suggestive of hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and general slowness in movement and speech. There is no mention of differentiated thyroid cancer (DTC), thyroidectomy, radioiodine treatment, or any specifics about TSH levels. \n\nThe clinical trial in question is focused on patients with differentiated thyroid cancer who have been treated by thyroidectomy and at least one ablation with 131-I over 5 months ago, and who currently have a TSH level of less than 4 imU/L. \n\nBased on the information provided in the patient note, there is no evidence that the patient meets the inclusion criteria for the clinical trial. Specifically, there is no mention of a history of differentiated thyroid cancer, treatment by thyroidectomy, or radioiodine treatment. Furthermore, TSH levels are not provided.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2168": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- 56-year-old Caucasian female\n- Symptoms suggestive of hypothyroidism (cold sensitivity, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, slow movement, and speech)\n\nClinical Trial Inclusion Criteria:\n- Age between 40 and 75 years old\n- Diagnosis of overt or subclinical hypothyroidism on two occasions with a minimum interval period of three months\n\nThe patient falls within the age range required for the clinical trial. Additionally, the symptoms presented in the patient note are highly suggestive of hypothyroidism, which aligns with the target condition for the clinical trial. However, to be eligible for the trial, the patient would need to have a confirmed diagnosis of hypothyroidism on two occasions at least three months apart. The patient note does not confirm that the patient has been diagnosed with hypothyroidism, nor does it provide information about any previous diagnosis or the interval between any such diagnoses.\n\nGiven the information provided, the patient appears to have symptoms consistent with hypothyroidism and meets the age criterion, but there is no explicit confirmation of the diagnosis required by the trial's inclusion criteria. Therefore, further investigation would be needed to confirm the diagnosis of hypothyroidism before referring this patient.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2169": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"The TRUST Study - Depression Substudy,\" we can assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- She exhibits symptoms that could suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, dry skin, slow movements, hyporeflexia with delayed relaxation of reflexes).\n- There is no mention of the patient's thyroid function or whether she has been diagnosed with subclinical hypothyroidism.\n\nClinical Trial Inclusion Criteria:\n- Community-dwelling patients aged >= 65 years with subclinical hypothyroidism.\n- Written informed consent.\n\nBased on the patient's age (56 years old), she does not meet the age criterion for the clinical trial, which requires participants to be aged 65 years or older. Additionally, there is no explicit mention of a diagnosis of subclinical hypothyroidism or thyroid hormone levels, which is a specific requirement of the trial.\n\nGiven that the patient does not meet the age inclusion criterion, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2170": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, the patient appears to have symptoms that are consistent with hypothyroidism. The symptoms described, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and slowed movements and speech, are common in individuals with hypothyroidism.\n\nThe clinical trial is specifically looking for patients with a diagnosis of hypothyroidism who require thyroid replacement therapy. The patient note does not explicitly mention the patient's diagnosis of hypothyroidism or current treatment with thyroid replacement therapy such as levothyroxine.\n\nGiven that the patient's symptoms strongly suggest hypothyroidism and the clinical trial's inclusion criteria requires a confirmed diagnosis and ongoing treatment, further investigation is required to determine if the patient has been diagnosed with hypothyroidism and is receiving thyroid replacement therapy.\n\nBased on the available information, I would assign a trial-level eligibility score of:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2171": {
        "output": "",
        "label": 0
    },
    "2172": {
        "output": "",
        "label": 0
    },
    "2173": {
        "output": "",
        "label": 0
    },
    "2174": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- She complains of increased sensitivity to cold, fatigue, decreased appetite, and constipation.\n- Physical examination reveals hyporeflexia, delayed relaxation of knee and ankle reflexes, and very dry skin.\n- The patient moves and talks slowly, which may suggest a systemic issue rather than just functional constipation.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must be between 18 and 80 years of age. The patient is 56 years old, which meets this criterion.\n- The patient must have chronic functional constipation according to the Rome III Diagnostic Criteria. Based on the patient note, she has tried home remedies for her constipation. However, the provided information is insufficient to confirm whether she meets at least two of the specified symptoms for chronic functional constipation as per the Rome III criteria.\n- The criteria must have been fulfilled for the last 3 months, with symptom onset at least 6 months prior to diagnosis. There is no information about the duration of the patient's symptoms.\n- The patient must agree to complete the Patient Diary for two weeks prior to study entry and for the duration of the study. The patient's willingness to comply with this requirement cannot be assessed from the patient note.\n\nGiven the fact that the patient does exhibit symptoms of constipation but we do not have enough information to definitively conclude that she meets the Rome III Diagnostic Criteria for chronic functional constipation, further investigation would be necessary to determine if the patient's constipation is indeed functional and chronic as required by the study.\n\nTherefore, based on the information provided and the need for further investigation to confirm the patient's constipation type and duration:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2175": {
        "output": "The patient is a 56-year-old Caucasian female presenting with symptoms that suggest hypothyroidism, indicated by cold sensitivity, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and slowed movement and speech. There is no mention of military service or muscle injury, which are relevant to the clinical trial in question.\n\nThe clinical trial is focused on muscle injury prevention and rehabilitation in military personnel, specifically those in the Reserve Officer Training Corps (ROTC) or individuals with muscle atrophy due to injury requiring immobilization. The inclusion criteria specify age (18-40 years) and physical requirements, such as a specific ankle range of motion.\n\nThe patient does not meet the inclusion criteria based on the following points:\n1. Age: The patient is 56 years old, which is outside the specified age range of 18-40 years.\n2. Health status: The patient's symptoms do not suggest a muscle injury or muscle atrophy due to injury.\n3. Military service: There is no information indicating that the patient is a member of the ROTC or has a military background.\n4. Injury: There is no mention of an injury to the lower leg requiring immobilization, which is an inclusion criterion for subjects with muscle atrophy.\n\nGiven that the patient does not meet the fundamental inclusion criteria for the trial, especially regarding age and health condition related to muscle injury and military service, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2176": {
        "output": "",
        "label": 0
    },
    "2177": {
        "output": "Based on the patient note, the 56-year-old female patient exhibits symptoms that are indicative of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, and hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.\n\nComparing this to the inclusion criteria of the clinical trial:\n\n1. Age 18 to 35 years, or 60 to 75 years: The patient is 56 years old, which does not meet the age criteria specified in the trial.\n2. Body mass index \u2264 27 kg\u2022m2: There is no information about the patient's BMI.\n3. Ability to sign informed consent: There is no information suggesting the patient is unable to sign informed consent, but without explicit confirmation, this remains unclear.\n4. Score of \u226526 for Mini-Mental State Exam: There is no information regarding the patient's Mini-Mental State Exam score.\n\nGiven the provided information, the patient does not meet the specified age criteria for the clinical trial. Therefore, the patient would not be eligible for this specific study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2178": {
        "output": "",
        "label": 0
    },
    "2179": {
        "output": "The patient note describes a 56-year-old Caucasian female who is experiencing symptoms that could be indicative of hypothyroidism (sensitivity to the cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, and general slowing of movement and speech). There is no mention of Multiple Sclerosis (MS) or a secondary progressive disease course in her note.\n\nThe clinical trial in question is specifically targeting individuals with Secondary Progressive Multiple Sclerosis (SPMS) and includes criteria such as a confirmed diagnosis of MS with a secondary progressive disease course, an Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5, and a timed 25-foot walk of 9 seconds or more.\n\nSince the patient's note does not mention MS or any related symptoms or diagnoses, she does not meet the inclusion criteria for the clinical trial. Therefore, she would not be considered for referral to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2180": {
        "output": "Based on the patient note provided, the patient is a 56-year-old Caucasian female who exhibits symptoms that may suggest hypothyroidism, such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and bradylalia (slow speech and movement). However, the clinical trial in question is specifically targeting men and women aged 70 years and older with persistent subclinical hypothyroidism, which is defined by an elevated TSH level in the setting of normal thyroid hormone levels.\n\nThe patient described does not meet the age criterion for the clinical trial, which requires participants to be aged 70 and older. Additionally, there is no information provided about the patient's TSH levels or whether she has been diagnosed with subclinical hypothyroidism. Without this information and the age discrepancy, it would not be appropriate to refer this patient to the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2181": {
        "output": "Based on the patient note, the 56-year-old Caucasian female displays symptoms that are consistent with hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and bradylalia (talking slowly).\n\nThe clinical trial in question is seeking participants with latent hypothyroidism to evaluate the effectiveness of osteopathic manual treatment to stimulate neurological segments c8-th5. Latent hypothyroidism, often referred to as subclinical hypothyroidism, is typically characterized by an elevated thyroid-stimulating hormone (TSH) level with normal free thyroxine (T4) levels and may or may not present with symptoms of hypothyroidism.\n\nThe patient's symptoms suggest hypothyroidism, but it is not clearly stated in the patient note whether the condition is diagnosed or what the thyroid function tests reveal. Before referring the patient, a confirmation of latent hypothyroidism diagnosis through appropriate lab tests (e.g., TSH and free T4 levels) is necessary. If the patient does indeed have latent hypothyroidism, then she would meet the inclusion criterion for the clinical trial.\n\nGiven this information, an initial assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2182": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 56-year-old Caucasian female.\n- She experiences increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, very dry skin, and generally slow movement and speech.\n\nClinical Trial Inclusion Criteria:\n- Newly diagnosed or clinically-suspected adenocarcinoma of the head, neck, or uncinate process of the pancreas.\n- Tumor must be surgically resectable.\n- ECOG Performance Status of 0 to 1.\n- Adequate organ function as defined by study-specified laboratory tests.\n- Must agree to use an acceptable form of birth control.\n\nComparison:\n- The patient's symptoms (sensitivity to cold, fatigue, constipation, hyporeflexia, dry skin, and slow movement/speech) suggest a possible thyroid disorder, such as hypothyroidism, rather than pancreatic adenocarcinoma.\n- There is no mention of the patient having pancreatic cancer, let alone a tumor in the head, neck, or uncinate process of the pancreas that is surgically resectable.\n- No information is provided regarding the patient's ECOG Performance Status or organ function.\n- The patient's gender and agreement to use birth control are not relevant factors in this case as there is no indication of the primary disease of interest for the trial.\n\nConsidering the information provided, the patient does not meet the inclusion criteria of having a diagnosis of adenocarcinoma of the pancreas. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2183": {
        "output": "Based on the patient note provided, the patient is a 56-year old Caucasian female with symptoms suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation, dry skin, and slow movement and speech).\n\nThe clinical trial in question is studying the efficacy of the combination of the TGF-\u03b2 receptor inhibitor Galunisertib (LY2157299) and Enzalutamide in metastatic castration-resistant prostate cancer.\n\nThe inclusion criteria for the trial are as follows:\n\n- Have metastatic castration-resistant prostate cancer\n- Must have had prior abiraterone treatment\n- Life expectancy of greater than 3 months\n- ECOG performance status 0 or 2\n- Age \u226518 years\n- Have measurable disease\n- Patients' acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)\n- Ability to take oral medication\n- Patients must have adequate organ and marrow function defined by study-specified laboratory tests\n- Must use an acceptable form of birth control while on study\n- Ability to understand and willingness to sign a written informed consent document\n\nThe patient described does not meet the primary inclusion criteria for the clinical trial, as there is no mention of metastatic castration-resistant prostate cancer, which is a specific disease the trial is targeting. Additionally, the trial is focused on a male-centric disease (prostate cancer), while the patient in question is a female.\n\nTherefore, this patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2184": {
        "output": "Based on the patient note provided, the patient exhibits symptoms that are suggestive of hypothyroidism, such as increased sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, and a general slowing of movement and speech. These symptoms are not indicative of type 2 diabetes or a healthy euthyroid state, which are the conditions specified in the inclusion criteria of the clinical trial.\n\nThe clinical trial is specifically looking at the effects of thyroxine on glucose and lipid metabolism in healthy euthyroid subjects or those with treatment-naive type 2 diabetes. The patient in question does not appear to fit the profile of healthy euthyroid or type 2 diabetes without previous treatment. Additionally, there is no information provided about the patient's thyroid gland texture or their level of recreational activity, stable body weight, or diet, which are also part of the inclusion criteria.\n\nGiven that the patient's symptoms do not match the conditions under investigation in the clinical trial, and the lack of information on other inclusion criteria, it would not be appropriate to refer this patient for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2185": {
        "output": "Based on the patient note provided, the 56-year-old Caucasian female is presenting with symptoms that suggest hypothyroidism such as sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, dry skin, and general slowness in movement and speech. There is no mention of pregnancy, preterm labor, or any obstetric conditions that the clinical trial is targeting.\n\nThe clinical trial in question is specifically looking for pregnant women presenting with signs or symptoms suggestive of preterm labor or obstetric indications for preterm delivery. The inclusion criteria are clear in terms of age, gestational age, and specific obstetric conditions.\n\nSince the patient does not fit the core requirements of being pregnant, presenting with threatened preterm labor, or having obstetric indications for preterm delivery, this patient would not be eligible for the trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2186": {
        "output": "The patient in the note is a 56-year-old Caucasian female who presents with symptoms that are suggestive of hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, dry skin, and slow movements and speech). There is no mention of her having total knee arthroplasty (TKA) or any plans to undergo such a procedure.\n\nThe clinical trial in question is assessing the effects of hyperbaric gaseous cryotherapy on knee flexion range of motion after total knee arthroplasty. The inclusion criteria for the clinical trial are quite specific:\n\n1. Planned unilateral TKA done at Verdun Hospital.\n2. Capacity to communicate in French or English.\n\nSince the patient's note does not indicate that the patient has undergone or is planning to undergo total knee arthroplasty, nor does it mention any knee-related issues, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2187": {
        "output": "Based on the patient note provided, the patient is a 56-year-old Caucasian female with symptoms that might suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, dry skin, and hyporeflexia). However, there is no mention of pregnancy or her being of Arab origin.\n\nThe clinical trial in question is specifically looking at the prevalence of Group B Streptococcal Carrier State among Arab pregnant women in the Northern Israel District. The inclusion criteria for the clinical trial are:\n\n1. Age: 18 to 40 years old\n2. Origin: Arab\n3. Gestational age: 34 to 40 weeks\n\nThe patient presented in the note does not meet the inclusion criteria on several counts:\n\n1. Age: The patient is 56 years old, which is outside the specified age range of 18 to 40 years for the trial.\n2. Origin: The patient is described as Caucasian, while the study is looking for Arab women.\n3. Gestational age: There's no indication that the patient is pregnant, let alone within the 34 to 40 weeks gestational age range required for the study.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2188": {
        "output": "The patient note describes a 56-year-old Caucasian female who is experiencing symptoms that may suggest hypothyroidism (sensitivity to cold, fatigue, decreased appetite, constipation, hyporeflexia with delayed relaxation of reflexes, very dry skin, slow movement, and speech). There is no mention of chronic obstructive pulmonary disease (COPD) or any respiratory issues in the patient's note.\n\nThe clinical trial is looking for participants to evaluate the immune responses to quadrivalent versus trivalent influenza vaccines. There are two sets of inclusion criteria for two different participant groups:\n\n1. Patients with COPD:\n   - Signed informed consent.\n   - Spirometric data confirming the diagnosis of COPD.\n   - Meeting GOLD Classification of Stage C or Stage D COPD.\n   - Ages 50-64.\n\n2. Healthy participants:\n   - Signed informed consent.\n   - No active symptoms of lung disease.\n   - Normal FEV1/FVC > 70% age predicted value.\n   - No history of tobacco use/abuse.\n   - No prior history of alpha-1 antitrypsin deficiency.\n   - Ages 50-64.\n\nThe patient in the note does not meet the criteria for either group as there is no indication of COPD or respiratory function testing results, nor is there any sign that the patient is a healthy participant without any active lung disease. The symptoms described are not consistent with COPD but rather suggest a thyroid dysfunction.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2189": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient note:\n- 56-year-old Caucasian female\n- Sensitive to the cold\n- Tiredness, decreased appetite, constipation\n- Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin\n- Slowed movements and speech\n\nClinical trial inclusion criteria for the chronic cough group:\n1. Cough lasting \u2265 8 weeks, characterized by irritating dry cough\n2. Sensitive to fumes, dust, the odorous, and cold air\n3. With normal chest x-rays\n4. 17-70 years old\n5. Without smoking history\n\nHealthy controls group:\n1. 17-70 years old\n2. Without smoking history or stopped smoking for more than 2 years\n3. Without chronic cough\n4. Without chronic respiratory diseases\n5. Without chronic heart, liver, kidney, and autoimmune disease\n6. With normal chest x-rays\n7. With normal pulmonary ventilation function, and histamine challenge test showed negative result\n\nThe patient is 56 years old, which fits within the age range of 17-70 years required by the trial. However, the patient has not reported a chronic cough, which is a key characteristic required for the chronic cough group in this trial. Additionally, the patient's symptoms suggest hypothyroidism (cold sensitivity, tiredness, constipation, hyporeflexia, dry skin, slowed movements and speech), which is not related to the focus of the study on cough hypersensitivity.\n\nGiven that the patient's symptoms do not align with those specified in the inclusion criteria for either the chronic cough group or the healthy controls group, the patient would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2190": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine whether the patient is eligible for the trial.\n\nPatient note:\n- 44-year-old man\n- Sustained a skull fracture in an automobile accident\n- Clear fluid dripping from nose post-accident\n- Severe headache and fever developed following day\n- Nuchal rigidity on physical examination\n\nClinical trial:\n- Focus on HIV-infected patients with neuropsychological impairments\n- Treatment with Retrovir (AZT)\n- Inclusion criteria specifically exclude patients with nervous system dysfunction caused by factors other than HIV infection, such as head trauma\n\nSince the patient has a recent history of head trauma from an automobile accident (skull fracture), and there is no mention of HIV infection or related neuropsychological impairments, the patient does not meet the inclusion criteria for the clinical trial. The presence of head trauma is a specific exclusion criterion for the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2191": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let us assess the patient's eligibility for the clinical trial titled \"Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease.\"\n\nPatient Note:\n- 44-year-old man\n- Recently in an automobile accident\n- Sustained a skull fracture\n- Clear fluid dripping from his nose (possible cerebrospinal fluid leak)\n- Severe headache and fever\n- Nuchal rigidity found on physical examination (a sign of meningeal irritation)\n\nClinical Trial Inclusion Criteria:\n- Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis\n- New neurological abnormality plus fever within the previous 4 days\n- CSF examination showing absence of organism on gram or fungal stain, WBC count \u2265 4/mm^3, and CSF: plasma glucose ratio \u2265 40%\nOR\n- Hospitalized patients without encephalitis/myelitis but with a positive IgM serology or PCR test for WNV, clinical illness compatible with WNV, and a risk factor for the development of WNV neurologic disease (age \u2265 40 years or age \u2265 18 years plus immunosuppression)\n\nThe patient in the note has had a severe headache, fever, and nuchal rigidity, which could be signs compatible with encephalitis or meningitis. However, there is no information provided about a positive test for West Nile Virus (WNV) or specific neurological abnormalities defined by the inclusion criteria (e.g., asymmetric extremity weakness without sensory abnormality). Moreover, the symptoms described could be related to the skull fracture and the accident, rather than WNV infection.\n\nGiven this information, the patient does not clearly meet the inclusion criteria as there is no specific evidence of encephalitis or myelitis due to WNV, nor is there a confirmed positive test for WNV. Additionally, the symptoms could have an alternate explanation (the skull fracture and possible CSF leak), which is part of the exclusion criteria.\n\nTherefore, based on the information provided, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2192": {
        "output": "In this scenario, the patient is a 44-year-old man who sustained a skull fracture in an automobile accident and is experiencing symptoms like clear fluid dripping from his nose, severe headache, and fever, along with nuchal rigidity on physical examination. These symptoms suggest a possible cerebrospinal fluid leak and potential infection, such as meningitis, following his skull fracture.\n\nThe clinical trial in question is focused on evaluating the safety of and immune response to an HIV-1 subtype C vaccine (AVX101) in HIV uninfected adults.\n\nBased on the provided information, we assess the patient's eligibility for the trial using the inclusion criteria:\n\n- HIV uninfected: There's no information provided about the patient's HIV status.\n- At low risk for HIV infection: There is no information on the patient's risk factors for HIV.\n- Willing to receive HIV test results: The patient's willingness to receive HIV test results is not mentioned.\n- Good general health: The patient is currently experiencing health issues related to the automobile accident, which might disqualify him from being considered in \"good general health\".\n- Acceptable methods of contraception for females of reproductive potential: This criterion is not applicable to the patient as he is male.\n- Hepatitis B surface antigen negative: The patient's hepatitis B status is not provided.\n- Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive: The patient's hepatitis C status is not provided.\n- Meets educational requirements of the study: There is no information about the patient's educational level or ability to meet the study's educational requirements.\n\nGiven the above assessment and the lack of information regarding the patient's HIV status, hepatitis status, and overall health condition, the patient does not clearly meet the inclusion criteria for this HIV vaccine trial. Furthermore, the patient's current health issues related to the automobile accident may require immediate attention and treatment that is unrelated to the objectives of the HIV vaccine trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2193": {
        "output": "The patient note describes a 44-year-old man who has sustained a skull fracture in an automobile accident, with symptoms that include clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity. These symptoms are indicative of a possible complication from the skull fracture, such as meningitis or a cerebrospinal fluid (CSF) leak.\n\nThe clinical trial in question is focused on the treatment of acute spinal cord injury (SCI) using CSF drainage and cytokine profiling. The inclusion criteria for this trial are very specific to spinal cord injuries:\n\n1. Complete or incomplete acute SCI between C0 and T11\n2. Admitted within 48 hours of injury\n3. Undergoing spinal decompressive surgery\n4. Undergoing lumbar puncture for spinal anesthetic or myelography\n5. Neurologically intact\n\nBased on the patient note, there is no mention of a spinal cord injury, nor is there any indication that the patient's skull fracture has led to a spinal injury. The patient's symptoms are more related to the skull fracture and potential meningitis rather than a spinal cord injury.\n\nGiven that the patient's medical condition does not meet the inclusion criteria related to spinal cord injury, it would not be appropriate to refer this patient for the clinical trial focused on SCI treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2194": {
        "output": "Based on the information provided in the patient note and the clinical trial details:\n\nPatient note:\n- 44-year-old man\n- Recently in an automobile accident with a skull fracture\n- Clear fluid dripping from his nose (suggesting possible cerebrospinal fluid leak)\n- Severe headache and fever post-accident\n- Nuchal rigidity on physical examination (a sign of meningitis)\n\nClinical trial:\n- Title: Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis\n- Focus: Observing vancomycin and CSF concentrations in adult patients with pneumococcal meningitis\n- Inclusion criteria: Adults (> 18 years) with suspicion of pneumococcal meningitis requiring intensive care unit\n\nThe patient's symptoms of clear fluid dripping from the nose after a skull fracture, severe headache, fever, and nuchal rigidity indicate a high suspicion of meningitis, which aligns with the clinical trial's focus on patients with suspected pneumococcal meningitis. Given that the patient's age is within the adult range and there is a suspicion of meningitis, which may require intensive care, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2195": {
        "output": "Based on the patient note provided:\n\n- A 44-year-old man was recently in an automobile accident where he sustained a skull fracture.\n- In the emergency room, he noted clear fluid dripping from his nose.\n- The following day he started complaining of severe headache and fever.\n- Nuchal rigidity was found on physical examination.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n- Adult (18 years old or older) HIV-infected patient.\n- Evidence of contrast-enhancing focal brain lesion(s) as seen on MRI or CT.\n- Willingness to give informed consent.\n- Willingness to undergo the procedures involved in the diagnostic evaluation.\n- Permit the storage of blood, CSF, and tissue samples for future research use.\n- Willingness to undergo HLA testing.\n\nAnd the exclusion criteria:\n\n- Previous PCNSL.\n- History of prior malignancy other than PCNSL unless in remission for 1 year or longer; non-melanoma skin cancer and Kaposi's sarcoma excepted.\n- History of previous diagnosis of toxoplasmic encephalitis or other CNS infection causing focal contrast-enhancing brain lesions.\n- Pregnancy or currently breastfeeding.\n- Any other condition that the research team considers a contraindication to participating in the study.\n\nThe patient note does not mention HIV infection, which is a mandatory condition for inclusion in the study. Moreover, the patient's symptoms are more consistent with a cerebrospinal fluid leak following a skull fracture rather than a focal brain lesion due to HIV-related complications. There is no information provided that the patient has undergone an MRI or CT scan to reveal brain lesions, nor is there any indication of HIV status.\n\nTherefore, based on the available information, the patient does not meet the key inclusion criterion of being HIV-infected with focal brain lesions. The patient should not be referred to this clinical trial as he does not fulfill the essential criteria for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2196": {
        "output": "",
        "label": 0
    },
    "2197": {
        "output": "",
        "label": 1
    },
    "2198": {
        "output": "Based on the provided information, the 44-year-old man does not meet the inclusion criteria for the clinical trial titled \"Treatment of Acute Migraine Headache in Children.\" The inclusion criteria specify that the trial is for males or females aged 8-18 years with a diagnosis of pediatric migrainous headache. Since the patient is 44 years old, he falls outside the specified age range for the trial. Additionally, the patient's symptoms suggest a possible cerebrospinal fluid leak due to the skull fracture and subsequent clear fluid dripping from the nose, which may not align with a migrainous headache but rather with a traumatic injury.\n\nTherefore, the patient is not eligible for this clinical trial based on the age criteria alone, and the diagnosis does not match the study's focus on pediatric migrainous headache.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2199": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient note:\n- 44-year-old man\n- Sustained a skull fracture in an automobile accident\n- Noted clear fluid dripping from his nose\n- Complaining of severe headache and fever\n- Nuchal rigidity found on physical examination\n\nClinical trial criteria:\n- Head injury\n- Nausea\n- Vomiting\n\nThe patient has sustained a head injury and has symptoms that could be associated with the injury, such as a severe headache and nuchal rigidity. However, the clinical trial specifically includes patients with nausea and vomiting as part of the inclusion criteria, which are not mentioned in the patient note. Since the patient note does not mention nausea and vomiting, we cannot confirm that the patient fully meets the inclusion criteria based solely on the information provided.\n\nTherefore, I would consider further investigation to determine if the patient has experienced nausea and vomiting related to the head injury before referring the patient to the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2200": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided:\n\nPatient note:\n- A 44-year-old man\n- Recently in an automobile accident with a sustained skull fracture\n- Noted clear fluid dripping from his nose post-accident\n- Developed severe headache and fever the following day\n- Found to have nuchal rigidity upon physical examination\n\nClinical trial:\n- Title: Cardiac Arrest Recovery EEG Study\n- Purpose: To collect EEG data from cardiac arrest patients to determine neurological status and potential for recovery\n- Inclusion criteria for Cardiac Arrest patients:\n  - 18 years and older\n  - With cardiac arrest in the hospital and successfully resuscitated, or\n  - With cardiac arrest out of the hospital and successfully resuscitated\n\nThere is no mention of cardiac arrest in the patient's note. Instead, the patient had an automobile accident with a skull fracture and symptoms suggesting a possible cerebrospinal fluid leak and meningitis (clear fluid from nose, severe headache, fever, nuchal rigidity). Therefore, this patient does not meet the inclusion criteria for the clinical trial focused on cardiac arrest patients. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2201": {
        "output": "The patient note describes a 44-year-old man who experienced an automobile accident resulting in a skull fracture, with subsequent symptoms of clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms suggest a possible cerebrospinal fluid leak post-trauma, but there is no mention of PTSD or any psychiatric evaluation that would indicate a diagnosis of PTSD.\n\nThe clinical trial in question is seeking to evaluate the efficacy of a medication (paroxetine) in Japanese patients with posttraumatic stress disorder (PTSD). The inclusion criteria specify that the patients must be primarily diagnosed with PTSD following DSM-IV-TR criteria, have experienced a motor vehicle accident with severe or potential severe physical injury more than 3 months ago but less than 12 months ago, be aged 20 to under 65, and have a CAPS-SX combined score over 50.\n\nGiven the information provided in the patient note, there is no indication that this patient has been diagnosed with PTSD, nor is there any assessment of PTSD symptoms such as the CAPS-SX score mentioned. While the patient did experience a motor vehicle accident, the primary concern at this point appears to be the physical injuries and complications thereof, not PTSD.\n\nBased on the available information, this patient does not meet the inclusion criteria for the clinical trial as no PTSD diagnosis or relevant symptom assessment is provided. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2202": {
        "output": "It appears that the clinical trial information is incomplete. The title and inclusion criteria are not provided in your message. Without this critical information, I cannot accurately assess the patient's eligibility for the clinical trial.\n\nTo perform the assessment, I would need details about the trial, such as the condition or disease it is focusing on, the interventions involved, and the specific inclusion criteria related to age, medical history, current symptoms, and any other relevant factors.\n\nPlease provide the complete clinical trial information, including the title and full inclusion criteria, so that I can determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial. (This is a placeholder response until the necessary trial details are provided.)",
        "label": 0
    },
    "2203": {
        "output": "Based on the information provided, the 44-year-old man sustained a skull fracture in an automobile accident, experienced cerebrospinal fluid leakage from his nose, and then developed severe headache and fever with nuchal rigidity. These symptoms are indicative of a potential cerebrospinal fluid (CSF) leak and possible infection such as meningitis, rather than a condition directly involving the spine that would require surgical intervention.\n\nThe clinical trial in question is looking to evaluate the safety and efficacy of a Spinal Sealant in patients undergoing spinal surgery that requires dural incision. The inclusion criteria for the trial are:\n\n1. Patients who are scheduled for an elective spinal procedure that requires a dural incision.\n2. The procedure must involve a surgical wound classification Class 1/Clean (per CDC criteria).\n3. Presence of a non-watertight dural closure, either spontaneously or upon Valsalva maneuver at 20-25 cm H2O for 5-10 seconds.\n\nThe patient described does not meet the inclusion criteria for this trial. He is not scheduled for an elective spinal procedure requiring dural incision, nor is there any mention of him having a non-watertight dural closure related to his spinal column. His current medical issues seem to be related to the skull fracture and subsequent complications, rather than an issue necessitating spinal surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2204": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient would not be eligible for the trial. The trial specifically targets children with possible or confirmed acute bacterial meningitis and includes all children aged \u2265 2 months admitted to Queen Elizabeth Hospital, Blantyre, Malawi.\n\nThe patient described in the note is a 44-year-old man who has sustained a skull fracture from an automobile accident and is showing symptoms that could be indicative of meningitis (clear fluid dripping from the nose, severe headache, fever, and nuchal rigidity), but there is no indication that the patient is a child or that he is in Malawi. Therefore, he does not meet the age and location criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2205": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial:\n\nPatient Note:\n- The patient is a 44-year-old man, which fits the age range of 18-45 years old required by the clinical trial.\n- The patient was in an automobile accident and sustained a skull fracture.\n- The patient experienced a clear fluid dripping from his nose, severe headache, and fever post-accident, and nuchal rigidity was found on physical examination.\n\nClinical Trial:\n- The study is looking for patients with Familial Mediterranean Fever (FMF).\n- Patients must fulfill the Tel Hashomer criteria for the diagnosis of FMF.\n- Patients must suffer from episodes of exertional leg pain and/or exertional ankle edema.\n- Patients must be on a stable (\u2265 2 weeks) dose of oral colchicine therapy.\n- Patients must be non-smokers.\n\nThe patient in the note does not mention FMF, exertional leg pain, or ankle edema. There is no information about the patient being on colchicine therapy or about his smoking status. The symptoms described in the patient note (clear fluid from the nose, severe headache, fever, and nuchal rigidity) are more suggestive of a possible skull fracture complication such as a cerebrospinal fluid leak and potential meningitis, rather than FMF.\n\nThe patient does not meet the specific criteria required for the clinical trial regarding diagnosis and symptoms of FMF, treatment with colchicine, or other FMF-related symptoms. Therefore, the patient is not eligible for the clinical trial on MR Spectroscopy in FMF patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2206": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 44-year-old man.\n- Recently in an automobile accident.\n- Sustained a skull fracture.\n- Noted clear fluid dripping from his nose (suggestive of CSF leak).\n- Started complaining of severe headache and fever after the accident (possible infection or other complication).\n- Nuchal rigidity found on physical examination (sign of meningismus).\n\nClinical Trial:\n- Title: Fibrin Sealant for the Sealing of Dura Sutures.\n- Investigating the efficacy and safety of a fibrin sealant for use in posterior fossa surgery to prevent CSF leakage.\n- Inclusion criteria include subjects undergoing elective craniotomy/craniectomy for posterior fossa pathologies requiring dura substitution, able to comply with the protocol, signed consent, age >= 3 years, and intraoperative conditions suitable for the use of the investigational product.\n\nAssessment:\n- The patient note indicates a recent skull fracture with symptoms suggesting CSF leakage, but it does not specify that the patient is scheduled for elective craniotomy/craniectomy for a posterior fossa pathology.\n- The trial specifically requires elective surgery for pathologies such as benign and malignant tumors, vascular malformations, and Chiari 1 malformations, not trauma-related emergency surgeries.\n\nGiven that the patient's condition does not align with the specific inclusion criteria of the clinical trial, which focuses on elective surgeries for certain posterior fossa pathologies rather than acute trauma like a skull fracture with potential CSF leakage, this patient would not be eligible for the trial as described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2207": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient note:\n- A 44-year-old man (meets age criterion)\n- Sustained a skull fracture in an automobile accident (possible candidate for a cranial procedure)\n- Clear fluid dripping from the nose post-accident (suggestive of cerebrospinal fluid leak which might necessitate a dural repair)\n- Severe headache and fever (symptoms possibly related to the skull fracture and CSF leak)\n- Nuchal rigidity found on physical examination (another sign that could be associated with his cranial injury)\n\nClinical trial inclusion criteria:\n- Patient is between 18 and 75 years of age (patient meets this criterion)\n- Patient is scheduled for an elective cranial procedure that entails a dural incision (the patient's condition might necessitate such a procedure, but it's not clear if it's already scheduled)\n- Evidence of intraoperative non-watertight closure (not applicable until surgery is performed)\n\nBased on the available information, the patient meets the age criterion and has a condition that may require a cranial procedure involving a dural incision. However, the note does not specify that the patient is scheduled for such a procedure yet, nor is there any mention of an elective procedure being planned. The patient's recent trauma suggests an urgent rather than elective situation, which may or may not align with the trial's requirements.\n\nTherefore, the patient could be considered for the clinical trial pending further information about his treatment plan, specifically whether he is scheduled for an elective cranial procedure that would entail a dural incision.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2208": {
        "output": "Based on the provided patient note, the patient is a 44-year-old man who was in an automobile accident and sustained a skull fracture, with subsequent symptoms including clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms suggest possible complications from the skull fracture such as a cerebrospinal fluid leak and potential infection, but there is no mention of convulsions or seizures, which is the focus of the clinical trial in question.\n\nThe clinical trial aims to compare the efficacy and adverse effect profile of intra-nasal versus intravenous routes of administration of lorazepam for the control of acute seizures in children. The inclusion criteria specify that the trial is looking for children within the age range of 6-14 years who are presenting convulsing to the pediatric emergency or developing seizure while in casualty.\n\nGiven the patient's age and the absence of any mention of seizures or their being within the specified age range for the trial, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2209": {
        "output": "The patient note describes a 44-year-old man with a recent skull fracture due to an automobile accident, presenting with clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity. These symptoms are indicative of a possible central nervous system infection or other complications related to his head injury.\n\nThe clinical trial in question is focused on the association between acute renal failure and BK virus reactivation in postoperative/posttraumatic critically ill patients with severe SIRS/sepsis and shock.\n\nGiven the information provided:\n\n- The patient is critically ill posttrauma, which matches one aspect of the inclusion criteria.\n- However, there is no mention of the patient having acute renal failure, SIRS/sepsis, or shock, which are specific conditions required for inclusion in the study.\n- The primary aim of the study revolves around renal dysfunction and BK virus, which does not seem to be directly related to the patient's current presentation.\n\nBased on these points, and without any evidence of the patient having renal issues or being in a state of shock or sepsis, the patient does not meet the specific inclusion criteria outlined for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2210": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- A 44-year-old man was recently in an automobile accident where he sustained a skull fracture.\n- He noted clear fluid dripping from his nose.\n- He started complaining of severe headache and fever the following day.\n- Nuchal rigidity was found on physical examination.\n\nClinical trial:\n- Title: Attentional Bias Modification in Patients With Posttraumatic Stress Disorder\n- Summary: Randomized, placebo-controlled trial of 9 sessions of computerized attentional bias training on attentional bias and on symptoms of Posttraumatic Stress Disorder.\n- Inclusion criteria: Diagnosis of Posttraumatic Stress Disorder\n\nThe patient in the note has been in an accident and is showing symptoms indicating a possible skull fracture and subsequent complications such as a cerebrospinal fluid leak (clear fluid dripping from the nose), severe headache, fever, and nuchal rigidity. However, there is no mention of Posttraumatic Stress Disorder (PTSD) or any symptoms directly related to PTSD. Since a diagnosis of PTSD is a requirement for inclusion in the clinical trial, the patient note does not provide evidence that this requirement is met.\n\nTherefore, based on the information provided, we cannot assume that the patient has been diagnosed with PTSD, which is essential for inclusion in the trial. As such, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2211": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific requirements for this PTSD study. The patient is described as having been in an automobile accident with a subsequent skull fracture and symptoms consistent with a cerebrospinal fluid leak (clear fluid dripping from the nose), severe headache, fever, and nuchal rigidity. These symptoms suggest a possible infection or other acute complications related to the trauma rather than chronic PTSD.\n\nThe inclusion criteria for the clinical trial specifically pertain to patients with chronic PTSD who are already on medications (such as antidepressants or benzodiazepines) but have not responded sufficiently to treatment. The trial is investigating the effects of the atypical neuroleptic paliperidone as an add-on treatment in these patients. The patient note does not mention PTSD, chronic anxiety, or any ongoing treatment for such conditions. Additionally, there is no information suggesting that the patient has been assessed with the Clinician-Administered PTSD Scale (CAPS) and has a minimum score of 50, which is a requirement for inclusion in the trial.\n\nGiven the lack of information regarding PTSD or any related treatment in the patient's history, and considering that the patient's current clinical presentation is not consistent with the target population for the trial, I would not refer this patient for the PTSD study focusing on paliperidone's effects.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2212": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial (Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray), let's compare the patient's characteristics to the trial's requirements:\n\nPatient Characteristics:\n- 44-year-old man\n- Recently in an automobile accident\n- Sustained a skull fracture\n- Noted clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak)\n- Complaining of severe headache and fever\n- Found to have nuchal rigidity on physical examination\n\nClinical Trial Inclusion Criteria:\n- Patients of Mongoloid race residing in Japan\n- Symptoms of perennial allergic rhinitis of moderate or severe degree\n- Score of at least 4 in the score of 4 nasal symptoms\n- Positive skin reaction test or specific IgE antibody quantitation for allergy\n- Positive cytological examination of nasal discharge (eosinophils) or nasal challenge test\n- At least 16 years of age\n- Ability to give written informed consent\n- Ability to keep a nasal allergy diary\n\nThe patient in question does not fit the inclusion criteria for the following reasons:\n- There is no indication that the patient is of Mongoloid race or resides in Japan.\n- The patient's symptoms (clear fluid from the nose, severe headache, fever, and nuchal rigidity) do not suggest perennial allergic rhinitis but rather complications from a skull fracture, possibly a cerebrospinal fluid leak and/or meningitis.\n- There is no information provided about the patient having allergic rhinitis, nor is there evidence of a positive allergy test.\n- The patient's current medical condition (post-accident with a skull fracture and potential meningitis) is not related to the condition being studied in the trial (perennial allergic rhinitis).\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2213": {
        "output": "Based on the patient's note and the clinical trial inclusion criteria provided, we can assess the patient's eligibility for the trial as follows:\n\nPatient Note:\n- 44-year-old man\n- Severe headache and fever post-automobile accident\n- Skull fracture\n- Clear fluid dripping from nose (suggestive of cerebrospinal fluid leak)\n- Nuchal rigidity on physical examination (suggestive of meningitis or another central nervous system issue)\n\nClinical Trial Inclusion Criteria:\n- Patients with perennial allergic rhinitis\n- Symptoms of moderate or severe perennial allergic rhinitis with a 4-nasal symptom score of 4 or over\n- Positive reaction to the eosinophil count in nasal discharge or nasal challenge test in addition to the skin test or specific IgE antibody test\n- Outpatients aged 16 years or over\n- Capable of giving written informed consent\n- Capable of recording nasal allergy diary every day\n\nAssessment:\nThe patient described in the note does not appear to have perennial allergic rhinitis. Instead, the patient's symptoms are acute, resulting from an automobile accident and potentially indicative of a cerebrospinal fluid leak and subsequent infection (noted by the fever and nuchal rigidity). The trial specifically looks for patients with perennial allergic rhinitis, and there is no evidence from the patient note that the patient has this condition or exhibits any of the required allergic symptoms or test results. Therefore, the patient does not meet the inclusion criteria for the clinical trial provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2214": {
        "output": "Based on the patient note provided, the 44-year-old man experienced a skull fracture and presented with symptoms including clear fluid dripping from his nose (suggestive of a cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity on physical examination. These symptoms may be indicative of a central nervous system infection such as meningitis.\n\nNow, let's compare this with the inclusion criteria for the clinical trial titled \"Treatment of West Nile Virus With MGAWN1\":\n\n1. The patient must provide written informed consent.\n2. The patient must be >=18 years of age at the time of enrollment.\n3. The patient must have West Nile Fever defined as temperature >38\u00b0C, headache, AND positive diagnostic test for West Nile Virus (WNV) Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF).\nOR the patient must have West Nile Neuroinvasive Disease, which can be encephalitis, meningitis, or acute flaccid paralysis with specific criteria for each.\n4. The patient must have epidemiological factors consistent with West Nile Virus infection.\n\nThe patient note does not mention a positive diagnostic test for West Nile Virus, nor does it describe epidemiological factors consistent with West Nile Virus infection. Also, the symptoms presented could be associated with other conditions resulting from the described skull fracture and do not specifically indicate West Nile Virus infection.\n\nConsidering the information provided, there is no clear evidence that this patient has West Nile Virus; hence, he does not meet the inclusion criteria specified for the clinical trial. Therefore, the patient would not be eligible for referral to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2215": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the key points are as follows:\n\nPatient Note:\n- 44-year-old man\n- Recent automobile accident\n- Skull fracture\n- Clear fluid dripping from the nose (suggestive of cerebrospinal fluid leak)\n- Severe headache and fever\n- Nuchal rigidity on physical examination\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis\n- Other type of cancer with evidence suggestive of carcinomatous meningitis\n- Meningeal syndrome without context of cancer\n- No other prior cancers\n- Not pregnant or nursing\n- No prior intrathecal treatment\n- At least 4 weeks since prior interferon\n- No concurrent participation in another clinical trial\n\nThe patient has symptoms that could be consistent with meningeal syndrome, notably the clear fluid from the nose following a skull fracture (suggesting a cerebrospinal fluid leak), along with severe headache and fever, and nuchal rigidity. However, there is no mention of cancer in the patient's history, which is a key disease characteristic for the clinical trial with the exception of meningeal syndrome without the context of cancer.\n\nGiven the provided information, it appears the patient may meet the criteria for \"Meningeal syndrome without context of cancer.\" However, further investigation would be necessary to confirm the diagnosis and exclude any other potential causes for the patient's symptoms. Additionally, there would need to be confirmation that the patient meets all other patient characteristics and prior therapy criteria.\n\nTherefore, the patient could be considered for referral to the clinical trial upon further investigation to confirm the diagnosis of meningeal syndrome and ensure no other exclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2216": {
        "output": "Based on the provided patient note and clinical trial information, let's assess the eligibility:\n\nPatient Note Summary:\n- A 44-year-old man\n- Sustained a skull fracture in an automobile accident\n- Clear fluid dripping from his nose (suggesting a possible cerebrospinal fluid leak)\n- Severe headache and fever started the following day\n- Nuchal rigidity found on physical examination (suggestive of meningitis or another serious condition)\n\nClinical Trial Summary:\n- Title: Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis (VMR)\n- Purpose: To examine safety and efficacy in treating symptoms of non-allergic VMR\n- Inclusion Criteria:\n  1. Diagnosis of VMR with at least 2 years of chronic non-allergic rhinitis\n  2. Negative skin tests to a panel of allergens and positive histamine test within the last 2 years\n  3. History of symptoms related to defined VMR triggers\n\nComparison:\n- The patient's symptoms (clear fluid from the nose, severe headache, fever, and nuchal rigidity) are not indicative of VMR but rather suggest a traumatic injury to the skull with possible complications such as cerebrospinal fluid leakage or infection like meningitis.\n- There is no information provided that the patient has a diagnosis of VMR or a history of chronic non-allergic rhinitis. Moreover, the acute symptoms appear to be related to a recent traumatic event rather than chronic rhinitis.\n- The patient does not meet the inclusion criteria of having a diagnosis of VMR with at least 2 years of history, nor is there any information about allergy testing or a history of VMR triggers.\n\nBased on the information given, the patient does not appear to meet the inclusion criteria for the clinical trial on VMR. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2217": {
        "output": "Given the patient note and the clinical trial information:\n\nPatient Note:\n- A 44-year-old man\n- Recently in an automobile accident, skull fracture\n- Clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak)\n- Severe headache and fever post-accident\n- Nuchal rigidity found on physical examination\n\nClinical Trial:\n- Study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis\n- Age range for subjects: 5 to 15 years\n- Diagnosis of perennial allergic rhinitis\n- Symptoms of moderate to severe degree\n- Allergic to non-seasonal environmental antigens\n\nThe patient described in the note is a 44-year-old male, which is outside the age range required for the clinical trial (5 to 15 years). Additionally, the patient's medical issues (skull fracture, possible CSF leak, severe headache, fever, and nuchal rigidity) are not related to perennial allergic rhinitis, which is the condition under study in the trial. There is no mention of allergic rhinitis or related symptoms in the patient's note. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2218": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines,\" we can assess the patient's eligibility for the trial.\n\nPatient Note:\n- 44-year-old man, which meets the age requirement as the trial does not specify an upper age limit.\n- Recently in an automobile accident, which indicates physical trauma.\n- Sustained a skull fracture, which could be consistent with TBI.\n- Clear fluid dripping from his nose post-accident, which might suggest a cerebrospinal fluid leak often associated with skull fractures and potential brain injury.\n- Complaints of severe headache and fever, which could be related to the trauma or a subsequent condition such as infection.\n- Nuchal rigidity found on physical examination, which is a sign that could be associated with TBI or other neurological concerns.\n\nClinical Trial Inclusion Criteria:\n- Adults and children with physical trauma (the patient is an adult with physical trauma).\n- Transported directly to or transferred to a level I Trauma Center (TC) by participating EMS agencies (not specified in the patient note, but given the severity, this is likely).\n- Have hospital diagnoses consistent with TBI (the patient's skull fracture and symptoms could be consistent with TBI).\n- Meet at least one definition for severe TBI:\n  a) Last prehospital GCS or first hospital/trauma center GCS <9 (not specified in the patient note).\n  b) AIS-head of \u22653 (not specified in the patient note).\n  c) CDC Barell Matrix-Type 1 (not specified in the patient note).\n  d) Undergo prehospital ETI, nasal intubation, or cricothyrotomy (not specified in the patient note).\n\nGiven that the patient note does not provide information on the Glasgow Coma Scale (GCS) score, the Abbreviated Injury Scale (AIS) for the head, or specific procedures performed such as ETI, nasal intubation, or cricothyrotomy, we cannot conclusively determine the patient's eligibility for severe TBI on the available information alone.\n\nHowever, the patient's symptoms and the fact that they sustained a skull fracture in a vehicle accident suggest a strong possibility of a TBI diagnosis that could meet the clinical trial's inclusion criteria. Further investigation is needed to determine the patient's GCS score and other specific details related to TBI severity.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2219": {
        "output": "Based on the patient note provided:\n\n- The patient is a 44-year-old man who sustained a skull fracture in an automobile accident.\n- In the emergency room, he noted clear fluid dripping from his nose, which could indicate a cerebrospinal fluid (CSF) leak.\n- He developed a severe headache and fever the following day.\n- Nuchal rigidity was found on physical examination, which can be a sign of meningitis or other significant intracranial issues.\n\nNow, comparing this patient's situation to the inclusion criteria of the clinical trial:\n\n- The trial is focused on the use of TachoSil\u00ae as an adjunct in sealing the dura mater post-skull base surgery.\n- The patient has recently experienced trauma that may have resulted in a dura mater injury, which is relevant to the trial.\n- The trial includes patients elected for skull base surgery, and the patient's injury may necessitate such a surgery.\n\nHowever, there are several points to consider:\n\n- The patient note does not specify if the patient is undergoing or has undergone skull base surgery, which is required for inclusion in the trial.\n- The trial has specific inclusion criteria regarding the type of surgical approach/procedure and exclusion criteria concerning previous neurosurgery and the use of certain materials during surgery.\n- The patient note lacks detailed information about the surgical approach taken or planned, whether the dura mater has been previously opened, whether the arachnoid membrane and CSF containing system remained intact, and whether the patient has more than one dura opening.\n\nGiven the information available, it is not clear if the patient fits the inclusion criteria for the clinical trial. There are indicators that he may be a candidate for a surgical procedure that could involve the dura mater, but the specifics needed to make a definitive assessment are not present in the patient note.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2220": {
        "output": "Based on the patient note provided:\n\nA 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.\n\nAnd the inclusion criteria for the clinical trial:\n\n- All patients have to sign the informed consent or give verbal confirmation prior to their inclusion in the study.\n- Outpatient (external) male or female over 18 years and under 50 years.\n- Patients with active rhinitis (anterior or posterior rhinorrhea, sneezing, nasal congestion and itching) persistent (\u2265 4 days a week for 4 consecutive weeks) or intermittent (< 4 days a week for \u2264 4 consecutive weeks).\n- Patient with medical history of rhinitis 2 years prior to their participation in this study and whose nasal symptoms have been severe enough to require continuous or intermittent treatment (it requires a patient's symptoms need treatment at least for a 4 weeks period).\n- Patient with the ability to understand the risks and benefits requirement while participating in the study and is able to accomplish the study treatment and with filling questionnaires and patient's diaries.\n\nThe patient note suggests that the clear fluid dripping from the man's nose, alongside his severe headache and fever, could be indicative of a cerebrospinal fluid leak following his skull fracture, and not active rhinitis. There is no mention of a history of rhinitis, nor the presence of typical rhinitis symptoms such as sneezing or nasal congestion and itching. The symptoms described in the patient note appear to be acute and related to the recent skull fracture, not related to a history of rhinitis.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires a medical history of rhinitis and active rhinitis symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2221": {
        "output": "",
        "label": 0
    },
    "2222": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 44-year-old man\n- Recent automobile accident\n- Sustained a skull fracture\n- Clear fluid dripping from nose (suggesting possible cerebrospinal fluid leak)\n- Severe headache and fever following the accident\n- Nuchal rigidity on physical examination\n\nClinical Trial:\n- Title: Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients\n- Target population: Pediatric patients with a history of minor head trauma\n- Intervention: Skull X-rays\n- Inclusion Criteria: Children who had radiography for head trauma\n\nThe patient described in the note is a 44-year-old man, which means he does not meet the age requirement for the pediatric clinical trial, which is specifically targeting children. Therefore, this patient would not be eligible for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2223": {
        "output": "The patient presented is a 44-year-old man who was in an automobile accident and sustained a skull fracture. He exhibited symptoms indicative of a cranial CSF leak, followed by severe headache and fever, along with nuchal rigidity on physical examination. These symptoms could be consistent with meningitis, possibly pneumococcal meningitis if further testing confirmed the presence of pneumococcal bacteria.\n\nHowever, based on the inclusion criteria provided for the clinical trial, the patient does not meet the age requirement of being at least 50 years old. The clinical trial is aimed at evaluating the efficacy of phenytoin in the prevention of seizures in patients with pneumococcal meningitis who are older than 50 years. Since the patient is 44 years old, he does not qualify for the trial based on age alone.\n\nFurthermore, there is no information given in the patient note that confirms a diagnosis of pneumococcal meningitis through a positive CSF Gram stain, detection of pneumococcal antigen, PCR, or associated risk factors such as myeloma or splenectomy. Without this information, we cannot definitively determine if the patient has pneumococcal meningitis, although the suspicion is reasonable given the clinical presentation.\n\nGiven the information provided and the specific inclusion criteria of the clinical trial, I would not refer this patient for this clinical trial due to the age requirement not being met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2224": {
        "output": "Given the patient note, the 44-year-old man has experienced a skull fracture and is showing signs of cerebrospinal fluid leak from the nose (likely indicating a basilar skull fracture), severe headache, fever, and nuchal rigidity. These symptoms could be indicative of complications such as meningitis, which is a medical emergency.\n\nThe clinical trial in question is focused on determining the optimal needle diameter for lumbar puncture procedures, comparing the flow rate and incidence of known complications between 22 gauge and 24 gauge Whitacre needles.\n\nThe inclusion criteria for the trial are:\n- All adult patients (>= 18 years old) referred at the Neurological Day Center to get a lumbar puncture\n\nThe patient is an adult over 18 years old and may require a lumbar puncture as part of the diagnostic workup for his symptoms, which could suggest meningitis. Since the inclusion criteria for the trial are broad and only specify that the participant needs to be an adult referred for a lumbar puncture, the patient fits the age requirement and potentially the referral for lumbar puncture.\n\nHowever, the information provided does not explicitly state that the patient has been referred for a lumbar puncture. The decision to refer this patient for the clinical trial may depend on whether a lumbar puncture is indicated and whether he is at the Neurological Day Center where the study is being conducted.\n\nAssuming the patient is at an appropriate facility and a lumbar puncture is indicated as part of his care, he could be considered for the study. However, without confirmation of the referral for lumbar puncture, we would need further investigation to ensure the patient's eligibility. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2225": {
        "output": "",
        "label": 0
    },
    "2226": {
        "output": "The patient note describes a 44-year-old man who was recently in an automobile accident, sustaining a skull fracture and showing symptoms suggestive of a cerebrospinal fluid (CSF) leak, as evidenced by clear fluid dripping from his nose, severe headache, and fever. Nuchal rigidity noted on physical examination may also indicate meningitis, which is a common complication of a CSF leak.\n\nThe clinical trial in question is investigating the use of bedside sedation for the prevention of post-dural puncture headache in patients undergoing a diagnostic lumbar puncture (LP) for the first time.\n\nTo determine eligibility, let's compare the patient's characteristics and situation with the inclusion criteria of the clinical trial:\n\nInclusion Criteria:\n1. 18-50 years old\n2. Undergoing diagnostic LP for any indication for the first time\n\nThe patient is within the age range specified by the trial. However, the patient note does not specify that the patient is undergoing or is scheduled to undergo a diagnostic LP. The patient does have symptoms that may indicate a need for LP (e.g., suspected CSF leak, nuchal rigidity), but this is not explicitly stated.\n\nGiven the information provided, there is a possibility that the patient may require a diagnostic LP as part of his medical care after the skull fracture and other symptoms. If an LP is indicated and has not been previously performed, the patient could be a candidate for the trial.\n\nTherefore, considering the potential but not confirmed need for an LP, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2227": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Bilhvax, a vaccine candidate against schistosomiasis, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 44-year-old man\n- Recently in an automobile accident\n- Sustained a skull fracture\n- Noted clear fluid dripping from his nose\n- Severe headache and fever\n- Nuchal rigidity found on physical examination\n\nClinical Trial Inclusion Criteria:\n- Caucasian volunteers\n- No smoker\n- Biological parameters (hematological, biochemical, renal, and hepatic) in normal range\n- Health Insurance\n- Sign informed consent\n\nThe patient note does not provide information regarding the patient's race or smoking status. Neither does it mention his biological parameters or whether he has health insurance or is willing to sign informed consent. However, the patient's current health condition (skull fracture, cerebrospinal fluid leakage indicated by clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity) suggests that he may not be in the range of normal biological parameters and might not be considered \"healthy,\" which is typically a requirement for vaccine trials in healthy volunteers.\n\nTherefore, without further information, it is not possible to definitively conclude the patient's eligibility. However, given the patient's acute medical issues following an automobile accident, it seems unlikely that he would currently be considered a healthy volunteer suitable for this vaccine trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2228": {
        "output": "In this case, the patient is a 44-year-old man who sustained a skull fracture in an automobile accident and is presenting with symptoms that may suggest bacterial meningitis, such as severe headache, fever, and nuchal rigidity. However, this patient does not meet the inclusion criteria for the clinical trial titled \"Daptomycin in Pediatric Patients With Bacterial Meningitis,\" since the trial is specifically for pediatric patients aged between 3 months and 16 years. The patient in the note is 44 years old, which is outside the age range for the trial. Therefore, regardless of the patient's diagnosis or condition, they would not be eligible for this pediatric study based on age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2229": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, here is the analysis:\n\nPatient Note:\n- A 44-year-old man with a recent skull fracture.\n- Clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak).\n- Severe headache and fever.\n- Nuchal rigidity on physical examination (a sign of meningitis).\n\nClinical Trial:\n- Title: Slow Initial \u03b2-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis.\n- Age range for participants: 2 months to 15 years.\n- Symptoms suggestive of bacterial meningitis.\n- Exclusion criteria include trauma, which the patient has experienced.\n\nThe patient in the note is a 44-year-old man, which is outside the age range of 2 months to 15 years specified in the inclusion criteria of the clinical trial. Additionally, the patient has experienced trauma, which is listed as an exclusion criterion for the trial.\n\nBased on this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2230": {
        "output": "Based on the patient note provided, the patient is a 44-year-old man who sustained a skull fracture in an automobile accident and presented with symptoms of clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms are suggestive of meningitis, possibly due to the skull fracture.\n\nThe clinical trial in question is investigating the pharmacokinetics and safety of meropenem in infants \u2264 90 days of postnatal age with probable or confirmed bacterial meningitis. The inclusion criteria for this trial are:\n\n- Informed consent form signed by the parents/carers\n- Chronological age below 90 days inclusive\n- The presence of clinical signs consistent with BM (hyperthermia or hypothermia or temperature instability PLUS 1 or more neurological findings among coma, seizures, neck stiffness, apnoea, bulging fontanelle), OR CSF pleocytosis (\u2265 20 cells/mm3), OR a positive Gram stain of CSF.\n\nThe patient does not meet the age criteria, as he is 44 years old, which is well above the maximum age of 90 days postnatal for trial participants. Therefore, he is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2231": {
        "output": "The patient in question is a 44-year-old man who recently experienced a skull fracture due to an automobile accident, and following this, he presented with symptoms including a clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms suggest a possible cerebrospinal fluid leak and potential infection, such as meningitis, rather than a migraine.\n\nThe clinical trial in question is seeking to evaluate the performance and safety of the PBASE-system in the treatment of acute migraine episodes. The inclusion criteria specify that participants must be:\n\n- 18 to 65 years of age\n- Diagnosed with migraine with or without aura according to IHS classification (ICHD-II)\n- Having a history of 2 to 6 migraine episodes per month during the previous 3 months, confirmed during a baseline period\n- Experiencing a majority of migraine episodes with moderate or severe pain intensity\n- Having at least 48 hours of freedom from headache between attacks\n- Having untreated migraine attack durations lasting 8 hours or more\n- Having the onset of migraine before age 50\n- Having a history of migraine for more than one year\n- Maintaining the same preventive headache medication regimen from baseline to post-treatment\n- Able to understand and complete the electronic diary\n- Experiencing an acute migraine attack of moderate to severe pain intensity at the time of treatment\n- Able to be treated within 5 hours of migraine onset\n\nThe patient's current medical issues do not align with the diagnosis of migraine as required by the trial's inclusion criteria. Instead, his symptoms are acute and related to a recent head injury, suggesting a different etiology than migraine. Furthermore, there is no mention of a history of migraines, which is a crucial criterion for the clinical trial.\n\nGiven that the patient's presentation does not meet the inclusion criteria for the clinical trial, specifically regarding the diagnosis of migraine and the detailed history required of migraine episodes, he is not a suitable candidate for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2232": {
        "output": "Based on the patient note provided:\n\nA 44-year-old man sustained a skull fracture in an automobile accident and subsequently presented with symptoms including clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity.\n\nAnd the inclusion criteria for the clinical trial titled \"Neisseria Meningitidis Burden of Disease Study\":\n\n- Subjects who the investigator believes can and will comply with the requirements of the protocol or subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.\n- Written informed consent obtained from the subject/from the parent(s)/LAR of the subject.\n- A male or female subject who visits the hospital with suspected bacterial meningitis.\n- CSF sample taken as part of routine practice.\n\nThe patient's presentation with clear fluid dripping from the nose (suggestive of cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity (signs consistent with meningitis) could indicate a suspected case of bacterial meningitis, which would align with the trial's inclusion criteria regarding the clinical presentation. Additionally, the patient is a male who visited the hospital, which is consistent with the trial's population of interest.\n\nHowever, to determine the patient's eligibility for the study, a confirmation that a CSF sample has been or will be taken as part of routine practice would be necessary, as this is one of the trial's specific inclusion criteria. Furthermore, eligibility would depend on the investigator's belief that the patient can and will comply with the protocol, and on obtaining written informed consent.\n\nGiven the information available and assuming that a CSF sample is part of the patient's routine care for suspected bacterial meningitis, the patient appears to meet several of the inclusion criteria. Therefore, I would consider referring this patient to the clinical trial upon further investigation to confirm these details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2233": {
        "output": "",
        "label": 2
    },
    "2234": {
        "output": "Based on the information provided, the patient in question has sustained a skull fracture from an automobile accident and is presenting symptoms consistent with a cerebrospinal fluid leak (clear fluid dripping from the nose), severe headache, fever, and nuchal rigidity. These symptoms may indicate a secondary bacterial meningitis, which is a possible complication following a skull fracture due to the potential for bacteria to enter the meninges.\n\nThe clinical trial in question is looking to enroll patients with suspected pneumonia requiring hospitalization or suspected bacterial meningitis. The inclusion criteria specifically mention enrolling patients of all ages with suspected bacterial meningitis. Since the patient is presenting with nuchal rigidity and other symptoms indicative of meningitis, and the study aims to enroll patients with suspected bacterial meningitis, the patient may be eligible for the clinical trial, provided that they also meet the additional inclusion criteria of being a resident of T\u00f4ne sanitary district and requiring hospitalization for at least one night.\n\nAlthough the symptoms are suggestive, a definitive diagnosis of bacterial meningitis would need to be made, typically through the analysis of cerebrospinal fluid obtained via lumbar puncture. If the patient meets the residency requirement and is hospitalized for the condition in a study site during the study period, they could potentially be referred for the clinical trial. \n\nHowever, without confirmation that the patient meets all of the geographical and hospitalization criteria, I can only suggest further investigation to ascertain eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2235": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial titled \"Myocardial Infarction - Stress Prevention Intervention.\"\n\nPatient Note:\n- 44-year-old man\n- Sustained a skull fracture in an automobile accident\n- Clear fluid dripping from his nose (suggestive of a cerebrospinal fluid leak)\n- Severe headache and fever post-accident\n- Nuchal rigidity on physical examination\n\nClinical Trial Inclusion Criteria:\n- Age over 18 years\n- STEMI (ST-elevated myocardial infarction) or non-STEMI\n- Stable circulatory condition\n- NRS score of at least 5 for pain (during MI)\n- NRS score of at least 5 for fear of dying (until admission to the CCU) and/or making sorrows and feeling helpless (when being told about having MI)\n- Written informed consent\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- The patient's medical issue is related to a skull fracture and potential cerebrospinal fluid leak, not a myocardial infarction.\n- There is no indication that the patient has experienced a STEMI or non-STEMI.\n- The symptoms described do not match those that the trial is seeking to address (PTSD following MI).\n\nGiven this information, the patient does not fit the criteria for the clinical trial focused on preventing PTSD after myocardial infarction. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2236": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 44-year-old man.\n- He was recently in an automobile accident and sustained a skull fracture.\n- He exhibited clear fluid dripping from his nose (suggestive of a cerebrospinal fluid leak).\n- He developed a severe headache and fever post-accident.\n- Nuchal rigidity was found on physical examination (a sign of meningitis or other CNS pathology).\n\nClinical Trial Analysis:\n- The study is focused on combat-exposed war veterans with PTSD.\n- Inclusion criteria include a diagnosis of PTSD as determined by SCID interview for DSMIV and CAPS, a history of active duty service, and discharge from active duty service.\n- Participants must be free of psychotropic medication for four weeks before the study.\n\nComparison:\n- The patient in the note does not have any mention of PTSD, military service, or combat exposure, which are essential for the study's inclusion criteria.\n- The patient's current medical concerns are related to the aftermath of an automobile accident, not PTSD or related psychiatric conditions.\n\nGiven that the patient does not meet the key inclusion criteria for the clinical trial, which specifically requires participants to have PTSD and a history of military service, the patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2237": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question has sustained a skull fracture from an automobile accident and presented with symptoms that might suggest a cerebrospinal fluid leak (clear fluid dripping from the nose), severe headache, and fever with nuchal rigidity. These symptoms may be indicative of meningitis.\n\nThe clinical trial in question is focused on tuberculous (TB) meningitis and is seeking to compare oral and intravenous preparations of rifampicin. The inclusion criteria for the trial are:\n\n1. Age 18 years or older\n2. Probable/possible tuberculosis meningitis using uniform case definition\n3. Agree to participate in the study\n\nWhile the patient does have symptoms that could be associated with meningitis, there is no specific indication that the meningitis is of tuberculous origin. In order to establish eligibility for the trial, further investigation would be needed to confirm a diagnosis of tuberculous meningitis. Only with such a diagnosis could the patient potentially meet the second inclusion criterion for the trial.\n\nGiven that there is a need for additional investigation to determine whether the patient's condition aligns with tuberculous meningitis, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2238": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 44-year-old man\n- Recently involved in an automobile accident\n- Sustained a skull fracture\n- Clear fluid dripping from his nose indicating cerebrospinal fluid leak\n- Severe headache and fever\n- Nuchal rigidity on physical examination\n\nClinical Trial:\n- Title: Ondansetron for Pediatric Mild Traumatic Brain Injury (mTBI)\n- Age Criteria: Children aged between 8 and 17 years old\n- mTBI Criteria: Head trauma, Glasgow coma scale of 13 to 15, and specific symptoms/conditions\n- Timeframe: Trauma occurred in the preceding 24 hours\n\nThe patient is an adult (44 years old), which does not meet the age criterion of the clinical trial that is specifically targeting children aged between 8 and 17 years old. Additionally, even though the patient has sustained a head injury, the age criterion is a key factor for inclusion in this trial. Given this discrepancy, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2239": {
        "output": "",
        "label": 0
    },
    "2240": {
        "output": "To determine the eligibility of the 44-year-old male patient for the clinical trial titled \"Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine,\" we need to assess the patient's condition and history against the inclusion and exclusion criteria provided for the trial.\n\nPatient note:\n- 44-year-old man\n- Recently in an automobile accident\n- Sustained a skull fracture\n- Clear fluid dripping from his nose\n- Severe headache and fever\n- Nuchal rigidity\n\nClinical trial inclusion criteria:\n- Willing and able to give informed consent\n- Male or female, aged 18 to 55 years old\n- In general good health with no significant chronic or acute conditions that would interfere with immune response or expected Adverse Event evaluation\n- Abstinence or use of effective contraception\n- Able to comply with all study requirements\n\nClinical trial exclusion criteria:\n- History of Guillain-Barr\u00e9 syndrome (GBS)\n- Pregnancy or lactation\n- Previous diagnosis of laboratory confirmed meningococcal disease\n- Previous meningococcal meningitis vaccination in the last five years\n- Laboratory abnormalities Grade 2 or higher\n- Known or suspected autoimmune or connective tissue disorders\n- Use of systemic immunosuppressive drugs or therapy within 6 months\n- History of anaphylactic shock, severe asthma, urticaria, or other allergic or hypersensitivity reactions following vaccination or known hypersensitivity to any vaccine component\n- Received blood, blood products, plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months\n- Use of systemic antibiotics within 72 hours prior to study enrollment\n- History of cirrhosis or hepatitis\n- Known bleeding disorder or condition associated with a prolonged bleeding time\n- Positive results for hepatitis B surface antigen, Hepatitis C or HIV-1 or HIV-2 antibodies\n- Positive drug screen\n- Current heavy smokers\n- Received another investigational product within the last 30 days\n- History of significant head trauma, alcohol or substance abuse or other medical illnesses that could cause a neurological deficit\n- Medication or alcohol use that may influence or bias the clinical outcome of the trial\n- History of any serious chronic medical or psychiatric illnesses or condition that might interfere with the evaluation of the study objectives\n- History of chronic or severe headaches, myalgia, arthralgia, malaise, fatigue or other systemic disorder commonly observed as AEs for licensed meningococcal vaccines\n- Currently experiencing a cold, flu or other acute illness\n\nBased on the patient's note, the man has recently experienced a significant head trauma due to an automobile accident, which resulted in a skull fracture. He also exhibits symptoms such as clear fluid dripping from his nose (suggestive of a cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity, which are concerning symptoms that may need immediate medical attention. These symptoms and the recent head trauma could potentially interfere with the evaluation of the study objectives and affect the immune response or expected adverse event evaluation.\n\nGiven the patient's current acute medical condition, he does not meet the inclusion criteria of being in general good health with no significant chronic or acute conditions that would interfere with immune response or expected AE evaluation. Additionally, he likely falls under the exclusion criterion of \"history of significant head trauma,\" which could cause a neurological deficit and would likely exclude him from participation in this vaccine trial.\n\nTherefore, the assessment of eligibility would be:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2241": {
        "output": "Based on the patient note provided:\n\n- A 44-year-old man sustained a skull fracture from an automobile accident.\n- Symptoms include clear fluid dripping from the nose, severe headache, fever, and nuchal rigidity.\n\nNow, let's compare this information to the inclusion criteria of the clinical trial:\n\n- Patients of more than 50 years old: The patient is 44 years old, does not meet this criterion.\n- Low trauma non vertebral fracture: The patient has a skull fracture; however, the trial specifically mentions \"non vertebral,\" and it is not clear if the fracture is considered \"low trauma.\"\n- Ambulatory patient: There is no information about the patient's mobility post-accident.\n- Direct access to mobile phone and ability to communicate via SMS: There is no information provided about the patient's access to a mobile phone or his ability to communicate via SMS.\n- Patient who doesn't oppose to his participation in the study: There is no information regarding the patient's willingness to participate.\n- Affiliation to the social security: There is no information provided about the patient's social security status.\n\nBased on the information available, the patient does not meet the age criterion, which is a definitive inclusion factor for the trial. Due to the lack of information on several other criteria, and the fact that he does not meet the age requirement, it is clear that this patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2242": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is the assessment:\n\nThe patient note indicates that the patient is a 44-year-old man who was recently in an automobile accident with a skull fracture. Following the accident, he experienced a clear fluid dripping from his nose, severe headache, and fever, as well as nuchal rigidity upon physical examination. These symptoms suggest the possibility of a cerebrospinal fluid leak or meningitis secondary to the skull fracture, which are not related to allergic rhinitis.\n\nThe clinical trial in question is evaluating the efficacy and safety of desloratadine in Japanese participants with perennial allergic rhinitis. The inclusion criteria specifically mention that participants need to be diagnosed with perennial allergic rhinitis and be outpatients.\n\nGiven that the patient's current medical issues do not align with perennial allergic rhinitis and there is no indication that the patient has this condition, he would not meet the inclusion criteria for the trial. Additionally, the trial is specific to Japanese participants with perennial allergic rhinitis, and there is no information in the patient note to suggest that the patient is Japanese or has been diagnosed with perennial allergic rhinitis.\n\nTherefore, the patient is not eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2243": {
        "output": "Based on the information provided, the patient is a 44-year-old man who recently sustained a skull fracture in an automobile accident and has symptoms that include clear fluid dripping from his nose, a severe headache, fever, and nuchal rigidity. These symptoms are indicative of a potential cerebrospinal fluid (CSF) leak due to the skull fracture, which is a serious condition that requires medical attention.\n\nThe clinical trial in question is investigating the correlation between headaches and contact between the nasal septum and nasal mucosa, as identified by CT scans. The inclusion criteria for the clinical trial are quite broad, simply stating that all patients older than 18 years who underwent sinuses or facial tomography are eligible.\n\nGiven that the patient has a headache and has likely undergone a CT scan as part of the standard assessment for a skull fracture in an automobile accident, he may technically meet the inclusion criteria for the clinical trial.\n\nHowever, the patient's headache and associated symptoms are more likely related to his recent skull fracture and potential CSF leak rather than to contact between the nasal septum and nasal mucosa. Therefore, while he may meet the technical inclusion criteria based on age and likely having had a CT scan, his clinical presentation is not primarily related to the research question of the trial. This disconnection between the patient's condition and the trial's research question might make the patient a less suitable candidate for this particular study.\n\nNevertheless, if the CT scan did show contact between the nasal septum and mucosa, and the researchers are interested in all forms of headaches regardless of the underlying cause, the patient could potentially be considered for the trial. Therefore, I would rate the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2244": {
        "output": "Based on the patient note provided:\n\nA 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.\n\nAnd the clinical trial's inclusion criteria:\n\n1. 18-85 years old\n2. Benign headache\n3. Physician intends to treat headache pain in the ED with either droperidol, prochlorperazine, or a parenteral narcotic\n\nThe patient is 44 years old, which meets the age criterion. However, the patient's headache is likely not benign, considering it is associated with a recent skull fracture, clear fluid dripping from the nose (suggestive of cerebrospinal fluid leak), severe headache, fever, and nuchal rigidity (which could indicate meningitis or another serious complication). Given the seriousness of these symptoms, it is highly likely that the headache is secondary to the trauma and not a primary headache disorder, which is what the trial is targeting.\n\nTherefore, it would not be appropriate to refer this patient for a clinical trial studying the effectiveness of a cooling device for primary headaches. The patient\u2019s headache is likely secondary to his skull fracture and other complications from the accident. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2245": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, the patient does not appear to be a fit for this specific trial. The patient has sustained a skull fracture and is experiencing symptoms that are suggestive of a cerebrospinal fluid (CSF) leak (clear fluid dripping from the nose, severe headache, fever, and nuchal rigidity), which is a serious condition requiring immediate medical attention. However, there is no indication that the patient has an inner ear malformation or that they meet the criteria for cochlear implantation, which are the specific requirements for inclusion in the trial focused on a new cochlear implant electrode for inner ear malformations.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2246": {
        "output": "",
        "label": 1
    },
    "2247": {
        "output": "The patient described in the note is a 44-year-old man who sustained a skull fracture in an automobile accident, with subsequent symptoms that include clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms and signs are suggestive of a basilar skull fracture and possible cerebrospinal fluid leakage, which could be serious complications following head trauma.\n\nThe clinical trial in question is focused on shared decision making in parents of children with head trauma. The inclusion criteria specify that it is for parents and their child who is seeking care for head trauma and that the child must be less than 18 years of age. The patient in the note is not a child and therefore does not meet the age criterion which is a crucial requirement for the trial.\n\nSince the patient is not a parent of a child with head trauma, but rather an adult who has experienced head trauma himself, he does not fit the population for which the trial is intended.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2248": {
        "output": "Based on the patient note provided, the 44-year-old man sustained a skull fracture from an automobile accident, experienced clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak, which is a sign of a serious head injury), and later developed severe headache and fever with nuchal rigidity. These symptoms and signs indicate that the patient has sustained a traumatic brain injury (TBI), which is likely more than a mild concussion given the evidence of a skull fracture and the subsequent symptoms.\n\nWhen comparing this to the inclusion criteria of the clinical trial, this patient may fit the criteria for a mild to moderate structural traumatic brain injury (TBI) as there is an indication of a skull fracture. The trial seeks patients who have evidence of structural brain injury or non-structural TBI (concussion) and are able to consent and willing to participate.\n\nGiven the patient's skull fracture and symptoms, it is reasonable to consider that this patient could be eligible under the category of mild to moderate structural TBI. However, it would be essential to confirm whether the CT scan demonstrates the presence of hemorrhage or brain contusion, as these are specific inclusion criteria for the trial.\n\nWithout complete information on imaging results, my assessment would be cautious, but considering the severity of the patient's presentation, it is reasonable to assume he could be eligible based on the skull fracture alone.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2249": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient appears eligible for the trial. The patient is a 44-year-old man who complains of severe headache (cephalalgia), which aligns with the trial's requirement for participants who complain about cephalalgia. Additionally, the patient is within the age range specified by the trial, which is 28 to 55 years.\n\nTherefore, the patient matches the inclusion criteria provided for the clinical trial titled \"Protocol to Ease Acute Cephalalgia in Emergency-department.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2250": {
        "output": "Assessing the patient's eligibility:\n\nPatient Characteristics:\n- 44-year-old man\n- Recent skull fracture from an automobile accident\n- Clear fluid dripping from the nose (suggestive of cerebrospinal fluid leak)\n- Severe headache and fever post-accident\n- Nuchal rigidity on physical examination\n\nClinical Trial Inclusion Criteria for Common Cold:\n- Male or female at least 2 but not older than 5 years of age at screening\n- Diagnosis of a common cold with acute onset of rhinorrhea and at least one other symptom (swollen nasal membranes or fever)\n\nClinical Trial Inclusion Criteria for Allergies:\n- Male or female at least 2 but not older than 5 years of age\n- Diagnosis of seasonal or perennial allergic rhinitis with a positive test and history\n- Symptoms of rhinorrhea for at least 48 hours\n\nGeneral Exclusion Criteria:\n- Significant systemic diseases\n- Higher than 102\u00b0F fever\n- Presence of otitis media\n- Certain medication restrictions\n\nThe patient in question does not meet the inclusion criteria for the clinical trial. The patient is not within the age range of 2-5 years, as required by the study. Additionally, the patient's symptoms are not related to a common cold or allergies but are likely due to a cerebrospinal fluid leak secondary to a skull fracture. Therefore, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2251": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, we can assess the patient's eligibility as follows:\n\nThe patient is a 44-year-old man, which fits within the age range of 18-50 years old specified in the inclusion criteria.\n\nHowever, the inclusion criteria also require that the patient must have completed a physical exam, ECG, medical history, and blood test within the last year. The patient note does not provide information on whether these requirements have been met.\n\nIn addition, the patient has sustained a skull fracture and is experiencing symptoms such as clear fluid dripping from the nose, severe headache, fever, and nuchal rigidity. These symptoms suggest a possible cerebrospinal fluid leak and potential infection such as meningitis, which would require immediate medical attention and are not related to the purpose of the clinical trial, which is to validate pulse oximetry and arterial blood samples during motion.\n\nGiven the lack of information about the completed medical assessments required by the trial and the patient's current acute medical condition, which is unrelated to the study's focus, the patient is not a good fit for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2252": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Spontaneous Intracranial Hypotension Treatment SIHT,\" I will assess the patient's eligibility.\n\nPatient note summary:\n- 44-year-old man\n- Recent skull fracture from an automobile accident\n- Noted clear fluid dripping from his nose\n- Severe headache and fever the following day\n- Nuchal rigidity found on physical examination\n\nClinical trial inclusion criteria:\n- 18 years or more\n- No contraindication for BPE (blood patch epidural)\n- Severe or moderate headache within 15 min standing, mild or no headache after 15 min bed rest\n- Headache from 5 to 28 days\n- Normal or evidence of low CSF on MRI\n- Signed informed consent\n\nAssessment:\n- The patient is 44 years old, which meets the age criterion.\n- There is no information suggesting a contraindication for BPE.\n- The patient has a severe headache, which could potentially meet the headache criteria if it worsens upon standing and improves with bed rest, but the patient note does not specify this behavior of the headache.\n- The duration of the headache is not specified, so it is unclear whether it fits the 5 to 28 days criterion.\n- There is no information about the results of an MRI, making it impossible to confirm normal or low CSF, which is a requirement.\n- There is no mention of the patient's ability or willingness to provide informed consent.\n\nGiven that there are several aspects of the inclusion criteria that cannot be confirmed from the patient note, and there are some criteria that are not addressed at all in the patient note, I cannot confidently state that the patient would be eligible for this trial. Further investigation would be needed to determine eligibility based on the missing information regarding headache behavior, headache duration, MRI results, and the patient's consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2253": {
        "output": "Given the provided patient note, the patient is a 44-year-old man who sustained a skull fracture in an automobile accident and is exhibiting symptoms that could be indicative of a cerebrospinal fluid leak, given the clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity.\n\nThe clinical trial in question is focused on Alzheimer's Disease and other neurodegenerative diseases and involves the use of mass spectrometry to detect specific biomarkers in cerebrospinal fluid (CSF). The inclusion criteria for the trial specify different groups with different criteria:\n\n- Group 1 and 2B: Patients aged between 55 and 85 years old with Alzheimer's Disease or other neurodegenerative diseases.\n- Group 2A: Adult patients requiring neurosurgery with CSF shunt due to brain trauma, acute hydrocephaly, or other conditions, with a favorable evolution that allows for the removal of the shunt.\n\nThe patient in the note does not fit into Group 1 and 2B due to his age (44 years old) and the absence of mention of Alzheimer's Disease or other neurodegenerative diseases. For Group 2A, while the patient has experienced brain trauma, there is no mention of a CSF shunt being placed or a requirement for neurosurgery with a CSF shunt.\n\nTherefore, based on the information provided, the patient does not meet the specified inclusion criteria for any of the groups in the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2254": {
        "output": "The patient note describes a 44-year-old man who sustained a skull fracture in an automobile accident and exhibited signs of cerebrospinal fluid rhinorrhea (clear fluid dripping from the nose), severe headache, fever, and nuchal rigidity following the accident. These symptoms are suggestive of a possible basilar skull fracture with subsequent cerebrospinal fluid leak and potential for meningitis, given the fever and nuchal rigidity.\n\nThe clinical trial in question is focused on patients with nonfunctioning pituitary adenomas (macroadenomas \u2265 1 cm) who are undergoing transsphenoidal surgery. The trial aims to compare the extent of resection and various outcomes between two different surgical techniques for pituitary adenoma removal.\n\nBased on the inclusion criteria provided for the clinical trial, the patient described in the patient note would not be eligible for this study because there is no indication that the patient has a nonfunctioning pituitary adenoma or that they are planned for transsphenoidal surgery. Instead, the patient's clinical presentation suggests an acute condition related to trauma and possible infection rather than a chronic endocrine condition like a pituitary adenoma.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires patients with suspected nonfunctioning pituitary macroadenomas and planned transsphenoidal surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2255": {
        "output": "The patient in question is a 44-year-old man who was recently in an automobile accident and sustained a skull fracture. The presence of clear fluid dripping from his nose following the accident could indicate a cerebrospinal fluid leak, which is often associated with skull fractures. Additionally, the patient developed severe headache and fever, and nuchal rigidity was found on physical examination. These symptoms could suggest complications such as meningitis, which can occur with skull fractures. However, the patient note does not mention the Glasgow Coma Scale (GCS) score, which is crucial for determining the severity of a traumatic brain injury (TBI).\n\nThe clinical trial is looking for participants with either severe traumatic brain injury, indicated by a GCS score of 8 or less, or a craniofacial fracture. Since the patient has a skull fracture, which falls under the category of craniofacial fractures, he meets one of the inclusion criteria for the clinical trial.\n\nGiven this information, and despite the absence of GCS score details, the patient's skull fracture makes him potentially eligible for the study. Further investigation would be necessary to assess the full extent of his brain injury and to ensure that his GCS score (if available) aligns with the severity level required by the study (severe TBI with a GCS score of 8 or less).\n\nBased on the provided patient note and the clinical trial inclusion criteria, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2256": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the eligibility:\n\nPatient Note:\n- 44-year-old man (meets age criterion of \u226518 years)\n- Sustained a skull fracture (potentially relevant to craniotomy/craniectomy)\n- Clear fluid dripping from his nose post-accident (suggestive of CSF leakage)\n- Severe headache and fever (symptoms not directly relevant to inclusion criteria)\n- Nuchal rigidity found on physical examination (symptom of meningitis or other complications, not directly relevant to inclusion criteria)\n\nClinical Trial Inclusion Criteria:\n- Subjects \u226518 years of age (patient is 44, so this criterion is met)\n- Undergoing craniotomy/craniectomy for pathological processes in the supratentorial region or posterior fossa (the patient has had a skull fracture, which could potentially require such a procedure)\n- Willing to participate and provide written informed consent (not mentioned but assumed possible for the patient)\n- Surgical wound classification Class I (not specified in the patient note)\n- Adequate cuff of native dura for suturing and adherence of the product (not specified in the patient note)\n- Presence of intra-operative CSF leakage after primary dural closure or Valsalva maneuver (the patient has clear fluid dripping from his nose, which could be CSF indicating a dural tear)\n\nThe patient's skull fracture and the presence of clear fluid dripping from his nose could potentially lead to the need for a craniotomy/craniectomy, and the CSF leak suggests that there might be a dura mater involvement that requires repair. However, the patient note does not provide enough information about the specific surgical requirements, the classification of the surgical wound, or the adequacy of the dura for suturing.\n\nConsidering the information provided, the patient is potentially a candidate for the study based on the information that aligns with some of the inclusion criteria (age and potential need for surgical intervention due to CSF leakage). However, additional information would be required to fully determine eligibility, especially regarding the exact nature of the surgery and the specifics of the dural injury.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2257": {
        "output": "The patient note describes a 44-year-old man who had an automobile accident resulting in a skull fracture. Post-accident, he experienced a clear fluid drip from his nose, severe headache, fever, and nuchal rigidity, which are symptoms suggestive of meningitis, possibly due to a cerebrospinal fluid leak secondary to the skull fracture.\n\nThe clinical trial in question is focusing on Vitamin D levels in children with bacterial meningitis. The inclusion criteria for the trial are specific to children with probable or confirmed bacterial meningitis, characterized by clinical manifestations such as fever and neck stiffness, along with specific cerebrospinal fluid (CSF) findings or a laboratory-confirmed bacterial pathogen in the CSF or blood.\n\nBased on the information provided, here are the points of consideration for eligibility:\n\n- The patient is a 44-year-old man, which means he is not a child, and therefore does not meet the age demographic specified in the inclusion criteria.\n- The clinical trial focuses on bacterial meningitis, and while the patient shows symptoms suggestive of meningitis, there is no clear indication that it is bacterial in nature or that it has been confirmed as such.\n- The trial's inclusion criteria require specific CSF findings or laboratory confirmation of a bacterial pathogen, none of which is mentioned in the patient note.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial as he is not within the correct age range, and there is no evidence provided to confirm a diagnosis of bacterial meningitis to fulfill the clinical or laboratory criteria outlined in the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2258": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 44-year-old man\n- Involved in an automobile accident\n- Sustained a skull fracture\n- Noted clear fluid dripping from his nose (suggestive of cerebrospinal fluid leak)\n- Severe headache and fever developed after the accident\n- Nuchal rigidity found on physical examination (indicative of potential meningitis or other complications)\n\nClinical trial:\n- Cases with traumatic and nontraumatic brain damage treated in the Intensive Care\n- Patients treated in the ICU with a diagnosis of traumatic or nontraumatic brain damage\n- More than a 24-hour stay required\n\nThe patient in question has sustained a skull fracture due to an automobile accident, which is a form of traumatic brain injury. The patient's symptoms, such as the clear fluid dripping from the nose and the severe headache coupled with nuchal rigidity, are consistent with brain damage and potential complications that would necessitate intensive care.\n\nGiven that the clinical trial is looking for patients with traumatic or nontraumatic brain damage being treated in the ICU, and the patient has a skull fracture with related symptoms requiring ICU-level care, this patient fits the inclusion criteria for the clinical trial.\n\nTherefore, based on the provided information, the assessment of eligibility is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2259": {
        "output": "",
        "label": 0
    },
    "2260": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 44-year-old man, which fits within the age range of 18-75 years required by the trial.\n- The patient sustained a skull fracture in an automobile accident, but there is no mention of an acute spinal cord injury (SCI), which is a requirement for the trial.\n- The patient has symptoms such as clear fluid dripping from his nose, severe headache, fever, and nuchal rigidity. These symptoms suggest a possible cerebrospinal fluid leak and meningitis, not necessarily an acute SCI.\n- There is no information provided about the timing of the injury concerning the 24-hour window mentioned in the trial criteria.\n- There is no information on the ISNCSCI Impairment Scale Grade or the neurological level of injury, which are specific to spinal cord injuries and required for the trial.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is specifically for patients with an acute SCI, which is not indicated in the patient's note.\n- The injury must be less than 24 hours old, and there is no information to confirm this timing.\n- Specific neurological criteria (ISNCSCI Impairment Scale Grade A, B or C and neurological level of injury between C4-C8) must be met, and there is no information on this in the patient note.\n\nGiven that the patient note does not indicate that the patient has an acute spinal cord injury, which is a fundamental requirement for the trial, and there is a lack of information on other specific inclusion criteria, it is not appropriate to refer this patient to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2261": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial in question. The trial is specifically looking for individuals who have received a booster dose of the Menactra vaccine approximately 4 years earlier as part of a previous study (MTA77). The patient note does not mention any history of vaccination with Menactra, nor does it indicate that the patient was a participant in trial MTA77. The patient's recent health issues related to an automobile accident and subsequent symptoms (clear fluid from the nose, headache, fever, and nuchal rigidity) suggest a different medical condition that is not related to the focus of the clinical trial.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2262": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders\" involves comparing the patient's characteristics and symptoms with the inclusion and exclusion criteria provided in the trial summary.\n\nThe patient in question is a 5-year-old boy with symptoms of a swallowing disorder, which includes dysphagia, drooling, fever, and vocal changes. These symptoms align with the conditions being studied in the trial, as the trial aims to characterize swallowing problems in various patient populations.\n\nHowever, the inclusion criteria specify that the clinical study is open to any Clinical Center inpatients and outpatients with known or suspected dysphagia, including patients enrolled in NIH neurology or speech pathology protocols or admitted specifically for this protocol. The patient does show appropriate signs and symptoms of dysphagia and oral motor impairment, which would make him a potential candidate based on these criteria alone.\n\nBut upon further review of the exclusion criteria, it is clear that infants and children under age 3 will be excluded due to radiation risk on the developing visual system. While the patient is older than 3 years of age, the exclusion criteria do not clearly state an age range, only specifying \"infants and children under age 3.\" The patient being 5 years old is above this exclusion range and thus would not be automatically excluded based on age.\n\nGiven that the patient shows signs and symptoms of dysphagia that could be assessed by the study and is not explicitly excluded by age based on the provided criteria, the patient may be considered for the clinical trial.\n\nHowever, it's essential to confirm with the clinical trial team whether there are any additional age-related considerations or risks before proceeding with a referral. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2263": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Sensory Function in Idiopathic Voice Disorders,\" we can determine the following:\n\nThe patient is a 5-year-old boy with symptoms including progressively worsening dysphagia, drooling, fever, and vocal changes. These symptoms suggest a possible acute condition that requires immediate medical attention, but do not specifically indicate a voice disorder due to uncontrolled muscle contractions affecting the voice box, which is the focus of the clinical trial.\n\nThe clinical trial has specific inclusion criteria for normal volunteers (20 to 80 years of age) and patients with spasmodic dysphonia or muscular tension dysphonia. Additionally, there are exclusion criteria that would disqualify certain individuals from participating.\n\nLet's assess the patient against the inclusion criteria for the clinical trial:\n\n1. Age: The patient is 5 years old, which is outside the age range specified for normal volunteers (20 to 80 years of age) and below the typical onset age for spasmodic dysphonia (usually first occurring after 40 years of age).\n\n2. Current Medical Condition: The patient's symptoms do not specifically align with spasmodic dysphonia or muscular tension dysphonia, which are the focus of the clinical trial. The symptoms described in the patient note suggest an acute infection or inflammation, not a chronic voice disorder.\n\n3. Exclusion Criteria: While the note does not provide specific information regarding the exclusion criteria, the age of the patient alone is enough to disqualify him from participating in this study.\n\nGiven that the patient does not meet the age requirement and does not exhibit the specific symptoms being studied in the clinical trial, it is clear that this patient is not eligible for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2264": {
        "output": "Based on the information provided:\n\nThe patient is a 5-year-old boy presenting with symptoms such as dysphagia, drooling, fever, and vocal changes. His condition seems to be acute and potentially serious, requiring immediate medical attention.\n\nThe clinical trial in question is focused on understanding how the brain controls voice production and is specifically looking for either healthy adult volunteers between the ages of 20 and 70 with normal vocal function, or patients with certain voice disorders such as spasmodic dysphonia, muscular tension dysphonia, or voice tremor. There are additional inclusion and exclusion criteria detailed, such as the absence of pulmonary, neurological, or psychiatric disorders.\n\nGiven the patient's age (5 years old), he does not meet the age requirement of 20 to 70 years old for the clinical trial. Furthermore, the patient's symptoms do not match the specific voice disorders being studied (spasmodic dysphonia, muscular tension dysphonia, or voice tremor), and the acute nature of his presentation suggests a different pathology than what is being studied in the trial.\n\nTherefore, the patient is not eligible for the clinical trial based on age and the type of voice disorder being investigated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2265": {
        "output": "Considering the patient note and the inclusion criteria of the clinical trial provided, here's the assessment:\n\nThe patient is a 5-year-old boy presenting with symptoms suggestive of a severe throat infection or similar condition (e.g., epiglottitis) characterized by dysphagia, drooling, fever, and vocal changes. The clinical trial in question is studying brain activation during simple vocal behaviors in individuals with normal hearing and voice function.\n\nThe inclusion criteria for the clinical trial specify that participants must be between the ages of 18 and 45 with normal hearing and voice function and have a steady heart rate. The patient in question does not meet the age criterion as he is only 5 years old. Additionally, the patient is currently experiencing vocal changes, which may indicate that his voice function is not normal at this time.\n\nBased on the information provided, the patient does not meet the key inclusion criteria for age and current voice function status. Therefore, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2266": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is evident that the patient does not meet the eligibility requirements for the clinical trial. The trial is seeking healthy volunteers between the ages of 20 and 60 with no cardiac, pulmonary, neurological, otolaryngological, psychiatric or speech, swallowing, and hearing problems. The patient in question is a 5-year-old boy with current health issues including dysphagia, drooling, fever, and vocal changes, indicating a possible acute condition which would not classify him as a healthy volunteer. Additionally, the patient's age is outside the specified range for the study.\n\nTherefore, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2267": {
        "output": "After reviewing the patient note and the clinical trial's inclusion criteria, it is apparent that the patient does not meet the specified criteria for the trial. The inclusion criteria require:\n\n1. A diagnosis of cerebral palsy\n2. Severe drooling\n3. Aged between 6-21 years\n4. Ability of the subjects (or their guardian) to understand the requirements of the study and sign the informed consent form\n\nThe patient note describes a 5-year-old boy, which immediately disqualifies him based on the age criterion alone, as the trial specifies participants should be aged between 6-21 years. Additionally, the patient's symptoms are associated with an acute illness rather than cerebral palsy. Therefore, he does not have the diagnosis required by the study.\n\nBased on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2268": {
        "output": "",
        "label": 1
    },
    "2269": {
        "output": "The inclusion criteria for the clinical trial specifically state that participants must be equal to or over 13 years of age. The patient in the note is a 5-year-old boy, which does not meet the age criterion for the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2270": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nThe patient is a 5-year-old boy, which is significantly older than the age range specified in the inclusion criteria (6-12 weeks). Additionally, the clinical trial is specifically designed to evaluate the safety and immunogenicity of a pneumococcal conjugate vaccine in a very young infant population, as described by the age range in the inclusion criteria.\n\nConsidering the patient's age does not fall within the specified range for the clinical trial, and there is no mention of the boy having a condition that this particular vaccine would address, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2271": {
        "output": "Assessing the eligibility of the 5-year-old boy for the clinical trial titled \"Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty,\" we need to compare the patient's characteristics and symptoms with the inclusion criteria of the clinical trial.\n\nPatient Characteristics and Symptoms:\n- Age: 5 years old\n- Presenting symptoms: progressively worsening dysphagia, drooling, fever, vocal changes, toxic appearance, \"hot potato\" voice\n- Additional information: leaning forward, delayed vaccines\n\nClinical Trial Inclusion Criteria:\n1. 1 year old to 18 years of age\n2. Clinical signs or symptoms of obstructive sleep apnea (snoring, witnessed apneas, daytime somnolence, restless sleeping, or cyanosis)\n3. Abnormal polysomnogram (mild, moderate, or severe OSA) including CO2 measures\n4. Failed or refused trial of CPAP, or not recommended by their pulmonologist or primary care doctor\n\nThe patient's age falls within the specified range of 1 to 18 years. However, the provided patient note does not mention obstructive sleep apnea or laryngomalacia, which are the conditions being investigated in the clinical trial. The symptoms described in the patient note suggest a possible airway obstruction or infection, such as epiglottitis, rather than obstructive sleep apnea. Additionally, there is no mention of a polysomnogram test or a trial of CPAP, nor is there any information about the recommendations of a pulmonologist or primary care doctor regarding this patient.\n\nBased on the available information, the patient's symptoms do not align with the specific conditions the clinical trial aims to treat. Therefore, it is unlikely that this patient would be eligible for the clinical trial based on the provided criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2272": {
        "output": "",
        "label": 0
    },
    "2273": {
        "output": "The patient note describes a 5-year-old boy with symptoms consistent with an acute onset of drooling, dysphagia, fever, and vocal changes, which could indicate a serious infection such as epiglottitis, rather than chronic drooling due to a neurological condition. There is no mention of cerebral palsy or other chronic neurologic conditions that would lead to pathologic chronic drooling. \n\nThe clinical trial is looking for patients aged 3 through 18 years with a diagnosis of cerebral palsy and/or mental retardation or any other neurologic impairment or condition that causes chronic drooling. The patient's current presentation does not match the chronic conditions specified in the inclusion criteria of the clinical trial; therefore, he does not meet the inclusion criteria.\n\nBased on the provided information, the patient's acute condition does not align with the chronic nature of the conditions sought by the trial, which is focused on chronic moderate to severe drooling in a pediatric population with specific neurological conditions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2274": {
        "output": "Based on the information provided, the patient in question is a 5-year-old boy presenting with symptoms that include dysphagia, drooling, fever, and vocal changes, indicative of a possible acute infection or inflammatory condition. The clinical trial is focused on the treatment of sialorrhea (excessive drooling) in Parkinson's Disease patients. The inclusion criteria for the trial specify that participants must be patients with Parkinson's Disease who have experienced sialorrhea for at least 3 months.\n\nGiven that the patient is a 5-year-old boy with no mention of Parkinson\u2019s Disease, he does not meet the inclusion criteria for the clinical trial, which is specifically targeted at Parkinson's Disease patients with sialorrhea. Therefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2275": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note:\n- The patient is a 5-year-old boy.\n- He presents with symptoms suggestive of an acute infection or inflammation, such as dysphagia, drooling, fever, and vocal changes.\n- The patient appears toxic and is showing signs of respiratory distress or infection.\n- There is no mention of the child being healthy, as he currently has an acute condition.\n- The note does not mention the current date or the child's birth date, which is required to establish if he was born within the same calendar quarter as the reference FluMist vaccinee.\n\nClinical Trial Inclusion Criteria:\n- The patient must be healthy.\n- The patient must have been born within the same calendar quarter as the reference FluMist vaccinee.\n\nAssessment:\n- The patient is not healthy at the time of the assessment, as he presents with acute symptoms.\n- The patient note does not provide information on the birth date to determine if he meets the age criteria based on the calendar quarter of birth.\n\nBased on the current information, the child does not meet the \"healthy\" criterion, which is necessary for inclusion in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2276": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet the requirements for this clinical trial. The patient is a 5-year-old boy with symptoms that suggest a possible upper airway obstruction or infection, such as acute epiglottitis, given the \"hot potato\" voice, drooling, and other symptoms. The clinical trial is focused on patients who are undergoing surgical rehabilitation for unilateral vocal cord paralysis, specifically thyroplasty or vocal fold augmentation, and it also specifies an age range for healthy subjects from 18 to 85 years old. This patient is not within the age range, does not have a diagnosis of unilateral vocal cord paralysis, and is not undergoing the specified surgical procedures.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2277": {
        "output": "In the provided case, the patient is a 5-year-old boy with symptoms suggesting a possible acute upper airway obstruction, such as epiglottitis. This patient does not meet the inclusion criteria of the clinical trial for the following reasons:\n\n1. Age: The trial requires participants to be between 18-80 years old.\n2. ASA Physical Status: The trial specifies the need for patients with an American Society of Anesthesiology (ASA) physical status grade I-II, typically indicating a healthy or mild systemic disease patient, which might not be applicable given the child's toxic appearance.\n3. Type of Surgery: The trial is specific to patients undergoing elective gynecological surgery.\n4. Position: The trial requires patients to be in a supine position, which is not relevant to the patient's presenting condition.\n\nGiven that the patient does not meet the inclusion criteria based on age, health status, the type of surgery involved, and the study's focus on anesthesia equipment rather than acute pediatric conditions, the trial-level eligibility would be:\n\n`Trial-level eligibility: 0) Would not refer this patient for this clinical trial.`",
        "label": 0
    },
    "2278": {
        "output": "Assessing the eligibility of the 5-year-old boy for the clinical trial on the effectiveness of Rotarix\u2122 against RV SGE in infants in Panama:\n\nInclusion Criteria Analysis:\n\n- The child must be born after 1 March 2006 and at least 12 weeks of age: The boy is 5 years old, which means he was born well after 1 March 2006, and he exceeds the minimum age requirement of 12 weeks.\n- Subject admitted to the study hospital for SGE during the study period: The patient note does not indicate that the boy has symptoms of severe gastroenteritis (SGE). Instead, he presents with symptoms suggestive of an upper respiratory infection or possibly epiglottitis, given the dysphagia, drooling, fever, and vocal changes.\n- Onset of SGE <= 14 days prior to admission: There is no mention of gastroenteritis or related symptoms in the patient note.\n- Laboratory confirmed RV positive stool sample: As there is no mention of gastroenteritis, it's assumed no stool sample test for rotavirus has been conducted.\n- Written informed consent obtained from the parent or guardian of the subject: This is a procedural requirement that can potentially be fulfilled if the child were eligible for the study.\n\nExclusion Criteria Analysis:\n\n- Hospitalisation is unrelated to GE: The patient's hospitalisation seems unrelated to gastroenteritis, as the symptoms described are not consistent with SGE.\n- Exclude children with vaccine-preventable diseases: The note indicates that the parents have delayed some of the child's vaccines. However, there is no indication that the current condition is one of the listed vaccine-preventable diseases.\n\nBased on the information provided, the 5-year-old boy does not meet the inclusion criteria for the clinical trial as he is not admitted with SGE and there is no indication of a laboratory-confirmed RV positive stool sample. Furthermore, his symptoms do not align with the focus of the clinical trial, which is on SGE related to rotavirus.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2279": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the 5-year-old boy for the trial:\n\nPatient note summary:\n- 5-year-old boy\n- Presents with symptoms suggestive of an infectious process (e.g., dysphagia, drooling, fever, muffled voice)\n- Delayed vaccinations\n\nClinical trial summary:\n- Evaluates the effectiveness of varicella vaccines in children in Germany\n- Inclusion criteria specify that the child must be at least one year of age, born on or after July 1, 2003, reside in Germany, have at least one previous well-child visit, and have parental consent\n- Specific inclusion for cases: Suspected primary varicella disease at the time of study entry\n\nThe patient's symptoms do not specifically suggest varicella (chickenpox), and there is no mention of the child having suspected primary varicella disease or being in Germany. Also, the information provided does not indicate whether the boy has had previous well-child visits, but he has delayed vaccinations, which could be relevant to the study's context regarding varicella vaccination effectiveness. \n\nHowever, without explicit evidence of suspected primary varicella disease and not knowing if the child resides in Germany, we cannot confidently refer this patient to the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2280": {
        "output": "",
        "label": 0
    },
    "2281": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial provided, the 5-year-old boy would not be eligible for the trial. The trial is specifically looking for infants of either sex, aged 16 - 20 months / 2 - 4 months, in good health, and the patient in question is a 5-year-old boy presenting with symptoms of an acute infection (toxic appearance, dysphagia, drooling, fever, and vocal changes), which likely indicates a current health issue that does not align with the requirement of being in good health as determined by medical history, physical examination, and clinical judgment of the investigator.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2282": {
        "output": "Based on the provided information, the patient in question is a 5-year-old boy, which immediately disqualifies him from the clinical trial in question as the trial's inclusion criteria specify that participants must be healthy adults aged between 18 and 54 years old. Therefore, without considering any other factors, the patient's age alone makes him ineligible for this trial.\n\nSince the patient does not meet the age criterion, there is no need to assess the other criteria; he is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2283": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, this 5-year-old boy would not be eligible for the trial. The inclusion criteria state that the trial is for patients who are 6 months to 17 years of age, which this patient meets. However, the patient must be undergoing an elective surgical procedure expected to last at least 45 minutes and have a normal airway, which is not indicated in the patient note. Additionally, the child is presenting with an acute condition (progressively worsening dysphagia, drooling, fever, and vocal changes with a \"hot potato\" voice), suggesting a possible airway infection like epiglottitis, which is an emergency situation and not an elective case.\n\nFurthermore, the clinical trial is looking for patients with a normal airway (Mallampati Classification), and the ASA Physical Status Classification should be I or II, indicating a healthy patient or a patient with mild systemic disease. The child's toxic appearance and severe symptoms suggest a more acute and potentially severe condition, likely excluding him from ASA I or II classification.\n\nThe trial is also focused on elective intubation utilizing the Shikani Optical Stylet, and the patient's current condition does not indicate that he is scheduled for an elective surgical procedure.\n\nTherefore, the patient does not meet several key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2284": {
        "output": "Based on the information provided, the patient is a 5-year-old boy presenting with symptoms suggestive of croup: dysphagia, drooling, fever, vocal changes, and the characteristic \"hot potato\" voice. The clinical trial in question is seeking to assess the efficacy of Nebulized Beclomethasone Dipropionate in the treatment of moderate croup.\n\nThe inclusion criteria for the clinical trial specify that the patient must be:\n1. Male or female aged between 6 months and 3 years.\n2. Presenting to the ER with an acute onset of barky cough, stridor, hoarseness, and respiratory distress.\n3. Diagnosed with moderate croup (Westley score of 3-8).\n\nThe patient described in the note does not meet the age criterion for the clinical trial as he is 5 years old, which is outside the specified age range of 6 months to 3 years. Therefore, despite the clinical presentation matching that of moderate croup, the patient would not be eligible for this clinical trial based on age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2285": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient is a 5-year-old boy presenting with symptoms suggestive of a severe infection, which could be indicative of a peri-tonsillar abscess (PTA or PLA), including dysphagia, drooling, fever, vocal changes, and a \"hot potato\" voice. The inclusion criteria for the clinical trial are the clinical existence of a PLA, validated by a senior ENT, with the visible appearance to the throat that justifies puncture, regardless of whether they had consulted for a sore throat in the 10 days preceding the diagnosis.\n\nAlthough the trial does not explicitly mention an age limit, it is reasonable to infer that it includes children as the summary refers to analyzing risk factors in both children and adults. The child's presentation with symptoms that could be indicative of a PLA (phlegmon) suggests that he could be eligible for the trial provided a senior ENT validates the diagnosis.\n\nGiven that the patient's symptoms align with the clinical picture of a PLA, which is the condition under study, and assuming an ENT specialist confirms the diagnosis, this patient would potentially meet the inclusion criteria. However, as there is no explicit mention of an ENT evaluation in the patient note, further investigation, such as an ENT consultation, would be required to confirm the diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2286": {
        "output": "Based on the information provided:\n\nThe patient is a 5-year-old boy presenting with symptoms suggestive of an upper respiratory infection or possibly a more serious condition such as epiglottitis, given the symptoms of progressively worsening dysphagia, drooling, fever, vocal changes, and the \"hot potato\" voice.\n\nThe clinical trial in question is focused on the outcomes related to voice and swallowing following revision anterior cervical spine surgery.\n\nThe inclusion criteria for the trial are:\n- Patients undergoing revision anterior cervical spine surgery\n\nThe patient note does not indicate that the boy has undergone any cervical spine surgery, let alone a revision surgery. Therefore, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2287": {
        "output": "",
        "label": 0
    },
    "2288": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the age requirement for the clinical trial. The trial is specifically for infants aged 6-12 months, and the patient is a 5-year-old boy. Therefore, he is not eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2289": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient in question would not be eligible for the trial.\n\nThe patient note describes a 5-year-old boy with symptoms suggestive of a severe throat infection, such as progressively worsening dysphagia, drooling, fever, and a muffled voice. There is no mention of thyroid carcinoma or any thyroid-related issues.\n\nThe clinical trial is specifically looking for patients who have either minimally invasive follicular thyroid carcinoma \u22644 cm in diameter or papillary thyroid carcinoma \u22642 cm in diameter to compare the outcomes of robotic versus conventional open thyroidectomy.\n\nSince the patient's condition does not match the target disease nor the inclusion criteria of the clinical trial, which is focused on thyroid carcinoma, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2290": {
        "output": "Based on the information provided, the patient is a 5-year-old boy, which fits within the age range specified in the clinical trial's inclusion criteria (13-59 months of age).\n\nHowever, the trial is evaluating the safety and immunogenicity of vaccines for Haemophilus influenzae type b (Hib) in healthy children. The patient note does not provide clear information on whether the symptoms presented (progressively worsening dysphagia, drooling, fever, and vocal changes) are due to Haemophilus influenzae type b infection or another underlying cause. The patient being toxic-appearing and presenting with a \"hot potato\" voice could be suggestive of epiglottitis, which could be caused by Hib, but this is not explicitly confirmed in the patient note.\n\nGiven the age match but lack of explicit confirmation of a Hib infection or that the child is otherwise healthy, there would need to be further investigation to determine if the child's current health condition aligns with the study's requirements. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2291": {
        "output": "Based on the information provided, the 5-year-old boy with symptoms of dysphagia, drooling, fever, and vocal changes does not meet the inclusion criteria for the clinical trial titled \"Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage for Cutaneous Abscesses.\" The inclusion criteria specify that patients must be presenting with an abscess less than 5 cm in diameter. The patient in question does not have an abscess mentioned in their presentation; instead, the symptoms suggest a potentially serious infection such as epiglottitis, which is a medical emergency.\n\nMoreover, the clinical trial is being conducted at The Ottawa Hospital's Civic Campus emergency department, and it is specified for adult emergency department patients. The patient in the note is a 5-year-old boy, which does not fit the adult criterion.\n\nTherefore, the patient does not meet the age requirement, the condition under investigation (cutaneous abscess), and there is no mention of him being at the specified hospital location for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2292": {
        "output": "",
        "label": 0
    },
    "2293": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient appears to meet the age requirement (5 years old) and is within the American Society of Anesthesiologists (ASA) physical status classification I or II, which is typical for children undergoing routine surgery like adenotonsillectomy.\n\nHowever, the patient note does not explicitly state the ASA physical status. The boy presents with symptoms suggestive of a serious infection or inflammatory condition of the throat, which may or may not be related to tonsillar issues that would require an adenotonsillectomy. The trial is specific to postoperative pain relief following adenotonsillectomy, and there is no mention in the patient note of the child being scheduled for or having undergone an adenotonsillectomy.\n\nGiven that the patient is of the correct age for the trial but we do not have confirmation of the ASA status or plans for adenotonsillectomy, further investigation would be needed to determine if the child is scheduled for an adenotonsillectomy and if his current condition is related to tonsillar issues that the surgery would address.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2294": {
        "output": "Based on the provided patient note and clinical trial information, the patient in question is a 5-year-old boy, which immediately disqualifies him from the clinical trial that is specifically targeting healthy infants between 365-569 days old (roughly 12 to 18 months of age).\n\nTherefore, the patient does not meet the age requirement of the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2295": {
        "output": "Given the patient note and the clinical trial information provided, the patient appears to be a 5-year-old boy presenting with symptoms suggestive of a peritonsillar abscess (PTA), including worsening dysphagia, drooling, fever, and vocal changes. \n\nThe inclusion criteria for the clinical trial are patients with PTA ages 18-65 who agreed to join the research. The exclusion criteria include hypersensitivity to dypiron and/or tramadol, pregnant women, individuals with mental illness, and soldiers.\n\nThe patient in question does not meet the age requirement for the clinical trial, as he is only 5 years old and the study is looking for participants aged 18-65. Therefore, this patient would not be eligible for the clinical trial based on age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2296": {
        "output": "Based on the patient's note and the clinical trial's inclusion criteria, the patient does not meet the key condition of having had a stroke. The trial is specifically targeting patients who have experienced a stroke and are suffering from dysphagia as a result. The 5-year-old boy in the patient's note presents with dysphagia, fever, and other symptoms, but there is no mention of a stroke or cerebrovascular accident. The symptoms described in the patient note suggest a possible case of acute infection or inflammation, such as epiglottitis, rather than post-stroke complications.\n\nTherefore, the patient does not fit the inclusion criteria for the clinical trial, which is specifically designed for stroke patients with dysphagia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2297": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Implications of Pacifier Use in Israeli Children,\" the 5-year-old boy does not meet the trial's inclusion criteria. The trial is specifically recruiting healthy children aged 3-4 years that use a pacifier. The patient in the note is 5 years old, which is outside the specified age range, and there is no mention of pacifier use. Additionally, the child is presenting with symptoms of illness (dysphagia, drooling, fever, vocal changes), which conflicts with the requirement for \"healthy children.\"\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2298": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient, a 5-year-old boy, does not meet the age requirement for the clinical trial, which is specified for adult patients. Additionally, there is no mention of the boy's ability to speak and understand Finnish or Swedish. Consequently, he does not satisfy the necessary conditions for inclusion in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2299": {
        "output": "Assessing the patient's eligibility for the clinical trial involves checking whether the patient's characteristics and condition match the inclusion criteria of the study. Let's go through the key points:\n\n1. Age: The trial is for children aged 6-10 years, and the patient is 5 years old. This does not meet the age requirement.\n2. Diagnosis: The inclusion criteria specify the presence of apparent vocal fold nodules. The patient note does not mention vocal fold nodules; instead, it describes symptoms that may suggest a different condition such as epiglottitis (e.g., \"hot potato\" voice, drooling, fever).\n3. Dysphonia Duration: The trial requires a dysphonia duration of at least 12 weeks. The patient note does not provide information on how long the dysphonia has been present.\n4. Voice Therapy: The trial excludes children who have previously received speech therapy targeting voice/resonance. The patient note does not mention any previous speech therapy, but this is not the immediate concern given the other mismatched criteria.\n5. Hearing Requirement: The inclusion criteria specify a hearing threshold in the better ear of 35 dB or better. There is no information about the patient's hearing in the note.\n6. Voice-Related Quality of Life: The trial requires baseline PVRQOL scores to be <87.5. The patient note does not provide PVRQOL scores or any indication that the child's voice-related quality of life is affected, although this is also not the primary concern given the other more definitive criteria mismatches.\n\nBased on these points, particularly the age and lack of evidence for vocal fold nodules in the patient's diagnosis, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2300": {
        "output": "Based on the patient note provided, the 5-year-old boy presents with symptoms of acute illness, including dysphagia, drooling, fever, vocal changes, and a toxic appearance. These symptoms do not align with chronic cough, as the acute nature of his presentation suggests a more immediate infection or inflammatory process, rather than a chronic condition.\n\nNow, let's assess the patient's eligibility for the clinical trial titled \"A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in the United Kingdom\" based on the inclusion criteria provided:\n\n- Subjects who the investigator believes that parent(s)/legally acceptable representative can and will comply with the requirements of the protocol: There is no information to suggest non-compliance.\n- A male or female child between, and including, six to 72 months of age at the time of enrolment: The patient is 5 years old, which is within the age range.\n- Written informed consent obtained from the parent(s)/legally acceptable representative of the subject: Assuming consent could be obtained.\n- No antibiotic therapy within four weeks prior to the visit: There is no information on antibiotic use.\n- No cystic fibrosis or known major immunodeficiency: There is no information suggesting such conditions.\n- No documented evidence or suspicion of gastroesophageal reflux disease: There is no information on this.\n- No evidence of an upper viral respiratory infection four weeks prior to the visit: The current symptoms could suggest a viral infection, but chronicity is not established.\n- Persistent cough greater than eight weeks: There is no mention of a persistent cough in the patient's note.\n- No response to five-day prednisolone treatment: There is no mention of treatment with prednisolone.\n- Chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality: There is no information on a chest X-ray.\n\nThe crucial criteria that are not met are related to the chronic nature of the cough (must be greater than eight weeks), no response to prednisolone treatment, and a chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality. Since the patient does not have a documented chronic cough or any information on treatment and X-ray findings, the patient does not meet the specific criteria for \"cases\" in this study.\n\nTherefore, the boy does not meet the inclusion criteria for the clinical trial as he does not present with a chronic cough nor is there any evidence that he has undergone the required prednisolone treatment or had a chest X-ray performed to rule out lobar pneumonia or structural abnormalities.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2301": {
        "output": "",
        "label": 0
    },
    "2302": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial for Quinvaxem vaccine, here are the key points to consider:\n\n- The patient is a 5-year-old boy, which is outside the age range specified in the inclusion criteria of the clinical trial. The trial is looking for infants at the age of DTP vaccination according to the local EPI program (60-120 days old).\n- The inclusion criteria also specify that the infants must be free from any obvious health problems and the patient in the note presents with severe symptoms including dysphagia, fever, and a \"hot potato\" voice, which could be indicative of a serious infection or other health issues.\n- The inclusion criteria require infants to have a normal gestational age (\u2265 37 weeks) and a birth weight > 2.5 kg, but there is no information provided about the patient's birth history.\n- There is no indication in the patient note of any congenital diseases or dermatological conditions, which are relevant exclusions for the trial.\n- There is also no information about whether the patient has already received the Hepatitis B vaccination at birth, which is an inclusion criterion for the trial.\n- Lastly, consent from the parent or legal guardian is required for participation in the study, but the note does not mention if consent would be given.\n\nGiven that the patient does not meet the age criterion, which is a fundamental requirement for this clinical trial, and there are other unmet or unspecified criteria, the patient would not be eligible for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2303": {
        "output": "Considering the provided patient note and the inclusion criteria of the clinical trial:\n\n- The patient is a 5-year-old boy which fits within the age range of 2 months to 5 years required for the trial.\n- The clinical trial is regarding the safety of Haemophilus Influenza Type b Vaccine in Korean children.\n\nAlthough the patient's symptoms (dysphagia, drooling, fever, and vocal changes) might suggest a condition that could be related to Haemophilus influenzae infection, the clinical trial is focused on the safety of the vaccine, not the treatment of the condition. Moreover, the clinical trial specifies it is for Korean children, and there is no indication that the patient is Korean. Additionally, the parents have delayed some of his vaccines, which may be an indication that he has not yet received the Haemophilus Influenza Type b vaccine. However, the emergency presentation and his current condition suggest that he may require immediate medical attention rather than participation in a vaccine safety trial.\n\nTherefore, based on the information provided, the patient does not meet the specific demographic criteria (Korean children) nor the implied clinical status appropriate for a post-marketing surveillance study of a vaccine.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2304": {
        "output": "Given the information provided:\n\nPatient note: The patient is a 5-year-old boy with symptoms suggestive of a severe throat infection or possibly epiglottitis given the dysphagia, drooling, fever, vocal changes, and \"hot potato\" voice. The note also mentions delayed vaccinations for the child.\n\nClinical trial: The trial is assessing the safety of a Group A, C polysaccharide meningococcal and type b Haemophilus influenzae conjugate vaccine in children. The inclusion criteria specify that the participants should be healthy subjects aged from 6 months to 5 years old, with no prior vaccination for the diseases in question, among other requirements.\n\nAssessment of trial-level eligibility based on the inclusion criteria and patient note:\n\n- The patient is within the age range of 6 months to 5 years old.\n- The trial requires participants to be healthy, which the patient currently is not, as he presents with an active infection or inflammation (suggestive of epiglottitis).\n- The patient should have a temperature <37\u00b0C on the axillary setting, and the provided note does not indicate the patient's temperature, yet the presence of fever suggests it might be elevated.\n- It is not mentioned if the patient has previously received the group A, C polysaccharide meningococcal vaccine and type b Haemophilus influenzae vaccine, but the note indicates some vaccines have been delayed.\n\nBased on the available information, the patient does not meet the criteria of being healthy, and the presence of fever suggests he may not have a temperature <37\u00b0C. Additionally, the current medical condition is an acute infection, which likely excludes him from participation in a vaccine safety trial intended for healthy individuals. However, without information on the patient's vaccination history regarding the specific vaccines in question, a definitive assessment cannot be made.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2305": {
        "output": "The patient is a 5-year-old boy, which fits within the 2 to 5 years age range specified in the inclusion criteria of the clinical trial. However, the patient presents with symptoms like dysphagia, drooling, fever, and vocal changes, which suggest he is currently unwell and possibly has an infection. The inclusion criteria require subjects to be healthy, have a temperature below 37\u00b0C, and be of normal intelligence.\n\nSince the patient is described as toxic-appearing and has a fever, he would not meet the criteria for being considered healthy or having a temperature below 37\u00b0C. Furthermore, the trial specifies that subjects must have never received the group A, C polysaccharide meningococcal vaccine and type b Haemophilus influenzae vaccine, but there is no information provided about the patient's vaccination status beyond the fact that some vaccines have been delayed. This lack of information means we cannot confirm his eligibility based on his vaccination history.\n\nTherefore, based on the information provided, the patient does not meet the health status requirements for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2306": {
        "output": "The patient note describes a 5-year-old boy with symptoms including dysphagia, drooling, fever, vocal changes, and a \"hot potato\" voice, which are suggestive of an acute condition affecting the throat, possibly an infection like epiglottitis. The clinical trial in question is focused on herpes esophagitis presenting as vocal fold palsy in patients.\n\nWhile the boy's symptoms include vocal changes, there is no indication that he has been diagnosed with herpes esophagitis or vocal fold palsy. The inclusion criteria for the trial specifically require a patient to have herpes esophagitis with vocal palsy presentation. The patient's age, symptoms, and lack of a specific diagnosis of herpes esophagitis or vocal palsy make him ineligible for the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2307": {
        "output": "Upon reviewing the patient note and the clinical trial information, let's evaluate the eligibility of the patient for the clinical trial.\n\nPatient Note:\n- A 5-year-old boy\n- Presents with symptoms suggesting a serious infection (e.g., possibly epiglottitis)\n- Has not received some vaccines (which could include the type b Haemophilus influenzae vaccine)\n\nClinical Trial Inclusion Criteria:\n- Healthy subjects aged 3 to 5 months\n- Normal intelligence\n- Able to comply with the trial requirements\n- Never received group A, C polysaccharide meningococcal vaccine and type b Haemophilus influenzae vaccine\n- Subjects with temperature <=37\u00b0C on axillary setting\n\nClinical Trial Exclusion Criteria:\n- A medical history of Meningitis or severe allergies, among other conditions\n- Any known immunological dysfunction\n- Received immunoglobulins or certain medications within specified time frames\n- Any acute infections or serious chronic diseases\n\nBased on the information provided:\n\n- The patient is 5 years old, which is outside the specified age range of 3 to 5 months for the clinical trial.\n- The patient is presenting with symptoms of a potentially serious infection, indicating that he is not a healthy subject as required by the trial.\n- The patient has delayed vaccines, which implies he may not have received the type b Haemophilus influenzae vaccine, but this is not equivalent to never having received it, and the patient's age still disqualifies him.\n- The patient's current symptoms and fever suggest he might not meet the criteria for health status and temperature requirement.\n\nGiven these discrepancies, particularly the age and health status, the patient would not qualify for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2308": {
        "output": "Based on the information given in the patient note and the inclusion criteria of the clinical trial, the 5-year-old boy would not be eligible for the \"Oropharyngeal Space in Videolaryngoscopy\" clinical trial. The inclusion criteria specify that participants must be over 18 years of age, amongst other requirements that are not relevant to assess given the patient's age already disqualifies him.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2309": {
        "output": "The patient in question is a 5-year-old boy who presents with symptoms that suggest a severe throat infection or other acute condition affecting his airway, which is unrelated to rotavirus infection or vaccination status. The clinical trial is focused on the clinical and cost impact of rotavirus vaccination among children aged less than 5 years.\n\nTo determine the trial-level eligibility for this patient, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\n1. Age: The patient is 5 years old, which fits within the age range of less than 5 years specified by the trial.\n\n2. Continuously enrolled from birth: There is no information provided about the child's insurance enrollment status from birth, so we cannot confirm this criterion.\n\n3. Received both medical and pharmacy benefits: There is no information available regarding the patient's receipt of medical and pharmacy benefits.\n\n4. The focus of the study: The study is specifically about rotavirus vaccination, whereas the patient has presented with symptoms that are not directly related to rotavirus infection or vaccination status.\n\nEven though the child's age falls within the range of the study population, the lack of information about his insurance enrollment status and benefits, and the fact that his current medical issue is not related to the focus of the study (rotavirus vaccination), means that the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2310": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the 5-year-old boy does not meet the age requirement specified in the trial's inclusion criteria, which is \"Older than 18 years of age.\" Additionally, the trial is specific to patients with a peritonsillar abscess that has been drained, and there is no indication in the patient note that the boy has been diagnosed with or treated for a peritonsillar abscess.\n\nTherefore, this patient would not be eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2311": {
        "output": "Based on the provided patient note and the inclusion criteria of the Neisseria Meningitidis Burden of Disease Study, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note:\n- A 5-year-old boy with symptoms consistent with a severe infection, possibly affecting the throat or upper respiratory tract (e.g., dysphagia, drooling, fever, vocal changes, toxic appearance).\n- The parents report that they are delaying some of his vaccines, which could potentially increase the risk for certain infections.\n\nClinical Trial Inclusion Criteria:\n- Subjects who the investigator believes can and will comply with the requirements of the protocol or subjects whose parent(s)/LAR(s) can and will comply with the requirements of the protocol.\n- Written informed consent obtained from the subject or from the parent(s)/LAR of the subject.\n- A male or female subject who visits the hospital with suspected bacterial meningitis.\n- CSF sample taken as part of routine practice.\n\nAnalysis:\n- The patient is a 5-year-old boy, which meets the age criterion as there is no specified age range.\n- The patient presents with severe symptoms that could potentially be related to an infectious process, but there is no specific mention of suspected bacterial meningitis in the note, which is a requirement for inclusion in the study.\n- Consent from the parent(s)/LAR can be obtained, as required.\n- It is not stated that a CSF sample has been taken, but this could be part of routine practice if bacterial meningitis is suspected.\n\nGiven the information, the patient shows signs of a severe infection, which might lead to a suspicion of bacterial meningitis. However, the eligibility for the trial specifically requires suspected bacterial meningitis, and this diagnosis has not been mentioned in the patient note. Therefore, further investigation would be needed to determine if the patient's condition is indeed suspected to be bacterial meningitis, and if a CSF sample has been or will be taken as part of routine practice.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2312": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the eligibility requirements for the trial. The inclusion criteria specify that the participant must be between the ages of 18 and 90 and fall under the ASA patient fitness categories I, II, or III. The patient in the note is a 5-year-old boy, which is below the minimum age requirement of 18 years.\n\nTherefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2313": {
        "output": "Based on the information provided about the patient and the clinical trial inclusion criteria, it is clear that the patient does not meet the specified criteria for the trial. The patient is a 5-year-old boy, while the inclusion criteria specifically state that the study is for \"any adult patient who meets criteria and is scheduled for tonsillectomy.\" Since the patient is not an adult and there is no mention of him being scheduled for a tonsillectomy, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2314": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient would not be eligible for the clinical trial. The trial is looking at the effects of Trazodone on sleep apnea severity, specifically obstructive sleep apnea (OSA), and requires participants to have a diagnosis of OSA (elevated AHI) and be within the age range of 18-70 years.\n\nThe patient in the note is a 5-year-old boy, which is well below the minimum age requirement of 18 years for the clinical trial. Additionally, there is no mention of the boy having obstructive sleep apnea or an elevated Apnea-Hypopnea Index (AHI), which is a measure used to diagnose OSA. Instead, the symptoms described (dysphagia, drooling, fever, vocal changes, and toxic appearance) suggest an acute condition, potentially a serious infection such as epiglottitis, rather than chronic sleep apnea.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2315": {
        "output": "",
        "label": 0
    },
    "2316": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 5-year-old boy does not meet the criteria for the following reasons:\n\n- Age: The trial requires participants to be at least 18 years old, and the patient is only 5.\n- Condition: The trial is for patients with dysphagia due to unresectable esophageal cancer, and there is no mention of esophageal cancer in the patient's note. The symptoms described are more consistent with an acute infection, such as epiglottitis, rather than cancer.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2317": {
        "output": "Assessing the patient note against the clinical trial inclusion criteria:\n\nPatient note:\n- A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever, and vocal changes.\n\nClinical trial inclusion criteria for unvaccinated siblings:\n- Age 5 to 9 years\n- Younger sibling living in the same household having participated in the FinIP trial\n- At least one parent with fluent Finnish\n- Informed consent from one parent\n\nThe patient is 5 years old, which matches the age range of 5 to 9 years for unvaccinated siblings in the clinical trial criteria. However, the note does not provide information about a younger sibling participating in the FinIP trial, the Finnish language proficiency of the parents, or informed consent from one parent. Given the lack of information on these key criteria, it is not possible to determine eligibility conclusively based on the provided patient note alone.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2318": {
        "output": "",
        "label": 0
    },
    "2319": {
        "output": "Based on the patient note and the clinical trial information provided, the patient in question is a 5-year-old boy with symptoms suggestive of a serious infection or inflammation in the throat, such as possible epiglottitis, given the dysphagia, drooling, fever, and \"hot potato\" voice.\n\nThe clinical trial in question is focused on speech-pathology interventions, specifically vocal warm-up and respiratory training in teachers who work in a public school, with or without complaints of vocal disorders.\n\nThe inclusion criteria for the trial are:\n\n- Age between 20-60.\n- No occurrence of speech therapy simultaneously to the intervention.\n\nThe patient is a 5-year-old boy, which does not meet the age criterion of the trial (which requires participants to be between 20-60 years of age). Additionally, the clinical trial is aimed at individuals with or without complaints of vocal disorders and is preventive in nature, whereas the patient is presenting with acute symptoms that require immediate medical attention rather than preventive care.\n\nTherefore, the patient is not eligible for this clinical trial based on the age criterion alone, as well as the nature of the clinical situation which does not align with the objectives of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2320": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient's eligibility can be assessed as follows:\n\nPatient Note Analysis:\n- The patient is a 5-year-old boy, which fits within the age range specified in the inclusion criteria (4-11 years).\n- The patient presents with dysphagia, drooling, fever, and vocal changes indicative of a potential upper respiratory tract issue or infection, rather than a diagnosis of vocal fold nodules.\n- There is no mention of vocal fold nodules in the patient's presentation.\n- The severity of the patient's current condition (toxic-appearing, leaning forward, drooling, muffled voice) suggests an acute and potentially severe infection such as epiglottitis.\n- The note does not provide information on the patient's English comprehension and production, behavioral and cognitive appropriateness, or willingness to participate in the protocol and voice therapy.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of vocal fold nodules.\n- Age 4-11 years.\n- Informed Consent.\n- English comprehension and production sufficient to participate in the protocol and in voice therapy.\n- Considered behaviorally and cognitively appropriate by the ear, nose, and throat physician and speech-language pathologist for voice therapy.\n- Parent and child willingness to participate in all aspects of the protocol and voice therapy.\n\nGiven that the patient does not have a diagnosis of vocal fold nodules, which is a key inclusion criterion for the clinical trial, the patient would not be eligible for referral to this clinical trial. The patient's current clinical presentation is not consistent with the characteristics required for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2321": {
        "output": "The patient note describes a 5-year-old boy presenting with symptoms that are indicative of a serious upper respiratory infection or a condition like epiglottitis, given the \"hot potato\" voice, drooling, and the toxic appearance. These symptoms are not related to obstructive sleep apnea (OSA), which is the condition under study in the clinical trial.\n\nFurthermore, the inclusion criteria for the clinical trial are:\n\n- Ages 18-70 years\n- Sleep study (with apnea hypopnea index > 5)\n- Diagnosis of obstructive sleep apnea\n\nGiven that the patient is a 5-year-old boy, he does not meet the age criterion for the study. There is also no information provided that suggests a diagnosis of obstructive sleep apnea or that a sleep study has been conducted.\n\nBased on this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2322": {
        "output": "Based on the patient note provided, the 5-year-old boy presents with symptoms suggestive of an infection in the throat area, given the dysphagia, drooling, fever, and vocal changes. The \"hot potato\" voice and toxic appearance are indicative of a serious infection that may be more in line with an abscess in the throat, such as a peritonsillar abscess. However, the clinical trial in question is focused on the treatment of soft tissue abscesses in the emergency department using either ultrasound-guided or blind incision and drainage (I&D).\n\nThe inclusion criteria for the clinical trial specify:\n\n1. Soft tissue abscess suspected by patient history and physical exam and confirmed by bedside ultrasound.\n2. Able to provide written consent/assent.\n3. Incision and drainage to be performed by ED physician.\n\nThe patient's condition does not explicitly mention a soft tissue abscess amenable to I&D in the ED, nor has there been a confirmation by bedside ultrasound as specified in the inclusion criteria. Additionally, the focus on a throat infection might necessitate different treatment considerations compared to typical soft tissue abscesses targeted by the clinical trial.\n\nGiven the provided information, the patient does not appear to meet the specified inclusion criteria for the clinical trial focused on soft tissue abscesses. Furthermore, as the patient is a 5-year-old boy, there may also be concerns regarding his ability to provide assent and the need for parental consent, which is not explicitly addressed in the inclusion criteria but is an ethical requirement for pediatric patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2323": {
        "output": "",
        "label": 0
    },
    "2324": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the criteria for participation in the study. The patient is a 5-year-old boy with symptoms suggestive of a serious infection, possibly epiglottitis, given the dysphagia, drooling, fever, vocal changes, and the \"hot potato\" voice. These symptoms are unrelated to the focus of the trial, which is on the effect of desipramine on genioglossus muscle activity in healthy adults, specifically in the context of obstructive sleep apnea (OSA).\n\nThe inclusion criteria for the trial specify \"Healthy control subjects,\" which implies that the trial is looking for adult participants without any significant health issues, particularly those related to the upper airway and sleep. The patient is not only a child, which excludes him based on age alone, but he is also currently experiencing a severe health issue that requires immediate medical attention, not related to the condition under study (OSA).\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2325": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient in question\u2014a 5-year-old boy with progressively worsening dysphagia, drooling, fever, vocal changes, and a \"hot potato\" voice\u2014does not meet the specified inclusion criteria for the clinical trial, which is focused on patients with diagnosed obstructive sleep apnea (OSA) with an apnea hypopnea index greater than 15 events/hr.\n\nThe patient's symptoms suggest an acute infection or inflammation, possibly epiglottitis, which is a medical emergency. This condition is not related to OSA and the patient's age is also not within the typical range for a study on OSA, which generally affects adults.\n\nGiven this mismatch between the patient's presentation and the trial's focus and inclusion criteria, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2326": {
        "output": "",
        "label": 0
    },
    "2327": {
        "output": "The patient in question is a 5-year-old boy presenting with dysphagia, drooling, fever, and vocal changes. Given the inclusion criteria for the clinical trial, which specifically state that the trial is for adult subjects aged 18 to 85 years, this patient does not meet the age requirement. Additionally, the trial is looking for adults with troublesome sialorrhea for at least 3 months secondary to disorders such as Parkinson's Disease, cerebral palsy, ALS, stroke, traumatic brain injury, oral cancer, or side effects of other medications.\n\nBased on the provided information, the patient is ineligible for the clinical trial due to the following reasons:\n\n1. Age criteria: The patient is 5 years old, which is below the minimum age requirement of 18 years.\n2. Treatment duration: There is no mention that the sialorrhea has been present for at least 3 months.\n3. Consent: The trial requires the ability to read and provide written informed consent, which a 5-year-old cannot do.\n\nAs a result, I would not refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2328": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the trial:\n\nPatient Characteristics:\n- The patient is a 27-year-old woman, satisfying the age requirement as the trial does not specify an age limit.\n- She is currently pregnant, which is a disqualifying condition according to the trial's criteria (\"Not pregnant or nursing\").\n- The trial requires a negative pregnancy test and effective contraception for fertile patients, which the patient cannot fulfill due to her current pregnancy.\n\nDisease Characteristics:\n- The patient note suggests a hematologic disorder with symptoms including anemia, elevated reticulocyte count, elevated LDH, anisocytosis, poikilocytosis, and presence of hemosiderin in the urine. These findings could be indicative of an autoimmune hematologic disease, but the diagnosis is not clearly stated as autoimmune hemolytic anemia or immune thrombocytopenia.\n- There is no information provided on the failure of standard treatments or the patient's ability to taper prednisone dose (if she was even on prednisone).\n\nOther Criteria:\n- Renal function appears to be normal, as the patient note mentions \"normal urea and electrolytes.\" However, specific creatinine levels are not provided to confirm if it is \"no greater than 2.5 mg/dL\" as required by the trial.\n- There is no information on the patient's cardiovascular function (ejection fraction) or pulmonary function (FVC, FEV1, or DLCO).\n\nGiven the information above, the most critical disqualifying factor is the patient's current pregnancy, which directly contravenes the trial's criteria. While there might be possible indications of autoimmune hematologic disease, the diagnosis is not explicit, and there is no clear evidence of treatment failure as specified by the trial's requirements. Hence, additional information would be required to fully assess the patient's eligibility based on disease characteristics and other criteria.\n\nHowever, due to the clear disqualification based on the patient's current pregnancy, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2329": {
        "output": "Based on the patient note provided, the 27-year-old pregnant woman does not meet the inclusion criteria for the clinical trial titled \"Lapdap and Coartemether for Uncomplicated Malaria.\" The inclusion criteria for the trial are:\n\n- Presentation at health center with febrile illness\n- Monoinfection with P falciparum\n- Parasitaemia >=500/microlitre\n- Fever or history of fever\n\nThe patient in question has not been noted to have a febrile illness, malaria, or any indication of a P falciparum infection. Instead, she has presented with findings consistent with mild iron deficiency anemia and potential hemolysis, as indicated by elevated reticulocyte count and elevated LDH, with some evidence of hemoglobinuria (presence of hemosiderin in urine). There is no mention of a fever, malaria, or any related symptoms.\n\nTherefore, the patient does not fit the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2330": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the trial:\n\nPatient Note:\n- A 27-year-old woman\n- 11 weeks gestation in her second pregnancy\n- Found to have a hemoglobin (Hb) of 9.0 g/dL\n- Mild iron deficiency\n- Already receiving iron supplementation\n- Difficulty swallowing\n- Elevated reticulocyte count\n- Negative DAT\n- Elevated LDH\n- Presence of hemosiderin in the urine\n- No specific mention of myelodysplastic syndrome (MDS) or related conditions\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of myelodysplastic syndrome (MDS) based on cytopenia in at least 1 cell line + dysplasia in 2 cell lines\n- Specific subtypes of MDS (e.g., RA, RARS, RAEB, CMML)\n- Erythrocyte transfusion need\n- Working knowledge of the national language\n- Written consent for participating in this study (informed consent)\n\nAssessment:\nThe patient presents with anemia and elevated reticulocyte count, suggesting a response to anemia. However, there is no indication in the patient's note that she has been diagnosed with myelodysplastic syndrome or any of its subtypes, which is a critical inclusion criterion for the clinical trial. Furthermore, the patient's anemia seems to be related to pregnancy and mild iron deficiency rather than MDS.\n\nGiven that the patient does not meet the primary diagnostic criteria of having myelodysplastic syndrome, she is not eligible for the clinical trial. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2331": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient is a 27-year-old pregnant woman with low hemoglobin levels and mild iron deficiency, already receiving iron supplementation. The clinical trial is focused on iron supplementation in children within school programs in Zambia, specifically targeting children in grades 2 and 3.\n\nThe inclusion criteria for the trial explicitly mention \"all schoolchildren, in grade 2 and 3, at four selected schools.\" The patient in question does not meet the inclusion criteria as she is an adult and not a schoolchild in the specified grades or schools. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2332": {
        "output": "After reviewing the patient note and the clinical trial information provided, we can determine the eligibility of the patient for the clinical trial titled \"Doppler or Amniocentesis to Predict Fetal Anemia.\"\n\nThe inclusion criteria for the trial are:\n1. Pregnant women with red cell alloimmunization associated with a risk of fetal anemia due to antibodies like D, E, c, or Duffy (Fya), alone or in combination with other antibodies.\n2. Gestational age between 12 and 34 weeks at study entry with a viable fetus and accurate dating.\n3. Maternal serum test-result above the threshold at which the fetus is considered to be at risk of developing hemolytic anemia and thus a potential candidate for invasive testing.\n\nThe patient in question is a 27-year-old woman at 11 weeks gestation in her second pregnancy. The patient is found to have mild iron deficiency anemia, evidenced by a low hemoglobin level, and is already receiving iron supplementation. There is no mention of red cell alloimmunization or the presence of specific antibodies such as D, E, c, or Duffy (Fya) that would put the fetus at risk of developing hemolytic anemia. Additionally, the gestational age at the time of the note is 11 weeks, which is one week shy of the minimum 12 weeks required by the trial.\n\nGiven that the patient does not meet the inclusion criteria of having red cell alloimmunization and is not within the gestational age range specified by the trial at the time of the note, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2333": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- A 27-year-old woman, which meets the age criteria (age 18 or over).\n- At 11 weeks gestation in her second pregnancy, which is just short of the required 12-16 weeks gestation for the trial.\n- The patient has not been diagnosed with S. japonicum, which is a requirement for the trial.\n- The patient has anemia (low hemoglobin level) and other blood abnormalities; however, the trial requires the participant to be otherwise healthy as determined by history, physical exam, ultrasound, and laboratory assessment.\n- The patient note does not mention any diagnosis or symptoms related to S. japonicum infection.\n\nClinical Trial Inclusion Criteria:\n- Female, age 18 or over (patient meets this criterion).\n- Infected with S. japonicum (patient does not meet this criterion based on the provided information).\n- Pregnancy between 12-16 weeks gestation (patient is at 11 weeks, barely missing this criterion).\n- Ability to provide informed consent to participate (assuming the patient can provide consent, but this is not mentioned in the patient note).\n\nGiven the patient's current gestation period is just short of the required window and there is no indication of S. japonicum infection, the patient does not meet all the inclusion criteria for the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2334": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial for etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia (JMML), it's clear that the patient does not meet several key inclusion criteria:\n\n1. The patient is a 27-year-old woman, which is outside the age range specified in the trial (greater than 6 months and less than 18 years of age).\n2. The patient does not have a diagnosis of JMML, as there is no mention of this condition in the patient note. Instead, the patient appears to have some form of anemia, likely related to pregnancy.\n3. The inclusion criteria specify certain diagnostic criteria for JMML, such as an absence of t(9;22) or BCR-ABL, absolute monocyte count >1000 (1 X 10^9/\u00b5L), and less than 20% bone marrow blasts, among others. None of these criteria are mentioned or suggested in the patient note.\n4. There is no indication that the patient has previously been treated for JMML, which is another condition for inclusion if the disease has recurred.\n\nGiven this information, the patient does not meet the inclusion criteria for age, diagnosis, or disease status. Therefore, the patient is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2335": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Intravenous Ferric Carboxymaltose (Ferinject\u00ae) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery,\" let's evaluate the patient's eligibility:\n\nPatient Note Review:\n- The patient is a 27-year-old woman, which satisfies the age criterion of being over 18 years old.\n- She is currently pregnant and not scheduled to undergo major orthopaedic surgery.\n- Her hemoglobin level is 8.9 g/dL, which is below the specified range for women (10 g/dL < Hb < 12.0 g/dL) in the inclusion criteria.\n- The patient has a mild iron deficiency, but there is no mention of her ferritin levels or transferrin saturation (TSat), which are required to meet the trial criteria.\n\nClinical Trial Inclusion Criteria:\n- Must be over 18 years of age and provide signed written informed consent.\n- Must be scheduled to undergo major orthopaedic surgery.\n- Must have a hemoglobin level within the specified range for their gender.\n- Must have a ferritin level < 100 \u03bcg/l or 100-300 with TSat < 20%.\n\nThe patient does not meet the inclusion criteria regarding the type of surgery (as she is not scheduled for any orthopaedic surgery) and the required hemoglobin levels. Therefore, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2336": {
        "output": "The patient in question is a 27-year-old woman in her second pregnancy, currently at 11 weeks gestation, with a hemoglobin level of 9.0 g/dL initially and 8.9 g/dL upon retesting. This Hb level is below the normal range, indicating she is anemic, and she is not yet in the second trimester of her pregnancy.\n\nThe clinical trial's inclusion criteria require participants to be healthy pregnant women between 18 and 45 years of age in the second or third trimester of pregnancy (24-32 weeks of gestational age) with normal Hb levels (Hb\u2265110g/L and Hb\u2264144g/L).\n\nBased on the information provided, the patient does not meet the inclusion criteria for the following reasons:\n1. She is not in the second or third trimester of pregnancy as required (she is at 11 weeks gestation).\n2. Her Hb levels are below the specified normal range (8.9 g/dL, which is less than the required 110 g/L).\n\nTherefore, the patient would not be eligible for the clinical trial based on her gestational age and hemoglobin levels.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2337": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 27-year-old woman who is currently pregnant and has been found to have anemia, as indicated by her low hemoglobin levels. The clinical trial in question is focused on the early detection of anemia during the first trimester of pregnancy.\n\nThe inclusion criteria for the clinical trial are not very specific, but they do mention that \"Every patient followed at the HME at the beginning of the pregnancy\" is eligible. Assuming HME refers to the healthcare facility or a specific program within a facility that is conducting the trial, and the patient in the note is followed at HME, she would be eligible for the trial based on the information given.\n\nHowever, since the inclusion criteria provided are not detailed and I do not have information confirming that the patient is followed at HME, I will rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be required to confirm whether the patient is indeed being followed at HME and meets any other potential but unstated inclusion criteria for the clinical trial.",
        "label": 1
    },
    "2338": {
        "output": "",
        "label": 0
    },
    "2339": {
        "output": "The patient in question is a 27-year-old pregnant woman with a hemoglobin level of 9.0 g/dL, which later decreased to 8.9 g/dL, indicating mild anemia. Further tests reveal mild iron deficiency with an elevated reticulocyte count and other symptoms associated with her condition. There are no indications that the patient has chronic hepatitis C or that she meets the specific inclusion criteria listed for the clinical trial focusing on high-dose ribavirin in the treatment of chronic hepatitis C.\n\nLooking at the inclusion criteria for the clinical trial:\n\n- Male and female patients aged 18-65 years: The patient meets this criterion.\n- Elevated liver enzymes levels: There are no indications of elevated liver enzymes in the patient's note.\n- Compensated liver disease: There is no mention of liver disease in the patient's note.\n- Available liver histology confirming METAVIR F2 fibrosis: No liver histology or mention of fibrosis is present in the patient's note.\n- Written consent to participation: This is not relevant to the eligibility assessment at this stage.\n\nExclusion Criteria:\n\n- Age <18, >65: The patient meets this criterion.\n- Prior ribavirin treatment: There is no mention of prior ribavirin treatment, but it's not relevant as the patient does not have hepatitis C.\n- Intolerance towards ribavirin, PegIFN or erythropoetin: There is no information on this.\n- Pregnancy or breast feeding: The patient is currently pregnant, which immediately excludes her from the trial.\n- Other criteria: Not relevant as the patient is already excluded on the basis of pregnancy.\n\nSince the patient is pregnant, she is ineligible for the clinical trial based on the exclusion criteria. The trial is for the treatment of chronic hepatitis C, and there is no indication that the patient is suffering from this condition. Therefore, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2340": {
        "output": "Based on the patient note and the clinical trial information provided, the 27-year-old woman does not meet the inclusion criteria for the clinical trial titled \"Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation.\" The inclusion criteria specify that participants must be women less than 4 weeks postpartum, 18 years of age or older, who took prenatal vitamins for at least 3 months during pregnancy, and have successfully initiated breastfeeding.\n\nThe patient in question is currently at 11 weeks gestation in her second pregnancy and is not yet postpartum, hence she does not qualify for the study which is focused on women who are already in the postpartum phase and breastfeeding.\n\nBased on this information, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2341": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 27-year-old woman\n- 11 weeks gestation in her second pregnancy\n- Hemoglobin (Hb) of 8.9-9.0 g/dL, indicating anemia\n- Iron deficiency (despite ongoing supplementation)\n- Difficulty swallowing\n- Elevated reticulocyte count and LDH\n- Presence of anisocytosis and poikilocytosis in blood smear\n- Presence of hemosiderin in the urine\n\nClinical Trial Inclusion Criteria:\n- Caucasian\n- Primiparous (first pregnancy)\n- Singleton pregnancy (week 20 to week 30)\n- Non-smokers\n- Pre-pregnancy BMI between 19.8 and 26\n- Healthy, free from iron metabolism disorders (excluding pregnancy-induced hypertension)\n- Not taking medicines known to influence iron status\n- Not taking iron supplements (multivitamins will be accounted for)\n- Free from gastrointestinal disorders\n- No allergies\n\nComparison:\n- The patient is in her second pregnancy, not primiparous, which does not meet the criterion of being in the first pregnancy.\n- The patient is at 11 weeks gestation, which is earlier than the required 20 to 30 weeks gestation.\n- The patient is currently taking iron supplements, which is against the criteria of not taking iron supplements.\n\nThe patient does not meet several of the clinical trial's inclusion criteria, specifically regarding parity (being primiparous), the gestational week, and current iron supplementation. Without additional information, we cannot determine whether the patient meets the other criteria such as being Caucasian, having a pre-pregnancy BMI between 19.8 and 26, not taking medicines that influence iron status, and being free from gastrointestinal disorders.\n\nBased on the information given, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2342": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients,\" we will compare the patient's characteristics and clinical findings with the inclusion criteria of the study.\n\nPatient's characteristics and clinical findings:\n- A 27-year-old woman\n- During second pregnancy at 11 weeks gestation\n- Hemoglobin (Hb) of 9.0 g/dL and 8.9 g/dL in two different measurements\n- Mild iron deficiency and receiving iron supplementation\n- Elevated reticulocyte count at 180 x 10^9/L\n- Negative direct antiglobulin test (DAT), elevated lactate dehydrogenase (LDH), and presence of hemosiderin in the urine\n- No mention of Chronic Kidney Disease (CKD) or being a pre-dialysis or haemodialysis patient\n\nClinical trial inclusion criteria:\n- Two groups of random routine anonymized blood samples will be used\n- Group 1: Individuals with normal red blood cell (RBC) indices, including Hemoglobin (Hb), Hematocrit, Mean Cell Volume (MCV), and Mean Cell Hemoglobin Content (MCHC)\n- Group 2: Individuals with iron deficiency as testified by routine laboratory tests\n- The trial is focused on renal patients and the study of Functional Iron Deficiency (FID) in those patients, especially concerning their response to erythropoietin therapy.\n\nThe patient does have some abnormal hematological findings, such as anemia and iron deficiency, which could potentially make her an interesting subject for an investigation into iron levels and reticulated haemoglobin content. However, the clinical trial specifically mentions that it is looking to study this in the context of renal patients, particularly those on pre-dialysis or haemodialysis.\n\nSince there is no indication that the patient has Chronic Kidney Disease or is a renal patient requiring dialysis, she does not meet the key demographic that the study is focused on. Therefore, despite her hematological abnormalities, she does not fit the inclusion criteria for the study as she is not a renal patient.\n\nBased on the patient's information and the criteria provided for the clinical trial, the patient would not be eligible for the trial as she does not meet the specific requirement of being a renal patient. Therefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2343": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women,\" let's review the patient's characteristics against the inclusion criteria:\n\n1. Pregnant women aged \u226518 - The patient is a 27-year-old woman, which meets this criterion.\n\n2. Gestational week \u226520, \u226433 at baseline visit with normal antenatal screening test results - The patient is at 11 weeks gestation, which does not meet this criterion as she is not yet at 20 weeks gestation.\n\n3. Iron deficiency anaemia defined as Hb concentration \u22658 g/dl and \u226410.4 g/dL and serum ferritin \u226420 mcg/L at screening - The patient has a hemoglobin level of 8.9 g/dL, which falls within the specified range. However, there is no information provided about her serum ferritin levels.\n\n4. Demonstrated the ability to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients (or their representative) must provide written informed consent for their participation in the study - There is no information in the patient note that allows us to assess this criterion.\n\nBased on the information provided, the patient does not meet the gestational week requirement, which is a key inclusion criterion for the trial. The lack of information on the patient's serum ferritin level and whether she can comply with study requirements are also factors that prevent us from determining her full eligibility.\n\nTherefore, the patient note does not provide sufficient information to meet all inclusion criteria of the clinical trial, particularly due to the gestational age requirement which is a firm criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2344": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility step by step:\n\n1. Age > 18 years: The patient is 27 years old, which meets the age requirement.\n\n2. AIHA defined at time of diagnosis by:\n   - Hgb level \u2264 10 g/dL: The patient has a hemoglobin level of 9.0 g/dL initially and 8.9 g/dL on repeat, which meets the criteria.\n   - Reticulocytes count > 120 x 10^9/L: The patient has a reticulocyte count of 180 x 10^9/L, which meets the criteria.\n   - Signs of hemolysis: The patient has elevated LDH, which is a sign of hemolysis, and presence of hemosiderin in the urine, but the haptoglobin level is not provided.\n   - Positive direct antiglobulin test (DAT): The patient's DAT is negative, which does not meet this criterion.\n\n3. Disease duration equal or less than 6 weeks at the time of inclusion or first episode of AIHA to hot antibody previously untreated or treated corticosteroids for less than 6 weeks: There is no information provided regarding the duration of the patient's illness or treatment history, so we cannot assess this criterion.\n\n4. Patients with associated autoimmune thrombocytopenia (Evans' syndrome) will be eligible if the platelet count is over 30 x 10^9/L at inclusion: The patient's platelet count is 119 x 10^9/L initially and 108 x 10^9/L on repeat, which meets the criteria. However, there is no information suggesting that the patient has Evans' syndrome.\n\n5. Normal level gammaglobulins in the serum: There is no information provided about the patient's serum gammaglobulin levels, so we cannot assess this criterion.\n\n6. Absence of detectable lymph nodes on a total body CT-scan: There is no information provided regarding any CT-scan results, so we cannot assess this criterion.\n\n7. Effective means of contraception during treatment and for six months after completion of treatment for all women of childbearing age: The patient is currently pregnant, which would make her ineligible for the study based on the need for effective contraception.\n\n8. Negative serum pregnancy test within 14 days prior to study entry: The patient is pregnant, therefore, she would not have a negative pregnancy test, which makes her ineligible.\n\n9. Written informed consent: This is a procedural criterion that could be met if the patient agrees to participate.\n\nBased on the information provided, the patient does not meet several key inclusion criteria, most notably the requirement for a positive DAT and not being pregnant. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2345": {
        "output": "Based on the patient note provided, we have a 27-year-old pregnant woman at 11 weeks gestation who is experiencing iron deficiency, as indicated by her hemoglobin levels and other bloodwork results. She is already receiving iron supplementation. The clinical trial in question is investigating the use of bovine lactoferrin to prevent and cure iron deficiency and iron deficiency anemia in pregnant women with hereditary thrombophilia (HT).\n\nTo determine trial-level eligibility, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial:\n\n1. The patient is a pregnant woman, which matches the population the clinical trial aims to study.\n2. There is clear evidence of iron deficiency (ID) and possibly iron deficiency anemia (IDA) given the hemoglobin concentration is below 11 g/dL.\n3. The patient is in her first trimester of pregnancy, which is within the \"different trimester of pregnancy\" mentioned in the inclusion criteria.\n4. The inclusion criteria specifically require pregnant women to have genetic thrombophilia markers or be affected by HT. However, there is no mention of the patient having hereditary thrombophilia or any of the specified genetic markers or conditions in the patient note.\n\nThe key element missing from the patient's information is whether she has hereditary thrombophilia or any of the genetic markers listed in the inclusion criteria. Without this information, we cannot conclusively determine that she meets all the inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she has hereditary thrombophilia or associated genetic markers.",
        "label": 1
    },
    "2346": {
        "output": "The patient described in the note is a 27-year-old woman who is 11 weeks pregnant in her second pregnancy. She has a hemoglobin level of 9.0 g/dL, indicating mild anemia likely due to iron deficiency, even though she is already receiving iron supplementation. The additional findings from the hematology consult suggest some form of hemolysis or bone marrow response, given the elevated reticulocyte count and LDH levels.\n\nThe clinical trial in question is focused on the presence of Plasmodium infection in parturient women who have received a combination of iron-fortified foods with iron supplements versus iron-fortified foods only.\n\nBased on the provided inclusion criteria for the clinical trial, the patient seems to fit within the parameters:\n\n1. She is within the age range of 15-45 years.\n2. She is pregnant with a gestational age of less than 23 weeks.\n\nThe patient note does not mention any information about residence in a predefined study area, which is a requirement mentioned in the inclusion criteria. Assuming the patient does reside in the study area (which cannot be confirmed from the information given), the patient would be eligible based on the other criteria. However, if she does not reside in the predefined study area, she would not be eligible.\n\nGiven the information available, we would consider referring this patient to the clinical trial upon further investigation to confirm her residence in the study area.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2347": {
        "output": "Based on the information provided, the patient is a 27-year-old woman with symptomatic anemia, evidenced by low hemoglobin levels and difficulty swallowing. The additional results provided indicate an elevated reticulocyte count, elevated LDH, anisocytosis, poikilocytosis, no fragments, no agglutination, polychromasia, and presence of hemosiderin in the urine. However, the Direct Antiglobulin Test (DAT) was negative. The clinical trial in question is recruiting participants with a diagnosis of idiopathic autoimmune hemolytic anemia (AIHA), either newly diagnosed or relapsed after first-line treatment with oral prednisone, and who have a positive DAT.\n\nThe patient in question does not meet the inclusion criteria for the trial as the DAT is negative, which contradicts the requirement for a positive DAT to diagnose warm or cold AIHA according to the trial criteria. Moreover, there is no indication in the patient note that the anemia is autoimmune in nature or that it has been diagnosed as AIHA. The patient's anemia is described with characteristics such as anisocytosis and poikilocytosis, and while these can be seen in hemolytic anemias, they are not specific to AIHA and do not confirm the diagnosis. Additionally, the patient's anemia could be related to her pregnancy or iron deficiency, neither of which is mentioned in the clinical trial's inclusion criteria.\n\nTherefore, this patient does not meet the specific diagnostic criteria required for participation in the clinical trial, namely the diagnosis of idiopathic AIHA with a positive DAT.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2348": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it is clear that this patient would not be eligible for the clinical trial in question. The clinical trial is focused on young children with non-anemic iron deficiency between the ages of 18 to 36 months. The patient in question is a 27-year-old pregnant woman, which is outside the age range specified in the trial's inclusion criteria. Additionally, the trial is designed to screen and treat young children for iron deficiency, whereas the patient has already been diagnosed with iron deficiency and is receiving treatment.\n\nTherefore, the patient does not meet the age criteria and the trial's focus does not match the patient's condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2349": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Carbon Monoxide Levels and Sickle Cell Disease Severity,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 27-year-old woman\n- Currently pregnant (11 weeks gestation)\n- Hemoglobin (Hb) levels are below the normal range (8.9 - 9.0 g/dL)\n- Elevated reticulocyte count, elevated LDH, anisocytosis, poikilocytosis, polychromasia, and presence of hemosiderin in the urine\n- No mention of sickle cell disease\n\nClinical Trial Inclusion Criteria for SCD Cohort:\n- Males or females 18 years of age or older\n- Diagnosis of sickle cell disease (any form; electrophoretic or HPLC documentation is required)\n\nClinical Trial Exclusion Criteria for SCD Cohort:\n- Chronic scheduled transfusions\n- Current known pregnancy or lactation\n- Hemoglobin <5.0 g/dL\n- Currently smoking\n- Certain other conditions (not relevant here)\n\nThe patient in the note does not have a diagnosis of sickle cell disease, which is a requirement for the sickle cell disease (SCD) cohort of the study. Instead, the patient has anemia with some abnormal laboratory findings that do not fit the description of sickle cell disease. Furthermore, the patient is currently pregnant, which is listed as an exclusion criterion for the sickle cell disease cohort.\n\nBased on the patient's characteristics and the study's inclusion and exclusion criteria, this patient would not be eligible for the SCD cohort of the clinical trial because she does not have sickle cell disease and is currently pregnant.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2350": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient note:\n- 27-year-old woman\n- 11 weeks gestation in her second pregnancy\n- Hemoglobin of 9.0 g/dL and 8.9 g/dL on two separate occasions, indicating anemia\n- Mild iron deficiency but already receiving iron supplementation\n- Elevated reticulocyte count\n- Difficulty swallowing\n- No indication of pre-existing medical complications listed in the trial criteria\n\nClinical trial:\n- Title: Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy\n- Inclusion Criteria:\n  - Singleton pregnancy\n  - Non-smoker\n  - No pre-existing medical complications (such as HIV-infection, eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis)\n\nFrom the information given, the patient appears to meet the clinical trial's inclusion criteria:\n- The patient is pregnant with a single fetus (singleton pregnancy).\n- There is no mention of smoking in the patient note, so we can assume she is a non-smoker.\n- There is no mention of any pre-existing medical complications that are listed in the trial inclusion criteria.\n\nHowever, there are a couple of factors that require further investigation or consideration:\n- The patient is in the first trimester, and the study is interested in the last trimester of pregnancy. This temporal discrepancy needs to be addressed.\n- Difficulty swallowing is mentioned, which may or may not be related to a gastrointestinal or malabsorption issue. This requires clarification since malabsorption diseases are part of the exclusion criteria.\n\nDue to the potential issue with the timing of the study and the need for clarification regarding the difficulty swallowing, a referral for this clinical trial would require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2351": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, it is clear that the patient in question does not meet the age requirement of the trial which is specifically for older babies and toddlers between 9-24 months of age. The patient is a 27-year-old woman, which is outside of the age range for the trial participants. Therefore, the patient is not eligible to participate in the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2352": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we can determine the following:\n\nPatient Note:\n- The patient is a 27-year-old woman.\n- She is at 11 weeks gestation in her second pregnancy.\n- She has a low hemoglobin level and other signs suggestive of a hematologic condition.\n- She is already receiving iron supplementation.\n\nClinical Trial:\n- The study is assessing the effect of lipid-based nutrition supplement (LNS) and micronutrient powder (MNP) to improve maternal nutritional status and prevent malnutrition in children in Bangladesh.\n- Inclusion criteria require participants to be at a gestational age \u2264 20 weeks and planning to remain in the study area during pregnancy and the following three years.\n\nThe patient meets the gestational age requirement of being \u2264 20 weeks. However, there is no information provided about her plans to remain in the study area (Bangladesh) during the specified time. Without this information, we cannot definitively determine if the patient would be eligible for the trial. The patient's current medical condition, including iron deficiency and potential hematologic issues, is not directly relevant to the inclusion criteria specified.\n\nAs such, based on the information provided, the patient's eligibility for the clinical trial cannot be confirmed without additional details regarding her residency plans. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2353": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia,\" we need to compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria for the trial:\n1. Women 18-45 years old with iron deficiency anaemia\n2. Haemoglobin level between 85 g/L and 105 g/L\n3. Serum ferritin level < 15 \u00b5g/L\n4. D14 + 7 days of the menstruation cycle on the day of pharmacokinetic evaluation\n5. Standard diet\n\nPatient's characteristics:\n- A 27-year-old woman (matches age criteria)\n- At 11 weeks gestation (this does not impact the inclusion criteria directly but should be considered as it affects physiological parameters)\n- Haemoglobin (Hb) of 9.0 g/dL initially, 8.9 g/dL on repeat (convert g/dL to g/L by multiplying by 10, which gives us 90 g/L and 89 g/L, respectively, which falls within the trial's specified range)\n- Already receiving iron supplementation (not specified in criteria, but indicates ongoing treatment for iron deficiency)\n- Mild iron deficiency (aligns with iron deficiency anaemia)\n- No serum ferritin level provided\n- No information provided on menstruation cycle day or standard diet adherence\n\nBased on the given information, the patient appears to meet several of the inclusion criteria: she is within the age range, has a haemoglobin level within the specified range, and has iron deficiency. However, there are a few pieces of information missing that are necessary to confirm her eligibility: her serum ferritin level and the specific day of her menstruation cycle on the day of pharmacokinetic evaluation. Additionally, it is not mentioned if she adheres to a standard diet, which is one of the criteria.\n\nConsidering the patient is pregnant, this might impact the study or the patient's safety, and this factor is not addressed in the inclusion criteria provided. It is essential to consider whether the pharmacokinetics of serum iron could be different in pregnant women and whether the study is designed to handle such variables.\n\nGiven the missing information and the pregnancy status of the patient, further investigation is required before making a definite decision on her eligibility. Therefore, I would consider referring this patient to the clinical trial upon further investigation to confirm the missing criteria and discuss the implications of her pregnancy on the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2354": {
        "output": "",
        "label": 0
    },
    "2355": {
        "output": "To determine trial-level eligibility, we must compare the patient's characteristics and clinical situation with the inclusion criteria of the clinical trial.\n\nPatient note summary:\n- 27-year-old woman\n- Currently 11 weeks pregnant\n- Hemoglobin levels suggest anemia (9.0 g/dL, decreased to 8.9 g/dL)\n- Elevated reticulocyte count, elevated LDH, and other blood cell abnormalities indicating some underlying condition\n- No specific mention of autoimmune diseases or Cervarix\u00ae vaccination\n\nClinical trial inclusion criteria:\n- The study is looking at females aged 9 to 25 years who have received the Cervarix\u00ae vaccine between September 2008 and August 2010, as well as unexposed cohorts for comparison.\n- Participants should be recorded in the CPRD GOLD for at least 12 months before the reference date.\n- For the exposed female cohort, they must have received the first dose of Cervarix\u00ae within the specified period and have a full date of vaccination available.\n- Subjects must be defined as acceptable in CPRD GOLD.\n\nBased on the provided information, we do not have sufficient data to determine if the patient received the Cervarix\u00ae vaccine, nor do we know if she is recorded in the CPRD GOLD database or if she is considered an acceptable subject within that database. Additionally, the patient's clinical situation involving anemia and possible hematological issues is not related to the study's focus on autoimmune diseases following the administration of the Cervarix\u00ae vaccine.\n\nTherefore, based on the information provided, the patient does not clearly meet the inclusion criteria for the clinical trial, as there is no mention of Cervarix\u00ae vaccination or her status in the CPRD GOLD database. Further information would be needed to make a definitive assessment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2356": {
        "output": "The patient is a 27-year-old woman who is currently pregnant and has been found to have iron deficiency anemia, as indicated by her hemoglobin levels and other lab findings. The inclusion criteria for the clinical trial specifies that patients must have proven iron deficiency anemia based on World Health Organisation (WHO) criteria and can be aged 13 - 18 as adolescents, and aged >18 as adults.\n\nThe patient fits the age criterion as she is older than 18. However, the clinical trial specifically aims to treat iron deficiency anemia in patients with inflammatory bowel disease (IBD), which is not mentioned in the patient's note. Therefore, since the patient does not have a confirmed diagnosis of IBD, she does not meet the specific condition for which the treatment is being investigated in the trial.\n\nBased on the provided information, the patient does not meet the condition-specific requirement (IBD) for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2357": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Fermented Iron-rich Supplement in Reducing Anemia,\" we must compare the patient's characteristics and condition with the inclusion criteria of the study:\n\nInclusion Criteria for the trial:\n1. Age 18-49 years\n2. Regular menstruation in the last three months\n3. Hemoglobin < 12 mg/dL\n4. Serum Ferritin < 20 mcg/L\n5. BMI 18.5 kg/m^2 to 29.9 kg/m^2\n\nPatient characteristics:\n1. Age: 27 years old (meets criteria)\n2. Pregnant woman at 11 weeks gestation (likely has had regular menstruation in the last three months prior to pregnancy, but this is not explicitly stated)\n3. Hemoglobin (Hb): 9.0 g/dL and later 8.9 g/dL, which is less than 12 mg/dL (meets criteria)\n4. Serum Ferritin: not provided in the patient note\n5. BMI: not provided in the patient note\n\nFrom the information provided, the patient meets the age and hemoglobin level criteria. However, two crucial pieces of information regarding the serum ferritin level and BMI are not available in the patient note. Additionally, while the patient is currently pregnant, we do not have explicit information on her menstruation history prior to pregnancy, which could affect eligibility.\n\nDue to the missing information, we cannot confirm that the patient fully meets all of the inclusion criteria. Hence, we would consider referring this patient to the clinical trial upon further investigation to obtain the missing information (serum ferritin level, BMI, and menstruation history).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2358": {
        "output": "",
        "label": 0
    },
    "2359": {
        "output": "After reviewing the patient note and the clinical trial information, the patient's eligibility can be assessed as follows:\n\n- The patient is a 27-year-old woman, which fits within the age range of 20-35 years old specified in the inclusion criteria of the clinical trial.\n- The patient is in her second pregnancy, which is consistent with the requirement for the clinical trial participants to be pregnant.\n- The patient has a hemoglobin level of 9.0 g/dL at the first measurement and 8.9 g/dL at the second, which is within the range of 7-9 g % required for the study.\n- However, the patient is at 11 weeks gestation, which is earlier than the 16-24 weeks gestation specified in the inclusion criteria.\n- The patient is already receiving iron supplementation, which is relevant to the study, but it is not specified whether this is an excluding factor for the trial.\n\nGiven that the patient does not meet the gestational age requirement, she would not be eligible for this clinical trial at her current stage of pregnancy. All other criteria seem to align with the study's requirements, but the gestational age is a critical factor that cannot be overlooked.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2360": {
        "output": "Based on the information provided in the patient note, the 27-year-old pregnant woman has findings suggestive of hemolytic anemia, as indicated by a low hemoglobin level, elevated reticulocyte count, elevated LDH, and presence of hemosiderin in the urine. However, there is no explicit mention that her hemolytic anemia is autoimmune in nature (AIHA) or that it is warm autoimmune hemolytic anemia (wAIHA).\n\nThe clinical trial is specifically interested in patients diagnosed with primary warm Autoimmune Hemolytic Anemia (wAIHA) or secondary AHAI, who are na\u00efve of treatment for hemolytic anemia or in relapse.\n\nAlthough the patient presents with anemia and some laboratory findings that could be associated with hemolytic anemia, the patient note does not confirm a diagnosis of AIHA, and there is no information about the presence of specific antibodies targeting red blood cells, which are characteristic of AIHA. Additionally, there is no indication regarding the temperature at which her antibodies act, which is necessary to classify it as \"warm.\" Furthermore, the patient is currently pregnant, which is not mentioned in the inclusion or exclusion criteria but could be a significant consideration in the context of a clinical trial.\n\nGiven the lack of specific diagnostic information confirming that the patient has wAIHA, and the potential complications of participating in a trial during pregnancy, I would be cautious about referring this patient without additional diagnostic confirmation and consideration of her pregnancy status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2361": {
        "output": "",
        "label": 0
    },
    "2362": {
        "output": "The patient in question is a 27-year-old pregnant woman with a confirmed diagnosis of iron deficiency, as evidenced by her low hemoglobin level and mild iron deficiency despite already receiving iron supplementation. The clinical trial is aiming to optimize iron bioavailability from iron supplements in females aged 18 to 45 years with serum ferritin levels <20 \u00b5g/L.\n\nThe patient's age and gender align with the trial's inclusion criteria. However, the patient's pregnancy status is not mentioned in the inclusion criteria provided, which is a significant consideration as pregnancy can affect iron metabolism and the safety of interventions. Additionally, the patient's serum ferritin level is not provided in the patient note, and it is an essential criterion for the trial. Body weight and BMI are also not specified in the patient note.\n\nConsidering these points, more information is needed to determine trial eligibility. Specifically, the patient's serum ferritin levels, body weight, BMI, and whether the trial allows for pregnant participants are critical factors that need clarification.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2363": {
        "output": "Based on the information provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Characteristics:\n- A 27-year-old woman\n- Currently pregnant (11 weeks gestation)\n- Hemoglobin (Hb) levels of 9.0 g/dL and 8.9 g/dL on two occasions\n- Mild iron deficiency, already receiving iron supplementation\n- Difficulty swallowing\n- Elevated reticulocyte count, elevated LDH\n- No history of diseases listed in the exclusion criteria provided\n\nClinical Trial Inclusion Criteria:\n- Mildly anemic (based on screening) volunteer males and non-pregnant and non-lactating females\n- Giving written informed consent\n- Normolipidemic, normotensive\n- No history of certain diseases and conditions in the last 5 years\n- No severe acute or chronic blood loss in the last 6 months\n- No bleeding or clotting abnormality in the last 1 year\n- No regular consumption of certain substances including vitamin E, vitamin B12, folate, iron, or antioxidants in the last 6 months prior to enrollment\n\nThe patient in question is mildly anemic, which fits the anemia criteria for the clinical trial. However, the inclusion criteria specifically state that participants must be non-pregnant and non-lactating females, which disqualifies the patient as she is currently pregnant. Additionally, the patient is already receiving iron supplementation, which may conflict with the study's exclusion criteria regarding the consumption of iron in the last 6 months prior to enrollment.\n\nGiven the information provided, the patient does not meet the inclusion criteria due to her pregnancy and current iron supplementation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2364": {
        "output": "Based on the patient note provided, the patient is a 27-year-old woman who is currently 11 weeks into her second pregnancy. She has been found to have mild iron deficiency anemia with a hemoglobin level of 9.0 g/dL initially and 8.9 g/dL two weeks later. She is already receiving iron supplementation.\n\nThe clinical trial in question is investigating the impact of iron/folic acid versus folic acid supplements during pregnancy on maternal and child health. The inclusion criteria for the trial specify that participants should be in an uncomplicated singleton pregnancy and that the first enrollment visit should be at 20 weeks gestation or earlier.\n\nThe patient meets the criteria for gestational age, as she is at 11 weeks gestation. The trial aims to evaluate the effects of iron/folic acid supplementation, and since the patient is experiencing mild iron deficiency and is already on iron supplementation, she would potentially benefit from participating in the trial.\n\nGiven that the patient meets the gestational age requirement and is experiencing a condition (iron deficiency) that the trial is designed to explore, she could be considered a candidate for the trial. However, the trial's summary and inclusion criteria do not mention specific hemoglobin values or other blood count anomalies as inclusion or exclusion factors. Therefore, while the patient seems to fit the general profile the trial is targeting, further investigation into the trial's specific requirements regarding blood count values and iron deficiency severity would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2365": {
        "output": "Given the patient note, we have a 27-year-old pregnant woman who is experiencing iron deficiency anemia, as indicated by her low hemoglobin levels and mild iron deficiency despite already receiving iron supplementation. The clinical trial is looking to compare the tolerability of two different prenatal vitamins among pregnant women with various conditions, including iron deficiency anemia.\n\nSince the patient in question has iron deficiency anemia and is currently pregnant, she fits the inclusion criteria for the clinical trial. Therefore, she would be a good candidate for referral to the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2366": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial \"Use of Cast Iron Pots to Improve Maternal Anemia,\" here is the assessment:\n\nPatient Note:\n- A 27-year-old woman\n- 11 weeks gestation in her second pregnancy\n- Hemoglobin (Hb) of 9.0 g/dL initially and 8.9 g/dL on retest\n- Already receiving iron supplementation\n- Mild iron deficiency\n- Difficulty swallowing\n- Elevated reticulocyte count\n\nClinical Trial Inclusion Criteria:\n- Pregnant women of any age in their first trimester of pregnancy\n- With anemia defined as a Hemoglobin less than 11 and/or a hematocrit less than 33\n- Willingness and ability to cook in provided cast iron pot at least 3x/week\n- Singleton gestations\n\nThe patient meets the following eligibility criteria for the clinical trial:\n- She is a pregnant woman within the first trimester of pregnancy.\n- She has anemia as defined by the trial (Hb less than 11 g/dL).\n- The patient note does not mention any inability or unwillingness to cook with a cast iron pot, so we would assume she meets this criterion unless stated otherwise.\n- The patient note does not mention multiple gestations, so we would assume a singleton pregnancy unless stated otherwise.\n\nGiven that the patient appears to meet all the listed inclusion criteria, the assessment is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2367": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the assessment of the patient's eligibility for the clinical trial titled \"To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy\" can be made as follows:\n\n- The patient is a 27-year-old woman, which meets the age requirement for the trial (age \u2265 18 years).\n- She is at 11 weeks gestation in her second pregnancy, which indicates that she has a singleton pregnancy, thus meeting this criterion.\n- The patient has a hemoglobin (Hb) level of 9.0 g/dL, which subsequently dropped to 8.9 g/dL, indicating anemia.\n- The patient note mentions mild iron deficiency and the patient is already receiving iron supplementation, which aligns with the iron deficiency anemia inclusion criterion.\n- The patient describes difficulty swallowing, which could be indicative of intolerance or low compliance for oral iron, although this would need to be confirmed.\n\nGiven the information provided, it seems that the patient meets the inclusion criteria for the clinical trial:\n\n1. Singleton pregnancy\n2. Iron deficiency anemia\n3. Intolerance or low compliance for oral iron (assuming difficulty swallowing is related to the oral iron supplementation and indicates intolerance or compliance issues)\n\nBased on this assessment, the patient appears to be a good candidate for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2368": {
        "output": "After examining the patient note and the clinical trial criteria, let's determine the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 27-year-old woman.\n- She is currently pregnant (11 weeks gestation).\n- She has a hemoglobin level of 8.9 g/dL, indicating anemia.\n- She has elevated reticulocyte count and elevated LDH, which could be indicative of hemolysis.\n- No mention of sickle cell disease or related hemoglobinopathies.\n- No mention of Transcranial Doppler velocities or previous stroke.\n\nClinical Trial Criteria:\n- Pediatric participants with severe forms of sickle cell anemia.\n- Age between 2 and 17 years.\n- Specific Transcranial Doppler ultrasonography velocity criteria related to sickle cell disease.\n- Parent or guardian consent and child assent.\n- Ability to comply with study-related treatments.\n\nComparison:\n- The patient is 27 years old, which is outside the age range of 2 to 17 years required by the trial.\n- The patient does not have a diagnosis of sickle cell anemia or related hemoglobinopathies, which is a requirement for the clinical trial.\n- The trial is focused on pediatric participants with sickle cell disease and specific Transcranial Doppler velocity criteria, none of which apply to the patient.\n\nBased on the information provided, the patient does not meet the inclusion criteria for age, disease type, or the specific medical condition being studied (sickle cell disease with Transcranial Doppler velocity criteria). Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2369": {
        "output": "",
        "label": 0
    },
    "2370": {
        "output": "Assessing the eligibility of the patient for the clinical trial involves comparing the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 27-year-old woman\n- 11 weeks gestation\n- Hemoglobin (Hb) of 9.0 g/dL initially and 8.9 g/dL on repeat\n- Mean Corpuscular Volume (MCV) 109 fL\n- Iron deficiency indicated by clinical context and presence of hemosiderin in the urine\n- Receiving iron supplementation\n- Elevated reticulocyte count at 180 x 10^9/L\n- Elevated LDH (2000 IU/L)\n- Negative DAT, normal clotting screen, normal urea and electrolytes, normal ALT\n- Anisocytosis, poikilocytosis, no fragments, no agglutination, polychromasia\n\nClinical Trial Inclusion Criteria:\n- Hemoglobin (Hb) < 120 g/L in men and Hb < 110 g/L in women\n- Mean Corpuscular Volume(MCV) < 80 fl\n- Mean Corpuscular Hemoglobin(MCH) < 27 pg\n- Mean Corpuscular Hemoglobin Concentration(MCHC) < 0.32\n- Serum ferritin < 12 g/L\n- Serum iron < 8.95 mol/L\n- Transferrin saturation <15%\n- Total iron binding capacity > 64.44 mol/L\n- History of Menorrhagia, monophagia, or eating disorders\n- Willing to sign an Informed Consent Form\n\nThe patient's hemoglobin levels are below the threshold for women as stated in the trial inclusion criteria. However, the patient's MCV is 109 fL, which is above the maximum MCV of 80 fL required by the trial. Other laboratory values required by the trial inclusion criteria, such as MCH, MCHC, serum ferritin, serum iron, transferrin saturation, and total iron binding capacity, are not provided in the patient note. Additionally, there is no mention of a history of menorrhagia, monophagia, or eating disorders.\n\nBased on the provided information, while the patient does have iron deficiency anemia, she does not meet all the specified hematological criteria for the trial, specifically the MCV which is above the required value. Without additional required laboratory values or medical history, we cannot determine full eligibility. However, given the discrepancy in the MCV value alone, the patient does not fully meet the inclusion criteria as specified.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2371": {
        "output": "To assess the eligibility of Karen for the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study, we need to compare her patient note to the inclusion criteria provided for the trial.\n\nThe inclusion criteria for the SHEP Pilot Study are:\n1. Men and women, aged 60 or over.\n2. Isolated systolic hypertension (ISH).\n3. Normal diastolic pressure of less than 90 mm Hg.\n\nKaren's patient note indicates the following:\n- She is a 72-year-old woman, which meets the age criterion.\n- Her blood pressure is reported as 120/70 mm Hg. This does not reflect isolated systolic hypertension, as her systolic pressure is not elevated (it is within the normal range), and her diastolic pressure is normal (less than 90 mm Hg).\n\nBased on the information provided, Karen does not meet the second inclusion criterion, which specifically requires isolated systolic hypertension. Her systolic blood pressure is normal, and thus she does not have the condition being studied in the trial.\n\nTherefore, Karen would not be eligible for the SHEP Pilot Study based on the criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2372": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with a history of hypertension, type 2 diabetes, and a recent cryptogenic stroke. She does not have a current diagnosis of atrial fibrillation (AF), but she reports occasional palpitations, shortness of breath, and chest pain, which could be suggestive of intermittent or paroxysmal AF. \n\nThe clinical trial in question is focused on atrial fibrillation and investigates two standard treatment strategies for AF with other risk factors for stroke. While Karen does have risk factors for stroke, there is no explicit mention of her having been diagnosed with atrial fibrillation, which is a key inclusion criterion for the trial. However, given her symptoms of palpitations, further investigation, such as monitoring for AF, could potentially uncover undiagnosed AF or confirm its absence.\n\nTherefore, Karen's eligibility for the AFFIRM trial is not clear-cut from the information given. A definitive diagnosis of AF would be necessary to determine her eligibility. \n\nGiven the above considerations, my assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2373": {
        "output": "",
        "label": 0
    },
    "2374": {
        "output": "To determine Karen's trial-level eligibility for the Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM) clinical trial, let's compare her patient note to the inclusion criteria of the trial:\n\nPatient Note:\n- 72-year-old woman\n- Hypertension\n- Type 2 diabetes\n- Hospitalized for cryptogenic stroke two weeks ago\n- Normal blood pressure and glucose currently\n- Occasional palpitations, shortness of breath, and chest pain\n\nClinical Trial Inclusion Criteria:\n- Patients of either gender, aged 18-75 years\n- Diagnosis of HCM caused by sarcomeric gene mutations\n- LV wall thickness of \u2265 20 mm by MRI\n- Severe symptoms refractory to medical treatment (NYHA class III or IV)\n- No LV outflow tract obstruction at rest >30 mm Hg\n- No coronary artery disease\n- No chronic atrial fibrillation\n- No bleeding disorder\n- No anemia\n- No renal impairment\n- No hepatitis B or C; nor unexplained abnormal LFTs\n- Ability to estimate LV wall thickness\n- No positive urine pregnancy test\n- Not pregnant or lactating\n- No concurrent use of immunosuppressives or steroids\n- No diabetes mellitus\n- No history of malignancy (other than certain skin tumors) in the last 5 years\n- No condition that excludes the patient from undergoing an MRI test\n\nBased on the information provided:\n- Karen is within the age range (72 years old).\n- However, Karen has type 2 diabetes, which is listed as an exclusion criterion.\n- There is no information provided about Karen having HCM or sarcomeric gene mutations.\n- The patient note does not mention LV wall thickness or any specific assessments related to HCM.\n- The symptoms reported (palpitations, shortness of breath, and chest pain) are not explicitly linked to HCM and do not indicate that she has severe symptoms refractory to medical treatment (NYHA class III or IV).\n\nGiven that Karen does not meet the specific inclusion criteria related to the diagnosis of HCM, LV wall thickness, and severe symptoms, and she has diabetes mellitus (which is an exclusion criterion), she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2375": {
        "output": "Given the patient note for Karen, a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for cryptogenic stroke, and the clinical trial titled \"Honolulu Heart Program,\" which aims to investigate coronary heart disease and stroke among American men of Japanese ancestry living on the island of Oahu in 1965, we can compare the patient's characteristics to the trial inclusion criteria.\n\nIn this case, the inclusion criteria provided for the clinical trial are non-specific, stating \"No eligibility criteria.\" Since no specific inclusion criteria are listed, theoretically, anyone could be considered for inclusion in the study. However, the summary of the trial specifies a cohort of American men of Japanese ancestry, which Karen does not fit as she is a woman and there is no mention of her being of Japanese ancestry.\n\nIn a practical setting, the absence of clear inclusion criteria could indicate an oversight or that the criteria are so broad nearly anyone could be included. However, given the context provided by the trial's summary, it seems that the study is focused on a very specific population group, which Karen does not belong to.\n\nTherefore, based on the information provided and considering that the inclusion criteria are not explicitly exclusionary but the context suggests a target demographic that does not include Karen, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2376": {
        "output": "Patient Note Analysis:\n- Karen is a 72-year-old woman, which aligns with the age criterion of the trial (65 years or older).\n- She has a history of hypertension and type 2 diabetes, which are known risk factors for coronary heart disease and stroke, relevant to the trial's focus.\n- She was hospitalized for cryptogenic stroke two weeks ago, which is directly related to the trial's interest in stroke.\n- She is currently noninstitutionalized and there is no indication that she requires a proxy respondent or is under hospice care, radiation therapy, or chemotherapy for cancer.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must be 65 years or older at the time of examination, which Karen meets.\n- The patient must be noninstitutionalized, which seems to be true for Karen.\n- The patient must be expected to remain in the area for the next three years; this information is not provided but could be clarified upon further investigation.\n- The patient must be able to give informed consent and not require a proxy respondent at baseline; Karen meets this criterion based on the information provided.\n- Individuals who are wheelchair-bound in the home at baseline or are receiving hospice treatment, radiation therapy, or chemotherapy for cancer are excluded; none of these exclusions are mentioned for Karen.\n\nGiven the information in the patient note, Karen seems to meet all the inclusion criteria based on her age, medical condition (stroke), and risk factors (hypertension and diabetes). There is no information to indicate that she would not be eligible based on the exclusion criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2377": {
        "output": "Given the details provided in the patient note, Karen is a 72-year-old woman with hypertension and type 2 diabetes, who has been hospitalized for cryptogenic stroke. The clinical trial in question is investigating the epidemiology of carotid disease in elderly adults. \n\nSince the provided clinical trial does not specify any inclusion criteria, theoretically, any patient could be considered for participation. However, in a real-world scenario, there would likely be some eligibility requirements to ensure the safety and relevance of the trial for potential participants.\n\nEven though the trial is about carotid disease and the patient had a stroke, without clear inclusion criteria related to the stroke or carotid disease, we cannot definitively conclude the patient's eligibility. Given these circumstances, and the fact that the patient has conditions often associated with vascular disease (hypertension and diabetes), I would consider referring this patient to the clinical trial upon further investigation to ensure it is appropriate for her specific medical situation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2378": {
        "output": "",
        "label": 1
    },
    "2379": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the study.\n\nPatient's characteristics:\n- 72-year-old woman\n- Hypertension\n- Type 2 diabetes\n- Hospitalization for cryptogenic stroke two weeks ago\n- Normal glucose\n- Normal sinus rhythm on a 12-lead electrocardiogram\n- History of occasional palpitations, shortness of breath, and chest pain\n\nClinical trial inclusion criteria for HCM Patients:\n- HCM defined as maximal left ventricular (LV) wall thickness by echocardiography greater than 13 mm in the absence of other causes of LVH or greater than 15 mm asymmetrical LV wall thickness if there is a history of mild hypertension\n- Non-obstructive HCM\n- Age greater than or equal to 21 years\n\nClinical trial exclusion criteria for HCM Patients:\n- Several criteria, but relevant to this patient:\n    - Uncontrolled hypertension\n    - Diabetes mellitus\n\nThe patient does not have a diagnosis of hypertrophic cardiomyopathy (HCM), which is a key inclusion criterion for the clinical trial. Furthermore, the patient has diabetes mellitus, which is listed as an exclusion criterion.\n\nGiven this information, the patient does not meet the inclusion criteria and does meet at least one of the exclusion criteria. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2380": {
        "output": "To determine Karen's eligibility for the \"PREVAIL: Prevention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin\" clinical trial, let's evaluate her condition against the inclusion and exclusion criteria of the trial:\n\nInclusion Criteria Assessment:\n\n1. Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head CT scan or brain MRI scan) providing results consistent with nonhemorrhagic stroke: Karen was hospitalized for a cryptogenic stroke two weeks ago, and her CT was negative for brain hemorrhage, which is consistent with a nonhemorrhagic stroke.\n\n2. Onset of symptoms of qualifying stroke within 48 hours prior to randomization: Karen's stroke occurred two weeks ago, which is beyond the 48-hour window required by the study.\n\n3. In patients receiving thrombolytic therapy for the acute stroke, such as tissue-type plasminogen activator (tPA), administration of study drug may not start until at least 24 hours after completion of thrombolytic therapy: Karen received thrombolytic therapy, but since it has been two weeks, this criterion is not a barrier.\n\n4. Significant motor impairment of the leg, as indicated by a NIHSS score \u22652 on item 6: There is no information provided regarding Karen's NIHSS score or her motor impairment.\n\n5. Inability to walk without assistance: There is no information provided about Karen's ability to walk.\n\nExclusion Criteria Assessment:\n\nWithout further information on Karen's NIHSS score or motor impairment and ability to walk, we cannot definitively rule her in or out based on the exclusion criteria. However, given the information provided, none of the exclusion criteria appear to apply directly to Karen's condition as described.\n\nBased on the available information, the primary disqualifying factor is the onset of stroke symptoms occurring more than 48 hours prior to potential randomization. This makes Karen ineligible for the trial based on the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2381": {
        "output": "To determine if Karen, the 72-year-old woman with hypertension and type 2 diabetes who was recently hospitalized for a cryptogenic stroke, is eligible for the clinical trial studying \"Endothelial Cell Dysfunction in Pulmonary Hypertension,\" we need to match her characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nFrom the patient note, we know:\n- She is 72 years old.\n- She has hypertension and type 2 diabetes.\n- She was hospitalized for a cryptogenic stroke, but currently presents with normal blood pressure, normal glucose, and normal sinus rhythm.\n\nNow let's compare this information with the inclusion and exclusion criteria of the clinical trial:\n\nInclusion criteria for PAH patients:\n- Patients diagnosed with IPAH or secondary pulmonary hypertension with similar histopathology (PAH) - Karen does not have a diagnosis of pulmonary arterial hypertension (PAH) or any conditions listed that would cause secondary PAH.\n\nExclusion criteria for PAH patients:\n- Pregnant women - Not applicable to Karen.\n- Age less than 18 years - Not applicable as Karen is 72.\n- Inability to provide informed written consent - No information suggests that Karen cannot provide consent.\n- Mean PA less than or equal to 25mmHg or PVR less than 3 wood units - No information provided about Karen's pulmonary artery pressure or pulmonary vascular resistance.\n- PCW greater than 16 mmHg - No information provided about Karen's pulmonary capillary wedge pressure.\n\nInclusion criteria for control subjects:\n- No history of diseases thought to be related to the development of endothelial dysfunction including systemic hypertension or diabetes requiring drug therapy - Karen has hypertension and diabetes requiring drug therapy, which disqualifies her as a control subject.\n\nGiven the information available, Karen does not meet the specific criteria for pulmonary arterial hypertension patients, and she is disqualified from being a control subject due to her history of hypertension and diabetes requiring drug therapy. As Karen does not fit the inclusion criteria for either patient or control groups, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2382": {
        "output": "Based on the provided patient note and the inclusion criteria of the Hypertension in the Very Elderly Trial (HYVET), Karen does not meet the specified inclusion criteria for the clinical trial.\n\nThe inclusion criteria for the HYVET are:\n- Aged 80 or older\n- Sitting systolic BP 160-199 mmHg AND sitting diastolic BP < 110 mmHg\n\nKaren's characteristics:\n- Aged 72 years old\n- Sitting blood pressure of 120/70 mm Hg\n\nKaren is not 80 years or older, and her blood pressure does not fall within the required range for the trial (her systolic BP is significantly lower than the 160-199 mmHg range required by the study). Therefore, she is not eligible for this clinical trial based on the criteria provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2383": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess Karen's eligibility for the trial:\n\n- The patient is a 72-year-old woman, which exceeds the age limit of the trial (18 to 65 years).\n- The patient was hospitalized for cryptogenic stroke, not migraine.\n- There is no mention of a current history of migraine with typical aura in the patient's note.\n- The trial requires patients to have experienced 1-4 moderate to severe migraine attacks per month for at least two months, which is not mentioned in the patient's history.\n- The trial is specific to patients with migraine with typical aura, and there is no indication that the patient's palpitations, shortness of breath, and chest pain are related to migraine with typical aura.\n\nGiven these points, Karen does not meet the age requirement, nor does she have a documented history of migraine with typical aura as required by the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2384": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate Karen's eligibility:\n\nThe inclusion criteria for the clinical trial are:\n1. Patients with essential hypertension (systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90, or treated with antihypertensive drugs)\n2. Patients with any finding of stroke, silent brain infarction, and white matter lesion on magnetic resonance imaging\n\nPatient's characteristics from the note:\n- Karen is a 72-year-old woman\n- She has hypertension and type 2 diabetes\n- She was hospitalized for cryptogenic stroke two weeks ago\n- She was treated with thrombolytic therapy with resolution of her symptoms\n- Imaging tests (computed tomography, transesophageal echocardiogram, and magnetic resonance angiogram of brain and great vessels) found no evidence of abnormalities\n- Current blood pressure is 120/70 mm Hg\n- She reports a history of occasional palpitations, shortness of breath, and chest pain\n\nFrom the patient's note, it is clear that Karen has hypertension and has had a stroke, which makes her a potential match for the inclusion criteria. However, the inclusion criteria specifically mention \"any finding of stroke, silent brain infarction, and white matter lesion on magnetic resonance imaging.\" The patient's note does not mention any findings of silent brain infarction or white matter lesions on MRI; it actually states that no evidence of abnormalities was found. Additionally, Karen's current blood pressure is controlled (120/70 mm Hg), which does not meet the hypertension criteria as stated (unless she is being treated with antihypertensive drugs, which is not specified in the note).\n\nGiven the information provided, Karen's eligibility is not clear-cut. While she has a history of hypertension and stroke, the absence of documented silent brain infarction or white matter lesions on MRI and her current controlled blood pressure do not strictly meet the inclusion criteria provided. Therefore, further investigation would be necessary to determine if she is being treated with antihypertensive drugs or if there is evidence of silent brain infarction or white matter lesions on other MRI records not mentioned in the note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2385": {
        "output": "Based on the patient note, Karen is a 72-year-old woman with hypertension and type 2 diabetes. The clinical trial in question is studying the effects of amlodipine/benazepril on albuminuria in hypertensive patients with type 2 diabetes mellitus.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Mild to moderate hypertension\n2. Type 2 diabetes mellitus\n3. Presence of protein in the urine (albuminuria)\n\nKaren has hypertension and type 2 diabetes, which aligns with the first two points of the inclusion criteria. However, there is no mention of protein in her urine (albuminuria) in the patient note. Without this information, we cannot definitively conclude that she meets all the inclusion criteria for the clinical trial. Further investigation would be needed to determine if she has albuminuria.\n\nTherefore, the assessment of Karen's eligibility for this clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2386": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the Valsartan in Elderly Isolated Systolic Hypertension Study, we can assess the eligibility as follows:\n\n1. Karen is a 72-year-old woman, which fits the age criteria of the trial, which requires patients to be over 70 years and less than 85 years of age.\n2. However, her current blood pressure is listed as 120/70 mm Hg, which does not meet the trial's requirement for stable seated systolic blood pressure of over 160 mmHg and diastolic blood pressure of less than 90 mmHg at two visits within 2 to 4 weeks.\n3. The patient note does not specify if Karen is currently untreated for hypertension or if she is on other therapy that can be converted to valsartan.\n\nGiven that Karen does not meet the blood pressure criteria for the trial and there is insufficient information about her current treatment status, she would not be considered eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2387": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with hypertension and type 2 diabetes. She was hospitalized for a cryptogenic stroke two weeks ago and has been treated accordingly. She presents with a blood pressure of 120/70 mm Hg, which indicates that her blood pressure is currently under control.\n\nHowever, to determine Karen's eligibility for the clinical trial titled \"Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria,\" we need to assess her against the specific inclusion criteria mentioned:\n\n1. Type 2 diabetes - Karen has this condition.\n2. Elevated blood pressure and pulse pressure - Karen's current blood pressure is controlled at 120/70 mm Hg, but she has a history of hypertension.\n3. Albuminuria - There is no mention of albuminuria or protein in the urine in Karen's patient note.\n\nWhile Karen meets two of the inclusion criteria (type 2 diabetes and a history of hypertension), there is no information provided about the presence of albuminuria, which is a specific condition required by the trial's inclusion criteria.\n\nTherefore, further investigation would be needed to determine if Karen has albuminuria before she can be considered for the trial. If albuminuria is present, she could potentially be eligible; if not, she would not meet all the necessary criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2388": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial:\n\nThe patient, Karen, is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. She presents with normal blood pressure, glucose levels, and normal sinus rhythm.\n\nThe inclusion criteria for the clinical trial are:\n- TC (Total Cholesterol): 220\uff5e270mg/dl\n- Male: 40-70 years old / Female: postmenopausal-70 years old\n- Less than 40kg in weight\n\nThe trial is evaluating the effect of low-dose pravastatin for primary prevention of coronary heart disease in Japanese hypercholesterolemic patients.\n\nKaren's eligibility for the trial cannot be determined based on the information provided since her cholesterol levels are not mentioned, and there is no indication that she is of Japanese descent or that she has hypercholesterolemia. Furthermore, her weight is not specified, and this is a criterion for the trial.\n\nGiven the missing relevant information and the specificity of the trial's inclusion criteria, it is not possible to refer Karen to this trial at this stage.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2389": {
        "output": "Based on the information provided:\n\nThe patient note describes a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for cryptogenic stroke. There is a mention of occasional palpitations, shortness of breath, and chest pain, but there is no indication that she has a history of atrial fibrillation, nor is there mention of her requiring mitral valve (MV) surgery.\n\nThe clinical trial is specifically looking to recruit patients who are undergoing MV surgery and have at least a 6-month history of continuous atrial fibrillation.\n\nSince the patient in question does not have a documented history of continuous atrial fibrillation and there is no indication that she requires MV surgery, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2390": {
        "output": "To determine the trial-level eligibility for Karen, a 72-year-old woman with hypertension and type 2 diabetes, for the clinical trial titled \"Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients,\" we need to compare the patient's characteristics and history with the inclusion and exclusion criteria of the trial.\n\n**Patient Characteristics:**\n- Age: 72 years old\n- History: Hypertension, type 2 diabetes, recent hospitalization for cryptogenic stroke, negative for brain hemorrhage\n- Treatments: Thrombolytic therapy\n- Current status: Stable blood pressure, normal glucose, normal sinus rhythm, reports of occasional palpitations, shortness of breath, and chest pain\n\n**Clinical Trial Inclusion Criteria:**\n1. 75 or more years of age\n2. Diagnosis of AMI with specific ECG criteria\n3. Consent to participate\n\n**Clinical Trial Exclusion Criteria:**\n- Contraindications to fibrinolytics (several listed)\n- Cardiogenic shock\n- Estimated door-to-needle time >120 minutes\n- Administration of fibrinolysis in the 14 days prior to randomization\n- Other specific medical history and treatments\n\n**Assessment:**\n\nKaren does not meet the age criterion for inclusion in the trial, as she is 72, and the trial requires participants to be 75 or older. Moreover, there is no mention of Karen having acute myocardial infarction (AMI) or any symptoms indicative of an AMI episode. Her recent medical history involves a cryptogenic stroke, not an AMI. Additionally, the exclusion criteria mention a history of previous cerebral vascular accident (CVA) as an exclusion factor, which could potentially apply to her recent stroke, but this is not clearly stated as it differentiates between a stroke and a CVA.\n\nBased on Karen's age and the absence of a diagnosis of AMI, she does not satisfy the necessary inclusion criteria for the clinical trial. There is no need to delve into the exclusion criteria further since she is already ineligible based on the inclusion criteria.\n\n**Trial-level eligibility: 0) Would not refer this patient for this clinical trial.**",
        "label": 0
    },
    "2391": {
        "output": "Given the patient note and the clinical trial information:\n\nPatient Note:\n- Karen, a 72-year-old woman\n- Hypertension and type 2 diabetes\n- Hospitalized for cryptogenic stroke, no brain hemorrhage, symptoms resolved post-thrombolytic therapy\n- No abnormalities found on a transesophageal echocardiogram and magnetic resonance angiogram of the brain and great vessels\n- Blood pressure: 120/70 mm Hg\n- Normal glucose\n- Normal sinus rhythm on a 12-lead electrocardiogram\n- History of occasional palpitations, shortness of breath, and chest pain\n\nClinical Trial:\n- Title: Effect of Exercise on Risk-factors of Elderly Women\n- Summary: Determine the impact of exercise training on risk factors and health costs of community-living women over 65 years.\n- Inclusion Criteria: Community living Caucasian woman \u2265 65 years; life expectancy > 2 years\n\nAssessment:\nKaren fits the age criterion (\u2265 65 years) and is a community-living woman. However, the clinical trial specifically states that the participants should be Caucasian, and there is no mention of Karen's ethnicity in the patient note. Furthermore, the trial is looking at the impact of exercise on risk factors, and while Karen does have hypertension and diabetes, which are risk factors that could potentially be impacted by exercise, there is no specific mention of these being the interest of the study.\n\nWithout the information about Karen's ethnicity and more details on whether her specific risk factors are of interest to the trial, I would suggest further investigation to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2392": {
        "output": "Based on the information provided:\n\nKaren is a 72-year-old woman with a history of hypertension and type 2 diabetes, who recently experienced a cryptogenic stroke. She underwent thrombolytic therapy, which resolved her symptoms. She does not currently have uncontrollable hypertension, as evidenced by her blood pressure reading of 120/70 mm Hg. There is no mention of intracerebral hemorrhage or subarachnoid hemorrhage in her history.\n\nThe clinical trial in question is investigating the use of double or triple concentrated intravenous Nicardipine for the control of hypertension in patients with acute ischemic cerebral stroke (IS) who have uncontrollable hypertension, intracerebral hemorrhagic (ICH) stroke, or subarachnoid hemorrhage (SAH) and require blood pressure control.\n\nKaren does not seem to fit the inclusion criteria at this time because she does not have uncontrollable hypertension, and her stroke symptoms have resolved with thrombolytic therapy. Additionally, there is no mention of her suffering from an ICH stroke or SAH.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2393": {
        "output": "The patient in question, Karen, is a 72-year-old woman with hypertension and type 2 diabetes. She has recently been hospitalized for a cryptogenic stroke and has a history of occasional palpitations, shortness of breath, and chest pain. Her blood pressure is currently controlled at 120/70 mm Hg.\n\nThe clinical trial is aimed at improving blood pressure management in patients with diabetes and hypertension. The inclusion criteria for the clinical trial are as follows:\n\n- Patients with either type 1 or type 2 diabetes.\n- Diabetes defined as those patients presently taking either oral hypoglycemic agents or insulin therapy for more than 6 months.\n\nKaren fits the inclusion criteria as she has type 2 diabetes and hypertension, conditions that the study is targeting. However, there is no information provided regarding her diabetes medication regimen, which is a key component of the inclusion criteria. If Karen has been on oral hypoglycemic agents or insulin therapy for more than 6 months, she would be eligible for the study. Since the patient note does not specify her diabetes treatment, further investigation is needed to confirm her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2394": {
        "output": "",
        "label": 0
    },
    "2395": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, it appears that the patient, Karen, does not meet the necessary requirements for the study.\n\nHere are the specific points of consideration:\n\n- Karen is a 72-year-old woman, which exceeds the age limit of 18 to 65 years set by the trial's inclusion criteria.\n- The patient's medical history does not mention smoking or a desire to quit smoking, which is central to the study's focus.\n- There is no information provided regarding her being sedentary or her willingness to engage in a moderate intensity exercise program.\n- There is no indication that she is willing to use the nicotine patch to attempt smoking cessation.\n\nGiven these points, this patient does not align with the trial's requirements which focus on healthy sedentary women smokers between the ages of 18 to 65 who are willing to participate in a smoking cessation and exercise program.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2396": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess whether Karen is eligible for the trial. The inclusion criteria for the Sitagliptin in the Elderly trial are:\n\n1. Type 2 diabetes managed by diet or metformin only\n2. A1c < 8.5%\n\nKaren's patient note indicates that she has type 2 diabetes, which fits the target condition for the trial. However, the note does not provide information about how her diabetes is managed (whether by diet, metformin, or other medications) or her current A1c level. Without this information, we cannot conclusively determine her eligibility.\n\nTherefore, the appropriate action would be to consider referring Karen to the clinical trial upon further investigation into her diabetes management and current A1c level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2397": {
        "output": "Karen is a 72-year-old woman with hypertension and type 2 diabetes, which fits within the age range specified by the clinical trial (> 65 years of age). She was hospitalized for a cryptogenic stroke two weeks ago but now presents with normal glucose levels, indicating that her diabetes may be under control. However, the patient note does not specify how her diabetes is being managed (diet, exercise, metformin, or other medications), nor does it provide her HgbA1C levels.\n\nThe inclusion criteria for the clinical trial are:\n\n- Type 2 diabetes > 3 months duration\n- Male or female\n- Over 65 years of age\n- Diet controlled only\n- HgbA1C < 8.5%\n\nBased on the patient note, Karen meets the age criterion and has type 2 diabetes, but we lack information about the duration of her diabetes, her current management plan, and her HgbA1C levels. Without this information, we cannot definitively determine if she meets all the inclusion criteria.\n\nTherefore, the assessment of eligibility based on the available information would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2398": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the \"Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial,\" we can determine the following:\n\n- The patient is 72 years old, which meets the age requirement of being 18 and over.\n- The patient has type 2 diabetes, which is specifically mentioned as not an excluding condition in the trial.\n- The patient's history of cryptogenic stroke and hospitalization does not seem to directly conflict with the inclusion criteria provided.\n- The inclusion criteria do not mention any exclusion due to a history of stroke or the specific therapies the patient has received.\n\nWe do not have information indicating that the patient is scheduled to receive a CT scan with intravenous contrast dye, which is a requirement for the trial. Therefore, unless the patient is scheduled for such a procedure, we cannot assume eligibility based solely on the information provided.\n\nGiven the data at hand, we would need confirmation of a scheduled CT scan with intravenous contrast dye to determine the patient's eligibility for the trial. Without this information, we cannot definitely refer the patient for the trial. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2399": {
        "output": "Based on the patient note for Karen and the inclusion criteria provided for the clinical trial titled \"Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008,\" let's determine the trial-level eligibility.\n\nPatient note summary:\n- Karen, a 72-year-old woman with hypertension and type 2 diabetes.\n- Hospitalized for cryptogenic stroke two weeks ago, now resolved.\n- Currently stable with normal blood pressure, glucose levels, and normal sinus rhythm.\n- History of occasional palpitations, shortness of breath, and chest pain.\n\nClinical trial inclusion criteria:\n- \u2265 18 years of age\n- Mentally competent\n- Willing and able to give informed consent prior to study entry\n- Available for all the visits scheduled in the study and able to comply with all study requirements\n- In good health as determined by:\n  - Medical history\n  - Physical examination\n  - Clinical judgment of the investigator\n- Written informed consent obtained from all subjects before enrollment in the study\n\nComparison:\n- Karen meets the age criterion (\u2265 18 years of age).\n- There's no information suggesting Karen is not mentally competent.\n- Assuming she is willing and able to give informed consent, she meets this criterion.\n- Her current state of health appears stable, with no mention of any acute illness or complications that would preclude her from a vaccine trial based on the provided note. However, the final decision on health status would be determined by the investigator's clinical judgment.\n\nKaren's stable health status post-stroke, her age, and the lack of indicated contraindications for a vaccine trial suggest she is a suitable candidate for the study. There is no information suggesting that she would be unable to comply with the study requirements or that she is in poor health in the context of a vaccine trial. Therefore, the patient seems to meet the inclusion criteria, but final eligibility would be determined by the investigator after a physical examination and review of her medical history.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2400": {
        "output": "Upon reviewing the patient note for Karen and comparing it to the inclusion and exclusion criteria for the clinical trial titled \"Tailored Treatment of Permanent Atrial Fibrillation,\" we can make the following observations:\n\nPatient Note Evaluation:\n- Karen is a 72-year-old woman, which is above the age range of 18 to 70 years specified in the inclusion criteria.\n- She has a history of hypertension and type 2 diabetes.\n- She was hospitalized for a cryptogenic stroke two weeks ago, which is an exclusion as the trial excludes any history of cerebral vascular disease including stroke.\n- She reports a history of occasional palpitations, shortness of breath, and chest pain, which could be consistent with atrial fibrillation symptoms; however, there is no specific mention of her having a diagnosis of atrial fibrillation.\n- There is no mention of her having continuous atrial fibrillation lasting greater than 1 year but less than 4 years, nor nonself-terminating atrial fibrillation lasting more than 7 days.\n- There is no information provided about any failed cardioversions or failure of rhythm control drugs.\n\nBased on the information provided, Karen does not meet the age criterion, and she has a recent history of stroke, which is an exclusion criterion for the trial. Additionally, there is insufficient evidence to conclude that she has a history of atrial fibrillation as defined by the trial's inclusion criteria.\n\nTherefore, Karen is not eligible for the clinical trial titled \"Tailored Treatment of Permanent Atrial Fibrillation.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2401": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet several of the inclusion criteria for the study. \n\nThe inclusion criteria for the study are as follows:\n- Patients must be male or female, age 18-65\n- Patients must have a definitive diagnosis by DSM-IV criteria of schizophrenia, bipolar or schizoaffective disorder.\n- Patients can be receiving inpatient or outpatient treatment at the time of enrollment.\n- Patients must have been treated with (Mellaril) thioridazine, (Risperdal) risperidone or (Seroquel) quetiapine at least three months at the time of enrollment.\n- Patients must be able to provide written informed consent.\n\nThe patient in the provided note:\n- Is a 72-year-old woman, which is outside the age range specified in the criteria (18-65).\n- Does not have a diagnosis of schizophrenia, bipolar, or schizoaffective disorder as required by the criteria.\n- There is no mention of the patient being treated with thioridazine, risperidone, or quetiapine, let alone for a minimum of three months.\n\nGiven this information, the patient does not meet the age requirement, the diagnostic criteria, or the medication treatment history required for inclusion in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2402": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS),\" we must compare the patient's characteristics and history with the trial's inclusion and exclusion criteria.\n\nInclusion criteria for the trial are:\n1. Sudden focal neurological deficit attributable to a stroke\n2. Clearly defined time of onset, allowing initiation of intravenous treatment within 3 hours of symptoms onset and intra-arterial treatment within 6 hours of symptoms onset.\n3. Age between 18 and 80 years\n\nExclusion criteria for the trial include (but are not limited to):\n1. Disability preceding stroke consistent with a modified Rankin scale score of 2-4\n2. Previous history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)\n3. Another stroke or serious head trauma within the preceding 3 months\n4. Any history of prior stroke and concomitant diabetes\n5. Severe uncontrolled hypertension defined by a blood pressure \u2265 185 mmHg systolic or diastolic \u2265 110 mm Hg\n6. Prognosis very poor regardless of therapy; likely to be dead within months.\n\nPatient's characteristics:\n- The patient is a 72-year-old woman with hypertension and type 2 diabetes.\n- She was hospitalized for cryptogenic stroke two weeks ago.\n- She had thrombolytic therapy with resolution of her symptoms.\n- No evidence of abnormalities on transesophageal echocardiogram and magnetic resonance angiogram.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the following reasons:\n- The patient is 72 years old, which fits the age inclusion criterion (3).\n- However, the patient has a history of stroke from two weeks ago and concomitant diabetes (exclusion criterion 4).\n- The patient's stroke occurred more than 3 hours from the potential initiation of the trial's treatment, which does not meet the trial's timing requirement (inclusion criterion 2).\n\nGiven this information, the patient does not meet the trial's inclusion criteria and does meet one of the exclusion criteria. Therefore, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2403": {
        "output": "",
        "label": 0
    },
    "2404": {
        "output": "Upon reviewing the patient note for Karen, a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for a cryptogenic stroke, and comparing it to the inclusion criteria of the clinical trial titled \"PFO ACCESS Registry,\" we can determine her eligibility.\n\nThe inclusion criteria for the trial are:\n1. Patent foramen ovale (PFO)\n2. Recurrent cryptogenic stroke\n3. Failed antiplatelet/anticoagulant therapy\n\nKaren's medical history notes a single cryptogenic stroke with no mention of a patent foramen ovale (PFO) or recurrence of stroke. Furthermore, there is no information indicating that she has failed antiplatelet/anticoagulant therapy. In fact, she was given thrombolytic therapy with resolution of her symptoms, and there is no mention of further strokes or failed therapy.\n\nBased on the available information, Karen does not meet the inclusion criteria for the clinical trial as she has not been documented to have a PFO, has not had recurrent strokes, and there is no evidence of failed antiplatelet/anticoagulant therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2405": {
        "output": "The patient note details a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for a cryptogenic stroke. She has a history of occasional palpitations, shortness of breath, and chest pain, but there is no explicit mention of atrial fibrillation (AF) in her medical history. The clinical trial is looking to recruit individuals with a history of or current atrial fibrillation for one group and controls without a history of atrial fibrillation for another group.\n\nSince the patient has a history of palpitations but no confirmed diagnosis of atrial fibrillation, it is not clear whether she would qualify for the atrial fibrillation group. However, the patient does not have an explicit history of atrial fibrillation, which might make her eligible for the control group.\n\nGiven the information provided, the patient could potentially be part of the control group if further investigation confirms that she does not have a history of atrial fibrillation. Therefore, I would consider referring this patient for this clinical trial upon further investigation to confirm the absence of a history of atrial fibrillation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2406": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's analyze whether Karen is eligible for the Stroke DOC Arizona TIME trial.\n\nThe inclusion criteria for the trial are:\n1. Written Informed Consent\n2. Eighteen years of age or older\n3. Symptoms consistent with acute stroke (ischemic or hemorrhagic)\n4. Acute presentation of stroke symptoms, per bedside physician discretion (onset generally less than 12 hours and likely less than 3 hours)\n\nKaren is a 72-year-old woman, which satisfies the age requirement. However, she was hospitalized for a cryptogenic stroke two weeks ago, which does not meet the criteria for an acute presentation of stroke symptoms as defined by the trial (onset generally less than 12 hours and likely less than 3 hours). Since Karen's stroke occurred two weeks prior and she was given thrombolytic therapy with resolution of her symptoms, she does not present with acute stroke symptoms at the time of consideration for the trial.\n\nTherefore, based on the provided information, Karen does not meet the criteria for acute presentation of stroke symptoms, which is essential for inclusion in the Stroke DOC Arizona TIME trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2407": {
        "output": "Based on the patient note provided and the inclusion criteria of the U-CHAMP clinical trial, here is the assessment of Karen's eligibility:\n\nKaren is a 72-year-old woman, which fits within the 18-85 years age range specified in the trial's inclusion criteria. She has a history of hypertension and type 2 diabetes, which are related to the increased risk of stroke and heart disease \u2013 the conditions that the U-CHAMP program aims to manage. Since the trial is looking to assist in the identification and management of people with elevated blood pressure, blood glucose, and cholesterol, and considering Karen's recent hospitalization for cryptogenic stroke and her ongoing management of hypertension and diabetes, she seems to be a good candidate for the program focused on reducing the risk of heart disease and stroke. Additionally, she would need to be able to sign consent, which is not indicated as an issue in the patient note.\n\nTherefore, Karen meets the inclusion criteria of being within the age range and having conditions that the trial aims to address. There is no information that would suggest she does not meet the consent requirement.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2408": {
        "output": "Based on the given patient note and the clinical trial information, the patient, Karen, who is 72 years old with hypertension and type 2 diabetes, seems to meet the inclusion criteria that require a clinical diagnosis of type 2 diabetes for the study on the effect of leucine on body composition and muscle characteristics in elderly, type 2 diabetes patients.\n\nThe trial does not specify any additional inclusion criteria that we can assess from the given patient note, such as age restrictions or specific diabetes-related criteria. Therefore, assuming no further exclusion criteria that we are unaware of, Karen appears to be eligible for the study based on her diagnosis of type 2 diabetes.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2409": {
        "output": "To assess Karen's eligibility for the clinical trial titled \"Patent Foramen Ovale in Cryptogenic Stroke Study,\" let's review the patient note against the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n1. Age 30-85\n2. Ischemic stroke within 30 days\n3. Glasgow outcome scale \u2265 3\n4. No contraindications to warfarin/aspirin\n\nPatient Note Review:\n- Karen is a 72-year-old woman, which fits the age criterion (30-85 years).\n- She was hospitalized for cryptogenic stroke two weeks ago, which is within the required 30-day period.\n- The Glasgow outcome scale is not explicitly mentioned in the patient note, but given that she had resolution of her symptoms and is currently presenting without neurological deficits, it can be inferred that her Glasgow outcome scale is likely \u2265 3.\n- She has no documented contraindications to warfarin or aspirin in the patient note.\n\nBased on the information provided, Karen meets all the stated inclusion criteria for the clinical trial. Therefore, it is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2410": {
        "output": "",
        "label": 0
    },
    "2411": {
        "output": "Based on the provided patient note and the clinical trial information, let's compare the patient's characteristics with the inclusion criteria of the trial:\n\nPatient Characteristics:\n- Age: 72 years old\n- Condition: Hospitalized for cryptogenic stroke two weeks ago\n- Current status: Blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead ECG\n- History of occasional palpitations, shortness of breath, and chest pain\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 80 years\n- Onset of symptoms until call at least 30 min prior to the end of the approved time window for thrombolysis (and not after awakening)\n- Clinical signs of ischemic stroke with suddenly occurring, measurable neurological deficits such as impairment of language, motor function, facial palsy, or asymmetry\n- Patient is willing to participate voluntarily and to sign a written informed consent\n\nLooking at the inclusion criteria, the patient meets the age requirement (between 18 and 80 years). However, the trial is specifically focused on acute management of ischemic stroke with a goal of reducing the response time for thrombolytic therapy. The patient described was hospitalized for a cryptogenic stroke two weeks ago and is no longer within the acute phase where thrombolytic therapy timing is critical. Therefore, the patient does not meet the criteria related to the timing of symptom onset and the requirement for immediate thrombolytic therapy.\n\nGiven that the patient's stroke occurred two weeks prior and the trial is designed for acute response, this patient would not be eligible for the clinical trial as the trial's focus is on immediate response to ischemic stroke, not post-stroke care or secondary prevention.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2412": {
        "output": "Based on the patient note provided:\n\n- The patient, Karen, is a 72-year-old woman, which meets the age requirement of the clinical trial (70 years and older).\n- She has a history of hypertension and type 2 diabetes, which also meets the inclusion criteria of the clinical trial that is specifically looking to examine elderly type 2 diabetic subjects.\n\nHowever, there is no mention in the patient note about orthostatic hypotension, which is the specific condition of interest in the clinical trial. Therefore, while the patient meets the general criteria based on age and diabetes mellitus, without information on her status regarding orthostatic hypotension, it is not possible to definitively determine her eligibility.\n\nGiven this, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2413": {
        "output": "Given the patient note and the clinical trial information provided, the patient, Karen, is a 72-year-old woman with a medical history of hypertension, type 2 diabetes, and a recent cryptogenic stroke. The clinical trial in question focuses on the safety evaluation of the ExAblate MRgFUS system for prostate cancer.\n\nThe inclusion criteria for the clinical trial are:\n1. Age of patients: up to 75 years.\n2. Men scheduled for radical prostatectomy due to prostate cancer.\n3. Patients who are able and willing to give consent and able to attend all study visits.\n\nKaren does not meet the inclusion criteria for the following reasons:\n1. Gender: The trial is specifically for men with prostate cancer, while Karen is a woman.\n2. Diagnosis: There is no mention of prostate cancer in Karen's medical history.\n3. Treatment: There is no indication that Karen is scheduled for a radical prostatectomy, which is a requirement for the trial.\n\nTherefore, Karen is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2414": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's assess the eligibility of the patient for the clinical trial titled \"Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin\u00ae in Acute Ischemic Hemispheric Stroke.\"\n\nThe inclusion criteria for the trial are:\n\n1. Female or male inpatients.\n2. Age: 18-80 years.\n3. If female, patient must not be pregnant.\n4. Clinical diagnosis of ischemic stroke causing a measurable neurological deficit.\n5. Onset of symptoms within 3 hours prior to initiation of rt-PA administration.\n6. Stroke symptoms are to be present for at least 30 minutes and have not significantly improved before treatment.\n7. Patient is willing to participate voluntarily and to sign a written patient informed consent.\n\nNow, let's compare the patient's details with the criteria:\n\n1. The patient, Karen, is 72 years old, which fits within the age range criterion.\n2. She is female, and there is no information suggesting that she is pregnant.\n3. She has had a clinical diagnosis of ischemic stroke, which aligns with the trial's target condition.\n4. However, there is a discrepancy with the timing of the symptoms and treatment initiation. Karen was hospitalized for a cryptogenic stroke two weeks ago, which is well beyond the 3-hour window specified in the trial criteria.\n5. Her stroke symptoms have resolved following thrombolytic therapy, and she is currently presenting with stable vital signs and no current neurological deficits.\n\nThe primary issue is the timing of symptom onset and treatment initiation. Since Karen's stroke and treatment occurred two weeks prior, and the trial requires treatment initiation within 3 hours of symptom onset, she would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2415": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n1. The patient had a cryptogenic stroke two weeks ago, which is within the 30-day timeframe.\n2. The computed tomography was negative for brain hemorrhage, which meets the criteria for a negative brain image for hemorrhagic stroke.\n3. The patient is currently in normal sinus rhythm at the time of presentation, which meets the requirement of being in sinus rhythm at the time of enrollment.\n\nClinical Trial Inclusion Criteria:\n1. Recent stroke (within 30 days)\n2. Negative brain image for hemorrhagic stroke\n3. In sinus rhythm at time of enrollment\n\nThe patient meets all the specified inclusion criteria for the clinical trial:\n\n1. The stroke occurred within the required 30-day window.\n2. The brain imaging was negative for hemorrhage.\n3. The patient is currently in sinus rhythm.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2416": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess Karen's eligibility for the trial:\n\n1. Age > 18 years: Karen is 72 years old, which meets this criterion.\n2. Seen at UCSF Medical Center for cryptogenic stroke or high-risk TIA: The patient note does not specify where Karen was treated for her cryptogenic stroke, so this information is missing.\n3. Onset of stroke or TIA symptoms within the previous 60 days: Karen was hospitalized for a cryptogenic stroke two weeks ago, which meets this criterion.\n\nWhile Karen does meet two of the three specified inclusion criteria (age and timing of stroke symptoms), the patient note does not confirm that she was seen at UCSF Medical Center. However, considering the information provided, it is reasonable to consider referring her to the clinical trial upon further investigation to determine if she was indeed treated at UCSF Medical Center.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2417": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for a cryptogenic stroke two weeks ago. She has no mention of previous pneumococcal vaccination in the provided information.\n\nThe clinical trial's inclusion criteria state that elderly subjects over the age of 65 years who have not received pneumococcal vaccination are eligible to participate. Since Karen falls within the age range and there is no information indicating that she has received pneumococcal vaccination, she may be eligible for this study.\n\nHowever, the patient note does not explicitly confirm whether Karen has not had the pneumococcal vaccination, which is an essential inclusion criterion for the trial. Therefore, further investigation would be needed to determine her vaccination status before making a definitive referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2418": {
        "output": "",
        "label": 0
    },
    "2419": {
        "output": "",
        "label": 0
    },
    "2420": {
        "output": "Based on the information provided, Karen is a 72-year-old woman with a history of cryptogenic stroke for which she received thrombolytic therapy with resolution of her symptoms. The clinical trial in question is focusing on the effect of implementing hyper-acute stroke guidelines on decision-making for or against thrombolytic therapy for stroke in the emergency department.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients presenting to the emergency department\n2. Signs and symptoms of acute ischemic stroke: impairment of language, motor function, cognition and/or gaze, vision or neglect.\n3. Patients with an NIH Stroke Scale score > 4\n\nKaren does not currently present with signs and symptoms of acute ischemic stroke; she had a stroke two weeks ago and her symptoms have resolved. Additionally, there is no current NIH Stroke Scale score provided, and her last treatment with thrombolytic therapy occurred in the past and is not happening in an emergency department setting as specified by the trial's inclusion criteria.\n\nGiven this information, Karen does not meet the inclusion criteria for the clinical trial since she is not currently presenting with acute ischemic stroke symptoms and is not within the emergency department setting for immediate decision-making regarding thrombolytic therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2421": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility as follows:\n\n1. Participant had at least five minutes of chest pain or equivalent symptoms within 24 hours of ED presentation: The patient reports a history of occasional palpitations, shortness of breath, and chest pain that stops on their own. However, there is no indication that these symptoms occurred within 24 hours of an emergency department presentation, nor that they warranted further risk stratification as determined by an ED attending.\n\n2. 2 or more cardiac risk factors: The patient has hypertension and type 2 diabetes, which are two cardiac risk factors.\n\n3. Able to provide a written informed consent: There is no information suggesting that the patient would be unable to provide consent.\n\n4. <75 years of age, but >40 years of age: The patient is 72 years old, which falls within the specified age range.\n\n5. Able to hold breath for at least 10 seconds: There is no information provided regarding the patient's ability to hold her breath.\n\n6. Sinus rhythm: The patient has a normal sinus rhythm on a 12-lead electrocardiogram.\n\nThe patient does meet some of the inclusion criteria, such as having two or more cardiac risk factors, being within the age range, and having a normal sinus rhythm. However, there is no clear indication that the patient experienced the specified chest pain or equivalent symptoms within 24 hours of ED presentation, which is a critical inclusion criterion. Additionally, the ability to hold breath is not mentioned, but this could be easily assessed.\n\nGiven the information provided, the patient note does not clearly indicate that the patient meets all of the mandatory inclusion criteria for the clinical trial. Therefore, further investigation would be needed to determine the exact timing and nature of the chest pain and to confirm the patient's ability to hold her breath.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2422": {
        "output": "Based on the information provided:\n\nPatient note:\n- Karen is a 72-year-old woman\n- Hospitalized for cryptogenic stroke two weeks ago\n- No evidence of a patent foramen ovale (PFO) since the transesophageal echocardiogram was negative\n- Underwent thrombolytic therapy with resolution of symptoms\n\nClinical trial:\n- Inclusion Criteria:\n  - 18 years old patients\n  - Signed informed consent\n  - All consecutive patients undergoing a successful percutaneous closure of a PFO secondary to a cryptogenic stroke\n\nThe patient does not meet the inclusion criteria for the clinical trial because there is no mention of her having undergone a percutaneous closure of a PFO. The transesophageal echocardiogram found no evidence of abnormalities, which suggests that a PFO closure was not indicated or performed. Therefore, she would not be eligible for this trial as it specifically requires patients who have undergone the procedure for PFO closure post-cryptogenic stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2423": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Use of Loop Recorders for Diagnosis of Palpitations in A&E,\" we need to match Karen's characteristics and symptoms with the trial's inclusion criteria.\n\nThe inclusion criteria are as follows:\n1. Age 18 years or older\n2. Good history of episodic symptomatic sustained palpitations (sudden onset and offset, fast heart beats, may be associated with shortness of breath or dizziness)\n3. Terminates before presentation to hospital\n4. Episodes occur at a frequency of less than once every two weeks\n5. Never previously caught on ECG or ambulatory monitoring\n6. Normal resting ECG\n\nKaren's characteristics and symptoms:\n- 72-year-old woman (matches age criteria)\n- History of occasional palpitations (matches history of palpitations)\n- Shortness of breath and chest pain associated with palpitations (palpitations associated with shortness of breath)\n- Symptoms stopping on their own (matches termination before presentation to hospital)\n- She does not mention the frequency, but it is stated as occasional (might match frequency criteria depending on further clarification)\n- Palpitations not caught on ECG (assuming \"normal sinus rhythm on a 12-lead electrocardiogram\" refers to her current state, not during an episode)\n- Normal resting ECG (matches normal resting ECG criteria)\n\nBased on the information provided, Karen seems to meet most of the inclusion criteria for the clinical trial. However, we do not have information on the exact frequency of her palpitations (whether they occur less than once every two weeks), and we assume that her palpitations have never been caught on ECG or ambulatory monitoring based on the information given.\n\nGiven that the patient note aligns well with the inclusion criteria, but we lack some details regarding the frequency of episodes and confirmation that they have never been captured on ECG or ambulatory monitoring, Karen would be considered for referral to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2424": {
        "output": "After reviewing the patient note for Karen, a 72-year-old woman, and the inclusion criteria for the clinical trial \"A Trial Using Double-Bolus THR-100 Versus Streptokinase,\" we can determine her trial-level eligibility.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Male or female patients aged 30 to < 75 years inclusive.\n2. Patients presenting within 12 hours with symptoms presumed secondary to an acute myocardial infarction lasting at least 20 minutes and accompanied by ECG evidence of > 1mm of ST elevation in 2 or more limb leads or > 2mm in 2 or more contiguous precordial leads or suspected new left bundle branch block will be eligible.\n3. Patients must be in the hospital or the emergency department and able to receive the study medication within 12 hours of onset of symptoms.\n4. Females of child-bearing age, not using a generally accepted method of contraception must have a negative urine pregnancy test.\n5. Written informed consent should be sought from the patient prior to inclusion in the study.\n\nKaren does meet the age criterion (1) as she is within the 30 to < 75 years age range. However, Karen was hospitalized for a cryptogenic stroke, not an acute myocardial infarction, which means she does not meet the second criterion (2). There is no indication in the patient note that she has had an acute myocardial infarction or fits the specific ECG criteria mentioned for the trial. Additionally, the trial specifies the need for treatment within 12 hours of symptom onset (3), which is not relevant to Karen\u2019s situation as she presented with a stroke, not myocardial infarction.\n\nTherefore, based on the information provided, Karen does not meet the key clinical condition requirements for this trial. The other criteria (4 and 5) are not applicable in this assessment since Karen's condition does not align with the trial's focus on myocardial infarction.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2425": {
        "output": "",
        "label": 0
    },
    "2426": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, Karen, the patient in question, would not be eligible for the clinical trial. The clinical trial is specifically looking at male patients with known or suspected coronary artery disease (CAD) and/or peripheral arterial disease (PAD) who are undergoing coronary or peripheral angiography. Karen does not meet the gender requirement as she is a woman, and there is no mention of her having CAD, PAD, or being scheduled for angiography.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2427": {
        "output": "",
        "label": 0
    },
    "2428": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess Karen's eligibility for the trial:\n\nPatient Note Points:\n- Karen is a 72-year-old woman, which satisfies the age criteria (\u2265 18 years of age).\n- She has a history of hypertension and type 2 diabetes.\n- She was hospitalized for cryptogenic stroke two weeks ago, not for stable angina or silent ischemia.\n- She has had occasional palpitations, shortness of breath, and chest pain which resolve on their own. This does not clearly indicate stable angina or silent ischemia.\n- The patient underwent thrombolytic therapy for stroke, which is not related to coronary artery disease or the need for PCI.\n- There is no mention of her being scheduled for coronary angiography or angioplasty, which is a requirement for the trial.\n- It is unknown if she is on dual anti-platelet therapy or willing to conform to study requirements as the patient note does not provide this information.\n- The patient note does not mention any contraindications or factors that would impair study results.\n- The patient's capacity to consent is not mentioned, but we assume it is not impaired unless stated otherwise.\n- The patient note does not indicate if she is of childbearing potential or if a pregnancy test has been performed.\n\nClinical Trial Inclusion Criteria Points:\n- The patient must present with stable angina pectoris or silent ischemia.\n- The patient must be scheduled for coronary angiography, with possible angioplasty.\n- The patient must be able to tolerate and be on dual anti-platelet therapy.\n- The patient must be able and willing to conform to the study requirements.\n- The patient must voluntarily sign an Informed Consent.\n- The patient should not present with any condition that would impair the study results.\n- Female patients of childbearing potential must have a negative pregnancy test.\n\nBased on the information provided, Karen does not meet several key inclusion criteria for the clinical trial, particularly those related to the condition being studied (stable angina or silent ischemia) and the required procedures (coronary angiography with possible angioplasty). Therefore, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2429": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it appears that Karen may be eligible for the trial. Here is a breakdown of her eligibility:\n\n- Karen experienced a cryptogenic stroke, which is part of the inclusion criteria.\n- Her cryptogenic stroke was verified by computed tomography (CT), which fits the criteria.\n- She is over 18 years of age.\n- There is no mention of her inability to provide written consent, so it can be assumed she has the capacity to consent.\n\nGiven this information, Karen meets the inclusion criteria for the clinical trial on finding atrial fibrillation in patients with unexplained stroke using long-term cardiac monitoring.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2430": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for cryptogenic stroke two weeks ago. There is no mention of her having chronic kidney disease or her estimated glomerular filtration rate (eGFR). Additionally, the patient is not mentioned to be scheduled for a coronary angiography study as part of her clinical care, which is a requirement for inclusion in the clinical trial.\n\nThe clinical trial is focused on monitoring renal blood flow in individuals with either reduced kidney function or normal kidney function who are scheduled for coronary angiography. The inclusion criteria specify two distinct groups for specific aims:\n- Aim 1: Subjects with reduced kidney function (eGFR between 30 - 59 ml/min/1.73 m2) who are scheduled for a coronary angiography study.\n- Aim 2: Subjects with normal kidney function who are also scheduled for a coronary angiography study.\n\nSince Karen's current medical condition does not align with the specifics of the clinical trial (no mention of kidney issues or scheduled coronary angiography), she would not meet the inclusion criteria for this trial. Therefore, she would not be referred to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2431": {
        "output": "Upon reviewing the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\n- The patient had a cryptogenic stroke two weeks ago, which fits within the trial's requirement of having had a cryptogenic stroke within the previous 3 months.\n- However, the patient does not have a documented diagnosis of high-risk Patent Foramen Ovale (PFO). The transesophageal echocardiogram found no evidence of abnormalities, which implies that a high-risk PFO was not identified.\n- The patient appears willing to participate in follow-up visits, as there is no information provided to suggest otherwise.\n- There is no indication of other potential causes of stroke, given that the computed tomography was negative for brain hemorrhage, and the transesophageal echocardiogram and magnetic resonance angiogram found no evidence of abnormalities.\n\nSince the key criterion of having been diagnosed with a high-risk PFO is not met according to the patient's medical findings, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2432": {
        "output": "",
        "label": 0
    },
    "2433": {
        "output": "In order to assess the trial-level eligibility of the patient for the clinical trial, let's compare the patient's characteristics with the inclusion criteria of the trial:\n\nPatient's Characteristics:\n- 72-year-old woman (qualifies as elderly > 65 years)\n- Has hypertension and type 2 diabetes (qualifies as having at least one calcification risk factor)\n- Recently hospitalized for cryptogenic stroke\n- Not specified whether she is on hemodialysis or has hyperphosphatemia\n- No information on intact-PTH levels\n- No information on life expectancy\n- No information on whether she has given written informed consent, but this could potentially be obtained if she meets other criteria\n\nClinical Trial Inclusion Criteria:\n- Hemodialysis patients with hyperphosphatemia who require phosphate binders\n- Hemodialysis for more than 3 months\n- Patients who have at least one calcification risk factor (elderly > 65 years, postmenopausal woman, type 2 diabetes mellitus)\n- Intact-PTH \u2264 240pg/mL\n- Life expectancy > 1 year\n- With written informed consent\n\nBased on the available information, while the patient does have some risk factors that are relevant to the clinical trial (age, postmenopausal status, type 2 diabetes), there is no information indicating that the patient is a hemodialysis patient or has hyperphosphatemia, which are key inclusion criteria for this trial. Without this information, we cannot assume that the patient meets the core requirement of being on hemodialysis with hyperphosphatemia.\n\nTherefore, based on the information provided, the patient does not meet the crucial inclusion criteria related to hemodialysis and hyperphosphatemia. As such, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2434": {
        "output": "Based on the information provided, the patient, Karen, is a 72-year-old woman with a history of hypertension and type 2 diabetes, and she was recently hospitalized for a cryptogenic stroke. There is no mention of atrial fibrillation (AF) in her current presentation; however, she reports a history of occasional palpitations. Palpitations can be a symptom of atrial fibrillation, but without a confirmed diagnosis of AF, it is unclear if she meets the specific inclusion criteria for the clinical trial which requires participants to have atrial fibrillation and be scheduled for catheter ablation.\n\nGiven the lack of information confirming a diagnosis of atrial fibrillation and no indication that she is scheduled for catheter ablation, there is not enough evidence to refer Karen to the clinical trial at this time. However, if her palpitations were to be further investigated and AF was diagnosed, she might become eligible for the trial. Therefore, further investigation would be needed before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2435": {
        "output": "To determine the eligibility of Karen for the clinical trial titled \"Pilot Safety Study of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room,\" let's evaluate the patient's information against the trial's inclusion criteria:\n\nInclusion Criteria for the trial:\n1. Patient is in Sinus Rhythm\n2. Typical or atypical chest pain lasting more than 5 min in the last 24 hs.\n3. Estimated pre-test probability of significant coronary artery disease more than 15%.\n4. Absence of ECG changes suggestive of myocardial ischemia (ST-segment deviation >1 mm or T Wave inversion > 4 mm in at least two contiguous leads).\n5. Negative initial troponins I at admission (<0.05 ng/ml)\n\nPatient Karen's information:\n- 72-year-old woman with hypertension and type 2 diabetes.\n- Hospitalized for cryptogenic stroke two weeks ago.\n- Computed tomography was negative for brain hemorrhage.\n- She was given thrombolytic therapy with resolution of her symptoms.\n- Transesophageal echocardiogram and magnetic resonance angiogram found no evidence of abnormalities.\n- Presents currently with a blood pressure of 120/70 mm Hg, normal glucose.\n- Normal sinus rhythm on a 12-lead electrocardiogram.\n- Reports history of occasional palpitations, shortness of breath, and chest pain lasting for a few minutes and then stopping on their own.\n\nAssessment:\n1. Karen is in normal sinus rhythm, which meets the first criterion.\n2. She reports a history of chest pain, which meets the second criterion.\n3. She has a history of hypertension and type 2 diabetes, factors that may increase her pre-test probability of significant coronary artery disease, potentially meeting the third criterion.\n4. There are no reported ECG changes suggestive of myocardial ischemia, which meets the fourth criterion.\n5. There is no mention of her troponin levels, but she was given thrombolytic therapy with resolution of symptoms, implying her initial presentation may have been without significantly elevated troponins.\n\nGiven the information provided, Karen seems to meet most of the inclusion criteria for the clinical trial. However, we lack specific data on her estimated pre-test probability of significant coronary artery disease and her troponin levels at admission. Based on the available information, further investigation would be needed to confirm her eligibility, particularly with respect to her pre-test probability of coronary artery disease and her troponin levels. Therefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2436": {
        "output": "",
        "label": 2
    },
    "2437": {
        "output": "In order to assess Karen's eligibility for the clinical trial titled \"PREdicting Atrial Fibrillation or Flutter,\" we need to evaluate her against the provided inclusion criteria:\n\n1. **Patient meets the approved FDA indication to receive the ICM**: The patient note does not specify whether Karen meets the FDA indication for an implantable cardiac monitor (ICM), so we cannot confirm this criterion without additional information.\n\n2. **Patient is suspected, based on demographics, to be at high risk of having AF, as determined by the clinical investigator**: Karen has a history of cryptogenic stroke, hypertension, and type 2 diabetes, which are risk factors for atrial fibrillation. However, it is not clear from the note whether she is suspected to be at high risk of AF by a clinical investigator.\n\n3. **Patient has a CHA2DS2-VASc score \u2265 2**: Karen has at least 3 points on the CHA2DS2-VASc score (1 point for age > 65, 1 point for hypertension, and 1 point for diabetes), which satisfies this criterion.\n\n4. **Stroke/TIA criterion as part of the CHA2DS2-VASc score for this trial is limited to either an ischemic stroke or TIA, which occurred more than one year prior to enrollment**: Karen's stroke occurred two weeks ago, not meeting the condition of having occurred more than one year prior to enrollment.\n\n5. **Patient is 18 years of age or older**: Karen is 72 years old, which meets this criterion.\n\n6. **Patient has a life expectancy of 18 months or more**: The patient note does not provide information about Karen's life expectancy, so we cannot confirm this criterion without additional information.\n\nBased on the information provided, Karen meets some of the inclusion criteria, such as being over 18 years old and having a CHA2DS2-VASc score \u2265 2. However, her recent stroke does not meet the trial's specific requirements regarding the timing of the stroke/TIA, and there is insufficient information regarding her risk of AF as determined by a clinical investigator and her life expectancy. Therefore, she would not be immediately eligible for the trial, but further investigation is needed to assess other criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2438": {
        "output": "Based on the information provided in the patient note, Karen is a 72-year-old woman with hypertension and type 2 diabetes. She was hospitalized for cryptogenic stroke and has a history of occasional palpitations, shortness of breath, and chest pain, which may suggest episodes of paroxysmal atrial fibrillation. However, it is not explicitly mentioned that she has been diagnosed with paroxysmal atrial fibrillation, which is a required inclusion criterion for the clinical trial.\n\nThe clinical trial is looking for participants with paroxysmal atrial fibrillation that is symptomatic. The patient's symptoms (palpitations, shortness of breath, and chest pain) could potentially be related to atrial fibrillation, but without a clear diagnosis of paroxysmal atrial fibrillation, we cannot definitively say she meets the inclusion criteria. Further investigation is needed to determine whether the patient's symptoms are indeed due to paroxysmal atrial fibrillation. Therefore, the patient might potentially be eligible for the trial if a diagnosis of paroxysmal atrial fibrillation is confirmed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2439": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Subclinical Atrial Fibrillation and Stroke Prevention Trial,\" we must compare the patient's characteristics and medical history with the inclusion criteria of the study.\n\nThe inclusion criteria for the trial are:\n1. Age >= 18 years\n2. CHADS2 score >= 2\n3. Sinus rhythm\n4. Cardiac Implantable Electronic Device (CIED)\n\nThe patient's characteristics and medical history:\n- Karen is a 72-year-old woman, which meets the age criterion.\n- She has hypertension and type 2 diabetes, which are two factors in the CHADS2 score. Given her age (>75 years is another point), her score would be at least 3, which meets the CHADS2 score criterion.\n- She presents with normal sinus rhythm on a 12-lead electrocardiogram, meeting the sinus rhythm criterion.\n- There is no mention of a Cardiac Implantable Electronic Device (CIED) in her patient note.\n\nWhile the patient meets three of the four inclusion criteria, the presence of a CIED is a specific requirement for participation that is not documented in the patient's history. As such, we cannot assume that she has a CIED. Therefore, she would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2440": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Ischemia Care Biomarkers of Acute Stroke Etiology (BASE).\"\n\nPatient Profile:\n- Age: 72 years old, meets the >18 years of age criterion.\n- Recent medical history: Hospitalized for cryptogenic stroke two weeks ago.\n- Imaging: CT negative for brain hemorrhage, meeting the criteria for ruling out hemorrhage, tumor, or other pathologies.\n- Treatment: Received thrombolytic therapy with symptom resolution, suggesting a likely ischemic stroke.\n- Current status: Stable vitals, no ongoing stroke symptoms mentioned.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients >18 years of age: The patient is 72, so this criterion is met.\n- Signs and symptoms suggestive of AIS or TIA: The patient had a cryptogenic stroke, which fits the criteria for signs and symptoms suggestive of AIS.\n- One of the following:\n  - BASE - Arrival within 18 hrs of symptom onset or last known normal time: This is not met as the patient had their stroke two weeks ago.\n  - BASE 24 - Arrival within 24 hours +/- 6 hours of symptom onset and clinical evidence suggesting AIS: This is also not met; the patient is past this time window.\n- Head CT or MRI ruling out other pathology: This is met as her CT was negative for other pathologies.\n- Informed consent obtained: This is not mentioned, but it is not a barrier at this point, as consent can be sought if the patient is otherwise eligible.\n\nThe key limiting factor here is the time window for presentation after the onset of stroke symptoms, which is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2441": {
        "output": "Given the information provided:\n\nPatient Note:\n- Karen is a 72-year-old woman with hypertension and type 2 diabetes.\n- She was hospitalized for cryptogenic stroke two weeks ago.\n- Her current blood pressure is 120/70 mm Hg.\n\nClinical Trial:\n- Title: Essential Hypotension and Allostasis Registry\n- Focus: Essential blood pressure disorders and allostasis\n- Inclusion Criteria: Any patient regardless of age or gender\n\nBased on the inclusion criteria of the clinical trial, which states that any patient regardless of age or gender can be included, Karen is eligible to participate in the Essential Hypotension and Allostasis Registry. Her current blood pressure and the recent hospitalization for stroke are relevant to the study's focus on blood pressure disorders.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "2442": {
        "output": "Based on the information provided:\n\nThe patient note describes a 72-year-old woman with hypertension and type 2 diabetes who had a cryptogenic stroke two weeks ago. She was treated with thrombolytic therapy and her current vitals are stable, with blood pressure at 120/70 mm Hg and normal glucose levels. The patient also has a history of occasional palpitations, shortness of breath, and chest pain.\n\nThe clinical trial in question is assessing the effects of low-dose prolonged administration of tissue type plasminogen activator (tPA) on patients with massive pulmonary embolism (PE).\n\nThe inclusion criteria for the trial are as follows:\n- Patients with massive PE\n- Aged 18 years or older\n- Confirmed PE with imaging documentation on computed tomography angiography\n- Presenting with signs of massive PE as defined in the criteria (sustained hypotension, pulselessness, or persistent profound bradycardia with signs or symptoms of shock)\n\nThe patient described in the note does not have a pulmonary embolism but rather had a stroke. There is no mention of her having PE or any symptoms or treatment related to PE. Therefore, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2443": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility of the patient:\n\nPatient Characteristics:\n- Age: 72 years old\n- Hypertension: Yes\n- Type 2 diabetes: Yes\n- Previous stroke (cryptogenic stroke two weeks ago): Yes\n- Currently with no evidence of atrial fibrillation on a 12-lead electrocardiogram\n\nClinical Trial Inclusion Criteria:\n- Age 70-90 years\n- Previously diagnosed with one or more of the following:\n  - Diabetes mellitus (type 1 or type 2, with or without medical therapy)\n  - Hypertension (with or without medical therapy)\n  - Heart failure\n  - Previous diagnosed stroke (previous transient ischemic attack is not considered an inclusion criterion)\n\nThe patient meets the age criterion (72 years old), has a history of hypertension and type 2 diabetes, and has been hospitalized for a stroke, which fits the inclusion criteria of the clinical trial. Although the patient has not been currently diagnosed with atrial fibrillation, the trial seems to aim at screening for AF in patients with risk factors for stroke, which the patient has.\n\nGiven this information, the patient appears to meet the inclusion criteria, and there is no mention of exclusion criteria that the patient would violate.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "2444": {
        "output": "Upon reviewing the patient note and the clinical trial criteria, we can determine the trial-level eligibility for Karen.\n\nKaren is a 72-year-old woman with a recent cryptogenic stroke, hypertension, and type 2 diabetes. There is no mention of permanent atrial fibrillation in her history. The symptoms she reports (occasional palpitations, shortness of breath, and chest pain) do not definitively diagnose her with atrial fibrillation, and even if she did have atrial fibrillation, there is no indication that it has been present for over 6 months, that it has been unsuitable for or failed ablation, or that she has been hospitalized for it in the previous year. Additionally, her current presentation includes normal sinus rhythm on a 12-lead electrocardiogram, which does not support the diagnosis of permanent atrial fibrillation.\n\nGiven the information provided, Karen does not meet the inclusion criteria for the clinical trial, which explicitly requires:\n\n1. Permanent atrial fibrillation (>6 months)\n2. Narrow QRS \u2264 110 ms\n3. Severely symptomatic (atrial fibrillation-related symptoms), refractory to drug therapy for rate control\n4. At least one hospitalization related to atrial fibrillation and/or heart failure in the previous year\n\nSince none of these criteria are met by the patient's current medical profile, Karen would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2445": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with a medical history of hypertension and type 2 diabetes. She was hospitalized for a cryptogenic stroke, and there is no mention of her being scheduled for a total hip replacement or having hip pain, which are part of the inclusion criteria for the clinical trial in question.\n\nThe clinical trial is specifically looking to prevent bedsores in patients who are candidates for total hip replacement. The inclusion criteria are:\n\n1. Age 60 years or older\n2. Both sexes\n3. Scheduled for total hip replacement\n\nSince the patient does not meet one of the key inclusion criteria\u2014being scheduled for a total hip replacement\u2014she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2446": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we need to determine whether Karen is eligible for the clinical trial.\n\nPatient note summary:\n- Karen is a 72-year-old woman.\n- She has hypertension and type 2 diabetes.\n- She was hospitalized for cryptogenic stroke two weeks ago.\n- She had a negative CT for brain hemorrhage.\n- She was given thrombolytic therapy with resolution of symptoms.\n- No evidence of abnormalities on transesophageal echocardiogram and MRA.\n- She presents with normal blood pressure, glucose, and sinus rhythm.\n- She reports occasional palpitations, shortness of breath, and chest pain.\n\nClinical trial inclusion criteria:\n- 80 or less years old patients with acute stroke produced by a main artery occlusion.\n- NIHSS score greater than 6.\n- Patients receiving EVT or IVT within 4.5 hours after onset.\n\nAnalysis:\n- Age: Karen is 72 years old, which fits within the age range of the criteria (<80 years).\n- Acute stroke: Karen had a cryptogenic stroke, but it was two weeks ago, which is outside the 4.5-hour window specified in the criteria.\n- NIHSS score: There is no mention of Karen's NIHSS score in the patient note, but she had a resolution of symptoms, suggesting it may not be greater than 6 at the time of assessment.\n- Treatment window: Karen received thrombolytic therapy two weeks ago, which is well beyond the 4.5-hour window after stroke onset required by the trial.\n\nGiven that Karen's stroke occurred two weeks prior and the trial focuses on treatment within 4.5 hours of stroke onset, she would not be eligible for this clinical trial that is testing treatments in the acute phase. There is also no information to suggest that she has severe neurological impairment as defined by an NIHSS score greater than 6.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2447": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- Karen is a 72-year-old woman with hypertension and type 2 diabetes.\n- Hospitalized for cryptogenic stroke two weeks ago.\n- CT negative for brain hemorrhage; given thrombolytic therapy with resolution of symptoms.\n- No evidence of abnormalities on transesophageal echocardiogram and magnetic resonance angiogram.\n- Reports occasional palpitations, shortness of breath, and chest pain.\n\nClinical Trial Inclusion Criteria:\n- Admitted with ischemic stroke at a single center.\n- Time from diagnosis to inclusion maximum 7 days.\n- Written informed consent or surrogate informed consent eligible.\n- Age > 18 years.\n\nKaren was hospitalized for a cryptogenic stroke two weeks ago, which exceeds the maximum time from diagnosis to inclusion for the clinical trial, which is 7 days. Therefore, based on the information provided, Karen would not be eligible for this clinical trial because she does not meet the time frame criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2448": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, here's the breakdown of the patient's eligibility:\n\nPatient Note:\n- 72-year-old woman with hypertension and type 2 diabetes.\n- Hospitalized for cryptogenic stroke two weeks ago.\n- Negative CT for brain hemorrhage at the time, received thrombolytic therapy.\n- Transesophageal echocardiogram and magnetic resonance angiogram showed no abnormalities.\n- Normal blood pressure, glucose, and sinus rhythm on a 12-lead electrocardiogram at the present.\n- History of occasional palpitations, shortness of breath, and chest pain.\n\nClinical Trial Inclusion Criteria:\n- Subjects with acute ischemic stroke presented within 7 days from symptom onset.\n- Subjects who had embolic infarction outside the perforator territory revealed by diffusion-weighted imaging.\n- Subjects with an undetermined cause of stroke despite an initial evaluation including electrocardiogram and brain imaging upon admission.\n- Subjects who performed brain MRI and MRA, cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline, and 24-hour Holter and/or telemonitoring).\n- Subjects with informed consent.\n\nBased on the provided information:\n\n- The patient had a stroke two weeks ago, which exceeds the 7-day window specified in the inclusion criteria.\n- There is no mention of diffusion-weighted imaging or the territory of the stroke, so we cannot confirm this criterion.\n- The cause of the stroke was not determined despite initial evaluation, which aligns with the inclusion criteria.\n- The patient has undergone some of the required work-ups (brain MRI, MRA, electrocardiogram, and transesophageal echocardiogram), but there's no mention of a 24-hour Holter or telemonitoring, or the use of agitated saline for echocardiography.\n- The patient's ability to give informed consent is not mentioned, but we can assume this ability unless otherwise specified.\n\nThe key exclusionary factor here is the time since symptom onset, which is beyond the 7-day window required by the trial. Thus, the patient does not meet all the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2449": {
        "output": "Based on the patient note provided for Karen and the inclusion criteria of the clinical trial titled \"Safe Implementation of Thrombolysis in Stroke - Monitoring Study,\" let's compare the relevant points:\n\nPatient Note:\n- Karen is a 72-year-old woman, which fits within the age range of 18 - 80 years required by the trial.\n- She has a history of hypertension and type 2 diabetes.\n- She was hospitalized for cryptogenic stroke two weeks ago, treated with thrombolytic therapy, and her symptoms resolved.\n- Her current health status includes normal blood pressure, glucose levels, and sinus rhythm.\n- She reports no current neurological deficits.\n\nClinical Trial Inclusion Criteria:\n- Female or male in-patient (Karen is female and was an in-patient when she had a stroke).\n- Age 18 - 80 years (Karen is 72 years old).\n- Clinical diagnosis of ischemic stroke causing a measurable neurological deficit (Karen had a cryptogenic stroke, which is not necessarily ischemic and currently does not seem to have any measurable neurological deficit).\n- Onset of symptoms within 3 hours prior to initiation of thrombolysis treatment (Karen's stroke was two weeks ago, and she already received thrombolysis).\n- Stroke symptoms present for at least 30 minutes that had not significantly improved before treatment (Karen's symptoms resolved after treatment).\n- Patients are willing to receive thrombolysis treatment and to give informed consent (Karen has already received thrombolysis treatment, so this is not applicable anymore).\n- Willingness and ability to comply with the study protocol (There is no information on Karen's willingness or ability to comply with a study protocol, but this is moot as her stroke was two weeks prior and she has already been treated).\n\nKaren does not currently have a measurable neurological deficit due to her previous stroke, and the onset of her stroke symptoms was not within 3 hours prior to potential initiation of thrombolysis treatment since her stroke was two weeks ago and she already received treatment. The trial is focused on the acute treatment phase of stroke with alteplase, whereas Karen is in the post-acute phase. Therefore, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2450": {
        "output": "In reviewing the patient's eligibility for the clinical trial titled \"Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke,\" let's consider the inclusion criteria provided:\n\n1. Patients with a recent ischemic stroke or transient ischemic attack (TIA) with brain infarction on brain imaging.\n   - Karen had a cryptogenic stroke, which aligns with having had a recent ischemic stroke.\n\n2. No history of atrial fibrillation or finding of atrial fibrillation on standard inpatient monitoring (electrocardiogram, telemetry, 24-hour Holter monitor)\n   - The patient note does not mention a history of atrial fibrillation or findings of it on monitoring.\n\n3. Have a presumed stroke etiology: [List of possible etiologies]\n   - The patient's stroke is described as cryptogenic, meaning no etiology was found, so this criterion is not explicitly met.\n\n4. Have virtual CHADS2 score \u22653 or Have 2 or more of the following co-morbidities: [List of co-morbidities]\n   - The patient note does not provide enough information to calculate the CHADS2 score or confirm the presence of the listed co-morbidities, except for hypertension.\n\n5. Patient or legally authorized representative who is willing to sign written consent form.\n   - Willingness to consent can not be determined from the patient note.\n\n6. Patient is \u226540 years old\n   - Karen is 72 years old, which meets this criterion.\n\n7. Patient can have the device implanted within 7 days of the incident ischemic event\n   - Since Karen was hospitalized for her stroke two weeks ago, this criterion is not met.\n\nBased on the information available, Karen meets some of the inclusion criteria: she is over 40 years old and had a recent ischemic stroke. However, there are key pieces of information missing that are necessary to definitively assess her eligibility (e.g., CHADS2 score, consent, exact stroke etiology, and the timing for device implantation). \n\nGiven this information, I would consider referring Karen for the clinical trial upon further investigation to clarify the missing information and confirm her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2451": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman who has a history of hypertension and type 2 diabetes and was recently hospitalized for a cryptogenic stroke. She does not currently present symptoms indicative of acute myocardial infarction, and her recent medical history does not mention ischemic cardiac pain of the duration specified in the inclusion criteria of the trial.\n\nThe clinical trial in question is focused on pre-hospital treatment of acute myocardial infarction (AMI) using thrombolysis with alteplase (Actilyse\u00ae) in patients who have experienced ischemic cardiac pain for more than 20 minutes but less than 6 hours. Karen does not fit the criteria as there is no mention of her experiencing ischemic cardiac pain within the specified timeframe or seeking treatment for AMI.\n\nFurthermore, Karen exceeds the age limit of 80 years set by the trial's inclusion criteria. Given that the primary inclusion criteria are not met, Karen would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2452": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, the patient, Karen, does not appear to meet the specific inclusion criteria outlined for the study. The clinical trial is focused on evaluating the association between new onset postoperative atrial fibrillation (POAF) and late cardiovascular morbidity and mortality. The inclusion criteria specifically mention patients who have had a previous cardiac operation, such as coronary artery bypass grafting (CABG) or aortic valve replacement (AVR).\n\nKaren's medical history, as described in the patient note, includes hypertension, type 2 diabetes, and a recent cryptogenic stroke for which she received thrombolytic therapy. There is no mention of her having undergone a cardiac operation, such as CABG or AVR, nor is there any indication of postoperative atrial fibrillation. Her current presentation includes normal blood pressure, normal glucose levels, and normal sinus rhythm on the electrocardiogram, with a history of occasional palpitations, shortness of breath, and chest pain that resolves spontaneously.\n\nSince Karen does not meet the key inclusion criterion of having had a previous cardiac operation, she would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2453": {
        "output": "Based on the patient note, Karen is a 72-year-old woman with hypertension and type 2 diabetes, which makes her eligible under the inclusion criterion of having type 2 diabetes mellitus. The inclusion criteria for the clinical trial specify that patients with type 2 diabetes mellitus are eligible if they are taking drugs for diabetes or meet the American Diabetes Association criteria for diagnosis.\n\nAdditionally, the trial is investigating sarcopenia (non-severe) in relation to glucose metabolism and inflammation. However, there's no indication that Karen has been diagnosed with sarcopenia or that she meets the criteria for this condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP). Moreover, the trial includes healthy volunteers without diabetes or sarcopenia, but Karen's history of hypertension and type 2 diabetes excludes her from this group.\n\nSince the clinical trial is also looking for healthy volunteers and Karen does not fulfill any of the exclusion criteria based on the information provided, she could potentially be considered for the study. However, more information on her muscle mass/function and physical performance would be necessary to fully assess her eligibility under the sarcopenic criteria or as a healthy volunteer.\n\nBased on the above, the assessment of Karen's eligibility for the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2454": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Post-Embolic Rhythm Detection With Implantable Versus External Monitoring,\" we need to analyze the patient note against the inclusion criteria provided.\n\nHere are the inclusion criteria for the trial:\n1. Diagnosis of the index event* made by a stroke specialist of an acute ischemic stroke or TIA occurring within the previous 90 days. The event must be either:\n   - an arterial ischemic stroke confirmed by neuroimaging; or\n   - transient ischemic attack with diffusion weighted positive lesion on MRI\n2. At least one 12-lead ECG has already been obtained as part of the routine clinical post-stroke/TIA work-up, and no ECGs have shown any episodes of atrial fibrillation or atrial flutter\n3. The patient is being actively investigated for the etiology of the stroke/TIA event and additional cardiac monitoring is desired to screen further for the possibility of occult paroxysmal atrial fibrillation/flutter\n4. Age 18 years or older\n5. Informed consent from the patient\n6. The patient is expected to survive at least 6 months.\n\nNow let's examine the patient's information:\n- Karen is a 72-year-old woman, which satisfies the age criterion.\n- She was hospitalized for a cryptogenic stroke two weeks ago, which falls within the 90-day window.\n- The stroke was confirmed by neuroimaging (CT) as negative for brain hemorrhage, and she was given thrombolytic therapy with resolution of her symptoms.\n- A transesophageal echocardiogram and magnetic resonance angiogram found no evidence of abnormalities, which does not exclude the patient from the study.\n- She presents with normal sinus rhythm on a 12-lead electrocardiogram, with no mention of atrial fibrillation or atrial flutter being detected.\n- She reports a history of occasional palpitations, which could be related to an underlying rhythm disorder like PAF.\n- There is no mention of her not being expected to survive at least 6 months, so we can assume she meets this criterion.\n- It is not explicitly stated that she has given informed consent, but we can assume that she would be able to give consent if she meets all other criteria.\n\nThe patient appears to meet all the necessary inclusion criteria. However, the criteria specify that the stroke needs to be confirmed by neuroimaging as an arterial ischemic stroke or a TIA with a diffusion-weighted positive lesion on MRI. The patient note does not provide enough information to definitively confirm that the stroke was arterial and ischemic based on MRI findings, which is a key inclusion criterion for the study.\n\nBased on the available information, we can infer that Karen may potentially be eligible for the study, but further investigation would be necessary to confirm the specific nature of her stroke as required by the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2455": {
        "output": "To determine the trial-level eligibility for Karen, we need to compare her patient note to the inclusion criteria of the clinical trial for the Mobile Diabetes Management Study with Type 2 Diabetes.\n\nThe inclusion criteria for the trial are:\n1. 20-80 years of age\n2. Type 2 diabetes patients (who have taken stably oral diabetic drugs or insulin, and been doing lifestyle improvement by doctor's advice for recent over 3 months)\n3. In case insulin treated, patients with basal insulin once a day or premixed insulin twice a day\n4. HbA1c between 7.0% and 10.0%\n5. Ability to understand and use smartphone application\n\nFrom the patient note:\n- Karen is a 72-year-old woman, which meets the age criterion.\n- She has type 2 diabetes, meeting the second criterion.\n- There is no mention of her specific diabetes treatment regimen, so it is uncertain whether she meets the third criterion.\n- Her HbA1c value is not provided in the patient note, so it is uncertain whether she meets the fourth criterion.\n- There is no indication of her ability to understand and use a smartphone application, so it is unclear whether she meets the fifth criterion.\n\nSince there is insufficient information about her diabetes treatment regimen, HbA1c levels, and ability to use a smartphone application, further investigation would be needed to determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2456": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial:\n\nInclusion Criteria for the trial:\n1. Age 18-80 years\n2. Have documented AF episodes\n3. The occurrence of ischemic stroke, TIA, or systemic thromboembolism at least one month before enrollment\n4. Capable of understanding and signing the CRF (Consent Form)\n\nPatient's characteristics:\n- Age: 72 years old\n- Documented AF episodes: The patient reports a history of occasional palpitations, which could be suggestive of AF episodes, but no documentation of atrial fibrillation (AF) is mentioned in the provided patient note.\n- Occurrence of ischemic stroke: The patient was hospitalized for a cryptogenic stroke two weeks ago.\n- Ability to understand and sign the CRF: There is no information suggesting that the patient is incapable of understanding and signing the consent form.\n\nBased on the information given in the patient note, the patient meets the age criterion and has had a recent ischemic stroke, which are both in line with the inclusion criteria. However, there is no explicit mention of documented atrial fibrillation (AF) episodes, which is a critical criterion for the study. The patient's history of palpitations might suggest undiagnosed or undocumented AF, but without confirmation of documented AF episodes, we cannot fully establish eligibility.\n\nGiven this uncertainty, further investigation would be necessary to confirm whether the patient has documented AF episodes. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2457": {
        "output": "Based on the provided patient note, Karen is a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for a cryptogenic stroke. She does not fit the inclusion criteria of the clinical trial, which are specifically tailored for resident physicians who have completed at least one month of cardiac rotation and are participating in a high fidelity simulation lab course as part of their educational activity.\n\nThe clinical trial is not a treatment or intervention study for patients with medical conditions; it is an educational activity geared towards resident physicians to improve their skills in cardiac-specific anesthesia scenarios.\n\nSince Karen is not a resident physician and the clinical trial is not designed to include patients for treatment purposes, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2458": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, it appears that Karen, the patient in question, has a history of hypertension, type 2 diabetes, and a recent cryptogenic stroke, but there is no mention of her having atrial fibrillation. The clinical trial is specifically looking to recruit patients who have agreed to undergo the hybrid ablation procedure because of atrial fibrillation.\n\nKaren has reported occasional palpitations, shortness of breath, and chest pain, which could be symptoms related to atrial fibrillation; however, there is no clear diagnosis of atrial fibrillation in her history. Without a confirmed diagnosis or mention of atrial fibrillation, we cannot confidently say that she would be eligible for the hybrid ablation registry trial that focuses on patients with atrial fibrillation.\n\nGiven this information, and assuming no atrial fibrillation has been diagnosed, I would not refer Karen for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2459": {
        "output": "Based on the patient note provided, Karen is a 72-year-old woman with a history of hypertension, type 2 diabetes, and a recent cryptogenic stroke. She has experienced occasional palpitations, shortness of breath, and chest pain but there is no mention of her being diagnosed with non-valvular atrial fibrillation (NVAF) nor any information about her being on anticoagulant therapy, let alone having changed her anticoagulant therapy to a direct oral anticoagulant (DOAC) within the past three months.\n\nThe clinical trial's inclusion criteria specifically require patients to have a diagnosis of non-valvular atrial fibrillation with a risk of stroke or systemic embolism, to be on regular treatment with anticoagulants, to have changed their therapeutic regimen to a DOAC at least three months prior to recruitment, and to have their first DOAC prescription written by a specialist.\n\nSince the patient note does not confirm that Karen meets any of these specific criteria, particularly the diagnosis of NVAF and treatment with a DOAC after a change in anticoagulant therapy, she does not appear to be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2460": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- Karen is a 72-year-old woman.\n- Has hypertension and type 2 diabetes.\n- Was hospitalized for cryptogenic stroke two weeks ago.\n- No evidence of atrial fibrillation (AF) at the time of the stroke.\n- Presents with normal blood pressure, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram.\n- Reports history of occasional palpitations, shortness of breath, and chest pain.\n\nClinical Trial Inclusion Criteria Summary:\n- Outpatients aged 60 years and older.\n- Diagnosed with arterial hypertension.\n- Decision to perform electrocardiography testing at the study visit as per routine practice.\n- Available medical records.\n- Written signed and dated informed consent.\n\nBased on the information provided, Karen meets the following criteria for inclusion in the study:\n- She is over 60 years old.\n- She has been diagnosed with arterial hypertension.\n- She has undergone a 12-lead electrocardiogram, which could be part of routine practice, although it's not explicitly stated that it was performed as part of routine practice.\n- It is reasonable to assume she has available medical records.\n- If she provides written signed and dated informed consent, she would meet this criterion as well.\n\nThere are no indications that Karen has any of the exclusion criteria:\n- There is no mention of her being a non-native speaker or not understanding the local language.\n- No indication of failure to cooperate due to major psychiatric disturbances, dementia, or substance use disorder.\n- No information about her participating in any investigational program or receiving investigational products prior to enrollment.\n\nSince Karen meets the age and diagnosis criteria and there is no evidence of exclusion criteria based on the information provided, I would consider referring her to this clinical trial upon further investigation to confirm routine practice for ECG testing and to obtain her consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2461": {
        "output": "",
        "label": 0
    },
    "2462": {
        "output": "Based on the provided information, the patient is a 4-year-old boy with a presentation of wheezing and a history of allergic rhinitis, but no previous history of wheezing. The clinical trial in question is focused on adult asthma, evaluating current therapies, new therapies, and management strategies for adult asthma.\n\nGiven that the inclusion criteria for the Asthma Clinical Research Network (ACRN) study specify patients with asthma and indicate that specific eligibility criteria vary for each study, it is important to note that the patient in question does not meet the age requirement as he is only 4 years old and the study targets adults. Additionally, the patient does not have a confirmed diagnosis of asthma, as this is his first episode of wheezing with no prior history of the condition.\n\nTherefore, this patient would not be eligible for referral to the Asthma Clinical Research Network (ACRN) based on the provided inclusion criteria and patient information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2463": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial for the effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia, we can determine the patient's eligibility as follows:\n\nPatient Note:\n- 4-year-old boy\n- No history of sickle cell anemia mentioned, only wheezing and allergic rhinitis\n- Currently presenting with wheezing after playing in a sandbox\n\nClinical Trial Inclusion Criteria:\n- Males or females 18 to 65 years of age\n- Diagnosis of sickle cell disease (electrophoretic documentation of SS homozygosity is required) or identification as a normal volunteer\n- Hematocrit greater than 18% (with an absolute reticulocyte count greater than 100,000/ml)\n\nThe patient in the note is a 4-year-old boy, which immediately disqualifies him based on the age criterion of the clinical trial, which requires participants to be between 18 and 65 years of age. Furthermore, there is no indication in the patient note that the boy has sickle cell disease, which is a requirement for the trial.\n\nBased on the provided information, the patient does not meet the inclusion criteria of the clinical trial. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2464": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question is a 4-year-old boy who presents with wheezing and has a history of allergic rhinitis. The clinical trial is looking for normal volunteers above the age of 18 years old who are healthy and capable of giving informed consent.\n\nThe inclusion criteria for the clinical trial clearly state that participants must be above the age of 18 years old. Since the patient is only 4 years old, he does not meet the age requirement for the study. Therefore, it is not appropriate to refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2465": {
        "output": "Based on the patient note and the clinical trial information provided, it is clear that the patient does not meet the inclusion criteria for the clinical trial:\n\n- The patient is a 4-year-old boy, whereas the inclusion criteria specify that participants must be healthy normal volunteers above the age of 18.\n- The patient has a history of allergic rhinitis and presents with wheezing, which could be indicative of a chronic respiratory illness (asthma is mentioned as an exclusion criterion). Even though the patient has no previous history of wheezing, the presence of wheezing could be a concern for a trial focused on healthy volunteers.\n\nGiven these points, the patient is not eligible to participate in the clinical trial that is investigating the role of prostaglandins in the regulation of brain blood flow.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2466": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let us compare the factors:\n\nPatient note:\n- The patient is a 4-year-old boy.\n- Presents with wheezing (no previous history of wheezing).\n- History of allergic rhinitis.\n- Wheezing heard in the mid-right chest area.\n- No mention of current use of inhaled beta-2-agonists or steroid inhaler therapy.\n- No mention of the use of products containing magnesium.\n- No mention of concurrent pulmonary diseases or medical diagnoses.\n- Not applicable regarding pregnancy or lactation.\n\nClinical trial inclusion criteria:\n- Mild to moderate persistent asthma (per NAEPP 1997 revised guidelines).\n- Current use of inhaled beta-2-agonists or steroid inhaler therapy only.\n- No use of products containing more than 50 mg Mg daily in the last 3 months.\n- No current use of certain asthma-related medications.\n- Nonsmoker.\n- No concurrent pulmonary disease or other specified medical diagnoses.\n- Not pregnant or lactating.\n- No mention of age restrictions in the inclusion criteria provided.\n\nAssessment:\n- The patient is 4 years old, which does not exclude him based on the criteria provided.\n- The patient presents with wheezing for the first time, and there is no mention of a diagnosis of asthma, let alone mild to moderate persistent asthma.\n- There is no mention of the patient's current use of asthma-related medications, which is a requirement in the inclusion criteria.\n- Due to the lack of information on the patient's medication use and the fact that the patient does not have a diagnosis of mild to moderate persistent asthma, we cannot assume that he fits the criteria for this trial.\n- Other criteria such as nonsmoker status and no concurrent diseases would not exclude the patient, but these are less relevant given the primary issues.\n\nGiven this information, the patient does not meet the key inclusion criteria of having a diagnosis of mild to moderate persistent asthma and being on a specific regimen of asthma-related medications. Therefore, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2467": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, the following points are considered:\n\nPatient Information:\n- Age: 4 years old\n- Symptoms: Wheezing, history of allergic rhinitis\n- No documented history of asthma\n- No mention of smoking status\n- No mention of positive allergy testing\n\nClinical Trial Inclusion Criteria:\n- Non-smoker\n- A 2-year documented history of seasonal allergic rhinitis\n- A 1-year documented history of chronic asthma\n- Positive allergy testing\n\nThe patient does not meet several key inclusion criteria for the clinical trial. Specifically, the patient's age does not align with the typical age group expected to have a 2-year documented history of seasonal allergic rhinitis or a 1-year documented history of chronic asthma. Additionally, there is no information provided about asthma or positive allergy testing in the patient's history.\n\nGiven this information, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2468": {
        "output": "",
        "label": 0
    },
    "2469": {
        "output": "",
        "label": 0
    },
    "2470": {
        "output": "",
        "label": 1
    },
    "2471": {
        "output": "Based on the information provided, the patient in question is a 4-year-old boy who presents with wheezing and has a history of allergic rhinitis. He does not have a history of asthma, but his current symptoms are relevant to respiratory concerns.\n\nThe clinical trial titled \"HealthSpark 2: Improving Asthma Care for Preschool Children\" is looking to enroll children ages 1 - 5 years who are enrolled in one of the designated SPARK child care centers. The study is focused on improving asthma care, and while the patient has wheezing, there is no clear indication that he has been diagnosed with asthma or that he is enrolled in one of the designated SPARK child care centers.\n\nGiven that the inclusion criteria specifically mention enrollment in one of the SPARK child care centers, and there is no information provided about the patient's enrollment in such a center, we cannot assume that the patient is eligible for this trial based on the information given. Additionally, without a diagnosis of asthma, the relevance of the trial to the patient's current medical issue is not established.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria as specified for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2472": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can make the following observations:\n\nPatient Characteristics:\n- 4-year-old boy\n- History of allergic rhinitis\n- No history of wheezing prior to this episode\n- Wheezing after playing in the sandbox\n- O2 sats 100% on room air\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with eczema (atopic dermatitis)\n- Family history of eczema, allergic rhinitis, or asthma\n- Allergy to one or more of the following: egg white, cow's milk, peanut, or soybean\n- Weigh at least 9.5 kg (20.9 lbs)\n- Parent or guardian willing to provide informed consent\n\nThe patient has a history of allergic rhinitis, which matches one of the family history criteria in the trial. However, there is no mention of the patient having eczema, a specific allergy to egg white, cow's milk, peanut, or soybean, or his weight. Also, the patient's age is appropriate, and the parent brought him to the emergency room, suggesting a willingness to seek medical care, which could imply a potential willingness to provide informed consent.\n\nSince the patient does have a history of allergic rhinitis but there is no information about a diagnosis of eczema, specific allergies, or weight, we would need more information to determine if he meets all the inclusion criteria for the trial. Therefore, the appropriate action is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2473": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 4-year-old boy\n- History of allergic rhinitis\n- No prior history of wheezing\n- Recent episode of coughing and wheezing after playing in the sandbox\n- Playful and well-appearing on examination\n- Wheezing heard in the mid-right chest area\n- O2 sats are 100% on room air\n\nClinical Trial Inclusion Criteria:\n- Asthma diagnosis\n- Receives asthma care at a clinic in Western Washington\n- Has access to the internet at home\n\nAssessment:\n- The patient note does not confirm the diagnosis of asthma; rather, it describes a single episode of wheezing in a child with a history of allergic rhinitis. A diagnosis of asthma typically requires recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.\n- There is no information about whether the patient receives care at a clinic in Western Washington.\n- There is no mention of the patient's access to the internet at home.\n\nGiven the lack of a confirmed asthma diagnosis and insufficient information on the other two criteria, we cannot assume this child would be eligible for the clinical trial based on the information provided. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2474": {
        "output": "To assess the eligibility of the 4-year-old boy for the clinical trial titled \"Children With Asthma in New Orleans After Hurricane Katrina,\" we need to review both the patient's history and the trial's inclusion and exclusion criteria.\n\nPatient Note Review:\n- The patient is a 4-year-old boy, which fits the age criterion of 4 to 12 years old.\n- The patient presents with wheezing but does not have a previous diagnosis of asthma; instead, he has a history of allergic rhinitis.\n- There is no mention of persistent asthma symptoms or evidence of uncontrolled disease as defined by the trial's criteria.\n- The patient has not been reported to be on long-term asthma control therapy.\n- There is no information on any previous asthma-related ED visits, hospitalizations, or use of oral corticosteroids.\n- The patient's mother brought him to the ED due to concern about his breathing not returning to normal.\n\nClinical Trial Inclusion Criteria Review:\n- The child must be 4 to 12 years old and living in Orleans Parish or surrounding areas impacted by flooding.\n- The child must have been previously diagnosed with asthma by a healthcare provider and have symptoms consistent with persistent asthma or evidence of uncontrolled disease.\n- The child is currently receiving long-term asthma control therapy and meets the specific criteria for persistent or uncontrolled asthma, or is not on long-term asthma control therapy but meets the criteria for persistent asthma and evidence of uncontrolled disease.\n\nBased on the information provided in the patient note, the boy does not have a diagnosis of asthma, which is a requirement for inclusion in the study. He also does not meet the specific criteria for persistent asthma or evidence of uncontrolled disease as he has no history of unscheduled visits, hospitalizations, or corticosteroid use for asthma. Therefore, he does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2475": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"China Case Control Avian Influenza,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nPatient characteristics:\n- Age: 4 years old\n- Symptoms: Wheezing, history of allergic rhinitis, no previous history of wheezing\n- Current condition: Audible wheezing in mid-right chest area, O2 sats are 100% on room air\n\nClinical trial inclusion criteria:\n- Informed consent by parents or legal guardians (for children)\n- Child age range: older than 1 year\n- Definition of cases and controls: Tested positive for influenza A (H5N1) in a previous surveillance program (for cases) or have not tested positive and have no fever or respiratory symptoms (for controls)\n\nThe patient note provides information about a 4-year-old boy, which fits the age criterion of being older than 1 year. However, there is no mention of the child having been tested for influenza A (H5N1) or being part of a previous surveillance program, which are essential criteria for determining if the child can be a case or a control in this study.\n\nSince we do not have information about the child's influenza A (H5N1) status or any details suggesting he meets the definition for cases or controls beyond the age criterion, we cannot conclusively determine his eligibility. Therefore, further investigation would be necessary to determine if he fits the definition of cases or controls.\n\nGiven the information provided, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2476": {
        "output": "Based on the patient note provided, the patient is a 4-year-old boy presenting with wheezing and a history of allergic rhinitis, but without a previous history of wheezing. The clinical trial in question is focused on patients with mild persistent asthma and includes the following inclusion criteria:\n\n- Patient is male or female, 6-14 years of age with mild persistent asthma.\n- Patient has a history of the following symptoms: wheezing, chest tightness, cough, etc.\n- Patient has asthma diagnosed by a doctor.\n\nThe boy does not meet the age criterion for the trial, as he is only 4 years old and the trial requires participants to be between 6-14 years of age. Additionally, while he presents with wheezing, there is no mention of a formal asthma diagnosis by a doctor, which is another requirement for participation in the study.\n\nGiven that the patient does not meet the age requirement and does not have a confirmed diagnosis of asthma by a doctor, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2477": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient note:\n- A 4-year-old boy with wheezing and a history of allergic rhinitis\n- No previous history of wheezing\n- Symptoms started suddenly 5 hours prior to ED visit\n- Wheezing heard in the mid-right chest area\n- O2 sats are 100% on room air\n\nClinical trial inclusion criteria:\n- Male or female subjects \u2265 12 years\n- 2 year history of seasonal allergic rhinitis\n- Documented hypersensitivity to local seasonal allergens (grass pollen)\n- Documented pollen-induced asthma\n- Without acute ongoing exacerbation of asthma or allergic rhinitis\n- No continuous ongoing treatment for rhinitis or asthma\n\nNow comparing the patient note to the clinical trial inclusion criteria:\n\n- Age: The patient is 4 years old, which is below the minimum age requirement of 12 years for the clinical trial.\n- History of seasonal allergic rhinitis: The patient has a history of allergic rhinitis, but there is no information provided about the duration of the history (2 years required) or whether it is specifically seasonal.\n- Documented hypersensitivity to seasonal allergens (grass pollen): There is no information provided about documented hypersensitivity to grass pollen.\n- Documented pollen-induced asthma: There is no information on whether the patient's asthma is pollen-induced.\n- No acute ongoing exacerbation of asthma or allergic rhinitis: The patient is currently experiencing wheezing, which could be considered an acute ongoing exacerbation.\n- No continuous ongoing treatment for rhinitis or asthma: There is no information provided about ongoing treatment.\n\nThe patient does not meet the age criteria, which is a fundamental requirement for the clinical trial. Therefore, regardless of the other criteria, the patient would not be eligible for the clinical trial due to the age restriction.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2478": {
        "output": "Based on the provided information, the patient is a 4-year-old boy with an episode of wheezing after playing in a sandbox. The clinical trial in question is seeking healthy adult males or females aged between 18 and 50 years with specific criteria related to lung function and smoking history.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Healthy adult male or female aged between 18 and 50 years.\n- Body mass index within the range 19-29.9 kilograms/metre^2\n- Forced Expiratory Volume in 1 second (FEV1) >80% predicted and a FEV1/Forced Vital Capacity (FVC) ratio > 0.7\n- Specific increases in sGaw after administration of salbutamol and ipratropium bromide\n- Non-smokers with a pack history of < 10 pack years.\n\nThe patient note describes a 4-year-old boy, which immediately disqualifies him based on the age criteria. Additionally, the boy has a history of allergic rhinitis and a recent episode of wheezing, which could suggest a history of respiratory disease, potentially disqualifying him based on the exclusion criteria for history of respiratory disease.\n\nTherefore, the patient is not eligible for the clinical trial based on both age and medical history. The assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2479": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- A 4-year-old boy\n- History of allergic rhinitis\n- Presenting with wheezing for the first time\n- No history of asthma mentioned\n\nClinical trial inclusion criteria:\n- Patients between 6 and 17 years old\n- Patients with allergic rhinitis\n- The trial also includes witnesses between 6 and 17 years old without allergic rhinitis and asthma\n\nThe patient in question does not meet the age criterion for the clinical trial, as he is only 4 years old, and the trial specifies inclusion of patients between the ages of 6 and 17 years old. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2480": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the clinical trial titled \"Using the Telephone to Improve Care in Childhood Asthma,\" we can determine the eligibility of the patient as follows:\n\n**Patient Note Summary:**\n- Patient: 4-year-old boy\n- Presenting with: Wheezing for the first time, history of allergic rhinitis, no previous history of wheezing\n- Current episode: Started 5 hours prior to ER visit, post playing in a sandbox\n- Clinical findings: Wheezing heard in the mid-right chest area, O2 sats are 100% on room air\n- Other: Child is playful and well appearing\n\n**Clinical Trial Inclusion Criteria Summary:**\n- Age: 5 to 12 years old\n- Diagnosis: Physician diagnosis of asthma for at least a year\n- Asthma exacerbation history: At least one acute exacerbation in past 12 months requiring emergency care, hospitalization, or an unscheduled office visit and/or a course of oral steroids\n- Medication: Taking daily controller medications or symptoms consistent with persistent asthma\n\n**Eligibility Assessment:**\n- Age: The patient is 4 years old, which is below the trial's age range of 5 to 12 years.\n- Diagnosis: There is no indication of a physician's diagnosis of asthma for at least a year; the patient is presenting with wheezing for the first time.\n- Asthma exacerbation history: There is no mention of any previous acute exacerbation of asthma.\n- Medication: There is no mention of the child taking daily controller medications or showing symptoms consistent with persistent asthma.\n\nBased on these points, the patient does not meet several key inclusion criteria of the clinical trial. The patient's age is below the specified range, there is no established history of asthma, nor is there any mention of previous acute asthma exacerbations or use of controller medications.\n\n**Trial-level eligibility: 0) Would not refer this patient for this clinical trial.**",
        "label": 0
    },
    "2481": {
        "output": "Based on the information provided, the patient note describes a 4-year-old boy with a history of allergic rhinitis and a new onset of wheezing. The clinical trial in question is studying the effect of Montelukast on basophils in individuals with allergic asthma or allergic rhinitis. \n\nInclusion criteria for the clinical trial are:\n1. Allergic asthma or allergic rhinitis\n2. Age 12+\n\nThe patient does have a history of allergic rhinitis, which meets one aspect of the inclusion criteria. However, the patient is only 4 years old, which does not meet the age criterion of the trial (age 12+).\n\nTherefore, the patient is not eligible for the clinical trial based on the age requirement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2482": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient appears to be eligible for the study. The key points from the patient note are:\n\n- The patient is a 4-year-old boy.\n- He presents with wheezing.\n- No previous history of wheezing but has had allergic rhinitis.\n- The symptoms started after playing in a sandbox.\n\nThe inclusion criteria for the clinical trial are:\n\n- Patient and/or parents/guardian signed informed consent.\n- Patients with cough or shortness of breath.\n\nThe patient has wheezing, which can be associated with shortness of breath and is a form of respiratory symptom. Since the patient is a minor, the parent or guardian's consent would be required for participation. There is no specific age limit mentioned in the inclusion criteria, and the wheezing symptom fits the criteria for cough or shortness of breath.\n\nTherefore, assuming the parent or guardian gives informed consent, the patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2483": {
        "output": "Considering the provided patient note and the inclusion criteria of the clinical trial, the eligibility of the patient can be assessed as follows:\n\nPatient Note:\n- 4 year old boy\n- History of allergic rhinitis, but no history of wheezing.\n- Sudden onset of coughing and wheezing after playing in the sandbox.\n- No previous wheezing episodes mentioned.\n\nClinical Trial Inclusion Criteria:\n- Age 3-23 months\n- Be delivered at >=37 weeks\n- First wheezing episode\n- Written informed consent from guardian\n\nThe patient is 4 years old, which is outside the age range specified by the clinical trial (3-23 months). Therefore, despite the fact that the patient is presenting with a first wheezing episode, he does not meet the age criterion for the trial. The rest of the inclusion criteria are not applicable due to the age mismatch.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2484": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note:\n- The patient is a 4-year-old boy.\n- He has a history of allergic rhinitis.\n- He presents with wheezing and a recent episode of coughing while playing in a sandbox.\n- No prior history of wheezing.\n- The mother reports that his breathing has not returned to normal.\n- Physical examination shows wheezing in the mid-right chest area.\n- O2 sats are 100% on room air.\n\nClinical Trial:\n- Title: Thoracic Computed Tomography Scan for Diagnosis of Aspirated Foreign Bodies.\n- Summary: To assess CT Scan as a diagnostic tool for foreign body aspiration.\n- Inclusion Criteria:\n  - Age between 6 months and 16 years.\n  - Suspicion of a foreign body aspiration.\n  - Health care assurance.\n  - Information of parents.\n\nAssessment:\n- Age: The patient is 4 years old, which falls within the specified age range of 6 months to 16 years.\n- Clinical Presentation: The recent onset of wheezing following coughing while playing in a sandbox raises suspicion of a foreign body aspiration, which meets the clinical trial's inclusion criteria.\n- Health Care Assurance: The patient note does not provide information regarding health care assurance. Assuming typical protocols, the patient in the emergency room would likely have some form of health care assurance or the hospital would ensure care in case of emergencies.\n- Parental Information: The patient's mother is present and concerned, indicating that parental information could be provided if needed.\n\nBased on the information provided, the patient fits the age criteria and presents with clinical symptoms that could suggest a foreign body aspiration, which is one of the criteria for inclusion in the clinical trial. While the health care assurance status is not explicitly stated, it is reasonable to infer that it could be obtained given the emergency room setting. Therefore, it is likely that this patient would be considered for referral to the clinical trial upon confirmation of health care assurance and obtaining informed consent from the parents.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2485": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 4-year-old boy\n- Presents with wheezing, no prior history of wheezing\n- History of allergic rhinitis\n- No mention of seasonal allergic rhinitis (SAR) or asthma diagnosis\n- Wheezing began after playing in the sandbox\n\nClinical trial inclusion criteria:\n- Children must be >= 6 to < 12 years of age\n- Diagnosis of seasonal allergic rhinitis (SAR) with or without intermittent asthma\n- Clinically symptomatic with SAR at Visit 1 (day 1)\n- Asthma symptoms will be evaluated, but only for children with concomitant asthma\n\nThe patient does not meet the age criterion as he is only 4 years old, and the trial requires children to be between 6 and 12 years of age. Additionally, there is no clear diagnosis of seasonal allergic rhinitis or asthma provided in the patient note. Therefore, based on the information given, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2486": {
        "output": "Comparing the patient note with the clinical trial inclusion criteria:\n\nPatient Note:\n- 4-year-old boy\n- History of allergic rhinitis\n- No history of wheezing before this incident\n- Audible wheezing after playing in the sandbox\n- O2 sats are 100% on room air\n\nClinical Trial Inclusion Criteria for Allergic Asthmatics:\n- History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.\n- Positive methacholine test.\n- FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours)\n- Allergic sensitization to at least one common allergen confirmed by positive allergy skin test (AST).\n\nThe patient is 4 years old, which is below the age specified in the inclusion criteria for allergic asthmatics (after age of 6 years). Additionally, there is no mention of a physician-diagnosed asthma or a positive methacholine test in the patient note. Even though the patient has a history of allergic rhinitis and is experiencing wheezing, there is no evidence of a previously diagnosed asthma condition or specific allergic sensitization confirmed by an allergy skin test.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial because he is under the age of 6, and there is no documentation of physician-diagnosed asthma or results from an allergy skin test.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2487": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 4 years old (meets the age criteria of > 3 and < 10 years)\n- Wheezing episode: First episode of wheezing, but no prior diagnosis of asthma\n- Emergency room visit: The patient is currently in the ED for wheezing\n- Location: The note does not specify if the patient resides in the Baltimore Metropolitan area\n- Not mentioned: No information on > 2 ED visits or > 1 hospitalization for asthma within the past 12 months\n- Not mentioned: No information on the frequency of asthma symptoms, rescue medication use, or nighttime symptoms\n- Not mentioned: No information on whether the patient is currently participating in another asthma study or if a sibling is enrolled in the PAAL study\n\nClinical Trial Inclusion Criteria:\n- Physician-diagnosed asthma\n- > 2 ED visits or > 1 hospitalization for asthma within the past 12 months\n- Mild persistent to severe persistent asthma based on NHLBI guidelines criteria\n- Age > 3 and < 10 years\n- Reside in Baltimore Metropolitan area\n- Not currently participating in another asthma study or sibling enrolled in PAAL study\n\nThe patient in the note is a 4-year-old boy, which fits the age range required by the trial. However, there is no physician diagnosis of asthma, no mention of previous ED visits or hospitalizations for asthma, no detailed asthma symptom frequency, and no information about the residency requirement or study participation. Thus, we cannot confirm that the patient meets the necessary criteria for the clinical trial.\n\nGiven the information provided, the patient does not currently meet all the inclusion criteria, particularly the requirement for a physician-diagnosed asthma and the history of ED visits or hospitalization for asthma. Therefore, the patient would likely not be referred for this clinical trial based on the information available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2488": {
        "output": "Based on the provided information, the patient note describes a 4-year-old boy with a recent episode of wheezing and a history of allergic rhinitis. He does not have a personal history of asthma or eczema as required by the study, but does have a history of allergic rhinitis. However, there is no information about the history of asthma, eczema, or allergic rhinitis in the biological father of the child. Additionally, the inclusion criteria for the clinical trial specify that the maternal vitamin D supplementation needs to occur between 10 and 18 weeks of gestational age, and the mother should be between 18 and 39 years old at the time of randomization.\n\nGiven that the patient is already 4 years old, the opportunity for maternal vitamin D supplementation during the specified gestational window is long past. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which are specifically designed for pregnant women within a certain gestational age window and require personal or familial history consistent with the study parameters.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2489": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the following:\n\nPatient characteristics: \n- A 4-year-old boy presenting with wheezing.\n- History of allergic rhinitis, but no history of wheezing.\n- Wheezing started suddenly while playing in a sandbox.\n- No indication that the patient has a clinical diagnosis of bronchial asthma.\n- Ability to swallow tablets is not mentioned.\n\nClinical trial inclusion criteria:\n- Clinical diagnosis of bronchial asthma.\n- Must be able to swallow tablets.\n\nThe patient does not have a documented clinical diagnosis of bronchial asthma; he is presenting with wheezing for the first time. Additionally, there is no information provided about the patient's ability to swallow tablets. While the presence of wheezing could warrant further investigation into the possibility of asthma, we cannot assume a diagnosis based on the information given. The trial specifically requires a clinical diagnosis of bronchial asthma.\n\nAs such, based on the available information, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2490": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 4-year-old boy with wheezing and a history of allergic rhinitis. No history of wheezing prior to the event described.\n- The wheezing started after the patient was playing in a sandbox.\n- The child is well appearing and playful despite the wheezing.\n\nClinical Trial:\n- Title: Avian Influenza Studies In Lebanon\n- Summary: Focus on seroprevalence of avian influenza in poultry-exposed and non-exposed human populations, identifying risk factors in poultry workers, and surveillance for avian influenza viruses.\n- Inclusion Criteria: Must be at least 18 years old, willing to participate by signing a consent form, completing a questionnaire, and providing a blood sample.\n\nThe patient does not meet the inclusion criteria for age, as the trial requires participants to be at least 18 years old. Additionally, there is no information provided in the patient note suggesting exposure to poultry or any occupation-related risk factors for avian influenza, which appear to be the focus of the clinical trial.\n\nTherefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2491": {
        "output": "Based on the provided patient note and clinical trial information, the patient is a 4-year-old boy presenting with wheezing and a history of allergic rhinitis. However, he has no prior history of wheezing. The clinical trial is assessing oxidative stress markers in atopic children treated with nebulized Beclomethasone, specifically targeting children with intermittent asthma and allergic rhinitis.\n\nThe patient's age fits the pediatric category, and he has allergic rhinitis, which aligns with the trial's inclusion criteria focusing on children with this condition. Although the patient does not have a previous history of wheezing, the current presentation with wheezing could suggest a new diagnosis of intermittent asthma, which is a common presentation in young children with allergic rhinitis.\n\nGiven that the patient's current symptoms may be indicative of the onset of intermittent asthma\u2014especially in the context of allergic rhinitis\u2014and that the trial is targeting children with both conditions, it seems appropriate to consider referring this patient to the clinical trial upon further confirmation of an asthma diagnosis.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2492": {
        "output": "The patient under consideration is a 4-year-old boy who presents with wheezing. According to the provided information, he has a history of allergic rhinitis but no prior history of wheezing. This is the first instance where wheezing has been observed, and it seems to have been triggered by an event while the child was playing.\n\nNow, let's compare this patient's information to the inclusion criteria of the clinical trial titled \"School-Based Preventive Asthma Care Technology\":\n\n1. Physician-diagnosed asthma (based on parent report).\n2. Persistent asthma (criteria based on NHLBI guidelines). Any 1 of the following:\n   - An average of >2 days per week with asthma symptoms\n   - >2 days per week with rescue medication use\n   - >2 days per month with nighttime symptoms\n   - \u22652 episodes of asthma during the past year that have required systemic corticosteroids\n3. Age \u22653 and \u226410 years.\n4. Attending school in participating Rochester City School District preschools or elementary schools.\n\nThe patient fulfills the age criterion (3 years old to 10 years old) and presumably attends school, which could potentially be within the qualifying school district. However, the patient does not have a physician-diagnosed asthma; the incident described seems to be an acute reaction, possibly an isolated event, rather than a chronic condition of persistent asthma as defined by the National Heart, Lung, and Blood Institute (NHLBI) guidelines.\n\nDue to the lack of a physician-diagnosed asthma and no evidence of persistent asthma as per the inclusion criteria, the patient does not seem to meet the necessary conditions for the clinical trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2493": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the 4-year-old boy would not be eligible for the clinical trial. The inclusion criteria specify that subjects must be over 18 years old and have allergic asthma and/or allergic rhinitis and are beginning allergen desensitization. Since the patient is only 4 years old, he does not meet the age requirement for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2494": {
        "output": "Based on the inclusion criteria provided for the clinical trial titled \"Salbutamol Tolerance Onset\" and the patient note for the 4-year-old boy with wheezing, we can determine the patient's eligibility for participation in the clinical trial.\n\nThe inclusion criteria for the trial are as follows:\n- Male or female\n- 18 to 65 years of age\n- Non-smoker\n- Beta agonist naive for at least 14 days\n- Baseline FEV1 at least 70% predicted\n- No respiratory tract infection or allergen exposure (if atopic) within 4 weeks of visit 1\n\nThe patient is a 4-year-old boy, which immediately disqualifies him based on the age criterion, as the trial requires participants to be between 18 and 65 years of age. None of the other criteria can be assessed because the age requirement is not met.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2495": {
        "output": "Assessing the provided patient note against the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- A 4-year-old boy with sudden onset wheezing, no previous history of wheezing, but a history of allergic rhinitis.\n- The episode occurred after playing in a sandbox.\n- He is well-appearing and playful, with wheezing localized to the mid-right chest area.\n- O2 saturation is 100% on room air.\n\nClinical Trial Inclusion Criteria Summary:\n- Male or female subjects with a history of mild atopic asthma.\n- Age between 18 and 60 years.\n- BMI between 18 and 35 kg/m^2.\n- Normal or clinically acceptable physical examination, laboratory values, and ECG.\n- History of mild atopic asthma acceptable.\n- Infrequent use of inhaled short-acting \u03b22-agonists to treat asthma.\n- No current exposure to allergens that cause asthmatic responses.\n- No other lung disease, asthma exacerbations, or lower respiratory infections within 6 weeks before screening.\n- Positive skin prick test to common aeroallergens at screening.\n\nThe patient in the note does not meet the following inclusion criteria:\n- Age: The patient is 4 years old, whereas the trial requires participants to be between 18 and 60 years old.\n- Diagnosis: The trial is for patients with mild atopic asthma, and while the child has a history of allergic rhinitis, there is no mention of an atopic asthma diagnosis.\n- Medication use: There is no information on the use of inhaled short-acting \u03b22-agonists, but it is unlikely to be applicable given the patient's age and sudden onset of symptoms.\n- Allergen exposure and skin prick test: No information is provided regarding these criteria.\n\nBased on the information provided and comparing it with the trial's inclusion criteria, the patient does not qualify for the clinical trial due to age and lack of a confirmed mild atopic asthma diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2496": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's analyze whether the patient is eligible for the clinical trial:\n\nPatient note:\n- 4-year-old boy\n- Presents with wheezing with no previous history of wheezing\n- History of allergic rhinitis\n- Currently not on any daily controller for asthma\n\nClinical trial inclusion criteria:\n- Females (6 to 9 years of age) and males (6 to 11 years of age)\n- History of physician diagnosed mild intermittent or mild persistent asthma\n- Height within normal limits (5th to 95th percentile)\n- Pre-pubertal (Tanner Stage 1 Sexual Maturity)\n- Subjects may be on current treatment with montelukast\n- Subjects must be willing to comply with study requirements\n\nThe patient does not meet the age criteria for the trial, as he is 4 years old and the trial requires male subjects to be between 6 to 11 years of age. Additionally, the patient does not have a documented history of asthma, which is a requirement for the trial. Therefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2497": {
        "output": "",
        "label": 0
    },
    "2498": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the inclusion criteria for several reasons:\n\n1. Age: The trial requires participants to be adolescents aged 12-17 years or adults aged 18-65 years. The patient is a 4-year-old boy.\n2. Severe Asthma: The trial is specifically for subjects with a documented clinical history of severe asthma requiring prednisone/prednisolone therapy. The patient note does not indicate a history of severe asthma; it mentions a single incident of wheezing after playing in the sandbox.\n\nTherefore, this patient does not meet the age requirement nor the condition-specific requirements for the clinical study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2499": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is evident that the patient does not meet several essential criteria for participation in the study:\n\n1. Age: The patient is a 4-year-old boy, but the trial requires subjects to be over the age of 18 for asthmatic subjects and over the age of 40 for COPD patients.\n2. Diagnosis: The trial is looking for patients with a clinical diagnosis of COPD or asthma with specific lung function criteria. The patient note only mentions a single incident of wheezing with no prior history of wheezing or any mention of a COPD or asthma diagnosis.\n3. Lung function: The inclusion criteria specify the need for airflow obstruction (FEV1/FVC<0.7) and other lung function metrics that have not been evaluated or mentioned in the patient's note.\n\nSince the patient does not meet the age requirement and there is no mention of a clinical diagnosis or lung function test results that align with the trial's inclusion criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2500": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- Age: 4 years old\n- Presents with wheezing, history of allergic rhinitis\n- No previous history of wheezing\n- Onset of symptoms occurred while playing in the backyard\n\nClinical Trial Inclusion Criteria:\n- Pediatric population: 6 months to 15 years of age\n- 2 or more episodes of croup in a 12-month period\n- Croup defined as acute onset inspiratory stridor, barking cough, with respiratory distress\n\nAssessment:\nThe patient's age (4 years old) falls within the trial's age range (6 months to 15 years of age). However, the patient does not have a history of croup, as they only present with wheezing and a history of allergic rhinitis. There is no mention of the patient having had two or more episodes of croup in the past 12 months or presenting with the specific symptoms of croup (inspiratory stridor, barking cough, respiratory distress).\n\nGiven the patient does not meet the criteria of having had two or more episodes of croup in the past 12 months and the symptoms described don't match the definition of croup provided by the clinical trial, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2501": {
        "output": "Based on the information provided:\n\nThe patient note describes a 4-year-old boy presenting with wheezing and a history of allergic rhinitis but no previous history of wheezing. The clinical trial in question is examining the effect of dietary intake of DHA and lutein on brain function in healthy children using fMRI.\n\nNow, let's assess the patient's eligibility based on the inclusion criteria specified for the clinical trial:\n\n1. The patient must be full-term and a single birth (no multiple births).\n2. The patient must not have had any major illness or surgery requiring hospitalization likely to impact the outcomes.\n3. The patient must not have any metabolic, congenital, or allergic disease that impacts food intakes.\n4. The parents must have sufficient command of the English language to complete the informed consent and study documents.\n5. The patient must fit into one of the specified dietary intake groups for DHA and lutein.\n\nThe patient note does not provide information on whether the child was full-term, a single birth, or has had any major illness or surgery. There is also no information regarding the parents' command of the English language or the child's dietary intake of DHA and lutein.\n\nHowever, there is one clear disqualifying factor: the patient is 4 years old, and the clinical trial does not specify an age range, but given the hypothesis mentions \"Children 6 years of age,\" it is implied that the trial is designed for children around that age. \n\nConsidering the lack of detailed information on the inclusion criteria and the fact that the child's age does not match the implied age range for the study, the assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2502": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 4-year-old boy does not meet several of the requirements for the study. The trial is specifically designed for COPD patients who are at least 50 years of age, and it appears to be focused on adults with diagnosed COPD at specific stages (II, III, IV).\n\nThe boy in the patient note has presented with wheezing and has a history of allergic rhinitis, but there is no mention of COPD, which is a condition typically not diagnosed in children. In addition, the boy is significantly younger than the required age for the study.\n\nTherefore, based on the information given, the boy is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2503": {
        "output": "",
        "label": 0
    },
    "2504": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient details:\n- Age: 4 years old\n- Presented to the emergency room with wheezing\n- History of allergic rhinitis\n- No prior history of wheezing\n- No mention of physician-diagnosed asthma\n\nClinical trial details:\n- Age range for the clinical trial: 1-17 years old\n- Must have physician-diagnosed asthma by parent report\n- The emergency department visit must be due to asthma\n- Attending physician must complete informed consent and be randomized to PACCI-ED or control group at the beginning of the study\n\nAssessment:\n- The patient falls within the age range of 1-17 years old.\n- However, there is no mention of the child having a physician-diagnosed asthma. The wheezing could be a result of another cause, such as a foreign body aspiration or a respiratory infection.\n- The attending physician has not determined that the emergency department visit is due to asthma. \n\nSince there is no clear indication that the child has physician-diagnosed asthma, which is a requirement for the study, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2505": {
        "output": "",
        "label": 0
    },
    "2506": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, we can determine the eligibility of the 4-year-old boy for the trial.\n\nPatient Note Key Points:\n- The patient is a 4-year-old boy.\n- He presents with wheezing and a history of allergic rhinitis but no previous wheezing.\n- The episode of wheezing occurred after playing in the sandbox.\n\nClinical Trial Inclusion Criteria:\n- Mother's age must be 14 and older and able to sign the Informed Consent Statement (ICS).\n- The mother of the child must have a physician diagnosis of asthma or be treated for asthma (for a subset of the study).\n- The child must be enrolled during the first week of life.\n- Signed informed consent from parent(s) or legal guardian(s).\n\nBased on the inclusion criteria, the 4-year-old boy would not be eligible for the clinical trial because he is not within the first week of life. The trial specifically requires the child to be enrolled during the first week of life, which is a clear criterion that the patient does not meet. Other criteria, such as the mother's asthma status, are not applicable since the age criteria is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2507": {
        "output": "",
        "label": 0
    },
    "2508": {
        "output": "Based on the information provided, the patient in question is a 4-year-old boy who presents to the emergency room with wheezing and a history of allergic rhinitis but no previous history of wheezing. The clinical trial is focused on the evaluation of pulmonary vascular disease using novel MRI techniques and is specifically assessing patients for possible pulmonary hypertension (PH).\n\nConsidering the inclusion criteria for the clinical trial, which states \"All cases referred to the clinic for assessment for possible pulmonary hypertension,\" there is no clear indication from the patient note that the child has pulmonary hypertension or is being assessed for PH. The child's main issue seems to be an acute episode of wheezing possibly related to an allergic reaction or an asthmatic episode.\n\nSince there is no mention of pulmonary hypertension or related symptoms in the patient's history, and the child's current condition doesn't directly align with the research focus of the trial, I would conclude that the patient is not an immediate fit for this clinical trial. However, if further assessment suggests the possibility of pulmonary hypertension, then the situation might change.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2509": {
        "output": "",
        "label": 0
    },
    "2510": {
        "output": "To assess the eligibility of the 4-year-old boy for the clinical trial on the Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma, let's go through the inclusion criteria provided for the trial:\n\n1. The written informed consent must be obtained from his/her parent or legally acceptable representative.\n2. Ethnic origin is Japanese.\n3. Aged >=6 months and <=4 years at Visit 1.\n4. Male and pre-menarchial female.\n5. Patient: outpatient.\n6. Diagnosis as a pediatric asthma has been made by reference to JPGL 2012.\n7. A patient who needs to be treated with ICS/LABA and fulfill certain conditions regarding exacerbations or regular treatment with ICS.\n\nNow, let's review the patient's information:\n\n- The patient is a 4-year-old boy, which meets the age criterion.\n- The patient presents with wheezing and has a history of allergic rhinitis, but no history of wheezing or asthma is mentioned.\n- It is not specified if the patient is Japanese or not.\n- The boy is currently an outpatient, which fits the trial's setting requirement.\n- There is no information on whether he has had a previous asthma diagnosis by JPGL 2012 or any recent exacerbations that would require ICS/LABA treatment.\n\nGiven the lack of information regarding the patient's ethnicity, previous diagnosis of pediatric asthma, and any previous treatments that meet the specific criteria for ICS/LABA usage, we cannot conclusively determine the boy's eligibility for the trial. Additionally, the mention of allergic rhinitis without a definitive asthma diagnosis suggests that the wheezing may not be due to asthma, which is the focus of the clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2511": {
        "output": "Based on the provided information, the patient is a 4-year-old boy with an episode of wheezing possibly related to allergic rhinitis, with no prior history of wheezing. The clinical trial in question is focused on patients aged 18 years or older with uncontrolled asthma on medium doses of inhaled corticosteroids plus long-acting beta2 agonists.\n\nThe patient does not meet the age criterion, as the inclusion criteria specifically state that participants must be 18 years of age or older. Additionally, there is no indication that the patient is on any asthma medication, let alone uncontrolled asthma on the specified treatment regimen. Therefore, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2512": {
        "output": "For the clinical trial titled \"Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm,\" the inclusion criteria are as follows:\n\n1. Male or female patients with a diagnosis of asthma according to the American Thoracic Society Criteria\n2. Patients aged 7 to 12 years inclusive\n3. Patients able to perform spirometry\n4. Patients with FEV1 (forced expiratory volume in the first second) \u2265 80% of predicted normal value after saline\n5. Patients with PD20 (provocative dose that reduces FEV1 by 20%) metacholine lower than 8 mg/ml\n6. Patients or responsible relatives willing and able to sign an informed consent form\n\nNow, let's compare the patient note with these criteria:\n\n- The patient is a 4-year-old boy, which does not meet the age criteria of 7 to 12 years.\n- The patient has a history of allergic rhinitis and is presenting with wheezing for the first time; there is no mention of a diagnosis of asthma.\n- It is not stated whether this patient is able to perform spirometry or the FEV1 status.\n- There is no information provided about the PD20 metacholine levels for this patient.\n- Even though the patient's responsible relative (mother) is present, their willingness and ability to sign an informed consent form is not mentioned.\n\nGiven the information from the patient note, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the patient's age and lack of an asthma diagnosis are clear disqualifiers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2513": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, it is clear that the patient does not meet the criteria for the COPD trial. The patient is a 4-year-old boy with wheezing and a history of allergic rhinitis, but no history of wheezing prior to this event. The clinical trial is specifically for patients with a diagnosis of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and/or emphysema. Furthermore, the trial is only for patients aged 40 years or older with a significant smoking history, neither of which applies to the patient in question.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2514": {
        "output": "To determine the trial-level eligibility for this clinical trial, let's evaluate the patient note based on the inclusion criteria provided:\n\n1. Boys or girls between 3 and 6 years old: The patient is a 4-year-old boy, which fits within the age range specified.\n2. Presenting to emergency departments with an acute asthmatic attack: The patient presents with wheezing, a symptom of an asthma attack, but there is no explicit diagnosis of asthma in the patient note.\n3. Requiring nebulised bronchodilator therapy: The patient's current treatment needs are not specified in the note, but he is in the emergency department with wheezing, suggesting a potential need for bronchodilator therapy.\n4. Rint increased by 200 % compared to theoretical Rint: There is no information provided on the patient's respiratory interrupter resistance (Rint), so this criterion cannot be assessed.\n5. Signed, informed consent obtained from the child's parents/legal guardian: Assuming that consent can be obtained, this criterion could be met.\n\nGiven the information provided, the patient appears to fit most of the inclusion criteria for the clinical trial. However, there is uncertainty regarding the diagnosis of an acute asthmatic attack and the specific requirement of Rint measurement. Therefore, further investigation is needed to confirm these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2515": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note:\n- The patient is a 4-year-old boy.\n- He presents with wheezing without a previous history of it, following an episode of coughing while playing in a sandbox.\n- He has a history of allergic rhinitis.\n\nClinical trial:\n- The trial is focused on nutrition education and household food production to improve child nutrition in Ethiopia.\n- The inclusion criteria specify that participants must be infants less than 12 months old, be permanent residents in the area, have no plans to move during the intervention period, be willing to adopt agriculture activities, and have adequate space and time for developed gardens and backyard poultry production.\n\nGiven that the patient in the note is a 4-year-old boy, he does not meet the age requirement for the clinical trial, which is specifically looking for infants less than 12 months old. Therefore, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2516": {
        "output": "To determine the trial-level eligibility of the 4-year-old boy for the CDC Medicaid Asthma Home Visit Project, we need to assess whether he meets the inclusion criteria based on the patient note provided and the inclusion criteria listed for the clinical trial.\n\nInclusion Criteria Checklist:\n1. Caretaker is age 18 or older and child is age 3-17: The child is 4 years old, so this criterion is met.\n2. Have not controlled asthma: The patient note indicates the child has a history of allergic rhinitis, but no history of wheezing, and this is the first instance of wheezing. There is no mention of asthma or its control status, so this is unclear from the provided information.\n3. Residence in King County: The patient note does not specify the residence, so this is unknown.\n4. Spoken language is English or Spanish: The patient note does not specify the language spoken, so this is unknown.\n5. Child is enrolled in a Medicaid managed care health plan offered by Community Health Plan of Washington (CHPW) or Molina Health Plan of Washington, Inc (Molina): The patient note does not mention the child's health plan, so this is unknown.\n\nBased on the patient note, the child's age falls within the required range for the clinical trial. However, the child's asthma control status, residence, spoken language, and Medicaid health plan enrollment are not specified. Without this information, we cannot determine with certainty if the child is eligible for the clinical trial. Therefore, further investigation is needed to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2517": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's consider the fit:\n\nPatient Note Analysis:\n- 4-year-old boy\n- Presents with wheezing, no prior history of wheezing\n- History of allergic rhinitis\n- Symptoms started 5 hours ago after playing in the sandbox\n- Currently well-appearing, playful, with wheezing in the mid-right chest area\n- O2 sats are 100% on room air\n\nClinical Trial Inclusion Criteria:\n- Presenting to the Emergency Department with cough, wheezing, and/or dyspnea (shortness of breath)\n- Referred for CXR and/or CT scan\n\nThe patient in the note is presenting to the ED with wheezing, which is one of the symptoms listed in the inclusion criteria for the clinical trial. The trial is evaluating the usefulness of lung ultrasound in patients with symptoms that include wheezing. Since the patient's current presentation includes wheezing and he is in the ED, he fits the inclusion criteria for symptoms. Additionally, there is no age restriction mentioned in the inclusion criteria, and the patient could potentially be referred for a CXR as part of the standard evaluation for his symptoms.\n\nGiven this information, the patient would be considered for the clinical trial as he meets the key inclusion criteria:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2518": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not meet the specified criteria for the trial. The inclusion criteria state that participants must have a history of asthma for at least 5 years and be diagnosed before 40 years old. The patient in the note is only 4 years old, and although he presents with wheezing, there is no confirmation that he has asthma, let alone a history of it for the minimum duration required.\n\nFurthermore, the criteria require uncontrolled asthma on low-medium doses of Inhaled CorticoSteroid (ICS) with an Asthma Control Questionnaire (ACQ) score of \u22651.5, a pre-bronchodilator FEV1 (Forced Expiratory Volume in 1 second) between \u226540% and <90% of their predicted normal value, and a positive reversibility test. None of these details are provided in the patient note.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial based on age, confirmed diagnosis, duration of asthma, asthma control status, and lung function parameters.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2519": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can assess the patient's trial-level eligibility based on the provided information.\n\nPatient Note Analysis:\n- The patient is a 4-year-old boy.\n- The patient presents with wheezing and a history of allergic rhinitis but no prior history of wheezing.\n- There is no mention of a diagnosis of asthma or prior asthma management.\n- The patient's current symptoms began suddenly while playing outside.\n\nClinical Trial Inclusion Criteria Analysis:\n- Subjects must be >=12 years of age.\n- Subjects must have had a diagnosis of asthma for at least 12 weeks.\n- Subjects must be receiving a mid-dose ICS plus LABA.\n- Subjects must have a FEV1 of >=80% of predicted normal value.\n\nBased on the above, the patient does not meet the following inclusion criteria for the clinical trial:\n- The patient is significantly younger than the required age of >=12 years.\n- There is no indication that the patient has been diagnosed with asthma, let alone for the required minimum duration of 12 weeks.\n- There is no information to suggest that the patient has been receiving mid-dose ICS plus LABA treatment for asthma.\n\nGiven this information, the patient is not eligible for the clinical trial as he does not meet several of the key inclusion criteria, including age, diagnosis, and treatment history.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2520": {
        "output": "Given the patient note and the criteria for the clinical trial, we can assess the patient's eligibility.\n\nPatient Note Summary:\n- 4-year-old boy\n- History of allergic rhinitis\n- No history of wheezing prior to this episode\n- Sudden onset of coughing and wheezing after playing in a sandbox\n- Wheezing heard in the mid-right chest area\n- O2 sats are 100% on room air\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of allergic rhinitis and/or asthma\n- Sensitized to more than 1 common aeroallergens\n\nAssessment:\nThe patient has a history of allergic rhinitis, which aligns with one of the conditions of interest for the clinical trial. However, there is no mention in the patient note of a diagnosis of asthma or sensitization to common aeroallergens, which are required for inclusion in the study. The patient is presenting with wheezing for the first time, and no further information is provided regarding testing for sensitization to aeroallergens.\n\nBased on the information provided, the patient meets part of the inclusion criteria (history of allergic rhinitis), but there is not enough information to fully determine if they meet the rest of the criteria (asthma diagnosis and sensitization to aeroallergens). Therefore, further investigation would be needed to assess sensitization to aeroallergens and to confirm or rule out a diagnosis of asthma.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2521": {
        "output": "",
        "label": 0
    },
    "2522": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial.\n\nPatient Note Analysis:\n- The patient is a 4-year-old boy.\n- The patient presents with wheezing.\n- The patient has a history of allergic rhinitis but no history of wheezing.\n- The wheezing started suddenly while the patient was playing in the backyard sandbox.\n\nClinical Trial Analysis:\n- The trial is focused on the use of anti-inflammatory H1 antihistamines for allergic rhinitis.\n- The inclusion criteria specify that participants must have persistent allergic rhinitis.\n\nComparison:\n- The patient does have a history of allergic rhinitis, which aligns with the condition being studied in the trial.\n- However, the trial specifically mentions \"persistent allergic rhinitis,\" and based on the provided patient note, we cannot confirm whether the boy's allergic rhinitis is persistent.\n- Additionally, the trial does not specify an age range, but clinical trials often have specific age groups, and interventions for a 4-year-old may differ from those for adults or older children.\n\nIn this case, there is not enough information to determine if the boy's allergic rhinitis is persistent, and his age may also be a factor in determining eligibility for this specific trial, which is not specified in the inclusion criteria.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2523": {
        "output": "Given the patient note:\n\n- The patient is a 4-year-old boy.\n- He presents with wheezing and a history of allergic rhinitis, but no previous history of wheezing.\n- The condition seems to be acute and related to an allergic reaction or possible foreign body aspiration while playing in the sandbox.\n\nNow, let's compare this with the inclusion criteria of the clinical trial:\n\n- The trial is for patients with a diagnosis of chronic obstructive pulmonary disorder (COPD) for at least 1 year.\n- The trial participants need to be clinically stable in the previous 4 weeks.\n- Participants must demonstrate reversibility to bronchodilators via spirometry with specific FEV1/FVC ratio and percentage of predicted normal values.\n- The trial requires participants to have a smoking history of \u226510 pack years.\n- There are specific requirements for BMI, weight, and ECG readings.\n- The trial requires informed consent, which a 4-year-old cannot legally provide.\n\nConsidering the differences between the patient's condition and the trial's target population, as well as the patient's age which makes him unable to provide informed consent:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2524": {
        "output": "To determine the eligibility of the 4-year-old boy for the clinical trial titled \"Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission,\" we need to compare the patient's characteristics to the inclusion and exclusion criteria of the trial.\n\nInclusion criteria for the trial:\n- Children between the ages of 6 months to 12 years of age\n- Typically developing and born of a full term pregnancy if under 24 months of age\n- Healthy\n- English speaking\n- Racially and ethnically diverse sample, as needed for study diversity\n\nExclusion criteria for the trial:\n- Children outside of the 6 month-12 year age range\n- Families not fluent in English\n- Children who are sick, not typically developing, born premature (if under 24 months of age), blind, or deaf\n- Children who do not add to the ethnic and racial diversity of the sample, if quotas have been met\n\nThe patient note specifies:\n- A 4-year-old boy (within the age range)\n- Presenting with wheezing and a history of allergic rhinitis (indicating a current health issue, but not necessarily a chronic or developmental condition)\n- There is no information provided on prematurity, developmental delays, or disabilities\n- There is no information provided about the family's English fluency or the child's ability to contribute to the diversity of the sample\n\nGiven the information provided, the child is within the correct age range for the study. However, the child is currently sick with wheezing, which may disqualify him based on the exclusion criteria that require participants to be healthy. There is no explicit mention of allergic rhinitis being a disqualifying condition, but the acute presentation of wheezing might be considered an exclusion due to the child being sick.\n\nWithout further information regarding the child's overall health status (aside from the acute wheezing episode), English fluency of the family, and whether the diversity quota has been met, it is difficult to make a definitive eligibility determination. \n\nConsidering the information at hand, the child's current health issue (wheezing) would likely exclude him from participation at this time. However, if his wheezing is a transient issue and he is typically healthy, he could potentially be eligible once he recovers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "2525": {
        "output": "Based on the patient note and clinical trial information provided:\n\nPatient Note:\n- A 4-year-old boy presents with wheezing and a history of allergic rhinitis.\n\nClinical Trial:\n- Title: Revaccination With Pollinex\u00ae Quattro\n- Inclusion Criteria: Adults and children from the age of 12 years on, diagnosed with recurrent seasonal allergic rhinitis (SAR) caused by grass pollen, and a previous specific immunotherapy finished at least five years ago had to be successful.\n\nThe patient in the note is only 4 years old, which does not meet the age requirement of the clinical trial that specifies participants must be 12 years of age or older. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2526": {
        "output": "",
        "label": 0
    },
    "2527": {
        "output": "Given the patient note and the clinical trial information, we need to assess whether the patient is eligible for the clinical trial based on the inclusion criteria provided. \n\nPatient Note Summary:\n- 32-year-old female\n- No previous medical history\n- General good health\n- Recent pap smear results: cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- Female with an intact uterus\n- Lifetime history of 0-4 sexual partners\n\nBased on the information provided, the patient is a 32-year-old female, which fits the gender and presumably the intact uterus criteria (as there is no indication of a hysterectomy or absence of the uterus). However, the patient's sexual history is not provided, which is a key component of the inclusion criteria.\n\nWithout knowledge of the patient's sexual history, we cannot definitively determine her eligibility for the clinical trial. Therefore, additional information would be needed to make a final assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2528": {
        "output": "Based on the information provided, the patient is a 32-year-old female who recently had a pap smear with results that were cytology negative but HPV positive. The clinical trial in question is examining the psychosocial outcomes of different management strategies for women with minor atypia detected on Pap smears and is specifically looking at women with:\n\n1. Low-grade epithelial abnormality;\n2. Minor changes in squamous cells;\n3. Minor changes in squamous cells with appearances consistent with Papillomavirus.\n\nGiven that the patient's pap smear was cytology negative but HPV positive, it does not explicitly state that she has 'minor atypia' or 'minor changes in squamous cells' as defined by the inclusion criteria. The HPV positive result might suggest a risk for such changes, but without clear evidence of 'minor atypia' in the patient's report, it is uncertain whether she meets the inclusion criteria for the trial based strictly on the information given.\n\nTherefore, further investigation would be needed to determine if the patient's HPV positive result is associated with any of the specific types of minor atypia described in the inclusion criteria. The patient falls into the category where she may or may not meet the specific inclusion criteria based on the information currently available in the patient's note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2529": {
        "output": "Based on the information provided, the patient, a 32-year-old female with a recent HPV-positive pap smear, does not meet the inclusion criteria for the clinical trial, which requires participants to have been part of a previous study (HPV-001) and to have received all three doses of vaccine/placebo from that study. There is no indication that the patient has participated in the specified previous study or received any doses of the vaccine/placebo.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2530": {
        "output": "The patient is a 32-year-old female, which fits within the age range of 15 to 25 years required by the clinical trial. However, the clinical trial specifically aims to enroll young adolescents and women up to 25 years of age, and the patient is 32 years old, which is outside the inclusion range for age.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient is not eligible for the trial due to age.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2531": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the inclusion and exclusion criteria provided:\n\nInclusion Criteria Checklist:\n- A woman who the investigator believes can and will comply with the requirements of the protocol: The patient note does not indicate any non-compliance issues.\n- A woman of at least 26 years of age at the time of the first vaccination: The patient is 32 years old, which meets this criterion.\n- Written informed consent obtained from the subject prior to enrolment: This is a process-related criterion that the patient can fulfill if she agrees to participate.\n- Free of obvious health problems as established by medical history and clinical examination before entering into the study: The patient is in general good health, which meets this criterion.\n- Subject must have an intact cervix: The patient note does not indicate any issue with this; therefore, we assume she meets this criterion.\n- Subject must have a negative urine pregnancy test: This is a process-related criterion that can be fulfilled at the time of enrolment.\n- Subject must be of non-childbearing potential, or if of childbearing potential, she must be abstinent or must be using an effective method of birth control: The patient note does not provide information about this, but it can be assessed and confirmed at the time of enrolment.\n\nExclusion Criteria Checklist:\n- Pregnant or breastfeeding: The patient note does not indicate pregnancy or breastfeeding.\n- Planning to become pregnant, likely to become pregnant, or planning to discontinue contraceptive precautions during the vaccination phase of the study: The patient note does not provide this information, but it can be assessed at the time of enrolment.\n- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine: The patient note does not indicate this.\n- Chronic administration of immunosuppressants or other immune-modifying drugs: The patient note does not indicate this.\n- Planned or previous administration of a vaccine not foreseen by the study protocol: The patient note does not indicate this.\n- Previous administration of components of the investigational vaccine: The patient note does not indicate this.\n- Previous vaccination against HPV or planned administration of any HPV vaccine: The patient is HPV positive, but there is no mention of previous vaccination.\n- History of HPV infection/treatment or planned treatment to evaluate an abnormal cervical cytology (Pap smear) test: The patient is HPV positive, but there is no mention of treatment, and the cytology is negative.\n- Any medically diagnosed or suspected immunodeficient condition: The patient note does not indicate this.\n- History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine: The patient note does not indicate this.\n- Hypersensitivity to latex: The patient note does not indicate this.\n- Known acute or chronic, clinically significant neurologic, hepatic, or renal functional abnormality: The patient note does not indicate this.\n- History of chronic condition(s) requiring treatment: The patient note does not indicate this.\n- Administration of immunoglobulins and/or any blood product: The patient note does not indicate this.\n- Acute disease at the time of enrolment: The patient note does not indicate this.\n- Heavy bleeding or heavy vaginal discharge: The patient note does not indicate this.\n\nBased on the information provided in the patient note and the criteria listed for the clinical trial, the patient appears to meet the inclusion criteria and does not meet any of the exclusion criteria as per available information. However, further investigation would be required to confirm details such as contraceptive use and to ensure that she is not planning to become pregnant or discontinue contraceptive precautions during the study. Therefore, I would assign the following rating:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2532": {
        "output": "Let's evaluate the patient's eligibility based on the clinical trial's inclusion and exclusion criteria:\n\nInclusion Criteria Evaluation:\n1. Subjects who the investigator believes can and will comply with the protocol: No information provided that suggests otherwise.\n2. A Japanese female subject between, and including, 20 and 25 years of age at the time of the first vaccination: The patient is 32 years old, which is outside the specified age range.\n3. Written informed consent obtained from the subject: This is procedural and can be obtained if other criteria are met.\n4. Healthy subjects as established by medical history and clinical examination: The patient is in general good health.\n5. Subjects must have a negative urine pregnancy test: Not specified, but this is a test that can be performed.\n6. Non-childbearing potential or adequate contraceptive precautions: Not specified, but this can be clarified with the patient.\n7. Subject must have an intact cervix: No information suggests otherwise.\n\nExclusion Criteria Evaluation:\n1. Use of investigational or non-registered products: No mention of such use.\n2. Pregnant or breastfeeding, or less than 3 months post-pregnancy: Not specified.\n3. Planning to become pregnant or discontinuing contraceptive precautions: Not specified.\n4. Previous administration of components of the investigational vaccine: No mention of previous vaccination.\n5. Chronic administration of immunosuppressants or immune-modifying drugs: No mention of such use.\n6. Planned administration of a non-study vaccine: No mention of this.\n7. Previous vaccination against HPV: Not specified, but this would be crucial to know.\n8. History of hepatitis A vaccination or disease: No mention of this.\n9. Administration of immunoglobulins or blood products: No mention of this.\n10. Immunocompromised condition: No mention of this.\n11. History of allergic reactions to vaccine components: No mention of this.\n12. Hypersensitivity to latex: No mention of this.\n13. Significant functional abnormality of major organs: No mention of this.\n14. Cancer or autoimmune disease under treatment: No mention of this.\n15. History of colposcopy or abnormal Pap smear requiring evaluation: The patient's PAP was cytology negative.\n16. Heavy bleeding or vaginal discharge: No mention of this.\n17. Acute disease or fever: No mention of this.\n18. Participation in another clinical study: No mention of this.\n\nThe major disqualifying factor in this case is the patient's age; she is 32 years old, which is outside the specified age range of 20 to 25 years for the trial. Even though the patient meets some of the inclusion criteria and none of the exclusion criteria are explicitly mentioned, the age criterion is strict and cannot be overlooked.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2533": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet the eligibility requirements for the clinical trial. The clinical trial is specifically targeting HIV-infected men who have sex with men (MSM) and is focused on the oral human papillomavirus (HPV) infection in this population.\n\nThe patient in the note is described as a 32-year-old female with a positive HPV result from a pap smear, and there is no mention of her being HIV-positive or belonging to the MSM category. Therefore, she does not fit the demographic or medical profile that the trial is aiming to study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2534": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- 32-year-old female\n- No previous medical history\n- General good health\n- Recent pap smear results: cytology negative, HPV positive\n\nClinical Trial Summary:\n- Title: Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer\n- Objective: To understand the relationship between HPV types and the development of cervical precancer and cancer\n- Inclusion Criteria: Women in KPNC aged 25 years or older who tested positive for HPV, and a random sample of women who tested negative for HPV\n- Exclusion Criteria: Male, Children under 18\n\nComparing the patient's characteristics with the inclusion criteria for the clinical trial:\n\n- The patient is a 32-year-old female, which fits the age criterion (25 years or older).\n- The patient has tested positive for HPV, which is one of the conditions for inclusion.\n- There is no indication that the patient is not a part of the Kaiser Permanente health plan in Northern California (KPNC), which is a criterion for inclusion; however, this would need to be confirmed.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial. However, confirmation of the patient's enrollment in the Kaiser Permanente health plan in Northern California would be necessary before a final recommendation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2535": {
        "output": "The patient in question is a 32-year-old female with no previous medical history who presents to discuss lab results from her recent pap smear. The results show that she is cytology negative but HPV positive. \n\nNow, let's review the inclusion criteria for the clinical trial titled \"Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta\":\n\n- Women who reside in the counties of Leflore, Sunflower, Washington, or Tallahatchie, Mississippi.\n- Women between 26 and 65 years of age who are not pregnant and who have not had a hysterectomy.\n\nThe patient meets the age criterion (32 years old). There is no information that suggests she is pregnant or has had a hysterectomy. However, it is not mentioned whether she resides in one of the specified counties in Mississippi. \n\nFor a comprehensive assessment, we would need confirmation of her residency to ensure she meets the geographical criteria for the trial. Without this information, we cannot proceed with a high level of certainty. Therefore, the appropriate action is to consider referring this patient to this clinical trial upon further investigation to confirm her residency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2536": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\n1. The patient is a 32-year-old female, which meets the age criterion of being \u2265 18 years of age.\n2. The patient underwent a Pap smear and was found to be HPV positive, which fits the inclusion criteria of having negative cytology but positive for high-risk human papillomavirus (HPV).\n3. There is no mention of HIV testing, but it is not explicitly required if the patient meets other criteria.\n4. There is no indication that the patient is pregnant, and the patient's cervix is assumed to be intact as there is no information suggesting otherwise.\n5. The patient is able to provide informed consent, as there is no suggestion of any incapacity.\n6. The inclusion criteria specifically list \"Negative cytology but positive for high-risk human papillomavirus (HPV)\" as one of the conditions for eligibility.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2537": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 32-year-old female\n- No previous medical history\n- Good general health\n- Recent PAP smear results: cytology negative, HPV positive\n\nClinical Trial:\n- Title: HPV Testing for Cervical Cancer Screening Study\n- Inclusion Criteria: Women from 25 to 65 years of age, registered with the Medical Services Plan in BC attending a collaborating healthcare provider for routine cervical screening in Metro Vancouver or Greater Victoria.\n\nThe patient is a 32-year-old female, which falls within the age range of 25 to 65 years required by the trial. She has an HPV positive result, which seems relevant to a study investigating HPV testing for cervical cancer screening. However, there is no information on whether she is registered with the Medical Services Plan in BC or if she is attending a healthcare provider in Metro Vancouver or Greater Victoria, which are required for inclusion in the study.\n\nSince we lack information about the patient's location and her registration with the Medical Services Plan in BC, we cannot definitively determine her eligibility. However, based on the age and HPV status, she could potentially be a candidate if she meets the geographical criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2538": {
        "output": "Based on the information provided:\n\nThe patient is a 32-year-old female, which fits within the age range of the inclusion criteria (18 to 26 years of age).\n\nThe patient is able to consent for herself, as no incapacity is noted.\n\nThe patient's referring Pap smear was cytology negative but HPV positive. The inclusion criteria specify that the referring Pap smear should be ASCUS (atypical squamous cells of undetermined significance) + HPV or LGSIL (low-grade squamous intraepithelial lesion). Although the patient is HPV positive, there is no indication of ASCUS or LGSIL, which are considered low-grade cervical abnormalities.\n\nThe patient has expressed interest in discussing the lab results and is in general good health, which may show her willingness to participate in medical interventions. However, the trial specifically seeks women with low-grade cervical dysplasia.\n\nGiven the information provided, the patient does not meet the exact Pap smear criteria for the clinical trial. Therefore, unless further information on the patient's Pap smear is provided that aligns with ASCUS or LGSIL, this patient would not be eligible for the clinical trial based on the inclusion criteria given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2539": {
        "output": "Given the patient note and the clinical trial information, we can assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- 32-year-old female\n- No previous medical history\n- Recent pap smear results: cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- Subjects who can and will comply with the requirements of the protocol\n- Subjects who participated in study 580299-007\n- Written informed consent obtained from the subject prior to enrollment\n\nThe key inclusion criterion here is that the subject must have participated in the previous study 580299-007. There is no mention of the patient in question having participated in the prior study, which is a requirement for eligibility in the current trial. Therefore, based on the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2540": {
        "output": "Based on the information provided:\n\nThe patient is a 32-year-old female, which fits within the age range of 18 to 45 years required by the clinical trial.\n\nHowever, the inclusion criteria for the clinical trial specify that participants must have recently experienced abnormal pap results within the past 3 months. The patient's pap smear results were reported as cytology negative, HPV positive. While the HPV positive result indicates the presence of the human papillomavirus, this does not equate to an abnormal pap result, which typically refers to the presence of abnormal or atypical cells on the cervix.\n\nGiven that the patient does not have abnormal pap results, she does not meet the inclusion criteria for the trial, which is focused on assessing the psychosocial burden in women who have experienced an abnormal pap result.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2541": {
        "output": "Based on the information provided, the 32-year-old female patient presents with no previous medical history, good general health, and recent lab results indicating a negative cytology but positive for HPV.\n\nThe clinical trial in question is evaluating an ELISA assay in an HPV-infected population. The inclusion criteria for this clinical trial are:\n\n- Healthy volunteers\n- People infected with HPV type 16 but without CIN lesions\n- Patients with CIN lesions\n- Patients with cervical cancer from National Taiwan University Hospital\n- Informed consent is obtained, and the protocols are reviewed and approved by the appropriate Investigative Review Boards\n\nThe patient appears to meet some of the inclusion criteria as she is a healthy volunteer and infected with HPV. However, the type of HPV is not specified in the patient note. If the patient is infected with HPV type 16 and does not have CIN lesions, she would fit the criteria for the clinical trial. Given the information provided and the need to confirm the type of HPV infection, I would categorize this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2542": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient is a 32-year-old female who is HPV positive but has no other specified medical issues. The clinical trial is focused on studying knowledge and perceptions about HPV and cervical cancer risk among young adults.\n\nThe inclusion criteria for the trial specify that participants should be currently enrolled in a college, university, or community college in the Greater Cleveland metropolitan area and currently single and never married. The patient note does not provide information on the patient's educational status, marital status, or location.\n\nSince the patient note does not provide enough information to determine if the patient meets all of the inclusion criteria, further investigation would be required to determine eligibility. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2543": {
        "output": "",
        "label": 2
    },
    "2544": {
        "output": "Based on the information provided, the patient is a 32-year-old female who is HPV positive but has no cytological evidence of cervical intraepithelial neoplasia (CIN) or cervical cancer as indicated by the negative PAP smear. The clinical trial in question is seeking to identify biomarkers in cervical cancers and is including healthy volunteers, people infected with HPV type 16 but without CIN lesions, patients with CIN lesions, and patients with cervical cancer from National Taiwan University Hospital.\n\nThe patient fits the inclusion criteria as a person infected with HPV. However, it is not specified if the HPV type she has is one of the high-risk types associated with cervical cancer, such as HPV 16. Assuming it is a high-risk type since it is mentioned in the summary of the trial, and given that the patient does not have CIN lesions or cervical cancer, she could potentially be eligible for the study as a participant infected with HPV but without CIN lesions.\n\nTherefore, based on this information, the patient seems to align with the inclusion criteria of the study, provided that her HPV type matches the ones of interest for the trial and all other protocols including informed consent are followed. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2545": {
        "output": "Based on the patient note and the clinical trial information provided, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 32-year-old female\n- No previous medical history\n- Reports no complaints and is in general good health\n- Recent PAP smear results were cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- Between the age of 18 and 26 years\n- Registered female sex worker living in Lima\n- Healthy with no known immune deficiency\n- Willing to participate in a study of HPV vaccine including a Pap smear, three pregnancy tests, blood draws, and three vaccine administrations over 7 months\n- Willing to provide informed consent\n\nComparing the patient's characteristics to the inclusion criteria, we find the following points of mismatch:\n- The patient is 32 years old, which is above the age range required for the trial (18-26 years).\n- There is no information provided to suggest that the patient is a registered female sex worker living in Lima, which is a specific requirement for the study.\n\nGiven these discrepancies, particularly the age and the lack of information confirming the patient's occupation and location, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2546": {
        "output": "Based on the information provided, the patient is a 32-year-old female who is HPV positive but has no other medical history mentioned, specifically no mention of inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.\n\nThe clinical trial in question is looking to study the immune response to the Human Papillomavirus (HPV) vaccine in young women with inflammatory bowel disease (IBD). The inclusion criteria specify that participants must be women between the ages of 9 and 26 and have inflammatory bowel disease.\n\nThis patient does not meet the inclusion criteria as there is no indication that she has inflammatory bowel disease, which is a requirement for the trial. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2547": {
        "output": "Based on the patient note provided, the patient is a 32-year-old female with no previous medical history, presenting to discuss lab results from a recent pap smear. The results were cytology negative but HPV positive.\n\nThe clinical trial in question is a crossover vaccination study for women who were previously randomized into the Costa Rica Vaccine Trial (Protocol 04-C-N191). The inclusion criteria specifically state that to be eligible for crossover vaccination, participants must have been previously randomized into the HPV-16/18 vaccine trial 04-C-N191.\n\nThe patient note does not indicate that the patient was a participant in the Costa Rica Vaccine Trial, which is a strict requirement for eligibility in this particular clinical trial. Therefore, based on the available information, the patient does not meet the inclusion criteria and would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2548": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 32-year-old female who presents with a recent pap smear that is cytology negative but HPV positive.\n\nThe inclusion criteria for the clinical trial are:\n- Women with a new LSIL diagnosis and HPV positivity on PAP smear.\n\nThe patient's PAP smear results do not indicate any cytological abnormalities such as LSIL (Low-grade Squamous Intraepithelial Lesion), which is a requirement for the clinical trial. The patient only has HPV positivity without cytological lesions.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial as it specifically requires a new diagnosis of LSIL in addition to HPV positivity.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2549": {
        "output": "Based on the information provided:\n\nThe patient is a 32-year-old female, which satisfies the age criterion of being 18 years or older. She has a recent pap smear result that is cytology negative but HPV positive. \n\nThe inclusion criteria for the clinical trial are:\n1. Diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL)\n2. 18 years or older\n3. Able to give informed consent with a reasonable likelihood of follow-up\n\nThe patient does not meet the primary diagnostic inclusion criterion as she doesn't have a diagnosis of ASCUS or LSIL; her cytology is negative. The HPV positive result alone does not qualify her for this trial as it specifically requires a diagnosis of ASCUS or LSIL. Therefore, she would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2550": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 32-year-old female\n- No previous medical history\n- Results of her PAP: cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- Women >= 18 years of age attending a clinic for gynaecological examination\n- Women who agree to provide a cervical sample for human papillomavirus testing\n- Written informed consent obtained from the subject\n\nComparison:\n- The patient is a 32-year-old female, which meets the age requirement of the clinical trial (>= 18 years of age).\n- The patient has attended a clinic to discuss lab results from her most recent pap smear, which can be considered a gynecological examination.\n- The patient has already undergone HPV testing and was found to be HPV positive.\n- There is no mention of the patient's consent, but since she has attended the clinic and is discussing her results, it can be assumed she may be willing to provide consent if asked.\n\nBased on the provided information, this patient meets the inclusion criteria for the clinical trial, as she is the appropriate age, has attended a clinic for a gynecological examination, and has already been tested for HPV. However, the final confirmation of eligibility would require her agreement to provide a cervical sample specifically for the study and her written informed consent.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2551": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not seem to be eligible for the trial. The inclusion criteria specifically mention \"All female patients with genital warts,\" and there is no indication in the patient note that the patient has genital warts. The patient has an HPV positive result from a pap smear, which is different from having genital warts.\n\nTherefore, the patient does not meet the inclusion criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2552": {
        "output": "Assessing the eligibility of the 32-year-old female patient for the clinical trial on the \"Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer\" based on the provided information:\n\nPatient Characteristics:\n- 32-year-old female\n- No previous medical history\n- General good health\n- Recent PAP smear results: cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- A female aged 21 years or more\n- Presenting with a lesion macroscopically suggestive of invasive cervical cancer\n- Scheduled for cervical biopsy as per routine procedure at the participating institution\n- No prior chemo- or radiotherapy for cervical cancer\n- Written or oral-witnessed informed consent obtained from the subject\n\nBased on the patient note, the patient is a 32-year-old female which meets the age criterion of the study. However, she does not present with a lesion suggestive of invasive cervical cancer; her PAP smear cytology was negative, and she only tested positive for HPV without any indication of invasive cervical cancer. Therefore, she does not meet the key inclusion criterion of having a suspected lesion of invasive cervical cancer.\n\nSince the patient does not have a suspected lesion of invasive cervical cancer, she would not be eligible for the study that specifically aims to assess HPV types in women diagnosed with invasive cervical cancer. The patient has not been scheduled for a cervical biopsy for suspected cancer, and there is no indication of prior chemo- or radiotherapy because there is no diagnosis of cervical cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2553": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the 32-year-old female patient is a candidate for the clinical trial. The patient has an HPV positive result from her most recent pap smear, which aligns with the study's aim to determine the prevalence of HPV types in women attending routine gynecological examinations.\n\nThe inclusion criteria for the clinical trial are:\n- Subjects/Subjects' parents or guardians who can and will comply with the requirements of the protocol.\n- Women aged 15 years or older attending a clinic for routine cervical screening.\n- Written informed consent obtained from the subject and/or subject's parent/guardian.\n\nThe patient meets these criteria as she is a woman older than 15 years of age, has attended a clinic for routine cervical screening (as evidenced by her recent pap smear), and there are no indications she wouldn't be able to comply with the study protocol.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2554": {
        "output": "Based on the patient note provided and the clinical trial's inclusion and exclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient Note:\n- A 32-year-old female\n- HPV positive\n- No previous medical history\n- Cytology negative (Pap smear)\n\nClinical Trial Inclusion Criteria:\n- Women between 25 and 65 years of age\n- Have not been previously diagnosed with cervical cancer\n- Have a cervix\n- Are not pregnant\n- Are physically able to undergo routine cervical cancer screening\n- Are able to provide informed consent\n\nClinical Trial Exclusion Criteria:\n- Are not married AND report never having had sexual intercourse (not mentioned in the patient note)\n- Have had a total hysterectomy (not mentioned in the patient note)\n- Have a history of cervical cancer (patient does not have this history)\n- Are physically or mentally unable to undergo routine cervical cancer screening or unable to provide informed consent (patient is physically able and has no medical history suggesting inability)\n- Are pregnant or have been pregnant in the last month (not mentioned in the patient note)\n- Women currently menstruating at the time of enrollment will be deferred (menstrual status not mentioned in the patient note)\n\nThe patient's age falls within the range specified in the inclusion criteria, and there is no indication in the patient note that would place her under any of the exclusion criteria. The patient has not been previously diagnosed with cervical cancer, has a cervix, is not pregnant to the best of our knowledge, appears physically able to undergo cervical cancer screening, and there is no information to suggest she would be unable to provide informed consent.\n\nTherefore, based on the information provided in the patient note, and assuming that the patient meets all other unstated inclusion and exclusion criteria (such as not currently menstruating at the time of enrollment), the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "2555": {
        "output": "Based on the information provided, the patient is a 32-year-old female with a recent pap smear that was cytology negative, but HPV positive. The clinical trial in question is focused on evaluating the performance of the APTIMA HPV 16 18/45 Genotype Assay on women with ASC-US or negative Pap test results who are HPV positive.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. The subject attended a colposcopy visit, and\n2. The referral Pap sample had a valid APTIMA HPV Assay result, and\n3. One of the following:\n   - The sample had an APTIMA HPV Assay positive result, or\n   - The sample had an APTIMA HPV Assay negative result and the subject had a consensus histology result of CIN2+ (CIN2, CIN3, or cervical cancer), or\n   - The sample had an APTIMA HPV Assay negative result and the subject had a consensus histology result of normal or CIN1 (<CIN2) and was randomly selected for inclusion.\n\nThe patient's note indicates that she has an HPV positive result, which fits one of the inclusion criteria. However, there is no mention of whether she has attended a colposcopy visit, which is a requirement. Without this information, we cannot conclusively determine her eligibility.\n\nGiven the information, I would consider referring this patient to the clinical trial upon further investigation to confirm whether she has had or is scheduled for a colposcopy visit.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2556": {
        "output": "Based on the information provided, the patient is a 32-year-old female who has had a recent pap smear with cytology negative and HPV positive results. To determine this patient's eligibility for the clinical trial described, we must compare her situation to the inclusion criteria of the trial.\n\nThe inclusion criteria for the clinical trial are:\n\n1. The sample had an aliquot with a valid positive or negative APTIMA HPV Assay TIGRIS System result (from testing under protocol 2007HPVASCUS30).\n2. An aliquot is available and suitable for testing.\n3. The sample was randomly selected for inclusion.\n\nGiven this information, the patient note indicates that the individual has a positive HPV result. However, it is not specified whether this result comes from an APTIMA HPV Assay TIGRIS System result or under the specific protocol mentioned. The patient note also does not provide information on whether an aliquot is available for testing or if the sample was randomly selected for inclusion as required by the clinical trial.\n\nWithout additional information confirming that the patient's HPV positive result is from the APTIMA HPV Assay TIGRIS System and meets the other criteria, we cannot definitively establish eligibility. Thus, the patient may require further investigation to determine if they are suitable for the study based on the precise tests and protocols used in their screening.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2557": {
        "output": "Based on the patient note provided:\n\n- The patient is a 32-year-old female\n- She has no previous medical history\n- She is in general good health\n- Her PAP test results were cytology negative, HPV positive\n- There is no mention of HIV infection or any related treatment\n\nAnd the clinical trial's inclusion criteria are:\n\n- Subjects aged 13-27 years, females and males\n- For HIV-infected subjects:\n  - HIV-positive\n  - Asymptomatic subjects\n  - Lymphocyte CD4+ count > or equal to 350 cells/mm3\n  - For subjects receiving HAART:\n    - Good compliance to therapy\n    - At least two suppressed viral loads HIV-RNA during 6 months prior to enrollment\n\nThe patient does not meet the inclusion criteria for the clinical trial as there is no indication in the patient note that she is HIV-positive, which is a requirement for the trial. Additionally, the patient is 32 years old, which is outside the age range specified in the trial's inclusion criteria (13-27 years).\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2558": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 32-year-old female who has recently had a pap smear that was cytology negative and HPV positive. The clinical trial in question is evaluating the performance of the careHPV (hybrid capture test) in mobile units of the Barretos Cancer Hospital, specifically targeting cervical samples from women in rural and remote Brazilian areas.\n\nThe inclusion criteria for the clinical trial are quite broad: any woman who comes to do the Papanicolaou test at the Barretos Cancer Hospital and in the mobile units on the remote Brazilian areas. Given that the patient has recently had a pap smear, she could potentially be eligible for the clinical trial if she is in a location serviced by the Barretos Cancer Hospital or its mobile units and if the trial is accepting participants who are HPV positive.\n\nSince the inclusion criteria do not specify any exclusions based on HPV status and the patient is a woman who has recently undergone a pap smear, which is related to cervical cancer screening, it seems that she could be a candidate for this trial. \n\nHowever, without information about the patient\u2019s location and whether she is in or can travel to the remote Brazilian areas where the trial is taking place, it is not possible to definitively determine her eligibility. Thus, I would consider referring this patient to this clinical trial upon further investigation regarding her location relative to the trial sites.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2559": {
        "output": "Given the patient's note and the clinical trial information provided, let's assess the eligibility:\n\nPatient Note:\n- 32-year-old female\n- No previous medical history\n- No complaints, in general good health\n- Recent Pap smear with results: cytology negative, HPV positive\n\nClinical Trial:\n- Title: Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening\n- Summary: This trial compares home-based HPV screening to clinic-based Pap screening for cervical cancer.\n- Inclusion Criteria: Able to provide informed consent in English\n\nThe patient is a 32-year-old female, which meets the general age requirement for clinical trials (\u2265 18 years). She has an HPV positive result, which is relevant to the study on HPV screening. Since there is no exclusion information provided and the inclusion criteria only specify that the participant must be able to provide informed consent in English, the patient appears to meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2560": {
        "output": "Based on the information provided, the patient in the note is a 32-year-old female with no previous medical history other than being HPV positive from her most recent pap smear. She does not fall under the target population for the clinical trial provided, which is specifically looking to recruit Thai men who have sex with men (MSM), both HIV positive and HIV negative, to assess biomarkers for detecting anal intraepithelial neoplasia.\n\nSince the patient is female and the inclusion criteria specifically mention MSM (which implies male participants), she does not meet the gender and demographic requirements of the study. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2561": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, the following assessment can be made:\n\nPatient Note Analysis:\n- The patient is a 32-year-old female.\n- She has recently had a pap smear.\n- The pap smear results were cytology negative but HPV positive.\n\nClinical Trial Inclusion Criteria:\n- Referred to follow up due to one or more abnormal Pap or an HPV infection.\n- Subjects who have provided informed consent.\n- Subjects who meet the minimum age set forth by the ethics committee (EC) and/or national screening guidelines.\n\nAssessment:\nThe patient has an HPV infection, which is one of the inclusion criteria for the clinical trial. Additionally, she meets the age requirement as she is 32 years old. However, the patient note does not specifically mention whether she has been referred for follow-up due to the HPV positive result. Usually, HPV positivity would lead to a follow-up, but this is not explicitly stated in the patient note.\n\nSince the patient has an HPV infection, she could potentially be eligible for the trial if she has been or will be referred for follow-up, which is likely given her HPV positive status. However, without confirmation of a referral for follow-up, the decision to refer her for this clinical trial should be made upon further investigation into whether she fulfills this specific criterion.\n\nTherefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2562": {
        "output": "",
        "label": 0
    },
    "2563": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Characteristics:\n- 32 years old female\n- General good health\n- Cytology negative, HPV positive on recent pap smear\n\nClinical Trial Inclusion Criteria:\n- Age 30 to 65 years\n- Female patients with an active sex life\n- Liquid-based cytology (TCT) check showing no intraepithelial lesions and malignant cells\n- HPV DNA typing test positive for high-risk HPV (including a single high-risk type positive, and more high-risk type of positive and high-and low-risk hybrid positive)\n- The clinical trial specifically lists 15 kinds of high-risk HPV types eligible for the study\n\nThe patient fits the age criteria (30 to 65 years) and is female, which are two of the inclusion criteria for the clinical trial. The patient's cytology is negative for intraepithelial lesions and malignancy, meeting another criterion. The patient is also positive for high-risk HPV, which is part of the inclusion criteria. However, we do not have information on the specific HPV type she is positive for, as the trial specifies 15 high-risk types that are eligible.\n\nSince the patient meets most of the inclusion criteria but we lack information about the exact high-risk HPV type, further investigation would be needed to confirm the patient's eligibility based on the specific HPV type(s) present.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2564": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 32-year-old female\n- No prior medical history\n- General good health\n- HPV positive\n- Cytology negative PAP smear results\n\nClinical trial inclusion criteria:\n- Fertile women between the age of 20 and 49\n- Patients with cervical intraepithelial neoplasia 1 (CIN1)\n- HPV positive\n- Specific blood count and chemistry values within a certain range\n- Normal EKG and chest X-ray\n- Ability to give written informed consent\n\nComparison:\n- The patient is within the age range of 20 to 49 (meets criteria).\n- The patient is HPV positive (meets criteria).\n- The patient does not have a diagnosis of CIN1 as per the information given; the PAP results were cytology negative, which does not indicate CIN1 (does not meet criteria).\n- There is no information about the patient's blood count, chemistry values, EKG, or chest X-ray, so it is not possible to determine eligibility based on these criteria (further investigation needed).\n\nThe patient does not meet one of the key inclusion criteria, which is having a diagnosis of CIN1. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2565": {
        "output": "Upon reviewing the patient note and the clinical trial information, we can assess the eligibility of the patient for the clinical trial as follows:\n\nPatient characteristics:\n- A 32-year-old female\n- No previous medical history\n- Recent pap smear results: cytology negative, HPV positive\n\nClinical trial inclusion criteria:\n- Aged 30-64 years\n- Mentally competent to understand the consent form\n- Able to communicate with study staff\n- Physically able to have a pelvic exam\n\nThe patient meets the age requirement, is presumably mentally competent and able to communicate with study staff, and should be physically able to have a pelvic exam since there is no indication otherwise in the patient note.\n\nSince all the inclusion criteria appear to be met by the patient, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2566": {
        "output": "Based on the information provided:\n\nThe patient is a 32-year-old female with no previous medical history other than an HPV positive result from her most recent pap smear. She reports no complaints and is in general good health. The pap smear results were cytology negative.\n\nThe clinical trial is looking to recruit women who are 40 years old or older with previous or current high grade cervical dysplasia or cervical cancer.\n\nThe patient in question does not meet the inclusion criteria for age, as she is 32 and the trial requires women to be at least 40 years old. Additionally, the patient does not have a history of high grade cervical dysplasia or cervical cancer, which is another requirement for the trial.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2567": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\n- The patient is a 32-year-old female, which meets the age and gender criteria of the trial.\n- The patient is able to give informed consent, as there are no indications otherwise.\n- The patient has not reported a prior history of invasive cervical cancer.\n- The note does not mention any issues with language, so we can assume she is English speaking.\n- The patient is willing to have biological specimens stored for future studies, as there is no indication to the contrary.\n- There is no information on the patient's residency, so it is unknown whether she is a resident of Appalachian Ohio.\n\nThe only uncertain criterion is whether the patient is a resident of Appalachian Ohio. If the patient meets this criterion, she would be eligible for the trial. Since this information is missing, I would rate the eligibility as follows:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2568": {
        "output": "Considering the provided patient note and the clinical trial inclusion criteria:\n\nPatient note:\n- A 32-year-old female with no previous medical history presents to the clinic to discuss lab results from her most recent pap smear.\n- She reports no complaints and is in general good health.\n- The results of her PAP were cytology negative, HPV positive.\n\nClinical trial inclusion criteria:\n- Australian residents with a cervix, aged 25-69 years who are attending for routine cervical screening.\n- Since April 2016, recruitment has been confined to the younger strata, i.e., women age-eligible for HPV vaccination aged at least 25 and born on or after 1st July 1980, as the recruitment target of the older cohort was met.\n- Participants may have been previously enrolled in the Compass Pilot but must have been discharged to routine screening.\n- Women may also be in follow-up management for a previous abnormality or unsatisfactory cytology.\n\nThe patient is 32 years old, which fits the age criteria of 25-69 years. She also appears to be in the age range for women targeted since April 2016 (age-eligible for HPV vaccination and born on or after 1st July 1980). She is attending the clinic for routine cervical screening, as indicated by her recent pap smear results, which fits the requirement for attending routine cervical screening.\n\nHowever, one important criterion that is not clear from the patient note is the patient's residency. The trial requires the participant to be an Australian resident. Without confirmation that the patient is an Australian resident, we cannot definitively state that she meets all the inclusion criteria.\n\nGiven the information provided, if the patient is an Australian resident, she would be highly likely to be eligible for the trial. However, since residency status is not provided, we would be cautious and consider referring the patient for the clinical trial upon further investigation to confirm her residency status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2569": {
        "output": "Let's assess the eligibility of the patient for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria for the Clinical Trial:\n1. Women between 25-59 years-old\n2. Not pregnant\n3. Had held their last Pap smear for over a year\n4. Could read\n\nPatient's Characteristics:\n1. A 32-year-old female (meets age criteria)\n2. No mention of pregnancy (assumed not pregnant unless specified)\n3. Recent pap smear (does not meet the criterion of having held their last Pap smear for over a year)\n4. No information on the ability to read, but given the patient is discussing lab results, we can infer she is likely literate.\n\nBased on the patient note provided, the patient meets the age criterion and is presumably not pregnant. However, the patient does not meet the criterion of having held their last Pap smear for over a year since she is presenting to discuss lab results from her most recent Pap smear. The assumption that the patient can read is made based on the context but is not explicitly confirmed.\n\nGiven that one of the key inclusion criteria is not met (the timing of the last Pap smear), the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2570": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility:\n\nPatient Note:\n- 32-year-old female\n- No previous medical history\n- Recent pap smear results were cytology negative, HPV positive\n\nClinical Trial Inclusion Criteria:\n- Women 30 years and older living in a household visited by Community Health Workers (CHWs)\n- Exclusion criteria include women with a previous HPV test, women with precancerous lesions or cervical cancer, current pregnancy, and women with mental disability.\n\nThe patient is 32 years old and has an HPV positive result from a recent test. This aligns with the age requirement for the clinical trial which is 30 years and older. However, the trial specifically excludes women who have had a previous HPV test, and it is not clear from the patient note whether this was the patient's first HPV test or a subsequent one. If this was her first HPV test, she may be eligible; otherwise, she would be excluded based on the trial's exclusion criteria.\n\nWithout additional information about whether this HPV test was the patient's first, we cannot definitively determine eligibility. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2571": {
        "output": "Given the patient note and the clinical trial criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient Information:\n- 32-year-old female\n- No previous medical history\n- Good health\n- Cytology negative, HPV positive from a recent pap smear\n\nClinical Trial Criteria:\n- Women aged 30 - 60 years (Patient is 32 years old, which meets this criterion)\n- Women attending gynecological practices for routine screening (Patient was attending a clinic to discuss lab results, which could be considered part of routine screening)\n- Women who gave informed consent to participation in the study (Assuming the patient can give informed consent)\n- Women with hysterectomy or known destructive therapy to the cervix (Not mentioned in the patient note, so assumed not applicable)\n- Women who are pregnant (Not mentioned in the patient note, so assumed not to be pregnant)\n- Women with an abnormal cytology result during the previous 6 months (Patient's cytology was negative, meeting this criterion)\n- Women with known HIV infection or history of transplants (Not mentioned in the patient note, so assumed not applicable)\n- Women vaccinated against HPV (Not mentioned in the patient note, so assumed not vaccinated)\n- Women participating in another research protocol (Not mentioned in the patient note, so assumed not participating)\n\nFrom the information provided, the patient meets all the inclusion criteria and none of the exclusion criteria are mentioned as being applicable. Therefore, she appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2572": {
        "output": "Based on the patient note provided, the 65-year-old African-American male patient presents with symptoms suggestive of heart failure, such as shortness of breath related to exertion, orthopnea (difficulty breathing when lying flat), and physical exam findings including bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These symptoms and signs are consistent with congestive heart failure, potentially classifying the patient as New York Heart Association functional class III or IV.\n\nThe clinical trial in question is looking to recruit men and women, ages 18 and over, who have compensated congestive heart failure due to idiopathic dilated cardiomyopathy or coronary disease with an ejection fraction less than or equal to 0.35. Participants need to be in the New York Heart Association functional class III or IV and should be taking standard heart failure therapy including an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic.\n\nBased on the information provided, the patient's symptoms align with the inclusion criteria's description of heart failure severity (NYHA class III or IV). However, the patient's ejection fraction is not mentioned, and there is no information on the patient's current medications or whether the heart failure is due to idiopathic dilated cardiomyopathy or coronary disease. These are critical pieces of information needed to determine eligibility fully.\n\nTherefore, without this additional information, the assessment would be:\n\n`Trial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.`\n\nFurther investigation would ideally clarify the underlying etiology of the heart failure, confirm the patient's ejection fraction, and verify current heart failure medications to ensure they meet the trial's inclusion criteria.",
        "label": 1
    },
    "2573": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided patient note and trial inclusion criteria:\n\nPatient Note Summary:\n- 65-year-old African-American male\n- Shortness of breath on exertion, worsening over three weeks\n- Difficulty breathing when lying flat, using extra pillows at night\n- Physical exam findings: bibasilar lung crackles, pitting ankle edema, jugular venous distension\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years with endothelial dysfunction requiring diagnostic cardiac catheterization\n- Controls include normal volunteers or patients with normal coronary arteries without risk factors for atherosclerosis\n- No unstable angina\n- No significant left main disease (greater than 50% stenosis)\n- No recent myocardial infarction (less than 1 month)\n- No pregnancy, lactation\n- No allergy to losartan\n- No renal failure (creatinine greater than 2.5 mg/dl)\n- Ability to withdraw ACE inhibitors\n\nComparison:\n- The patient is over 18 years old, which meets the age criteria.\n- The symptoms described (shortness of breath, difficulty breathing when lying flat, edema, and jugular venous distension) suggest potential cardiac issues which might necessitate diagnostic cardiac catheterization, indicating possible endothelial dysfunction.\n- There is no information on the patient's coronary artery status, stability of angina, recent myocardial infarction, allergy status, renal function, or current use of ACE inhibitors.\n\nGiven the limited information provided in the patient note, it is not possible to definitively determine whether the patient has endothelial dysfunction requiring diagnostic cardiac catheterization, which is a key inclusion criterion for the trial. However, the patient's symptoms suggest the possibility of a cardiac issue that might require further investigation, including the potential need for cardiac catheterization.\n\nDue to the lack of specific information about the patient's coronary artery status and other factors, I would consider referring this patient to the clinical trial upon further investigation to clarify the patient's medical condition and see if it aligns with the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2574": {
        "output": "Based on the patient note provided, the 65-year-old African-American male patient is experiencing symptoms consistent with heart failure, such as shortness of breath on exertion, difficulty breathing when lying flat (orthopnea), use of pillows to aid breathing at night, bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These symptoms suggest that the patient may have a cardiac condition that could be related to coronary vascular function, which is the focus of the clinical trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Patient must be over 18 years of age requiring diagnostic cardiac catheterization will participate.\n- Women on chronic estrogen therapy are eligible for the study.\n- Patients investigated for chest pain syndrome with normal coronary arteries with and without risk factors for atherosclerosis, patients with coronary artery disease, and patients with heart failure.\n- Exclusion criteria include unstable angina; significant left main disease; recent myocardial infarction; pregnancy, lactation; allergy to losartan; renal failure; inability to withdraw ACE inhibitors.\n\nThe patient appears to meet the following inclusion criteria:\n- He is over 18 years old.\n- He may require diagnostic cardiac catheterization given his symptoms, which may be indicative of heart failure.\n\nHowever, the patient note does not provide enough information to fully determine eligibility. Important details that are missing include:\n- Whether the patient is currently undergoing diagnostic cardiac catheterization or if it's indicated for his condition.\n- If the patient has been investigated for chest pain syndrome with normal coronary arteries or has coronary artery disease.\n- Confirmation that the patient doesn't have any of the exclusion conditions, such as unstable angina, significant left main disease, recent myocardial infarction, pregnancy, lactation, allergy to losartan, renal failure, or is not able to withdraw ACE inhibitors if currently being used.\n\nGiven the information provided, the patient appears to potentially be eligible for the clinical trial but further investigation is required to confirm the absence of exclusion criteria and to ensure that the patient's condition warrants diagnostic cardiac catheterization. Therefore, the appropriate assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2575": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"The Jackson Heart Study of Cardiovascular Disease Among African Americans,\" we can evaluate the patient's eligibility for the trial.\n\nPatient note review:\n- The patient is a 65-year-old African-American male.\n- The patient presents with symptoms consistent with cardiovascular disease, including shortness of breath on exertion, difficulty breathing when lying flat, use of pillows at night to alleviate breathing difficulties, bibasilar lung crackles, pitting ankle edema, and jugular venous distension.\n\nClinical trial inclusion criteria review:\n- The participant must be African American.\n- The participant must be a resident of Jackson, Mississippi.\n\nBased on the given information, the patient meets the ethnic criteria for the clinical trial, as he is African-American. However, there is no information provided about the patient's residency. To determine if the patient is indeed eligible, we would need to confirm his place of residence. If the patient is a resident of Jackson, Mississippi, he would likely be highly eligible for the study, given his symptoms that suggest cardiovascular disease. If the patient is not a resident of Jackson, Mississippi, he would not meet the geographic inclusion criteria for this trial.\n\nSince the patient's residency is not specified in the patient note, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2576": {
        "output": "Based on the information given, the clinical trial titled \"Congestive Heart Failure Trends in the Elderly 1970-94\" does not provide specific inclusion criteria. The patient note describes a 65-year-old African-American male with symptoms that are suggestive of congestive heart failure (CHF), such as shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), bibasilar lung crackles, pitting ankle edema, and jugular venous distension.\n\nAlthough the patient's symptoms seem relevant to the clinical trial's focus on CHF, the absence of stated inclusion criteria in the trial information does not allow us to definitively determine eligibility based on the usual factors such as age, diagnosis, disease severity, etc. However, given that the patient's condition appears to align with the subject of the trial, and there are no exclusion criteria provided that would rule him out, we would consider referring the patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2577": {
        "output": "Based on the patient note provided, the 65-year-old African-American male presents with symptoms that are consistent with chronic heart failure (CHF), such as shortness of breath related to exertion, difficulty breathing when lying flat (orthopnea), using extra pillows at night to ease breathing (suggestive of paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These clinical signs and symptoms are typical for a patient with CHF.\n\nThe clinical trial in question is investigating the efficacy and cost-effectiveness of relaxation in response to CHF. To be eligible for the trial, participants must have a diagnosis of CHF and be at NYHA (New York Heart Association) stage 2 or 3. Although the NYHA functional classification is not directly mentioned in the patient note, the symptoms described could indicate that the patient is at NYHA stage 2 or 3. NYHA stage 2 refers to patients with symptoms of heart failure on ordinary exertion, while NYHA stage 3 refers to patients with symptoms of heart failure on less than ordinary exertion.\n\nGiven that the patient has CHF and the described symptoms suggest NYHA stage 2 or 3, it is reasonable to consider that the patient could potentially meet the inclusion criteria for the trial. However, the exact NYHA stage would need to be clinically assessed to ensure proper classification.\n\nTherefore, without confirmation of the NYHA stage, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2578": {
        "output": "The patient note describes a 65-year-old African-American male with symptoms indicative of congestive heart failure (CHF), including exertional shortness of breath, orthopnea (difficulty breathing when lying flat), use of extra pillows at night (suggesting paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These are common signs and symptoms associated with CHF.\n\nThe clinical trial in question is focused on the implementation of CHF guidelines through a tailored message program. To be eligible for the trial, candidates must meet the following inclusion criteria:\n\n- Ejection fraction (EF) < 40%\n- Getting the majority of care at the VA\n- Not enrolled in another CHF study\n- Ability to read English\n\nBased on the patient note, there is a strong indication that the patient may have CHF. However, the note does not provide information on the patient's ejection fraction, whether they are receiving the majority of their care at the VA, if they are enrolled in another CHF study, or if they can read English.\n\nGiven the lack of information on these specific criteria, we cannot definitively determine the patient's eligibility for this clinical trial. Further investigation would be required to obtain this information before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2579": {
        "output": "Given the patient note and the clinical trial information, we can analyze the patient's eligibility for the clinical trial titled \"Heart Failure in the Community.\"\n\nThe patient note describes:\n- A 65-year-old African-American male\n- Shortness of breath related to exertion, worsening over three weeks\n- Orthopnea (difficulty breathing when lying flat)\n- Use of extra pillows at night (suggesting orthopnea)\n- Physical exam findings: bibasilar lung crackles, pitting ankle edema, and jugular venous distension\n\nThese symptoms and findings are suggestive of heart failure.\n\nThe clinical trial aims to:\n- Monitor trends in congestive heart failure in Olmsted County, Minnesota\n\nInclusion criteria for the clinical trial:\n- No specific eligibility criteria are provided\n\nSince the inclusion criteria are not specified, and the patient presents with symptoms that are commonly associated with heart failure, we cannot exclude the patient from the trial based on the provided information. The patient could potentially contribute to the understanding of heart failure trends in the community, as per the summary of the clinical trial.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "2580": {
        "output": "",
        "label": 0
    },
    "2581": {
        "output": "Based on the patient note provided, the 65-year-old African-American male is experiencing symptoms indicative of heart failure, such as shortness of breath related to exertion, difficulty breathing when lying flat (orthopnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. However, the clinical trial in question is investigating the effects of angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) on the development or progression of silent brain infarction and cognitive decline in Japanese patients with essential hypertension.\n\nThe inclusion criteria for the trial are:\n\n1. Patients with essential hypertension (systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90, or treated with antihypertensive drugs).\n2. Patients with any finding of stroke, silent brain infarction, and white matter lesion on magnetic resonance imaging.\n\nThe patient note does not provide any information on the patient's blood pressure, use of antihypertensive drugs, or any findings of stroke, silent brain infarction, or white matter lesions on imaging studies. Given that the patient's primary issue seems to be heart failure and there is no mention of hypertension or related neurological findings, this patient does not appear to meet the inclusion criteria of the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2582": {
        "output": "Based on the patient note provided, the 65-year-old African-American male patient presents with symptoms suggestive of cardiovascular issues, such as shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These signs and symptoms point toward a diagnosis of congestive heart failure (CHF), which is one of the conditions listed in the inclusion criteria for the clinical trial.\n\nThe patient\u2019s symptoms and physical exam findings align with the types of patients the trial is designed to study, which is those with cardiovascular diseases, including congestive heart failure. Although the patient note does not explicitly mention a diagnosis of hypertension or ischemic heart disease, the symptoms and physical findings strongly indicate CHF, which is sufficient to consider the patient's eligibility for the trial.\n\nGiven this information, it is reasonable to consider this patient for the clinical trial, as they meet the inclusion criteria of having a clinical diagnosis of congestive heart failure. However, further investigation would be necessary to confirm the diagnosis and ensure no exclusion criteria are met before a final decision could be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2583": {
        "output": "Based on the patient note provided, the 65-year-old African-American male is experiencing symptoms that are suggestive of heart failure, including shortness of breath on exertion, difficulty breathing when lying flat (orthopnea), use of extra pillows at night to ease breathing (suggestive of paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These symptoms and signs are consistent with a clinical diagnosis of chronic heart failure, which is one of the risk factors listed in the inclusion criteria for the clinical trial.\n\nThe clinical trial in question is assessing the add-on effect of valsartan on morbidity and mortality in high-risk patients in Japan with hypertension and associated risk factors. The patient's symptoms suggest that he may have chronic heart failure (NYHA II-III), which is included in the list of risk factors in the trial's inclusion criteria. However, there is no explicit mention in the patient's note of a clinical diagnosis of hypertension, which is a requirement for inclusion in the study.\n\nTherefore, unless the patient has a documented diagnosis of hypertension and falls within the other criteria specified in the trial, we cannot conclusively determine that he is eligible based solely on the information provided.\n\nGiven the potential for chronic heart failure and the possibility that the patient also has hypertension (a common comorbidity with heart failure), further investigation would be required to confirm a diagnosis of hypertension and to assess other inclusion criteria such as the presence of additional risk factors, and whether the patient is already receiving conventional treatment for hypertension.\n\nThus, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2584": {
        "output": "Based on the patient note provided, the 65-year-old African-American male patient exhibits signs and symptoms suggestive of congestive heart failure (CHF), such as shortness of breath on exertion, difficulty breathing when lying flat, using extra pillows to sleep (orthopnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension.\n\nThe clinical trial in question is seeking to characterize atrial arrhythmias in patients indicated for Cardiac Resynchronization Therapy (CRT). The inclusion criteria for the trial require:\n\n- Patient\u2019s willingness and ability to comply with the protocol\n- Patient\u2019s willingness to sign written informed consent\n- Patient\u2019s availability for follow-up visits\n- Patient age is 18 years and older\n- Patient is on a stable medication regimen for at least 4 weeks prior to enrollment\n- New York Heart Association functional classification III or IV\n- QRS duration > 130 ms\n- Left ventricular ejection fraction < 35%\n- Left ventricular end diastolic dimension > 55 mm\n\nThe patient note does not provide information on several of these specific baseline criteria, including:\n- Whether the patient has atrial fibrillation or is indicated for CRT\n- The patient's New York Heart Association functional classification\n- The QRS duration\n- The left ventricular ejection fraction\n- The left ventricular end diastolic dimension\n\nThe note also does not mention the patient's willingness to comply with the protocol, consent to the study, availability for follow-up visits, or whether the patient is on a stable medication regimen. \n\nGiven the lack of information directly linking the patient's condition to the specific inclusion criteria of the clinical trial, it is not possible to definitively determine eligibility. Further investigation would be required to obtain the necessary information to assess the patient's eligibility for the trial.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2585": {
        "output": "Based on the provided patient note, the 65-year-old African-American male presents with symptoms that are consistent with congestive heart failure (CHF), such as shortness of breath related to exertion, difficulty breathing when lying flat (orthopnea), and physical exam findings including bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These symptoms and signs suggest the presence of stable CHF.\n\nHowever, the patient note does not explicitly mention impaired renal function or whether the patient is currently taking an oral loop diuretic, which are both part of the inclusion criteria for the clinical trial. While the patient does show signs that could be associated with CHF and potential renal impairment, such as edema, further investigation is required to confirm renal function status and current medication use.\n\nGiven the information available, the patient's eligibility for the clinical trial titled \"Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment\" would be on the scale of:\n\n1) Would consider referring this patient to this clinical trial upon further investigation to confirm impaired renal function and use of an oral loop diuretic.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2586": {
        "output": "Based on the information provided in the patient note, the patient is a 65-year-old African-American male who presents with symptoms consistent with heart failure (shortness of breath on exertion, difficulty breathing when lying flat, using extra pillows at night, bibasilar lung crackles, pitting ankle edema, and jugular venous distension). These symptoms suggest the patient could be experiencing heart failure worsening.\n\nThe clinical trial in question is investigating the continuation versus interruption of beta-blockers in patients with heart failure worsening that requires hospital admission due to pulmonary edema. To be eligible for this clinical trial, patients must meet the following inclusion criteria:\n\n1. Patients with heart failure treated with a beta-blocker.\n2. Hospitalization for heart failure worsening with pulmonary edema.\n3. Left ventricular ejection fraction less than 40%.\n\nThe patient note does not specifically mention whether the patient is currently being treated with a beta-blocker, nor does it provide information about the patient's left ventricular ejection fraction (LVEF). These are critical pieces of data needed to determine eligibility for the clinical trial.\n\nGiven the lack of information on beta-blocker treatment and the patient's LVEF, we cannot confirm if the patient meets all the inclusion criteria for the clinical trial. Therefore, further investigation would be needed to assess these aspects of the patient's medical condition.\n\nIn conclusion, based on the available patient note and the inclusion criteria of the clinical trial:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2587": {
        "output": "The patient described is a 65-year-old African-American male with symptoms that are suggestive of heart failure, such as shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), and physical findings including bibasilar lung crackles, pitting ankle edema, and jugular venous distension. \n\nThe clinical trial in question is looking to recruit nursing home patients who are 65 years of age or over to study the effects of heart failure on functional and cognitive decline, as well as psychiatric symptoms.\n\nBased on the information provided, the patient meets the age criterion (65 years or over) for the clinical trial. However, the patient note does not specify if the patient is a new resident to a participating long-term care facility, which is one of the inclusion criteria. \n\nGiven that the patient's symptoms are consistent with heart failure and they meet the age requirement, I would consider referring this patient to the clinical trial upon further investigation regarding his residence status in a long-term care facility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2588": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's compare the relevant factors:\n\nPatient note:\n- A 65-year-old African-American male\n- Symptoms include shortness of breath related to exertion, difficulty breathing when lying flat, using additional pillows at night\n- Significant physical exam findings include bibasilar lung crackles, pitting ankle edema, and jugular venous distension\n\nClinical trial inclusion criteria:\n- Diagnosed with dilated cardiomyopathy\n- Normal heart anatomy or those with repaired congenital defects that have a 4 chambered heart\n- Referred for a Biventricular pacemaker implantation or upgrade with the diagnosis of dilated cardiomyopathy or for an echocardiogram due to the diagnosis of dilated cardiomyopathy without pacemaker\n- Signed informed consent\n\nAssessment:\nFrom the patient note, there is no mention of dilated cardiomyopathy or any existing diagnosis or treatment related to heart anatomy or device implantations. The symptoms mentioned in the patient note (shortness of breath, difficulty breathing when lying flat, bibasilar lung crackles, pitting ankle edema, and jugular venous distension) could be indicative of heart failure or other cardiopulmonary conditions, but without a specific diagnosis of dilated cardiomyopathy, we cannot assume eligibility for the trial. Therefore, the patient does not meet the inclusion criteria as specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2589": {
        "output": "Based on the patient note provided, the patient presents with symptoms consistent with congestive heart failure, such as shortness of breath on exertion, difficulty breathing when lying flat (orthopnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These signs and symptoms suggest that the patient likely has congestive heart failure.\n\nThe clinical trial in question is looking to enroll patients with congestive heart failure, patients with normal cortical function, patients who are on diuretic therapy, and patients who are clinically stable and have maintained the same body weight for at least 3 days without signs of fluid retention.\n\nWhile the patient's note does indicate symptoms of heart failure, there is no information on whether the patient is currently on diuretic therapy, has normal cortical function, or is clinically stable with a maintained body weight without signs of fluid retention. Without this specific information, it is not possible to definitively determine if the patient meets all of the inclusion criteria. \n\nTherefore, based on the available information, I would categorize the patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include confirming the patient's current use of diuretics, assessing cortical function, and evaluating clinical stability and body weight maintenance.",
        "label": 1
    },
    "2590": {
        "output": "",
        "label": 2
    },
    "2591": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility for the clinical trial titled \"Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia\" can be assessed as follows:\n\nThe patient in the note is a 65-year-old African-American male presenting with symptoms suggestive of a cardiovascular issue, such as heart failure (shortness of breath on exertion, orthopnea, bibasilar lung crackles, pitting ankle edema, and jugular venous distension).\n\nThe inclusion criteria for the clinical trial are specific to patients with a diagnosis of acute myeloid leukemia (AML) who are previously untreated, among other specific requirements related to the disease and patient's general health status.\n\nGiven that the patient note does not mention acute myeloid leukemia or any indication of such a diagnosis, and the symptoms presented are not consistent with AML but rather suggestive of a cardiac condition, the patient does not meet the disease-specific inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided, the patient would not qualify for the clinical trial focused on treating patients with newly diagnosed acute myeloid leukemia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2592": {
        "output": "Based on the patient note, the patient is a 65-year-old African-American male presenting with symptoms consistent with heart failure: exertional shortness of breath, orthopnea (difficulty breathing when lying flat), and signs including bibasilar lung crackles, pitting ankle edema, and jugular venous distension. \n\nThe clinical trial in question is evaluating the effect of cardiac resynchronization therapy (CRT) combined with beta-blocker therapy in patients with symptomatic heart failure who have either not tolerated beta-blocker therapy or are on sub-optimal dosages of it.\n\nTo assess the patient's eligibility for the trial, we need to compare the patient's condition with the inclusion criteria:\n\n1. Symptomatic heart failure: The patient's symptoms and physical exam findings suggest he likely has symptomatic heart failure, meeting this criterion.\n2. Indication for cardiac resynchronization therapy (CRT): The patient note does not specifically mention CRT, so further investigation would be required to determine if the patient has an indication for CRT.\n3. Hemodynamic stability: The patient note does not provide information on hemodynamic stability, so this would need to be confirmed.\n4. Documented intolerance to beta-blocker therapy or treatment with beta-blocking agents at sub-optimal dosages: The patient note does not mention the patient's current medication regimen or any intolerance to beta-blocker therapy, so this information would need to be obtained.\n\nGiven the information provided, the patient seems to have symptomatic heart failure, which fits the trial's target population. However, additional information regarding his indication for CRT, hemodynamic stability, and history with beta-blocker therapy is needed to fully assess his eligibility.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2593": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 65-year-old African-American male.\n- He presents with symptoms suggestive of heart failure, such as shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), and he is using extra pillows at night (indicating possible paroxysmal nocturnal dyspnea).\n- Physical examination findings include bibasilar lung crackles, pitting ankle edema, and jugular venous distension, which are signs consistent with heart failure.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focusing on cerebrospinal fluid levels of Erlotinib in patients receiving Erlotinib for Stage III non-small cell lung cancer.\n- Key inclusion criteria include:\n  - Enrollment in a specific Phase I/II trial for non-small cell lung cancer (NSCLC) and being in the maintenance therapy phase.\n  - Having received Erlotinib for at least one week.\n  - No known CNS primary or metastatic cancer.\n  - No MRI evidence of pathological enhancement.\n  - Various patient and therapy-related requirements, including the absence of certain medical conditions and not being on certain medications.\n\nDoes the Patient Fit the Inclusion Criteria?\n- There is no information provided indicating that the patient has non-small cell lung cancer or that he is enrolled in the specified Phase I/II trial for NSCLC.\n- The patient's symptoms are more suggestive of heart failure rather than lung cancer, and there is no mention of any cancer diagnosis.\n- There is no information provided regarding the patient's use of Erlotinib or any other cancer-related treatments.\n\nConclusion:\nThe provided patient note does not align with the inclusion criteria of the clinical trial, which is specific to patients with Stage III non-small cell lung cancer who are already part of another ongoing trial. The patient's symptoms and history do not suggest that he has NSCLC or that he is on any cancer treatment. Therefore, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "2594": {
        "output": "Based on the provided patient note, the 65-year-old African-American male presents with symptoms that are suggestive of congestive heart failure (CHF), such as shortness of breath on exertion, difficulty breathing when lying flat (orthopnea), using extra pillows at night to ease breathing (suggestive of paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension.\n\nThe clinical trial in question is seeking to improve clinical outcomes for patients with CHF using telemedicine. The inclusion criteria for the trial are:\n1. Physician diagnosed CHF\n2. Member of Kaiser Permanente Georgia\n\nBased on the patient note alone, we can infer that the patient likely has CHF given the symptoms described. However, we do not have information on whether the patient has been formally diagnosed with CHF by a physician or whether the patient is a member of Kaiser Permanente Georgia. These two factors are essential to determine eligibility.\n\nGiven that we lack this crucial information, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to confirm the diagnosis of CHF by a physician and to establish whether the patient is a member of Kaiser Permanente Georgia before the patient can be referred for the trial.",
        "label": 2
    },
    "2595": {
        "output": "Patient Note Analysis:\n- 65-year-old African-American male\n- Symptoms: shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), using extra pillows at night to ease breathing\n- Physical exam findings: bibasilar lung crackles, pitting ankle edema, jugular venous distension (JVD)\n\nClinical Trial Inclusion Criteria Analysis:\n- Older than 18 (Patient is 65 years old, meets criteria)\n- Not pregnant (Male patient, meets criteria)\n- Have heart failure with worsening hypervolemia despite oral diuretics (Patient has symptoms consistent with heart failure and hypervolemia)\n- Have at least two of the following signs or symptoms of hypervolemia: JVD, edema >1+, rales, pulmonary edema on chest x-ray, orthopnea or PND (Patient has JVD, edema, and orthopnea, meets criteria)\n- Not more than 10 kg above their usual baseline weight (Not specified in the patient note, further information needed)\n- Need for a minimum of 2 liters of volume removal (Not specified in the patient note, but given the symptoms, it is likely that the treating physician may determine this need)\n\nBased on the available information, the patient appears to meet most of the inclusion criteria for the clinical trial. However, there are two criteria for which we do not have enough information, specifically the patient's usual baseline weight and the treating physician's assessment of the need for volume removal.\n\nGiven this information, the assessment for trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2596": {
        "output": "The patient note describes a 65-year-old African-American male with symptoms that are consistent with heart failure, including shortness of breath related to exertion, difficulty breathing when lying flat (orthopnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These symptoms suggest that the patient may be experiencing an episode of worsening heart failure.\n\nThe clinical trial in question is seeking to improve care for hospitalized patients with heart failure and is looking at patients who have been hospitalized for an episode of worsening heart failure or who develop significant heart failure symptoms during their hospital stay, regardless of whether heart failure was the primary cause of admission. The inclusion criteria also specify that patients should have either systolic dysfunction (LVEF < 40%) or heart failure symptoms in the setting of preserved systolic function (diastolic dysfunction).\n\nWhile the patient's symptoms are suggestive of heart failure, the patient note does not provide specific information about whether the patient is currently hospitalized for heart failure or about the patient's left ventricular ejection fraction (LVEF) to confirm systolic dysfunction. Further investigation would be needed to determine these specific details to confirm the patient's eligibility for the trial.\n\nBased on the information provided, it is reasonable to consider referring the patient to the clinical trial upon further investigation to confirm heart failure diagnosis, hospitalization status, and the type of heart failure (systolic or diastolic dysfunction).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "2597": {
        "output": "Based on the patient note provided, the patient exhibits symptoms that are consistent with congestive heart failure (CHF), such as shortness of breath on exertion, orthopnea (difficulty breathing when lying flat), need for extra pillows at night (suggesting paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These are all clinical signs that can be associated with heart failure.\n\nNow, let's evaluate this patient against the inclusion criteria of the clinical trial:\n\n1. Clinical diagnosis of heart failure based on a slight modification of the Framingham criteria as previously described within 6 months before the entry - The patient note does indicate signs consistent with heart failure, which could potentially meet the modified Framingham criteria mentioned.\n\n2. Current status of heart failure is NYHA II or III - The symptoms described, such as shortness of breath related to exertion and difficulty breathing when lying flat, could suggest that the patient is NYHA Class II or III, but this requires a formal assessment to confirm.\n\n3. Currently, loop diuretic(s) is (are) administered - The patient note does not specify whether the patient is currently on loop diuretics.\n\n4. No change in baseline therapy and symptoms of heart failure within a month - The patient note does not provide information about the stability of the heart failure therapy and symptoms in the last month.\n\nGiven the information available in the patient note, it seems that the patient may meet some of the inclusion criteria for the clinical trial, especially the diagnosis of heart failure. However, there is not enough information to confirm the NYHA classification, current use of loop diuretics, or the stability of therapy and symptoms. Therefore, further investigation would be required to determine if the patient is suitable for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "2598": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's analyze the factors for eligibility:\n\nPatient Note Analysis:\n- The patient is a 65-year-old African-American male.\n- There is no mention of type 2 diabetes in the patient's note.\n- The patient presents with symptoms suggestive of heart failure (shortness of breath on exertion, orthopnea, bibasilar lung crackles, pitting ankle edema, and jugular venous distension) but not specifically hypertension or its measurements.\n- There is no information provided about the patient's blood pressure or HbA1C levels.\n\nClinical Trial Inclusion Criteria:\n- African-American males and females are eligible.\n- Must have a current diagnosis of type 2 diabetes documented by medical history.\n- Mean sitting diastolic blood pressure of \u2265 90 and \u2264 110 mm Hg.\n- HbA1C \u2264 9.5%.\n\nAssessment:\nThe patient is African-American and male, which meets part of the demographic criteria. However, there is no information on a diagnosis of type 2 diabetes, nor is there any information on the patient's blood pressure or HbA1C levels. Without this information, we cannot confidently refer the patient to this specific trial. Further investigation would be needed to ascertain whether the patient has type 2 diabetes and meets the other inclusion criteria regarding blood pressure and HbA1C levels.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2599": {
        "output": "Based on the patient note, the 65-year-old African-American male is experiencing symptoms consistent with heart failure, such as shortness of breath on exertion, difficulty breathing when lying flat, and the use of extra pillows at night to ease breathing (orthopnea). The physical exam findings of bibasilar lung crackles, pitting ankle edema, and jugular venous distension further support a diagnosis of heart failure.\n\nComparing these details to the clinical trial's inclusion criteria:\n- The patient is over 18 years of age, which meets the age criterion.\n- The clinical trial is looking for patients primarily hospitalized with heart failure, and although it is not explicitly stated, the patient's symptoms suggest that he may be a candidate for hospitalization.\n- The trial requires the left ventricular ejection fraction (LVEF) to be less than 40%. This information is not provided in the patient note, so it is unknown.\n- Patient informed consent is required, which can only be determined upon discussion with the patient.\n- The trial specifies the absence of pulmonary congestion as an inclusion criterion, which seems to contradict the patient's symptoms of bibasilar lung crackles, suggesting the presence of pulmonary congestion.\n\nGiven the information provided, it appears that the presence of pulmonary congestion would make the patient ineligible for the trial. However, since the LVEF is not provided, and we do not have confirmation of the primary hospitalization for heart failure, further investigation would be necessary to determine the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "2600": {
        "output": "Based on the patient note provided, the patient is a 65-year-old African-American male with symptoms that are suggestive of congestive heart failure (CHF), such as shortness of breath related to exertion, difficulty breathing when lying flat (orthopnea), using extra pillows at night to breathe better (suggestive of paroxysmal nocturnal dyspnea), bibasilar lung crackles, pitting ankle edema, and jugular venous distension. These clinical signs and symptoms are consistent with CHF.\n\nComparing the patient's characteristics to the inclusion criteria of the EarlySense Monitoring Device Evaluation on CHF Patients clinical trial, we find the following:\n\n- Age over 45 years old: The patient is 65 years old, which meets this criterion.\n- CHF class II or III with LVEF<40%: The patient's symptoms are suggestive of CHF; however, the note does not provide information about the left ventricular ejection fraction (LVEF) or the specific New York Heart Association (NYHA) class II or III.\n- Hospitalized at least once for CHF deterioration over the previous 12 month period: The note does not indicate whether the patient has been hospitalized for CHF deterioration in the past year.\n- Able and willing to cooperate with this trial for at least a 3 month period: The patient's willingness to cooperate is not stated in the note.\n- Home close to participating center: The distance of the patient's home from the participating center is not provided in the note.\n\nGiven the information available, the patient appears to meet some of the inclusion criteria (age and symptoms suggestive of CHF), but there is insufficient information to determine if they meet all the criteria (CHF classification, LVEF, hospitalizations, willingness to participate, and proximity to the center). Therefore, additional information would be required to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    }
}